<SEC-DOCUMENT>0001193125-26-073317.txt : 20260226
<SEC-HEADER>0001193125-26-073317.hdr.sgml : 20260226
<ACCEPTANCE-DATETIME>20260226063942
ACCESSION NUMBER:		0001193125-26-073317
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260226
DATE AS OF CHANGE:		20260226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nuvalent, Inc.
		CENTRAL INDEX KEY:			0001861560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40671
		FILM NUMBER:		26681592

	BUSINESS ADDRESS:	
		STREET 1:		ONE BROADWAY, 14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		508-446-2272

	MAIL ADDRESS:	
		STREET 1:		ONE BROADWAY, 14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nuvl-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-02-25T15:36:21.6225+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:nuvl="http://www.nuvalent.com/20251231" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_b805326d-b0b8-4b7d-bbfd-39a4c67c2a5d" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea">FY</ix:nonNumeric><ix:nonNumeric id="F_81256ce3-959b-4b93-84e1-a8e06ee0a849" name="dei:AmendmentFlag" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_2960a5ae-7bfc-437f-b348-7f55e9e1cdbd" name="dei:EntityCentralIndexKey" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea">0001861560</ix:nonNumeric><ix:nonFraction id="F_0d2d81e3-69a3-4524-9293-717092943f94" name="us-gaap:CommitmentsAndContingencies" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_8f9dc6b8-8eae-47ed-8d70-8d9905e57973" name="us-gaap:CommitmentsAndContingencies" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_2bc711c3-dec2-4073-ad3b-8876b685c8e8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_eb77daac-31d6-4c33-89c6-be1bd2d47291" format="ixt-sec:durwordsen">three years</ix:nonNumeric><ix:nonNumeric id="F_9bb6efd4-414b-479c-bbd1-d6eec4dc4cc3" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea">http://fasb.org/us-gaap/2025#AccountingStandardsUpdate202309Member</ix:nonNumeric><ix:nonNumeric id="F_b03806a6-1c81-405a-b304-d4fc62c72a8c" name="us-gaap:OpenTaxYear" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"> 2022 2023 2024 2025</ix:nonNumeric><ix:nonNumeric id="F_d7650aa4-5b78-4427-b72b-9d9f6eb1e03c" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonNumeric id="F_c878b86a-9508-4bbd-ac26-41dc1d148b19" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea">http://fasb.org/us-gaap/2025#SegmentReportingExpenseInformationUsedByCodmConsolidatedMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nuvl-20251231.xsd"/></ix:references><ix:resources><xbrli:context id="C_804b901c-8280-4ee4-8d08-720119428cfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nuvl:RelatedPartyRevenueShareLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84e19387-66ac-4596-b28a-643c9b3fb129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87166674-75a3-43e1-b506-e4931d232803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nuvl:RelatedPartyRevenueShareLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_871a772b-11eb-4b5f-8988-87609b488c50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89ef94e8-5fe8-4da1-8b41-06e3cb2b86a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c05b7a3-8cdf-43a6-a7e8-093ffb97f438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c5fa58b-cce8-41df-a7c1-f605951d05f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d3a377b-6ff7-4302-9183-32b0389e7d83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9197732a-6f19-4a46-a09e-bbf59e2e5565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93016deb-ee08-467a-a576-f8fa9b49422a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93b7517e-8570-4d83-b09d-74c6833d8f47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:NeladalkibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93c55488-e02d-4971-b17c-5355e98cdfa9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_995479a7-c042-4eed-b4f4-cb48506a82ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bf007c6-b63f-40c9-9e02-abfd50766d7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cdf4307-9ead-4afc-bdf8-f81ea96995ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nuvl:ClassAAndClassBCommonStockOutstandingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-28</xbrli:startDate><xbrli:endDate>2021-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e99d067-33f9-44b7-ad37-2b11d6b976ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:ZidesamtinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ed360b9-2aab-458b-bda7-0463d9f71263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f83a502-9a23-4e89-997b-59b9c16ccdcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a003efa2-9b6b-4b5b-8e24-3f682b981042"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvl:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a35f2a79-4ef6-43ea-a2a6-e4132c6ac5cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a45f72dc-0315-4ee6-825d-858c0027d5b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4c171d8-3da3-4eb9-89e1-62dacc43ee28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a59b2dc3-40a3-4254-a8ce-3b9d4e32e2ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7c68923-25e9-4e81-bde0-d29cb0d28c74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a88ce5aa-19e3-4d4f-ad4b-227efe228c24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:DiscoveryProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9763b57-1db2-4f46-9ff1-ae604892960c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abcc8928-5878-4175-910a-b88480310852"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ade98c0e-cd81-4850-a29e-7a084963f5ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">nuvl:NetOperatingLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aee1bc3b-ea55-48a0-b0ff-337c01baa3ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_afdd3fb0-ef69-40ad-bdc6-6e7c62bedfaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:AlexandraBalcomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b31225ef-7fb3-476b-bede-da08638f612a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3cff3c2-044c-46b7-89c3-2f4680873e9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4f67603-f7f4-4146-9b75-51864e400238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5d7c4e7-18e6-4f91-bcaf-b360fe129db5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b91245ac-3eac-4609-a0fd-52cfb27df07b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:ZidesamtinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b96b8a89-ec86-4975-9a70-f67d031a9eca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9cdf8b1-21d2-4c81-8860-bfb22facc2be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bba0ffcf-7930-4541-851f-def4fb4b8a99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be9e56dd-5d09-42b5-a3e0-25987a1ec13c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2cf0b0d-1d62-4db0-b62f-ddbc77d261d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5190b6e-fe0c-4289-8dbf-a33c66c7be66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:HenryPelishMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6bbbfaf-9812-4257-bac4-0186503112d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c712640c-07a0-45da-b2b2-bcb02c4fd3e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cade3bc7-f32f-4684-8800-eec9caada9bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_caf3d18a-ea80-40be-9716-306c4b3b915d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cbc6ed71-c5cd-44a8-8b33-02e5252b1e57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cbcb2363-568f-4092-88ad-525c58d12120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nuvl:RelatedPartyRevenueShareLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbef92a0-50ca-4971-bfcf-4cc694bd98f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd8ca3b9-735d-497f-8b2f-206e366ae9a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdabc5c6-3cd2-4eb9-9dc6-41bbf0db7742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdbd7a9d-c51f-4155-98da-a38460114f3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cdee423f-13dc-4cee-9db9-89de0a74a37e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce0c1f70-1e86-4aae-bde4-2bb3ccddfaa6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d099b530-0cf4-48be-a348-63560b2d2db7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nuvl:RelatedPartyRevenueShareLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d47345ec-2ef1-4025-9501-8c6905454377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvl:RevenueSharingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4753189-18cd-4f14-9c1a-96a8faae97b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d715c616-aabd-4724-8a14-e0643645f7fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d76a48ae-1458-49f4-880c-993e1969d630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db861eb5-13ac-4eb3-ad97-2e20abffc3c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dcbf0a58-6a1b-4202-9cdf-1ee677e03399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de369d63-3940-4ffe-ab65-7d8fb85e29f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e04f47c1-ee6d-40d2-ad63-924abbcdd776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:AlexandraBalcomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1e6998a-a42a-435c-9db6-9c17a1e2d9d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e20707b9-ffb3-4b91-af22-0d9378f431f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e23cc770-0e42-4f32-8905-235f71ad32fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e296d935-9d7a-4619-b857-c867a08d6bf1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2c0f06b-9e84-41cf-840f-bb816b9bcc96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvl:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4d077ae-e343-4a79-ae30-25df3168dd9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5c11e44-2976-420e-8d41-594249e44ff8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e69823d8-ed01-4d08-984d-1b2999947be0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e991fd94-9f04-42a7-9ea3-29c75a8aa6ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">nuvl:OrphanDrugCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb77daac-31d6-4c33-89c6-be1bd2d47291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eba66bbe-f103-4138-86da-3992c8897615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee20e1d0-82c0-4f31-a59e-df781ca5bef7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:DiscoveryProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef0a437f-257a-4262-a85f-63baab8addb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2bb14c0-23f4-4a61-858f-bd386111223c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4890ed2-89d0-425e-bad2-ca3f8727c10d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f59252bc-b763-4e51-83d2-54d4bba5a6f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f899193c-c2e3-484b-bdb4-f0e98446f558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nuvl:NonExpirableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f95ded5a-49e8-49b9-b5a3-63dc2b4d4aa1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nuvl:NonExpirableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fed5ef36-c783-45d6-bccf-aedf6738ae46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0000066a-157e-4f4a-ba87-0eadc35447f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01cd509e-be11-4515-a517-f7b5049d7dd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04cf2475-3d52-4702-8abf-c08e477d27e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0750e3c9-8640-41ad-9503-347848c2d04a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:NeladalkibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07fcdeda-4594-41d5-be5c-795db943ad90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b6fa2d9-3207-4641-a3d5-2ca8fe718b5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e122157-f19c-4bac-ba06-7e7e26e67d60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ed9a5c8-bc77-4159-80cc-631b58767dd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f57ea6c-80f3-41df-a06f-6bbb78d913d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_115fa72c-632f-4dc3-a356-8cde960ebdc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_116dea71-ba5e-4119-8d49-e7ee6561f1e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:NeladalkibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1199f4a9-3a4a-4346-9b3c-1e5dfe502dce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nuvl:RelatedPartyRevenueShareLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11b35f3d-891f-4171-b4d4-acada2917088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nuvl:RelatedPartyRevenueShareLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12c1df21-95c0-4db5-83c4-037d4d91afe3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13717a87-7c59-4d14-9edc-e3677683fc0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:DiscoveryProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1933430c-8e7f-4e70-bb06-113d64f132d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nuvl:DebtSecuritiesAvailableForSalesSecuritiesDueAxis">nuvl:DueFromOneToThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b1f7158-edca-404e-aa34-c73afe046033"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b7c2420-1c2c-4ebf-8428-9cac99f1ca29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c1aeab6-5cb0-40f4-a1b3-94770256e0b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1cd91e04-8d02-4ef7-b3c0-68167cbe59fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1cd95e71-e453-489e-afd8-afbc6cfad37f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nuvl:ClassBConvertibleCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d01bc0b-7ded-4bd0-9911-fdca86bb46a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1dad83de-cc46-4271-b61b-c56d9259a2a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e086995-98e4-44a7-b73f-1985518eb0f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20130f2c-c4db-45fd-abba-1f8188d4bd9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">nuvl:NetOperatingLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21c5a8f9-d69c-4f2f-9b56-7302217a3a00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:NVL-330Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22a8e1ba-3f11-4756-a8b5-7e71665e826e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_246b0188-59cf-48e1-84da-c53c20eff235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:NVL-330Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_249fe9c5-035a-4be4-bda3-5a7f5c5d842f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nuvl:DebtSecuritiesAvailableForSalesSecuritiesDueAxis">nuvl:DueWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27e304bf-4878-4185-b218-ef61b37c5fd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nuvl:ClassBConvertibleCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e334b49-451c-4916-9273-f6e7d4df64dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2eb94656-ce71-41b7-8316-033ff3cd4fea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2faab416-a590-4339-bcf2-a0d2b4d28bcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_311675e3-d4bb-45f1-8ba5-f59f04c6601e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_315a253c-12d3-4e3f-8582-c49af65387fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35482e0d-c33b-47c3-848d-21781d777547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38c713ba-cdc7-468e-8239-8bb281da925a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b2c84ab-d113-49df-ac68-ee96b2c40bcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b49c627-bb81-455e-91fc-cab076e3df66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">nuvl:NetOperatingLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d1f51e0-4a93-4b50-a43a-e08057aecfba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nuvl:ExpirableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3eba6714-0731-48ae-b4f4-7f4ce2c35d2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:ZidesamtinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4012f4dc-f825-4c85-81de-f4ed79e455ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40396d26-77ba-42d0-a54a-49ced53d5b71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_466cca9b-97be-4208-8bc1-360fd88d3e92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nuvl:RelatedPartyRevenueShareLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47a42871-276f-471d-89af-7b2d8728791f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:JamesPorterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b2153d7-580e-498d-a2f9-c607f8bbecf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b81bd74-b327-44d2-baca-063efd69c11c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c059091-923a-455f-b4b2-a218c67cdf6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:AnnaProtopapasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f8e7dd3-78fe-4d02-b566-4230ae65335a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fff95ac-8ff6-451a-8631-2a1193c942a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:HenryPelishMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5375c9d0-2105-44e2-b95c-e77a2e65b0ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57e49bd8-5824-43bf-b177-9a36dba04b3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59caff5d-8166-4377-8ad8-d90aab14d4f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59e85967-08c8-41ab-9f65-d108262ec6c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b210e3a-65e3-4ee7-b4af-e26ecefa2931"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b2c061b-d1fc-4fbb-80d8-2da875f202a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ced912f-8b63-48e6-a3cd-afdf5cd699b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ecefa5a-caed-49e8-bd54-e1b9762e2e0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6094352e-f262-4238-af9a-9fad395992a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:NVL-330Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62eeefb2-1e14-4bca-8787-bc752cc63c08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64c133f5-2609-4c1b-9738-f16ce3dfd8c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_651bca55-01de-4bcf-b62d-18da05e75cbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6656ba66-9dab-4e91-9c45-bf8d51c0b1f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66ccad61-3ba5-4582-a264-afb3cb89f898"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69edaadf-ec5e-4f6b-a8f9-bf8b5f259318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b6f2b20-abff-42cb-90e5-af03ff62b7f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c8c683b-7a90-4cec-ad1b-80a3610a19bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6edd2b6c-842b-450b-bfa3-6954cfc7acbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7026295c-45c4-4065-af2d-da1e39b72fb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7113a74e-6c90-4126-9b38-7b6f500f4532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:AnnaProtopapasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72818106-430d-4e9d-ac04-dff4e3f376f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:JamesPorterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_739ac674-8392-417c-8c4a-3fc04e811f6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76fd5dc0-bfbc-4e89-bf40-514de9d64090"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_794390d5-c9fe-4091-8a4b-34dc63c137c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79da2e27-729f-4d64-9d13-dfa7ed04d4ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ab55318-ef2a-434f-8bd9-380fef2ea246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7afb1013-38c2-4d5e-b701-12fe832c3317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvl:ExcludingPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ba5c3d8-bf4d-45c7-b12b-5b3d1c87d47e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ce3ca05-ba69-4be9-a104-7719ff79cd1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nuvl:ExpirableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d73a6a9-9a14-4d7d-ac5c-0d24cfad2b78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7eb103db-61c7-4a1d-bd4c-ff51a5d2f879"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvl:ExcludingPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7fb5a364-b725-42f1-ad2c-b3730193541d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>nuvl:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_2c80a555-b7c4-4850-83cf-ca017df36dc6" fromRefs="F_99d37f8b-f9bc-44f2-8755-46a77d453983 F_534a07f3-eb73-4e0f-a151-8b1ec63eab1e F_7ea2888c-43cb-4789-b097-84b1ddb9f65a"/></ix:resources></ix:header></div>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.1in;z-index:2;min-height:0.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________________________________________________</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3674a9f3-5752-449c-bece-cdde11b798ae" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________________________________________________</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:98%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_4948668e-974b-4713-b1c3-c22059b58fdd" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2747a553-19fe-4305-b088-8fa9b69b964b" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d10611d-fbc8-43f0-93f7-e2f269ac43e1" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b7a660ea-42e7-485d-bbdc-db2334f840ec" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:98%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_77046829-f83d-4874-8aa0-be55f67acbf1" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                    </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission file number: </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3cf87df0-8518-4d07-a7ec-88a9375ba518" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-40671</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________________________________________________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img123481027_0.jpg" alt="img123481027_0.jpg" style="width:118px;height:35px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:13.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8b34456b-d6a6-4da2-9a9c-576f8185e782" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVALENT, INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________________________________________________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_4f8e5431-1b03-406f-9624-bca20749257a" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_f6587e63-92cd-488c-93bc-fbe14bd00143" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">81-5112298</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_efa60fb9-2e0f-49a0-ad7f-72d100abe0a8" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">One Broadway</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_264d9065-3d0f-456a-918c-5f7ef414053b" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">14</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-weight:bold;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> Floor</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_8245a999-a394-4844-bb23-cec6976b9c4b" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cambridge</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_ce52a3f4-bd55-468c-9b91-ef6e99a33b62" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_c661d012-4c9c-45c1-93e3-4a6ca140e8e9" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">02142</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_983460da-bf98-4afd-ae20-63b0fe0cdbba" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b67257e7-21c2-4de9-b625-9824c65ccea7" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">357-7000</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________________________________________________</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:35%;box-sizing:content-box;"/>
     <td style="width:31.66%;box-sizing:content-box;"/>
     <td style="width:33.34%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">on which registered</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_a66cc186-5a5c-40db-b5a0-cf29c33a28ab" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_394c0d4d-b0df-491c-b6f3-d79fd7ad008c" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NUVL</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">The </span><span style="font-size:8.5pt;"><ix:nonNumeric id="F_6f38f4d4-f177-44d3-a1fc-3134f229c726" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span></p><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d6eda7b0-7d23-4acb-84c6-0b3f007afd9e" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    No   &#9744;</span></p><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  &#9744;    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2744adc2-48ad-460c-8677-14d1053beda5" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1408c37-d233-4e28-b09e-e2efde675610" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    No  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d0f6da1-60d8-466a-9746-560b1b06f0fe" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    No  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:20.619%;box-sizing:content-box;"/>
     <td style="width:1.031%;box-sizing:content-box;"/>
     <td style="width:53.464%;box-sizing:content-box;"/>
     <td style="width:1.031%;box-sizing:content-box;"/>
     <td style="width:20.619%;box-sizing:content-box;"/>
     <td style="width:1.031%;box-sizing:content-box;"/>
     <td style="width:2.206%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_228b6e9f-1232-414d-b3b2-e9d7b654753b" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_5411d3bd-6bdc-429b-8da5-896e5f4d379e" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_9e68e42a-7829-47a7-838e-91b82cfa0639" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f642ac0-1e8e-4eba-8d76-83c9ab6231cd" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0061c33f-b4b3-4d8e-b9c1-828c76a013d0" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  &#9744;    No  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6d8e33c-047e-4295-8b67-7c355000ccd1" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the closing price of the registrant&#8217;s Class A common stock on the last business day of the registrant&#8217;s most recently completed second fiscal quarter, which was a closing price of $76.30 per share on June 30, 2025, as reported on the Nasdaq Global Select Market, the aggregate market value of its Class A common stock and Class B common stock held by non-affiliates was approximately $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d61a867c-2866-4e40-960e-ae0c1254f83d" contextRef="C_cade3bc7-f32f-4684-8800-eec9caada9bf" name="dei:EntityPublicFloat" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion.</span></p><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 19, 2026, the registrant had </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0905edc2-8692-4335-9400-a9817deb3ff3" contextRef="C_2faab416-a590-4339-bcf2-a0d2b4d28bcf" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">73,181,747</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, $0.0001 par value per share, outstanding and </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4abc14f-4730-4fe7-ae96-8c3b0d3a9406" contextRef="C_bba0ffcf-7930-4541-851f-def4fb4b8a99" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,435,254</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class B common stock, $0.0001 par value per share, outstanding.</span></p><div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_719a2515-b4b3-4cf6-9e57-0153287862a6" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the registrant&#8217;s Proxy Statement for its 2026 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.1in;min-height:0.2in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc"><span id="mypage"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvalent, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc_page"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Contents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:84%;box-sizing:content-box;"/>
     <td style="width:8%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
    </tr>
    <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">1</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1A.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">38</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1B.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_1b"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">91</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1C.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">91</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 2.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">92</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 3.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">92</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 4.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">92</span></a></p></td>
    </tr>
    <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
    </tr>
    <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 5.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_5_market_for_registrants"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">93</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 6.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_6"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">94</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_management_discussion_analysis"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 7.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_management_discussion_analysis"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_7_management_discussion_analysis"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">95</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 7A.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">104</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_and_supp"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 8.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_and_supp"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_8_financial_statements_and_supp"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">106</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_disagreements_with_acct"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 9.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_disagreements_with_acct"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_9_changes_disagreements_with_acct"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">124</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 9A.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">124</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 9B.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">124</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9c"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 9C.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9c"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item9c"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">125</span></a></p></td>
    </tr>
    <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
    </tr>
    <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 10.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_10_directors_executive_officers"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">126</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_exec_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 11.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_exec_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_11_exec_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">126</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 12.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_12"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">126</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 13.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_13"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">126</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accountant_fees"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 14.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accountant_fees"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_14_principal_accountant_fees"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">126</span></a></p></td>
    </tr>
    <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
    </tr>
    <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 15.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_15"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">127</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 16.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#item_16form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">127</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibit_index"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibit Index</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#exhibit_index"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">128</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">130</span></a></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K (Annual Report) of Nuvalent, Inc. contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), that are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements contained in this Annual Report include, among other things, statements about:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, timing, progress, results, and costs of our zidesamtinib (NVL-520), neladalkib (NVL-655), NVL-330 and discovery programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, alignment with the U.S. Food and Drug Administration (FDA) regarding the design of trials, and when the results of the studies or trials will become available;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our preclinical studies and clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, scope and likelihood of regulatory filings and approvals, including timing of Investigational New Drug applications (INDs), New Drug Applications (NDAs), and final FDA approval of our current product candidates or any future product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, scope or likelihood of foreign regulatory filings and approvals;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop product candidates, including by applying learnings from one program to other programs and from one indication to other indications;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates of the number of patients that we will enroll and our ability to initiate, recruit, and enroll patients in and conduct and successfully complete our clinical trials at the pace that we project;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to scale-up our manufacturing and processing approaches to appropriately address our anticipated commercial needs, which will require significant resources;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain and further develop the specific shipping, storage, handling and administration of zidesamtinib, neladalkib and NVL-330 at clinical sites;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to take advantage of accelerated regulatory pathways for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to commercialize our product candidates, if approved, including the geographic areas of focus and sales strategy;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the pricing and reimbursement of our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the implementation of our business model, and strategic plans for our business, product candidates, and technology;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">estimates of our future expenses, revenues, capital requirements, and our needs for additional funding;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the period over which we estimate our existing cash, cash equivalents and marketable securities will be sufficient to fund our future operating expenses and capital expenditure requirements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future agreements with third parties in connection with the development and commercialization of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial performance;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate and degree of market acceptance of our product candidates, if approved;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ii</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory developments in the United States (the U.S.) and foreign countries;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to produce our product candidates with advantages in turnaround times or manufacturing cost;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitive position and the success of competing therapies that are or may become available;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our need for and ability to attract, retain and hire key scientific, management, sales and marketing and other personnel;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of laws and regulations;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments relating to our competitors and our industry;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of public health emergencies, natural disasters or geopolitical events, including actual or threatened tariffs or other changes in trade policy, civil or political unrest or military conflicts, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and clinical trials; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other risks and uncertainties, including those listed under the section titled &#8220;Risk Factors.&#8221;</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;seek,&#8221; &#8220;predict,&#8221; &#8220;future,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;aim&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and elsewhere in this Annual Report. If one or more of these risks or uncertainties were to occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Annual Report and the documents that we reference in this Annual Report and have filed with the Securities and Exchange Commission (SEC) completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The forward-looking statements in this Annual Report represent our views as of the date of this Annual Report. We do not undertake any obligation to publicly update any forward-looking statement except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. All of the market data used in this Annual Report involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except where the context otherwise requires or where otherwise indicated, the terms &#8220;Nuvalent,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;our Company,&#8221; &#8220;the Company,&#8221; and &#8220;our business&#8221; in this Annual Report refer to Nuvalent, Inc. and its consolidated subsidiary. Solely for convenience, the trademarks and trade names in this Annual Report may be referred to without the symbols </span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and &#153;. Nuvalent and associated logos are trademarks of Nuvalent. Other brands, names and trademarks contained in this Annual Report are the property of their respective owners.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iii</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUMMARY OF RISK FACTORS</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the section titled &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Annual Report and our other filings with the SEC before making investment decisions regarding our common stock.</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a limited operating history, have no products approved for commercial sale and have not generated any revenue, which may make it difficult for investors to evaluate our current business and likelihood of success and viability;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant net losses in each period since our inception, and we expect to continue to incur significant net losses for the foreseeable future;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future prospects are substantially dependent on zidesamtinib (NVL-520), neladalkib (NVL-655) and NVL-330. If we are unable to advance these product candidates through development, obtain regulatory approval and ultimately commercialize such product candidates, or experience significant delays in doing so, our business will be materially harmed. Even if we obtain regulatory approval for such candidates, there is no assurance that our commercialization efforts will be successful or that we will be able to generate revenues or profits at the levels or on the timing we expect, if at all;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our preclinical studies and clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates, which would prevent or delay development, regulatory approval and commercialization;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our discovery and development activities are focused on the development of targeted therapeutics for patients with cancer-associated genomic alterations, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs may never lead to approved or marketable products;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later-stage clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, European Medicines Agency (EMA) or other comparable foreign regulatory authorities and we may not be able to commercialize our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to zidesamtinib, neladalkib and NVL-330, our prospects depend in part upon discovering, developing and commercializing additional product candidates from our discovery programs, which may fail in development or suffer delays that adversely affect their commercial viability;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates may cause significant adverse events, toxicities or other undesirable adverse events when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could prevent regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interim, preliminary and topline data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we experience delays or difficulties in the enrollment or maintenance of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never commercialized a product candidate as a company before and currently lack substantially all of the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if one of our product candidates receives marketing approval, we or others may later discover that the product is less effective or tolerable than previously believed or causes undesirable side effects that were not previously identified, which could compromise our ability, or that of our collaborators, to market the product;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face substantial competition which may result in others discovering, developing or commercializing products before or more successfully than we do;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market opportunities for any product candidates we develop, if approved, may be limited to certain smaller patient subsets and may be smaller than we estimate them to be;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, may be unable to commercialize our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iv</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where appropriate, we plan to pursue approval from the FDA, EMA or comparable foreign regulatory authorities through the use of accelerated registration pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, EMA or comparable regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA, EMA or such other regulatory authorities may seek to withdraw accelerated approval;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidates are licensed for marketing and receive federal healthcare reimbursement, any relationships we may have with healthcare providers will be subject to applicable healthcare fraud and abuse laws and regulations, which could expose us to criminal and civil penalties and exclusion from participation in government healthcare programs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to establish adequate sales, marketing and distribution capabilities or enter into agreements with third parties to sell, market or distribute our product candidates, we may not be able to successfully commercialize our product candidates that obtain regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may allege that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on our business;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets and other proprietary information, our business and competitive position would be adversely affected;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we decide to establish collaborations, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our principal stockholders own a significant percentage of our stock and can exert significant control over matters subject to stockholder approval. Two of our directors are affiliated with one of our principal stockholders; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">v</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We leverage our team&#8217;s deep expertise in chemistry and structure-based drug design to develop innovative small molecules that are designed with the aim to overcome the limitations of existing therapies for clinically proven kinase targets.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations faced by currently available kinase inhibitors can include (i) kinase resistance, or the emergence of new mutations in the kinase target that can enable resistance to existing therapies, (ii) kinase selectivity, or the potential for existing therapies to inhibit other structurally similar kinase targets and lead to off-target adverse events, and (iii) limited brain penetrance, or the ability for the therapy to treat disease that has spread or metastasized to the brain. By prioritizing target selectivity, we believe our drug candidates have the potential to overcome resistance, avoid dose-limiting off-target adverse events, address brain metastases, and drive more durable responses. This may result in the potential to drive deeper, more durable responses with minimal adverse events, and we believe these potential benefits may support opportunities for clinical utility earlier in the treatment paradigm.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Zidesamtinib (NVL-520)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our first lead product candidate, zidesamtinib (NVL-520), is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). Zidesamtinib is a novel ROS1-selective inhibitor designed with the aim to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of currently available ROS1 tyrosine kinase inhibitors (TKIs). Zidesamtinib has received FDA Breakthrough Therapy designation for the treatment of patients with locally advanced or metastatic (advanced) ROS1-positive NSCLC who have previously been treated with two or more prior ROS1 TKIs, and orphan drug designation for ROS1-positive NSCLC.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ARROS-1 clinical trial is a first-in-human global Phase 1/2, multicenter, open-label, dose-escalation and expansion study evaluating zidesamtinib as an oral monotherapy in patients with advanced ROS1-positive NSCLC and other solid tumors. Dosing was initiated in the Phase 1 portion of the ARROS-1 clinical trial in January 2022. From January 2022 to August 2023, the Phase 1 portion of the ARROS-1 trial enrolled 104 patients (99 NSCLC, 5 other solid tumors).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we announced the initiation of the Phase 2 portion of the ARROS-1 clinical trial, following alignment with the FDA on a recommended Phase 2 dose (RP2D) of 100 mg once daily (QD). The Phase 2 portion of the ARROS-1 clinical trial is designed to evaluate the safety and activity of zidesamtinib in patients with advanced ROS1-positive NSCLC and other solid tumors, examining several specific cohorts of patients based on the prior anti-cancer therapies that such patients have received. The Phase 2 cohorts have been designed to support potential registration in TKI-na&#239;ve and/or TKI pre-treated ROS1-positive NSCLC patients.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Between September 2023 and June 16, 2025, 435 patients were enrolled in the Phase 2 portion of the ARROS-1 clinical trial. In June 2025, we announced positive pivotal data for zidesamtinib in TKI pre-treated patients with advanced ROS1-positive NSCLC from the global ARROS-1 Phase 1/2 clinical trial, and in September 2025, we presented the pivotal dataset at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer. The primary efficacy analysis population for this pivotal dataset consisted of 117 TKI pre-treated patients with advanced ROS1-positive NSCLC with measurable disease who received zidesamtinib at the RP2D by May 31, 2024, with duration of response (DOR) follow-up of at least 6 months available for nearly all responders.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2025, we also shared preliminary data from the Phase 2 TKI-na&#239;ve cohort in the ARROS-1 clinical trial, in which enrollment is ongoing. Encouraging preliminary data were available for 35 TKI-na&#239;ve patients with advanced ROS1-positive NSCLC treated with zidesamtinib at RP2D as of August 31, 2024. As of June 16, 2025, a total of 104 patients had been enrolled in the ongoing TKI-na&#239;ve cohort of the ARROS-1 trial.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, the FDA accepted for filing our NDA for zidesamtinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who received at least 1 prior ROS1 TKI. The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 18, 2026. Additionally, we plan to submit data from the ongoing TKI-na&#239;ve cohort in the Phase 2 portion of the ARROS-1 clinical trial to the FDA to support a potential label expansion of zidesamtinib in TKI-na&#239;ve patients with advanced ROS1-positive NSCLC in the second half of 2026.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Neladalkib (NVL-655)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our second lead product candidate, neladalkib (NVL-655), is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. Neladalkib is a brain-penetrant ALK-selective inhibitor designed with the aim to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that may limit the use of first-generation (1G; crizotinib), second-generation (2G; ceritinib, alectinib, or brigatinib), and third-generation (3G; lorlatinib) ALK inhibitors. Neladalkib has received FDA Breakthrough Therapy designation for the treatment of patients with locally advanced or metastatic ALK-positive NSCLC who have been previously treated with two or more ALK TKIs, and orphan drug designation for ALK-positive NSCLC.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ALKOVE-1 clinical trial is a first-in-human global Phase 1/2, multicenter, open-label, dose-escalation and expansion study evaluating neladalkib as an oral monotherapy in patients with advanced ALK-positive NSCLC and other solid tumors. Dosing was initiated in the Phase 1 portion of the ALKOVE-1 clinical trial in June 2022. From June 2022 to February 2024, the Phase 1 portion of the ALKOVE-1 clinical trial enrolled 133 patients (131 NSCLC, 2 other solid tumors).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, we announced the initiation of the Phase 2 portion of the ALKOVE-1 clinical trial, following alignment with the FDA on a RP2D of 150 mg QD. The Phase 2 portion of the ALKOVE-1 clinical trial is designed to evaluate the safety and activity of neladalkib in several expansion cohorts of patients defined based on the number and type of prior anti-cancer therapies they have received. The Phase 2 cohorts are designed with registrational intent for TKI pre-treated patients with ALK-positive NSCLC and to enable preliminary evaluation for patients with ALK-positive NSCLC who are TKI-na&#239;ve.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, we announced the initiation of the ALKAZAR Phase 3 clinical trial with registrational intent for TKI-na&#239;ve patients with advanced ALK-positive NSCLC. The ALKAZAR clinical trial is a global, randomized, controlled trial designed to evaluate neladalkib versus the current standard of care. Patients are randomized 1:1 to receive neladalkib monotherapy or ALECENSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(alectinib) monotherapy, reflecting input from collaborating physician-scientists and alignment with global regulatory agencies. The ALKAZAR clinical trial is designed to enroll approximately 450 patients with TKI-na&#239;ve ALK-positive NSCLC. The primary endpoint is progression free survival (PFS) based on Blinded Independent Central Review (BICR). Secondary endpoints include overall survival, PFS based on investigator&#8217;s assessment, time to intracranial response, and BICR assessment of intracranial objective response rate (IC-ORR), intracranial duration of response (IC-DOR), objective response rate (ORR), DOR, time to intracranial progression, and safety.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the European Society for Medical Oncology Congress (ESMO) in October 2025, we presented preliminary data for neladalkib in patients with advanced ALK-positive solid tumors outside of NSCLC from the ongoing ALKOVE-1 clinical trial. Neladalkib demonstrated encouraging preliminary activity across a diverse set of ALK TKI-na&#239;ve and previously treated advanced ALK-positive solid tumors, and was considered generally safe and well-tolerated with a preliminary overall safety profile consistent with its ALK-selective, tropomyosin receptor kinase (TRK)-sparing design, and with previously reported data.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, we announced positive topline data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from the global ALKOVE-1 Phase 1/2 clinical trial. In this topline dataset, data were pooled across Phase 1 and 2 and reported for the primary endpoint of objective response rate (ORR, RECIST 1.1) by BICR. Key secondary endpoints include DOR, IC-ORR, and safety.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the data cut-off date of August 29, 2025, 781 patients with ALK-positive solid tumors had received neladalkib at any starting dose across the Phase 1 and Phase 2 portions of the ALKOVE-1 clinical trial. Of these, 656 patients with advanced ALK-positive NSCLC were treated with neladalkib at the RP2D.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary analysis population consisted of 253 TKI pre-treated patients with advanced ALK-positive NSCLC with measurable disease by BICR who received neladalkib at the RP2D by September 30, 2024, with DOR follow-up of at least 6 months available for nearly all responders.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary analysis population was distinct from the ALK TKI pre-treated populations that have been reported for the currently available ALK TKIs:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients received a median of 3 prior lines of therapy (range, 1 &#8211; 11) and 51% had received prior chemotherapy.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78% of patients had received 2 or more prior ALK TKIs </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#177; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prior chemotherapy, of which 91% had received prior lorlatinib. No approved therapies have demonstrated activity after lorlatinib.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19% of patients had a secondary ALK G1202R resistance mutation, and 17% had a compound ALK resistance mutation, which are key drivers of disease progression.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40% of patients had active CNS disease by BICR at baseline.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the overall TKI pre-treated population, 25% (63/253) of patients were lorlatinib-na&#239;ve. Within this subpopulation:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25% received prior chemotherapy.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100% had received &#8805; 1 prior 2G ALK TKI &#177; prior chemotherapy, of which 70% received prior alectinib only. No patients received crizotinib as their only ALK TKI.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19% of patients had a secondary ALK G1202R mutation.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35% had active CNS disease by BICR at baseline.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Activity was observed across subsets of TKI pre-treated patients, and DOR was assessed as the probability of patients remaining in response for at least 6, 12, and 18 months by Kaplan-Meier estimate (Table 1).</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:48.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:24.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:24.84%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Table 1.</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Any prior ALK TKI<br/>&#177; chemotherapy</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">a</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TKI Pre-treated,<br/>Lorlatinib-na&#239;ve</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">b</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">n</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">253</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ORR, % (n/N)<br/>(95% CI)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31% (79/253)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">c,d</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(26, 37)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46% (29/63)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">e</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(33, 59)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% DOR &#8805; 6 months</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">f</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(95% CI)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76%<br/>(64, 84)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89%<br/>(69, 96)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% DOR &#8805; 12 months</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">f</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(95% CI)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64%<br/>(51, 75)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80%<br/>(58, 91)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% DOR &#8805; 18 months</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">f</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(95% CI)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53%<br/>(34, 68)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60%<br/>(19, 85)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="5" style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">G1202R mutation</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">g</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">n</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ORR, % (n/N)<br/>(95% CI)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68% (32/47)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">h,i<br/></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(53, 81)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83% (10/12)<br/>(52, 98)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% DOR &#8805; 6 months</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">f</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(95% CI)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84%<br/>(65, 93)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90%<br/>(47, 99)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% DOR &#8805; 12 months</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">f</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(95% CI)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80%<br/>(61, 91)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77%<br/>(34, 94)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% DOR &#8805; 18 months</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">f</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(95% CI)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70%<br/>(42, 86)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77%<br/>(34, 94)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="5" style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Measurable CNS lesions</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">n</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">j</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">k</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IC-ORR, % (n/N)<br/>(95% CI)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32% (29/92)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">l,m</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(22, 42)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63% (15/24)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">l</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(41, 81)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IC-CR, % (n/N)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13% (12/92)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">n</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21% (5/24)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">n</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% IC-DOR &#8805; 6 months</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">f</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(95% CI)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81%<br/>(59, 91)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92%<br/>(57, 99)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% IC-DOR &#8805; 12 months</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">f</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(95% CI)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71%<br/>(48, 85)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92%<br/>(57, 99)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% IC-DOR &#8805; 18 months</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">f</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(95% CI)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71%<br/>(48, 85)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92%<br/>(57, 99)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:1.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:97.76%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">a</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Median DOR (mDOR) not reached with median follow-up of 11.3 months.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">b</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">mDOR not reached.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">c</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Includes 2 unconfirmed partial responses (uPRs).</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">d</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Includes responses in patients previously treated with lorlatinib (ORR = 26% (50/190 including 2 uPRs) with mDOR = 17.6 months (95% CI: 6.9, not estimable (NE))).</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">e</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">For patients receiving only 1 prior 2G ALK TKI (alectinib (n = 44) or brigatinib (n = 2)) &#177; chemotherapy, ORR was 48% (22/46) with mDOR not reached, and DOR &#8805; 12 and 18 months of 74% (95% CI: 48, 88).</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">f</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated for responders by Kaplan-Meier analysis.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">g</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ALK G1202R mutation identified in local or central testing of blood or tissue. Patients may have had other mutations in addition to ALK G1202R.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">h</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Includes responses in patients with compound ALK mutations (&#8805; 2 ALK mutations, cis allelic configuration not determined in all cases) after &#8805; 2 prior ALK TKIs (ORR = 58% (25/43, including 1 uPR) with DOR &#8805; 12 months of 69% (95% CI: 45, 84)) and in patients with ALK resistance mutations other than G1202R, including C1156Y, I1171N, I1171T, F1174C, F1174L, V1180L, L1196M, L1198F, D1203N, E1210K, and G1269A.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">i</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Includes 1 uPR.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">j</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">For intracranial (IC) responders, the emerging IC-mDOR was 21.6 months (95% CI: 10.1, NE) and continues to mature.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">k</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">For IC-responders, the emerging IC-mDOR was 21.6 months (95% CI: 21.6, NE) and continues to mature.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">l</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Includes 2 IC-uPRs.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">m</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IC responses were also observed in lorlatinib-experienced patients with measurable CNS lesions at baseline (IC-ORR = 21%, 14/68) with IC-mDOR not reached, IC-DOR &#8805; 6 months of 71% (95% CI: 41, 88), and IC-DOR &#8805; 12 and 18 months of 55% (95% CI: 26, 77).</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">n</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Includes 1 intracranial unconfirmed complete response (IC-uCR) with prior confirmed IC-PR.</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, we also shared preliminary data from the Phase 2 exploratory cohort for TKI-na&#239;ve patients with advanced ALK-positive NSCLC from the ALKOVE-1 study. Encouraging preliminary data were available for 44 TKI-na&#239;ve patients with advanced</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALK-positive NSCLC and measurable disease by BICR. These patients were treated with neladalkib at RP2D in an exploratory cohort of ALKOVE-1, with data cut-off of August 29, 2025. Patients may have received up to one prior line of chemotherapy.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the TKI-na&#239;ve ALK-positive NSCLC population, the preliminary ORR was 86% (38/44; 2 uPRs) and a CR rate of 9% (4/44; 1 uCR with prior confirmed PR) was observed. DOR ranged from 1.7+ to 14.8+ months with DOR &#8805; 6 and 12 months of 91% (95% CI: 70, 98) and only two progression events among responders. In 9 patients with measurable intracranial lesions, the IC-ORR was 78% (7/9) and the intracranial CR rate was 44% (4/9; 1 IC-uCR with prior confirmed IC-PR). The IC-DOR ranged from 3.1+ to 7.0+ months with no CNS progression among responders.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neladalkib demonstrated a generally well-tolerated safety profile consistent with its ALK-selective, TRK-sparing design. In the 656 patients with advanced ALK-positive NSCLC treated at RP2D as of the data cut-off date, the median duration of exposure was 6.0 months (range, 0.1, 28.4). The most frequent treatment-emergent adverse events (TEAEs) occurring in &#8805; 15% of patients were alanine aminotransferase increased (47%), aspartate aminotransferase increased (44%), constipation (28%), dysgeusia (23%), peripheral edema (18%) and cough and nausea (16% each). The most common TEAE of transaminase elevations were generally observed to be asymptomatic lab abnormalities that were low-grade, transient, and reversible with dose interruptions or reductions. Preliminary data suggest increased incidence in less heavily pre-treated patients. Enhanced monitoring for transaminase elevations and prompt dose interventions have been implemented in the protocol for the ALKAZAR Phase 3 randomized, controlled clinical trial. Across the 656 patients treated in ALKOVE-1 at RP2D, dose reductions due to TEAEs occurred in 17% of patients and 5% of patients discontinued treatment due to TEAEs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have completed our pre-NDA meeting with the FDA and plan to move forward with an NDA submission of the data for TKI pre-treated patients with advanced ALK-positive NSCLC from our ALKOVE-1 study of neladalkib in the first half of 2026. We plan to present detailed study results at a future medical meeting.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NVL-330</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our third product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed with the aim to address the combined medical needs of treating tumors driven by HER2 mutations and alterations, including HER2 exon 20 insertion mutations (HER2ex20), treating brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type epidermal growth factor receptor (EGFR). Preclinical data have shown that NVL-330 inhibited a broad range of HER2 oncogenic alterations, including HER2ex20, in cell-based assays, was brain penetrant and was selective for HER2 oncogenic alterations over the structurally related wild-type EGFR. Additionally, new preclinical data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2025, further supporting NVL-330&#8217;s potentially differentiated brain-penetrant profile. Compared to several currently available and investigational HER2 TKIs in the same preclinical assays, NVL-330 demonstrated a favorable efflux ratio and brain partitioning, metrics that are potentially positive predictors of brain exposure in humans. In preclinical models of intracranial activity, NVL-330 induced deep intracranial regression in mice. In the same models, the approved therapies Enhertu (T-DXd) and Hernexeos (zongertinib) did not induce intracranial regression at their clinically relevant doses. Additionally, NVL-330 induced intracranial tumor regression in mice that had progressed in the CNS on zongertinib.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently enrolling patients in the HEROEX-1 clinical trial, a global Phase 1a/1b, multicenter, open-label, dose-escalation and expansion trial evaluating NVL-330 in pre-treated patients with advanced HER2-altered NSCLC, including those with HER2ex20 mutations. In July 2024, we announced that the first patient was dosed with NVL-330 in the HEROEX-1 trial. The HEROEX-1 trial is evaluating the overall safety and tolerability of NVL-330. Additional objectives include determination of the RP2D, characterization of the pharmacokinetic profile, and preliminary evaluation of anti-tumor activity.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Discovery Programs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have prioritized a number of additional small molecule research programs following an assessment of medical need. Research for these programs is ongoing, and we plan to disclose a new development candidate by year-end 2026.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our approach</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our approach is built on four core principles:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patient-driven focus.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We prioritize therapeutic targets where patient needs and limitations of existing therapies can be identified and characterized in partnership with physician-scientists. Leveraging our team&#8217;s deep expertise and experience in drug discovery, we translate those medical insights into detailed target product profiles with well-defined selection criteria to ensure that our product candidates are purpose-built to address specific and current medical needs.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deep expertise in chemistry and structure-based drug design to achieve precise selectivity (&#8220;Threading the needle&#8221;). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We prioritize exquisite target selectivity in the design of our molecules to precisely meet the selection criteria we have pre-defined in our target product profiles. Leveraging our team&#8217;s deep expertise in chemistry and structure-based drug design, we &#8216;thread the needle&#8217; to navigate competing molecular challenges and develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, optimize CNS activity, and drive more durable responses.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Efficient drug discovery and development. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We prioritize programs that may leverage our pipeline discovery and development efforts and experience, with a specific focus on clinically proven kinase targets, with the goal of bringing our therapies to patients as soon as possible. Building on existing discovery tools and processes for the investigation of clinically proven kinase targets, we further leverage our team&#8217;s deep experience in the advancement of oncology product candidates from nomination through product launch, including potential opportunities for accelerated regulatory pathways, to achieve an efficient approach to drug discovery and development.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commercialization of our product candidates, if approved, in key geographies. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We retain full development and worldwide commercialization rights to our pipeline of precisely targeted therapies. We are building a fully integrated, commercial-stage biotechnology company capable of not only discovering and developing, but delivering new medicines for patients living with cancer.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With the continued increase in the adoption of kinase inhibitors as the standard of care across a broadening set of indications, we believe that opportunities to apply our established approach of efficient drug discovery and development will continue to grow.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our programs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently advancing two parallel lead programs in addition to multiple early-stage development and discovery programs, as summarized in Figure 1 below. We hold worldwide development and commercialization rights to our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 1. Our pipeline of kinase inhibitor product candidates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img123481027_1.gif" alt="img123481027_1.gif" style="width:720px;height:335px;"/></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Zidesamtinib (NVL-520, ROS1-Selective inhibitor)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ROS1 rearrangements occur in up to approximately 3% of metastatic NSCLCs. At the time of diagnosis, up to 40% of these patients present with accompanying brain metastases. Beyond NSCLC, ROS1 rearrangements have also been reported across a wide range of solid tumors as well as lymphoma.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are four FDA-approved TKIs for the treatment of patients with ROS1-positive NSCLC: Xalkori (crizotinib), Rozlytrek (entrectinib), Augtyro (repotrectinib), and Ibtrozi (taletrectinib). Additional treatment options for patients who are TKI pre-treated include the TKI lorlatinib, recommended for use according to the National Comprehensive Cancer Network (NCCN) guidelines, chemotherapy with or without immunotherapy, or experimental therapies in clinical trials. The current standard of care for TKI-na&#239;ve patients with ROS1-positive NSCLC is crizotinib. There is no clear standard of care for TKI pre-treated patients with ROS1-positive NSCLC.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Zidesamtinib is a brain-penetrant ROS1-selective inhibitor designed with the aim to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with the prevalent G2032R resistance mutation and those with the S1986Y/F, F2004C, F2004V, L2026M, D2033N, or G2101A resistance mutations. We believe we have optimized zidesamtinib for brain penetrance and ROS1 selectivity to potentially improve treatment options for patients with brain metastases and avoid CNS adverse events related to off-target inhibition of the structurally related TRK family.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently investigating zidesamtinib in the Phase 2 portion of our ARROS-1 clinical trial, a first-in-human global Phase 1/2, multicenter, open-label, dose-escalation and expansion study evaluating zidesamtinib as an oral monotherapy in patients with advanced ROS1-positive NSCLC and other solid tumors. The Phase 1 dose-escalation portion of the ARROS-1 clinical trial was conducted in patients with advanced ROS1-positive NSCLC or other solid tumors who had received at least one prior ROS1 TKI or any prior therapy, respectively, and evaluated the safety, tolerability and RP2D of zidesamtinib, among other objectives. Upon determination of the RP2D (100 mg QD), the trial transitioned into the ongoing Phase 2 portion designed to evaluate zidesamtinib in patients with advanced ROS1-positive NSCLC and other solid tumors and to support potential registration of zidesamtinib in TKI-na&#239;ve and/or TKI pre-treated ROS1-positive NSCLC patients.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, the FDA accepted for filing our NDA for zidesamtinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who received at least 1 prior ROS1 TKI. The application has been assigned a PDUFA target action date of September 18, 2026. Additionally, we plan to submit data from the ongoing TKI-na&#239;ve cohort in the Phase 2 portion of the ARROS-1 trial to the FDA to support a potential label expansion of zidesamtinib in TKI-na&#239;ve patients with advanced ROS1-positive NSCLC in the second half of 2026.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neladalkib (NVL-655, ALK-Selective inhibitor)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALK rearrangements occur in approximately 5% of metastatic NSCLCs. At the time of initial diagnosis, up to 40% of these patients present with accompanying brain metastases. Beyond NSCLC, ALK fusions have also been reported in various other solid tumors as well as lymphoma.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are six FDA-approved TKIs for the treatment of patients with ALK-positive NSCLC: Xalkori (crizotinib), Zykadia (ceritinib), Alecensa (alectinib), Alunbrig (brigatinib), Lorbrena (lorlatinib), and Ensacove (ensartinib). Additional treatment options for patients who are TKI pre-treated include chemotherapy with or without immunotherapy, or experimental therapies in clinical trials. The current standard of care for TKI-na&#239;ve patients with ALK-positive NSCLC is alectinib, which had an estimated $1.9 billion in reported global 2025 net sales. Following treatment with alectinib, the current second-line TKI standard of care is lorlatinib with an estimated $1.0 billion in reported global 2025 net sales across all indications. There is no clear third-line TKI standard of care for patients with ALK-positive NSCLC.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neladalkib is a brain-penetrant ALK-selective inhibitor designed with the aim to remain active in tumors that have developed resistance to first-, second-, and third-generation ALK inhibitors, including tumors with the G1202R resistance mutation or compound resistance mutations, including G1202R/L1196M, G1202R/G1269A, or G1202R/L1198F. We believe we have optimized neladalkib for brain penetrance and ALK selectivity to potentially improve treatment options for patients with brain metastases and avoid CNS adverse events related to off-target inhibition of the structurally related TRK family.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently investigating neladalkib in the Phase 2 portion of our ALKOVE-1 clinical trial, a first-in-human global Phase 1/2, multicenter, open-label, dose-escalation and expansion study evaluating neladalkib as an oral monotherapy in patients with advanced ALK-positive NSCLC and other solid tumors. The Phase 1 dose-escalation portion of the ALKOVE-1 clinical trial was conducted in patients with advanced ALK-positive NSCLC or other solid tumors who had received at least one prior ALK TKI or at least one prior systemic anticancer therapy, respectively, and evaluated the safety, tolerability and RP2D of neladalkib, among other objectives. Upon determination of the RP2D (150 mg QD), the trial transitioned into the ongoing Phase 2 portion designed to evaluate neladalkib in patients with advanced ALK-positive NSCLC and other solid tumors, to support potential registration of neladalkib for TKI pre-treated patients with ALK-positive NSCLC, and to enable preliminary evaluation for patients with ALK-positive NSCLC who are TKI-na&#239;ve.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have completed our pre-NDA meeting with the FDA and plan to move forward with an NDA submission of the data for TKI pre-treated patients with advanced ALK-positive NSCLC from our ALKOVE-1 study of neladalkib in the first half of 2026. We plan to present detailed study results at a future medical meeting.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also investigating neladalkib in the ALKAZAR Phase 3 clinical trial with registrational intent for TKI-na&#239;ve patients. The ALKAZAR clinical trial is a global, randomized, controlled trial evaluating neladalkib versus the current standard of care, alectinib, for the treatment of patients with TKI-na&#239;ve ALK-positive NSCLC.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NVL-330 (HER2-Selective inhibitor)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mutations and alterations in HER2 are oncogenic and are found in approximately 3% of cancers, including up to 4% of advanced NSCLC patients. Within NSCLC, 90% of HER2 mutations occur through HER2ex20. HER2 mutations have also been identified in multiple cancers, including breast, esophageal, endometrial, bladder, colorectal, skin, ovarian, head and neck, and cervical. Brain metastases are present at diagnosis in an estimated 19% of HER2 mutant-positive NSCLC patients, and more patients will develop them during treatment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are two HER2 inhibitors approved by the FDA for the treatment of HER2-altered NSCLC: Hernexeos (zongertinib) and Hyrnuo (sevabertinib). Additionally, Enhertu (T-DXd), an antibody-drug conjugate, has been approved by the FDA for the treatment of HER2 mutant NSCLC.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NVL-330 is a brain-penetrant HER2-selective inhibitor which we believe we have optimized for selectivity versus the structurally related wild-type EGFR that is associated with dose-limiting side effects including skin rash and gastrointestinal toxicity. We are currently investigating NVL-330 in our HEROEX-1 clinical trial, a first-in-human global Phase 1a/1b, multicenter, open-label, dose-escalation and expansion trial evaluating NVL-330 as an oral monotherapy in pre-treated patients with advanced HER2-altered NSCLC, including those with HER2ex20 mutations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discovery programs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to evaluate new program areas with a focus on addressing the limitations of existing therapies for other clinically proven kinase targets in oncology. As treatment landscapes evolve, we also continue to work with our physician-scientist partners to anticipate emerging patient needs in established areas of development and leverage our existing expertise in the area with the aim to efficiently discover and develop new product candidates with the potential to comprehensively address those emerging challenges. We believe that opportunities to apply our established model of efficient drug discovery and development continue to expand, and align with the increasing adoption of kinase inhibitors as standard of care across a broadening set of indications. We plan to disclose a new development candidate by year-end 2026.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OnTarget 2026 operating plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OnTarget 2026 delineates our three-year operating plan towards bringing new, potential best-in-class medicines to patients with cancer and is summarized in Figure 2 below. As part of this plan announced in January 2024, we completed the below milestones in 2024 and 2025:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024: Execute on Global Registrational Strategies</span></div></div><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#10003;   </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Progress the Phase 2 portion of the ARROS-1 trial of zidesamtinib in patients with advanced ROS1-positive NSCLC with registrational intent;</span></p><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#10003;   </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initiate the Phase 2 portion of the ALKOVE-1 trial of neladalkib in patients with advanced ALK-positive NSCLC with registrational intent;</span></p><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#10003;   </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Launch our front-line development strategy for our ALK program;</span></p><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#10003;   </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Present interim data from the ongoing ARROS-1 and ALKOVE-1 clinical trials at medical meetings; and</span></p><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#10003;   </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initiate a Phase 1 trial for our HER2 program.</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025: First Pivotal Data</span></div></div><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#10003;   </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report pivotal data for TKI pre-treated patients with advanced ROS1-positive NSCLC from our ARROS-1 Phase 1/2 trial of zidesamtinib in the first half of 2025;</span></p><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#10003;   </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Complete a rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC in the third quarter of 2025;</span></p><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#10003;   </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report pivotal data for TKI pre-treated patients with advanced ALK-positive NSCLC from our ALKOVE-1 Phase 1/2 trial of neladalkib by year-end 2025;</span></p><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#10003;   </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initiate the ALKAZAR Phase 3 randomized, controlled trial of neladalkib for TKI-na&#239;ve patients with ALK-positive NSCLC early in the second half of 2025; and</span></p><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#10003;   </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Progress the HEROEX-1 Phase 1a/1b trial of NVL-330 for patients with advanced HER2-altered NSCLC.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2026, we outlined anticipated milestones for 2026, leading to our first potential U.S. commercial launch:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026: First Approved Product</span></div></div><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    Commercial launch in the U.S. of zidesamtinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who received at least 1 prior ROS1 TKI, pending FDA review;</span></p><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    Submit data to the FDA for potential label expansion of zidesamtinib in TKI-na&#239;ve patients with advanced ROS1-positive NSCLC in the second half of 2026;</span></p><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    Submit an NDA for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC in the first half of 2026;</span></p><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    Progress the ongoing ALKAZAR Phase 3 randomized, controlled trial of neladalkib for TKI-na&#239;ve patients with ALK-positive NSCLC;</span></p><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    Progress the ongoing HEROEX-1 Phase 1a/1b trial of NVL-330 for patients with advanced HER2-altered NSCLC; and</span></p><p style="margin-left:2.533%;text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    Disclose a new development candidate by year-end 2026.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 2. OnTarget 2026 Operating Plan: The Path to Patient Impact</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img123481027_2.gif" alt="img123481027_2.gif" style="width:720px;height:396px;"/></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our team</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have assembled a management team of biopharmaceutical industry veterans with extensive experience in developing novel oncology therapies from research through commercialization.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our seasoned leadership team has broad experience at both large global organizations, including C.H. Boehringer Sohn AG &amp; Ko. KG, Pfizer, Sanofi S.A., EMD Serono, GlaxoSmithKline plc, and BeiGene, Ltd., as well as established biotech companies, including Infinity, Agios Pharmaceuticals Inc., Blueprint Medicines Corporation, and ARIAD Pharmaceuticals, Inc. Together, our leadership team has contributed directly to the regulatory approval of 12 therapies, including five kinase inhibitors, nine oncology therapeutics, and 10 small molecules: CLOLAR/Evoltra (clofarabine), FABRAZYME (agalsidase beta), COPIKTRA (duvelisib), BRUKINSA (zanubrutinib), MOZOBIL (plerixafor injection), BAVENCIO (avelumab), TIBSOVO (ivosidenib tablets), TIVICAY (dolutegravir), ICLUSIG (ponatinib), GAVRETO (pralsetinib), ALUNBRIG (brigatinib) and PYRUKYND (mitapivat).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our values</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our three core values are:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patient Impact</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We care deeply about what we are building to change the future for patients.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Empowerment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We are all responsible for delivering on our mission to develop new medicines for patients: listen, speak up, and engage.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We know that we are better together and thrive when we challenge each other to find a better way for patients.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our strategy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our goal is to be a leading biopharmaceutical company that translates our deep expertise in structure-based drug design to discover, develop, and deliver novel, selective therapeutics that enable durable responses for patients with cancer. The key elements of our strategy include:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtain regulatory approval for zidesamtinib, our first lead product candidate and a differentiated ROS1-selective inhibitor, for TKI pre-treated patients with ROS1-positive NSCLC and advance toward potential label expansion in TKI-na&#239;ve patients with ROS1-positive NSCLC. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has accepted for filing our NDA for zidesamtinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who received at least 1 prior ROS1 TKI, and assigned a PDUFA target action date of September 18, 2026. Additionally, we plan to submit data from the ongoing TKI-na&#239;ve cohort in the Phase 2 portion of the </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARROS-1 clinical trial to the FDA to support a potential label expansion of zidesamtinib in TKI-na&#239;ve patients with advanced ROS1-positive NSCLC in the second half of 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advance the ongoing clinical development of neladalkib, our second lead product candidate and a differentiated ALK-selective inhibitor, through the Phase 2 portion of our ALKOVE-1 study designed to support potential regulatory approval for patients with TKI pre-treated ALK-positive NSCLC. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical investigation is ongoing in the Phase 2 portion of our ALKOVE-1 study, a first-in-human, global Phase 1/2 clinical trial investigating neladalkib in advanced ALK-positive NSCLC and other solid tumors. Neladalkib has received FDA Breakthrough Therapy designation for the treatment of patients with locally advanced or metastatic ALK-positive NSCLC who have been previously treated with two or more ALK TKIs. In November 2025, we announced positive topline data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from the ALKOVE-1 Phase 1/2 clinical trial. We have completed our pre-NDA meeting with the FDA and plan to move forward with an NDA submission of the data for TKI pre-treated patients with advanced ALK-positive NSCLC from our ALKOVE-1 study of neladalkib in the first half of 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commercialize our product candidates, including, if approved, zidesamtinib and neladalkib, in key geographies and opportunistically pursue strategic collaborations to maximize the full potential of our pipeline. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We retain full development and worldwide commercialization rights to our pipeline of precisely targeted therapies. We are building a fully integrated, commercial-stage biotechnology company capable of not only discovering and developing, but delivering new medicines for patients living with cancer. We are actively building the commercial infrastructure required, including our focused sales, market access, and marketing organization, to support our potential U.S. commercial launch of zidesamtinib for TKI pre-treated patients with ROS1-positive NSCLC in 2026, if approved, as well as planning for U.S. commercial launch readiness for neladalkib, as well as potential label expansions for both programs. In the future, we may enter into strategic collaborations around certain targets, product candidates, disease areas, or geographies, if we believe these collaborations could accelerate the development and commercialization of our product candidates and allow us to realize the full potential of our pipeline.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Progress our ALKAZAR Phase 3 randomized, controlled trial of neladalkib versus ALECENSA (alectinib), designed to support potential regulatory approval for patients with TKI-na&#239;ve ALK-positive NSCLC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Clinical investigation is ongoing in our ALKAZAR clinical trial, a global, Phase 3, randomized, controlled trial evaluating neladalkib versus the current standard of care. The ALKAZAR clinical trial is designed to enroll approximately 450 patients with TKI-na&#239;ve ALK-positive NSCLC, randomized 1:1 to receive neladalkib monotherapy or ALECENSA (alectinib) monotherapy, reflecting input from collaborating physician-scientists and alignment with global regulatory agencies and patients.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Progress our other development and discovery stage programs, including for HER2-altered NSCLC, while continuing to expand our pipeline of precisely targeted novel product candidates. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We prioritize clinically proven kinase targets where the design of exquisitely selective inhibitors may overcome challenges of existing therapies including kinase resistance, kinase selectivity, and limited CNS activity. We intend to develop product candidates as monotherapy treatment and may also strategically pursue the development of synergistic combinations. We are progressing our HEROEX-1 Phase 1a/1b clinical trial of NVL-330 for patients with advanced HER2-altered NSCLC and plan to disclose a new development candidate by year-end 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Continue to partner with physician-scientists to characterize current and emerging medical needs for patients and the limitations of existing therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We prioritize clinically proven kinase targets where clear remaining or emerging medical needs for patients can be defined by our physician-scientist partners, and where we believe those needs can be addressed through the design of highly selective small molecule inhibitors. Combining clinical insight with our drug design capabilities and our development expertise, we seek to meet real-world medical needs through the development of detailed product profiles and well-defined selection criteria. Accordingly, we plan to disclose a new development candidate by year-end 2026. We believe this approach maximizes our opportunity to address the challenges of existing therapies and develop molecules that achieve deep, durable responses with minimal adverse events.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. While we believe that our technology, the expertise of our team, and our development experience and scientific knowledge provide us with competitive advantages, we face competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product candidates that we successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future, and we cannot predict what the standard of care will be as our product candidates progress through clinical development into commercialization. We believe the key competitive factors affecting the success of all of our programs are likely to be efficacy, including DOR, safety, and patient convenience. Potentially competitive therapies fall primarily into the following groups of treatment:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">traditional cancer therapies, including surgery, radiation, and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy or a combination of such methods;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approved kinase inhibitors, including FDA-approved ROS1 TKIs (Xalkori, Rozlytrek, Augtyro, and Ibtrozi marketed by Pfizer, Roche, Bristol-Myers Squibb Company, and Nuvation Bio Inc., respectively), FDA-approved ALK TKIs (Xalkori, Zykadia, Alecensa, Alunbrig, Lorbrena and Ensacove, marketed by Pfizer, Novartis AG, Chugai Pharmaceutical Co. Ltd./Roche, Takeda Pharmaceutical Company Limited, Pfizer, and Xcovery Holdings, Inc., respectively), FDA-approved HER2 TKIs (Hernexeos and Hyrnuo, marketed by Boehringer Ingelheim and Bayer HealthCare Pharmaceuticals, respectively) and FDA-approved antibody drug conjugate (Enhertu, jointly marketed by Daiichi Sankyo and AstraZeneca);</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ROS1 TKIs in clinical development;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALK TKIs in clinical development;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HER2ex20 TKIs in clinical development;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TKIs not approved but recommended for use in the NCCN guidelines; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other therapies targeting kinases, including antibody or antibody-drug conjugate approaches, that are approved or in clinical development.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the market, and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Some cancer treatments are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. In addition, our competitors may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market will pose challenges.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Sharing Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Sharing Agreement with Deerfield</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are party to an Amended and Restated Revenue Sharing Agreement with Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund IV, L.P. (collectively, Deerfield) pursuant to which we are obligated to pay Deerfield a fixed low single-digit percentage rate of net sales of certain commercial products discovered, identified or generated by us during the period commencing on February 2, 2017 and ending on the date that is the earlier of (i) five years after Deerfield&#8217;s last investment in our capital stock and (ii) the fifth anniversary of our initial public offering. Any payments in respect of such products would be through the later of 12 years from the first commercial sale in a country or the expiration of the last-to-expire patent in that country. To date, we have not recorded any net sales and, as a result, have not paid any amounts under this agreement. There are no upfront fees or milestone payments required to be paid by us under this agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Sharing Agreement with our scientific founder</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are party to an Amended and Restated Revenue Sharing Agreement with our scientific founder, Matthew Shair, Ph.D., pursuant to which we were obligated to pay Dr. Shair 1.5% of net sales of certain commercial products that either have a mechanism of action of (i) ROS1 inhibition and contain zidesamtinib or a backup compound substituted therefor in the event of a product development failure or (ii) ALK inhibition and contain neladalkib or a backup compound substituted therefor in the event of a product development failure, in each case through the later of 12 years from the first commercial sale in a country or the expiration of the last-to-expire patent in that country. Dr. Shair assigned this agreement to Royalty Pharma plc (Royalty Pharma) in December 2025 and, as a result, any payments we are obligated to make under the agreement will be made to Royalty Pharma. To date, we have not recorded any net sales and, as a result, have not paid any amounts under this agreement. There are no upfront fees or milestone payments required to be paid by us under this agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on our ability (i) to obtain and maintain patent and other proprietary and/or intellectual property rights and protection for our technology, inventions, and improvements; (ii) to protect and preserve the confidentiality of our trade secrets; (iii) to defend and enforce our proprietary and intellectual property rights, including any patents that we may own or license in the future; and (iv) to operate without infringing the valid and enforceable patents and other proprietary and/or intellectual property rights of third parties.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We wholly own Patent Cooperation Treaty (PCT) applications, U.S. patent applications, U.S. patents, U.S. provisional patent applications, foreign patents, and foreign patent applications relating to our lead and planned product candidates. We strive to protect our proprietary position by, among other methods, filing patent applications in the U.S. and in jurisdictions outside of the U.S. directed to our proprietary technology, inventions, improvements, and product candidates that are important to the development and implementation of our business. We also rely on trade secrets and know-how relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position in the field of oncology. Our strategic plans also include reliance on data exclusivity, market exclusivity, and patent term extensions when available.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to stop third parties from making, using, selling, offering to sell, or importing products identical or similar to ours will depend on the extent to which we have rights under valid and enforceable patents, trade secrets, or other intellectual property rights that cover these activities. The patent rights of biotechnology and pharmaceutical companies like ours are generally uncertain and can involve complex legal, scientific, and factual issues. Our and any future licensor&#8217;s current and future patent applications may not result in the issuance of any patent in any particular jurisdiction, and the claims of any current or future issued patents, even if those claims are valid and enforceable, may not provide sufficient protection from competitors. Any owned or in-licensed patent rights we may obtain may not enable us to prevent others from replicating, manufacturing, using, or administering our product candidates for any indication. Moreover, the subject matter initially claimed in a patent application may be significantly reduced before a patent is issued, and a patent&#8217;s scope can be reinterpreted after issuance. In addition, any patent we may own or in-license may be challenged, circumvented or invalidated by third parties. As a result, we cannot ensure that any of our product candidates will be protected by valid and enforceable patents.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have filed certain patent applications directed generally to compositions of matter, pharmaceutical formulations, and therapeutic methods of using the foregoing related to our ROS1, ALK, and HER2 programs, as summarized below. We also possess substantial know-how and trade secrets relating to the development and commercialization of our product candidates, including related manufacturing processes and technology. In addition, we own certain registered trademarks and pending trademark applications in the U.S. and other countries.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to our ROS1 program, we own one pending PCT patent application, five pending U.S. patent applications, three issued U.S. patents, 61 pending foreign patent applications, and three issued foreign patents directed to compositions of matter for our ROS1 inhibitory compounds (e.g., zidesamtinib) and related solid forms as well as methods of use. Any U.S. or foreign patent that has issued or may issue based on the pending patent applications is expected to expire no earlier than 2041, not including any patent term adjustments or patent term extensions that may be awarded. With respect to our ALK program, we own two pending PCT patent applications, three pending U.S. patent applications, two issued U.S. patents, two pending U.S. provisional patent applications, 60 pending foreign patent applications, and three issued foreign patents directed to compositions of matter for our ALK inhibitory compounds (e.g., neladalkib) and related solid forms as well as methods of use. Any U.S. or foreign patent that has issued or may issue based on the pending patent applications is expected to expire no earlier than 2041, not including any patent term adjustments or patent term extensions that may be awarded. With respect to our HER2 program, we own one pending U.S. patent application, one issued U.S. patent, 25 pending foreign patent applications, and two issued foreign patents directed to compositions of matter for our HER2 inhibitory compounds (e.g., NVL-330) and related methods of use. Any U.S. or foreign patent that has issued or may issue based on the pending patent applications is expected to expire no earlier than 2042, not including any patent term adjustments or patent term extensions that may be awarded.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our pending and planned applications may not result in issued patents and we cannot provide any assurance that any patents that might be issued in the future will protect our current and future product candidates or provide us with any competitive advantage. Moreover, U.S. provisional patent applications are not eligible to become issued patents until, among other things, we file a non-provisional patent application within 12 months of the filing of the related provisional patent applications. With regard to our provisional patent applications, if we do not timely file one or more non-provisional patent applications, we may lose our priority date with respect to our provisional patent applications and therefore any patent protection on the inventions disclosed in such provisional patent applications. While we intend to timely file one or more non-provisional patent applications relating to our provisional patent applications, we cannot predict whether any such patent applications will result in the issuance of patent(s) that provide us with any competitive advantage. For more information regarding the risks related to our intellectual property, please see &#8220;Risk Factors&#8212;Risks related to our intellectual property.&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We retain full development and worldwide commercialization rights to our product candidates. We are actively building the commercial infrastructure required, including our focused sales, market access, and marketing organization, to support our potential U.S. commercial launch of zidesamtinib for TKI pre-treated patients with ROS1-positive NSCLC in 2026, if approved, as well as planning for U.S. commercial launch readiness for neladalkib, as well as potential label expansions for both programs. We plan to commercialize zidesamtinib and neladalkib, if approved, on our own in the U.S. We intend to explore commercialization on our own, or potentially with a collaboration partner, in jurisdictions outside of the U.S. for these product candidates, if approved. Clinical data, the size of the addressable patient population, and the size of the commercial infrastructure and manufacturing needs all influence our current and future commercialization plans.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacturing if any of our product candidates obtain marketing approval. We also rely, and expect to continue to rely, on third parties to package, label, store and distribute our investigational product candidates, as well as our commercial products if marketing approval is obtained.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment, and personnel while also enabling us to focus our expertise and resources on the development and commercialization, if approved, of our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our product candidates are small molecules and are manufactured in synthetic processes from available starting materials. The chemistry appears amenable to scale-up and does not currently require unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Currently, active pharmaceutical ingredients (API) (i.e., drug substance) for zidesamtinib, neladalkib and NVL-330 are manufactured in accordance with current good manufacturing practices (cGMPs). The drug product formulation is being developed with the goal of producing tablets with consistent, immediate release dissolution profiles that can be reproducibly manufactured using automated equipment. All manufacturing activities for zidesamtinib, neladalkib and NVL-330 drug products are performed in accordance with cGMPs and we currently rely on the vendors performing these manufacturing activities as single-source contract manufacturing organizations (CMOs).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are continuing to develop our supply chain for each of our product candidates and have or intend to put in place framework agreements under which third-party CMOs will generally provide us with necessary quantities of API and drug product on a project-by-project basis based on our development needs, as well as for commercial manufacturing needs if any of our product candidates obtain marketing approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we advance our product candidates through development and, if approved, into commercialization, we will continue to explore adding additional backup suppliers across the supply chain, including for key starting material, API and drug product for each of our product candidates to protect against any potential supply disruptions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We generally expect to rely on third parties for the manufacture of any companion diagnostics we may develop.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, there are no assurances that our manufacturing and supply chain infrastructure will remain uninterrupted and reliable, or that the third parties we rely on will be able to satisfy our demand in a timely manner and not have supply chain disruptions due to stock-outs or raw material shortages and/or greater than anticipated demand or quality issues given the operational challenges and raw material shortages that have been experienced in the past.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government regulation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The research, development, testing, manufacture, quality control, packaging, labeling, storage, record-keeping, distribution, import, export, promotion, advertising, marketing, sale, pricing and reimbursement of drug products are extensively regulated by governmental authorities in the U.S. and other countries and jurisdictions, including the European Union (EU). The processes for obtaining regulatory approvals in the U.S. and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory requirements, both pre-approval and post-approval, require the expenditure of substantial time and financial resources. The regulatory requirements applicable to drug product development, approval and marketing are subject to change, and regulations and administrative guidance often are revised or reinterpreted by the agencies in ways that may have a significant impact on our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. Government Regulation of Drug Products</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., the FDA approves and regulates human drug products under the Federal Food, Drug, and Cosmetic Act (FDCA). A company, institution, or organization that takes responsibility for the initiation and management of a clinical development program for such products is typically referred to as a sponsor. The failure of a sponsor to comply with applicable U.S. requirements may result in FDA delays or refusal to approve pending NDAs, and may subject the sponsor to administrative or judicial sanctions, such as issuance of warning letters, or the imposition of fines, civil penalties, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or civil or criminal prosecution brought by the FDA and the U.S. Department of Justice or other governmental entities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA must approve our product candidates for therapeutic indications before they may be marketed in the U.S. A sponsor seeking approval to market and distribute a new drug product in the U.S. must satisfactorily complete each of the following steps:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of preclinical laboratory tests, animal studies and formulation studies according to good laboratory practices (GLP) regulations or other applicable regulations;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">design of a clinical protocol and submission to the FDA of an IND, which must become effective before human clinical trials may begin and must be updated when certain changes are made;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an independent institutional review board (IRB) or ethics committee representing each clinical trial site before each clinical trial may be initiated;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practices (GCPs) and other clinical-trial related regulations to evaluate the safety and efficacy of the investigational product for each proposed indication;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation and submission to the FDA of an NDA requesting marketing approval for one or more proposed indications, including payment of application user fees;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of user fees pursuant to PDUFA;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review of the NDA by an FDA advisory committee, where applicable;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug is produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality, and purity;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of any FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data submitted in support of the NDA; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the NDA, which may be subject to additional post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (REMS), and any post-approval studies required by the FDA.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Studies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before a sponsor begins testing a product candidate with potential therapeutic value in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, formulation, and stability, as well as other studies to evaluate, among other things, the toxicity of the product candidate. These studies are typically referred to as IND-enabling studies. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">standards and the U.S. Department of Agriculture&#8217;s Animal Welfare Act, if applicable</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and long-term toxicity studies, may continue after the IND is submitted.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The IND and IRB Processes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. An IND must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an approved NDA. The FDA will review an IND to assure the safety and rights of patients and to help assure that the quality of the investigation will be adequate to permit an evaluation of the investigational drug product. In support of a request for an IND, sponsors must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial may proceed. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a partial clinical hold might state that a specific protocol or part of a protocol may not proceed, while other parts of a protocol or other protocols may do so. No more than 30 days after the imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following the issuance of a clinical hold or partial clinical hold, a clinical investigation may only resume once the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed or recommence. Occasionally, clinical holds are imposed due to manufacturing issues that may present safety issues for the clinical study subjects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB, which must operate in compliance with FDA regulations, must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects and must monitor the trial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">until completed. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data monitoring committee (DMC). This group provides authorization as to whether or not a trial may move forward at designated checkpoints based on review of available data from the study, to which only the DMC maintains access. Suspension or termination of development during any phase of a clinical trial can occur if the DMC determines that the participants or patients are being exposed to an unacceptable health risk.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expanded Access</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational new products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational products for patients who may benefit from investigational therapies. The FDA&#8217;s regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or Treatment IND Application.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational product for the requested treatment will not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no obligation for a sponsor to make its investigational products available for expanded access; however, as required by amendments to the FDCA included in the 21</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Century Cures Act (the Cures Act), passed in 2016, if a sponsor has a policy regarding how it responds to expanded access requests with respect to product candidates in development to treat serious diseases or conditions, it must make that policy publicly available. Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 study for a covered investigational product; or 15 days after the investigational product receives designation from the FDA as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a manufacturer to make its products available to eligible patients as a result of the Right to Try Act, but the manufacturer must develop an internal policy and respond to patient requests according to that policy.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Human Clinical Trials</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational product candidate to human subjects under the supervision of a qualified investigator in accordance with GCP requirements which include, among other things, the requirement that all research subjects provide their informed consent in writing before they participate in any clinical trial. Clinical trials are conducted under written clinical trial protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol, and any subsequent material amendment to the protocol, must be submitted to the FDA as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may also be required after approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials are initially conducted in a limited population, which may be healthy volunteers or subjects with the target disease, to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics in healthy humans or in patients. During Phase 1 clinical trials, information about the product candidate&#8217;s pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. Phase 2 clinical trials are typically well-controlled and closely monitored.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken using a larger patient population to further evaluate dosage, provide substantial evidence of clinical efficacy, and further test for safety in an expanded and diverse patient population at multiple geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 clinical trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a new prescription drug product. Such Phase 3 clinical trials are referred to as &#8220;pivotal&#8221; trials. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company&#8217;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Moreover, as noted above, a pivotal trial is a clinical trial that is believed to satisfy FDA requirements for the evaluation of a product candidate&#8217;s safety and efficacy such that it can be used, alone or with other pivotal or non-pivotal trials, to support regulatory approval. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, the FDA may approve an NDA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety and effectiveness after approval. Such post-approval trials, typically referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of a larger number of patients in the intended treatment group. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials, such as to verify clinical benefit in the case of products approved under accelerated approval regulations. Failure to exhibit due diligence with regard to conducting mandatory Phase 4 clinical trials could result in withdrawal of FDA approval for products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022, the FDA released final guidance entitled &#8220;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#8221; which outlines how developers can utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology product development (i.e., the first-in-human clinical trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by the FDA. Expansion cohort trials can potentially bring efficiency to product development and reduce developmental costs and time.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2023, the FDA issued draft guidance with updated recommendations for GCPs aimed at modernizing the design and conduct of clinical trials. The updates are intended to help pave the way for more efficient clinical trials to facilitate the development of medical products. The draft guidance is adopted from the International Council for Harmonisation&#8217;s recently updated E6(R3) draft guideline that was developed to enable the incorporation of rapidly developing technological and methodological innovations into the clinical trial enterprise. In addition, the FDA issued draft guidance outlining recommendations for the implementation of decentralized clinical trials.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, with the passage of the Food and Drug Omnibus Reform Act (FDORA), Congress required sponsors to develop and submit a diversity action plan (DAP) for each Phase 3 clinical trial or any other &#8220;pivotal trial&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically, action plans must include the sponsor&#8217;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them. In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans (DAPs). In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for DAPs. Unlike most guidance documents issued by the FDA, the DAP guidance when finalized will have the force of law, because FDORA specifically dictates that the form and manner for submission of DAPs are to be specified in FDA guidance. On January 27, 2025, in response to an Executive Order issued by President Trump on January 21, 2025 regarding diversity, equity and inclusion programs, the FDA removed this draft guidance from its website. This action raises questions about the applicability of statutory obligations to submit DAPs and the FDA&#8217;s current thinking on best practices for clinical development.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Typically, clinical trials are designed in consultation with the FDA or foreign regulatory authorities during these development phases. The indications under development can influence the study designs employed during the conduct of clinical trials, such as for a first-line cancer treatment indication which may require head-to-head comparison data demonstrating clinical superiority or non-inferiority to currently available therapies. The timeline for first-line cancer indication development programs may also be longer than for indications sought in subsequent or later lines of treatment due to a desire for regulatory authorities to expedite access to treatments for patients whose cancer has progressed on prior treatments and in settings where there may be no available therapy option. As such, many new oncology products initially seek an indication for second or third-line treatment, which may be a smaller available treatment population in any oncology indication that has limited or no other therapy options, with subsequent development sought for those products in earlier front lines of treatment which target a larger treatment population and may require the conduct of additional clinical trials to provide comparative data against an available therapy option to show clinical superiority.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Studies Outside the U.S. in Support of FDA Approval</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with our clinical development program, we have trial sites outside the U.S. When a foreign clinical trial is conducted under an IND, all IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the trial complies with certain regulatory requirements of the FDA in order to use the trial as support for an IND or application for marketing approval. Specifically, the studies must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee (IEC) and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. The regulations further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The acceptance by the FDA of trial data from clinical trials conducted outside the U.S. in support of U.S. approval may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone, unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, even where the foreign trial data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval, unless the trial is well-designed and well-conducted in accordance with GCP requirements, and the FDA is able to validate the data from the trial through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reporting Clinical Trial Results</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsors of clinical trials of certain FDA-regulated products, including prescription drugs, are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the U.S. National Institutes of Health (NIH). In particular, information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Although sponsors are also obligated to disclose the results of their clinical trials after completion, disclosure of the results can be delayed in some cases for up to two years after the date of completion of the trial. The NIH&#8217;s Final Rule on registration and reporting requirements for clinical trials became effective in 2017.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Public Health Service Act grants the Secretary of Health and Human Services the authority to issue a notice of noncompliance to a responsible party for failure to submit clinical trial information as required. The responsible party, however, is allowed 30 days to correct the noncompliance and submit the required information. The FDA regularly issues notices of non-compliance, thereby signaling the government&#8217;s willingness to enforce these requirements against non-compliant clinical trial sponsors. While these notices of non-compliance did not result in civil monetary penalties, the failure to submit clinical trial information to clinicaltrials.gov is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues. Violations may also result in injunctions and/or criminal prosecution or disqualification from federal grants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interactions with the FDA During the Clinical Development Program</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the clearance of an IND and the commencement of clinical trials, the sponsor will continue to have interactions with the FDA. Progress reports detailing the results of clinical trials must be submitted annually within 60 days of the anniversary dates that the IND went into effect and more frequently if serious adverse events occur. These reports must include a development safety update report. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the occurrence of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, sponsors are given opportunities to meet with the FDA at certain points in the clinical development program. Specifically, sponsors may meet with the FDA prior to the submission of an IND (pre-IND meeting), at the end of Phase 2 clinical trial (EOP2 meeting) and before an NDA is submitted (pre-NDA meeting). Meetings at other times may also be requested. There are five types of meetings that occur between sponsors and the FDA. Type A meetings are those that are necessary for an otherwise stalled product development program to proceed or to address an important safety issue. Type B meetings include pre-IND and pre-NDA meetings as well as end of phase meetings such as EOP2 meetings. A Type C meeting is any meeting other than a Type A or Type B meeting regarding the development and review of a product, including for example meetings to facilitate early consultations on the use of a biomarker as a new surrogate endpoint that has never been previously used as the primary basis for product approval in the proposed context of use. A type D meeting is focused on a narrow set of issues (should be limited to no more than two focused topics) and should not require input from more than three disciplines or divisions. Finally, INTERACT meetings are intended for novel products and development programs that present unique challenges in the early development of an investigational product.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These meetings provide an opportunity for the sponsor to share information about the data gathered to date with the FDA and for the FDA to provide advice on the next phase of development. The FDA has indicated that its responses, as conveyed in meeting minutes and advice letters, only constitute mere recommendations and/or advice made to a sponsor and, as such, sponsors are not bound by such recommendations and/or advice. Nonetheless, from a practical perspective, a sponsor&#8217;s failure to follow the FDA&#8217;s recommendations for design of a clinical program may put the program at significant risk of failure.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing and Other Regulatory Requirements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrently with clinical trials, sponsors usually complete additional animal safety studies, develop additional information about the chemistry and physical characteristics of the product candidate, and finalize a process for manufacturing commercial quantities of the product candidate in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other criteria, the sponsor must develop methods for testing the identity, strength, quality, and purity of the finished product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, the FDA&#8217;s regulations require that pharmaceutical products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports, and returned or salvaged products. Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their establishments with the FDA and some state agencies, and they are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other requirements. The PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign drug manufacturing establishments are subject to registration and listing requirements even if a drug undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside the U.S. prior to being imported or offered for import into the U.S.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inspections must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. Changes to the manufacturing process, specifications or container closure system for an approved product are strictly regulated and often require prior FDA approval before being implemented. The FDA&#8217;s regulations also require, among other things, the investigation and correction of any deviations from cGMP and the imposition of reporting and documentation requirements upon the sponsor and any third-party manufacturers involved in producing the approved product. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Studies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Pediatric Research Equity Act (PREA), applications and certain types of supplements to applications must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor must submit an initial Pediatric Study Plan (PSP) within 60 days of an end-of-Phase 2 meeting or as may be agreed between the sponsor and the FDA. Those plans must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The sponsor and the FDA must reach agreement on a final plan. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from nonclinical studies, early phase clinical trials, and/or other clinical development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For investigational products intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of a sponsor, meet to discuss preparation of the initial PSP or to discuss deferral or waiver of pediatric assessments. In addition, the FDA will meet early in the development process to discuss pediatric study plans with sponsors, and the FDA must meet with sponsors by no later than the end-of-Phase 1 meeting for serious or life-threatening diseases and by no later than 90 days after the FDA&#8217;s receipt of the study plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The law now requires the FDA to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension, or have failed to request approval for a required pediatric formulation. It further requires the FDA to publicly post the PREA Non-Compliance letter and sponsor&#8217;s response. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan drug designation, although the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA has recently taken steps to limit what it considers abuse of this statutory exemption in PREA by announcing that it does not intend to grant any additional orphan drug designations for rare pediatric subpopulations of what is otherwise a common disease. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population. In May 2023, the FDA issued draft guidance that further describes the pediatric study requirements under PREA.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Review Programs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For certain drug products, the FDA is authorized to expedite the review and approval of applications in several ways. None of these expedited programs change the standards for approval, but they may help expedite the development and approval process governing product candidates.</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fast Track designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Candidate products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Breakthrough therapy designation. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Priority review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention compared to marketed products. The FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accelerated approval. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials.</span></div></div><p style="margin-left:2.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, Congress modified certain provisions governing accelerated approval of drug products. Specifically, the new legislation authorized the FDA to require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded and to submit progress reports on its post-approval studies to FDA every six months until the study is completed. Moreover, FDORA established expedited procedures authorizing the FDA to withdraw an accelerated approval if certain conditions are met, including where a required confirmatory study fails to verify and describe the predicted clinical benefit or where evidence demonstrates the product is not shown to be safe or effective under the conditions of use. The FDA may also use such procedures to withdraw an accelerated approval if a sponsor fails to conduct any required post-approval trial of the product with due diligence, including with respect to &#8220;conditions specified by the Secretary.&#8221; The new procedures include the provision of due notice and an explanation for a proposed withdrawal, and opportunities for a meeting with the Commissioner of the FDA or the Commissioner&#8217;s designee and a written appeal, among other things.</span></p><p style="margin-left:2.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2023, the FDA issued draft guidance that outlines its current thinking and approach to accelerated approval. The FDA indicated that the accelerated approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. While a randomized controlled trial is the preferred approach, the guidance states that there can be circumstances wherein a single-arm trial is appropriate in the development of a drug for accelerated approval. To that end, the FDA outlined considerations for designing, conducting, and analyzing data for trials intended to support accelerated approvals of oncology therapeutics. Subsequently, in December 2024 and January 2025, the FDA issued additional draft guidance relating to accelerated approval. This guidance describes the FDA&#8217;s latest thinking on what it means to conduct a confirmatory trial with due diligence and how the FDA plans to interpret whether such a study needs to be underway at the time of approval. While this guidance is currently only in draft form and will ultimately not be legally binding even when finalized, sponsors typically observe the FDA&#8217;s guidance closely to ensure that their investigational products qualify for accelerated approval.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regenerative advanced therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> With passage of the Cures Act in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review, and accelerated approval based on surrogate or intermediate endpoints. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 505(b)(2) NDAs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NDAs for most new drug products are based on two full clinical studies which must contain substantial evidence of the safety and efficacy of the proposed new product for the proposed use. These applications are submitted under Section 505(b)(1) of the FDCA. The FDA is, however, authorized to approve an alternative type of NDA under Section 505(b)(2) of the FDCA. This type of application allows the sponsor to rely, in part, on the FDA&#8217;s previous findings of safety and efficacy for a similar product, or published literature. Specifically, Section 505(b)(2) applies to NDAs for a drug for which the investigations made to show whether or not the drug is safe for use and effective in use and relied upon by the sponsor for approval of the application &#8220;were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted.&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 505(b)(2) thus authorizes the FDA to approve an NDA based on safety and effectiveness data that were not developed by the applicant. NDAs filed under Section 505(b)(2) may provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses of previously approved products. If the 505(b)(2) applicant can establish that reliance on the FDA&#8217;s previous approval is scientifically appropriate, the applicant may eliminate the need to conduct certain preclinical or clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the referenced product has been approved as well as for any new indication sought by the Section 505(b)(2) applicant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Submission and Filing of NDAs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with information relating to the product&#8217;s chemistry, manufacturing, controls, safety updates, patent information, abuse information, and proposed labeling, are submitted to the FDA as part of an application requesting approval to market the product candidate for one or more indications. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of a drug product to the satisfaction of the FDA. The fee required for the submission and review of an application under PDUFA is substantial (for example, for fiscal year 2025, this application fee is $4,310,002), and the sponsor of an approved application is also subject to an annual program fee, currently set at $403,889 per eligible prescription product. These fees are typically adjusted annually, and exemptions and waivers may be available under certain circumstances, such as where a waiver is necessary to protect the public health, where the fee would present a significant barrier to innovation, or where the sponsor is a small business submitting its first human therapeutic application for review.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA conducts a preliminary review of all applications within 60 days of receipt and must inform the sponsor at that time or before whether an application is sufficiently complete to permit substantive review. In pertinent part, the FDA&#8217;s regulations state that an application &#8220;shall not be considered as filed until all pertinent information and data have been received&#8221; by the FDA. In the event that the FDA determines that an application does not satisfy this standard, it will issue a Refuse to File (RTF) determination to the applicant. Typically, an RTF will be based on administrative incompleteness, such as clear omission of information or sections of required information; scientific incompleteness, such as omission of critical data, information, or analyses needed to evaluate safety and efficacy or provide adequate directions for use; or inadequate content, presentation, or organization of information such that substantive and meaningful review is precluded. The FDA may request additional information rather than accept an application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the submission is accepted for filing, the FDA begins an in-depth substantive review of the application. The FDA reviews the application to determine, among other things, whether the proposed product is safe and effective for its intended use, whether it has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months from the filing date in which to complete its initial review of a standard application that is a new molecular entity, and six months from the filing date for an application with &#8220;priority review.&#8221; The review process may be extended by the FDA for three additional months to consider new information or in the case of a clarification provided by the sponsor to address an outstanding deficiency identified by the FDA following the original submission. Despite these review goals, it is not uncommon for FDA review of an application to extend beyond the PDUFA goal date.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with its review of an application, the FDA will typically submit information requests to the sponsor and set deadlines for responses thereto. The FDA will also conduct a pre-approval inspection of the manufacturing facilities for the new product to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determine whether the manufacturing processes and facilities comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with IND and GCP requirements and the integrity of the clinical data submitted to the FDA. To ensure cGMP and GCP compliance by its employees and third-party contractors, a sponsor may incur significant expenditure of time, money, and effort in the areas of training, record keeping, production, and quality control.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the FDA will review a sponsor&#8217;s financial relationship with the principal investigators who conducted the clinical trials in support of the NDA. That is because, under certain circumstances, principal investigators at a clinical trial site may also serve as scientific advisors or consultants to a sponsor and receive compensation in connection with such services. Depending on the level of that compensation and any other financial interest a principal investigator may have in a sponsor, the sponsor may be required to report these relationships to the FDA. The FDA will then evaluate that financial relationship and determine whether it creates a conflict of interest or otherwise affects the interpretation of the trial or the integrity of the data generated at the principal investigator&#8217;s clinical trial site. If so, the FDA may exclude data from the clinical trial site in connection with its determination of safety and efficacy of the investigational product.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the FDA may refer an application, including applications for novel product candidates which present difficult questions of safety or efficacy, to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved and under what conditions. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on approval. Data from clinical trials are not always conclusive, and the FDA or its advisory committee may interpret data differently than the sponsor interprets the same data. The FDA may also re-analyze the clinical trial data, which could result in extensive discussions between the FDA and the sponsor during the review process.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA also may require submission of a REMS if it determines that a REMS is necessary to ensure that the benefits of the product outweigh its risks and to assure the safe use of the product. The REMS could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS and the FDA will not approve the application without a REMS.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Decisions</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> on NDAs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA reviews an application to determine, among other things, whether the product is safe and whether it is effective for its intended use(s), with the latter determination being made on the basis of substantial evidence. The term &#8220;substantial evidence&#8221; is defined under the FDCA as &#8220;evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the product involved, on the basis of which it could fairly and responsibly be concluded by such experts that the product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling thereof.&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has interpreted this evidentiary standard to require at least two adequate and well-controlled clinical investigations to establish effectiveness of a new product. Under certain circumstances, however, the FDA has indicated that a single trial with certain characteristics and additional information may satisfy this standard. This approach was subsequently endorsed by Congress in 1998 with legislation providing, in pertinent part, that if the FDA determines, &#8220;based on relevant science, that data from one adequate and well-controlled clinical investigation and confirmatory evidence (obtained prior to or after such investigation) are sufficient to establish effectiveness, FDA may consider such data and evidence to constitute substantial evidence.&#8221; This modification to the law recognized the potential for the FDA to find that one adequate and well controlled clinical investigation with confirmatory evidence, including supportive data outside of a controlled trial, is sufficient to establish effectiveness. In December 2019, the FDA issued draft guidance further explaining the studies that are needed to establish substantial evidence of effectiveness. Although the FDA has not yet finalized that guidance, it did issue additional draft guidance in September 2023 that outlines considerations for relying on confirmatory evidence in lieu of a second clinical study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After evaluating the application and all related information, including the advisory committee recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA will issue either a Complete Response Letter (CRL) or an approval letter. To reach this determination, the FDA must determine that the drug is effective and that its expected benefits outweigh its potential risks to patients. This &#8220;benefit-risk&#8221; assessment is informed by the extensive body of evidence about the product&#8217;s safety and efficacy in the NDA. This assessment is also informed by other factors, including: the severity of the underlying condition and how well patients&#8217; medical needs are addressed by currently available therapies; uncertainty about how the premarket clinical trial evidence will extrapolate to real-world use of the product in the post-market setting; and whether risk management tools are necessary to manage specific risks. In connection with this assessment, the FDA review team will assemble all individual reviews and other documents into an &#8220;action package,&#8221; which becomes the record for FDA review. The review team then issues a recommendation, and a senior FDA official makes a decision.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, preclinical studies, or manufacturing. If a CRL is issued, the sponsor will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor an additional six month extension to respond. The FDA has committed to reviewing resubmissions in response to an issued CRL in either two or six months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. The FDA has taken the position that a CRL is not final agency action making the determination subject to judicial review. Sponsors may request the FDA for a formal hearing on the CRL or they may file a request for reconsideration or a request for a formal dispute resolution.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications. That is, the approval will be limited to the conditions of use (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> patient population, indication) described in the FDA-approved labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings, or precautions be included in the product labeling, require that post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Ensuring Innovation Act, which was signed into law in April 2021, the FDA must publish action packages summarizing its decisions to approve new drug products within 30 days of approval of such products. To date, CRLs are not publicly available documents.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-approval</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Requirements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following approval of a new prescription product, the manufacturer, the approved product, and the product&#8217;s manufacturing locations are subject to pervasive and continuing regulation by the FDA, governing, among other things, monitoring and record-keeping activities, reporting of adverse experiences with the product and product problems to the FDA, product sampling and distribution, manufacturing, and promotion and advertising. Although physicians may prescribe legally available products for unapproved uses or patient populations (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8220;off-label uses&#8221;), manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to carefully navigate the FDA&#8217;s various regulations, guidance and policies, along with recently enacted legislation, to ensure compliance with restrictions governing promotion of our products, if approved. In September 2021, the FDA published final regulations which describe the types of evidence that the FDA will consider in determining the intended use of a drug or biologic. Moreover, with passage of the Pre-Approval Information Exchange Act in December 2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite patient access upon product approval. In addition, in January 2025, the FDA published final guidance outlining its policies governing the distribution of scientific information to healthcare providers about unapproved uses of approved products. The final guidance calls for such communications to be truthful, non-misleading and scientifically sound and to include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use of the approved product. If a company engages in such communications consistent with the guidance&#8217;s recommendations, the FDA indicated that it will not treat such communications as evidence of unlawful promotion of a new intended use for the approved product. While this guidance only applies to communications about unapproved uses of approved products, it may be helpful in understanding the FDA&#8217;s approach to communications about unapproved products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a company is found to have promoted off-label uses, it may become subject to administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the U.S. Department of Health and Human Services (HHS), as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes products, as well as adverse public relations and reputational harm. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if there are any modifications to the product, including changes in indications, labeling, or manufacturing processes or facilities, the sponsor may be required to submit and obtain FDA approval of a new application or supplement, which may require the sponsor to develop additional data or conduct additional preclinical studies and clinical trials. Securing FDA approval for new indications is similar to the process for approval of the original indication and requires, among other things, submitting data from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adequate and well-controlled clinical trials to demonstrate the product&#8217;s safety and efficacy in the new indication. Even if such trials are conducted, the FDA may not approve any expansion of the labeled indications for use in a timely fashion, or at all. There also are continuing, annual user fee requirements that are now assessed as program fees for certain products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information, imposition of a post-market clinical trials requirement to assess new safety risks, or imposition of distribution or other restrictions under a REMS program.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other potential consequences include, among other things:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings or other safety information about a product;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mandated modification of promotional materials and labeling and issuance of corrective information;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters, untitled letters, or other enforcement-related letters or clinical holds on post-approval clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the distribution of prescription pharmaceutical products is subject to a variety of federal and state laws, the most recent of which is still in the process of being phased into the U.S. supply chain and regulatory framework. The Prescription Drug Marketing Act (PDMA) was the first federal law to set minimum standards for the registration and regulation of drug distributors by the states and to regulate the distribution of drug samples. Today, both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. In November 2013, the federal Drug Supply Chain Security Act became effective in the U.S., mandating an industry-wide, electronic, interoperable system to trace prescription drugs through the pharmaceutical distribution supply chain with a ten-year phase-in process. Manufacturers were required by November 2023 to have such systems and processes. So as not to disrupt supply chains, the FDA has granted certain exemptions from enhanced drug distribution security requirements for eligible trading partners for particular periods of time.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Generic Drugs and Regulatory Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 1984, with passage of the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, Congress established an abbreviated regulatory scheme authorizing the FDA to approve generic drugs that are shown to contain the same active ingredients as, and to be bioequivalent to, drugs previously approved by the FDA pursuant to NDAs, and also enacted Section 505(b)(2). To obtain approval of a generic drug, a sponsor must submit an abbreviated new drug application (ANDA) to the FDA. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing conducted for a drug product previously approved under an NDA, known as the reference listed drug (RLD).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, the strength of the drug, and the conditions of use of the drug. At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if &#8220;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug.&#8221; Upon approval of an ANDA, the FDA indicates whether the generic product is &#8220;therapeutically equivalent&#8221; to the RLD in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider a therapeutic equivalent generic drug to be fully substitutable for the RLD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Hatch-Waxman Act, the FDA may not approve an ANDA or 505(b)(2) application until any applicable period of regulatory exclusivity for the RLD has expired. The FDCA provides a period of five years of regulatory exclusivity for a new drug containing a new chemical entity (NCE). For the purposes of this provision, the FDA has consistently taken the position that an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. This interpretation was confirmed with enactment of the Ensuring Innovation Act in April 2021. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, a generic or follow-on drug</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">application may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the sponsor may submit its application four years following the original product approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDCA also provides for a period of three years of regulatory exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the sponsor and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as new indications, dosage forms, route of administration or combination of ingredients. Three-year regulatory exclusivity would be available for a drug product that contains a previously approved active moiety, provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs or 505(b)(2) NDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product; rather, this three-year exclusivity covers only the conditions of use associated with the new clinical investigations and, as a general matter, does not prohibit the FDA from approving follow-on applications for drugs containing the original active ingredient.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Five-year and three-year regulatory exclusivity also will not delay the submission or approval of a traditional NDA filed under Section 505(b)(1) of the FDCA; however, a sponsor submitting a traditional NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the submission of an NDA or certain supplemental applications, NDA sponsors are required to list with the FDA each patent with claims that cover the sponsor&#8217;s product or an approved method of using the product. Upon approval of a new drug, each of the patents listed in the application for the drug is then published in the Orange Book. The FDA&#8217;s regulations governing patent listings were largely codified into law with enactment of the Orange Book Modernization Act in January 2021. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book. Specifically, the ANDA applicant must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the new product. Moreover, to the extent that the Section 505(b)(2) NDA applicant is relying on studies conducted for an already approved product, the applicant also is required to certify to the FDA concerning any patents listed for the NDA-approved product in the Orange Book to the same extent that an ANDA applicant would.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the generic drug or follow-on drug applicant does not challenge the innovator&#8217;s listed patents, the FDA will not approve the ANDA or 505(b)(2) application until all the listed patents claiming the referenced product have expired. A certification that the new generic product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA owner and patent holders once the ANDA has been accepted for filing by the FDA. The NDA owner and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earliest of 30 months after the receipt of the Paragraph IV notice, expiration of the patent and a decision in the infringement case that is favorable to the ANDA or 505(b)(2) NDA applicant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan drug designation in the U.S. is designed to encourage sponsors to develop products intended for treatment of rare diseases or conditions. In the U.S., a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the U.S. or that affects more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making available the product for the disease or condition will be recovered from sales of the product in the U.S.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan drug designation qualifies a company for tax credits and potentially market exclusivity for seven years following the date of the product&#8217;s approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development at the FDA based on acceptable confidential requests. The product must then go through the review and approval process like any other product.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first approved product. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same product for the same disease or condition for seven years, except in certain limited circumstances. If a product designated as an orphan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The period of market exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the disease or condition for which the product has been designated. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if the company with orphan drug exclusivity is not able to meet market demand or the subsequent product is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care. This is the case despite an earlier court opinion holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan drug exclusivity regardless of a showing of clinical superiority. Under Omnibus legislation signed by President Trump on December 27, 2020, the requirement for a product to show clinical superiority applies to drug products that received orphan drug designation before enactment of amendments to the FDCA in 2017 but have not yet been approved by the FDA.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is also possible that current or future litigation or action by Congress could change the scope of available orphan exclusivity. Any changes to the orphan drug provisions could change our opportunities for, or likelihood of success in obtaining, orphan drug exclusivity and could have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Exclusivity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatric exclusivity is a type of non-patent marketing exclusivity in the U.S. and, if granted, provides for the attachment of an additional six months of exclusivity to the term of any existing patent or regulatory exclusivity for drug products, including the orphan exclusivity and regulatory exclusivities available under the Hatch-Waxman provisions of the FDCA. The conditions for pediatric exclusivity include the FDA&#8217;s determination that information relating to the use of a new product in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric clinical trials, and the sponsor agreeing to perform, and reporting on, the requested clinical trials within the statutory timeframe. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patents that cover the product are extended by six months. Although this is not a patent term extension, it effectively extends the regulatory period during which the FDA cannot approve another application.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Term Restoration and Extension</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., a patent claiming a new product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one-half the time between the effective date of the IND involving human beings and the submission date of the NDA, plus the time between the submission date of the application and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date in the U.S. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office reviews and approves the application for any patent term extension in consultation with the FDA.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Companion Diagnostics</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2014, the FDA issued final guidance clarifying the requirements that will apply to the approval of therapeutic products and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> companion diagnostics. According to the guidance, for novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#8217;s labeling. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the therapeutic product and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> companion diagnostic device on issues related to co-development of the products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2014 guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a product candidate generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption (IDE) regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a product are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND application alone, or both an IND- and IDE-application.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2020, the FDA issued additional guidance which describes considerations for the development and labeling of companion diagnostic devices to support the indicated uses of multiple drug or biological oncology products, when appropriate. This guidance builds upon existing policy regarding the labeling of companion diagnostics. In its 2014 guidance, the FDA stated that if evidence is sufficient to conclude that the companion diagnostic is appropriate for use with a specific group of therapeutic products, the companion diagnostic&#8217;s intended use/indications for use should name the specific group of therapeutic products, rather than specific products. The 2020 guidance expands on the policy statement in the 2014 guidance by recommending that companion diagnostic developers consider a number of factors when determining whether their test could be developed, or the labeling for approved companion diagnostics could be revised through a supplement, to support a broader labeling claim such as use with a specific group of oncology therapeutic products (rather than listing an individual therapeutic product(s)).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the FDCA, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> diagnostics, including companion diagnostics, are regulated as medical devices. In the U.S., the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import and post-market surveillance. Unless an exemption applies, diagnostic tests require pre-notification marketing clearance or approval from the FDA prior to commercial distribution.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA previously has required </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> companion diagnostics intended to select the patients who will respond to the product candidate to obtain pre-market approval (PMA) simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the sponsor must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. For federal fiscal year 2025 the standard fee is $540,783 and the small business fee is $135,196.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the Quality System Regulation, which covers the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging, and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare Compliance</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., biopharmaceutical manufacturers and their products are subject to extensive regulation at the federal and state level, such as laws intended to prevent fraud and abuse in the healthcare industry. Healthcare providers and third-party payors play a primary role in the recommendation, prescription, and coverage of pharmaceutical products that are granted marketing approval. Arrangements with providers, consultants, third-party payors, and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, reporting of payments to healthcare providers, patient privacy laws and regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations include, but are not limited to, the following:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal false claims, false statements, and civil monetary penalties laws prohibiting, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Anti-Kickback Statute, a broad criminal statute which prohibits, among other things, knowingly and willfully offering, soliciting, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce, or in return for, either the referral of an individual for, or the purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under federal healthcare programs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Physician Payment Sunshine Act, which requires applicable pharmaceutical and medical device manufacturers of covered drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, among others, to collect and report information on certain financial interactions with certain healthcare providers to the Centers for Medicare &amp; Medicaid Services (CMS) for annual publication in a searchable form on a public website, as well as ownership and investment interests held by physicians and their immediate family members;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous state laws and regulations, including: state anti-kickback and false claims laws; state laws requiring pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to healthcare providers or marketing expenditures; and state laws governing privacy, security and breaches of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws and regulations prohibiting bribery and corruption such as the U.S. Foreign Corrupt Practices Act (FCPA), which, among other things, prohibits U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Violations of these laws are punishable by criminal and/or civil sanctions, including, in some instances, exclusion from participation in federal and state healthcare programs, such as Medicare and Medicaid. Ensuring compliance is time consuming and costly. Similar healthcare laws and regulations exist in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of personal information.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S. and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government healthcare programs in the U.S. such as Medicare and Medicaid, commercial health insurers, and managed care organizations, provide coverage and establish adequate reimbursement levels for the product. In the U.S., no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans, or federal healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations, and financial condition. Factors that payors consider in determining reimbursement include whether the product is (i) a covered benefit under its health plan; (ii) safe, effective, and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational. Additionally, a third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product and the level of coverage and reimbursement can differ significantly from payor to payor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net prices for drugs may be reduced by mandatory discounts or rebates required by federal healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government in order to receive coverage for their products under federal healthcare programs such as Medicare Part B and Medicaid. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by federal healthcare programs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The containment of healthcare costs has become a priority of federal, state and foreign governments and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party payor reimbursement rates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing of drug products, limiting coverage and reimbursement for medical products and other changes to the healthcare system in the U.S.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2010, the U.S. Congress enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the PPACA), which, among other things, includes changes to the coverage and payment for pharmaceutical products under government healthcare programs. Other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and, due to subsequent statutory amendments, will remain in effect through the first eleven months of the President&#8217;s fiscal year 2032 sequestration order unless additional congressional action is taken, with the exception of a temporary suspension, and later a temporary reduction instituted during the COVID-19 pandemic that expired on July 1, 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since enactment of the PPACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by President Trump on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On June 17, 2021, the U.S. Supreme Court dismissed a judicial challenge to the PPACA brought by several states who argued that, without the individual mandate, the entire PPACA was unconstitutional. The U.S. Supreme Court&#8217;s dismissal of the lawsuit did not specifically rule on the constitutionality of the PPACA. Litigation and legislation over the PPACA may continue, with unpredictable and uncertain results.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pharmaceutical Prices</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the U.S. There have been several recent U.S. Congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. For example, on August 16, 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law by former President Biden. The legislation requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation; and replaces the Part D coverage gap discount program with a new discounting program. The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for 10 high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least nine years and biologics that have been licensed for 13 years. When originally enacted, the IRA explicitly excluded from price negotiation orphan drugs designated for only one rare disease or condition and for which the only active approved indication is for such disease or condition. However, the One Big Beautiful Bill Act (OBBBA), signed into law in July 2025, amended the applicable statute to broaden the orphan drug exclusion to include products with more than one orphan designation and more than one approved indication. Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law. The legislation also requires manufacturers to pay rebates for drugs in Medicare Parts B and D whose price increases exceed inflation and capped Medicare beneficiary out-of-pocket drug costs at $2,000 a year.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023. On August 15, 2024, HHS published the results of the first Medicare drug price negotiations for 10 selected drugs that treat a range of conditions, including diabetes, chronic kidney disease, and rheumatoid arthritis. The prices of these 10 drugs became effective on January 1, 2026. In January 2025, CMS announced its selection of 15 additional drugs covered by Medicare Part D for the second cycle of negotiations, and in November 2025, CMS released negotiated prices for such products that will go into effect beginning January 1, 2027. While it remains to be seen how the drug pricing provisions imposed by the IRA will affect the broader pharmaceutical industry, several pharmaceutical manufacturers and other industry stakeholders have challenged the law, including through lawsuits brought against the HHS, the Secretary of the HHS, CMS, and the CMS Administrator challenging the constitutionality and administrative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implementation of the IRA&#8217;s drug price negotiation provisions. This litigation is ongoing and the results, and potential impacts on our business, are uncertain.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, CMS issued a public statement declaring that lowering the cost of prescription drugs is a top priority of the current presidential administration and CMS is committed to considering opportunities to bring greater pricing transparency. Moreover, President Trump has signed multiple executive orders addressing prescription drug pricing and access, and has exerted pressure on drug manufacturers to implement &#8220;most favored nation&#8221; pricing, including by suggesting that the administration may impose significant tariffs on pharmaceuticals if such manufacturers do not reach agreements to implement &#8220;most favored nation&#8221; pricing. Additionally, in November 2025, CMS announced a new voluntary payment initiative called the GENEROUS Model (GENErating cost Reductions for U.S. Medicaid Model) where drug manufacturers may voluntarily offer supplemental rebates to participating state Medicaid programs that are intended to provide such Medicaid programs with a &#8220;most favored nation&#8221; price for participating manufacturers&#8217; products. Most recently, in December 2025, CMS announced new mandatory payment models through two proposed rules, the Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) models where manufacturers of certain Medicare Part B and Medicare Part D drugs will be assessed rebates if the prices for such products exceed those paid in economically comparable countries. It remains to be seen how these drug pricing initiatives will affect the broader pharmaceutical industry.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program (SIP) to import certain prescription drugs from Canada into the U.S. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America (PhRMA) but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue HHS. Several states have passed laws allowing for the importation of products from Canada. Other states have passed legislation establishing workgroups to examine the impact of a state importation program or submitted SIP proposals to the FDA for review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, and wholesale distributors, to disclose information about pricing of pharmaceuticals, including, but not limited to, information in connection with new product launches that exceed certain levels as identified in the relevant statutes. This is increasingly true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval. In addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription pharmaceutical and other healthcare programs. These measures could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Federal and State Data Privacy Laws</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are multiple privacy and data security laws that may impact our business activities, in the U.S. and in other countries where we conduct trials or where we may do business in the future. These laws are evolving and may increase both our obligations and our regulatory risks in the future. In the healthcare industry generally, under HIPAA, HHS has issued regulations to protect the privacy and security of protected health information (PHI) used or disclosed by covered entities including certain healthcare providers, health plans, and healthcare clearinghouses. HIPAA also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. HIPAA may apply to us in certain circumstances and may also apply to our business partners in ways that may impact our relationships with them. Our clinical trials are regulated by the Common Rule, which also includes specific privacy-related provisions. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that may be applicable to our business. In addition to possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. State attorneys general also have authority to enforce state privacy and security laws. New laws and regulations governing privacy and security may be adopted in the future as well.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2018, California passed into law the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020, and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s requirements are similar to those found in the General Data Protection Regulation (GDPR), including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">also affords California residents the right to opt-out of &#8220;sales&#8221; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act (CPRA), which went into effect on January 1, 2023, and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency &#8211; the California Privacy Protection Agency &#8211; whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to California, several other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. Other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plaintiffs&#8217; lawyers are also increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our current or future business activities, including certain clinical research, sales and marketing practices, and the provision of certain items and services to our customers, could be subject to challenge under one or more of such privacy and data security laws. The heightening compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance and/or reporting requirements in multiple jurisdictions could increase the possibility that a healthcare company may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any of the privacy or data security laws or regulations described above that are applicable to us, or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil, and administrative penalties, damages, fines, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a consent decree or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Approval and Regulation of Medical Products in the EU</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to regulations in the U.S., we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products outside of the U.S. Whether or not we obtain FDA approval for a product candidate, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the 27-member EU, before we may commence clinical trials or market products in those countries or areas. In the EU, our product candidates also may be subject to extensive regulatory requirements. As in the U.S., medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained. Similar to the U.S., the various phases of preclinical and clinical research in the EU are subject to significant regulatory controls.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With the exception of the EU/European Economic Area (EEA) applying the harmonized regulatory rules for medicinal products, the approval process and requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary greatly between countries and jurisdictions and can involve additional testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-clinical Studies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical (pharmaco-toxicological) studies must be conducted in compliance with the principles of GLP as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products &#8211; e.g., radio-pharmaceutical precursors for radio-labeling purposes). In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trials</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 31, 2022, the new Clinical Trials Regulation (EU) No 536/2014 (the CTR) became effective in the EU and replaced the prior Clinical Trials Directive 2001/20/EC (Clinical Trials Directive). The new CTR aims at simplifying and streamlining the authorization, conduct and transparency of clinical trials in the EU. Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial to be conducted in more than one EU Member State will only be required to submit a single application for approval. The submission will be made through the Clinical Trials Information System, a new clinical trials portal overseen by the EMA and available to clinical trial sponsors, competent authorities of the EU Member States and the public.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the &#8220;EU Portal and Database&#8221;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the appointed reporting EU Member State, whose assessment report is submitted for review by the sponsor and all other competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted, or concerned EU Member States. Part II is assessed separately by each concerned EU Member State. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned member state. However, overall related timelines will be defined by the CTR.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The new CTR did not change the preexisting requirement that a sponsor must obtain prior approval from the competent national authority of the EU Member State in which the clinical trial is to be conducted. If the clinical trial is conducted in different EU Member States, the competent authorities in each of these EU Member States must provide their approval for the conduct of the clinical trial. Furthermore, the sponsor may only start a clinical trial at a specific clinical site after the applicable ethics committee has issued a favorable opinion.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties conducting certain clinical trials must, as in the U.S., post clinical trial information in the EU at the EudraCT website: https://eudract.ema.europa.eu.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Authorization</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketing authorization applications (MAAs) can be filed either under the so-called centralized or national authorization procedures, albeit through the Mutual Recognition or Decentralized procedure for a product to be authorized in more than one EU member state.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The centralized procedure provides for the grant of a single marketing authorization (MA) following a favorable opinion by the EMA that is valid in all EU Member States, as well as Iceland, Liechtenstein, and Norway, which are part of the EEA. The centralized procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products, advanced-therapy medicines (such as gene-therapy, somatic cell-therapy or tissue-engineered medicines), and products with a new active substance indicated for the treatment of specified diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases, and other immune dysfunctions and viral diseases. The centralized procedure is optional for products that represent a significant therapeutic, scientific, or technical innovation, or whose authorization would be in the interest of public health. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the sponsor in response to questions asked by the Committee for Medicinal Products for Human Use (CHMP). Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is 150 days, excluding stop-clocks.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also two other possible routes to authorize medicinal products in several EU countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Decentralized procedure</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Using the decentralized procedure, a sponsor may apply for simultaneous authorization in more than one EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized procedure. The sponsor may choose a member state as the reference member state to lead the scientific evaluation of the application.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mutual recognition procedure</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the mutual recognition procedure, a medicine is first authorized in one EU Member State (which acts as the reference member state), in accordance with the national procedures of that country. Following this, further marketing authorizations can be progressively sought from other EU countries in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization produced by the reference member state.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the above-described procedures, before granting the marketing authorization, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety, and efficacy.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conditional Approval</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular circumstances, EU legislation (Article 14&#8211;a Regulation (EC) No 726/2004 (as amended by Regulation (EU) 2019/5 and Regulation (EC) No 507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use)) enables sponsors to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1) the product candidate is intended for the treatment, prevention, or medical diagnosis of seriously debilitating or life-threatening diseases; (2) the product candidate is intended to meet unmet medical needs of patients; (3) a marketing authorization may be granted prior to submission of comprehensive clinical data provided that the benefit of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required; (4) the risk-benefit balance of the product candidate is positive, and (5) it is likely that the sponsor will be in a position to provide the required comprehensive clinical trial data. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exceptional Circumstances</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A MA may also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. This may arise in particular when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This MA is close to the conditional MA as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a MA. However, unlike the conditional MA, the applicant does not have to provide the missing data and will never have to. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable. Under these procedures, before granting the MA, the EMA or the competent authorities of the member states make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety, and efficacy. Except for conditional MAs, MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Studies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to obtaining a marketing authorization in the EU, sponsors have to demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan (PIP), covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form, or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA (PDCO) may grant deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine in children is not needed or is not appropriate because (a) the product is likely to be ineffective or unsafe in part or all of the pediatric population; (b) the disease or condition occurs only in adult population; or (c) the product does not represent a significant therapeutic benefit over existing treatments for pediatric population. Before a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PRIME Designation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines (PRIME) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises (SMEs) may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated agency contact and rapporteur from the CHMP or Committee for Advanced Therapies are appointed early in the PRIME scheme, facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance to the sponsor on the overall development and regulatory strategies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Periods of Authorization and Renewals</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A MA is valid for five years in principle and the MA may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety, and efficacy, including all variations introduced since the MA was granted, at least nine months before the marketing authorization ceases to be valid. Once renewed, the MA is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid (the so-called sunset clause).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Requirements after Marketing Authorization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As in the U.S., both marketing authorization holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA and the competent authorities of the individual EU Member States both before and after grant of the manufacturing and marketing authorizations. The holder of an EU marketing authorization for a medicinal product must, for example, comply with EU pharmacovigilance legislation and its related regulations and guidelines which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. The manufacturing process for medicinal products in the EU is also highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, including compliance with EU cGMP standards when manufacturing medicinal products and API.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, the advertising and promotion of approved products are subject to EU Member States&#8217; laws governing promotion of medicinal products, interactions with clinicians, misleading and comparative advertising, and unfair commercial practices. In addition, other legislation adopted by individual EU Member States may apply to the advertising and promotion of medicinal products. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics (SmPC) as approved by the competent authorities. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion, which is prohibited in the EU.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusivity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, new products authorized for marketing (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic sponsors from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic sponsor from commercializing its product in the EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The ten-year market exclusivity period can be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The criteria for designating an orphan medicinal product in the EU are similar in principle to those in the U.S. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition, (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment, and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. The term &#8216;significant benefit&#8217; is defined in Regulation (EC) 847/2000 to mean a clinically relevant advantage or a major contribution to patient care.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to 10 years of market exclusivity for the approved therapeutic indication. During this ten-year market exclusivity period, the EMA or the competent authorities of the Member States of the EEA, cannot accept an application for a marketing authorization for a similar medicinal product for the same indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The sponsor will receive a fee reduction for the MAA if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ten-year market exclusivity in the EU may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) the second sponsor can establish that its product, although similar, is safer, more effective, or otherwise clinically superior; (2) the sponsor consents to a second orphan medicinal product application; or (3) the sponsor cannot supply enough orphan medicinal product.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Exclusivity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a sponsor obtains a marketing authorization in all EU Member States, or a marketing authorization granted in the centralized procedure by the European Commission, and the study results for the pediatric population are included in the product information, even when negative, the medicine is then eligible for an additional six-month period of qualifying patent protection through extension of the term of the Supplementary Protection Certificate (SPC) or alternatively a one year extension of the regulatory market exclusivity from ten to eleven years, as selected by the marketing authorization holder.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Term Extensions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EU also provides for patent term extension through SPCs. The rules and requirements for obtaining an SPC are similar to those in the U.S. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date and can provide up to a maximum of 15 years of marketing exclusivity for a drug. In certain circumstances, these periods may be extended for six additional months if pediatric exclusivity is obtained. Although SPCs are available throughout the EU, sponsors must apply on a country-by-country basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the EU.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reimbursement and Pricing of Prescription Pharmaceuticals</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, similar political, economic, and regulatory developments to those in the U.S. may affect our ability to profitably commercialize our product candidates, if approved. In markets outside of the U.S. and the EU, reimbursement and healthcare payment systems vary significantly by country and many countries have instituted price ceilings on specific products and therapies. In many countries, including those of the EU, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, pharmaceutical firms may be required to conduct a clinical trial that compares the cost-effectiveness of the product to other available therapies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EU provides options for its Member States to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other Member States allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reference pricing used by various EU Member States, and parallel trade (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, arbitrage between low-priced and high-priced Member States) can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any product candidates, if approved in those countries.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Approval of Companion Diagnostic Devices</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, medical devices such as companion diagnostics must comply with the General Safety and Performance Requirements (SPRs) detailed in Annex I of the EU Medical Devices Regulation (Regulation (EU) 2017/745) (MDR), which came into force in May 2021 and replaced the previously applicable EU Medical Devices Directive (Council Directive 93/42/EEC). Compliance with SPRs and additional requirements applicable to companion medical devices is a prerequisite to be able to affix the Conformit&#232; Europ&#235;enne mark of conformity to medical devices, without which they cannot be marketed or sold. To demonstrate compliance with the SPRs, a manufacturer must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. The MDR is meant to establish a uniform, transparent, predictable, and sustainable regulatory framework across the EU for medical devices.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separately, the regulatory authorities in the EU also adopted a new In Vitro Diagnostic Regulation (Regulation (EU) 2017/746) (IVDR) for In vitro diagnostic medical devices (IVDs). The IVDR, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">strengthens the rules on placing devices on the market and reinforces surveillance once they are available;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishes explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance, and safety of devices placed on the market;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">improves the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishes a central database to provide patients, healthcare professionals, and the public with comprehensive information on products available in the EU; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">strengthens rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IVDR became applicable in May 2022, but transitional periods for legacy devices have been extended, with deadlines on device class (e.g., Class D until December 31, 2027, Class C until December 31, 2028, and Class B/Class A sterile until December 31, 2029), subject to specified conditions. Certain provisions for in-house devices manufactured and used by health institutions apply as of May 26, 2028. The extended transition periods apply only to legacy devices that continue to comply with prior rules, undergo no significant design or intended-use changes, do not pose unacceptable risks, and for manufacturers implement an IVDR-compliant quality management system and submit a timely application to a notified body, where required.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General Data Protection Regulation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EEA, including personal health data, is subject to the GDPR, which became effective on May 25, 2018. In the United Kingdom (U.K.), the GDPR is retained in domestic law as the U.K. GDPR and sits alongside an amended version of the U.K. Data Protection Act 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the U.S., and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues of the respective group of companies, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance. In July 2020 the Court of Justice of the European Union (CJEU) invalidated the EU-U.S. Privacy Shield framework, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the U.S. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the U.S. Following the withdrawal of the U.K. from the EU, the U.K. Data Protection Act 2018 applies to the processing of personal data that takes place in the U.K. and includes parallel obligations to those set forth by GDPR.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2022, former President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield. The EU initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022 and the European Commission adopted the adequacy decision on July 10, 2023. The adequacy decision permits U.S. companies who self-certify to the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the EU to the U.S. However, some privacy advocacy groups have challenged the EU-U.S. Data Privacy Framework. If these challenges are successful, they may not only impact the EU-U.S. Data Privacy Framework, but also further limit the viability of the standard contractual clauses and other data transfer mechanisms.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Brexit and the Regulatory Framework in the United Kingdom</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.K.&#8217;s withdrawal from the EU, commonly referred to as Brexit, took place on January 31, 2020. The EU and the U.K. reached an agreement on their new partnership in the Trade and Cooperation Agreement, which entered into force on May 1, 2021. As of January 1, 2021, the Medicines and Healthcare Products Regulatory Agency (MHRA) became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland, and Wales under domestic law, whereas Northern Ireland continues to be subject to EU rules under the Northern Ireland Protocol, as amended by a set of arrangements, known as the &#8220;Windsor Framework,&#8221; agreed in February 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of January 1, 2025, the changes introduced by the Windsor Framework resulted in the MHRA being responsible for approving all medicinal products destined for the U.K. market (i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. The MHRA relies on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended) (HMR) as the basis for regulating medicines. The HMR has incorporated into the domestic law the body of EU law instruments governing medicinal products that pre-existed prior to the U.K.&#8217;s withdrawal from the EU.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of January 1, 2024, a new international recognition procedure (IRP) applies that intends to facilitate approval of pharmaceutical products in the U.K. The IRP is open to applicants that have already received an authorization for the same product from one of the MHRA&#8217;s specified Reference Regulators (RRs). The RRs notably include the EMA and regulators in the EEA Member States for approvals in the EU centralized procedure and mutual recognition procedure as well as the FDA (for product approvals granted in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S.). The RR assessment must have undergone a full and standalone review. RR assessments based on reliance or recognition cannot be used to support an IRP application. A CHMP positive opinion or a mutual recognition/decentralized positive end of procedure outcome is an RR authorization for the purposes of IRP.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other U.S. environmental, health, and safety laws and regulations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development, or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties, or other sanctions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees and Human Capital</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had 228 full-time employees, of which 144 are engaged in research and development. From time to time, we also retain independent contractors and other service providers to support our organization. None of our employees are represented by a labor union or covered by collective bargaining agreements, and we believe our relationship with our employees is positive.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consider the intellectual capital of our employees to be an essential driver of our business. Our workforce expanded substantially during 2025; new employees were hired to support our clinical and preclinical pipeline and commercialization efforts, with additions in our research, clinical development, operations and general and administrative functions, including commercial. We expect to continue to add additional employees in 2026 with a focus on increasing expertise in commercialization and clinical and preclinical research and development as well as expanding critical capabilities across our organization.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continually evaluate our business needs and opportunities and strive to balance in house expertise and capacity with outsourced expertise and capacity. Currently, we outsource substantially all clinical trial work to contract research organizations and manufacturing to CMOs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and future employees. The principal purposes of our short-term and long-term incentive programs are to attract, retain and motivate employees and consultants. In addition, through the granting of stock-based compensation awards we seek to align our incentive compensation with the interests of our stockholders. We provide a comprehensive benefits package to help employees manage health, well-being, finances and life outside of work, including health, dental and vision insurance, life insurance, short-term and long-term disability insurance, paid sick leave, a 401(k) plan, a flexible spending account program and paid vacation time. We also strive to build an integrated, cohesive culture and safe work environment, designed so that the organization is structured and aligned to operate efficiently, decision making is timely and effective, and employees are supported, encouraged and motivated to do their best to support our mission and our values.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about our Executive Officers (as of February 19, 2026)</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:43.6%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:44.08%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Position</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James R. Porter, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer, President and Director</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alexandra Balcom, MBA, CPA</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Treasurer</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deborah Miller, Ph.D., J.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Legal Officer and Secretary</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Darlene Noci, A.L.M.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Development Officer</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Christopher D. Turner, M.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Medical Officer</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Henry E. Pelish, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Scientific Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">James R. Porter, Ph.D.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Chief Executive Officer and President and as a member of our board of directors since February 2020. Prior to that, Dr. Porter served as our Vice President, Product Development from April 2018 to January 2020 and worked as a consultant to the Company from January 2018 to April 2018. From July 2002 to December 2016, Dr. Porter held various roles at Infinity, including most recently as Vice President of Product Development. Over the course of over 14 years at Infinity, he contributed to the research and development programs of six different compounds entering clinical trials. As the duvelisib product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development team leader, Dr. Porter led a cross-functional development team from development candidate nomination through NDA submission, resulting in the FDA approval of COPIKTRA for patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia. Following Infinity&#8217;s licensing of duvelisib to Verastem, Inc., a biopharmaceutical company (Verastem), Dr. Porter served as Consultant, Product Development at Verastem from January 2017 to December 2017, where he led the transition, product development team and NDA submission for the duvelisib program. Dr. Porter received his B.A. in chemistry at the College of the Holy Cross and his Ph.D. in organic chemistry from Boston College.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alexandra Balcom, MBA, CPA,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Chief Financial Officer since January 2021. Ms. Balcom brings over 20 years of strategic, financial and operational experience in the biotechnology industry to her role. Before joining Nuvalent, she held various roles at SQZ Biotechnologies Company, a biotechnology company, from April 2017 to March 2021, including Vice President of Finance, where she was responsible for strategic planning, finance and accounting. Prior to that, Ms. Balcom served as Corporate Controller at Agios Pharmaceuticals Inc., a pharmaceutical company. Ms. Balcom was responsible for all financial functions of the company including strategic planning, treasury, tax, finance, and accounting. Earlier in her career, Ms. Balcom held positions at both Molecular Insight Pharmaceuticals Inc., a pharmaceutical company that was acquired by Progenics Pharmaceuticals, Inc., a biotechnology company, in 2013 and Coley Pharmaceutical Group, Inc., a biopharmaceutical company that was acquired by Pfizer in 2007. Ms. Balcom earned her B.B.A. in finance from the University of Massachusetts, Amherst and her MBA from Boston College. Ms. Balcom is also a certified public accountant in Massachusetts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deborah Miller, Ph.D., J.D.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Chief Legal Officer since June 2021. Before joining Nuvalent, she held various roles at Sumitomo Dainippon Pharma America, Inc., a pharmaceutical company (SDPA), from April 2020 to June 2021, including Senior Vice President, Deputy General Counsel and Chief IP Counsel, where she was responsible for providing legal services to all of the North American companies of Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo). Prior to that, Dr. Miller served as Deputy General Counsel &amp; Chief IP Counsel at Sunovion Pharmaceuticals Inc., a subsidiary of SDPA, from March 2017 to April 2020, and held various roles at Infinity from March 2010 to March 2017, including Vice President, Deputy General Counsel and Chief Patent Counsel, where she built and managed the intellectual property group and supported various in-licensing, out-licensing and financing ventures. Earlier in her career, Dr. Miller was IP corporate counsel at Sepracor Inc. (currently, Sunovion Pharmaceuticals Inc.), a biopharmaceutical company, which was acquired by Sumitomo in 2010, and an associate at the law firm Nutter McClennen &amp; Fish LLP. She received her B.A. in chemistry from Swarthmore College, her M.M.Sc. from Harvard Medical School, her Ph.D. in biological chemistry and molecular pharmacology from Harvard University and her J.D. from Suffolk University Law School.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Darlene Noci, A.L.M.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Chief Development Officer since July 2022. Prior to that, she served as our Senior Vice President of Product Development &amp; Regulatory Affairs from January 2021 until July 2022. Before joining Nuvalent, she founded her own regulatory consulting firm, Noci Strategic Consulting, LLC, in May 2018. Prior to that, Ms. Noci served as Vice President, Regulatory Affairs and Quality Assurance at X4 Pharmaceuticals, Inc., a biopharmaceutical company, from January 2016 to May 2018. Prior to that, Ms. Noci served as Global Regulatory Lead Strategist, Immuno-Oncology at EMD Serono, the North America biopharma business of Merck KgaA, Darmstadt, Germany, a pharmaceutical company, from June 2014 to January 2016, where she led the global regulatory strategy and portfolio for Bavencio, the company&#8217;s anti-programmed death-ligand 1 antibody. Prior to that, she held various roles at several biotechnology companies, including Infinity, Sanofi and Genzyme (acquired by Sanofi in 2011). Ms. Noci received her B.A. from Adelphi University and her A.L.M. in government from Harvard University Extension School.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Christopher D. Turner, M.D.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Chief Medical Officer since March 2021. Before joining Nuvalent, Dr. Turner served as Vice President of Clinical Development at Blueprint Medicines Corporation, a global precision therapy company, from June 2018 to March 2021, where he oversaw the development and approval of kinase inhibitor GAVRETO (pralsetinib) in RET-fusion positive NSCLC and RET-altered thyroid cancer. From July 2014 to May 2018, Dr. Turner served as Vice President of Clinical Science at Celldex Therapeutics, Inc., a biopharmaceutical company, where he led the development of novel antibody-drug conjugate and immune-oncology pipeline compounds. From July 2008 to July 2014, Dr. Turner held various roles at ARIAD Pharmaceuticals, Inc., a pharmaceutical company that was acquired by Takeda Oncology in 2017, including Head of Clinical Research, where he led the development of ICLUSIG (ponatinib), a kinase inhibitor therapy for patients with chronic myeloid leukemia, and ALUNBRIG (brigatinib), a kinase inhibitor therapy for patients with ALK positive NSCLC. Prior to that, Dr. Turner was Director of the Pediatric Neuro-Oncology Outcomes Clinic at the Dana-Farber Cancer Institute/Children&#8217;s Hospital Boston and an Instructor of Pediatrics at Harvard Medical School. Dr. Turner is board certified in both Pediatrics and Pediatric Hematology and Oncology and is a Fellow of the American Academy of Pediatrics. He received his B.A. in biochemistry from Bowdoin College and his M.D. from the University of Rochester School of Medicine and Dentistry. He completed a residency in General Pediatrics at Children&#8217;s National Medical Center in Washington, DC and fellowships in both Pediatric Hematology/Oncology and Pediatric Neuro-Oncology at Duke University Medical Center in Durham, North Carolina.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Henry E. Pelish, Ph.D., </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as our Chief Scientific Officer since July 2024. Prior to that, he served as our Senior Vice President, Drug Discovery from February 2023 until July 2024. Prior to that, he served as our Vice President, Drug Discovery from September 2022 until February 2023, Vice President, Biology from July 2019 until September 2022, and Senior Director, Biology from April 2018 until July 2019. Before his employment with Nuvalent, Dr. Pelish worked as a consultant to Nuvalent from February 2017 to April 2018. Dr. Pelish contributed scientifically to the creation of Nuvalent. Prior to April 2018, Dr. Pelish served as a Research Associate at Harvard University, where he contributed to the discovery of a new mechanism for targeting acute myeloid</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">leukemia cells that resulted in a licensing agreement and research collaboration with Merck. Dr. Pelish received a B.S. from Johns Hopkins, an M.S. from Stanford, and a Ph.D. in Chemistry and Chemical Biology from Harvard University.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Corporate Information</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated under the laws of the state of Delaware on January 25, 2017 under the name Nuvalent, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our principal executive offices are located at One Broadway, 14</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Floor, Cambridge, MA 02142 and our telephone number is (857) 357-7000. Our website address is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">http://www.nuvalent.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The information contained on, or accessible through, our website does not constitute part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Internet address is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.nuvalent.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act are available through the &#8220;Investors&#8221; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not part of this Annual Report or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC&#8217;s Interactive Data Electronic Applications system at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">http://www.sec.gov</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In evaluating the Company and our business, careful consideration should be given to the following risk factors, in addition to the other information set forth in this Annual Report and in other documents that we file with the SEC. Our business faces significant risks and uncertainties. Investing in our common stock involves a high degree of risk. If any of the following risks and uncertainties were to actually occur, our business, prospects, financial condition or results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks facing the Company. New risk factors can emerge from time to time, and it is not possible to predict the impact that any one factor or combination of factors may have on our business, prospects, financial condition or results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to our financial position and need for additional capital</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a limited operating history, have no products approved for commercial sale and have not generated any revenue, which may make it difficult for investors to evaluate our current business and likelihood of success and viability.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a biopharmaceutical company with an operating history limited to research and development upon which investors can evaluate our business and prospects. We commenced significant operations in 2018, have no products approved for commercial sale and have never generated any revenue. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. To date, we have devoted substantially all of our resources to research and development activities, including with respect to zidesamtinib (NVL-520), our ROS proto-oncogene 1 (ROS1)-selective inhibitor, neladalkib (NVL-655), our anaplastic lymphoma kinase (ALK)-selective inhibitor, NVL-330, our human epidermal growth factor receptor 2 (HER2)-selective inhibitor, and our discovery programs, business planning, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, preparing for potential commercialization and providing general and administrative support for these operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2025, we announced the completion of our New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zidesamtinib in tyrosine kinase inhibitors (TKI) pre-treated patients with locally advanced or metastatic (advanced) ROS1-positive non-small cell lung cancer (NSCLC) and subsequently, the FDA accepted for filing our NDA and assigned us a target action date of September 18, 2026 under the Prescription Drug User Fee Act (PDUFA). We cannot provide any assurances that the FDA will approve our NDA for zidesamtinib by the PDUFA target action date, or ever. We have not yet demonstrated our ability to successfully obtain marketing approvals, manufacture a commercial product at peak scale or have a third party do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Accordingly, investors should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by clinical-stage biopharmaceutical companies such as ours. Any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by biopharmaceutical companies at our stage of development in rapidly evolving fields. As we approach the PDUFA target action date for zidesamtinib, we will also need to transition from a company with a primarily research and development focus to a company capable of undertaking commercial activities. We have not yet demonstrated an ability to successfully overcome such risks and difficulties, or to make such a transition. While we are in the process of establishing a commercial infrastructure in preparation for a commercial launch of zidesamtinib, if it is approved, and have been incurring costs in connection with such preparations, there can be no assurance that we will be able to obtain marketing approval for zidesamtinib or any of our other product candidates. Even if we are able to do so, we may not generate any meaningful return from the investments we have made and expect to make in the development of our product candidates or in connection with preparations for the commercial launch of our product candidates. We expect that our costs will continue to increase over time as we expand our operations, including our commercialization efforts. If we obtain marketing approval for zidesamtinib or our other product candidates, we will incur significant sales, marketing, manufacturing and distribution expenses. In addition, we may not be successful in building out the commercial, medical affairs and other functional capabilities that we believe will be necessary to operate as a fully integrated commercial-stage biopharmaceutical company, and our failure to do so could have an adverse effect on our anticipated development and commercialization timelines and on our financial condition and results of operations. If we do not adequately address these risks and difficulties or successfully make a transition to a commercial-stage company, our business will suffer.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred significant net losses in each period since our inception, and we expect to continue to incur significant net losses for the foreseeable future.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant net losses in each reporting period since our inception, have not generated any revenue to date and have financed our operations principally through private placements and public offerings of securities. Our net losses were $425.4 million, $260.8 million and $126.2 million for the years ended December 31, 2025, 2024 and 2023, respectively. As of December 31, 2025, we had an accumulated deficit of $972.4 million. Our ability to generate revenue from product sales will depend heavily on the successful clinical development of, receipt of marketing approval from regulatory authorities for, and commercialization of one or more of our product candidates. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses in order to discover, develop and market additional potential products.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to incur significant expenses and significant net losses for the foreseeable future. We anticipate that our expenses will increase over time as we prepare for the potential commercialization of zidesamtinib, including due to the impact of increased headcount, and to support our clinical and commercialization activities and expanded infrastructure, among other things. If we obtain marketing approval of zidesamtinib, we expect to incur further increased sales, marketing, distribution and manufacturing expenses. Further, the net losses we incur may fluctuate from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the pace of our development and commercialization activities and the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital, our ability to fund the development of our product candidates and our ability to achieve and maintain profitability and the performance of our stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve our objectives relating to the discovery, development and commercialization of our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on our team&#8217;s expertise in chemistry, structure-based drug design, oncology drug development, business development and our patient-driven approach to develop our product candidates. Our business depends significantly on the success of our approach and the development and commercialization of the product candidates that we discover with this approach. We have been incurring commercialization expenses related to zidesamtinib, including costs associated with building a commercial infrastructure, and expect to incur additional commercialization expenses in advance of potentially receiving marketing approval for zidesamtinib. However, we currently have no products approved for commercial sale, and we have not generated any revenue to date. Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful and timely completion of preclinical and clinical development of our current and future product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining current and establishing new relationships with contract research organizations (CROs) and clinical sites for the clinical development of our current and future product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timely receipt of marketing approvals from applicable regulatory authorities for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing an efficient and scalable manufacturing process for our product candidates, including the production of finished products that are appropriately packaged for sale if our product candidates obtain marketing approvals;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining current and establishing new commercially viable supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and meet the market demand for our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful commercial launch following any marketing approval, including the development of a commercial infrastructure;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining an acceptable safety profile following any marketing approval of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercial acceptance of our product candidates by patients, the medical community and third-party payors, including the willingness of physicians to use our product candidates, if approved, in lieu of (or in conjunction with) other approved therapies;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfying any required post-marketing approval commitments to applicable regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying, assessing and developing new product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the United States (U.S.) and internationally;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">defending against third-party interference or infringement claims, if any;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entering into, on favorable terms, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining coverage, adequate pricing and adequate reimbursement by third-party payors for our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addressing any competing therapies and technological and market developments; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attracting, hiring and retaining qualified personnel.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may never be successful in achieving our objectives and, even if we do, may never generate revenue that is significant or large enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our Class A common stock and could impair our ability to maintain or further our research and development efforts, raise additional necessary capital, grow our business and continue our operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may require additional funding to finance our operations. If we are unable to obtain such funding when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and drug development programs, commercialization efforts, product development or other operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have used substantial amounts of cash to fund our operations, and we expect to incur significant expenses for the foreseeable future in connection with our ongoing activities, particularly as we continue the research and development of, initiate additional clinical trials of, seek marketing approval for, prepare for the commercialization of, and, if approved, commercialize our product candidates. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Even if one or more of our product candidates or any future product candidates that we develop are approved for commercial sale, we anticipate incurring significant costs associated with sales, marketing, manufacturing and distribution activities. Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency (EMA) or other regulatory authorities to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. Because the success of our research, development and commercialization activities is highly uncertain, we cannot reasonably estimate the actual amount of resources and funding that will be necessary to successfully complete the development and commercialization of our product candidates or any future product candidates. We are not permitted to market or promote any product candidate before we receive marketing approval from the FDA, EMA or any comparable foreign regulatory authorities. Accordingly, we may need to obtain additional funding in order to continue our operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities as of the date of this Annual Report will be sufficient to fund our operating expenses and capital expenditure requirements into 2029. Advancing the development of zidesamtinib, neladalkib, NVL-330 and our discovery programs and ultimately commercializing them, if approved, will require a significant amount of capital. Our existing cash, cash equivalents and marketable securities may not be sufficient to fund all of our product candidates through regulatory approval and into commercialization, if approved. We cannot be certain as to when, if ever, we will be able to generate substantial product revenues sufficient to fund our operations. We may, therefore, need to raise additional capital to complete the development and commercialization of our product candidates. Our estimate as to how long we expect our existing cash, cash equivalents and marketable securities to fund our operations does not include potential product revenue and is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, that we can generate substantial product revenues, we may be required to finance our funding needs through public or private equity financings, debt financings, collaborative agreements, licensing arrangements or other sources of financing, which may dilute our stockholders or restrict our operating activities. We do not have any committed external source of funds. Adequate additional funding may not be available to us on acceptable terms, or at all. Our ability to raise additional funds may be adversely impacted by general economic conditions, both inside and outside the U.S., including disruptions to, and instability and volatility in, the credit and financial markets in the U.S. and worldwide, including heightened inflation, interest rate and currency rate fluctuations, and economic slowdown or recession as well as concerns related to public health emergencies, natural disasters or geopolitical events, including actual or threatened tariffs or other changes in trade policy, civil or political unrest or military conflicts. In addition, market instability and volatility, high levels of inflation and interest rate fluctuations may increase our cost of financing or restrict our access to potential sources of future liquidity. To the extent that we raise additional capital through the sale of equity or convertible debt securities, each investor&#8217;s ownership interests will be diluted, and the terms may include liquidation or other preferences that adversely affect each investor&#8217;s rights as a stockholder. Debt financing may result in imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through upfront payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. In addition, we may opportunistically seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our failure to obtain funding as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research or drug development programs, clinical trials or commercialization efforts.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to the discovery, development and commercialization of our product candidates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future prospects are substantially dependent on zidesamtinib, neladalkib and NVL-330. If we are unable to advance these product candidates through development, obtain regulatory approval and ultimately commercialize such product candidates, or experience significant delays in doing so, our business will be materially harmed. Even if we obtain regulatory approval for such candidates, there is no assurance that our commercialization efforts will be successful or that we will be able to generate revenues or profits at the levels or on the timing we expect, if at all.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently conducting Phase 1/2 clinical trials of zidesamtinib and neladalkib, a Phase 3 clinical trial of neladalkib, and a Phase 1 clinical trial of NVL-330. In November 2025, the FDA accepted for filing our NDA for zidesamtinib in TKI pre-treated patients with advanced ROS1-positive NSCLC and assigned us a target action date of September 18, 2026 under PDUFA. We cannot provide any assurances that the FDA will approve our NDA for zidesamtinib by the PDUFA target action date, or ever.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate product revenue will depend heavily on the successful clinical development of, receipt of marketing approval from regulatory authorities for, and commercialization of one or more product candidates. We are not permitted to market or promote any product candidate before we receive marketing approval from the FDA, EMA or any comparable foreign regulatory authorities, and we may never receive such marketing approvals.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our product candidates will depend on several factors, including the following:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful and timely completion of preclinical studies;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission of Investigational New Drug applications (INDs) in the U.S. and clinical trial applications (CTAs) and/or comparable applications outside the U.S. for regulatory authority review and agreement to proceed with our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful initiation and completion of clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful and timely patient selection and enrollment in and completion of clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining and establishing relationships with CROs and clinical sites for the clinical development of our product candidates both in the U.S. and internationally;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining and growing an organization of scientific, medical and other professionals who can develop and commercialize our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the frequency and severity of adverse events in clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining positive data that support demonstration of efficacy, safety and tolerability profiles and durability of effect for our product candidates that are satisfactory to the FDA, EMA or any comparable foreign regulatory authority for marketing approval;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timely receipt of marketing approvals from applicable regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timely identification, development and approval of companion diagnostic tests, if required;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent of any required post-marketing approval commitments to applicable regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the maintenance of existing or the establishment of new supply arrangements with third-party drug product suppliers and manufacturers for clinical development and, if approved, commercialization of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the U.S. and internationally;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the protection of our rights in our intellectual property portfolio;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continuing to build sales, marketing and distribution capabilities and the successful launch of commercial sales of our product candidates if and when approved for marketing, whether alone or in collaboration with others;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining an acceptable safety profile following any marketing approval;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercial acceptance by patients, the medical community and third-party payors, including the willingness of physicians to use our product candidates, if approved, in lieu of (or in conjunction with) other approved therapies;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to compete with other therapies; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to address any potential delays resulting from factors related to public health emergencies, natural disasters or geopolitical events.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have complete control over many of these factors, including certain aspects of preclinical and clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any product candidates from our lead programs, which would materially harm our business. If we do not receive marketing approvals for such product candidates, we may not be able to continue our operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval for any of our product candidates, we may never be able to successfully commercialize any product to achieve profitability. We have never marketed, sold or distributed for commercial use any pharmaceutical product. We may encounter issues, delays or other challenges in launching or commercializing a product candidate or generating revenues, if approved,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which could impair our ability to successfully commercialize the product or to generate revenues or profits or to meet our expectations with respect to the amount or timing of revenues or profits.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our preclinical studies and clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates, which would prevent or delay development, regulatory approval and commercialization.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining marketing approval from the FDA, EMA or other comparable foreign regulatory authorities for the sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Preclinical and clinical testing is expensive, difficult to design and implement, can take many years to complete and the ultimate outcome is uncertain. Failure can occur at any time during the preclinical study and clinical trial processes, there is a high risk of failure, and we may never succeed in developing marketable products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent receipt of marketing approval or our ability to commercialize our product candidates, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of our product candidates in preclinical studies or clinical trials to demonstrate safety and efficacy;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt of feedback from regulatory authorities that requires us to modify the design of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negative or inconclusive clinical trial results that may require us to conduct additional clinical trials or abandon certain research, discovery and/or drug development programs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients required for clinical trials being larger than anticipated, enrollment in these clinical trials being slower than anticipated, particularly if there are other trials enrolling the same or overlapping precisely targeted patient populations, or participants dropping out of these clinical trials at a higher rate than anticipated;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the suspension or termination of our clinical trials for various reasons, including non-compliance with regulatory requirements or a finding that our product candidates have undesirable adverse events or other unexpected characteristics or risks;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of clinical trials of our product candidates being greater than anticipated;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates being insufficient or inadequate;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators determining that the requirements for approving our product candidates are different than what we expect or are different from regulatory precedent, including potentially in connection with feedback from the FDA regarding what data from our clinical trials may constitute pivotal data sufficient to support NDA submissions; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators revising the requirements for approving our product candidates.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we are currently contemplating, if we are unable to successfully complete clinical trials of our product candidates or other testing in a timely manner, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may incur unplanned costs, be delayed in seeking and obtaining marketing approval, if we receive such approval at all, receive more limited or restrictive marketing approval, be subject to additional post-marketing testing requirements or have the drug removed from the market after obtaining marketing approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our discovery and development activities are focused on the development of targeted therapeutics for patients with cancer-associated genomic alterations, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs may never lead to approved or marketable products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The discovery and development of targeted therapeutics for patients with cancer-associated genomic alterations is an emerging field, and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are evolving. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. Although we believe, based on our preclinical work and clinical trials to date, that the genomic alterations targeted by our programs are oncogenic drivers, clinical results may not confirm this hypothesis or may only confirm it for certain alterations or certain tumor types. The patient populations for our product candidates are limited to those with specific target alterations and may not be completely defined but are substantially smaller than the general treated cancer population, and we will need to screen and identify these patients with targeted alterations. Successful identification of patients is dependent on several factors, including achieving certainty as to how specific alterations respond to our product candidates and the ability to identify such alterations, which may require the use of companion diagnostic tests. Furthermore, even if we are successful in identifying patients, we cannot be certain that the resulting patient populations for each mutation will be large enough to allow us to successfully obtain approval for each mutation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">type and commercialize our product candidates and achieve profitability. We do not know if our approach of focusing on treating patients with cancer-associated genomic alterations will be successful, and if our approach is unsuccessful, our business will suffer.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any delays in the commencement or completion, or termination or suspension, of our current, planned or future clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before we can initiate clinical trials of any product candidate in any indication, we must submit the results of preclinical studies to the FDA, EMA or other comparable foreign regulatory authorities along with other information, including information about the product candidate&#8217;s chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND or similar regulatory submission under which we must receive authorization to proceed with clinical development. The FDA, EMA or other comparable foreign regulatory authorities may require us to conduct additional preclinical studies for any product candidate before they allow us to initiate clinical trials under any IND, CTA or comparable application which may lead to additional delays and increase the costs of our preclinical development programs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining marketing approval from the FDA of any of our product candidates, including any future product candidates, in any indication, we must conduct extensive clinical studies to demonstrate safety and efficacy. Clinical testing is expensive, time consuming and uncertain as to outcome. In addition, we expect to rely in part on preclinical, clinical and quality data generated by our CROs and other third parties for regulatory submissions for our product candidates. While we have or will have agreements governing these third parties&#8217; services, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase. We are currently conducting Phase 1/2 clinical trials of zidesamtinib and neladalkib, a Phase 3 clinical trial of neladalkib, and a Phase 1 clinical trial of NVL-330. An IND submission must become effective prior to initiating any clinical trials in the U.S. for any of our future product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, by an institutional review board (IRB) or independent ethics committee (IEC) of the institutions in which such trials are being conducted, by a data monitoring committee for such trial or by the FDA or foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse events, failure to demonstrate a benefit from using a pharmaceutical, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs/IECs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted. For example, in December 2022, with the passage of the Food and Drug Omnibus Reform Act (FDORA), Congress required sponsors to develop and submit a diversity action plan (DAP) for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for diversity action plans (DAPs). Unlike most guidance documents issued by the FDA, if the DAP guidance is finalized, it would have the force of law because FDORA specifically dictates that the form and manner for submission of DAPs are to be specified in FDA guidance.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, in response to an executive order issued by President Trump, relating to diversity, equity and inclusion programs, the FDA removed the draft DAP guidance from its website. That action, along with similar actions by the Trump administration to remove certain other healthcare webpages, is currently the subject of ongoing litigation. Accordingly, in light of these ongoing actions, there is considerable uncertainty surrounding the draft DAP guidance and how the FDA will consider DAPs in connection with its review of NDAs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, the regulatory landscape related to clinical trials in the European Union (EU) recently evolved. The Clinical Trials Regulation (EU) No 536/2014 (CTR), which was adopted in April 2014 and repealed the Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate CTA to be submitted in each member state, to both the competent national health authority and an IEC, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our current or future scientific advisors or consultants who receive compensation from us may become investigators for our future clinical trials. Under certain circumstances, we may be required to report some of these relationships to the FDA. Although we expect any such relationships to be within the FDA&#8217;s guidelines, the FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates. If we experience delays in the completion of, or termination of, any clinical trial of any product candidate, the commercial prospects of such product candidate will be harmed, and our ability to generate product revenue will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our development and approval process and jeopardize our ability to commence product sales and generate revenue, which may harm our business, financial condition, results of operations and prospects significantly.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later-stage clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities and we may not be able to commercialize our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each of our product candidates, we are required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for use before we can seek marketing approvals for their commercial sale. Preclinical and clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Further, we have limited experience as a company in conducting and managing clinical trials, including later-stage clinical trials, necessary to support applications for marketing approval. Failure can occur at any time during the preclinical study and clinical trial processes, there is a high risk of failure, and we cannot guarantee that we will succeed in developing and commercializing marketable products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of preclinical studies may not be predictive of the results of clinical trials of our product candidates, and the results of early clinical trials may not be predictive of the results of later-stage clinical trials. Although product candidates may demonstrate promising results in preclinical studies and early clinical trials, they may not prove to be safe or effective in subsequent clinical trials. Favorable results from certain animal studies may not accurately predict the results of other animal studies or of human trials, due to the inherent biologic differences in species, the differences between testing conditions in animal studies and human trials, and the particular goals, purposes, and designs of the relevant studies and trials. Similarly, certain of our hypotheses regarding the potential clinical and therapeutic benefits of our product candidates compared to other products or molecules in development are based on observations from the preclinical studies and early clinical trials that we have completed, and results from such preclinical studies and early clinical trials are not necessarily predictive of the results of later preclinical studies or clinical trials.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is typically an extremely high rate of attrition from the failure of product candidates proceeding through preclinical studies and clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. Likewise, early, smaller-scale clinical trials may not be predictive of eventual safety or effectiveness in large-scale pivotal clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy, insufficient durability of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence preclinical studies and clinical trials are never approved as products. The development of our product candidates and our stock price may also be impacted by inferences, whether correct or not, that are drawn between the success or failure of preclinical studies or clinical trials of our competitors or other companies in the biopharmaceutical industry, in addition to our own preclinical studies and clinical trials.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dose and dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause adverse events that are unrelated to our product candidates. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any preclinical studies or clinical trials that we conduct may not demonstrate the safety and efficacy necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety and efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for such product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain marketing approval for any of our product candidates, the commercialization prospects and our business and financial prospects would be materially adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In addition to zidesamtinib, neladalkib and NVL-330, our prospects depend in part upon discovering, developing and commercializing additional product candidates from our discovery programs, which may fail in development or suffer delays that adversely affect their commercial viability.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future operating results are dependent on our ability to successfully discover, develop, obtain regulatory approval for and commercialize zidesamtinib, neladalkib, NVL-330 and future product candidates from our discovery programs. A research candidate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">can unexpectedly fail at any stage of development. The historical failure rate for research candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care and other unpredictable variables. The results from preclinical testing or early clinical trials of a product candidate may not be predictive of the results that will be obtained in later-stage clinical trials of the product candidate.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of other research candidates that we may develop will depend on many factors, including the following:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">generating sufficient data to support the initiation or continuation of preclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining regulatory permission to initiate clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contracting with the necessary parties to conduct clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful enrollment of patients in, and the completion of, clinical trials on a timely basis;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timely manufacture of sufficient quantities of a product candidate for use in clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse events in clinical trials; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addressing any delays resulting from factors related to public health emergencies, natural disasters or geopolitical events.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we successfully advance any research candidates into preclinical and clinical development, their success will be subject to all of the preclinical, clinical, regulatory and commercial risks described elsewhere in this &#8220;Risk Factors&#8221; section.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The regulatory approval processes of the FDA, EMA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval of our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining approval by the FDA, EMA and other comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval for our product candidates, the FDA, EMA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested or may impose other prescribing limitations or warnings that limit the product candidate&#8217;s commercial potential. Even if approved, we may be required to conduct additional studies to verify or confirm the clinical benefits of our products. We have not obtained regulatory approval for any product candidate, nor have we submitted for regulatory approval for any product candidate other than zidesamtinib, and it is possible that none of our product candidates will ever obtain regulatory approval. Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, under the Pediatric Research Equity Act (PREA), an NDA or supplement to an NDA for certain drug products must contain data to assess the safety, potency and purity of the drug product in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe, potent and pure, unless the sponsor receives a deferral or waiver from the FDA. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety, potency and purity data need to be collected before the pediatric trials begin. The law requires the FDA to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. It further requires the FDA to publicly post the PREA Non-Compliance letter and the sponsor&#8217;s response. The applicable legislation in the EU also requires sponsors to either conduct clinical trials in a pediatric population in accordance with a Pediatric Investigation Plan approved by the Pediatric Committee of the EMA or to obtain a waiver or deferral from the conduct of these studies by this Committee.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For any of our product candidates for which we are seeking regulatory approval in the U.S. or the EU, we cannot guarantee that we will be able to obtain a waiver or alternatively complete any required studies and other requirements in a timely manner, or at all, which could result in an issuance and publication of a PREA Non-Compliance letter and associated reputational harm, our product candidate being considered misbranded and subject to relevant enforcement action, invalidation of the marketing application, and/or financial penalties.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, are only moderately effective or have undesirable or unintended adverse events, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical data of the clinical trial may fail to meet the level of statistical significance required to obtain approval of our product candidates by the FDA, EMA or other comparable foreign regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate to the FDA, EMA or other comparable foreign regulatory authorities that our product candidates&#8217; risk-benefit ratios for their proposed indications are acceptable;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, EMA or other comparable regulatory authorities may fail to approve companion diagnostic tests required for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not obtain or maintain adequate funding to complete the clinical trial in a manner that is satisfactory to the FDA, EMA or other comparable foreign regulatory authorities; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates may cause significant adverse events, toxicities or other undesirable adverse events when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could prevent regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidates are associated with undesirable adverse events or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable adverse events or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related adverse events could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly. There have been, and it is likely that there will be additional, adverse events associated with the use of our product candidates as is typically the case with oncology drugs. Results of our studies or trials could reveal a high and unacceptable severity and prevalence of these or other adverse events. In such an event, our trials could be suspended or terminated and the FDA, EMA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Drug-related adverse events could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our product candidates may be used in populations for which safety concerns may be particularly scrutinized by regulatory authorities. Our product candidates may be studied in combination with other therapies, which may exacerbate adverse events associated with the therapy. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments, which can cause adverse events that are unrelated to our product candidates but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses. For example, it is expected that some of the patients to be enrolled in our current or future clinical trials may die or experience major clinical events either during the course of our clinical trials or after participating in such trials for non-treatment related reasons.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If significant adverse events are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, EMA, other comparable foreign regulatory authorities or an IRB may suspend clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse events. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause adverse events that prevented their further development. Even if the adverse events do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable adverse events may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects. Further, if any of our product candidates obtain marketing approval, toxicities associated with such product candidates previously not seen during clinical testing may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early-stage clinical trials.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, preliminary and topline data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have publicly disclosed interim, preliminary or topline data from our preclinical studies and clinical trials and we expect to do so in the future. These interim updates are based on preliminary analyses of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. For example, we may report responses in certain patients that are unconfirmed at the time and which do not ultimately result in confirmed responses to treatment after follow-up evaluations. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, preliminary or topline results that we report may differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim, preliminary and topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the interim, preliminary or topline data we previously published. As a result, interim, preliminary and topline data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim, preliminary and topline data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse changes between interim, preliminary or topline data and final data could significantly harm our business and prospects. Further, additional disclosure of interim, preliminary or topline data by us or by our competitors in the future could result in volatility in the price of our Class A common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the information we choose to publicly disclose regarding a particular study or trial is typically selected from a more extensive amount of available information. Investors may not agree with what we determine is the material or otherwise appropriate information to include in our public disclosures, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, preliminary or topline data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, any of our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we experience delays or difficulties in the enrollment or maintenance of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#8217;s conclusion as required by the FDA, EMA or other comparable foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials. Our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. We utilize genomic profiling of patients&#8217; tumors to identify suitable patients for recruitment into our clinical trials. For these clinical trials, we seek patients with specific genomic alterations that our product candidates are designed to precisely target. We cannot be certain (i) how many patients will have the requisite genomic alterations that qualify for inclusion in our clinical trials, (ii) that the number of patients enrolled in each program will suffice for regulatory approval or (iii) if regulatory approval is obtained, whether each specific ROS1, ALK or HER2 alteration will be included in the approved drug label. Additionally, we face competition, including from large pharmaceutical companies with significantly more resources than us, for enrollment of our precisely targeted patient populations, which may impact our ability to successfully recruit patients for our clinical trials. If our strategies for patient identification and enrollment prove unsuccessful, we may have difficulty enrolling or maintaining patients appropriate for our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient enrollment may be affected if our competitors have ongoing clinical trials for programs that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#8217; programs. Patient enrollment for our current or future clinical trials may be affected by other factors, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">size and nature of the patient population;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">severity of the disease under investigation;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability and efficacy of approved drugs for the disease under investigation;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient eligibility criteria for the trial in question as defined in the protocol, including biomarker-driven identification and/or certain highly-specific criteria related to stage of disease progression, which may limit the patient populations eligible for our clinical trials to a greater extent than competing clinical trials for the same indication that do not have a biomarker-driven patient eligibility criteria;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perceived risks and benefits of the product candidate under study;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved or other product candidates being investigated for the indications we are investigating;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; willingness to screen their patients for biomarkers to indicate which patients may be eligible for enrollment in our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient referral practices of physicians;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to monitor patients adequately during and after treatment;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proximity and availability of clinical trial sites for prospective patients; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining participation in our clinical trials through the treatment and any follow-up periods.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have never commercialized a product candidate as a company before and currently lack substantially all of the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never commercialized a product candidate as a company. While we are in the process of establishing a commercial infrastructure in preparation for a potential future product launch if one or more of our product candidates receives marketing approval, we may license certain rights with respect to our product candidates to collaborators, and, if so, we will rely on the assistance and guidance of those collaborators. For product candidates for which we retain commercialization rights and marketing approval, we will have to continue to build our own sales, marketing and supply organization or outsource these activities to a third party.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factors that may affect our ability to commercialize our product candidates, if approved, on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, developing adequate educational and marketing programs to increase public acceptance of our approved product candidates, ensuring regulatory compliance of our Company, employees and third parties under applicable healthcare laws, and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our product candidates upon approval. We may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may not generate revenue from them or be able to reach or sustain profitability.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if one of our product candidates receives marketing approval, we or others may later discover that the product is less effective or tolerable than previously believed or causes undesirable side effects that were not previously identified, which could compromise our ability, or that of our collaborators, to market the product.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of a product candidate, we or others discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw their approval of the product or seize the product;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to recall the product, change the way the product is administered or conduct additional clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular product;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our collaborators, could be sued and held liable for harm caused to patients;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product may become less competitive; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could harm our business and operations and could negatively impact our stock price.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have limited resources and are currently focusing our efforts on zidesamtinib, neladalkib and NVL-330 in particular indications and advancing our discovery programs. As a result, we may fail to capitalize on other indications or product candidates that may ultimately have proven to be more profitable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently focusing our resources and efforts on our lead product candidates, zidesamtinib and neladalkib, for advanced ROS1-positive NSCLC and other solid tumors and advanced ALK-positive NSCLC and other solid tumors, respectively, on NVL-330 for advanced HER2-altered NSCLC, and on advancing our discovery programs. As a result, because we have limited resources, we may forgo or delay pursuit of opportunities for other indications or with other product candidates that may have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development activities for zidesamtinib, neladalkib, NVL-330 and our discovery programs may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target markets for zidesamtinib, neladalkib, NVL-330 or any future product candidates we identify through our discovery programs, we may enter into collaboration, licensing or other strategic arrangements with the effect of relinquishing valuable rights in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face substantial competition which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of product candidates are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In addition, our product candidates may need to compete with drugs physicians use off-label to treat the indications for which we seek approval. This may make it difficult for us to replace existing therapies with our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, there is intense competition in the field of oncology. We have competitors both in the U.S. and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up companies, universities and other research institutions. We also compete with these organizations to recruit and retain qualified personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to face competition from existing products and products in development for each of our lead programs and in particular, our competitors that are developing product candidates often have the advantage of significant financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For zidesamtinib, there are currently four ROS1-targeted kinase inhibitors approved by the FDA for use in TKI-na&#239;ve ROS1-positive NSCLC: Xalkori (crizotinib), Rozlytrek (entrectinib), Augtyro (repotrectinib) and Ibtrozi (taletrectinib). Crizotinib has also received approval for treatment of ALK-positive NSCLC. Lorbrena (lorlatinib) is another therapy recommended for use in ROS1-positive NSCLC patients according to the National Comprehensive Cancer Network guidelines. Lorlatinib is a dual ALK/ROS1 inhibitor that has received marketing approval for the treatment of ALK-positive NSCLC and has demonstrated central nervous system activity as reported in its prescribing information.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For neladalkib, there are six ALK inhibitors approved by the FDA for the treatment of ALK-positive NSCLC: crizotinib, Zykadia (ceritinib), Alecensa (alectinib), Alunbrig (brigatinib), lorlatinib and Ensacove (ensartinib). All six have line-agnostic approvals for the treatment of ALK-positive NSCLC patients, including for patients who are TKI-na&#239;ve. Additionally, lorlatinib has demonstrated activity in patients that have progressed on crizotinib, alectinib, or ceritinib.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For NVL-330, there are two HER2 inhibitors approved by the FDA for the treatment of HER2-altered NSCLC: Hernexeos (zongertinib) and Hyrnuo (sevabertinib). Additionally, Enhertu (T-DXd), an antibody-drug conjugate, has been approved by the FDA for the treatment of HER2 mutant NSCLC.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the market, and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology product candidates. These companies also have significantly greater research and marketing capabilities than we do and may also have product candidates that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result of all of these factors, our competitors may succeed in obtaining approval from the FDA, EMA or other comparable foreign regulatory authorities or in discovering, developing and commercializing product candidates in our field before we do.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our potential commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe adverse events, are more convenient, have a broader label, are marketed more effectively, are more widely reimbursed or are less expensive than any products that we may develop. Physicians may be more willing to prescribe our competitors&#8217; products for various reasons, and may rely on guidelines related to treatment of patients issued by medical societies, industry groups or other organizations, which may not include, and may never include, our products. Our competitors also may obtain marketing approval from the FDA, EMA or other comparable foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development and marketing more complicated. Even if the product candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, as well as sophisticated quality assurance and quality control procedures. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturers, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. Contaminations can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our third-party manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. For example, we may introduce an alternative formulation of one or more of our product candidates during the course of our clinical trials. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and impair our ability to generate revenue.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, third-party payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of the product candidate as well as competitive products;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which a product candidate is approved;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the use of product candidates in the labeling approved by regulatory authorities, such as boxed warnings or contraindications in labeling, or a Risk Evaluation and Mitigation Strategy (REMS), if any, which may not be required of alternative treatments and competitor products;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential and perceived advantages of our product candidates over alternative treatments;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of treatment in relation to alternative treatments;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage and adequate reimbursement by third-party payors, including government authorities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to establish appropriate sales prices for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">willingness of physicians to use our product candidates, if approved, in lieu of (or in conjunction with) other approved therapies;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of an approved product candidate for use as a combination therapy;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative convenience and ease of administration;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of the target patient population to try new therapies and undergo required diagnostic screening to determine treatment eligibility and of physicians to prescribe these therapies and diagnostic tests;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of sales and marketing efforts;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable publicity relating to our product candidates; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval of other new therapies for the same indications.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates are approved but do not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market opportunities for any product candidates we develop, if approved, may be limited to certain smaller patient subsets and may be smaller than we estimate them to be.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When cancer is detected early (referred to as localized disease), conventional treatments, which include chemotherapy, hormone therapy, surgery and radiation therapy and/or selected targeted therapies, may be adequate to cure the patient in many cases. However, once cancer has spread to other areas (advanced or metastatic disease), cancer treatments may not be sufficient to provide a cure but often can significantly prolong life without curing the cancer. First-line therapies designate treatments that are initially administered to patients with advanced or metastatic disease, while second- and third-line therapies are administered to patients when the prior therapies lose their effectiveness. The FDA, EMA and other regulatory bodies often approve cancer therapies for a particular line of treatment. Typically, drug approvals are initially granted for use in later lines of treatment, but with additional evidence of significant efficacy from clinical trials, biopharmaceutical companies can successfully seek and gain approval for use in earlier lines of treatment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to initially seek approval of zidesamtinib, neladalkib, NVL-330 and any other future product candidates in most instances for previously treated patients with advanced or metastatic cancer where at least one prior therapy has limited clinical benefit or where tumors have developed resistance to such therapy. For those product candidates that prove to be sufficiently safe and effective, if any, we would potentially expect to seek approval ultimately as a first line TKI therapy. There is no guarantee that our product candidates, even if approved for previously treated patients would be approved for an earlier line of therapy, and prior to any such approvals we may have to conduct additional clinical trials that may be costly, time-consuming and subject to risk.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive a particular line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new data and studies may change the estimated incidence or prevalence of the cancers that we are targeting, especially if new therapies that are approved while we advance our product candidates affect the treatment paradigm and/or the size of the target population. The potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Consequently, even if our product candidates are approved, the number of patients that may be eligible for treatment with our product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">candidates may turn out to be much lower than expected. In addition, we have not yet conducted market research to determine how treating physicians would expect to prescribe a product that is approved for multiple tumor types if there are different lines of approved therapies for each such tumor type. Even if we obtain significant market share for our products, if approved, if the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we are able to commercialize any of our product candidates, the drugs may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients rely on insurance coverage by third-party payors (third-party payors include federal healthcare programs such as Medicare and Medicaid and commercial insurance companies such as Blue Cross Blue Shield, Humana, Cigna, etc.), to pay for products. The availability and extent of coverage and adequate reimbursement by third-party payors, including federal healthcare programs, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the U.S. and internationally, on the extent to which the costs of such product candidates will be covered and reimbursed by third-party payors. No uniform policy exists for coverage and reimbursement in the U.S. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the U.S., for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services (CMS), an agency within the U.S. Department of Health and Human Services (HHS). CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly. Factors payors consider in determining reimbursement include: (i) a covered benefit under its health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational. This process may require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As federal and state governments implement additional healthcare cost containment measures, including measures to lower prescription drug pricing, we cannot be sure that our products, if approved, will be covered by private or public payors, and if covered, whether the reimbursement will be adequate or competitive with other marketed products. Such other actions by federal and state governments and health plans may put additional downward pressure on pharmaceutical pricing and healthcare costs, which could negatively impact coverage and reimbursement for our products if approved, our revenue, and our ability to compete with other marketed products and to recoup the costs of our research and development. For further discussion, see &#8220;&#8212; Current and future legislation may increase the difficulty and cost for us to obtain reimbursement for our product candidates;&#8221; and &#8220;&#8212; The prices of prescription pharmaceuticals in the U.S. and foreign jurisdictions are the subject of considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed for marketing.&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or products, will apply to companion diagnostics. Additionally, if any companion diagnostic provider is unable to obtain reimbursement or is inadequately reimbursed, that may limit the availability of such companion diagnostic, which would negatively impact prescriptions for our product candidates, if approved.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the U.S., the commercialization of therapeutics is generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the EU, medical product prices are subject to varying price control mechanisms as part of national health systems. In</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the U.S. Other countries allow companies to fix their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the U.S., the reimbursement for our products may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenue and profits.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to establish or sustain coverage and adequate reimbursement for any product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business exposes us to significant product liability and other risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability and other claims or incidents, such as cyber incidents and breaches, could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA, EMA or other regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs. FDA, EMA or other regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources and substantial monetary awards to trial participants or patients. We currently have product liability and other insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to advancing our product candidates into later stages of development or marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial, product liability, and other types of insurance (such as cyber insurance) is becoming increasingly expensive and difficult to obtain. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability or other claims or incidents, including data breach and incidents, that could have an adverse effect on our business and financial condition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to regulatory approval and other legal compliance matters</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, may be unable to commercialize our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates are and will continue to be subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process must be successfully completed in the U.S. and in many foreign jurisdictions before a new drug can be approved for marketing. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. We cannot provide any assurance that any product candidate we may develop will progress through required clinical testing and obtain the regulatory approvals necessary for us to begin selling them.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the FDA accepted for filing our NDA for zidesamtinib in TKI pre-treated patients with advanced ROS1-positive NSCLC and assigned us a target action date of September 18, 2026 under PDUFA, we have not completed the regulatory approval process with the FDA, EMA or any other regulatory authority. The time required to obtain approvals from the FDA, EMA and other regulatory authorities is unpredictable and requires successful completion of extensive clinical trials which typically takes many years, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when evaluating clinical trial data can, and often does, change during drug development, which makes it difficult to predict with any certainty how they will be applied. We may also encounter unexpected delays or increased costs due to new government regulations, including future legislation or administrative action, or changes in applicable FDA, EMA or other regulatory policy during the period of drug development, clinical trials and regulatory review.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective or have undesirable or unintended adverse events, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate to the FDA, EMA or other comparable foreign regulatory authorities that our product candidates&#8217; risk-benefit ratios for their proposed indications are acceptable;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any delay or failure in seeking or obtaining required approvals would have a material and adverse effect on our ability to generate revenue from any particular product candidates we are developing and for which we are seeking approval. Furthermore, any regulatory approval to market a drug may be subject to significant limitations on the approved uses or indications for which we may market, promote and advertise the drug or the labeling or other restrictions. In addition, the FDA has the authority to require a REMS plan as part of approving an NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. These requirements or restrictions might include limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the drug and affect reimbursement by third-party payors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we could be adversely affected by several significant administrative law cases decided by the U.S. Supreme Court in 2024. In Loper Bright Enterprises v. Raimondo, for example, the U.S. Supreme Court overruled Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc., which previously required federal courts to defer to permissible agency interpretations of statutes that are silent or ambiguous on a particular topic. The U.S. Supreme Court stripped federal agencies of this presumptive deference and held that courts must exercise their independent judgment when deciding whether an agency such as the FDA acted within its statutory authority under the U.S. Administrative Procedure Act (APA). Additionally, in Corner Post, Inc. v. Board of Governors of the Federal Reserve System, the U.S. Supreme Court held that actions to challenge a federal regulation under the APA can be initiated within six years of the date of injury to the plaintiff, rather than the date the rule is finalized. The decision appears to give prospective plaintiffs a personal statute of limitations to challenge longstanding agency regulations. Another decision, Securities and Exchange Commission v. Jarkesy, overturned regulatory agencies&#8217; ability to impose civil penalties in administrative proceedings. These decisions could introduce additional uncertainty into the regulatory process and may result in additional legal challenges to actions taken by federal regulatory agencies, including the FDA and CMS, that we rely on. In addition to potential changes to regulations as a result of legal challenges, these decisions may result in increased regulatory uncertainty, delays and other impacts, any of which could adversely impact our business and operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, substantial uncertainty remains as to how, if at all, the current presidential administration will seek to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates. The impending uncertainty could present new challenges or potential opportunities as we navigate the clinical development and approval process for our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries, and generally includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may develop our current or future product candidates in combination with other therapies, which would expose us to additional risks.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may develop our current or future product candidates in combination with one or more currently approved cancer therapies or therapies in development. Even if any of our current or future product candidates were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA, EMA or other comparable foreign regulatory authorities could revoke approval of the therapy used in combination with any of our product candidates, or safety, efficacy, manufacturing or supply issues could arise with these existing therapies. In addition, it is possible that existing therapies with which our product candidates are approved for use could themselves fall out of favor or be relegated to later lines of treatment. This could result in the need to identify other combination therapies for our product candidates or our own products being removed from the market or being less successful commercially.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also evaluate our current or future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA, EMA or comparable foreign regulatory authorities. We will not be able to market and sell any product candidate in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA, EMA or other comparable foreign regulatory authorities do not approve or withdraw their approval of these other therapies, or if safety, efficacy, commercial adoption, manufacturing or supply issues arise with the therapies we choose to evaluate in combination with any of our current or future product candidates, we may be unable to obtain approval of or successfully market any one or all of the current or future product candidates we develop. Additionally, if the third-party providers of therapies or therapies in development used in combination with our current or future product candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our current or future product candidates, or if the cost of combination therapies are prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have conducted and intend to continue conducting certain of our clinical trials globally. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans may be delayed, which could materially harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have conducted and intend to continue conducting certain of our clinical trials globally. The acceptance by the FDA or other regulatory authorities of study data from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to good clinical practice (GCP) regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements, and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conducting clinical trials outside the U.S. also exposes us to additional risks, including risks associated with:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional foreign regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign exchange fluctuations;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with foreign manufacturing, customs, shipment and storage requirements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cultural differences in medical practice and clinical research;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diminished protection of intellectual property in some countries; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruptions or delays in our trials resulting from geopolitical events, including actual or threatened tariffs or other changes in trade policy, civil or political unrest or military conflicts.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA or EMA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the U.S., including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the U.S., a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our potential product candidates will be harmed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we could face heightened risks with respect to obtaining marketing authorization in the United Kingdom (U.K.) as a result of the withdrawal of the U.K. from the EU, commonly referred to as Brexit. The U.K. is no longer part of the European Single Market and EU Customs Union. As of January 1, 2025, the Medicines and Healthcare Products Regulatory Agency (MHRA) is responsible for approving all medicinal products destined for the U.K. market (i.e., Great Britain and Northern Ireland). In April 2025, the U.K. Parliament adopted amendments to improve and strengthen the U.K.&#8217;s clinical trials regulatory regime; they will take effect in April 2026. These changes were needed since the current U.K. requirements are based upon the now-repealed EU Clinical Trials Directive (2001/20/EC), which has been replaced by the European Clinical Trials Regulation (Regulation EU No 536/2014) (EU CTR). Since the U.K. left the EU prior to the date on which the EU CTR took effect, the U.K. legal framework did not benefit from the same revisions as occurred at EU level.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the same time, a new international recognition procedure (IRP) will apply, which intends to facilitate approval of pharmaceutical products in the U.K. The IRP is open to applicants that have already received an authorization for the same product from one of the MHRA&#8217;s specified Reference Regulators (RRs). The RRs notably include the EMA and regulators in the European Economic Area (EEA) Member States for approvals in the EU centralized procedure and mutual recognition procedure as well as the FDA (for product approvals granted in the U.S.). However, the concrete functioning of the IRP is currently unclear. Any delay in obtaining, or an inability to obtain, any marketing approvals may force us or our collaborators to restrict or delay efforts to seek regulatory approval in the U.K. for our product candidates, which could significantly and materially harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April 26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is anticipated in 2026. The revisions may, however, have a significant impact on the pharmaceutical industry and our business in the long term. On June 4, 2025, the European Council adopted its position on the proposed overhaul of the EU general pharmaceutical legislative framework, which is known as the new Pharma Package. This proposal will be the subject of additional negotiations and technical meetings, with the objective of reaching agreement on issues such as the regulatory data protection framework and the access and supply obligations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit, the ongoing review of EU pharmaceutical legislation or otherwise, may force us to restrict or delay efforts to seek regulatory approval for our product candidates in the U.K., the EU or other foreign jurisdictions, which could significantly and materially harm our business. Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for our product candidates may be withdrawn. If we fail to comply with the applicable regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects could be harmed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and ongoing surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements and regulatory inspection. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, EMA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as ongoing compliance with current good manufacturing practices (cGMPs) and GCP for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA, EMA and other regulatory authorities for compliance with cGMP regulations and standards. The PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign drug manufacturing establishments are subject to registration and listing requirements even if a drug or biologic undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside the U.S. prior to being imported or offered for import into the U.S. If we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA, EMA and other comparable foreign regulatory requirements may subject our Company to administrative or judicially imposed sanctions, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in or the rejection of product approvals;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the products, manufacturers or manufacturing process;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning or untitled letters;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">civil and criminal penalties;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or withdrawal of regulatory approvals;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizures, detentions or import bans;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">voluntary or mandatory product recalls and publicity requirements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">total or partial suspension of production;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of restrictions on operations, including costly new manufacturing requirements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a REMS, which may include distribution or use restrictions; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to conduct additional post-market clinical trials to assess the safety of the product.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA, EMA and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA, EMA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA, EMA and other regulatory authorities strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted in the U.S. for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling, or in other jurisdictions for uses that differ from the labeling or uses approved by the applicable regulatory authorities. While physicians may prescribe products for off-label uses, the FDA, EMA and other regulatory authorities actively enforce laws and regulations that prohibit the promotion of off-label uses by companies, including promotional communications made by companies&#8217; sales force with respect to off-label uses that are not consistent with the approved labeling, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the regulatory restrictions on off-label promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading, and non-promotional scientific communications concerning their products in certain circumstances. For example, in January 2025, the FDA published final guidance outlining the FDA&#8217;s non-binding policies governing the distribution of scientific information on unapproved uses of approved products to healthcare providers. This final guidance calls for such communications to be truthful, non-misleading, factual, and unbiased and include all information necessary for healthcare providers to interpret the strengths, weaknesses, validity and utility of the information about the unapproved use of the approved product. If a company engages in such communications consistent with the guidance&#8217;s recommendations, the FDA indicated that it will not treat such communications as evidence of unlawful promotion of a new intended use for the approved product. In addition, under recent guidance from the FDA and the Pre-Approval Information Exchange Act, signed into law as part of the Consolidated Appropriations Act (CAA), companies may also promote information that is consistent with the prescribing information and proactively speak to formulary committee members of payors regarding data for an unapproved drug or unapproved uses of an approved drug. We may engage in these discussions and communicate with healthcare providers, payors and other constituencies in compliance with all applicable laws, regulatory guidance and industry best practices. We will need to carefully navigate the FDA&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">various regulations, guidance and policies, along with recently enacted legislation, to ensure compliance with restrictions governing promotion of our products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are required by the FDA, EMA or comparable regulatory authority to obtain clearance or approval of a companion diagnostic test in connection with approval of any of our product candidates or a group of therapeutic products, and we do not obtain or we face delays in obtaining clearance or approval of a diagnostic test, we may not be able to commercialize the product candidate and our ability to generate revenue may be materially impaired.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are required by the FDA, EMA or a comparable regulatory authority to obtain clearance or approval of a companion diagnostic test in connection with approval of any of our product candidates, such companion diagnostic test would be used during our more advanced phase clinical trials as well as in connection with the commercialization of our product candidates. To be successful in developing and commercializing product candidates in combination with these companion diagnostics, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to ensuring the safe and effective use of a novel therapeutic product or new indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared. In certain circumstances (for example, when a therapeutic product is intended to treat a serious or life-threatening condition for which no satisfactory available therapy exists or when the labeling of an approved product needs to be revised to address a serious safety issue), however, the FDA may approve a therapeutic product without the prior or contemporaneous marketing authorization of a companion diagnostic. In this case, approval of a companion diagnostic may be a post-marketing requirement or commitment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Co-development of companion diagnostics and therapeutic products is critical to the advancement of precision medicine. Whether initiated at the outset of development or at a later point, co-development should generally be conducted in a way that will facilitate obtaining contemporaneous marketing authorizations for the therapeutic product and the associated companion diagnostic. If a companion diagnostic is required to identify patients who are most likely to benefit from receiving the product, to be at increased risk for serious adverse events as a result of treatment with a particular therapeutic product, or to monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness, then the FDA has required marketing approval of all companion diagnostic tests essential for the safe and effective use of a therapeutic product for cancer therapies. Various foreign regulatory authorities also regulate in vitro companion diagnostics as medical devices and, under those regulatory frameworks, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of any future diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization in those countries.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The approval of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express the specific genomic alteration or mutation alteration that the companion diagnostic was developed to detect. If the FDA, EMA or a comparable regulatory authority requires clearance or approval of a companion diagnostic for any of our product candidates, whether before, concurrently with approval, or post-approval of the product candidate, we, and/or future collaborators, may encounter difficulties in developing and obtaining clearance or approval for these companion diagnostics. The process of obtaining or creating such diagnostic is time consuming and costly. The FDA previously has required in vitro companion diagnostics intended to select the patients who will respond to a product candidate to obtain pre-market approval (PMA), simultaneously with approval of the therapeutic candidate. The PMA process, including the gathering of preclinical and clinical data and the submission and review by the FDA, can take several years or longer. It involves a rigorous pre-market review during which the sponsor must prepare and provide FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. After a device is placed on the market, it remains subject to significant regulatory requirements, including requirements governing development, testing, manufacturing, distribution, marketing, promotion, labeling, import, export, record-keeping, and adverse event reporting.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any delay or failure by us or third-party collaborators to develop or obtain regulatory clearance or approval of a companion diagnostic could delay or prevent approval or continued marketing of our related product candidates. Further, in April 2020, the FDA issued new guidance on developing and labeling companion diagnostics for a specific group of oncology therapeutic products, including recommendations to support a broader labeling claim rather than individual therapeutic products. We will continue to evaluate the impact of this guidance on our companion diagnostic development and strategy. This guidance and future issuances from the FDA, EMA and other regulatory authorities may impact our development of a companion diagnostic for our product candidates and could result in delays in regulatory clearance or approval or a change in the determination for whether or not a companion diagnostic is still required for our product candidates. We may be required to conduct additional studies to support a broader claim or more narrowed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">claim for a subset population. Also, to the extent other approved diagnostics are able to broaden their labeling claims to include any of our future approved product candidates covered indications, we may no longer need to continue our companion diagnostic development plans or we may need to alter those companion diagnostic development strategies, which could adversely impact our ability to generate revenue from the sale of our companion diagnostic test.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we may rely on third parties for the design, development and manufacture of companion diagnostic tests for our product candidates. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining clearance or approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory clearance or approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later-stage clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory clearance or approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our product candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so, the development of our product candidates may be adversely affected, our product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of our product candidates that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the co-development or commercialization of our companion diagnostic and therapeutic product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Where appropriate, we plan to pursue approval from the FDA, EMA or comparable foreign regulatory authorities through the use of accelerated registration pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, EMA or comparable regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA, EMA or such other regulatory authorities may seek to withdraw accelerated approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where appropriate, we plan to pursue accelerated development strategies in areas of medical need. We may seek an accelerated approval pathway for one or more of our product candidates from the FDA, EMA or comparable foreign regulatory authorities. Under the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, and the FDA&#8217;s implementing regulations, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug. Further, the FDA has issued guidances outlining its current thinking and approach to accelerated approval. While these guidances are currently only in draft form and will ultimately not be legally binding even when finalized, we would need to observe the FDA&#8217;s guidances closely should our products qualify for accelerated approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, there can be no assurance that we will satisfy all FDA requirements, including new provisions, that govern accelerated approval. For example, with passage of FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded and to submit progress reports on its post-approval studies to the FDA every six months until the study is completed. Moreover, FDORA established expedited procedures authorizing the FDA to withdraw an accelerated approval if certain conditions are met, including where a required confirmatory study fails to verify and describe the predicted clinical benefit or where evidence demonstrates the product is not shown to be safe or effective under the conditions of use. The FDA may also use such procedures to withdraw an accelerated approval if a sponsor fails to conduct any required post-approval study of the product with due diligence, including with respect to &#8220;conditions specified by the Secretary.&#8221; The new procedures include the provision of due notice and an explanation for a proposed withdrawal, and opportunities for a meeting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with the Commissioner of the FDA or the Commissioner&#8217;s designee and a written appeal, among other things. We will need to fully comply with these and other requirements in connection with the development and approval of any product candidate that is granted accelerated approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, a &#8220;conditional&#8221; marketing authorization may be granted in cases where all the required safety and efficacy data are not yet available. A conditional marketing authorization is subject to conditions to be fulfilled for generating missing data or ensuring increased safety measures. A conditional marketing authorization is valid for one year and has to be renewed annually until fulfillment of all relevant conditions. Once the applicable pending studies are provided, a conditional marketing authorization can become a &#8220;standard&#8221; marketing authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA, the marketing authorization will cease to be renewed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to seeking accelerated approval, we will seek feedback from the FDA, EMA or comparable foreign regulatory authorities and will otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent feedback from the FDA, EMA or comparable foreign regulatory authorities, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or any other form of expedited development, review or approval, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA, EMA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review in the U.S., and PRIME (priority medicines) in the EU, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Zidesamtinib has received FDA Breakthrough Therapy designation for the treatment of patients with advanced ROS1-positive NSCLC who have previously been treated with two or more ROS1 TKIs, and neladalkib has received FDA Breakthrough Therapy designation for the treatment of patients with locally advanced or metastatic ALK-positive NSCLC who have been previously treated with two or more ALK TKIs. We may seek certain designations for our other current or future product candidates or other designations for zidesamtinib and neladalkib that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough Therapies, early and frequent interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development. Sponsors may also have greater interactions with the FDA and the FDA may initiate review of sections of the NDA of a product candidate with Breakthrough Therapy designation before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of data submitted by the sponsor, that a product with Breakthrough Therapy designation may be effective.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also seek Fast Track designation for one or more of our product candidates. The FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. Like with Breakthrough Therapy designation, sponsors with Fast Track products may have greater FDA interactions and the FDA may initiate review of sections of a Fast Track product&#8217;s NDA before the application is complete if it determines, after its preliminary data evaluation, that the product may be effective.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also seek a priority review designation for one or more of our product candidates. If the FDA determines that a product candidate intended to treat a serious condition and, if approved, offers a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation shortens the goal for the FDA to review an application within six months, rather than the standard review period of ten months.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These designations require a sponsor to submit an application for review and approval by the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if our product candidates qualify for these designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, we may seek PRIME for some of our product candidates in the future. PRIME is a voluntary program launched by the EMA that is aimed at enhancing the scientific and regulatory support for the development and accelerated assessment of new product candidates that target an unmet medical need. PRIME is aimed to offer early and proactive support to sponsors to optimize the generation of robust data on the product&#8217;s benefits and risks and enable accelerated regulatory assessment of new marketing applications. To be eligible for PRIME, a product candidate must meet the eligibility criteria in respect to its potential to offer a major therapeutic advantage over existing treatments, or benefit patients who do not have any treatment options. The benefits of PRIME include the appointment of a Committee for Medicinal Products for Human Use rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME enables an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. We may apply for PRIME and it may not be granted. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#8217;s grant of a marketing authorization.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA, EMA or other comparable foreign regulatory authorities, from approving competing products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the U.S. and the EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the U.S., or a patient population greater than 200,000 in the U.S. where there is no reasonable expectation that the cost of researching and developing the drug will be recovered from sales in the U.S. Our target indications may include diseases with large patient populations or may include orphan indications. Zidesamtinib has received orphan drug designation for ROS1-positive NSCLC. Neladalkib has received orphan drug designation for ALK-positive NSCLC. There can be no assurances that we will be able to obtain orphan designation for our other current product candidate or candidates we may discover and develop in the future.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product candidate that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product candidate is entitled to orphan drug exclusivity. Orphan drug exclusivity in the U.S. provides that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances. The applicable exclusivity period is 10 years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain orphan drug designation for a product candidate, we may not be able to obtain or maintain orphan drug exclusivity for that product candidate. We may not be the first to obtain marketing approval of any product candidate for which we have obtained orphan drug designation for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the U.S. may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to ensure that we will be able to manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the product candidate any advantage in the regulatory review or approval process or entitles the product candidate to Priority Review.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is also possible that current or future litigation or action by Congress could change the scope of available orphan exclusivity. Any changes to the orphan drug provisions could change our opportunities for, or likelihood of success in obtaining, orphan drug exclusivity and could materially affect our business, financial condition, results of operations, cash flows and prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current and future legislation may increase the difficulty and cost for us to obtain reimbursement for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S. and some foreign jurisdictions, there have been and continue to be a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved products. If reimbursement of our products is unavailable or limited in scope, our business could be materially harmed.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, since enactment of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the PPACA), there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017 (Tax Act), Congress repealed the &#8220;individual mandate.&#8221; Litigation and legislation over the PPACA may continue, with unpredictable and uncertain results.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Further, with passage of the Inflation Reduction Act of 2022 (IRA) in August 2022, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars. This provision is limited in terms of the number of pharmaceuticals whose prices can be negotiated in any given year and it only applies to drug products that have been approved for at least nine years and biologics that have been licensed for 13 years. Drugs and biologics that have been approved for a single rare disease or condition are categorically excluded from price negotiation. With the passage of the One Big Beautiful Bill Act (OBBBA) in July 2025, Congress extended this exemption to drugs and biologics with more than one orphan drug designation and more than one approved indication. In addition, the legislation provides that if pharmaceutical companies raise prices in Medicare faster than the rate of inflation, they must pay rebates back to the government for the difference. The IRA also capped Medicare beneficiary out-of-pocket drug costs at an estimated $2,000 a year beginning in 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These laws and other healthcare reform measures may result in additional reductions in Medicare and other healthcare funding and otherwise affect the reimbursement we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product is prescribed or used. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in reimbursement from private payors. Accordingly, the implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The prices of prescription pharmaceuticals in the U.S. and foreign jurisdictions are the subject of considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed for marketing.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The prices of prescription pharmaceuticals have been the subject of considerable discussion in the U.S. There have been several recent U.S. Congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program (SIP) to import certain prescription drugs from Canada into the U.S. Several states have passed laws allowing for the importation of drugs from Canada, while others have passed legislation establishing workgroups to examine the impact of a state SIP. In May 2025, the FDA announced that it would offer individual states the opportunity to submit a draft proposal for pre-review and meet with the agency to obtain initial feedback from the FDA prior to formally submitting their SIP proposal. The intent of these meetings is to assist states in developing their proposals by further clarifying requirements, enhancing the quality of proposals submitted to the agency and ultimately shortening the review timeline.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 16, 2022, the IRA was signed into law by former President Biden. This requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation; and replaces the Part D coverage gap discount program with a new discounting program. The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least nine years and biologics that have been licensed for 13 years. When originally enacted, the IRA explicitly excluded from price negotiation orphan drugs designated for only one rare disease or condition and for which the only active approved indication is for such disease or condition. However, the OBBBA, signed into law in July 2025, amended the applicable statute to broaden the orphan drug exclusion to include products with more than one orphan designation and more than one approved indication. Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law. The legislation also requires manufacturers to pay rebates for drugs in Medicare Parts B and D whose price increases exceed inflation and capped Medicare beneficiary out-of-pocket drug costs at $2,000 a year.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023. On August 15, 2024, HHS published the results of the first Medicare drug price negotiations for 10 selected drugs that treat a range of conditions, including diabetes, chronic kidney disease, and rheumatoid arthritis. The prices of these 10 drugs became effective on January 1, 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, CMS announced its selection of 15 additional drugs covered by Medicare Part D for the second cycle of negotiations, and in November 2025, CMS released negotiated prices for such products that will go into effect beginning on January 1, 2027. While it remains to be seen how the drug pricing provisions imposed by the IRA will affect the broader pharmaceutical industry, several pharmaceutical manufacturers and other industry stakeholders have challenged the law, including through lawsuits brought against the HHS, the Secretary of the HHS, CMS, and the CMS Administrator challenging the constitutionality and administrative implementation of the IRA&#8217;s drug price negotiation provisions. This litigation is ongoing and the results, and potential impacts on our business, are uncertain.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2025, President Trump issued an executive order which directs HHS to take steps to reduce the prices of pharmaceutical products (the Order). The Order repeats many of the proposals advanced during the first Trump administration, including directing the FDA to streamline and improve its existing drug importation program so as to make it easier for states to obtain approval without sacrificing the safety or quality of drug products. With respect to the IRA&#8217;s Medicare drug pricing program, the Order, among other things, calls for alignment in &#8220;the treatment of small molecule prescription drugs with that of biological products, ending the distortion that undermines relative investment in small molecule prescription drugs, coupled with other reforms to prevent any increase in overall costs to Medicare and its beneficiaries.&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequently, in May 2025, President Trump issued an additional executive order (the Additional Order) calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the U.S. The Additional Order directs the Secretary of HHS to communicate most-favored-nation (MFN) price targets to pharmaceutical manufacturers to bring prices in line with comparably developed nations. Since the Additional Order, the Trump administration has continued to exert pressure on drug manufacturers to implement &#8220;most favored nation&#8221; pricing, including by suggesting that the administration may impose significant tariffs on pharmaceuticals if such manufacturers do not reach agreements to implement &#8220;most favored nation&#8221; pricing. Additionally, in November 2025, CMS announced a new voluntary payment initiative called the GENEROUS Model (GENErating cost Reductions fOr U.S. Medicaid Model) where drug manufacturers may voluntarily offer supplemental rebates to participating state Medicaid programs that are intended to provide such Medicaid programs with a &#8220;most favored nation&#8221; price for participating manufacturers&#8217; products. Most recently, in December 2025, CMS announced new mandatory payment models through two proposed rules, the Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) models where manufacturers of certain Medicare Part B and Medicare Part D drugs will be assessed rebates if the prices for such products exceed those paid in economically comparable countries. It remains to be seen how these drug pricing initiatives will affect the broader pharmaceutical industry.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the U.S. state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. This is increasingly true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription product and other healthcare programs. These measures could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing. In addition, in some countries, including member states of the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take a significant amount of time after the receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices, and in certain instances render commercialization in certain markets infeasible or disadvantageous from a financial perspective. In some countries, we or our collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our products to other available products in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third party payors or government authorities may lead to further pressure on the prices or reimbursement levels. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, the commercial launch of our products could be delayed, possibly for lengthy periods of time, we or our collaborators may not launch at all in a particular country, we may not be able to recoup our investment in one or more products, and there could be a material adverse effect on our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are or may become subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are multiple privacy and data security laws that may impact our business activities in the U.S. and in other countries where we conduct trials or where we may do business in the future. These laws are evolving and may increase both our obligations and our regulatory risks in the future. In the healthcare industry generally, for example, under the Health Insurance Portability and Accountability Act of 1996 (HIPAA), HHS has issued regulations to protect the privacy and security of protected health information used or disclosed by specific covered entities including certain healthcare providers, health plans and healthcare clearinghouses. We are not currently classified as a covered entity or business associate under HIPAA. Thus, we are not directly subject to HIPAA&#8217;s requirements or penalties. However, healthcare providers, including certain research institutions from which we may obtain patient or subject health information, may be subject to privacy, security, and breach notification requirements under HIPAA. Additionally, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face criminal penalties if we knowingly receive individually identifiable health information from a HIPAA covered entity, business associate or subcontractor that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive personally identifiable information, including health and genetic information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who may enroll in patient assistance programs if we choose to implement such programs. As such, in addition to risks and obligations related to HIPAA, we also may be subject to various state laws regulating the use or disclosure of this information or requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws and genetic information laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#8217; health information. Individuals from whom we or our collaborators may obtain health information, as well as the healthcare providers who may share this information with us, may have statutory or contractual rights that limit the ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the collection and use of personal data, including data concerning health, in the EU is governed by the General Data Privacy Regulation (GDPR), which extends the geographical scope of EU data protection law to non-EU entities under certain conditions and imposes substantial obligations upon companies and new rights for individuals, as discussed below in &#8220;&#8212;Processing of personal data is governed by restrictive laws and regulations in the jurisdictions in which we operate.&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Brexit may adversely impact our ability to obtain regulatory approvals for our product candidates in the EU, result in restrictions or imposition of taxes and duties for importing our product candidates into the EU, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the EU.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development programs and develop and secure approval of our product candidates in a timely manner, which would negatively impact our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and comparable regulatory agencies in foreign jurisdictions, such as the EMA, play an important role in the development of our product candidates by providing guidance on our clinical development programs and reviewing our regulatory submissions, including INDs, requests for special designations and marketing applications. If these oversight and review activities are disrupted, then our ability to develop and secure timely approval of our product candidates could be impacted in a negative manner, accordingly.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, the regulatory reform measures being implemented by the Trump administration across the government, some of which ordered the loss of FDA leadership and personnel, could lead to disruptions and delays in FDA guidance, review and approval of our product candidates. In March 2025, the Secretary of HHS announced a reorganization and Reduction in Force (RIF) across HHS of approximately 20,000 employees (82,000 to 62,000), with the FDA&#8217;s workforce to decrease by 3,500 full-time employees. Shortly thereafter, thousands of employees at the FDA were fired. In addition, President Trump has issued a number of executive orders that could have a significant impact on the manner in which the FDA conducts its operations and engages in regulatory and oversight activities. If current or future orders or executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, while the FDA&#8217;s review of marketing applications and other activities for new drugs and biologics is largely funded through the user fee program established under PDUFA, it remains unclear how the administration&#8217;s RIF and budget cuts will impact this</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">program and the ability of the FDA to provide guidance and review our product candidates in a timely manner. For example, while the FDA RIF did not reportedly specifically target FDA reviewers, many operations, administrative and policy staff that help support such reviews were affected and those losses could lead to delays in PDUFA reviews and related activities. In addition, while currently unclear, there is a risk that the RIF and budget cutbacks could threaten the integrity of the PDUFA program itself. That is because, for the FDA to obligate user fees collected under PDUFA in the first place, a certain amount of non-user fee appropriations must be spent on the process for the review of applications plus certain other costs during the same fiscal year. For example, one company disclosed in June 2025 that the FDA had notified it that a previously disclosed PDUFA goal date would not be met due to heavy workload and limited resources. While the impact of these staffing disruptions remains uncertain, there can be no assurance that staff responsible for managing the PDUFA program will not be impacted and that companies will not experience delays in processing of NDAs and BLAs that may result in a longer than expected review period or delayed PDUFA dates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, government funding of the Securities and Exchange Commission (SEC) and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the same time, disruptions at the FDA and other government agencies may result from public health events similar to the COVID-19 pandemic. For example, during the pandemic, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. In the event of a similar public health emergency in the future, the FDA may not be able to continue its current pace and review timelines could be extended. Regulatory authorities outside the United States facing similar circumstances may adopt similar restrictions or other policy measures in response to a similar public health emergency and may also experience delays in their regulatory activities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, if any of the foregoing developments and others impact the ability of the FDA to provide us with guidance regarding our clinical development programs or delay the agency&#8217;s review and processing of our regulatory submissions, including INDs and NDAs, our business would be negatively impacted. Further, any future government shutdown could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our product candidates are licensed for marketing and receive federal healthcare reimbursement, any relationships we may have with healthcare providers will be subject to applicable healthcare fraud and abuse laws and regulations, which could expose us to criminal and civil penalties and exclusion from participation in government healthcare programs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any products for which we are able to obtain marketing approval. Any arrangements we have with healthcare providers, third-party payors and customers will subject us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws and regulations may constrain the business or financial arrangements and relationships through which we conduct clinical research, market, sell and distribute any products for which we obtain marketing approval. These include the following:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-Kickback Statute.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration (including any kickback, bribe or rebate), directly or indirectly, in cash or in kind, to induce or reward or in return for, either the referral of an individual for or the purchase, lease or order of a good, facility, item or service for which payment may be made under a federal healthcare program such as Medicare and Medicaid.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">False Claims Laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The federal false claims and civil monetary penalties laws, including the federal civil False Claims Act, impose criminal and civil penalties, including through civil whistleblower or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> actions against individuals or entities for, among other things, knowingly presenting or causing to be presented false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">HIPAA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> HIPAA imposes criminal and civil liability for, among other things, executing a scheme or making materially false statements in connection with the delivery of or payment for healthcare benefits, items or services. Additionally, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations on covered entities and their business associates that perform certain functions or activities that involve the use or disclosure of protected health information on their behalf, including mandatory contractual terms and technical safeguards, with respect to maintaining the privacy, security and transmission of individually identifiable health information.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transparency Requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or transfers of value made to physicians, other healthcare providers and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Analogous State and Foreign Laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, can apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors and are generally broad and are enforced by many different federal and state agencies as well as through private actions.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. Infringement of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct applicable in the EU Member States. Our failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efforts to ensure that any business arrangements we have with third parties and our business generally will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm and the curtailment or restructuring of our operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Processing of personal data is governed by restrictive laws and regulations in the jurisdictions in which we operate.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are or may become subject to many cybersecurity, privacy and data protection laws in the U.S. and around the world. In the U.S., we are subject to numerous federal and state laws governing the collection, processing, use, transmission, disclosure, and sale (collectively, Processing) of personal data (which may also be referred to as personal information, personally identifiable information, and/or non-public personal information).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission (FTC) and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws are also being considered at both the state and federal levels. For example, the FTC has been particularly focused on the unpermitted processing of health and genetic data through its recent enforcement actions and is expanding the types of privacy violations that it interprets to be &#8220;unfair&#8221; under Section 5 of the Federal Trade Commission Act, as well as the types of activities it views to trigger the Health Breach Notification Rule (which the FTC also has the authority to enforce). The FTC is also in the process of developing rules related to commercial surveillance and data security that may impact our business. We will need to account for the FTC&#8217;s evolving rules and guidance for proper privacy and data security practices in order to mitigate our risk for a potential enforcement action, which may be costly. If we are subject to a potential FTC enforcement action, we may be subject to a settlement order that requires us to adhere to very specific privacy and data security practices, which may impact our business. We may also be required to pay fines as part of a settlement (depending on the nature of the alleged violations). If we violate any consent order that we reach with the FTC, we may be subject to additional fines and compliance requirements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New laws are also being considered and implemented at the state level. For example, the California Consumer Privacy Act (CCPA) went into effect on January 1, 2020, and established a new privacy framework for covered businesses such as ours. The CCPA imposed many requirements on businesses that process the personal information of California residents. Further, in November 2020, California voters passed the California Privacy Rights Act (CPRA), which significantly expanded the CCPA to incorporate additional GDPR-like provisions and create a new enforcement agency &#8211; the California Privacy Protection Agency &#8211; whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. While certain of our business activities will not be subject to these laws, it remains unclear how various provisions of the CCPA and CPRA will be interpreted and enforced.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to California, several other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data (which includes health data in some cases). There are also states that are currently regulating health information specifically, or considering passing new laws to do so. These laws and regulations may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plaintiffs&#8217; lawyers are also increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulating wiretapping, as well as the federal Video Privacy Protection Act. The rise in these types of lawsuits creates potential risk for our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, outside of the U.S., we are subject to foreign rules and regulations. Many countries outside of the U.S. maintain rigorous laws governing the privacy and security of personal information. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the EEA, and the processing of personal data that takes place in the EEA, is subject to the GDPR, which became effective on May 25, 2018. This provision expanded the scope of data protection in the EU to foreign companies who process the personal data of EU residents, imposed a strict data protection compliance regime with stringent penalties for noncompliance and included new rights for data subjects such as the &#8220;portability&#8221; of personal data. In particular, under the GDPR, fines of up to &#8364;20 million, or up to 4% of the annual global revenue of the noncompliant company, whichever is greater, could be imposed for violations of certain of the GDPR&#8217;s requirements. If we were found to be in breach of the GDPR, the potential penalties we might face could have a material adverse impact on our business, financial condition, results of operations, and cash flows. Compliance with the GDPR requires time and expense and may require us to make changes to our business operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While the GDPR applies uniformly across the EU, each EU Member State is permitted to issue nation-specific data protection legislation, which has created inconsistencies on a country-by-country basis. Brexit has created further uncertainty and could result in the application of new data privacy and protection laws and standards to our operations in the U.K., our handling of personal data of users located in the U.K., and transfers of personal data between the EU and the U.K. Following the withdrawal of the U.K. from the EU, the U.K. Data Protection Act of 2018 applies to the processing of personal data that takes place in the U.K. and includes parallel obligations to those set forth by GDPR. A decision from the European Commission appears to deem the U.K. as being &#8220;essentially adequate&#8221; for purposes of data transfer from the EU to the U.K., although this decision may be re-evaluated in the future. Further, despite the current effectiveness of the Data Protection Act of 2018 in the U.K., it is still unclear whether transfer of data from the EEA to the U.K. will remain lawful under the GDPR. The U.K. and the U.S. also have agreed on a framework for personal data to be transferred between the U.K. and the U.S., called the U.K.-U.S. Data Bridge, but this may be challenged in the future as well.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are ongoing concerns about the ability of companies to transfer personal data from the EU to other countries. On July 16, 2020, the European Court of Justice invalidated the EU-U.S. Privacy Shield Framework, a mechanism under which personal data could be transferred from the EEA to U.S. entities that had self-certified under the Privacy Shield Framework. In October 2022, former President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield, for which the European Commission adopted an adequacy decision on July 10, 2023. The adequacy decision will permit U.S. companies who self-certify to the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the EU to the U.S. However, some privacy advocacy groups have already suggested that they will be challenging the EU-U.S. Data Privacy Framework. The uncertainty around this issue has the potential to impact our business at the international level.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and any eventual sale and distribution of commercial products. Such laws may have potentially conflicting requirements or burdensome obligations that would make compliance challenging or expensive. Such changes may also require us to modify our products and features, and may limit our ability to make use of the data that we collect, may require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to these provisions restricting the transfer of personal information to the U.S., a new U.S. law also restricts the transfer of certain kinds of personal data in certain situations outside of the U.S. to &#8220;countries of concern,&#8221; including but not limited to China. On April 8, 2025, the U.S. Department of Justice&#8217;s National Security Division implemented the Data Security Program Rule under Executive Order 14117 and the International Emergency Economic Powers Act. This rule establishes restrictions on certain data-related transactions involving U.S. persons and entities, particularly those that may result in access to U.S. government-related data or bulk sensitive personal data of U.S. persons by foreign adversaries or entities under their control. The rule effectively imposes export control-like restrictions on the transfer, sale, or sharing of sensitive data&#8212;including genomic, geolocation, biometric, health, financial, and other personal data&#8212;to or with entities in countries of concern, as well as entities and persons associated with those countries. It also imposes additional due diligence obligations on U.S. companies concerning personal data they collect, store, or transmit. Failure to comply with the Data Security Program Rule could result in civil or criminal penalties, reputational harm, and restrictions on our ability to engage in certain business activities. Compliance may require us to modify our data handling practices, implement new controls, or terminate existing relationships with certain foreign vendors, customers, or partners. These changes could increase our operational costs, limit our market opportunities, and adversely affect our financial performance. Additionally, the scope and interpretation of the rule may evolve, and future guidance or enforcement actions could impose further obligations or restrictions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to Process data (including personal data), or in some cases, impact our ability to operate in certain jurisdictions. Any actual or alleged failure to comply with U.S. or international laws and regulations relating to privacy, data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">protection, and data security could result in governmental investigations, proceedings and enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity, harm to our reputation, and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to Process the information or impose other obligations or restrictions in connection with our Processing of information, and we may otherwise face contractual restrictions applicable to our Processing of information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage or may have engaged in misconduct or other improper activities. Misconduct by these parties could include failures to comply with SEC, FDA, EMA or comparable foreign regulatory authority regulations, provide accurate information to regulatory authorities, comply with federal and state healthcare fraud and abuse laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, research, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct and engage contractors that agree to undertake certain measures with respect to their employees, but it is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business activities may be subject to the U.S. Foreign Corrupt Practices Act (FCPA) and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The FCPA generally prohibits companies and their employees and third-party intermediaries from offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals are owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the FCPA. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, disgorgement, and other sanctions and remedial measures, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our business, prospects, operating results and financial condition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our products may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international or domestic sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulations, could result in decreased use of our products by, or in our decreased ability to export our products to, existing or potential customers with international operations. Any decreased use of our products or limitation on our ability to export or sell our products would likely adversely affect our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to employee matters, managing our growth and other risks related to our business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our success is highly dependent on our ability to attract, hire and retain highly skilled executive officers and employees.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, our team was primarily focused on research and development of small molecule kinase inhibitors. More recently, we began to establish a commercial infrastructure in preparation for a future product launch if one or more of our product candidates receives marketing approval, including the hiring of sales, marketing and other commercially focused personnel. We continue to build this commercial infrastructure. To succeed, we must recruit, hire, retain, manage and motivate qualified clinical, scientific, technical, sales and marketing, and management personnel, and we face significant competition for experienced personnel. Personnel with the required skills and experience may be scarce or may not be available at all. In addition, competition for these skilled personnel is intense and recruiting and retaining skilled employees is difficult, particularly for a precommercial-stage company such as ours. Even if we are successful in identifying, attracting, hiring and retaining qualified employees, recent market changes, including labor shortages, and rising inflation have increased employee-related costs substantially, which may negatively affect our operating results.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on the principal members of our management, commercial and scientific and medical staff. If we do not succeed in attracting and retaining qualified personnel in these positions, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide higher compensation, more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we rely on our physician-scientist partners and other scientific and clinical advisors and consultants to assist us in formulating our research, development and clinical strategies. Most of these advisors and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, these advisors and consultants typically will not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. Furthermore, our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours. In particular, if we are unable to maintain consulting or employment relationships with our physician-scientist partners and other scientific and clinical advisors, or if they provide services to our competitors, our development and commercialization efforts will be impaired and our business will be significantly harmed. For example, if we are no longer able to access our network of physician-scientists, our ability to define and characterize patients&#8217; needs for future product candidate development may be negatively affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug and clinical development, regulatory affairs, medical affairs, commercialization, sales and marketing. As of December 31, 2025, we had 228 full time employees. This growth will impose significant added responsibilities on members of management, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying, recruiting, integrating, maintaining, retaining and motivating our current and additional employees;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing our internal development efforts effectively, including the preclinical, clinical, FDA, EMA and other comparable foreign regulatory authorities&#8217; review process for zidesamtinib, neladalkib, NVL-330 and our discovery programs, while complying with any contractual obligations to contractors and other third parties;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing increasing operational and managerial complexity;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparing for potential commercialization of our product candidates; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future financial performance and our ability to successfully develop and, if approved, commercialize zidesamtinib, neladalkib, NVL-330 and any future product candidates developed from our discovery programs and other product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. Any inability to manage such growth could delay the execution of our business plans or disrupt our operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including key aspects of research, clinical development and manufacturing. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third-party service providers is compromised for any reason, our preclinical studies and clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval for our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing third-party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third-party service providers, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer actual or suspected security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations, and potentially significant delays in our delivery to market.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the implementation of security measures in an effort to protect systems that store our data, given their size and complexity and the increasing amount of information maintained on our internal information technology systems and external processing and storage systems (i.e., cloud), and those of our third-party CROs, other contractors (including sites performing our clinical trials) and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our data. The risk of a security breach or disruption through cyber-attacks has generally increased as the number, intensity and sophistication of attempted attacks from around the world have increased. For example, companies have experienced an increase in phishing and social engineering attacks from third parties. Also, a majority of our employees are working remotely. As a result, we may have increased cybersecurity and data security risks, due to increased use of home wi-fi networks and virtual private networks, as well as increased disbursement of physical machines. While we implement IT controls to reduce the risk of a cybersecurity or data security breach, there is no guarantee that these measures will be adequate to safeguard all systems.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that any disruption or security breach were to result in a loss, destruction, unavailability, alteration or dissemination of, or damage to, our data (including confidential information and personal data) or applications, or for it to be believed or reported that any of these occurred, we could incur liability and reputational damage and the development and commercialization of our product candidates could be delayed. There can be no assurance that our data protection efforts and our investment in information technology, or the efforts or investments of CROs, consultants or other third parties, will prevent significant breakdowns or breaches in systems or other cyber incidents that cause loss, destruction, unavailability, alteration or dissemination of, or damage to, our data that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data, as well as claims or investigations from regulators or other third parties. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, data (including trade secrets or other confidential information, intellectual property, proprietary business information, and personal data), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal data, including personal data regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to financial exposure related to investigation of the incident (including cost of forensic examinations), subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of data, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notifications, follow-up actions, claims and investigations related to a security incident could impact our reputation and cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. We expect to incur significant costs in an effort to detect and prevent security incidents, and we may face increased costs and requirements to expend substantial resources in the event of an actual or perceived security breach. We also rely</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security incident were to result in a loss, destruction or alteration of, or damage to, our data (including personal data), or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or privacy and security laws from countries outside of the U.S.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in or, failure or security breach of our systems or third-party systems where information important to our business operations or commercial development is stored. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in and uncertainty surrounding U.S. trade policy could have a material adverse impact on our business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of numerous changes in tariffs and trade restrictions that have been announced and/or implemented by the Trump administration since taking office, and other countries in response to the Trump administration&#8217;s actions, and the underlying uncertainty currently surrounding international trade, we could experience a negative impact on our costs of materials or supply chain disruptions and delays. If we are unable to obtain necessary raw materials or product components in sufficient quantity and in a timely manner due to disruptions in the global supply chain caused by macroeconomic events and conditions, the development, testing and clinical trials of our product candidates may be delayed or rendered infeasible, and regulatory approval or commercial launch of any resulting product may be delayed, which could significantly harm our business. We cannot yet predict the effect of recently imposed U.S. tariffs, or of possible future U.S. tariffs, including, but not limited to, tariffs on pharmaceuticals, pharmaceutical ingredients, including finished drug products, medical countermeasures, critical inputs such as active pharmaceutical ingredients (API) and key starting materials, and derivative products of those items, on imports, or the extent to which other countries will impose quotas, duties, tariffs, taxes or other similar restrictions upon imports or exports in the future, nor can we predict future trade policy or the terms of any renegotiated trade agreements and their impact on our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our manufacturers and suppliers are located in China. Trade tensions and conflicts between the U.S. and China have been escalating in recent years and, as such, we are exposed to the possibility of product supply disruption and increased costs and expenses in the event of changes to the laws, rules, regulations and policies of the governments of the U.S. or China, or as a result of geopolitical unrest or unstable economic conditions. Certain Chinese biotechnology companies may become subject to trade restrictions, sanctions, other regulatory requirements or proposed legislation by the U.S. government, which could restrict or even prohibit our ability to work with such entities, thereby potentially disrupting their supply of material to us. For example, in February 2024, U.S. lawmakers called for investigations into and the imposition of possible trade sanctions against certain Chinese biotechnology companies, including WuXi AppTec and WuXi Biologics (collectively, WuXi), over alleged ties to the Chinese military. In December 2025, Congress enacted a law, which, subject to certain grandfather provisions, will restrict U.S. federal agencies from procuring or obtaining &#8220;biotechnology equipment or services&#8221; from certain Chinese companies designated as &#8220;biotechnology companies of concern.&#8221; It will also prohibit U.S. federal agencies from entering into, extending, or renewing contracts with any entity that either uses biotechnology equipment or services provided by a company designated as a biotechnology company of concern in performance of the contract or enters into any contract with a third party that requires either party to use biotechnology equipment or services produced or provided by a company designated as a biotechnology company of concern. In addition, it prohibits an executive agency from obligating or expending a loan or grant to procure biotechnology equipment or services produced or provided by a &#8220;biotechnology company of concern.&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sustained uncertainty about or further escalating trade and political tensions between the U.S. and China may prevent or hinder the export of materials or technical information among us, our contract development and manufacturing organizations (CDMOs) and other relevant third parties, such as pharmaceutical partners, or could result in trade or retaliatory restrictions that may hinder or potentially inhibit our ability to rely on CDMOs and other service providers that operate in China. Further, regulatory or legislative action taken by the U.S. to impose restrictions on transactions with China, like the restrictions described above, could have the potential to severely restrict the ability of companies like ours to contract with Chinese biotechnology companies of concern, which could have adverse effects on the development of our product candidates and our business operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any unfavorable government policies on international trade, such as export controls, capital controls or tariffs, may increase the cost of manufacturing our product candidates, affect the demand for our drug products (if and once approved), the competitive position of our product candidates, and the import or export of raw materials and finished product candidate used in our and our collaborators&#8217; preclinical studies and clinical trials, particularly with respect to any product candidates and materials that we import from China, including pursuant to our manufacturing service arrangements with WuXi. If any new tariffs, export controls, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or, in particular, if either the U.S. or Chinese government</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">takes retaliatory trade actions due to the recent trade tension, such changes could have an adverse effect on our business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our operations are vulnerable to interruption by flood, fire, earthquakes, power loss, telecommunications failure, terrorist activity, pandemics and other events beyond our control, which could harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We lease office space for our corporate headquarters, which is located in Cambridge, Massachusetts. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major flood, fire, earthquake, power loss, telecommunications failure, terrorist activity, pandemics or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information and personal data.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issues in the use of artificial intelligence, combined with an uncertain regulatory environment, may result in reputational harm, liability or other adverse consequences to our business operations. As with many technological innovations, artificial intelligence presents risks and challenges that could impact our business. Our vendors may incorporate generative artificial intelligence tools into their offerings without disclosing this use to us, and the providers of these generative artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards with respect to privacy and data protection and may inhibit our or our vendors&#8217; ability to maintain an adequate level of service and experience. If any of our vendors experience an actual or perceived breach or privacy or security incident because of the use of generative artificial intelligence, we may lose valuable intellectual property and confidential information and our reputation and the public perception of the effectiveness of our security measures could be harmed. Further, bad actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these outcomes could damage our reputation, result in the loss of valuable property and information, and adversely impact our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to establish adequate sales, marketing and distribution capabilities or enter into agreements with third parties to sell, market or distribute our product candidates, we may not be able to successfully commercialize our product candidates that obtain regulatory approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have begun to establish a commercial infrastructure in preparation for a future product launch if one or more of our product candidates receives marketing approval, in order to successfully commercialize any product candidates, if approved, we must successfully build robust marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell or market our product candidates. We may not be successful in accomplishing these required tasks.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Establishing a full internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates will be expensive and time-consuming and will require significant attention of our executive officers to manage. Further, we may underestimate the size of the sales or marketing force required for a successful product launch and may need to expand our sales and marketing force earlier and at a higher cost than we anticipated. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of any of our product candidates that we obtain approval to market if we do not have arrangements in place with third parties to provide such services on our behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration and such arrangements may prove to be less profitable than commercializing the product on our own. If we are unable to enter into such arrangements when needed, on acceptable terms or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval, or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer, and we may incur significant additional losses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek regulatory approval of our product candidates outside of the U.S. and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing regulatory requirements and reimbursement regimes in foreign countries, such as the lack of pathways for accelerated drug approval, may result in foreign regulatory approvals taking longer and being more costly than obtaining approval in the U.S.;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials or our interpretation of data from preclinical studies or clinical trials;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval policies or regulations of foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of pandemics or other public health emergencies, natural disasters and geopolitical events on our ability to produce our product candidates and conduct clinical trials in foreign countries;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with legal requirements applicable to privacy, data protection, information security and other matters;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign taxes, including withholding of payroll taxes;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties staffing and managing foreign operations;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complexities associated with managing multiple payor reimbursement regimes and government payors in foreign countries;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential liability under the FCPA or comparable foreign regulations;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the U.S.;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geopolitical events, including war and terrorism, trade policies, treaties and tariffs.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other risks associated with international operations may materially adversely affect our ability to attain or maintain profitable operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax law could adversely affect our business and financial condition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, the U.S. Treasury Department and other applicable tax authorities. Changes to tax laws (which changes may have retroactive application), including the OBBBA passed in July 2025, could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our federal net operating loss (NOL) carryforwards may be unavailable to offset future taxable income because of restrictions under U.S. tax law. Under the Tax Act as amended by the Coronavirus Aid, Relief, and Economic Security Act, our federal NOLs generated in tax years beginning after December 31, 2017 may be carried forward indefinitely but the utilization of our federal NOL carryforward is limited to 80% of current year taxable income. As of December 31, 2025, we had available federal NOL carryforwards of approximately $503.2 million and available state NOL carryforwards of approximately $531.1 million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a cumulative change in the corporation&#8217;s ownership by &#8220;5-percent shareholders&#8221; that exceeds 50 percentage points (by value) over a rolling three-year period), the corporation&#8217;s ability to use its pre-change NOL carryforwards and certain other pre-change tax attributes to offset its post-change taxable income may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. We have not conducted any studies to determine annual limitations, if any, that could result from such changes in ownership. There is also a risk that due to regulatory changes, such as suspensions on the use of NOL carryforwards, or other unforeseen reasons, our existing NOL carryforwards could expire or otherwise be unavailable to offset future income tax liabilities. Because our ability to utilize our NOL carryforwards and certain other tax attributes could be limited as described above, we may not be able to utilize a material portion of our NOL carryforwards and certain other tax attributes, which could have a material adverse effect on our cash flows and results of operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to our intellectual property</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derivation proceedings provoked by third parties or brought by us or declared by the U.S. Patent and Trademark Office (USPTO) may be necessary to determine the priority of inventions with respect to one or more of our patents or patent applications or those of our future licensors. An unfavorable outcome may require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be adversely affected if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our development programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain protection of the intellectual property rights we own (either solely and jointly with others), or may in the future license from third parties (in particular, worldwide patents relating to any proprietary technology and product candidates we develop). We seek to protect our proprietary position by filing patent applications in the U.S. and select other countries related to our technologies and product candidates that are important to our business and by in-licensing intellectual property related to such technologies and product candidates. We do not yet have issued patents for all of our most advanced product candidates in all markets in which we may commercialize them, but we continue to actively pursue patent protection for our technology and product candidates in certain jurisdictions around the world. However, we cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, or the methods of use or manufacture of those products. If we are unable to obtain and maintain meaningful patent protection in jurisdictions important to our business for our product candidates, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment, or other proprietary technologies, our business, financial condition, results of operations and prospects could be adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain or defend all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances involving technology that we may license from third parties, we may not have the sole right to control the preparation, filing and prosecution of patent applications or to maintain, enforce and defend the in-licensed patents. Therefore, any in-licensed patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner consistent with the best interests of our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent rights of pharmaceutical and biotechnology companies, like ours, generally are highly uncertain, involve complex legal and factual questions and have been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents, particularly those related to oncology, has emerged in the U.S. The relevant patent laws and their interpretation outside of the U.S. are also uncertain. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the scope of patent eligibility of certain inventions or discoveries relating to biotechnology. These decisions conclude, among other things, that abstract ideas, natural phenomena and laws of nature are not themselves patent eligible subject matter. Precisely what constitutes a law of nature or abstract idea is uncertain, and certain aspects of our technology could be considered ineligible for patenting under applicable law. In addition, the scope of patent protection outside the U.S. is uncertain, and laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. or vice versa. For example, European patent law precludes the patentability of methods of treatment of the human body. We cannot predict whether the patent applications we are currently pursuing will issue as patents that protect our technology and product candidates, in whole or in part, in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Changes in either the patent laws or interpretation of the patent laws in the U.S. or other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend and enforce our patent rights, narrow the scope of our patent protection and, more generally, affect the value or narrow the scope of our patent rights.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, third parties may have intellectual property rights relating to our product candidates of which we are unaware. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases are not published at all. Therefore, neither we nor our future licensors can know with certainty whether either we or our future licensors were</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the first to make the inventions claimed in the patent applications we own or any patents or patent applications we may own or in-license in the future, or that either we or any of our future licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our owned and future in-licensed patent rights are uncertain. For example, currently unpublished patent applications may later publish and limit our ability to obtain valid and enforceable patents.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, any issued patents we do obtain or in-license may be challenged, invalidated, or circumvented. We or our future licensors may be subject to a third-party pre-issuance submission of prior art to the USPTO, or to a foreign patent office, or become involved in opposition, derivation, revocation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by any patents we obtain and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Moreover, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents we may obtain. For these reasons and others, we may face competition with respect to our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned and any future in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and any patents we do obtain may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such challenges also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Furthermore, our competitors may be able to circumvent any patents we obtain or in-license in the future by developing similar or alternative technologies or products in a non-infringing manner. For these reasons, even if we are successful in obtaining patents or in-licensing patents in the future, our patent portfolio may not provide us with sufficient rights to exclude others from using or commercializing technology and products similar or identical to any of our technology and product candidates for any period of time.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may not protect our competitive position for an adequate amount of time.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issued patents can provide protection for varying periods of time, depending, for example, upon the type of patent, the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. However, patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the statutory expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. The term of a patent outside of the U.S. varies in accordance with the laws of the foreign jurisdiction. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are approved for use or commercialized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not obtain patent term extension in the U.S. under the Hatch-Waxman Act and in foreign countries under similar legislation, which if granted could extend the term of our marketing exclusivity for any product candidates we may develop, our business may be materially and adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., the term of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration date of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. In addition, the patent term of only one patent applicable to an approved drug may be extended, and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other non-U.S. jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on any patents that issue covering those product candidates, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted and, even if granted, the length of such extensions. We may not be granted patent term extension either in the U.S. or in any foreign country, even where we obtain a patent that is eligible for patent term extension, if, for example, an applicable government authority determines that we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we obtain such an extension, it may be for a shorter period than we had sought. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations and prospects could be materially and adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, for any patents we may in-license in the future, we may not have the right to control prosecution, including filing with the USPTO, of a petition for patent term extension under the Hatch-Waxman Act. Thus, if a patent we in-license in the future is eligible for patent term extension under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a patent term extension is filed or whether the requested extension is obtained from the USPTO.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. We may be unable to obtain or in-license patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we or our future licensors submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated NDA filed with the FDA to obtain permission to sell a generic version of such product candidate.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes to patent laws in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in either the patent laws or interpretation of patent laws in the U.S. or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of our owned and any future in-licensed patent applications and the maintenance, enforcement or defense of any issued patents we may obtain or in-license.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. For example, the USPTO regularly revises its policies and procedures for patent examination. Future political changes may impose new difficulties in obtaining patent protection. This combination of events has increased uncertainty with respect to the validity and enforceability of patents once obtained. Similarly, foreign courts and patent offices have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain patent protection in the future.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors and other third parties may infringe, misappropriate or otherwise violate patents or other intellectual property that we own or license. As a result, we or our future licensors may need to file infringement, misappropriation or other intellectual property claims, which can be expensive and time-consuming. Any claims we assert against others could provoke them to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property rights. Our ability to stop third parties from making, using, selling, offering to sell, or importing products that infringe our intellectual property will depend in part on the extent to which we obtain and enforce patent claims that cover our technology, inventions, and improvements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. In a patent infringement proceeding, the perceived infringers could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are common. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, such as opposition proceedings in the European Patent Office. The outcomes of allegations of invalidity or unenforceability are unpredictable. With respect to validity, for example, even if we are successful in obtaining patents or in-licensing patents, we cannot be certain that there is no invalidating prior art of which the patent examiner and we or our future licensing partners were unaware during prosecution.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An adverse result in any such proceeding could put one or more of the patents that we may own or in-license in the future at risk of being invalidated or interpreted narrowly, and could put any of our present or future owned or in-licensed patent applications at risk of not yielding an issued patent. A court may also refuse to stop the third party from using the technology at issue in a proceeding, for example, on the basis that our owned or in-licensed patents do not cover that technology. Furthermore, if the breadth or strength of protection provided by our patent applications and any future patents is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products, diagnostic tests or services.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patent applications or any future patents. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be adversely affected if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise funds as needed to continue our clinical trials, continue our discovery programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during litigation. Any of the foregoing could allow third parties to develop and commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third parties may allege that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries. We may become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post grant review, inter partes review and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, including our competitors, exist in the fields in which we are pursuing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our technologies or product candidates may be subject to claims that they infringe the patent rights of third parties. Our competitors and others may have significantly larger and more mature patent portfolios than we have. In addition, future litigation may be initiated by patent holding companies or other third parties who have no relevant product or service revenue and against whom our future patents, if any, may provide little or no deterrence or protection. Competitors may also assert that our product candidates infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources and management attention to defend. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain greater visibility as a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. Because patent applications can take many years to issue, pending patent applications may result in issued patents that our product candidates infringe. For example, there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the discovery, use or manufacture of our product candidates or technologies. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates, or we may incorrectly conclude that third-party intellectual property is invalid or that our activities and product candidates do not infringe the intellectual property rights of third parties. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party&#8217;s intellectual property rights. Parties making claims against us may also obtain injunctive or other equitable relief. For example, if any third-party patents were held to cover the manufacturing process of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidates. In the event of a successful claim of infringement against us, we may also have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, indemnify customers, collaborators or other third parties, seek new regulatory approvals, and redesign our infringing products, which may not be possible or practical. If we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we may be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and could require us to make substantial licensing and royalty payments. Claims that we have misappropriated the confidential information, trade secrets or other intellectual property rights of third parties could have a similar material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain licenses from third parties on commercially reasonable terms, our business could be adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from the third parties. The in-licensing and acquisition of third-party intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rights is a competitive area, and a number of more established companies are also pursuing strategies to in-license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to sell, assign or license rights to us. In addition, we expect that competition for the in-licensing or acquisition of third-party intellectual property rights for product candidates that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, such as substantial licensing or royalty payments, our business could be materially and adversely affected. If we are unable to obtain a necessary license, the third parties owning such intellectual property rights could seek an injunction prohibiting our sales or we may be unable to otherwise develop or commercialize the affected product candidates, which could materially harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain rights to required third-party intellectual property rights, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations, and prospects significantly.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations in any future intellectual property licenses with third parties that we may enter into, or otherwise experience disruptions to our business relationships with our future licensors, we could lose intellectual property rights that are important to our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future enter into licensing and funding arrangements with third parties that may impose, among other things, diligence, development, and commercialization timelines, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with those obligations, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements, or our counterparties may require us to grant them certain rights. Such an occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations, and prospects, or impede, delay or prohibit the further development or commercialization of, one or more product candidates that rely on such agreements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, disputes may arise regarding intellectual property that is or becomes subject to a licensing agreement, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license agreement and other matters of contract interpretation;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and the extent to which our technology and processes infringe the intellectual property rights of the licensor that are not subject to the licensing agreement;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether our licensor or its licensor had the right to grant the license agreement;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the intellectual property rights without their authorization;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our involvement in the prosecution of licensed patents and our licensors&#8217; overall patent enforcement strategy;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amounts of royalties, milestones or other payments due under the license agreement;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sublicensing of patent and other rights under collaborative development relationships;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the priority of invention of patented technology.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not prevail in such disputes, we may lose any or all of our rights under such license agreements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, intellectual property license agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we may license prevent or impair our ability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications we may in-license. If other third parties have ownership rights to patents and/or patent applications we may in-license, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our in-licensed patents in order to enforce such patents against third parties, and we may not receive such cooperation. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite our efforts, our future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors could seek regulatory approval for and market products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may attempt to develop and commercialize competitive products in foreign countries where we do not have any patent protection and/or where legal recourse may be limited. This may have a significant commercial impact on our foreign business operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S., and even where such protection is nominally available, adequate judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling our inventions in such countries or importing products made using our inventions into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we do obtain patent protection or future licenses but enforcement is not as strong as that in the U.S. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to pharmaceutical and biotechnology products, which could make it difficult for us to stop the infringement of any patents we do obtain or in-license or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect, to the same extent as the U.S. or at all, inventions that constitute new methods of treatment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put any patents we obtain at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We work with third-party contractors located in China to develop certain of our intellectual property. On December 1, 2020, the Chinese government implemented a new Export Control Law which regulates the export of certain technologies outside of China. As currently implemented, we do not believe the Export Control Law applies to our product candidates, and we do not expect it to impact our business; however, the Export Control Law could be amended in the future in a way that could adversely affect our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many countries, including India, China and certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we do obtain or in-license patents and we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business, financial condition, results of operations, and prospects may be adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our future licensors may be subject to claims that current or former employees, collaborators, CROs, universities or other third parties have an interest in our owned or future in-licensed patents and patent applications, trade secrets or other intellectual property as an inventor, co-inventor, owner or co-owner. For example, we or our future licensors may have inventorship or ownership disputes that arise from conflicting obligations of employees, consultants, CROs or others who are involved in developing our product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership of any owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, we may be required to pay monetary damages and we may also lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to protect our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Additionally, if residents of other countries can claim inventorship of our patents and patent applications, we may be required to fulfill additional obligations. For example, some countries, including China, require a patent owner to provide remuneration to inventors who assign rights to inventions developed during course of their employment. Litigation may be necessary to defend against claims based on foreign inventors. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property discovered through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future develop, acquire, or license intellectual property rights that have been generated through the use of U.S. government funding or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the invention; (2) government action is necessary to meet public health or safety needs; or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). If the U.S. government exercises its &#8220;march-in&#8221; rights in any future intellectual property rights that are generated through the use of U.S. government funding or grants, we could be forced to license or sublicense intellectual property developed by us or that we may license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for the exercise of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the U.S. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the U.S. or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. Any exercise by the government of any of the foregoing rights could harm our competitive position, business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of such third parties, or that they have wrongfully used or disclosed alleged trade secrets of their current or former employers, or that we have misappropriated their intellectual property, or that they own what we regard as our own intellectual property.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our employees, physician-scientist partners, consultants and contractors are or were previously employed at or engaged by universities or other pharmaceutical or biotechnology companies, including our competitors or potential competitors. Many of them executed proprietary rights, non-disclosure and/or non-competition agreements in connection with such previous employment or engagement. Although we try to ensure that the individuals who work for us do not use the intellectual property rights, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or they have, inadvertently or otherwise, used, infringed, misappropriated or otherwise violated the intellectual property rights, or disclosed the alleged trade secrets or other proprietary information, of these former employers, competitors or other third parties. We may also be subject to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. Any litigation or the threat of litigation may adversely affect our ability to hire employees or engage consultants and contractors. A loss of key personnel or their work product could hamper or prevent us from developing and commercializing products and product candidates, which could have an adverse effect on our business, results of operations, or prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, while it is our policy to require our employees, physician-scientist partners, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in obtaining such an agreement from each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Additionally, assignment agreements and related agreements may be interpreted under the laws of a foreign country, which may be unpredictable. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail in prosecuting or defending any such claims, we may be required to pay monetary damages, and we may also lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets and other proprietary information, our business and competitive position would be adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, consultants, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, advisors and other third parties. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, our unpublished patent applications or other confidential research, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate such trade secrets, from using that technology or information to compete with us.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, we expect that, over time, our trade secrets, know-how and proprietary information may be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel to and from academic and industry scientific positions. Consequently, without costly efforts to protect our proprietary technology, we may be unable to prevent others from exploiting that technology, which could affect our ability to expand in domestic and international markets. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. These security measures may be breached or otherwise accessed in an unauthorized manner, and we may not have adequate remedies for any breach.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition or cancellation proceedings. This can be time-consuming and expensive, particularly for a company of our size. In addition, in an infringement proceeding, a court may decide that a trademark of ours is not valid or is unenforceable, or may determine another trademark is not infringing our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these trademarks or trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trademarks or trade names similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark or trade name infringement claims brought by owners of other registered trademarks or trade names that incorporate variations of our trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks and trade names may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current trademark applications and additional trademark applications we may file in the future may not proceed to registration and/or may be opposed by third parties. Even if such applications proceed to registration, third parties may challenge our use of such trademarks or seek to invalidate our registration in the future. Other companies in our industry may be using trademarks that are similar to ours and may in the future allege that the use of our trademarks in connection with our products infringes or otherwise violates their trademark rights. Trademark-granting authorities may decide to investigate our trademarks on their own initiative if they believe that there may be potential issues to be resolved. In addition, failure to maintain our trademark registrations, or to obtain new trademark registrations in the future, could limit our ability to protect and enforce our trademarks and impede our marketing efforts in the countries in which we operate. Over the long term, if we are unable to establish brand recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to our dependence on third parties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract manufacturing organizations (CMOs), and strategic partners (collectively, partners) to conduct and support our preclinical studies and our clinical trials under agreements with us and plan to continue to do so for our future preclinical studies and clinical trials. These third parties have had and will continue to have a significant role in the conduct of our preclinical studies and clinical trials and the subsequent collection and analysis of data. For example, our partners contribute highly enabling technologies and services that include: (i) numerous physician-scientists at leading CROs, (ii) support for our translational research efforts, (iii) crystallography to enable structure-based drug discovery, (iv) biochemical and cell-based assays to guide lead generation and optimization, and (v) patient-derived, cell and xenograft models to translate our findings to the clinical setting.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These third parties are not our employees, and except for remedies available to us under our agreements with such third parties, we have limited ability to control the amount or timing of resources that any such third party will devote to our preclinical studies or our clinical trials. The third parties we rely on for these services may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could affect their performance on our behalf. Some of these third parties may terminate their engagements with us at any time. We also have to negotiate budgets and contracts with CROs, clinical trial sites and CMOs and we may not be able to do so on favorable terms, which may result in delays to our development timelines and increased costs. If we need to enter into alternative arrangements with, or replace or add any third parties, it would involve substantial cost and require extensive management time and focus, or involve a transition period, and may delay our drug development activities, as well as materially impact our ability to meet our desired clinical development timelines.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our heavy reliance on these third parties for such drug development and clinical trial activities reduces our control over these activities. As a result, we have less direct control over the conduct, timing and completion of preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with GCP standards, regulations for conducting, recording and reporting the results of clinical trials to assure that data and reported results are reliable and accurate and that the rights, integrity and confidentiality of trial participants are protected. The EMA also requires us to comply with similar standards. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials substantially comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations and require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients, may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, or if these third parties need to be replaced, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We contract with third parties for the manufacture of our product candidates for preclinical studies and clinical trials, and expect to continue to do so for additional preclinical studies, clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quality and quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. If we were to experience an unexpected loss of supply of any of our product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing preclinical studies or clinical trials.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure of the third party to manufacture our product candidates according to our schedule and specifications, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the breach by the third-party contractors of our agreements with them;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure of third-party contractors to comply with applicable regulatory requirements, including cGMP;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the misappropriation of our proprietary information, including our trade secrets and know-how.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have complete control over all aspects of the manufacturing process of our contract manufacturing partners and are dependent on these contract manufacturing partners for general project management, in-person oversight and for compliance with cGMP regulations for manufacturing both API and finished drug products. To date, we have obtained API and drug product for our product candidates from a limited group of third-party contract manufacturers, and we continue to develop our supply chain for each of our product candidates. As we advance our product candidates through development and into commercialization, if approved, we will continue to take steps to protect against any potential supply disruptions through the use of a safety stock strategy and by maintaining relationships and contracting with additional suppliers. However, we may be unsuccessful in maintaining or putting in place additional framework agreements or protecting against potential supply disruptions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the U.S. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or comparable regulatory authorities, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we will need to find alternative manufacturing facilities, and those new facilities would need to be inspected and approved by the FDA, EMA or a comparable regulatory authority prior to commencing manufacturing, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any third-party manufacturer with whom we contract fails to perform its obligations, we may be forced to enter into an agreement with a different third-party manufacturer, which we may not be able to do on reasonable terms, if at all. As a result, our clinical trial supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our product candidates may be unique or proprietary to the original third-party manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change third-party manufacturers for any reason, we will be required to verify that the new third-party manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new third-party manufacturer could negatively affect our ability to develop product candidates or commercialize our anticipated products in a timely manner or within budget. Furthermore, a third-party manufacturer may possess technology related to the manufacture of our product candidate that such third-party manufacturer owns independently. This would increase our reliance on such third-party manufacturer or require us to obtain a license from them in order to have another third-party manufacturer manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our manufacturing process needs to comply with FDA regulations relating to the quality and reliability of such processes. Any failure to comply with relevant regulations could result in delays in or termination of our clinical programs and suspension or withdrawal of any regulatory approvals.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to commercially produce our products either at a third party&#8217;s facility or in any facility of ours, we will need to comply with the FDA&#8217;s cGMP regulations and guidelines. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable foreign regulatory authorities to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our precision medicines as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of our precision medicines for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant non-compliance could also result in the imposition of sanctions, including warning or untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation and our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products, product candidates, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased operating expenses and cash requirements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the assumption of additional indebtedness or contingent liabilities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the issuance of our equity securities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the diversion of our management&#8217;s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products, product candidates and marketing approvals; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we undertake acquisitions or pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our third-party manufacturers use hazardous materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical materials, by our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the U.S. and local laws in other foreign jurisdictions governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state, federal or foreign authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we decide to establish collaborations, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our drug development programs and the potential commercialization of our product candidates may require additional cash to fund expenses. We may seek to selectively form collaborations to expand our capabilities, potentially accelerate research and development activities and provide for commercialization activities by third parties. Any of these relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for a collaboration depends, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of preclinical studies or clinical trials, the likelihood of approval by the FDA, EMA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property and industry and market conditions generally. The potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we are successful in entering into a collaboration, the terms and conditions of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If and when we seek to enter into collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our discovery programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may enter into collaborations with third parties for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we enter into any collaboration arrangements with any third parties for the development and commercialization of our product candidates, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product candidates would pose numerous risks to us, including the following:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations and may not perform their obligations as expected;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may de-emphasize or not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus, including as a result of a business combination or sale or disposition of a business unit or development function, or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and distribution of our product relative to other products;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may grant exclusive rights to our collaborators that would prevent us from collaborating with others;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate our proprietary information and intellectual property or expose us to potential litigation or other intellectual property related proceedings;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not provide us with timely and accurate information regarding development progress and activities under the collaboration or may limit our ability to share such information, which could adversely impact our ability to report progress to our investors and otherwise plan our own development of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may own or co-own intellectual property covering our products or product candidates that result from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to ownership of our common stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market price of our Class A common stock may be volatile, and our investors could lose all or part of their investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of our Class A common stock has been and is likely to continue to be highly volatile and subject to wide fluctuations in response to various factors, many of which we cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Broad market and industry factors may negatively affect the market price of our Class A common stock, regardless of our actual operating performance. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report, these factors include, without limitation:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and results of INDs, NDAs, preclinical studies and clinical trials of our product candidates or those of our competitors;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competitive products or announcements by potential competitors of their product development efforts;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our success in commercializing our drug candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory actions with respect to our products or product candidates or our competitors&#8217; products or product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in our growth rate relative to our competitors;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the U.S. and other countries;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments or disputes concerning our patent applications, issued patents, or other proprietary rights;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the recruitment or departure of key personnel;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sector;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcement or expectation of additional financing efforts;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our common stock by us, our insiders or our other stockholders;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expiration of market stand-off or lock-up agreements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of any public health emergencies, natural disasters, or geopolitical events, including actual or threatened tariffs or other changes in trade policy, civil or political unrest or military conflicts; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, political, industry and market conditions.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our Class A common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our Class A common stock may be influenced by the research and reports that securities or industry analysts publish about us, our business or our market. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements or strategic partnerships with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award, and recognize the cost as an expense over the employee&#8217;s requisite service period. Compensation cost for stock-based awards with performance-based vesting conditions is recognized on a straight-line basis over the requisite service period for each separately vesting portion of the underlying stock award when the performance-based vesting condition is deemed probable to occur. As the variables that we use as a basis for valuing these awards change over time, including our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and cost of, and level of investment in, research and development activities relating to our programs, which will change from time to time;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to enroll patients in clinical trials and the timing of enrollment;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing our current product candidates and any future product candidates, which may vary depending on FDA, EMA or other comparable foreign regulatory authority guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenditures that we will or may incur to acquire or develop additional product candidates and technologies or other assets;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and outcomes of preclinical studies and clinical trials for our product candidates, or competing product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competition from existing and potential future products that compete with our product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any delays in regulatory review or approval of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of demand for any of our product candidates, if approved, which may fluctuate significantly and be difficult to predict;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to commercialize our product candidates, if approved, inside and outside of the U.S., either independently or working with third parties;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain collaborations, licensing or other arrangements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to adequately support future growth;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential unforeseen business disruptions that increase our costs or expenses;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the changing, volatile and instable global economic and political environment.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our Class A common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Global credit and financial markets have experienced extreme instability, volatility and disruptions in the past several years due to a number of factors, including the COVID-19 pandemic, ongoing military conflicts, bank failures and other market-influencing developments, including severely diminished liquidity and credit availability, declines in consumer confidence, increases in interest rates, declines in economic growth, increases in unemployment rates, increases in inflation and uncertainty about international trade policy and economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions, whether due to changes in trade policy, public health emergencies, military conflicts, bank failures or otherwise, will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to secure additional financing, as needed, in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans or commercialization efforts. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. Our stock price may decline due in part to the volatility of the stock market and the general economic downturn.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our principal stockholders own a significant percentage of our stock and can exert significant control over matters subject to stockholder approval. Two of our directors are affiliated with one of our principal stockholders.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our holders of 5% or more of our capital stock and their respective affiliates beneficially own a substantial amount of our outstanding Class A common stock and Class B common stock and a substantial amount of our Class A voting stock. Two of our directors, Joseph Pearlberg, M.D., Ph.D. and Cameron A. Wheeler, Ph.D., are affiliated with Deerfield Management Company, L.P., certain affiliates of which, collectively, constitute our largest stockholder. Our principal stockholders, acting together or on their own, could exert significant control over matters requiring stockholder approval. For example, they may be able to impact elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that investors may feel are in their best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with each investor&#8217;s interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our Class A common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The dual class structure of our common stock and the option of the holders of shares of our Class B common stock to convert into shares of our Class A common stock may limit our Class A common stockholders&#8217; ability to influence corporate matters.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Class A common stock has one vote per share, while our Class B common stock is non-voting. Nonetheless, each share of our Class B common stock may be converted at any time into one share of Class A common stock at the option of its holder, subject to the limitations provided for in our third amended and restated certificate of incorporation, as amended, that prohibit the conversion of our Class B common stock into shares of Class A common stock to the extent that, upon such conversion, such holder and any other persons with whom such holder&#8217;s beneficial ownership would be aggregated for purposes of Section 13(d) of the Exchange Act would beneficially own in excess of 4.9% or 9.9%, as applicable, based on the holder&#8217;s election of any class of our securities registered under the Exchange Act. Consequently, if holders of Class B common stock exercise their option to make this conversion, such exercise will have the effect of increasing the relative voting power of those prior holders of our Class B common stock (subject to the ownership limitation described in the previous sentence) and increasing the number of outstanding shares of our voting common stock, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">correspondingly decreasing the relative voting power of the current holders of our Class A common stock, which may limit our Class A common stockholders&#8217; ability to influence corporate matters. Because our Class B common stock is generally non-voting, stockholders who own more than 10% of our common stock overall but 10% or less of our Class A common stock will not be required to report changes in their ownership from transactions in our common stock pursuant to Section 16(a) of the Exchange Act and would not be subject to the short-swing profit provisions of Section 16(b) of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our 2021 Stock Option and Incentive Plan (2021 Plan), could result in dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by such sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our 2021 Plan, our management is authorized to grant stock options and restricted stock units, among other award types, to our employees, directors and consultants. If the number of shares reserved under our 2021 Plan is increased pursuant to the terms of our 2021 Plan, our stockholders may experience dilution, which could cause our stock price to fall.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we may need to finance our cash needs through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through future strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms unfavorable to us.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We incur significant costs as a result of operating as a public company, and our management is devoting substantial time to related compliance initiatives.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we incur significant legal, accounting and other expenses. We are and will continue to be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, and the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and Nasdaq. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, significant legal and financial compliance costs, and making some activities more time consuming. We have had to hire additional accounting, finance, and other personnel in connection with our status as a public company, and our management and other personnel devote a substantial amount of time to these compliance initiatives and we cannot accurately predict or estimate the amount or timing of additional costs we may incur to respond to these requirements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as a public company we are required to incur additional costs and obligations in order to comply with SEC rules that implement Section 404 of the Sarbanes-Oxley Act. Under these rules, we are required to maintain effective disclosure and financial controls and to make a formal assessment of the effectiveness of our internal control over financial reporting. In addition, we are subject to Section 404(b) of the Sarbanes-Oxley Act, which requires us to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. Compliance with Section 404 has been and will continue to be both costly and time-consuming for our management.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future discover material weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. Accordingly, we cannot assure our stockholders that we will not in the future identify material weaknesses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we have a material weakness in our internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our investors could lose confidence in our reported financial information, the market price of our stock could decline, and we could be subject to sanctions or investigations by the stock exchange on which our Class A common stock is listed, the SEC or other regulatory authorities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These inherent limitations include the fact that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to securities litigation, which is expensive and could divert management attention.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our Class A common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of their stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-takeover provisions in our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change in control of our Company or changes in our management and, therefore, depress the market price of our Class A common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our third amended and restated certificate of incorporation, as amended, and amended and restated bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our Company or changes in our management that the stockholders of our Company may deem advantageous. These provisions, among other things, include:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a prohibition on stockholder actions through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement that special meetings of stockholders be called only by our board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the authority of our board of directors to issue preferred stock on terms determined by our board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, Section 203 of the General Corporation Law of the State of Delaware (the DGCL) prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any provision of our third amended and restated certificate of incorporation, as amended, our amended and restated bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of, or a claim based on, fiduciary duty owed by any of our current or former directors, officers, and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, our third amended and restated certificate of incorporation or our amended and restated bylaws or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein (the Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the U.S. shall be the sole and exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act (the Federal Forum Provision). In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court were &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the U.S. may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item</span><span id="item_1b"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 1B. Unresolved Staff Comments.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><div><ix:nonNumeric id="F_12886c78-ec1c-4fa2-b10c-579d037cae1d" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_12886c78-ec1c-4fa2-b10c-579d037cae1d_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Cybersecurity.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity Incident Response Plan (IRP). Our cybersecurity risk management program is a key component of our overall risk management process, and includes similar characteristics, reporting channels and governance processes to those that apply across other legal, compliance, strategic, operational and financial risk areas within the Company.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></p><div><ix:nonNumeric id="F_7c35c2dc-c932-4159-88dd-1b694695de94" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true" continuedAt="F_7c35c2dc-c932-4159-88dd-1b694695de94_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program includes:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;</span></div></div></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_12886c78-ec1c-4fa2-b10c-579d037cae1d_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7c35c2dc-c932-4159-88dd-1b694695de94_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity awareness training of our employees, incident response personnel and senior management;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a cybersecurity IRP that includes procedures for responding to cybersecurity incidents; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0edf967c-54c0-4c6b-bc82-d14f36683ae6" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a third-party risk management process for service providers, suppliers and vendors</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5aea571d-02da-4096-88f3-ed0426529d02" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not identified risks from known cybersecurity threats,</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations or financial condition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Governance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_696dbe25-ce73-4d40-9b5d-b263780ee031" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a3a1b3b-aec0-4e55-b411-10ccadcd75ab" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to its audit committee oversight of cybersecurity and other information technology risks. The audit committee oversees management&#8217;s implementation of our cybersecurity risk management program</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><div><ix:nonNumeric id="F_42ebe525-53f0-4a60-8c41-d20b45434f8c" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives reports from management on our cybersecurity risks at least annually. In addition, management updates the audit committee regarding all material cybersecurity incidents, as well as any incidents with lesser impact potential that management, in its discretion, determines may be relevant for audit committee review. The </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2bcea2be-9d5d-4be6-ba78-e91f28f05bb0" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">audit committee reports to the board of directors</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> regarding its activities, including those related to cybersecurity.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5afffa15-e2fd-45de-a23e-808c956209c1" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5860e5c6-b0ae-44e9-9469-91e9e59b8dcb" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34d671d1-6e2d-4ea9-bf7e-65428c32a1e7" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer, working closely with our Vice President, Information Technologies and our Director, Cybersecurity and Compliance (collectively, our Cybersecurity Oversight Team)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, is responsible for assessing and managing our material risks from cybersecurity threats</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Cybersecurity Oversight Team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dd363d52-1837-48ef-8af1-293951f7dda2" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Cybersecurity Oversight Team&#8217;s experience includes a combined 50+ years in the pharmaceutical industry and information technology. This includes software and systems development, cybersecurity program oversight and overall IT management. Our Cybersecurity Oversight Team has over two decades of experience dedicated to supporting enterprise architecture and over a decade of experience specializing in cybersecurity, implementing cybersecurity frameworks, assessing and managing cybersecurity risks and executing incident response plans.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Cybersecurity Oversight Team supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, which include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74ee1ff7-bcb8-439c-b9c6-fb04bc438dba" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engaged</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by us; and alerts and reports produced by security tools deployed in the IT environment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our IRP, all of our employees are trained to report a suspected cybersecurity incident or breach to our information technology team. Reporting guidelines under the IRP describe how to report an incident and what details to include. As a first step under the IRP, our information technology team assesses the reported risk or breach and escalates it to our Incident Response Team (IRT), as appropriate. The IRT is comprised of the members of our Cybersecurity Oversight Team and other critical business function leaders, including members of our legal and communications teams. Following notification from our information technology team, the IRT is responsible for continuing to assess the suspected risk or breach to determine its potential impact on our organization, systems and data. Based on that assessment, the IRT may raise the incident or breach to other members of management or the audit committee for further review and triage.</span></p></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tem 2. Properties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We lease office space for our corporate headquarters, which is located in Cambridge, Massachusetts. We believe our leased office space is adequate for our current needs and that suitable additional or alternative space will be available in the future on commercially reasonable terms, if required.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Legal Proceedings.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we were not party to any material legal proceedings.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tem 4. Mine Safety Disclosures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Information Regarding the Trading of Our Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Class A common stock trades under the symbol &#8220;NUVL&#8221; on the Nasdaq Global Select Market and has been publicly traded since July 29, 2021. Prior to this time, there was no public market for our Class A common stock. Our Class B common stock is not listed or traded on any stock exchange.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of Our Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 19, 2026, there were approximately 5 holders of record of shares of our Class A common stock and 2 holders of record of shares of our Class B common stock. This number does not include stockholders for whom shares are held in &#8220;nominee&#8221; or &#8220;street&#8221; name.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid cash dividends on our common stock since our inception. We currently intend to retain all available funds and any future earnings to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on then-existing conditions, including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Performance Graph</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The stock performance graph below compares the performance of our common stock to The Nasdaq Biotechnology Index (Nasdaq Biotechnology) and The Nasdaq Composite Index (Nasdaq Composite) from July 29, 2021 to December 31, 2025. The comparisons assume an investment of $100 in our Class A common stock and in each of the foregoing indices, and assume reinvestment of dividends, if any. The comparisons shown in the stock performance graph below are based upon historical data and are not necessarily indicative of, nor are they intended to forecast, the potential future performance of our common stock. The following stock performance graph and related information shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission for purposes of Section 18 of the Exchange Act, nor shall such information be incorporated by reference into any future filing under the Securities Act, except to the extent that we specifically incorporate it by reference into such filing.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img123481027_3.jpg" alt="img123481027_3.jpg" style="width:605px;height:370px;"/></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no shares of equity securities sold or issued by us during the period covered by this Annual Report that were not registered under the Securities Act, and that were not previously reported in an Annual Report on Form 10-K, Quarterly Report on Form 10-Q or Current Report on Form 8-K.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did not purchase any of our registered equity securities during the period from October 1, 2025 to December 31, 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. [Reserved.]</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_management_discussion_analysis"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. For a detailed discussion of our business environment, please read Item 1. Business, included in this Annual Report. As a result of many factors, including those factors set forth in Item 1A. Risk Factors of this Annual Report, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We leverage our team&#8217;s deep expertise in chemistry and structure-based drug design to develop innovative small molecules that are designed with the aim to overcome the limitations of existing therapies for clinically proven kinase targets.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations faced by currently available kinase inhibitors can include (i) kinase resistance, or the emergence of new mutations in the kinase target that can enable resistance to existing therapies, (ii) kinase selectivity, or the potential for existing therapies to inhibit other structurally similar kinase targets and lead to off-target adverse events, and (iii) limited brain penetrance, or the ability for the therapy to treat disease that has spread or metastasized to the brain. By prioritizing target selectivity, we believe our drug candidates have the potential to overcome resistance, avoid dose-limiting off-target adverse events, address brain metastases, and drive more durable responses. This may result in the potential to drive deeper, more durable responses with minimal adverse events, and we believe these potential benefits may support opportunities for clinical utility earlier in the treatment paradigm.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Candidate Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Zidesamtinib (NVL-520)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our first lead product candidate, zidesamtinib (NVL-520), is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). Zidesamtinib is a novel ROS1-selective inhibitor designed with the aim to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of currently available ROS1 tyrosine kinase inhibitors (TKIs). Zidesamtinib has received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for the treatment of patients with locally advanced or metastatic (advanced) ROS1-positive NSCLC who have previously been treated with two or more prior ROS1 TKIs, and orphan drug designation for ROS1-positive NSCLC.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ARROS-1 clinical trial is a first-in-human global Phase 1/2, multicenter, open-label, dose-escalation and expansion study evaluating zidesamtinib as an oral monotherapy in patients with advanced ROS1-positive NSCLC and other solid tumors. Dosing was initiated in the Phase 1 portion of the ARROS-1 clinical trial in January 2022. From January 2022 to August 2023, the Phase 1 portion of the ARROS-1 trial enrolled 104 patients (99 NSCLC, 5 other solid tumors).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we announced the initiation of the Phase 2 portion of the ARROS-1 clinical trial, following alignment with the FDA on a recommended Phase 2 dose (RP2D) of 100 mg once daily (QD). The Phase 2 portion of the ARROS-1 clinical trial is designed to evaluate the safety and activity of zidesamtinib in patients with advanced ROS1-positive NSCLC and other solid tumors, examining several specific cohorts of patients based on the prior anti-cancer therapies that such patients have received. The Phase 2 cohorts have been designed to support potential registration in TKI-na&#239;ve and/or TKI pre-treated ROS1-positive NSCLC patients.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Between September 2023 and June 16, 2025, 435 patients were enrolled in the Phase 2 portion of the ARROS-1 clinical trial. In June 2025, we announced positive pivotal data for zidesamtinib in TKI pre-treated patients with advanced ROS1-positive NSCLC from the global ARROS-1 Phase 1/2 clinical trial, and in September 2025, we presented the pivotal dataset at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer. The primary efficacy analysis population for this pivotal dataset consisted of 117 TKI pre-treated patients with advanced ROS1-positive NSCLC with measurable disease who received zidesamtinib at the RP2D by May 31, 2024, with duration of response (DOR) follow-up of at least 6 months available for nearly all responders.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2025, we also shared preliminary data from the Phase 2 TKI-na&#239;ve cohort in the ARROS-1 clinical trial, in which enrollment is ongoing. Encouraging preliminary data were available for 35 TKI-na&#239;ve patients with advanced ROS1-positive NSCLC treated with zidesamtinib at RP2D as of August 31, 2024. As of June 16, 2025, a total of 104 patients had been enrolled in the ongoing TKI-na&#239;ve cohort of the ARROS-1 trial.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, the FDA accepted for filing our New Drug Application (NDA) for zidesamtinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who received at least 1 prior ROS1 TKI. The application has been assigned a Prescription Drug User Fee Act target action date of September 18, 2026. Additionally, we plan to submit data from the ongoing TKI-na&#239;ve cohort in the Phase 2 portion of the ARROS-1 clinical trial to the FDA to support a potential label expansion of zidesamtinib in TKI-na&#239;ve patients with advanced ROS1-positive NSCLC in the second half of 2026.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Neladalkib (NVL-655)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our second lead product candidate, neladalkib (NVL-655), is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. Neladalkib is a brain-penetrant ALK-selective inhibitor designed with the aim to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that may limit the use of first-generation (1G; crizotinib), second-generation (2G; ceritinib, alectinib, or brigatinib), and third-generation (3G; lorlatinib) ALK inhibitors. Neladalkib has received FDA Breakthrough Therapy designation for the treatment of patients with locally advanced or metastatic ALK-positive NSCLC who have been previously treated with two or more ALK TKIs, and orphan drug designation for ALK-positive NSCLC.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ALKOVE-1 clinical trial is a first-in-human global Phase 1/2, multicenter, open-label, dose-escalation and expansion study evaluating neladalkib as an oral monotherapy in patients with advanced ALK-positive NSCLC and other solid tumors. Dosing was initiated in the Phase 1 portion of the ALKOVE-1 clinical trial in June 2022. From June 2022 to February 2024, the Phase 1 portion of the ALKOVE-1 clinical trial enrolled 133 patients (131 NSCLC, 2 other solid tumors).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, we announced the initiation of the Phase 2 portion of the ALKOVE-1 clinical trial, following alignment with the FDA on a RP2D of 150 mg QD. The Phase 2 portion of the ALKOVE-1 clinical trial is designed to evaluate the safety and activity of neladalkib in several expansion cohorts of patients defined based on the number and type of prior anti-cancer therapies they have received. The Phase 2 cohorts are designed with registrational intent for TKI pre-treated patients with ALK-positive NSCLC and to enable preliminary evaluation for patients with ALK-positive NSCLC who are TKI-na&#239;ve.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, we announced the initiation of the ALKAZAR Phase 3 clinical trial with registrational intent for TKI-na&#239;ve patients with advanced ALK-positive NSCLC. The ALKAZAR clinical trial is a global, randomized, controlled trial designed to evaluate neladalkib versus the current standard of care. Patients are randomized 1:1 to receive neladalkib monotherapy or ALECENSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(alectinib) monotherapy, reflecting input from collaborating physician-scientists and alignment with global regulatory agencies. The ALKAZAR clinical trial is designed to enroll approximately 450 patients with TKI-na&#239;ve ALK-positive NSCLC. The primary endpoint is progression-free survival (PFS) based on Blinded Independent Central Review (BICR). Secondary endpoints include overall survival, PFS based on investigator&#8217;s assessment, time to intracranial response, and BICR assessment of intracranial objective response rate, intracranial duration of response, objective response rate, DOR, time to intracranial progression, and safety.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the European Society for Medical Oncology Congress in October 2025, we presented preliminary data for neladalkib in patients with advanced ALK-positive solid tumors outside of NSCLC from the ongoing ALKOVE-1 clinical trial. Neladalkib demonstrated encouraging preliminary activity across a diverse set of ALK TKI-na&#239;ve and previously treated advanced ALK-positive solid tumors, and was considered generally safe and well-tolerated with a preliminary overall safety profile consistent with its ALK-selective, tropomyosin receptor kinase-sparing design, and with previously reported data.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, we announced positive topline data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from the global ALKOVE-1 Phase 1/2 clinical trial. The primary analysis population for this topline dataset consisted of 253 TKI pre-treated patients with advanced ALK-positive NSCLC with measurable disease who received neladalkib at the RP2D by September 30, 2024, with DOR follow-up of at least 6 months available for nearly all responders.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, we also shared preliminary data from the Phase 2 exploratory cohort for TKI-na&#239;ve patients with advanced ALK-positive NSCLC from the ALKOVE-1 study. Encouraging preliminary data were available for 44 TKI-na&#239;ve patients with advanced ALK-positive NSCLC treated with neladalkib at RP2D as of August 29, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have completed our pre-NDA meeting with the FDA and plan to move forward with an NDA submission of the data for TKI pre-treated patients with advanced ALK-positive NSCLC from our ALKOVE-1 study of neladalkib in the first half of 2026. We plan to present detailed study results at a future medical meeting.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NVL-330</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our third product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed with the aim to address the combined medical needs of treating tumors driven by HER2 mutations and alterations, including HER2 exon 20 insertion mutations (HER2ex20), treating brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type epidermal growth factor receptor (EGFR). Preclinical data have shown that NVL-330 inhibited a broad range of HER2 oncogenic alterations, including HER2ex20, in cell-based assays, was brain penetrant and was selective for HER2 oncogenic alterations over the structurally related wild-type EGFR. Additionally, new preclinical data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2025, further supporting NVL-330&#8217;s potentially differentiated brain-penetrant profile. Compared to several currently available and investigational HER2 TKIs in the same preclinical assays, NVL-330 demonstrated a favorable efflux ratio and brain partitioning, metrics that are potentially positive predictors of brain exposure in humans. In preclinical models of intracranial activity, NVL-330 induced deep intracranial regression in mice. In the same models, the approved therapies Enhertu (T-DXd) and Hernexeos (zongertinib) did not induce intracranial regression at their clinically relevant doses. Additionally, NVL-330 induced intracranial tumor regression in mice that had progressed in the CNS on zongertinib.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently enrolling patients in the HEROEX-1 clinical trial, a global Phase 1a/1b, multicenter, open-label, dose-escalation and expansion trial evaluating NVL-330 in pre-treated patients with advanced HER2-altered NSCLC, including those with HER2ex20 mutations. In July 2024, we announced that the first patient was dosed with NVL-330 in the HEROEX-1 trial. The HEROEX-1 trial is evaluating the overall safety and tolerability of NVL-330. Additional objectives include determination of the RP2D, characterization of the pharmacokinetic profile, and preliminary evaluation of anti-tumor activity.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Discovery Programs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have prioritized a number of additional small molecule research programs following an assessment of medical need. Research for these programs is ongoing, and we plan to disclose a new development candidate by year-end 2026.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since commencing significant operations in 2018, we have focused substantially all of our efforts and financial resources on research and development activities for our programs, including zidesamtinib, neladalkib and NVL-330, establishing and maintaining our intellectual property portfolio, organizing and staffing our Company, business planning, raising capital, preparing for potential commercialization and providing general and administrative support for these operations. We do not have any products approved for sale and have not generated revenue from product sales or any other source.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant net losses since our inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development of, receipt of marketing approval from regulatory authorities for, and eventual commercialization of our product candidates. We reported net losses of $425.4 million, $260.8 million and $126.2 million for the years ended December 31, 2025, 2024 and 2023, respectively. As of December 31, 2025, we had an accumulated deficit of $972.4 million. We expect to incur significant expenses for the foreseeable future in connection with ongoing activities, particularly if and as we:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to advance zidesamtinib, neladalkib and NVL-330 in clinical development;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance the development of our discovery programs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expand our pipeline of product candidates through our product discovery and development efforts;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory approvals for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to build a sales, marketing and distribution infrastructure to commercialize any approved product candidates and incur related commercial manufacturing costs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implement operational, financial and management systems;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attract, hire and retain additional clinical, scientific, management, sales and marketing and administrative personnel;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and know-how;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or in-license other product candidates and technologies; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operate as a public company.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will not generate revenue from product sales unless and until we successfully complete clinical development of, obtain regulatory approval for and successfully commercialize one or more of our product candidates. As a result, we may need additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. Our ability to raise additional funds may be adversely impacted by general economic conditions, both inside and outside the U.S., including disruptions to, and instability and volatility in, the credit and financial markets in the U.S. and worldwide, including heightened inflation, interest rate and currency rate fluctuations, and economic slowdown or recession as well as concerns related to public health emergencies, natural disasters or geopolitical events, including actual or threatened tariffs or other changes in trade policy, civil or political unrest or military conflicts. In addition, market instability and volatility, high levels of inflation and interest rate fluctuations may increase our cost of financing or restrict our access to potential sources of future liquidity. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of operations or financial condition, including requiring us to have to delay, reduce or eliminate our product development or commercialization efforts. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our development efforts.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had cash, cash equivalents and marketable securities of $1.4 billion. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into 2029. Our existing cash, cash equivalents and marketable securities may not be sufficient to fund all of our product candidates through regulatory approval, and we may need to raise additional capital to complete the development and commercialization of our product candidates. See </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;&#8212;Liquidity and Capital Resources.&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Our Results of Operations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating expenses are comprised of research and development expenses and general and administrative expenses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel engaged in research and development functions; costs incurred in connection with the advancement of our discovery programs and product candidates in preclinical and clinical studies, including under agreements with contract research organizations (CROs); and the cost of developing and scaling our manufacturing process, including under agreements with contract manufacturing organizations (CMOs), to manufacture drug substance and drug product for use in our research and preclinical and clinical studies and manufacture commercial-scale validation batches in preparation for the commercial launch of our product candidates that obtain regulatory approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We track our direct external research and development expenses on a program-by-program basis, including costs incurred with our CROs and CMOs, in connection with our preclinical, clinical and manufacturing activities. Costs incurred prior to nominating a development candidate are included in discovery programs. We do not allocate employee costs or other indirect costs to specific product development programs because these costs are deployed across multiple programs and, as such, are not separately classified.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to incur substantial research and development expenses as we continue to advance zidesamtinib, neladalkib and NVL-330 in clinical development, and expand our discovery, research and preclinical activities in the near term and in the future. Although the ALKAZAR Phase 3 clinical trial, the Phase 2 portions of our ARROS-1 and ALKOVE-1 clinical trials and the HEROEX-1 Phase 1 clinical trial are ongoing, at this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any product candidates we may develop. A change in the outcome of any number of variables with respect to product candidates we may develop could significantly change the costs and timing associated with the development of that product candidate. The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, including:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and progress of development activities relating to zidesamtinib, neladalkib, NVL-330 and any future product candidates from our discovery programs, including any additional costs that may result from delays in enrollment or other factors;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and scope of preclinical and clinical programs we decide to pursue;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain our current research and development programs and to establish new ones;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful patient enrollment in, and the initiation and completion of, clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of trials required for regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the countries in which the trials are conducted;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the length of time required to enroll eligible subjects and initiate clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of subjects that participate in the trials and per subject trial costs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential additional safety monitoring requested by regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the duration of subject participation in the trials and follow-up;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to applicable regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the receipt of approvals from applicable regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, receipt and terms of any marketing approvals and post-marketing approval commitments from applicable regulatory authorities;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we establish collaborations, strategic partnerships or other strategic arrangements with third parties, if any, and the performance of any such third party;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing commercial manufacturing capabilities including making arrangements with CMOs; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial launch.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any changes in the outcome of any of these factors could significantly impact the costs, timing and viability associated with the development of our product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance, commercial and administrative functions. General and administrative expenses also include professional fees for legal, patent, consulting, investor and public relations and accounting and audit services, as well as expenses relating to commercialization preparation activities. We anticipate that our general and administrative expenses will increase over time as we increase our headcount to support the growth of our organization as well as prepare for the commercial launch of our product candidates that obtain regulatory approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other income (expense)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in fair value of related party revenue share liability</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a revenue sharing agreement with Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund IV, L.P. (collectively, Deerfield), each an investor in the Company, to pay Deerfield a fixed low single-digit percentage rate of net sales of certain commercial products. We account for the liability to Deerfield at fair value with changes recognized in the consolidated statements of operations and comprehensive loss.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest income and other income (expense), net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income and other income (expense), net consists of interest income earned on our cash, cash equivalents and marketable securities and other income (expense) unrelated to our core operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following discussion and analysis of our results of operations includes a comparison of the year ended December 31, 2025 to the year ended December 31, 2024. For the discussion and analysis of our results of operations for the year ended December 31, 2024 compared to the year ended December 31, 2023, refer to Part II, Item 7 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on February 27, 2025 (the 2024 Form 10-K), which is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended December 31, 2025 and 2024</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2025 and 2024 (in thousands):</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:56.809%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.418000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.538%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.237%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306,970</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217,774</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,196</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,337</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,594</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,743</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">414,307</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">280,368</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,939</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(414,307</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(280,368</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(133,939</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of related party revenue share liability</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(55,220</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(17,940</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(37,280</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income and other income (expense), net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,735</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,316</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,419</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income (expense), net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,485</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,376</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(30,861</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(424,792</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(259,992</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(164,800</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax provision</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">585</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">764</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(179</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(425,377</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(260,756</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(164,621</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses for the years ended December 31, 2025 and 2024 (in thousands):</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:56.82%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.4%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.540000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct external research and development expenses by program:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Zidesamtinib</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,519</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,110</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,591</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Neladalkib</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,446</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,778</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,668</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NVL-330</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,819</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,293</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,526</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discovery programs</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,875</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,178</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,697</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unallocated research and development expenses:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related (including stock-based compensation)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,987</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,594</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,393</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,324</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,821</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,503</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306,970</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217,774</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,196</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses were $307.0 million for the year ended December 31, 2025, compared to $217.8 million for the year ended December 31, 2024. The increase in direct external research and development expenses related to neladalkib of $37.7 million was primarily due to costs related to the ongoing Phase 2 portion of the ALKOVE-1 clinical trial and the Phase 3 ALKAZAR clinical trial, which was initiated in July 2025, and professional services. The increase in direct external research and development expenses related to NVL-330 of $13.5 million was primarily due to costs related to the ongoing HEROEX-1 Phase 1 clinical trial and manufacturing costs. The increase in personnel-related expenses of $33.4 million was primarily due to an increase of $16.7 million in stock-based compensation expense and an increase in headcount. For the years ended December 31, 2025 and 2024, stock-based compensation expense was $48.1 million and $31.4 million, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our general and administrative expenses for the years ended December 31, 2025 and 2024 (in thousands):</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:56.82%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.4%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.540000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related (including stock-based compensation)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,678</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,106</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,572</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional and consultant fees</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,033</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,854</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,179</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial preparation and other</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,626</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,634</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,992</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,337</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,594</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,743</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $107.3 million for the year ended December 31, 2025, compared to $62.6 million for the year ended December 31, 2024. The increase in personnel-related expenses of $21.6 million was primarily due to an increase in headcount and an increase of $9.2 million in stock-based compensation expense. For the years ended December 31, 2025 and 2024, stock-based compensation expense was $38.4 million and $29.2 million, respectively. The increase in commercial preparation and other expenses of $19.0 million was primarily due to costs incurred in preparation for the potential commercial launch of our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other income (expense)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in fair value of related party revenue share liability</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The change in fair value of the related party revenue share liability was $55.2 million and $17.9 million for the years ended December 31, 2025 and 2024, respectively. For the years ended December 31, 2025 and 2024, the change in fair value of the related party revenue share liability was due to changes in certain assumptions in the model used to calculate fair value such as the probability and timing of obtaining regulatory approval due to the progression of our product candidates in clinical development towards potential commercialization, and estimated future product revenues.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest income and other income (expense), net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income and other income (expense), net for the years ended December 31, 2025 and 2024, consisted primarily of interest income of $44.8 million and $38.4 million, respectively. The increase in interest income was primarily due to an increase in cash, cash equivalents and marketable securities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have incurred significant net losses. We have not yet commercialized any of our product candidates and our ability to generate revenue from product sales will depend heavily on the successful clinical development of, receipt of marketing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval from regulatory authorities for, and eventual commercialization of one or more of our product candidates. Through December 31, 2025, we have funded our operations primarily with proceeds from the sales of convertible preferred stock, the issuance of convertible notes, debt financing from stockholders and proceeds from the sale of common stock in our public offerings. As of December 31, 2025, we had cash, cash equivalents and marketable securities of $1.4 billion and accounts payable and accrued expenses and other current liabilities of $91.2 million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, we issued and sold 4,950,496 shares of our Class A common stock in an underwritten public offering at a public offering price of $101.00 per share. We received net proceeds of $471.8 million, after deducting equity issuance costs and underwriting discounts and commissions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following discussion and analysis of a summary of our cash flows includes a comparison of the year ended December 31, 2025 to the year ended December 31, 2024. For the discussion and analysis that compares our summary of cash flows for the year ended December 31, 2024 to the year ended December 31, 2023, refer to Part II, Item 7 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our 2024 Form 10-K, which is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our cash flows for each of the years ended December 31, 2025 and 2024 (in thousands):</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:67.64%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.92%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.440000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(275,209</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(185,064</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(124,077</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(573,514</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">515,340</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568,882</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,054</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(189,696</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, operating activities used $275.2 million of cash, resulting from our net loss of $425.4 million adjusted for non-cash items, primarily stock-based compensation expense of $86.5 million, change in fair value of related party revenue share liability of $55.2 million and net accretion on marketable securities of $11.1 million, and net cash provided by changes in our operating assets and liabilities of $19.2 million. Our net loss was primarily due to clinical trial and manufacturing costs to support the development of our product candidates, personnel-related expenses due to the growth of our Company, costs related to professional services and costs incurred in preparation for the potential commercial launch of our product candidates, partially offset by interest income due to our cash, cash equivalents and marketable securities. Net cash provided by changes in our operating assets and liabilities was primarily due to increases in accounts payable and accrued expenses and other liabilities of $36.1 million, partially offset by increases in other assets and prepaid expenses and other current assets of $16.9 million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, operating activities used $185.1 million of cash, resulting from our net loss of $260.8 million adjusted for non-cash items, including stock-based compensation expense of $60.6 million, change in fair value of related<br/>party revenue share liability of $17.9 million and net accretion on marketable securities of $14.7 million, and net cash provided by changes in our operating assets and liabilities of $11.8 million. Net cash provided by changes in our operating assets and liabilities was due to an increase in accrued expenses and other current liabilities of $26.9 million, partially offset by an increase in prepaid expenses and other current assets of $7.6 million, a decrease in accounts payable of $4.0 million, and an increase in other assets of $3.4 million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in prepaid expenses and other current assets, other assets, accounts payable, and accrued expenses and other liabilities were generally due to growth in our business, the advancement of our research and development programs and the timing of vendor invoicing and payments.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, net cash used in investing activities was $124.1 million, primarily due to purchases of marketable securities of $1.1 billion, partially offset by proceeds from maturities of marketable securities of $932.8 million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, net cash used in investing activities was $573.5 million, primarily due to purchases of marketable securities of $1.0 billion, partially offset by proceeds from maturities of marketable securities of $450.5 million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, net cash provided by financing activities was $515.3 million, primarily due to proceeds from an underwritten public offering of $472.5 million, net of underwriting discounts and commissions, and proceeds from the exercise of options to purchase common stock of $42.0 million.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, net cash provided by financing activities was $568.9 million, primarily due to proceeds from an underwritten public offering of $540.5 million, net of underwriting discounts and commissions, and proceeds from the exercise of options to purchase common stock of $28.8 million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding Requirements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to incur significant expenses in connection with our ongoing activities, particularly as we advance our preclinical, clinical, and commercialization preparation activities for our product candidates in development and any future product candidates. The timing and amount of our operating expenditures will depend largely on:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our discovery programs and product candidates, including the advancement of zidesamtinib, neladalkib and NVL-330 throughout clinical development;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical development plans we establish for our product candidates, including zidesamtinib, neladalkib and NVL-330;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and characteristics of product candidates that we discover and develop through our product discovery and research efforts;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms of any collaboration agreements we may choose to pursue;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the European Medicines Agency and other comparable foreign regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of competing technological and market developments;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of completion of commercial-scale outsourced manufacturing activities; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of continuing to build sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had cash, cash equivalents and marketable securities of $1.4 billion. We expect that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into 2029. Our existing cash, cash equivalents and marketable securities may not be sufficient to fund all of our product candidates through regulatory approval, and we may need to raise additional capital to complete the development and commercialization of our product candidates. Our estimate as to how long we expect our existing cash, cash equivalents and marketable securities to fund our operations does not include potential product revenue and is based on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including those listed above.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contractual Obligations and Other Commitments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have an obligation under a revenue sharing agreement with Deerfield to pay Deerfield a fixed low single-digit percentage rate of net sales of certain commercial products. We are also party to a revenue sharing agreement with our scientific founder, Matthew Shair, Ph.D., pursuant to which we were obligated to pay Dr. Shair 1.5% of net sales of certain commercial products. In December 2025, Dr. Shair assigned the revenue sharing agreement to Royalty Pharma plc (Royalty Pharma) and, as a result, any payments we are obligated to make under this agreement will be made to Royalty Pharma. See Note 10 in the notes to the consolidated financial statements included elsewhere in this Annual Report for additional information regarding our obligations under the revenue sharing agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We lease office space for our corporate headquarters, which is located in Cambridge, Massachusetts. We enter into contracts in the normal course of business with our CMOs, CROs and other third parties to support research and development, commercial preparation, and other business activities. These contracts are generally terminable by us for convenience or for breach after reasonable cure periods.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Arrangements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not entered into any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Related party revenue share liability</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for the related party revenue share liability with Deerfield at fair value. The revenue sharing agreement with Deerfield obligates us to pay a fixed low single-digit percentage rate of net sales of certain commercial products. In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we elected the fair value option. Each reporting period, we remeasure the liability to estimated fair value using a discounted cash flow model based on the most recent assumptions such as the probability and timing of product approval, future product revenues and discount rate. These assumptions are estimates and can change based on factors such as the progression of our product candidates in clinical development and potential commercialization, current market conditions, competition, estimated clinical benefit and pricing. Changes to these assumptions can result in a material impact to our consolidated financial statements. Changes in fair value in each reporting period are recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The estimated fair value as of December 31, 2025 and 2024 was determined to be $73.2 million and $17.9 million, respectively. We have not recorded any net sales and, as a result, have not paid any amounts under this obligation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of services performed and the associated cost incurred for the services when we have not yet been invoiced or otherwise notified of actual costs. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include activities with vendors in connection with preclinical and clinical development activities, CROs in connection with preclinical and clinical studies and testing, and CMOs in connection with the process development and scale up activities and the production of materials.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We base the expense recorded related to contract research, manufacturing, or other vendors on our estimates of the services received and efforts expended pursuant to the terms of the individual agreements with the CROs, CMOs, or other vendors that conduct services and supply materials. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses. While the majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met, some require advance payments. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. We record these as prepaid expenses and other current assets and other assets on our consolidated balance sheets.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for our stock-based compensation awards in accordance with FASB ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation &#8212; Stock Compensation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ASC 718). We have granted stock options and restricted stock units (RSUs), both of which are subject to service-based vesting conditions, and RSUs with performance-based vesting conditions (PSUs). In accordance with ASC 718, we recognize stock-based compensation expense in the consolidated statements of operations and comprehensive loss based on a stock-based award&#8217;s grant-date fair value.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use the Black-Scholes option-pricing model to determine the fair value of stock options granted. For RSUs and PSUs, the fair value is equal to the market price of a share of our Class A common stock on the grant date. We recognize forfeitures as they occur. Stock-based compensation expense for stock awards with service-based vesting conditions is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting period. Stock awards with service-based vesting conditions generally vest over three- or four-year service periods and stock options expire after ten years. Stock-based compensation expense for stock awards with performance-based vesting conditions is recognized on a straight-line basis over the requisite service period for each separately vesting portion of the underlying stock award when the performance-based vesting condition is deemed probable to occur. We reassess the probability of vesting at each reporting period and adjust stock-based compensation expense, if applicable, based on our probability assessment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record stock-based compensation expense to research and development expense or general and administrative expense based on the underlying function of the individual that was granted the stock-based compensation award. Shares issued upon stock option exercise and RSU and PSU vesting are newly-issued shares.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in our Black-Scholes option-pricing model for stock options are as follows:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; As we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, we utilize the &#8220;simplified&#8221; method, as prescribed in the SEC&#8217;s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetical average of the vesting term and the original contractual term of the stock option.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; The expected volatility is based on our historical volatility and that of similar entities within our industry for periods corresponding with the expected term of the grant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant for a period that corresponds with the expected term of the grant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Dividends</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; The expected dividend yield is 0% as we have not historically paid, and do not expect for the foreseeable future to pay, a dividend on our common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in our Black-Scholes option-pricing model are inherently subjective and represent management&#8217;s best estimates. These assumptions involve a number of variables, uncertainties and the application of management&#8217;s judgment. If any assumptions change, our stock-based compensation expense could be materially different in the future.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense for stock awards with service-based vesting conditions was $86.5 million, $60.6 million and $25.6 million for the years ended December 31, 2025, 2024 and 2023, respectively. The performance-based vesting conditions under the PSUs have not been deemed probable to occur, and accordingly, no stock-based compensation expense has been recognized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, total unrecognized compensation cost, excluding unrecognized compensation costs related to PSUs, was $170.4 million, which is expected to be recognized over a weighted-average period of 2.3 years. As of December 31, 2025, total unrecognized compensation cost related to PSUs was $11.1 million, which will be recognized when the performance-based vesting conditions are deemed probable to occur.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our consolidated financial statements included in this Annual Report.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities related to our cash, cash equivalents and marketable securities. As of December 31, 2025, we had $261.7 million in cash and cash equivalents and $1.1 billion in marketable securities classified as available-for-sale securities. We invest our excess cash in money market funds, commercial paper, corporate bonds, government and agency securities and U.S. treasury bills. We mitigate credit risk by maintaining a diversified portfolio, placing our cash with high credit quality financial institutions and limiting the amount of investment exposure as to maturity and investment type according to our investment policy. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income is sensitive to changes in the general level of interest rates; however, due to the short-term maturities and low risk profiles of our investments, we do not anticipate a significant exposure to interest rate risk. A 10% change in market interest rates would not be expected to have a material impact on our financial condition or results of operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_and_supp"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Financial Statements and Supplementary Data.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVALENT, INC.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Index to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:91.82%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.18%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: </span><span><ix:nonNumeric id="F_45eba015-3bac-403f-8f75-8388c9f3b8b4" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">185</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#report_of_independent"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">107</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.111%;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">109</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.111%;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#statements_of_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">110</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#stockholders_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.111%;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#stockholders_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">111</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.111%;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#consolidated_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">112</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.111%;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><a href="#notes_to_consolidated_financial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">113</span></a></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_of_independent"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registered Public Accounting Firm</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and Board of Directors<br/>Nuvalent, Inc.:</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2af0d644-f343-4dd7-b31e-4031b466b87c" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinions on the Consolidated Financial Statements and Internal Control Over Financial Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Nuvalent, Inc. and subsidiary (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2025, and the related notes (collectively, the consolidated financial statements). We also have audited the Company&#8217;s internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025 based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for Opinions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements and an opinion on the Company&#8217;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Definition and Limitations of Internal Control Over Financial Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Audit Matter</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Valuation of the related party revenue share liability</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed in Note 4 to the consolidated financial statements, the Company&#8217;s related party revenue share liability balance as of December 31, 2025 was $73.2 million. As discussed in Note 2, the revenue share liability is remeasured at the end of each reporting period using a discounted cash flow model to calculate the estimated payments that could become due following commercialization. Assumptions in the model include but are not limited to probability and timing of product approval, future product revenues and discount rate.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We identified the assessment of the valuation of the related party revenue share liability as a critical audit matter. Subjective and challenging auditor judgment and specialized skills and knowledge were required to evaluate certain assumptions used to determine the fair value of the liability. These assumptions included probability and timing of product approval, future product revenues, and discount rate. The assessment of these assumptions was challenging because they were derived from unobservable inputs. Additionally, changes to probability and timing of product approval or future product revenues could have had a significant impact on the determination of the fair value.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company&#8217;s valuation process for the related party revenue share liability, including certain controls related to management&#8217;s determination of the probability and timing of product approval, future product revenues and discount rate. We evaluated the Company&#8217;s probability and timing of product approval and future product revenues by comparing these assumptions to externally available publications and scientific studies for comparable products. We involved valuation professionals with specialized skills and knowledge, who assisted in evaluating the discount rate used by the Company by comparing the Company&#8217;s inputs to the discount rate to publicly available data for comparable entities and assessing the resulting discount rate.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0966265-3e7b-4029-b79c-bb90d6bb0e0a" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2020.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a911614-176c-4ade-a79c-505bfd0fd9f5" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Boston, Massachusetts</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 26, 2026</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVALENT, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED BA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LANCE SHEETS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:69.294%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.062000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.643%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_363d662b-462e-4811-ade2-88874626a9bf" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,745</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c51eeca-b102-4e17-8c98-63a29d26ad82" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145,691</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aeacf3a8-100b-4e9c-a631-a53d19a2c9b4" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,110,207</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d4a5fcf-9f70-47da-80f6-584910cbcd93" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">972,611</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38ae861f-e306-422e-9589-b53140ccf38e" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,474</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b32c9144-cb0d-4c4e-ae54-d42c0cdcc95e" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,146</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e450f521-445c-469e-8911-f268c68e45ab" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,392,426</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b82157a-b365-4518-b24c-929320e5b3f7" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,132,448</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2a75ce8-6b3b-4005-9b2a-088a662e781c" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,279</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c6a297a-28f5-40a5-9b12-3b5e3c4f0200" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,304</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dc29295-7c85-4025-879b-4e1e8c3fab65" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,412,705</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49802752-7abe-49e6-b4bd-ad94c58366cc" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,141,752</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad5104ab-9df6-4ec0-97bf-d233cf8bf697" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,158</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bbf03b1-206e-4b00-9a2d-0b712d09c6a3" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,225</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5770a79b-b74b-4744-bc8d-15fd96a546be" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,013</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95b639ea-7ccb-449a-99d4-bbcf65be96ba" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,795</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6196e69-5a55-4f98-a80a-fba39a4802cf" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,171</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d409f04e-9a0c-4ed0-b42a-e1ad8c72b0c0" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,020</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Related party revenue share liability</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3939cb7a-5673-455d-a091-39a09546d937" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="nuvl:RelatedPartyRevenueShareLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,160</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f972c6c-9b8d-46fd-936d-3ed5168d1d8b" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="nuvl:RelatedPartyRevenueShareLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,940</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_245331b9-67c6-4502-acaa-de2300226adb" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99c7373c-d972-41ac-ad0c-c38288d4234c" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f969cf2-65af-4b6c-a988-43193e100598" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,366</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08d1a415-42fd-49dd-933e-7133e2749001" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,960</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_0d2d81e3-69a3-4524-9293-717092943f94;"><span style="-sec-ix-hidden:F_8f9dc6b8-8eae-47ed-8d70-8d9905e57973;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 10)</span></span></span></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5137dbd-2bee-4f33-bab9-981a77934593" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b6b6629f-9404-4b91-9f8d-abe22f481ac7" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f57b05c-1895-4a92-8eba-8477e6c1d6c0" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_68fda303-cd15-487a-b347-cd1c9cd5fd16" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized;<br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e70c6d8e-3e8c-4355-9cb8-a607258883a6" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_11247f71-c30d-40dc-baf6-a721dc5fb1d6" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_454d048e-d4ff-46c9-958c-01b8d2f936b5" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f4f62f90-7ac2-4a99-8b18-474afc912dfd" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued or outstanding</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7590693-7308-45e2-be7f-abed79d96559" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bdc6541-76b9-414f-875a-efed4b15515b" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82c94d2b-f519-4166-ab14-c5b88157378c" contextRef="C_66ccad61-3ba5-4582-a264-afb3cb89f898" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d30f65d0-530b-4ddd-9419-cfa1458edc06" contextRef="C_2e334b49-451c-4916-9273-f6e7d4df64dd" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b80750fa-f1a2-4195-9a2a-a34ff9e3a7ba" contextRef="C_66ccad61-3ba5-4582-a264-afb3cb89f898" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a63945d7-9be2-40a9-a95c-c5a5e229e8b7" contextRef="C_2e334b49-451c-4916-9273-f6e7d4df64dd" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">140,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized;<br/>&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5135710-f796-4217-a0d2-a90e7b70225c" contextRef="C_66ccad61-3ba5-4582-a264-afb3cb89f898" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_42891881-af08-42b2-96e2-c5188459fa77" contextRef="C_66ccad61-3ba5-4582-a264-afb3cb89f898" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">72,804,111</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9051b9e4-bf93-4220-b542-e5cff2ac4374" contextRef="C_2e334b49-451c-4916-9273-f6e7d4df64dd" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a377ced1-06ee-4dcf-9210-b7adf038b187" contextRef="C_2e334b49-451c-4916-9273-f6e7d4df64dd" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,909,564</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at <br/>&#160;&#160;December 31, 2025 and 2024, respectively</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02d23299-89d9-4ba1-84db-44ee4ad93ffc" contextRef="C_66ccad61-3ba5-4582-a264-afb3cb89f898" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d827361-773e-48ed-a661-7510b12addd1" contextRef="C_2e334b49-451c-4916-9273-f6e7d4df64dd" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class B convertible common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cd53bcf-795b-4290-819e-a71527fff858" contextRef="C_1cd95e71-e453-489e-afd8-afbc6cfad37f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9def3d76-e2e7-4fb7-9cc6-37fab6491137" contextRef="C_27e304bf-4878-4185-b218-ef61b37c5fd0" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55f10be4-19cf-441a-ab40-aaa592751ea8" contextRef="C_1cd95e71-e453-489e-afd8-afbc6cfad37f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a3610ee8-50ff-471c-b40e-475933d8ab36" contextRef="C_27e304bf-4878-4185-b218-ef61b37c5fd0" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized; <br/>&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71c55276-7ed9-4cac-9a68-7395a50f66fe" contextRef="C_1cd95e71-e453-489e-afd8-afbc6cfad37f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c61f328d-89f3-4e8c-b0a3-f8e525b0411d" contextRef="C_1cd95e71-e453-489e-afd8-afbc6cfad37f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_29a10f7b-6eed-4dda-9f9e-21e29ee7da43" contextRef="C_27e304bf-4878-4185-b218-ef61b37c5fd0" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d49cc454-4a35-4930-be54-e0427b5ab994" contextRef="C_27e304bf-4878-4185-b218-ef61b37c5fd0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,435,254</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2025 and 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0a39f25-dc34-488e-b19f-6492d37013db" contextRef="C_1cd95e71-e453-489e-afd8-afbc6cfad37f" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cdfd375-ea57-4b02-950b-274aab0bcf26" contextRef="C_27e304bf-4878-4185-b218-ef61b37c5fd0" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7da1318e-5e92-4d11-be0f-ae9f02db1cb5" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,218,407</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5bcd61b-9171-4aad-bd34-62e4d273b774" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,616,895</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income (loss)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b28fb97a-d175-4671-945f-4b48f549a8c0" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,353</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de25dcc5-5ac9-4d43-89c8-70381ec3f8c8" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74692fc2-6084-4ebc-8944-00a26b1b1242" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">972,429</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffd598e1-e4b8-4eb3-9782-e9b164dda3d8" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">547,052</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c798898b-8011-44ef-881e-ff7ba676205c" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,248,339</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98cca7f3-efb0-4dd1-bcad-099566fe5913" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,069,792</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e518e438-6b9e-491e-8e4e-5f9088b6f0ee" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,412,705</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c43c941f-9109-415e-b7e1-a5b023444f73" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,141,752</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVALENT, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_of_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPERATIO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NS AND COMPREHENSIVE LOSS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:60.044%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.984%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.984%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.984%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="background-color:#cff0fc;padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26b54445-839a-462d-932b-246152a531d8" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,970</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19049f73-bb26-4af1-ad95-b2d15e138e90" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217,774</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67593c40-dae4-4e36-9bfb-5e89bee8078c" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,243</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e04a645e-c2ec-48e4-a2ab-db26e03922cc" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,337</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff556f41-79de-422c-9a3e-ef46f0ab5648" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,594</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51cb3d8c-b2f0-41d1-a694-6cfde0b7e6c1" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,249</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf0a6fd4-5cb2-474e-900a-b02474346ccb" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">414,307</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fd197c3-9468-413a-9f96-1e7e9dcbed1f" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">280,368</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a705a07b-5dbc-4dd9-9b2e-bc99194c1fce" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">149,492</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a8bfe7e-6776-4bdb-9ca8-c5d00c6ddf48" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">414,307</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_666b461c-c88b-4b17-9dfc-cbacb2adfefb" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">280,368</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3af188c9-11b1-457a-88fb-c319acf2913d" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,492</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense)</span></p></td>
     <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of related party revenue share liability</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d95f02d-51bc-4c01-91d3-92f7400aaaf3" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,220</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7daacb6-a7f6-4f62-ab43-ee74d703530b" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17,940</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63bb86b9-3de8-40a8-b66f-4278f7450f10" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income and other income (expense), net</span></p></td>
     <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c9c8c5c-8ff2-41f9-8a39-643819bf9ec4" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="nuvl:InterestAndOtherIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,735</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec4c1bd4-0136-41e3-8f22-d599787f793f" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="nuvl:InterestAndOtherIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,316</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2405ca8e-8723-43aa-ae29-7096404759d3" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="nuvl:InterestAndOtherIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,273</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income (expense), net</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd74e0e4-8e6c-4902-9b35-610a18a6f638" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,485</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bc1f241-c099-49b8-8a16-eacde8e96321" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,376</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afc1b2b8-388f-494b-8667-16864105c0ae" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,273</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
     <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10ed102b-2f86-4903-be3e-b289bcdc2f8f" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">424,792</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_170b9fd4-01ea-4d58-aed5-a82907786d05" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">259,992</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4421dca0-c603-4cac-a554-01961440481f" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">126,219</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax provision</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7922d2e1-957e-42ab-a119-f5f2a2ddc531" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">585</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cebb7278-aede-40a6-89f6-62f2aa1d241b" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">764</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48961e08-0f0d-418c-bf6b-3039653342f7" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37e3aec4-6590-4fb3-a6b5-c646a98fac95" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">425,377</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3686687c-355c-42aa-a06c-febf00ac1ec4" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">260,756</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7916baa9-1f67-4aa4-975e-41101271ed8f" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">126,219</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to Class A and Class B common stockholders, basic and diluted</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ae6be40-dba7-4f5f-89b2-e35d26b8c1e7" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c7e05491-b652-4cce-8bde-e032b5e8e7f0" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">5.85</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb869057-70fb-4eb0-ae5c-1b5007783e48" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_33dc9796-8c8e-44e8-bf1d-25197c727fb2" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.93</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_367ad345-c183-4c6e-aced-ed0c2013339f" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bc515826-05e2-40f1-9045-44fbaff7f7ba" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.17</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares of Class A and Class B common stock outstanding, basic and diluted</span></p></td>
     <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_147b1b66-ad66-4b19-bf01-c4970d2d868a" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1cc8a7ed-e122-422d-9e49-277feb03dfed" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">72,686,749</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b88c7663-f747-4665-a645-0f0eb762782b" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3b3bbfaf-0d93-479a-9dfb-1b6abc0f696c" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">66,408,807</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d54317a8-1a79-48bc-a3b7-8954c24b4f98" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1baba27d-ec44-47a7-ab82-3b17bc41fc96" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">58,223,339</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_903ac264-bc6d-4fe3-93c5-f39b840df7a9" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">425,377</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc050254-15cf-45d8-ab71-ace3f9adce6a" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">260,756</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79637e13-3ec7-43ab-bada-5d479c8603a1" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">126,219</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income (loss)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gains (losses) on marketable securities</span></p></td>
     <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a25947ae-2278-4178-b493-d649a411d183" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,412</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_909edf97-ef2a-4a92-a47a-22818e92511e" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed6372a0-d9e2-4729-a6af-74668b665c25" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">525</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43163eb9-7a7f-4bc8-bf41-55214a6d9a51" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">422,965</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_836f9335-1bea-40a7-b905-d93abb4d200b" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">260,846</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae558ee3-f91b-4a91-b311-790c4952e0db" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,694</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVALENT, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="stockholders_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCKHOLDERS&#8217; EQUITY</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:28%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Class A</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Class B</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Other</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-in</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders'</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income (Loss)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances at December 31, 2022</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26eab8ca-b36f-481d-b702-242be6363819" contextRef="C_fed5ef36-c783-45d6-bccf-aedf6738ae46" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">51,233,701</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07836f21-249e-4a0e-8cbc-aa0115aca573" contextRef="C_fed5ef36-c783-45d6-bccf-aedf6738ae46" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cad9f159-b315-4fa0-af78-d2d82d98942a" contextRef="C_7fb5a364-b725-42f1-ad2c-b3730193541d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,435,254</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6a4793a-147b-4ace-8984-6c0abc40af06" contextRef="C_7fb5a364-b725-42f1-ad2c-b3730193541d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cf4b24f-ba7b-4614-b3e4-f695c56977f0" contextRef="C_e5c11e44-2976-420e-8d41-594249e44ff8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">623,543</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee31305f-4814-4374-8ca3-44b88032c061" contextRef="C_6656ba66-9dab-4e91-9c45-bf8d51c0b1f7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">494</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e2414d4-5694-4d72-bca8-efb2344d5c2b" contextRef="C_db861eb5-13ac-4eb3-ad97-2e20abffc3c3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">160,077</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa5ed29c-03d8-44ff-a324-dc64ccd7ed18" contextRef="C_eba66bbe-f103-4138-86da-3992c8897615" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">462,978</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon public offering, net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0db35670-3c98-46b9-b25d-7b130f74cde5" contextRef="C_9ed360b9-2aab-458b-bda7-0463d9f71263" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,160,714</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3f6e2cf-43ba-411a-ad7f-fa443c0ec856" contextRef="C_9ed360b9-2aab-458b-bda7-0463d9f71263" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9924d34f-098d-440d-b301-f405a6b7478b" contextRef="C_0b6fa2d9-3207-4641-a3d5-2ca8fe718b5f" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">323,533</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6ff31c3-5552-4cd1-8c6e-a694b5da0300" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">323,534</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d0e3843-ec50-4019-abf6-74d9b456f05a" contextRef="C_9ed360b9-2aab-458b-bda7-0463d9f71263" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,222,294</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cb84d7d-c7a0-4844-a9c0-97d3b24b8a50" contextRef="C_0b6fa2d9-3207-4641-a3d5-2ca8fe718b5f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,793</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd23352a-9450-42e0-84ba-db3127ed1140" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,793</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28d656b0-e892-46a0-990b-d144ad60ac44" contextRef="C_9ed360b9-2aab-458b-bda7-0463d9f71263" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,187</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d1f8fff-88d9-42fd-98ff-4a2f9d6a0490" contextRef="C_0b6fa2d9-3207-4641-a3d5-2ca8fe718b5f" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">387</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7640a2c7-c305-4474-b310-b83aefd9b967" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">387</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gains on marketable securities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a259ac58-3a63-4d8b-9ca1-60170a64b62c" contextRef="C_1b1f7158-edca-404e-aa34-c73afe046033" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">525</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e93da32b-80f8-43df-b121-e2d8a9e63cd4" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">525</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fb9a1a1-52ba-4d21-8122-e3a93074a145" contextRef="C_0b6fa2d9-3207-4641-a3d5-2ca8fe718b5f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,563</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4100b92-d00f-4fbb-a972-62f805a7ad40" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,563</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e9dc22a-5a4b-4b31-a510-0acb6fb2e901" contextRef="C_69edaadf-ec5e-4f6b-a8f9-bf8b5f259318" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">126,219</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28180d79-5319-4f30-8bf8-f28e3b1b1324" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">126,219</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances at December 31, 2023</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21675a97-8c3c-4c73-a5d1-53be86ec78b8" contextRef="C_8c5fa58b-cce8-41df-a7c1-f605951d05f0" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,629,896</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0f12a75-1a76-451a-95de-d0ba404da2dd" contextRef="C_8c5fa58b-cce8-41df-a7c1-f605951d05f0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3071b8ef-c222-45d1-a71b-646a0bfdad05" contextRef="C_abcc8928-5878-4175-910a-b88480310852" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,435,254</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d41f0ff0-67bc-42ed-8361-38436beb0c80" contextRef="C_abcc8928-5878-4175-910a-b88480310852" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b13e14ba-99a4-483c-b7b0-780b30649a00" contextRef="C_739ac674-8392-417c-8c4a-3fc04e811f6e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">986,819</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54ace6c5-d05c-4664-92d9-edc2ad8ec34b" contextRef="C_f4890ed2-89d0-425e-bad2-ca3f8727c10d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84f9c287-ac44-4192-b883-db102f6e100f" contextRef="C_cbc6ed71-c5cd-44a8-8b33-02e5252b1e57" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">286,296</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6878d696-3193-4727-9813-d74b9301f514" contextRef="C_a7c68923-25e9-4e81-bde0-d29cb0d28c74" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">700,561</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon public offering, net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c629f3d4-108e-4916-aa31-a8683db8076b" contextRef="C_59caff5d-8166-4377-8ad8-d90aab14d4f4" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28cdb97e-0848-41f5-8435-6c2b262a8b43" contextRef="C_59caff5d-8166-4377-8ad8-d90aab14d4f4" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b04e0f0f-d4b4-4e54-9760-15e3287fff1c" contextRef="C_6b6f2b20-abff-42cb-90e5-af03ff62b7f2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">540,011</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed4b50c5-a6e4-4de1-9db8-a55fd4821b34" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">540,012</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44e9a578-9dd7-465a-a1f3-6719dfb03ee4" contextRef="C_59caff5d-8166-4377-8ad8-d90aab14d4f4" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,518,096</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f120395-81ad-4021-ad79-d7bd69e95af1" contextRef="C_6b6f2b20-abff-42cb-90e5-af03ff62b7f2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,834</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2b3ea39-c031-440c-aecf-219a03384531" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,834</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c69fff74-a7c9-4e23-8898-21dd1be14110" contextRef="C_59caff5d-8166-4377-8ad8-d90aab14d4f4" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,572</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c6c41bf-b022-48ea-a19f-66ed491e5065" contextRef="C_6b6f2b20-abff-42cb-90e5-af03ff62b7f2" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">652</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44f06978-9a7a-4d28-8a4b-ec2c0be364b8" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">652</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized losses on marketable securities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_752b9913-af4c-4e09-9622-c6e865ac590b" contextRef="C_cdbd7a9d-c51f-4155-98da-a38460114f3d" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccef38d4-d741-43c1-a645-cda66e1f8087" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3eb78cf6-780c-48c9-9619-074daaa2f705" contextRef="C_6b6f2b20-abff-42cb-90e5-af03ff62b7f2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,579</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78f8e8a8-355a-4e37-ada9-651f88250824" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,579</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9a8ae5f-b90f-42a3-a1a9-fe47b5597783" contextRef="C_e23cc770-0e42-4f32-8905-235f71ad32fa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">260,756</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf058987-ae51-4d62-84a3-5cff91b2d082" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">260,756</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances at December 31, 2024</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44b7272e-d1e5-4dde-a9b4-4f91734c2c2a" contextRef="C_4b2153d7-580e-498d-a2f9-c607f8bbecf4" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,909,564</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d85b058a-009d-48d6-be77-f1e5b2e780a9" contextRef="C_4b2153d7-580e-498d-a2f9-c607f8bbecf4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a32fbf28-99fc-423e-a475-e9c7c4afbc88" contextRef="C_38c713ba-cdc7-468e-8239-8bb281da925a" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,435,254</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32cc4bdf-eccc-4e5e-a65f-e82f1b251c44" contextRef="C_38c713ba-cdc7-468e-8239-8bb281da925a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca10883f-6aa2-4809-b52b-bf01cf2b9cb0" contextRef="C_871a772b-11eb-4b5f-8988-87609b488c50" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,616,895</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b935ad26-60ce-4881-811f-58ee132f096a" contextRef="C_b31225ef-7fb3-476b-bede-da08638f612a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b5c83d0-82c8-479a-892c-9a891678407e" contextRef="C_3b2c84ab-d113-49df-ac68-ee96b2c40bcc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">547,052</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56be793a-f658-4a44-93df-be7d21dd2f49" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,069,792</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon public offering, net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6f9708d-68ab-4125-a625-36539e5bf359" contextRef="C_76fd5dc0-bfbc-4e89-bf40-514de9d64090" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,950,496</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4a23997-f77f-4d3f-a748-d49751ea69a4" contextRef="C_d715c616-aabd-4724-8a14-e0643645f7fc" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">471,787</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_506f3c2d-9473-428f-ac1b-c1f76d5e44b4" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">471,787</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of stock options and restricted stock unit vesting</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8d5b0d1-0905-42ba-868c-cf151cf999f5" contextRef="C_76fd5dc0-bfbc-4e89-bf40-514de9d64090" name="nuvl:StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,925,600</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12a39bef-113e-4289-b8b8-4cb61c068117" contextRef="C_d715c616-aabd-4724-8a14-e0643645f7fc" name="nuvl:StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,037</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d275d91-c232-4a34-8759-360f49e0123c" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="nuvl:StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,037</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dfaa887-684e-4061-90b3-c08484d2bc6c" contextRef="C_76fd5dc0-bfbc-4e89-bf40-514de9d64090" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,451</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfaa3d5e-dd68-40d5-a8dc-c856ef10bd9d" contextRef="C_d715c616-aabd-4724-8a14-e0643645f7fc" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,186</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd96daa8-010e-4d76-8875-0ae453d217df" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,186</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gains on marketable securities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e2e7b3b-dd6f-4d4d-98de-3cf19c352dd0" contextRef="C_0e122157-f19c-4bac-ba06-7e7e26e67d60" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,412</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14cccc86-d2f1-428a-8a4e-04bf64e4500f" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,412</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20be84d1-656a-465c-aed8-14400a6feb9c" contextRef="C_d715c616-aabd-4724-8a14-e0643645f7fc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,502</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4976d9d-d3ba-4f27-834d-827ffcdc0960" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,502</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82c83018-ec62-4277-8921-5d306a91e0dc" contextRef="C_89ef94e8-5fe8-4da1-8b41-06e3cb2b86a7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">425,377</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc4a418e-176d-402b-ab3e-a1b6526c0f07" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">425,377</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances at December 31, 2025</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01683ca0-7e61-4f3c-ae32-a1acb238ab31" contextRef="C_4f8e7dd3-78fe-4d02-b566-4230ae65335a" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">72,804,111</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c375cefd-e227-4ca9-95ab-de2aecbcbeff" contextRef="C_4f8e7dd3-78fe-4d02-b566-4230ae65335a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_390af39d-126a-4b54-a43c-5697437bb7bc" contextRef="C_de369d63-3940-4ffe-ab65-7d8fb85e29f4" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,435,254</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d48fc5c6-156e-4e97-b3f5-493ed705d0d2" contextRef="C_de369d63-3940-4ffe-ab65-7d8fb85e29f4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c2a0c64-f16a-44b2-9997-e2154ee69611" contextRef="C_cbef92a0-50ca-4971-bfcf-4cc694bd98f6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,218,407</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_739a1b93-ae77-43ee-acfb-cb444cffd7cd" contextRef="C_8d3a377b-6ff7-4302-9183-32b0389e7d83" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,353</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2be77ea6-677d-4f6a-b908-9cf94756c45f" contextRef="C_b9cdf8b1-21d2-4c81-8860-bfb22facc2be" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">972,429</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d96a9239-1877-4f3d-93f4-53a3204f33ae" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,248,339</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVALENT, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:59.992%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.162%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.162%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.682%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9deed3b-47d5-40aa-b0a0-aeefc9b5ff3e" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">425,377</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53451094-8fc4-4a8d-bf7a-c41b9c743c1f" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">260,756</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca6f4021-4607-411a-b709-82b60e712090" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">126,219</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1710f28b-7a29-4dcb-badd-bf350ea0ab8a" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,502</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8981a07a-def9-4778-bdc8-2301c075c525" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,579</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d98375b-2ec3-49e5-83bf-16a05981bfb3" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,563</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net accretion on marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ee1b927-0ad9-4471-876a-31142b653999" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,107</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64b681c7-5650-4065-8ec4-74ac1b1e6afa" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,669</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc1e3faa-b3df-4992-ad41-d43a964c37c5" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,109</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of related party revenue share liability</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b84aa55c-47b0-4e3b-9b5f-9b980797de52" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,220</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb5a9b66-ffac-4175-aab9-ae1e76e177f2" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17,940</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60310df9-7178-4c0c-bf3d-3aab3f383e07" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_550d3044-6d2f-456d-9dac-d0cfaa692f03" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">345</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4d8047a-8398-47de-9a1c-28f9bd93a560" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fee24038-4bb7-4bf0-b067-4581a94271a8" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a7e07d2-a40b-43d6-8aed-dc610e8bcaf2" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,342</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be66b4ed-2bb3-4f93-9e26-40ae7c28d47f" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,563</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7664a3aa-442f-4983-8610-6e6f84e066b7" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">644</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae839f3a-0045-4eca-a9b6-d2a2104149eb" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,508</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee963342-6ee0-4679-803b-09d1d2862c1f" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,408</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f94ca225-c507-4e53-b997-0b514b9cf00e" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,428</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e586d958-0d2a-4f2b-b587-4ae20b3f679d" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,599</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bdf6938-1f64-4feb-8012-93486728fc12" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,049</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_413772fd-aedf-4578-a470-86c1b82cc198" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,169</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_742f56c0-5691-4899-a3e4-89e9e90a400f" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,459</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c85573a-dea1-4d91-b4c4-15201cc5c0ea" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,862</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4863b5c2-1cad-4e20-98c4-0002f99de12f" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,641</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35226bd9-b60a-4a11-b19a-f1a950aad9cb" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">275,209</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07bcbd7e-7d2e-4a2c-9900-4cfef503b40c" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">185,064</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae24822b-8a70-4266-abb0-fa4bcd9b8c76" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,739</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79198637-3511-40a9-83ed-9fee997f8d8a" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,057,766</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e92007e-8d7c-40af-af49-e805d0f8d7f7" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,024,963</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22cd4984-f969-476f-8faa-91d53433af6f" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">459,486</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from maturities and sales of marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_773e63d3-ecb3-4024-96da-9103d389c013" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">933,689</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53c72cdd-4250-4053-b7a1-ce9a058b69b0" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">451,449</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c977748-5aca-4b9e-84ff-75b02af53ebc" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">315,959</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f46e80bb-1155-46ef-89b6-f0f09e23a818" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">124,077</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4c4e458-c3a7-44f2-abdb-21b2425519ed" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">573,514</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7592029d-aec4-408c-823b-8fb32d060be2" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">143,527</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ae94172-2e36-4324-964d-64837aed6328" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">515,722</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e753f624-b847-4fef-a328-cee35085191a" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">569,987</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c50b845-7559-45c0-a231-889cc057e3bb" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">338,480</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments of equity issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e47fe4ca-6e94-4683-b9f6-2e2cd15dfd48" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">382</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97fe3f34-81f2-4254-8879-7319ff945f2e" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">483</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0ecb895-2696-40fd-985f-108967e20a5c" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">856</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments of insurance costs financed by a third-party</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04376436-cb1a-4d85-a2f3-9f27dd94bc40" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56b83a07-e11f-4ed0-bef5-a6f34e555c10" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">622</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0c7e57b-eb6f-43b0-97fc-09e149e8d666" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">777</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_275e3a9c-520b-4806-b8cd-62f0da96d5c4" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">515,340</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b40dca52-949e-4202-bc3c-dfa915ac4a65" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">568,882</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66191f69-56d2-452b-8dfb-cb8ec8af89f5" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">336,847</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1ba247f-f022-4876-8c6d-0b5077fd3b62" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,054</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50a08c74-722f-4d23-b12f-395175616314" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">189,696</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a767f57a-f14f-49e8-9a51-c725527abad4" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,581</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87397fdb-11d9-41a0-9cf3-30c76eb4b9ce" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145,691</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e42d52f-9dae-4e9d-a44f-aab051c5aa2e" contextRef="C_a7c68923-25e9-4e81-bde0-d29cb0d28c74" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">335,387</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62701e2f-7b40-4cde-a98f-867844b86602" contextRef="C_eba66bbe-f103-4138-86da-3992c8897615" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">241,806</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5292e25-4b76-46ca-836a-7bdc5ad0adef" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,745</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_146adba5-0820-498f-9544-881ec789a664" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145,691</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_790173ae-b2ea-4b83-bddf-3f6196159210" contextRef="C_a7c68923-25e9-4e81-bde0-d29cb0d28c74" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">335,387</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of noncash investing and financing information:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65f42082-9856-416d-a884-54bd1704791f" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">798</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e11eca2-da2f-45fb-a94d-4f2d2d95ae6e" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d10820d-e893-49c5-b18a-bb698285f420" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity issuance costs</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25028b75-75a1-430c-9630-a746951bb81b" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="nuvl:EquityIssuanceCostsIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cff21163-4dd9-49ca-9249-837212e14ca9" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="nuvl:EquityIssuanceCostsIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e8645c2-f075-44dd-bea4-4e4ab997467c" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="nuvl:EquityIssuanceCostsIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insurance premium financed by a third-party</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27ce9ca0-becf-4c01-bf94-3780602a6eb1" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="nuvl:InsurancePremiumFinancedByThirdParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b3e98a1-381e-48f1-adea-1b8daf3fb35a" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="nuvl:InsurancePremiumFinancedByThirdParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1febc81-0fce-49e1-b807-3311f4331e68" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="nuvl:InsurancePremiumFinancedByThirdParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,399</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVALENT, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FIN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANCIAL STATEMENTS</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3eef388-5f59-4769-8455-792eeb930ce4" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:NatureOfOperations" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Nature of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvalent, Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The Company was founded in January 2017 as a Delaware corporation. The Company is headquartered in Cambridge, Massachusetts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks similar to those of other pre-commercial stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of which are larger and better capitalized, the need for adequate financing to fund the development of its product candidates, the need to obtain and maintain adequate protection for the Company&#8217;s intellectual property, and the impact of geopolitical events on the Company&#8217;s business. There can be no assurance that the Company&#8217;s research and development will be successful, that adequate protection for the Company&#8217;s intellectual property will be obtained and maintained, that any product candidates will receive required regulatory approval, or that approved products, if any, will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred recurring losses since inception, including net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c2a2955-8f69-41ea-989f-4d97267be289" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">425.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38c1f440-d48e-4289-aaa9-b5b647f0e507" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">260.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf455fc4-48cf-4e32-874a-9d2aa1597264" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">126.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2025, 2024 and 2023, respectively. As of December 31, 2025, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a1b8e6d-b93d-42ff-af3c-cb4b2f2484bf" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">972.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company expects to continue to generate net losses for the foreseeable future. The Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the date of issuance of these consolidated financial statements.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_4e2a9a8f-1d77-484c-9d77-353cd8cc43ba" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_4e2a9a8f-1d77-484c-9d77-353cd8cc43ba_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Basis of Presentation and Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16c8f743-ff5f-43e6-994b-001ac8089376" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><ix:nonNumeric id="F_2999d14f-1e6a-4dee-a09d-42217ce5d540" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of presentation and consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and under the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nuvalent Securities Corporation. All intercompany balances and transactions have been eliminated in consolidation. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain prior period amounts have been reclassified to conform with current period presentation.</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f5436379-1f7d-42b2-a4ab-019ea40dd315" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair value of the related party revenue share liability, the accounting for research and development contracts, including clinical trial accruals, and valuation of equity instruments. The Company bases its estimates, assumptions, and judgments on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b523126-0f51-4670-9561-1aa51e47d176" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="nuvl:ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of credit risk and of significant suppliers</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company&#8217;s cash, cash equivalents and marketable securities may be held in accounts at financial institutions that may exceed federally insured limits. However, the Company mitigates credit risk by maintaining a diversified portfolio, placing its cash with high credit quality financial institutions and limiting the amount of investment exposure as to maturity and investment type according to its investment policy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant credit risk beyond the standard credit risk associated with commercial banking relationships.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party vendors for the manufacturing of its product candidates. In particular, the Company relies, and expects to continue to rely, on a small number of vendors to manufacture materials and components required for the production of its product candidates. These programs could be adversely affected by a significant interruption in the manufacturing process.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_d5baa16a-6761-46c5-858a-908a5f514fd2" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" continuedAt="F_d5baa16a-6761-46c5-858a-908a5f514fd2_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents may include money market funds and marketable securities. The Company records interest income received on cash, cash equivalents, and marketable securities to other income (expense) in the consolidated statements of operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_4e2a9a8f-1d77-484c-9d77-353cd8cc43ba_1" continuedAt="F_4e2a9a8f-1d77-484c-9d77-353cd8cc43ba_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d5baa16a-6761-46c5-858a-908a5f514fd2_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">comprehensive loss. The Company invests its excess cash in money market funds, commercial paper, corporate bonds, government and agency securities and U.S. treasury bills.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5220b512-fd9f-48ce-b91c-a73f1700d9f8" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair value measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows the provision of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASC 820&#8221;), which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 &#8212; quoted prices for identical assets or liabilities in active markets.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 &#8212; quoted prices for similar assets or liabilities in active markets or inputs that are observable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 &#8212; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cash equivalents, marketable securities, and related party revenue share liability are carried at fair value, determined according to the fair value hierarchy described above (see Note 4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0921dd8b-f694-45e5-b819-5b821e9392ae" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for marketable securities in accordance with FASB ASC Topic 320, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments - Debt and Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company&#8217;s marketable securities are classified as available-for-sale debt securities and recorded at fair value based on inputs that are observable, either directly or indirectly, such as quoted prices for identical securities in active markets (Level 1) or quoted prices for similar securities in active markets or inputs that are observable (Level 2). At the time of purchase, the Company classifies marketable securities with maturities of three months or less as cash equivalents on the consolidated balance sheets. The Company&#8217;s available-for-sale securities are classified as current assets as they are readily available to be converted to cash and for use in the Company&#8217;s current operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unrealized gains and losses are included as a component of accumulated other comprehensive income (loss) in the consolidated statements of stockholders&#8217; equity. Realized gains and losses are recorded to other income (expense) in the consolidated statements of operations and comprehensive loss.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When the fair value is below the amortized cost of an available-for-sale security, the Company must determine if the decline in fair value below the amortized cost basis has resulted from a credit loss or other factors. If the Company determines that the decline in fair value below the amortized cost basis is due to credit-related factors, the Company measures the credit loss and recognizes an allowance for credit losses in the consolidated balance sheet and the credit-related impairment in the consolidated statements of operations and comprehensive loss. The allowance for credit losses is measured as the amount by which the amortized cost basis exceeds the present value of expected cash flows, limited to the difference between the amortized cost basis and the security&#8217;s fair value. The Company subsequently assesses whether the measurement of credit losses has increased or decreased and adjusts the allowance for credit losses with corresponding gains or losses recognized in the consolidated statements of operations and comprehensive loss. Impairments not relating to credit losses are recorded to other comprehensive income (loss).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company intends to sell the available for sale security or it is more likely than not that the Company will be required to sell the security prior to the recovery of its amortized cost basis, then the allowance for the credit losses is written off and the excess of the amortized cost basis of the asset over its fair value is recorded in the consolidated statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b886b0c8-fc20-4ca7-b162-9d3be46ff579" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair value option for related party revenue share liability</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a revenue sharing agreement with Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund IV, L.P. (collectively, &#8220;Deerfield&#8221;), each an investor in the Company, to pay a fixed low single-digit percentage rate of net sales of certain commercial products, which represents a freestanding financial instrument. In accordance with FASB ASC Topic 825, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company elected the fair value option. Accordingly, the related party revenue share liability was measured at fair value upon issuance and is remeasured at the end of each reporting period with changes in fair value recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The fair value of the related party revenue share liability is estimated using a discounted cash flow model to calculate the estimated payments that could become due following commercialization. Assumptions in the model include but are not limited to the following: probability and timing of product approval, future product revenues and discount rate. The fair value measurement is based on significant inputs that are not observable in the market and thus represents a Level 3 measurement.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_619583cc-a6c3-4cf1-b25e-69cbec0a27cd" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_619583cc-a6c3-4cf1-b25e-69cbec0a27cd_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development and clinical trial accruals</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. These consist primarily of salaries and related costs, including stock-based compensation, for personnel engaged in research and development functions; costs incurred in connection with the advancement of the Company&#8217;s discovery programs and product candidates in preclinical and clinical studies, including under agreements with contract</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_4e2a9a8f-1d77-484c-9d77-353cd8cc43ba_2" continuedAt="F_4e2a9a8f-1d77-484c-9d77-353cd8cc43ba_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_619583cc-a6c3-4cf1-b25e-69cbec0a27cd_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">research organizations (&#8220;CROs&#8221;); and the cost of developing and scaling the Company&#8217;s manufacturing process, including under agreements with contract manufacturing organizations, to manufacture drug substance and drug product for use in the Company&#8217;s research and preclinical and clinical studies and manufacture commercial-scale validation batches in preparation for the commercial launch of the Company&#8217;s product candidates that obtain regulatory approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and may be reflected in the consolidated balance sheets as prepaid or accrued expenses. Determining the prepaid and accrued expenses balances at the end of any reporting period incorporates certain judgments and estimates by management that are based on information available to the Company including information provided by employees and vendors regarding the progress to completion of specific tasks or costs incurred.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc19dbbd-2108-4daa-bfe8-fdfe5391365b" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent costs</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34967d6a-f479-42bb-9a30-c1fdf972ebe5" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation &#8212; Stock Compensation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASC 718&#8221;). The Company has granted stock options and restricted stock units (&#8220;RSUs&#8221;), both of which are subject to service-based vesting conditions, and RSUs with performance-based vesting conditions (&#8220;PSUs&#8221;). In accordance with ASC 718, the Company recognizes stock-based compensation expense in the consolidated statements of operations and comprehensive loss based on a stock award&#8217;s grant-date fair value.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. For RSUs and PSUs, the fair value is equal to the market price of a share of the Company&#8217;s Class A common stock on the grant date. The Company recognizes forfeitures as they occur. Stock-based compensation expense for stock awards with service-based vesting conditions is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting period. Stock awards with service-based vesting conditions generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_2bc711c3-dec2-4073-ad3b-8876b685c8e8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- or</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e2e21f0-2542-4789-b802-a2f64eb433b9" contextRef="C_4012f4dc-f825-4c85-81de-f4ed79e455ba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> service periods and stock options expire after </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8de07f3-e36e-4de5-a2b2-b1aa425d184e" contextRef="C_59e85967-08c8-41ab-9f65-d108262ec6c3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Stock-based compensation expense for stock awards with performance-based vesting conditions is recognized on a straight-line basis over the requisite </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">service period for</span><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each separately vesting portion of the underlying stock award when the performance-based vesting condition is deemed probable to occur. The Company reassesses the probability of vesting at each reporting period and adjusts stock-based compensation expense, if applicable, based on its probability assessment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records stock-based compensation expense to research and development expense or general and administrative expense based on the underlying function of the individual that was granted the award. Shares issued upon stock option exercise and RSU and PSU vesting are newly-issued shares.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Company&#8217;s Black-Scholes option-pricing model for stock options are as follows:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; As the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the Company utilizes the &#8220;simplified&#8221; method, as prescribed in the SEC&#8217;s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetical average of the vesting term and the original contractual term of the stock option.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; The expected volatility is based on the historical volatility of the Company and that of similar entities within the Company&#8217;s industry for periods corresponding with the expected term of the grant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant for a period that corresponds with the expected term of the grant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Dividends</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; The expected dividend yield is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3c080af-d4c2-49f3-8df9-cd2df9d5375f" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% as the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Company&#8217;s Black-Scholes option-pricing model are inherently subjective and represent management&#8217;s best estimates. These assumptions involve a number of variables, uncertainties and the application of management&#8217;s judgment. If any assumptions change, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e3bec4af-f152-4218-8600-5cc07e904bde" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net income (loss) per share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, including potentially dilutive common shares. For periods in which the Company reported a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_4184cc40-064a-4b76-a60b-308eacd082d6" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_4184cc40-064a-4b76-a60b-308eacd082d6_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income taxes</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4e2a9a8f-1d77-484c-9d77-353cd8cc43ba_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4184cc40-064a-4b76-a60b-308eacd082d6_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7b67733-e920-41ef-99ba-57942c13febb" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently adopted accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15279d41-3622-409e-adb0-40d89efade77" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company prospectively </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d845723-e597-43c6-ba4a-9c9eadc96af0" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9bb6efd4-414b-479c-bbd1-d6eec4dc4cc3;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-09</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;) on an annual basis, which requires public entities to provide disclosure of specific categories in their income tax rate reconciliations, as well as disclosure of income taxes paid disaggregated by jurisdiction.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently issued accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASU 2024-03&#8221;), which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the consolidated financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company does not expect the impact of the adoption of this standard to be material to its consolidated financial statements or disclosures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangibles &#8212; Goodwill and Other &#8212; Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASU 2025-06&#8221;), which modernizes the accounting for internal use software. The standard removes references to project stages and clarifies the criteria for capitalizing software costs. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company does not expect the impact of the adoption of this standard to be material to its consolidated financial statements or disclosures.</span></p></ix:nonNumeric></div></ix:continuation></div><div><ix:nonNumeric id="F_17935072-b37c-4b02-93f7-a9017319a0a5" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true" continuedAt="F_17935072-b37c-4b02-93f7-a9017319a0a5_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Marketable Securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae8945a6-beab-425a-beed-79405ff04bcf" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:MarketableSecuritiesTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables provide the amortized cost and fair value of the Company&#8217;s available-for-sale securities by security type (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.93%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.982%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.982%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.982%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.122%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77a015f9-fa8a-4c5b-bc2c-a33f9259f0e4" contextRef="C_d4753189-18cd-4f14-9c1a-96a8faae97b4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,889</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e6e51ff-4a05-415a-88a9-4e709e78435e" contextRef="C_d4753189-18cd-4f14-9c1a-96a8faae97b4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24bd43a0-151d-4dd5-8f00-870a1ce21cb3" contextRef="C_d4753189-18cd-4f14-9c1a-96a8faae97b4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d6a8935-973c-4fb7-872a-a899defb9800" contextRef="C_d4753189-18cd-4f14-9c1a-96a8faae97b4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,884</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ab5329a-ad66-43c1-8588-4a00418415cc" contextRef="C_e296d935-9d7a-4619-b857-c867a08d6bf1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">772,457</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55aaa139-8f85-4d7a-a910-2e28c224a143" contextRef="C_e296d935-9d7a-4619-b857-c867a08d6bf1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,233</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efca8337-405c-4d4c-a966-00b67014e9c7" contextRef="C_e296d935-9d7a-4619-b857-c867a08d6bf1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">184</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c3e9ee3-c6a8-43b5-b22b-6a1c8c2661cd" contextRef="C_e296d935-9d7a-4619-b857-c867a08d6bf1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">774,506</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government and agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3dcdffe3-54fa-4a70-92dc-76f810b0d222" contextRef="C_5b2c061b-d1fc-4fbb-80d8-2da875f202a6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207,684</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4336a6e3-3d3b-4e9c-bf46-71ce619eabe4" contextRef="C_5b2c061b-d1fc-4fbb-80d8-2da875f202a6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">340</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d606832f-1cbf-4de4-9bb5-011251cca867" contextRef="C_5b2c061b-d1fc-4fbb-80d8-2da875f202a6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dbe60b5-f891-4662-bca1-aebd1502fd7e" contextRef="C_5b2c061b-d1fc-4fbb-80d8-2da875f202a6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207,990</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury bills</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08631bf4-f19f-48f2-a9cd-a09d5fb26996" contextRef="C_ce0c1f70-1e86-4aae-bde4-2bb3ccddfaa6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,824</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74cab563-1b53-4613-96da-5a7684751fdf" contextRef="C_ce0c1f70-1e86-4aae-bde4-2bb3ccddfaa6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31bd3403-c1b2-42c9-b626-e0c3f8f1f9b6" contextRef="C_ce0c1f70-1e86-4aae-bde4-2bb3ccddfaa6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_735a419e-20c7-41fe-8b7e-94a45bc354c0" contextRef="C_ce0c1f70-1e86-4aae-bde4-2bb3ccddfaa6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,827</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce2de8d0-e9c9-40c5-973c-8889e24fe6b1" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,107,854</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df664bd7-b8a0-4d3c-80d0-7c921d789400" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,593</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78861d2a-14df-45e7-aa65-0fd64def7d37" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a9e1ebe-2624-47cc-9d01-07e4562eba90" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,110,207</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.93%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.982%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.982%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.982%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.122%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7bcf7e5-daa3-4286-a756-df93dec9a9da" contextRef="C_a4c171d8-3da3-4eb9-89e1-62dacc43ee28" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,473</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d226947e-fe62-4c2f-8382-f70e0ffe657d" contextRef="C_a4c171d8-3da3-4eb9-89e1-62dacc43ee28" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6496cb1-21fd-4d30-9444-bdb779af3922" contextRef="C_a4c171d8-3da3-4eb9-89e1-62dacc43ee28" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1bb7b7b-c018-4e89-ae45-001a7d819475" contextRef="C_a4c171d8-3da3-4eb9-89e1-62dacc43ee28" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,309</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b561c923-f6a3-4315-9770-6081dcdeb393" contextRef="C_5ecefa5a-caed-49e8-bd54-e1b9762e2e0e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">468,673</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8eed0ae-0963-4c1c-a979-8df9d10c21ef" contextRef="C_5ecefa5a-caed-49e8-bd54-e1b9762e2e0e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">532</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f71613cc-2df9-4467-ad1e-d7277136b5df" contextRef="C_5ecefa5a-caed-49e8-bd54-e1b9762e2e0e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">588</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9f681d5-0487-4f12-a301-b1ebf339c68d" contextRef="C_5ecefa5a-caed-49e8-bd54-e1b9762e2e0e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">468,617</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government and agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f229a214-f33a-4ff9-85a9-9b6cb54c6d9b" contextRef="C_84e19387-66ac-4596-b28a-643c9b3fb129" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,783</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9608aa7f-58b0-4d38-be23-7999fe9355e8" contextRef="C_84e19387-66ac-4596-b28a-643c9b3fb129" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d67eade2-08a3-4430-82d7-ed10cb19e28f" contextRef="C_84e19387-66ac-4596-b28a-643c9b3fb129" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94e2f4b0-64ed-40c2-b8a8-8b72f09dd27e" contextRef="C_84e19387-66ac-4596-b28a-643c9b3fb129" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,886</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury bills</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_114aaf3c-0fd9-4ce6-a76b-59c2996b8b64" contextRef="C_5ced912f-8b63-48e6-a3cd-afdf5cd699b3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,741</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5bee53b-f896-456a-a752-1d9e0cfa460c" contextRef="C_5ced912f-8b63-48e6-a3cd-afdf5cd699b3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec975bb8-deb3-4190-b8d4-bd1c5ef4c370" contextRef="C_5ced912f-8b63-48e6-a3cd-afdf5cd699b3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f731c899-57b0-49d6-b9d5-48feece2c54f" contextRef="C_5ced912f-8b63-48e6-a3cd-afdf5cd699b3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,799</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_780d920e-73ce-497d-aa4a-6880d4e07201" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">972,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c7e6bb9-485b-4ab3-9f38-014cb4d60b9a" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">736</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_225cd399-2bd3-4c8f-a286-a2158052b289" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">795</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ad48e36-2d4b-4a6c-8e78-4cb93a938873" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">972,611</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_17935072-b37c-4b02-93f7-a9017319a0a5_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9ec5836-44bb-4ad8-b7a1-823c9ac65f24" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the amortized cost and fair value of the Company&#8217;s available-for-sale securities by contractual maturity (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due within one year</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f36293a-6d05-4717-bed4-36ab0c15f639" contextRef="C_249fe9c5-035a-4be4-bda3-5a7f5c5d842f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">523,630</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2d11018-d445-47cc-8c83-4553ca128310" contextRef="C_249fe9c5-035a-4be4-bda3-5a7f5c5d842f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">524,421</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due after one year through three years</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e75ed1d7-3171-40ba-82a4-d6966e2e2c47" contextRef="C_1933430c-8e7f-4e70-bb06-113d64f132d9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">584,224</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_548d2039-ea89-4683-976a-dace7d739bd9" contextRef="C_1933430c-8e7f-4e70-bb06-113d64f132d9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">585,786</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a8405aa-34cc-4ae0-903f-5ba03dc0ee4b" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,107,854</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad9a07a8-2369-4ca3-8008-13c56e6c9cdb" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,110,207</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97aa6a23-2aad-430a-af0d-2b8e388b3a72" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a146a6a2-9c28-48b3-8cb9-4fb2d0f462ac" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a1322991-256b-4682-a78c-24ce39d59ecc" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> credit losses recorded during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, 2024 and 2023. Interest income for the years ended December 31, 2025, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c4354ca-2acb-4de5-8913-1a44632cdb27" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">44.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fe1cc20-8178-429b-9e74-4624e6e50279" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">38.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04db7a0e-b561-4341-b281-2fc542604350" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31490cec-25c5-41bd-a41e-910fdc318298" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_4_fair_value_measurements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Fair Value Measurements</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b6145a5-b2a4-48ce-91b9-998c0c8bfda9" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present the Company&#8217;s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.99%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.958%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.978%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.978%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.097999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7c5e23e-614f-4a49-ad08-dec28bb644b8" contextRef="C_cdee423f-13dc-4cee-9db9-89de0a74a37e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,567</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e399400c-da07-4218-8592-957aa37b55b0" contextRef="C_a35f2a79-4ef6-43ea-a2a6-e4132c6ac5cf" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,567</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c1624fe-e7a1-4200-ad77-5d96704bfed6" contextRef="C_0000066a-157e-4f4a-ba87-0eadc35447f3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,884</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f58ecf9-1293-4a11-8ffe-3f0412b8441b" contextRef="C_311675e3-d4bb-45f1-8ba5-f59f04c6601e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,884</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9de4f68-d6da-41aa-af6b-04e1aebc77e6" contextRef="C_a59b2dc3-40a3-4254-a8ce-3b9d4e32e2ab" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">774,506</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_131170b8-bd58-4f7d-b06e-b6f99524f3e4" contextRef="C_7d73a6a9-9a14-4d7d-ac5c-0d24cfad2b78" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">774,506</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government and agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_401e7453-b301-4551-907f-753a4b94e64d" contextRef="C_62eeefb2-1e14-4bca-8787-bc752cc63c08" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207,990</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_801f1641-9cc5-4aa4-920f-c469bb912027" contextRef="C_7ab55318-ef2a-434f-8bd9-380fef2ea246" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207,990</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury bills</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0fd68d0-c4df-4ada-82be-8d987999e969" contextRef="C_6edd2b6c-842b-450b-bfa3-6954cfc7acbe" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,827</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b50ed9ad-7f0f-4886-bce1-a438d5a780b5" contextRef="C_04cf2475-3d52-4702-8abf-c08e477d27e7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,827</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2df387f-dd02-40d0-ae8b-f8fb614485d0" contextRef="C_cdee423f-13dc-4cee-9db9-89de0a74a37e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,567</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2c558a8-7ff7-4fc7-8dc0-762c7cfac36b" contextRef="C_dcbf0a58-6a1b-4202-9cdf-1ee677e03399" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,110,207</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b59fbc5-ef16-493a-bdf1-d65507b17ad8" contextRef="C_a35f2a79-4ef6-43ea-a2a6-e4132c6ac5cf" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,361,774</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Related party revenue share liability</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44619aa4-6518-4f33-874f-fba07dd6b995" contextRef="C_804b901c-8280-4ee4-8d08-720119428cfc" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,160</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32a27351-77a8-4a42-93fa-f132b4683f7c" contextRef="C_466cca9b-97be-4208-8bc1-360fd88d3e92" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,160</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:48%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1230e37-1bf1-4507-86d6-9f067cbacbd4" contextRef="C_9197732a-6f19-4a46-a09e-bbf59e2e5565" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135,902</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b74733b-9aa2-4ca3-9cf8-eec78bb296a2" contextRef="C_5375c9d0-2105-44e2-b95c-e77a2e65b0ee" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135,902</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca42f460-a140-40db-a3e5-f72f139b7c9f" contextRef="C_40396d26-77ba-42d0-a54a-49ced53d5b71" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,309</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40d50fa6-834a-40c0-8572-9821cb90c54a" contextRef="C_e4d077ae-e343-4a79-ae30-25df3168dd9b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,309</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f05065e6-e5cc-42e4-9c6e-0defa9c8ebf6" contextRef="C_b96b8a89-ec86-4975-9a70-f67d031a9eca" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">468,617</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b46a176-309f-4c3d-bd8e-173da6342042" contextRef="C_c2cf0b0d-1d62-4db0-b62f-ddbc77d261d4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">468,617</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government and agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ff3b17c-fc06-4d08-8250-9b7c0acf4d0d" contextRef="C_e1e6998a-a42a-435c-9db6-9c17a1e2d9d3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,886</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6478776-f70c-4345-95ef-be4fb95647f1" contextRef="C_115fa72c-632f-4dc3-a356-8cde960ebdc7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,886</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury bills</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd680b98-68f8-4f72-94fb-e5b8bd0d3e46" contextRef="C_651bca55-01de-4bcf-b62d-18da05e75cbb" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,799</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3375830-2a87-477a-9e25-c53b7e4c7b49" contextRef="C_b4f67603-f7f4-4146-9b75-51864e400238" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,799</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b81b1748-df00-435e-be48-c0522c1ed11a" contextRef="C_9197732a-6f19-4a46-a09e-bbf59e2e5565" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135,902</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da9789d0-b410-4803-9a35-65e1ddc5db02" contextRef="C_caf3d18a-ea80-40be-9716-306c4b3b915d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">972,611</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a6a8e14-1b8c-4cdd-99d8-54a46f55c23e" contextRef="C_5375c9d0-2105-44e2-b95c-e77a2e65b0ee" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,108,513</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Related party revenue share liability</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbc8aba0-8833-45ba-b361-05619ff8ced8" contextRef="C_87166674-75a3-43e1-b506-e4931d232803" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,940</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7fe232b-733b-4efe-922d-9bc4b0a18ca7" contextRef="C_1199f4a9-3a4a-4346-9b3c-1e5dfe502dce" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,940</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents were valued by the Company based on quoted market prices for identical securities, which represent a Level 1 measurement within the fair value hierarchy. Commercial paper, corporate bonds, government and agency securities, and U.S. treasury bills were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. During the periods presented, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5ea0780-5bdc-46f9-bea8-cc1a17833fff" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_be4e064d-4563-4586-b85c-9e8c30b53840" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers in or out of Level 3. The carrying values of the Company&#8217;s accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these liabilities.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76c93c25-168c-4a30-8791-ac24eaa41fb5" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the changes in estimated fair value of the Company&#8217;s related party revenue share liability for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, which represents a Level 3 measurement within the fair value hierarchy (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:83.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated fair value as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17ff202a-fb38-4dc0-b6dd-490c628f3788" contextRef="C_d099b530-0cf4-48be-a348-63560b2d2db7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,940</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_887c8a9e-6046-44b6-9adb-149f6579e659" contextRef="C_cbcb2363-568f-4092-88ad-525c58d12120" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,220</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated fair value as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94885505-e810-48c0-86d2-5b85be0b31d7" contextRef="C_11b35f3d-891f-4171-b4d4-acada2917088" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,160</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the related party revenue share liability was estimated using a discounted cash flow model to calculate the estimated payments that could become due following commercialization. Assumptions in the model include but are not limited to the following: probability and timing of product approval, future product revenues and discount rate. Changes in fair value each reporting period are recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. See Note 10 for additional information regarding the revenue sharing agreement with Deerfield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_7fa3f80b-03ab-4474-9f46-616961136983" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5c8ef4a-5967-4b86-a9a2-c94dd320dbc6" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="nuvl:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" escape="true" continuedAt="F_c5c8ef4a-5967-4b86-a9a2-c94dd320dbc6_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:60.072%;box-sizing:content-box;"/>
         <td style="width:1.001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.203%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.722%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical and other research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ff10a88-8ab3-47d3-9f48-0da0446c8d7e" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,235</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ceebddb0-ed45-4d9c-99bd-3c13d7bfbd45" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,555</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued manufacturing</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e40c7c1-c23b-4ffb-8953-998e179aeda2" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="nuvl:AccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,976</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3d56848-4069-431e-87d8-df935ccdb382" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="nuvl:AccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,511</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued employee compensation and benefits</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4717fbd0-dc6d-44bd-9103-a168781d53b4" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,935</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e4e224f-e83a-431f-9052-3ce234f062a5" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,452</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8eaa256f-107a-447d-9c8e-7a09c8252f22" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="nuvl:AccruedOtherAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,867</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12f9ac23-c118-440d-a6f0-be3baa7a0a46" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="nuvl:AccruedOtherAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,277</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4186d6b6-070c-4078-b9d9-a284d763f5f7" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,013</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cb344b2-5f36-4e0e-8e9a-bd012cd8a471" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,795</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_c5c8ef4a-5967-4b86-a9a2-c94dd320dbc6_1"></ix:continuation></div><p style="text-indent:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a790c75d-970b-4727-870d-5efeb26cd5ae" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_2bb2c6d1-41bd-4d86-ad8c-b3b76d005af1" contextRef="C_d76a48ae-1458-49f4-880c-993e1969d630" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,950,496</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its Class A common stock in an underwritten public offering at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_ee3a4075-da4d-4dcf-b865-32fe18bbb7dc" contextRef="C_8c05b7a3-8cdf-43a6-a7e8-093ffb97f438" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">101.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (the &#8220;2025 Public Offering&#8221;). Upon the closing of the 2025 Public Offering, the Company received net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_ff15236d-3320-44af-8994-fc594fb48636" contextRef="C_b3cff3c2-044c-46b7-89c3-2f4680873e9a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">471.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting equity issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_07eaae10-942e-4735-9810-7a8efa423d3e" contextRef="C_b3cff3c2-044c-46b7-89c3-2f4680873e9a" name="nuvl:EquityIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in addition to underwriting discounts and commissions. In addition, the underwriters exercised their option in full to purchase an additional </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_a956e966-7a5a-4431-a205-b8d0dcc4d75b" contextRef="C_0f57ea6c-80f3-41df-a06f-6bbb78d913d8" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">742,574</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Class A common stock (the &#8220;Additional Shares&#8221;) from Deerfield. The Company did not receive any proceeds from the sale of the Additional Shares by Deerfield.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7b06a76-5a78-4503-b9fa-5b29507c438b" contextRef="C_794390d5-c9fe-4091-8a4b-34dc63c137c2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its Class A common stock in an underwritten public offering, including the exercise in full by the underwriters of their option to purchase an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3547899f-c501-4fd6-b21c-3b9bb319407e" contextRef="C_9bf007c6-b63f-40c9-9e02-abfd50766d7d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">750,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Class A common stock, at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_120fb6af-3a32-4d2e-9057-18028515cd4a" contextRef="C_a9763b57-1db2-4f46-9ff1-ae604892960c" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">100.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (the &#8220;2024 Public Offering&#8221;). Upon the closing of the 2024 Public Offering, the Company received net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_274d51ff-a720-42b5-9851-244c62c50d4a" contextRef="C_01cd509e-be11-4515-a517-f7b5049d7dd3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">540.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting equity issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_add0fe51-2d04-4855-94bb-019f7d76bee6" contextRef="C_01cd509e-be11-4515-a517-f7b5049d7dd3" name="nuvl:EquityIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in addition to underwriting discounts and commissions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3529fe26-a7c1-4e08-97ed-1df936dc37ea" contextRef="C_93c55488-e02d-4971-b17c-5355e98cdfa9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,160,714</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its Class A common stock in an underwritten public offering, including the exercise in full by the underwriters of their option to purchase an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebea4d66-15dc-405e-be28-c72bc6fcee19" contextRef="C_1d01bc0b-7ded-4bd0-9911-fdca86bb46a7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">803,571</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Class A common stock, at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebeb748f-d094-4d26-8870-666c41582290" contextRef="C_7ba5c3d8-bf4d-45c7-b12b-5b3d1c87d47e" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">56.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (the &#8220;2023 Public Offering&#8221;). Upon the closing of the 2023 Public Offering, the Company received net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d28f04f3-b61a-44b7-84ce-c4f4690f4ac1" contextRef="C_9f83a502-9a23-4e89-997b-59b9c16ccdcc" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">323.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting equity issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_337f1a8e-6ddd-4246-948a-bc751847f645" contextRef="C_9f83a502-9a23-4e89-997b-59b9c16ccdcc" name="nuvl:EquityIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in addition to underwriting discounts and commissions.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_217a7142-87c2-472a-91bb-352a4ce12b2c" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_217a7142-87c2-472a-91bb-352a4ce12b2c_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Stock-Based Compensation</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89200fa5-0f5a-4500-be17-1d1739c78beb" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded stock-based compensation expense within its consolidated statements of operations and comprehensive loss as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:60.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.040000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.040000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.66%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43eef0fe-e486-4e80-b15d-519d493dff4f" contextRef="C_f59252bc-b763-4e51-83d2-54d4bba5a6f8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,097</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d91fee4-e614-4003-b82e-e5f96435148d" contextRef="C_4b81bd74-b327-44d2-baca-063efd69c11c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,369</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_358207a2-c139-4364-8dd2-100582a3241e" contextRef="C_c6bbbfaf-9812-4257-bac4-0186503112d4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,600</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7411a013-8737-425d-9324-6e93f6fc6ff9" contextRef="C_0ed9a5c8-bc77-4159-80cc-631b58767dd4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,405</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e21a4e94-00aa-4702-8340-7be990c42d67" contextRef="C_1c1aeab6-5cb0-40f4-a1b3-94770256e0b4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,210</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d55dbe5-48e6-4cab-917e-3eba47841632" contextRef="C_1cd91e04-8d02-4ef7-b3c0-68167cbe59fc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,963</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8d8f3cd-7805-4054-a07e-2e5422a65e79" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,502</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_399a9e88-9d88-4405-aa1d-ca5f65546387" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,579</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b78dab88-5a95-496a-ba4e-0e8b6047ba5d" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,563</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2021 Plan (as defined below), the Company has granted stock options, RSUs and PSUs. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total unrecognized compensation cost, excluding unrecognized compensation cost related to PSUs, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97426675-d38a-4ce3-8815-0229629e913e" contextRef="C_7afb1013-38c2-4d5e-b701-12fe832c3317" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">170.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d920e19a-aa39-4bcd-8d04-ff5cb8d866ef" contextRef="C_7eb103db-61c7-4a1d-bd4c-ff51a5d2f879" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. Stock-based compensation expense for PSUs is recognized on a straight-line basis over the requisite service period for each separately vesting portion of the PSUs when the performance-based vesting condition is deemed probable to occur. The performance-based vesting conditions under the PSUs have not been deemed probable to occur, and accordingly, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48cfbafe-1689-4263-b9b7-27b9b1225615" contextRef="C_e2c0f06b-9e84-41cf-840f-bb816b9bcc96" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock-based compensation expense has been recognized. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, total unrecognized compensation cost related to PSUs was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4183fee3-653c-4dcb-9d80-6ffc21d6cd9b" contextRef="C_a003efa2-9b6b-4b5b-8e24-3f682b981042" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which will be recognized when the performance-based vesting conditions are deemed probable to occur.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 equity incentive plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2021, the Company adopted the 2021 Stock Option and Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, RSUs (including PSUs), unrestricted stock awards, cash-based awards and dividend equivalent rights. The number of shares of Class A common stock reserved for issuance under the 2021 Plan is subject to increase on each January 1 thereafter by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42a61614-3c1a-447e-80c2-3d7eb225ef83" contextRef="C_9cdf4307-9ead-4afc-bdf8-f81ea96995ae" name="nuvl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the number of shares of the Company&#8217;s Class A and Class B common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#8217;s board of directors or compensation committee of the board of directors. The shares of Class A common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expired or are otherwise</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_217a7142-87c2-472a-91bb-352a4ce12b2c_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(other than by exercise) under the 2021 Plan will be added back to the shares of Class A common stock available under the 2021 Plan. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3acdaab-4200-4c99-b4f1-cffcee923159" contextRef="C_57e49bd8-5824-43bf-b177-9a36dba04b3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,244,716</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock remained available for future issuance under the 2021 Plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 employee stock purchase plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2021, the Company adopted the 2021 Employee Stock Purchase Plan (as amended and restated, the &#8220;ESPP&#8221;). The ESPP permits eligible employees to purchase shares of Class A common stock at a discount in accordance with the terms of the offering and consists of consecutive, overlapping 12-month offering periods, each consisting of two six-month purchase periods. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e2081e6-ba6c-400c-9d9f-719aab96452d" contextRef="C_22a8e1ba-3f11-4756-a8b5-7e71665e826e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,322,110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remained available for issuance and sale under the ESPP.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad66c881-0439-4e96-9e64-38dbd9d5f418" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the range of assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.26%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="5" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average expected option term (years)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8a299053-6b3e-444e-8f34-36cad9345bc9" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_10598e9a-00a9-4c26-aad0-35e58ceaa51d" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_945320ef-9522-4c58-b8c4-d2207ff8a6a8" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Range of expected stock price volatility</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3737f21-6e55-4694-bde6-5af81f26e41a" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5d31215-1d27-473e-b7d0-00f108f831c5" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">71</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fde80fcf-8f11-4418-be28-327cc394ebb7" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c00e2c0-e09a-469e-af36-16dfd608620d" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">76</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf93c1ce-ddf0-47fe-a808-4d279388d04f" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">76</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68ee586f-6b13-4da1-8768-569f40b1f25d" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">82</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average expected stock price volatility</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dd11834-a41e-4801-b719-dc71527ea0af" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">71</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_706a1703-26f9-4554-92f1-37137d0a2f68" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ca6ca5b-fc8c-44a5-8264-c1b7f76b154b" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Range of risk-free interest rate</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d832dd20-e922-4e0d-8a2d-b778c3ca18b1" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a497d092-9262-43aa-ab87-4359c4bf8f55" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70d9eee8-444c-4f6a-b427-8f2b94131587" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_885507dd-aa95-4afe-8c1d-0483840706c9" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_010c694b-e81b-4025-a59c-c107109cfe6c" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4e75072-0579-43e0-87d0-95b447c28586" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend rate</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3941197-e573-42a4-939a-4ce95702cd1e" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecf1fbcc-fd58-4f32-9093-3fe9126c228e" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c636a88-d8cb-4341-a417-b1db5206cd76" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb1e486f-6df9-4382-9990-5ff4d2202ef9" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.6%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.120000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">of Shares</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59546cc3-6ab9-471a-85fc-66b23ca4e0d5" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,980,047</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66cccfb4-1fab-40a8-97b2-0ca5f491dc9a" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">28.93</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c8627a07-b43f-44ac-8783-931654268f7e" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.45</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1952d4de-c8cb-4cdf-9053-9280f82659ad" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">398,407</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af16a85a-59d2-4e7e-9c04-02ab034f0172" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,544,070</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6e90d04-4913-4e74-b061-eb31883dd04e" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">78.51</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78cb0b2e-6b4f-4d48-95ff-7028cf5fa28d" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,672,786</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b963bf3a-c40a-4531-8cbc-bfb9694a5f53" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">25.13</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled or forfeited</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c2c2212-f9b1-4147-9163-425d448f35fd" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">133,690</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3dce7b28-407f-4ba7-9f2f-ca976225b010" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">73.63</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14fa97a1-f427-400c-9a9e-bf2ec5f1c564" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,717,641</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2c112f9-3d61-4845-8db6-f17dc509b5b5" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">38.90</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c4fb1e45-df2b-4d0b-ae22-a8ccf3b47a7b" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.90</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c8a6b8d-604e-49ef-b33b-af8e1212b57d" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">476,355</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7be742de-fa20-433c-b303-265913c5d37d" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,701,612</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51941c17-3036-473f-be51-e63a9900f1a4" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">22.06</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1b3a001e-f319-4c72-abd5-c189492a7125" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.95</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a64c65e5-9e34-4279-bb4f-b5936cfe781f" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">369,254</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of stock options exercised during the years ended December 31, 2025, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61840871-1793-47e4-aa3b-4c858e7bde66" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">107.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_951a2dc3-444b-42b4-ab60-d8bc701c6c10" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">102.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c07fda8a-ea72-4371-9181-5042b1816e33" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">52.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock on the date of exercise.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average grant-date fair value of stock options granted during the years ended December 31, 2025, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5daceb74-b17f-45e5-84bb-8f89175e24cc" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">51.94</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_853ac31d-a56b-43ba-9689-f4cb11f23237" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">53.07</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26228a59-2e93-488e-9028-2c72ccbd7d20" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">23.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSUs</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3ea395f-4c7f-4411-9331-a1606790f58a" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s RSU activity since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:55.98%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:20%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Grant-Date Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a936c76-2bc4-4303-87fb-1191d815c943" contextRef="C_b5d7c4e7-18e6-4f91-bcaf-b360fe129db5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">716,921</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a991edf0-17ae-45aa-88e1-436e4337926b" contextRef="C_b5d7c4e7-18e6-4f91-bcaf-b360fe129db5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">75.13</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac543a1e-d50c-4089-8e8e-0d267e0642e5" contextRef="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">657,148</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70648255-76f5-41dd-bcaa-c43653324753" contextRef="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">78.05</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e0effac-61d1-4669-be7d-4c9c4dd921df" contextRef="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">252,814</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5668d5f-fdf0-4d3a-9c98-89096243b774" contextRef="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">75.29</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_540c1878-6b62-46f0-829f-b963eeec3402" contextRef="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">30,139</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7a69d40-6553-4bb2-bcf7-0e50c9e179e2" contextRef="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">77.97</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_603700d8-05e6-4078-8648-57250ce5ce95" contextRef="C_2eb94656-ce71-41b7-8316-033ff3cd4fea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,091,116</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89b11864-4f16-41e3-b64d-144c540ca528" contextRef="C_2eb94656-ce71-41b7-8316-033ff3cd4fea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">76.77</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RSU activity above includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b957bf38-63e1-4dbc-a7aa-f082d92a97d2" contextRef="C_a003efa2-9b6b-4b5b-8e24-3f682b981042" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">141,935</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of outstanding PSUs. The total fair value of RSUs vested during the year ended December 31, 2025 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a686909-aa1f-4232-b174-2b8576afebfa" contextRef="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f387c378-b019-4206-880a-595d1de75dc2" contextRef="C_64c133f5-2609-4c1b-9738-f16ce3dfd8c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e6b8f015-b498-495f-ba74-54b9970cbf39" contextRef="C_aee1bc3b-ea55-48a0-b0ff-337c01baa3ba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs vested during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_55d695b5-7752-4bf5-bc41-45cfd323b410" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="F_55d695b5-7752-4bf5-bc41-45cfd323b410_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Net Loss Per Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has two classes of common stock outstanding: Class A common stock and Class B common stock. The rights of the holders of Class A common stock and Class B common stock are substantially identical, except with respect to voting and conversion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_55d695b5-7752-4bf5-bc41-45cfd323b410_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c721f272-9179-460f-b731-8899a4cf3962" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each share of Class A common stock is entitled to one vote. Class B common stock is nonvoting</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1570cb88-3496-4e8c-b598-d6507cb29f47" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:CommonStockConversionFeatures"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each share of Class B common stock is convertible into one share of Class A common stock at the option of the holder at any time, subject to the ownership limitations provided for in the Company&#8217;s amended and restated certificate of incorporation.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company allocates undistributed earnings attributable to common stock between the common stock classes on a one-to-one basis when computing net loss per share. As a result, basic and diluted net loss per share of Class A common stock and per share of Class B common stock are equivalent.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01accf24-f7a9-4773-8fb7-bc2221020604" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.27%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.097%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.097%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.537%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc397491-d2a2-409b-87a8-6f190d2034a5" contextRef="C_f2bb14c0-23f4-4a61-858f-bd386111223c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,717,641</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2017c4d3-7fb5-42f8-b25c-27e9bcc3152a" contextRef="C_c712640c-07a0-45da-b2b2-bcb02c4fd3e7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,980,047</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcf7bdd6-a6b0-4cee-b1de-205054e0c8b5" contextRef="C_e69823d8-ed01-4d08-984d-1b2999947be0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,034,755</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3e8181f-0e13-46fe-a240-c89dcf2210ea" contextRef="C_79da2e27-729f-4d64-9d13-dfa7ed04d4ac" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,091,116</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a0ef687-2945-44b6-8404-46f2f96e11c2" contextRef="C_ef0a437f-257a-4262-a85f-63baab8addb5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">716,921</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02bce5a4-7e12-46a9-853b-be5410f7f91f" contextRef="C_a45f72dc-0315-4ee6-825d-858c0027d5b1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ESPP</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cfc24c9-779a-4725-94ae-8ff2875e3eff" contextRef="C_e20707b9-ffb3-4b91-af22-0d9378f431f6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">18,400</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fc37056-fa62-4327-8ee9-02a2b4807991" contextRef="C_6c8c683b-7a90-4cec-ad1b-80a3610a19bc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01c84b7f-96a6-4d18-9618-3b31875580b0" contextRef="C_be9e56dd-5d09-42b5-a3e0-25987a1ec13c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_790fdc6c-b536-42e3-9f50-dca805a33db3" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,827,157</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a8ad3e9-3b7f-4f18-8df1-a6143fc9d4e3" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,696,968</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_831aa4ed-1d7b-4abd-982a-db5a48b02664" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,034,755</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_492677ce-aaea-48da-8b91-043b8d8b0f3f" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_492677ce-aaea-48da-8b91-043b8d8b0f3f_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of the Company&#8217;s net losses have been generated in the United States. The Company recognized income tax provisions of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_14e119ce-5079-4da0-9a39-c346150768b4" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6073a905-4d44-42b8-b5b9-8c0097fd203a" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, as a result of investment income earned in Nuvalent Securities Corporation. The Company recognized </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc1ba153-58c0-452c-8942-c5ffc8334fad" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> income tax provision during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reconciliation of federal statutory income tax rate to effective income tax rate</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has elected to prospectively adopt the guidance in ASU 2023-09. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_338781c3-1b30-47cb-96e4-2cb3a1dfb8e5" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_338781c3-1b30-47cb-96e4-2cb3a1dfb8e5_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present reconciliations of the U.S. federal statutory income tax rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76b50ddf-be3c-4d4d-9a44-5bbb57366348" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_40da1c99-4de7-4437-bbf4-eb30a866c293" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ec055a24-5029-401f-ae31-97692895e1d2" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">21</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to the Company&#8217;s effective income tax rate for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (dollar values in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_338781c3-1b30-47cb-96e4-2cb3a1dfb8e5_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:60.98%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal statutory income tax rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af963288-7ad5-48f7-812c-6de987e29401" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,206</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01b98f07-c58f-45f2-bbc7-e793031fc697" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local income tax, net of federal (national) income tax effect</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73e46d97-0ef7-41d4-aedb-702b518182de" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">585</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4efa60d-8a52-4200-8cc2-4405690458af" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign tax effects</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8252134-775c-454f-92e9-8ff3ef6cc317" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc5fe61f-ca91-46f5-b5e2-3a2bdf0220aa" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of changes in tax laws or rates enacted in the current period</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_511a4bf2-64b2-42ac-a77e-5a6b14429a3c" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d216386-3a6d-4791-a5e4-ea2140f35504" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of cross-border tax laws</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_432b7cb5-9da4-454e-a6ee-f6f4b60e6c62" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_661f7ab9-2ce2-4ed2-8d08-a57a973c0013" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Orphan drug credit</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5ce758d-dc1e-44e8-b2c7-1f88f19ea141" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="nuvl:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,137</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a723f68a-6556-4d43-9385-c7ba2a4bfb4a" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="nuvl:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D credit</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc877a4a-4a20-403c-8b3e-1ae13117d70f" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,061</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5702fe55-6e81-4458-90f1-fc86f888cb3e" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in valuation allowances</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87c1337f-6b7c-41a7-8e65-2f17fe8b8ec0" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,819</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_714fb330-5e68-4671-81e8-02d3435dbfa3" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">27.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 162(m) limitation</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c71b48ea-56fe-4387-ac6f-d58030ab622f" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="nuvl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,316</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2cb7b5e-494b-4a9f-a739-c2e6cb457c76" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="nuvl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb77ee73-1ab8-4bd9-a15a-b979f2e5bd0e" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,413</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e85246f4-51e3-4b11-94e3-9659ce9136e5" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent adjustments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc456cff-8dd9-4fe3-9db4-940a2327c6ae" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e8dafe1-377f-4c59-b2c2-bd22573adc06" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in unrecognized tax benefits</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e80b7922-8a61-4790-8354-9752bab572d0" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxReconciliationTaxContingencies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7cb2469-d2b3-4a96-becf-9f9106646354" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other adjustments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b4e47f1-43a3-41c5-88e4-055f7df6779b" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">447</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f635e850-6ec1-464c-80c3-74e7ff40ee9b" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67dba121-3731-4972-9741-ec20f6b810d6" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">585</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c615cab-1961-40ff-8570-014430a07667" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.58%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal statutory income tax rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ad10dc8-47e3-437f-8399-1f2f06be581b" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47486161-7743-4c50-a6dd-914bc379d60e" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5660442d-adbe-4048-b532-ba08ec6cf370" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.7</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d7b077b-d75e-4551-9821-fbb4af2fd66b" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.3</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits generated</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbc85169-da9a-4eb8-8513-a9a66d43e6f4" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">14.3</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f698b4ac-e72c-4e4f-9385-97abc72cb4f5" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">5.7</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50807843-398c-44aa-8374-ef3dbe766146" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">45.8</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa878fa0-c798-49e6-b206-23ded666c390" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">38.7</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12e9b4d6-2d59-417d-84c6-5787f88a7fe8" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cbae004-d18d-4e0e-a1b8-84b147c288fd" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9c9ca30-7c34-4726-a40e-b016d21a89e8" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e8dea2a-5f93-498b-a3e6-d8665ecd6f2b" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42428d12-a286-49bd-9669-31839b1c1da2" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d22cb1c0-911c-4377-a0a7-e273bbe44f12" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2025, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07d629a9-ec03-42be-86a8-35f2788057bb" contextRef="C_1b7c2420-1c2c-4ebf-8428-9cac99f1ca29" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_321e1cfb-c827-4f37-abf3-cd59fe208e8f" contextRef="C_12c1df21-95c0-4db5-83c4-037d4d91afe3" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_12005634-a146-4342-b846-ffec85fca265" contextRef="C_07fcdeda-4594-41d5-be5c-795db943ad90" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_32f89643-1d0e-49d3-a77f-5564abe0a3e3" contextRef="C_20130f2c-c4db-45fd-abba-1f8188d4bd9a" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_897c6ee0-de41-4e4a-82c3-15c01016899c" contextRef="C_3b49c627-bb81-455e-91fc-cab076e3df66" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7c7b24a1-832a-4414-9964-5b7f97f3dc47" contextRef="C_ade98c0e-cd81-4850-a29e-7a084963f5ce" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each year, due to its uncertainty of realizing a benefit from those items.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_492677ce-aaea-48da-8b91-043b8d8b0f3f_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8423f05c-9cf2-4a1e-8983-6d8836289446" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net deferred tax assets consisted of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b46e4b5a-f570-4c09-9a58-2868aacba441" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,120</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12e13536-e0ca-4b1a-8f82-fffd3a49c97c" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,677</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13e5fb44-616b-4cab-88c1-b408db8495bc" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="nuvl:DeferredTaxAssetsCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,127</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20034f11-53f4-4e0b-8cfd-ebeda93c1075" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="nuvl:DeferredTaxAssetsCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,002</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credit carryforwards</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64b28085-858b-4f7a-a6c3-b83a8246a373" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,361</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3767e649-1271-4b48-a60d-84d9538cf1b5" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,117</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of related party revenue share liability</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dd8bff7-c2ea-4bd2-a981-9f788bd52c0c" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="nuvl:DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,284</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f22b317-5b37-49ed-8fb8-3e452a75c10b" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="nuvl:DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,785</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4995675f-786d-4b49-ba8c-43c01bd7ca5c" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,225</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e7d46ad-6737-4ac8-9a9c-98353acbcd9d" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,705</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68307125-4b8e-4eed-a352-2215cd87b939" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,648</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c304980-2560-4717-a09e-7354c0cbc9e0" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,714</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d7c59ee-7403-48ff-bad2-762472bfb90b" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362,765</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf144aba-ff6a-4390-a2da-3c071d904a8b" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d949d7ff-e74e-4991-9394-eaa495e97c8a" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362,495</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b731392-ba17-4f79-b2d3-c7b5d7ebb131" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total net deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85276c30-ab11-455f-9dc1-ee865e4079b6" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95ff5ec8-e09a-4f97-be7f-379ea0a27d0d" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6ce3562-e9bb-44a9-b994-41dc08da6c54" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b69e0ec-a3e0-429d-910b-22298dedc88b" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0b1bbf7-8cfa-4959-9851-0c26d0363821" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c0d6b84-f344-4062-a5b7-3b511b96bbd5" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de0de38c-1444-4b18-8f5f-14d8e788e810" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbee00a5-3fc0-4e2c-8ff8-82a7c302406d" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the Company had U.S. federal and state net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a578ec95-a07a-4cc0-93c9-490d6e48e361" contextRef="C_cdabc5c6-3cd2-4eb9-9dc6-41bbf0db7742" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">503.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_751b40f9-9939-47f3-a42a-32708345670a" contextRef="C_35482e0d-c33b-47c3-848d-21781d777547" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">531.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which may be available to offset future taxable income. The federal net operating losses include $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a317644b-f078-4cb1-a38b-90d55df20fc7" contextRef="C_3d1f51e0-4a93-4b50-a43a-e08057aecfba" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16486249-4cfa-488c-b1ad-c417c753c504" contextRef="C_7ce3ca05-ba69-4be9-a104-7719ff79cd1a" name="nuvl:OperatingLossCarryforwardExpirationYearStart"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b509224-786c-4696-99e2-7f1a1c0606c7" contextRef="C_f95ded5a-49e8-49b9-b5a3-63dc2b4d4aa1" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">502.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which carryforward indefinitely, but may only be used to offset </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7df4e036-7c4c-4ec5-9a94-414354756a12" contextRef="C_f899193c-c2e3-484b-bdb4-f0e98446f558" name="nuvl:OperatingLossCarryforwardOffsetLimitPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of annual taxable income. The state net operating losses expire at various dates beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42aca9a7-bc5a-49da-9409-132b21b093d4" contextRef="C_1e086995-98e4-44a7-b73f-1985518eb0f9" name="nuvl:OperatingLossCarryforwardExpirationYearStart"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2025, the Company also had federal and state research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b3a0900-d451-4077-9381-e7afffd382de" contextRef="C_cd8ca3b9-735d-497f-8b2f-206e366ae9a9" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72df05b8-578b-49b6-9850-7eae412e6b7a" contextRef="C_5b210e3a-65e3-4ee7-b4af-e26ecefa2931" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and federal orphan drug credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12237d21-d6e0-415e-b369-c2c60e38a94d" contextRef="C_e991fd94-9f04-42a7-9ea3-29c75a8aa6ed" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">56.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which may be available to offset future tax liabilities. The federal and state research and development tax credit carryforwards and the federal orphan drug credits expire at various dates beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_929e775e-e257-4c04-80c4-92e58b09ce41" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="nuvl:ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2033</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilization of the U.S. federal and state net operating loss carryforwards, as well as the research and development tax credit carryforwards and federal orphan drug credits may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986 (&#8220;IRC&#8221;), and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards, research and development tax credit carryforwards or the federal orphan drug credits would be subject to an annual limitation under Section 382. Any limitation may result in expiration of a portion of the net operating loss carryforwards, research and development tax credit carryforwards or the federal orphan drug credits before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the net deferred tax assets. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception and that the Company has yet to commercialize any of its product candidates to generate revenue from product sales and has concluded that it is more likely than not that the Company will not realize the benefits of the net deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2025 and 2024. Management reevaluates the positive and negative evidence at each reporting period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_f06324e4-efc9-4462-87b1-d652904513ed" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">142.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cbe5e44-5859-4c59-9561-674aa9f1df12" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">119.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f20a8f1a-bc0a-4f4d-a275-6d04e34d3c60" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">48.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the years ended December 31, 2025, 2024 and 2023, respectively, primarily as a result of increases in net operating loss carryforwards, research and development tax credit carryforwards, the change in fair value of related party revenue share liability and research and development costs capitalized under Section 174 of the IRC.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits and tax examinations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a869287-9987-42e3-83f5-7de120959efb" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_607c664e-d1dd-4d81-bf11-ad41a020bfc5" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any amounts for unrecognized tax benefits. The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates.</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10b08993-461b-475f-a113-30d41eb50525" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxExaminationDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b03806a6-1c81-405a-b304-d4fc62c72a8c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2022</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the present.</span></ix:nonNumeric></span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc1cc93c-1942-42c2-a018-30df20c8bd48" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_10_commitments_and_contingencies"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue sharing agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a revenue sharing agreement with Deerfield pursuant to which the Company is obligated to pay Deerfield a fixed low single-digit percentage rate of net sales of certain commercial products (the &#8220;Deerfield Revenue Sharing Agreement&#8221;). The Company is also party to a revenue sharing agreement with its scientific founder pursuant to which the Company was obligated to pay the scientific founder </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3a31252-6a90-4dc5-bff4-b9f0f199bae6" contextRef="C_d47345ec-2ef1-4025-9501-8c6905454377" name="nuvl:PercentageOfNetSalesPayable" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales of certain commercial products (the &#8220;Scientific Founder Revenue Sharing Agreement&#8221; and together with the Deerfield Revenue Sharing Agreement, the &#8220;Revenue Sharing Agreements&#8221;). In December 2025, the scientific founder assigned the Scientific Founder Revenue Sharing Agreement to Royalty Pharma plc (&#8220;Royalty Pharma&#8221;) and, as a result, any payments the Company is obligated to make under the Scientific Founder Revenue Sharing Agreement will be made to Royalty Pharma.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Revenue Sharing Agreements, the payment obligation in respect of such products expires on the later of 12 years from the first commercial sale in a country or the expiration of the last-to-expire patent in that country. The Company accounts for the liability with Deerfield at fair value with changes recognized in the consolidated statements of operations and comprehensive loss (see Note 4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The Company accounts for the obligation to Royalty Pharma as a contingent liability and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a76e12e-3ec5-4aee-9229-a05a8ae83f58" contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad" name="us-gaap:LossContingencyAccrualAtCarryingValue" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_aa77e5b2-ca8b-461b-b6da-2c9cf8796d1d" contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa" name="us-gaap:LossContingencyAccrualAtCarryingValue" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t accrued any liability as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 or 2024. The Company has not recorded any net sales and, as a result, has not paid any amounts under the Revenue Sharing Agreements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, CROs, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_0684b5f8-9a18-4a90-8330-bfbd40325c3d" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" continuedAt="F_0684b5f8-9a18-4a90-8330-bfbd40325c3d_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Segment Information</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is a clinical-stage biopharmaceutical company and has not generated any revenue since commencing significant operations in 2018. The Company&#8217;s operations are organized and reported as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c4290d8-9055-493a-a458-ffa510ef149c" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which includes all activities related to the discovery, development, and commercialization of precisely targeted therapies for patients with cancer. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e06cdd7-6632-4a1e-b4e6-1817f32bdb47" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This presentation is consistent with how the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d7650aa4-5b78-4427-b72b-9d9f6eb1e03c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, assesses the performance of the Company and makes operating decisions on a consolidated basis. The accounting policies of the consolidated segment are the same as those described in the summary of significant accounting policies (see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The CODM assesses performance and decides how to allocate resources based on consolidated net loss as reported on the consolidated statements of operations and comprehensive loss. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c878b86a-9508-4bbd-ac26-41dc1d148b19;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM uses consolidated net loss to monitor budget versus actual results, assess cash runway, and benchmark against the Company&#8217;s competitors.</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The measure of segment assets is reported on the consolidated balance sheets as total assets. The Company&#8217;s assets are held in the United States.</span></ix:nonNumeric></span></p><div><ix:nonNumeric id="F_c0323470-1add-4bcc-b9af-62538ff52465" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" continuedAt="F_c0323470-1add-4bcc-b9af-62538ff52465_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the Company&#8217;s segment information (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.36%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.020000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.020000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.6%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct external expenses by program:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Zidesamtinib</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d60fc2ef-be1d-4fe7-80be-a6543d2c25ec" contextRef="C_9e99d067-33f9-44b7-ad37-2b11d6b976ab" name="nuvl:DirectExpensesRelatedToProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,519</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_011ee3b7-ff1c-40a2-bf81-669701f9aa29" contextRef="C_3eba6714-0731-48ae-b4f4-7f4ce2c35d2b" name="nuvl:DirectExpensesRelatedToProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,110</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a919322-8022-44b6-84c2-8f25fbffde22" contextRef="C_b91245ac-3eac-4609-a0fd-52cfb27df07b" name="nuvl:DirectExpensesRelatedToProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,878</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Neladalkib</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31042129-ad78-4792-bff8-f0af866261fb" contextRef="C_116dea71-ba5e-4119-8d49-e7ee6561f1e6" name="nuvl:DirectExpensesRelatedToProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,446</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6fec522-46a9-4e13-9fae-c79e3c5a90f4" contextRef="C_0750e3c9-8640-41ad-9503-347848c2d04a" name="nuvl:DirectExpensesRelatedToProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,778</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_331dd354-a19d-443a-832e-41e1cfb76ccf" contextRef="C_93b7517e-8570-4d83-b09d-74c6833d8f47" name="nuvl:DirectExpensesRelatedToProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,894</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NVL-330</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08146d94-0911-44b0-a2aa-3d498e85c077" contextRef="C_6094352e-f262-4238-af9a-9fad395992a8" name="nuvl:DirectExpensesRelatedToProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,819</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d38a60e3-3316-432d-b2fc-0d56ed4c88a7" contextRef="C_246b0188-59cf-48e1-84da-c53c20eff235" name="nuvl:DirectExpensesRelatedToProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,293</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_094cd678-2d67-43a3-82d4-36979cb21cc5" contextRef="C_21c5a8f9-d69c-4f2f-9b56-7302217a3a00" name="nuvl:DirectExpensesRelatedToProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,634</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discovery programs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d142bd4c-f97d-4d9e-90b4-1b18df754342" contextRef="C_13717a87-7c59-4d14-9edc-e3677683fc0b" name="nuvl:DirectExpensesRelatedToProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,875</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb01da37-1987-474a-b8a1-d2b6dd0bd79b" contextRef="C_ee20e1d0-82c0-4f31-a59e-df781ca5bef7" name="nuvl:DirectExpensesRelatedToProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,178</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d61cc4cd-0927-4ec6-8f01-a89a90f9f45c" contextRef="C_a88ce5aa-19e3-4d4f-ad4b-227efe228c24" name="nuvl:DirectExpensesRelatedToProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,586</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40124466-5ddd-4e36-8709-ba7117ec6d71" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:LaborAndRelatedExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,163</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7513ec7-a618-44a9-b57e-21d4e9769df8" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:LaborAndRelatedExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,121</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69015115-2c4a-4a27-ad77-a528c2c769f7" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:LaborAndRelatedExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,225</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85bcbf95-55be-41dd-9149-0ba315f9ba6f" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,502</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f798b4f-fd53-492c-83c1-9c81b5d64ade" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,579</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_617e3096-6193-4fc2-9a29-87e7fe2f0079" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,563</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative professional and consultant fees</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26fd97fc-19df-49d2-ac01-3f28b13118e6" contextRef="C_0ed9a5c8-bc77-4159-80cc-631b58767dd4" name="us-gaap:ProfessionalFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,033</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d328e1f-416c-47e0-9456-660a2be30585" contextRef="C_1c1aeab6-5cb0-40f4-a1b3-94770256e0b4" name="us-gaap:ProfessionalFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,854</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9f0d6f6-f047-4838-976b-ced0ddcaa32a" contextRef="C_1cd91e04-8d02-4ef7-b3c0-68167cbe59fc" name="us-gaap:ProfessionalFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,423</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of related party revenue share liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d332cbe2-c3c6-4046-8db5-f23b69b757bd" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,220</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3e4287c-73e9-4f61-b84a-d18e75232197" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17,940</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a390e94b-a87e-4e9d-872a-3d28be6af82d" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4058e24e-cab6-4039-bb53-349182c185d9" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,794</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff27a853-01df-4f1b-bb08-3ee618c53e08" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,372</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88be9365-586c-443a-a3ee-88ac92d28cb4" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,277</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99d37f8b-f9bc-44f2-8755-46a77d453983" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,009</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ea2888c-43cb-4789-b097-84b1ddb9f65a" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,511</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_534a07f3-eb73-4e0f-a151-8b1ec63eab1e" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,293</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax provision</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11c45c09-c88c-43e8-8cb5-3a981467782b" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">585</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25c4dc10-2009-4598-a093-e5dd0c953acf" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">764</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5328c4e2-a662-4a26-abef-bfc89096d456" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consolidated net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43700a42-cde9-4db2-bb3d-f72ca2c8727a" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">425,377</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e671d86-b279-46fa-bac7-59d8de8695b7" contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">260,756</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e88590d-33b6-4260-bba0-e6786f55a3e9" contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">126,219</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_0684b5f8-9a18-4a90-8330-bfbd40325c3d_1"><div style="font-size:6.7pt;font-family:Times New Roman;"><ix:continuation id="F_c0323470-1add-4bcc-b9af-62538ff52465_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><ix:footnote id="FNT_2c80a555-b7c4-4850-83cf-ca017df36dc6" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items included in consolidated net loss include expenses for commercialization preparation activities, research and development consulting services, information technology, insurance, employee recruitment and other miscellaneous activities.</span></ix:footnote></p></ix:continuation></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_disagreements_with_acct"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Controls and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our President and Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial and accounting officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2025. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the evaluation of our disclosure controls and procedures as of December 31, 2025, our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in &#8220;Internal Control-Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management concluded that, as of December 31, 2025, our internal control over financial reporting was effective.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our independent registered public accounting firm, KPMG LLP, which audited the consolidated financial statements included in this Annual Report, has issued an attestation report on our internal control over financial reporting, which is included herein.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended December 31, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director and Officer Trading Arrangements</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d89a0294-18db-4a12-8ab8-cd078a493431" contextRef="C_1dad83de-cc46-4271-b61b-c56d9259a2a0" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table describes for the quarterly period ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a Rule 10b5-1 trading arrangement) or (2) a &#8220;non-Rule 10b5-1 trading arrangement&#8221; (as defined in Item 408(c) of Regulation S-K):</span></p>
     <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
      <tr style="visibility:collapse;">
       <td style="width:13%;box-sizing:content-box;"/>
       <td style="width:14.42%;box-sizing:content-box;"/>
       <td style="width:22%;box-sizing:content-box;"/>
       <td style="width:12%;box-sizing:content-box;"/>
       <td style="width:26%;box-sizing:content-box;"/>
       <td style="width:12.58%;box-sizing:content-box;"/>
      </tr>
      <tr style="height:8pt;background-color:#f2f2f2;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name (Title)</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action Taken <br/>(Date of Action)</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Type of Trading Arrangement</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nature of Trading <br/>Arrangement</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Duration of Trading <br/>Arrangement</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Number <br/>of Securities</span></p></td>
      </tr>
      <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_aca48628-ecce-49d4-90aa-924840ee78ff" contextRef="C_e04f47c1-ee6d-40d2-ad63-924abbcdd776" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alexandra Balcom</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><ix:nonNumeric id="F_580ae24b-6786-4deb-af8e-34085f2eaccc" contextRef="C_e04f47c1-ee6d-40d2-ad63-924abbcdd776" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_49eb2a05-328a-4266-a4c7-46fcc126318f" contextRef="C_e04f47c1-ee6d-40d2-ad63-924abbcdd776" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><ix:nonNumeric id="F_11799ffd-2fd4-4759-9a27-a85c33b05036" contextRef="C_e04f47c1-ee6d-40d2-ad63-924abbcdd776" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">December 23, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Until </span><span style="font-size:9pt;"><ix:nonNumeric id="F_77ef289b-469d-419b-a5c7-d2dfdb386b3d" contextRef="C_e04f47c1-ee6d-40d2-ad63-924abbcdd776" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 11, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">, or such earlier date upon which all transactions are completed or expire without execution</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Up to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_430cff61-62c6-40cd-b0ae-6cb5b4d199ff" contextRef="C_afdd3fb0-ef69-40ad-bdc6-6e7c62bedfaf" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">128,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares of Class A common stock</span></p></td>
      </tr>
      <tr style="height:9pt;background-color:#f2f2f2;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_ffef0de4-6418-4dfe-b9d5-230d4266199c" contextRef="C_c5190b6e-fe0c-4289-8dbf-a33c66c7be66" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Henry Pelish</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><ix:nonNumeric id="F_5a15f78b-3779-446b-9c60-c3404679bf78" contextRef="C_c5190b6e-fe0c-4289-8dbf-a33c66c7be66" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Scientific Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_10d3f965-aae5-47a0-aabd-7de4cb129ca8" contextRef="C_c5190b6e-fe0c-4289-8dbf-a33c66c7be66" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><ix:nonNumeric id="F_2120a01a-e8c2-462d-988f-ab75922b251e" contextRef="C_c5190b6e-fe0c-4289-8dbf-a33c66c7be66" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">December 11, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Until </span><span style="font-size:9pt;"><ix:nonNumeric id="F_81bc2c0e-e59d-426d-9348-5cec4a1aa009" contextRef="C_c5190b6e-fe0c-4289-8dbf-a33c66c7be66" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 30, 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">, or such earlier date upon which all transactions are completed or expire without execution</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Up to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37c7c21a-8bb5-4bba-9e01-936c0cfbf7ff" contextRef="C_4fff95ac-8ff6-451a-8631-2a1193c942a6" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">116,306</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares of Class A common stock</span></p></td>
      </tr>
      <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0f229b54-99c3-485b-9bbe-aac2fc5477b4" contextRef="C_47a42871-276f-471d-89af-7b2d8728791f" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James Porter</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><ix:nonNumeric id="F_7809f62d-8ac2-421c-b100-935c82447600" contextRef="C_47a42871-276f-471d-89af-7b2d8728791f" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e1891381-c091-417c-88f0-f7aaa703ee43" contextRef="C_47a42871-276f-471d-89af-7b2d8728791f" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><ix:nonNumeric id="F_518ac040-bde4-4e8d-a650-5afa62411199" contextRef="C_47a42871-276f-471d-89af-7b2d8728791f" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">December 4, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Until </span><span style="font-size:9pt;"><ix:nonNumeric id="F_99d2ff3c-37ae-420c-b9ae-ffdd4c91eba6" contextRef="C_47a42871-276f-471d-89af-7b2d8728791f" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 10, 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">, or such earlier date upon which all transactions are completed or expire without execution</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Up to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_892627f0-3cd3-497b-bae4-d3dbd6af7f42" contextRef="C_72818106-430d-4e9d-ac04-dff4e3f376f2" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">390,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares of Class A common stock</span></p></td>
      </tr>
      <tr style="height:9pt;background-color:#f2f2f2;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_3ea89e93-ee76-4b81-80fc-53416cd7e1b5" contextRef="C_4c059091-923a-455f-b4b2-a218c67cdf6b" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Anna Protopapas</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><ix:nonNumeric id="F_97e69462-4621-4276-acc6-ddfbbdce4b42" contextRef="C_4c059091-923a-455f-b4b2-a218c67cdf6b" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_b67065c1-d6cb-4c7a-b69f-95fbf9af4201" contextRef="C_4c059091-923a-455f-b4b2-a218c67cdf6b" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><ix:nonNumeric id="F_fe38609c-e7ef-4e4d-8a47-694ca94e632f" contextRef="C_4c059091-923a-455f-b4b2-a218c67cdf6b" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">December 7, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Until </span><span style="font-size:9pt;"><ix:nonNumeric id="F_5393bce6-eef1-4c10-836c-e8713d4c82dd" contextRef="C_4c059091-923a-455f-b4b2-a218c67cdf6b" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 31, 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">, or such earlier date upon which all transactions are completed or expire without execution</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Up to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de9eb739-a266-445a-adda-75781adde251" contextRef="C_7113a74e-6c90-4126-9b38-7b6f500f4532" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares of Class A common stock</span></p></td>
      </tr>
     </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9c"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART III</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_officers"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Officers and Corporate Governance</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information concerning our executive officers is set forth under the heading &#8220;Information about our Executive Officers&#8221; in Item 1 of this Annual Report on Form 10-K. The remaining information required by this Item 10 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_exec_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executive Compensation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders, which, for the avoidance of doubt, does not include the information required by Item 402(v) of Regulation S-K, and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related Transactions, and Director Independence</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accountant_fees"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accountant Fees and Services.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART IV</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits and Financial Statement Schedules.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements, financial statement schedules, and exhibits filed as part of this Annual Report are as follows:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">1. Financial Statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See &#8220;Index to Consolidated Financial Statements&#8221; beginning on page </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this Annual Report.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2. Financial Statement Schedules</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">3. Exhibits</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report are listed in the Exhibit Index immediately preceding the signature page of this Annual Report. The exhibits listed in the Exhibit Index are incorporated by reference herein.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. Form </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">0-K Summary.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="exhibit_index"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit Index.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:7.44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:44.06%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.38%;box-sizing:content-box;"/>
     <td style="width:1.12%;box-sizing:content-box;"/>
     <td style="width:10.2%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:7.14%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:9.18%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:9.42%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed Herewith</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000095017023028601/nuvl-ex3_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Amended and Restated Certificate of Incorporation of the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40671</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/16/2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000095017023008284/nuvl-ex3_2.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws of the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40671</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/16/2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312521209001/d174530dex41.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Class A Common Stock Certificate</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-257730</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/7/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312521209001/d174530dex42.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Class B Common Stock Certificate</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-257730</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/7/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312521209001/d174530dex43.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Investors&#8217; Rights Agreement among the Registrant and certain of its stockholders, effective as of April 30, 2021</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-257730</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/7/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312522087401/d319667dex44.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities Registered Under Section 12 of the Exchange Act</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40671</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/29/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312521223640/d174530dex102.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2021 Stock Option and Incentive Plan and forms of award agreements thereunder</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-257730</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/26/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000095017024020607/nuvl-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Revised Form of Restricted Stock Unit Award Agreement under 2021 Stock Option and Incentive Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40671</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/27/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312524272853/d756615dex991.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Unit Award Agreement (Performance-Vesting) under 2021 Stock Option and Incentive Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40671</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/9/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312522216780/d295365dex101.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated 2021 Employee Stock Purchase Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40671</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/10/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312521209001/d174530dex104.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its directors</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-257730</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/7/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312521209001/d174530dex105.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its executive officers</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-257730</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/7/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312521209001/d174530dex106.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Senior Executive Cash Incentive Bonus Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-257730</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/7/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8#</span><span style="color:#000000;white-space:pre-wrap;font-family:'Myriad Pro',sans-serif;font-kerning:none;min-width:fit-content;">&#945;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000095017024124518/nuvl-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Executive Employment Agreement, as amended</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40671</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/12/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000095017024056232/nuvl-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Non-Employee Director Compensation Policy</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40671</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/9/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312521209001/d174530dex109.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, by and between the Registrant and James R. Porter, effective August 2, 2021</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-257730</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/7/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000095017024124518/nuvl-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Employment Agreement by and between the Registrant and James R. Porter, dated as of November 5, 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40671</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/12/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312521209001/d174530dex1011.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Revenue Sharing Agreement, by and between the Registrant and Matthew Shair, effective as of February 2, 2017</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-257730</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/7/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312521209001/d174530dex1012.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Revenue Sharing Agreement, by and between the Registrant, Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund, IV, L.P., effective as of February 2, 2017</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-257730</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/7/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312522216866/d280159dex12.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sales Agreement, by and between the Registrant and Cowen and Company, LLC, effective as of August 10, 2022</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-266731</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/10/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312522275066/d411684dex12.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to the Sales Agreement with Cowen and Company, LLC, effective as of October 31, 2022</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40671</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/1/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:7.44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:44.06%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.38%;box-sizing:content-box;"/>
     <td style="width:1.12%;box-sizing:content-box;"/>
     <td style="width:10.2%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:7.14%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:9.18%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:9.42%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed Herewith</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="nuvl-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated</span><span><ix:nonNumeric id="F_d7d34bef-706f-43a0-9abe-715e28760e4e" contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> Insider Trading Policy</span></ix:nonNumeric></span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000119312522087401/d319667dex211.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Subsidiaries of the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40671</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/29/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="nuvl-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of KPMG LLP, independent registered public accounting firm</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="nuvl-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="nuvl-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="nuvl-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="nuvl-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000095017024020607/nuvl-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Nuvalent Inc. Dodd-Frank Compensation Recovery Policy</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40671</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/27/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:5%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:94%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Indicates a management contract or any compensatory plan, contract or arrangement.</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#945;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nuvalent, Inc. has entered into an Executive Employment Agreement, as amended, with each of Alexandra Balcom, Deborah Miller, Darlene Noci, Henry E. Pelish and Christopher D. Turner.</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Portions of this exhibit (indicated by asterisks) have been omitted in accordance with Item 601(b)(10) of Regulation S-K.</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to be furnished with this Annual Report on Form 10-K and will not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TURES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:48.154%;box-sizing:content-box;"/>
     <td style="width:1.003%;box-sizing:content-box;"/>
     <td style="width:1.003%;box-sizing:content-box;"/>
     <td style="width:3.03%;box-sizing:content-box;"/>
     <td style="width:46.81%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">NUVALENT, INC.</span></p></td>
    </tr>
    <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 26, 2026</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ James R. Porter</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">James R. Porter, Ph.D.</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="sig"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:34.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:44.14%;box-sizing:content-box;"/>
     <td style="width:1.26%;box-sizing:content-box;"/>
     <td style="width:18.76%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ James R. Porter</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James R. Porter, Ph.D.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alexandra Balcom</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alexandra Balcom</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Grant Bogle</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Grant Bogle</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael L. Meyers</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael L. Meyers, M.D., Ph.D.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Christy Oliger</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Christy Oliger</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Joseph Pearlberg</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Joseph Pearlberg, M.D., Ph.D.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Anna Protopapas</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Anna Protopapas</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Ron Squarer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ron Squarer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Sapna Srivastava</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sapna Srivastava, Ph.D.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Cameron A. Wheeler</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cameron A. Wheeler, Ph.D.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>2
<FILENAME>nuvl-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-02-25T15:36:20.4853+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVALENT, INC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMENDED AND RESTATED INSIDER TRADING POLICY</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This memorandum sets forth the policy of Nuvalent, Inc. (the &#x201c;Company&#x201d;) regarding trading in the Company&#x2019;s securities as described below and the disclosure of information concerning the Company. This Amended and Restated Insider Trading Policy (as amended and restated, the &#x201c;Insider Trading Policy&#x201d;) is designed to prevent insider trading or the appearance of impropriety, to satisfy the Company&#x2019;s obligations to reasonably supervise the activities of Company personnel and to publicly disclose information related to the Company&#x2019;s insider trading policies and practices and the use of certain trading arrangements by certain Insiders (as defined below), and to help Company personnel avoid the severe consequences associated with violations of insider trading laws. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is your obligation to understand and comply with this Insider Trading Policy.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I. OVERVIEW</font></p><p style="text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A. 		To Whom does this Insider Trading Policy Apply?</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy is applicable to the Company&#x2019;s directors, officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the &#x201c;Exchange Act&#x201d;)),</font><font style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employees and designated consultants (collectively, and solely for the purposes of this Insider Trading Policy, these persons are referred to as &#x201c;Insiders&#x201d;) and applies to any and all transactions by such persons and their Affiliated Persons (as defined below) in the Company&#x2019;s securities, including its common stock, options to purchase common stock, any other type of securities that the Company may issue (such as preferred stock, convertible debentures, warrants, exchange-traded options or other derivative securities), and any derivative securities that provide the economic equivalent of ownership of any of the Company&#x2019;s securities or an opportunity, direct or indirect, to profit from any change in the value of the Company&#x2019;s securities.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All Insiders must comply with the trading prohibitions set forth in Part I, Section B of this Insider Trading Policy (the &#x201c;Trading Prohibitions&#x201d;). In addition, all Insiders must comply with the Trading Procedures set forth in Part II of this Insider Trading Policy (the &#x201c;Trading Procedures&#x201d;) to the extent the Trading Procedures are applicable to them. Among other things, the Trading Procedures establish trading windows outside of which certain Insiders will be restricted from trading in the Company&#x2019;s securities and also require pre-clearance and post-transaction notification by certain Insiders with respect to transactions in the Company&#x2019;s securities.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy, including, if applicable, the Trading Procedures, also applies to the following persons (collectively, these persons and entities are referred to as &#x201c;Affiliated Persons&#x201d;):</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any spouse, child, parent, significant other or other family member of an Insider, in each case, living in the same household as the Insider and any other person who shares the same address as the Insider (other than (a) an employee or tenant of the Insider or (b) another unrelated person whom the Compliance Officer (as defined below), or the Chief Executive Officer in the case of the Compliance Officer, determines should not be covered by this Insider Trading Policy);</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all investment funds, trusts, retirement plans, partnerships, corporations and other types of entities over which an Insider or such Insider&#x2019;s Affiliated Persons have the ability to influence or direct investment decisions concerning securities; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that this Insider Trading Policy</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall not apply to any such entity that has established its own insider trading controls and procedures in compliance with applicable securities laws designed to ensure that such Insider and such Insider&#x2019;s Affiliated Persons cannot influence transactions by the entity involving the Company&#x2019;s securities.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, nothing in this Insider Trading Policy is intended to limit the ability of a venture capital partnership or other similar entity with which a director is affiliated to distribute Company securities to its partners, members or other similar persons. It is the responsibility of each affected director and the affiliated entity, in consultation with their own counsel (as appropriate), to determine the timing of any distributions, based on all relevant facts and circumstances and applicable securities laws. In addition, nothing in this Insider Trading Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is intended to limit the ability of any Insider to sell Company securities as a selling stockholder in an underwritten public offering pursuant to an effective registration statement in accordance with applicable securities law.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You are responsible for ensuring compliance with this Insider Trading Policy, including, if applicable, the Trading Procedures, by all of your Affiliated Persons.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that you leave the Company for any reason at a time when you or your Affiliated Persons are aware of material, nonpublic information concerning the Company, the Trading Prohibitions</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will continue to apply to you and your Affiliated Persons until the first trading day after any material, nonpublic information known to you has become public or is no longer material.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While this Insider Trading Policy does not apply to transactions by the Company itself, transactions by the Company will only be made in accordance with applicable U.S. federal securities laws, including those related to insider trading.</font></p><p style="text-indent:-2.599%;padding-left:2.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B. 		What is Prohibited by this Insider Trading Policy?</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is generally illegal for you to trade in the securities of the Company, whether for your account or for the account of another, while in the possession of material, nonpublic information about the Company. It is also generally illegal for you to disclose material, nonpublic information about the Company to others who may trade on the basis of that information. These illegal activities are commonly referred to as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">insider trading</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as otherwise provided in Part III of this Insider Trading Policy, when you know or are in possession of material, nonpublic information about the Company, whether positive or negative, you are prohibited from the following activities:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchasing, selling or gifting (whether for your account or for the account of another) the Company&#x2019;s securities, which includes common stock, options to purchase common stock, any other type of securities that the Company may issue (such as preferred stock, convertible debentures, warrants, exchange-traded options or other derivative securities), and any derivative securities that provide the economic equivalent of ownership of any of the Company&#x2019;s securities or an opportunity, direct or indirect, to profit from any change in the value of the Company&#x2019;s securities; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">giving trading advice of any kind about the Company; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disclosing the material, nonpublic information about the Company, whether positive or negative, to anyone else who might then trade, or recommending to anyone that they purchase or sell the Company&#x2019;s securities when you are aware of material, nonpublic information (these practices are commonly known as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">tipping</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, you may not:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchase, sell or gift any securities of another company while you are aware of any material, nonpublic information concerning such other company that you learned in the course of your service as a director, officer, employee or consultant of the Company or recommend to another person that they do so; or</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tip or otherwise disclose to any other person any material, nonpublic information concerning another company that you learned in the course of your service as a director, officer, employee or consultant of the Company.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These prohibitions continue whenever and for as long as you know or are in possession of material, nonpublic information. Remember, anyone scrutinizing your transactions will be doing so after the fact, with the benefit of hindsight.  As a practical matter, before engaging in any transaction, you should carefully consider how enforcement authorities and others might view the transaction in hindsight.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">C. 		What is Material, Nonpublic Information?</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy prohibits you from trading in the Company&#x2019;s securities if you are in possession of information about the Company that is both &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">material</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">nonpublic</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; If you have a question whether certain information you are aware of is material or has been made public, you are encouraged to consult with the Chief Legal Officer of the Company (or his or her designee, the &#x201c;Compliance Officer&#x201d;).</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Material&#x201d; Information</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about the Company is &#x201c;material&#x201d; if it could reasonably be expected to affect the investment or voting decisions of a stockholder or investor, or if the disclosure of the information could reasonably be expected to significantly alter the total mix of information in the marketplace about the Company. In simple terms, material information is any type of information that could reasonably be expected to affect the market price of the Company&#x2019;s securities. Both positive and negative information may be material. While it is not possible to identify all information that would be deemed &#x201c;material,&#x201d; the following items are types of information that should be considered carefully to determine whether they are material:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments regarding any programs in preclinical or clinical development, including recent regulatory interaction and/or data that have been recently generated from ongoing or recently completed preclinical or clinical trials; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments regarding the intellectual property and/or freedom to operate for any of the current programs or product candidates under development; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">projections of future earnings or losses, or other earnings guidance; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">earnings or revenue that are inconsistent with the consensus expectations of the investment community; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential restatements of the Company&#x2019;s financial statements, changes in auditors or auditor notification that the Company may no longer rely on an auditor&#x2019;s audit report;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pending or proposed corporate mergers, acquisitions, tender offers, joint ventures or dispositions of significant assets; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in management or the Board of Directors; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant actual or threatened litigation or governmental investigations or major developments in such matters; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a cybersecurity incident; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant developments regarding products, customers, suppliers, orders, contracts or financing sources (e.g., the acquisition or loss of a contract); </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in dividend policy, declarations of stock splits, or public or private sales of additional securities; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential defaults under the Company&#x2019;s credit agreements or indentures, or the existence of material liquidity deficiencies; and </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bankruptcies or receiverships. </font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By including the list above, the Company does not mean to imply that each of these items above is </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">per</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">se</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> material. The information and events on this list still require determinations as to their materiality (although some determinations will be reached more easily than others). For example, some new products or contracts may clearly be material to an issuer; yet that does not mean that all product developments or contracts will be material. This demonstrates, in our view, why no &#x201c;bright-line&#x201d; standard or list of items can adequately address the range of situations that may arise. Furthermore, the Company cannot create an exclusive list of events and information that have a higher probability of being considered material.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Securities and Exchange Commission (the &#x201c;SEC&#x201d;) has stated that there is no fixed quantitative threshold amount for determining materiality, and that even very small quantitative changes can be qualitatively material if they would result in a movement in the price of the Company&#x2019;s securities.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Nonpublic&#x201d; Information</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material information is &#x201c;nonpublic&#x201d; if it has not been disseminated in a manner making it available to investors generally. To show that information is public, it is necessary to point to some fact that establishes that the information has become publicly available, such as the filing of a report with the SEC, the distribution of a press release through a widely disseminated news or wire service, or by other means that are reasonably designed to provide broad public access. Before a person who possesses material, nonpublic information can trade, there also must be adequate time for the market as a whole to absorb the information that has been disclosed. For the purposes of this Insider Trading Policy, information will be considered public after the close of trading on the first full trading day following the Company&#x2019;s public release of the information.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, if the Company announces material, nonpublic information of which you are aware before trading begins on a Tuesday, the first time you can buy or sell Company securities is the opening of the market on Wednesday. However, if the Company announces this material information after trading begins on that Tuesday, the first time that you can buy or sell Company securities is the opening of the market on Thursday.</font></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">D. 		What are the Penalties for Insider Trading and Noncompliance with this Insider Trading Policy?</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both the SEC and the national securities exchanges, through the Financial Industry Regulatory Authority (FINRA), investigate and are very effective at detecting insider trading. The SEC, together with the U.S. Attorneys, pursue insider trading violations vigorously. For instance, cases have been successfully prosecuted against trading by employees in foreign accounts, trading by family members and friends, and trading involving only a small number of shares.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The penalties for violating insider trading or tipping rules can be severe and include:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disgorgement of the profit gained or loss avoided by the trading; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of the loss suffered by the persons who, contemporaneously with the purchase or sale of securities that are subject of such violation, have purchased or sold, as applicable, securities of the same class; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of criminal penalties;  </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of civil penalties;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">being barred from service as an officer or director of a public company; and </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imprisonment. </font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company and/or the supervisors of the person engaged in insider trading may also be required to pay civil penalties and criminal penalties, and could under certain circumstances be subject to private lawsuits.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Violation of this Insider Trading Policy or any federal or state insider trading laws may subject the person violating such policy or laws to disciplinary action by the Company up to and including termination. The Company reserves the right to determine, in its own discretion and on the basis of the information available to it, whether this Insider Trading Policy has been violated. The Company may determine that specific conduct violates this Insider Trading Policy, whether or not the conduct also violates the law. It is not necessary for the Company to await the filing or conclusion of a civil or criminal action against the alleged violator before taking disciplinary action.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">E. 		How Do You Report a Violation of this Insider Trading Policy?</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you have a question about this Insider Trading Policy, including whether certain information you are aware of is material or has been made public, you are encouraged to consult with the Compliance Officer. In addition, if you violate this Insider Trading Policy or any federal or state laws governing insider trading, or know of any such violation by any Insider, you should report the violation immediately to the Compliance Officer. However, if the conduct in question involves the Compliance Officer, or if you have reported such conduct to the Compliance Officer and you do not believe the Compliance Officer has dealt with it properly, or if you do not feel that you can discuss the matter with the Compliance Officer, you may raise the matter with the Chief Executive Officer.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II. TRADING PROCEDURES</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A. 		Special Trading Restrictions</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the Trading Prohibitions set forth above, Insiders and their Affiliated Persons are subject to the following special trading restrictions, except as otherwise provided in Part III of this Insider Trading Policy:</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Trading During Regular Blackout Windows.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Company director, no officer (as defined in Rule 16a-1(f) under the Exchange Act), no member of the Company&#x2019;s Leadership Team, no other Insider as may be designated from time to time by the Board of Directors or the Compliance Officer (collectively, the &#x201c;Further Restricted Insiders&#x201d;) and no Affiliated Person of a Further Restricted Insider may purchase, sell or gift Company securities during the period beginning on the first calendar day following the completion of the Company&#x2019;s fiscal quarter and ending upon completion of the first full trading day after the Company&#x2019;s public announcement of earnings for such quarter (a &#x201c;Regular Blackout Window&#x201d;). </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Trading During Special Blackout Windows. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> There are times when the Company or certain members of its Board of Directors or senior management or support staff may be aware of a material, nonpublic development. Although an Insider may not know the specifics of such development, if an Insider engages in a purchase, sale or gift before such development is disclosed to the public or resolved, such Insider and the Company might be exposed to a charge of insider trading that could be costly and difficult to refute. In addition, a purchase, sale or gift by an Insider during such a period could result in adverse publicity for the Company. Therefore, Insiders may not purchase, sell or gift Company securities if they are notified by the Compliance Officer that the trading window is closed (a &#x201c;Special Blackout Window&#x201d;). Regular Blackout Windows and Special Blackout Windows are each referred to as &#x201c;Blackout Windows&#x201d; in this Insider Trading Policy. The Compliance Officer will subsequently notify the Insiders once the material, nonpublic development is disclosed to the public or resolved and that, as a result, the trading window is again open.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Short Sales.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  No Insider may at any time sell any securities of the Company that are not owned by such Insider at the time of the sale (a &#x201c;short sale&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Purchases or Sales of Derivative Securities or Hedging Transactions.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  No Insider may buy or sell puts, calls, other derivative securities of the Company or any derivative securities that provide the economic equivalent of ownership of any of the Company&#x2019;s securities or an opportunity, direct or indirect, to profit from any change in the value of the Company&#x2019;s securities or engage in any other hedging transaction with respect to the Company&#x2019;s securities, at any time.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Company Securities Subject to Margin Calls.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  No Insider may use the Company&#x2019;s securities as collateral in a margin account.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Pledges.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  No Insider may pledge Company securities as collateral for a loan (or modify an existing pledge).</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B. 		Pre-Clearance Procedures</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as otherwise provided in Part III of this Insider Trading Policy, no Further Restricted Insider</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may purchase, sell, gift, transfer, or otherwise acquire or dispose of Company securities, either directly or indirectly,</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unless the transaction has been approved by the Compliance Officer in accordance with the procedures set forth</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">below. The Compliance Officer will review and either approve or prohibit all such proposed transactions by Further Restricted Insiders in accordance with the procedures set forth below. The Compliance Officer may consult with the Company&#x2019;s other officers and/or outside legal counsel and will receive approval for his or her own such transactions from the Chief Executive Officer.</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Procedures. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Further Restricted Insider may engage in transactions subject to this Part II, Section B until:</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Further Restricted Insider has notified the Compliance Officer (or the Chief Executive Officer as applicable) of the amount and nature of the proposed transaction using the Stock Transaction Request form attached to this Insider Trading Policy, or any other form approved by the Company for this purpose, including whether the transaction is proposed to be effected pursuant to a contract, instruction or written plan that is intended either to satisfy the affirmative defense conditions of Rule 10b5-1(c) (for the avoidance of doubt, transactions pursuant to pre-approved Rule 105-1 Plans meeting the conditions specified in Part III, Section A below are not required to be pre-cleared) or to constitute a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K). In order to provide adequate time for the preparation of any required reports under Section 16 of the Exchange Act, a Stock Transaction Request or other applicable form should, if practicable, be received by the Compliance Officer (or the Chief Executive Officer as applicable) at least two (2) business days prior to the intended transaction date;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Further Restricted Insider has certified to the Compliance Officer (or the Chief Executive Officer as applicable) in writing prior to the proposed transaction that the Further Restricted Insider is not in possession of material, nonpublic information concerning the Company;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Further Restricted Insider has informed the Compliance Officer (or the Chief Executive Officer as applicable) using the Stock Transaction Request form attached hereto, or any other form approved by the Company for this purpose, whether, to the Further Restricted Insider&#x2019;s best knowledge, (a) the Further Restricted Insider has (or is deemed to have) engaged in any opposite way transactions within the previous six months that were not exempt from Section 16(b) of the Exchange Act and (b) the transaction involves a sale by an &#x201c;affiliate&#x201d; of the Company or of &#x201c;restricted securities&#x201d; (as such terms are defined under Rule 144 under the Securities Act of 1933, as amended (&#x201c;Rule 144&#x201d;)), and whether the transaction meets all of the applicable conditions of Rule 144; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compliance Officer (or the Chief Executive Officer as applicable) or his or her designee has approved the transaction and has certified such approval in writing. Such certification may be made via digitally-signed electronic mail.</font></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compliance Officer (or the Chief Executive Officer as applicable) does not assume the responsibility for, and approval from the Compliance Officer (or the Chief Executive Officer as applicable) does not protect the Further Restricted Insider from, the consequences of prohibited insider trading.</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Information.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further Restricted Insiders shall provide to the Compliance Officer (or the Chief Executive Officer as applicable) any documentation reasonably requested by him or her in furtherance of the foregoing procedures. Any failure to provide such requested information will be grounds for denial of approval by the Compliance Officer (or the Chief Executive Officer as applicable).</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Obligation to Approve Transactions.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The existence of the foregoing approval procedures does not in any way obligate the Compliance Officer (or the Chief Executive Officer as applicable) to approve any transaction requested by a Further Restricted Insider. The Compliance Officer (or the Chief Executive Officer as applicable) may reject any transaction request at his or her sole discretion.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Completion of Transactions.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After receiving written clearance to engage in a transaction from the Compliance Officer (or the Chief Executive Officer as applicable) or his or her designee, a Further Restricted Insider must complete the proposed transaction within two (2) business days or make a new transaction request. If following receipt of pre-clearance of a transaction and prior to completion of the transaction, a Further Restricted Insider becomes aware of material, nonpublic information or becomes subject to a Blackout Window, the Further Restricted Insider must make a new transaction request and the transaction may not be completed to the extent prohibited under this Insider Trading Policy.</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Transaction Reporting.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The completion of any transactions by a Further Restricted Insider</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to pre-clearance under Part II, Section B, as well as any transactions effected by a Further Restricted Insider pursuant to a Rule 10b5-1 Plan (as defined below),</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">must be reported to the Compliance Officer by completing the &#x201c;Confirmation of Transaction&#x201d; section of the Stock Transaction Request form attached to this Insider Trading Policy, or any other form approved by the Company for this purpose, on the same day in which such a transaction occurs. Each report a Further Restricted Insider makes to the Compliance Officer should include the date of the transaction, quantity of shares, price and broker-dealer through which the transaction was effected and indicate whether the transaction was effected pursuant to a contract, instruction or written plan that is intended either to satisfy the affirmative defense conditions of Rule 10b5-1(c) or to constitute a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K). This reporting requirement may be satisfied by sending (or having such Further Restricted Insider&#x2019;s broker send) duplicate confirmations of trades with all such required information to the Compliance Officer if such information is received by the Compliance Officer on or before the required date. Compliance by directors and officers</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with this provision is imperative given the requirement of Section 16 of the Exchange Act that these persons generally must report changes in ownership of Company securities within two (2) business days. The sanctions for noncompliance with this reporting deadline include mandatory disclosure in the Company&#x2019;s proxy statement for the next annual meeting of stockholders, as well as possible civil or criminal sanctions for chronic or egregious violators.</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deemed Time of a Transaction.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Part II, Section B, a purchase, sale, gift, transfer or other acquisition or disposition shall be deemed to occur at the time the person becomes irrevocably committed to it (for example, in the case of an open market purchase or sale, this occurs when the trade is executed, not when it settles).</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART III. EXEMPTIONS</font></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A. 		Pre-Approved Rule 10b5-1 Plans</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 under the Exchange Act provides an affirmative defense from insider trading liability under the federal securities laws for trading plans and purchase and sale contracts or instructions that meet certain requirements. A binding contract, written plan or specific instruction that satisfies the applicable affirmative defense conditions of Rule 10b5-1(c), including, as applicable, the requirements applicable to an eligible sell-to-cover transaction as defined in Rule 10b5-1(c)(1)(ii)(D)(3), or for which the affirmative defense is available under Rule 10b5-1(c) because such plan was adopted prior to February 27, 2023, met the affirmative defense conditions in effect at the time of adoption, and was not modified or changed on or after February 27, 2023 (a &#x201c;Rule 10b5-1 Plan&#x201d;) enables Insiders to establish arrangements to trade in Company securities outside of the Company&#x2019;s</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading windows, even when in possession of material, nonpublic information.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions effected pursuant to a Rule 10b5-1 Plan will not be subject to the Trading Prohibitions or the Trading Procedures, and Further Restricted Insiders will not be required to complete a Stock Transaction Request form for such transactions, if the Rule 10b5-1 Plan is:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">documented in writing; and</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pre-approved by the Compliance Officer (or the Chief Executive Officer in the case of a Rule 10b5-1 Plan proposed by the Compliance Officer).</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compliance Officer (or the Chief Executive Officer, as applicable) may refuse to approve a Rule 10b5-1 Plan as he or she deems appropriate including, without limitation, if he or she determines that such plan does not satisfy the requirements of Rule 10b5-1. Any modification or termination of an Insider&#x2019;s Rule 10b5-1 Plan (including, without limitation, any change to the amount, price or timing of any purchase or sale thereunder) requires pre-approval by the Compliance Officer (or the Chief Executive Officer, as applicable).</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, any transaction pursuant to a Rule 10b5-1 Plan by a Further Restricted Insider must be timely reported following the transaction in accordance with the post-transaction reporting procedures described in Part II, Section B.5 above.</font></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B. 		Other Transactions</font></p><div class="item-list-element-wrapper" style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.53%;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise of Stock Options or Other Equity Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Trading Prohibitions and the Trading Procedures do not apply to the exercise of an option to purchase securities of the Company or any other equity award of the Company in a manner permitted by the applicable equity award agreement;</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided, however, that the securities so acquired may not be sold (either outright or in connection with a &#x201c;cashless&#x201d; exercise transaction through a broker) while the Insider (together with the Insider&#x2019;s Affiliated Persons) is aware of material, nonpublic information or during an applicable Blackout Window (as defined in Part II, Section A).</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, the exercise of a stock option or other equity award of the Company may be subject to the current reporting requirements of Section 16 of the Exchange Act and, therefore, Further Restricted Insiders must comply with the post-transaction reporting procedures described in Part II, Section B.5 above for any such transaction, notwithstanding the exemption provided above. In addition, the securities acquired upon the exercise of an option to purchase Company securities or other equity award of the Company are subject to all of the requirements of this Insider Trading Policy, including the Trading Prohibitions and the Trading Procedures. Moreover, the</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading Prohibitions and the Trading Procedures shall apply to any sale of stock as part of a broker-assisted cashless exercise of an option or other equity award of the Company, or any other market sale of Company securities for the purpose of generating the cash needed to pay the exercise price of an option or other equity award of the Company.</font></p><div class="item-list-element-wrapper" style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.53%;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tax Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Trading Prohibitions and the Trading Procedures do not apply to the surrender of shares of stock or other equity interests to the Company under any restricted stock award, restricted stock units or other equity award of the Company to satisfy applicable tax withholding requirements in each case in a manner permitted by the applicable equity award agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.53%;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Transactions with the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Trading Prohibitions and the Trading Procedures do not apply to other purchases of securities from the Company (including elections to participate in the Company&#x2019;s employee stock purchase plan (&#x201c;ESPP&#x201d;) and purchases thereunder, provided that the shares to be issued under the ESPP will be issued by the Company out of authorized but unissued shares and will not involve open market purchases) or sales of securities to the Company; provided, however, that if the transaction involves the exercise of stock options or other equity awards or the surrender of shares or other equity interests to the Company to satisfy applicable tax withholding requirements, the transaction must be permitted by Part III, Section B.1 and Part III, Section B.2, respectively.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.53%;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gifts</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Trading Prohibitions and the Trading Procedures do not apply to bona fide gifts that are approved in advance by the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.53%;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Individual Account Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Trading Prohibitions and the Trading Procedures do not apply to acquisitions or dispositions of Company securities under the Company&#x2019;s 401(k) or other individual account plan that are made pursuant to standing instructions, in a form approved by the Company, that are not entered into or modified while the Insider is aware of material, nonpublic information or during an applicable Blackout Window.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART IV. </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous</font></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A. 		Waivers and Amendments</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A waiver of any provision of this Insider Trading Policy</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in a specific instance may be authorized in writing by the Compliance Officer (or the Chief Executive Officer in the case of a waiver with respect to the Compliance Officer), or his or her designee, and any such waiver shall be reported to the Audit Committee of the Board of Directors (the &#x201c;Audit Committee&#x201d;). An amendment of any provision of this Insider Trading Policy must be authorized by the Audit Committee.</font></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B. 		Limitation on Liability</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of the Company, the Compliance Officer, the Chief Executive Officer or the Company&#x2019;s other employees will have any liability for any delay in reviewing, or refusal of, a request for approval of a transaction or a Rule 10b5-1 Plan pursuant to the procedures described above. Notwithstanding any approval of a transaction or a Rule 10b5-1 Plan, none of the Company, the Compliance Officer, the Chief Executive Officer or the Company&#x2019;s other employees assumes any liability for the legality or consequences of such transaction or Rule 10b5-1 Plan to the person engaging in or adopting such transaction or Rule 10b5-1 Plan.</font></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">C. 		Regulation BTR</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company is required to impose a &#x201c;pension fund blackout period&#x201d; under Regulation BTR, each director and officer shall not, directly or indirectly sell, purchase or otherwise transfer during such blackout period any equity securities of the Company acquired in connection with the service of such person as a director or officer of the Company, except as permitted by Regulation BTR.</font></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">D. 		Education</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall take reasonable steps designed to ensure that Insiders are educated about, and periodically reminded of, the federal securities law restrictions and Company policies regarding insider trading.</font></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">E. 		Assistance</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall provide reasonable assistance to all directors and officers, as requested by such directors and officers, in connection with the filing of Forms 3, 4 and 5 under Section 16 of the Exchange Act. However, the ultimate responsibility, and liability, for timely filing remains with the directors and officers.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART V. ACKNOWLEDGEMENT</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy will be delivered to all current Insiders and to all directors, officers, employees and designated consultants at the start of their employment or relationship with the Company. Upon first receiving a copy of this Insider Trading Policy, each individual must acknowledge that he or she has received a copy and agrees to comply with the terms of this Insider Trading Policy, and, if applicable, the Trading Procedures contained herein. The acknowledgment attached hereto must be returned within ten (10) days of receipt to:</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deborah Miller</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Legal Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvalent, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One Broadway, 14</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Floor</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cambridge, MA 02142</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This acknowledgment will constitute consent for the Company to impose sanctions for violation of the Insider Trading Policy and to issue any necessary stop-transfer orders to the Company&#x2019;s transfer agent to ensure compliance.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All Insiders will be required upon the Company&#x2019;s request to re-acknowledge and agree to comply with the Insider Trading Policy (including any amendments or modifications). For such purpose, an individual will be deemed to have acknowledged and agreed to comply with the Insider Trading Policy, as amended from time to time, when copies of such items have been delivered by regular or electronic mail (or other delivery option used by the Company) by the Compliance Officer or his or her designee.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*	*	*</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Questions regarding this Insider Trading Policy are encouraged and may be directed to the Compliance Officer.</font></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Amended and Restated Insider Trading Policy is being adopted on September 30, 2025.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT A</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCK TRANSACTION REQUEST</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvalent, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2019;s Amended and Restated Insider Trading Policy, I hereby notify </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvalent, Inc. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the &#x201c;Company&#x201d;) of my intent to purchase, sell, gift, transfer, or otherwise acquire or dispose of Company securities, either directly or indirectly, as indicated below:</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:26%;box-sizing:content-box;"></td>
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:64.8%;box-sizing:content-box;"></td>
     <td style="width:6.2%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="4" style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">REQUESTER INFORMATION</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Further Restricted Insider's Name:</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">INTENT TO PURCHASE</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of shares:</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intended trade</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">date:</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Means of</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">acquiring shares</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition through employee benefit plan (please specify):</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase through a broker on the open market</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (please specify): ____________________________________________________________</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">INTENT TO SELL</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of shares:</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intended trade</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">date:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Means of selling</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale through employee benefit plan (please specify):</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">shares:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale through a broker on the open market</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (please specify): ____________________________________________________________</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="4" style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">INTENT TO GIFT OR OTHERWISE TRANSFER</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of shares:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intended gift/transaction date:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nature of gift/transaction:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:2.995%;box-sizing:content-box;"></td>
     <td style="width:45.989%;box-sizing:content-box;"></td>
     <td style="width:1.005%;box-sizing:content-box;"></td>
     <td style="width:50.011%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="border-top:0.5pt solid;padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td rowspan="2" style="border-top:0.5pt solid;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SECTION 16</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td rowspan="2" style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">RULE 144 (Not applicable if transaction requested involves a purchase)</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:46%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:47%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="border-top:0.5pt solid;padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">I am not subject to Section 16.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">I am not an &#x201c;affiliate&#x201d; of the Company and the transaction requested above does not involve the sale of &#x201c;restricted securities&#x201d; (as such terms are defined under Rule 144 under the Securities Act of 1933, as amended).</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">To the best of my knowledge, I have not (and am not deemed to have) engaged in an opposite way transaction within the previous 6 months that was not exempt from Section 16(b) of the Exchange Act.</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">To the best of my knowledge, the transaction requested above will meet all of the applicable conditions of Rule 144.</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None of the above.</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The transaction requested is being made pursuant to an effective registration statement covering such transaction.</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None of the above.</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="5" style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Rule 10B5-1 Plan OR non-Rule 10b5-1 trading arrangement</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td colspan="4" style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">This transaction will be made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
     <td colspan="4" style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">This transaction will be made pursuant to a contract, instruction or written plan that is intended to constitute a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="5" style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">If checking either box above, please provide a description of the material terms of the trading arrangement (other than terms with respect to price), including the proposed duration of the trading arrangement and the aggregate number of securities that may be purchased or sold pursuant to the trading arrangement:</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="5" style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">CERTIFICATION</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="5" style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">I hereby certify that I am not (1) in possession of any material, nonpublic information concerning the Company, as defined in the Company&#x2019;s Amended and Restated Insider Trading Policy and (2) proposing to transact in any securities of the Company in contravention of the restrictions under the Company&#x2019;s Amended and Restated Insider Trading Policy. I understand that, if I trade while possessing such information or engage in transactions in violation of such restrictions, I may be subject to severe civil and/or criminal penalties, and may be subject to discipline by the Company including termination.</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Insider's Signature</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Date</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="5" style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">AUTHORIZED APPROVAL</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Signature of Compliance Officer (or designee)</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Date</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">*NOTE: Multiple lots must be listed on separate forms or broken out herein.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:21.004%;box-sizing:content-box;"></td>
     <td style="width:1.14%;box-sizing:content-box;"></td>
     <td style="width:21.004%;box-sizing:content-box;"></td>
     <td style="width:6.001%;box-sizing:content-box;"></td>
     <td style="width:26.285%;box-sizing:content-box;"></td>
     <td style="width:14.283%;box-sizing:content-box;"></td>
     <td style="width:10.282%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="7" style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CONFIRMATION OF TRANSACTION</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insider's Name:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of Shares:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date of Transaction:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Type of Transaction:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="5" style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744; Purchase   &#9744; Sale   &#9744; Gift   &#9744; Other Transfer: ________________________________________________________________________</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Price per</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executing Broker:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="7" style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744; This transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="7" style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744; This transaction was made pursuant to a contract, instruction or written plan that is intended to constitute a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="7" style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">If checking either box above, please provide the date on which the contract, instruction or written plan was pre-approved under the Company's Amended and Restated Insider Trading Policy and the date on which the contract, instruction or written plan was adopted:</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date of Pre-Clearance:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date of Adoption:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insider's Signature</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT B</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACKNOWLEDGMENT</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I hereby acknowledge that I have read, that I understand, and that I agree to comply with, the Amended and Restated Insider Trading Policy (as amended and restated, the &#x201c;Insider Trading Policy&#x201d;) of Nuvalent, Inc. (the &#x201c;Company&#x201d;). I further acknowledge and agree that I am responsible for ensuring compliance with the Insider Trading Policy and the Trading Procedures included therein by all of my &#x201c;Affiliated Persons&#x201d; (including such persons listed below). I also understand and agree that I will be subject to sanctions, including termination of employment, that may be imposed by the Company, in its sole discretion, for violation of the Insider Trading Policy, and that the Company may give stop-transfer and other instructions to the Company&#x2019;s transfer agent against the transfer of any Company securities in a transaction that the Company considers to be in contravention of the Insider Trading Policy.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:35.78%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:10%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:41.22%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Affiliated Persons</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>nuvl-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-02-25T15:36:20.2928+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the registration statements (Nos. 333-258237, 333-263926, 333-270594, 333-277379, and 333-285299) on Form S-8 and (Nos. 333-270593 and 333-292329) on Form S-3 of our report dated February 26, 2026, with respect to the consolidated financial statements of Nuvalent, Inc. and the effectiveness of internal control over financial reporting.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ KPMG LLP</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Boston, Massachusetts</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 26, 2026</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>nuvl-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-02-25T15:36:20.3039+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, James R. Porter, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Nuvalent, Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 26, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ James R. Porter</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">James R. Porter</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>nuvl-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-02-25T15:36:20.3050+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Alexandra Balcom, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Nuvalent, Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 26, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alexandra Balcom</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Alexandra Balcom</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>nuvl-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-02-25T15:36:20.3109+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, James R. Porter, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Annual Report on Form 10-K of Nuvalent, Inc. for the fiscal year ended December 31, 2025 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Nuvalent, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 26, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ James R. Porter</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">James R. Porter</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>nuvl-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-02-25T15:36:20.3061+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Alexandra Balcom, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Annual Report on Form 10-K of Nuvalent, Inc. for the fiscal year ended December 31, 2025 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Nuvalent, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 26, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alexandra Balcom</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Alexandra Balcom</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img123481027_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img123481027_0.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X
M @ )  8 ,0  86-S<$U31E0     245#('-21T(                  /;6
M  $     TRU(4" @
M                   18W!R=    5     S9&5S8P   80   !L=W1P=
M ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA9
M6@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&
M=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M   ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M  !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD
M &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U)'
M0B!)14,V,3DV-BTR+C$
M                         %A96B        #S40 !     1;,6%E:(
M                  !865H@        ;Z(  #CU   #D%A96B        !B
MF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@
M        9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M         &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M          !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %8
M65H@      !,"58 4    %<?YVUE87,          0
M      */     G-I9R      0U)4(&-U<G8        $      4 "@ / !0
M&0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"&
M (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8
M^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!@P&+
M 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X D$"
M2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#(0,M
M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$
M2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&
M!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'
M!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((E@BJ
M"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*
MF JN"L4*W KS"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG
M#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/
M"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,
M$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4
M:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E
M%XD7KA?2%_<8&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:
MQ1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY
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M ?_$ .\  0 " @,! 0$!           )"P@*!08'! (# 0$!  ,! 0$! 0$
M          8'" 4$ P(!"1   00" 0("! 4+#0P) P('  $" P0%!@<1"!()
M(1,4"B(5MW@Y,;46=K8W=Y<8.!I!([/3M)755M875U@9,B14U'66AXB8N,A)
M46%"4C-#):?74S388B9Q@70UJ.AI$0$  0(# P4'#PD&!0,$ @,  0(#$00%
M(3$&05%A$@=QL2)R$W0V@3)"4F*2LB-SD[,4%347D:'1@M)3@U06P:+",T/#
M\*/3)#1C1$7QXY0E5>)D92;_V@ , P$  A$#$0 _ -_@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\
M
M
M
M
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M(FNU5X-VCQJ)VX<G6IZU$SCA5.#OISTH
M
M
M
M
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M@
M
M
M
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M_0
M
M
M
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M?%-C+U_5]6F-MBY,15,\ODZO6W(W^M\/",:J*8>S'%6$
M
M
M
M
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MA:G    !&EW:_?3K_:IB/W9E2SN$/NJ?EJN]2Q[VZ>FM'F-KX=UC$2E30
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MS%%VF/74[KE$\U=$^%3T3AU9WTS,;7<3Q)
M
M
M
M
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M4<M1G,A=MWLI7&--=%454SW)C&.B>:=D[7WGS>H
M
M
M
M
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MLS[6O#FBJJ63"*BHBHO5%]**GU%3_I0C"XM^V-P
M
M
M
M
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MC&JQ<PIN1SS3MPN4^ZHF<(PZT4S.#U8Y*;@
M
M
M
M
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MDXSVBYBW?L;,>K/A4S/)71.%5$]%41/+&QV8\KL@
M
M
M
M
M      'XEECACDFFD9%#$Q\LLLKVQQQ1QM5SY)'N5&L8QJ*JJJHB(@B,=D;R
M9B(QG<UQ_,6]X][5^T_X]XW[;6XONJYTJ,LT9+.O9AK.$-(RK?'#_P#N;?,<
MZ9^XW<?,K9'XW >MBE\#X)LC1F3T6%P_V>ZGJG5S&HXY7)3MVQ\95'13/K<>
M>KNQ35"NN(NT;2M*ZV6TW#-9Z-FR?BJ9]U5'KICFH[DU4RT;N\KO_P"ZWOUW
MAVZ]R7*>7VR"I=M6]5T''.?A.,="BLM]3[+IFCTY5Q6,>VHUD$EZ5+&5N1QM
M6W:L2=7K=.D:%I>AV/(Z=:BB9CPJIVUU>-5OGN;*8Y(A1^LZ_JNO7_+:E=FN
M(GP:(V44^+3NCFQVU3RS+#,Z[C@               "3SR7_ *4WLD_#5B_K
M1F"-\8>C.=^1GOPDW!GI1DOEH[TK5PS"U.    "-+NU^^G7^U3$?NS*EG<(?
M=4_+5=ZECWMT]-:/,;7P[K&(E*F@               !SFO;+G]3R<.8US*W
M,1D8/[FS3E\'C9XD<L-B)R.@M5GJU/%%*U\;NGI:IY\SE<OF[4V<S137;GDG
MOQRQ/3&UTM*UC5-#SE.?TB_<R^;IW543AC'-5&ZJF>6FJ)IGEB6<7&?=?C<B
MM?$\C5H\1<=X(H]CQ\4CL5.Y?@HN1I-];/CGJO3K)&LD*JJJK8FH075.$KMK
M&]ILS71[2?71XL[I[DX3W9:2X.[<<GF^KD>+:(L9C9$7Z(F;=7RE&VJW//53
MUJ,9F9BBF&85*]2R52O?QUNM?HVXVS5;E.>*S5L1/_N98)X7/BEC=^HK55"&
MUVZ[5<V[D33<B<)B8PF.[$K]R^9R^<L49K*7*+N6KC&FNB8JIJB=TQ5&,3'3
M$OJ/P^P
M
M
M
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M>Z45Q#QOK.O]:S-7D-/G_3HG?'NZM]?<V4^Y0SDO0X
M$GGDO_2F]DGX:L7]:,P1OC#T9SOR,]^$FX,]*,E\M'>E:N&86IP    1I=VO
MWTZ_VJ8C]V94L[A#[JGY:KO4L>]NGIK1YC:^'=8Q$I4T
M  #T;0>5MTXXM)+KN4?["^1'VL)>\=K#V_3\)9*BO;ZB5WZLL+HY?U/%T]!S
M-0TG(ZE1AF:/C.2J-E4>KR]R<8Z$MX7XWXBX1O=?2;\_5IG&JS7X5JKNTX^#
M/NJ)IJZ<-C/_ (T[C=+WQ:^-R3VZKLDJLB;CLC.U:%Z9WH1N,RBMBAD>]W1&
MQ3)%*YSD:Q'_ %2O=3X;SVGXW;7QN6CEIC;$>ZIW^K&,<^#4O!W:WP[Q/-&3
MS<QDM7JPCR=R8ZE<_P#IW-D3,\E-75JF9PIBK>R%(ZM4
M
M
M
M
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M7TF]'UF(QJLUX4W:.[3C/6B/;4353TXO1SFI<
M
M
M
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M51RQ#G3X.D
M
M
M
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MIB*>7#%1NN<2ZOQ!=Z^H7)\E$XTVZ=ENGN4X[9]U5,U<F.# 4[K@@
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MO6Z;MFJFNU5$3%43$Q,3MB8F-DQ/),/ZG\?L
M
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M56ZXB.[,QA#ZV=5TO,7(LV,SEZ[M6ZFFY1,SR[(B9F7OAX7O
M
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MRS3ACRX['>3P)*
M
M                                   1[^;']&?WU?-AY=^Y+(G>X6](
M\EYS;^%"/\5^C6>\UN?!E4WFI&4@   EQ\B#Z6GLS^W7=ODBY"(KQOZ*YSQ*
M?I*$LX%]+,GX]7T=:TG,SM0@
M
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M:^V7XKX=S=^C+9?-VJ[]RJ*::8F<9F=T1LY4A9P$A
M
M           CW\V/Z,_OJ^;#R[]R61.]PMZ1Y+SFW\*$?XK]&L]YK<^#*IO-
M2,I   !+CY$'TM/9G]NN[?)%R$17C?T5SGB4_24)9P+Z69/QZOHZUI.9G:A
M
M                                     86>9+]'7W\?,L[IOD-WH['#
MOI!D?/+/TE+B\2>CN?\ ,K_T52HZ-5,F
M)//)?^E-[)/PU8OZT9@C?&'HSG?D9[\)-P9Z49+Y:.]*U<,PM3@    C2[M?
MOIU_M4Q'[LRI9W"'W5/RU7>I8][=/36CS&U\.ZQB)2IH
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MYMSDZ1K.3UNU=S&0GK9>UF+EGK<E55N8BJ:>>GK8Q$\L1C&R78CS.L
M           'F'-VD_SE\+\N\<>K]=_.!QAOVD^I\/C];]E6J9;!>K\'M-/Q
M^/V_IT]=%UZ_W;?[I/3DKWU;.6LQ^[NTU>]JB?['ESMCZSDKV6_>6JZ??4S'
M1SJ;8URQX   &]![N)YO+>1L!@_+X[D=H;_.!J>-]F[9=XS=Q/6;MI^+JNDE
MX?REJQT<_:=-HUW2X.1SW>WXACZG2.6C![92G:%PI]7N5:]IU/Q%<_'4Q[&J
M?]2/<U3Z[FJV[8JG"\>SGB[ZS;IX?U*K_N*(^)JF?74Q_IS[JF/6\].S9-,=
M;;X*H6X                   !2SFPF,@"0?RG?I,.Q7YS_ !%]UV..#Q3Z
M.9WS:Y\&7?X4])<CYU;^%"V1,MM7
M                                                          1[
M^;']&?WU?-AY=^Y+(G>X6](\EYS;^%"/\5^C6>\UN?!E4WFI&4@   EQ\B#Z
M6GLS^W7=ODBY"(KQOZ*YSQ*?I*$LX%]+,GX]7T=:TG,SM0@
M
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MSR5U43NQ<1VK?>EI_P"7<U^S1'VXL^]ZODZ>\\'8EZ"V_.;W?AD>1I;@
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MQ%]UV..#Q3Z.9WS:Y\&7?X4])<CYU;^%"V1,MM7
M
M         1[^;']&?WU?-AY=^Y+(G>X6](\EYS;^%"/\5^C6>\UN?!E4WFI&
M4@   EQ\B#Z6GLS^W7=ODBY"(KQOZ*YSQ*?I*$LX%]+,GX]7T=:TG,SM0@
M
M                                   ,+/,E^CK[^/F6=TWR&[T=CAWT
M@R/GEGZ2EQ>)/1W/^97_ **I4=&JF3                            $G
MGDO_ $IO9)^&K%_6C,$;XP]&<[\C/?A)N#/2C)?+1WI6KAF%J<    $:7=K]
M].O]JF(_=F5+.X0^ZI^6J[U+'O;IZ:T>8VOAW6,1*5-
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M@R[_  IZ2Y'SJW\*%LB9;:N
M                                                     CW\V/Z,
M_OJ^;#R[]R61.]PMZ1Y+SFW\*$?XK]&L]YK<^#*IO-2,I   !+CY$'TM/9G]
MNN[?)%R$17C?T5SGB4_24)9P+Z69/QZOHZUI.9G:A
M
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MX1REDLE).^U;[TM/_+N:_9HBK>+/O>KY.GO-E]B7H+;\YO=^&1Y&EN
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M\G;SV2KBO+7*<8F/SQ/-,3LF)VQ,3$O8#R/8                *6<V$QD
M2#^4[])AV*_.?XB^Z[''!XI]',[YM<^#+O\ "GI+D?.K?PH6R)EMJX
M
M                       "/?S8_HS^^KYL/+OW)9$[W"WI'DO.;?PH1_BO
MT:SWFMSX,JF\U(RD   $N/D0?2T]F?VZ[M\D7(1%>-_17.>)3])0EG OI9D_
M'J^CK6DYF=J$
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MS)?HZ^_CYEG=-\AN]'8X=](,CYY9^DI<7B3T=S_F5_Z*I4=&JF3
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M]',[YM<^#+O\*>DN1\ZM_"A;(F6VK@
M                                                           (
M]_-C^C/[ZOFP\N_<ED3O<+>D>2\YM_"A'^*_1K/>:W/@RJ;S4C*0   2X^1!
M]+3V9_;KNWR1<A$5XW]%<YXE/TE"6<"^EF3\>KZ.M:3F9VH0
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MN ).^U;[TM/_ "[FOV:(JWBS[WJ^3I[S9?8EZ"V_.;W?AD>1I;@
M         *N[S^,3-A?-U[QZ=B2*62;/\699KH?'X$AS_ W%F=K1KXVL7UL-
M?),8_P!'3QM7HJIT5=*\"UQ7PIE)CVM<?DNUQ_8S#Q[1-'%N<IGVU$_EM43_
M &H>"6H@       VM?=\?.<_)YV' =CW=%M3F<#[AF75.%>1L_=E?7X:V_,S
M>)FFYV[:G<RAQ=MN4?\ WO*C6Q83+672R^&E9L3TZOX]X0^OVZM:TRG_ +ZB
M/C*(C_,ICV41RUTQO]M3&$;8B)M3L_XR^S[E.AZI7_V-=7Q=<S_EU3[&9Y**
MIW>UJG&?!F9C?C*-7R               4LYL)C( D'\IWZ3#L5^<_Q%]UV.
M.#Q3Z.9WS:Y\&7?X4])<CYU;^%"V1,MM7
M
M   1[^;']&?WU?-AY=^Y+(G>X6](\EYS;^%"/\5^C6>\UN?!E4WFI&4@   E
MQ\B#Z6GLS^W7=ODBY"(KQOZ*YSQ*?I*$LX%]+,GX]7T=:TG,SM0@
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MWH['#OI!D?/+/TE+B\2>CN?\RO\ T52HZ-5,F
M     )//)?\ I3>R3\-6+^M&8(WQAZ,YWY&>_"3<&>E&2^6CO2M7#,+4X
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MKL<<'BGT<SOFUSX,N_PIZ2Y'SJW\*%LB9;:N
M
M      CW\V/Z,_OJ^;#R[]R61.]PMZ1Y+SFW\*$?XK]&L]YK<^#*IO-2,I
M !+CY$'TM/9G]NN[?)%R$17C?T5SGB4_24)9P+Z69/QZOHZUI.9G:A
M                                                           &
ML-[V']'7PQ\]/CKY#>XPLGLN](+WF=?TEI67:MZ.V?/:/HKRO@+Y9_    !<
M7=MGYNO 7X%>+/N&P1DG4?O"_P#+5_"EL#3?N[+_ "-'P8>U'C>T
M               86>9+]'7W\?,L[IOD-WH['#OI!D?/+/TE+B\2>CN?\RO_
M $52HZ-5,F                            )//)?^E-[)/PU8OZT9@C?&
M'HSG?D9[\)-P9Z49+Y:.]*U<,PM3@    C2[M?OIU_M4Q'[LRI9W"'W5/RU7
M>I8][=/36CS&U\.ZQB)2IH        ]FXWX+WCDAT-NI4^)M>>[X>PY6.2*K
M(Q%3Q?%M;X-C*2=.J(L:)#XD5KI&*<34]>R.F1-%<]?,^TIW_K3NI]7;S1*P
M>$.S3B3BZJF_8M_5]*F=M^[$Q3,?^G3ZZY/-U? QC"JNF4@'&_!NC\;LAM4J
M?QQL+&)ZS8<K''+;9(K>C_BV#HM?%1KU<B>K19E8OA?(]"O=3U[/:G,T5U=3
M+>TIW?K3OJ]79CNB&I>$.S7AOA"FF_E[?UC58C;?NQ$U1/+Y.GUMN-_K?"PG
M"JNI[$YS6-<][FL8QJN>]RHUK6M3JYSG+T1K6HG557ZAQ8B9G"-ZP*JHIB:J
MIB*8C&9GD8N\E=T.J:K[1C-/;#MV<9XXUM12JFNT94141TMV)4?E'-=T7P5E
M]6Y.J>N:Y.A*M,X5S>;PNYS&S8YO9SZGL>[5M]S*EN,.VC0]$ZV3T"*<_J48
MQUHGXBB>FN-MS#9LM^#,8_&4S&# S<^0-MW_ "'QAM.8L9!S'/6K314@QM!K
M_JLHT(O#7@ZM1$<_HLCT1/&YR^DG^2T[)Z?;\GE*(IYYWU3W9WSWHY(AF+B'
MBG7>*<U]:UK,5W9B9ZM&ZW1CR441X-/-,X=:<(ZTS.UTP]R/@     >N<*<=
M2<D[S0Q<\;UP6.Z978945S4^+J\C>E-'M<Q6RY.=6PIX5\;6.<].O@4X^N:E
M&F9"J[3/Q]7@T>-/+^K&WFW1RIWV=<)5<7\2VLE=B?LVU\;?G_TZ9CP,=FVY
M5A1&$XQ$U51ZV4M<<<<4;(HF,CBC8V...-J,CCC8B-8QC&HC6,8U.B(GH1"H
M9F9G&=LRW533313%%$1%$1A$1LB(C=$1R1".'NDY)^R;:6:9B["OPNIRR,O*
MQ?UJYL2HL=M5_P"\W%1JM=O7ZDJS?5144LKA33/JN4^NW8^/O1LZ*.3WV_N=
M5D?MJXP^V=:CA[)5XZ=D:IBO#=7?W5?-1X$<U7E-\82Q6)8I(  2=]JWWI:?
M^7<U^S1%6\6?>]7R=/>;+[$O06WYS>[\,CR-+<                  !6&^
M\._3#=WW^@#_ '7N$S27 /HEE/XOTUQF7M"]+\Y_"^@MH628(8 36>='Y3>T
M>6US<F=TFIE\]VH\LY>_/Q%M]A+-Z34,HYDV1N<0[ADWK,Y-AP51DDF,LSO\
M>:Q4*SM5T]>\R"'<'\4VN(LEU+TQ3JEJ(\I3NZT;O*4QS3RQ'K:MFZ:<9IQG
MPI=X;SOE+$35I5V9\G5OZL[_ "=4\\>QF?74[=\580IDQ0L    '(8C+Y77\
MKC,]@<GD,)G,)D*67PV9Q%VSC<KB,KC;,5S'9/&9&G+#<H9"A<A9+#-$]DD4
MC&N:Y'(BGYKHIN4S17$5451A,3MB8G?$QRQ+]45UVZXN6YFFNF8F)B<)B8VQ
M,3&Z8Y)6/'D5><-C._SC*+@OF[,4J'=]Q5KS9<Q+(C*D'-ND8U\-*/D?"P-8
MRO!M&.2>"'8J$:]%LO2_68VO8DKTL^<;<)5:%F?KN2B9TF[5L_\ 3JGV$^YG
M;U)YO!G;&-6B^!N,*-?RWU'.S$:O:IV_^I3&SKQ[J-D5QS^%&R<*=A @2P
M           *6<V$QD 2#^4[])AV*_.?XB^Z[''!XI]',[YM<^#+O\*>DN1\
MZM_"A;(F6VK@
M                                         (]_-C^C/[ZOFP\N_<ED
M3O<+>D>2\YM_"A'^*_1K/>:W/@RJ;S4C*0   2X^1!]+3V9_;KNWR1<A$5XW
M]%<YXE/TE"6<"^EF3\>KZ.M:3F9VH0
M                                  !K#>]A_1U\,?/3XZ^0WN,+)[+O
M2"]YG7]):5EVK>CMGSVCZ*\KX"^6?P    7%W;9^;KP%^!7BS[AL$9)U'[PO
M_+5_"EL#3?N[+_(T?!A[4>-[0                      !A9YDOT=??Q\R
MSNF^0W>CL<.^D&1\\L_24N+Q)Z.Y_P RO_15*CHU4R8
M           D\\E_Z4WLD_#5B_K1F"-\8>C.=^1GOPDW!GI1DOEH[TK5PS"U
M.    "-+NU^^G7^U3$?NS*EG<(?=4_+5=ZECWMT]-:/,;7P[K&(E*F@
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M3OTF'8K\Y_B+[KL<<'BGT<SOFUSX,N_PIZ2Y'SJW\*%LB9;:N
M
M                   CW\V/Z,_OJ^;#R[]R61.]PMZ1Y+SFW\*$?XK]&L]Y
MK<^#*IO-2,I   !+CY$'TM/9G]NN[?)%R$17C?T5SGB4_24)9P+Z69/QZOHZ
MUI.9G:A
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M,QR3$[)C\FS:R_J>F9O2,]<T_/4]7,6YPGFF.2J)Y8F-L3^7"<8>!'N>
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M]!_6?!__ /+:;_\ E6/VS^<_C3^D/1O\[<!_" ^RM3_EK_S=?Z#^L^#_ /\
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MFJJU733$=,S3$1ZK[6-<T3,W:;&6SF5N7ZIPBFF[;JJF>B(JF9]1E0<QU
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M^DVPZM'(R:6;[ ]STES7Y!ST?-ZM8VM<Q/5)&WQ-7RW>S7ANYZSZQ;\6N/\
M%35N_P#KB]5GM/XGM^O^KW/&MS'P:J=__P!,&>G$OO<N\59*U7G;LVU3.12/
M8VYG.)>3\OJLE2/Q)ZR6MJNXZ]N3<@_P_4C?F:R=?JO.'FNRJQ.,Y+.54SS5
MT15_>IFG#WLN]E.UJ_$Q&>R=%4<LVZYI_NU15C[Z$TW;7[Q3Y8_<-9QF$S/*
M>>[=MKR7AB9ANX+7F:CA6V6QHZ?UG(N$R&S<;8ZDU_5(YLEE<>Z1J)\!KE\"
M0_4>S_B3(1-=%JG,6HY;4]:?>3$5S/<IE---[0^&=0F**[M67NSR78ZL>_B9
MHB.[5";C7MBU_;L)B]FU3.X;9];S=.+(878->R=+-83+T)T\4%[%Y7&SV:%^
MG,WTLEBD>QR?44AERW<M5S;NTS3<IG"8F)B8GFF)VPFMNY;O41=M54U6ZHQB
M8F)B8YXF-DN9/P_8      #HG)/*7&/#6I7]_P"7^1M$XIT3%ST:V3W7DG;]
M?T;4L=9R=R''XVO?V/9\AB\/4GR-^Q'! R29KIIGM8Q%<J(OWR^6S.<NQ8RE
MNN[?G'"FBF:JIPVSA%,3.R-LOAF<UELG:G,9RY;M6(PQJKJBFF,=D8S5,1MG
M9&UC/_:2^77_ %^.RS_:FX-_ET='^G>(/Y'.?,W/V7,_J3AW^?R7S]K]H_M)
M?+K_ *_'99_M3<&_RZ'].\0?R.<^9N?LG]2<._S^2^?M?M-=7WFKNW[4^>^P
M[B73^#.YOM[YHVW&]W.A[+D=6XGYHXXY%V*AKM/AOGO%V\_=PFG[)F,G5PM7
M)YBI7DM/B; R>U#&YR/E8CK [.-*U3(ZY=NYW+9BS:G*51%5=NNB)GREJ<,:
MHB,<(F<-^$3S*\[2]6TK/Z%:LY',Y>]=C-TS--NY17,1Y.[&,Q3,SAC,1CNQ
MF.=HR%U*/    !:T=OWF)>7[AN!N$L/F.^GLYQ.7Q/$7&V-RF+R7<WPI1R.-
MR-'3<+5O8_(4;6[Q6:=VG9B='+%(ULD<C5:Y$5%0S!G^']>KSUZNC)9N:)NU
MS$Q9N3$Q-4X3$]7<U1I_$.@49"Q17GLG%<6:(F)O6XF)BF,8F.MO>N_VDOEU
M_P!?CLL_VIN#?Y='D_IWB#^1SGS-S]EZ_P"I.'?Y_)?/VOVC^TE\NO\ K\=E
MG^U-P;_+H?T[Q!_(YSYFY^R?U)P[_/Y+Y^U^T?VDOEU_U^.RS_:FX-_ET/Z=
MX@_D<Y\S<_9/ZDX=_G\E\_:_:>X<0]Q/;]W!5LY<X$YTX<YNJ:Q/0K;+:XAY
M.TGDJMKUG*1VI<97SD^F9O-18F?(Q49W0,L+&Z9L+U8BHQW3Q9O3\_D)IC/6
M+UF:L</*4548X;\.M$8X8QC@]V4U'3]0BJ<A?LWXIPZWDZZ:\,=V/5F<,<)P
MQ>QGD>P                  &%GF2_1U]_'S+.Z;Y#=Z.QP[Z09'SRS])2X
MO$GH[G_,K_T52HZ-5,F                            )//)?^E-[)/PU
M8OZT9@C?&'HSG?D9[\)-P9Z49+Y:.]*U<,PM3@    C2[M?OIU_M4Q'[LRI9
MW"'W5/RU7>I8][=/36CS&U\.ZQB)2IH _<<;Y7LBB8^261[8XXXVJ]\CWJC6
M,8QJ*YSW.7HB)Z54_DS$1C.R(?JFFJNJ**(F:YG"(C;,S.Z(CEF64G&G:YM.
MT>SY3<GS:GA'^"1M-T;5V&[$J=>C*LB+'BVN_P"]819$_P#I*GI(IJ?%64RN
M-K)87K_/["/5]EZFSI75P?V+:UK75SO$$U9'3IPGJ3'Q]<=%,[+<=-?A>XF-
MK/+3=!U/0<>F.U?#U\>QR-]IM=/79"\]J)^N7;TOBL6%Z^E&J[P,Z]&M:GH(
M#G=0S>H7/*9JN:IY(W1'<C='?YVG.'^%]#X7RGU31<O1:IGUU6^Y7//77/A5
M=S'".2(ASN9S>(UW'SY7.9*GBL=63K-<O3LKPM547PL1SU3QROZ=&L;U>Y?0
MB*IY[-B]F;D6;%-5=V=T1&,_\=+I:AJ.0TG*59[4KUNQE*-]=<Q3$=&W?,\D
M1C,[HB6%?)7=F]WM&*XTJ>!OPHW;1E:Z.>OU/US%8J9%:WZGHDM-=U3_ ,E%
MZ*3?3.$8C"[J<_J4S\*J.]3[YG;C#MSJGKY'@^C"-WUFY3M[MJU.[QKD3\G&
M]A=ELQE<[?GRF:R-S*9&T[QSW;UB2S8D7]1%DE<YR,8GH:U.C6IZ$1$)M9LV
MLO;BU8IIHMQNB(PAGG/9_.ZGFJL[J-VY?S=<XU5UU355/JSR1R1NB-D;'''U
M>0         ?70HV\G>IXVA!):O9"U7I4ZT2(LEBU:E9!7AC151/'+*]&IU5
M$ZJ?BY<HM6ZKMR<+=,3,SS1&V9??+9:_G,S;RF5IFO,W:Z:**8WU553$4Q'3
M,S$)?N+]$J<<Z9B=;KI&^W%'[7F+<:+TO9BRUCKMCJO1SHV.:D477HJ0QL1?
M24YJN?KU+.UYFK'J3.%,<U,;H_MGIF6]N"^&;'"7#UC2+6$WZ8ZUVJ/9W:L.
MO5W(];3[FFF'E_<MR3]A>F.P.-L>KV#;HYZ$*QNZ2TL/X49E+R*U?%')*R1*
M\2^A?%(Y[5ZQG5X8TSZ[G?K%V,<O9PF>FKV,?VSW,)WH7VP\7_T]P].EY2K#
M5<_%5$8;Z+6ZY7T3,3U*=VVJ:HG&A&,6BQL    "3OM6^]+3_P NYK]FB*MX
ML^]ZODZ>\V7V)>@MOSF]WX9'D:6X                  "L-]X=^F&[OO\
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MRF*J:HW3$[I_XVQRLT9G+7\GF*\KFJ9HS%NJ::J9WQ,;X_XV3OC8Z2?9\0
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M=R8Q_P#J_P ]M3T_,Z3J-_3,W&&9R]VJW5W:9F)F.>)PQB>6)B7%'V>$
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MX3,1BOOASBO2^)+..5GJ9RF,:K54QUHZ8]M3C[*.CK13,X)/B-).
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M]NG!/UCY0*8[5O\ R,EXEWOT+L[)/_'SWCVN]6W&"I%P@
M   PL\R7Z.OOX^99W3?(;O1V.'?2#(^>6?I*7%XD]'<_YE?^BJ5'1JIDP
M                        !)YY+_TIO9)^&K%_6C,$;XP]&<[\C/?A)N#/
M2C)?+1WI6KAF%J<    $:7=K]].O]JF(_=F5+.X0^ZI^6J[U+'O;IZ:T>8VO
MAW6,1*5-/:>-N"-XY'=#<KU?B/77JBNV#*Q21UYH^JHJXNK\"QE'^A>BL\,*
M.3HZ1J]#AZGK^1TW&BJ?*9GVE.^/&G=3ZNWFB5B<(=F7$G%TTYBU1]6TF?\
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MAL>>G210    $G?:M]Z6G_EW-?LT15O%GWO5\G3WFR^Q+T%M^<WN_#(\C2W
M                  5AOO#OTPW=]_H _P!U[A,TEP#Z)93^+]-<9E[0O2_.
M?POH+:%DF"& %TP8];-  &NMYZWDT8OOQT2UW$<"8BABN[SC? >KDI1(E6IS
MSI&#K7+$>CY7U;4B9R#BVNZ:_DY/_&:GQ;;=[.ZI8Q\_X)XOJT._&GYZ9G2;
ME7S54^RCW,^SC]:-N,55YQSP=1KMB=0R$1&KVZ?G:8]C/NX]A5^K.S"::Z#+
MXC*Z_E<G@<]C,AA,YA,A=Q&9PV7I6<;E<1E<;9EIY'&9/'7(H;E#(4+D+XIH
M96,DBD8YKFHY%0T#173<IBNB8JHJC&)C;$Q.Z8GEB6=ZZ*[=<V[D3373,Q,3
M&$Q,;)B8G=,<L.//T_(    )FO)S\VK>_+4YD3%[&_*[?VM<FYG&P<O<?QV+
M-B?6YGO@I+RKQ_0=,E2'<\'08U+5?PMCSE"%*DKXY8ZEFK$.+N%;'$64ZUO"
MC4[<3Y.KGY>I5/M9G=/L9VQLQB9EP?Q9?X;SG4N8UZ7=F/*4>UY.O1'MHC?'
MLHC"=N$Q9B<9<FZ!S-Q_J/*G%FV8;>>/-\P=+8]1VS 6DMXK-8>_'XX+,#U:
MR6&6-R.CF@E9'8K3L?#,QDK'L;G/,Y:_D[]>5S5$T9BBJ8JIG?$Q_P ;)W3&
MV-C2F6S.7SF7HS65KBO+W*8FFJ-TQ/\ QMC?$[)VN]'P?<        I9S83&
M0!(/Y3OTF'8K\Y_B+[KL<<'BGT<SOFUSX,N_PIZ2Y'SJW\*%LB9;:N
MK=O>;_I3=L_ MP[]9\@:&[-_1FCY:YWX9R[3/2FOY&WWI:^!/%?@  !LB>ZS
M?289[YL/*?W6\8E>=IOHY3YS1\&M8W9=Z2U>:U_"H6*A0#0X       !XKW)
M_FZ\^_@5Y3^X;.GLT[[PL?+4?"AXM2^[LQ\C7\&5.B:V8_    !OU>Z7?F8=
MR'SGI_DIX\*,[4_OC+^;?XZU\]D_W-F?.O\ !0VKBL%J  #71]Y8[*D[D>QE
M_.VK8OVODSM%R-_D)CZ\+'W,CQ%FXJ5#EC%^-71>"#"UJ-#87R.<[U=?"SL8
MQ73=4L#LZUC[.UOZC=G#+9N(H[ER,9HGU<9H[M4<RN^TG1?M+0_KUJ,<SE)F
MONVYPBY'J817W*9YU<J:"9V    !.+[OAW@IVI>8OQQA-@RCJ'&W<I77@'<T
MFG>RA5S6U7Z=CC'.2P+_ 'M[13Y#IT:#K,BL2IC\I<?XD:KFNA?'ND_:G#]R
MNW&.9RWQM//A3'AQ[S&<.6:83?L_U?[*XBMT7)PRV9CR57-C5/@3[_",>2*I
M6:9G%I8  1U]VND_%&VX[<JD/AI[36]FR#FHOA9F<5%%#XW=$1K/;,=ZI6I]
M5SH9'?\ 261PAGO+9.K)5SX=J<8\6K;^:K'\L,F]NO#GU#7;/$%BG#+YVCJU
M\T7;<1&,\W7M]7#GFBN6))+U%   !ZUPAI2;WR/@<5/#Z[%T95S>::YOBC7&
MXQS)702I^K'>MNBKK_U2]?U#CZ[GOJ&FW+M,X7:HZM/C5<OJ1C/J)UV;\._U
M-Q=E<E=IZV2MU>6O<WD[>$X3T5U=6B?&2X%0-V@&+7>UW-:_V;]J'.W<ML;:
ML]?BC0,KF\+C+DZ5:^P;I=6'!Z#J[['I=#]E&[93'X_QM1SF>T^)&NZ=%Z>C
M:;<U?5+&G6\<;MR(F>:F-M57ZM,3/J.7K6IV]'TJ_J5S"8M6YF(YZIV44_K5
M3$>JJ+=NVO8-[VO9]XVW*6LYM6Y;#FMKV;-7I%ENYC8-AR5G+YG*7)5],EK(
M9*Y)+([]5[U4U7:M6[%JFS:B*;5%,4Q$;HB(PB/4ADJ]=N7[M5^],U7:ZIJJ
MF=\S,XS/JRZ\?1\P#8J]VW[#_P J/O2BY[W;#>V\0=H_Q/OLGMD'CQ^?YDR$
MUG^:G!M]8UK9_L=MXZSL<KHW.6"?%4XY6^KMMZP#M#US[,T?ZC9G#-YO&GIB
MW'KY]7&*.Y5,QN6'V<:%]J:U]?OTXY/*85=$W)]9'J837T33$3O6-QGQHH
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M92   "7'R(/I:>S/[==V^2+D(BO&_HKG/$I^DH2S@7TLR?CU?1UK2<S.U"
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MZ       TL_>_?\ EY_ZV?\ PSEP]D__ +_^!_O*8[7?_C_X_P#LM+,N%3(
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M>T?T3O\ CVOI*5:$:+9L             W@/=$?O=]\?VZ<$_6/E ICM6_\
M(R7B7>_0NSLD_P#'SWCVN]6W&"I%P@                  PL\R7Z.OOX^9
M9W3?(;O1V.'?2#(^>6?I*7%XD]'<_P"97_HJE1T:J9,
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M     "3OM6^]+3_R[FOV:(JWBS[WJ^3I[S9?8EZ"V_.;W?AD>1I;@
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MFJ.B8PGHW<C5FCZKE]:TVUJ66_R[M..'+35&RJF>FF8F.G?NEDZ<UTP
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M=$;<:>C&(]:TAP#Q-.NZ9.6S=6.I9:(BJ9WUT[J:^F=F%73A,^N3\D%3T
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M':X7$'!.J\-Y*G/9ZYEZ[5=V+<1;JKF<9IJJQGK6Z8PPIGEQQPV(<R6H>
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M8     $G?:M]Z6G_ )=S7[-$5;Q9][U?)T]YLOL2]!;?G-[OPR/(TMP
M             %8'[PC=JW_. [P9Z<[+$,=K@ZD^2-55K;6-[:N&\=>@7JB?
M#K7JLD;O_P!3%-)\!1-/">4B=^%S\]ZY,?F9D[0*HJXOSDT[8QM1^2S;B?SH
M8R7H: 73!CULT    &DM[P1Y(ZX23;N_7L_TUSL-/+8S_<CPUJF*:B8-ZLL6
M\QS9IF*I(W_T:9[/6;+0KQ*ZK*]V48BP.O.K7)P'QGU^IH>K5^'NLW*IW\UN
MJ9Y?:3._UN_JXTKQ_P $]2:]>T>CP-]ZW3&[GN4Q')[>(W>NW=;#30+>4X
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MK[^/F6=TWR&[T=CAWT@R/GEGZ2EQ>)/1W/\ F5_Z*I4=&JF3
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M>>_]+3WF?;KI/R1<>FF."/17)^)5])6R]QUZ69SQZ?HZ$1Q*D3 +I@QZV:
M  #^4\$-J&:M9ABL5[$4D%BO/&R6&>&5BQRPS12(Z.6*6-RM<UR*CD7HI_8F
M8G&-[^3$3&$[F@5Y^7DF/[8<QG^\SM2U5J=N.R9:.QREQAKF.MO3@K8<HYRR
M;)AZU=+$-;B3/9%?#X$]3#@+T\=:-J4YH&5KTX&XR^TJ*=(U2K_]A3'@5S/^
M9$<D^[B/?1&.^)QH3CW@K[,KJUG2J/\ ]=5/AT1'^5,\L?\ IS/J43.$;)C#
M5A+-5<     !M<^0KYXC>W.W@.S/O!W"Y)P+E;E3$\,<K[!=2:#@_(69710Z
M=M5VPU;$?$^4L2M2M;?*L>MS>A[6XV1\E"K^.>"_M"*M7TFB/KT1C<HB/\R/
M;4^[CECV?C>NM7@/C?[.FG1M8KGZA,X6[DS_ )4^UJG]W/)/L)]SMIWW6N:]
MK7L<U['M1S'M5'-<UR=6N:Y.J.:Y%ZHJ?5*-7P_0     4LYL)C( D'\IWZ3
M#L5^<_Q%]UV..#Q3Z.9WS:Y\&7?X4])<CYU;^%"V1,MM7      5NWO-_P!*
M;MGX%N'?K/D#0W9OZ,T?+7._#.7:9Z4U_(V^]+7P)XK\   -D3W6;Z3#/?-A
MY3^ZWC$KSM-]'*?.:/@UK&[+O26KS6OX5"Q4* :'        /%>Y/\W7GW\"
MO*?W#9T]FG?>%CY:CX4/%J7W=F/D:_@RIT36S'X    -^KW2[\S#N0^<]/\
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MX    +B[ML_-UX"_ KQ9]PV",DZC]X7_ ):OX4M@:;]W9?Y&CX,/:CQO:
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MDMJBHQ$:GZB=#(F:M18S-RS&ZBY53^29AL;*W9OY6W?G?7;IJ_+$2[Z?!]P
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M_)T3&S]:K#U*9CE6EV7:-3F]2N:O>C&UEJ<*/E*XG;^K3CZM43R-_ HM?8
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M,L[IOD-WH['#OI!D?/+/TE+B\2>CN?\ ,K_T52HZ-5,F
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M3N8U[8.,/ZBXAG3,G7UM)R$S13ANKN[KE?-,1,=2F=V%,U1.%3&\DRH@
M   "3OM6^]+3_P NYK]FB*MXL^]ZODZ>\V7V)>@MOSF]WX9'D:6X
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M7\&5.B:V8_    !OU>Z7?F8=R'SGI_DIX\*,[4_OC+^;?XZU\]D_W-F?.O\
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M,XU?K58SW,(G<U#P7H?V%H5NQ=C#.7?C+G/%541A3^K3A3/3$S&]+:15+
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M7M;H?LYS$WN&*+<_Z5VY1^?K_P"-G#M*R\6.*;ER/]6S;K_-U/\  U_2=H"
M  %J9Y*G.5KN"\L#M%W7)VW6\[K_ !PO$^=DE5765O<-9O*\7U+%V16IZZYD
M\+JM2X^3JYTBV?$Y5>KC,?&.2C(<2YNS3&%%5SKQ_$B*_P TU3'J-2\%YZ=0
MX8RE^J<;E-OJ3W;<S1M[L4Q/JI3",I0   &EG[W[_P O/_6S_P"&<N'LG_\
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M]2B=D=$U8S[F)7%P[V7V[?5S7$-77KW^1HGP?UZXVSTQ3A'NIAMT\=\;\?\
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MJ]2F<(GDJJB4Z[/]"^V=<IO7J<<EE<+E7--6/Q=/JU1UICEIIF.59?&<VDP
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ML\E;+-   #2S][]_Y>?^MG_PSEP]D_\ [_\ @?[RF.UW_P"/_C_[+2S+A4R
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M/>9]NND_)%QZ:8X(]%<GXE7TE;+W'7I9G/'I^CH1'$J1, NF#'K9H
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MOC:.>8ICPZ>?;3C,1RU12K'#2#,X    -KOW5GO(_FW[CN3>S7:LIZK6.X7
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M,3[7J\S3W!&ASH>@V[=VG#.7OC+G/$U1LIGQ:<(F/;=;#>F$(DEX
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M6?<-@C).H_>%_P"6K^%+8&F_=V7^1H^##VH\;V@
M #"SS)?HZ^_CYEG=-\AN]'8X=](,CYY9^DI<7B3T=S_F5_Z*I4=&JF3
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M       'BO<G^;KS[^!7E/[ALZ>S3OO"Q\M1\*'BU+[NS'R-?P94Z)K9C\
M  &_5[I=^9AW(?.>G^2GCPHSM3^^,OYM_CK7SV3_ '-F?.O\%#:N*P6H
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M=??Q\RSNF^0W>CL<.^D&1\\L_24N+Q)Z.Y_S*_\ 15*CHU4R8
M       #./LI\N;NX[_]O76>W'B[(YS"T+L%/:^4-A6;7.)]&29T*O?L^[6:
MTU3VV*O.DZ8RA'?S-B!KGUZ<R-=TXNL\0:5H5KRFH78IKF/!HC;75W*>;DQG
M"F)WS#MZ+P[JVOWO):=:FJB)PJKG9;I\:KGY>K&-4QNB6\MY=GNZ7:3V@K@^
M1>>(J'=5SU1=6R$&0W#"Q1\0:3DXVK(U=.XWNONUL[?HSR? RF>==D]9!%9J
M5<=,BH4KQ!V@:KJW6R^1QRN1G9A3/QE4>ZKY(GVM.&^8F:H7AP]V=Z3I'5S.
M>PS6?C;C5'Q=,^YHVXS'MJL=T3$4RV'6M:QK6,:UC&-1K&-1&M:UJ=&M:U.B
M-:U$Z(B?4("L)#!YB'GG=F?8''G-+?GF\\=PN/BF@AX4XSRM&P[ Y5(U=#!R
MANR,OX/CV)'>'UM967LVQDC)&XY\3O6),- X*U?7>K>ZOD,A/^I7$[8]Q3LF
MON[*?=8H9Q#QQHV@=:S-7E]0C_3HF-D^[JVQ1W-M7N<&B9W_ 'F]]YGF'Y._
MC>5-Y=IG#?MZ6<)P)QQ+>P/'-.*M82;&S[+$MF7*<@9RHL;)/;,O-89#8\;Z
M<%-C_5)=NA<)Z1H%,596CKYO#;=KPFOIPY*8Z*8C9OF=ZC-?XNUGB&J:<U7U
M,GCLM48Q1T=;EKGIJF=NZ(W(NR2HP  )//)?^E-[)/PU8OZT9@C?&'HSG?D9
M[\)-P9Z49+Y:.]*U<,PM3@    C2[M?OIU_M4Q'[LRI9W"'W5/RU7>I8][=/
M36CS&U\.ZQB)2IH            #./M+XV15N<E96O\ W*SXK5VR-]'546++
M95B*G7JB*M6)R+T],Z*G]RI!.+]3];IEJ>:JO_#3_BG]5I+L+X0QFYQAGJ-W
M6M9;'\EV['T=,_*1,;I9JYG+X_ 8G(YO*V&U<;BJ=B]=L.]/JZ]:-TDGA:GP
MI)'(WHQB=7/<J-1%540A%FS<S%ZFQ9C&[75$1'3+1.H9_*Z7D;NHYZN*,I8M
MU5UU3R4TQC/=GDB(VS.$1ME#QO\ N60W[;<QM.1ZL?D+*^R5O%XFT<="GJJ%
M%G3HWI7K-:CG(B>.3Q/7TN4N73\E;T_)T96WNIC;//,[Y]6?R1LY&!.*.(,U
MQ1KN8UK-[*KM?@T\E%N-E%$>+3$8SRU8U;YETX]J/@         !)WVK?>EI
M_P"7<U^S1%6\6?>]7R=/>;+[$O06WYS>[\,CR-+<                  !5
ML>>_]+3WF?;KI/R1<>FF."/17)^)5])6R]QUZ69SQZ?HZ$1Q*D3 +I@QZV:
M          ".OS+_ "XN'_,H[?[W%'(,<6O;[KCKV?X9Y6IU(I<YQWNDE)T#
M'2.1J3Y33-@\$4&;Q2O;'=@CCE8L=RM4L02#ASB'-\.Y^,UE_"L581<HY*Z?
M[*HWTU<D[-L3,3'N)>'<GQ)I\Y3,>#?IQFW7RT58?GIG=53RQMV3$3%7GW,=
MM?+_ &B\U[QP!SGK$NJ\B:%DO8LC51[K.*RU"Q&VSA]FUO)^KBCS&L[#CI([
M5*TUK5?#(B/9'*V2-FE-.U'*:KDZ,_DJNME[D;.>)Y8F.28G9,?V,PZGIN<T
MC.UY#/4]3,6YPGFF.2J)Y:9C;$_V['@Y[GA    !Z_P)SQRIVR\NZ-SEPMMF
M1TOD?CW-5\WK^:Q\TK&/6-5CNXC+5F21QY;7L[1?)4R%&;Q07*<TD,C58]4/
M)GLCE=2RE>2SE$5Y>Y3A,3^:8YIB=L3OB=L/7D,_FM,S=&>R5<T9FW5C$Q^>
M)YXF-DQ.R8V2M"/*V\RSBWS+>WRER-K2T-9Y;T^+%X+G+BIMJ-UW2]NGIJY,
MKB*\MNUD+7'^US5K$V%NRJKGLBEKRN]IK6&MS7Q-PYF>',_.7N8U96O&;=?M
MJ>:>3K4[.M'<F-DPT[POQ)E>)=/C,VL*<W1A%VCEIJYXY>I5MFF>[$[8E5,&
MGV5P#-/RVOI%.P?YZ?:S\N6BG'XB]'\]YG>^CJ=GAOTBR'GMCZ6E;BF56M
M    *W;WF_Z4W;/P+<._6?(&ANS?T9H^6N=^&<NTSTIK^1M]Z6O@3Q7X   ;
M(GNLWTF&>^;#RG]UO&)7G:;Z.4^<T?!K6-V7>DM7FM?PJ%BH4 T.
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MUN>%?\R-Y_;1^*NG_P I>]]2?A+J/\W9][4?HC_<5_6YX5_S(WG]M'XJZ?\
MRE[WU)^$NH_S=GWM1^B/]Q7];GA7_,C>?VT?BKI_\I>]]2?A+J/\W9][4?HC
M_<5_6YX5_P R-Y_;1^*NG_RE[WU)^$NH_P W9][4?HC_ '%?UN>%?\R-Y_;1
M^*NG_P I>]]2?A+J/\W9][4?HC_<5_6YX5_S(WG]M'XJZ?\ RE[WU)^$NH_S
M=GWM386\F'RO=]\K[C+FG0]\Y1U'E&WRCO> VZA?U'#YG#UL76P^OR8:2I<C
MS+G2S3S2O\;7,^"C?0OI(%QAQ+8XES-F_8M5VHM433,53$XXSCR+!X-X8O\
M#&6O6+]VB[-VY%433$QAA&'*F@(>F8   :6?O?O_ "\_];/_ (9RX>R?_P!_
M_ _WE,=KO_Q_\?\ V6EF7"ID   .Z<;??$T'[=-6^OE$^.8_\>OQ*N]+[9;_
M ,BWX]/?A<R&0VQP        !6&^\._3#=WW^@#_ '7N$S27 /HEE/XOTUQF
M7M"]+\Y_"^@MH628(8   &U;[I=^>?W(?-@G^5;CLK#M3^Y\OYS_ (*UI]D_
MWUF?-?\ <H;]91B^@     -8;WL/Z.OACYZ?'7R&]QA9/9=Z07O,Z_I+2LNU
M;T=L^>T?17E? 7RS^    "XN[;/S=> OP*\6?<-@C).H_>%_Y:OX4M@:;]W9
M?Y&CX,/:CQO:                       ,+/,E^CK[^/F6=TWR&[T=CAWT
M@R/GEGZ2EQ>)/1W/^97_ **I4=&JF3                !Z_P &\ <U=R_(
M6)XIX#XSV[E;D',]7U-:T_%39*S#49+%#8RV6M?K>.P&!HOG9[3D+TU:C5:Y
M'32L;Z3R9W/Y/3LO.:SURBU8CEJG#U(Y9F>2(QF>2'KR.GYW4LQ&5R%JN[F)
MY*8Q]6>2(CEF<(CEEN5^7A[K?I^K?$/)_F%[1!O>=:R'(0=NG'.7NT]*QMA>
MKXJO(O(M"2EFMKG@9(WUU#"+CZ<=F+I[??K.<U]1:_VEWKO6RV@4]2C=Y6N/
M"GQ*)QBGNU8SA[&F5Q\/=E]FUU<SQ!5Y2YO\C1,Q3'CUQA-73%.$8^RJAMP:
M'H&B\6ZC@] XTTW5^/\ 1M8I,QVNZ?IF"QFM:U@Z$:N<VIBL)AZU/'48?&Y7
M*V.-OB<Y7+U554JJ_?OYF[5?S-=5R_5.,U53,S,],SME;-C+V,K9IR^6HIMV
M*8PBFF(BF(Z(C9#$GO6\QKM'[ -0^R;N.Y1Q^$S=^E/<U3B_74AV/EC>5A;-
MX&:QI5:S#;]BFL0+ N3OR4,-7G<UEBY"KF]>KHW#^JZ[=\GI]J:J(GPJYV44
M]VKGY<(QJF-T2Y.M<1:3H%GRNHW8IKF/!HC;<J\6GFY.M.%,3OF&C3YB?O%O
M=MW?IG>.N");_:KP+>2SCY\=IV:EDY>W;%R.2-R;CR1292M8.A>@C^'B\"VE
M'ZN>6M;M9&%44NKA_L_TK2>KF,]AFL]&W&J/BZ9]S1RS'MJL=T3$4RI#B+M$
MU;5^ME\ACE<A.S"F?C*H]U7&&$3[6G#?,3-4->-SG/<Y[W.>][E<YSE5SG.<
MO5SG.7JJN55ZJJD^5Z_(    D\\E_P"E-[)/PU8OZT9@C?&'HSG?D9[\)-P9
MZ49+Y:.]*U<,PM3@    C2[M?OIU_M4Q'[LRI9W"'W5/RU7>I8][=/36CS&U
M\.ZQB)2IH           ';]#T_(;YMF&U;&HK9<E91MBSX5<RC0B19KUZ1/0
MGAK5F.<B*J>-_A8GI<AXL_G;>GY2O-7=U,;(YYY(]6?R;W>X8T#-<3ZYE]%R
MFRN]7X56&,441MKKGQ:8F8CEG"F-LPF'PF&Q^NXC&X/%0)6QV*IP4:<*=%5L
M-=B,:KW=$\<K^GB>Y?2YZJJ^E2FK]ZYF;U5^].-VNJ9F>F?^-C?FG:?E-)R%
MG3<C3U,I8MQ11'-%,8;>>9WS/+,S,[V&'=GR5T;4XUQ5A.K_ %&4VA8U]*-1
M6S8G%2?J)XG(EJ1/J^B%>O17(3;A'3-LZG>CGIM]ZJK_  Q^LSUVZ<7X4V^#
M\C7MGJW,SA^6U:GZ2J.BWTPP8)XS4           "3OM6^]+3_R[FOV:(JWB
MS[WJ^3I[S9?8EZ"V_.;W?AD>1I;@                  *MCSW_ *6GO,^W
M72?DBX]-,<$>BN3\2KZ2ME[CKTLSGCT_1T(CB5(F 73!CULT
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M<@ S3\MKZ13L'^>GVL_+EHIQ^(O1_/>9WOHZG9X;](LAY[8^EI6XIE5K0
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M1LHI\6F-D=W;5/+,KWT?A_2="L^2TVS315AMKG;75XU4[9[FRF.2(9H''=D
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M]*.[5*)C5,M<Y)R\Q^2N?TKW[)JXG2<U1RQF(G\M$?H;895RU@
M          &EG[W[_P O/_6S_P"&<N'LG_\ ?_P/]Y3':[_\?_'_ -EI9EPJ
M9   #NG&WWQ-!^W35OKY1/CF/_'K\2KO2^V6_P#(M^/3WX7,AD-L<
M  5AOO#OTPW=]_H _P!U[A,TEP#Z)93^+]-<9E[0O2_.?POH+:%DF"&   !M
M6^Z7?GG]R'S8)_E6X[*P[4_N?+^<_P""M:?9/]]9GS7_ '*&_648OH     #
M6&][#^CKX8^>GQU\AO<863V7>D%[S.OZ2TK+M6]';/GM'T5Y7P%\L_@    N
M+NVS\W7@+\"O%GW#8(R3J/WA?^6K^%+8&F_=V7^1H^##VH\;V@
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M1'_&U@+4M0S>K9^]J>>JZ^;OW*JZYZ:IQV1R1&Z(W1$1$;(<6?9X@
M    2=]JWWI:?^7<U^S1%6\6?>]7R=/>;+[$O06WYS>[\,CR-+<
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M3NMHVE589Z8^,N1_IQ,>MI]W,;9GV,;O"G&FU> N":=2ZNM:M3CD8GXNW/\
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MR(9,[;.+_M;6*>&\G5CD,C5/E,-U5_#"?FHF:/&JKB=T,4"7*.
M   D[[5OO2T_\NYK]FB*MXL^]ZODZ>\V7V)>@MOSF]WX9'D:6X
M        "K8\]_Z6GO,^W72?DBX]-,<$>BN3\2KZ2ME[CKTLSGCT_1T(CB5(
MF 73!CULT               U7O/V\E"/N:P>>[S>U/5&)W%:SB_:^6>-M?H
MUH'<Y:SBX7.DV7#U8$A6URSKM"/PK&B/FS]")L#/%<@KQV;-X%XR^S:Z='U2
MK_\ 7U3X%<S_ )<SR3[B9][.W=,X5;Q[P5&IT5:SI5'_ .QICXRB(_S:8Y8_
M]2(]6N-F^(B= IS7,<YCVN8]CE:YKD5KFN:O1S7-7HJ.14Z*BEZJ$?D
M &:?EM?2*=@_ST^UGY<M%./Q%Z/Y[S.]]'4[/#?I%D//;'TM*W%,JM:
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M3ZO.RWQKD)T[B?-VL,+==SRE/-A<\/9W*IF/4YD5!)T6   ";7W>ON%B[?\
MS1N#H<E>;C]<YUH;-V]9^5TOJDFEY KU;^CT?#T\,[LARIK6 A1BJGI?XDZN
M:B+#>/<A.?X9OS3&-RQ,78_5V53ZE$U)KV?:A&0XHL15.%N_%5J?U]M,>K7%
M$+.,S>TP                     TL_>_?^7G_K9_\ #.7#V3_^_P#X'^\I
MCM=_^/\ X_\ LM+,N%3(   =TXV^^)H/VZ:M]?*)\<Q_X]?B5=Z7VRW_ )%O
MQZ>_"YD,AMC@        "L-]X=^F&[OO] '^Z]PF:2X!]$LI_%^FN,R]H7I?
MG/X7T%M"R3!#    VK?=+OSS^Y#YL$_RK<=E8=J?W/E_.?\ !6M/LG^^LSYK
M_N4-^LHQ?0     &L-[V']'7PQ\]/CKY#>XPLGLN](+WF=?TEI67:MZ.V?/:
M/HKRO@+Y9_    !<7=MGYNO 7X%>+/N&P1DG4?O"_P#+5_"EL#3?N[+_ "-'
MP8>U'C>T                       86>9+]'7W\?,L[IOD-WH['#OI!D?/
M+/TE+B\2>CN?\RO_ $52HZ-5,F          !G?V2>6UW=>8%MB8#MXXQOY/
M6Z5^*CM7*VS>OUWBG2UD;ZQ_Q]M\]::&Q?CA^&F.QT5[*2,7Q,K.;U<G$UGB
M+2M!M>4U"[$7)C&FB-M=7<IYNF<*>EW=$X;U?7[OD]/M3-N)PJN5;+=/=JY^
MB,:NAO,^77[N[VC]G/Q%R)S37I=TG/E'U-V/.;GAH6\6:;DF^JF8NE<<7'WJ
M=^[0G9^M93,NNV?&QLU>&B_JTI7B#C_5=7ZV7R>.6R,[,*9\.J/=5[,,?:TX
M1R3-2\.'NSS2-'ZN8SN&:S\;<:H\"F?<T;<9CVU6,\L12V#FM:QK6,:UC&-1
MK&-1&M:UJ=&M:U.B-:U$Z(B?4($L!"5YB/GP=FW88F:T?&YEG<)W!X_VBHO$
M7&N7I24=8RD3$5L/)N^-COX73?5O=TEIPQY#,,7IXJ36.]8DST#@C5]<ZMZJ
M/J^0G_4KB<9CW%.R:N[LIZ4*XAXZT;0NM8IJ^L:A'^G1.RF?=U;8I[FVKW/*
MT5>_GS;^\SS#\K9I\O[\[6.)HK_MF!X(XY=>UWC+&^HD5U&UFJ/MEC);SG*K
M?A-O9FQ<?!(^1:K*L;UB2Z]"X5TC0*<<I;ZV:PVW:\)KGGPG=3'13$8\N,[5
M&:]Q;K/$-<QG+G5RF.RU1C%$<V,;ZIZ:IG#DPC8C()(C0          2>>2_
M]*;V2?AJQ?UHS!&^,/1G._(SWX2;@STHR7RT=Z5JX9A:G    !&EW:_?3K_:
MIB/W9E2SN$/NJ?EJN]2Q[VZ>FM'F-KX=UC$2E30         (BJO1/2J^A$3
MZJJ?P2J=OO&R<>Z/7DO5_5;'LB0Y7-^-.DM9BL=\78IW_=2A7E57I]5)Y9/2
MJ=.E4<1:G]HY^8MSCEK6--/3[:KU9W=$0VWV5\(?TIPW35F:>KJ^<PN7L=],
M8?%V_P!2F9F8]O57R8.P<S<AQ<;:-DLS$^/XYN(N+UZ!_A<K\K:C?X+*QN1R
M/AQT373O14\+O C%5%>AYM%TZ=3S]-F?\BGPJY]S')W9W>KCR.KV@\5T<(<-
M7M0HF/M"Y\78B>6Y5$X58<L6XQKG'9/5BG&)JA$?+++/++//(^:::1\LTLCE
M?)++(Y7R22/<JN>][U555?2JJ7!$13$4TQA3$;&$;E==VN;MR9JN53,S,[9F
M9VS,SRS,[W\S^OR            !)WVK?>EI_P"7<U^S1%6\6?>]7R=/>;+[
M$O06WYS>[\,CR-+<                  !5L>>_]+3WF?;KI/R1<>FF."/1
M7)^)5])6R]QUZ69SQZ?HZ$1Q*D3 +I@QZV:                -+?WA'R4/
M6?9IY@/:3J;6O1MW9^YWB;7ZL44:QQ11R9'FK2<-3KQIZWI')8VNI%U=(Y79
M1K/%\82.N'@+C+#J:#JM719KG\UNJ?S43^K[53/:!P7CU]?TFC;MJO6X_/<I
MC\]<?K^V:5Y<*F      ,T_+:^D4[!_GI]K/RY:*<?B+T?SWF=[Z.IV>&_2+
M(>>V/I:5N*95:T      KO?>I-2EP'F0Z9GTJMCK;SVN<;YM+<44[8[-W%;S
MRGJMF*:>1C8)+]6K@JZO;&YW@@DA5W17%^]F-WRG#U=O';1F:X]2::*OR;9]
M7%GKM2M3;XCHN8;*\K1/Y*JZ?R[(]3!K4EBJW   "9#R!.2:_&?FQ]J=R_.V
M#&;AEM]XVN]7.:LMC?.,MQP.N0-5'M8KI-OL8[T.1R*G5$3Q*UR1'CK+SF>%
MLU%/KJ(IK][73,_W<4PX!S,9;BO*S5ZVN:Z)_6HJB/[V"T(,UM.@       &
MK'[UAW'UM"[/.)>VW&Y")FQ\_P#*D6QYNBRRBS.X[XBJLRUQ+--B*]D5S?,[
M@I())%:QRT94:CW-<L=F]F&GS?U>[J-4?%V+6$3[NYL^#%6/=A5W:IJ,6-'M
M:;3/QF8NXS'N+>V?[TTX=R6@&7JH,    &_5[I=^9AW(?.>G^2GCPHSM3^^,
MOYM_CK7SV3_<V9\Z_P %#:N*P6H         *[CWF_LO?P'WKX_N/U7#OJ\<
M=V6%?L60FK0-;CL9S)IT&/PV_P!'I#$C*S]DQ<N,SGBF>LER]>ON9U;$Y&W]
MV;ZQ]>T:=/NSCF,K5A'/-NK&:9]2>M3T1%/.SUVF:-]0UJ-1M1AE\W3C/-%R
MG"*H]6.K5TS-7,UKBQ%;@  !V33=OV3C[;]5WW3LM:P.W:1LF#V_5<Y1?ZN[
MA=DUK*5<S@\M3>J*C+6.R=**:->GH>Q#YWK5N_:JL7HBJU73--43NF)C"8]6
M'TLWKF7O49BS,TWJ*HJIF.2:9QB?4F%NOV8=R^M]XG:SP=W*ZLE>&CRQH6)S
M^3QM5SWQ:_MM=),1O&KHZ2261SM7W+&W\>KE<Y7^S>+JJ*BKE/6-.N:1J=_3
MKOKK5R8B>>G?35^M3,3ZK6VC:E;UC2[&I6O6W;<3,<U6ZJG]6J)CU&3IS73
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M519R>2CUE55=<]VF*::?A5+B[)<I3-[.YZ?7TTV[<=RJ:JJO@TMW0IE=8
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M+2S+A4R   '=.-OOB:#]NFK?7RB?',?^/7XE7>E]LM_Y%OQZ>_"YD,AMC@
M      "L-]X=^F&[OO\ 0!_NO<)FDN ?1+*?Q?IKC,O:%Z7YS^%]!;0LDP0P
M   -JWW2[\\_N0^;!/\ *MQV5AVI_<^7\Y_P5K3[)_OK,^:_[E#?K*,7T
M  !K#>]A_1U\,?/3XZ^0WN,+)[+O2"]YG7]):5EVK>CMGSVCZ*\KX"^6?P
M  7%W;9^;KP%^!7BS[AL$9)U'[PO_+5_"EL#3?N[+_(T?!A[4>-[0
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MLHW^%CC0W'W!?V=75K>E4?\ Z^J<;E$?Z=4SZZF.2W,\GL)W>#,13JG%GJK
M   !FGY;7TBG8/\ /3[6?ERT4X_$7H_GO,[WT=3L\-^D60\]L?2TK<4RJUH
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MC*0   2X^1!]+3V9_;KNWR1<A$5XW]%<YXE/TE"6<"^EF3\>KZ.M:3F9VH0
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M9F%D=G7$U.D9Z=+SE6&GYFJ,)G=1<W1,\T51A35/),4SLB)6(Y0+0H
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M55KV/:J*BHJHJ*9*U*,-1OQ._P M7\*6P--F)T[+S&[R%'P8>VGB>T
M                 86>9+]'7W\?,L[IOD-WH['#OI!D?/+/TE+B\2>CN?\
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MNU_B_P#ISAR=/RE6&JY^*K=.$[:+>&%VOHG"8HIW3UJNM'K)1@%IL9
M         $G?:M]Z6G_EW-?LT15O%GWO5\G3WFR^Q+T%M^<WN_#(\C2W
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M.(Q\:*L=Z^^S+B"G.:=.B9BK_NLOC-&.^JU,\GB3.'13-.&Z6U"5DM(
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MV4[9V13$9MXQXMO\29SJ6L:-*M3/DZ=TU3NZ]?NIY(]C&R-LU3,+I,$,
M!;\]D?YF':)\V#@+Y*=3,GZU]\9OSF[\.IKG1/N7*>:VOHZ63YS74    !'O
MYL?T9_?5\V'EW[DLB=[A;TCR7G-OX4(_Q7Z-9[S6Y\&53>:D92   "7'R(/I
M:>S/[==V^2+D(BO&_HKG/$I^DH2S@7TLR?CU?1UK2<S.U"     !I@>\]>67
M;OI5\QOAO7_:)*E7"ZAW0X?%546PM.JRMA-%Y@DBAC\=AE*!M? YF17.=' W
M&RHSU4=N9EO]FW$<4X\/9RK9,S59F?RU6_5VU4]/6C?A"FNTWAF:L.(LG3MB
M(IOQ'-NIN>ILHJZ.K.Z)EI3%QJ7    !O&>1!Y[^-W+&Z9V3=[.YT\7NN+IX
M[5N!^>-IR,52CO%&I%%0PO&G)>:ORLAK[S7A8ROA\Q8>C<ZU&U;3OC/U4N2I
M?C?@BJS57K.C43-F9FJ[:IC;3.^:Z(CV/+53'K=\>#C%-W<"\=4WJ:-%UJN(
MOQ$4VKM4[*HW117,^RY*:I]=NGPL)JW#"I5O@       'XEECACDFFD9%#$Q
M\LLLKVQQQ1QM5SY)'N5&L8QJ*JJJHB(@B,=D;R9B(QG<U,?-O]X\TGA^OL_;
MUV!9S#<B\M^&QB-J[B*OL&=XTXYE5RPV:?''C;;QG)&X1-1W_J'23 4'*Q6.
MR$JRQ5K3X5[/;V;FG/Z[3-O*[Z;6V*Z_'Y:*>CUT^YC"9J?BWM&L9.*M/T"J
MFYF]U5W9-%'B<E=73ZV/=3C$:*^U;7M&];+GMSW78LYMVW[3E;V=V7:-FRM[
M.;#L&;R=A]O(Y?-9G)SV<AD\E?M2NDFGFD?)(]RJY552Z[5JU8MTV;---%JF
M(B*8B(B(C=$1&R(CF4;=NW;]VJ]?JJKO5S,U553,S,SOF9G;,SSRV0?=6./T
MVCS%=ZW*Q$U:O&?;-ON7JSJCG+'G-DW/CK4:<+499A\+IL+E\D[QN9,Q$C5O
MA1SF/97O:=?\EP_19C?<S-,>I%-=7?B%C]EF7\KQ%<O3NM9:J?5FJBF/S3*P
MX*#:#    !I9^]^_\O/_ %L_^&<N'LG_ /?_ ,#_ 'E,=KO_ ,?_ !_]EI9E
MPJ9   #NG&WWQ-!^W35OKY1/CF/_ !Z_$J[TOMEO_(M^/3WX7,AD-L<
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M3UL4LN!AKRT-@Y4NU)8NC75GX["O1[)H;]QB.A=9O#_9OG<YU<SK4SE\MO\
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M=%,1$\N,[5&:[Q7K/$-?_>W.KE<=EJC&FW'-C&.-4]-4S,<F$;$;1(D<
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MJWWI:?\ EW-?LT15O%GWO5\G3WFR^Q+T%M^<WN_#(\C2W
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M8WT\N,853G'BS@S.\-WIO6NM=TFJ?!N8;:<?8W,-T\D5;*:N3"<:8A1)BA8
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MLUS[FJJCO]?^U[5^E^__ ///_P#RS_\ ]9SQ_A/_ /Y__(_^\]OXN_\ ^O\
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MBKJ5^)7/@S/137LCIK:')=ZB@   WZO=+OS,.Y#YST_R4\>%&=J?WQE_-O\
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M5RJJB.K1,S,1OPC'9&/1N:_MTU46Z::YZU<4Q$SNQF(VSAT[W,GX?L
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M=L>VJQGECJ[D^Y!4]      TL_>_?^7G_K9_\,Y</9/_ .__ ('^\ICM=_\
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M:>"OM+YP^2+;B'=H?HK?\>W])2FG9QZ66/$N_1U++XSFTH
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MY)9E[<N+_K.;M\)9*KXBQ,7+\Q.^Y,>!;V<E%,]:J-OA54[IH88DV9Z
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M/RY:*?CB+T?SWF=[Z.I^^&_2+(>>V/I:5N*95:T         $7'F$^4-V?\
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M56W]7I6CV9</7OM"YK&=MU44V:>I;BJ)B9KJCPIC&/8T[/U^AO.%*KP
M      !PNR:WKVXZ_FM3VW!8C9]7V3%WL)L.N9_'5,O@\YALG7DJ9'%9;%WX
M9Z60QUZK*Z.:&5CXY&.5KD5%/W;N7+-R+MJJ:;M,Q,3$X3$QNF)C;$P_%RW;
MO6ZK5VF*K543$Q,8Q,3OB8G9,3S--;S+/=@)LED\_P O^7/D,?5;=?9RF4[8
MMTS3*%6&U(]TLD7$F^YFRE2K5F<Y$CQ&>GBB@Z.6/))&L5:.W>'>TJ*::<IQ
M!$SALB]3&/OZ8^%3&WVN^5.\2=F,U559SAV8C';-FJ</FZY^#5.SVVZ&G_S'
MP9S)V\[K>XZYSXPWCB?=\?XW3ZWO>N9/7,C+6;/+79D<>W(UX8LMB+$L#O47
M:KIJEAJ>*.1[>BEL93.Y//V8S&2NT7;,\M,Q,=R<-T\\3MCE5#G,CG-/O3E\
M]:KM7XY*HF)[L8[XYIC9/(\J/4\H    /OQ>+R>;R-+$87'7\OELC8BIX_%X
MNI8OY&_;F<C(:M*E4CELVK$KUZ-8QKG.7T(A^:JJ:*9KKF(HC?,[(CU7]HHJ
MKJBBB)FN9V1&V9[D)\>QWW<WON[K+6*V7EK .[2.([+H9[&R<MX>U_.3DJ3U
M_76ZQPVVSC=F2XQJM<BYZ7 5GQN\44LRM5BP;6NT'1-+B;>5J^M9N.2B? CN
MW-L>]ZT\\0GNA]G>NZK,7<W3]4RD\MR/#F/<V]E7ONI'-,MX#L&\K/M$\NC6
M9*/!>COR7(66I-I[?S9OCZ>P<I[1&KDDEI?'3*5.EK&O/D8S_P!+P]:A2D6*
M.2=D]AJSNIC7>)M5X@N=;.UX9>)\&W3LHIZ<-]4^ZJF9YL(V+MT'A?2.';75
MR-&.8F/"N5;:ZNC'#"F/<TQ$<^,[4C!'TB=<V_4-5Y U78M'WC7<-MNG;;AL
MAKVSZQL./JY;!9_!9:K)2R>)RV,NQS5+U"]4F=')'(US7-<J*A]+5V[8NTWK
M-4T7J)B::HG"8F-TQ/),/G>LVLQ:JL7Z::[-=,Q53,8Q,3LF)B=\2T/O-.]V
MSY8X7RVR<U=A&(S?,?#$S[.7RG!T<LV6YAXVC>YTTU33X7^.YRMJE9W5M>.%
M7['7C='$^#(>"6Z7=PSVB97.44Y/7)BSG-T7-UNOQO:5<_L)WXT[*5%<4]F^
M;R==6=T&*KV3WS:WW*/%_>4\WLXW85;:FJUE,7D\'DK^&S6.OX?,8JY8Q^4Q
M64IV,?DL;?J2N@MT;]&W'#:IW*L[',DBD:U['HJ*B*A9U-5-=,5T3$T3&,3&
MV)CGB5654545317$Q7$X3$[)B>:8? ?I_    E+\J;M8[QN4>[;MMYE[=N N
M1-^UWB;GGC#>L]N]?$.PO'&.QFF;OA\UL-'+<A["_%:=7L2XBA9C=3]M6].W
MQLABD?T:1GBC4](RVE9C)ZA?MV[EVQ73%..-<S53,1,41C5OF-N&$<LI1PKI
M>L9K5LMG-.R]RY;M7Z*IJPPHB*:HF8FN<*=T3LQQGDA:FF8VI0 !@1YIN(RN
M?\N+O;PN"QF0S69RG;7RO1QF)Q-*SD<GD;MC5,A'7IT*%.*:U;M3R*C61QL<
M]RKT1%4[G#-=-'$.2KKF(HC,T3,SLB/"C?+@\4T5W.',[1;B:JYRU<1$1C,S
MU9W0JQ_R;>XG^@/FG\5F\_P$::^T-/\ W]GW]/Z67/LW4?Y>][RK]!^3;W$_
MT!\T_BLWG^ A]H:?^_L^_I_2?9NH_P O>]Y5^@_)M[B?Z ^:?Q6;S_ 0^T-/
M_?V??T_I/LW4?Y>][RK]!^3;W$_T!\T_BLWG^ A]H:?^_L^_I_2?9NH_R][W
ME7Z$K7D?<&\UZMYJ?9_G]GX>Y2US!8W<=RER.:SW'^V8C$T(Y>*-^KQR7<ED
M,17IU626)F,:KWM17N1J>E40B_&F=R=WAC-V[=VU57-%.$153,SX=/)$I5P3
MD<[:XIR=R[9NTVXKJQF:*HB/ JWS,+-4SBTN          &$_>-Y=W:#WXZV
MF"[D^'<!MV7I4)*&N<BXQKM<Y1U")72S1,US?,1[/G(*$%R99UQUA]G%3S>F
M>K*G5%[.D:_JVAW.OIUZJBB9QFB=M%7=IG9CR8QA5'),.+K'#VD:[;\GJ5FF
MNN(PBN-E=/<JC;ACMPG&F>6):DG>)[J7S3ITF5VCLGY@PO,. :^>S3XMY;DH
M:)R/6K^*3V?&XK=ZS6<?[9=Z(SQ37H]8A3JOH7HGBM32.U#)WL+6LV9LW/;T
M8U4=V:?74QW.NJ;6.RO.V9F[HMZF];]I<PIK[D5>LJGN]1K:]PG9AW7=J.3E
MQ?<5V_<I\3>"TZE!F=IU3(Q:CE+#7K&K<#N]*.YINQ,5Z=$?0OV8U7ZBEAY#
M6-+U2GK:??M7=FZFJ.M'=IGPH]6(5QJ&C:KI575U'+W;6W?53/5GN51C3/J3
M+&0Z3F      ?14J6\A;JT*%6Q=O7;$-2E2J0R6;=NW9D;#7JU:\+7S6+%B9
MZ,8QB*Y[E1$154_DS%,355.%,/[$35,4TQ,U3.R$NG:OY%GF5]ULN-O8+@+*
M\/Z1D'1JO(?<(^UQ3@H:\R,?#=K:[E*%KDG.T+,+E?%8QF"NUWM3KZQ/$WK%
M-3XVX=TN)IKOQ>O1["UX<]S&)ZD3T35$I;I? W$FJS%5&7FS8GV=WXN.[A,=
M>8Z::9CI;3_9/[KYVF<(3X3=>ZO;,OW3[[1]5<=IWL\^D<(T+R+',R.?7J5R
M?;-U^+[#/"U^0R5?'78^J6,9X7>!*RUGM*U7.Q59TNB,K8GV7KKDQW9\&G'H
MB9CDJ6EHO9CI.1FF]JM<YJ_'L?6VXGN1X56'3,1/+2V7-3U'5-"UO#:;HVL:
M]I>H:[2CQNOZKJ>%QNNZW@L=#U6''X;!X>M3QF,I1*Y?#%!$R-O7T(5U=NW;
M]R;U^JJN[5.,U53,S,\\S.V?563:LVK%N+-BFFBS3&$4TQ$1$<T1&R([CL)\
MWT       :='O9O&W(O(7Y ?V Z#NN\?%'Y5'QM]A^K9S9?BOV_\G#V#XQ^)
M:-WV+VWV*;U/K?#ZSU+_  ]?"[I;?99F,O8^O>7KHHQ\CAUJHC'#RN.&,J?[
M5\MF,Q]0^KVZZ\/+X]6F:L,?(X8X1.&.$M.?\FWN)_H#YI_%9O/\!%M_:&G_
M +^S[^G]*GOLW4?Y>][RK]!^3;W$_P! ?-/XK-Y_@(?:&G_O[/OZ?TGV;J/\
MO>]Y5^@_)M[B?Z ^:?Q6;S_ 0^T-/_?V??T_I/LW4?Y>][RK]!^3;W$_T!\T
M_BLWG^ A]H:?^_L^_I_2?9NH_P O>]Y5^AW'COMR[A8>0-%FFX'YFBABW'6)
M999>+]WCCBCCS=%SY)'NP:-8QC455551$1#Y9C4,A-BN(OV<>I/LZ>:>E]LO
MIVH1F*)FQ>PZ]/L*N>.A;_&3FNP        !6N>?WPES/M_FW=V6Q:GQ%R?M
M&OY#^8CV#.Z[H.UYK#WO9.VCAJC:]CR>-Q-FE9]FNUI(9/ ]W@EC<Q>CFJB:
M)X%SF3M<*Y6W=NVZ;D>5QB:J8F/CKD[IEF[C[)9V]Q9F[EJS=JMSY+"8HJF)
M^)MQOB,-Z'/\FWN)_H#YI_%9O/\  1+?M#3_ -_9]_3^E#_LW4?Y>][RK]!^
M3;W$_P! ?-/XK-Y_@(?:&G_O[/OZ?TGV;J/\O>]Y5^@_)M[B?Z ^:?Q6;S_
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MUZV)4]"KZQC7)UC*NXHU/Z[G?JUJ?^WLXQW:O93ZFZ.Y,QO;'['>$/Z?X?\
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M4TU3'5JPG"<)WQLVQMC9,/?R/+2
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M+/FGZ9G='XNR>0S]$T9BC.V.Y,>5IPJIGEIGDGU)PF)A:BF9&I
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MJ>[5AUI]6631S73
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M5LBKN3A5[G#:H/B+@36-!ZU^B/K&GQ_J41MICW=&V:>F8ZU/NL=B$0F:$@
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MB,)\K<B.K1/_ *5O;%'15/6KCDJB)P>]D?6>
M                         P?[L>P3@[NWWSMNY=W+&_$7,7:US;Q9S#QE
MR3AZD#LXE/CWD37=ZS''.=1SX$R^G;A'@WP^KD>K\9<E;<K^E)X;/:TO7<[I
M5C,92S/6RF:LUVZZ)W>'1-,5QS54X^K&R>28XFJZ#D=6OY;-WHZN<RM^BY17
M&_P*XJFB>>FK##HG;'+$YP'%=L
M
M
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M\DRH[6N'=6T"]Y+4;4TT3/@UQMMU>+5S]$X51RQ#!H[3B
M        "3SR7_I3>R3\-6+^M&8(WQAZ,YWY&>_"3<&>E&2^6CO2M7#,+4X
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MNJ:ZYF:YWS.V9[LKXLV;.6M4V,O13;L41A333$4TQ$;HB(PB(Z(?W/R^H
M
M
M
M
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M=4
M
M
M
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MO5YU;]M/%_V)H<:#DZL-2S],Q5A.VBQ&RN?XD_%QR33Y3;C$(V2S60@
M       />^-.WK=N05KY"S"[6=:E\$GQQDX'^T7(7(CD=B<:KHI[C7M<BME>
ML4"HJ^%[E3PD?U3B+(Z=C;IGRN:CV-,[(GW56Z.YMGH6?P=V4\1\5=3-WJ9R
M>CU83Y6Y3/6KC_TK>RJO'DJF::)C=5,Q@D!X]XBTGC:NU,#C4FRCH_!:SV1\
M%K+V/$G1[6S^!K*<#T^K% V-B]/A(Y>JK7FHZQGM3J_[BK"UR41LICU.6>F<
M9:FX5X#X<X0M8:79ZV=F,*KUS"J[5S^%A$44S[6B*8YXF=KTXY:9
M
M
M
M
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MDH8R#K'0I-Z*K>L4"(KU3HCY7.=]5RERZ=D;>G9.C*V_8QMGGJG?/Y=W1A#
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M:N/BJ)]Q;G&)F.2JOK3C&-,4;F1Q&EN
M
M
M
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M5NBUE:(PIHHIBFFF.:*8B(A]A^'H
M
M
M
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M@\.:+PUDXR6BY>BS:V=:8VUUS'+77.-54]V=FZ,(V.UGD=P
M
M
M
M
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M(YV4.V[B_P"U-6IX9R56.1R56-W"=E5^8PP_A4S-/C55Q,;(8E$O44
M ]IXVX(WCD=T-RO5^(]=>J*[8,K%)'7FCZJBKBZOP+&4?Z%Z*SPPHY.CI&KT
M.'J>OY'3<:*I\IF?:4[X\:=U/J[>:)6)PAV9<2<733F+5'U;29_U[L3%,Q_Z
M=.RJY._;&%&,837$I!..>$]'XVCCGQE'XRSJ,Z3;#E6QV,AXE:K7MHM\*08R
M%R.<G2%J/<U>CWOZ(I7FI:YG]3F:;M75R_M*=D>KRU3W=G-$-3\)=G7#?"%$
M7<G:\MJ>&V_<PJN=/4Y+<;9C"B(F8V5558/73CIX
M
M
M
M
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M33313%-,84Q&$1S0P?=NW+]VJ]>JFJ[75-54S.,S,SC,S/+,SMF7\C]/P
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M$:UJ)T1$^H169F9QG>N:FF*8BFF(BF(PB(Y'Z#^@
M
M
M
M
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M(Y9WS,[9G;,S+DCY/8
M
M
M
M
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M:+8IMS,1%5<^%<KP]O7.V=NV*=E,>QIB'=SPI(
M
M
M
M
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M9'<IJPJY(QWJ-XBX U?1.MF,M$YG3XV]:B/"ICW=&V>[53C3RSU=R!(G"!@
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M[J=]7YHZ&I^#^S#AOA**<S31]:U>,/CKD1,TS_Z5&VFWT3&-?)-<P]N.&L<
M
M
M
M
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MJ9JJF9JE>-NW1:HBW:IBFW3&$1$81$1NB(C9$1S/Z'\?L
M
M
M
M
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M8F8GG9H^2_\ 2F]DGX:L7]:,P<?C#T9SOR,]^'9X,]*,E\M'>E:N&86IP
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MZ(
M
M
M
M
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MG&>EWN&."N'N$;'D](L1&8F,*KU>%5VONUX;(V1X-$4T8[>KCM>B'-2P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
F                                               /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img123481027_1.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img123481027_1.gif
M1TE&.#EAY1#A!_<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
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MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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M(,[2DM#LI@?S*/\K?FI3?\$<9C3O"4;'&;(]:HSG0# 83&MNTI_CX>4[L0E
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M)#3")#S")DQ",G@$!*24'"B[W.L]X,/"W]-"X=N]X+,W+\R0(^O!,21#HK
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MA*'1R)F>%&5(X4),V321G!?UE.=4_U'DTJ$3&?JB?I%J!.E!"A(T*0*:QH2
MG3="5*)7F!ZT*$-N6LJ5CI+6Z>J?+9Y$*D$FA:K1H ?M22="MVHVGZ^<S2"#
MIRHZ:NR%$ZE:+  /,NML0YPRFVBR7E&+P$C+3F3J0?EMV.V=V/)Z4([XC8O
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MU0SMR,NC%_=Y0:M/];A8O<[H8YH]_[R*=C3^F]]#Z3Y^H9HM/91R!\ !$K"
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M)D%6'T!R)B""Q42.)N4P)&F>)E=ET96H)FJVYECY0RLH@RD0PVR"@D5:Y#"
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M<%9G-$1#;,9FGN[IHRI#>$Z$I_;#</(#HD(#JL+LH28JGJYLFI L="J#"0&
M,@0GSCZLT XM%Y6!K1*M5R4"['W!("1"*\Q"/V 2'?%#*R1"&42?S0U"L%ZI
ML1;KUAYKUXI,LCY1F$GE6YJ>U36+MKI:,YJIVVJ>FCHC<\%?B=J8ABK;E^$=
M0H#/BL0/X % U7CBA#:$=3$9]DBHOD[=L?SMV*6-F2HNM;(M?& 7@U[=V@Y1
MPB+_K>8J3L-N[M"V0@68DQ?L(U=8K#=AK(]LK#=Y+(]D+%>X;N7X0W-" P!$
M R@,JN?FKNY*4*3M[F3!@PX(ZT .K_ 6+]=^[2.-K1 5S4B8JU9<7I=Z"K>
MS_0N1/6Z6H/&Y=VQV@.N'7-=3RUNEXVR6G[Z1-NPA]M9S:IQE]>5VO<VQ'\R
M*W/)"]EQUT_BE_=\Z!-EKN_VK\UTKO^^*>BZ4Q=XA>EV$^KVB.IV+.E.A""
M$P3D0 ,3$28&L 5?<.3T+@8CEB $[_$.:]@B;PB#L C7D/*FTJSEUN,R&"(<
M[0:_,)( , PG9,1^$XP=<#?1&@YO4P+SR )S$^L.A#]$_Y,X629+^$-T=2E$
M7$%::<0\D*AY6-<5=,0\."^K.< 53+!HM,(5. !S/8"38A"[RF?=6;&7=L2\
MXA>P/2-+F/$8SS <8TXB%' <^U4'&R_8EC )[S'Q?O!R>$X=!W)4P)@@%S*1
MR+ A.UXK7"QN=03'=A,A-\0.:U,/[\@/Q]/HJM]RN8-7^,,5+%>$%80Z/!OL
M7H4@G 0+[..JS4 I>\0L6-<,]&QZY H8:U"#<$L#@HNKZ2<)TN@MLC$SNG B
M#_/B*"TQC]4=^S$>>RT?+_,(][%M=- Q'[-43;,UEP<B7W.[+?(W:?%$U,XW
MB=DD9U,E:^PCJ]/<>G-!X(-6R/_#>?B7 X1Q_:SP2)SR?NB</\#7%(]&/IR$
M \BR>="R/%M0K)0OW!QH&G<-+P, 7OH),/]B,VJS1#-.(B3=1&>5/'AP'C>S
M,G?T1D,S,_]Q&MT4<R'N,A[0^9I)7,:/^#[OL>$7D;GK&^-4-8>0/P@""R
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M!%-OV^@NOWQBWP(/\28N^9Y" ENOOBH0]N[-V3 /\FR/!F-O('(PH7:O"1%
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M?"CCD-(W;>HFH MC%*G!T)%#(,(@9V#0%([P&.XYB^+OAJ0W_ZW<&@Z$2@T
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M=&3T[)/FO1DM3R'P>Q='<!61 96+70[ID57FI[P_68L_$%D6 J6'I(<@8C_
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M1QJ" (ATXBQAX?\%8*,8:E06UI5&I)8^$]%%.?%V(R(V!^0%$*A:%G@5UG5
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MP![T0B HB:02L2K(*!#UX'9/RF15R'PM06B(8(^T!J=)(:>61J<<B79-TJ@
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M6=+D290I5:YDV=(E1B\>&[9Z"5&?3(8/"T[$F;!,S9->^(#JI2D3*$U\KCQ
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M'__[YW___0_I"DBE_QNR^>N\SQO U2M !$0__9.TBR.UU]$BRI+ !:Q "[S
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MP _>AQ=*W/_-W6# F%_#96&>Y*!]U$/FA1R*N"''X9_G_8RN,2$5DMZ742
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MS1HMTA;MT3:M#CQMU%I #A@MU1JM#E#M#& MU&ZMUN8 UWYMV&ZMV)+MV.I
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M5H?U8 .,1X/U88\U8G/.56^U8@NV8S=V8DMV6D<V97<U4U9 N01V93^VP,S
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ML_V66W"W'=?;<,TE5]QR@4HVU8.NNB>V>%V;%S9Z6ZL7WWOUE3=??O>UU]^
M9T.66=Z V\]7WS)<:-59.3S.UH-FJ"[18B^L[D3DI"N3/8L"_T6 6(D+54C6
M44WT@F(ZW[,-943O3+BB06WT=5C!8(:HH93WHV_1AJB+*&21@./O8QXC'0@1
M7('FTECUH%.I9>"6BW2&DGX6%("&D28)$>>2V_I5@8(-Z>CJ9%A8H;#M&PB^
M=M'$<%EE*R58;G;I=KO@N/&N.^^Y0[T;\+\%USMPP@?WNTLFE53<R;[M/OQQ
MPR5'G/+(*W<<<[XUWYOSPB_?W'/+1<^\<\A)#_UTTT%7O?3)%PI49@;#\\V+
M(7LND3V"=N-YH(H;HEFBC5N22 9%)2KU:$W_ CXBX5\BWOB(.':X+ZV5-S!J
M!+S;#68$NEB)9[%K4EOWUI/GK^2!MO\W<&*3\U.[>+]VQ?G%[(,^2.OR;TO?
M.L&2:[M%]8F?=MB#DU>9QR5-$Q^D)%(.1- #$?5XH!>4UL"3\ X!OIM0^#(8
M$P4.9 ;K$U.@PM0TU*W.=:D;D+/4U<)TO?!<+HPA#-$U0QO6$(<RS"$-==A#
M'OY0+I_#VU0"!C C]NN(_T+B$I78Q"(R\8E.=,S 6.>GHWVL5C.YV=8X5+8.
MZJ0>^8,8RS"&O?6<T7T:ZIA)I"8R]<"D'>0[CLR8-Y#OJ>Q_@:FC]TZ(&Z>1
M!SA5^QU[[D>2*R)@(QP<H&ZRQT?Y* V-".R+TQ9I,(G4+D0'C,[S?+.^A6#0
M(!O9(@( ^$C_IUT/([XY#P#(]SM-2I)D:^RCF;Q AA2B4(BSK.(N;]FZ7/+R
ME[W4I3"!.3I<&M.7'6(<XY YS& ^LYG%5"$TIQE-8EZ3FL>LYC:UV<UD<O.;
MWG2F-;,93G/>!G8>&AD Y@?""-V.2IY2D->05A+FQ>XDW?OC<WP30I_E;I\X
M.9\>N8//C.@3B_O\B"<5@L&$%NU2F1K,0P&*Q3MB9* (DN>9-!G)I8W$>A1*
MXTDJ>-&#P),DKZPH(2,*J]RT3WWN.5Z*1LE/?OJ3(;[9D=;&!B>=^L=E4$/.
MF(PC$88FJ)WZH]'-2@DC$TI3G%!-)@N!N,,;^O"J5<6J5;FZ5:]J_Q6L615K
M5\/Z%G)*Z%U15&L2UPI%MK[5K7&5HEP%1AML"NB0*GF(;XI7$HLR1Z5'!1E,
M((F 2@I5IUO2F)MD2;25'L"51ZW-!WM:01 .*&FD.FD>&V19@F"V')H]",P<
M**&.-G5'?_1@824%&,JBYX^E3(@^5XD???:U);0%43^!^M.%)/58(3G.=Y(C
M,W:6!VT *&Q/(90_@X)S0X*P93G'"5VI5C>J=[6N=K-+W>M^E[OG!._GEHDD
M)9UUN]X-+W;%N][QHK>[\&VO>NDK7_;>][WIM6]^XZM?TJ5S1.MT;19C@M(;
M 12W#=EK1$RZD'LJB+?05"!V'FRA"(LH??\1&PEPY4?"W#32>2I2)$U8J^$%
M:5*##;%L*!O"O_-8+7>BC8DF*Z@=F&HO.U<;;/7JP]R,W%B$"EEN33"%R==M
M-$H=-6YQGN/C^'2OP2PIJO0N")SD@I%\)CY(:%.LDR$K:,H#^=-3W5OF^L:$
M#&0=ZU?77%8VJQG.;Y:SF^G<9CO'65QV/?-"IG(8NL)UKH%NJZ !/6A#%QI@
M5#3S?A?MW_X^>KZ,WG.D'=VY!=L1OXT^B'0U36E(9WK2H);TJ"LMZE+SU].I
M3E!YFT3J3Z/:U*_N=*Q5#6M;S_K6H<ZUJVN-:U_K^M>\IC5C(:+E4P?[V,!6
MMK!WG6QF(UO6RW;_]K3KA@@ 0KO7TH[VL[6=;6XS^A%4,2XV$<&51"#ZS^DF
MM+H/S6YTKUO0BN[VL)N];6I[^][TQK:^YUUO=AHYW_[F][<#OF^!']S@">\W
MM%E]WH(O'.($M_?$\4WQ@3]<XA77^,4MCO"(8QSDXH3I<SNN\(QS?.,>/[G*
M0YYRD[=\X-9V^<=+3O.9K_SE-8\//PHCEC+H8Q9=FH4^RC 6,MS#W4F'=[N7
M_FZF/]WIGIE!*U!>=9;K'.97OWG6<[YU2%N[ZU8/N];%;O.RX]SL9*]WPQN'
M=;=['>YGYWK:QUYWNM\=[7F?N][?+O>^J]WN?(\[X/&^=\/_/?"'!TPB_^Y(
M>,'[??")1WSAQ3D+1/3<+DAJNM*ASOFH>Q[TFQ>]/J8.>=,[?C[JB=CI#8?0
M32J>]3=!!/#.-OG'2Q7LE(^\[F-_>\GOWO>\7[MYET3\X!\_Y$GRP@P>T/SF
MYR '74@$\FT/>]17'_O M_[O>[]]X7/_^MK/?O?''W[RBQ_]Y^\]X]-O?O>#
M'_[?ES^!K/WYT=N_\_</??[Y[_0</$+]($>!5N_]0"3,=HQ9+JU\7FZ+4.DF
M_DC+,BO6DLK8L.YKG*S@5*J,$(:O'(MZP@\1="#^J*_]1M#[2#  3;#\1H+M
M4/!*<L#Y8K#Y=. E9# &96LAR, &G<] &$\'=O_0!@%.H(#P ?B$"!\@$?[#
M"YPO![CD"&V0!E?D"7>02Y80"H&P"0UI"K<0"[40"&N""YN/#*X#$8!P^G"#
M".%C/[H "*.0)!(!!H]0#>?O!.MP!>GP#EV0<&YL(!),HXKM+W3L:Z '0KKF
ML:QL/X;*3/9(H2X+#TOP$5,P$@M0#R=1!=V&_22Q$C?1#B&1$[OK'G0 _T9Q
M_TA1_TZQ_TH1-OYOX#J* /T!. ".@_K'0NA)S(8'I<0()SZH(1#,E"0*S.8H
M(QQJLBZ0(_+JGR@BR!2" G%BN&Q# 3L(QFI&N 0,J2CJ>A#BB@2I%^\CIX21
MSY CR@I+)I3LH'R#Q0#_P(NPIJ&@XWIT+,@.<($40I]8[ !KZR V<+,H"55T
MK)!,PA81[,K0+Q0O41,[\2#S$"$I<2%SK@4;LB7B< =MY3_2T"]T\ M[Y >_
M< @Y\D[8\ B7+%2 < X!0")ED")O@@@1@B0#PPIEL D3H@M9)!&(, D7Y"5M
M$ QW< P!X A?H@QW\ S[PB+7L US B.#D"$5DBD]$2(_T2G[1)Z2BN1."A!E
M*B(D2T,4,,1T1!&WI()DK"D3,BK+DBS/<BG-,BW'"0[5TB#7$B[?4B[I"Q]$
M4151T113$2_O4B^?CA41[HJ$4&*00[/NL4! R4'JL3;*YA4!0!X9)E!PD)6L
M__%!AD8E<L>D#B8CHC'%.,@!V8FS]N1CEM&-($*VKF@@S>1C)D4!HXPX+.LV
MZBAD#C ;->*5?,K U'&Q\D.U2,(R,P+$#@(Q>R0PEV6+#HL>3\F#""S[ZG(N
MH1(MG_,IIW,LX[)1'K(Z1^((<\!'+!(WDE(G?>0D8S +R28,B7!0_F,\N7 X
M!B0G8_ OTA!"5K(V:G('&P^C/!(E9M)%[%,HB9,^T9 G5R(D42(H;7 H\Z,H
M3P(DS_,(HU ZL],2)Q0ZK?/DD PE+NQUKE(W^-!I,/ @KD8RK>0K*X1_)+1"
M(]0M*90Z5S1%Y^\14O)%9[1%HY-%);0N\U)'^7)']__21_N2K:0OY@9QQQ:L
M N5((FK3'S00 74S(EZLQ0ZQ'9[K9EZQ:<YF2#HJ*QVS@ 2#M6)FR[:T+Y!4
M&@?)HTA3/YBT>72C-6'DD,P&1?2I/' J.8<%N/HP-6M#2ULK))*F$8.# .L!
MQ?CC:@RJ:4KKMY01  01A+3R(-81'!ULI#;H3WVQ).C!0U<SQU@*Y?)!!&_4
M16O40D5516V41@$ .]5R.]7$._L"/&5P2P[4!LO3/#U2F-[S!C.B01UT"YM*
M.SFR)'"U^;Q@5^&S!G>05G?$/Q$40/5300?408KU!LW0+Q945X^R07Z25$'5
M5+?U5$,5=##T4MEC>\0U1,K_AHZZ]$U*%$ X=511U%OC%5[G%5SKM?=F04;E
MU5[?=5]+E5\9(A]RH$>!E$<+]D<'%F$A0TC_E6']]9K>M#%=C1_IM5M1R%C$
M$NX\U6'])A_>U#?<X4$>@?A&-DD2@1\:EEM1]ELKME\7(E5[3UAY52=MHE7S
MXU5E%@C;TR5BEE=U5AUQ%@A'8EEA=4BT]5FI\$%Z%47X,T&&-@9O$J\"E"BA
ME4&DE5H%= =+LB&L%FB=;V,)A!\<0"*\ 3K(%@&N@&_>(2+,UC?8=FS+%FZ!
MPVT1 &09I!\VLFOS]@9+8DA:@6OU=@IU0!_"Q&D!-W 3XFMASUQEXJ9L0F'\
MXY6X_Y$E O( (G;VU .U- :")&AS'RB"'DC*FHPFXBA7])5E3U=E33=U*79U
M.01?6W9E6Q=U$W?R]$%@#99@#Q9W$U9W47%A:1=V51=X9S=E@==VAQ=%],$+
M6*!2/6H@ZC8E1+9)2%9)J)=Q$.$1!I=X8Q=YN[=XL^EE95=\O9=[O[=\1>0*
M$&!N":(?&F(>U!<ZYB%.U'8@W%80"N>0V)8T[W8+J])$_$$0*F +/U4F;C8,
M=0 1:.,ZE)?Y9-8"J$XG>#8-\T&!M</REL\&'SC@^ $.#]=\A?>#69=\0?A\
M2=B$13A$7G=[3SAX4;B$HTT?*H!W<Y>&9]B&=Y>N?C>$6_^8AU?8A5F89?FA
M A*W'[R 42G*>1L1>D5">JMW>I_8B:/X>J%8<1[A9'\8BWMX?'<8N\)WA+/8
MA[7XB\5X%M+W;3_+0NZA;2,"9*N$?N$W(NY7FO!A;27" ;QC(_AW"OWW4? 6
M""U@(?+!07.@@@E&$!RT)&?A/-TPYRS/CPWW 0@8B+?XA<68BREYDL<XC#51
MA3$9C#W9DBO9F83XAGNWAG'8E$LY8'18E$'Y(&N*2(/+G@Y10S<KB4EI9]:&
M/"Y9D_FU'QX@0IM7EVTJEI4X9*T7F:DXF:48>]L7=<R8/=1!S^;$'>QXD_FK
M$>7!E;=9\KR8E[^YE7M9G&W.5];_%P&NN$;4UIP==2;>V'Y11Q[J."(<8'#S
M^)%S5G/N60:C\)##\ Q]!!I,@1A,(1- (1H I'#3L(+]09\=5/KX%M@2VOET
M0! D>)_'.9S!.9,U^I,Q>J,S6G04.90_FJ0[FJ/'Y)=56:51^913F:4=@Y5+
M>J3G58R@% "><7([J5VK(QT!H %]>@9$%$UGFJC)TA^ ^4:%&9"6FIB-V3^:
M>(J969F3Y!':-R'X062OES;TH4D25'64.A\<I9IYA9NS*9O+6B02X1T.*$\]
MNIN\&:1E^IK=NJASK1\TB6W1UD]F06[9QD/<62+DF'!:@7G[FI1T0H^?D(\K
MQ%/]&2-:_^$\T[,AHD&@*QL4*GL83 $4-*$7-"$3,J$7#+I!+%H&O=I!0A&2
MF\\"!*&0!<Z VY"NY_JD93NN3;JVZSJV3:<(:5NNT;JWO?>H5]JEA[NEBUNX
M]2&F;?NW*>].,58;:8<#DY1]D&M <-IQ1R6WLWO>D/H3E;JID7B8G_>8IUI)
M$B'H% *KEYEQS-L?+(^*O3ING.8> (".D9B>K62L(X*WN^FLO_A/VWJV^0NN
ME_NV]QNW YR8R $Z#AMS[KI^?>,=: 2P#7N-*?R,*QP!6."?82*Q4QMG37LC
M^OD)9V =,GN@35RS*WN@!UH96B$:_$$9/)NS/1NT9UP9M*.A@?]0C@NF%7*\
M?S-"D3V\^78\-UY[!R59N9/\P O<MY7<P)^\R;]IMZ,<RK6;R9_S 8Y;RU^:
MRXD;_[Q@PZ\<P><M4VD9!^5Q;2K)]9S7?[Q[J*M\S$^.NZG3NXL9O)E:O/VC
M@CE8JOL\JM?@BMW;S^&[4>3;@PI[I1" R'<COV6Y):#Y8]HX2-)W/?2:(V:!
M<B]I)?1ABL.:(>2Q\0 28N;;)AH=H.8;0OK[)GJC/ 23(4S=-/5#;+_;L)8L
M']24BU+]H0!<S)-EP)T<O(35#9>\(;T ^F850S9%^<9S!G3 5V&B@640/^/<
MT7K#G*\];C'\PK<](EB@M3=BP@/I"KK_X!T0 1_..R/P0:785L.KI,.WT *:
MO98$H60K.MK/4VO_XMUW$ $>  '$=F."3N#;F^ '_KQCO+,SP<87TT$A-)CP
M-0R?O9F,' JMG, O'M@M/N.I?>-I] &F&>.)O>-#7A,? !^ZW+A1?LN]G/.2
M6^1?'LY[G>1=><[GM<YO'KQEP O0^:G5V^>I&G&A6KT)_4L,74'4W<X10)HS
MPM2O ]+90](KA-*AP]+]@M6I'L@3^&(F54Y:P1W(]!9S0M5%0DU'U"\2X:$>
M9-8'T0$V D+ 7A!TO:)X?>;CYM=AGG5B%FIIXCRG/:WQV0NSMD5L$FJD-IQ\
MG#V3%B87%@"2_V0+_7XAUM/Y0#S'S9Z=2%+CDPFO(\+3Q\O4S9;(P5V>!T*P
MH001S/G?&<IN$;_Y%OLD[L$"&M[M7:(5F*_?_[T^#J +6N'<6L'W3Y[W$>/W
M?3\1?%^"O$ 'HGT&.#L3HB ,%_TV\.$\*T#>O<#ZD;\+DA]HJ>C3*/ZB.1[O
M,S_FZQ[\QW_D%5+>9/[\P[_\+=3D51[^65[^4W[TNJ KV5_]\9_\\U_]'L"9
MZ1P@$" X(+"@0((&#R94*)"%EWX _,V2-\,@PH+N(@+8R#'B(T2)$*T!*9+D
MR) G2X:<M5%?RI<F8Z),U%%C39LU_=W$": @P7LY=^J\J?-*PHL%9?^H2[AQ
M:%"C%C%R=-J1*@"C2 M>$;J37\6C AWDF\H1ZL 91(4F6GBQ'$V>:P<N1&"U
M:4>?">7QY%AN+D$90=,*#IS3 5N!7:IRY=B%H4$O=7GB38@HLN7%A!4/UIR9
M[&;/G>U^%AUZ+VG.J%^^'&VZ]676KTO'1@V:]NG:N&^3[O*@M^_>9'3C_/T[
M,0#BQ-4B[XV(\'+?PH=Z>6[<]/3GF&V[SJYC>>[ML)4_?X#V]/CFKQ.-?QN9
M]W(OX>/+SOY]=GWZT?&#+]WOJT%O". SGWS:.;640  6!!].[Q24H$""Y"<?
M/@XFQ$(^L?73W7B^-7??9K/,P*%O"#S@ 'G_+,V'"!E>M.CBBS"V^$"))8[X
M7 5>S&+?:;,(LJ&-0 :I@SX#%ED@?F0$^8 ..^YW)($?&AGEDU)*6*634V9I
M)95<:HGEEEXV*:9^8T()YIE?IEGFE6MVB6:;89(IIYEJSLFFG6[622><;^(9
MYYY^]@GHH$7.D"*?>MY):)Z(-AIHHHP^ZNBB?RIJ::24"GIII9AN*F$%^+22
MCS[YB$JJJ:6.FNJIJJ+J:JNPLBKKJK2^.JNMM<::ZZVZXNIKK\#R*NRNQ/XZ
MK+'%!IOLL<HB:ZH7'D[J*:2<5JMII]A:2^VUVDJ;+;?@;BNNM]U*:FZFXYX[
M+;D 5,"/NM^FN]ED_V 9Q((@$$4DR%=9.1:501E9]A%*,JFD4CXLS6(P3 0W
MO/!;Y3:%%U#Q^B/(80;E1T^] K5B)3_T&I2.G>Z$#&&;<?4[PVPISS6;R7I=
M)@/'"%1:<G2&U5N=DXW)E1!DV9F,0&7P1KQNT>&VJ9I)Z+(K[]%-;Z3><N7M
M1YUG'+(W-7(>XH;(>#M/]9P.HUWG7=2;_:CD>VVJC5S5G+EW=FSC!>>:VQU"
MK7?%2#_--]I[&_TWU%/3.&/."A&D. +MS-**!6OWEH..?3MM>>68 S[XYH)W
MGG3F@7^NN>=^DW[YZ**'7GKJG+-N.NBMKR[[Z:K3'KOMH!GJ^NZSP_XZZO^]
M X\[[\.O/HL^CR12!AG, ^$%$&0L7P8BC^B3XNV^$[]1!?<XV^SWS(:_[/C>
MBU\^^>"C;W[ZY[?/_OO"=L%>]L'73G_Q^-^OO_#[V\____X+(/8 Z*8<$(F
MO\M,0<A!- #,XATSZ)?/:":T"0HD8$(9V,)D<L"/,&R##OO@&B"6NGY,3'7X
M\$_-L-0?";I0("O;B" D.#(S\8,%?D$ /:Y4,HQQ+", \,(+"S(_CL!,35[P
MX;_  L3Z(&XR.YM-S_H%M-$@ H=*+,A8$*@]+OIM:2CQ8O[$.*>M(2=*5].-
MV9"SQM]T+3IF),Y;V@B='=$1.O(1D9**6*4X_H;_;)W) 8< R:7QP"<]XZG/
M>028P $RLHN/K)\C6S>+?)3!"SJ8005&5($9> $?A^K?)!M)2DB.TI2EE&0J
MQQA)5IY2E:B,)2QGZ<I5BM*69,QE*V\IRS7ICI:\!*8N7UG+7@:SEOQ@$1"6
M^3QF+M-Y9$@$Y6 SBT0HTYG8=%X0WD7,8VXD!_5PW_K&J;YRBM.<\$,G.<_)
MSG2V<YVCDI\QAXG+7=)SGO;,9S?O*4Q]UG.?GM+!%OUI3(N1HX)#I*"_$(!!
MHF@0)H_023]"6# 1QN01W.PG0#?ZSX[BDZ,?]:A&14H5,(J$G\4<*6F^MAQ
MTFTYU7G-'9?SQOW(S48Q_\7/3-<&MS_1T0LD]$<BO"!(#N4@,GJ,W(A,4]3G
M+ @ B-CI VJ*U.>0,*185:E64\I5;Z+4JP3=*EA!*M:OFC6L73TK6=.*UK&2
MU*U99>M:X5K6 ,[ 8W6=JUK?NM>XTM4^^7#>,YM)AHR^DA]ER.;SKBK7B.6
M'N]4IV0C2UEW6A:>F)WL934[3J#ZM:]YY6M;0=O8SX[VM'I%K;5T("#2!I,?
M7IC9$F=KLH;FY*&(H%PK*,I;ZKVKM*$U;6J'*UKB"K>X_S3I&ES+W$VQE(W
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M>)'(/5JQJ:, P OY0Y-49F% _3W  O\;(%"(XH\(3C H%:1@4*H'D7&5:P9
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MYGRFFBY+Q+KMJI1LW;;M>D') :2FVCYM98#B,1&&$W5!QYX(Z$PJWO(MJ\V
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M3+_T3+NT3<<T3>?T3=<T3N^T3D]Q&2R;Y;9K4-<@-;DQ'<^Q4I,N4\MQ@ "
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M)DN&3'E2)4H .O(!\ > 9DV9-FO.Q'ESITZ</FT"S;F3YT^B_A D55HTZ%$
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M5OW56YVQ'R$S9X(?1-B>;54?3H1W^B;PX_U5<EWF05VFK>+76S 1WL$W.QT
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M@L@:9Z:YYAJ)S (1/V:BJ2:=;;;YIC^SW$EGE5:>5. ] ."3H'\.Z/,6 .[
M)V6C6%[Y)*19=E5H>?(\FFBDF4XJ4:7E(:+IGZ)&B>FHCDI59YJIKB%IJYNZ
M:FJII(8Z*Z>VPEHKKJ?>^FJOL=*ZJZZR!NMKE*T\@&RRRBZK@W,'S3+#LM(J
M*Y]6.DR+;2+ .I4(MM/:R) 7WHX+)Z\'"<(E JU0U8\#7!JY+;"(I(O .^8>
MI Z7#O"S5#XL< DJ6/D5R$(KORIT19@(7!KOO<0>+&S#$3L\;/_%$A?[<*X8
M6TSQQ1!O[+'&'X\L<LD9G\SQQ"J#W''+*Y,,%&W,_6;<S,+)7'/.R^FL7,\X
M[PRTSS0'_;/0-P]M=')%+XTTTT<_K7334D-M<]14\^RTU5I7[5@6+K-L4!:#
M?0%SRMIQ%S+*:9L]TY;IK<?AC4B*Z#9",8J)0#D+#8S>#!Q]V)Y.[X%984<)
M@DLCB@<=;G>ZA#/:9(0_A6ED1R/V9Z)_!DU8H(XXX0WZ@-QA=3<"/AXT.'N(
MX!AX=O5P+GE!I1\PNG64PS5[[2:SO?O:#7N!^,N]/^>IVZ$;7[S"9!(U"T+\
MV D]F]&OVB:_ .PY/9Y@IVBAH"@A\B__\N@)DM2B[,&5,-YD2IDPF%=D-(L,
M7I8W.D3Z4)_(0# !.6#E'LE/H1EXKR+F\Y2@I.(IAL5D8!7R0E$*N"7=$<5=
M\]./C0R2#\Z!;D$(%%_ A*>VKY7-8ZM:%0AY%\(3^DZ$PU,A"U.XO1&^$(4T
M7*$+726N<2F+?%LA@PZ5I8.;7.N'R-*6R[I%Q"1BZX(PC)%]9N L+*7/0"Z<
MHH4*]C%_P X][PN6!DGD.:?PC418W%T_QAA!B-@PABUD(PQE>$,WUG"&:X2C
M'.O81COJ,8]\?&,?YQC'/?IQD("\(Y2RQC6L36UKBKP:T1:9R$<Z,FF1I&0C
M&2E)3%HRDY5$_^0E.PG)3XJ2DZ/<I"D1&<5"BF<6D1E$(/.X'57^$8]2<IN.
MBL*E, * /P"3R.5*-"LT^LTB@"N/@S87I XA(G6,ZM26@H=,A97G=!.9EW^\
MP"2$U,,+\KME3!(DP8Q\L3R^%)_"CCD[8G)IF"5ID:1*1\V*S*YU"8'/#'14
MCU\6J2=;9$\[/KC, :TH18_CDD3ZV1Z .G&@ % 2>YA$2UD2LB# $Z1$#6?.
M@E8P>>>1@1>L5R8^26^D^!OI(PKBCSF15*1NBF&@L(*/+X))'<U3" 2%5!0K
M=FE]W6E?NKIX$@;^M"%[JNE!''JA%+;"'0AE3P<5IL"'C)-(X4Q)(O_$-Q0*
MBLD!:HQ)4\LCB*=6Z(.&?.5$Z8B0$K;)K!>-J%O1RM:WQA6N9:VK1>5JUZ/X
M,(E^4@LBE%@[C0R1B$94&1*5J$-ZH<=@O;,F>UA@5)$A=!UMY$=3A[G"TB&
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MZ8)9 ) /BH61&:F1Z4(."S%5=:=>]S!4X<(E=1<R!0<?*=>.:\%,535WK04
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M*L )HN2YH>'9H28ZHAD#:.9YHBSJ*]SGHN/)3%!G.6[_<SJOJ3BH<SN3 UI
M,:.W-$X=,8@3,4YW.:-""1%!@A"(=TL!%203F($/*J1S6$WN*3 !1!*:<Q!
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M8DR(L.-&A1T!@/2H423)D0;+1:1H\N-)F"]ENJ3)<:;-FB%OZLQ9$N?_3YY
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MCNB)DBHZW8/,(M/N1.#)EX#<R\:$FHP(T,/4E"A/0@>*DB(J8S0HRBEE\O,
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MZN&P<**J@X SGCYI6Q"#^4MA0A0[7H@4+R5J&<^%,Z-M3%%E$L>XLCRN(/T
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ML+^K'Q;<@S)('_^^[X@03Y2I,W19@9M\.G7SYXFB+W^G/[C!X:$H.PU5832
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MCY4,9!G*C*KR/4!WR\&D_$HYND?J GBO/%\$<'G+"*BNF![LY>Z*ZL'[#6*
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MN7WVK_WVM,WV:+_V=*_V=M_V<@_WM#KJ230+$#O<P@W<@,_#Q'W<QJTOKXY
MRWUZ2-SD8.T-$,[&\C7GY0C /B_Y\-W0#%[>#_]_7AR.WJW_<0+NU?=GQSW]
MQ1''^>;S^.-XUPTY)?37@)MW^3 "T362X !N)+X>[/75Y%&2Q1QH;4@"UG([
M^_P5[M#>\7VX^1U7\=Z%V?4C%0D__1Q.A!=._0A?_=J?_1#5Y@P/XN>WYYW_
MSLT>7E^"[A?)U$[YER,M9:3XB<^?[U(V]"\B<5?][HT(9G?M#VB>_[$')0#1
MY0 "@NT '/1W$$#"@P,)>B.(P"$"B 0G5D103Z&_+A81R%BX423"B-YF(!P9
M$N5*E8C:E8QX,:+!E0(CEDO)4"5%@C-T_NS($^1/1![=J43J#Y$[B3 ]/D1P
M].=!FP0ULOPY RJ]I#$18,TIDJG,_Z<\RT(<JA#C 41@:TZ\FC0LRY<6NV M
M:K;+5(1Y*\IUFS2H0\"%E<IH^G"N7'J)$? 5#/6L5\E-I2Z&G!GSYL":.W,V
M#-JS83*"@'@!DAKUZM2G7:-6_;HU:]BR:].>+3LVZ]VN>]_6;3LW;^&_A_LN
MGARW<>;*@R]W3ASZ].?5I5M'3OWZ]NS8@7/_WAW\\?#ER9]OKEW\>O/IO:./
MSAZ^>MB/1M\7G1_K(^*(^.73)Y__],%G0 $!+!#  PDT<, $ W2P000E9%#!
M""V<$,,*(<R0PPT7?!!$"D.\T$,2.Q11PQ,_+#%%$T>$4<487Y1QAEGP^RS'
MT-SJ8JVONO^JC*\99+HLL+H20P3'D,8J";.@,%(R(<F2U ](H0!SS,>OH@2@
M+)H6TLHL!'#2\2?*]L(L3(S(W+'-* ?KB4L JJ+HKL+*<<JGC?*::#29L**,
MRAP1T5),LBQS4R$\/7++T)3J<4K0A>!$ $VLPG1(4H9F6.NDD!#K4S]$+K)3
MSD3+!$T0,E!E]517386UREA;G?5566^E%5=;<^5U5U]K!5;78'L=]E=ACR46
M66.395:E1!!Y-I%G'X&V6&N5O;;9;)?E=EMOL057VW"['?=;<<\E%UUSTV5W
M77?+A5?=>-N=]UUY[Z6W68R\:2M1R9)2DR!-<X*)V)(\'6W?E([_Y/<SIBKR
MPM[(>"JR,(;[U>QA@B(6-F $!D8H8+>\P.A+R!0FUJ^/W#R85T);!NSE@D:2
M>4S.S-*S42@5NA@OR7).2N6*&2(YHK@R"Y@K,Z'*56,$..YU48HPGJMHJW"U
MVN:149[X+U/W+;5*AG_$[]]9:Y8X[7K71H@,W% C0[BX<9M;MKI9N]NUO.&6
MNV^Z_;8;<+P%UYMPOO]&//#$!U^\\,8/5SQRQB5WG'+()\>\\LPOU[QSSC\'
M8N_0#1_]\=(M/WWSU#U?'7317R<==M-E=ZW??-E%)'4R%H2&PMXU_-W#X'GW
MO7C@C1<>>>*/9S[YYI=W/GKHIQ]P^.J5_[_^^>REWY[Z'&YD>]>L(0++Z3H!
MK<RD(EUR:FJZ8')'4"^DWGDE,?=MWZ3/I@06IK30OQ]!D+*O&5R&'N/;F)#P
M5Q",+05G2PM@^LAV$$ZUKQT-=!K0.%*9HRT&4F;+C_D6&$&MR46"]) ?_8R6
M$A4.+2=/BA-FG'*JFD%$:5U0&@4)>)!Z>(QB2/G@E3(#PZL! ($$85-"1(C#
MEK2C"XA1(,SJ$39\U6H>J[J=VJH8/BUFD8M?W&(8O2C&+I81C&-$HQG/-2UH
M1:M:9U1C&N$X1S+248YUQ.,=]1A'/MJQCWG\XQ[].$A $E*0A=311:BVO\3<
MR2LY!.! # :5__]A"2,=/$C/=M2CF<"13U%IDR8]P\F9]8IA5 08TV(V$9,1
M3)6Q A5!+.7(AR!,/V+R3,U:>1#ZH7(JB*F(!A<6D[OH)3,%,XS0 $,G3*:2
M)Y"<U%-V1:==NBJ(D@Q-8^""JP<N1FH'\&67NEDFCX&,AHHDIT>@*2>T&3*0
M[W2;?-PSGGG*,S[MN>=\WE-/?-)'G_3,)S__:4]_"M2@ 45H01.ZSX4"5*$/
M92A$'1I1BDH'B^\<23Q9@P@6H:A%'_5H2#LZTA65=$8N0BE(27I2E9I41B^E
M44Q3*E*7RC1"-L+H2FI6#EN^SR.5!,IDO+29QA0JF,UDB*':=Y&>IC'_:3M"
MQ#<1L$X  ),RQN1,%U1XED6"2:A9FF!-MIJEKBIQ2 )3TI$.T%3\Q+(R#IG!
M!6E%1+!6*I=K*BO-T.DF2ID3,M>$65;.,@.EJ:FK:F7K2,[*P:KB\E$^E E0
M%;74O"*R,*JR;$X/N5G-=M:=G\TL:#DK6L^&EE5NE!8BJ)6(TH[6M*Z%;6ME
M2UK:OG:VMJUM;'-[6]WBUK>]1>.^*FM"L^RH@@\I*S)AE;^-7?" ^'-A)DLR
M7,&*2:XJ\4([U!3.7%7&N?,+*P!$F2;O+C*[V[T4_S:B)I$5!KJ(F"(415+4
M@U5LBDZ+V0*]4(^E')<B['79#ENRID[Z['XX_W2)QXXK3+"<,)D_(PHE?\B7
MK"%UO5L!C'_1LE]$/#>P%[:N>;7[D'!:M9;QF^+/+GDK$'8&)E0]R C+@6#^
MND/#,<0*76>,PAH'4+( J"%STR>J8/+6R-C2*.IHI[HELZ[)KHM=E&<G9253
MF<E6=C*6H3QE+E>YRU?^<I;#O&4OEQG,9A8SFLD\N'Z0-G!DP!Z K"?G..MC
MSG:N\YWUG&<^:X_.?L8SH/<LZ#YS[\^&#C3W<M"*(_^VT<!]=*1W.VE'RZHH
MV36O"G\,Z3-BEM.5!O6G12WI4)-ZU)0^=:DYP\;41LO4KT8UK%4]ZU376M:V
MCG6N:7UK7NL:U[MVY?]_46+CDG&77O30JE=D$%?J"LN!P:QFL) MU65?]SX.
MA&NT.<,^BQ0PE#,P\9@0K*04-T4&L]S6B"GF5Z+2:<:AM3$KFYU'[;J5V:B:
MMO_N?:IDVP7&MNZ"C:G=!0L[; 8#+_BO%<YKMRW<U[T&=L0=+O$^YHYNNJU;
M;,A@4YJRM.,PG>E*0=Y2CXN<XR8/>4U37G*5DWSD$UHTQ"<^<YG7_.$W+S6F
MEOH1=E-\7)ZVN<^%3G.<$WWH03=ZTAF"6E8CW>E%?_K1H3YUJ5==Z52_NM6C
MGO51?UCK6-]ZV,$^]J^7G>MBUU8BO'!VLK/=[&AW^Q[+(+JVJ,WBNJ/>H?/_
MGNB]#QK1?N][H0-/:,+_7?#=0[S>$\_WQ5LOYFV'>^0A/_FW4S[NQ4+$VB]O
M><E7WO.;_WSG>\MJU(K>])Q'?>A3#WK6GU[UKV_]ZHWL]=C#WO6UQ_WM=2][
MV2?B+KNW/>^#/_RDYP,]NQM7/I+<&_]\_.0M=_[*7XYRES^?Y=>?/O2I'_WJ
M2_]%WP-^[H4O?N*'W_RZ OKXSU]^];>?_>\W.M-5^T;XKY_\][=__MV/__WK
MO_[]!\#_$T#^&T#_(\ #-#*U0\  7, "9,"T280G*P/5T@?P\8=9Z(=9T =J
M*8,UVYW&.SS%$T'&&T'  \'"&SS#0\$35,$63,$7_V1! 0&_!Z1!![3!!L1!
MN$.$BZK!'.Q! P3"'W0_TH,6^O/!&PQ")!1")63"(W3")'S")8S")H3"*I1"
M*ZR_S)O"+<1"+G2_6;B[?F(HCLH^[+.^,D3#,U1#[V/#[G-#[H/#[9-#[2N0
M&:3"*\3#.]1#+\RC>M"\+@3$/.3#00S$>Y&_U2I$0A3$1&3$173$/6Q$2'Q$
M193$2J3$2XS$4?,]3)S$3/1$7_/#$@Q!$B1%$Q3%%3Q%%XS!54Q%&&Q%5BS%
M431%QK-#3D0)^D*NMU,9@K"_L6DQOEJV8K/$61F?>6.]^!*3=^.Z>M"!8>S$
M9W3&:+3%?"%"5X/&:?Q$:?_,1FR\QFWTQFX$1VT,1VX4QW*D.07\1G-,1W+4
M(V9,PS:,0SHT0WB<PWE\PWI\QWN4QWR,1WZHQ?-SJ\<("VWZ"'0#.\J@%\;R
M.8)4C%8YE$/1-LM2(:ECDE*B.40(R)*9BYIY2-I[-&94QW%<QY$42>$[1"/L
MM1QX@)5DR99TR9>$R0> C)A\@#\<B42@R9QL21V8 6,D"IT$2I;4/,!(!)4,
MRIV$%:!L1O$)2AVHNULQ2IW$I*.DRI=<"2^@R:H!RH33B7J(R<JBR:&<"D2H
MRI?4@;4CR9!42W9,2[8LR;5LR[A\2_S;1+F$R[FT2U>Y!QUXQ;Z,153\2U7T
MRUG_)$Q9-$S +$S$/+P<X <CP\@(2I+'M*'\8JZT"+<1,IDGFK!'$;(2^B6S
MH)++7!E8H2NT$*\7DPL1BB&-L4P2TDB6Z"$)LD@N\3#9A)J0P$42BLA/2<8J
MB4T20JKV^DWA8HFQ@J[4=$W"8HQNRDW39(BH:I\DVA,(DTS4S(SJ3)\2 \T-
MVLZ;08LD(:+;G(H@20D!,[6]O,OT=$OUS$M9JT:4'+NH+$N:G,F8M,FKG,^F
MO ^LS,^7%$N%Z$^7U ^</,I=*4M3F0&J]!25"-"C?$HCRDJWH$JT]*"OE%#[
M# O^;-"6%$^\]%#V_-!IK+?$Z )K$Q5URS:?')<1E;=__VO/$'U1$)71UBO*
M];31&+U17=E+?L3'-=1'>^Q''MU''PU2(NU1>I3''+"/2<M(3QG.F.BI48D4
MAB"E:%(J".,9KZ@87\R(R7H*#:*K@1B*3YI-S"!3]Q$OR H;AGPF*_61&_HJ
MN.K*/(D+:DN4W!R(^%$BL$*)MW(*@P0+-JV(G@, P$* N#H(Z/Q%J:HE'II2
MJC J*$6)C"R57>S2/JVKT+S2,6F+Q6I3""(2KQ*3HSG3<L 8!0NJND(44QF;
M34NJ-U54)+DU],S1&<716X51MCE)UF+ G*10E@C+D8G0T$ $'<C)'# ,#;7*
M6%%6E^1*J(1)+S#6:-4/FO1*:O\]E9@$@)A$UM.B216%4&V]4 6M4)@$2PP%
MBV9E21WPC)S,55M]UUI=..8J$X\$@.8L(/A:BF+L#$N%"!3;UZTB+J^Y%=&4
M 0X[(%_L4'AE6'G%U8;EM4= UH=UV'A=QQT-3%?,6%A,3,'<V,$\3(_M6(T=
M68[%GAS@U5!KU0SC&J4@3QTQSY$8'UL2H;!XV=-4KTEU+)BUSOFRKHUX5)T"
M&Z&UU]PTF6?K61?+6:08FRV%GU_QUYL8B=[L"V)3KH- H!R3C [%TN*\6B/:
M*@W*DZD0H:["'Z_]Q3U]S1I:TR.2%(4MEK.%*N.46K.C58K%6XO56XA=M?EK
M-?@L/_G_?,G1"%; 4%>6S _!;<D%_8G#74EC45RA')=K?<E$P%IN917ZW%9M
MO8]I=4DLBDG&736:M-Q3<=P'F O[] =W_2L+!8S"E0O'9=>Y(%"8W-N*Y=O<
MY:R#85.N]$B=<U&B^EE\&U@!DA/_.H#\"%[=S5OFO=WFS2*)Q=WIA=Y,Q%@D
M!=(C_5$AS=XAQ5[N!5\C]5Z20]G2(B6)2*QPBPM#/17DG0NJM5(Y?:&GF"6F
MTEH2Q1%#*2M+U8DW7<XUF=J+R(DS[11W(+@JD0D8DU(,>\ZU,+;C#54IV523
M.#<+,Y]HFZ'J(HPHFHQJ,S:UFJJ@Z5J5H).&(>&UR"ORQ%/__RG1X>J4<\F2
MN2AAY=1@'$LZ?%C*ZGW>'7;>'G:6(DPM1&P_LBQ<PD57"AM6'#G=^UR(TUT6
MS\W)',::F)R*L,01S06 VG7)_P16F-0)S/56UU7B)!X)U3T(=X5-,2YC=(W=
MF)Q=O+!B'J9>.=9A6I&BI+42_7$F@K5CJ(@N6TE;)PED'Z[C.29D.B8MZ2WD
M149DXL-AD%7,2!;9D"592C992:YD3%[%\JVM\4&EK;K-(.+CT%#?L BW5"TR
MFL$?2+H?SO3C4VEEHOU%N9W3FU7;%3*P5-:7I_U, +:?ED66K%V(75S8T%!(
M[(I97L+C32%.TQW:/#9>L1A>W(1?G?]H(6KV95@&YF0)-VTKY?0RBV)^-!P^
MY'(VY'-NWO=,6=Q+4,Q5DB*663+6D79^R6YMW U]@ =-"BVF2GO># SE"RA>
M7,[ XH6(T*F(W(D%4)@4W1SAYY8LW3$6U]>-UI_(R76F7)<\5VQMXPT]RT9&
M9Y!F9 #2XU<ML#Q.+ #PU!73$?I):4 N+G);9I&F:7,>Z9 F(T6N:9SF:2A\
M9/'MWJ .W^\%ZJ'>WJ)&:J)>.4Y6V:M:$Q@"*DK95+*=8! ;U*D05*=&*Y$(
MR&9Z85>)5*M89JVVB%T<F(R,"9_MR*6]#\A:JL2RY<WPT[D6IA6>:TW9N;N&
M#!!>5+)V#.G_S$WI5&8&GD[\+>RP=@Q,XLB\OE3>9.E=4=6'I*+(IBR?BFE4
M(^>>WNF;YNPEW-6P(V(V?N<CCN>)'FV8E&*$.-VC3.T=201Z;LK R.B6'"XG
MWI&"3@C'7>?5Q=8OALEN/96'9DEPM6V*]L^ _E8>4N.5@-VI6.W^;.W.MNG-
M%LG?35M[M6S].IF2>.#\&&2+^5K-GN[Q%N_R+J-94&CREF[SMKR?+EE(GF1-
MAN],CN_ZIN_[OF15[(+=IF[UGM_NI+6)9.^JTS!PA:U\B.X0[0=!0(RC< MJ
M>80V6^\)[V_04^>H$^B6].=6@6?\-&W..-VR<F)[$6X.Y0M\-N-Q_QW<FXS0
M#'^ -T:*T!U0TF65XC[QBLX)%U_)1)CMX5;Q+<Y0-[X/,J!)&*=P_T9R+L3N
M$@;:1MV5Q:X8EQ:7[_ZKF4[R(Q_P+*]>]-;R"L?R6T-PHRY2I3YJ,A_S,D?S
M,U=S[>VX_?YR'EYL)[^M$C;P-T>7:WKIULJ'#6?+69"'E8X(!P<," =B:,F'
M6;AR+U=T ?QLR^MQB*Z5#L<N>4ZFG$2J$>>BT#[N/4%Q-#;N%<>*LOS5&/_M
M&5_N';'Q-=YT8:W*C?;/($=M_,A)*+R'B+#U0Y5P>'D',;%UC.CU6Z\,8&>!
M+H"'?,CU7.D'@:X F%SVEVQVEWQVEIR!L_],A$//+ U,!$'P@ARP@ >(=I9<
M]K,D WP 'T#"=FWG=F]G]A?W@G$O]RY7%^P>9OZ1][()Y^IRSF.A\@%FZT6'
M]W^W\Y[F\H G>'_OHCV?[_S&[X1G^(]U^/=^>$MN>(BW'C<W^(M/](P'+GW@
M<RQ$!'/H3(P0=+Y8K2(L>3>B%@S$>(!?>8B[\,F+W)5L:%^1=**A]*Y\;M1-
MUJR$E685YX-X;=95",?EP7D.UAOW8E@'RL60\3"&R8@&\9L_8QSOC)SW\4\'
M\G05<MK524*<A2MPS8AX!UT/>]DL^[,_U'Q(E&3O] ;5 41G%WX@\K:G20OP
M K@'EEFP>A1WRG?___)Z3U2C:BH\65Y1%=/_C0F?[ B#W'>W0-X\WQ/YTOB"
MG_R6O\)9. G*9_G*_RV.%W,V!_WQ77/1#WVA3NHT+WV+Y_S-9WW-+Q9]J !I
MI >WGFLQ&?F1('34\MM"/_E6\'O+7WW7UU4@;CK(V_NR3(F:OURZSV<W.7Z=
M%-U.G\J8?%:L.%TCG_JD=XL2%THCKF=3-]<:E_K-7754#TI7S_J.;OOJ;\!\
M8('V^76H* =_N!9XB* NF =$R/_]U__^Y__\!PAY@N!YN3)#!H*$"A%X4]@P
M84-W /P!J$C1(H!^.AYP[.CQ(\B0(D>*U-%O8D64&%>B].>%),R8,CM6_Q"D
M\N9%G(EF\IQ9(<>LG$)3#F59%"?1I$:5(EWJM"G4HU*93GU:-2I5H@YG6$V*
M\"%#KC?K.2P+T2R">EDM(CKKEB':AC*0O@5K=^O2KW'W(D!T]>]:K%T'"RX,
MF/!APX$3,U[L&/%CQ9 G2Z[<F/)ERY$S<][L&?-GS:!'BR[=F?1ITZ%3_YW%
ME?7JV*AEJYYMNS9NV+=UYZ;-^[?OX+N%]WZJ+T<^?=#X)<_'7/ESY\F7-W].
M79]TZ-6G1[?>G?MV[=B]A[^>W3SY\>#5BS__O7UZ]^7?HU\OGWU]^/;C\]_O
M7S^ ^0G870Z) #<<@L4I>.""Q#'XH(,1)@CAA/\2-E@AAA=J2&%I_%20(8<A
M$H7(%7#5Q9>)*4KDU".().(B(BV^.&.,,-(HHXV(S'*2B"!:V..&/PKI(Y%!
M%@DDDD,:V=2+,M)HH)))8H1(3S*)-58.'^EPY5'U;#23#CEXX04BLR'R994?
MJ;64%VC"Y 642YT)DA>U;1G2FBHE,L-'!?Z%R$L>S9 #8?5DZ9$.>2;6II9U
M4C:HEHHJM:='.1#:V)P@Z5 5I95NNE:G,UGJA:1'1GFJ15Z<R (_%ZF*%@*)
M#/=.B@\)\N"K=RE4)E(:R22K:8\PRI,7LW3E:YH@69"##EV$Z6:R'=DTE3_0
MIEG!#!9D6Z6Q2^JVXRS__( K;C_=2NDMJNB:NJZZ[9[[;KKPLBNON_':.^^]
M]>*[K[[]MO9:OO0*'##!_ YL<,'^)GRNA^'A\][##D,\L<05LQ?QQ11G;'%V
M&'>L\<<</^?QR""7+')R)*=L\LHHZZ/RRRS'[#+,-?/319P*([RSSCT?[//"
M0?/\,]%"]^SAT$935,\58!V UM-O19WBU&"MV%2+.-Z88Y-<U_CDU_J8JS39
M29L-]-E%IUTVVDS:V'7.:K<M-]ULU[TVWG/;O;=3):)5SMALG8C K<'!4VM"
M\W"HCP.K^C,4LC !RQLB%<!409U%N69YE5T$7AD^ULI$AE&S]#1#4++-XH4%
M_P_$K?0LF?*D0]YWZUT[W[?K;COON?>.._"[^SY\\)RY)GSQQ".__._,*]]\
MPP'2-_U\U>-'_?76W[=]?])KW_V W_\7?O;E<S\^]N=[;S[XW77AU_/Q)S^_
M\_0W?[_\]??<SX?Z'XB(.E"D*\0-CH (N%I1M/:U'"D0;@STF@)39[_\X6^"
M%O0?!8D'MR=5$(,7[" (,_A!$7H0)S,XT14$DP\6Q,51G:&5K@KG(QB:908G
MP4CD2#*Y".6#<R/Q@E!V4B5>*2B',OF4180HDPKHHX1'X0<9^!0M+8VPBDXD
M80BMF,4K:A&+7NPB&+D8%=.)<8MF_&(9T7A&=O&/9O\RLYD;X[BQ.8:,CB>S
M8\OP.#,]PI&/;_RC'.LHR#L.,H\?>]\:TQC&-2*B'% KRURFHI>$5$TAY:#*
M":F&EE*9D)*/1$ 7$BE*-9*0?XLDY2E3J4A](:"2B4/E*D=IMB?!39:QA*4M
M<XG+7<XODV^Y)&+R,3@@QN9PNE+<J?HA@P'2(RE&%,D.$:1$D52 'Q5Q34](
M9Z1I_@HCHAM)!8C8P4--<22TNZ4J=9E.7J*SG>IT)SO?*<]XD7&>Z[PG//%I
MSWZU<7WJ(]\_T]<^\?ESH.Q#'T$!:M" )E2@"#UH01_J'$3&LZ+Z)-A79N .
M^ $ $0-LAU)F8!>QY.0NS;S_B$<3,@.05J0>F;R+45ZJ$$[NLZ86;9<I\]D4
M PZPIP)$$0*5HL &+G!K8"/J(ZQYD5GDXYI-K) QT3(/(;DC138%G@&G>M&M
MZO0T&[315;MZT["2=:SQ[,*J^G&9E-:%5XVAH5MD&"1](&23SOSF1Z)9'"J1
MQ (GZ>'L;J@9?_#C$Z= #%Y#4J:E2C%9<,*?(,I9$JZ6E;)FM2QFQ9K9RFJV
MLZRIYV4]&UK.DC:T_2SD'E';1]4"TH^!)"1L#1G;U,YVM;5M+6M?*]O=TI:W
M-L-9:3<[6N*THX9"06LK$Q)*IA37DQ(!C-2ZL)(95,VMPQ4N=G&3TZLF5VJ?
MU*1W_\.KHK5D#8+F/>K;) @ ?>#H$4WT1^P2T=0*]:.[X%WN<*H*EN"BS;Y@
MT:IHLUM96GZ-OP:^;H 3?& B"6* +- K8Y"K*_4")JIN02:(9L%"7>$7)<\,
M"82#$UF8D($BY(S)I3;##V68@A@M!D4F-*$,P\SBQ#!!W5#TT3K)/J ".GC=
MV?3APP?,@ QBLP@99B=@!"]8P4Q^\I*C[&0IOPNT5(;RE+/<9+GU4Z$272B8
MORSFB)+9RV5VZ)D;JF:(FKG-W7DLEK<<9Z_4BJ0I:2Y<GLL4F K&"[JB"T__
M-N<K"[A_W/5I 1$=Z+<$=25#/>\#DTJ4620"O8FP)@!B)_^C^5YHT7"902M@
MHU^%R'E?61WT3GLZWU+?[JLS8C6L41UK0KNS%1LV"S%GTP]?IN@*GYL*7$TD
MUP.M<"_RZ%5B.Q+BT80*G(LU'4\6NY85M]@4H*@V,6"<B5YHHA>F $R@9@)D
M/366QQSQT_.2#"9:SUK+LGXWN^'M[GBGT\KSOG>[\RUOSE1 M[W]MVU]B]O;
M^CO@ !^XP N.\(,K7.%PIC>^ASO)Y)Y4*6Q-KE.H9MV57#QJ,Y!*)J/6890Z
M#0$0U_<B'X!9_RK$E2SWI'A+SFCR%A5&#<R'N<)57DO'B$<W'Y)]Z=&XER=W
MJIT9=4)0;B2B [C41#_ QB..-P+_RTCI5M\WUD_.M@"^!0$?5Q ^]E+QKEC8
M1!C.S2SH(5(4-?VNW:Q,N1!!!M:EZ1Z3[LFTB-(/%KNX[]BN-K<SL6U-Q)@8
MC@FW3![!F%D(8L?F)O(CNB((RPV9)B&I/$=\:+EQ"T7=1]0ZZ*4N^JN'GO2C
MSWIO5&[ZU:.>]>GL=YK9C&8WKYFALJ]]F&-O^]WGGO:W__U$.=_ZX=NO+;62
M;I_M@GRA&'^_(;U+)!<#R:;XV2'+)_[I4[YR17/_IP5LM$H>W20>322^-H=T
MDRC2#_%S^D IPD=*:)7H&32U,4A'P%7$Q8]^Z)__J4M,/N3#/>0#/@@@(A3@
M>TW:_O4?_P/^6E \('Q%((55A/\MX/\%!C[,@#D0D$:YT&><&FEDX#"!WV%4
M8 5"!3Y(6%E<01>TWV*$2P7RE" ,8 '>PP%BFNM=B*NY2 [V(/;Y8.EE1=@Q
MDY"4B*Y\75<$VT-T 3^T CX@@CQT@4&PP- MQ$)TWUNP0-1!3K(]7D^$6!=V
MQ Q0&]]5V[7YG=\-P^ )7N!M&RA8Q2/P!.:@W9Q@WNDXH(T]'NW\A>?%Q#D!
M8?8%(B .X@\68A!VD>H9HB J(B&F7,.Y%B3F5B02W"0F7"4RW"4:G"8NW":Z
MT<,MXB'Z3_.UW'=YP_551,E%G]I5TMBM'<R!EXETDGWEB2.Y!?\2@B(NBI+*
M!=C3E2(IQMPOCA>+Q(C8+!5[H=_Y@4VWZ(-1V8@+(HA]P=]*Z,,&OJ+3G")6
MW-]5^ W+Z1EA<&/)I=!0^(,KLIPX3IIY49@@O*(Z,$7866,PRAQ<F(-D,-UF
MY$HPED,'UB)XY9I@+%,PMF/8N1Q!;@5%2(4*PJ-"MI*=A2*%4!T/,J)$.N1$
MYN(]GDCT84BQ9>%334798:&G(9H,M-VQA*$7BD0.M$)7\(/CA<05_)V+E:$R
M\ ,T7$11]$,;MF'A/0Y3W$-/6$"&(4)+1EL0G:1'U-]B]"%,_&%%-J)%4B14
M/J54.N7 )&)44F539N70/,"8^1[O=>7_[(4E[H'E6.I>[XDE\)WE]P"75DZE
MTLA4HEE25MS?2(T=2M!#2):%79(<7_@C5E[EPNSBH7E?7L;ES%F%^2$5,G9-
MZK2" QG5,Q;'^ZW%.J*(%G:%-@8&.):%-Q;&9I[%.;*$,!50,ZV$IMG<2MC:
M"D)%-2* -&+%/?#4JJT%"&+%X(P<58SF7=!C50!D :7#8N1  9%DJL7%%K;E
M@>R@\ 'F;92;&"(G=!I%'CX H;CESO@#/RK:%5IAU\$*838$/&"%$GXG=_(4
M-C;&AQDE211+8G1!1UR!(.S!%5Q!1SC  ]@G CQ  EJ$ V)$-(!"3G8;* P%
M/E2)3:P+XL7$_X'ZC%*2!%,RIW5&Z%]*:'12*(1VQ@-,X(56Z(1VZ&IP929R
MHH@^HB26*"6:J"6B*":J:">&J,10U(;&J(7.J(<.304<Y&7U(C N9$&^17@.
MHV+R7#,:"U,%J3,"W=2\YE3H0]/$HT+XVE)DYE-P8R5UYC8^4F@BQ3P\G0,8
MA8Q@&DH8H4( )X*T0D$.ACT^A3QZ0T/VF<L!4U/X)LN]0ST2Y'&NQ-/=*8U*
M"$0NYYZ"1H)V!%8$*DCXZ45P4T<H"E^%A%]ZQDC@!*%RA+Z8)$EP"55XP73&
M1.9X1J:.A*4ZA4@TJHP"!^. I*F2YVUZ) $-VV8D9(JL0VRDYT=H4_]K1&I?
M*=4+.J='Y"<"5"$"K .XE(NP!BNQ8@0Q$!ZR#@-%(.KE;.JZ0-M,. J#*MF?
M5FN-6BN'9NNHOEN&7JNW:BNV6@7L>:5:IB59FJM9GNM7IBN[DJNZ@MDG?NNV
MSFNXUBN_X>A6%::^]E07J,5!=@&=#F,S#FPRNLA[F1_!PDUDZL9D0@8]R.D
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M+LK%:&&,%:8^YSGJ/6U4HWF8/UK3JM#,XHUC-*,=\?C%.^K19[QZS1[%V)3
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M"7[\Q7_PS3_]T7_] 9_]SU^2!;_]Y;_&*_[5[5_CLQS6.U[_/_[^+2+R 0*
M0'\" 1 <6/"@P80,$3I<^%"AQ(80*TX4V Z!1F\:$7#<V/$C@HDR/(:<$1%
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M2OI0 508AV(8GF3(AN)9GN0IA^EIGNJ)GNOIGNT)GV?(GO+YGO09GV_8;JV
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MS>9=<TZ/'?UZ]>?=LW_??K[\^O'OP\]/'_]^_?;]\_=??P,*6"!ZB'@1H((
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M7B579J57;F55@N584@T !)E3CDOF]8U.Z.1.8%B$9=HM?8]/T$]'Z-GT3!@
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MZ6W]I"]\<:=_*IL] '3ZVC^LN#]"6*M][I;ZI$0^3UC\*[& 9R=F=@,$ '\
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M;__[X;</F>_<9CS+^?QU3G_YU6Q^][<?_FR.?YZ1!G//HD['%I'Z6 QOD7:
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M3J<YH/ CFJ=[A&5$A[G488E$K"-=/[3).M!]Z1Z@699F^,$"'@FB<>H #0L
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M=9PC1#"A)5H'%!:%0SX@!K$D8]X5%E9D<SKF8DIG8T[G9= >Z^2 2;[A&UI
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M0R!+BA5A<Z3 DD&Z$CJ9PQ]VL1Z401_0$BTQ$BWU808L4Z+ZH?K*H@MNR3+
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M4WM?K=@L4;&+/'_2&4-^QS2><D4<CX#3*\22F=?(ZRN_;G]?S?- TWU$%G^
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MW,:=',GY8\C]X\6!7#]B7$'NX[Q!G/_$05S%E=S$65P7(-Q#%MS "5R_21S
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M[[T/GWSP_\T?_WSQU2\?_?;73Y_]]]V/GW[X[9__?OGUKQ___O?/GW__\U\
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M%_1_7?3=5Z3</7#?&(%/GUPF.FA!2'Y7&6'2WFA]-Y/%A>V%.V)D6%G2'@$
M^2!P./$U/Z/P5U2LF/@I1=5II=[)OEF2UUB0G\^U?O&E)=T7)O1G1=ZIFUF0
MG_8'XK%K]U1\5_D?9?V?VU+&/U3*O^VG97CMNHW67XS5OY C'R 0?$- <. [
M /X *%R(D"&B@@0%(JC7D*'"A!8K6L2X$0#$@C(R<F0X\..,D0M17F0XXZ/
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MFA7YD3A%Q,RED2ML4U<%F[4,Q:$\R:)<RO^@_,N>U</XFQ-H)LF(1<N#S%.
M[%2V:507N[1GY5Y19<P (,UG)I!O=69YY5Z[M9S1C,,DB<U# <ZH&9/5:5+F
M2579Z5@W7,N]VL(Q%:\F)9YQ19ZYU<Y!7,DKN9XN&+ZN$J$07+<+0:600AGR
M*8[ )$ $5<"M>6C/H;X0+!#_1(3,L<#(5*7Y>";2>QNX*R 9_17JE$X\N!R_
M"[T-C8KV^;TJ[<\K+;PN#;XOW=(P/=,R7=,L?=,QC=.89+LA%W.OJ[OX,:,8
M+:4V34E"VKJ"^Q29_)\H?:DT'8A'?;O.F+NG:Q_9&-&S6]1/G=-5,;[25KT
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M.VA43^5R*[)R3[R"_T^^FL^XJL_WE+O\E$_]I$_^M$__Q,_]%-#^'-#_+-
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MLE5.#\4DZ4?(3EK%9N'D!+K%]#__JMNL2T(/B$9_=T*(4!(<T'I_F;(66P(
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MH?QDL8>=[&,W>]G1?G:UIYU"(5J6/DH4);E7:>Y0HOO=[9YW*NE]2GW'TI8
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M(^9R3_7<XB])P_O60Y5"ST73XOO*\C#D2G-=+VZU#BV0[S32K7UUKU:Z]U!
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MKXHUK&3EJI:R>*<^56JM;&VK6]\*U[C*=:YTK:M=[XK7O.IUKWSMJU__"MC
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M/_J%A5:I:]'I2F^Z_8]^__KC?__Z[S_]_Y]_ ,A_ NA_ 6B 8V(B!*B !UB
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M#O  YHN^ZIN^Y]N^Z^N^[#N^]Y$#.<"^#T &\ 2_^_N^[UN_9 "$;U*^\4O
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MLLC Z7O JDW K V_JOT3K=V^W>P1)NS:[7O;YIO;QOR^-.P5\H#;#LS;J^W
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M/O9F/T7B&Z&VOL%1H<*T_1'@?<":$>K"[=U2<>K\*\ H[-Y<0<%__^\C*6S
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MAF0X.H1 +:HCD$BPD'PYB: BH9 UK#@Y)X)(F\R*@^M(A@.ZC 2ZRBA)G42
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M5$QV'7GH@G7 ;,W.1-C)A\S^;,T&;=$.;=+.[';H G>@AWK@!WX('T0@ R^
M;3+H MF.[=BF;=N6;=RN[=DF T% A'M@;:WSAUD 6_[%!WX VTHV1>+6!WXX
M[N2>A4I&B,JV9,UH5K (I V#XBM.2*/0[FJM",B@M??29.O>9/.N;O5.;_9&
M[[9@Z/5V[_.>[_BF;]9Q8SO.;SS>[SG6[_[F[SO^;W'38_FN;P.G'Z/%)/]
M1L9__6#[+O#V]IE$AO#]F05XN,"61 !(3@M);FI;<H1\F 4*?W 2/_ 1-_&X
M4%M/+KW%O8[ZQ0VY/;N_:X[!#>;7P-ONJ)+*[ []?66^Y;L)@0[(@XW#K98?
MCX[A:(\7C]T)H3T9I]O*9;S:R%P@ISW+<Y#$O0V^7?(J[(<+I)4DF9@/H0<P
MYY>.*?,S-W-F"0<9: ?Y;0ZL_0VBD7,ZGW,[KW,\GW/:_E\JT0=$Z (+N'-!
MQ_,96!RH1A%^^/,\7_0Y+W1Z./0!%A/8I8TF'$@HK5T,(18+1<&ATY#>S0[\
MBW11'W52+W53EPV&/G557W56GPV-%M_OC77M'5__6I=U6)]U6_=>7-_U6^]U
M7?=U/U'I5A]V8B]V4Z??][V'V]47B]#?U^#?U)CD:)>RUC9V:[_V 2[@KP[C
M9(I#LV;4ROEV/(M@Q$ $W=C@:C8*@R+$T(#KK 7B4#Q@QM$<LK[@1_1#O C%
MNA%W4_W$P"Z,%EY5QCAA5TT+/1SB>9M$!6[L$N9A4!SK>0OB8T9QO- '1RY2
M&8%TZID''^WXH_[X$W4 AY !1%ANP8CSJ$EY!5;YRF'YMDEY'9AXZYD%J)'S
ME;_YEO^-&2"#UJX>,K%SG'_YH!<T0=#X"%=B)JZ+):KBT2%OKI!'![<YKL#B
MPU#.G2,,A3WQH]]ZK>_Z_Q+G^J]/'_@&>XHG>[/W^JG$;P#W[P!O>[9_^[6/
M>P'W-@(/>[LO>[0_^[O7>\^8\+T'#7Z@AYS,\";9\+#H<-20]L2?]L0W>;S_
M>\A_?,EOMDYF6XL.3[@$S5MV@,+U!U,NR[[TY8_JO]<.:]$_YE_R<;9Q+-47
M-#(8'-7(/+#<I=-/+,"EU7(*S&^R55_V:UT:YL(JYG%2JF16&LFL*+,V3,V/
MYF6FYFH29<T#IMC7?$B[?*Y^*XY?&'8!!QG@\]0D<V97F/!/&?*W"AF8AYA"
M>49?_T%O_T6?@>'4+,!A?_IW_SF?P]:BL?K??_L/CH6H:H  (%"@OX$&"QHD
MF/]0X4*$"1T>7 @ XD"*#!]*M#@Q(T>#"!!\0X .8\,N'T.>%/GP(P)W%3,B
M2HF@BT9S+%$BTNBPWHR/+A."9!FQH<1Z-S_.T&G0),B.))\.A?J2*%6I%Z-B
MG6IU8]6L5[5ZY;I5:5>P9K^B%1N6[%BG:]V>51N7[=NR:>G.A7M7K]R]=OL"
MQNNW[5_!@?D:3HQX<6'&A!_7A9R77X[(EO,VSBQY\&7.F#<?UMPY-&C%HC^/
M-EW:<6K6J%][CDVZ]6F"LW+H@Z8O7^[=O7GK!NX[^._BQ(\/3RY\N7'ES9DC
MA^X\^O/JU*]/SRY]NW7MW;EC!^\]_/??.O#!GIU>->W_U;75RV:_WG5\^O#O
MRZ__/C]^^_S_^Q?@?@*Z5V![!Z+63V4 #MB@@9CIL\Y1,@5%(4H@R9-6/HD@
MXDB''W+HH8B(A/BA(_G,0A&##^K'8G\.(MABC"^ZN.*,-LX'8XXU$GACCUJ9
MB$B08CE4I%9&7H0DD4<RF623 ,CSP ,5." EE596.6665VJ)I95(<AEFADYZ
M$>:69WK9I9I7(K+D15&NB6:<:>;@$)QFIHGGFO>\5*:<9"@9Z$ YY%FE%TO.
M^8";&_E9J)2+(J1GG4\:B8B>%?#I))F7"CKGH8(JE&B8F2*J)Z!'>B&JG)=N
M22JHD%(:JZ:PSOJJK4TR9>&$_PZPT":MOQ8YCZX(.("2 RP5^]&QRAK+4H7/
M7FAL.Y3>5H&44UYKK979<KNMM]A^JRVXX^K0CZQN(C*#M>*RV^VX[8;K+KOH
MU7HD(N_*FV^\^V);09NWUALPL.<"/+# !2-,\+D7FG.N410VS- ,!QSU3A?U
M(%)/%S9]1/%']32)B,?/FG-QQHB\@\#((8%<)$LKOSQA2UIQ_.P!)F/\SL1'
MR6"PSPD?K'#00_\L=-%$ WVTTDDS;7332#L=-=13+RUUU50_?;7667-M===8
M>QVVP)2!7?;68I]M]M=IL[VVVVB_K3;<<\M==]MT<W7;;OP$Q_?>?0/^M^#Y
M^$UXX/^&#UZXXH<OGCCCCSL>.>*3-TXYY)9+7KGFEV^>.>>?>QXZYJ/SG4,^
M=]L=-^JKJ]XZWJZG_KKLL=/.^NRVUPX[[KLC-,L,M^L>_$OR[$PAS!W+[/$\
M@NKS2) >.C\B],\C$KT^*0*??>[:\\Z]\-N#WWWXWXM??L)!5O^A1.NSW[[[
M[\/OOI_K.D"__5K>3Z7]$N5?_Z'KRZ-_ L0? :F4 U_!;WX%K-\"^U<9@^2
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M??YG?OIG;J%B+!HH+<JB*QZH@B+H@B;H@P*.+0;HA YH\*CE-J*>="*7S<Q
MRR#",M[$5*#>B'[#D92>+YY=06C,-X0>@%:H@'X/-;ZH0J0>B1JCC6*H,"+
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M#YY/!N*918_/$X_ (.M^_? AFF>VR[HNZ6:0<X! N]_M QVP&'Q[EAPJ>(#
M 0LD\($*9AB0P001--#! R6,D$((%1SIM!PJ?)!#'0Z"QA1E3$DFQ!%+)%%$
M$7O1I)=,5FRQET^4B8T?#2WD\$ =//(.M'X0$7##"6\\<,!$U-,AR"2'W# '
MXNAI4,@'NXB.1^NHO)*Z*K7$TLHLN=S2RS"['!-,,K\\4\PRU433S#397-/-
M.-N<$TXZW[Q3SCKUQ-/./*E\P,] ^QQT3T$+)93/0Q5-E%%#&T74_]%( 7A
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MA[MY]XV%ER3D[ZX+7'B74)3<!3$\*0=:;J;QBY]$X^)J]]!/4AD94Q>[H76
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M2'B(_TT"Q^+.1,,,N0(K'\@?7) G2NR$2E5^K)AP_ %XOZR>!J<+2#<V#^
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M+<U-RQD870#@W-T+W9ZUBY*%+N@47H\XK8>=E[^9W+FMWNMU6.O-7NR5WIC
MP(!M2(Y\R(@,7_(=7XRT2//-2/5-7_05W_5U7_9]W_;=2/FUW_C%W_K-W_(M
MJR#L']TUWC/]'[M,*[*$(-LZ*'_857?HT'4\60<N#TV$1(X1#:-DI4/=0=A-
M-)(0I<Z%1.&<("$-H$M:K3 =X7;_W&"1B$+U"4L.BL*J 6 $:D.W(F %:N%>
M:F'YV4)/@LHBM%H7FL1A5:&II:E$I$%&#-VFS;<]2JL-<9[+Y:E,E"$HIE_^
MU5\0(H-)5<4M]L5@O$5A_.(PWD4P'F,Q_D4R/F,S]N(R9N,T;N,U=N,XAN-@
MO(_]=2M$:!*N.M\K%E5OW$8_[L8_%N1 )F1N-&1 /N1!3N2.PM4JWN,0JB_#
MY)_6Y>#HC%".V-6$@M#> I\!D\(KMF*QRN32R$Z[F^#ZJ)_HE&1V=41" JV-
M2*^Y<&4B1*IE133KB<)5AEX\1+L0#MX[],,&^ESF@U]07LB_L>-B#N5'9F9E
M;F9'=N9H_X;F:9[?:KY?8WXICPS8[MW>;N;F;]9><.;><";G<39G;Z:,F%2*
M'0:\RDT]5'Y,\NC8CN!)EM"]Y\4CE&'>=H9,S$M:!7X[FWCAC!F[FVA*F/#'
MJ$29^.S:S4U9FB MO?3=B;4)MOR)LT3:P.2*>EZ,0#P*BQ9,DD'/AWX)W@SI
M""F\!GN*0TP,_]KGRM!-\JQ*V&)9M2BTU9WI:]FOJS"[>2[GX.&QOA7JO27J
MH3;JHG82$SO)62@QPCW-QU5<R(WJJ69<JH;JJIY-R45G\N+DHOC-0G*^V'5H
M=O;<B%9=S(60T7VUC,6LF5UHD"C/GT4C*)),E_59B5[+H6W,E?^!K[-.+B<F
MB;.\/J=X/)'EBGN.#.L$@*]>B?$\3NO"9YX(Z[0@6::8[+#XK@@69_<[Y\WV
M[)_^[,X&[=%6#  %7W]%[=16[=5F[=9V;=9NT#J[TM(HM#$\C0G]C0Q-C4OS
M-Y'8M-3 .WDC4DE#C2X M$&ZM?UPT>E0RT/#8$5;;M78ME^#[K3^X%$B#49-
M#2I5[BA5#2J-T#?5C7-+M]VXI?(VC1_EC>8VC30L#>.&9]?(-?*0U]0@TW=;
MC37DC7AKCD%%C>$N&?]>U#BL$2>]9-C0[M<XU@-_[='(XH4[Z@A':@FG\ FG
M.#&;E6FZN"WKXUF5U5<=U0]WU1&W51'_+_$01_%837$/7W$0/[E&/KKZ2M;4
M %8 .%8P[.[9-F\#MW%>)1%A0VF1 '!Z14IIVS1K/>6X8-9BY;5N[59%M>_H
MW+=5<^!8J^\[XS8C%RYF90WX?FX906+><-*<X54DQ_(\$]1I9<S5H%*LW8UX
M97,^M6W8X+9UU57J;O \U_,]YW-9 =C0".VM%O1 )W32'G1#+W315O1#-YB(
M7>>LE.E_EHFG;4O5"HJ/[<D:ICO-3N+(' FRU".Q%@F/_II,Y E/K@G0JPGJ
MC%D X-A=0MVYIF]_UFB;<72CU=B9>+V7OCO").G&,.F=8+VHC0JBE)B%F;L@
M3AG"UNO<BZW>_\V)G0Y;3B<7XY/9Z$1;M@V^H^CIE]BMR&:\G3&B!UYIP.9V
M<6=T?*G;"JOP=K=P=X?W=U^3.JXR/$;&ABU<K+[J?9=J?>]W?K?J?[^(1D[T
ME.B]I!@MW2O.C_[+LR@TI:E=?A9=M,::WC2[I22)=6.^@[_9G*8NYV),R$,M
M3X^[AC>):=-=D>?KIQ#9F*FOA&_UE1CEJ#COQ.Z\D8#=P/Y=EL!VGBE>CA N
MPK N7N_9B:G+X4)TTUST@F?ZI%]ZIT_W_/Q>#91F:TYF:K[F9:[ZK']FJ\=F
MK+]ZK]=ZL/]ZL>]ZKM_ZL$=[LA\?_]TAH\^>7!;$?..:(]39[4%@TO^PK4?T
M"+7-.P@F./W1PR?-GUSN99) A >II3J$'T^6Y?SAY7%7Y</?+$KL41]2Y\>6
M\NBYX?89Z*!T/.M))6(& +4%1\!SF 3*0SO<5276("+^GS E_5W>D$N&O%S^
M4I 8/ML'T\COY X%_GI(_+H3_N)O8"HR8AD,<P'20S.7=</+GR\,S]*@SB\-
MB5>#>]$X;^/G_N"G?N'B?>R7O+)?^Q5\\&/B8F!,?S2>X_578_=_8_B78_EO
M_RZF__NW__Q7?_UG?_S??R<!B$?^ ! L"&"@08(($RXTV+#@0X4))29\1.8B
M$#(99T4\.-'CQ(XB/XX,2?)D%T30].73M[+_Y4N7+&7"G!GSILV<-7?2[(F3
MYT^?.H4"'1KTJ-&D19<2;8J4Z5.G2J5"G1KU)1EZ$$^:[,J0ZU>O#L&.%;OU
M'8)O"-9^(PN [=JT<=4B0%2681>X:TN&+8B6+H)Z!=W-78MH8#VY:]VYI:@X
MK5V#70!_FT%Q!F49$PG#?0<2$64$)M$]YNLP[^/0>@-O)<A9<62*82<7]CR6
MM&K%,TP3I U7MD%SA5?G5BN8]UO YB .WTT0\UR2B(@//SPQM6B0?<NF[F(V
M>6'@K?O60_U-\_;Q=]>K;R_^O7;V\!^F1![?_?WYC?/SM^]__W_?]0<@@0(&
MF)Y^!A:(X( *.LC@_X'R-0CA@A)&B-^%"5+XH(458NBAAAUR^.&((9+8%R*.
MI(C(BBIJMQ",X\4HVXPORG@CC3C:F"./._I8(Y Z!MGCD#\*>2212!J9))-+
M.EDDE$I&V>243TIY)9586IDEEUMZ62686H;9Y9A?BGDFF6B:F2:;:[I9)IQJ
MQMGFG&_*>2>=>*[YF&!4AF=D8H =,-X!T>7IVER1!2D#;#/.4"A<,LP@'%SE
M0=I%C8FM=8!W2R("J6*8'ID8J((.AT"A;'[:G#DS1 H J(NB>FJIELU:%Y33
M/<8ID;K6*BFHRVV:W8R^L4:DJ[,>-QZEM^XZ5Z<P^DHKK3A"-^QJA6H&6/^?
M7Z)6Z+(]OJ96C\V:FNU<,X3[(K7HLJ5H:\Z>^^Q:RQUJIV-T.=>DN6OM"]*C
M[3ZK69']8DLO9+*]5FI<#*_5[4(&R]MPHO?6>;&><'IAES\9>:P1R!^+'#+)
M(YM<,LHGJYPRRRN[W#+,+\L<,\TSVUPSSC?KG#//._O<,] _>\QQQD43A(C)
M^AB-+],+I90//R]%S=+44$M]-=586YTUUUM[73786H?=]=A?BWTVV6B;G3;;
M:[M=-MQJQ]WVW&_+?3?=5V?5]-(8=SGN6DZ:^LZULQ*,8Q<,7S8O7=HMS!I"
MB1<FF*9R>09FLG2)JM"W_L:X&F,*3;L71.895B/_X)<C*;F[N@7Y5\/P$FGZ
MPS>6Q[CG0G9.>HX'XWXPQ$)2?#A!#!.<>>"O%^ZP=0I1S/N7PVW^X_,(^,VW
MQ7TKF5+VW6/__?7A:^^]^.2/#_[YY:-O/OOKNZ\^_.G+GV.++#ZRXD?YZ[\_
M__W[_S\  RC  1*P@ 8\( (3J, %,K"!#GP@!",HP0E2L((6O" &,ZC!#7*P
M@Q[\( @%B!IP6": OBEA_] "#G]-!';H8. ]Y/+"_E5NAODKW K9(H-[].9=
M^IM!#F/#OQ@"QH8 Q.&I5FB; X(F+CFT7$%TV#_<.#$NYHA-YH2XO\JMT(C[
MP\=JGA@Z .00A1/1%0G]_X>(,O8/<&MYXC>T^!$JOC&)G>(?$),X QX2A#0K
MY., \XB ._;O6F;,7ST8A0 X5A$!,Q@C#4>81']!\B.5 PPCZRC%$$YDA(?L
M7Q/7XL6$(*)9F5SD'@<HR3#ZJUL?$>1C3KE"_JTREJWD)"X92(8^"2UHONPE
M,'\IS& 2<YC&+"8RCZG,9.Z,#+G,'T9(-HMG1K +9,")/H2236QJLYO<_&9.
MMAE.;XX3G#41YSG)F4YSR@2=[53G.]FY$G?.$Y[UE&<V[9E/?-)SG^4,Y]ZH
M"4+8O=%_FD0 8V+(2%JN)B&-C"4^#*+"N+@2  1=)#Z(&)=*$J0>R#LH)@D)
M@/\NP!$]!GE-#@VRR(JI%).3!)T)&WHT4[+P(RA=BTCW9ZP__H]V*UVB_DCZ
MI_RY<:6L_$T C8H >[74B9;!(0 ]RDJ'+K2 L<SI1Y1*+H%R595R["I8PRK6
ML9*UK&8]*UK3RE5$W$]%;,5?_-H7U_?-CZYRK>M<\XK7O=ZUKW;]JU[]&EC
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MQ"EFQ$4XPO].,B6%S$/\Y9I8XAI9\MI8FF59^EI:GJ5:HJ5;MB5+ )M/.N6
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MMDN)H,KD#T3,Z5,GH4@3C_>^U]FO)%-,'1E[,SHFZBA_C1NC6W 7I-[(P(S
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MR.#'ABZHP^R+R!-"?KB*(  LH :A5H3\(/2VOAC,O\,++(0\I*G:P@BRB>"
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MYN/^S3DOSQ$YTNDA6-5T%6VTZ5X#2,('QFD2%?HHGM0:O%X@_-VUH!TY_+;
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MPQ#C:A$S,RHHD;)J^('91TVW8M,8$T[7I(@#,4[D-!/IU%";(H1\C883F%G
MM%@1.*D^F"&J5-%2T1Q0F"2F&%#? UE+<3_2IT\C\8BC!X<*-4[]--R2#4U'
M37KON'0DE1=/E8\S]5-1=5,]59!%%9#_N(\#F9 /V9#]>)!)59&]P!J%+A%
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M1- XYM^BH<S!&>@MS3POXQBW(,#MIS['M0SF"I1-:'RB%Z! G'$'/%P"%[?
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MYHN]Y6MQ+-N^Z<N^\<N]\"N^\XN^]MLDV!FD/]J__/N_0QK 0CK _BO !4S
MKU*DZEN_+WHOZ "H\IN_"WR_N/%H/2'!$3S!&,PT5DN_%,S &1S"'KS!^*O!
M)BS")2R?H)IJK;NZKMO"H>O"K_-[>#M\Q:>J-1Q>^OD7;LNJ<7LZ<UO#=8L5
M_H##:FN?]. V_C +^* /]X!-U]NN^L /3?S$O I<^- .7; .6TJL,KR65GIW
M='IX@D$06JBE9!P]84PO]6"&,?S&,!S'+SS'7[Q'UTK'<(S'<ES'D/&XDOO'
MEPO(F?^+N80LR(7L/YN;QWR\R(K<R'L,Q_FJQY+,R(]<R9-L1P*;:EN[R9S<
MR;%X#QO+;")+O V; P_K2!';L!3+218KL=,FLAAQMJZ<B*9L203! G&5R^Q(
M#EWPJHQ$#^P8#L6G2>K@ $L%#H272*I9S.QXS+FLI;XL2OQ #^6@RPA #K",
MLI2U$,G,2)$EDJ:!I2"96(Y4#^(<DX!E&C.)20(9CT'BR? <S_(\SPCUOO1\
MS_A\L/N;M/PLM#X;M  -M (]M/Z,M 5]M C=SP%-T O]SP.]DOD<T1(]T;7H
M"&I*T1B=T1J-DUT;JI=LR93\T2+->_QPQ-K%MABAJF\;73K_$,5OT<-X^\-V
M$\2R.L0'H90Y_'QP>1CYX'>\V9PUP0)Z*1:S@,ON C=%O13SX!;]L X__=25
MZ0 LX,9LDPZ0F:5>[,AM4YD4<60VL15XA81JA0@$03!I'&9E-M9E?863)G=;
M4X(=\Z=M3*=/U(8A?==:C=<@G==\?3R(  1['=@CW=?*ZL>!?-B#;,B*C=B'
MG-B,S3X0+=AZ/=B23=B3W1:1?-F6O=F5W=F4C3NP.[ I/,(G3-HHO+ZFG=JC
MO=JH;1#Z$&U+N5R/8!NMC)\5<-&_D;S4N[P'%Z#5BWS0RP\J'=O$7;?K,0\.
M,#(;X0"#)P,R<*4RP-QEM!$R %BM_U',8.4M@#(/(\,"^HD1^K"&V<VD6NP.
M79 .SMV2):EK\"C4JN0LV S"JNT:RMUULO'.I6'6R2$MO+&#3+8:]1!&8E=X
M2M<A8'K!RP%"I<W:\LW@'_S@)-S:$M[@$P[AGF?/$4[A&F[AI[WA&<[AIKW/
M"&S  #SB)G[ *%[B*4[B+"XLB>SA"U[A'S[C,0[C'0[B#HZBB8#;-8[C,M[C
M-'[C03[?-D[D/EX5*SQ[G/W9FNW93<YIQ9+3S67=)<$/*WU=EQD6,'V5,GTW
M--V468D(5\Z45&X7NUD1+$ /P^P5/1V9"B$#:XYX+%3FBI% 2+8.6E',P>G+
M;Z&:U=S=L/_D-NV@YA@1UM22U96M.I:7Y54!:<RY$%0-&(;^=XY!U3:D&+CY
MG'T1Z4_>Z4ONZ4[^Z:&+#RW-Y*(>ZJA>>X;MV*S>V*Z^V*T.ZZ^.R IDZJD.
MZK:>Z_BG#ZB+Z[Y^ZKH.[+_.-IG<I1M][,B>[*(QO:%L[**1F*%< 8&^2*GL
MRJN\2;7MRJ0\R\G6>9)T0KG\DHS4#^J@W@B0Q*PA Z"%YYA$5T?A (_5#^JN
M+V;J2+-@U>SH[:"DC@T1WR_[S2$16>F<&P#O61OA[([TD?9M2>L<2?MX><H>
M\1(_\?A,ZA1_\1CO3R+>T ;-\0E]T H]T [-T"+?\27_\1X?\B3_O_(0G?$N
M__(P/TG\<-$Q7_,V?_.>U-$L'.RW+NP^W_-< VQI"UZ]7A;W(.7,]K O/>9P
MB^@SW7PF'?6WV@5*/Q@T\41XOC7^L(85T0Y7T83>339.W4,U2 [ZX@!\3AAX
M==2A\W0RX/3##A&L"0"U">ED,?>/[D.70415"!F(EAAV%O>"__,\7_B#KV'Y
M4.J';_B$O_B?MNJS'NN//?F27_F17\B)#/2,K_F.W_@=-O.>S_FAO_FDOZ^A
MK<E&/N0Y#N2L+^2MG_JO7V^)L-O*J_C5\7NV#5VVG]N/6+V1N&J^W9^_/?R)
MZ  R$,TUD@/ILD-YXM/@H.\?49I+'29)_WT4^> 4/AT.>JLE]"#=A.4 GR@U
M+WC-V:3ZV8O?(5&0MX'^8$<N1[+H1.,P\I&"?67^1;[ZKI__L*__^+___M__
M  % ( !_ PT6-"@08<*%!Q,J?$@P8L.!%"$*Q*?C(L.)'1]:E/C1(T>1)4F>
M=&@R)<J*(U>^;*DR)LN-,&O.M!F2ILZ<('VZQ!GTYE">0HL2_2D3*="E2H\^
M3;HS:D^F4*LF1=1%7SY]T+9V_>J5JUBP8\.>-9NV[%JR;=&R?>M6K5RX<^/>
MM9NW[EZZ??'R_>M7KV# @P-O!?# Z-3%5QT[9=Q4ZN/)D"E3M9RY\F;,G!MK
M!M!%!H)O"-YYEO_<6?5GU%9!LUZ=&O9LV;5=MXY\.[9NVHZZ7*;-VW9NXL"'
M&Q>>O/CKX\R5(U^.&_ITY]%W6P^.O;GTZM2Y?[_N?24B1^01F2^O<^'ZF>PW
MNE??7O[[^?'IW[>?'_[^^OSQ^]>O/P'_&S!  @\T,$$ %RR0000=5+!!"1^<
M,$(*+[0P0P@WK)!##.'CIX('1'Q@Q!)-+%'$62C,@4047Q2Q B\"S,=%&T\D
M<899/+1PEAEBQ#'(%(6$$4<''$ @R2X*@A">)!$XX$EZ.IRIG2=+2Q*?EN1Q
M(,HDOW& 'PTKZB))+Q% IZ5[', 22@3F&?.]=<Q\\K0/^T.$3AEVI/+_3C_C
M!)3'A=HTIR4Z$5AR)D+E&ZU-+Q%Q<(9%_USOR2@O1,111"CM,]!.!?TT5$Y'
M]9144$T5M5153UTU559?=3565&=ME598;96UUOCRR>%677T%-M=@<27V5V&/
M+7988Y-%=ME5L^)'K&BWFC:?:J^5-EMJM;666VRW!;?;<+\5MUQRS_4VW7'5
M-9===->%M]UXWY6W7GKO=3??Q)Q5MM]F_64V8'[_%96T)PL5&&  W)E!SR[J
M*;">+MYQ$X$9S/E-0=$JGL&=30=.F."01_Z5G]\41EEDD%=.F>2665;Y99EC
MIMGEFF&V^4[TSGO$O(A^!CIHH8<FNFBCCT8Z_VFEEV:Z::>?ACIJJ:>FNFJK
MK\8Z:ZVO[@)(KTV,\6.C0P2[[*_U";I&L]>N8(:M9VF1;;F_]OK(*,&!T@$6
MT"ZZ'Q80P#M)<#*66H;  4<@'89&,SA)=YC&QX'#2]/2H#D%3U*&?J)&9'($
M9+BZ\R?)V7QKTT\_&O,T$[H2S8A4%QH=Q+]\$IS*@68<;SNCGAT!I/.<'77A
MAR>^>../1SYYY9=GOGGGGX<^>HQRD+YZZZ_'/GOMM^?^=ZW,T@>N\-T:_ZSR
MP1<_??+5-Y]]]->'O_WXWY>_?OKO!^O\_-W??_[^[?\?_KRBOP'RKX#DVU?W
M%*B]+GC.8D&C6)L6N/\\=]3.-!/$B.S:Y$#7 2U3%J0=YGYV#TF!L'& <]O/
MNK#!UF'.<1B$8?1,%L,)N@-.0,O'BFBX0Q[VT(<_!*+S$-&S\@S19S/+&<Z4
MB,0EWHR)3W1B%),(Q2F*B@Q$NE&)O."A1&"12!80$WW4-B0RHDA' /,1D,J8
MQ2*E"$F'2A*2'+ [_R#B3*5A03^ !;PSL2 ?%\F'HQ"01QZIHX6)@LC?[IBQ
M5_4CA(,LW1YIMR<J-E%@9T*83LQA*=_I!),#6B$G:7<:]U0, 8\S5>LNU(4[
M2M&2KZQD+%TIRRK6$I:SQ*4M:7E+71Z+5[L$9BYY.<Q@]M*8Q!3F$Q&1 WS_
MS2M?SH2FO9XIS6@VDYK7M&8VIZG-:F[3F\[<5S&1>4QEU:.%;B*EHBS%R&2V
MDSYP%">#(BC*$YX)/H)\9"LO$DHXXI,T[:&G/TM#3G>.DU\SC&=!024Q+,V#
M/_KHV2/XP2>"5M2@";4H1B^J4(YFM"5&+&)YTM,=DH(G.^(Y:4G#H]*4FG0[
M*W7I<UCZTI;"U*8UQ2E-=2K3F()$'W0+4HQF8!'&>.%&:@3;C$""#Z .2:@H
MK0G<CEHDI-;-E AP0#CDB%4'Y*!T*"G3"5?'TY3,HAPMG%)+K+1!PL$F'X]D
M 4(0P@\'BHVL IG%.%JW-^T<Y8-)(MU.^SI8J-Z5_W9CW6>;OL$Z@R%6-V%5
M[ 4;TK#&NO2$J@$>ENQ*V)G>5;"%Y6Q/03O:SH;VII\M+6E%FUK6KM:UI_5L
M;$V;4]FJ=B7XH%YM6PO;V:+VM;3MK6Y_ZUO>VA:XQB7N<5F[S,,8QKF%@2YA
MI-O<Z%)WNL^];G6Q:UWN;M>[=4F@<(N[6^4.5[P F.<C%_N1S"8)4L@];W*;
MPD_2@,Z\P=VDQ3RFD/:.,B'F#.%[!T)9+*50(8S#&,0*8L[((LHA#$[24.$;
M7 I/V,+,>41;RSO>^WI''_+XFV+E091\)&)GC_@JAU6\81;+-[XOKC!Y71SC
M#LL8QA>N\4EVMK.->M3'/?\&LD:%W-$@$SF8<5MC4+7$HWY4U8N)$",;LWA&
M9*6QC5>VT<;>^*2M=MD!%+6/# 293E09TE'L%(@^&(<E!T",0OX0,R?AM!Y\
MJ%<&Z9@!.JZ 9W3,@,][SK.?\PSH/O.9LGW\F"3=1$DC-WHCDXI/>A$PJ(-1
MR9R+O$@)DY3)5W$24YKZ\9!#[>@BC]K4I4:UJ%--ZF#^DM6O/K6J90WK5<?Z
M7\OD)C:_J>MN]IK7O\YUL'<M;%\3&]C9"B>M9VU11Q$XPNZ9@3XC'>US1DD&
M B9(?[&]$  ;[#V(&,T=+97HEC3*O04Q-YT4+!!6GM/-ZG$V B %64NE<#]A
M%??_ILG-WTD"H![.!AVKNMVF=_N#CT^ZIZ<5U%\H[7MA5W+XLFL]\?7P@WH2
MQR@BTE'M)#E4/A#=67EZQB>,*]ODMD8YQ4^N<IV)E&<^"V+,93YSFM?<YMM#
MQ-S*-J.@S0(?B*"'%^(&5**;2 <I'HC:BOY4K4E5YT2_73JZC%6N'LGJ#GC
MNQ_2C]P]:<15LY(+$6D0T6&.!4BCF-@M\M?>L?"1'(1[Z\)A5ZF5'0&!O?GP
M8.=!%WYL[TR3M-;#&KBI]2YI8L][XA6_>,8WWO&/]R&O(#]YRE?>\C1$1#L
M>,#-A\^ GO<?YP4(^LX3D/2C-WWJ/Z_ZT)\^@*\7/>Q=_Q][VL_>]JPO/0 <
M</G&#SY) ,@OXG8GD(%?\"&RB_MA#4)?<!B8L1(T2-??#O&';+#.)YS<;V:0
M?+H+1*SQ;GOWNYU\!&1R(/1EV"-1Z31)-Y]UD^N^]PU?-.9W\/F_YWW^#3(+
M#>O_:/V !\,YI\GYNI_)!R("J01\!'W0(?]SP >$P @,'01,0):SP))+.0R\
MP)73P X<"+*1LB#1(7[@!T30@1_!,B]*,J=2JI88HQ1\ "HC%BL+P3+2@3 *
M"7K@,JJ3(ZQ#@ ? .@<@ _KPARYIG3F+E78PPB])%/:8$TQ3$'U0I"?)HV_K
M)[W1&QF0@2S<0A;00BX$0R_LPO\O%$.]^:-?:2]&R\""^B3\*#Z(:<- X20R
M [XKL;=/4:4,><,-7,,^Y,,_]$ _#$1 Y$"3TX=>*41!3$1"5,1&9$0T9*9A
MD\1BF\1CH\1+M,1,-+9-K$1A2S9''$2 ,254,J7UD@A)8X]PLT-2 K=Z8J=#
MD;#$&C=^,R6,(3[P6P]\:YV 8[@S>9Q+L\.-J*!^F@&(*3Z+68]#>Y+U.\9M
M"RB%.Q7ZLC:=&$:#H4.$L*-@3)!J]))8# EIM$,9&+M07,0G@IM'9"*)Z:=G
M?).'0L!W-(]WY!MT+,=Z!$5[I,=[)) $Y#$;H[$5FS$< \@;\T>!;#&"S+&!
M_,>#7,C_@%R^J3HJ%&RJM7$JJK)(%7D(IJ)(LW&^#7.ZBIPJ,OB)R*DZJP/"
MDPS"!R"<]5BS.BDO0PJAMEH(?FC))$DKUQ! VKG)BZ"K%MHL@ZP-ML.[AD1(
MA00*Y;,)MON&]G*LY3@AK?,^2-..RZ(-^EI*ATQ(A@3*HM3*@O3*K,1*H_Q*
ML01+K@S+KBQ+HJ0QR3/+ME3+K7S+L41+LJ3+N;3+L\1+F6*N[\JNONPN[0),
MO^3+OQ3,P"3,PQS,Q-2]NW1+N'1,D]C#T @AYU,L--.T^F*O1UJ(X!NHA*C&
MTD@G23._@5"L.P2 $RH-Q^),A".[R70(#;H2^S*(R(((V$P2_Z@,C<J$"$DK
M#:CLJ]5$QOO#OYJ@-P=;C)HLOXDXIP9+3KG,R[A,2^,X1^=L3);J!WHX*_5:
MSBOY.I HL9!#!!-SN?(03T28A<V!SKI\SL>,3NI,3\9\S_5T3_8<#Y?C,7+4
MQWS43_S<3WP,Q"Y:01@4T!H44!U@CQ<D4# ;%AI4P0=@IO[@NAY\@!],R91\
M  .-"7!4AU_QATURE!MR#WUX$C=A 06MDD/:#W\(L76*M8-3P_XD&:F4#V!\
M)$X3B&B+N)G@3-/,-C@JN/JHH&N$1@E1Q4V+F(:!T23ESR7USR;-3R9]4IHY
M1"A54B>MTBC%4F+"M4[D4DSD1"_M4O]-#-,O%5,P79=/O-(TY0]4'(C@BQ)2
MTD5Y6XC/_)S\$+?=?,J*.#A$68@[ND.)<=/?FU.?9 \XLM'<9-&0R$;_*E13
M0@AJ^Y*6>(?+G,8^;2%="=3@E$4S0;.0J*<<50AE--+[*$5VG#0KI5)@.<=4
M=95\6 <V,=5\JQB/HP^0&\\$=#D$%"D&9-4L[54U1=5@998=0T )--9C1=9D
MC3E_T(&G<]:E>]:Y.<.!^*EHQ<&K<3IH]2JBZ8<9J%"4/,D3<="'T,'>(0>0
M:!I].!R\F;N@F8?><;^@8;C1?(B-<Z$90#JMZ8(^,P<MO!@9X%=_38=K30B[
MPSME'9J_2UC_[+._@6B=>P :V4'*GP$_QS*(>T"_A^B=>D"$>T"$>L 'C^58
MD;T=@[@^ZP.:+@@^<$#8EG79EX79F.6A0Y39FK79FUV@O90]W$.]U?/9UN/9
MG?W9TAO:G@7:HA7:HU5:HD6@W</9[F&K][N2&SV<T7PDH#G9)S&(:M2=@;B'
MWC$_\..^XSNA]1L(N_L&V8P^%WJ(>.L_ $!;^SK&MK,@B\W:X82:E7T2W!0(
MZ8L_?[.@X7L(Z2.-OR6:R^S:I\6@Z91 >4!.\G,[TBC B#C >+1<D;M<!22/
M'%+<SO7<S]T:?BS67R5=80567S7=TJ40C0Q0 G7=!G7=E02 )H/=_Q,YNBJ3
MR 9]4 19!W M$:P35Z-C$H'P&T)UE3A%@'+HC^)T@':0CWR 53,)DP"AAR4T
MF"EI&4BMI[TR45HLC1=576>)PP41U>945(%BQVV;B6Z3U?;E47_@N'RJM/<H
M7_15M]/%W_#5W]3E7]3UWXV:TO[-7P'>W_\MX&R+1#,MTP4FTP8>TP=68 >.
M8&13C /6WSA5C^(LQM99-T0UD_>]T6:[B%H4B$7U-D]%7QGH&% % !&&MP K
MI?&-ROG-X)A$M^W]DAD0Q_5S#VED80=ANV[TCU*4#Q]=7WHZU#&!(QXFX"9^
MCU5UX@#!AR[X&_FU8AQN'%J-#UO57,SUXO\N-B*)&F #CF(++N-"Y$>7HT_X
M7&/Y;,\W5L_JA&,VGL\ZGF/)&+J@ND@]ADBSR0$=^..N*1N0/)%K9=:-!"HR
M^"K3^DA$=E#T! I_R(%O#5ZOR:V!4,(-D@$Q(:PZBZS)?0K@Q+:!F 5R:"%]
MB(INA:M(LBW1<(!QD $OA&46>.58EH%R"*.U:Y.A;&,YOJEY:LJ1&#BU%<;M
M]"_,2C?47$:A4$ICMD:6X,US,@>'B^/X]&4ZON-K=N-J[F5K]N9N!F<[YN:O
MI%EM-N=O%F=L'N=L1F=V#N?VU-G"E&?$-,S$K.=[GF=[SF=\IF?!7,QM5N>
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M/?1^R^="]+"  #C%Y1:P2 0#+'#!R)GDK#[C'(P=.%U F\\Z"4,\,,86/XP
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MNK;5;UC]ZU:K"EBN#E:P@1WJ89M:6,02-K%49:QA&RO9R%(6LHA%C645Z]B
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MQQ$37'XZ'KA(4+P5%8>NX:+67.E I<91+X6<M>U<CK58\'70I\?0X3=_$8Z
M(OL[Q!K/S:]!'N1!LG:ZT5WNRUU.7.C./.;.M3G-'8OSG=>\YSKWN71O#G28
M#UWF/S]ZT'.>=)XCG>A--_K2BR[TIT\]ZE17NM.MKO6L<QWJ7:_ZU['N];&#
MG>QB9V5^K\[TK9M][6%W>]NE?O:YP[WL=E<)G/6J=[[N_:Y]WZO?^2[XP!,>
M\(;_.^('?_BZ_Q)1[7*O.]T?+WG'4Y[M=X<\YB=O^<A7_NU!L33G-R^3WGZV
MLZ8O_6=)6Q'3KABV33FM; G2R];KBC[\8"U35CUSTH=6=8T5;G$T[_G.AS*Y
MQ+]\5'L[Q^&+7OC3K6[+2Q[PZ?>;^BJWOO2KK_WK;S_[W/^^]\./_?%WG_S@
M-S\@P8W^]9>__>=WOYO03>_YQ[O^\[8_O.^O__SSWTGVAC_[O9\ BA\ %B"&
M'<;Y'=S)B=P"-N!S*!Q6,)RNN!CGD%/XW!B+A9HC5$]MX1[G9!Q)Y$C^%-R2
M[8>/B<0 ,A&1$2!>8%'*L2!Y/5FO !L-UJ -WB .YJ .[B /]J /_O\@$ :A
M$$I9V@VA$1XA$D*+/LR G^G9H2E:$Q):%#ZA$RZ:% H:%&)A%4ZA%5+A%2(:
M%WY-XR4A&9:A&9YAL( >EK4:Y/3:IF5:IGG:18":PV7./9D:KYB1PU&3!*H:
MMJA3P<"3/.2/&P+,#, 3LLB:2-#:#>*#/MQ#/BR9L]Q:M$3B([I,/Y!'CHQ,
MLV!:RJ$ALPP2E,%@ )*B 9IB"IYB*:ZB*K9B*KXB*L8B*\+B+,JB*]HBB?B#
M?M4B+]YB+])B@,D?_M'?_A%C_PTC,A9C,AXC-/P?,#XC+D;C+TIC]<U  CI@
MB14< \(1 D#@5/3A&74< /!#'E)<';969-#_UL-]8(E8T1T.A#MDXV\%1AV1
M1%N@CL%5CE]T 3?JAL00Q3V4V.I,1 >NXR-(!3\,W+U<Q3W,@ (>@#R\@WN(
M',EQ14-N8W&H7E[( (FMCE0@ D=J(P*D SR=13MD8SX:ASE,HPFQW R&'O/%
M9-P='TS.9//19.;AI/,AGT[VY$W^I$SR)%#:9%#6I% 694X.Y5$2)5,NI5,:
M)50F)5+N9%12I50V957ZY'+IHE9BY54^Y5=FI5**Y51V)5C:Q!(J7N(5WEHN
M'ENJ)5R^I5RZ)5VVI5T.WAB6Y5B&)5]:I5^:)5EZY5_NY6#J9=:9R5E>'>\M
MYNGU7NH-!>OE'JBH_R-KN5YJT1X?7J8'ZIYC 2+'(.) ](,Z-.8W=($PY03P
M+6(E=0'JS8-%L:9CFJ9$( +IX9I G%IE+@4B"D0_N ]N !=-X,,,,";JM9+Q
MC90^$*=COF-1.,QGP1,^<*1C3N<WO-I,Q*-R<A8Z$"9@]N5)0%^O4"-8R$,.
M,(8#),9YAHM@D$$.5,!Y,H:G745YFB=ZUB=]WJ=[\DM5($(.E*=[(@;XH,@]
MD %^GF=_^@<BO.=_%BAZ]B<9Q">$>$$.**B"YH!R\<4]].>"5@"$^@494.@#
M6.A<2"B%]F=7\*=_OF> GBB(,BAC]&<.K*AXSBA+^J*-0F.-XNB-TNB.YO\H
MC^HHD Z&+OXHD?JHD?;H?>3# RRC,38IDSZI,D8I,TZIESACD2)ID!YIEF(I
M()F)]#TD2F+DB8'1(\P6I%"@P[V8!QZD08A1BX&@2##G0>A#.62C:\;%"2+
M/?8C1.XCP5W!5MP&GWJ,5%!@'IXF<> &"\CI0,Q /YK##+R#/KR#/! 'GR+
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MI.JS."(X:YK89MIE T A!@P\/*(E0J(CHKB).V(&OZ$DKFT;(H"C&4LZP.%
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M)-:C0Z2>WD1QLT1\+>IA?>)SEC./_[/I47M$%7#O-3Y+*%_35_W=R?.0 Z]
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M(_QXB^C#X^R"?#KW_,?_M5=\UUUYZ0G('P+/%?7.#.UYUQPB"9DSX#LH#8B
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M;;)AYO=_4N9_4]8^ VB >4$_ $B "2B "!B !>B "_B # B!"GB %AB!%]B
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M=52IT@3%L/2OO\18HIJ-LV9)@25$BPF05+Q8P/E.J<I*IXEU^*APO\5=;PD
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MD8?015D0H -5BU:LH\I<B\ULXLLLHY5.3 .?HI*B#),X\#F2Y19)!2:F8\O
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M9X 1<7K_!PY5URA0AW\/2$G_^9=UNE<G8\=_7I*!M=<C,U"!YH D]Q> 2D*
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MF[AAN[B(R[A@V[ATU)..2[9C6[F%.[F 54Z8>[F0^Q7BZ$@W"Y"A&759^JX
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M(WJ*(_< M%=:H@D1C^=\O_BWH^UL@N2<$-;\=02\HCH:$>E,=M^,I! ;NN!
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M\'0"#?6]W;X<WN =\;TLZ*?*\+=J\<H #="@JJ&,):SZGPH_/XC@#NQ<#UU
MI?V#F5L[73B- (-*;%U@#JD[I2 .)/<0\QR*#C5_)3??B""Z\]FUS"$_]'>"
MYD3/)-2<)0'=[ MHH4M*S\^[I/AP\Q#*Y$4:=>@P UF/\D^*I.?,?X5\T/\F
M/A #^*#):_*$.M,T8JA9APX)I6\QRLX(J,T @/8U6M!B2J([WZ<!?/?[;-!B
M[B,M&L#BG*01?7\O7]A>?R-V^@TR@/),Z\X/\8$K.(&,B(81FM+NP,]U:J&/
MGQ"1OW\/P?:LEU#S7*0GK2.4'WI.V@6)O](TTM(&,?,=./))*M,8VB,U;:0/
M4?;W]PZ2QM"VF;MFKB4YT/'Q1 ]=*0\VD@\R\@CZ</32GRA%3?#6+^IV#CK0
M -]Z[JE2;9+>O^?S[:GDOVFG2NC B*H9K_ZIBJJL%LK5D>@;KPS1P&K9CR'=
M'K-XS>G%'H><<88 @0"!.0 %_14$\$T@@@,(#QK_=!@1XD0 #RM*O$C1XD:,
M'#5B5"CP "*#"P\@>)=1I<>5'5U^A-DR)DN:+V7>//@.04A$-6?:](D3Z-"?
M184:#9J4:)>3 NL1/7JSWL*0")1"U!ERQM6,7:H2G#E#I, N7,T"122PZDBD
M7=0B>$I3[$Z35$W.,%IO[EJ[8^-*I"OP+$6];\<:9@@WZN#%4!D_=AP9*=0<
MLR9?;HP9LF;)F3UO_MP9]&C1I3F?#HV:M&K3J5VO?BVQ K_6L&W7QLU:=^S=
MMSG3(^/[L]O 5CL2K^HNHLZFQ9LGCSCU>5W$3[$F%@CV(N+I(KMHW$L=@?*2
MAGNZS"J>K]KO*^=V'^^0__KYB<[[8A_8<;Y'1'Q/(X+ON??(XJBZY?#3CB;D
MU*.NK(ADL(\[O%2:BKN%-EKPL @=A&BJ]8HSQZZ4S$HKPITB,A FK^ZB*,#[
MFEJI+_H:@Q"ZCRS$<2N0ZOJK-\ERT"<WWH84#C)]YF&AKWEJTN<11!Q!Q,E'
M^B%2R"*MQ-)'+:O<\LHNL^0R3"_%!'/,VZ)\$I$TH42H38O<;!,C..-4:<XX
MWY0S3XKLY%//.OW$<T] Z?Q34$,+13301 E5M%%&'Z73T4@AO9/2/@^5M-))
M-]6TTTL7Y?333$6U=-!03?4455)/Q;345ED%-=5798UU55I'537766WE%2-E
ME/])QI1@AQ6V6&*5,=:488I=-MAFE4WVV&*5R8=:9?11!IIKLU6&GVRA\58?
M<+N%IA]EHAF7GW++U<>?=OGQA]U^P!U76VVQQ9>V7G?5M=9^<>4W8'\%!GA@
M@_TIL2J%[UM8K0D?*D[2&11N#T[##G858U@+/@B=P.B;>"'K;LV8XY)/WACE
M.-VABB2-24XY9IAGWO?EFM]<<&2"+4W8KAYI#5$MESF&D*Z?W2Q:*Y-EOG1%
MQ,B3U6G%]NPYNR[J0:2>+M)SBM(*B_OFZJRW#OFM2.W:N:"O*<9:ZW?*IHOI
M?U6^F>ZYY4X;H<J6IOGNOO.N&V^;_0[\[\$!)SQQQ!?_/[QQO@N'7'''+<V!
MML<EOYSQS"<7?'//[=:<TGF&!OWP_A8RYV%"67Y+AC_U:AALQ1Z"._:&.02@
M,*/CK"=IADFG<VV?VY0ZP4<];GA"#Q% IU/AW^JQ>$BECAWJ.:6/M&H=\3X=
ML;#5;IE.UG=27>WP=$X4$>09#K]2KF4?D="@P7;]3O5E]]YE.)=_NJ#NISZ8
M[][2O#:-[QOEL]_Z$# CA/Q/82Z;'_H @#V#K0V!<'K?[1S%M>T9SG.5\V#I
M/M<Y$3(*$>K WT[D<:A\)&)-:7+A+%@2N="1T(8AO"$-.8=#'NIPA#W$7 ES
M&,0AUA"(1GSA"\GT)28NT8EF_RI3%)L(Q2E*\8E6I.(5J[A%+78QBU\$2C^(
M-<9HF0)9P4+6LM)H1F@YBXUJ3!:RY&A&;%4+7_7JUK>\I2YO::N/]1H7ML*5
M1WQMJY#JPF(BN0C&12JR."-+"MID B"J(- BSU&D%S/)2$URACD"F1$G1;E)
M*4H-DECB'WZ@II2QN&XPV.G@1@:$@%B2TB#$Z4XM-8++V1VH*J>D",MB\KQ0
M8D1WJRP(?AA#S* <TY:=A&86*]-(:D;SF:.L)C:MF<UK=I.;6P22-[<YSL&T
MPA1?R,(+7+  %+!S 2YX 1:^,(A6:-.>+@'./;^IDNG\C'8"VJ<^R2E.@1:4
MH <-*/]"!TK-<";4H;R9!3R*YB($+,DE37HAE)P$)4?DPS(+!:E!'RK2D"J4
MI"<U*2F3N%']$<JE+X5I3&4Z4YK6U*8WQ6E.=;I3GO;4IS\%:E"%.E2B%M6H
M1T5J4I6Z5*8VU:?Y2 :PHB55,DJKJFTL(QK9*,=JV9%;XH)&(,4:+D"JZUY?
M16LASQI61#G5K6^%:UQKNA!P(. >-BV.2SWVEKO"]&)R!6Q@!4M4 [9TL(=%
M[$R)4]>^$M64 /@K3;M05X%8KZ8&K%B;2D39"=&T*D6=K,B*5E<"PC2T7:/3
M_,"!CY[BPS"9G2EKZ23)F[HV,+"5J6P3NUO>ZNVCO05N<(7_.USB%M>XQ_4I
M")&[W)OV8Q!8*  !%B!=ZD9WNM<E@'6I.]T"2&$05&*N4>EAV/ *%3$OE5%Y
MU;M>]K;7O>^%;YP:&E^WWD-JE"T.?K^QPI?F@Z7_31-+':$O^A;8P =&<((3
MC"8H,9@D*!UI2B,\X9)2&,(5QO"%-2SA#'<&&EF-X[1$#$<2OY&-9)3CK\SX
MJSH2,H]AW6.Z9-Q'0@;2Q7=4ES\.LF$+<YC'^ $F3NI"F.$%92V)?%MSW &\
MJ&BM1@*9@3G: V%$&! !,L"=;;H@ [A)V9]#T5ISI'P=GE"Q"ZEKW=5JL^7;
M!KF9;&[*#-PQ93 SI9+QNTR5[X)G_SNC-DSC8PL YA?H2)HM-!?;2(GB3**Q
M="EG@J[D3!Y=(.P4<S*I=+-D(A893/O8TSTV2@[ R^,.@[K4IR9UJC^-:M/,
M5]6FYDHKLE#=[-::N[76;G1U3>M=3S<+K6!U%?.YZBP"^D7WR32LB;UL93<[
MV,]^-;1_%"1G"Y0?]'BRACX4$HM^!*,:#7"XP:U1\$J[VLPV=[JCO6YT0]'!
M2BSB#GTHQ"/*FXCU_N&\XYWO>^L;W_3V=\#[/7 C"KS@!+=WZ,X(XJLV'*M:
MO>H<N6JM0F++CWK$.(RY16,:6SQ=!#YXR!,^<GZ+O.2U&MZJ-HT0NY2V58@N
M87I<6379'?\M.BEL6$OQQ+_,^J/(EJ*M0^YGN_8%KG;LHZ6H,B0[UQ6V/K]T
M55X=(D"<UX]/R*G?\\!&WD YD'VN)%3OO(?L4F6P+WAYM ]]]Q>NX:Y/'-P7
M!1%FF ZNZG\E?RP NJRGO*MD?@H1',4T)\F""9[D $?XR15OM[TAWN2./_R^
M(;]XR5?^WY8W>.0OO_G,YSN<E.=\XB</@'Y\P=:GSS6M;[UZU*N^UE\H=^='
M+[/Q/A[S]W9'>,:.@)[//O2V_[WF97][X \_^* W?O)%3_R#S;?XR[^\/M:!
M=)Q3A;^*:F%&$>%"CL(PHQ[%$_*AK_SGEU_XXT>_^<6O?M^3?X?_2>R^NML]
M_W/77_[V9S?^Z7__4IN+X65<.#D*JWGQ!WAYEWE1%VS9JA7[E6UA,8J[EK+"
M.#[*.'K1N'ZPG/W+/_ZCHD=R#,+3/<_ I-T8'W-0M"L3FT\R-(^8@>=0LX<X
ML[H .R+SCHF@)+48BFS+,L@"LN6 FX;X#P'!,ST[#$NKB!/,CJRI,MVKM$2#
MN9@8M"E#0CD3NO<A-(EPFAFPH'<8&^YXB?\Y"2S#FG>(0?;0B/UP"#:KBII(
MI0/0PK&!$/A(MD-K0OEP&*,8-"9+B@&)"R0TPJ3H&4?SBXN(PPLYCD'DB#:T
M)+0HPM50)L?PPPV4Q$R:)@[4P$O4OTRT_T1-S#]7PT1I&P362SUVRH)3\(Q3
MR()V:KW5$X1//(MAXT17E,58I,5-M,5)K$5&\L1<Q!)Y:,%CPY$(Z;:6^+87
M$C!Q,\8GT0<9FL5;;$9<=$9>E,;86*DT4;!KQ,9LU,9MY,9N],9^.#&J,A85
MZY8,)*J#H!(#1,"QBD ^HA=UF1<,)#UOI$?WHBN[PJO/LBV>P*G(\JGW 8?.
MFBT;H1.W("\ZV:N=.$@ N <$H"S<>I^8DAJ78TB'7(B8LDB!X*FDBZFUL;HX
M:4C\DB#_$0C](J_QJ2N)+$GFB9. E*F0A+*76BS40:^,Q"WP6<G&(A0(@:W-
MTDB_RDB7^I_5<O^IAJP*QC(O_"(4N!G)V;)(BIPKS@( GUR@GOH?T!))XO%'
MXLE*O<K(CZFI&< O[?BIH)LIL:3)>O3&2E3+MG3+MX1+^'*^N#0J*< NUEL
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MC_PTC>S<P[> T-BT4,_H@H_BS=WDT O=4 ^E/QT S0\EIU; -5Z3 F![HE:
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M:J!&:B(W\B&'C2ZH@ =8\B9G\B=?<AU(<B>G<BAG\F-NC7JH\BU_  O \IA
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MT\;&A59"UT8ZU$@X<+B?=A,ZS, [Y ,\S,,D"980/Y".YM%$XQ+N/E=5<;
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M8HNR?<QD@0P,;-N3'& XLHQQPT=B!()5;6@$$/%LGIA[U:TIBUO&;#ZNOW%
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M"(<P"(GP"(VP522%4YSP4C8%"CLE_PHS10J?L JQL FM< NSD%*X4 N[$%/
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M^ OD*2,?NJ!Y:3"'2001$"Q'<R,;!RT6;_6[,?L=):; $4-J$%[.( /-U&Q
M/!G_XSOLP5E#BB-FP@$#A_DK5LV^?+7X;HXZ]HUZ]ND9H =ZGF^_J&M?]G<?
M($_M=8$?)(6_CP,YD!4/>O)8>L;J*P$YCRO@_2@'$6C<W=L=WFT<=OSA):_<
M-4.**EA@!M*A"]YA'N0!$>JA8N?GR3G'7T_)'':J*6V:TA7:^V7 $]NA"^"!
M'FQ6%B,F''KRO  "P3<$!+\YR <@84)_"ALR;+@P(2)P! 42=(!/X4.(&QU"
MC/BQH\:/ $2"Y$C29,F4+!L61( .94)W%;]U"?FQRT""YD:BLUA0QL^= F_*
M/.H1ITN@3(D2==<2Z R5#.LUA3G#7,V*]49^U/HR;%.%_S3%.JTYXR31GB&[
M%$R+Z*Q9!%VIHCVI4*K5N6*[XAWY#B@BJBV1>C7\-_%*I8@7-R;,..GCPI(K
M'[:L&/+DR)<[9Z;LV3%FT:$UCS9=&O1GSJLWNSZMFG1KV*QEVT8].W5MU(C(
MX+X=^[?PX,1W%W^M&WGNY<"-.U?>'/KPY[2E'Z^./7EVYM.M4R>#*/IV\=K+
M<[]NGG2K&@0*$%C0_GU\^.[IRZ\_/[_[&@C/4T_?777UD.&?=P:.%R" Z!6(
MX(+D,:C@?Q!.^&"%"5)XH84.9LCAAAY*J"&('8I(!CT'1GAB:TYUX1< ^G0Q
MSE9\736C4_(HED\BB#BR8X\Z\O_(XR,,^?-(CSS^:"0B2 *I9)(\SB)B84[U
MUR!G^K1#%#C)]2-#C3)*U0\ 0\G818+RT"A0>,C!@Z9<3*&3SXSHR//./)*Y
M^8V:N,V#YY=]HJ//:#'.!55UZ_B) #SB]<,"FN!T46<[ZXPSRX@IAGBII54"
MD&22CFT$ZF&AGC3JIZ*>2BJJIJ;*ZJJNE@JKJK&V.NNKLMY**ZZVYLKKKK[6
M"JRNP?8Z[*_"'DLLLL8FR^RRSA8+K;*@>O% !0]<:RVVUU:[;;;<:@ONM^)Z
M2VZWYE:00Z4*W6-MN>%:J\.0TJIZS[OF8MMBK?D\X "_V_Y[+C^_NL74 5\:
M')8#+*S_XPXB]SPT;!<(6R2#NKG2X\#$.Y4Y;[,,=4F4QA6)C(#",JC3Q3SZ
MR-LK6$!Q?%)90!W4\4KY.! R08/5'*W'/".K4T6%KLI4OJ*.C !(,TQL]$*(
M)-WSLG$1!/.G3[\,ZUVK+ET16Z9VB?!4A\ELL RFUA,TU%XA,'&P+YD]JL1?
M-LUU07JN'7;6!&D\0UT:S; WU;7N)5!:S_[L<^*'*QYUXX@O#KGCC#\N>>24
M7SYYYI9K7GGGF&_N&#T$@NXYYY^73OKIJIO.>NJMHP[[ZJ[/'OOK7I%AI^VZ
MTRY[L?T,@H5]PNMW7_$+2#%(F+7SOCM#O2T/?>_2-S\]\]9'_T]]]M=7C_WV
MVG<//O<=XR[^]Z>6_(Y&B*13\,'NBT4RVP3-$ZL^13(9I)']S>(D(O<G^3\F
M!;!'0E)=6%8FO7O4[5D$BY_(6+"SA/0#:04Q2N/.)+^7J,-R@7&@C&9P#XU@
MT(,9"17\=!:UP)QPA0*YD;' ]J5V'.M0.2-(^HBE#QBR\!MA\IX/PV>^B'3J
M?R0IHA&/B,0D*G&)3&RB$Y\(Q2A*<8I4K*(5KXC%+&IQBUSLHA>_B$5]M(M;
M8RPC&<]HQG;EP M=(,,]^-$/BR6$#&BLH[4$IA!^I-&.9.P"(O Q"WW,@A^#
M'&0_"(E(0R82D?W8""+VF$8U+7$6,_\ V+C(. ,H(1$?#J (03S)%' X0 8I
MPZ,5]=&H+$GRB%T )5%"",:/3*0BKJ0E L8Q@W8@PI15M$J6$)"1C[P#9[1T
M0*"LZ(\NU7)HL6SF%;N$ (K LHA7\^0J/_(33QHE(82SB3.M:$LC2J6(,LL3
M$@DVD!LVA&">G.)6EDB4F) $G00Q7!'OP11Q!D6<KC2;$;N9M"3F\YL$+:A!
M#XK0A"ITH0QMJ$,?FL7>0'2B%*VH12^*T8QJ=**(,-%&/[K%5ISB"UAX@0M>
M@((%I/2D6/B"*5H!TH,.**8TK:E-;XK3G.ITISQ=8D=[^D1^N,,!8JGE)[]D
MU&@BM28N+&+_/OX'U1YILA]1S9]5_4? K%Y5DT!5"#UDH*4H^B,?[I !"SJ)
M !G,8!W7Y.D[Y)%-K, IF$:$QPP&@HYUS!6A\WC'#-!Q5X+H=09T[6H_Z)$.
M:+) *"GK85<?JQ"L\DBRX0'B#\MWV2!F=K.6[2QF/:M9T'+V<5T8H[WLU:X9
MZ$ 0CW#LL"AY6G'%2R-T=-<E47M)T]816W2MUVW'U31;Z<.2L=6!*4OUD\ 5
MQ 'I0,0QK7<HY<K M5Z91:/$4@Z(58\?T!09*>G',MH!+H,(2,?8*$@SS?4C
MNB%;1WA%"U^\561P[UR5W @RM*I();[,JAL"],8VPX'J:NGTE<L._R!?@DB.
M*6Z3']R\DC8$Y/=H@6/5?BEL$5Y%V&L -IC?0OO9$(-XQ*,E,7]+C.(3JUC$
MD!.=B5F\XA?+.,4PKO&,8TSCS)'OQC;.L8]Q[+GG]1C(0RXRCX_\8R,G&<E$
M9K*29[7C)7OO:CND8/NJK%R@T.]4]M.J9 7F#_Y5E;)C+K/_P/SDG]FIR5)F
MLYO3[.0XMYE3__-4E.Z<J0_E&<^;ZC.*_(PA/0,:4X/6U)\/'6@^(YK0B_9'
M/W;+1W3MDM$1*>T9M55&*@& DGO$=&X_72[=M@LASC.CI]MU3=/P ]3GRL%M
M\%'4%C6:)?P@YDL4)1EZ(-6"@DZ-/&PM$/^,[%DFLPQ+!%<2&*>D=]'194HY
M'#MK12<:*?7%3(0GG)=]<H2>".A;KZ<-@/$.1"D7ADA@"1)<CXP) <<NIS\1
M5%_-K"4E]/RP3,Y-EY1HS23C3$U8FH-O64=[V(7^-J4/;FAP#[S@TD:XP1/N
M\(9#?.(/KSAGA"QQBQ-\X1Q7N,<COO&/4SSC) \YR!E.\)^.W.0K1[G+.WYR
MF&_D'J-KN<PU_G*1X_SF (BP-]>Y(IV7/.<Q%SK+"^,R<QY]Z#Q?NM,=\E.B
MVYPY].!VFQ#E);.X4"4YZI^.-,F/(WE][/AKTB,$:72I[SSM35<[T]D.]Z++
M?>IS7WMT.L6D.<O_^<U[A[/>_\YWP/M=<G2,K;>.C;I]_99<VV1(/FP+^7LM
M7O+DZJWANQ7<P8F:\@_P JO\.Y '?\_J+.@AJ*QNL!""UKID\FPZ@'T &82W
MG!>A4NGH(1=A]SU[#+Z5<A$/ ) 1Q%4 #5SZ0-N%I%N9* #^AH ULOSH9UGI
M#$FVX#I&W@:'WKY,DY6X\SVJ#(J-5"-[?JLT=C=2?=_>@6__X-^_>\''W_WS
M][N+Y8]_^N<?_ONOO__U'F7Z)X#\-X#)@G']AX"U WK2]U\$*"K?IS8+,5X(
MDX .^'^=TWH66('^APBYLX&DTP_#5$-71H(C6$-;EBI=5G:/@$?\<U4"_]0_
M ^0(@E2 'UB#-ZB!.'B![S=$/0)9/PB$02B$0TB$7>0/D(1&KN9%.A!I9)0N
M$#$+.8"$4]B$4T@ECU2%U=)62U1;65@!T]00NB86'D50^A .MH0 'K@0PG=4
MX4 /\]!1'1B'<$@/<EB'=&B'>8B'>QB''8%!1!$.S_5-\X"&:0@1(EA,@HA%
MOH2&QU:$111.2@10$'%M251-<]-,^)14FQA0)-%O$*%41;54+Z%.,T%+VQ1%
MU89$\51$] 2&111PD*AMGNA)]H1$Z[:%#1&+C\B+O>B+OPB,03A3P4B,Q6B,
MQ_B(48>,RPB$-,>,()5<H;14.X5/K-@0FM@UQ?\88>!06,_81-;W2=[(C,J(
MC.LSBM(HBNG80D?T5%ZF2>UX56:V52HACO5HC_>(CSY59T2D@S:8@_^X@P'I
MCP+I65AX>1506:>#").G+>E7$HDP Y%W>1,Y+I;'D-62>;=B:10I1Q]3,-,U
M6NJ0,37A ,HC0==%7B;(@!ZT0_[$$#F4,^;E6<GD78Y!-K5W.JB4DHDRD)M#
M7AD)$I6X$.7'+(APD]V&/:#GD _A7QUF?B41;_/20=>7.+V7*X$C>HL184!9
M$A,(?FNS$^/W*?NF*B$C*TA#D #9D_W(EFK9EFFI/</XEFOIEG4)EW1YET#4
M@7:)EWVY8@<XEX&I/EC_ED' ]W\'A@#'IQ#*IYAY*2P4Y)=\*9B.F3B(T%23
M"3GYT 6-PI(E*'TH:"HJB%4%1"1DYF5E=ER2J9J4&9FLB9EM25EV]G1M1YMQ
M1W>W:7>X^79UMYNZ.9NV:7"69FIHI(B)QFFL=BVS]1>(P(2=!FG#"9W50FJ<
M$IUEE&JQT0\Y\)QGI)P2853TX)OW0%1,D5_\D$I8=W59EYYBR29B\8IIMQ>J
M%!'@&&R:!G+<552\UINY21GK-QG&QA#K1FC?5XH@YVZ1\7WD%I8F@6_8YAJ3
M*!U1R1CSUA8O86])L8L<09:@&):G06##1QB,B)3\N9\E^IN\>:*^Z78I2J(L
M_VJB*PJCAW: ,0J<+UJ;*$JC.'JC*KJC+9JC*KJ7/%JC+DJD/]JB]^!Y.CJD
M1BIM/J>?RH$(Y@!-/X<;45I/Z88([[!A,]"8*"$6(B$6M)%\0D,2]3"EWF8:
M68IOYO"D'@I8&T,8],E,"J*E22<#[[!*52JE%;0:8\JGKY&E6]JE@.:G$N:0
M25&H/\>D1=JCN[&7BPJIG4$/^-8GZOD-6T<270<D- @ ^5!V2^(C!,2I-KJD
MC<JHI8JJ2JJJ0KJJ/FJJ>.>#K[F:K4FKLNJ:LPH^L^ %.M %O.JKO0JLO.H;
MV[.KP6JLOZH#)DDKLY /B" (9-"K.2"M%3 #.1"1U_]*K=9*K=M:K=@:D725
M#VR$K,?:JW35,[- KN/JJ^:Z#F?EK@[P;".6 V<E PKC .;02 DQ"^5@K^,P
M2O9Z5OY:K^\JL #K  5+L/^:L .[#@N13 ;+ EV@K)GE#^:@L HCL0H!#_VJ
M,#-@>Y_3GN2U0;>J84_QF"_1<VU3,Q3*.^!8-:.";\WWE RA7#YILHG3E+Y'
M,=S'%=YGH423-QA6-KORDZI23D]JJ[6*JTM+LDK;M-U3#TF:M%/+M$YKM50K
M8Y99M5A[M?.""%[ M6P)F<5BEB*:DDB+EA'F88Y1?#LYHD&I,?JIMG([,3VA
M0^0I$2K9I1M!>].75J92LX3_0S)5([CO\[(^Z[9%JQ8C P!F&[>I,I4G9+;!
MU;8D(Y8/<5]%$93SQH8IN90 $+GM,[E;:X%:^[2(PP_M,)XJZ;?*!9JA(IH%
M1%4Q&(/YH"YA2[JGJ[M=N[O1TX,\DH_!*[S#2[S%:[S'B[QBA8Q'U8E*-#4$
M$8V*2A* ]9[K=%0%FA!A"D6$ PZV"!'/JU3BU*$D07O5RT27V&U'I$!A]1$$
MJD36F!,O8;ZZ2!0"EVT"\6X?$8H6(4^RY$JH6$2XF+P#3, %;,!5)%$'K, +
MS, U]:@-#,%5A*01[$6! 4IS>DY']::%6+^'N+\N4XL-T;:<V+\* 8$? 4WM
M9&ZD_[B_O\1N+AQ*W0@ ?=O"M.2]K=0U*;Q4TV3!YZAT2J3#ZK@3U\1.6 '#
M'7R--<R\H>2]C>O#ME3""7'"$*'#]&E438R-0FS#%$Q%B # P>L/]1!76KS$
ME\J.][,_IAF/B"!'7.S&;PS'6Q2;_)B[O&O'N-N[=8S'=ZS'?9S'?RQEY?2Y
MD+N361DJ;,@B"H$VRG6Y"I$S[(<K2JDT8:FRY+<W,YNW2$-* Z:ES'<8;=LP
M]6"47LEN<1,R7(H(BWRX6&E?2/PJ7@G) %!N8_D6RM4%H9RY!58K++O'O>S'
M? S(OAQ_41O,ORS,P(S,PFRZR6S,??RUQZQ_G>G)2C.X&_^1,UVJ?#QQ$T:I
M$59G-%;QN(O!%!R6O74[$H[[MY@;/_E"08CW02:4?7\#/[R69=BFMH-L*UE&
MSN&6,]2<@0EQS5HI,O:&F CPLMY\SF<;$69+SN"\%3(00>!K,'"[%01-08=;
MS$?FQ<T\.?BPF2LI(Z\[$ET&=FN</RS(S!F=TBL-S4L;FWE'JJT:TZQ*TZZ:
MJC4]TS8MTZ>ZTY%ZTSJ-TSP=U#[=TZ9*U/Q&%-CQ):/1MFYBORNQ;@WX'V8K
M%X:#LC(QRTD!OI5:.(K1U)B($U1=$T_*L@Y1;P#GR@ZQH2XQQ#WG)5%,%5,:
M4$-MU'7]TSF-UT(-U'N=UT?-UX;_,:-V7=1WK==]+=AT3=A^;=C@MM&(/=B/
M[=B171@3#-E_K=@28:ESO12?"-5% XIC\1?TN<\)P6VH2'M=>MH0D<V.^*$\
MX164NDI]\=I!Q]9KK7P"YP\R$B)-T58T:Y79&Q:V&*">;8HO =?9ZQ0>S,O6
M^S(-P9B.L=I0%]Q\NQ7'+<O)O=B5/=,;?=G=?1CR(-<U@JD?D2,M&*KX8[O9
M+=GJ;=F'W=Z)[=[L+=^N :O V](J?=\LS='ZC=_[G=__[=\PUD")>5EHLQ9<
M6F)&B19[>SI=H%9\@Z=<R<EKBN 1<V")W)9^5;=(BRKB!^#]#>+\+>(?[BS$
M/.(!'N(D_Z[B-L;=)Y[B=?G,*"Y_:OL^P"?:AZ%\FTN4JR+1FJWC>T//\1P1
M7SH26=8T:CNS#ZV5K+N3]G:3AAQ\OZU?$^.@M?+<I2(R\SG..!Z51'X2 "5Z
M/<XJ<SOD0KX2LDW1?^K;T\RV2K[B(];B;_XK^; .([E"(AT1G!IV6C6J+N[G
M<@[H,AX^OYN+<6SHAX[HB:[HB\[H4!2]C0[I3?3HD4[IE6[ISI3 EZ[IFTZ\
M+<[I#$S9GZZ_S.M$OT02L-;<FZW"113$7WR_UJ00./RGL9XE "SKFCOJH4@2
M<JKJ/MP%U;O$) &^C_(1Y?M$J)[4K1C<#6'J'X'L5$/KIQC Q/^=$*VN3Z$H
M2;<NO3U7ZR0QQ:3=[=-+[9ONZ0O<#XA0#AS<5"TA9E(%;:(.[_&.CW,<JX)N
M[R^.[W]^[_J>[X'>[[D[R_[.[VM)3_]N\ ,O\ G/E\Z(\/NN\ ?_\#S>> Y/
M\?47XQ!?8Z%;Y:(RX&^[&/B&8%INSA:&?JGBT 4AST#Q*:2\\O\6*AK/Y16V
M$B<O84##-^I7L_"\H$!SRI\7,A;4\8W,SXPK@;]GRCO^$)YK\BF9\CO1\AE$
M-+Q,RH:)Y!@/YQ-O]<YR#]R&YX[AJ?[S7!$O]A7?\%D?*R_M@_/MW?#-]MI=
MV&^_]FX?]^L-]_%=]VU/]W/_WG(O<Q__.JAVK_=J#_B##XYYNO=Y/_AX?_B+
M+_B*W_A\KW"![?AW#_F5C_B3'_B4?_FBT=B,K_F>G_DHQ_";3_IZ=A:XW1*P
M'1)NOI@536W&IM6G7]NN#1);+L*V#]VJZ#33K<A;4:"F 8&&?]W92(FT+1S<
M)I;.S?I#;S>K_S8?[Q1MU;=5(\NP[Q5;G6]YL=P,3;ZNSY317^S__/F/SR'E
M7OKD#P ;:\:W\0CIG?B6#_KO?_[C3_^A+__'4=\):?9D/_;[[_]E#Q  _ $@
M.+ @08$(#28\V)#APX41%4YT*+$B18@8+6:\V)'CQXTA-8[T*+(D29 H3:8\
MV9+ERY4Q5<YT_RFS)DV8*.LAX/D-T4V@.8/:%%J4Z%&<2(<F9;K4J5&$WW@B
MJ-<4ZE.E5[5FY6JU*U:O8<&.W2JV+-FO9]6F96NV+5J<][S I;O6[=VZ;^WF
MQ;O7KU[ ?0/S)?RW*:(N@A47'FR8\6+'=A&1:5P9LF6TB'I./3I5JHR,[Q <
MF.INXF8$,TS.D,KSP R'YCSS1+30W532[Q[>WJS;-FX$OD\C:*V:X@S2/7\F
MW-EZ=%/B4\UAY!U=>,$9KFDK190\>M6%.[6GCC@;M$31WDUC1]TE//">QYV_
MCCT;06V$U7/OGGT]X7CCV(L. ?<0$F\TSRY3\#$&A4)LP<@PBQ!""?\KI/#"
M!BW,$,,)-_2P0Q U- P11TA$!)%'3$1H119;=/%%&&.4<48::[3Q1AQSU'%'
M'GOT\4<@@Q1R2"*+-/)())-4<DDFFW3R22BCE')**JNT\DHLL]1R2RZ[]/)+
M,,,4<TPRRS3SR,G.5'---MMT\TTX<7PP3CKK!/.>,>S4L\4NG /'/@3^5&Y%
MT9Q;CT5T9F.QSZG 22Q&S0(%5- !86.1)TI;1 T!327ER45&,7WTTLW0:5$&
M3"?MC\7J_M2MQ42=<W$&2OU$X!X;8VU459ZJ(G1 ! Y=,='-6$3$UDUK#:[%
M2)5-%35+5WR64U)EY;/640DZ=M=D5]U3SSG_OQ5W7'++-?=<=.U$T<1U2PR1
M0Q'CA7?>#^6ME]YW[]4W7W[M[1=??P,&>.!]!2Z8X'\/5CAAA@UN&&&'(X9X
MXH4EKICBAR_66"NY-K8X8Y _%AGCD3TF&<-P2P[Y9)-;3@@1(%26&6#X@/6N
MM8=DTZZB2(N+*#L$.8T)T)MY"I"A+FY^U*!01UN:H*0]>[H@^$(#]M"%=+89
M4(E0]<ZB;5VS-**>:SZJB_&V[A4CK4GC&5J)=BI:[$(YTXAH^XYF6NF&FCY@
M:H& QCGNH&V>H6Z>9G99PT1&57SEQ5F&?/+'*Y?<\L@S?[?=$TMTM\6%5@P=
M(]%='-VATD$W?775_UMG\?2'4G^=]=E=E_UVTG-'7??8>8?]=]IQWWWXWHD'
MWG;?@T\>>>.5;Y[YXJ,_OG;JA9?>^>NAG][Z[9>OWGONL>_^^>_)#U][\=-'
M?_WRLV]_?/?/?U_]^=F7_W[P\S=?__CYA_]_^N%O?P/L'P$!:#__!3"!"#2@
M AO(P )&\(#UHZ  )>C "T)P@A;<X (KZ$$.8K"##_P@"4.H01&F$(4K+&$&
M6]A!?,1,A2^<X0EIR$(;YA"$.S0A#UVHPQX&\8<^'.$0A5C$#3X(B34D(A./
MZ$0C1G&).,1(QZ0(Q2G>4(M O"(5F_<.UDBG"[YJHA<EV 5TA)$GYNC"._^6
M\T30H7% 8U1@/9IFCL-U\7MV+,ZAG/.-L:T.C,YA(QGA^$$^&LV/G@FD&;/(
MQ4>6\77ZR)8>(8E%3#HRDUN4Y"4U^4E.'M*3H;1D)TTIRE.6$I6K=)^)2N3*
MGV".<I>CI>9D><M:SM*6N<3E+GVI2V#V,IB\).8OA7G,8@[3F,E$YC*=J4QH
M?@P?.GAF,Z/)3&Q6,YO7'$OCMFE-<&(39N'49CFY>4YRK@5HR4%G4M;YJ73&
MDR#>-*<\Z_E-?-Y3G^W<)RYAR;ET!52@ R5H00UZ4(0F5*$+96A#'?I0B$94
MHA.E*)&F65&,9E2C&YT1)3GZT2U9$:0C)2E!U>C_*6!1RI!K.JFS4+K2DB;)
M$96,:4UM>E.<YA0 G .H/?GY4Y\&-9] ':I0^UE4I!Y5J41=JE&9^E2G1C6I
M4)VJ5)N*,'SDX*I;I2I7K=I5;M(3K%\E:UC&656T>C6M8X57S>8CG:*ZM6;3
M4:LS^>&XM9:UKFS=JU[Y^E>!\=1S;QQE85,9258B5I6+56QC-VG8Q#[VL)*-
M+"@ARUC*8M:RD]UL94GIV,YJ]K.9!>UH0UO:RZ*6LZ9E;6I)^]K3PK:UJW5M
M;&T[6\_6%K>BU2WN\J$#U>:6ML,5;G%Y2]SC&C>XR64N:F?:7-GV%KG+I>X,
M\3$7Z-Y6NLJ-[G2[RUWM_WJ7('9$%2'S6%U0DA=8>/3/=K.[V\9ZU+WHA>]W
MWSM?^](7O^$%;WWY>U_Q^E>+_QPL8/-ZX+XBV, )9O""'>Q7""LXP@V>\(,E
M?&$*8]C"&7Y*5CF\81!76,0:-LA=27SB#P_DK"E&<8A;/&(6QW@O)I8QC%U<
MXQ?G&,?W^F>*/J=3( =9R$,F<I&-?&0D)UG)2V9RD[^5#ZTZ6<I37K)\J8QD
MD5Y9RUOF<DQIW&4PAUG,2.:ICV.IXQNGV<9K1C.;=ZSF-L?YS6Z&\YSE7&<\
MTUG/R?RMG?V<YSOOF4%B%32@EQG#0B<ZT(O^LZ(S]PB\-IK1AJ:THRL=9\&J
MZ/^_^@WP?@7L:5!W6M3]#36I1PU@4Z<:U:OFM*I;S>K\QGK3LO[TJ5]]:UJ7
M&M:SYG6M79UK6P/[U[WV;0YP3>Q@(WO8OMXULX_M;&''SL3/UC6UDPUM]EVT
MV=6.MK67S6UE;_O:X,9VN<DM.GY$>=SK_C:[Q=UN>+];WMZ>=[=I36 565K?
MD]ZWI/U]Z7_W&^ #%WC!^7WP@".<X-N$<L(=OO"'PQC2"C?XQ:99<8AG'.,;
MISA-)A[QCH-<Y!H/^>8&"] QIUSE*V=YRUW^<IC'7.8SISE"&EYSG.><3.G6
MN4:UW7.@!UWH.N+YT(U^=*0GJ<SY+CG'1^YTDC^]Z5/_EWK5HWYUJ&>=ZEC?
MNHANKG6K@YWKCX[TV,UNH=^*7>U=9WO8$3R+LJ_=[7,_>]L!G>D?G]O=].:[
MO</=][_[W=Q[%[S>XPWXP1^^\(0/?.,37V_'&Q[RCT>\Y"O/>,HO7O&1WZ$^
MC*WYR5L>])???.8Y7_K;\9STH<>\Z%FH[=7'?O2S/SWK4=]ZW-_^\$7/O>U]
M+_O: ]_TPW<]\7M?6GR[2^YUI_ORG6_WYS<?^M.7?O69?_WH8Q\EGK=^]KU/
M_;W,0MW?[SX T@Y^\FN__.O/E_C1_W[VIU_^Q.RQII-^?_SG7__[YW___?]_
M -P2[@M  MP_WBM =/DY!%Q _P;,*?=K0 B,0"Y;.N6#/_6[P/F+/PO,0 S<
M0 _40!#LP!#D0!$90!+\0!%,P:]X0!5$09DXOQ%T01F,01IDP1.DP1;$P1M,
M";PCK..C/>/3O=\#PN(KPA\,/B(\PB <0B1LPB44/B,40BA4PBADPB=,0BG$
M0BNL0FOSO"G,0B?D0BW\PBVD0O<C0S0<0\&#/34,0RI\0S"\0C>,0S&<0X%@
M03J$PS+,0S[<0S],0SL$Q)TZN0+;04.<P1Q,Q$/4041<1$5L1$AD1$F$)A.,
MQ$><1+FS04M\/AB\1$]T1%!L.TW$Q$TL15+4P/K+.PE<159L15=\15B,15F<
MQ24Y0/]:O$4IPT-<5!,%W$5?_$4UZ0=U T9B+,: HL S.\5/-,5E5,90=$9F
M?,9FG$9IK,:M*SIKA$9M7+!1I$8/[,1L],9M#$=RFH5H(<=H3,=Q9+L>;$,Y
M?,<ZA$<]%,1XK,=Y=$=[[$-ZO,= Q$=^E$=]],> [$>"!,@_%,@RY(<*V,>!
M-$B&/,B"S$=+$D:(=$B$?#8VC,A_E,B'[,B+_$B-E$**Y$B0M,B0K$B2/$F/
M5,D92KYD%$>81,=UG,F85,>:I$F9O$F=S$E_P4:;Y,F?U#%S#$JW@S*@Q$FB
MW,E\&DJD;$JE=$JA2D4?-$:JK$JKO$JLS$JMW$HWZ8<*X$K_L,2HD0Q++/$P
MLCQ+M*P174Q+MFQ+(T'&#B&#!YC+"G  NIS+!ZC+NZ1+N\Q+O-1+O^3+O<S+
MOJR ORS,PQQ,P#1,P0Q,PE1,Q&Q,QGQ,QUS,Q*S,R*3,R;1,R;S,S<Q,SM1,
MSQS-SBQ-T33-T$Q-T%Q-R&Q-S'3-SX1-TCQ-VE1-V41-UGQ-W8S-W9Q-V^Q-
MW+S-VLQ-WBQ.WR3.XQ3.WS3.X 3.X51.Y&Q.YGQ.YUS.Y*S.Z*3.Z;1.Z;S.
M[<Q.[M1.[QS/[BQ/\33/\$Q/\%Q/Z&Q/['3/[X1/\CQ/^E1/^41/]GQ/_8S/
M_9Q/^^Q/_+S/^LQ/_BQ0_R30 Q70__\TT  %T %54 1M4 9]4 ==T 2MT BE
MT FU4 GUS,+,4 [5T O=4! M40@]40Q%41)5T1%MT0Y]41&%T1"=41--41M=
MT1MUT1C=41IE41FM41P-4AWMT1S]41_E42 =TB0UTB)%TB,E4B%ETBAUTB:%
M4B5]TB6ETBFU4BF]TBK-4B[54B_=4C M4RP]TR]%4S)5TS%MTRY%3WJ8F':T
M++E<3 <P3#O%TP_54[[D4\+TT[H$U#O5S$'-4T(55$0]5$4U5$;=TT5UU$;M
MTT>5U$C]TTFUU$H-U$O5U$PM5$C]5$H%54P554XE54\-550=U50MU54]555]
M55:%55>-5?]:G55;3=1.Q553U=56Y559]=5:!=9;W=1AS55B%59D/59E-59F
MW=5E==9F[=5GE=9H_=5IM=9J#=9KU=9L+59H_59J!5=L%5=N)5=O#5=T'==T
M+==U/5=U?5=VA5=WC5=ZG5=[3=9NQ5=SU==VY5=Y]==Z!=A[W=:!S5>"%5B$
M/5B%-5B&W=>%==B&[=>'E=B(_=>)M=B*#=B+U=B,+5B(_5B*!5F,%5F.)5F/
M#5F4'=F4+=F5/5F5?5F6A5F7C5F:G5F;3=B.Q5F3U=F6Y5F9]=F:!=J;W=BA
MS5FB%5JD/5JE-5JFW=FE==JF[=FGE=JH_=FIM=JJ#=JKU=JL+5K_J/U:JK5+
M'Z0OEXS+#Y7,LR54M%U;M6U;.V7;MW7;M(U;NIU;NX7;NY5;O-U;O>W;NN7;
MO_7;O U<PAU<PP7<PQ5<Q%U<Q6W<PF7<QW7<Q(U<RIU<RX7<RY5<S-U<S>W<
MRN7<S_7<S U=TAU=TP7=TQ5=U%U=U6W=TF7=UW7=U(U=VIU=VX7=VY5=W-U=
MW>W=VN7=W_7=W U>XAU>XP7>XQ5>Y%U>Y6W>XF7>YW7>Y(U>ZIU>ZX7>ZY5>
M[-U>[>W>ZN7>[_7>[ U?\AU?\P7?\Q5?]%U?]6W?\F7?]W7?](U?^IU?^X7?
M^Y5?_-U?_>W?^N7?__7?_ U@ AY@ P;@_\F-TX.12K=L8 =^8 B.8 F>8)7S
M2@J^X#I92PP>$K/<8 _&17\8Q@\>X;:$RZ-\2A0^815.RA6&2A9^81>.X8&S
MX!2&X1IF,*:\X;HS2AMN81WV87O)82#N82*6862:4Y-,XI14XHULXH9<8BAV
M8I24XI5DXB>FXI*,XBO>XBGFXBK6XBX&,']8R"S&8I8\8RL.8RCT!]CX8C-.
MXRPR2S?VXC*F8S0&XSE68Q%B8SBN8SV^XS?&8S_.XV<KVR$VXB+^X40^9$5&
M9$=N9$AF9(>A84E>9$MN&2&^9)(#1TVNY$?VY$S^Y$X>95'FL9,S,Q).955>
M959N95=^92098_]8GN4IX6-:SI&;NV5=SK\'V&5?ID43)N5(%F9/'N92-F9D
M+F9E)F9F)@A*;N9DAF:#">5HQC$OE&9L/N9#GH5>UN9LKF9PMA D%F1 MN,^
M+N<_/F=U)N=U#F1W-F=VCN=W3F=YAN=Y)N1!SF?.&V-\1N=^;F=[#NA2ZN5_
MKF=ZQHBOTV> /FB!+NA[5F@Q[.:']F>(GNB%=NB&5FA#_N9E]F:/#F>.#NF/
M[FB0'FD%>V:33NF29@EN%FE XV&5)FF99L9S=.F9CFEL9N!?WFF>[FF?_FF@
M[K^O#&JBOA&)+FJ"R&6D7FHQ.VJF?NJC"V:<GNJ5ONFJMFFLIFJKWNK_K-Z*
MH>9JK?[FF@[KH[IFLK[JL\X^B09KM&[K91YGBS9HC&9HNIYKNZ[HC*9HO;YH
MO*[KOK[KO9;KOQ[LP(YK@B#CPLYKODYLOV;LT2%HPEYLR4YHQXYLP:YLS);L
MRQXMIP9LS39LQ=YLT0;M9MOHM.YJMDYMU%[MTVYMMV;M%.YFU7;MG%QKV)8J
MLWYMVKYM%'0 WMYMX%Y&G89JXBYNXSYNY$[N<QEJY2YJIR[J 6QNZ1:RYYYN
MZP8SJ=9M[9[M[?[M[@YN[@YO[R9!V1YO\Y9AVP9O?-('X#KO[WYOM79O\59O
MZ8/KT"9MSQ[M^][OQOYL_LYO_+;L ,]L_>[O_P('\/\6\"U&;/\V\ %O< 0O
M0\@F\ >/1\J&< 5W\ 2G\ W'<-7I[ R/<!$/<1+G< U_"-.&;_E><?I6\1:?
M;Q>/<1@G*S*><1;78=]^\?5N;QWO<1EOL?3^<1^W<9 ;[NL^<B1/<B5?\B5G
M<":_Y>H.ZNA^<BJ7J"BO<BS7J>PF<B'O<B[_\AL'\R$/<S)'BQHO<R]/Y" 7
M\VMB;S9_<S3WJ;%.\S&O\TNS[Q,?<1/7<P_O\P,O\>KAAP[_\ST'=$+W\PI/
M]$%7]#ROXPKH!T-G=#X_=$K?H0E']$6/PTHL=$[']$;O]$H/2! '=4F/]$S_
M=$__YQ2'<SMG=157!O]04(8XG_56IW4ZE_$SKW5=O[XY=_69R6U?M_5@UYPU
M%W9CWW6I,O(L7_:L-(5> (5DR =FGW9JKW8 >'1K7^5H6>HISW9O)Y<'F(5O
M'_>,VO)CO_5AOW5BR(1G3P93D/5TC_=SEW=D=T%LIW=TM\1BK_># ?9Y_W=^
M!YD9$/=\#WA\3W8S@R531_509_A2)_53?TAH^(1>H'AH-P5W%_2&G_2'3_6%
MY_B(_WB1AWB''R!L)WF0+WF53_GN"7>6'_ERVW2/1WF8W_B:[_A+&GB;IWF>
MGWF?W_DD7G6 +WBBGW%GUX1>8/>+5P:,E_:B'_J#AWJIC[][G_JGMSZ=OWK_
MHO)W@[?ZJ*^+ /EZK1?[<%)V<C][!M2'I%][I+]X=W][?4![N9][GSYYNI?@
MK.=V$;Y[OA^3'"#XO@_\8TQX5"9[KS]\3%2&7D!Z=F?\80  ?7AWC)?\9-!X
MP^]ZS!][Q*^TJL_\RZ>TK/]\@>%ZS??\S9>0T#]]U3?]!4[X NMYH(]]G)_]
MD(=]'X(&4*AXMD_Z80@=:*#\R<_XGZ?]E;_YVA_^XY?]Y"=^C*X C4?^XK?]
MY5_^@7]YZ7\OF5?^Z(=^Z^=^X[^@O]?^[A?_[Q]_YF])0F0ZUB]]]I=)?UCW
MQ=_]3!B&?MB(WV=Z=\=_4X"&]E_]_E]_@/ '8*! _X(# 11$># APX4.#4)4
M&+'AQ(<2+U+$:#$CQXT>*X+4&++CR(\B3Y)$:3(ERY4N2XZLT$\E3)HV6];$
M>?/ESIP\=0+]*=0GT9Y&@Q9%>G3HTJ1,E4)]*M5IR!FSJ#;-&A7K5JU3O7+]
MVK6COAQCQ:(-JQ8LV[-KW;9-&_>M7+AVZ^*EJW<NW[M[X5K]F[?O8+^$!2,^
MK-@PX\*.$S>&_'CQY,B4*R)RE!D1HD>;#X(.+7HTZ=*F3Z-.K7HUZ]:N7\..
M+7LV[=JV;^/.K7LW[]Z^?P,/+GPX;V6@>F5"KEP3<F*IH9E*%GVZ=.G0B&//
MKGT[]^[>OX,/+WX\^?+FS_^C3Z]^/?OVM7/P<R]_/OWZ]N_C?W\U/__^ZLOZ
M%Z"  Q)8H($'&IC#?@@RV*"##T(8H839=;99A9I=EJ%E&U;6H60?:NAAB"!R
M2**()8Z8(HHKGFB1,I_TPEQR,L;H7$G02:?,=#I:IV*+)@+I8Y L#OFCD$<2
MB:2123*YI)-%0JEDE$U.^:245S($'Y964KEEE5]Z&6:78W+)4V!BE@DFF6I*
MQ8]9::+)IIQQTKEFG7#:F2>>>T9TIIYS_GDGH'P*6FB@AQ**:)47<J89AJ(E
M!%JD%DDZVJ0150JII9MJVFEHEUZ4Z:><CNJIJ*=2FBJFJH;**JBODHKJJK.V
M2BO_K*:Z&FNNN-JJ:Z^\UAKLK:42*ZNPOAX+[+#&+KMKL<XRBVRSOSY+;;3*
M2ILMMMM6FVRWD?HSS'')P3CC,#.-BB-UINBH3$'3>GOMM]K.RZV\]T*;K[7Z
MQLLOO/_2B^^^ _=+,,#V^AMPP@@;K'###!<<\<'U4BRPQ Y?#/'$%F^\<,4>
M<XQQQP]_3'+(&HN<,LHKEYPQ:!7$Q_+)+8_L\LPW@YRSR3K;S'/-/ZM,<] X
M[UQTSSLK"+3,/@_-]-)&*RWTTQ>Y"7735D\=-=%'<ZVUTU*#O;776(?]M=A7
M=XWVV&EGG;*"9[<==]EDPSTWVW:OG;?:>\M=M]]F TYW_^!W_RUX1)MIAC@B
MAB;:^*"/,PZYHI%3/KGECH<8S;@Q+C?,NP"HRR.[^>B#^>62FYXZZJM7KGKK
MK)_^NNRQT^YZ[; OI.7ML]O>.^Z_\PY\5W[Z'KSQE[NYN_+%+R\\\\\['_WQ
M)KT]_>.SR",# O.0]8@^^S5OO?CADP_]^(TKSNB$Z[/?OOOOPQ\_?LHHEYRY
MH*];7<SR\]^___\#,( "'" !"\@?+1FP-/S0ASY:88I3/- 4#FP% ]&5P MB
M,$+5RR 'O5.U#H(PA"(<(0<W2,+1X*,++$  "[\A#]/DPS.:><3^3FC#&^+0
M0(Q27_FDU\/S^=!\/QRBD;SP@/\'5."(2%1B$H]8@7SD919,G*(3E:B#AN"C
MB4NL(A>WZ$4M@I&*7SQB#C22@R168 85R $;=9 #-^J@"W$$@A?(4,<ZDH$,
MB-"C'AWQ/7Z ;RC\6(YR0)&C'?&#B$%<)! ;J4A'"C&2C'PD)24)R4GB*0>E
MJR1=_,&/4PS"%*$<I2A+2<I3FC(?_+ @)R_IRE;^L'JPM.0LZ9(\6N(2D[I\
M92YYN<O8R;*72>H'(K1W !8BX!LLY)Y']"%#1CV"E<*<YB^IZ<MKUFZ'CEI<
MWP:GMVX:CG#>Y!O>R%DX<8;SF^4$)SK;Z34OA!&-4ZS )H<FQ7B.40<1R>(8
MY5E%?R[_$:#RQ"<8NV"1+J!1C3FP !O?V% @= &B$+5C'BNZQXMN,Q&=*=W
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M X%G0$L\4-7>YIXF7K$^0\//@:X8QC*.,8W1:%#1('2W:5QC;]\HQXAVP0M
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M8A^GJ+4 -K"40],%VTZYOT,>\99ORF44L2@M+NIDCEA))E">$B5BKE$H*0:
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M:/8;*I+1L6Z;6Y1J2;.Q=<@,-"L:A^PV(L%UDV(1T%B3(H*X)3WN DL:0<Q
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M8>\$?!\[>F%4]BSX!RDD.G'O1DN6D/.V$_W\$'$_TX]%2\2GR_)50S#H"Y^
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MF4+<49K><9JFF9JHN9K3P6XM*9I<H0_7P4VP"9JOF8NUF9NXN9N<>9N]:9O
MJ9N_21H#,IR\F9*^B9S!>9R?*9PI.6?,&9K1F9S-.9W+:9S8J9S.69W9R9W:
M"1C1@F/=*9WY,9)VY)WH29[?J1_SP)/K^9X&DI;KLI3S&9;P,&YSD0^JXBG[
MF2K6]"F.@"V4V)^B\I_CMIT <%O[IACZ4)F+T@6T*5F\XBO#\G#B\2MJ>1P3
M.2QKR1".P&4$P6OI<)T @ _S0&F+4AS?DALHZA265AP0Q2BYH2Z1&2 ;Y!23
MXBWK8DG4J9[IV:,]"C">$HMI^(HK>#0. /^,58.D./.) H,(Y8BDIL-S3!JE
M.=-%06.E2Y.E%1!U*U&E6PJF20HR8EJF0P.+:&JD19HZ-O=V#'E"73=V7V<P
M<2IV=OH 7N %:H<(<Y@/_&!M?MJG?_H(@4JH@THP]7BG#R K5I.H@F,VHR1)
MHM@U 0@\>2=)WFAR?]<Y%7%W$9&IPB0Z1#JJ:;JFI*JFIVJJI9JJK+JJKHJJ
MKZJJL#JKLEJKK3I&II"G0N2 0^1#.L2KP+JKPOJKPQI$Q,I">(BJ_6"LM'JK
MMAJKSAJMT&J&:"BMS3JMUTJ#9Y2MS\JMUMJMX/JMXMH0C-B&F^.M6K-_&12N
MV!I29\BN'O5]]F?_?GVD#MWB#^X 30HSA_\)3GNX*M74*OU03?X*;N$4KYR:
M-4;(?/IJB+[D3JRDB,>W??7D3@*H$O'3B/63#_@P>N;7B;!$<YLJ@&_(2I]J
MBILTHEN#;LMG:!3#4>@:LT4Z4J#R<39+9U0U-L"X4E/5LSH%4UB5LSQU6$<E
MM$;KLQH35M)85$?+M%:UC4C;M%GUM":E-%QUM<]XLUJ[M4QU5H6U5F7E5E];
M-O\($E[K5V@[MFFK5A'Z2&N;5OMV4@ZIMAJ#:OJ@::O%5*8F%G?K%)959.:B
M:0]'$'T[3JZ%DER;N(J[N(S;N([[N) ;N9([N91;N6=&!B-FN2319-*A_W%)
MY@_;X;F:.[JD6[ITUIZFF[JJ^U+0N;JN^[JP2[K#-FR)QKC<-;N-%+O(AKJJ
M^VSLA;O1]KOM J+T@&X'<7$@86W_JH?@]@BNV6_,.W('2E;E!E/U "NFME@L
MT";N9A"2>%*E)F]'];N8N%+HEKVH6%+ZL&<(=U+XL [9"[P986+2MG   +_R
MRW'D&VU_^V^S>VSGQG']:U+/EKFZJ[6S2%+M.J[HNG(.T'(\$W1'DS%GVC5*
MYS?GF#<3O,'.B(Q=%#)&Y\"$DP.@.C!0"G,<O#0Y4*T(4W07K'0KO, R++-5
MAW5R^C=O"D)U^J@9 W8'$W2*>L-!/,0@*A".ZO]U^7@U\_!V;?./!+.)Z/2'
M5Z,YVZ,PO'9_&_M9[] M*Y%8D=2P#N.Q+W%,B(< B@>O:,S :3S#:TS#;*S&
M</S&<NS&=-S&=AS'SZ-V>*Q%_-" &#BJ_;"!/92L=SS'A5S'>YS("$.-A]S(
MBHS(5@.#AOS(CCS)E@S)'HAYI"@96GC)$".$LG=_[^"DGDS) ,"[I6PU)4NO
M)=L%D.-/78!/P"*'T1N]LR 0_%#+R]N'!$5"\R!\F]F1"- K%N-_Q^LUY0I^
M/M,/(,D^!>,/WI>)53.RO(,.Y+2)K 2RD41SS<S*\PHC+EL3H1P1[< UZ+9)
MX<PP;^B*E8S)I3.+0_K_HR0JSP@*I//LH_ALS_5L$_) !CD0,\SXS^^:+_=
M!E[PS\WXSWK<D@?MPCF5=@.MS]:YSQ0]T18]*([ZD!J3Q/$HMO<X=DZ<6A^=
MD ))TB;=-A5 R%^AT0_)D+<1D".-TAI#M$+AH.+K(%3<$Q)K$8EU(R\Z%_<
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MPB ,0S/,0IOKN3*TPC3L0KDBNC%$PS=T0S(\PS:DPSRTPSJ<0\0(/SS4N%F
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MBV0<HQ?-F,8N6E&-;62C08QW1C>6$8YH?",7\SA'.]+QCG74XQH!F:K..="
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MH='6A 6<?C?^N0R\+AR8P1D<L&>V@@'B$2)'B![Y X#P8$*$ !0V9.@P(D0
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M=9:P,RB0=[^4&0*4_)@5-$*)2TD_[SO S,,\!?P^!D3 !73 !DS "'Q "83
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M1OVJ6,,ZRZZ2%:QI1>M:S3K6MI8UJ6=]JUKGRM:XNO6N<-VJ7?=:5[_FE:Z
MY:M<!?O7OA86L8=5+&$7B]>?\<-]61P518=C49U>EJ>8O:EF>]I9SGXVLZ'=
MK&@]2UK0CA:UI4WM:57;6M:^UK2Q7:UL74M;V,X6M[45D3\H:RU4L?.#CPBA
M0XE;7.,>%[G)5>YRF=M<YS[_%[K1E>YTJ5M=ZUX7N]G5+@77R4'O(N)5$16O
MGO0QB^'>5K?I1>]Z;=O>W++WO>Y5KWSA.]_XWM>^^:WO?NG;7_SR][_^U:^
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=OWSG-Q_ZQY<^\Z?__.I'G_K9M[[VL?]Z404$ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img123481027_2.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img123481027_2.gif
M1TE&.#EAIA L"?<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
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MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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MF8U9:F+<>)I>BII?*CGCN&.NB9N@$YMHNHYJNCFTR3SO:*9&)CJ[>8(IV(_
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MS(9SL^;E+'K5NRM]U(9THX.-Z4R'.M7-X 'NC*?KYBE/>^;3O[;;)X#Y"6"
M%MAX SWH\1)<4(2F!S[*:VB$'2IA_424HA>V*(8)Q"",?M3#'07QA\DGHI#.
MR*3JHZF*X*?2EK*4Q2_.7XQA]-(3Q33%-Z82DH#JTP5V"8%!/2"/A9Q3(!_5
MJ$<V__)1D\JGI5YUJTZ>:I2A/.6L2KG*5'[RE;7,P:[2<%2A#6]9QSMFT98Y
MS+&5:U_5G&8V4U&O:W8S7]NLUCG_E<YQAO.=]6RK+]Y57(\%=* %/6A"%]K0
MAT9THOD5649/EKSGI2RD'YW>2%-ZTF@&LWC-K&G5=IJ:GZ;M:$7=W5%[.M2D
MMB2F2PWJV=H6N]+T+7=?'6M:S[JWUHVN<Z<K76#R&M>[UG6O@_UK85\WU\;6
MY=Z(_4M;:[?6SO[;J7NFZDV+N=KKO72EL=WH\FI[L CQA^F\\ XRP#>=M+$-
M.V]SWW>V+L#X%'"\X8V[?O[.P @.7H/UK>!],SAY%)YPP/\!#M&'9MC@%CZX
M1#D<8H:+N.$/UQ")?W1BD>*X2"N6<8LU#F,7)X#&$_]XCBT^4YOVU.0Z#3*8
M'#CD'1,9R2]/,LQESF0\-7G+5LYRSG&^<RSS_.8]!_K/L=IE&7Z7TT>W]IF-
MGG2D+V[/?L9SG:'^]#=+O>I1QSK5Y9QU.W=]7E[/%[<5/7:RE]WL9T=[VM7.
M1K%;NNW;=O3;O9UMNLL]TTS'.[5+UFK7]MV[?U^UM%GM]\#/5N^#!SRJ/2UK
MP/6%\8]_-N2;S=UE0Q?8R"[VL35_^<UGGO.?]WSH*^]KZKYR])%'_>13WWB^
MW_WP>1=KW&7?[;K/GG(+\<(5WIO_3M+-9ITYJ"^[6<>=U[W;^/^E-X'MO7S?
M"73!S^^W01\\<(%7'^#2JRC"M9_]!EG4X=^'>/@_*O'\4=S\%L=XQ]6_\8QS
M7$8?ERG(1^Z^DK?<_D6^DH]3?G^6]SC_,P? F%.R,5DRG0LZ Q0Z!%1 GUO
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M"U6E"]H!$>8!$53C:*#0D5I!!LCC(>2KV:QCP#)CDECITAHBT]SPE#B--J[
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M(S)L8Q+!BR@"YT2B@D;&Z"Z2\"C((R=F)S^E932"5&WF4?.B)"SP4A^ 50$
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M$>Y!'SS4II-<3#ZDQK5<OFK\RH_<RL%<0[E\S+<\1,!\R:.75'0\QRMJ!J[
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M]=B(F0B0#)%^!:@4[<<A&^AL"*E9&,B0$9B!+;)__?=_#RF !#@[!^B0#?F
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MJ9^\J13DX!")( -X1HF@)0@S0)!]5VSG1D3U *!*49(#\A+D4*!.)@/\"7\
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M6JCWW[_\G^WL<O$'?Z : N02 6RS_$M _%O _E/ _IL_ (Q ")S _Z- ^KM
M":Q 1ZNI5*,709 U6YLULCG I0E!6A/!'T'!CE)!$V2;$WQ!%XQ!#/2GM1'
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MS.H6UFJK%F*OKN*N!NNOMF*R#FLF)N(DAN*S?N(E5FNW;FNX;N+9%&NZ+FN
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MX!MQ 'AH/5JY!WY_$1F 9'=+!&2=@582!'- +QSI,8,G%1@WM)I6:CJ9!7E
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M=V]^IN>3G[[WX&O::?CON\^B^/*C;[_Z,^9/?_O\ZQ]___O[D  '2, "&O"
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MWZW_=.____X7@/TW@/Q7@ !(@ =H@ *H@$$$7/%&;_2F6?AW?]<Q?D#B#X@
M*OW67/^GDBH>.%UM9'#6Y7#9I7#;I2QV5'$4ARP2MX(N"'%]A'$@-X,>5X,T
M."XBMW(CUW(K]W(\^(,L%X0^*'-$"& ]=X0_EX1(N(1*V(1,^(1#!W12.#-5
M]W16Z$Q8.&)+AQ5-UX5'-W9@*'9BJ'9CF'9F&(9DF(9G6(9HZ#1F]X9N&(=M
M.(=NTW:,EWAWZ'AV^'AZ&'>-EX> R(>!N(>$Z(=X*(B(6(B'-XB&"$V1%SJ6
M%XF>5WF71XF5-XF82'J3AXGU($B8YXF=UXF<!XJD.(J<5XECX7FB)VBLF&>K
MB(JP9U,^E5.L@VB^=SNH\WN 81B\TWNF@XNW"'R9H1ICQ3W_\5=]\*=\QYB,
MSX>,[.>,SR9]TH=][_>,S7B-U&A^VKB-W-B-WB@@UIB-X?B-Y"B.[<>,Y@B-
MZHB-V2>-%6@C#VAO]99_F,6 ]IB ^+B ^8B ^MB/_/B/]^B/ 0F0^SB0JN6
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MR1!$6$)X:$*D><(NZ )UDZMV@[<S]*LUV4(MY$PN[*O/#$,R',/0)$W&,DW
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MH()0.AGEDP4&:.6 [RGFCQ=>D"%(EUYT(2:95^AP10YHSK#FF@_(\  +<#Z
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M@@(@$1Y+@$47.K%UP@9B)UW72%N3B'=Y3*&Q>2E.0^HQ+Q2T8SI]0$<!X-*
MQ90UB3#93\D%M=3,(J#IBN=TADHV<_'T-4>=F]J(IJ^2F6VK4J,;RJSV+[!B
M%655O<[0>L92P[03;/ADFM[B*M>YTK6N=KTK7O.J5Z\%[F]_Z]L:YD$/R FV
M<(:5'.'H,;G)56YQEGN<YN;Q.=$-KG24)1WE)ELZS&ZVL_=@'6@=U[K7T?^N
M'K?+'>]\AX_>#:^UQBM>\IPG6^9%KR#0>][U[J=;[?'6>]O[;6^_!]SX%61\
M[C,N!=7W0.6B1"@J24E+H.M<Y.JO(LY+WO'RD5WK5@\CSW6* J>+E.B.UR4)
M7*!X*YA<^%%0@N%S+WL?"%\'7K" !72*53HHQU8&\I6#E&5_ :R7/N+&+@0.
MXQ</#,8%*[C!5O0B=OA"H3)>18T<E$H_,#P4^VZXPS+A\(>?0A4THG&_()+,
M%J_3Q0>S>(HK=O$3&=SB!,_XQ32&<8ISK.,=\U@UH$&-C8,<XS%.^,(R(4F(
M&S@0?FAD%AG)AY/U(1%]2+D55,Z'E:M\98U(V<G_36;RDIF<Y R3.(YF[)&
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MSEX3I^5XAK")E?+3#K/3%C..3"T)OF<D/[(D0S(C1X<9\9)^BNT:DBV PJ&
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ME*BT0/F>!X@<M)*4JZ1E*7%9RUSN4I>]W&4%9E"!!P#3_P(#><QC+G(1%N
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MI6_HI=O6++=N'6:ZY,Z=ITVN;E6N)H/(+F]:W=_(I^<(J'%.-I'ZCXIZWW4
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MC^VQT3^+C;;680\]PSORR"/(/'(C0D\]]2!R3WCY@)6/=_SP0U@_@/<C>."
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M(%I-H\B*,7H'K8A-K$ C5GVCLU@+S&.+W)S5S>/-/-I%7R3.8/1-_V'$!V5
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M$'_:A712/__1]$Q3[XI5K+PV8O7*$U_-LV (GO7%UC)F[_5EU_^O+F#__7^
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M@N?9B6NVLJNWMFNX)J-Y"IYZOEX]4F-[UH1[HD7JP>/TZ2=^:N2_CF-_OBB
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M&Q_]Q5<_^)=$9,"X/_?OER+\?R_[^MN^]OGGD9.5O'\L^[_9H$P E8T O:D
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M#=]HQZ_0)HMOQ,X9,Y@</0;%'7-)SFVJ(T@W^J62&4PD MK82.L<QR9U5",
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M%GV3/^L^$#V(^6QS3\FB\*8V.9W=T'$W^:%N(L^\ASG,=E^TH'C::$<7GB>
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M, =_L >W@V_>A3YX@0>?, BG\"]J,, &* 9KK+YZ;#BN+ UWV,BNX\GF,(]
M* _K<(3Z< ^G8Q#_\ [_,(26X^59J#AR'A,K\<RZ&!0WR>J-*!7K;,^2:(X=
M;8H*+=#^&-+R6=/>WXP*99E&I(MB[9=ZTAE'RE!N;8U"V8]^[9:*DDB*+;>
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M_$^TH&M&K@/ EB, 0" ",) @_ST$!Q$>]$*P8,*$ ADR].*08L2!_"@^M C
M(;^-&4$JW)@H9,F$"3*B1%!O8TN7'U4BB/F29KV#,56RI$F3'TZ$"5KJN_F3
MZ-"A"S>V\PEQYT:?1F4B3+338%2H3ZUFQ;H50<N)/E&"U1IUYL:O69&:'>M2
M*5&4+4D.#>MV;()V&^O-3= %KUZR?^=.M7C6+U"+B  G+JQ8ILZ(^A9'9CQW
MEM/)405')"F9<\LNG*.Z_)PX<\2VB^6NM2PVI^BYJ??BA4V7-5^+57'2V]CE
M:M&QO8'_%LXU./'A/Q$E0K1F>?+EI>J5N@>=>O3IT;%+K[X]>W?NW[W3HRZ>
M?*GRY?_GP9/W;CT\=_#>O7,G7SY\^.W9O[,?_SU_^/7U>T] _.11KY1Y#C1/
MP7KFP:Y!Z![,[CKMK*/'.NKNL5 Z#3.<KL,-/:1G.GQ$I(?$#$\TL41\ZD%Q
MQ19-A)%%$EE$L1X:;XP1QQUUU/'&'&>L)Y\;E1F212.%O&?(?*!A4A]HGGQR
M22"IW#')(W]$,A\EZ]%'22CQ<3+,>_0)$\HS^4$SGS3Y61.:-METLQ]]TIQS
M3G_XN5,?._?L\\X\]<&S'W[P+!1000E-U)]^"F4TT3__]"?00PF=%%)+,14T
M4TH-;73161CM!]1/'=6TGWRBY%++++\LTTDTZ=R3'W[TF27_3WYLG=7607?%
M]=9>@?U56%[[X?778GTEUEAED\4566"?/7999Z<%E5EKF\46VFN?[9;;;ZD-
M5UMOJ1756W.))55=<S_U9]U9W!4U7GC;K5=>>^F]5]]\^9W77WS_W3?@4?<-
ME5^#YT7XW83Q59C=@AN.&.*)#Y:X8HH9QGCAC1^^V..!00989(%'[K?DD#7N
M.&.34V;9991?/EEFDFF.N6:8<9[9YIUSOEGGGGG^66B?6S;8Z'>/[CAI@IE>
MVFFDH58ZZJ:G?EKJJZG&VNJL0>W::*])!=M<L;UNFNRQOU;Z[+75;MMLM],N
M&VUBO:8;76?KQAMMN?G>V^^R]1[7_]9QP15<7%$/'[Q;Q>D^O'!R"7<\\<D-
MKWQQR2//'/+-'^\<<\X_]UQST4$?/?3334^]]-5);QUUUE]W777989\]]MMM
MS[WVW6GO'7?>?_===^%9OUMNNZWUN]B^F?_;>;;?YGIIH*D?.FBBKS?9'^W[
MA9?>[<'_WGOPW1T?7@#"!Q]]\_U9/WWWX5<__5G>Z<(=+P3QXOXNO&C'BRZZ
M<(4<7&$&!)S!#&3P !G,@ 4/8($#6& 2"4Z0@A4,R3WJ49FF;)"##-%'/4"(
MB'KPQH(E-.$)49@0SZ00(8YAR#HDZ!4)WL4B0G%(:38(PY P12(Q[*!+; B2
MM-"D'271(/]-9L%"%Q($([XY"0*&R!"'E&4POC%.:RS2DZ+0T")QT8IN-H*8
M*_[$-H<9"P\)THKC%.<G^MB(#5UB12AR4(QR'(H,Q\C&@\BP-Z])S!UKZ,>Y
M1'$@7@S+$G\(@+S0YB >V8D-#YE(//YE-I4$#"(! $E*_D62$6'-03"Y2$%N
MTB\W\<PH_;@1+:*2BYYDI"7?LII78O(T=9%)&1F"FY^ L9, T.5->,D0$N9Q
MC<4DYC'M:$SG,(<YRED#AJ#I'0E%DT+@L69TQ(/-\2CH/ I"4'K6TQX! 0A
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MO;6"K+5]X3=^Y7=^Z;=^Y1=<^;5<<_ &=7!_\Y5> ?A_!1A?";A>"SB #WB
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M-_KM[;MH!\"]O6XO]_L#^*Y>=?SD]IY_U>6GVRP&5L=>;_0<:-]ZN_&WX'0
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M5^-_WWU9[;>_UEC@"X\06/6KS[[X9-VO55?\5Q2^^M4D@+8;H $-AT#$446
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MYWCM"(]Q)X_O.(^#9X_Q.#N2<UN!IW>^!5_&4WF 9WD .7<#63SX*&/958^
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M7+JEK,J?W,JLO,JO+,NQO!.:^[B:_+J7F\O1N,FSA[2_+,BVB[N:JKMLFUK
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M)G;*G.W$G>UAP&P1_X9<J;<+?L6\J<NES,?-N^7WELT<S<T]S<<K?X^1#S.
MS7)$&JJ!W?U79=XL@.'LSM\-WN$MWN--WN5MWN>-WL@!S^ZKA_J6O^N+B/A,
M4QY-+P&<G0Z7<!4GG0),T/@KT(E85/X-KSZUP1.=,!L'T1UL51UGC!7=T@/+
M5!4\<0!++P1N5 %,#P?3, V>X"9-TBR-X/> <2.M<25NP-]IBA!NX!_GP:X8
MPK-(PA:+TQJ;TRB\PO3)UI\3U!-Y8T1]U#",U$'N-5<-M#7LU$U=<T:7Q%%-
M%5W<71-ZPRK+5OYYLA/JC'2:H4ILH(^:NIG-VU_NY4=TV97MMV%MQ?/ '/_K
M4)]IS>:HAAPST-8$,0.^,0."UZHR("=P?L;E,"?S,-<QR!M2NCN 3B?E4-AC
MH1Q=T-==0>C$M->#7=QP>P6#1 YQBWF2?1!H_AMJ7N9EBMD]X>:[T06:#>94
M,>:E3NIAOI6XK,LG=*CST.CD@ BOK=JQK3;K,.>Y,0.5?I2AKANC;NM)*0^^
MP>NE^QO!CNRU#A-=0 ZBKNR$.NFME.RL_>R]3N?5/NVTWNJB#;NI3GV^3;NL
M5Q8=.LS#3-PMG,S)K>[I;EC+#1=R24;0_-SSCKPZZP6@ 0_9;-UUQ,W1JT?@
MW-WI+? #3_ %;_ 'C_ )K_!Q L_OVU&%R+Z]F;[_D1AN[CJ_Y9JN\VW!^!U4
M?KCQ^HU3'WWA &XKG9C2&6[B#P[1$.O!YEE5'4=5"_XP'X?@.M7Q]&;R!;O0
M& ?35!55(5W ("XQQCBP*/_2,3\Q1 _1W(FP#MOB(#QR%+LQ6T7UL(C3+%?C
M-*[3*Y/C73\Z)&NS#LDZ/B[D13VRF#/#*6%U2/[45R>T6CY\=J-6/8</(TZ=
MQ3$<^"#B!6.,/=,T(0/E<+\2C$6T2VS*G*WJWJ[XJ,[X.'3LC=0;5VW5)N,;
M,N /S1[Y.&XRC9X;_ZCIO:'GBYZCN7Y+IE/'O]$%QN7KNB$#%FDYG^\;P 7Y
MS#&VJX\ HP['',G'NH_7_P3Q&XB %K8S^[P1^H-KN(H]R7>[^(D/YI#MZ<O_
MZ= O_0!VVTD7[;RA#M2N_:ALZ[\Q#]JO[3WT^ZK-^;<![-B._N _8<>>_N&?
M[>\O$[\A#_"O_NUOZ[P\_08&[DLD[OLCW.8.$/UF"23HK^#!@083(NRGT)]#
MB (?2HPX:Z+%BA<U9N1(T2/&CQLI^@.)D>3&DP\MKGQXDJ5*E_X Q+0XDV7-
MDS9E^D-TQ0L\+UV\N O:Q:C1*SEF+)TAH^D#%@ZB(D# @NI5K%FU;N7:U>M7
ML&'%CB5;UNQ9M&G5KF7;UNU;N''ESJ5;U^Y=O'GU[N7;U^]?P($%#R9<V/!8
M1/^)$*U9G'BQNW?NY+V#]V[RY'GP+ENVK/E=9LREY,$#S1FSYE+S4I>BM[JU
MZM>LY;6F-[M4O7FM<=<K=6\>;M^\@]_^W;OX;N/"Z=TKA6_Y<^;WZ F_W7MZ
M[^K2HS_'5\^Y\^W2P3?G[KU>OGOH]:5GG^\\^_7JVZ=_[QZ]??KQVT.+SY_^
M_?/,Z^X[[^@9T, "#QRP'GWPT8<_"/F!$+WNW"/P0@0KO.=!#OUS;[T'^<E'
MPG[T(=%$:$244$0.\;GOG@7%,P_ _CI4,<41<5PQQQ+[@:9':/S1IT0A?>Q1
M'W_X(9*?))MD\LDD^^%G%BB?3&C*AK!4*,N%NFP((9G_P 0@I#%+"M/,,L]4
MLR(N^Y&2RAZ5'-+$.?FI\\X2[<P33W[T['/(/_-,41]]1LSGQ1B? ^XZZ1:5
M#I%Z[O$.Q@T==#"?!_>4TL\W^YQ2R4_MA//3$D<UU4U2L>ST351/9?5556,=
M"-9996WU5EIQM3577G?UM59@=0VVUV%_%?988I']%51@F6W5V62C-5;:8*FL
MUM8NNNH"U6RY0L16:]TDIZMYK+VBJW4&"I?56;RZ(DEUM9PG+!F^C?=*=0O"
M,M\9PMH67H+P#;A-=67PZEY4$?D*$8+US5=@=<_M:H:!X9V7JW(;\DJ&? %N
MMRN!]I7UJVW9)<CD:D_&LE^N_RCV^.1Y6,;XVEJ]X,I@L#)^4^*MTA66YZRZ
M14L&8G&6JU>;N>K"5Z&S MHLBGN5.2YEB[6ZGZ:Q6D>M&8Q5V*L9?.YGGJ^U
MQ75<KJX@%BRB?S5:*W*NIK9J7+>>2^Z+XRJ767[:VGM5M%M>YULI>_H*6E*Y
MLCNMOZ=\^JRE3>4G:ZR67C5QNB3OE/*K+$]5\\_Y?I,NM4-_4YZO9(B<'T10
M]TH=T+\:G%EYN@@< <(G9ZMMT'L7/?2RM_H=3L77DL?WRY$WG9^ITTK^\:O2
M';YONDQ7!VSI"Z\=J[A_Y_PJ<CR?11Y$%D>@Z^2G3W_]Y9NE%7&YIY4_?OKI
MGMO-E/_SOS5?_ =^V/^* 7!+'6/(E@P8DHZ8*8$B42 "'=A "#*P)0I,B41>
M0I,)Q@0F+-$)!S&H$Q"21"CO\$()B7*4HB3E"DQ9"@MF$)6I4,4!AZ%A#6UX
M0QSF4(<[Y&$/??A#( 91B$,D8A&->,2M.(8QC%',&CPSF<IL1HJFH6(43>,9
MU631-:O18A==8QOD[&8>C1KC=,JX*#1:!SC%&4X;&;4<ZXC'0!D*D(;L,Z/_
MX%$^^>"/B]KS'@W9L5)\[)"-(G3($$&HD.GQ4",;U"%",A) DV1DC1@IH41F
MTI$N@@: %O1)/&K21CR:DY.BA"0Y'4E0+.KC';\#G?(XYX[_A@P1CU+THR'A
M\D1&RF614+DD4U;IE,$$6#&Q5*8O>:F88B)3,]'D3#6E29H?:=.J .4G/:%H
ME=I$D9UV],A.;N@_,#*/C# $2E"^*!\NNE2AO*G+:^I#>?,<WK/>=T]9P<]^
M\]NG^_*)3W_2#W[ZO-_\!@I0>[9/?9]+:/T*ZE!^)FM=4_**K/*F%;%A*7A9
MB5JLO%*TKL1M?^!:F5GV1K.1;C0L/INHNBZJE<B%;"""^$I+97K3<.54=^A"
M&)6ZPC&1S>)[5"F9X\B%4G:1%*+Q2QI==&8KE6;%7O9[:59X5=6L/'58MW,:
MK=ZFE?H-M:C!BNI5CE76JTPU5\VK_YRNV(J5^4&/*AE=JJ[02A6&24U;MGHK
M7NTYCRZL$"PBO9Q7[,6LKY*,KV9[:-4..B77=44>R1HJ L[VT7^&SBOBXUM?
M$<#9] T5?:GJB6>QDCM3)18KHP7=7=L7V:W0LW 5U=S&V#<JPR[/M;)5:#^X
MRM'>4D]IGU,M58Z72GX(0AU=*.YJY<FWRE*E>Z42W7.MN5LY\5:[B.T*[(8G
M5ZJP]G?8O>U"0>?9KFUW55@UJV8G9EXE>66R[OW*<<N[JK"@%K[W#>X\&_K?
MY $XH@.N:V,EJK+_H<Q- /Q?@QE"P/\=4)E@6F"%'RA!"T<PPRBA8(<U<L&;
M9-"#(>Y@3O],C)-9U*,+[0B*%TAH%!8C)0<K9*$+83A#&2)1QSOF<8]]_&,@
M!UG(0R9RD8U\9"2318F-:2)J5"./U9QFBE)T\A9A(P_86)DU6Z8-<5K3*#7&
M$3IQ/&,9M5,>&:5YCF=F,QWOHT@XWPB3BA2G>N!<2TW.6<_^T<^+1KDC0.,H
MSXB\Y:!%2>@_WY)$.9(SI@K]Z =%DH]O[@^-".W-7SZW25P2)I.R-,Q4<G-%
M?*9/=]2L'3&;FAY^CA"C>43*7<YI2;/.-*B#*3" (=.8N-82A24RIIE,$TTY
M^36Q:_)K9$/PTYP^DHJZZ>A(#Y(]GW2S'NL33D+ZL4&$=#0K,:W_J>SNEZ'\
M#:B 735N O>SGX\M=X#)74]WH_O<\V9W0\6MWOZ:6]T&3K=OR<6KCQKV6)X=
M:]V\(HA^^TIV2 WJ2 <279N";>#NLFG%9=5<JC@<:UUAF,5-*URM7,'B#$<8
MOV?EKKE]15A>T2K=!)ZKE_\*MF U^,VD]7&KL3SG1U76;F\E6OO]%BLFQY5\
MDW57M^Y5H B]'%HC-_/V#J2OGP)ZO.G-].#F]NH4Y2FSP(L WE;6NTVGK7G+
M_N[[FB\KO%.?T*E2NMAQO+_QE6SRFCOVUX*M[76?^_KD"=[I6I=4SZWL9*WK
M=@1<053(77R<&A\JP5/I\50R+5:(%GDE_R$>[N&V9G2W8E]207WHIA-]U/>>
MMN299;J?0N^]I^=9_4J)X,&]Z^KG6?K/O_NN4NU[[_UK==<37?@)+S""!Z;@
M_O&/P0)D?H2;G\QD8OC"&Z;^]*VOX0J:Q,,. ;$&/_A]$I]X)P/Q@D]&V.(8
M!W;&,Z!Q4U[X0JGD.,GSIW_][7]__.=?__OG?__]'\0E8Z+%>"+. (W4J+(K
MZS+:L(TNPPW=. X(Y TQ.C-50R<!R1 $,:?ZF(]MDS9UF@]\2 ]V*I1:"C1!
MZ0=7PS-!6\%&VR5=^A%7"S1O2T$=J<%&4T$]>[43V4%<4B59>T$@625&0S0Z
MRS9#>S0@(29/V_\T8S(()EQ"*#2E3ZLN'QRU%KDC.<I"##P0"[FV44O"4@I#
M7O+!(XD286J39>(U*7S"@1"V-4FV:(+#$$*Q\:M#8:LF4%$1:',10+I "YRD
M3F*03KJS2V,T48LG*7$\0*$N1O2]X,NL=B,^Q\*ZWW-$M+-$>:LWX+M$?*O$
MK2LP2206P(N?L; ]71$M8Y$X6&DJF-(JP$(\K#@I-^D*+R";6/$"C .?8F%%
MK9@6M9N8P;DI05@'7A2XD5.ZFTJJDR.+DA.9RJ*K?9.543R6+OC%K>"=FKO&
M@BK&JTBO4WPO4I2[86$O\,DK?N#&KH"[;-0*;'P5:Z2*=MP5HX.JKYC_ 9UY
MQ^&BQ*J91H#2.<2)+G.\NG5@F4P\';)8G5<IB]@CE>M1ND>4',^#Q\-"!%C$
MJ^E)G?6I2-L3'5@,&S@!+,OZG'K<K]HQ&+R3G-RZK5&<GMU;'42X'K8KE95L
MQ%G(1=[9GK' /)D,*3C129U<'K&8 ?(!%<^+2>MJ2,GJR4VQ+D"Q':K IN=2
M&*%LO'@BGKJ+/-Q[.T1HRO!A/)_<KH.[2+F[K:SL1/@"R.69FLV3$E0\KY$L
MG*_3BO3I%] *'50$G,1+NY_BQ(<T-TTLR% ,3% L/OU!/@!*OI-Y/@@+(.>;
M,,>,ONK3L.N3/LFL3 Z[3(A("0S:(,T,/\^T_T.2Z(>>, H7:S&AD+$5:C^G
ML+'X0P <^S_8C$W9G$W:K$W;O$W<S$W=])8F8K+%X"(MJPT%]#+B#",V@HY(
MR4#E-+5)$20_\Z,/_,!M:R<6[#;KQ#,'Z2,2K,$3I),JU*5\.,$8!$)1(T\>
M%$) "T]96\]L.L_RU)12JJZ>!+4XH;5ARJ4@?#89U$$8C#4S7,->PS6'0<,
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M*K.0"/XPTI'P&81_(RE* <UR$,>H9'XR>8I=^ ' @72A@@?)($\&.)$"'J2
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M]-R\'H0Z+-=\= 3(G@K$&@1@2EZS?FQE@=Y'G)ZG6(W))M#HM2;,VNPL:.Q
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MF#@C5T=@65=@FGA'75<D9@>*#^8E9S=(%6:*:J)AJ?\(C. 9GN(YGN19*#-
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M)L+L.^+AOLP7'\LB8&=B-Y*_&558*6[8T11MELW T6;9HLIK6)<QSG[7,&[
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MYJ;"TB9N,NS")JS#1BS$$N&J?1,2YJF7.J'B#:=P1F&P66&QA:QR]E,7EFQ
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M^<H W7*6N:QE,']9_\Q>WIA 98I0L_5TI8UE<WD1>]XVP]G-07US11.+#R^
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M'9;H(-8A'B*ID0H&']ZA1%XH1H[=-]5BF1VB=W9GL$VI2N$B=9($_R(HZ R
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M4,D (C@56.G@#RLJ*I99HYJ++IY9I':;JH9'P4WHI2HK/VPJ4"5;F"KK_Z>
M*HN)JK>!HJDFA'E"<;&\QX,F7!?L\-.UPJ^>5="=HR_<:AD3ZZ#TX[$*B[4B
M%$0PJ[>$BPRSQ+'\:J^L"U9IY^\^9 B#JP@O<B.#,",_LHGT"+1-A[G&W<9<
M%MVMZTBV $FV%KR.%LZ(EKVV)"G/:TPZGMU:;&R5YEKH@]1<WVLE@&@\K%<2
M;2U;S>!6A%%BS6H$)>GI<D3,WMLDK$38S="B[=JD!G$Q+43<#<9B!-[T*_Q&
M1"L49LEFK8*\[]LZ5^O)Y5[VQBO/I=M6A%YJU\>6Y3=7AA?4)0!H&=]HAMP&
MWX)4;6PPIGY YHCF).V<[>)9!CK/T=A.<SF35_\_[W+LM/)9W ,_WR$_?$%]
MZ8X\V_/4$@\YFR9^B8<^W%="5Q[P. ;V&0]N:,\#&#2KS>SZZ&UAI)[B0N?C
MLO1+-VY+R[3B2N<:L#"V'C).5RXB8^X):R[MFN9,W; -1RI0F^[LGFX/]9A\
MQD5/_!@HY.-1VVY_&G55)S5'\(,0":CN#BB %FA/ V\-#O6$-J! C)S $98^
M"$+)]3#SDG7(.6"G*O**1"^G36_U7G!>4[,&>Q,EC=H;MED$BY(.((+_^HWV
MDL$&LX<@M&$._)(%4W/J&3:I55I@W<,",YICTQID5_-DZ]DVYII@%],$[[5B
ME[9>4V^2\C4U,RF2.O+_7(=P(>:;">=TCJ2P1JWP3ZN%"P\;# -R1M0)F<[
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M[\./KR3M_Q_ZOOSQU3]_??'9?]_]^,&'_WSOTZ\?__+USY___?WO'X#_$V
M"3A  ZJD?AI)H/^"\I.A^ 2"#8S@ R5800I>T($9G* &+<A!#&X0A"WIS6X<
M13,3VNR$H4+A"E780D;)+(4OO!FC2I.8N)2+7O_B%[,$4\/-)"8UK8D*/Y0!
M"LEDPC)&G PH/@$*9001B*N)HA _ \4?7K&*4L2B9[CHPRQZY36QL<T8==,;
M,O+FC+X!S@Q+>!7CZ&J'UI)C#MWACZ,I#8\&P<<<==@OO[! $/S(H]'VI)[K
M!:D^;<*3(N'$2!#UPRA4.N0D*7G()>4I1)4DD0Y:(2=/+A( DO_4)(9T@(\W
MI>F3C3PE040Y2OCH@$AZ@B207%E+6]YR1#GXS2>YA$OV?&F5CL0D*D&YIF*F
MDIBJ-*8RD<DB.MGIF$F[XS0)*<UJ\JE0S-*F=&080[! 2IO,JE0W62@03863
M+Y[B6!M=6"A=[<N/>6'!#-21". <#)\,^U6NT)F77N5S80%%V+H2<04<QM.?
M5T"$(,T"CW[2Q5X 95<KW#$#&>CKH?.JB[9H-95G990N5Q H/OF!49"F:Z I
ME>@L\-$%@[[SH=")J#ZS0E&+\E&C.?77/!5*TY'Z5*5 7:E0B:HND!&#92J+
MV%(O!K%?X"(7N-!8R*(1#8OT8V0B(]G_,I+J,HQ%C!@Q(Z<+V3G6:U*3244:
MI#79NE:WHO6M9Y4KSQ#A- 0][6E3<ZG5L*:UK0$);&#;6]W>YK:VX6VPB"7L
M8A7;6+OU[;&*DRSB*#M9RU(6<GRCW.8VR[G.?A9SH 7=Y6976MJ9%K6G56UJ
M6;M:TN'N=]8#GB\W%-OH,4]ZN-7M\W++V]W>UK?+8Y]M<TO;$FUO?O)K7W+)
M][[QV8]^RY5N=*FKW.HR][GT.^!V"]A=[G[7N^$%;TT6F+\.AO"#YU5O>MGK
M0?>B][WKC6][X5M?C8SP-F75;Z/X"\-R[M>_9.TO&P>LQ<_<$)[7 MB"\<("
M1$S'P%VTXL>(_V%$"U>F,DA4!C^LZD4)1]C#(9[PAZE(XBF>>(LBSLHLBB(;
M-)8QC3&&,2)V&>"QSN*-?51P'.E21[C^^#Q[S*%.>5PM5YD2R&TUI''=D\A@
M/GF9:9J%%RK 9"M;^9+"7$@OC0N!&>PRFLP$92MI6X8UACF9:1XF*[$<RS_Y
MB)97EO.<@S0#>_*2R<",\IJU#.5F]GG/@/ZSG]'\S$S<2<QQ;6N2%>U6$-D8
MP 2&=('_2VD!3QK3DK[44'_:Z:!ZFM.?%G6H25W449NZU*!&]:I5W>I3NSK5
MKY9UK&G-ZEG;.M95\4=50T:,4$CLJ5_UJL6>NHQHW#C2WK2TT=0*-/^S+IK9
MT)9VHQE=[;GVZ3>S:(<.%"2(I[E#:N'N E\-ZM>_ABUP>C,L8@^K;L<FUMWQ
M3BQD"Q?9RM[[LOG&]^$R&UI_<_;?G@VX: 7>6H.[]N )1_C"4PO;^!"W>G2.
M>&^!6W&*7_RW& ^NQ7=+/8A#7.+<:^YTK>L^D2/W?MDE.7:ONW*7MYQ_V87N
M>,5;<YK?W.8Y-TEY]2=?^]+7YT$'^M#G6_2?&UWH2"\)?FF3[$IG6ME0K[2*
M2TSU2V]:+@G&*8-1!0]-I] ?1<3PA9EH"JM>/>I?G_J(K9YBMK\=Q' 7(C]D
M_&*[FW'&N &SW%&<8R(CE(\^OK:UA:SCK<?_\<C4EBN9:>MD:T.;'V2(<\@I
M/\HL0YG+M/7RWM4LZ(DP'I<Z0 2A$]WY)WL!2<:%I7VHPP]$3+[RL0^YG0,=
MELS?4L^#KOWN==][-/.9]*:/LJ$1_7C%3_N.PL</LBW-?*FC_>EJOW2M88UK
MZU<?^[?./O6UWWWN?__ZW@\_^+<_?O.7'_WB3W^NT][^Z+L?^O%WOO3G#_]F
M2W_P^4>^_H^/[7PT+:_$+=RN@-QRP-RZ)FP$2V_4A@'9[=T82]X@$-[J3=\J
M<-\L$ /_IM\ C@,%K@-!ZP-#I^ 8C@05S@1+$ 5;R^%T)_8^[N$X;N,T#@9G
M4 9K4'D\[@5ESWS@_Z/D6,[DT,=\4 [F>O#EB' (@7#FD%#GEA#GFI )=4Z!
MR$L*E8X*C\X*D^X*B2X+JQ +NW#I;(.$FL_IY&\,Z^_]SE# % /3$ SPAHSK
MZF(&&*J;_ $:3*&)*J.)D(@8^ '"T- ,R9"_VNZ+4&P0W2[N#K'J"$(?'@'O
M[J[N&A$2C8+S$E&+_.X-#V]7!&__K*GP_F['4"7QC(^:0 ^7'(__J,D?;L^X
M<N#.?L_SV"S//&3W5/&6-H_W7#%+7&3..,GW2@_X/.0>Y&SU&(D41\D+*J47
ME0\7;]$7/8\672GWEC$9?W$:7U$9FS'XG*E.#FT3^T\4"XD:#^/Y_I <R__0
M'/N+_-1/'=.1'<]O'=VQ'=</'N=1'NOQ'>TQ'N]1'_.1'\]Q'/V1_@#2_@32
M#\?P% ^R&[]1*Q#A"KS@K@)0KPCP:LKMW+Q&L BKW0KK 3<R CERWC[R D,R
M T<2<S1KX$XR!%-R!#]G)5/0)4\0)E\2!5=PMBK/!5G0!F,PXW92)WN2!B<.
M*&,/N=9'Y(K0!YT+?TY."8V2*8^P*9-0YI30":?R":G2*LV+@;(2*[E0"[V0
M*[]R"\/2*\62OIAN*<00+?\Q+0-R+0>R+:>.#3]1+G%*!CCJ*?R!'RH,%$!A
M&"R,&)!1+0.3+8=#$$W,$"D1,0G1,*N([O(N$AW_\Q'):!(5TX<LL<@\,?#L
M""$'J1,OT0T1KPN0;#.#IAAMR103<D_Z0?*LK *.\1I?<\JP3!;EY!EKR1:K
M$<JF+/7FK!6ST1KCQ$<D;AA/Z1&LS,ZD$3FQD1E?,T]J4Y,L0! F\3>GTS>K
M<SG#43F3D?A0DSN]$3<!43#=,CP+,BW[$1_I<1_1TSS3\SS;DSW?<SWC4SWG
MTSWELSYM;=/";S E+1WW4SS]DSP5TCN[\\>R[1UTP*X2)-P49&K([0"!!+
M9P$=L",K= (E$$/3C20W5"0[= ,]$$1!,$11LB5)2R9C$D5/5$55<'ANDO)<
M5+9\,B=_4D9YDD9S4 ?G_Z<H=] I84XI?S3F>M0(A_0HE^M^]B<JKU))JY))
MEW3GIO!)P7(LI[0KJU1*K90LKU0ES'(-"!(\ ?1+_U-, S0N,7$N/U,\KD /
M3^'8O+0<WS),UPX1*9/O#I-.#8S%&#$R(9-/'9'&9-%.K\@RV]#P>LR.[#1
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M5OI4IX].^I&IJVXZZ["O+CN4I:O^9.VV4XF[_^NV7^F[EED&C^7POPM?//'
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MF[(H&S+<^3/@B8DP2XHR2Y[H2;,SVXGJN0;QJ9_XV9$]6Z4[ZS6PB%F;8:U
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MULB<]H$6T,6-]XD?'H+?]_\UQ*"5'_K]8?KQS?JYG]+!7_LQ6M/I5OWYQ+4
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MD@Y0P:OMQ KPA"M(T(Y196M<F@KAU@3@OD2\"N"\^JB]/FZ_WFOD)BR4]JO
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MW]+^>_"R.N@1@E'] ?'*EX.:%0",E5HZ<3)/7?LER.G57R (U2F>%5[ =2@
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M"9;+UWLGL7MA67QPF97&EWP3UGIKB3Y-\7M2P6!'_]%AUI<_TB<_VU=BW1=
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M8G-  1HP@:]1H %7\T#6E :"$HR@:2@H0=I (Q\9K$UM-DA!""X0-1;,X&V
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MBZS1&950G6U2_[$-V["5T7C\6IY=1QHU6[HBVQNM4*"-S_0RH:9=6ME0#<]
MA'N@"WS8VWK06[I A+KX6[_MV[U%!'SHV]1(7+O-AU; #:I%6N,@4@$[4U3!
MV;'%7+?-6>>+4H)$4P_-T(EQ@)(1B(GI JC+T3C%4F/Z4C+E4"#RT2$5VMEU
M6;EEV5\,VMKM#@$STC2E621=7>%]4]8MWN%5%3I5O>7;),V]TUE L^C[R'/I
M@I ,U'9Y #<KR4A55.X]U.YEU$5UU$8=7T@M7TL]WTE%WTK5U)T,5??]5/A]
M7_D5FE%-0%)U5?QM5?U55?YEU?XE-5AEJ5\=8& E8 ,N8 0^8 5.8/\&7F"Q
M,AMC54+&/%8*5L+':JSE(:QHW6 .[F /1KB+,$V)P];T2</.XJRN:,/:9$/8
M)%<6_E9T_5;:8M?;:E<'6JY#/$ZLJ]BCP]<>CD1\#6)5#-CK%%@C+F(D)N+B
M0,4E+MB$]4Z-!5F&W<5># _S5"&)U>&?T[FAZRY^W;KR_,XG[DZ-)5F%%>.3
MC>*XJSM>9.,JYB\!FUDYWMS,Y5P[KF.Q!5L+^=G^FMVB3=JE?=S4 *%[. 1#
M$(-",(1#3N1"0&1%=N1&3N1%-H1(?F1&=N1);F1#. 1Z6%R<RP=0?MREK5JH
MRUT-#=&S364Z7N7FO>-%8MN]3-M81EM:5N7_61Y;-9W9V!U:I\6YQ+T'P*4'
M1*"'J$"$>9@':P4$2L9D2&;F2Y;D9H;F9[9D0P"$0X '>9 '03CF>1CFM!#<
MP!6-3Q[EJPU&_UI3UFME/&9E5U9G'?%<;.'CVKW:33-=[$4$,TU3XU5(=,[1
M,JT.@-;=K_OCHXW:0 ;E3[[;NU5<?*#F1OYE3[Y;N\4'479:JBWGHJ7=]O#=
MX"7>X]UG.0WI6TG>@5QG=\['6;@"<(E>/Z4^:QK)[&VTE/S>1/7>[F-)A D_
M\=WI[95)];W4GP[J]&5?GIQ?HXY?I#YJ3JU?K0$U_WWJ_/W?_87JJ8YJ 8Y5
M!VY@K<YJKMYJK^YJ_[#^ZF"MX"6<8 E&'K->P@M>Z\-RK.?Y8+B.:[A65F3]
M"1'N'C1$X?!QPQ2&36XUK1@.[/[)"QGF'^&D84*\X=(X3J';X7JEUTC\X>?T
MUWT]8B(&14F4SLL>6.M<XLD-8X,-8S-^H>:0XK'3K_W$8N[RH'M@[0NR(-B>
MC>W"NJ++.O;LS^'HSS%6S]_ [?XD6M\6T(^E(?N<.[L[;K;;403-#V@TZ79^
M;N>.;BXR,0UYHM 5:*-M6D$6C7I89FGV;H=&9$,>MZ^=A54XA$K.9&<&;\X0
MYXHFY=W=NP0-$>H^:>AF9^F&,5B.45GF[UI6V_U>6Q6U[@[U44#&C5^^B_]O
M)F9Y,&3P5N_O+@1#=DH CY!5<(1IAO#P!@1Y@(=M+N;!1=S4: 7)-66NO6_[
MSF\47W'EM3U.Z="\&]K> &7279D:?X ;M_'2]8)\[FB1)I9^OE GPNZD1<]!
M5@U\$ 0WR_&28?+1'1H'"&\GQW$H'YHNZ(+/2-QQ=EJON]J6W>@>[V>0'O./
M+O-I65X73_.*9''\%K-$@":.E#YJNO+J8Q?K=;.85AF;GND]KVGPS>GQY6F7
M--]V2E]#K]1#Q]23(6JE3FI';W1(]R>FGG2JEFI+KW1,MVH ]DI.]\"P_G2Q
M!G51#W52'W53!RJO6DRT7G55;W5B)6NVIFNWEO7_##8LN;[UP9(W7:]K7I_U
M5Q>(NPXYP4 Y/B2,8I=A<#W7N2C7&1[VU0I$/\P?&Q[.=\UA1&QLY(QL;0]B
M?17BR:YLWF;/];3.S-YLR^9LT Y%)V[B,W9/*7[WLB-/W?#E!WHY0JP@V6[M
MY>H@? @Z[TK/V[Y.6!1/5]Q7W][/*YY;  50JEOX]")&-798 \6O*&KN-D_Q
MBV=SC&<1(9_G5X1:7[X+2G[P:(X%$[L.14[O: [O"'?D"U^\6%#Y##<$RMCR
MCY<A'Y79C%=QGM]Y?0QPH.]O ?_O6VY;S5737>:-0$[P>G *8S;DE<_D0T!,
M?M!PJX_Z9C:$6/C!:UL%_Y)_9C'@@FQ&9F^N^<0E<:QU#AA'99_?>(U_^Q:#
MYU2Z[OB\#4%^\OB]<2?W ADB4S$W\UQ^7?"H^P,'(7B8 1U/?):9<L:7\BI7
M?)1A_)29@2P?9,B%;Q,?4S$E<X_N_!\_<S67>SN%^[9_/#* <Y;^2.I-EQFX
M<^RM%W[R<]FG:=J_Z96\?4$GW_.35$3O?:!.]/,E:OE[=.*/=.,O?J<VFJ3)
M]*IN_DO7=.>_:ND/8.H_=>LO=>R_?NW/?NYWX%3_];)F=?!/:_(7_UZO]?/'
M8/6/]5WW]?1G__=O:_1W?\8J?U>/X/ /X6F-N#58]A9.5X"@AX_>/8(&"Q8<
MB/_0H$*!# \RK+=P(D2*]TI9%"A18\)Z^.KENY</I,A[^O#I@Y8RGTJ1*E^F
M3,GOY4R9-*'-Y)<O)\Z>/&?VZQD4J%!]0(U"&YH4:3^F3H\>#=I4JCZJ49=>
MG;J4*M>M7K6"K>K5'[^F9,V6U7=6;=JS_,C"?2LW+MQ^=/G-LBMW*M*:)O&%
M/!D8<,G!AO\>%FRR94R<^63N= P5Z]:JEODVG:PS9^3-6/-EOBQZ;;^TI3&+
M#HT:+6NVK6>5Q1L[;UVRM/O-\N</MS\ O7\#"-Y;>'#?Q8<;)ZX\.7/DSH]#
M7_Y<>O3FU:=;IZX].W?LWJ^#W_Y=?/CNY<>;)Z\^/7O_].[/PU_O+S< WK;[
M\=67KU6^D(<,&5*(&(4 .&" 8O!3W'( S *@@ 0:8N"#!1(X8805&GCA@1!*
MF&&''&((X7^'6#B@6@H>YXB(^+"HGS[ZP,8/7G;9-Y]\\;6'XWLW\IACCSOZ
M&"200^I8Y(]&"HDDD2@RIR!R3C+99'50,OGDE%<NJ"225*)H999?2@GFDDD>
M*1Y]]LG&#XS]$580(O3, \B'%!JR2I3(:5ABB'3JN2&?'NZ9)Z!^KO*?GX8<
M N:#.,@PCSSSS(.(1"(]E@]LI=U&WWR_S5(FF9^.&:J6GHI*ZJB@GEHJJJ:2
MVFESKCH'ZW&R"@=K;KOEA:F:__OE@P\"#SCPP*_!#BLLL,82:^RORR+;++,(
MY%!/;M-R6JNUOMEZK8W8:ILMMIQN>BMNN*4)XXN/L7@/(ETHZVR[R3(+K[OQ
MMCOLG_(6^^RQ^N*[[[OM7H$(8"A5&N.,^(E[ZZ;<,KRMP]X^W*W$#4-<\<01
M4WRQQ1ESC+''&W^LL72T-CSKR">OFK*J*Z?:,JLJNYQ=;CITX87--WM1L\XZ
M7)'#%3, '330#[! M-$()( T DLGS?322CL=-=13-TWUTU5C?;7262?-]=9?
M=PVVV&&3/;;2PI:-]M=JLWVVVTFW#??;R\I=-]UWQXWWW&TK*W??^KI=K^"
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M/72!$C[AK\P B/6'B#F2P>2*T=G'&N;&G^@&&YH8?UW*U?F78+"(9@6A$3K
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MQ(*7&(?GE2:'&$*8K%;J550US9W?T2;=X5T9E.8AJ%/=P1/@#9X^_:8]39,
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M^W36$@Q6$K7+)=QG1%(GI:HGM^J.6.YA&BXG^\;C/LW*?.%43R:2U"U75S4
M>('=/DU8!TGE)B[FAM)60^X!*,GFVL:$.2IAK-:=C+"$F5UP\,,.4\AIW@D
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MNC9&>>]K?^^#TPD@X!-MP^?YVAYZ&Z_Y\G;PP2]P#_!^%W#^MA5_/CWV,O>
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M%%%$49\%4VQQ1!C[D5&?$&>TL<88<0S1GQS]X6?&'X,$4A\ABR3RQR21A+%
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M_K31373LQR G=:YRD<&)L]"4(BO%2$LM$I*-C*2E\F'$!PBBD>:2U" =Q8]
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ME&'NTWP=P@S[!U74UXQ:Q3\KK\#4DZ3DDW@!(/3,\#P_13T-5*7<EU,@-/0
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M7;D+W(&55;D=_]:!E3.Z"])!$ $H%D:Y4SZF9DMZ5GOF@(K78Q;L#W) *F:
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M),42R<A%.A*1CU0D)"<IR4K>< 8ZZ((7-OD.+VCRDUVX@@ZND(,9F/*4,W@
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M'P"&#/TUY.<E@9>'#1FV*GC08$:.#S9ZU/C 7<.* -P]6%B28;V0'3\ZM C
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M>,#[0;&!Z,&+,#+8280#4C(0*L(4+#.>.+,2,@BX:C0_Z[2&H DGK,",4+5
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MSP+@K;<+A8L1N2$9I=!/Z1*UKE'L[M0NO._*JVZ\],[KKKWYXKMOO?S>VR_
M_PJL;\ $#^ROP0DCO#"\[<PPU@%D1=P.(@<73,\,Y8 U<<$,6UR/%Q!+W-4,
M[2C<,0#UC SQ##*4?++% B/2CE@1(Y QS I[H7%7$<M0<<X>!XURS$,7+332
M1!N]=-)'*]TTTT]+[33545<--=931\USS1*7C @]5B/BLLU==;$P(F'9/$/8
M_@KU$LT]D]SVU+,XK/;*77D1-E \N13RQGGC+3)8,_CM$P S>RU#O&\C_CC&
M,HC5CN-]/VXYYI4+92ZZ0'%^[N8^?<[Y1R>5CA+_ZJ>7>Q'IK;,.D^L5123[
MZ[3;OOKML^/^D$"\YU[[[KH+#[SPO0]?D<-EAU4.T+\[+Q BR@<^5CE?/W]\
MV@A(+W=8+J]3L?$,A9_0^ (]/'W7A;?3!3W&^_X^1.7[@\@ZZ \.E@Q=D"^[
M_.9S;W;\^"? L6DO+/H3'__H8;\%_J\K\R >0V:PO0*RK!U["QX$61([FZAN
M@R3A8$U"F!,0CE"$.B'A"4V(PA6Z2W,M9-<[DK(4&3JE"U"1"E6N@A6M\+ K
M7UD+$(,HQ"$2,2UQ"<L1"Z-$P!"&B4L4S!.;"$4G4A&*B\$,8ZR(F<IP<8M>
MC QG$A/&TH@Q-JTQXVMD_X/&-:JQC6=T8QK/J)O>Y$:.=HP.'J>CQSSR<8]^
M[",@_RC(0!(G/(:T#B*QDTCM8(A"%WJDA!HI24@Z,I*4G*0E,UG)36*2DY?\
MI"8[*4I0>I*1F?E0ASJTH370HT2M1-&*7-2B%\4(1C"JT2UOI*,_V8E7A&(5
M,(T4S"AYJDIN<A.5M!0J98*JF<PL%30A%<UI2E-,H0)FD'35IU[BJ9M\0I0O
M7Y7-7H43F=0\9S7+)*DD5:J=D[(4IC15J4;5XYFI*I.CTJFF99I*G_E\E*^L
M9*N!WDJ;!#6HJVRU)'P\JIWZ$!8_B)4L8TT46<VJ:+*6A=&+]H,?R)J%1Y<5
M4O^06C2D%SU61DMJ48V>E*772JFV8OHM@XSK> @!7=:NIK6<6JVG//WI3H.J
M4ZIE;X(^\T+,%*>VG!$.J3Z-WLK81C"NW0\!0?/"!,NAK_,UT'!"!8 "C4J6
MH:8K;N@C*U#1^M6T^G2M;E4K7-L:5[;2]:URO6M=[T7!R=EK%I*KJA<.)Z\%
MFBQS'#G?]I#J0I4 #F]\8R%!N&J_P.8D>U5%0&$YZ$&&0!5BB/@@:$VBP 8N
M<+.I&XA1*7M:V+%6@ZW5[&M#NUK7TA:#U\N@;7-KT]TB$'Z]#:!O]Q=<]P&W
MN+\]KG"-FUSD$I>Y^W-N_\35W&>%[UF2%6M7UD'3Z7+_EWPTFR!UR=</R]JO
M=^$U;^_J1]J"G'=^V*TN=PFG/^)"3W)&!5]RZ3N/].$/O^ZS[F6[TM[>[M>H
M]&WO1_V1OAF(]\ "Z4)5T?O<Y5+8?:1%P'PG#+T (Z <Y9(?;GE[V]K*MH.Q
M+2&*4YABR*JXQ2SN20R5PA0:/F4J-M;A#+(B@QYZI8@^_C&0@WR6) (&B5$\
M<A6EJ&0D3[')2[ZB8[+8Q2E_L<I4'N-JRK@9-KZQRW'\,I?!#,<PDWF.OJEC
M;>XXR#43DLUN;C.<WRSG."^2.W5&CYT5J6=3\KF4?AYE*$D)Z#\+NM"!/C2A
M$3WH11LZT97,,Y\A#6E4>FB5_[*TY2QE%"-<XJC3WC04/I2Q35Z26IBF_I0R
MCUG,3ZT:F:M653&=="5[\O-4^-0G.MW)3ESK<YUJ\K6OPQ3L2/':UI "=J^+
M74UW"NNAFY(GJ'AUZF3>L]KHO#6M4;7,*9%SU+72!S[^*<UPSRJ@"Q7WKM4)
MK&8/*Z(>=3=(.]I1?F"*'_3F%*8>J@^0WMO>^_8WO__=[X'7N]_MIG>\W]W1
MA#.\'PO?J$N[E=N\XM6N%+^XQ3,^5ZW]%7TFP_C FJK6T>ZU*X4U&F+'XM2%
M894L6MT7>97WV9W&'"QT\T=CI_=5L_YOXSZO^,]!#O2A"[WH&B?Z6Q<K+Z47
M9>DO;/_<TYT.]:EGI.1@H9P(S2J]S$:=L"O6B%&]>L*PJIS$!['O6&%K]H*0
M'6)J?SM$.ENSYNF6(.25VV/]T04#B]@BJ>T[X$,L^!'7G?"!-_S@FYO<:-$W
MO\)%,.2)R_B$3%["_Y4\=:_%WFPEF/&:[WSF.?]YRK>W\C$UGND]+_K5GWY:
M5 6+AS=_X2Z$OO6K_RY9:L_XR]K^].JU>N^;13@$:)Y;\BW^L_8N,?UQ*Z9R
M5QOSD2]Q:+U>;NUH?K4@G#Y$2)_Z$I.PZF.J_09RGO28=S#Y9A_YQ\]B^(X?
MKH;C']W"T]^F)3:MZE2H_Z_S_R8QGF$-U1A5Y) .Z1@/?<7_#PF9 BX@ QJ1
M6SQ@DC'9DD4@!3J9!%Z@E"F&%E$9!UJ9!VX9"'8&9HB9EY'9F)U@":(@":[@
M;:@9FK5@FM'9G,V@#-8@#=Z@#>;@GDD:GO5@>_#@#_I@?$":HS&:HC6:$18A
M$B[A$3:A$CIA$N('$ ZA$![2#@KA;E":*G%(/>12+MV)+H4A&,Z)IWT3J!F4
MH*C:.,':J:FAJT@;JTW;,+%AMM5A/UW;.Z5;'NZAKO$AL>DAL@'B'_KA/+U3
M(0:B'PJB(NZAL TB(@X;'N(AL\53IE3B'KZ)G[3AJV7;'+[:K%4;/]4:I)@;
MK)!BK#"4F"!BEG#;*3:4F4"B(4Z*_[-Q"CQ!U+TY&S_D@S[D0ROH(C[DXB[V
MXBX"8[#H8C$.HS$2HS(F8S+J S(.HS,&RT/EPRSH&\/!F\.95/=%RTG@U-$9
M7=!]HSB&(SG"S-U1$-"XB_9A5\TP5?JL7%!QC?3PU(4QF,ZP(X?-X]1(C&K1
MBSR&A=CE#,_M53F"(](5Y#@>I$(:I-M$7=,]I& Q740ZY$12'8M=Y/ZY6$:"
MD-5=6$>B8^K,A-=IY$$,9-E0CKE$F&D55=F]W0=!A/)YUN%!SWW-I()M3X9=
M1,=Q#X/5W=^QSOPIE^(-I?R]G^-!EU$VGE+FU_JA7ND]Y?GM3^KI'E6"WS9>
MY?1A'U;&E/]69N56=B57?J58>B59AF6WK*-8F"6TD!S>S -8<@N$X2,#%9 ,
MO.6T_)Y<>F3LV67[\5<^5@Q?QI0$?9]:VN7(U.57\E[VD9;^C*7>Y6/>C*7Z
M6>7YF:3-E1]FGEZ#):50%B7\@1CB$=[]G=ALN63_0=;_S5@-X="-%> #[-A6
M]%@#SB9MUJ98$%E@&%D%3J %[B8&]B9P/MD&:F '%N<'>B"6L8:6B6 (LJ *
MFF *1J=S2F>9N:!PO. +ZJ!VXB!W;J=W=B=X0H<51EH5WED0GB<5HN<3KF<4
M,B%[NF=[0B%\-L@4CF=]FF=ZYF=XS)D6HM*FB6$9SHDRS F ?AK_CH@:.'7;
M.*WA&V(3,2UH@T*H&SZ)J[&A)SH3*&*HN*%;(G;H(SIB+#);B(ZHB)8HB1(B
MBB+;(<:B'C:BND6BLJG;) K+.V7*.OW2+VGBM'&BM8WBLA&;B;93L/"A+GKH
M(#(*N8%;DZ"BBS+BD3ZIB>(;+=(;I?BB,#*4E?KB+N8#/ESI+H*;E^8#EVXI
MEHZIEHHIEH+;E_YB,R*<O\E;2#T<2C7?3 U$38D.GAH6U4'DY4ADGU+DG^YI
M12(DH1J-GV*.1OCEV3Q-RT&,.PX./ X5 T7JR6@=7QU-HXK%RW7,8#HJPGAD
M7G[DIA:-97;%4!TJJ@*JGDH=J_+IJKIJ_ZH*:J"R*D:>YD8.*JS>JJWN*DF6
MYFBNG8D!*_X-:^+ISOU]I':]9+%.Q$@6'EJ*A=V)3-X13^_@GMMY)G!Y9(5A
MZ_-MC']Q9E^"JN LD PDV.4)EU%E6&9.950Z9;N.'NN%'UB"'F5N7F%6Y;V6
M96#NJV/RJ[[V*\#^J\#F*\'Z:\$&[/B)Z_!5%6!B95SFWL#N*UZFI<'RY?%U
M2\J)!>WIJU@UYL#&9,U$W\ BJ_],SPP$[&.6U\$*[&06+%M.3V#2JU1"Y<RV
MZV8N)<YN:U ZU[**IND0*[!J1&K26%.P9@[@6(X=H%;(IFTVK=/6)FY&[6_R
M)M5.K=7Z9@9F+?\6':=Q=BURCB#8-B=T3B?9CJW9/J<:F9G:6N=WMFUXOJW;
MQBW<SBUSV&=Y7J%ZXJ?=YBW>RJ??ON??QF<IW6??[JU^ZBWB%J[<TEE_KE*!
M/BX9&JCD]DB.(.@9=ILP2:B"1BCGPJ'G8FZ#ZF@<CBZUA6*,=FB3?NBN!6F-
MCJB-QN+KLJ[LGNCLJN[IPF@TU2ZT90H]Z0F#JIJ%8FCN@FB4MBZ-'N_N&F_R
M(F\?VNZ'KF@A-FGJ&N*05LJ4XF(T+F,P-N,S'B,O,N/V@ALQ7BDPIBF;0F,N
M5J/!*5R<:N-*35_/UE_\VN3\UB_J>&/GA([GY*G^QFJKXBH (TZW*JS_7VX,
MJB[L7-J,8HG0RQ(P9#[6K68J9"(P!,M$SIUDK<J+9'%/I&I.J19PSV6P".MJ
MKXXPKYIP"0.M:?KJSY)FL*[P"QMK"X=F#-NO_-(PMB+E9PK0#B\ER8(K$!,7
M89GKS18QLU1?1VYLS2ZQN^[D1X;JVGR>%$_? &L/^%QEPEJ?P79JR!8L%"_?
MRH9QQ:+L&$<L&9^Q&:>Q&*-QOL(4MZ04'+?4^[IQQ)DE';^OMMRQ'LMQ'$=<
M'!M8'\]Q2['D6/BQ'#]L(0NR(2^R(EO4Q(9%($<R'T_RLERL)/_>X%#R'-<<
M CLP]VFR)+O4.0(R*+]QM"3L%W>/Q3[QN';5_QH/K,S&LODQ\2R?JRT',0]W
M)FC>\.[\*@P/!%+,$-$FA=$B+6P>(-,^K3(O\VQ*+5Q<;7!"<]5B;31K;91M
MK==F,]>&+7-V\W*6+=I29SB#LSB7<PS"(#IC)]VN\^*RLSNW,SS#K>'.<^*2
M)]_:\^$JKC[C,SWO,^'R<SW_LT#?+4#[,Q;&,T(?1^-RX1@&*(Y0KD-/KH#6
M2>7Z;JY8M)V(VB_]B.9V](-V[N:Z(?!>J!V*8JG8[O0NHNZ^+DLK;^RZ-$PS
M+^V.:(O>KDW#*.NVM*]%:"824X:>-/'.-/+J].[.HE%7HE$/M5 +=?4N->X*
M=5++(J5@+\)9HU57-?]6[]M5:W7Z3B.54N-6QUN]+1PVRFD=!V:=<J/F,00W
MSK)$W"E<6\2=TDY<1T1=O[5<YS7]XK -[S4O^S5@][5@\S5A__5@&W9A!W9B
M'[9B([9C-S9D V4NZ[ N&[&]WK+E&25EUREF7[9E$W%FA[9GBS9HC[9IES9J
MUUYILRL3PZMFKBO-QC+*RC9LOVN\LG$9O[)NYS9OX[9OJW%O _=O[S96WO'*
M[C$C!W(>EW)R7]1'A?)SS_%S.[<?3[=&67<C0[=V,W=V8_=UP[%WAW=UC[=T
MDS=XFS=UE[=ZG_=ZIS=[O[=[Q_=WM_=\PW=]<[=]1W=^;W=S]W=V<_=R#W?_
M<!.W<$^?+-<V+6<F:@/Q9B_V\_CR: YM '9!,>/8CATS C*SAF\XU$+@;4HS
MB%/S-%>S!4*99%CS-FNSBBLG&;7X.)^M.<,X.<\X;*SM.:LS';VSCB<TC^^X
MC_<XC_=S00_Y0-]SD><SD1/TD0OYD@/YCS\Y<2ST&D!N1%/YIU$NEA-HJ)$:
MC5@NY7IY16_TEGMT.86T@_82Z'[N[PY3A9KN4Z<)+#HOD"XU4==Y3"_O4C?O
M3>\Y3N?YL_%NN=E)G*RY'/8HG ?U2M?H4<,34C<ZH]<BI+/T+"JO[O;AF\^Y
M0S6;IA?<6'?Z-5[*I_\;68-Z1'6ZO'EZJ7]Z^ZH4_\3]]TN9LH#'>H$3.*T/
MN*W+>O#A*VWG>KWNNKSJ^A3SNKW^>J\'.[$/>VS7LK(CN+LF^&L_.VLWN[0O
M^VDWI70]UX!E>W?!%[9O^[5S.[A;-F=_.[EO5[>?>[B;>[K;J;>K>[E7._IU
M=FK'^V=;.VDCF,[6.[W?^[Z;]K'O^KRS'[+;++-3>[0;/+"7Y;0SN['CZZW/
M^L/7.JY'/,5/O,5#_%@B-[9H?("[NL=W/'][?,B//'Z7_'W[-\F?O'[+]\JK
M_'>S_,N[O'C3=\O7?,S;_,SO=\[#_,[+/'K[/,W?O-#W/,ZCO,GC<<5CO-)+
M/,%#>[*3-H/G._P=-H2WL/\@R)!JTI!4X) QOR8R)R"'VV8]T ,B=&'8*Z S
M?_@SBWB(D_B(O[T2F;C<#^>*U[T7)2?><_,WRSC?O[C?Q_C?Y[C@G]EU%KZ3
M'SZ4TR"[ $#[(;[CTV ]M (_](1&Z$,BM,/C]U$B4/Y.),+<;KZZA$R;.0[G
MITSF)_[I [F4BR$W93E$2W2 OGZ6@SGKRXE&;WF7<_F87[28WSZ:+V@:FCF.
M@G3F^C1)JXH=7KJ<KZZ?R[12/S^TF:A*\[GP5O^E,[^*SK0E[G3K]_1(M[GU
MOR*BNZY+4Z+Y._JP1'I4TR+[-_],2^^33F^)KG^^P2FRC/JJ9^/]Y__#]3__
M_S__0,SJUX^?0((&"_;SEW"AP(8*&?9S*%$A17\6,4[4Z._BQHX59W',*-+C
MR(\=2:9$N5*BRI8L0\)T&?-E39HW9^:4N=.FSIX\<0+U&?1G4:)'AR85NM2H
MTIX"<4)-*14EU9960V+UIY4ITJXYM89].C;JTZU3SU9->W5MUK9G0P)@&W>N
M/[ENZ>*U6_<NW+UZ^[H-?'9PUKI2\1ZNJS;JV\1Z$1/F.QDP9;^%_UZV+'BS
M8[B*]3+>"MIO9,.GIY)-79;U:M=55<-N+?OUXJNQ;\_.7=MKTZ^_?0?O/=PI
M<>#&A1=7?GQY<N;/G4='/KTY]9,V06:'J3TC=XW>P5___RX^?'?RY\VG'Z^^
M/%3VZ->[_^[^(WV*]N5GQW]??_?]__T+<#X!^QO0P (1K(] !0]D,$'^&H3P
MP?P<K%!""RF\4,,,X_.NN@^ALTZZ#]T2S43;0CNLM!7C6A$ %V%L44:["*MQ
MQA=E! !'&F?1T48?<]P1 $&\Z,*+=XI,TL@NNK@B!R>OF$%**5EX0(8'JF0!
M 2T1Z-+++\$,4\PQR2S33#/KH:=''=FTB\TVWX0SSA?GI'-.-^/$\QY$ZDD3
MD2O.[#(!,0<-LU P#TW42T4%7=311B%%0%$[W_1"TD?YJ7.K1R^-E-%.0?UT
MT%$=);514R\E5=5465W5U59A??]55@0>@+7656]E-5=2<^WU4E\'!9;67XD-
MMMAAC4UVV+C>U(=2-I45MM9G=;14VF,?N!, +Y3U0EM]:O4U7&*]E;.5-]U,
M!-EAQVV7W7?;=1;=:N&M=\TW,[W3W7V'3>3.6>JM]5PY=>378'CGU;$=?M?$
M4T=P$7X6X(,I#MCBBC&^6..,.=ZXWW0M;GA.=3O>UV$V/2XYY955=M=?.:UE
M^=V!?:2W99EOSAGGG77NF>>?2T8D$436(%IHHNO!)^FDZ5':Z:25R6?IIZF>
MFNFJJY::ZJBM5EKK>K3F>NNOG5:F;+*[%AMLJ/.Y!Q^QS6:;[7ND;OMMN^&V
M&VRW]Z[_F^Z^P8:F;L$)SP<:?0A'W'#%#T_<\<4?;QSQR26OG)_&+T<\<V@V
MO]QSSD'_7/30H>F']-%1!UUSS%FGW/7&(8\=]MD-E[UVV@O/7?;7>:^\]\Y/
M!]WTX4E7W&VUOTY^Z=H#W]WQWE]//773+Z>^='V&Q_YZXK.O7OM^]/&^^N!'
M7_WSU:'W7?W?R0^?\^_Y&3[^A Z"J,/]X LO(H<2FH6A__D70/MI9W\#/$D!
M\Y? ]RRP0PILH$D@6!()@H0D%!1/!;>30>R$"$0CXN '/1A"I(A%-ZBAS0EW
M@T(3II"%*W3A:$H(0][(4(4T;*$-7TC"&>JPACR\H0]SB)L@_S:&B&@IHFED
MR)G*+-$O)TK1$YN(HBA"L412!"(.L7A%+0HQBUS<(G&^V$$1C5&,900A&<]H
M1A&J<3H67.,%X1C!F;AQ@AJ\"1WQ:$<,;I"/#_1C>P#IP$ R<)!_!%"$[K>@
M#?$'0XQ<Y"$GY$@.29*2D,S/)25DR4QN$I.3A*2#.LE)48:2E)549"D1:4I4
MJC*2GWSD*2GI0#;.,HUIK"(5/5-$T2 1,CRZ3(Q^>2,;^5)(P\01D'B$S&,6
MLV%Q(9*1D.0%)16I24]ZTI2D=*4K96E+@?+F-\$93B^EZ5X$2UB>-)5.;;&)
M'WVB!Y\$P25QCNE07ZHGI^S)*5'ID_^?C:+6MD+EI7+-JPN0JH<ZT5G02S$K
M3OQ05Y>*],\7K0H!^7H3P%1UT)/YR%*D0L1&)>J/CDK*61M%Q*6\T YS J!8
M!ZV9CAR*TBZ\#  3^]5+V52/F'FA'@T;Z;6BU5*"K8NF;5)74(WUSY@A=5W9
M0B>WSLD/H#;U4G6J1[MPJB-BC<M87'W72KW ,8W&Z5U%!5G%B@HDB]&,4E<%
MVCD7%C!O;31FX<KJ2N^J59>=3!\DHY4[7K;1?=U5I\/BJ4_K-5 XZ6.G%D67
M7WVV+Y=2ZV>*!2E?W857:D&L5I;5$63[-:^^LJL=:;43O\QJ,YF%5%/C$EFS
M_.H%=^ 5M9?_U51=@9;;R.J6M[O=U]&*5K2AK8%ORLM:U^B!-J]U;6U4:UK:
MC-O<J3WWN-6=&O+DYERLY6UNR[U;<<'K-Z\5=WE_8]YY!=<\]:+W=NV='>->
M![GT40YXZ%,=^? KO>+=M[[J<][@ +S>]+*W<,W3W8%OQ[@$/V]]#9YO\+)'
MO,U][1[4?8;6+KR\ 4<.O@Q^<'^G)SSAN8][)/Z>^_1[/@>O6!_X4#"+&YSB
MZU4O?M!8"$$N4K^'")+'YD'@C\<#Y$(.N<=_+#*1":G'.-:QCWN\HY+?&&4T
M2IF65!9*&'OH12W'$,L_W/(.OYQE+H?9RV,V,YC/+&8CKMF)I2&-_Q(UP\1;
M3I'.<[9S+MEL13SWT#%D'B*: :UF09=YAK6T\J&GG.@J*]K0C$:TDR$-E#PV
M><F3?G(?/51I*#/9R$GV=*=!C>10Y\^5GH1EJ5G9R%6N>I2M9O6K71UK6,]:
MUK6F]:UM'6M5YQJ3NTXEJO'WZ?9$^M&-7C18S*)+/1]118 !IF" R4QB&I/:
MS4PF,Y6Y%64^\TC37)(.KE#-*&%3FUC"4C?GF6YUAY.<ZT2GN\\9;QU5F$_W
MJ,<,UJWN>T8JGX;J9T ]Y2C6NIL?E@HX B;[IG;LLTOF-#C )=4%=.K#5"9M
M54G)^JJ/SFFDLK*H;>&MHY.2JEP@!T!AE?\U*(;&>Q;U8.I4<V5:?QR5J@DX
MIUN#JM2:[]RI\^+69!V&49[?E+)(37B;W-55PUXVZ1I++0! BU5JN16U_S+L
M7.LDU=[*.Z\X"NO%LFK3?:ET3E2O5R(^CE V11T!K3!Y3<T^+B^\7;-N\NW5
MG_ZF5N@6I!XCF-8KYEFH.]VQ=?_LV1.&6Y6QU4V*1\"['=\NLC=TKQSO[>7O
MGGG,8QZX1AON\D#OW;V)/KK*92X^J'M=XR87N6%S/7.-JS:LJ3Z[W'W;[+>K
M7-MC=[RD-^^& TS@!?_WO1Y>,8A9)V,5(__!L6NN[5G_7;^Y5[XP;KY_B_]@
M[>=7Q,13W-7 CWK_#"</^+GKL//2QWS\6H_])!:QC.T+7WPLN,4=IEQ[76Q^
MZR>_?326'XXAXB)V3-B.K  )\ !'#0%%;=@TC=(BR-*(C=..S=AX M\0X #$
M! /!9 ;6H0OF 81.Z@(S< 3!!!&:PH<0H1W 1 -7L$LX,(;Z B4 8!TL4 -G
M0$T"K244JDM8\$LTL NXJ 7#I >]A AY\$L^JH8L\ B'\$MFH!VZ  >[+(BZ
M0 9$< .ET(M\D 2%L N[Y -O"!'*H0:[! BY#,^ZH!RX< O;X:-0 \[@\"S2
M, .[H,X<@P:9L Z5#9=B @];4 ;<, =7J K!I!S<T,^Z*,T(;="HXXJ>_T,-
MF[ )9: +UB$)BZTF$*&@C' &RL$ZUJ$(UQ 4(]%+9. WYF$'05$&9N 2':T5
M(; !+RT6(_ 5']"."LG)%M  $W 7%S#84HD\@.W4A/'7AK&5>"V3^F>4DA$J
MEE$BFE$^(/$*O7 &K@ 1YN&2GO$9)<(*MW 4RZ%)$"$;L7$<(:0@NF )I;$;
MR_ :CY$99X$;1;$+O[$:V[% YF$&>I ::8T30;$+3) 8#Z0+R"$4$< #)^DC
MNL (TS$>U=$'9V "61$B^3#/)I*76.39A@G:A&DCIXTCL>TC?T1(Z"%)D&1)
ME 3<Q V;9J#<N$F>\NTE87*<U"3DNH[N:M)'ZO^!3_P$4&)RGO8-5/H-XA@N
MH'1N*!GNZ!1F*$LN3A3J4V0.8/SI9$HEH%!E538N3CHN5B;/86:E*V,%5A2+
MHVQE+!D/ "ANZ'*.KU[N5R2.KJA*YV".Z'RN6]9IJ4(+9M!R6,H2 /:N5X[.
M3?IRJZC*J[*.8R8/71SO*2U&\   \'@&KB(K["[F,'-*ZH+.8A)AH]BN8LJ2
MLVBE\'0D[C8O7+Q%-/G%[5H+:$ JK@[F[S)&\*+.ZJI.3MCNZ2)O9?;2\1C3
M'0XF,^<D,,?%-[%R-(E3\XRS.#>F\X0+:4@O]$9/NO2F],JK;IQ3.IOS;D)/
M]L*ON5+O;&#O.\>F]F+_+SJSZ_E>[[NN$SHWS&N@@3W9$\!PA_BV;_O4KWSX
M"\;:Z_F4IL+VD[JB+VK*C_[V[_Z*3SXY[$ )=#[7[[Y0KS^=QC^=)L-([\!>
MS$"KC[Y:YSY'A_W>+WAZA_KR3T%%=$#Y3W1(K,9NC!]R3,AT,984L$5U<18W
MS=)R\=-DU $E$!8E<D?]H2'K4";$D 3_42D^D0F]A$14 Q^YL!)G: Z/L!VN
M"!5[L#4"(QJ)<(:"5!!E2$G#I!,3D3<BT0Q3 Q&L4"$/X! 5\1V]4!3%-##"
M+!H=\DMKJ O7P<S*= 2A--GF82'S4#+D;%/XE$^'=,Y"T$AQL,W$@@Q'L4O:
M_Z&&9((JBK0%E6,*L8@"(Y*# K5.=6)/C31.0X13&3(>K0Q4MQ ,IRP$S31,
M&HV.YFA&715':3%'7W16#8E6C9$7@;$8?>U6>757>^V5<"T8 9*3Q+$<R5$^
MBA59C_4^BI5.W?$^[G0(S9!9L7$$NT!9)>(>.]5+V!%;D14=.]4,L[%00_4*
M_&=9F=%:26E/4Q4!5C&4&&1;"]+64/$*W_56H_4/#XE=O:1.(XD\R+4'3=!2
M6Y%'DR,L]FS9DN@B>VE&-#*8(%;:)+;:KBTD+38N= J:I,G;4!)*5)(ES\TE
M>W)DYZG=WNUDN6[@4':Q[$TGYZ%62#:<?G)F_VV?PO\Q3NCAX(3R4: T3D:N
M9AV%IPR/L79VY>AE5-JA2*XR3[+2"PJO'D[E*U5EIE(6,%TN5L9JG5KA:E_%
M:=4N$;H@Y8Z%5R1E*W4D,->2+O.$YCH+-%56ZX*E'AB/;;&E[9[64LI)8>(R
M6C".36:!6VA%7@S/W18&Z_Q6,,6%JF#S78067VXS./GJ<2^FIUYJ,W$F:QM3
M<M.J%5B3<04WJ_RJJ(C67;P6WA+AZS!&;FTR$3KW9AJW[EKN.//N85SFI5J!
M-U,&Z,SR-KV@;]?V+NUB=!DW[4Q39DH71SSS8%ZWZPK.8XXW-(\S>I%3>JE7
M.8'+O,K+]WH/<**3O-*3/+'_4WO-LSK!<WRMZVE,S_1P#[G6=VMRKSJ]]SD-
MYST-C/H*S'Z'KT"SCT39Y_K.CSM1[QY*08#K88!+H8 KC#^9QO76LWXC)W_/
M#\$"AWY=CVX ]&[:,V\0%,8V!W$:E!X46($;=(&31D(E5#WATWXCV/XL)T.5
M#[_BBVX$1X;S(?\NE']Q6$%-U/^B(44%: !QU59A5(B).(B-N$:/6$>5N!9A
M]3E\U"?J]0K%="DB]4K3*&#!1$LI54J_A,NJ. /15(N35"&]]"NP(DQ5(R'I
M4$YW@TN=\#9"M5$7,87@M @?DE*==8;0<4IWZ"VP^$LH$H:V58[)-0][XH\1
MX%!O_P@FX/$(2_$ES/1'/2A2M]!@"Y9@=S13J<,+J0,1%/(:14*AC/"#2!44
M3;55^ZB4-? ?%8*20?%&97&)97668Y4!F3B)"4E8>Q58=]G4AG57?967@WG5
MM#%8D=&8B1E=G5&9S]58G=E;J?69H]E9EQE"7/D(KS6:D55=M5DB $4A_16:
MU50AD[6;9X%?AY"9^8&;62U4$6#5Y'5:5ZU>;3#6]OA+Y#G5A'F1$!D!!K:)
M+S6@%4V+$K8BFPUB'S:A*79B/7*AM0TDX^(>2')CW>$DP\UCR<U*S$U+1#9F
M/?I,_*0>6M:=ZBTG25JD33JD1UJE4_J=4%HG77JE8[JE2__ZX3X:G&C6WW36
M*(%VIWMZ9WTZJ"4%<ZO6\B@*5J)64;QRJ:6VJ9EZ5G9E;*5:;-,V+_?6JNNV
MJJ]ZJ[,:J[6ZJZ_%JYINK-]%Z1+WK*<WK:E7K=EZK=VZK>'ZK>4ZKNEZKNVZ
MKJWW\]:W>\77.KDWO+@S;![T/'D/.K?3.[V+]W9/][:KL=DW_+I3/"%[L,EW
M0@?G>Q&,0@\4_7#XAFU'=]9&@ GX@$N!'D@;@4D[@9MFM1^TM2&;L&%;LL/W
M/[4&0B?[ML6O/"%XP$1ZM?D3A&U[A(4[^DRX]#3;0CFX1)5;Q10G;M W:FBX
M<*(;?Q]8<&RX<.9OAFN'AKE;0%__!WSX 7OF!Y?)&XD#"8&2C$4M0KU_>+V#
M[+T)"+X/2+[=.[[M>XC+&[^UHR'=^0I9^57[L+_;M4N(XYZ[I(Q[(E!3M0Z3
M@XN]A(P<?$WEF(S<^$L0?(P65< M$8V^^,%SPI/!F(U-J(YY\(ZY2";R&"A4
MN5_3="LZG%O%;)!9 E7#Y%W] 9$5F3C4.$R,8L6[),>)= 0M><@Q&5/!F3HB
MW)^=@B$E.2@&<@@?4I85HI2/T%1KV1^.'-(,' $ZD49E"1;-6[_%7 %U&9CW
MV9=[69_1?)A=K9C;7)V369J?59RK&97*><[-N<[SO)GIG,_W_,ZK>4WE55 !
MW7\(,E"[__7/W8/&P:0+"KT9=WP%61G/T[4)LYG2]5R4PV32.2F>Z54([Y64
MZ-E+NIS5S'R2^OF?XR,"B5R@D?0,]] .&_8B=T2A&_K6.S+7E^EB[0(?)MI(
M*OK;+OJ:,GJ;0O:FD1U-8CK9F;W99990H%VG@7K:>5JHJYW:?_K:E9HJN7W;
MG]JIP?W;Q7VJUX5L<64LOSK=O7K=N5K=VYW=P3K>S1IQZ7W>[;U>[OVN];VN
M^7W?_;W? ?[?!3[@"7[@?VNX/(\YK:;TXA=\N5>WO7>U41NU!=BU<]N[HH_V
MOK<\RP9K(OOVTL:QM0NWS==\;<^P-QX?",>R)SBS5WBS]??ED?_;O3 ^@ W8
MM L8YTO[M <8A$LA@'W;MG];M.FA@'-^YTT[Z7=^'DJ!Z95>YXT>N!VTMUM;
MZJ4^_+@F^*#&0:U^Z)\KA(,[[,>OA(T[A6&>A3'4OOI+P=SFZS^^;Z ;/9U[
MNE0[@7N^[M^^;:;OKQ<G_SZ'( YBO,'#%XF,O0T(@.Z[OG<,\76,?A!_\7\8
M\9NY?IH9\@\_\C'_\C7?\CG_\3T_\SL?]#\_\=N[] U(\5%_/'P4/"J\"(&0
MQUZ\2ZZ<TF*_2X##6K\BR2^Y)5J?!RF<C!,-C8E"4?$Y.J)XP/G;4*V#Q"\P
MRM<HQ9LBR1'@0SBY.+:5P8FBD*58'8'_?"=J?]"1OTN&E(J%O,A=W?P539.=
M0OM94#@R'/RYL,M=E<I%T,IM\2($_- WL8C#G/_'G!<!8E8_@?X&&B1XT&!!
M@0S[+4SXL&%$A0D1-K0(L:)#C1,O:O0(<F-(D/Q(FOQ8L63*DQ=5CD3)T.5!
MF3%9SK19<Z7.EC@'TO39<]9/H4%5(CAZ] #2=3EY[KR9$JE4I5V<SB*'5*G4
M*T2?SKJ"0*O4L$4O)AU[=*A:M&$15(7J%-'4L3 KRFB+MBY(M%J[Z#4H-^O8
M>2\]=A29T3#@N4@1(7ZXT!_D@9(I1[YL.?.LRILQ=];,.;1GT:!'FRX-FF%H
MU9$W?W;M[W7L_]FM9ZN&C7LV -NZ>6_>G1NX/^'$>_\V/AQY\5D B.OKTL7+
M.R_1W5&GKN-*ERLYKLSX_IW% QD/Q+- <)ZM^O7LV[M_S[8>/43U[L&_CS^_
M_OW\X2=@^Q]: 8XU8(%(&7@4@@@HR."!#B;XX((1-@AAA1):2.&%&O['H8,=
M0OBAA"%V2**()I:(XHDJILCBBA(^H"*,)<IH(HT=VOABCO_1R*.."/2XHX]
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MMW];#]"LMR-JMWG;6"%*N+4(-88[N-S<HKRLN)7%B^16H0,GC'"[HY8K6_T
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M[^,^C^Q(D 2_D/P^DL2R-"F_+(,EE5P_]6M)EGS)09N_^'L_F33 F*1) !Q
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MI<<]Z:^5^U./F<NI'W[O6=]ED2&?GL GOO)IIM.>YK/4RL<S1#\]43I3'_N
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MO'7,J7K1.\?VKK>/%M*0?$'T(3\.)!%7,)$A"YG(_,*(1HX,<"1WU"-5&OC
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M1__[Y1]_9@>[V/A7MOWWNNS[Z]__R09MU#: D46 )&> VY: WF-NWJ=N[L:
MVZ<8#MB WA:!$#AN$WB!Y387%MA]'<A] !>"".=OU$6""1=Q*"B"$I=Q++B"
M+IB"+0B#+WB"-!B#-3B#M25P)DAO,MB#-+B#'\AQ(/A]WA5RX'6$)T=RLX=8
M:K1\+0=S4.A>3E@A>;0A53A?5TA??Z2%LS /.;!S*,)?@^1S,B(C09<C+.
M13=U;-B&;OB&<!B'<CB'=%B'=KA*KX1AL4)BT%1VTE0N:&=DC>=B1^9-0O]V
MB$<VB'#79)=G94OFB#/&=I'(9!HS8SAF,'P74(#7,H/7B6!6-I[G,H)'4 )%
M3_Z$,8BHB!3S8XAHB K#>2QS#X37B)(W3YX83YDH3Z0X,KR8>5Y&>(&74* G
M9C<3-"@E-*9GC!/E,VS6>JRG-*_7-.K7$716$M6X$DUX>[;W:">Q.)9C.;X7
M?,!'5)=S.4FE08@5$DVU.>4(9YQ6''BC&Y86?7I3?3YX?4,8A/KH@?R8CQ>4
M@7,Q?^R'?NMH.N,WD @ID II58C0!3-0#C]R #PR ^N "/.PD"2Q#EWP2$!R
M #-@(O- ?_W'?_O7A5VP#C/ (Q+Y(XYTDO*3;##_.9+"]G\(*( %>),'B),*
M*)-$N(%1H9)#<@ ^V9/VLX_8%90_TH]"N)0:2)1YX5E*:91,.6_UAG$X>)4^
M:(-:N8((L))!(I%;^5M=X)4=V04(!Y1"DI58>8.R47QMB51:.99(>05K&99L
M.0M7\)4_L@YW:9=^.8- B$)3Z8\T%49A 7)(F)@EAW+$DXW,%X5/*(60Z80X
M187PE859:',C,G,VUP\QLE\GX@Z%Y%\QD@,U<H8R($E%MX9WV)JN^9JP&9NR
M.9NT69NV"255QTJE<$RQ9$QF!XC+A'9D%W;_DF/<A'?(J8JN^(B1EXF6UYQ.
M1@_NM(C-^6+3- \)4WB;_RAX".6)G2<V"C6,X@D-HFA0L1B+LPAYD^B(E;>*
M4B8SP@@S*M-EA0=E Q6,Y"F+*!-EP7B+IGAY *J+L!B>HG>,QXAZH_<VS%A1
M;?9ZKM=ZL%=_R <3UTBA&X%[D<8@DY9R5U-]XOBA@?:-AO:-B.:6?--!\9@Y
M/^,U8-,U9@.*8],RH-BB"1JBG1:/O3&/0"5]YIAQ@_FC4AFD43FDA FDW"4D
M9!F10(((!HE^*:FD2"HDN"8#>LDCY,!8>9FD:$F1-V&1?8*69OEJ4*J7B'(1
M\V B7SD#^<</8_HC89I_\]"F<HJ655JE,Q!73]J12"D#-#D+7TJG(5F2.3FH
M.__Y5UT:I8A:IWJ* &_R@./6$S+BE>30!118I$+:11L))%QJI)9*I)SZJ9<*
MJL]7E25(<:9*72R8IUT))&99EZYJ'/*@J,/5!>2@J72IE@17)ZN:EC=8JW3*
M([?:E^]8CZ_:1+JZJ CPEO2X<(C@JS]R!8WZE[@JK+(1IXA:K-)*K7<9F-45
MJMZJ/U9!$>':%HII1NEXKAPZF>HJF>P:F>HE<UN8F?"EF?:EA9J)"(0$#V+8
M7XI4(^808*F9AFEXFP1;L 9[L B;L J[L Q+*KGY2L,B+,'4FR8F+;PB3'_(
MAX&89#@FB))XG E#G96W>,E98XRWBG'W3HQW+W_W>>3_&3.C>)\%Q9W?Z;*A
M!WJ=US(P*XPO"Y_Y29\6$YU.)K,6XTX+,Y[#F%#SB3)81I\VN[/].8P&:HPT
M,Z,QJWFP6 ]A)K7%2'I>*U$+JJ(6!8TJZHP9%:%2$WL)>3O5:%B-5J$8NHUQ
MFZX@E:*1 VCA*&CC*'R9)J)9HU*@!Z/ZB0@(,P^$6S!+AC"/!XL'138&2F@E
MFJ,\2CG4-ZPC&$*B"AC?<1B;2ZHAF+F<ZUR*]KE2"94/Z*QZ>@4%(:?!BFIQ
MJJ4(<*7]H*ID2:D/M Y(R:C2XZQ:^J9]6FS6*J?I][NTJZG,)I>(VJB"BC]4
MBJP(H*9OA0BP*Y1_NJL\0JEW_X647:!9 S$#TZNF +D]TXL V]MM.8&Z2LJG
M?_&K"" #.B$JSBL5BLJD#.2]0V(0Q9NH"-!%B$"EXRLDLENGZVN]0!*H=M&\
M4-H3_IN[0;(>\Z"J[+NE A'!%LB[0'*^#*RG2]6L<TK Z1NM3>&\"" /("3"
MK9L7?YJDH2M=+X244_&D_PLD%H<:$.S!$=R5;P(;QVK#/$R6.2P<N*N_<QJF
MOQ&\M2L8P2O"0!FLK*&H'2RIQR'")(Q#.QS#/.*^21R1=SH;%@PD)&RB]DBL
M;YF7R'JE\F"_0FRE<+E[LW#&2MS#,S#%.H2^-TR66RP0"%S'N7NG8IQPL4K!
MPI'%*O^9PW_<PT'BOM,:&]5KR$%"Q)B!QE_YPWL3JU:LQ?Q0Q3]RI;XAO1G<
MII+\&H+,R#\BQ]F:@Z7JJ=]J:N):A/1!;>;ZRI%%7H[IKI2YKK3\1O":RWS$
MF5M8KY*VF?E:2*)I(OVU2*<I8&I(20V[S,S<S,[\S- <S=+,8 ][=;MTS;L2
ML<"BS=D,+".F=7Y(L1I[G-2$G9B(N"YFSBMK=\OI8R+;M/"$>?S)B9OHBV V
MBM\9-F2VSV/FLPB5L_U)S_*)STI+T/M),N>)GT@;G@;-B7ZWGT\+GF%VH!0E
MMGT&M@ME4/7)B+KXG07:M1B=.:IG40JZ>F-[MB@-9V<KDK?_1HT7"K<PK:':
M.-.QYJ%Z^[<CE0^GE[<KFE(DE;2>UV58QIQ!:S&(L+@SZS*.ZS4GQ7N4RQHZ
MJJR1ZZ.8^X$\N!JGJH(LK-4_")A9W;G_&$#<DZ5#(KL)<<-QD:A/L<@KR<<-
M!,=KVH6B7)9Q#5<PW,D\$J@TR=9)&19!S,-\I7]G/;^+%<&^RP]WS:M)@;Q?
M66H+'"1N';Y!0=9I;,@RH+R,\=?C>]GF ;]0ZM9.H:O_"]H_T<4RC!>C_1>4
M/)=\H=F'3!FAG*2(+!60K,%YX<2S71@[_*NVJUU9#+NRZQ0U[)7;,:<E+*>;
M8<1"0AET;,.5D;M?[;G\P-C.>\>!_P'7JI''!-RJQD'&GOP;XTO*M,'7S]M#
M?YVZSI&_D1P;NVV]?.D;U&W)R.'==*K)J"':0?G)G&':!3S)=6K?8&RY JX/
M>"T( :X.N<O=G";"-@U]BMJCF.RF83SAPTK906+?4IWA!S>_OC'7^GW)-ZP.
MVLJF4BQ$^ W9@<S \C!#M0VE(.P:ZKV_O,7?R8JM$H>/H!NJ'W>8Y%H?)O?C
MC*ER%UK+[4KDM]RNNCQ?B'-SO.S+FRD(72":*#+,^F4B_]5(-7(C JO,T]SE
M7O[E8![F8C[F75[-L'3-M41,$BNQV7RQXHQ,?1CG&XMWZHR=TFGGB'OG2V;G
MT?G.["FT /^ZG>=Y4#23LPU-Z/U,H/ 9BM[I,B ]M3>[S^.IU#P[GHF^T,)8
M-C&CSV/VTPEZZ0S-,IP'M 5%C&46CRF--6]V-(*!T?T<LW''T5D+9B"-H#P3
MMA1UT@[ZC*O.>A&::VW+TC$M(H0CTSLEMQTB*+=G.U93&QJEMRI%>CD#U-VY
MB_8LL]Z9U(WK,E]3HWR+HQ2>R-87W5M=RN-^RC+$< &>@B:8XT]AW#O1XH-\
M$(G-JJCMPGW1)[";7>T-NWK-;CS1W$G:NDPQOJI+%3&.  0/\+/POX?]$*XM
MPP^TV05QXD B"!A8@9\#[^VAQXI!V",TOO/ %R5N&"G,J@(TQ.?_8>% $MQ4
MP>&1T</TRQTLOY>38?"-0=ZDS7VYB]EX<=Y*RL0]4=F5K,;!H>]"XL@1'[NK
MJZ5\_!A(C^(CCALW;, XU,/<71#RWI76S1ST3< ?CI<\+.)>/]=/G,EA#_6(
M^O2T =W&4?5-U/.V4<B_FO:<MO3 .N!RW\<4#L;QK9)=+^ (?JV/431X;?;/
M.[DZ6B)Z#-F3RVD$3L&/[Y91[\1 &7WD[<BU4?E ,D1S^N*ST/AZ*?0X'W$E
MGQL6W]_B\?==F?6Q<?9! OJ[(?JJ;^/WF,KN/I0T,:Y^M9@AD81)R(3F9<M&
M7ORV;)DS)Z]-OH6_[.1S\B*%Q',M8N7&_]Q(0I?,/\+E9+[]W-_]WO_]X!_^
M"6;FNVE,:>[FZ'_^YR0NPHEX7N=V'!W/64:+N8CMVYF>2#UXA![I4ROMD@ZS
M *$/FD!^ Z'QRU>P7T)H"PLB?&@0H4"*!@E*Q$B08<&+'0]F/+A1Y,.1(4DJ
MU*=0I,:+$2OFJY?O7CZ+ _'1K BQH;Y^^OSQZ_FS'[]9_7[. LKOYU*C2ITN
M]0G4)\^=)#O>TS<S9CU\]+K>*W6/7KVP],3BXQIS)M:;6"4R[(DR*,^H<_M!
M$SHUZ%.G18\V+0J@GU^B3?T9!FQT<#_! /P)GO68L;_#D2%3'BS9<N;+G3E_
MCEP9,^&B0W_RH_]K%9^^MC+1PNR*-G9:V&IATL19LR)+DP=3\N2'>JAPJ4A1
M(QV*G&A2Y<V9/T\.?7ETZM.M-^]7O?3U[-RU=\>N7;IS\>6OCT=OGOQY]>G9
MOU^/7!_Y^=#KMU</GKG^Y/P+]P?0N_\&W*ZH+A! $($#$D2@"_ >[&<=!A-<
M<$(%$?PNN2LNM'"= O=#A,$*$[PBP (A)!!""1$<D<$437P0J1-G$''"$@N3
M408.)SR@*!D?/)!""[O ,<4?^Z-12 N+])&H>7A,<)XFIQR,J""5A#+!&6(T
M\D4O3X01QB199'#+, <,LD4*P>3G2B6)9#/.#=5$T$,49]FPQCKC!,__PA&E
MA) <+!,\<Y8G]63P3#?);-#+-(<D<+^A!D40D4AGH/-"_[8+<<<:-[TSU/ZZ
MR/0 !S-<SE,*$?%O3"4MC<^]6)/3,5-^+%20U>A(Q76>13F< 3Y9A\5O155O
MG%501AF$E;DY<>V1V%(1D*$\>2A% #]^.K5U5F'+FW987OT,EKK[C%6SQ/NF
M6Q>I<7DDTMQ9_$Q0G:%Z(D_9+!&4S[EW18R77?H&EJJ?91F\#SA\I1+DX 3)
MD>]>?6N4IZ?A$KXXXN 4!NZX@C?6N!]UH*V48Z1<;3%>C(O[>&&+69;W.4'"
MC;E3AV$6N$U$&]766^<PA;;<;^'+$TL/I<,6_T[T4,9UZ%FGK=9II.E%(%B?
MB96Z9ZSC$_7+KODL]&NQ83R2R1@7Z\_'LZE4N[+%_'I[,;?GEKONT.P>3;&[
M]QZM;]'^S@QPO@7W.W##!S^\<,3YCHQQ?QS?K/'''YO<,<LJ?[P?+Z[PH@LO
MWNG<BW8Z[^**'*Z8 ?499I!A!A8<>)T%!!W M7;;;\<]=]UWY[UWWW\'/GCA
MAR>^>../1SYYY9=GOGGGGX<^>NFGI[YZZZ_'/GOMM^>^>^^_?QZ11!!9@WSQ
MR8='GE+F27]]]^=QGY[X2Y&_GGGJO[\4^\G:ORS[Q2(+ .<!0*^D139J><T]
M$O@:VM!F+:R1"03=XO\1@42P+1+,"5Q24I6=W"4NO=')1$ (%PVBQ(0<=,@(
M3_C!%+:0A"J!80?I8C&ZY"4O%NM@#G%XEQARQ""Y\4@(\Z$1N=0E*DSY"Q(+
MHT3"'":)2D&,$FU8,*HLY"I9N8U6:K-%KM#C-O7 8F]:6$4R>G"#+*RA5(3"
M%R<ND8UO;"-I&(,WT7@F<IK!H^7R6#G0X'%N[/I@063BFJT<D($+C DT8%)!
MW8 DA&?\35PZQK&+W<MD]B&8UC0IH/!P4E)9 ^75\-.NK95RDZ(,I2E3F1]4
M=3).GP0;4:AFM:[9C%+(<@^VU*,C1$'LD]A2E<,8)8@4N6E:5..1F5Z$+DC_
MQ;(H0$/FSH )L5"5C60R*!N5TL:/)!T3 8#:9FF,A2BOA2U O_*F-,DD UB%
M"A'3&MM_#A7,,,U33^8<IY"0A2)ND8QJMDR9.^$)(X!.Z$[[,2:# O:A?M@3
MF&JZ5J:.UK--):6?2_+6HR:D-/'L2YW!Y*BP@NDIH>7+GPF*6JP2RJ!JD=)E
M3KO61],II(I]RZ'"'&F++/72]3S40N)YYTEEFB#XU I7ZO 93EUZ'WW-5![$
MZ4G#1KJRA:W4HZLJ&J,0<<FH*C5D5%TJ<IHJ5)]6C:N3--A5<:JF=7A,.!$E
M*T[E\=6A6'5G1(+J62V92:(8U4)(Q20OL018ETU2_ZKD[!<F5:F<N.9TH4"Y
M*8?4\ZQH8DD>&DU039OC5[4&TVK/@69G,^7+4R[6M*4M%"SCZ<S5MI9L73J1
MVM*&-AR]K;9P4QMNXT8WW?)6;WK+&^&$F[CA+DYQQRTN<HF[7,E!KF^2NPQT
M)R?=RQ6E%:;S'.@\-[HNE*YTIUL=Z\0;N]F!S[SG16]ZU;M>]K;7O>^%;WSE
M.U_ZUM>^]\5O?G%UOO*5;WQKD ?\!$P_><B/'@767_[LAS_^S>-_9BG@60PX
MX07.Y((7M$D%V6)!#K.%-R)$S4,V&.*0?'B()LD'&FFXXM2@<,0;@20-5PA)
MX=!8C#.DB@UQ+&,9JK@N4/]<"AS52$46^Z.&1S:C&6=\%R/OQ31]20P3?_M$
M.5)YRDN4FQNK+.0I.GG'-DXAB$\<0I#DQ)$OE&&3C[AFJ'29+[VU&W#MF$?.
M\+&Z=+[CG/]XPQ>_Q":XT0H6$PG$1@9Q(Q]!8XUE3$F<H=+1IUUEI!^MR; J
M-F:7SAFF)RUI2&^:H9$R$2Q%'6I2@]K4GT9U12F*6OB JI6N]5HVJQ1;V";F
M1W^1=:ZU/&M>ZYJUYBQGL/GD:R[1VMC%AO6OA9UL9I?:F:->-K"5'4MT(HB6
MTFZV)YWM:FU_BYDL/26W/=UI2W.:U>,NCTM+5=)&J]*?S3IW>BJMZ7;SM-[F
MQC?_NK,V[TEJS&,ORVO&/O9OM X<K%]%>,L.KO"$OZRP>V5XQ!V^\(DW7*\@
M,[@E!0YP1@=\8QK'.,=!3G"!$\>M_3:XOU=&\I"CG.,JAWG*94YO>]<\WZ=U
MZ<WCO7.=]US?/Y>5N+,][:$C.YQK0_ILV1;GML4-SD^?,AVE;MSD5IVYRJ7Z
MU:W>W.=.3C22^SKFN*Y'/<["'3GP'#Q"YSG/7>&[JA-OZUCP -F]3K]WQWO>
M];YWOO?=[W\'?. %/WC"%[YW_#7??_'1E7H$F,#X@WR" PAAM-R#*PI$H&W6
MDD .KV:(JWF+B45?XJJD&,RG/Z$0$4+#+AM1QSQ^I,<+_]MZ%M<^C5Y>8^N5
MT_HU8N>)O3<,S'[LYB#S?LA/3F*6M]Q;+%=9^5&'^A^7#WWJ2S_*N_Z]4EQ?
M1A?'<(Q%5+/QO8P4*1]&,,G'+9[5/V>RUSG/?83,]?GLDD;B9"8_+/1'6O*1
MB)@P-1WG*G/+.:#C.0+<-[Y*K(HKMP3,-)\CMU7KME1K)6B30 <LP =LM0G$
MM@V,MEBKM:,#0;,)0;8QFQ\AMA'D-0XDNM<Z-A4L.A>$P0Y<P5,3-PH4.G,:
MJFB: <VZ01E\P0C4CYQJ+'+8*4E3-0M$0@-4PGJK#X!*'9J;MP9TEU)Y+$I#
M0":\PIJ+0@9<P@NTP@44OHTKN/^7DSF3JP\S'#D 3,,TM#B(4\ WO+B'"\,Y
ME,/"XD(LM+0XI+B+8SF6DT./ T0UG#F7(T0Q-,26.\0^7+DMQ$.:$\ L9$0M
MS,(DQ, NI$0O=)H>G,%-;*T3O*U>LZW<LC6F(\7HBS/?$AS@XBVL8\6M:T6M
M@T7C KO,F$6N"[L[HR[*:1Q]F(&T6[O0<;M@S('5:1VYHSO8H1W;R13#8\9F
M=,9GA,9HE,9II,9JM,9K[![$\R_RR8XAN@>Q$*!P'(L!&D?+L[P#<HVUZ# L
MVK )P@<Q&SW54R$.(C';2S07LT>]P+'P(R/P^S+QTT<U8[TO8STUNKTW0CZG
MB([B [+_-XNBY0BR_&#(-II(A81(AT2_*VNBZW,^4WRZX#J<ZCO%D?3(ZFL^
MCI2_X(M(USL^EL2](;.RC%Q%]H,_]]NC/!,[7<0S^:,B^F.DGU0D_-L-1^(_
M1*.Q_P.YB3M$201#IH3"242W2)1*Y7!#/83$JZS$2JQ!:;-!#:1!3+3$L!P/
M32PZ3]0F$43+LU3+%$Q+MES+&.1$N#2ZMI3+NO1!NXS+N]3+9]LVK^0:O]S*
MKP1"P"1,GSM"L03+K/3"J6Q*QGS*IF0/Q\PTJY0X*;PWQ+Q$R4Q$ (PY,S2.
M,03-2BI#E$/#C#--D3O-0J3#/:S*.ZQ#UES--HS-0:S*VIQ-_SBTS3]<Q)@C
MP]Y4345L.,MT2N&43-<LSD:\Q.3$S.54S$S$RQ]<RURC+5%4.E#4K:83150D
M2>@#R:SSSE?\3E<4SZOSD:YSKEO4R5PD.W\(';4#'7<@G>X2QO :KV,D+]G9
MG9ERGGJ@!T2H!\OS3_[T3P"M!P']SWH(T/X\T 0=4 0M4 4E4 .-4 AU4 FM
M!R_ 1F:LAUD  ,<  'WXE0P5T>])A XUT5G(IVEL!T1XC Z5I1&%T1A%GA+U
M4 ! T>MA41.UT7:04?O21OY"D9Z "7'D3W L($0BI'0<)'5L1PVCB'<\,3,S
ML9,@/7F,BX0H(2Q-O9+0B7N,O30#BO_2N]*"Q+TRVD>#7#0:(C^+9$ASR8LU
M?5,X4DEVB=/R8].'K,CB0\F8=".*W-/MY-./7$7MU*WX<QM#!0TY2YS+J"/F
M4D5 Q;Y(A5,HBTE K<GWN[/.H)SUS%0[TTD[XDG8R[^A)%7]*\J(X*'N0\K4
M%,TWG,S<A,W73$#'#$#CS"3*5$J)JU7D9,[$]%7E;,Y>34*R?$X4-$NW1-9C
ME;5B%4Q7ZDI.@LYH9=:\I%9IW<NO>59G[4M@_55A5<+##-:@ZU9>)=?AM-7&
MI,K;Q-5755=8M;AS=42L?,QY)4YYY4-!],U6#4V,\\R/\U?4!-A]#43>_,W=
MU%5W/5AUG57_A,7-=G58V8--X*1-1*18B>W->D77C*57!MRXY;!8C-W8<!W7
MD>76?+/6:E76Z72Z3S1!I]LMER54D4R_09TZ\+39\0S/6'RNQ*G%Z3+/],S)
M]L.3+H!/SRG:[O(NTX&[8F0=9$00_-0=_1PIXN%/#M71&KW:%LW:J^U0K=51
MKS51L.W:#XW0F!(\K/U:KD7;L.W0>;F=''516V*OM+71'K5;[%D'M;V5:Z2'
MM>71NSW;K05<Y,G;L7517/&0L:6'$ 6>=EA;?:B>M06 P>6='_VOWXH.CEB\
MM##2SH4P"3,DS4M2)EW'#%L-T!N]>_32,6-=(JJ*'5.X^2LQSQ,(_TLZC=F%
M("A=O98,)"RMS3[S#=3H/=[]C>%UT^>8R.!;R(N</CO=LB!KWN=#Q89L7NR3
M7NLM5+Q!U#MJU/3;7C]*U.[M&T:]5/#%5/-%7_(MR4.=.D7UT/(5VD^U24WM
M5$R],J&@QS(;55/UH?X[57Q<U5QUU86M6(/-UW\]*WC%U05F6$838 =FX'(=
M0)$M66^E8 LN3&UMUFP]V0Z>UH/B2F?K-&*]U@\VX1*6P6Q5X6W5X IT)1#>
M8!:^X!GNUL!TX14^-1H^0(T%V1[F6(>5U8FUV C63=DT5PF65Q^^39 M6",V
M8('%5]*$XC44XB?>3"?&XH1]J0:V33^,V/\HUM<NMN(")M@KKN(DAE<E=LHF
M/N/*3.,WODP=QN *7BP2KE873-G84MG<^D2WP<Z7S4Y+G=GVQ=F;U=E"+N3R
M1,]%IL6<5$\[$X3N"AWM6KNW"R^Y<QVG10"HS1VIE5K>J5JN%5O))>51-N4.
M[8<*[4_!8D;)95Q<L0RNM1#'!5MZP)6^/66NW5M<<5RZW5H3E5L$H%NWQ94N
M,-Q?1N9=GA!$.&9?/E';\0)15ENPA=SAP64=I=%<UM%@1AAD=N8._95F!H"_
MQ153MIU>9EM;!IXNT.9O/MS:06=QEF=B1I!LUE%ZQA4:_=I$6))I]F<3Q=!;
M]EO;X8=_]F9PMAW_KK44@TY;<IZ0K)T%?3AHP^V"PBWE>\8=JW7G@=ZO6KYH
MKJT'!K%G:1;E@%[G=D[G"2EHDC[H:B[GJYT/E.[:VS%FMF5I7U9FHK+IR:V=
M:/[HEN;EGW9FDT: OMUHL'5H?I'GBTYJPK-<;DPMUF"-ROO/")NPT<4'"UO'
MFSA="Y+JT]6'UL7=S^O22%*X,4T)TUL]'-/<+,IJJ>XQL\9-NH!3_H#=ZCB,
MES2/.#6-E#P*Z8@CCMP/._53PO;K/HTR2&6^C?R]Q*[>QW;LR$XNFO3>1=5>
MRSY?\15?RI:,]SW?QEB_/M)L^(6_3:TSS][4FU1M^MW)/>M)_MU?*:T)___U
M7Q^3I*0$8XI]32HNS8 -8P2&5=S&[2QNV <>;BV&8.+>U2,FV3EV;CG&X3O^
MDN@&U^;6R@SF8!EF80_^$M01D2=$8>D6[Y.-[JVI[@P<S/1N8>BV[O:F8U\]
M3N:F53$N8S)F5>#&[R%F6#6.[_ZN;_V>0T5DP_LF#D$8&4;9P9(KN'[M;2G^
M[4"D8M_.[T4<\.+^XO_FS#:6<(GMUP,&\ \?XX]-8S,.6?GF37;UXEMU0_Z&
M2O9^[Q?W&>X>;^G4XQJWSM_ZXQP79.ZDV9SU<4/^<42F19[UND9VKK(+6COC
M1<[)KM#A+DNF3Q;(9+LKKZAM+$^.JU">:*'>:?]W[HH&=15H=.7>&>609A!:
MOEIU5JBEY@>BMIU8UM%7QIUAMA")3ELUMQVXQ>@$L6BQO='<D6BPQ1V?WN?@
MN68=;6H&T>BPG1 TUU$\QQ4[9UL+J0>U-?,$.>:5KM$)L6@=35'=Z7,=Q9U.
M-]&<1@ X-U'<B6</A71-U]%+QW2QY?2=AO6F45L+.7033>I03_7<D>:FUEO<
MJ?1FMI"M=6E8)O8\%]M%\6FOY>?;6?297N9EOQU)']O:D>;CT72M_?3D<?5>
MMQ _OYU5?PQ()W5IMQU>!P!31X!M!_<$(?<.5?7')1Y'-U%(CW59AF91?O8W
M3_;">^HUZ(Z1&Z)\6%+_JA8+_WR-UE"@S=LPVOVSS0,CL+ZP0>)J,?._VXZD
MVZ,DUBTB,G7)Y79@*(*],9/KI5KQ]3!>[C!L*D->ZGU(QL;>F)?LZXV^DYS>
MZ%U?F*_4F_](]=4,[N3L[^7LT>9>T2;MST[ZT%9ZG$1M#]VCI_?4^*7Z2[W?
M, TD_2W5H>S?_T75H[QM L]M"#?-TC3[?35NY%9N+@;B6'7[M5]B.&;N"C[O
MYZYA[-;N&(9Q%[?[\);Q?@@J>@D5IF&0?3KA[0CS';&3O+_A$-;[QG]\&ZY[
M<:%"OK=\]YZT2#QP*,$E]3!;A]$LG$/CML=PWMQ\MAI8L8]PU0SB$O?OA&6Y
M_YGQ)T$H1 G)%'L9S8NIM@9Q<'[M_9-3\."?\-5_\+$W?N*W[PW/< \/<8/M
M<#9F_M+7<-;GMXZ5>U(:XNM7<23F8;G?>\R_?/1^X<,ORP_\Q.ILV>LL19EE
M?R$/\D.&__=G'"(_3R/'HUR$KL5 !+=K<K8C'6$$B"LS!LJ8P<*@ Q8($#A8
MZ/ AQ ,0%TJ<6#'B1 07'VY<6(_>+  B1_H;:;*D29$H4ZX\F5*ER5GU/B+Z
MJ# CSIPZ=_+LZ1,B@)8BN_0D^3)CNZ IZ?UT&)(E@'8/9PD%@*CI0Y< 9DVD
M!Y7I3JHOK_[D]S*HEX=>A4K%ZM;AVI1M<3X].5&I2?]];W-"U=?%I5J\(A/%
M-;G7H=&1.]>=Y3<1456BAX&ZU%LO,8!U.#$[GKRP\,BYB&$JWNGE9<F,9_WM
M-$L:0.>LE74^;:D3\DO)LEMR]8P =TK=&?5!W5S<-P+7@NMA32H4;$;EAC-6
M[8TSJ4OHHUDNYAP=LVJM.YVGU NQ]G2D@D5JSUIU)VKKR.?3IX\H$:(U^>_G
MY]=/'S_YY(-//O?<,T\]"-*#SST,%HA//05*2. ] Q:H#S[XT'-//1QF.&"
M&&(XH#[YE!@B/B%"HV*(^; (X(HFXB-BBB[F\Q^._NDSBX[]] C@C0#JXV,_
M0?(3XY$XZN./CDS^YR0_4/+_Z..4_,S2#Y/^8&GEEE)N6>6567[YI7]<BLED
MF%&.>::9;::I)9MA]O/FFF;.B>6=6LJ9YIYKYODGGW[VJ2>>>Y8TIS^$*HHH
M ( 6^JBB;@HZJ9Z'#@JHI8DRZFBC8FU*5:6=:NHIJ)^.FFFHB*9*:J:BNLJH
M/ZP&)6NLK99TJUBWNEKKKK3ZVJJIKY(*:93^0?/?D2Q"H\^RS3+[K+/-'LGL
MM"M:F^RQ,"([I)#;>LL//]R&2^20X):;X[@]FDNNC^FB>VZYZ<H+;[OTKJMN
MCOG:JR^[^.[[;[__30GOP.06K./! ON;\(X+.ZPOPQ$_W+#"5)8)YL496[RQ
ME1IW_\PQQB!['/+')9-\\L@IBTQE/R"W;/++8,9\\<PLN[RRR2KGC#/*/.O<
M\\X?SR.91 6M S2/B*PS T4(R-#%/$B/''/+2\L0T0Q7(,*ES5Q[?677L\C3
MA68//?WUU1TM%#758;?]]=M@<TGV#%<_1$X7\KA],\Q\(]WRT%=HM- ,>-/L
M]^$E(R(01T[/<'3B,OM]11?D,/U0X7EO+7G?G7-.EMK)28WSXI4[5%'F/ZON
M,^LY5W[Y0EH'/3H_I7.4]<84EUDQP1?+,[A%$D.LL>ZT)ZU.W1#A+?O (5,<
M[_/U'BP(\F9W$?V][XJ-D4/U]NLN]$2JTT5!&]6=MR#J@O_OO?KVKI\]] >'
M*S_V\[?_O?OYXT_D[TU#]+[]TB6(T$GD7OP8F]T(IX[T!;!A#>31 \T%00=2
M<((^Z@+R$K@0O,EC7A:4X+TP"+N%Y U_]#OA_5)(O<L5[7K2:Q\*<R1"#2*
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M,S^#V6=J]??;8/YM\($5S/[Y\[?^Z+\__"?O?BT*O. #_[__!2#";1CB#*
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M]H*8N?"%*ZW9BF%4,YJ-,48P*W1AQV#(,1F*[(0O_(T(9U@8&Y),-"KS36V
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M22WC*TKY\?'_-@)SK90@_Z<?#P\L28*;QG1UN]3OTI2^N 1UG4R!^*L[5M=
M1K=/O4+ :E<!/\^^Z%1U:U=.NYF;W_2;2Q(GTYEV"4Q0DY<F8Q+X5O+V?!=I
M ^XEH1>?%VPH@1)X3XQY5\SZ,I7&J->@H;=ZKU>AJZ]WL_<A"4\KG4.8C?F5
M]T][H0,LT>B7S[>CX>BC!SA^Z?=8LXS*:EE^^5;]"GBED559D_572SJFJU"
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M/O2>VW]G_L=G KA/U39M_5=_O!91Y$=K^O=KU[=K)$5L&85LQC9K"YA_PO:
M#'B!]Y=J'ZAI$2B"&TB"&FB"$%B"*'B"([B"*?@RHN:"#@B"S[9L--AL%8B#
M-9B#0X6 !NB#86-M!ZAMV>8U0VB$IP=N!B9NWK:$Y89N3@B%<_,WT+%N[F:%
M[8:%59B%\69O"T)OB=.%]R97^89OJN=O K=[:?AO:XB&I@-8HX-P"Z<BJ=-P
M(6)Q72!Q$7<[78!Q.3!9E759#N!QF6420D=S,]=:,C=TBWB(C)B(-=>(D?B(
MB&B(D^B(E8B),,<^0,>)G7@_5Y ( *#_.J)(BJ)H.B'! D:GBDJA S+@B:\(
MB[$HBQ^1B8HHB111= &$= ?T7/B@7$Y'%T\G&FFQ=1EC771"36UQ05=U7<R%
M0EYW7Y#!&&O')&9G7N_5)$Q"%]GXC-'80PHV?2,&'#0T&],W7UB68-XH0T/4
M8(.G-H<G8FX!CY77'17V8&)D+4RD'E!$1,;!>/781:&'1K+7150XD(O'1.!!
MC^TA=YSGD!,&CV&5(+!'>@&I1A;F8H<4?!4I?!R91QZY>KFWAKTWDDI6DKXG
MDBD)?)US8;LQ2\77)<^G)<RW?*:T)5JBCL8W2_VE=](W0Z^T)@^D2RS(,=U'
M*$>)*TC9@DNI_X)%>7[+5$[G5TQ)2951:7_H=Y5T%H 1))7L%WY965#1UH!,
MB8$O-8$?R'\)J'X%&&EC X#S!Y89&((Q2)9TV93#YDTV2(-B69:V!H-UJ8#C
MMU* >9=V291X"8)]>9B&R9B$N9A,^9=^F8)G.98*<U,ZB)DWF)EZN8.<:5#4
M!H1"^(/R482E.55%B(1_EYJKR6!/2&ZO>6Y0.(7O1IM7J(6W^6[S%H:"TU:[
M*88,,H:+8V-UU8;%27!L>)R7 SJ$!8?-N2-TN'  PH<2!P]>D(=\V(>]4UDS
MX''&@UDE48N0:(FWJ(GC:9[A28GEB9Z7J)[M:8OGZ9[BR5JS2)^<>/\%B/ @
MI6B*^KF?_'F*()&*QD5  GI<!8H4.?"=]:F@"\J@-K&>Y/F>0I>+!$1>]X (
M4U$7=]%=;^% "A1='WJ-""2B2Y>AHA$H( 0:S;6,4+E+'C2-"61>U:B-]7 /
M]( (-%H/3=$4)R2C^O5\0/1?U+<F*G2.0?F3"K9!G-$;(C9W T:.#$9XES=X
MI1&.\HAA2Q0> PEZ, 9CIS>/G+1&8V1'7B20@0=[_V@W)Z::N.%AF3>E[+B0
M46I&KC=C'CFFVA&F2208!&)(:<AO?5IZ@#J<,]*GD]-7),)OR*F&)&F<0_9C
M+*8;T"!@\C63-DF3IW23R<=*,0F3M-1?T=?_D^.XDTI*=:4:E+>D@M^GE">*
MC*NZ?5ZIJHTI@2N3EG'YF>Z'+%U)J[KZE5CIJ^H'E[[J?L!ZJUPIF(XIJR9%
MF4?3@])$K,VJE<&JF926K/,RE-:*JGMRK<CJ4'+9@4"EF-7*K84YKH])KN=J
MKI'YK3=CKNTJKNA::HGI@96YKI1YF4)3KW+IF=-J@_>ZK_\JK60#FJ1YF@5+
ML-^VI@B[FJX9F[#)L'Q#A;69A1*+F^G&A5OHA;OYA?SAFV48G,%YAK67G".K
MAHVZALN9<*7CG'-86'5H6/H <5Y0G7E8.[>3.]KI.RS G8)H/ C0LR+QH/ 9
MH?&9GD-KM/))M.QY_[1%B[1+J[1-"[5,VZ!3:Q/E@)_ZF9]8RY^CZ)];^Y\?
M$: #*K8&2J"K.+8#Y 4Y0+5KR[8W%[1OF[006EP#JHJ[V!2(< _WD*-Y6P]X
M6UX5E'7=]2;%2*O]\D%6H5R!LBH:1$'2M29GXV3^M4+L=:,UJE[JM8W6Z*/3
M^!GOQ:F305Y[N[FDFAF/&V)NJH[/J!E6NAMNTA[>Z&4,"9$)N:;FX7B&!Y""
M!T8W1F[V^+!QXX\WIF);>KM<RH0/V:;(BWC*RZ0+>Z;":Y$0YF3K,9%F*+*T
MYT9F"KW[1DC8^Z>'2K**^GN.BI*\9Y+#.7R?JGSK>V4UV4,XR:G.]ZE<EO^.
M,/1E1TJZM62J^GNM_0NOJ!:KG"*5V^>N)_A0M?JKL,JK_+? F%:5%<7 #PRK
M:AF6"8BK%6RK$?QJ[UK 8V:O&4S! ;MJT"IK\]K!,N._VIJM<Y+"++S"Y6K"
M,;S!,$S#_VO#)\S!.5S#'#A2ZJK#-RRK'SS#]"K#EU;$0FS$W;J9G4DQ_JJO
M3+S$"<Q4IGFP6V.P39BP6,R:4=BP7?R$LVF;%"O&86RQ;)6Q][:Q;O6;'UM(
M(,N]X6NR<0S'=V5PT9FR+*MPB658_8 (B_4ZC56S?'AQ-SM9Y5!9@B@0/QL2
M<.NT<BNU3_O(C@S)DRS)E2RT44O)EQS)FIS)\]G_MIW( M8IRA)'RJ-LRJ6,
MRJ>LRJE,RET@$GZH.["<<;$\ [1LR[.,R[*LR[6<.S^ALX;L.X;<$\ \ ^7P
M )]</UX+ /+ B8R,R9;LS(\\H4<1N(=;7<LUHL#HN-9,,X+;N$YWC(*KN.TX
M0U@GN6O'0A4J7E*!7^F5SF?W&=G(=HAQC?#U&8T!CJ,JI.)(?)JZN@-V?&.2
MCY0'E*:!D ,M51[&3J>;8>/V8HXWO&.4>/DQ'KY+D<,+O1!FT>(6-E<T>7$J
M8&PZ'U-5O:_'>M[Q>2.M9ED*T8/*D71*IX$C8S$MJ-<KOL0YQR5[OBNI>Y :
MN5EVJ>W+OLT7OT4==_.+_]3*E,][MU]!R;_\:\XMG$NINJIMAJN\2L0['*]9
MG<1=C<1?+8/F)\$B7*QOF<!DS=4^C*S;"L3C"M91S*]-?,1AK5)2K291C=?<
ME=<NK,)]/9AM#=@XK-6#'=@_+-B%3=B'K=B3^=?YRC(#$Z[ 5FO*FI?S"K!P
M?=EQC3 D+$]F0X17K(1& J4*.]I:_+L.R\5A-<832\9;:,:' ]N\^59KW,:U
M#9(AJ].Y?=,Y'3IOJ+*_C<<,)X>L P\Q"\@5=[.X,UD;QYV!^'$C$<V='+><
M#,W3'=W5W<C4K=W7O=W6[=W9[<G(7#\RP+5:V[7G;=[I78K^T JH:+9D>[9E
MB_\(9' %/3L#72"V@G#,"- %2$$&.J'>I/@.->$ 60L KBS>\J/,S&P_W(V>
M#G %W0W>WUUST[P&]8#A>*NW%_JWONAUB&NW4E%>'9ZBU/7-P@CB*7[-VL6B
M*/JX*[U=*<IVVMBC5"'/Z3S/['6Y>XNY./[.GML9/YJZ0.UV/'K43MH/=8>.
M;JIY) 3CFB>[ (V_3!ZG!]UZN)O2PO*[&!V],,WE!-G28(X?H\>[7=K1*CW2
M(.9Y ;:\[AACVHM';Z[F%3W3-5V18'[1);UB+FWGB:J2NHW;XRMDX@NR;?33
M[YM\419*H!$EE'JIF?JY^R7I])O4H0IW>V>DW*5==^W_UU/=Z9P>Q/A7?I6F
MP5W-PXEMV(*&Q)1-F&^=UMXZUY:VV'5IUVOQPHA]?:Z.F%P]ZRA8ZU.'ZL&.
MZ[U.[*DN[,5^[,8^[,J>KG3-[$^,V5"LV=-^V20\Q:%I-=F6FJ,IL$&XQ::=
MVN'>NZM=L:R]5K&]L6F\F_K6.+8-G&\\)'(,Z+QMLBAKQ_>NQW?LL@B'.[)#
M.\C=AQH'B-V)60E*BQ2^R0Z.\-(]X0W_S!+^\ KO\ F_\-@=\::5X")!W@9.
MBAS?GP'^\>OMM>T-H._]WF0P P9QWR8OH!&. #- MO^=$_Q0BNG0!>A-BB[/
M$@5>BEZ0\?## @M.$A)_\4<+_P\=SY\03_$3OX@67J%-L>%\"_5]6Z%^:Z%/
MCZ&\F,V]F"30A>*"FQ=*G"M8=T%@S[GYY<[LI?:A6[GTL.,YGLZ8*Z.J*UWW
M;';OM4*:ZW;Y"QL)%N74IW9V9XY*WB4O2;K\#*=MVF&1BQM6[OC+>[QQVI#'
MH3=>GGK1F[W92].7#^=%]*8/*;OJ08]Z;OE7SI!-*M"$)Y#P?M)C6J9Y3N9\
M+OO7^[V$BM.ZO9$GRY)O-*GG*(WQM>B-'OR+7G9 +M3PZZFQ]$J6'KOJ:U].
M_>FV'OW #NI">>O2S]?9+^QO#7YSF>S?O^S@W^NZ'NM\&>OPVL*GJM?K;ZI[
M[>G:#__J[T_KUZ_LJ_[LO\[6R-YK0NDF]"_^.0P0^6;IXZ=O(#^!! TJ/+BP
M8$.(#"4^G.C08D2*&2]6Q+A18T>0'$5^'.G19$B2*4^61+E294N8+&6^G.G2
M9DR:.6_6Q&F0W\>?/A\&G474Z%"D0I463<ITZ=&G3:$ZI3K5JE2L4;56S<IU
M:]!^4,,.[:=OK,^R9XNF-<J6K-FV<-^JY>=6*5VV9=?R6XN6;UV_>P77_1MV
ML&'"APLO5BRXG^''?"//FEP9\F7)F"EKKDQYLV3/G?MY!CW:=&C*_DZ;5HVZ
M7^O5L&6/]C=[5FW:K7'?UMT[]V_>P'</]QW<.''ANCT/OWW_O#ES?[<!1*<N
MO3KUZ<]GS?#RSDL7+^Z^=P%_I<N5'%=FK%\OXP$+!_ 1S*=?O_X!^_/QY]]O
MO__]_!#XC[X!]0NP0 $/5)"_!?UK$$ &(W100@@GM+!"# E\4$,*.;S0PPP-
M[%#$#TD,,<$142Q1Q1,1='%#$T&4,48:69S1QAI?3%''%7EL$48<@T0P0"*+
M-/)()).483H FG22R2>;]"=**:F$,LHIJ?2G%2-96 ,1,F9P@+X9ND@$D2_/
M3!--1-1LDTTWR6!A/B_@M/-+,I+4D\A9GEPG0'7ZQ#+*=_9$P($LF_0"R7P&
M;5(>0^>[\DE_$"'R'4>=O"*_'-Y<__/+'.R;H<HF]9DAP$1(S912*]T!D@4K
MIX3TQ_GN<3)1)UMQ9P;QW+F5RAE\E!17)_E!0 9!56552P#Z&5/&*R;]E=DH
M6Q$V1R"O%3);;NOS]$Y\\+D'D7O$123<>_)!5UUVUT4W7'';U2<?=>>M%Y][
MZ\UGWH+F;65??.P-F%Y\_O5WWWS^;7?A@A$N**.$$.HW'X3T"1C?=-<MMQY\
MZKF''D0\YGAC<3LN>61Q+5898XOSN:?EE].5V>6586[Y8IHOMCE@:"3.IRQ^
M>MY7Z* ?_EDAH*%)NF*A]6FZ9X*.1FAIBI4V"ZZR_ $LK*RW)@CJJ:_N2^NN
MR]:';*S3!O_ZZK +XAIKR;0F>[&Y59-[LL02>ZTPO^SFQ^^]_!9\[]3B_IMP
MQ+5.C;6X66,<\+WG+EQRP-!&.ZVK,3?[;<XK]UROOT-7//3")__\[-.!/KIL
MPR&W[37'%W?=\-+QADSQQ%O/??;%>X?=]^)^WTUXVY [KCCCDT<^>-D.1\SM
MKYF>U^GIH:G^>FCRL7Y[I[6GGGOPOQ>?^Z&9-K_\JB6V.NBDUW8?Z:_?9Q_^
MH ^*.&*'\+<?(_VCMM]H $8M@!(3H/\*2$ $4NR ]S.:ZHS&OYY$D"<<(0I#
M*MB4">I$@AK,X$XXB$$0>E"$&QQA!TD(D0LNQ8)N TL+6?C"NUS_184AI(H)
M9](_A$!P@3J$V/\,F, !*C"!/@3B H-X1"/^4(CWV]]$<%C"#UXDA2>T812;
M:,4J0M&#..0B#[5(12R&L8M.].(5\U?&'YXQBV#\XAK=&,8VPI&-<WQC'.U(
M1SF:<(I[[(H,O?)'/P:RCX/\"B$!:4A!%A(M<EDD7AC9%T=&,BZ2G,LDQ1*7
MJMCE,(')&V(\R9A.@O*3C0FE8SASRLRD\C.KM(PJ6TD:5H8&,JYQ#6Q"8\O8
MQ2:7S$M.+X_G2^4!<WG"%,YRE$.=8SH'.]>QCG:FM,Q9U*,+XO%">+[CA7:,
M!SWJ8<\,9# #^,@G2=HB9[=Z9$Y:G7-'_^B\43G7^4YUQC.=\VPG.[$%3WK>
M4Y[UQ"<_]ZG/?&ZKGP#U9T#=^4^!(E1/2R*6LJ:UJH<N"TN)Z-*GON4FC-[I
M6Z%"P PR:M$X14JDR0+ GY(T W[$ZDF(F%. $/6D+C J4[,RE+2D9*DC/3-6
MB[*/#,K0)AEHR%=/XL>I$.HBE0* IS6"%;-H&B-?-10 KEKGDB1:CAG9E$GW
M4.>H(@J 3?$('E\%0$(-:D^S%E2M,?K6IT0FKGMDC&$"8U?&S%6N<;E+709+
M&, $=K._$BRP>W68/N8U$'X9MJ_Z8FS#+#8QR/I58R9[*\DX=ME[7#9>+..L
MRUS6L<_6([2A/?^99V?V,HR9MGKG<YKZ&A@UJJW,L_@:6&N1YK6BH:^U57/?
MUG K-:OE)7/#=2#ZYA<VX5KN<Z)$G>;2MLFZB2YR>I-;WNXV.M9MDI37I=WO
MO/LZ\#:N=KCC;E\"ESKB!C>XPU4NZ,)2M\CMCG2G:V]SB6O=PY7WN[O4'7GS
M2SOJ=M>_D]M=XA@'O%T"AWBQ"^8O'=S@!B^8P)YDV].N-S3L>0]\&E99]L+W
MX>[QK,/BJ^W37)N^],5/Q<==7X7EMSZP08.(8^PA&6U<1!PO$8DYWK&.DYCC
M&:,QAW5$(5",+,4\)OF.1&:RDO$(11HO^25\1'*5BVSE%6+9R4W>8I#_?^QC
M'G\Y@(DE()D5:&;(%A#-BNWQ V^LQBW3D,J'G&&=GWSG)C\1SW&6<ARC;$9
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MCJ$NE6&LI:$7K&$R/5,;&@@U7=.#Y-H<.N(D0J(E,B*!!JB!2B*"8F*!9J*
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MO=S2)"M-&BC),:\TL\R3SCRHS)*65$B@-TN:,R$Z$;H3SCSMU+/./DF"J*)
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MZ35T0D=^XV=T2[=T3J=^BO@SMR%_2N-^D#AU5U=U %:).R6 F,AU!N9_!QB
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MCJJ"C'Z<_L['?>/)W=4PVMRG3J/2?>HFF:,0IL)I=,*L^^H4/YO<W>2VWKN
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MISFZ3]5#D"W5\UO(S2795?7<DR4JT639T=T0EQ4[U22[EST[2GP[FN75U@W
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MM_=.KW=\W_1]O_=\]W=^G]-/1_6!?^X?C]\<][,=%_6%+W7D;GCI*O@7=S2
M#]]'J-!!UE0=R-@&GO7UL\Q2B_)&GG+Q)N@JQW)?1UE$!/;UMK\N_^M'1%UC
MOY%/)N5,%&4SQ_F:Q]T0BVPU9__SQ^;H:@=2.;=L.\=LH^=V/._LSV;Z7?YS
M=POT8#;MU5;T1K=ZJB]TK$_TK"=TV1XXT_OW?J?XL1?[LM=WLP_[LU?[M&=[
M-!-X>7QXPBW4N$=X@C=UJ9YXM"=[=!$:Y<#XBTTIR15(!\[#MY;KD4?\5AMO
MNV;\DU=1O1;VR/\Z8H_Y8Y?ORY]OG7?VS5]A:A=Z)9EV8_U\;!=I ;]V9B5P
M'OY=IGU:<&?I6"3W!]?2Y$5WY:GIK'5W><_]=H=WWM=]SJ+WO6][O2?^M1?^
MXR_^X3?^Y$=^#'K[N[=[@X]^AJ][NG?XZL=^Y(YX/U5^P\P+!1YD#>T^]U)R
MPC?\6\__W,,OU5SG=92W\@U6>9;GZ_;V\F(G))D?\PZ[><WG?\).<YX'B <"
M!Q(L:/ @PH0$$QQD*-#A X@2!TY\V/"BPHP:-W+LZ/$CR!D$(0@4.9#D Y,"
M4<Y ^8"ERY@G2\I,6;/E3)LY<9*$^?(G!)Y A?8D^M)HT)Y#E19E"O2ITZA0
M@4*(6A7JU:H]LU9MR37I5Z];P8X5^[*KUK-DU9K5VA9MV+1NY<(M2W?MW+AZ
M[>YE>_<MWKI^^^;E:WCPX<*(%RMN+-AQ8 B($DVN_&BR/P":,V_6#(#S9\^@
M1XLNW?ET:-2D59M.[7KUZ]:P9\NNS?IV;-RT==O.[7OW[][ _X<++\[[>'#D
MQ)4;3^Y\^?/FT*=+K\[\>G3LU+5;S^Y]^_?NX,>++\_]?'CTY-6;3^]^_?OV
M\.?+K\_^?GS\]/7;S^]__W_] 3B@@ 7R=V" "!*HH($).KC@@PU".*&$%3)X
M8808CC>+:AR^YN%H((HFXF8D?F:B/RB"N&*)+9[H8HHPLO@BC3'6.*.-.>*X
MHXP]W@CCB!WZJ..0//YX))%(&IDDDTLZ6:20'T89XI1!2GDEE5A:2:&&%F;X
M)9=@>ADFF>+-XH\77:3I!3QD>+&FFEUT<44.=,YP)YXL/* GGP[HB0"@"0 Z
M:*"$#BIHH8DB@"@"#QPZJ*. 1MHHI/^52KHHI9<*ZNBFF')*::>A@CKJIZ5Z
M2JFICJ:**JNJMOJJJ['".JNLM=)ZJZVQ,M3JKA&I*E"CO0+K:["J]GJLL<D6
M6RQ#S?KJ++3/2AOM1,Y:=*VOV%:4+;?;>HL12.&*.VY&$"U$$;CGDKLNNPFI
M1-"[ \5;TD'SIE3O2/32I.]*^_:KT[\X ?S3P#X!+##"!B?L+T\+)[7OPQ$W
MW-11%$ML\5)0(3655!TOE57%A-4E%LF%E3RRR2FCO#)9)[>L\LLLNSPSS#3+
M7#/.-^L<,\\V]YSSSSO[/+16B%Q&&=*8C;ETETV+Z7294#/]--515SVUU5EC
MO;7475_MM=;_8'/]-=EAESVVV6FCO;;8;9_MMMIPL_TVW7'7/;?=>>,MG8I5
M OEWC5L*#GB.@P=.>-]:(N[WX4I"Z3CD33XN>>1/5CZYY91KGCGGF'M^.>B;
M?RYZZ)V7/KJ3_9R2B2:39#))ZYG(/KOLFK#^B2G*M**//M'TTX\__>!H>.&+
M*]ZXWG(K?_?R><\B2!?OK"E]G&G.62?V>*8T@PQ[>@_HGXHR2BBCY3\J_OF8
M7JKHI()VJBFIIXIJZOSRQU\__O>_VFFNN/K?/P#_][]>H0I9RR(6 @V(P&$)
M2UD#8=8#I641:TT+7=2J8+6Z)<$*3E"#%(R60<S5+HV(<(0@*:$&_[6%+FRI
MJR H1*$)8RC#&-KK72S)U[UV<I.:$(Q@ O/A#G4H1*7HA"E(.6)4D*BQ)'JL
MB1SC&,C&@A4I_J6*(HL,8+)HQ<0\IHM8W")CO*C%*XZ1BU\D(Q@A4\8PGM&,
M:U1C&JM2F:0=+7G,NZ,=\[@WYF1&C\W;(QX!Z<= _K&0A#SD(!,IR$4:4I&-
M9"0B(>G(2#ZRDI2\Y"0S*<E-6E*3G<1:XK(D2N*%DI2H.^7I4DFZ50[/>*Q$
MY2M5:;I8KM*4QRL>\DH)I&B @G6R@YWK?&F[UMGN=;*KPR^1^3ID,C,3=9A$
M':+IS&GRX1/5-(4I]-$/3F*2FY[LIH80<?\%-I%!'EZ@'IRN9R<\L5-/#O@>
M L*G/D.9#WWKFV?[+)6I?9H*?O33WS\#:C^!\B]^ 3RH !&JT(0.L%8*5" #
M?^7 ATXT6<Z"X 4SRL&-?DN%'DTA2+?5PAF2U(0O7*$+TU72E88$7P:IH4L+
M8D-^^5!>-Q1BP'AH," R3&$^[2E0B^BPH5IL8A4[ZL60JD0C.K&I3\1+R-P(
M-*();:I6K2I6@Z95JF[UJEW-*E?#ZE6Q@A5F1IOC'+^I5F^R]9/]0,0Z9C H
M!USA3 *Z#%[S\0A^H*BMX/SK6C\I6,#Z-;"$':QA$UO8Q2*6L8=]K&(;*UG(
M.C:RE%6/+G/).%S_<C:SG=VL9T,[I59J]I:S/"TL45NY/JJ6EJU];6IC*TO9
MNI:VL$VE,D"!"TW<@IB9  4_(-</?O"C%<K(AS), 0I0?.(3TWPF,Z$IS6C6
MX0W4O2X=J$N'/7PB'Z-T967#.UG+;F<6]\B!FN Q/3A9;YU7P),,N.<]/DTJ
MG_:<9SWQFS[[[I-1]1TH@/-'4( &F, %716"&;K0!2L85P2LZ $IVJB(3MB!
M$84(!#N8P0UC<(,@Y*B'0_S!#7:0I2:6X4D_VM&4AO#$+GZQ1V::PX#A4,8_
MW*E._<73G.*4IT1<:L:8NL0A"[G(3SUR4Z.HEBDN.8YM9.,;Q>CD*#\9_XYH
MO+)4L0SE*7-9RU;.,IBW_!6T4J:.XKTLFLE;GA3QPPLL,)0W!N4-NMI5/WA%
MZYWWFN8S]Y$?K.N%)GH!"M^I>;Q\/K2A$[UG11=ZT8YN-*01_6A)1YK1E+ZT
MI3,]Z>:)UK2@':UMB\3:4,\V<K84Y6UK6VI5L[K3WRWMJSG;#V(0$YBV,T6L
M^\H=?^@CN9_80R;V<-UH9K?8=2C%II-=:667)D7C3"][XZ2#*UR/G7?J7O?H
M*T_^YM>_^_WV/?\;[E/YL\ #/C> 777@4S&XW0UV-[P/6$ +TSO"$$[@O36J
M[PY_N-\H73' _RWP%L.XX.4"5XI9;/"%TU1>,?^%U\,=OI,:VU3'.+9XCW]Z
M,(TO;.- ?9A0?9+4D1N5Y!@[.5*1K'(F1I'*9/TJS%\N\['2O*PVCWG-<7[S
MF>\<:&=-&M*6+71,8U(?[R54G %U #D/Z@!T'M#1?HYG,N=C%ML<>B']D5O9
M 9KKM@/%,$X1#69K&NMD/[O9TTYTM9=][6YO.]S1_G:YQYWMSW'UJ?,.WKW#
M6N]]Y_MG/8VE5!.>U*TV?.%7G?C#*Q[QCI_M*7K;6]CUEABM];N-HA&-92Q#
M&='(+7:U&\T]Z /O=9^[W;6&INJ]J7IQ4F<.K/V ;'\O ?+L=OIP?U]OL^]1
M[S,P\-$M8'.SVZ#&CS?_\M^=T ?;N_GX=CZ%(]C #%O4@AZ\_KXYK&'K:Q_$
M%"PQC&%H\(0'7,4J92'#TW]B&U-\XAG'>,'@?V/Y!_''3"1RD/./\HCI?^7^
MIR)56 45>9F4$6"5%6"8?9F8)2 "+J #*B $-F $'B %NMQ=D-G/I1[J;:""
MS$(]S(D# $K2(< (EB#3B>#3W974E1D&1AT=&4WIG9XA)=>?%9,O90*@X8XR
M!!?=]: &RJ /<F 0 N$/#J$1%B$2"F$2$J$2-B$3EIWI_1VL+1X5/E[@Y9H5
M5F'CR9(_="%I72'F=5IN[9;D:0(N@,(R2"%G54?P:)XR=![G?5XO,=-T$9MV
M_YG"$QZA$];-++R#FI"!()Q3M,'>.K73?,G*[N6>/O$>/^G3?_V>\ 4?\=6/
MNNV/\B4?)EXBK3#?\TF?1!U0]$E8)T8+1O&;*79?^874P*DB^K6B^KVB*XH4
M2HT4+*Y?Q#4<+LX8Q+D?C075COUB$/&8QPUCQQ7C3X&<486<4A45,RYCRNW?
MQCB5-+:<7$058O"<SF4C-FYCSG%CSWVC-G:C.(*C6*Q@6NWA$NIA9P2//,@5
M"3;="2+ THD@/-*CTJ6@G5E&"^XCT*U@Z:UA'H9)-)B"<W4=#A93UP4:*!"#
MYJ&C0P;D0ZJC1*8C149D14(D1DZD16YD1F9-%((AX/]]I$A^FN!A84F&(:AM
M(>.MI!:R9!:^I$JVUC(0 R[@@B_8)$[6Y$WN)"[D@DWZ0C$0PS+X3C1T84P.
M2300PTV:(6]I@B\HPTJ2DAMR'AQRGN<M RA85S1I)1^4GBD F^A] O!@'D=J
M9$>*!AF,D_2\R5IZ03NTU[35B;6)A+:)FWXE(E[VUR*2FR0.GU_V)6#*RKJM
M6R86IB8ZT+PYGRA&'V-6WX5Q'V1N7_9Y'_9%)F6*T/?-HHN)7\&1WRK*8BR>
M7RV.)KNP'R\"(_V]7_RMYORQIE,44?_Q'S3>GY'MW__=)E,HV5TTF03V9@5V
M&0/^I@%:X' "YP/Z)G$&9W+_'F=D\.-%FN79]4,7R "<Q:,)VN,[8F<)XN-_
MW-D+]J,+ZB-XMJ ^0.>$).5!S@Y"VN P"9HRF&=9/J=\QB=]GJ5]PN=]SF=^
MUB=^]J=^^B?>C.1)PM*IM62JH>11)JA+(LFL\:2#_B1/^N2#3BA.[J0O7.B%
M%L,RC&5(GD8T7"@9,J4O\*!)QIIL](-54N4;#N50CETTM((S21<R\0$TI(8I
MA%X=[ $>[B>/ NAMS (]H->;K)?K5=L,O->UR9<[P9->WA=_/:DC5@HD3F)@
M4JE 5:)@'J:6&B8F<B)$U=LHYIN83B:9BA@KGFDJIB(MDN:)>2;!*1R;KA1,
MO=0M_^JBQ,E4^_7B,*+F:O*I,0;5GQ*CR!&5,YI<H99<R<5F-.+F4U&CHQJ&
M-X8C.8ZCI%9JI%XJI6+JI&:5.08=?_[G)/5#(L##%;R9TL7C/&:G/*(JJV*G
MT]45U(GGU(TGK<[JK%;=U7VJ>/!#;AFDKZZGUPD:,;3"V(&JKO:HL2+KL?HH
MLR9KLRZKLT8KM**-@)8H@EIKAPZH&E;KM6Z)@<+D@H;KMRKHN+I6-!1#A58H
M,9#HDOB#YG$>,12#+] DA?*D3J:KA1*#4*XH/Q2KAT1#*.#K;A5EN'K&NU8E
MPD+#6*:(/YC"<T%3L-6HB_2#L-5!=D73)[3"J-W2M"HKW/\EPCBQY2"^'IT@
M*7P=(GTI8E[J'CZ!6_R4VU]&HLP2'Y:R"F%N*<YVJ4.)J6*"Z?0MD&,&K;^-
M6)ENG]%>IF5^&/B]&&?"HINBJ6@V;9Q.;;B8II[Z:8X)(]:J9FL:!6S.)OZ!
M;6T^(Z-*(Y/EY@"F+7,NYP2R+7(:9]O"[=L6)]TJI]P*IQDY9\<^*]C,@CX@
M@CI8I^!JY^"JZG4:+G?.AW?*ZG?::N,^KC[F&5]Y;'QL'7MZG7IB[D$.@RD4
M)>5*Z^?N+>CR+>F.KNF*+NJ&KNJ6;NI.)+>ZTA>Z6KEF3K=F*[:2ZRDUJ, 6
M@[].CMZAZ$PJ)88*;+VFJQE:Z%#_UF[@! ]5?IZ*QN'8J8;#-M.,OB=MW.C%
M,A.NG>[J"IW?RHD7" (9M&61EFSL65M=-LJVN2PC,J)=OB]?SFS,6JG-6B*7
MYBS^*I27^NPG FW/_F\%E6*9#BW4FI\!%S"<4NWX(5S4*G!)S2F>TJD$1S %
MUQ0O=MS6_DL&!RH'<]R@?O"A-J.ACK"BFJT)!^#',!66::JE9JH+;VH+PS +
MS_ +\TRG*DWWMNZ"^(,[S,";I>H( G$]JJH0GZJKMBH1)ZY\1%UXLF"M0JX3
M.R[C6L8_ZG!I\-*O:FX6IZ?L+*3GYC 8LVX8<Z\8ES$9G[$5CW$:F[&$O.ZV
MDN3M@N0;_VNK'->Q&U]A[(+K[.HQ'^.N'V?>,A O,0#/'BM)&SJO4J9K31[O
M3PXEX1WL4*XH'!*:X/@#C![3-(&"*922/^0#CIK"Y'*L&H\R)LV"G*A)(*(3
MR6)/(=X+[?V)JZRLRK9L[Q7*E,XO+E=I+F<I+^>O+R/?_@+PEX(B_V*8F:+B
M,9]BTB;ST1)PPC'M:#YMFFIF:#JP-6\$!%OPU5Y<GP9C!G^SR/E8"8<MV<IF
M.2_J"9NP;GX%;Z:MV^+MVM[M.\^S/-=SW<;S/<>M >HM*:,Q<NB#(%P!=1;N
MX18T01\TX:(@K*I@>#;Q#3LT1/.C%)=9(I097Z%Q-/##, 1:[?]H[@T:Y$<K
M)#&80HWZ,QOW\QJ;M$JG-$NCM$N?-$RO]$MGDJ[1<2CEL4WW,9,HKQW#L;?J
M-#_(Z^XNP^79[JD![U7.Y"_@)"//:U&Z6C],921398L^1ROTTC2]CAU )71
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MQ8<8?*\Y@#*@3@$4M)(_.NLF;B(&8R(&Q1(&R1)!2NL33JL>U7(@G6_0,&2
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M%$E?\B5K\GMB,CHX\$RE4BJ7LMS\8WTRH4W?]#\@*A/^D_=: 1KZ(?PJHA]
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M\X!%0?A^:5JG0%AV,I"IRU27.(@E3<8@^E!_QAHF3?\Z)PV8K+9JI]N:%EV
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MAU^?_*QW,_#RW=MU!GC[FILEGQG< LPO! 3A9[ZI$*&KO[^TFB&MFO\<Y._
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M759GK<FFTDFW:3:M8KN?G$V"B#N-L5:^0TIYF5:(B!F_\Z/%,3QO':NAK C
M8KRAS"S(>SW'5->YPIC'PQD9+0AV19O%LSR\;":':,O?R#S'HHS3U+SI0+'6
M0<NR#"R]3-BR? P0=-C(P-:)2$/:\$O*\"[1F@W 3 A6<PPUW9F,M8C((2Z0
M=:[F.\T1W:U[Q1S*U,SNNTSFVK[A$KW?2C[/6[_TNE< *+_67+Z;<-GRRLSW
M^QR*C4W>:::,4!WW:MKW*Q_WFK_-U FH9< (?$"K1<"LE< &A$#_K3U KKU:
MKPW;K^W:K<5:L(4 "KS56FW;S-! =8Q;)\*X><#5D(J&4VBQ\CPA$1()%G1!
MM\U5^>B'HWC/^3Q<^52*'52H'AS&'_PE$9F'5A!5:]$'03"'9'K<([0@%K!4
M!WW1.HK0P+5;70HD+M/* #'#[HA1,0R-#RTV,#NT+LB\C<0./ES1\+#=0CJD
MP*U01OI#:=G1-KO$T2U>MLVD3C1>P1603T)%9A.I)45%:=.652S"5O2M>Q!"
M!'$ =U!*Y>T@-ITE!] @MWV'S&VB<NR@; M(?\6,;S3"=SC1ZV"20D6G]+5'
M3 6 ="1"=LQ4D_-?<R+"0VU'CMM?<LQ?_U^1A\=U@%0B7?+H!U,AAF4 NE4Q
M* N.U6*08(4D4H\PE5,=E5V9D>90559A586XR(*2E>5UX!7^7A>NE6<*UBZ@
MPJAS*96<J7;)NF/%29YJ5FA]5IM4.X@1XK:+V+:+JIZT2Z3"F+;[3@]KN].,
MF:-$J\SK*K%Z .]EB*?$&7=0BY*1&<_#2IFAV(&H/*RTV86-UXL R_H$R]#3
MB,7!R\=HWXBPT-*@74KD6:Q!#M"*8[YZV#^&FMBCC-\$ (EU#$9$$^DH9.&]
MOK=,3$B>6#@^K<8(#[7AK9.-K9BE'>]J+YD=#MO23)XES><*S5*.6=",V?1K
M"."1KAD 3M>L3?^IB,W4%#W5V2Z, ;^=1;[W@RWU<UI@+EK>%$"]) /W(0/X
MFDYE;LYEALYFEDYFCF9GEF9HGN8(JTZA>.$6!M+MW%(_#3D6\(*"U68 @ 9]
M((88$XF3,(EA, 5ER.)MCN>IF 4=3-SXO&<:0EP=!%'YN$_^1- F"^<<K:)\
M0";\_&<%G0%YL-L'?4)^EF=R'@A]Z-#0U=!"]()66#I3HV@(18WOY8>/)23<
MC8I\X&@QRH%'H%RWM>/NT(%<0D0([5$6GNF(YL3V&+::AFC\T \D?5Y3?#9O
MUHKIE19JV[;KC0E$P%R RU-.RMX6:9%V +;PY38$&%]XIM598+*0NU__&NGF
MBZ/C2_VK1G4+)0QK0;73>(,0ID;4L^;3@]LV0&5KN=XX!1YKK=C'1&WK,3%?
MN]X+&1"$+9PX BX(?3@G)D4R+QUL35WL_S5KDXO@#+Y@?UI57%B5#'XH&*PY
M4XF&AFK!A,()$N:YC5J(9;!@A#I>B$9MFE;M*L*.;E$IJ!.7J8NI8M7AA^$Z
MA$G6( 9B']YMFN1AG-2)(_Y)OY(JB\B[G5RNM@-7Q,@JKPJK<S69CAT/YRX\
MZ XL/4:/O9HKV ,9U"6(=7U7H$ED#SLLHO'CQPA9X+P)X"#O9OF\0 ;!M0SD
M2O:HSW#OJ&#IT6C9S<H)EJ;8.,;DBQ%9 ;\L_Y2ES*NYY)QQ%J'=G>9J#N!)
M+_DV#]:\+O-2/Y\MKIMX6MU1(*;5G>S&">NI6IY%+[(]<;0UV[0=VQ07V[-E
M<1A_<1E?\1EOP+5-;1S'1+C=7,W-"Q:0WR+EAV$ !910Y_(<.G[(N9Q>;?J@
M9R##YR?/9WNFSTUJW!Z_\JK&ZT^\AV7$<AXW!Q'&TBMJ)-%E;3-?(#""4 T%
MW2?,4!AL!1(-W8$^<_W.HI&FB4>(\RSZ[N6%\T+";^>R(TL$<B8O])Q.WC,W
M]$YJWH#T:8^*WH <ZFNIWFHZZIGHAZFN)GTD=(D^$G64 7TPMDS_H2Z]ZA ,
M%&94;YTP7[FEM_+H!_]X8%1@DH$1N9IQ!*;[1>"O,6!O B?'5FR34T9NM%XM
MQY994 =95T<6N )#^2,OF%2Y+0=.3W3[\ <(GF#)1LB#"BA?NY6;NSF?HXC0
MILC17@:#G"A< %QJ7_<<7_*V302G@^WDD>'9/I?:AI>;TKJOZVU^YVVR VXB
M%DJG\MS.JBJ!WTGF'A-MW2K?J0>#;RHOJ$L=&VZG,HRJB,HN]K!R13RDG.Z'
MX =Q1<J,K]C-FU?V3H"(+XRKM#PW-IE"'I.PI)XT;'FQ 6O8N,JJ 70^;>2)
MI:KT'AJ>)PTR[F?Z#F2//P@=&XV7#Y"@?PQ !]C5HN3&G..A2<-(SIF1R3[_
MQV@^DT6<V*F*5&:</YR;F6V<YIF(1! $4Z;9S;D/SS'E0QKGA_",L$]-\M:O
MVFQ-7W8.6LY[Z)J%NKR'"-=EVOD"WTEZ#G<ON9<(I.6^E-\,M9?:8ZZ<SJ#F
M9[Y\R\]\:ZYFSL?\S??\XL1FGG!W=L?$;NYKU.</:8?H:&@Q&5OG3  %8FB%
MSU;T=N_J5M!G*8=RT8^AQ>4A?P;HD,,@$S-U+X/TM$[]$).!A[ZQAA;TYB?]
M%:YSZF C-+HSE_;(W(@S-\_Q.5+$Y1B//7S"EY9G?C#I,UQE\FCZZI=IZ;=]
M^#<((7W_XMUI@$O29CO%BY/T:2EJ:+-T@   P)_ _X$%_>6[@F#AP@,,O3%T
MN! B0P0L',B8D;&<1ADL*CZ,&+(APW2(!!)$>7"ERI8&7:9\B>CC1)$U&3JX
MTB\F3Y8O?_:$Z3.H080T$4A$0!'I2*0SS'5YAPC?+'Y5^=T3=$6C@YM*NRJU
M&9:A%YBSS KLY^5CTJ5MQ;IMZM#=P+-U4<[JPM3KVX7K[/H#+!@OX;L ^,T@
MR7>D('V##0<N'!GRX\F1_;5+O'?LYKB+O;(H"U1P/LV?.?<%>7$U6,^HY3YT
M,&^6Y8. ;:,=G9OG;<FX@0X-+G2XP6C1E"TK5@R7+URYF$-OC@OZ<U^^B/E2
M;EPX<*'&D2\[OFS\LGXPE_]%=^X+0#1BT*<W7T9T/G?ZQ.UWSX]_?_W^]_WK
M!R!__Q$88($#&I@@@@BJU847#GKAQ3L/4MA%%U?H<$4.6\W0X0,S/"## RP\
M@$")"9B( (HGIK@0BR^JF.**,<(XHXTRXEACCC3R>&.)/_((Y(Q $IEBD4<:
MF2222RK9))-/*IG D5*:2.4#5F+Y8Y95_OB EEU^::*77(KYI91>2IFFEU?V
M9I 75ZZIIIQPSHDFG7'>::>:>L+)YYEW_EDGGG^N6:BAAR*:J**%$KJHHX]"
MBFBC=E+:IZ6!XEDIHY)R&JFGGX(:JJBCDKHHB(>>ZB4$7J;ZP*H?%OKJ#*^Z
MRBK_K;+>NF:N'^XZJZZV_LIKL+ZJ"FRQPJZ*:ZW)^IJLJ\TN"RVSSDZ[[+/4
M7FLM!-)F2RVWV(*KK;CADKLL!.">JVVZU*[;;K+NNGKNK.[.^^ZVY]I;;[SW
MTHOOOOKB"["\_@9,\,#](IROP?PJG/"_"PO,\,,.%TSQP0UC/''&^"*22,<?
M/]+Q@@*2?&#)"IX\LLDKO^0//)HM%7-3,GM%\U@.I-.FRBBOW(\RH/2B2="9
M" T*T;V 0@P_.S.=LM,L-PVU@%5Y'++'5R-B]<=5;PURUUQC?74BM#V='S]K
M<6:SVC.SO5 Y@A 4-<_="4).VVG?O79-+"Q=MMQ>5%!J_ZDZD"VUX7/+'9A5
M^;223R*"D*%#X(5._D#EE0N>N>9>ZA#U(Y9O'JH7A2/N-P""6! ZJ#,\$K?I
MA^_<3R(YJ!ZI!53Q]V;MCN: 2-QDNQY8\'4-7]OO*AU?%&1%W19W(KKOGJ@%
MHB&>2/2+ZN 8[*^7OKWWW8.?N'\^"VV*^-^?'S[W@;VL-V<(S&!>^KR55I'[
M".2#/B(UMSW#;"R7YB/N&V#>[@8_0:C/<#,IX$1RLI/UK6^!!.0?!?&&  >H
M8Q;S (G-$"":D2'$;A6<(-[H4AN\Z(6$Z_@-;W93D'[ C(&-82$-?6/#Y>&%
M'C(@(0E#<Z!9M ,L(V2@!8NX-O^=S ^"Z%-B@J*Q#&(4PQ>_2$]SJIB>*3)G
M/,9Y('^^0Q[P; <ER[ .%:F8'=<M,8T)7&,2U=A&-C+QC5&;A2 H!(\(20B/
M#K*0AK;"(0^!B$2"U%&)7-2C'?GHD(14)".'M",A.2F24)JD)"M)R4M:,DI3
M"A.<R+0F3XZIDZ+<TB@YF24U<6E.4JK'4+R@2D!=*D^QK!2F:)FI6>)R4I;:
MU/5ZZ<M.&:J6P03F+XM9NU:M"9FL0I0R884J9D)S6+%:IK%:I:QC$:M6PCJ6
M-K-YS6Y>DUCB#"<YJUE.9(TS6^BLUKVZU:QWLA.>[HPG/;7UK6^-*Y_EVN>X
MUG4M?TK_;%H68UB]"EHQ@A[4H!=3*$(7FM"'.C2B#9TH0RL*48I>U*(2U2A&
M-YK1@V;M:R*+(TG=6%(X$F@6+SN-:UH*%['DS*12BX8IA@&TFR)M:$F+!AI1
MZE,YGE2.5$L$UK165)$:U6MA"ZG82)>^L[$%-BQ]J6(XTPZ=!94E&J1J9[B:
MFK>P !'\R"IQO) Z8QZ*<$"5:7=F<0\R-!.M<LU<YY[VN;D6R@*M^"G)H(=7
M'2"0K6MU$UX?<#NG#F46.B@L8QN;N1Q@]3[6FZL.\A%9O@J6K)C=K,K(EPGS
M:7:PHIW:.V;PU:; 3WYQG$7]I/J^_+%Q?UVM*D7\=UG\] ,1_^9XS51IZU6&
ML* +^N"L?Q;8VX4X<+2'TP?:7.K;YVXF-&-E'V_?]\$:XK N:I'!;X\+$1-6
M)B^S'>]?)!->\PH$,=#M2V/.2QGTOC>^EIF%.W;8W>HNQ8>ZV2]!\H&VXYX6
MP!7I CVR>T(#ZRS!+KSA@1L<6J?%S8E1M"*%IU/&YA"#&.$92C_& T8P^F.,
M5H1/>C:<V1,3%\7*33&+5SP@?5S!CF2(T!XK=*$-=2C'(!(1B9*4R!\C,LB+
M!/*0A=S()CD21IA<<B:9[&0G6<E(I)RR*3D92BM=&4RI_*0LZ^0%HM2CR[!\
M):;V!$L_#2J69A:4H/CDV%N^.5&Z%/\FG6\I3%X.\U"ZC#.?^]Q,:U(3F]-T
M)C9[M2MM@G-8AE8THPO-:&<A*]'> M<]*6UI>UYZTIC>-#\[K<]/LPM=HE:7
MO?9E:HBA>J 16W6J-W8QC<'ZH+%^M:QK3>M;!Q37K%9UJV>=ZU\C=:0J?O"P
MB]T=E\5PB,HV(D/*<=N@GH(80--$)HPV;:01HQ71(':+N>UBV_ #;%U+JKB/
MNE1R=VQL;X0JLY=-0G<\&\7Y: T1>3B2+L"VVRX!7&/5ZNVGT5$'<>TSP155
M5\-]#G-HG4$BIOMOO\Z5#.8Q=A(A;LS#XG9V!=\XP1G>T_U,5J[9B[>^2_YM
MBI>,?+T +<K_6][M?"!"'C&?N<SG07.:)^+C$,RMS'L^<YO[O.8DWP\=!0'T
MFQ_=Y]J#(T+HH17N@J2"47=;%P2!B*6?O#O\H,?-@][UJ2#6Y42'^3RZ /6I
MHQU^[D#$/;":#T%8O>>"\+H\AOM3MR+"YO#H0CIFL)JT#QC!^/@ZW1$!=WQ@
MM\%MXCGANV[T5DP<P0N6/']_HX^\Q]P+5[A".1QP%, ?X+J'DYW3U2'$J7=P
MZC&VN=U-_F^QOZX?QAD/,:8XQ0KCGCG9@:*&PZ,,)XK'PKF7C^MA;_SB(S_K
MW_8'A2 '#S+4N,9]S(&..R0B'H\(DC R))&/7.3O,U+[/FXR^9]L__[RHW^3
MF@2EE=OO22J_O\I;/N68Z_]*-.,_EW;>ORW[CTL\ R#'$=R<P5D!:HH .M:?
M19.A*. S.2 ##AJ@$9HX1>"B.1HW?5,&FM,&;E,Z=> Y>6 (5LLZ 4L[F: \
MG6 ]I> \L:"FN6"T>%H,@AJH 13 _-.D\9I'Z6!'\2!'^>!'[> /!B$0]B 1
M"F$1#N'%,-77*-_K)5])J52RC5> X9=8L,#0Q9XRF,(GX%07$L,I;%L3'I\8
MWAU1C5NPG1L:GF%3K1O:4*%S36%3P-OQS=MZN18<@A6^.:%9]5O8/:%9(,)B
M(> @.LK!=<]=%1;KZ-RP61Q:29P3BD\C_O\2QG$'/Y !(6*B7#&<:AU(R*%5
M96'A&$+B*,J49['<'Z(B&:HB*:8B*ZZB*-Y'*%8>@RG8+%)>"]FBXL'7?.VB
M>_&B?/EB,/;B, (C,?[B,29>+>+B,B;CY.EB+BIC,T*C,T8C+++8=Q1#AI%1
MA9&8%55'>L"'+Y2'*Y*C-;YB*YHC'5F(%T .A%3(@VQ(/%9?B&1?CXE?]^&C
MD>4C^'6?^/EC^@'D^0DDE*D?D<!?*;%?0HI2EI7)EF59F:E91$(DF8G9FE6D
M1*;91&8D,3G6GO49 ?I?G?E? !Y@26;B26Y. PJ:-+'D!2::2QZ:!F[32]*D
M3')+I"G+"[(3#'+_&D_J9+?X9%#NY%#.H P:Y:F9RZB%VJG!2Z_9VJ_MFJM!
MI5/J&E5.90Y*953ZFE8^)5=6I;N@X3F*93D:"+*Y6[W=36@,UUKU@[15&]*\
MI;5MFSF2Y5C^D!FB6UZJH;E]C;HQ$;O9VUEZQ1RB8AVVVV%.D!ZZ'+\QEK^E
M(R*@9&0:BB&J3,(E(O \7&,](EV:C"3ZDE[Y84Q8HF229NAL8O7\%=;5Y6IR
M9@*IW"G:)3K*9FS2)FO.IFW69FL2'37R9BZNEC,F5F\RHV[B9G$2YQ*%&'9<
M6'3X D\9YVT>)W1*Y_S,P@Q$!3OJD8U-GX;,(_;9HSZ")S^&9_@]4GD._^1Y
M!F1Z"F24R1^789G[(61\4ADJV5]]4B2;B5E(\I_^Z6=_YEEI\AE([I(!#BB
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M_Z^/EN^.FF_ZHN_ZXBB0;LWA%FX:%6D5GBG]SM8,C!7+T)2TN>Q-?=9<QF\
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M Z6_&7;OQR46EA>LI6W*#B(8WN-,O=4) M5?O=5C_=9K?==/_=-#377C%1F
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M^T71B5JTHAB]Z+P,5J^$80MC$WO81RGF48F)U*0H31C'+':RD;7TI3V36="
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M*77$@WJ^.933*8SF29[G.9[J>7==AYX,01?WX':&N1,ZP$CNN9[I69[WJ9\
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MQQ[76$.0T4>.E;QD(+G1+T2&8AJQ=,8UR7'*5?+27I+<1SX6LH]?]G*8$?D
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M?TFS2J&T61JK!^A++JK#>[$T0 E-P+B'.SN:/J073OE-3$$_9-$'3^S$\X0
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M/N>3OD_5(.O[M'R(CGD82[%$U5-%(15J(?-+2[=\@.RL(?B;OUJM#>\\0/A
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M /@ BS/6^!^-+CX 8UN(K/@CC5YLER*013[0TBPKTFBD/C MJ2*4--;SDHQ
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M1>#73)4^((([A)@%YLU!24MWJ-R*K=/B7,% @,X]-%B%?4TP$2!;9,Z1N>
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M_B5BSB*4NJ*4QF*44FDA>1N6YF(EZ6(Q!B,R>JDQABF8CFF7EBDQ*J,MU5*
M JA_KJF;MBF<?F><LJF<UBF=(EP_Y,,\0- ^S>/$49Q5S4,_7%,K_-- &13/
M%9P@'*K9E,-/C,PLW(,7K),"]JG7.( ,7($[F!CKM ([RJ-.J$//351#A"-
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MPTUW'=+15;=TTO],*PWUT]\]YQW53+?'7M98;ZUUU]YYT2)"_=03WGS8#8@
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MZ[9G>[[F&[CIR[[KZ[[H^[[J"[_SFY$#:[#W6[#Y:[]N2H?XVR_Y2IW_*L
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MW>,(DIC,+I"KRRPFS?3#<SG(SUQ($&4?^6O(TRQ1U+P[U:S(U[3( &S-_1G
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MK7WJ+>'F[>&&U; &*[$R[N(Z[K/)[=I*+G22P:%0JX+6Y 5FX+9VZZ=XZZB
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M%KN#'S)411'T1,_1'%]T0%TT1F%T*_(A'5941'.41+.D'6Z$'[I@1W441UD
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MA%&5A -R]U:U55'X(!DE5A/%"R;3-&IU+R+2A?N"UJ:C(VM-URHK<7\#^Q[
M)#43)5_269?E5()8+(C-'99W+Y8H(]<O*WL%AA=#*I_E6QUV8NL"_YKM6WOR
M*E62VA3SBJYM6/J"A<Q%7LGU8=./8B#R7!036;H8C^087+H#8=OH_B20..[X
M4Q2V+P6I7$366S@6DZ98!C/6CTZ6,P]VD4X26SS6'VK361196E*6C\18DC/Y
M-C79-CL9-SGYD[%%_S<U9FEYDPMWECJUL+VJUI17V6G-D Q-.6J)4PVI5KV4
MUI61-CBQ=FI9V96OUC>1T^1D"2-4)N3L$)D'K)I>HN=N L(H3&L*,9W4ML/8
MUND8<6VK69L556ZYN6[SUIOI5ISO=F[G4X%'-WEY; 8&E9WW%(D[(Q_V-$%G
MH N*Y H$59X%X3/.5Y[[^4'9=SHH-$X)%73/V:!/%YT3^J!CC 4(>J#;^4$%
M84<@&@%88 :N0!#6808:FJ(Y5#/PUZ%#NIU[E#.$]Z'].4>I=*$5^IK).9SM
MUH#'%'H!>*9E>H!;RAE/6J=%.DL0H3T6#Q$H&@%F8!TR>J-Y.DMFT'NR0O\&
M=IJBH_0=V.=]*5H=O*!G\Z$5\ $1YB%_'(!$H_IY;[J<P1EN7;JLR3H^TQE&
M$Z%'!NU2M4J"$\VKF"1*&LU38X^#9T^O136$2_A43=BO.TB%[^K47M6P":6%
M#>4N%X56$<56&\6G9]CX='6&?!6117)5Y)B(-CLD =,&+\M9APU:B_@!CNM7
MJI57GCB+Y%5;GZU3O,!B'3/_ 'F2P;A<:;N2;?N2:_+=V$@Q77!<X'4PV=A@
MLQ)>X'B-[0*-^W5;E&QA'X9.,<-?8>@L&3E<_+BZ+S.0'7E?U&V38GLJ^L5<
M-1:2*%F2\ )D/T60#5-D858(ZX((=5M<,-EE;9;_9N_;OO.;96=VCZ %9SL&
ME2LNX[[PEDNYK0;<:E4Y#+&SY'[)OL;P(Z;3EE.9P*^3O5A9XGJ6'NIA"R?<
MP\50(1Z\F6 9:/HKYI)I/*6I:<#IF<5I:R[LZ)9NFS-QQK/YI='ZF\=:QV]\
MQ\^ZQ[O9QQ%ZI8?\;?)4065 'DY#'N!W?PNW7GF2R=,7>3NCH9M\>+\&,Y9<
M<%E HDOC?2TW1*\ .YJZ=^O!R'>7B8E<K=><I=E<S7&#G[-$!J;\H_77>Y-<
M,^*9?Y,:-?PAR@U7,\!/1)&\->:!=8<7H"_#I.%73=O<T6T1"2%]76JZ@"G=
M?>K7>O]7T[?W>CM]T\D7_WS,P7O+(;*;<7H$'<QSE!Y _76^W'/S@=7C(Y[5
MUP&<YT!G5P;F@1=EU\I[7:+;S M2W1MF0"JRL1J-O7J//=,K7:R;/:R?/40>
MG6\184C>X8'?^AU5[PH6[8)=[X,UF-*Z)-PUN(/WD50!&]W_6MU'V-3:O=3>
M_; 36['RPOD*A3#;0H9-VU &ME!8,_@2%R01J[,3(++Q K,'/B7;0@,)HUAA
MLC(<,HAZ6"I))5N/[5L!P(FOE=E8&U?8KXK?C[LQY8JCI2Z9;9*6S9*1")./
M+2QOA8I-R2SCE;@;9HK)\EV0>[J=M6,5<RIL7KT!^5Z44H_AHKJX:%P4DX\3
M'O\QLULO!HE<VGM;3MZ3#+F2QAN5S!LPT;N1[_)9S!4 )EXVL9XKY1M9Z-N3
M01GM-UGMSW[M0YE91CD1YJ$>YH$>2F'NYS[#*Z["5[G .>Z7%ZYH=WDDV.OB
MX 3OY1[C\'[# WP+^UX,KS8+"W_QN[#Q&4[Q(S\Z3P+D:&EKMU/F&&P/5;SF
MI*:9@T["*$R:,TS&;?QN:[R:O\[U<7R<9=^L@=SV<YS'<]_-A9SWD8QSG3H'
M4E.G$WTSIAI'F_1M6H&BR2$YE!]'M0)(I33->U_:=]_ZJQ_[+T<0*'H=.N/W
M"9JD"_U,J;1NZ@&I9Z"D";K1WYS]'77V?SR?8IK9H9W_IIU=@.D_I:"Q?4V]
M&:-_I]\!(&;Y ^!/(,&#[Q H]*80 <.%"-X1-%AP8,6# ]TU?.AP(P(6$P%@
M##FRH$B+)%$6E-<1HLN6753..HEQUDN.#Q&9+#F3)TV+/67^3%ESZ$ZA/I,B
M75I4:5.5(DM&A6ITZLBJ6*5FI:JU*]>O5[U:I4GV8-F!9\>:78N6K=JV<-_*
M34O7;=VX=^>R)=/%RSLO?;T 'MRERY4<AV<H5OQ ,8L'#AX\1B#Y04/+"A-<
MWJP0,V7.GSMOUNS9,NG1GT^K3LW:=&L$JUW+AOTZ-NW9EG&_SGW[LV[>P'T+
M#TY\N''B]=2Z"ZY3+]ZUQ^/J_[-+G5]QRUZ>:[=:+W>"W,GC>O%._#ME\P_2
M(_"2MVYW]-/CWB-/.?Y8+^<M.W<^"_WW[_=0MQU9#_Q78(%NZ7.@@?^QQU8B
M!C[07'MF>?%=>M^Q)]^!&*;W #_[T66AAQ<6F,A9XW&H(HAEE>@BB3!ZF)Y!
M%(JGHHP/. C7+#CVZ"..(;J5HH<LKO7C T&%2.-!"OY8Y(!V]1AD6];U""64
MW?687%E#]JBA5?,=J5:5/E+8Y8=N=2AC@#:6*&,"29[DHX-K98EC F,M>26/
M*K[8HYMQ$A1C>B>RE:*;1*J%J)IW^KCHC8.^Z>BD?U+::*687JJII(SZV>>@
MCX;J(?\BCR"2B*FH)C)//:NV2D\IK+)Z#SVRTC/KK?/@.FNMM]I*#R+US(I/
ML+_ZBHBO^!B+++'#"NOKKKG:&FVMU+9:+;38&DOLL;,"VZVVW_9Z3[3?\EJL
MN;UZ^^NV]0SK;KOMTN.NO/#F4^^][PZ;SSWV[MOO/?KR6\^^ >^K#SX&(WS/
MP0GKL[#"^D 3,3_Y4-R//A=GK(\__' \2S\ @#R0R"%+!19*54$5E\HFM\SR
MRVZA+);,)\=L\\HW6T5S6#7C[+/..6_%\] [%QWTS$?W#/3/0AO-M%@U3BEU
MU%0+.+7555]YM=99;^UUUV!C#< ]'BET0-D('(!(7?PT=/;_2V?+('9<&KW=
M4MH-7?$UUOW8S9'?#4F4M2!FHWW #&1U 7CA"P7*]=Q[/RYYY)2'/;GEE4..
M^>::=WZYYYE_+GKHI',^>GN"_&UX0_G,U<KB>"^$N.==P%UV3*4?A,_=L+\]
MH=7T\.Z1.Z";GOOIQ2>_YUF.)PF44<X3];Q3TS-5_5/87Z^]]"E1%)3W)X$_
M4?7B7W14^>B3KW[WZY_?_O?OAQ__^.S7[[[]\.,O/_Y ^>-%[VCCA_>>APC5
MP:T+^S-?^6; ..&M1X$)S-_]SC>/V#FP)3J18$_(UL"_S0Z"])N@!B-(PA".
MT(0E!*$*TZ<_%+K0>MP[2O9B&#T9_V[/AC2$G@ZII[SC^=!X0!1;/P;C!;[X
MA3" ,8P.#G.%Q2SF 3*HS&LRTQ#-4%$T5PP-;;!(F].(QHNU">-L;$-&,?:F
MC&,T(QK/J$;CG(8W;]S-<>9X'3H>IQZSL \ $+$<.]:Q.%[ (TWT@0@_TK$>
M_7B22/I1#R_T\3KH\4TDZ7.@_%BRD@?"HQXGTLCE^(>2ZL%D*-$SRMRH9TR5
M3(0>9V&G_)3(E>E!A !ITD@&P2A""_H4+FW9(5OZ\@&:- LK$S$>7N;R1;O,
M)88$(TNKZ(.5M]2E-)$YS6A2\YJ-<H<7[J&G/":"4YLZDCC'2<YRFI.<W*02
M,<<I*B\E0O^1 )@%/]99SFTN28#W^.8YO:!*8=KIG  -J$#GE,ZHX'.@C *G
M0B/%T(0V%%+IX><J_PFJBG;*HI^ZJ$8SRE%/>12C']UH2#L*TI**U*0DS=1"
M'<I2"9WJI:0RE;5F6@]:3>NFV>(53I7EK'"1JU@]I5=0FR6O90656\_RU;5H
MFJM6I8NGSYH'4KFUTVO9-%WLZE96Z96L=]E+7_&:UU<'!B^O FQ@9R486?_%
M5K3:RV$&D]C"Y!HQA]5UKA.#!C^@<;&]:HQC%^.8QT!&LL(2S65+0ZS24J;8
MQL+,:8EM6M(.^[3%(JVRE(WL935KV<YF5K*8A2QH.3NT("+OM#__[*%I4XO:
MU;H6 #A!&T?FH9=TR-8C\@"=/^X6V\:YU@&]Y:U"LC.U*P3W(8+ 2Q>.NQ''
ML?:YKVVM:J<KW>I"E[K7M6YTL\O=[49-'\*]B4)^AY<9,'<A:_.<3<)[-Y"M
M5KSB%03D@L=<XFD7N][%KWXG)]K-CO:__@VP9V]8PP+O$(8X3+"!>:C@ \^P
MP0Q>\%(&:,+^5?C"YJN)RBA2$[*=MR6MD(E*9/!A;VPLA ].!'SO!F$$%WC%
ML:4'#V&'D_*U0AY>6$<7TC&#*W3!'8*@AX0?/&0".]C($3YR#@7\62;W=\"3
M?7)I]]M=*N<72OHHC!?@043!$$:)3'1B_V-F\)C(3.8CI:DB:-+,139K<39?
M?#,;TTCG.=MYC7AN8W#B^)O>_-&0?PXTH <MZ$(3^M"&+O0D+RE)2GZ2,J6$
M-"@G?<E'8]+2YD$EILEC(%A^\I>@/J:H0TUJ4?>RFJ<>J:I1NNJ3NCJEL/;4
M2B%*ZT<A]-:XSK6N=\WK7OOZU\ .:#O#V=)AS]K8#T7VJUL=:U8[>]G/;C:T
M-WIL2U5;I<D>5:E@^M*9CBM65PVW5:TJKI_J"EQ"37>RPE5483%KJU,EUCWD
M+>ZFU@-63@UWN;,UKIS>]%C5 OA/!2XNJ*IK7D1-.+[("M9\<;6L#'>KQ/WE
MUH<EK&%XQ:M>*__&5WWX%6,;X\?%Y.FQD7VL9(]UK,I3SO*5NUQI+ ,PE$,;
MY9K3_.:DE;+.;9YSGLN\R?<->I6%?N6A&]UX,K"@ 3NB-R@U1.EN0\ FN28#
M *+7M R$>@<_."4'V,ZW=E'<ZL!.="N;O>QH/_K9U9[VHKM][6]ONX"\?L&_
M(=!JN[6Z0YR;%Q;4O2'XR%TYQGXW<TB-OE'_^M\;J Z^P_WQ<M=.\YBGY!83
MN?)%7K*+,9]"%HJP\_-;8>@]?T+1M]#TGW\AA15H8=9C>/6P;[U!P-O!Q#L$
M=ZXO2#X6KY#8J[[V#7SFZ.?G=^!;,!VD!X 7ELY\VS>_@>0(\>F3K_K_X4_?
M^JE7X>63S/W-=W_[WF=*W-E.?O< A@SP,.)?^L)^PR#&B3.0 6.B^)C)@-&*
M6\P__O'O&?ZKF8N: 49PIF=W1H!Y5F<'6( (*$=]QF=^QH"(%H&))H$4.($6
MV&C#L6B7YF@<6&D=N(&2=DF1YB$(H&FF1&G*Q&DDF(+&U((L^(+)%(.C-H.E
MADVI9DTX>(,Z:&H\Z((R:(,\>&J2HFRT%FQ&>(3%9FU(N(1,V(1.>"1$&(5*
MF(381H7$5FM3B(69PFRREFU5J(57*(5?*(9AZ".I@BK;5E7VIH;?QH;2<F[]
M!E7KIFY&U6[J%E;, E7\%E7^UH9^J&]*Y8;C_[93[/94Y#9P<OAN754O:86'
MR7)PCCAQC1@P!;,P_&*)%Y=Q>S4Q'/=7( =8 M0/_M /)V=8(W,0IOARJMAR
MK.ARC-5R/[=S.!>+/N=DM3AS/3>+MJB+GC5^O@AYY0>,O]A:!71;+Y%;[3$+
M)88 .],>YF6,#J$CE+-[R_A 4N-AMP42 [)<T.@-CA=YP0B.PQB.Y#B.YBB,
MZ"B.V,42U4A><H&-*P827>-W'T9;IJ-B[!5;\  ZB =CW=B-TGB.ZCB00%>0
MLIB+"$F+/I-YEH=DX0=^$.F0$:EY$]F0%"E[K:=A/($2"5&-^9!A&5E!'Z:-
M*$9@_J@0@O1]U5-(^?_H$;35D-QXDBTIDQR16Q)YDQ>9DQ:YDS64D+OHD[BH
MD*0ED.68CFHA"(*!?H/Q%X+1?F'61(HA?S-0&?6'&6>F1?Z716ZVE:B19@*H
M@&"9@&)I@!#H@&99@6AY@6J9EFRYEF[):)2$@2 H2BA(2G7Y@9OF@7HYE[;D
M:2I8@S08F(#Y2SOH@])VF%P8;8DY;8=Y;5?XA) 9F9(YF919F;A&AHZ9F5Y8
MAF.8A9BYF9IIA:$)AJ/YF2U%3C'%;3)5<(,8*]Y6;WV85'$8A^:"5'.8<'HH
MF^1"B($8F]12"G\XB+ZIA@ GFTE%;L:I5>ZVB,N)5@T'+^ZFG$#U<&/U5=3_
MR8AO=8EP97%XA0\4$S']T(D@]U<=$XJC6(JH:!"I2#*MB!+LN8KPV9[Q"90&
M>8OUR8OW29\'*93\^9/]29!$&:!&*:#213B*]S<!R3?/AS<@<CDSH'?>D%ZG
M@P@0VA#K<#4:87SJ$")B=Z#?6)0 .J B&J(D"J(F2J GJCDQJ746A(R0LWL0
MZC7TZ'R 1SGL2*.,0UQADP_'@@CY<'+/$9Z"\*"$9T R4*(HFC63QQ8,V:2<
MIY(ZZ:1*07VH5WI4>J789Z59"GK7UZ79AZ77UZ&\)V01)'O]R*(LX'LK9'QV
M(WQ>^CT)4:$(D%Q:&A+/R*8-80[-,4&(,*-X*GM<__JE6UI];QJH4OJ0.,F3
M3XJH%!DUS3BB*7HYLZ!-@D &E=H7ZT<82Y0#\!=_4$254G1__Z=_H]I_H)&5
M721G7SF6"]BJ84F6KLJJ#]B ;M26MOJ6N'JK?J2!O%H>>/FK>YF7*VB7(GB7
M(4B7L%1*KP2#J-:#S J$@RF8SOJ#.3BMS6J8T/JLU8JMC8(HN#1KEAFNY62:
MXEJNYGJNG)FNI>F9[-J9[JJNH!FOHBFOI/E01GB&IY*&<"B(KWF(3\5NW *<
M/%4*<QBP^WJP;PB;@$A5YR:<">NPY>*&LXF(O8*<!2>="!>)U0EQT4F'S4EQ
MUNE5V(F)W%E7$G.R%/-Q_?_0<8$%<A\S6"&CGJ@XLZ=8LRAWL^XI%>\IGSP[
MGRGWG_D)M/OIGT0;E$4;M$<[M$@*J4G*M$[[./J0=#/9$6QR-<77DE5+-236
MC1]:%X-'DQ(J-3<J7N'!H276M4\;J6K;M$O;MFN;MFP[-?IPM2/)(OPUM=[0
M"ETCD^X%.OVPM3(9(.=(>WB+MFX;MWFAM$AKM(Q[GX=:D8^;J)$;I8L*N95[
M0_I9C#*9IIB'$M3(M1EIDE.KJ >1#\#UCPJ!#Y&[HL>5"#C9#O^HC9-+NHQ*
MNQ6Y- RIG_:IN(J;%E*&N' +.05Q!5Y0J>F'J4C4!9O:J5%$?Z"Z9J4:O6T&
MO=/_&V=>J:JP^JJQFKUK!$>UNF>ZFJOB&[[D.[YQ>;[!:JS#>H+%VKY\":SO
MF[Y^.;_2&JWV6[_;^H*,N9B(J9C^N[_T2H3H.L $7, &?,"_1JX*W*[P.J\.
M7*\/3*[HFIKXNIO#B2U.E6_HDK#B(K#A4@I392L>;,$/2\(3B\$6J[ .N\+\
M2G#)>9S_!HAP>(<=*[(.E[',F50VS'#4F58"LYUVI8DH*YXK2YX>4YZEB)XV
M6U@R:W)+W,0WN[,X2[,C(<52W+/R^8KP*;2[V\7XR;M>K+M?',; >[C!:\8#
MF74+>C;VM3?K@*-XTW12 Z.$MZ%5\\8'ZC9W)SKKM<9%_PK'$&JX;XO&@US(
M96S(9XS(4/*U+.HW\J5:1'J@"7HE+/E\.JJB?JP0%XJB5]#(&_'(A%S&2[HC
METNY4&J[DEO*M NFJ%RHA"JHKEREBTJE$=D/= O(8>N0X'.GC9Q<KU<]!FIU
M=#I\D<Q[[E"GG[=\@ S*5"JU5B<0K(S,TFRHU/S*!0:HUIQ"EGO*LSN[]'G(
M CD3K4"\QNMEF>J4G I_SEN55VFJ6;1_TIM_[HR5O6&]7:F]^"RK^LR]!.B]
MX/O/PN& YEN^!#W0?]2K&0B_PKK0\#N"#JV^#YVL*JBL^4NMA:FM-WB_V6K1
MUKK1UXK1'5W1S2J$T?2N"(RN$O]\TBJ]TBS-P.MJT@'LTO;:TKJ&KZEIPH2(
MTWMX*Q[<;@2++"(,ASU]FT!]5$'-P12KTSREU">LFPCKKQS,AR]\L<_R;AB[
M<-4YB3R,PUQ%#QO;<#U<,/4 Q!+CG2BK5QWW<7L%6"$W6# ;BB5#6#(KUZ=(
MUU%,Q>M)Q3D+%7F-Q9L5<_/)Q6,\V&)<V()MV$EKG^"<R(L=RG.#'WB+  @D
M76USDA\I-7[*7H_#$C29 Z;3QZ@;V33YR8VMR*9=VJC-V*KMV,^!QW@[R5_3
M"LLX=<X1NYJ3.J%MQZL- )U<8H7"VJ=-QHE-V(==W,-=V'Z=Q<=MW%!F6V K
MM)K;DJ'_:S.$RUSE$&6L"XWM@-@H06,;<:0O1W?,);O0LV$;UKD;R<VJW)/K
MK<K<O;CP#<; 3: "@0CDC'[JIZE=@!CI[$3-"ZKM?*H"7KUR1N#7>^#WO,_;
MN^#Y_+T![> &7= 2'N$4#F@(#1P,?:S$BJP<GN'Q^^$>WI>BYI<:C;\E?M')
M!, JWK\KSK_\^]*/2=,R/N,T7N,V?N,XWFL4S&WXML+ F<'WYIJ[(K!0?0\]
M;9MUJ' ?ZXA>S>1*[K% 96Y(S6\Y3=47K,*\"8F/:-5WF,-<;5:4Z)R2*-8@
MJYV7Z"^86'$,DW$FF[(;I[(A%UA(+(KF6>=)+-=X'K-V35@Q_VMR>ZZ>4+R>
M@8[74)S<.0/8,+?<BMZX\OW>C<[<\)W:\[W;;%O)@(P <A-TZZ5W+@HENX.G
M)%D7NY?'9N, J]61ET[JGJQXNCWIKA[<KR[IL#[KKU5!>"H[K_7IB^>.=$&A
M1<IUO9[)"$ .@TQW>D<\LLZVAMO-[:W>SEZ[S/[LVPSMS4[MTHZ3":'J![#'
MT]X4MK[J'[EZ18';;.K9U./KJFX.T8X4NO[,(I;>5PM &/G+L:RFTYS-^)Y[
MT5S-UM[OW9[*4$/I9RP07G#?7-:47\9$_3U_SYL  ?[.HPK/$ ^  T[/JXJ]
M#*[@#9[Q_%QG_OS@ %WA(C_A)(_AOO^:T/(+X@K-OAW.\AO^\BX?\\N*2Q+-
MK2C^T=1ZXB%]\Q[=\R+M\SQ?K20]]/2:XY*9TD:?]$J_]$Q?KC:];3W>XVOH
MAT#.KP@[+DA>PWBH]4-5U%W>U1EKU$8NU!?+U.L"L"6\TU.>B(OHY4Z^]5^?
MU6%^FV\?YF1M5W0%,71UUIRX5VZ>,=#@#Y^(Q'/NUG -(B!S^'&-GGS>^'&M
MYY!/BGGN^'7=YU$\Z#9KZ#^#Z/$MW(SN^9U/W(L>^M\L\+%N^N2X.]78!3K6
M#E[@^G_Q#H( #[-?^[1_^[8?9%C#R^?%ZP1AH"46MLPSVC[6^H[D%[F/^\IO
M^WOZ0]E]$X+_G.RH+_VG7_VT/OW*8^G^6/S'KTVRO_S@S_Q]%]DR]AS9/K6!
M)^JA[0V&P?K=C_SA'_XR5A>W+-GICS7^  _B;=O63_W[\>@  <"?0(( " X<
M:!!AP8,,%R9L"/&AP8@4)RILB'&A1H<9*W*4Z/'B1Y(C38I$N;%DRHXJ3[ID
M&1(F0D$($'BS>3,G3IO>'%SILJY+NR[NO+P3!"_I4J5-F29%-%/@+!8Z>^[<
MZ>#>QUGEL%X%BT ?RWM?K9Y%T 7H.B]&C2)U&O>I4GHQ 83E>=9;EXD+\YG-
MFW?=P5E]"T<\_' 6R,6(#1MF'!FQ9,6,(4_&7#FS79 6.:^4*K/E_VC1I3W#
MQ)BZH^J0K#V[AKU:=NO9KVLK+.SEBA=!9.!Y =[%B_ N:G-<R3%#N?(',AZP
M>!X=>LX'U',FL&X3N\WJVK,CZ [^>_CJV,DC,&\]_7KQ[,NWA_]>/OKX].>[
MMY\??_7Y_//[3P] \?PC<$ #"T3P0 439'!!!QN$\$$)(Z1P0@L?2 #!# _<
MD, ./^2OPP="Y&]$\$0D$3P3,4R1Q1-;!/%%&5VD$<0,;:R111QOU+%''G_T
M,4@@AQ1RQ"!'!!))(S-4LDD6G63R22FCI'))*Z&\<LHLJ\2R2RV]C-)(*<4,
M,TLRQ40S33779+---]^$,TXYYZ2S3COOQ/\S3SWWY+-//_\$-%!!!R7T340>
M02211!=-I)1ZYGDT4DCGH4>>1^EQ=%))-X6TE'LFO8>>1T,=5=1Y2#W5U% _
M7=53>D+%IQY89:4G5EA?K?754O#!E==;?\T56%_I0:177(M=%5=45TVUU% 1
MH7589%-E555E7Z7V6F2)/?;8:.N)-=QZ\@%WW'MBS>=<<]%5-UUVT06WUG+)
MY=56;F=E-UU][M$7'WVAT0<:?O()>&!^H.DGGX,37EB??O3QAQ]_():XXHAG
MZ>?BC/G!6&, .-X8XX]%Y@> ?DQ&N>23^^D89(U?=AEDDT5F>66:;Q[HY)P)
MTKFAGA?ZN:*^A";_[;2B.T,:M*.5-BWIEY9^NFFFC98Z:JJO=OJSDV*CK6O;
MO.;Z:['#)OLVL\$^>^RTRT:[;;7=#MNF \R:.ZRZS[H[K[QSNAN>M[NPFV[!
M P=+XK=ED'MPO!77>W"^WH8<-B_V3KRGQN!>.W/,-X]<\\XY9_MST4,GW?/2
M03<]==17'UWUUED__779R^:'<;YMKWQQL*)2VYS;"=<]>+T=Z#FVG(3_'?G<
M&[_*'=DH1P!ZZ7%'0)#978\]>^RWASUMA"XGC++P-_M>_/+)G\K\]-'W!_SS
M-8-__/C?E[]^^N]??_[\[=\?__;5_Q_[W+<^?"2/><J+'O7JE@_]D4.!_P_L
MR0S\MYA9'-""!L3@\FYGO?GUHRK NZ &-;B5]GW/A%,Y80E1N$(5MC Q+TSA
MY5Z(F_?!D(4RK&$,=9B_&=Z0ACR<(  '&$#]$9%_1@SBU+*FO>XU\7JKP]AQ
M>..;X521.,?!XG*8XQSH3,<!T^'.=<3H'3+2IXS;$4\9PX/&->8GC.EY8WWP
M,T<YUO$^=M0/'NEX1S[FL4 !JH^ _G@A0E;(D(5$Y"$5F<@.#:B1+7(DC"0Y
MHQCEB)(E:M&*4#0C36*2DR2*THM"V:-.5HE'2CKED529I%46B4A$0J664LE*
M6I*RE;.T92UQN4M9]M*4OD13*F.9IC(5RIC'M/]3,<=D)F0VTYG/A&8TI3E-
M:DZ348M"5").I2EN8BI2F:H'.+<93DDMRUJC I6JTHE.=E*+6JX25J^B)<]X
M"NM;L[(GL%J5K%8-RU[2PE:RM@70:CV+GO+"E[SJ-2^&OLM<Y-H71/EUCX@^
M=%T6==>XXA4NA3Z4HOC85\ *!C"!$:RD"U,8PAQ&L8E%[&(5:UE,81JRF7I,
M9BK[6,I2%M.0]11F)./IR$XFLYJA;&='-6I2>[94GA%M:*'!FA*E:K6L0;6J
M4--:5JTZ5:UB=:M4Y=X3Q<K$L8:5K&<UJ^>J$AC M!4O;CV+/#J'CQF\U:YZ
M^0KOV%97O-Z5K7YUZ^/_T-J:+OQ5+^ ;;%F=F%C&IG6QCE5L9!O[6,I*%K*3
MM2QEX6I8SFXVKW!#Q ?[.EK.:B5SHNTL8%6+5[_1IAV>7>U?KU RS-;VLK>M
MK&US6YNO=K5JOHTJ6(4+W*O^MK?']6IR]0%;TC+WKQ +KD!"Z]S-S@ ?R3U>
M:IL;6ZS,HV@/*2QU_>J >C@U,81YC&/4JYCT%G&(YTTB>]=[Q/<",+K(-6YR
M\[O?^^(VL_\]W2SPD0/A>(&*Q+&B<9"CQ1DT1SK\ :,9TRCA-H91C>/!L(4G
M/)\XGF>/?@3QAT6L1Q(/TL0& N0B59Q(%J_8Q2V&L8L?.:-(7O*3-Z91)U64
M_\E)6M+'E02R)'DDRAP-V95'?B62E:Q+8,:22U^"\I.EO"4J@ZG*4;[RE*WL
MI#,14TW*5&8UQ3QF,I?9S&=&<YK5[,Q#75-1C>*4-REE*4IE2L[D[*8X.;5G
M4'6JG'Y>9[,$W4]CX3-8A_;G/1&ZZ'\6^EJ-KB>C'>U/1V\K6?]4-$<UW5"-
MYLNC$:7H1 .F+U'SZ].FSFBJ42UJDAYLI %C&,)2^K!^0*.E+.5837/]4E[O
MVM<\A=E.>RK4G_HT9L ^MK$[5E26Y>PPS9Z9LZ6M5*=6N[C]Y>^UM<U5_&+;
MV]L>;K?!G57= MB_Y4;WN2$[;15"N]TV=/>S>PB[6?_0HPOFD 'T6#"#+B#B
M9(.5]PGCS>Z KS#>Z1[(P.I1+$3<(Q&H4?=N)6[NB2.<XA>W>,8CCO&-:]R%
M! =YM T.;['R Q%7F,%:?R<#<W2AO(\=N,C?+7!XVQ!U^D!$.U+N !$ZP!Q>
MJ(<_*MYQH@_=Z!QWF[BY&CJEAUN_W^:V?NLK0"%6W3$8*PS6V]=LK7>=ZU_/
M.MBMKAA]""(=?*6<#';S<OJJ#^Q;#WO<X3YWK\L]ZT(T3#UTP_,$@H7E@AB+
M? 5O<\+O\.,W-#P.@8AXQA.Q\(TG_ ^1V#_*3][R4W?OV-O./J@?W>,4GP4B
MB@,<*R88.:=/#H.Y&!V;1!C_C:\?HX1A?V':4UB,<*Q/AT-<XMWW<<2^Y_WO
M02Q(%"LHQ>AQ'F,1,:#RJH8?$**M0[Q@(+T6I!\QQOZ+(;G]%T4_(==_@!<Z
MXH4>!]G&.>8QCC>)?AQG;Q;NR&7\,]1\S<V"_+\TI1<V-XLDY]_[%'D^)[,2
M7L*_ 6RR5A(_KQ' 6/H_ . _ V02_?N<6> R9B*ASN$'\DN3K]% //&"P.N<
M>L 3V) 3,/NR$YP3+T"LVZ! -Z$_B C -Y% U5BS&K3!&\3!/'&S-M.F2[$S
M.O,F>9"S(;2S(O3!;SI";L*S3?&4/G.607-">$*T@]JTA((TA<)"3%LH0]/"
M+-RH_R]<J##T0G@APXM*%W(Y0S-LEU5#0S;\-&C(!X I-5*CPU.K0U7KEW\I
M&),R&)5JF(>)&$"4&)8B1)<BQ%F J43LM:"ZJ9L9*I2IF6*3Q&2;1* :*D><
M&9M!*FAC*J1ZJFISNFR+.E$,Q<XCKE$TQ:8[Q>'ZO%8L.J2#15?TO%>4Q5BD
MQ5N<Q5RT15VLQ5[$Q5T$1E_DQ5\4QF DQF,<QE(<-U5DQJ=;1F=$Q6<DQ56D
MQF:<1FM,16B,&OABH6K41F^\QN^:KQ1"KW'L1G)$QW-4QQ8J1\%KQW=,1W:,
M1\R+"6X,QWO,1GP<MV+D1X>8!4$8/>!XA](K#M1;,-5[,/_P<+WO8*/8J[ -
MRS"(U# .R[W@LTC@P\C>TTCBX\A \DCM2SZS6C[^>$$ 3!!$<(WG4Y#J2XA9
MR+Z7U#X:X[Y9 $$1/!$OB#Z]TS$C43]/8K\?*[^@/#^T>KY7FL&PNK\@:4""
M (X;283_NP=?^D"SB4$MP[(MNTHLN\#8Z, G:\ '=)*E'(BF')&G](RH[#(C
M.:L.'!$.M)-$(*L8I).' \!$6+,$E!U]8).2- BY;).CA(@<%,S!)$S!Y$$W
M^\$DK!0?K!0B5$PCK+/'W#-Q6I9 ,Z=VVJ=)H\(OM,)OV4)$ T-&"TUQH9>.
M*DW2C!=ZZ;35Q$.+ K6*.L-0HT/_V:R'BK)-5HO#B"*IW)Q#UUPU3XM-D1*8
MX8RUXERIB1%$06PI?E#.0E3$7U.V84NV3*3.2*3$ZT2V[(S.3/0'9L-$3GRV
MIIJ(H/E$98S&\S3/] 3'?&1/:6Q/9#3&9(S/^>Q'^:Q/^H3/^]3/_.1/^^Q/
M_/3/  70 =U/ 2W0^<1&]U10]%S/!57/!&50:Z3'^-J\S*.Z"[70#*6OQ)M'
MS:/0#ZV\"0W1]FK'QSN\$S71%.50R%M1%&U1%84\R<.\>:O0&@51RWM/]3S0
M^IR%XB@PTD.P@LPB+7H Y>@BUL.]V9.]V%/2)F7()]4P[, ]BLQ(X;/2B]3(
M*ZU2X^/2_Q/C2-J OPOARX\A$.=I#9=L$)8T"/"#R0EQ![@D")QKL7J@28;@
MAT30.P[1$*$$RO,S/QI9N/_#.?C;R4)-OP=PC:0LI15L'R>#TY#02R;+$+Q4
M#?@[I<-(#43H/R0#3/M[@#&M2OGK)4$]0$FUDJV<"E0=B*C\I:\T)4PM"$V%
MP&!:I@104X5@RPHT$IK<0-;(U3>1#;_\2P#X56FB4XRXAV)E)EU=)EU]U->P
M2S4!U3@!3(HHS&O%UFRMIAW,IE)H3,C$,\>,S'%=0G R5R0$M'#Z%'6U3%W)
MS'N )RFDM$C#-"[D3-!,J-/D--5,M7E9PS8$6-F4PSMTPS2$S?\Y'-B/XLW<
M]!> :5A]>%B2$D[A=+7A%,Z%G2C@%#60NH>!V4.4^D.*:4Y#)-E!=*ECTS5$
M+#:A8EGOM)F7I<Y&C$Z;TDZ:E<Z@<EF1ZT1J\T2BZ0R(>]!OA-"@U<<(%=JC
M_:T=_4^E-="E==JFA5H"?5JIC5JFI=JKM=JLG5JMK=JM]=JC&]H&-=JBU5&D
MS5&Q)=JS#=NU15I[M$>U?3H2G<?R!$6A<5NY7<>[-4=YS%N\Y=N_U5MWG-N]
M#5QX-%L'1=O$Y=I=G(7=> <R(#V"5+ A;3 C9;T".2.'U-S::\B)C,CST#W=
MT](LQ=+1_;".[(^/;%,$ 5-#FE;PH W_E8R06T73EU13MBL;FRP0\4N=,$T1
M1@74CM!+',-=@M#=$0G)_?O3/TU44'*1KTD$(%G*HEPR%AE3?_""'[G5J8"E
M6^JE:<5*K_0,Z@W?+'L 56U!VA#!L'P-L'P2NF2-%K3*,RF9UHA69@TS,7%+
M:B7!9J)4@D#+#92(.L4<9'K6U-A+VQ#6-:E6@]#6!X;@" Z4PWRS1/%6(01"
MR!37.P-7#3[73EG7)BR5)WS7>+VT29LG>D7ASA1#?O57C=58@*U-?AE8AUW8
MW:SA@Z7#''Y8&AXU'LY-B17B5[/8(CZ8(TZIBJU8D:)-@_7A5DOB67,86SM.
MYG3.Y:S$F<7._Y?-XNITQ"P&XRT.8^WT8DWDV:2BVZTYW+&%6[)-7+9UX]Y:
MW#G^6JRM8SKNVCRV8SW&XSWVXSX&Y#L69#X>Y#\NY,2"X[.UN$1&W- 0T<NS
MKT8.40^=9 PMT1:UT4K6T!?%9$YFT4]V45"&T5 FY5$V94\N952FT1M]Y%:6
M9#<.Y%Q,!.$8R!\-CN&87 9C#NAP -;+W%]>4F!VTBB%T@F34HB<4M+=TF56
MYF8V73Q"W?]0W0!I73%58$:MW0JY53:-R>UMGRXHTZ_)Y@%Q&-UUD ,6B.PM
M$. %$=JP,0[L$!#$"/+;L9MLC9$TU/;#'EG5I.TE5.^E$G&>)485Z/_J!1+P
M!6@#)-4"7,!64E4 X!'7B%06<54().CX;>@'0.=5K=5F]6A$]54Y$9MG^E^.
M5I/9N%\C$4ME?1,3-)(&%HCH/<'KO1X)MNF;QNDXX58+ELQQW> /9M=R15?,
M7"<3=M=K@=<3AM=YG4(59F$LY-=_5<,X/$.'%:F(G=@AUNJLYNJM]FHB5N)6
M$^N1.N+A+.M:*^NT-FN$66LD+NN+%6*/76OC!,0JQF)]4%DQQLZ4G:F<NL2;
M!6R_)K8M'FPRGDZ995F9[6)F@T3QM#;>6N.T?>4VINS)MNQ#QFQ"UFQ#WNQ8
MYNS/]NS0SFS0'FW1[NS21NW35FVQ860&O<__UI9L-K[LV*9MP_W;RIX:ORW<
MP17<OB5<W0;NWQ;NW@;<X";NW?;MVH9MQ<4JT\XLT?."WQ!(R;T"'3A(+7*.
MU8NPAU32A_3NS97(\ ;=BJ129R[=\V;FXU/O+BV^F&1=V_#="0%5WFV-Z=/F
M,VW36[7O!:E?S\ ^^K:(1*@QX!UPUI#I'7-G%P'>G<R0Y*4($5S>%LD>==X1
M?S9H'<'F3>WOL"%?[T5H*;OH^BM?)7EH]F4-(^%+]YVR#:^-#D^ C0:  ,9?
M%&S+D(Z3D7:FDH[Q-1'>876(E.X3WNV(!4X3FM:>G$;R)$=R"F:4"U[,.J,'
MG_;@R:3R*%S703MJ_W5%:GD]ZJ3N\F#A\GP:0].4ZM9,PZJ&V""&ZZYF\['^
MZC</:[66\[DFSCI?&.+4ASMOF#WW0[;6\Y,J*;#F0RFN->04V2O&M;Q6=)I:
MQ.>TQ#'6XII%V9]*V4BW=$BO3L<FSY5PC>7V],A^8U!?;N<F]=0F[=4N=50W
M]50_]59G]5=?]5A7]5EW=5DWQ=<6];:E9$B6;4MFY5U_+U3.9,=3Y6('Y4L6
M96-/Y61G]F5W]E-N]LCS(5_7Y&%_9-QF15OW.#(0CM^@9>K&(I3#[NCHY>UF
MTG,79G2W/<XMYC9*YG=';_-.[WA_YM2U=VGNCVJFD-=] +$<YY-LC=KQ#_\
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M\I7#MN4HQQ[,:1OSXG*/YC:O.<YOKO.<\[PB^5,+=<_;W:&+5^A%1\L$L;O
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MNA#_-0(:]2QT,6@RQ!9[,1@K;$^;<13B&JFE*OZR\5DCM6#B U_7"#[ @R#
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M=3-]79LV;=LW[PDX@W >*"4X=V=^CQ. \;=^#8I_DS. :0TZ:PW79+BY8YA
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M*O"!"YQ@ Q=8CP0R4(,9Q" '&9B/>^2C'B$<80E)*$)HZ".%CVJA"E_X*'[
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MS "%*IS! UCX&0<\P $.8 $.K'8(>A'-:E';H0Y[R,,?*BT6.&2:#.HB0Z;
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M\9N^[YN_\YN\;:_W !QQ YR]!;QP"5RX"US!$YS!_WO!';S!$1S")US"*WS
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M*D<C&K,H?,(J3&4RV\(2V:(6":,P&K0_:Z,V7,,X'*,Y"I)$V\-+^\-)&\1
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M"^T09G<#%?5P'%X@K4:A#UZP["!-H]#^[.+WD=2>^]:^^UXP%;/P'=B^[5W
M%?VP^EM;#V%1$4K:!1KA%;/0!;ID$6&Q^DH*X=[^'XG@^UX0[@^ _%G!#Q+^
M %TP.&B1"-;O!=[O->"_I5Y _H*W_2Z^X2&"_EH#_AUN)5Z0%JL?XB<.3NX/
M$@#AY4&"@04?%"1(T/_++'\ '/J;)3"A080%]3%T"(!?HH,3"7:L"'*B2(H>
M#U;\B/*D29(I6:IL>1)!R <S1]:D:9.BSI0\9>8$>E/GS(-#?Q(DBI,@HD1,
MG3YB^FY>J:GSX,F3>I7J5GI<N<J;VE5LJ;%=Z\TS6ZJ>VGEKSZZ]1^]>J;AU
MY=Z-BZ\>/GIZ^?KMNS?P7\& #0O.M[=>OGMZ\T%+S#@RY,64'U^&G!GSY,W0
M]&7^_/CS:-">38LV35IU:M:K74/CUUKV:]JR47>6_,RO8L*]!_/^O=OQXGN8
M7\=&#EMY<N;+E?>#!KV?/NG4H^N+#3UVZ-.V9[/>KOPSOWSC38='GZ^Y]NC_
MSYTWA_]>/C_LSJ=GKW^_??7L^ZU/KR[ ZP0$<$!]_*'N0'ZF\X<?!&=QD)]9
M^@& PH8L!* A#3-JZ"$.,P1QPPT]'#%$$$D\T<0.5?RP1!%;3/%%%%>4D<49
M8:31Q!L]Y#'&#WO,$<@??12R2"*/#!+)(9-D<DDGC6P2RB>5E+)**J^,$LLI
ML^1R2R^M[!+,+[44LTPRSPP3S3'39'---\UL$\XWU92S3CKOC!//.?/D<T\_
M[>P3T#_U%+100@\-%-%!NW111QM9?#%22'ULM%)*+\W1TDPQQ;'3'1^M,51'
M1=744U!'1;5425>=E%576X7U55ECI7566VO%]59=_W/E=5=?>P7V5V&#)798
M8XM%]EAED?V45$Z;3?794TN%EMI3A6S4T$1SU*>++KP %QXOOB6WBRO,S>&*
M'&9@MUT6'I#A@7<1H+<F>N_%-U]]]^6W7W__[1>1>N)"9-\$#$:8WH,5OG=A
M!!R&N.%[[7UX8HGKO7BFC"GFV&*,/]88Y(X/'CEDC1-P9]$?"ZXI@7J&Y*?E
MDV?BA\A^9JX)D2!OEKGGBGTF66.?<?I9Z**)#AIIHXEF>FFGFX;Z::FC;EKG
ME:?&FNJLM]:Z:ZZE)M)KL;\>.VHO@)PE:Z287EMHI+RL!^JUYWX@27<*2LJH
MHAYX.<>8\RZH9K3W7IMPG/\,!YQNHQ3'NR N$V$<J;-C]()Q?>Y<7*D'!+\S
MYHGN\5$?S2?RB6[.\_1\],9-LELEDUYW/7;89T=I%BE3IYV@OC_$7?;)<\Q=
M=N&#)WYXU>DF7:72CV=^>>>5ASYRS3.G?O7I"T($JJ:V9VHKK.9YY_OPMPKK
MJ[+( HLL]==*JWVUWG^++KGDG\LNO?(J+'_?#MM?_\442XQC&O,_ 7*&. :4
M3&4XHYGN<,>!I;E- []3F^-\)X(/),UEBG/  T)F@PEDC'#Z<A>^X"\O)$2A
M7>J7PA&:\#>2F:!SS+.>_?B'/^+Q##XD4YQ[Z(.'/F0,$'OXP]*8QX@X) UZ
MEJ/_'OO,QXGQH6$4[9,?]_0'/P3Z3Q:QN$5H((A!"U(0@AK4H J5\4*TJI:T
MG+4I-IIJC6Z,5AO3*,=I*4I;*KMC'NVXQVWAD8]^[*,> _E'00+2D(5$)"$5
M.4A&'G*1CFQD(B/Y2$E"TI*5Q*2>K/7&.<)QDW&<5">7-:Q.EK*.=.3D*3VI
M1E":,I5O'&6R9!G+2&%$1+8,$2XUI,M6\1(BM02FBGPYS&#>LIBY/.8NDYDA
M8@ISF;]T9C2-*4UDSM*:M+QF-K&Y36V&4I6N;.4WQ?G*<(HJDWW*A[?&Y85W
MK+-<ZH+GNMK%KG?%:UX(8 ' ]+E/?O937P(CV+\<AJ^!_V8L8@Q#:,42>E"%
M-I2A#_580RGFL(E&]&!!8QA&<6:QH'4T2>T VD9=!C.?)2))?^NHQJS&(WZ(
MU*4AA6G14AK3F<ITHTIK6M)NNM.A?6VE)V(9V81:MJ$6U6MA,VI2B4JTWW$H
M;65KV_40\-,.4=4A3XUJYEHG/:/LSD.B&THBA 16ZU&OJ0ZY&U?+>I3#U>U'
M&.$1RPI7D[-FJ')M1<"2[IHXO#:N*&(ETE,1)Q/;:>0G7@4160W7$X0 -DA8
MW0E""MN[Q;*5L4()2F0QNUG-E@0A=84(8ALBNI>81+0 ("U-/ ): ,3$M3!1
M765E&UO:^F2VMJUM9B_;V=WNEO^OOV4K< <[7,TYA7O:4U]5O!(6>8BEN>IS
M[OG8]S[WN84M<)F?_4@XL,%TEW_!V<LS D@<?(@7@(TQKP#+"\(/6L:]"\0-
M XT#P1A2L+[W?0UJ,BC?#_8W,OT5X?U:V$+Z%;@N\L/N"N'2%KHP.'[W8'#]
M#+S= A;Q//*13@T+Q)[PZ$.'//QOB#DH1"#B]\)') \4G[AB%;?X.?F!<7^X
MN&$M#LC&-!:0%[N8H 9]D8S]^+$9A<RJ&TE*2I]$,BN3C,IR-CE;E(3R)*5\
MR2@[B5[>N!>6KYQE+F_YRHB 4L$0H.4QW^ME59H!F=4\)C5WN<Q>?O.;K6JE
M<KBYS7#_UO(,PN2%.X]Y3GWV!IB5A&<[%YK07X:2H>,,:#-3F4EB9O2AXWSF
M.]59TMZ8 9@@S65Z5/F<C@;UIT7M:3PI.M)OUM*ANY"F4[<: 2GCTZ8OW64]
M3\G5LSZT59>\2B9ST]>P N>N@ZUD8O>ZV+Q&MBB[^6MF+]O9JS)UM/,JJRX<
MFE>W7C27VU$L66?[T+5F%;;%32^K-=O<ST;WN;DY;&.W.]GC=/*Q1]VD=)*+
MG>X<E[G0I:YYRF &]907Q1R @('[T^ '-_@,VG&/=LP@8?DJ:$():E"*+W1C
M%T]H14%&T8AV3&0=+QK&-.HSD9_LHS0]&:57A-*4 :E@-0W:_YQY9E.4\RU&
M#X#UE[QP4Y4[Q LM]Y% C,9:(_UMJ4Y3$UDU]J.;%99;32/ZD8SN-+B>Z6Y"
M.ZV4KLZTFK%IYUIS[):<[E2E+@U(D*O)DM@F-[?V**W78]QIC7ZV(,FUKW,=
M2EWO1ER]7<]P0=KYV!\R"\6!=J\% 7J.A+Y6Z3'I\&IE'.B>7CVZ.=XDS[M\
M]"IRNHPLK^< ^/F8>H<\ZR4O;J;W4>^>)_>*.(^UF8=]ZS6?O-C37O:U+WWN
M2;_[YC$>[K^G//!]'_S,9<^XQDUN\NGQW.5'5_G0A;[[QG(6LT0XN]O%7_^T
M[UT AG>\ 4PO <,?0@Z"T#+M12!E0O^C0 E>D+X8-'%^V]_^\@_PN[L)(/=5
MB!?Z\?_ <4DP!&NP!7,+!S/  D3  >R_PYBO"KJB]DB.T?@P("(O K+ []N@
M$M- T"B.[U"B\6"BY. P%L,P$E0Q]D#!&+NQ&L.Q%9PQ'H-!'[N(""DC#,$0
M<OHD;)$W>!,V'MQ!<IJW4".U*0M",:&7 W S)(0S)8RS<A@3)B0S),PY(+D7
M**27,['"(TS"+92!,XG"+5S")/R2+LA"!#B /ZO"+!.T)I&!."O#-P1#/TNT
M,*1#-Z276CNG:C/#./S".B2SS[N2/K1#>N&2;D/"3B/"(13"1&3$171$0.'#
M- S#+NP2.ES_-3:3Q$'4Q"^<0B5QATV< 41T"$1H."TDQ"FQM$W,1$'L0Q]T
MMR)+MUC$P1^,MU=TQ7>;15O,15GDQ5%JIFD"QFH*1F6B)F($QE5$1E,L,TK\
M13W,0F9:)CCT0V3<-F@*QG;8PR4,Q1 A18>+,VNLIE241E541BV#QEY$1W5+
MQW5<%G;#Q5I\QQX$PD?"!W7ZEG:R-V^))WZ;IW\+N'O*)X03R($D2(A[N(G3
M%XBRN(5TJ(IK2(;DN(S#.(F2F)$+N8T2N9.C.9D"1'Y@K2Z N8V:LY:J.9K+
M.A"IAZ^K!P=9DD3@R"F)FX>I!Y<,&B+Y.J-A21ZY29PR&IVJFKK;_YHI\<B9
M< =$V+II^Y&=U)B</!&E? "Z0ZV@@CHA63RC02JMF;.G&KK'0CK'TYBP0YNR
MPXG$RXBC?(#+R9&87#NAV2KA6YO3T@<O:$OB*RN]&[Z[K+RDM(FJZQ#!HBL@
M.;R]0<LM"4R_X\NR]"N_4\R9@,N[N[O#1*O@DLS;RBS.<XC= L0524G=<1*U
MY*S>LBR;FSS=$DU#HLS/#,W3Y*W4S"W4Y+O$[+O8A,W9Q#O:=$SA6DS;/+ZF
M0*ZN4"[F&HOR 4[T.9_I6Q^T@)_K6D *X[[A6*_N>T[G3*_I!+_J]"\%*K_W
MPL[+8+_Y<C_WVR_[$D_6B*_-("_=X W]"?^,$W*AP\B^YEQ/O/ _^50P!9PN
MZE/.^-'/ \S/[/(^"YNA*D(B +- _KG \PJQ(1*-#H2_"@I0%X-0$W2B$<0/
M&;LQ&W+!#"T0'=M0Z_ B!9%!" DR&X1':-%!72S16W3'%57$(FS1%VU$(3DT
MN;0D27-"'O$V!+A1+[2S+A"D;ELS,?G$;:L2/K,S-,2S-?03>LC1S%R30NO$
M&*62-"LT440S1K/20'0S;"2T+*41($4 +WU$&!U3*373,H4D*/TC56.U'@VS
M;^,2/;RS*FN(>JA2%<53==13-,K3%-U%%OW3/E45=B34/3747%%36I+3+KNV
M'G45,$4 <&N51?7_,G2TTRXMU$P]U$W55#X-U$_UTU"51U0II'NPQWO+1WV+
MIW[S1WL2.((KR%B558.+N(9"R(?$584TF8BD2(GT59/Q.& %N8^SR&(-&8T,
MR9;I2"=QAV0M&IE[J8TDF=-J5IX2$I#$.K4[FIE1TH=P2J$AR\@4RZD"RJ,Z
M.ZSI5KN:FG % +,DFR@% +6TRB#IFK#4&L$S+*&A2JT!+:T\.J*9LZB9,P P
M"K=INQ0QRZQJ'+D[DKW+3:@LE*^KS8D]V*K*&WR%B+4!3*[R@J[3N<4Y$KI4
M*\G[$+*"O)#%2[=46<LD6.L!Q+>CO;"QO9G5/9Q@/9I]RS_"/=[#O-OS_UF<
M55F1#=J4%=JB)=JCA;P',#[NV9[G$TZGA=KF@[[[/,X /+ 2@L_J/"_G/,_O
M\S[H'+\!8B_'.+_T,UOV>R#PC+\8^L[M+-L*'"\#U5KIQ$"NC=OT[)_]^[_L
M>I^Y*,#BC#[J$ESK(MR^'0P&!8\IVHX/RI_VY"ZYA4ZXO4X-U"'/Z"$/O+ (
MU5P)E:(4M*+KL- 6Q+$#B4'2A8X/U3'4!:,QDA @JQD*N4%1U9)1I5U:K%T4
M==$SS5TTK:1RI)=+3"1QY+(NO%0[A%<K>4,?W2,X/%X[(D,Q-!-63-<V8=(R
M=%(PV<+FU=T,H=1LQ$,TZ5XE!%XM5<9MJUXWR_],0PQ3,MW=]F7?]]U>)LG>
M-1W$\<T25E1>-AS$[V62\&VT0BJ1XK5",;W=3N'4 [;=!$;1 @94V47@!X84
M7XK@9_I%8;1@8[S@<QQ&#:9&#<Y@<#1&9V14$/;@AGA#&@W&-LQ"/6M&WZ47
M>JA@#);A$@8 )@U#49QA$H;@'>Y4'CZ6!F;@/A64)SM34[4W<$G5?92G=@FX
M> F9@)S5*);B?:K5*G9(7<7B*]9BAM2X7;6H+S;6D4'6:!VI'OD;&@5,:56I
M("%)-8:IT\)6F!I,#ZF'C@)$D%)C/U)+=DV2F(RY<L4:D@ID0Y%7F_630EXZ
M>I6:Z=T3IK)7J>G7L@/_+9?4FI8T6+8<DK=;&H5M3 0@.HF%.R!3&9,=6H(H
MU[D191[AF8V]S>#R@CGVD<*!S':U3=QDS-!I9<*998>538JUY< 9$KYZV<F$
MS-RD6-#L9-),YL]D+=7\95^>3&/.96E^YFGN96NNY6B^YFKFJ]U<VJ@EG^6*
MVN>BVNI+P+UES^9,SQ *VP+JVJUMY^U$/[<]6^[T3N\8S]7H, OJ#MRH/Q$S
M/PT"Z'EFK_^*3N"X/_JDB[YE: +,S\ USNI*3K?PS_6R,!&LH=!H# )#9W7V
M6O7ZYY#>0/U*W,TU:<Z%0,75L/_ 4-'UT)?^(@8I7=2=:0>Y'!J$74]MLA.-
M_T<%[ND%ID7WC5_>A5]#FM%&_$1LNU[R7;3\Q2,CQ3.G1B2H7C0D731&%A,F
M[;.EYI)$)6H:*31*]),VW&I,A#,BC5>O?@@P%5.A_NJW=NNX7B2U5A0V->NF
M+A)$8#3M_1"MCC89&-@^J=,[W44?[F%> 6*?3FR@9FQD,^S'/FQU\^I1ZEYS
MO!5 N\1(T>O)AA6_GC7 YJ;B;3,<CNS2ANS3)I;%_NG5;F"YKE-\PT=W4M5T
MD2=_\S>  TAZ*;@IYNW>3LB#W.)<=<@N)NZ)Y-5@1>YA%=8P/L4>P6-G+>,4
M0:F9@.4.F;F:@M:2G"EJ3=9K39IAWE:9P=AO_=>BFO\SJ00;,_::\2Z[Z?57
M</411$X[13:;1RYOUL*:2"YOF[LCI=.<UKGDM2Q-#S$Z@F#9C!4^Q+'+UX3F
MO[N:X,+8\69PX&.M>_COEDS:ZB'9KRKEBN40M#/:# ?F'LF<88Z<8@YQX6,]
MNESQX7N]#D_Q&$=:&)]Q&1?Q&Z=QQCF(I=U-J%4NWPQG("^+](GHB;:^%4)R
MCXY<\JO;"Q3;K75RLJUG[5P_[DS;^;OR?$8B\O0.>_8O#QIHNWURZ10.]10P
MK 7 B5Z?P+U/_L3/-G?H--_;!).+PNA DG[0C/Z?^N%/^T$,__EHR1WH!<5S
MV2"//#_I1)_0$GS #6MI%H3_Z1V3Z4D'4=.U]#&Z"->M01")W=96;$']=%#-
MP:)V;;@F=1]QX6Q41;&V$RY51;Y&WDA,]1V-$E6/0JQVWC>T:BC$]2XY7SCC
MZBV1=5NOPDR#,M%.0UCW1$T,=H<01+1N",]6=5I7W[8^]:$N]6R_]CT9=C@T
MPOIMTU0?1RP#[3U!!!7N]O5MDP!&1@(^-M0V;-66=U!O;-6&]W2+81K6X7S?
M=PKV]V+D8'&/Q!RV)1&NU'XWD7%/QCTL=X+7;+)>^ '6]WRW83LD;83?8!TV
M[8V_=\B>=U$/ZFVG8WQ#8ME68E8%N"?V[95G^=]V>8.$R.#.XIBG^5ZU>5[%
M^8ML_YDQIJF.!!IH_Y Z%DDV)N.7.LGIWGF]>DGGKCDA$?J8XLFHYZEG39*@
M5.^L<?K]SBL@H9KJCM>H(1+T9IJLT_H!/Y'WQKE9AHBDNLJM&5AW]?#(5%A.
MQN6E\=$^)EJ[Q/'@.V6X4WL.>;R#W<S?.W#"PRNPE.YH!KJ8V9MDGG $0/R5
ML\W%SV;#85EASF1BIN\&IV:S'ZW.7^;;;.;.?WQMKGS21_UM-GW.5_W2=_T<
M5UJF_68@_\UP?EHA%V>IG;X(,URKI3#QPS^Q!3#QNDXOEW*XU4Y[?J]^?K_F
M5]L&75LMQPT"-= R5Z_QP]ON^C\UA[ X=S#H(F?DQ$_=)__GANX_[>H-ZD3<
M"LJPV$B,-'^+>>AHK+T_*"_H#H)^?<Y<E%9T%Z-0T 4(:/V@\1-H<"!"?0D7
M"E38D&$_A_X4ZO/'+^)$C!<K;K0XT2,_ /U$ O!7\J3)E !6JC3)$N5*F"YE
MQFQ9$^9+E3E/[IQIL^=-G32!$AUJ].=1G#R7^KSY\BE3IU&A-J4JM>K4K%BW
M7NUJ]:M6KV'!<K6* (&WLVC/>BD[]JU)&6O/IJ6KMBZ"=F+=XNW;A>Q>IS/Z
MWOT+-_!7+X3I(EZZ&"TBP(#IS:U<K_'6NYK='9;<.6L]S78YN^4J]W'IF(_U
M0@UMUZZ,DHA>KZ7W.;5GW+<Q\\[_W7NW[^# A^LN_MNGZ,J/^T8^3+MN%]W+
MDR^?(;STC.?4#1LWZ5HY MLVQ],D;[X\^O/JT[-?[[X]_/?RX].?;Q]]T?OZ
MZ_/?[[\_@/\)&""!*5%WX'.(R->%=@CP-UV#RLTPX'C9@?=<= 1^1YAX!7I(
MX8<A@CBBB"62N%Y^2B&UHHHM"L7BBRX2=UQ@B'C1Q8U>O),CCEUT<<6/.5R1
MPPPSR&#D#"P\(,,#2I[%@EI12CDEE55:>26666JYY5D)4.GEE&!**2:9:I79
MI9EIGO6 F@BPB>::;;Z)@)ASVJG6G7'JZ2:>?7KY)E;ML/DGG7P2FL!E4/$S
MJ*%\*GB5_Q>%LOGH4_TTRBBFDDIZF7%/19KI XDNY0ZHE[H9TG4KL;DJGZRZ
MVBJLJXK*E3ZO2K5HK+D^@"IPKSZ0ZDOU^.IF:J2VRAFPL_G*:VHA^32+KM&R
MZ859PUKK(%70NMKI25[(&A6N#R3P:B*)N3GNN:NB&RI/VJZ[[@/JKAIONF[2
M*^X#52E[+[QLEJN5M_(RV]NG_ I,(TOXNGG/<(N^NRO")2D\\</I#KQ2O?C.
M&A.I%8L[2U7R9NPQNM3.*&S&G-X4+LG36M7RR")3+#/,,\=\L\TYU[PSS3WC
MS#/.!MLKL]#Q$OT (H\@DLC232=2RCQ02QTUU:70(_7546<]M?_56'M]=3WS
MU%/*/6*3??8]]-Q#MMKTX%,//F[#+3<^S^0#=SWYW/.VWG?WG?<]?@>>-S2"
M\SWXW_D4#KC?BR>^N#Z.0RZYXI%77C@TEF>.N>:1>[[YYZ&#/OKGBIO...IZ
MUYTXXJT+[C?>;\<=]]IIUZXVVVG3WK;NN*<]=MA7;[UUU<-W'3;PI8QM>RF[
MRTZWW7O;S3GI!%D_4$$%Y:/V/&";7?;ROK?M_-RRIQ[XYI>KGW[UHA<4^?O6
MPV]]]O3;7S_^]^N?/_;V1U000AXBP(A Q"'].Z !$X@1BF2D(@QT($AF,9*1
MF(2"AXD1!J.2P:9L,"@:_" '0>C!$)+_<(0F3%&,@#4C%7*KA1%S(0M?V)6S
M'$ T&8HA6/!20[I8!P#E2$X-8\.M'5;F -R1(0"Z0$0=8@N&8U$B$'N#"";2
MI3DNI,P2U;*QZP 1 :1!X@I+TD4$4.HV#"KB66[X%BKFI2M83$XY9H/&#N$P
MC$Z\(QCQ6$<]VC&/?F1)%[^X1P#09H=JY(M:EGC$E\@EBV=A31^?,L5$:D8O
MJ1'*=[+8H1.9J).<_*0G0PE*\@!EE*(\I7] )A-5MH25*'%E2F!9$EGZ@Y:V
M',\M5XG+7>I2C#2LY"QYV4IAGM&1P>RE2AR)@ .T996GH>0C7RE,:2)3-LJL
MH26I.4R84*:0_^&I9BRG&4Y4DM.4YBPG.O>#0A&NLX3M/&%2.CC(5-G('3G:
M48]N%*0A#:E(16*2D@+Z)BAQJ: &/2A"$PJG,7VIH0L]4Z$>VB:(4G2B<KKH
M0N=4)XP6BE!Q\JBI#A72D69*I"4EJ:9,FE(WJ>PE7?A3%V;!K$2\%*4JO:E-
MW>0%1%R,'_R@J4I912BAYFJHAJK'+/3!$W[4XU/2>NJU5K73GO(#$<:*JIO<
MP=.:S )E6+V6%Y#Z$GUT]:MDY,<L%)4(+SC5K(A0JDOZT52HTM6L=JTK7JVU
MKE;M569\]55?,_;7G_E,9X4%FF$)F[$N;'6L<DTL9!. "*3"-28_G?_KQ(JF
MV:-E3+.33>I2+ELPSF:6M/WJK&GGE=JAH;:UI77M:5\KV]C25K6PM>UL<5M;
MUN:6M[LUVFU]J]OA"K>XP.UM9 ^KW)@YK6E*>YKQM"8/K7F-NM;MVG6%ISRS
M(2]WO'/;^,#[//.I[GR->QWASIO>]9ZNO91C+^4P9SKJK:]SH[M<Z=I7/?RR
M3W/S_:]\ PQ@]QI.;K837^\2#%X%,P]\RILN=N$Q#WC(XQWS>$>%BR</[P&/
MN\KS+OGJ)KOIG;=Z_'-(0>(6O.V&[W:ZJ\>+9X>WOA4.?:+CK^AR;&+[S2]_
M/MX?D'\LY.L1.8!&/@B2_V<0  9YR0-4X$/_.*(1BTB0)"B*)SNQ[$XMPQ-&
M6?;REL'<91GQL<Q_C"2:S3S/J#2HF6OVAQP7,Z&;/),VY?C-<A89QG8@:,YO
M5LV!?$.9U<APT,G9XFT.),@TTRA"WI#B=.BXQN1 $BL;0E!M&/WG36NZTVKV
M])D_C1SM+!J/#3JD6/*<PP-)FH^7'LUNO,/J=-+ZG+:N-:YOK>M<\WK7O@Z0
MHCUYQL4\:#OGB?0I7[V6;-Y'V6G99*^C_>MI2_O+9!ZS/+G\SFUKN]MBYK1)
M;(1/'?%(G_P4$I'\>20E 72@"GTWO./];C%%B=YMJK=%)9I1CFYTW_Z.*)_V
ME*> $WS@=P)IICZ:_].3,GRE#<?IPUD:%7= W.$6-VJI,JXIHKX*XQO/*\CO
M*O*0DWSD)B\YRD^N\I2S?.5Z!2S,8Q78B0W658CUV&:#>]S?YARY/>?Y:G>^
MW.0JENA&O_G0D5YTI1\]Z4Y?^M.;#O6I2[WJ0-?YSXDK=./&*VG-91ITL0;A
MZ&*W[,/;<-? =KP/=Y=YM,L=B,L'-[O->&^I<YSKV(NX]Q(8ONKMNW_IVU_!
MVW=] V;?X?O^N/^FM\:PXUOY</?V$--MP6Q#7O<^+#P(3SC#%+;PYZ,FC[1K
MGL5G6]Z'W2[>N=_M<"5VG__HAP]\D.U[WPMOC.F6M]TO?O#YU3'P-Q>_X?\+
MO_@];O*0D^_D^BD9@4Q^/O+E)_T?.__)4T;K!$]BP4M:.]O?]O:UN?W]\8<_
M*> .-?K/KWY0__(UJ,8A(JZIYYGPN?US^8S\_^P.--JY"W2<[+ EDA7MA86P
M45K(@!K5@U4MTQB5T14Q(&T@6G$$$J@EBP$FT@QHE4]T09U!H&7@&32UD63P
MWQQ5H F*6OJ=8 JBX/IEAC>5F@QY$P*\7U88X/S51)R%H%O47V64@__Q! #*
M(&3X!B:%X+-5&[4E(1(NH1(V8:_ETC9%H39-X3A)8152X3%9819B82T)DQ&V
M41>"TQ9683&)QAB>X34U4Q3*D3*%X3;Q(!'YH'C_@ PBT$,9%M*C:*$;GD0W
ME: >0B$7 N(5#N(9[B$A&B(3)J(2BE_YD9_W-2(D/F(+WH2XW5.Y^<BY78$_
M_5.3=**3( !!R9LHCB(I5HF]+12^Z1O 590JLN(JYMLK[DF_ 9Q&]0F:@)27
M()RF*%S$]>+%+=PO8DI+G41-^6+%'2,P(J,O<ARL>)PS%A4TNES+3:,T5B,U
M7J,U9B,VRES,V5PWUAPX1AW3C:,XEB/5D2/6!5W6<9TZMF,ZOJ//N6,\PN/5
MS:,]UB,^:MTZ;IW5F6,_GB/2@)US+8W5C%UUF=W7D)YVC8W:=1CJM1C<'=AX
MS4WK 0[?\!W>_1U&:B3C_Q&8?#5>X-47X=W7?B'>2!H>Y41//JCDW9D.XL0.
MC/$.W%&>\_@.=V5>/: =/7">V&47UU!70YI>@R%8Y8U8>0$8[/&/_6S/VTFD
MW!V.Z[5D@ 4?5>K7\1%?_5QE]"D?5SI9]1W05NK/_ 2?D.D# #$0/U!9]E40
M?H#?([YE]\5EF$6B7&*;M4TB7JI@7K(@FUV(7R[' %)% +Z&FX7%_@&F9T#(
M7XJ& ^X%(G2@8C[&G0G'#SD:IN&%!-*(H47@"UVF9YY%9F[:8'SF8I[%9 X'
MH>6&9^[E"K8F:[ZF7L:F"X('#,;0J4G'=DA&%ZB:5A0@:1(&#,*ELWV3$Q:G
M(O\>IW$F)W(NIW*>2+"=R&#>WWSDF7OLIK&EAV]:)JF%R'!"6W,R)WA^IWC6
M)2/"Y5S")E<( KGAR+CUR#ZAVS\A";MUXI.4HGW>IWV>(L"E8BSVIRO6HBS:
M(BWRFX :7($>J"XF:,$%(X,J8X,F(X0:(THQ(X6:2H5JG,=IHX9NXX9V*(=^
MJ(>&*(?.'(E^HU^=J&#Y8SZR(SWJHSRN*#_NXSZBXS_6*(W>J(KF*$#NJ(T6
MEHR^J(NV*(O>HVIYG4""'4+Z9'89I-HUJ5"F'CU Y%#F'GG5'7HIWD;ZG98"
MWGL5WN"A9$=NI(!E:=^HI)F6*9JVCHC-38.EWNW=SO+_W*1#;I?W;)Z=%J23
M[J22DE[;06F+?9=3QDU%NE=2^H\!9<[NR9BBFI=4'IZ75F55QL_G$-]83I_Q
M66I7*E__=&6E2JI5DHZ-44^G&H1'D-5:6MD%D:=;JJHCLBI=SJ4DRJ9KRBIZ
MSBI?WJJMYE$7N,,,5.9<S$ [!&8D(4([&(D'>H.1=$%HTBJSXNID$*NQZE"R
M5EJNUJJU-FNU8NNU.JNV=BNW%&L'^J &\H9YFM!XGFMXIBNZKFM["&(ANBLB
MQBN\SJLXO6N]RNN]TJL8XNN^ZNL?\A*X>J /!BN__FN_YBO"'JS";M/VJ5+#
MLN4X/>R^JBO%CF=YNFJYIDH*_^V&>HY;>YH;NFGB)K:;0-4G?IXLRL:;?JXL
M++JBR[8LS*HB@!+<+-;L+IH*+_I)A#ZHA/8LS_ZL@P;MS@:5A18MAD9C,X*H
MTHHHTRZMTS9MAY8H-TZM-U)MS>$HCV)MCV:MCFYMC +ID,+HCPKIUY+MV!)I
MV':MUJZMVN;HUQEI05;-GAJ/=M5MZ;5=E$8D44XDY*W.WG'DF(HDF/K=1SKJ
M27YI2;;7WQ+N?%F.1=*=WZY.2BKN2K9>VR3/G';7BFTN3LJIZ6TNVF'>4":/
M=@&E4"*8WKK8@NF>4<;7I.H/ 1F$Y=A=E5[DE8[IHXXDI'XJ619?5HHE\&9J
M6 [9[O]6I4M>::C"3SZ<Y41(D$60Q/:]JEW"*L96+_5>[_1F[[9F*[=V+_=^
M[_:&K[>"[_B*K_>:+_F>;_FNK_JV;_J^[_EE;,7.+[O6+_W>K_WF+_[NK_XZ
M8?1"+$S\+ZJJA  7,/\>,+5=+/8JL/;V4<>2 7M>XGN*+)*LVY+0)RBFK 9O
M<$*Q;)C$K'\2:(".,,T>J,"9\(*>L((>W((*K<^Z,- .[<Y>Z,<=;<<A+=0^
MK0[G, _OL _WL,E);=4.<3BFJ!%[K=B";=FB[1(GL=DJ\=FR+==.L==&<9 R
ML16GK18W\17#*-(9Z=?%;=D5ST':K9/VZ4->7MQ1Z5-:I-[_ :Y'-JZ -9X<
M(R7NWK'@(B[E0F[LL"265NY3%J7<'1CI(J099][O?*[GKICMS$,BBV[>.MB*
MV2UU2>G>XM[J\JU*3N6.G65":(^:GH_MTO'AVM?O\2XJ]^ZHKK*E:J4K!R^/
MI;(LZT,H'V7R$L3R1ID_],,N:Q]\E!)],+ PK^H"$W,#MZK[HJ\RLR_\,O,R
M)[,S1S,T3W,S4_,S5S,V7[,VRVJY]B\"?[,WAW.[)JS!EG,@DO,Y+VPZF_,A
M^NLZOW,[HW,\J_,\L_,Q22P^4U,^1ZP^P[.]TO,_VW/!^O- US-!NS.[#C,R
M'[/T3F+'6F(^8:(.\).Z&8DG8G H_W*P1F\T?W;TO8'PR[8B2(\T"<^L2:?)
M"NLL"[^P#+.T2\?P2\.P@]+P,]ZP32<M$/^P3N<T3^\T-@IQ$=,<B@KU$0NQ
M%"-QVU+Q42]U4B.U4C<U4S^U5#LU57M,.+[M<XDQV9&QW3(DVYVNBZ6N( LJ
MZTG/'Y-RXB%N[N;Q6JNUJ/J>'A>.F1IE65>N? 4.Y!I8Y3VRAYFQ0@JEV#BR
MY-5=W^KUV[S8@:V-YGYU5T.I@I%/[\A8C/6QX8ZJ)S=$_!QOHP9N*9-D\<[R
MZ'AJI;[N*^=/:<>R:8/V[FHVZ[Q.:%M/!)VJ &/O?"AT0QNS;<OO0F^S-4MS
M-OLV;_]V;_\/MW 7=W ?-W G-W$C]W*G*FV#,W2+LW1'-W5/MW7#QVQ7MR_;
MA %S-TUT=P"'4G9?-WE3=VY;+T-OK L]< 1'] 17M 6WF\ER-'W7MP<SU >+
MM'X/Z+_9;$FCL(&>L JW,(&O-$P?N$RW-()/J-'6L(/7M$_WM(1'.(5/N(6'
M'% /=887M8E.=<UD,1=O,8B/.!27^!.?.!:;>(JCN!.ON(L?=5"7*!@?:9+6
MN%\O)$[Z:>K&G:)&3]^V))"?=1US,EL+WI"W=5L/V!N_,>0^ ]\:=N3!J2+/
MJ8--J=Y")>,$SMY >6+77F.GL5<G3Z".-9GSK53J&/.1*HJ!#C[_W&Z8IO61
MZZYJ[QCL[:YH2Q]IOW:=ZSF?K[;CN7%K9\X]5"H!<<3SRO9MO\=Y%_-NX[:C
M-SJ+,+=Q*_>D-[>E5SJF2[JF4_JF7WJG9SJG<S-ZES>I:W>ICQ)"!_1!R[.J
M&[2KMSJL%W2LI[JLUSJMWSHO]0,K.>RN5U"O#[##]C,_#_L]"_NL)^P^%SNQ
MVSJK,SM .[M T_K]+GIZH[=OS,-Z9KM[9B)\7_0G9G1]ASM'W[='[W=(A["Y
MDW0)_W=_WVS"X:R")WA,QSN]S[N]/S@.-SB$T_"%]WN%_[N_\_"&$S7!#[S!
M0S7">WC"5_7"1S7#*SS$/[S$UTR,=[A0_V,U0=*M(?\UAWUU(EOYF-.UW[HY
M6J,U9\=YD9]RD>.8D9\\XSAY($]DER<V)A^V3(ZN&DMDS;=QH-.RX> -E>).
M=RTDVOB.QS=/S,^8TO\XZXRR'%MVDD%99O^M6Z?\G'_VGF/]U6^]UM_8GP<Z
MR_-#+A>Z3 & LPQPM?\:M:_]HR=ZBWPZW(>ZI\L]J,^]W=<]WL?]W>M]WM/]
M)*IWVINKJ0_^J1.^X2=GL"][XA]^>2Q^&";[XYN(XT\^ $>^XE<^Y0,[YF^^
MYG<^Y)<(>!/P=QN[Y2N[Z9<^ZN/ZQ!8^NK(]I$.B5;"WMH,L1<>G!9=L!HN[
M[H<[N7]TNO_^NO\'_TG_6X"GL/$;>,XF?[TO^+W+._/C-/33=+X'/,!7/_5?
MO_7O],%;K89;_/9+/(FS>!>/OXBK>(N?/_F'N/J'_XNGO\-7//=S>/SCRXP[
MC8W_=9A[6!HK]NF!V/C )$#@>Y:O'KYZ^>X1S =-(<.##A<VE/APH3Z&%RM>
MM)B1([2-'C6&[/B1I$B0%DNB/+E2I<J(# <6I&<0W\QZ]V;2P[E39T^>-&WB
MK"GTILV:- \F3*I0*4*#!)'RO%=J:KU25NE=U?JSZ%"C!PLF?1H6(5.S2]&^
M; F2'[2V;Z'UT]<O[MRX;D%RI)B7KUJ3:P&S%!R8\&##A1$?5CPR).+_IF3)
M-DVXDE^^MO[T^>,WJQ^ SOX\ P#]630 TZ!1FRZ=FO5JUZUAOY8=._9IU[93
MXRZM&S1OU:U]!Y<M'/APX\5[[U:>G/EOY[:A+W\N/7KSZM.M4]>>G3MV[]?!
M;_\N/GSW\N/-DU>?GCUZ]^?AKW\O/W[[^O/MT]>?GS]^__<!W.\_ 0/LK\ !
M#210P0091-#! R%<\$$)(VSPO-R.NRU##)&;S4/:/@P1Q!%%+)'$$TU,$<45
M56R1Q1==C!'&&6>;!38;7\.1-1U7XQ$U'T4#TA\AB;S12,]TQ+&?)$=C$LD?
MFX3RR2"CI#(T*7<\,LL<M>RQ2RR]Y'+*(:LD_W-,)9W<4LTPEY2R32O?-#-.
M--UT<LXRZ833SCWK[%-//^6TD\U!W623SS\1#130/,UL-,U'L814S#7!K-1*
M2B\-$]-&9>R41.(T[)##4$D=U53Q!/'B'2^Z4)755[OHXHH<9KUBAEMEF$&&
M!UC@U5<$'& !@6&)+=;88Y%-5MEEF6W6V6>AC;;8!)"E]EAK$<!66V*W';;;
M;+D-UUMQP1W7W'+1_?8!<M<]MUUTWZ66VG?7G9?8>A&@%UQ\^=W77WL!SO=?
M@0/NM^"!#298X8091MCA@R%>^&&)(U[78G\OMC=C@3>^N-^..0[98Y%)'MGD
MDE$^6>6465[9Y99A?O]9YIAIGMGFFG&^6>>4$S"Y9Y%_]CAHCH>VN.A\CWX@
MZ:6-;AIIIY6&.NBII:[ZZ:NCQIIJK:W.VNNMO^X:[+'%+IOKL\-&FVRUS4[;
M[;7?;AONN>5NFVB?\08Z;Z'WOKME1!(!7/!' -<JJ\-+01SQ>N:QRG&JMHK<
MJI]Z HJFF)ZZ1Z"7_&*,<[Y*\ASTOT@7/27!,BJLK<0"XYRB@3"*/9^!-,><
M]LT+>L;RL'8_2B:DG*)=H<B0\OVHRBN7J2RQTFH*(N<C@AZC>D(W#*[K[Y*+
M+NWQ<FETQKQG73'QR1_?_/)3EUU]UO%AJGC>TVK,K;DRXT>ST$@C#43?:.S_
MW],6076JY@C0.00,H'0,2"$%6FB!$V+@ QT8P0I)L($3M& %,0C!"VHP@Q3D
MX <]&,(-BK"#(S1A"5$(PA.J,(4D[$X"185 &0[P?_ZS80UQ>$,=YI"'._1A
M#X'X0R&61G\J4A*AX(1$.2GQB(4:XA.OE$0G2I&*2YRB%:O8Q"R.AHE<O*(6
ML1A&,([1BUN,HAC+B,8SDG&-:62C_A@51S?B:8YMM..FV(C'+V4*BGT,(A /
M2$-!%G"&A!RD;5+U#C*T:E6M<J2L:$6K6^F*DKVR9+N$)2U-;I*3G?3D)\DU
MK6J1ZUNE9-<IW85*>*E27\-JI<!<>2]9QM)>M(2E_\1LV;"*34R7%/-E+X')
M2V$>#&3%E)@Q/W;,G"US9\UDYC.=&4UH3E.:U:3F-:V9S9PQ36_=Y)LW_?9-
M<8:3;FPS9]S0]@"HJ1-K[/2:.X,&3XO),U_T5.<Z\=G.?+YSG_'LYSS_6<^
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M4Y9R'W6)Y3]JV1_]J4]NNKR@+^\1S%S.99CYPZ!.WF>0:V9-F[W,9C.76<V
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M@5XO]F9O$'HP"5OG=6>O=F)GD!E8"6NG]FN/S_!B]FWO O1)]FOG=G/O]7)
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M.JT*L7#]IM *J7 +LU#3RD_\Q'#\S&\,S; ,SU -_],PU=B(#,GPDCPH_F9
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M<BOW%AV7G/G!.<HY<@&@'FZTG2/W<@LW& ]W<8GTGYJT<[FC=<<9>+N G0%
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M__%S3S_I][>>/_WSV^]__P"L7P#Q]S\!&I"  ]1? 1%X0 4FD'\-A" #)^A
M^+7/@N^[H 8SR$'W>1"#']P@^P1"PD0@XA$" 4E#3)*1>[!P)$H!"5. HL**
MO' F+;RA2C!"E]30<",X_&%,:O@4&;K$)IX!RDY,$Q35^# I3H2B5J!B%:J(
M)2M5R>(5KT)%@GC%*E\$"VO&6)8RDO&,9BR+&,48FZO$Q8VU4<MD# .:Q-0Q
M,'F)S&+T^!@\^K$Q=PQD9CI#R,L4TC*(Y(PA+_.9T 3F(* 1C22?\1!*$L22
M7-1B6%I#&SC2YI.VB0UN<-,/?>B&-]7JAXQP1*OHN/_R7)WJ5K;*52K]F.M
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MQD(,LA2SV&0KN[',@FRS)&.!9V=+]Z&YEF9(NWO=]\[WOL.LMD/+[M*JA@
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M+Y63G.=4$YOR!"=VIO--[FSGG@8B3SS-<YWUQ"<]]=FG?/+)GG7Z9S\!RJB
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M[,I=?57"%=P'=N (;N )'EP*AF +EN *GM6Q[-4_PM\P_\-<^R6+8Y7)\87
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MUCRSUKG_/@A^&,$2S&%OY27"!&(100 77&(606)R->+"SL%VO4%W74S#;K3
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MH11B(15>(1=J3KZ16Q(VX6(-(1"286,]UL -S\$EW!JV(1OVW'+%8</YG/)
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M 3B [U):1[" ^U+2KK5?%3B!&=A:'1A;(1A?]S5?)5A?+;B",5@R*;@%$P$
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M)#,@"0L0<,BWN"4OC)S+3?[3H$B.1I+-J61K^H&4&31RDXQT2X,.PQ8$O <
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ML$WIZK.Y^FROC!4P9PWK5\*BK6PA%JQJ_2NWT^*6MB[F+M]>*[CR.M>[T&7
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M *K5E.>DE:OQ%,2I5;Q5&\!!W+1!6T4XP+%9FU-MV[NIH.8X! T*&U,A0#L
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M+QO:I189<D?.$U0KI]<E*YG)D<N<Z3XG9=156714OG+J2+<ZV&E9=K6C7?#
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MCG[)EO)PF ?Q5^X1EW$13S-^T/Z$'F^1W=G%7=QM7N#U'78-7FDD_Q=U)1F
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M8K:)X2Y^##FRY,F4*UN^C#FSYLV<.WO^##JTZ-&D2YL^C3JUZM63 >0$X!J
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MA8J9S6=6BIG*JJ:[GTG-;7I-1 0J9C21M:YT;5.=_#XGG(>4SQ^U<)_Y1%+
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MW?4=D^NF?B]Z..;^<"_S,90;G[";\FUU2?:K]X;GTYTN'_F+[QWOQ=N/SB-
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M-C(7@7'#51=0=O]TU\Y UXQ7SW;)[79>U.J55U]ZW]W7WW[AY3=?@ EV*^!
M\3WXW81OT]-A,1%^V."$ _Y7X((7QGCCBQNF&.(M(Q83S+R^+-G*DT=6.4R6
MO9Q8XXK/-/ABFBVVF>*;89889YYU[CGFD(,&>NB=?>8X9X633G?IC-<%-V="
ME<Y88:?MK=II8FF%]-NL:_7:5+#_8WUU;$==+1L_5=O#[SGEW&L[O[?9-A#
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M+$=N7# !$\<!PT8?^;MIY#O-]+9NS"\IHB*X$U$-[;S#PT?,*R,/&\C,D<>
M-#$VVD9I)$=IQ"+.$R,9 <C6#$@>;='.(;V'\2XC44C\7$@CQ3$DM4\=ZS$J
M:5(QZ4]&(L6684M=P[W=LT@L[9)4&S(J!4S!K#6G+,F9G#X=%,JE1$J:7,R?
M;$S&?$R<7-.;#%/$E-.F_RQ,,(6:,[VF.\W*P)S3I1R:NJ1+%1S4OB34%BQ
M&#3!!RRHC"I41T5!L0342 U42NV]1A54M(Q WNM "IPH#.Q4G]- 3L4HB_K
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MT(9]V?%A>-P8'S,FR)<9S) 74^3']#C)/U:RD(GL9",'!I   $\9;R,>)"-
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M'%G+,+\L<U>4H4PS:S;C%AQE- _G3\^S :V<S[,5/;31.Q-]M'+N=.&.%^]
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MQ[F;[F/B\?>RKEG+EL^:F'\^_6<?P"D_5^WBS^%!!S&!$WA ],! ]W#Z-&Y
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MMN\N'N,O#N/]'N_[%E9BM>-^TN)Y<M82L59'C2-)U381;N,1ED@'/W!)\N-
MWF.D,U=R3==V15<,YW!#UO!U-623A-<17^0L8=\@+)-\O>05!VQ,[M[UA?%_
M%=A/+BI1)EA23MA04=B'1>55YO%3P4I6$3RT.JN_DV5<*8==L66G!5FS=5N[
M==DGEW*\A?(JG_(HI_(KM_(LYW(L]_*SS69N%O-M=LR@;9BA#><N> !F<0"E
M-=HWSP%CF0&B)4U_[F=CD>=,:0=B081MS@?6O$U\!H"OO7/$W/(OUW)C(>A$
M[_]RF%WHGFWH1F?T]-/;F8$;BZX'C-[IC(X;%+,;M[DOD#;<CA9IDKY<ZV0P
MPN&_1X2,!9G.5!?<4R]<S/7T]LQI_+ITS\7U7=\P#I3?F*Y TJU/W$GJ*TU!
M\YQJ (MLIV;!$OQ#_W7VY4G0!*U1&5S>N"X2X<7!;2_1Z"'>?CWKOM;)&_W=
MVN6Q*)1VV*5VN3Y"LM[0"6WKV[W1,Q3W;_?"\_G>?(?1,"3?\#5L.!1?]55L
M&EK?*0U 'H)?+56QA*?L_<RTS+[?0NSL%CQ$Y+;XX\;X^@95A<N,1K7@!!Y4
M*V;@]P[O[I;@X8Y@D4]YDU?OD==5EE_4 P<W!P=A5?S_>';C8#FF1BG.>-/V
M^8O'[I;G>>G ;_(^QOTH^F1<QOD.X!?6;XT/^J6W>"PV^J07N*C'MTME>JR'
M>J$G>G(D^:YW;[''U:>O^B>.-JJG;^[F;_(VXSF&^[>7>X.$8Q,F\#<F$#R>
M2#6.2&NJ8SJ&2/W@X\&O\ DG?,,O?'#=<$)65Q$_Y)-"Y!(G<2]!DT9^216O
M24N62<VO=RP,RIWT$QD7_4X&9:%$RJ/$\=,W9:;L\=;_<51!A'00<K*:E5A6
M*ZU$<L2+*X_%&(..Z-]W:. 7:(3V_> W_N&'Z.-/:.%??N4O?N1G_N=O?NAW
M_FBFRS G\WG.?MMKA<N:S)L9_V?5ZDPZ)_^>F8%DZ0)PCEKB1Y8\'_1O,8=6
MV&9Y<("\%'0ON*U\8$QY(.;&1 3' H@N_@ 0'%B0H)<#"!9Z0R C$2*($!]%
MC#@#0<.%[0@",-B*Q4*,(0_,N->1H\&3!U<"<!<R(P*%#$<N5&ES'LV9"V6*
M7%@N$<N40E&VC/DR9\^8LX+.DB%2!J*A08G2FP&3)\PK1*=R[9A(IU&P6)%>
M/;K3;-BD8\^*1;LV;5FP%24BHICH7KY[^.KEW=N7KUZ\^/#AU0N8<-Z\^O#E
MP[?X,>-[BQM/EARY,F1^^?3ET^Q9'S]H_$!W!@VM'VA]J$>C;DUZ=;[5ISO3
MAJS8</]BP+?S\:UW;]X]>L'W^BV,V;ACR_J4WPNM3S2TY\Y%;XY^&:]NR=%/
MJ^:NN5]L:/ZZMQ9/_GSHZ>EG]YN=OKIFZ;1EEQ^/VKX^^^;O\[NO.O]Y[?G3
M7WX$XC?@> @6F*"!!OYW8(/\\<?@A/S,TL^ L_"3(886=GAAAAMZ&"*'"(H(
MXH@IHJAAB2I^^&*+*VZXH(4S0N@?COO]UYYK$#(X'HLUDNABB0#B:&2!.?I(
MI(L ]',A !XZ"263*\*HXHE76AFCEEU.V4^44#X)II1C?GFFF6F*N2:83PZD
MYINSQ/FFDU/&V2:;9TI98X[@O2?==NH%.NASA4('***'*BK_J'SO.>H>I/0%
MR!V/DTH:&FR9OK;I=YS&YJFFG8KZZ:BADGJJJ:F"NJIFLWCJJJC_=>H:>+2J
M]BFMN.ZHJZV][KBI:[/*RBNPP]I:ZJNLHJJLJL@&2ZRPFCY[++354@L;K*=F
MBVVRHVY+VK>M%OLM:N3J8ZZTO_JZKKKMLONNN_&RR]JOL8:;S[W-+HLLO_OZ
MJR_ S K<;\#B>LOIN=V2FG"TXZ;F&JR_1KP:PPN'6W&V]VJL,+<$*YMQ:B"/
M)C+&(2LLLK8<#_PON">;;'#%%),\L\HCUXSOS07C?##/*??<L<]! PUTQ#3_
MW/+1!@N-]-)*#\WTTTH7C73)-L-L__3.56N]<=([-^UUU%Y/?3756(^=M=DO
MHUWVRPR[/?;;;<,-\</_36QWW>7F+6^\] ;;KM^J$4CKX'QK&/C=K?&#^.(2
M-P[QXSL./KGBE0MN>3^47[YYYN5JKJ'EH&\N>N?G?GYZZ)J77KKHK1/HNN>Q
MFRX[[+/S:3OL?.H.^N[]"=E[B)D'::6&Q+M8_(O(<[E\E5TN/V:)T(\(/?4@
M5H_A]?YD7[T_VE_X??=C@F_G^&Z6+Z>=Z;NI/OKKN]\^_'.R+__[<\YR11?P
M>*%_%UZXXT47NG"%' QP@#.8@0P0. ,6.("!#@P)!,$"DPFBA8(2K" &+ZC!
MI%B0@QGTX/\&.RC"#XXPA"0\H0E3",(5EI"%*'2A"ELHPQ?.,(8TO*$-<PC#
M'=:0ASCTH0Y[*,0?#C&(1/RA#+9B$ZDL48E,?")!6C%"!F;$ 5<@0T7L,I>Z
M;'$B7?2" Q;2!;IHD2YD,&(,EW*2=JSP'4Y$R2S8*$,'K*0++<S'&W$BQ#<"
M !$B1$17^G&1I'2AC!'IPE%8@"$X.H6"YFCB/:R"%G?P,1\U;")!<*)"?+S1
M'"ST E=XR$>;] .1')R!/C!Y$D3.$!ZJ]$<8@2C+(L[RB#KD(ETD4IB]( (W
M@6E,8B+3&,3\<C""H4P^*'.992+S,9MQS#,YLYCXX",^M8&F,YO_69I8A<H[
MU+'-+@_3F^+XI1[XH <B?$,/XF3G,9;9C62PLQS%.*::UGG,H>JYG'G&DS>&
MHD]GW$,J2A$4H']:5$#]!"G/4 =3#XI0DG;E)UT-Z$@]LI&#)!11_91'4AJM
MZ.QH)*,AF6BD(OI1BDQ4T@]EB7E;:IY+G?>[((%400=Z4("0=-,CV12C0QH>
M2RFDTX?VZ:$_;2E,I??2E1[UIT'%4DRCJE0\82]/:JHJ5;V'ISNQ;ZMH@I]7
MK_K5IX)4-O%9%*$49:BU;H>MB6)46]':J(9&*J$)-8U'"XK7O7JLKRSSJ\X"
MNS+!^I5KN +;K<BU+V/5C9M["Y6L(@M9_\-&+69J"QME+ZM9JUD,81>C&&@;
M6S7$.FVSI#UM9DLK-;6=[6PR0UAHZ16XT&*.;_"Z[=[NQEG70JVW@!TL<'\K
MW+]N\U2C&=5QB:NOU**6;61[[MJLMC7G1K>ZO%7M:4W%W.UZEKJ8#:YR7;9;
MUI)WO)PEFF^;VS7"AK>P-^-NU^#[-?E^-[[O[2YT6UO>Z>8WO?3U[WWM15W]
MFM>R!4[;@0<LMP5+%VX.9G#<&MPVNLG6;:^ML&XMC#?$Y;9Q#QY9Y$#<8 ^'
MC,0B=AQK5*=BS*V8<RU>W8MCS.(9NYC&,)8=ZU 7TMKEKL>O\YV/A0?D(0NY
MR+T37C^0C#PE>_\(>4YN,I2_=SR84GE+4]5J]*RG9:QB>7M;[K*<P!R^[[G)
M>_X GYG/=^;ZJ7E^;J[?F^,WOUD(H@OO\,*=[_R_ !90@#DXH#D4R(('/! D
M$20+HMFB%K<PNBV.7O2CXP+I24NZTHF&RZ7?HNE&4SK3G+:THD&-Z5![.M*E
M[C2I4SWJ56_:U*IN-:I9_>E3BQK6M9[UJW$M:U?O.M:VIC6P<\WK7PL[UDGL
M"A21/4JI2!'1#]FB(;V82UQ"&Y$'>$ 6NTCM,_I:UUA1XT"N@&H'\&/9LP")
MINFHDH1P&H]3D4>OK\)'/R*:!?F (CW4X@ R>-$!6 &D32 XED>Z9-C_"'CD
M$P?9:E5JDM6@Q*0=3\W)H'CAU>!V(B**S8)R8W(6$+2T*Y\8RUL;O.3=-CG)
M8ZUMNX2S+X)!##,+DYABTK.9U8RF/NMIS;-2<S(YER8VH1E,>DZ3-L>E*VQZ
M?IW=C!.=P@&.<.C!F^+PYB_[;$YR^*GUI=?#G97)S=;GZISFS*?LC_),;.:#
MUX"JQZZ.PI5>'2H@G%:*I^11NX PRM.,&HE2?>]H=VXDTA.=U*="6M!&"2]4
MH#HU1DA]*94@_Z(P39[*)9T1BQ!_([W._:-T!Y!0$V2Z'XU^IAA*O-UY%- E
M 97RKC?3GB#_^ Y=OO&FCVJ3IJHGJ_*>JF/]_RI7WQ?6.@F_J[^7GDWO?E"X
MPM6M<65^6J=C*$&=W>VG@4Y>LV\IOK:W^^S]/GC!/]S6+*M6P"H_8Z=5+]NR
M_UKULM:JU#]^@:E?_HR5+;0 ![CY!IC_]OV__W56PPP@L>#6ZDB. ;8?W\R6
MPP"@^'E?^$4@8*D=VB&7!$)@OR"8@6F8WF"8=XG6A476Q6!-V&A7_]67=>W7
M?PV781$8?Z7@>9G6"F(@#3Z@"3H@@.$@=LT@#_:?"VI@"ZH@T_2@#JH7#+[@
M=8F-$/97@C$A?T48%(8@A4E,;CU6NR0.!V8A%M*69!E.%<Y6Y'0@%3(.&-J8
MC(V.CN58ZJPA&K*A&O^V(1R^H1S^&!OR&!WN&!W>#N\$&>X0V9']X1X2GI!Q
MB?)$6?),F>3A7B(FE95]F9=QV2.*F5:AF?B83R7&3YO!F2;*V2;2#R=^HB<.
MA#[D0/_<6?_L60#YF0'-0* E$ LL4 /%TJ&A42W1(BW=HBW5HB[BHBWF(B_N
MHB\&8R\.(S 2XR\>HS 6HS(BHS$F(S,ZQ+)%H[)UQ3P,T@@]6[11&QFM7$2(
M&P+D@#9FV[1QVS-.T,7)$0IU 9@@FR!(D+H9A!?<41[-TKRUD#E<'$NL@UG,
M "+D@$X(!",MXTN4Q"M5' PQ7 8!Y%1XTAY-Q3VP$#[:1#G<4%<4G N%G!/_
MC9PS;F0STF(X2H0Y%1/,U=PQO=PNG20P!1W/X9PRV1S0^1S0[9P^<$;/1=,S
MK21-;H;17=-QD%-O! <B1%U0_L9PM)-Q'&75^5)2+F4_]5/78<?4Z<;-+9_U
M,91"*10_9!UR-,I F15\8-]===Y080K>;52[<)3;P9U!^9W@U1[JZ11$^8CF
M&=5,&1Z*])1*E1Y>BM13+6+D59Y?*MY;)E_J$=1.)1[IX65=JM3A':9C&E7I
M^26759E,#4_A*6)E9F:69569;-F7:-5G7A5H%A]I\E[P?5E*.<C9Q56B.)]K
MIM7TP29KRM4W(1W;65][.)3<>=.E>,=?^:8-<I^^_R17TGD*VB4=!187<G['
M3LZ?>R7-!GY6L7 A=5JA@%VG &;GA07@=J)@=VY6=.+7$9)@#G)G>7KGQXCG
M=\9@A1V+_KDG;C$@AWF@$Z(,$=8@>!$G:>CG9U@@<AG=?@)H?Q97!0;H@"87
M@EX@>JY6$T8A"$X8A$H8>Y*6@1GA@EKH$,I@SJS,??Z@@DWH# ;G@!:G<_H+
M?RJG@I[@>:[H#JJH:B'A$H[GAV)HBQ9A:L$H>[[@=GHH= *A<T'AAP$IA 4I
MD0ZID4JHD")ID2KID;Z-B9E.BIFAE-88E=Y8E9ZAE68IEIXAZ=SA'-+.'09B
M[.BA'XHI()8IFB+9('H(D_])F9L^B2%R2"&^*69*52/"2"3FJ2/NZ9A559]2
MHIP ZIH%JB5B8B?&62@B*J)>" #Y#YXY:BJJXI^QHJ#!(@/-X@<16[P%VZ86
M6\I]*J=JJJAZ&ZFB7*B6ZLFE*JAZZJF:*JN^:J?&ZJBZJJRBZJK6*JW.JJJV
MZJZJVK&]DC0":T$@ D,B  MX <<U&ZD]VS9.6S9J41DTD@YPH[-6!#GR:J5=
M'"L!&PM$Q2B5TDZ\(T+ FKLU$;R):CUZ6A>\TKG)&IBDA*&I*D$F6T$*&T*2
M&L(%*[TF&ZM%I$'0&ZN6&Q/!PZQA9%!H)*SJZJTJ++:&!+6:DV^$I%\(4\Q]
MW6#_2.QA*$=MXN3/)5,]M:1RW%Q.?D9.@A-,VJ38P8<P&48Z 27$_@7,OBQ2
M-N5Q,%W,GA,[@5T\84:@L%WTF9U 865TO)/&6B7=!>UM<F5]'&U>H:6H(.VC
M -[>A=[G[25^7!20^!3B629*95Y-:>W7DLC@V1[CQ1Y@GBV'4%[:FJW86BW?
M[92.<%350J:"<"U4-6;5VDA.U>WLM0CQ!2;9VJ7B_0Y3469,?69G^IY8+2Y8
M'5_C,J[B]I[:XFVM^*Q\O-5L2M]LQB9;:6YK1E_/1BUN8A_V[56E[.:EX&<&
MIFB) DQR'N=K)*>(=E^^3*?M)J"O$*#[R1_MNBB-TNC]_U7H?W6@>=9H\687
MA]9,^BUO=3(@[BJ@?.K*"#:@=K+H[]9NZ[+N3I*H<;VN]_ZG?ZIN[V+GW*S?
M\\++?,IH$=Z@^"Z7[][GCFHH=,6O\9:@]LXN_M[O^^ZOC8H7COZOC]:G_\)O
MAC:A$@HP E<7_0+PC_*H@TK7%$;PAHTA!4NP&%JP%GYA!4\P!F.A!X?AE4ZI
MEKJAEY8PCIEP2'UI"J-PEX*I"^/A"_.AF/:AD9FI#0]9\-3EFAH/#Q^B9-:I
MX5Z9$-\IF$'BGAKQGY;9)2:QH39QHAXJ%(.BHJ[/F;T)(N!/_V1QHV:Q*LX
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MN2XO.5AT)RU9IW;S(G<VB9/F8I.I<SJC@EIYAUGSQWCJ-92Y5S:ZIU[OMW^
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MIH7:J47:_Z-EVJ25VJRM6JR]6JWU6J[]VJ>UVK'MVK(56ZK=6K4]VBXHLD0
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M;\C;U],[;].+XX%=&/)NK+G,8[N,[Y7I&(:=[]^[[S_&[XJ%V*DN9/_"1&0
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M0[[(R\C62SOHRQ4$W[_,0#D(#&H=3,(XYF,._^#\T>S^U:S_Q5\ $F#.\BP
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MFV_"!]<;[\0#5]QPP!L7W''$%Y_\<<8EKYSRRS4O?//#.?_<\] C!]WI&;Q
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M8.?ZU\D>]K*/W>QI1_O:Q=[VL[M=[7!G^]OI'O>ZS]WN><?[WN7>][O[7>^
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MX[.9^?,V$U2:H7E!J9E!8==U'71""70_N[F:O7F:_U-X9Y><+[1US9E"2Y1
M2Y2=071$1;2=/31%/91%4_1&8U1(7S2?C?2>;72?TY=^ 9I,!SJ@"SI^QW1]
M$YJ@[3=__QLZ?)&431]:HMU7?@6Z3+GT2>FT3?MT3CG:3C^ZH_&4HT<Z4-V4
M4RWUI#,UI3<5I5M:I5V:I5]:IF.:IE?:I@D55,D@ZKXOB%'U N_ECQD9D1>9
MJ(.ZJ(?:J),:J9=:J VY:9GZJ)LZJJ=:J:6ZJJD:JJ]:J[.:JZVZJ[':J\,:
MK,=ZJ\6ZK,GZJ\]:K=.:K<VZK=%Z5_D!D]^!'N9!:YV+81[S:]=A,BO3,F7
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M__SNCS_\Y\_^]9?__?7'__WE[\^<*^OFUT)FVD)!6?=U7G> !8B 79> #+B
M#FB #0B!#ZB $EB!%'B!$8B!$YB!'!@PFT9I(&AIG/:!(AB"G6:".Z>!%EB"
M+'B"+;B"&QB#,-A"^= %[G :.&AV, ,;5S #:B=;B&<T==?_1K8&1[<F1[BV
M:]<Q1X!$;$[8A%#H1[MU;(-W;,QVA<W62$?S;%D325XX()1T;6*X2=G&2>AV
M;JG4(9OG;NJV..5VAG!8.*S'>JK7>9PG2W@X;_%V;_662[&7;P 7B'(BB(3(
M?+V#3+RW?!47<*QS<1;F?!,'?9(8B2:F38D(B>&$<9!23IRX?1[7?2+G<C$W
MBBPG<Z)8BJ1XBJIHBJQH*_V79@ X+6GV"/H0=)\U5H6%BX.EBYS%B[<H5R75
M@3,8+K]X5Z$%C+N(C+VHC,68B\QXC,;HB]#HC-'XC-)XC=:8C=6XC=38C<G(
MC=_HC<L(CN,HCLT8CNA8CNEXCNK8_XZ418S3.(S"F&COJ!3L>(_QF%GSN(\R
MJ(+^R(_R*&?U6!26E8_XB(WD>)#::(Y8A1HJ(P_T( \NTQI>Y!IA]%ID)%MN
M5UM[%S1  W=2HS1\-Y+.MH4FR6S$586!IUPL*3;/U9+1Q9+:55[8]37559,S
MB9/8Q5UQXUW@97F2=UZ=1%[KM5YWZ'GM13B7HY2D5U^C)V"H5WJA!Y50^90%
M!F!8.94&5C@*1GNBHWN?\V"YMWMD28F$,F*&.'S*AXG/Q)9IJ8AJV7S<-(D+
M!V-M<GUVB9<I1GW8AW%%YGV:DF5=)IA@1IAA9IB(N66'J9B)R62.*66#R9B2
M^9A:1IF1:?^9A3F9D)F9F+F8G5ED9#"+L5@0S$)FLP"0_]B/J+F:JMF: ?F:
MJ0F;K"F;KAF;MCF;MUF;N+F;NJET).B"P/F;PBE$*$B<O"F!P^E$+YB;M-F<
MS"D4^; .660:7.0%K=$%8)1VKX8;W-E<1HB$N29'O#:>2VA'PY9WPI:>Q#:%
M*TF%)VE<6!B?6?B>C!1):P.&8VAMF*2?F8=MVQ:'WA:':^@W!%I*;YB& 8J@
MIE1*[':4[C5+\J9+]#:A]B:AM8=O]5:(@V@['*JA =>A:@F)=0F7T.1[E8A\
M)VJ6U"1]</)-UZ2B:,EP%/=BTD=RR_-QG9BC(><IIC)RH+**J=C_BJ@XI$!*
MI$):I$AJ3SI 9LX2BV/P+,JR9KWIG,?YG%6*FP-)I5-JI5MZI5WZI5H:IEPJ
MIEY*IF ZIFA:IFEZIFK:IFSJ&/[0!3%#=M8Y&JHF,ZV6 S<#:])U6[=UA.A!
M=_J1DB)9J!UYJ'J7J(3JGHS:GH[*7(IG>#"9>#49J<GU>#'Y'SY9()MJ297W
MDW6#>>!FE!>"E XZ;I CE5:9E:?7JJF'.70(>J@:.:]7>YTS>V&)>U_IE6$)
M82.Z8;]7?,!'HKP3?&NYB&^9K,BZB&PYB<_'HLW#EWDYK7N)8N&D*1B'/: X
M8^!'?N+7K>#ZK0!D?^.J?^4J?_F'KOM'_W_KFJ[L>J[OVG[Q2J[RNBH)Y A=
M@&8Y1XMO:J;^NJ;_ZJ8!VZ\ 6[ ":[ $>[ *F[ ,.[ .B["-D9R7%IS&2;'*
M:;$3FX(+VT$2.X(5^[ ;"[$^-POUT!KP0 ;4:9VKT1I7X%KH8#.QUJ?A26M'
M2&M$R(3641TX^VM1J)X]^X15(TB-"GAW-Y_RF1^+"FV<ZAY>&(;[66U0NR#6
MIFT BH:H-*"QU(:%<Z )FJ!:.ZMU2*"F"F]Z6+86RH>QYX>U!X@>6DQM"TS"
M%)<;:HDH*K?'Y$PQFCO-JJ+.RK<<5HF_ZDU\4J,Z6KB>F$ZA>*2*&Z2,:Z2-
MFZ2/N[B.2Z2AN?^O ^4LIFF "IF0!MFY",F0GWM8#?N<FPNZ"SF:I^N.GINZ
MI;N.J\NYH:NZL=NZLLNZKVNZL&N[LWN[KKN[OJN[P)N[PHN[XD@O[!BRR!M8
M=4&[S#NZR0NRSAN]T MH6?I70W59OSN\O1N\Q+N]<T40JI5%J+9%-BBGL"$;
M8Z21./FGO<6>4\-;\+MWP56T6EB_Q:62^#NIB&=<AW>I,9F3-YF3 JR3TA64
M!@RJ1%EYZ-63(D*J8NN@3+DB$>R4%(Q?JBIZ_I7! Z;!3;G!'HS!'^PD!W9[
M8*FKO3J68EF6?=M[RVJW).J6?^N(+4RL,RR7??NKS,,F>EE]/*R7UZK_9(#)
M/>#ZF9I9F>='Q$B\F9ZIQ(W)Q$5\F4Z<Q$8\Q5!,Q9P9Q4+F!4QJ<PY$<]WR
MO"(+QF(LO6%,QF,\O66,QF><QFR\QFYLQG",G!7;L<5YL73<@K^IQAYTQQCK
ML6^LQX!<0OZ "*MV&F20:M?):CDP ]L9L]AULS7+A$JHA#GKL^<9;$!KR<7V
MJ(UGO\1UM$9[OX/*M &"GT^;GV68RA_RGPI:M: TM@5*;I'3M58K(UI[7G)X
MJGF8(Q1JMKW<A\#\M@*W;\,LS'/KPB*:HB[\B(/(PGH[EWZ;<<7CHM%,MS4\
MHYI(H]>*HY[8B=S\*3[JHY,+N>,LN>1\SN:<_\Z1ZXH%Q<76DG/,<IIQW,;S
M_,?TS(OVG,_UO,^!K,_]S,_W'-#^+-  /= &7= (_<] =T6G%I&G8:<5V5IB
M!+/=B1M<LY[O(:C#-<KRBZCMZ]'QJ[1#V\F<[)Y>0ZDN6:DJ3:GYBZG2!GGB
MA9_AY:E B<"BNLIZH\NPO)0<7)4]_:JN&M0+"JM#?7JU>JNVZCD-9L(FW&"^
MJLS=%*S'7,S+_*%6_<Q5G=4TC,S5/&'0VI<]3*UA'6/DE*W?%YAG'7YJ[:UK
M;:[UVJYP#:_N.M=Q_=9R7=?TFM=NK=?J^C]>L"W/$H#94HL*3="%?="'G="&
MO=B(S=B*W=B0_=B2G?_8E*TO?'S9<YS9=JS9DVW9G.W'$UO9D2W:74$/70 /
M#EUV*[N#$NV#V^F=OE%WD1S)Y*FSYKFSF9S;/]NS[)F_5OB>H S*2=N% 2)M
MIWS<_)G*4DO+KIR&6"NKK6?+M1R'7_MY<ZC3#OK+VGVAP9S4O63,Q S>^E;5
MB)BW6SVL)BK#(=K5[+W"V,S,R32XTJQ]AEO?GY@]ZUS.^8W.^ZW.^OW?_)TK
M"$1F$,2D%MB\V=N]M:N]"YY6HVV+O-O@V^M3#([@W.N]"F[A%1[A&I[A'/[A
M"8[A(B[A)-[A(V[B)0[B%Y[B%'.\G0W&U:L5*.[BI%WCCFWC#XZ:,5X3!1G_
MXBR^XC.NXFLU"W.*LO0 #Q.9&A'M6GL*A!9M2'\*DA^=J+TE=QQ=DBAYY;[-
MR9CZDE[.Y?]+P&(^P&3.7=ZUJ4+YJ3&]YFE^-PM,7@ULAW+N(1,<7R#<P7A^
MP51YE5J9E:.GYW>^YP#F(R.\JP[6U& )82J<>^Y-<->LU;$#PV<)N(]^WLKJ
MZ(T>33DLUCO<Z=DG/5 6Q$%LQ4M,ZDULZD]\Q:@NQ57<ZJKNZJ4.ZZ<NZZD>
MZU=&!@8^+:49V#G^XKZ.X[]^X\+>Z\!>[,,>[,1^[,:>[%2$V9O][!G[V76,
M[)HF[7AL[=2^["^.,J>1VEATG=F)D3:3&T]^TC=;_]N2W&O= ;0\B\F[+84C
MW:CT&\K!O4A:OK229,K)C<I#288XW<H S]P//.<&.LO3'?!%[2$-.N<X J&^
M'*';C;;<+=[#VJ'&VK9Q:^G6C.D:OTV!R_&9+M_$0\V9>,.4OMZ-DO(;9Z/H
MU,W7\\T[:BOA'. T[]\UW]\X#^ V_RLSL$ 1I.L*M"P4I.U$K^Q&S^S9?O1)
MC_1%S_1*W_1+'_50/_5/7_5.?_6.P0_F^Y"F;:<[V ZN]8-\JI,\J]%8WG=,
M$](DB:@@N>5N3]*,E]*6ZEPKO;_]"^9Q;^9+.].21],(K.8WG3<S$FX#'\OC
M!N@^'<) O?A"#;;0':NP1_^KWIW42UW"B7[Y'X^WFI_Q($K#%\^LE7[I'?_"
MT!SR7_UBU<KIJA]C.&K6W;RM;2VNL3_[='W7MF_7N,_7\[K7O-_7N=_[N^_[
MNE_[L?**S"(M!34+5(_URR_U5N_\S/_\S3_]TE_]T7_]T!\QSA[MT [:WC_M
MWX_]>8'MVT_]XE_&!#$/6'2R*:N#V.FR%*W2:92$0RB>Y7G_OJ;;EZS)&)T=
M<$_2 (' @4 6 PT*1'A084*&"QT2=%@0XD0'$A](K#CP <*+&CE^]!@2P4:1
M)!V81#GRI,J-#U:Z;/E29DR:+%G 9'GRY$V=,'G"[)D3Y]"9+(T"]8ET)]*?
M/7__/DVZ=.F#BTFIWKQ*M6I6KEMA=CT)5FM8K53)ED6;5NW:LC/8OH4;5ZM;
MJG0?V,4[5ZU;NW7OZO4;^*_@O(31\CW\M_!@QHL1YWVL6')DRI,M5\9\67-D
MOX@->[;<^2Z$QZ1)*X;PP/2,U:U9OW8=&S;K!Q9FI[:=VG1MVKEYX^X='/CP
MW\5]'Q=N/#ERXLR5-U\>'?KTY]6=7Y=N/3MVZMRU=]^^W(LC1.0= 4 _ICRB
M1XAF^4,/ #[Z^?+CU\=_7S_]_?;Y__<OP/P '%# _@I$\$ %"5S00 8?=##"
M!"&<4,(&*\3P0@TIW-!"#C_T,,0,01Q1Q Y+1#$^%>M;_U'%_EIT,4 8763Q
M11L!G#''&V7<L48<>XR1QQ^'%+)('XT,\D@EDV0RQB6=;)+&*'4D\DDIH<3R
M2BVI1#)++JW\<DH@O1QSRS+#)+-*,=5,LTLSV7S3333C!/-,.^&<,\\[Y=RS
M3CS[7)///P<5M% _#0WT4$43993$$QNE,\H4':74Q$HGM3133#=]]-).-06T
MS45%A71&3CU%%=143U6U559?_13656.E=59;7:T5UUMEU;577G_-%=A=@R5V
M6&-;U9/042,EM5EFGTT646>C79;:1/GIH@MXZ)&'#'B\Z,*+=[+MHITNULE!
MG1S2F4$&=]\M*-Z,$$*@H7KMK?]WH7P90@"CA/PU"&![%1)X7H,Q0CA@A2E*
M6%Z( '98X809EC@C>2^VV &-,>8XXXX_]MCCCBX>F:2;XC4Y98)21GGE@E:J
MJ*J=-):Y9JBDLOD!&6H^:>>F=(9IYYZ#)GKHGHPN&BFAE58*Z*.=AGKIGJ1.
M>NJFJ::*:K=V-NLOKF':^J^3PB8;Z+)WSBSMT-9V#+#&W&[;L,_>!BTST>)^
M6^Z\]\:[;[CUJGLSP0/W[+3"Z3I--<07IRIQQQE7?+3%5Y.<M-QFNSQSOC2_
MB_,9/ ?]-=LZ%WWSX$BWW/344?]<]=99'[WUU65_G?;80Y\=]]IUO[UTV%WO
M/7??;0?_OOC?CR<>>=Z-3[[YY5'/@;SV'.D"O>G9TZ=87[47=OMCNP>?>_&_
M']][\\,G/_WSRT=_??7;AY]]^=^?WWW[XZ<___OKQW]__?L'(/\$^+\!^L^
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MSVXS./A\SJML*/OT./ZLSX,#T &-S@+=3P.U(/]4SP#53P9UT/=\T/M A'9
M(F[Q,24:Q2&;@2([,K#_8D6:J\N\+$L[NKE;U$L/1=$RR\6>:QBE"QFC0[H8
M==&/$<:GJSJH.\:HHSH=M3J4>(JLF\'*_#JK\;IJC)JJ05*SL\:V,U(E95*D
MH<:L08JY,T=R/$>]NSLLQ2S7S$)[),TO5<>^$U/5)%,P]1M\K,(FY$? "$B
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MJBA&U911*5FT2@YEZ((FFB:.;O2B&CTI25%JTI2"M*40?>E'8?I0Z/0#4%Z
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M^(>'V(>-F#(\]D3220TEYSCSB]@LKSGY,'I7EHJA[7JOLV5CMCJWF(JU6/7
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M;_;<.7/H_\^B09LNC9JTZM&L3Z]VW3IU[->R8=NNC9NV[MF\;V_FN10X4^%
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MF5J5FFJ_56E\%"<3H1JJ=[F7=)F7Y1+  /R_=DG _HO !ZS !LS 8^G :_G
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M/O=N3_=W;_>2">B%+N@UC.A-3>A^W^=\3_B"7ZWF^O=U'_=*YP_T039A9TD
M7KH$4J^VR<S7/(--G-9IS>G_VJ1NG4MP+=?'V?%S3>JNCOH6^YQAW(3_$]O%
M#+O7*J^QL\_&;USK(XO[BWTH)@O9O8^RP!Z' %W90K[0,:NS3%GD.J[\R1[D
MQN[/$'W:?DCMUI[:JTVTUU_)XQ[NX.[MV^_]W0_^'I7;I,S>^6W^Y8_^><\S
M['[^]SU7R@W_\0__[L_^Z>_=^HW?]I__](__VZW__@\0_@ ,) A 8,&!!Q$J
M+,B0H,.$""-*A&A0HD6*%RMNU-@QX\>%'D.";"BR),F')E.BG#C2Y<F7*V.V
MA%E3IDV:-W7FY(EQID^<0'<*[<F1)5&D1GTJ9"JS:<NG2YU.A4I5:E6L5[5&
MY6JU:]:O256"'2OVJ-*@2L.N]=J6[-NM;N/"_V5+5V[=N7GQ[KW;U^Y?O7X#
M ^9+6'#AP8D1+S[<V/!CQ8XC0V9,63)>F)B'HMU<EG-1SZ'/BO[YV6QITFD?
M>NGB11Z9>5[@=6G]CG:7=CG6Y5"78\8,&<"!.Y!!W,%Q%@Z2(U#>//ERY\V9
M/W? ?+KTZ-"U1[].W7OVYLC!?R<_WGQY] ^H3U>O_ %[^.[CLWCO/KF#^O3O
MM\=/O_]Q]1[H3\  !S2PP !E0) ^!?TCL,$'%,1/P@@?M'#""PG$$+\--:R0
MPPQ!I%#$#$<,\<0.203Q@0\)9%%!%O&;H<(8'Y@11@)OM#''"G7TL4<@9_Q1
MR!V)-+)()&=D\<@E6?_<L4DHGY12R2F=I/)**[.,DLDDLSP22R*WU+)*,<LD
M\TPLS4P3S3&Y_+++-^.L,DP(F*Q3RSL?R'-/)?EDT4\]^Q32SQGN+/10"P9%
M]- ZZTRTT44=7=3&1V=(E-))+<VTTDLUE1333SW5%-0'.N54R%-!'5544S=U
M-=14647UU55CM9765F'%=59=>ZUU5U5S_=5788OE=5ADC0WV6&5E77;91Q!Q
M!)%HHYUV,FPKR_8R;BWS=MMOM16W6W#+'3=<<L\U-UUVT75WW7?5E;==>.N=
M-UYZ[[4W7W[Q]7???_45N%^ "QXX8((/-CAAAA%V>.&'%9:X88@KGCABBB__
MMCACCC'V>&.[!&I*Y)1(CLADBU F>62I5$ZYY)9C9GEFAEVV66:8:3X9YYUU
M?MGGE7,6NN>A?RXZ:*(-NUECICL&^>FF/XX:ZK[RR:&UU^1AC;7;;LOABJ]S
M"$Y!LB,$SSKLMD/[NK6K<[MMN-^6.VZZYW8;.K35;H_M^A#8NV_ K0N\NL']
M9@X_P0]_CT#%_4:<<<@?EWSQR1VG?$$"'=0\<P\'M-SSR"^W?/3023\01 <'
M3!WS S=OG7,6-X_=2?IFMSW VVO'W<7=\;O=2=Z!%WYXXJD$?LWCBR=^>>:;
M'S-Y-=N4/DPDFZ3>3>FC%Y-ZZ^=D<WOOY10?3O(/_RW?4"O1'W_]ZKO4GLWK
MVU?42TB+A"!00^^'=']&^^?_?__ACU'X(^"C"EBH ][/@ M$( ,5V$ (/E""
MI8H@!2?H0 MF$(,;K" '+]A!$'Y0A!H,(0E'Z$$3IA"%*RPA"T_80AB^<(36
MHI:T;.BTJ>40ASN4&@^IUD,@_E"(F@'-:(R(FB.J)HF=":(.F^A#)PX1BE-\
M8A6E:,4H9I&*5^2B%K&X12]V$8QC_&(9Q6C&,*:1C&=DHQK1N$8WMA&.<WQC
M'>5HQSA&;1;RH(UKZ*&UV;2F:U?H MC2(9RQ#><[W;E;(]F6-D="$F]GH^0B
M*\F=2SY2;9=<S]G:LYY/#O^./O/)3RE)V3C[, Y #K*<ZUCW2E>BSD,F2E&)
M.M<B$.7REKKDY2Y]N;K7Z1*8".JE[VY9(V3R3D;*W)$QEZF@&3VS2M#T4OBJ
M:;SV10EZPL/F^]:$O.=E[WON&^<WQ6E.;YY3G>F,'_O<6;[SV6E^@;(1H.PI
MJ#_ADY[F$V#^^E=/__6O4I ::*0$:M!324JALEIH0AGJ*0M"-*$1=:!$(T71
M"%I4H1B5H$8]6E&09C2D'1TI1TTZ491>-*4;7>E'1?I2DL+TI"JE*4MKZM)I
M32L1-KQ6'NEX1Z#Z%(\_%6I0B7K4H2;5J$HM:E.1NE2H.I6I3Y5J5*EZU:EF
MU:K_6JUJ5[&Z5;!Z56D\,UK2RGI6I*'U969-:UO7JE:7X6MI1WNK6^?*UKKF
M]:YP):M=^ZK7OU9EKV(-ZU<)>U@P]D.09'@-/+9FFT'RQC>(!$Z MM/)368V
MDGFS6]T\VUF[35*3D5S.WJ3SM](*+K6$2QQK76LX +6V<K$M76TK9]O+L9)S
MI]NMAX8Y.1"93G2XE:4P?5E<W_;6E;+#7.YH]USG)E-WQIRNDXP)O.LZ3[O;
MY29WO?O=;I9SG=F47WG3>=XS=2]Y\4,O]M[Y7GBZ-[[S?6?WT&E-^UY3?0"U
MG_D&"$  !S3  XYHHPI<00.[4(4Q7+ ,&_Q@!4>8P1)V_S"%(3QA#%<XPQ?6
M<(<?D-,:TI")2"2Q$DL\8A.G&,4K+N*)6VQBQ'+UJ2I^,8M/0^,;V]@T.T[-
M4"[R8R '6<A#)G*1C>SB'-=8R4EF,H^7N&0G(SG*.)ZRCGL,Y2LW.<M5QO*3
MM>QE+G]9RELF,YC+/&8SIQG-:Z;RF=NLYC>SV<IPGK.<97QG-F9&,G'F<YWU
MC.<8%Q;0AB7TH TM:$0'.BQ][K*=Q<SH1_M9THU6(B+<,8:L,99KM''';7;3
MFT..308-,LY]."E)N762D:,=+7K,(Q[JP/H\LW9UK>V3G5"RYSFFE$^O]>-K
M_I12<ZM4;K&#B3D(D6AU%&*V+?]K64M:XA)%TGYVBYJMRVAG^Y8F>I&'=%2C
M;_.(FM+\$37-O:-SPQ>^^6WO>._[[FO&.[_M%&^[[5UO?)N3WNK&K_OV2T^
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M0F&/NG1ZKQE:D8.0-+"1+FE\+["10K!R%!D]1^D\Z[<]/T*5UK1M5!,(B_"
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M?)L^M?/53Y_]MMIGZOWUW9\_KO=CJS\VW? W#;C:^O\?+P",BP!G0$ #YB^
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M%[!_G,F7^I/7Y5(_O%J.F<J7N8Z7',NE?.ID+DUTM\FU',P)^\O%/,O)7.M
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MLM,J*JRP%EA;;;;7;EMMM]S.$&ZV?HZKJ+GE>ILNMN>J*ZZ[Z+[+[KKOKOL
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MAY^@YN=9^G.V_HFB__WCYUDX9%".=K2#'O>8!6'[P;5-?]33<A. ;S. <4.
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MO+,=W)\7/+?7O7CXO6_U^DL^]]+WOGOON_/::]_X[M=[A\](^LR'/,4;WO"
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MMMMPOZV93>5(=@#>>J^6-]][(\#"/*_%33C=A?_/C;C<@OFCC"F]S*=)+YG
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M'@Y+!QY$GQ%1>#XD3D__B2#IAS(D=YPD2G&)4SSB;TB"N^0]*1VBH:)Y3N6
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M9X4Y49PY>67;BM$YL.LY%M6(R]"ZEW,-FKLGQXW<NI0,I'/%I7-6S#TUQG
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M,P(XIVWHPSH0UG$>P!6(:*,BPFNUIP/4-%25IS??5O/Q*U]5\\&L _N5"C_
M="Z3AGUJRCFM52Z_@SYX;KCXYTF7'V59ED\?0&:I2[3E0SIXZ%KB1Q?< T/7
MQJ(=YU&B SU(-([ (3R$]4H3RSP8M49;DXS23-- ;XJB:-,XEXSRUIM ((V^
M:&=T+\O8:(\6C7'1\D<[=F-#]C_5'9+*8"N6C0W:( ZN391.Z=P4#O]] 3"6
MSA< XU?BX%>7^A>"'=AJDREKFRF9.@"#]1CEH*F@<M@46H:$R?9-F#"'A=B<
M3H2%@;#S<+!NF Z;@EIMVW!LWX@TQQBHB>&=,D9LUP8_>,&0+:I&8/=4&\6C
M^NGW)%GY+.NP@K>3%3&-8$^7[39T^ /VU'%P<VI\8Z(H@9F88;%F"/&I&L1Y
MCPP:+\2QWL:E9AH9RZ+=1M"KWI!BY#>NQFJD&3@ V*IB0!I)T),.S4BR%CAN
M8#A)0#-DD$^G$412+*M65(53<.M$Z 2L)06%P8F9G=I]VT:*BT5/,$9&UNN-
MTVN.RRN.[[B.V^N/\_BR/9M/1K9=%WE%6-O_MY$?_/'?]0&,#'1X,4-#;_S&
M;QC'NO7"5?[SD7/YPO0#Q28SOHHY6'+L5'>QDK0WR.X?D[.YD[LY:8B3'A.R
M1URGA#3YFK^YDF.<.(?QF4/0S@%>H,?())MMGQ?ZG*O@S2'CG^-=HZL(]04C
MHQ2MH%,Z(LR1GX_@U5*ZHX<(?[;@IQ/ZQ]6#/G/ZW_7)HJ?=II.=#K1PI"NZ
MH1N>SI5)J>-= U_>I-,ZTKDFII/@H?>ZG/\ZJ,.ZL&O>WO8ML0=[J",[KU-Q
MX.IYFX^>K\N<X3[[];V'[M'<SBXNGM]>X])>JYENM7.[_:T#(@ B]QR(/'0!
M3M_YMS6<+RH[]RA?_^@U'V23BVVUN>II2#UXR"RTQY);>^K22M/6KO2]!PNT
M0SMT 3S0@SPT/"(XO#Q ?,/K0V3$[KC[R^Q:9\'''NX2YBS(@X?FNYX/;#IT
MP3O,@\1'_,2K/"* GV3P0SN0?/VQP RX@[GWZ?<B @U>6_TIBP.4PW@:^4^J
M"V_D-7$Q3=+##,WP1C1L>;CTS&!+8&$S1@5"[YOT0S'L]<Q$>2TQN[2#/;!_
MO=B'_;*7?;R',47<0PZ0USRX+_QFMI/*;]K0KY3V8!(&(1(FF-[C?=_S_1)B
MX0)/L.!'(>$;\.!+<..DSIA^(>,OMP9'-^2_5QK*#NZ<#B(V,!R>X>5SOO_E
MGS#EWPX9W .,"LJ ?/[I@[[OX'"@"&+QO.&.S,(]6%@C>G[JP\/K2X3OP:;O
M7*(EGLX0_[[OL"(UQCXJDN+Q5^(#R(,X,HKPX8,H3O@U;J\2\4/SG)FD^;>K
M$GB>;;\!D0$^,,GOB:I^1S_V7W_V$[@@,+_IA:OVH__[<S_\W\_YT[^OEK^O
M2A "T?_W<P[P)4(\ @2$&0\>""1HL. ,??AF\0/P\&$_?OC()#PXT&)&@63R
MS8((@)^_? 9G("2)D P^?OT^@IR5C\S DC,MS!0HL.9-FCMQ\IQ1\\'/G4%S
M"B6ZDU]'ARUGJ10$5&C/HP(3X?/'\B._I#&E1C7_ZA5JT; E'XSM*E8FVJE?
MU8)-.]3M6K-LX;:U6Q?OV;QT]?;E^W=NX+=^!<N=\0B1(T2($2L&X \BY(>2
M'T>V//ER9<R;-7>F_#DS:,ZB/8<V/?IT:=2K5;>&W(]>.02SO\U&<,!V[=FX
M:=OFC4#W[=R^9\]8ZCHU:>7)F2L#U>M3K^>9>FGJ1=VZLFC(62_OSOQ[>.[C
MO9,'W[G?K,6)URMNW![^>_GLY[M?[+!\_LNSWLG8/?R_W@($CC@!A3.0A77N
M,4\\_1[2IPL6"!PPN-\J!/# "3/\1@;\SG.0P8H(JH"@!T@<L<0334R1111=
M7!%%'2 #D<8/;6SP1@9U__1.1!A]5!'(%G\4DL0*NMC1,GV"?'')(9DDDL4*
M9B!#GQQK1 V1)K6$\LDN5R3#0QS%1/([?Q!9<4LOTW32Q!Q"(F\6+]:<D\L?
M<TB$I2O)W'/&1W(HLDXZU23(BUGTO&?01-D,LH(<#+42TC'UG#12/BNE%+5^
ME+E.&4LEO1343R6=QS\+"YS0@70DP]0U?F1PP%0*9W-@05$[F^?4"WN3 9'C
MO.,/PU@WG)6%+MY!A!Y$ZE$6$7FZ2,<_#775D#<'V@G5O'H<"&Y:W1PH-DQ/
MQ?7'GWFVS15=!!QXY\WE^$$$'0QMHQ9#=VZ<Q9QTAY5576[GE8<U"/G=MPM6
M)?^;A1Q]+71 GD=MK9&?&7X3EF( SQ70 7A2RT<>"2LV,-9O94"GBW:Z<.?9
M&23L5F';$JQG7&P-EKDR:)8AAAA<?-&9YYU][KEG7Y99YBIL^XE&NZ21C@8:
M<C-3YF=?I.[''ZB!]H68HA^F>>NN8_9Z9K"Y_IIL_?R9!9XNNB!#'K;)@,>+
M+N)6NXLK<K![AKQGD&'O!V3P^P$6O@W< 74%-[SPQ!%7E_%O$S^<\,4?8#SR
MR0NW' ',-:><\\O5=6!S!T#/?'31)W]@=-1/3YWUU5TG_77588>=!=E5KQUT
MW ._7770<^^==]A]C[WUV6TO_GC7A]=]>>"9Y_WWZ'?_E[Y6S[P@2/?:L2]1
M^]VW_][[\+L?OT30P3<__!+35Y_]]MU_WWV,X)=???I+M!_^_/4G"/^@[O^?
M?P#T7P ).$#_R>1_\D.@ @^80 ,RL( 0?*  &8C  "[0@16<8 0SV,$+-A"#
M(03A"$580I*0L('\.Z$*2XC"%KYP@A8<(0=IN,$8WE"#%=3) 7<H$P@DY"1
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MGC4XXT#$C*Y)CV@=LS?%HJ5.Q\2/*X25E]N2@3J,10]XT.,=78@6AG0I QG
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M;JS& 7;&99PA9.S%=6S&6VS'>8S'8(Q[M&(K.JID/1I,PA)E4:8L8WM_11J
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M]47?9VVKIH&WJO=ZRK(M1,!YB4]TZSCIN-^?=0CYD\?[KC*'7E9TCJ"'R'&
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M];D2+G&13='4I1H&FIFJJ][1#."+DGB!OG @!WK!HO72JZK@KMZ1_/$1L )
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MXQL?$!@JSG%-B,@!'-F(1S>BD8]Y[.,>_1A(0 X2,#,2B#[TF,@_*I(S= 0
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M*U[QFL%EZ44OH%U,7PA86%E ^UE^>;:SGYT8::%T6M6&EK6I;:UGR^(QUSK
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M5=8!$23<'^:A"ZJ;%_OU^]M$*]<)H.@J1  "'C\  /P1+'C0($&#][J@DX$
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M:[FB:[JIB[JE.SFLJ[AS6X:VT[J5Z[JUN[JE*SS$ T'FL [IT [I\+LY(+S
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MX(,-[O?@@1U!Q.%'$(G88?(J3L]B]C!N3V..1?('&GV4T0<:]O)QIXMQED(
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M(L=Q%$=S3$=T7,=R9,=S;$=X?$=Y5,=XI,=Y=$>RLKNX^S-^##1 \S-_[$>
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M. 0&"QK\9A !0@0*#RY\R##BPH82+5:D"#%A1HX;'78$^5$ABR[] *#TAQ*
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MV<E,QO*6M5R31^AC%BEV,9E/_/_B,9NYS&A>\YG;K&8WISG.6+05G0.CQ=>
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M'#\SFP.@$Z?.FCK46I7,@HY^]:J%PPS$:%C,*#[;J!#!0ZRM]3[?M4-T095
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MFZ(K)-VREK@,YC"+@PY$B)*71ZE.%Y#_=$5;5O&9SE1(%^YQR&1:$YL1Z<>
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M4 S+L O#L L5+"M>9W0Z['-H;,;BD&[( "P*# [-IW:63'L Q\F^QP_WL'H
MT7BD9V<$,7L"$1&O9P^3+! 9L0^UY\CBY\4BL7XFD<S&#!/#C'_6)W[48A,9
MJ'X^,7\X,13C!X'RYQ0YB'[2R2LP"!5!415C,15G$19I\15OT7U,+=34BH=X
M$:BTZA=]$1B'41B+\:>(\1B-,4. :/_$[_N^B1_T01ZZZIV^BJJLD:8H;8^^
MZ-+(*-1&@M/ T1O#,=1<(AP=X1'T82;&CQV?L1V=$1[#3Q[?<1[=T1[CD1[S
M,=82Z9/ZT9/^L9,"4I,&TA\%\I,@0S1F >CTR!__YF$&(,V*Q ,1[H$?\@&(
M?-$?9D$?^ 'CTJ5?]JH=3B^;,JZLX"JLTD$>YF$BHU$C_:$?9H*?9B$?.!(1
MYB'Y2O*>].ZCU$D>?@FL&B4=O( >\D$F$@J&.(4?^@$?\@&Q>&6G]@[T9JT?
MKH.IM&WPV*Y>5"-@)&;PGNX \*,>\9$IMJD7NDDLSU*(9+(B^V$F9:(MV;(B
M97*L[C%1,A+CYF'IXJ2MN'+KRF$=W($>AE(=JZXBX[(MU=(B PVP,G(C,8X>
M:A(1T$\RTX\R)?-0&@2(W-(P-U,S6?&:@*@C$:VL!"]3-BX\U,$+YH$H13):
M] $N.Q,Q$;,?%I*/,C,V_]NR,#5S, DM*9=2M1YS,H.S,B>RUY+R,''S. T3
M.HIE(Y$3,7-3)F<3FX"H.7.3,PMS-T5).W_"']0Q.9WS+8%..Y4JKJ3(J9(1
M-!&A^H;*I++/I)I*!KH 'A !']81&=7J/L=3'_3A,=U!--F.+R5F'&9@X>2!
M/B\2&/G!.K^3(YUE.WMQAJJC)L<-^TQJX]RSY8ZN"U12)H((/Z7/. %PM2*S
M,DL4_>;S'EA3']%R1</219^E'\8%'L[O_!S+L=PE!]YELB8K_NRE938&2"^&
MZ^POLS[+ 4:KXL*R'U+K'D9KHT8&N:#4MIQK2I,+MZR42E=&MK +:6!0#2\"
M!O^G-&.6RR>:*[F*XAVR5&G"-$Q;T+JZ= *YE +-J[>ZJV3&R[OR%$_W5 ?)
MB[W\%+YRD+W<:U#_RU /%< 055$7E5'Y"PW1\$L?@@O?,+XT[,O(\ PQ%76D
MD%*?,,<>55.#;'.^#B)>YP[E$%5/]<.\ ,)4-55?U57=<,<RHL>6L V'C%(]
M#%<O3%>3#,7R$%B5[%>7+!(M<1+MS'NV[!*7-1.;E5F9%<T"R%FG]5FIU5K#
MC!Q1B"Y;M->T!!KFDD6W58XX!.>4!5/([E/.5>8:HM(X(HS>U1OAU8SDM4/#
MU5Y?5%SOE5N[A5^_Q?_^M?\"EO\&=EL EF"!K5\-MF#_!79A#]9;%#9H@D;8
M/(-B0<-B*Q9C+W8S9H#:H*MA%U975@7K),I##Y;Z*I1&9*":(/8K]"%%OF3G
M?"Z"(E8B8D3Y=BXYK$H?8 AAM:)#ZJ,[<L,S/S8KC&3W,*4=M#!A^:([9PI=
M5\3R?H\HEY-!.&4_&<9 +>AA&;9G6;9?3:Y MM9AEW9L^:AKN59L]35?]^AL
M"38LHS$?1O0Q2<LB2U9M[Q9?\79?]7;D*B7B5$13,*\J%#0?] $?]*$H]S9O
M^6PV#_<WZ1-Q[9-O)W=QT99LB39MVQ9S+U=S)0(1Q&6QY,$+UJ_]KJ +>+2R
M[,5'Y^]?6C=@7G=?](]F9S=A__*A85*+'@Q0=X5TN(14 8-49'YK9.24>..T
MMU[F>"E&:R5B:J &9W0G*SRP:%B5+EK+3:MF!+-W:8 &,5K+:8R&#* 7,?@A
M$;!& Z53(LA@9OX',?!!!^]E9@.$Q,@F;60 ?1^"#-Z&?0_#?8L0?L>7Q.RF
M"/5&? ^CM4Z,G]:P<#PV>E$G?D/0</B!@<%E4GUL(P\&B4)':275#7FU:S('
MQ!Y 03&8#4N'#K?"?7],?/F!# SG);-"'@Y'+B0BAA'LA!.C5@,G?E^G@+?"
M@W]XQB[88/#!5/'F@1&CN920<KPL8G-8> 1A@J,Q$;,'BA'#']2,$+V">A1Q
M>>G"=_^F>!'W%X<=$0\K:(*M6,U&*'RJ.$#@9X,E8A;2F']NF"XF"!9I%LP&
MB-V"S53UF"LPR&S.N!47R('8^"$4%(2Z&(..& !Z[(,>>80@>8,D680FF8%.
MR"32*ADW^4,Y^4&#T9,UN9-'^9-Y(B*^-2HK=VV+A93:2:^J$98C1!L)22/G
M-5YOV99SN2.R4W%[>95_F7)].9B!696'V9B+.5'X$2 )<ID+DID-LIF/33*F
MS0O(($433^,""J-45(X"3J2 25AXR1UP4ML88F4+JY5-DJ9*$)Q21:KX"A]2
M&8\X)!W(.3EF@$SC2*:BZ>C0CU.$&9D'B2S-,J")&: /VJ#_$_J8$7JA%;J@
M%[J4E3&B0YDBR).ISA.425F4)UJC(;2C,YJC0WJC1]JC1?JA3YJA4=JAX4@0
MS&^QX,%&VT]<)(NRY&]U.48!0ZM(*^^S>AI)[Y4??C.UA.I*J]2HBQJIU10"
M*W!.Y=2ZB,NXU#2Y\EDBS/2UO  IO !+V71-73!,%9,I[H$"N=DITG1/?V(6
M'H"L(X)G6(!ZI612W>N[N%.MMX1ZWIHJXAH*LP:OI2*'Y0NMZ[HGDMB]UMHB
MDKAPL'HG$D%UP+I-6IAO(A4  CA7*SMK6I5T0)"((%MTB&+(R  H(NQN>$R$
M7P3'A"R+W01O2!5/KL(.4S7%4OM9_S2'Q=9(5>%H=FA3=C@P0S2;K5.GKQN$
M>OC&L \9R*B66$Z[?7)F)\A MH4"QPR;'^0, J*U0=(8>(+;'QC;RC8$ GQ;
M*;#[?73[S'K"NI'B6M,;6=?LSN LS_BNH>/;->5YI>L; &8SX-!-YV1OOV>#
MTGC)TL01U#ZMT\JQP G\U 8\U7;3OE4ZOAT<PE-:PAM\PA^\L#I7(O !,Y0-
MDIBM,C@<Q)_MPT5\,W(@?#52<OGL'GH$TB!E3/Y*Z21N'?1ICBI*OQT '>HA
M*C'<)OK!94O2T>9)H!&!'#[NI&A<L#).661@9PF)'] AJCS.H^B*PJM<N <D
M;*T\PK6\PO^WW,*Y',R_7,R]'%#\EK\#-\S)O,O7/,W9?,SST1_6Q5QH5'1E
M6EPB*[)Z5/[PY> X!G8K#_^X3G;+UFLGPA_N00"95$]ZE]$1< &A]-$54$N'
M=TJ+EZDM?4X=X *]PGRQE[D[T&HP)RY0905+_7K9I%^;RVC4$&%G@4TMUU\E
MHK4$-7.]Y8"-4-1[5JP]+&"'.S0,-JT/AWJW K$AIVS%>@HW.,XSM6N^$'3V
M&'-3&'34(G7H&"+\P7 (_2$8&W:06S\X.VM8_6$M6XG-!M;]H8AG *?^X[81
M5@\U6V@>$7,*?8NSIVS=-Q$!=KK+6'S_U>HJL=_//3_RF'NT=C__[(>.*8*[
M[0<".I<?&)Y[=AP 5'%H>W9Y9+$6,QX7;1'C7U$7.4VB21JD13X_23[D/;K'
MI5/-*9R?VF&)8OF@KK$@9MF0N%' N]$<QU'GQ\A%5O[-VQSH?U[H?9[HW?Q%
M6?A=*-:9ESZ:H7G9+&,&1.,1)!B9P"\?UN&@U$'\\&$&[NFC0B^;K4@GZ?O6
M?O:48,:(YB&NS('=!$T>G(ZA(@6;4L6<9* =_CGHU7R@O<GH^S[O_7[H ;_H
M_Y[P\=&D1[ZD4\BBU=D\68FB$1_R2S[Q)S_R3[[R'U_R+W^4"W_P Y_S"2I'
MYUS]8EI=W ]>:OJFZ2](B71(.<M(?WH>__.A29D4'B ]M!@P2I,:2W?_J*5:
MNK94!H/? 20; '"+:&1K3 <[2P6W)]+T3;OZ>MV:)ZRWM^#!1<1ZMZ@:(D00
M9;1;:+AK*MKZ ;J@01 W:ZP_*,I+O<*_:^"A_)/XJ-)_OHQ"K[OF].K_LI,B
M@Q\ 'A)AUOD?(  (]"<0@#\O#Q(J?."%GT%]"QD2'"@PT8R($@7.NJ?P8L*+
M@@P6G.C%XP./B2:*!("PX\F(%TW&?$!QH#^9"<D,G(7/Y<<'\$:.)(.39DV#
M+W\J)*-RXJR9"YL*!; QI\.C!)6^="B57]*D*05^G:$/ZTA]@DZ67;G2XLN9
M<-_*->LU[HQ94O\%]K3K!>M3N78!"[;+="J M'&OL@V<5R3B!_C8=A5,,R]1
MGWBG7OXXL:G<GR&]_@19D)];G#,*'Q4$(6YDLP(10U#<F" ^HA B-][;NO5)
MP_YZ/^@]@[A.R1:)]X9MT!^^UF2X&BY.O3?M@M6KOY9<\'9Q?)VG)L^NG+SY
M\NC/JT]/W!$B]X\0Q7</O#[SVO:YW\^/?[]__0#ZXX]#_?!GX'_]!7B@@@@N
MF&""^<R3C@S@(&!AA19^8R$"&"*@X84;?LAAB!MVJ"$+7138X'[ZQ#>??._!
M"%^,+]9(XXTS/M)B/H]<MR*#0#[HX) _"EDDD4$B:6221S;)Y)-+%L3_EI0J
M42FE859>.2667!Z5Y955=KFEEV*&2>:98Z9IIII:LJGEFG"V&>>;<M9)YYU@
MVIDGGE_V6::>?J(Y9YLV]3.+/OSDX\@]B-!#AA=D=.&%I%WH4&D..5RJ Z8Y
M;(JIIYUR"NJH760ZZ:-DT(.(?/IDMB:AL,:ZYZP#==&AB0B,@TB@;M**I3[M
MC CBA3($Q>N:]<@PK(<E=I&/K- *JB<_78S#[++@R""/KX+>DXZPUW+8Q3V]
M'@MH0?0H"^Z'#J03'I^&Z=.%# Z(>*NV*DH+;[31#FKNON7^";"_I2G3BR;*
M",QMP/HN3'##C?T[ZY(4*VFQDQ5C?#& $G^9_S&4&W\L<L@D:VPRR">/G'+)
M*+>LLLLL-^6/.@[@NBR[\JCX\LXQ][SRSS #S;/0/@?=<L<*(]VPT@PW_;#3
MYYI53Q?PI$J&/%=/.FD77)>Z3@Y7Y)#.##*03?8#],KP  L.L.UVVW"_+7?<
M#M1S#S3\YJTW/_>L<H_=],S P@,(M$VXX84/GOC:B!O.M@.'#_XXXY /7KD#
ME3^0^>9K:]XYYY9_WKG:H0].^K-MJ@VYZFA[SOIV4GJUNNL/O*-W/_"T#OGN
MNGL^.^\.$-H[[ZP7OY:6P ^?KY3]_*XYK+FS#CGL5XKF^47&:MD2Y!?) /WU
MK5,?^TMJ8T]H2:U?U/_F7X&)#X!=L-;UV4O"C^736'UI"9']6A5U4OY7VI],
MCB<E]*'&?E QRI781YD&QN0XU2N*\/R7&CGU3X%:VLQ7"-43I22B36ZYH @5
M4[W[D:5^!TQA0@C%C\"0IDV7@0L$I<1 %8X&@4F!0$A@J!3?D+ @P_%(:P@H
M)=8(T2.S8&%"?#.<]1UQB1=!W96"F) D:LDWU('B29B(12[&I(O%V>&5\F&!
M+Q9'B@LT8VLL$"LCKK$XRRM(/XA3QM80JHXSP",>9UB0T^@15D31H_K:1$;J
ME/$!<11('@T914(]Y8TG*:,C%QE)1E82DHO$I" O2<E,=G*3GBRCC5[$'8+_
M#$TDIA1**BFR2E0:[93XX8<_\I5*J;02ED7#)=%L@H]YL(!$%CH ,!$@S QM
MJ)CA0J:(4%2@H1UJ1M"4D31M%$UJPJA'F=G/+5W)RE?F\IN[]&8X=2G.<I+S
MG. T9SK1.<YUNK.=\%1G@_PQ"T/1DQ_US*>A\&FH?LZ"G__4)S?E*<]9S$-=
MRK20#.CQ+H*JY!X(!:8#S-'0!^'CEPG=D SFD4V'YF<>#@BF1,VACVWZIPL9
M)28"9%#2=XJD'X@HQS"%R0)Z'(]BP$IFB!S0CHZRTZ/Q_"E!^F&P3"1,J"Y%
M:E"3RM2E.A6H4%5J5)LZU:=*E6?;S&HIMVI+KJK2_ZO=[*I8O^J4;QE3I&<E
MI@/DX=.!UI*L< UK7%TY5KG:E:YS?>M=]8K7O;KUKUJM:U\'R]>K4M6P5CVL
M8A.K30# @VM7BRP\M$8I'80M;#/(K-G4QEG&*2ZD<$, XQ(7TM&:EA[W* MB
M9X%:P-$#<J*%+>8(Y[G8TA:VM<TM;G=[V][:UK:A Z[G2C?<XG*.=XH+RU%X
M^]O<DNLH$&DN;M]1T?ITP;C%#1WGGLL6CH .NY;3CQ>(FY#!):0QYNU<983B
ME?2Z%S@*@5QYJYB7ELQWO12Q'D84Z)G]TG<J+?'(6IJ"/HR8[RBYBXA^$N%?
MA2BW+?XUR4(\XH6\A)!_&/^FL(7C\H 'DR2!'&Z@7RAH0I\<IRGZD"!6<)B:
MO/SEABY6H6Z$LI>.P!?$@WG+@(?BP@<TIL<]WHY*Y.?"'0\DQ1UI3?YD!N0<
M [FB-\FQC][W&?W$T'XAF8Q,/BB9 -]/C"I)RT>XW)4KV]"!\P-S=[:812$7
M1#99O,B,*?*<('91S0+A!W&VR-^1H,?.,UCR2,:C'*S<A#UNU@MZIGR>1!^&
M/2TVC!O70VE(6[K2ZK$F?1A;U:GV8T"+[31B438+><@@'.$2D:J'N>JTGBA%
M/6N1--WCGD3$B-:(L#6N:WWK&-GZ$?FPXJB''6IB<]K8HBZVLH^][&0S^]G.
M!A+_TYY&[:A!;6!Z>I ^TE&S82*@"XD=D#E8O=)\T-) @;,9LV30A6KC:60P
ME:FK-T0/(K%67:W>:'7;R>U6,XM<%6NAOS4D UD636+(3KAA^&$PA#5;X="&
M>+0E3O&'6SSB%Y]XQBL>U)G5B]QG7:O.-DYRC)M<XR?G.,I73FRN56T>9*A:
M%R+5M:[EX&MA*YO.ST:ON<V-M$ /+=SLAC=L&]U7_;@'/>IAMU4(+G)07YS4
M&R?;S\J6<X7#.GBW_MVNBTZ[J N3]&B7O#F7ANR^ZQT\.NJGY+D][9#[(4'>
M3G>@Q ON:1^<W!V;]S9!A'<)V9T5:^*YP,?7R +97GP7__X2^5Z/[6(I'_A8
M^J8"GP3R2Z.Q2V;@]Z_<T,=>NM^$]QOH-PFPQ E)+3Z/M;\)$]$@]D4]ALWT
M8C3C@Q\&Y]:%/3*F#/.Q.1=\DS]$^(!M':6#+Q$CG3.,^@<71(,XV?L-SWP1
MZ131R2>9H5,(DZ4:8K_)@[12C:DX$^L#\<Z,)S\7E7]V*CX \U![CA!_Z"6T
M>)'-6J2./O#QSS_)?\_40Q"3AG['!VE;,D?F,2;IL4=9,AYX! '=QTC*D65C
M](!PM"6>U!O/$B:"8(%O-!MYD@]T9!X>&$H2:((?B((J*$BXIFLQPG(EER0$
M,64C8U(PF'+YH0^(L XR\$MHI?]3:952R,1,Y:0/T81K+X*$O59-K%)/,:AR
M4/B$4HB#5'B#5AB%58B%5SB%0*4/J!:$"& .B$!LZ@"$"( BJK4@90B&A5-O
M&.<.'_>#&O(.G^8@_+ .<:A2&0)NT18X<DAO1,(/X_:'WW9N6<B%/$-4O6!4
M6WB(CMB(D*B%DHB(E/B(6 56A 58F%A8FBA8G!A8>=6)JC0+9J6'9O@-:^4J
MFRB*?@6*K;B*KIB)L?B)L%B+GLB*F6B)E1B)NSB)]+0.D"4/7H UE%)S77!9
M.:!9F]4ZI$,W0<<VSUA:T.@ J)6&B:4/2O<W]R /M55:6>=;LR5=OJ5;X\A<
MY"B.P<7_=7D'=QY6$+S%.[8%.=RE$M%UCO;X#L(&7\B%=\F#7GA'7)D#<.SU
M=<65$#=5$.]0D-S17@KA7ODX$ T97PG1C@! !NDE7PM9>!'A !758!U67PIV
M,APA81GID?BU$B;98!4F'A+6$8AG)+LWD?5U0*/7DH/$9"9$D4&"9$IQ8R:D
M&BO!0%$Q%=X'&MPQ?@\PCP7!$<078B<D&68F%XSV?8+1&(_A0H*V$WPQ8O,#
M?H)!@341E8DQ'7(!EB)!9%^9D7#!,LCG$4#9'] G%V:W)&WY$HYF1("A0T?Y
M%GO&>4=1%WUY8WUI'%A!:,711)+Q2.>!9P#P?]7!:.AQEY8V_V6.>6F6B6F7
M"6E*2$JZ6(6R9(.3V)DNXP_Y@ AFE8?JEIHD0H0K(VO6])HX(A^.$!\!%9J\
M*)JVF9OI-&W6YFX.TYO >72\*9Q)4YR9=YS7]IO$B9R^.9S*J3?0&9W2.9W4
M>70P53CVLB'N0'_-:9P L XE0B+A( -*B2?Z( ]LDYV%,PY=\'K5F9S,0P\W
MTRS'R0_H$)X@LE'.R9O^@ BJR5%/DP]=,)\6 @\CMYQIHC?=R9S!^9S[63 '
MDS ,BJ +FIQ1XIVZB9LNY9P9>IL>VJ$@VHN'Y7&J&7(YHZ$H^J$B6H4/.J$.
MBJ$-VJ+P":-'UY\N1P8PAS58\P[&6/\JZI #/[ISG=5SGD4W/F>D=$-T[[FD
M>M$W3'</[= XDB.EG@5UD[,XI3-;6>IU $F07-HZQ$4Z '0EQ8-VK],FLM,[
M8^<\JS.F5T(&Q(-W8T<HT2.G:,==4O)W:3=V],=WTH.F:"=?@R<EK6-XW>.>
MBM<]@'H1W),^@PI$DA>IB-H]O\&D4;:66F(]3GD^36E";BH0I_<1[JDWH:H6
M;>)ET[=Y&Z0EWC<#?;HW*J8EOF=!]D.K_F-\5U*7[M,/S#=",$1BB00 %X1C
M,T$H5SD8OT<5W,>J3MF5SEI!;2)F6)1#U=<F/<1^>:9%[J>7F:JM3$H5VRI$
MV$HHF^$;:"3_G2*H1N<:&X>4'18PKKQQ@FV"@"E(*"-8'LGJ@(;D1)QT2.-:
M2) 4K";X .MZ&*!41\%:2/T:$P=K20/[L VK28PT2B\8HM!6(,U$,J"YHHTX
M"U/#-D(X4\-$A,YDA-,4F[ )'ZV2HA:KHBS+L2T;LS [LR];LRHJH"*24/.@
M<:;F;\)4#TF"#S*0LR0B VWU;/G@@T X XY6&_I +RF%#KLR<8C A@@ #_O&
M'<&246W3GB[[M8E85$=%LV!+MC)KLV=;MFBK;+.(B[1XBVT;M[88BJM$BB(;
MA*D(MW/[BGK;MW2[M[((N&_[MW[K5VM[N&J;N#5(<SHZC#17C*6"_XS*J'/,
M6*6% W2C%5J'(UK0^ #5R'+]4 ^-HHWH$([V:(ZH6XZJ*UR\U:5=NH_)HS@K
M>10<(8[-U1BU>[JJ"SFV@Q5)NX[:)3JXJX[$!6Z305[J!7I'X5XK=+P165X=
M:7CW19&Q9UXEZ5\/B10-1KU*D;T'T9):,7K[=;T-MF I*;ZSVQ8X,9< (#]*
MD;X3$9,?"6#$RF(*P94_49[MRS\G=A:QZADI])8:49/*&Y0J9):V\17Z.WSU
MFT(O*99;099>67Z2EI=P\9)(9D99V1PR,:T3_  T2)75>A1Q@<!BT:PF[+Z7
MAQ6HVJLNC!+X 144690/P)CQJA!WR6;3:O_"CLF7?99G@_G#!A'$Q+'!_I <
M@ :!DG%H21Q&AE&9Q0&9Y"&9ZV&5F8F96'S%Y:%I4ZNXRI:QB)NV#X((/*JT
M T=NK.E-KKF$N<;&O_8>K6*(7AS&9EO'='S'<YS'8GQP-/JB+BJCO@DA!^4
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M8[))&)NU-IN(@!>N;-K%C-NCG=NGW=N\_=NC34_ZT _X--S%78?$-C5$:TQ
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MW''312\=]=-)7SUUUE6'_?7P%,J*]HUJE]UUW4U7YSS?&__[CB]_VDFL<@3
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MQ<U?^L7?_M5?_RTX^Y7?]Q7@^#5@^ V\>>B"=Q OSN-7=GQ/,TD'T6.O^70
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M4R>'\B>7\L8\5*>B0^<>(']6[N;F\N/V\BW_<BP7\RXOH%F AW5PS6C&Q71
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MTFIA6T>.^%::W92&1S*81V<PQ ]T!'.8B)D!/G*YDKPM1I@(6,?/^L$/><R
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MJO6M[F<K_-W*UKFJ4%1NQ?]K8/-/Q,<&B__Y_[]?!6!? =QB-=QKI18"&IS
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M:4?<<^R((*M% )DH$0-"X60D-)P1#K8AC7T08@]$!OLD0O\07JB.%_"12H,
MJ4>'8:W[\*-:P?"#M-,I;5@3XH4$[M:M7^5M6V'TUXC4]C*"2 29[OH]'QWD
MM4M:+$30"MOZI?6LWXON JO#12Y>29[LI&=WP?M=\<Z3O-XM;WC/.U[SKA>]
M[%5O>^'[7OFF-[V[2M:R(DE)C&V,OQ\#TST<L$D!>^M@^FHC/_!AM@%WLEDS
MP)^>\C'*4A;LE!6*[\@0X3 &;Q@!Z["P'>7%X0&[8[[NI:^)47SA%)=8Q2UF
M\8M/[.(8PWC%,[9QC7$LXQS36,<UZP=%+)(U>&C$"USK6A?"-@.QC:0D ^U;
MW7 2Y9E(N29N<V@]ZD&3NMW$;5S_9LE"O_R4,(]9<&0.7$RJ$N8T4P[-;&Z<
M62!74CG'&7(GQ5SP?I=GT.VY=ZG#L^]\QYX^]2-UA=[*HW1SND,ENLZ=RAWF
M4&I20)\F=;"A"VPP[1I-4WIXQMOT=#BM/$]CSWG1@P[VF(/J05WWK/KQZE2Y
M&A^O2H?6O64?7/L$&?;-6CVU!NY7XQ<I^MEZ1KCMDUQI!"J^WN]5\OAJ$1^R
MO_@H*K/$3D\1%9)"0"'0VC+2MD \6]W$9B]0T%[(6 /T;8%0,#O4?NR$'BPH
M9 -(B ]877,%G1 GB@>*+N24(*[X -&"VX8]+/@.$7YPA>MPX0;'H6@#F_!\
M"TKA('R/_Q.IN$1]8]R*'<=BP/O]<8]S7.0E;V&4HI0(*:V<QRV_<8]=ON.7
MQQSF,[>YS'%>\YS3G.<WU_G/YT1(6WKKE8O<N9O<X8!7EG+IBJ0'/WCFCW[0
MHPLJN26'W2'+-XGRZM\ZI6R/;IY[2)C#2V_'+MVHK2Z4_6$RT(?/>QYVH,.=
M[G*/^]S#3DYP[AV=?+]F.?_N=VH*_II]-WS@#^\FO2>^\(AW?-WQ'OF[3Q[R
ME+>[>_#1!7B00<@7V:?7UO&1'(BDR7MN&Y>KG/J<4%DG#?U)09\24:5,-/87
MI7U%;1\6C8+4I;R':4CA''Q)3VXMMTG(+" S%^,/A*=;B59[9O_1>X]"&M L
M6&ZV#&WGIMQ4,5XH#V3F_-/#!+6GE4,J2SB+&,Z\0[@/24RF/P,/X7:H*>\2
M#*-?0P:=#F866J5-GH;M,N0/(3I$ "=#-V1C^;2D_X(CM;QD%JJ-.8PM372+
M@ :02PHP2%[-"["-(?A!M_)J(+S#MV:DK@HBL&!DX$Y$/JY/()#MU=0C1^0C
M!!=BV7Z-.3B+'U@(1\(-?A+DN?PAW"++@4ZD_0Q"E'X0LPS$^Y20N@Z$"0EK
M"!VD!9N+>SZ,(.;MW4;D13CP1Z0-0+J0N>:C/X;M!KLM/-RCK*@0N_;#JMB0
MNJ9+NE@M#M\'Y;J(BRXO#R6O\GII:IK_AE_X4 \M3T[\L+^@IA ]YA"9QA"E
M9A$3L1'WZQ$141$CD1+_T!$MD1$G$1(OL1(Y41,Q\1,E\;[JI5XH21_Z(1_X
M 16A8153T15;$155D15=<1;[(19?D19E$19KD1=E45^ 2"#R 1T<H!0C"1P<
M !VZ@!Z L1#[H1ZZP!QD0%TVJ5XV29>BR0\CK%LV#%_T@1]R,1QM<1Q[<1?-
M41S+$1W/T=Q:IQ_4H92L$9?(H0LF$!&K1AT<@!HAQEZZH ,S41)#<1,%,B!M
M)1#WL(P&TA,34E8,<A =LB$A4A C\B I\B%W;B%!42$)4B,YLA-E91ZZ(,@N
M AXF@I^.+,F8_XQLG S*6!)N6O)LNF 5NL!LX"9O_*8F"X>@S&QP>'(GGXS,
M$N=O@G(H%>/-S(^DZ PID?)R>H<%FK%/]JQS\J%0WH$)K:4?_NS/_ S0W Y3
M".W.N/(!8 <EV-%ULI(O:H?/3 <LFP)][*UUD UYF@)_"B*?I 4]DN>'\L?9
ML*<OK:= L ?76@<O>8,N*4,>[O)(]+)UG U&+&A:&I,S5*@,.:,LJ:6POL<R
M,64Q"X(RX9#9D,6M#*A/;/!8 NL,'\ P-TZMI(7;S- X+ )\9.BWO*U0,'/<
M/K,Z,$5"RC(+%6LW#60T5R@WCT1:V*U)Z@V&+&XU<8C?"O-8.JCA$O^.X7"(
M,P5BA]A1$(136J*3.AWN.VGH*?ND.UNH+/MO.DU(XPI"LDPNY$CN/=TS/J=H
MY.23/3E.N[P($2RR(B=R/_VS/P%4(@64/P?T/PLT0 DT0=VH'PJI69:NZPI&
MZ1))0C>,0NW%0B/T07%)0V/BE69@*F]F'LR&0SGI0A%@!MP!$>@A'_*A']ZN
M'V8!ZOAA%O)!'^H!$=I!PDB40QV '/0S:$2)E"!T0R>41XVT2)&T0IO. =P!
M[.@$$;AE1Q\F'>BA'OH!1IO1/6 4&A#!'<B.Z2:4'@YT3!4400VT3,GT3-7T
M2Q;O\1IO\!BO3>'43>7T3>VT3NL43?5T3=/_U$S]-.PF8O.R1I],LFM$[Y]4
MLG)X$O4.2J%@+Z(<5?9J;_8HZO9R;_=R[_>D;U-_[RS((BF/<OA$]<N<E*5:
M,$^F+R\B32VH<%4AA_OLKR&"RJ= 0_QD]:B,ZOS$,F=4HZ_ I M:XU2_Q#=B
MS3@F<%BAPP3-) *%=4.DXUB[Y#1YXV2DE3.4=4Z89&4HDS:O]07E T<8,#N@
MU3_>4#R<% ">@TP@< [1B@>E,-T 0PBUT$'^ D7 %5XCI#E&2%T!3@JOU1\J
M:UX'9 W?K3UP4PZM*V&-$#Y8D&A0\S4O0UB3*SH(EKJ T'42]F#+=6/%C3C+
M"C_ML$]%=D__E&1'_Y9/339E479E2Y9E3]9/23&2%FS"9+9F1<QF:9;#[F4Y
M&;$?$ $?X_%FN=&0#L"0A@*7@C9G2RD=?A1GME%I9S9J<59JA19J<<D=@)$1
M_:$>S"9IJQ%I92 =NL =NH!KR-9LNV =9F <D'9J&TP>KO!EY59E6[9NY]9E
MZ?9N[39O^19O_79O_Q9+KB D.6\DCZQK_BDD$O4D:/(E58_*M.STMFS+;!+V
MPLS+:,\GRVQSV^S,#J=OQL(HV\Q3037\0M5T'2!KH1+/0'13\B'16K=0Y$(M
M]2S[LF+B . K;9<N$$VU.G-W3<K14L=54\=3D.\RZ"I4/LTP&25]YG)VW_\*
M4TX3>MZE4% 0>DCM+U--/%8M8Y\S5<8*'^[*5ZU7UMHP-&,CA5:Q?+S 4JK-
M. 13('3-K7 7/JP#"O]$-B7%M"X#VH0-8B704+SU@])/WF2D-TG0.7 7 &SP
MP]R--O773UPS@3E#W6Z3#IN$5"BH@%W0L.K501SX@T?$W Y"7D4D.>MWWY#H
M./#WV.HSBV XX'SW.@O.1PB%N&PX(2)..GF8X0XE'R3N'S7%.]&SB'L8/(_8
MB&O(#E4N9 'WB?4VBOL6BJ=8B@.WBK'XBK7XY82.[;P83+]X2!TTDJ1TPSX4
M9OJ!'[9%2(F.C-TXC-O8C.$!ZM:(Z^(8C/%8C$O_5(_+F.ED &M1)A6C](WS
M^([Y.)%FX![B-HNI>(NMN)$A^9%1#$_/B4XK>4XQ^4XO69,!+Y.MB9$E&91%
MV9&GF!^N()\*=\BNYG"1S)^6C'$SAZ!2KU&GK)91;_4>5:(BE?8DM9<OU:(J
M5?=\;YA355,AYU.%CWCYHE3GXE0#ZRYB%R$X=7BKCPJ!UZ:P)/E.UW& RC+,
M+U=SA QPU2T&HP(_XU\!0#=Z-2NBV2 JT*DXPZ[\+S:LRC?0&0%GHYWMJ3;D
MV?\N=JQ: UH!NMB:,-D> C*,%:B,9/]$$("G YWEY'K#HSPR$-;,MSI4$"[>
MMX*[Q!]LT+?<56.9! A-_UA@%23:!.0*1_ W\Y5 U$U+/#I;!\.D!]:UAO!4
M$9JF!?8*D^2X)L,W(]8QO!=A::2%XR)\FI5FB-ICE[JI.=9)[)!*\'"4(YFJ
M@08C =*JM=J7L%J(1=&KN_JKQ3JLR7HC/3(CSSJKTQJLS1JMW5JMWYJM.U(3
M8Y8;X?$8\9K#DG:O\[J4=C884T4?YL%AU(6O];JOO]998!)$UUI0Y 61#/NN
M#WNR);NR$UNR_U@SK050^ $>\,NN+SNT]_&RF<4<GJZMX3JUY;JQ-[&J_;:L
MYUJU27FV7;NV0YFV;]NV"1&U5SNNQYJW?_M7$&%PLV90O8 D6;D+$C<E3>)L
M*O^7*5PRNE]2NO$&)R-W;PQ'<SU7<W/RR=9L*(V2*)5RF\=[SIBR=)P24Z*2
MG7%'=E#B6+8ROM=R=Y93('1WOE\'4RQS%MR[SVZG4![M+.5[,T\C>![ I^='
M+E-3>Q2<>?0;>ZN''4?0+Y\G.[#'PK5G1%038W'SP6-$PB$X/M03 +Z0,S:\
MQ">:@\+'.K/P6#8Z/[:S"HESPZTE8-GG6"HZ@;>3@0D(;O/GH_EG-D43L">(
M776S4/*A0!#XR 7E.-/M,9L\0:3%R!.KO@TB/TK(.:V<Q)V3B).XX*P3 + 3
M4V;(AK1'B9'XAL2S3WA8LX/1R^$\S>4<S>E<X? 3#W7_&[>W.L_Y/+?]?,__
M7,\%O<_3R!_DH0O080;081W20=$9W=$;?=$C_=$E'=(MO=(QG=(U?=(Y_=)'
MHI+&:!;J81[45F ZE)#%6$)98 ;401[JX5QY1B+,808Z/=%KG=8]_=9U/==Y
M'=-Q71GG =;?)!\0H=0+>8SA&-ESJ0OFH1\(?= #_=FE/=JI'="M'=JO?=JS
M_>@P I6%C,A.LI5'C[EA&70AUZ!8;Z$@=5+9W9>#^2DR*MZ+F9BG>?I(M[Q+
MM_KT'0&8&2Q:\-'RHH )HMZ5V0%:5=\GA_MRA/R^.7*Z65=S=3.X@P''F06,
MFB R[5K?[S7B#V9:HWK'A &E_ZJ>S7<\SJ,W0!YEB%4?4HNA)V.@GU.LW.KB
MV41 +GX$G80&_6%;NPVB,9"L=G6VU ,.3_4XQ>>POL1C0SJT<,;)'^LO$%J(
MG)2U"CIA44C8$>(Y#/9=I]"F'^M4T6U",-A[%C:Q?#HP*O#:_L*A/SQ+-KI\
MDMID'E:DQY[*B;-\0);EMGWOL;WOM=WOJQWP^?[O"3_O<G<A#.SP"2+Q&1_Q
M'7_Q'U_Q);_Q(;_R)U^VO<0?H$X?\N'0R0$!"GNT<4DERJ%L53%&%WF/+)_R
M+W_U(Y_U8?_U9?^3H\8^8I0?[F$>S,&0GJ48VW9H'70EUD$>OM'9!?_X"W_P
M S_YD?]_^9U?^:&_^:._FHC,(JS_N%G9E167W'5R<L_=EB.WR[R_RRH7<\$L
M<SFW)]-_S3H7<4)W<D97I/(=W^D_*U1W/5DW43@G+*U<S[1RT@#B@0-]  #X
M*UBPGP.!#!<Z;/B@X$&$ . )[$=1(@!^$!^R:)A1HI>'"S^2?& 2XD2*LTX^
M:$B&XLJ%+Q?BRWC0(DV&-1_<7"DSI$&A!V<PY#<T)%  1F4\,!I1(\*G5*%6
M]8FSXLNK5G\2_:H4P-:M1F\&#1OR'MFM]X2J?6D5:J*S6=%2I/H@)L*)L^*N
M?>!E*8"^?_$:]NN5(L>X$Y?B.[P5J=+"?N&2)9AT*F3+G!__"!(,E#+EO13)
M=/8KF;1=N@9/7[5L%&K6Q[&IIM:X6#4 05Q[US;Z>?75VTG)_/:-/#9FH/YF
M0#CN_+<7J0CY/7]]O?:#[->WQ^[.'>HLP>%?)A)L_"5XH\0/>E</=3W\^>\Q
M"MY(7[YWS#+]O?\/GB!$Y1=?@00>"*"!"2*H7X,*KN<((A$F(F&%F:V$H6X9
M4K?AA1I^R"&('H9(XH@F=HBBB"F6N.*)*K[((HPNQDCCC#:VB*.,.=:XXXTZ
M_L@CD#X&2>201O:(I)!)%KGDD4H^R2243D9)Y916-HFEE%E6N>656G[))9A>
MADGFF&9VB::8:9:YYIEJOLDFG";J_Y////3(<^>=\\B#R#T8N1EGH( .VF:A
M<AHJ***$'LIHHHTNZFBDD$ZJ:*6/6BHIII1>RFFFG6[J::B@CJIIJ9^:*FJ3
M^N30!1GRN$H&/%YT,6NM771Q10ZYSC"##+T^X)13+#CP$0(.&#LLLL<2NVRR
MS"* 4K/'1@MML@\86^VTV%ZK;;?0;@MNMPN%.ZZXUS)D[+CHKJMNN^>Z"RV\
M[+Z+TKPIQ5MO21WEV]!XJLWKP'FJC40OODAEB&_" #.4DD<"2]72OAXQU.$[
M#+7%8<0I;2S0B%YP_!+(]88<%8;^C8PR"]-Y2/)+&&=F4<L\/?#REEZ,Q5^+
M8VTUXLX^N_^L6\P_ TWFS3LGYB1M1WNH]&G+22ET7AG#MM8,*YM<V6:0U8R0
M/I#!HZ$^62,]42*=43T6<".:7;76<>FU87JN<39B>MKU1K7:&-J=7-_0Z:;T
M;[-D/(.'O$'G]U-7J\:W61<2AGCD7#V<%.2)H^B%Y)HG_EMC>_GVM$B(OY3:
M2L?EW;9? G;($>JN4\Y7UJKW++MH<[MM.^ZWU[[[2Q%&^ @BP4=X:O&I&D\J
M\JB.RIINS5/W?&9T+4^]\M8?7V/T]VT/5EW>:]\]^*LY3S[TY4M_/O?CF\\^
M^NVK_WWZX<N_OOOVPR]^_._/OW_]^-.OO_OQ3X#^&^#_^A?  Q+_,($&;& !
M'\A ".8O>D*IH 45B$$'1G"#$P1@!Q'X00M6,(,2]* )07C"!8:0A!Q,(0NK
MA[WDQ;!)*]1@#4LXP^O)<(<PY*$.>PC$'PHQAT3T81&#>$0YW;"%*&RB"EUH
M0RCB4(#XN)47Y@$K>=BJ"^ZX50[6\<4<I*-79 P6LV3 K&&I,8UL7*,;VPC'
M-[HQ6G-<([+HR*V/J#&/?+RC'XG%QSW><5CETJ,#2G)(?A%2D0QKI+X>R4A(
M<DQ8$!'6GS("+(8XQ0'Y$(H7-IG)A3B%. 4Y"2@?<LI05I(_%%%()??EE KJ
M1"!Z\:0I06)+5:(2E@P12L1>DLH'S"4D_[-P2D\<1Q%Y9+(G37D V$+"D84T
M<YJ9I*93K-F;:UY%!A5,'#(1HDS)R4,HBTE=[J!"RL%D34 A>4QGOED0=VZF
MEBSA'>YF0$^*^$4[^2R(Y4Z'-ZK $S^5Z6<\1]--W1G&@N?,W3B%XC6%%DXH
MII%H81Y:&GO6[FZQ$4H^(,,><@KE<)SK#3M#(K:J6#!PYG3=4UBY%^UD!R_7
M&6A!%$33RC@(08,+B7[2*3?Y7/(N.UW0>TX*308]: ;IG(51 Y30HDIUJ4JM
MZE.I>M7A"6^KQ$.B$;_JU; .$:QC%6L2STI6M)HUK6Q=JUO+"E>UQK6M<WVK
M7.]*5[S:-:]\W?^K7^L*6+T&MJ^#_:M@#TM8Q!HVL8Q=K&,+"UG%1K:Q()K%
M/&X5*R^\2E:TNE47='"K7(V15[X*5B8%.2UG64NUWJ(6M[[5VG#!=K:OK6VZ
M;)O(A.467;N5EV\+-B^%_?9>CHRD<1M6W(DAP%]2"2[L"D(PX3[@8*21KG21
M"\F ;6@6>H0(QQ92,4<R-S->TQ?)'."QC\A,O2G;RD="9!'VLO<=&OKHS+A6
M$(OYC+U1N=#0_@M@ %LE;3T[VUKPJY4 :RC #.[O2EJW,[V1IFD"91KN0N0:
MCKZ&*B&2Y^EZBB'"],XU""[G.^N6M^=*)*!4.VF&2*IA#5N&; 616T#_.QJW
MS4EN=7OAFXXYIQNU1&Z\*8)QXN!24Q0_Y3FAJ]R/(Z?B?_H-1#XN*4"O#.+/
M<728&,H<2*>K&XV*AL?4@;"8.1-E,9,Y*18=<9O??.8V:U6KQ).LG2E[Y\?F
M>;)ZQK.?^PQH/@MZSX3^\Z -7>CE+3'0B7Y4_AB-Z$A#>M*'IG2C+RWI2FL:
MTY;.-*<W[>E0=WK4'Y)'%^"115AY=E9>!*,Z<E#:,@(+D&]4EJV?A6O6*LN.
M<-SUL^CX:]1FJUC=(K:Q^PC(/Q*[D-QB]KT2^6Q(XNN[QRTNM:GM@#^%)I6<
MA-XG>0G34NI2DQ(K]T"@Y\J3J+MD&9GE0Z@;_Y*).80H!).W=_?%O5G6)-P'
MB>96;)(5?<],FI2CR$ZDN4R&4!/AVF0X9+3I8(JD-,98"8K0 "K,^]S-P!QW
MGV'&DLZW&.9E,LD=@L7"\8\7QG',Z4QPW"?B&XL&:04I)T>_0E++M*<Z%5TG
M6&PL&X0D@C=SZVF9&PH7Y_4<Z89Q<8WCO%&\S$;F\/:>D2=:D*$GQ^B9L7F%
MV2?EW]3RGTTVR).7K+Z@?G@B:L?.=\1#GK>;!SUR?\_.HV/5[HQ7,7E?*K_]
M(U6D?FY!.[]JWP]O^,1#J$(4^ATB1 UJ4G]Z\I"GO.0KC_G+:S[RG+=\YS/_
M^<U[?O2@)[WH2X_ZT_^K/O2L-WWK4__ZU;M^]K!OM#]F0:M7:7&S6PRMKG+
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M%G"!^PL4M2DEP3Y9,($/;.#_ #]8PE]L,(0='.'WSJ,+2?5"'O>X1^[X,1V
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MNM/CB>>LRY/J[*<?UM_O_OC?UOZ YOK6F4NJY@HH?M(G BP4@ K _DM _U-
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MJ??BDZ_HJ8MV>K[ZZ;-O?OO,O[^^^_/#OVK]L+Z:OZJM2OMI(I<EXAV*2L3
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M8 97[\$0O=Z$E[>][UVXPMW3,$;#1[\.GP_$\1LQ_>3'0!-[M*/M$^FOX@@
M%1I+6@AXC$U/=9AOE;A3;M2(MN9WDPYZU*B#.6"K3@@8D\985$TTR++PMV0
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M/<93A*%.R!6,#(74495%%,;#E.$#1,0>KE[L?1:H(<6E^5[I(>(AF=;L'6+
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M//@KB)9TP3N%R9A(_? ,6&P.L%\']OT+]OU+ZOYKZF'?(P4#! L'+!X@&/A
M($&#! 4Z*'C_L"%"!PX)4IR(\ '%C!@U=N3XL2+(C01E(,P' &5* %X<.BP9
MTB7&DC%I/IAI<^--G3DWML3ILV90GD!_]BSJ\R92HT)K[B2:=*A1J$P?J+2J
M#UY/,OCZ64WI\\'1!S-PAG5(MJ39L64WH@W;%B?9LW'AEG1[EZ[=O&O)XNU+
M]V]@OH,%%R9\6'#8Q(<5OR7;&/+:R(\E5Z9\V7'FR9HM<\:\&73GOXU',S:]
MV'#JS*51#P[]N?-KS[-EUXY]&W9NVKAWZ[;MF_?OWL.%RV;M^C3RUL>9BT;\
M7'5TZ-.E5Z=^W7IV[-NC/T+D")%W[^ !^$MI'B7Z\N?9IV^_WGU\__CSU==_
M;U\^?OKW^>?OO]^_  $<4+\"_S-00 0)/)#!!!M<T,$((9Q0P0H?M%!"#"F\
MD,,,.]S0PQ!!'%'#$C\T440423R1Q11;7-'%&&&<4<4:7[111AQIO)''''O<
MT<<@@1Q2QR)_-%)()(D\DLDDFUS2R2BAG%+)*I^T4DHLJ;R2RRR[W-++,,$<
M4TLKS;/O3/;2=&_-]=I,$TTRU=SO33?GC!//.QFLLTX/^:03T#S9#%3/006U
M\U X"T5T444-;=3.1R5E=%)'*;W4TDR_+'/33L7D]-,+$>F"#'B\D*=4+[I0
MM8M67<WABAQFF$$&6G%ZZ2*#$)!H5X%T=?]@(6 ' I;787?5E=>'>B46V6:9
M??98:!]RR%EJGZ5V(X.PW;:@;+WE=E=PO^U67&Y#"O<C=$-:=Z1V.TH$/Y;:
M15<C=.T=]]YRR=TW7WZ7^L@GF# 26&"/V#7879$0#HM=AMMU&&*,()[%QBXD
MOIB@B!W2^*V,WXKXXXT_'IGDDDT^V63*/E:Y9)8C6[EEE&6>F>::*X.99.!T
M)BZXY)HCS3G,FA.ZYYV+*YKGY8(>66FBG5YMZ:.?!GIJGY?6#FONM,Z:ZZV]
MQAJ"PL(F;.S RN;K[*[5_IKMM;E.>ZSQPON.;D_E#!7ON_4&=6^[^?[;[\#S
M!GQPP?LN'/'#%2?_?''#&7_<\<@3UU(E]2KW:K[+O;+\/<VMXEP^ST7OG/30
M2\_\=-!1-WURR1MO'?;798<\=MIG=]WVW''?O7;>;^\=^-^%USUXXH?WW?CD
MD5^^> [](8/4><A 51Y6775UG1RRG[76[FURH"09AO75V/'+)Q]]8=,/-MB$
MU#>_?6,E<G]9A8A-2-GY\U_H(?O][Q^ _--6 ',%D6Q=Y%P('-?!%-9 !K+@
M))F35\$ )A:J3*4H3K'@!HG2P7]Y$(0?%&$(0TA!"@;L7P4CPSTPISI]Z ,L
M_U++##="0Y'=\"TX5(M<<K@6'+IEAW29BUZ&V!F]-.:(5JM:TYAV,^0 _PUG
M3<Q9S*8HM:1=\66<B6(4C88TXW@1C%T4(Q;#2,8Q6A&-94SC&=78QIT-#6I+
M5,X<X4BU.+8-CV[+XQ[UF!WP@"<1="./\II7R.,9DI"'5&0B&<F\13JRD8B$
MY"0E6<E'6C*2E]1D)CE)R4UZLI.8!.4H15G*3YHRE*=4I9'^E*A(8>J5FFHE
MI&99J5C>LI:PS*6F_+-+7!+*EKX4)C!U24Q9&O.7KARF,I'I2U22<I70K)"J
MIE=-4ZWJ>JV*5:RX9ZOPS>]\POK5^L+)/OFM+UF^RI\ZG14M=^Y/6NV<%CRM
M54]^Y0I?^=17O_BISW0ES(0I%*@'Z34NG_1SG__^5-= C1)0$E8081%U($ I
MJA&'650D$?/81CO648UZ]&(B\YA(>\@Q&H:L9"*SV4I9VE*7.;&E,96IS5Y:
M4RJZT8PQ8UEIH*C$G*[QISC-8A9Y^D2C,A&H2<5I'7UJ1SOVD8]1A>I4I5I5
MJEY5JG^<F]RDV=5G?C6:8$VEAD;'NM6=575I;>%:-\?6S[FUK&B%:^KF:E:U
MMA6O;\UK7.^J5[_RM:YRW2M=!VO7P/85L(45[%\)RUC#*A:QC4VL8Q<[6<M*
M%K./I6QD-7O9SF:VLI@3[6A)6UK3GA:UJ57M:EG;6M="]K"QA>UL-RO;VM+6
MLZ'][&YUVUO.^M:VN?W_[7"#"]J^ZDBXQ=6L\3PW5J^&%;K.%>MSI1M=ZEYW
MNMFU;NR2BUOC?JX+\""#]*CG!7ADLU79X^:L:.5-\'W/??$UGWSI.U_[UA>_
M]QT?./&'/_[Y]R "#/" _R=@AA!8(M8ZL$4,ID")/K"B$WU)NR:L%(%-6(,9
MCHJ&G_(OJ& 0Q!X6<8=)+)4-C]C$)5:*BJ.RXAJ*)2Q0B7$/@5@7&K.EB#S$
M2X[W@A>]_'@M0!:,7OY"9*M.QZG)42H;F1S4)B<9J4WU&I3I*%0K/_G*3M;R
MDK><92Y;D:E1%G.5Y1CF(V,5S7ND<E_D)IZZ51?.V-WNG..LW3K36<YWUG.>
M__ELYS[CV<^!!O2@]RSH0A/ZSX=6=*(9;>A&-VZ9M&SFI)E9:4CYB=*2MG0P
M,\WI31?ST\<,=3(U76H'1=K1J48T2O+1!521-U785!6KMBFK]GX35_8S)_G&
M^;YEL6^=TF)G/(G]SFK1$]GVPJ<]$>JOA#Y[7^=*V$(?'&$4$D4A#77VMIO=
M;84R]-KM(AA#(5SM:E\48P]+]T?9O6YW<[3=)*7A2$'Z,8^A=*;YEN*^;5K%
M?>L;X#+K][^[C.4R.V?-49.RP0M^13,7=<P/5SC#$WYPBY\9XVG6>,8Y+C:/
MD^WC9@LYVD:^\=2T69"(>/2B5<WR5;_<Y3%?^<Q;3O]SF-M<YA+J[FUYCMSO
M>I>WQ 7Z8G-^\YH?W>A)+_K2<=YTI#/]Z4Y7NM2A/O6HNZ<>X1UO-:N'S6RJ
M-P?HN+5[#TR_<)J=G&GWM7WCES[Z\?=^Y:M?L'5-P (CV,#S%+""T^7@>4K;
MW!,-?+FU[6+#M_C$34'QX1_:^!$^WO$>=*@()Q_NR+^8*&J)H0XQ7]+.!_&'
MG:]Q$8-(Q"#[\/2826+$)T[F)N[4B0/?HA9I_V4OPQ3W Z=XZX_#Y=[??O?!
M;[CMA4_\X0/?]16_H_*9O_#D.U_B%V\^ZY>HU4!JU>K9K_KVJ=[]JVO?^^#_
M/O?''W[RBQ_]YU>_^=E??O?_I[_]\"\<JD%MZOI[VOZ\[/3]^2_J_),:_P*P
M_P!P .G/_P300 SPEMYO_1)''EQMZU#EFJQ'!VJ-O6Y-)N#.G'IMU]8.G3XP
M[MYIV(RMV.")!*/%6E PV0X(VKRM!;_-(Z@-HF:P\HRBH+CEH&"0V_RI!CW"
M\B@/W"*,\(90W1HFH]X-I. -"4TJI$!*WCX/"O%M9%0JX*JP9E[*"K-0WV2O
M]I#O:& &]L)P^93,"\L0RV8/XF)/#<6P^,S0X7@/#I_&Y#J.#N?0#NNP#K7*
MS<B# >.O >4/$)OK07:.$'^.YPHQZ)0+N(9.Z [1$!%Q$1TQ$1E1$1L1$BWQ
M$3-Q_Q(E,1(OL1(_<>A>2Q1'D11+T11/$151$1,WT1,IT14Y<14[41-ED15G
M,19O$11AT:U\KA9[D1:GI!7]Z@^'T0^+L0^/$1")$1G_,!B#T3Q:Y=6X#GI:
MQ7JT)P?4(0>Z!P/%I^ST2[XF(K_"T1O'$;_@KNP ",#.,>_6$<'2,<'0$8'\
M+B+611Z%T!ZKK<)XXL(R4/'Z,8,2[Q]9S(-"3" WB"!3+" 3DO$,<O$0[X*,
M8L9B""I&[_1*[\9,;\=2S\9\3".%## TLLCPT#JF[_C:T"1S*OK&D(FD@R1_
M[R2-#R;=,"9?4B9K\HWB4"6?C_IR,B5;$B=]4OH( ^6X2O\9D]$8C7(9C[(H
MEU(IFS(IGQ(IHY(IH7(JI=(IK9(JK[(J%TT!NW+_#K  OY( P9(LQ](LO7+4
MT/+_U!(!S3(KW_)V_&$6K@ "JT<"9^UZ+)"]O.>;^LL#Q>DO?TU^D&4$DT6>
M#K,$$3,%]8X%[^D%'W,'H0WP!(\R?[!>M.T&(U,S75 S>[""&*+P*),(%^8(
MC5 )3S,)4[/=4#/>G+#>7O.DM'"EN-#?9F^H<$\V 8XV<Z\DAZ,G=1(XS6PF
M>_,W>PHH>;+U?.\GH4\DF_,.G],YHQ,ZJP/EL \NMU(KL_,ZM1,KNQ,[MQ,\
M9Z09;3$7Q],7<?$5=^X[O9,[U]/_/=L3/L/S/>4S/MF3/N\3YOCA"DXE J%G
M&K,)5JXQ&\<N?/2K ]$N,,OI[!;4[<X)?C10?PASP*+E[BK4[O1NP/@N(@8H
M@6+P'D7S0QG(,BOH(%V,PQ!R(2]/12&/124O"+'M16F0136O\S;/\S@/1V_T
MQD(O]-)B(W^4QY#(B)9S)Y/,.(_JIFR3-_V-)ME(276/.),SRURR-X?32FVR
M2K'T2D_R-XN4.8/22\,T.(G4^E+./L]T/M&T/M.43=?43?&S3>'T3=543NN4
M3N\T3O%T3DV$+<,R+<6R3\LR4,\24 OU3P]U+0TU41'5ENST/?T!$=:A+JO)
MZ_(R0"^0_R]Q0KXV,$'5#MA \->"[01-D%014P6/#54;DS-750?[93)?-6%&
MU#-QL%5K55]D-48=;_)&$T0QRC2+4#674%CIC0F)M0F9D IC4UESDUEWDUF?
ME69VLTG)" Q?SUI)<DNSM(O0< VO%6JJ58ZR=3B[=$SE4#K/=3K155U30P_G
MA@_UU%'W5%[SBJS(,SWM51?O]3S+$U_-\Q?1,U\#UE\!=F#Y=5_U]5\--F$1
M5G52T6$?%F(C5F(GEF#[U6(/5F O=F$S%F,+EF$5%F!Y<6/5TW4\%EY/-D]3
M=EY1=F7SU&1?]CY&!0)A#57> ;T$%!NU$=?,!QS)<2)\5AR#%O]HS3%"(:(=
M\0YI+=0=-]1H-70DY+$>!R]$*4PD\C$F]M$?3U1K&U(H2M0A&;(@M_8APY9K
MP19%WT+&Q((BUQ;'*A)(-9+'/%)N.Q(DZ]8OFO,XQ55+L91<4Y(EOU1; U=O
MIW5P!7=O"1=I^I9(RQ4YP91QL35NZ&8/54YEX]5R6?9R*Q=S-U=S.[=E/S=S
M09=S1==S0]=TK6M04U=1VU)U&=5/%Q5V67=U7U=V75=0Q?)TL=,?6*6\4$76
M7@7L,-562$)_/!4P074P0U!42S4QF_=4K\4QHY=5(7-Z_TEJ)0I7"RK;B*)Z
MNY<'8W3<Q@U&K[=7T\U7@74U@Y4UA]7_-8O5\^X--E\,6F<&2FNS"YUU?ETJ
M20UWC!0W;YVO<(%*<=FP<0N8RL9U<?UV71<X71N8@:6S.NLF=TF7@B?8@D?W
M@DL7@X4'9CM68RO6@T,X$C68A"MX@TLX@TT8A4]8A5LXA>V,&J-Q M&K"P2T
MFW#-'!5T4W6X4]\'07_80=]N4XMV[IS%0MGQB#.4@.RI0ZVW?'F55W%U(;W6
M'Z>X1:]X1;/XBF<U5KO8![&XAVS41FU(1\D8]';T(M/8(G5,B#122!UW@+WU
M2-/0?F^S?@^76N_WIA"W-923C_D7D ,8CP7YCPEY-N+X?\=L2\L4^U;8D5V8
MA5\XDB?YD26Y_Y(I&9(O69,SF9,MF8);-W9I5Y1OUW8)M91!N79#F915V919
M>5 ]N?SZ(0=6A7JFQWJJ,7CW\E;B$4%_I0-_N9R*19W024)'U529EP07<X!2
ME=EL=3.=60:CV=J\6$8)ZE\RTWLE$WQS-33##8JGEC1_]7S3EYR%]0G/N7VA
M,%GEU_/R5S:QT)WC&66D-9![IEKO^5L!>)#W&3:X50SQ>8Z!TY#]V( !]S@=
M&*$?.*']2'+=5>5@&9,AFAD_&&0K^F,OFF-'EJ(QNH,U6H1!V*-#&J1'VJ(S
MFJ0G%J536J57FJ5-NJ0[^J1=FJ,W6J9K&J9?^DENFEY+EJ8W6:([.?^B@]JG
MNU.G;1I?6XV6(W#6;!9 L?&&O0GN>E8<I1IHJUIHXXMHE_9HDYBKBW;!X-%I
M&0PDHO:)IS8?B7<?L38AQ7:MR_;#W!JNR;;$-,B*Y?ILQ_;%TE:OU=C&+'*-
MWS8C.5*P>^PC[]:PU15R"YF?HQ2.<?)OQ72@%SNR%9NRZ[FR)]NR+7LHWPRH
MA]JS.QNT?UJTA3JT27NT/_NT2QNU39NU3WEV5SF58WN46UFV87NV4?FV7YNV
M!S"UX_4>=""I:YF&K7&]N$=3!P9^CA<P?UF8A<VYC=EYD1E#3U55JYMZH5D'
M895\"0^%M'=?<O"ZPULSI5C<NAF<R_I\TYO_?<MY?=M;?=\7ODD&?I=5GO5X
MGO?7CNM;"^D9L_W7H/7YLJ=T.0,:D0&<L0M:3!=:H1=<P1L<,2+X75=;PE6;
MPGN[M2&YJ 51U3*<ICG\HW'ZPS%ZPBU\Q"^<Q"O<Q%.\Q%<<Q95D'F)XZ\ZK
M4ETE5IQZ&W=9'-NNAX&Y07O<AX,8R(=Y0HGX0I&XR)&6[Y;9[SBT,;4;O<N7
MO/&ZKMO:KK78RL'XH;CXB[>\FA^/1G%HC-6YC,7\C,N\KP&[C?'BC3-C]1[W
MOPF<X/*[CI=4LF_C2?%[L:D4L_>\S@/<SS.;S_\\T N.D3G[Q ]=Q5M<T1&=
MQ1E]T1/=T2,=TB>]_]$3';=M&]-W.],O7=,[G=,_7;=!O=)+N.NDT7=OMM8R
MM4"[D9PXD(>9&WD+4]:C^YA1%7J9F3&;6;RSV8F=W#.Y&)NO&;NU>7S-F\N+
MG;R_66K1C:/&>;V?W5BC/;Y?S%C7V=KU.POQ%]NAE;_Y#=!Y\Y_S69'[_-O]
M68Z1--P3^]NY-(';O;'-U<'CG<$EHUVY2M)'_='YQL-%&L3Y?:9#W*@!?M]C
M>N#[O:53B^ [_. 7GN$;WN$?7K427N 5?N(KWM\#_N(+7L1?1.-KNEX!'M_O
M/=]'7N3ALN-/GJ:#VYJL)YMB)1WVTKU6?5BH.K]HWJIO/FBS>JOAL:N-7/^K
M-;2 OGH>GW:[SYM=SOJX+<S$B#=K ?)$IUS*OY:*S=9$G3ZN[YKJI1XB84QM
MVY9M?93TT!PC"7MN!]LC0W+(%ES=!YWMW1W!M2:1YZCM!9W<YW[=[][N\QXW
M-GN02)[2_3[D_[[D!9_P ]_P 1_Q!__P%7]W1-V50QWR75OR'W_R:]O3(Y_R
M+ZWPVW,65D6\RHM4AIN;!A2'07.'7=W5A?Q3E;>8I;O6FU>9"TC7<_V9=SV[
M%\CHIYG+MW=>AKWV?S_*NQ@TO3GWSZTTT1?:WYN]E9_:I_T)[2VEMGW.X5G.
MXQPWI?]DNIV+[MZ_$UQ*Z;[)"CSN"WQ:R=_-Y1W__><]_=4&PA]Z\QD?_M]?
M_A=?D5#>XH_+D>P_XRE^_^^_WR4>( #X T!P8$&" A$:3'BP(<.'"R,JG.A0
M8D6*$#%:S'BQ(\>/&T-J'.E19$F2(%&:3'FR)<N7*V.JG.E29DV:,'':S'FS
M)\^?.X/J'.I3:%&B0)$:37JT*=.G2Z,JG>I4:E6J4+%:S7JU*]>O6\-J'>M5
M;%FR8-&:30N 7Q<O\\C(DTL&7I>[>+M<T9MCAM\9,@ _D#%XL ,6AQ,C7NP
M@>+$CA%';@RYLF3+CR<SU@SY 6/)GC.'9O' ,8+1I1NG)FUZM>O(KP_'9NW
M06S;L$GCKNWYP6[;NDO[_^X-?'CPX\:3%U].O'EPV\QM$X8^?/IPZ=>K:\?.
M/;MUZM^S4Q\OOCSY\^;3HU^O/#MR\L_;4X_/GOR#\O?M#\]_?[]_V_P%.-P,
M_SU (( #%D@@8?PM:&""A!WX8(3].4C@?196^."%&SZ(88<?$LBAB!YVR&&(
M_:&8XHD:IOBABR6N"&.)([9(HXTUOGBCCCFZR**.,L+8XY X%LFCAB0>J>2.
M3!*YI)--&AGEDU)":6656%*IY91<7KFEEUUF&>:78H)I9IEHDJGFF&R:Z0@B
M;R8"YYP)#;36G6KE>=:>;/6))Y]_^JFGH( .&NBAAB9:Z**$-HHHHX\ZJJBD
MD/].&NFEEF9:Z::4=HHIIY]ZJJFHH(X:ZJFFIEKJJJ2VBBJKK[JJJJAV3E3K
M0;?6*>M1N=8J4:^ZXIH1L,0.:^ROQ]J:K+#(-JNLL\P^*VVTU.H*K;738ENM
MK]ERNVVPVH;KK;C@CFMNN>@6>ZU0ZLX:Z[ONQ@LK(EW(Y<5<\-"5%UXY7-$7
M8  31MABH4UF,&4'FX;9P:!=UC!EH+46L6H3G];:Q:IA;''&'&^\F\?"_19R
M:K@-=UK)*(]\LLHFMYSRRC"WM_)[[I5'7W/DK4R=SBZS_'+/,?\,G\U$UY?>
MS30GW9[2S"%WG]/.]4?:TU)73?75O6$]==;^;8V@UU;_%R@@@BF2W9_9,Z:M
M]MILMSWCCS&Z+??<=-<MY-MXW[WFF6O*R&*22 9>(^!\MYFFX7N+&63@?OL8
M-^ J"BYYXI0C;OF5A(-HXN2;HSCXC9F'#OKHGY?..8FF>WZZYJBO+GKJG<?>
M^@-OOOD((K>_*>^NO,,+Z^Z^]P[\\+^[A-!#QR^4_/$8+<\\\LU'[Y#SS"LO
M/?337V]]]MQC[_WVWS\?_O/@ER^^^>2?KW[Z[%>_OOOM4R^_]N_/WSWZ\.=O
M__CZ7R_^_P ,H  '2, "&O" "-P?_O:7P 8Z\($0C* $)TC!"EKP@A!<(/WB
MM\'^W:]^'50@"#_(01)ZD'\B_RPA"D/(0A.F\(0:=&$+5RC#&M+PAC$47O%T
MR,/@^9!X/03B#W<XQ" 248A(/*(2&_7")LXPAU <(0ZEB#XRU(L>=)&'%^RR
M+[WPQ2^!":-A!/:8VGSF,6=,(QK7J,8VLA&-HU%,'',C&SK2YHZSR2/![.@:
MQ.R&-'X,3=-XP[2H-6UIB!Q8<A0)'IP5AC36B>1V"M,=259RDHTT6GBZDTGO
ME&>3E/0D>2P9RDZ:$I.HY&0J2]F?\-S'E85I4"PA=+8)U3)#ML&E+264(0KY
M<I>%Z24P242AUAES<\=,)C)9Q\S7':YPT'RF-"L'N]G)KIFD6Z8S5<?-:U)S
MFI<#9_\TOTG.<)9SG.9,)SK7*<YVGM.=-,H=[N:INW4ET8CX+*(^[[G/)?8S
MG_P,J#\%"M"!&K2@"/VG0@FZT(,V-*$,C:A#)0K1B5JTHAA]J$8IBJAV?:M0
M'B572,\UTG0M2Z0G)6E*36K/DKITI2]M*4QG*M.:=HNE-XUI3FFZ4WM>=*,_
MY:A:O%"ON."+J$3-2[^6"D;!" PU!+N,PJ0*L:J>QF$4R^K&KMJQU&S5JV#5
M6%@Y]C&2C?5EO F:S]:JUK8"K6?!F1E<$7G(Z,@G.3QC37G<*C2VOK6O<AV:
M8),3'Z31U9"(51K5BK-8KFWML6&#K-8B2]G)"@AL6/O:C+;_5C:[>;9M< NM
MC19'VM&:]K.HG9MH]>:X=WYSF]>L)C9EFSG7JA.>ULRMYB+73=W"UK?9M.V9
M?CM;UP57F\A5IG*3R]SE.K>YT'VN=*-+W>DZ5Y[RU%U0MYM1H7(7J-W]KG?#
M2U[PFG>\Y[5A%%6X7AA2\;WLA:][XTO?^=K7B>J5+WZG6-_]MM>_^GUB@$V8
MWO*B]\#B3;"!%5S@!B-XP1!V,(,?+.$(4_C"$\[P7<B Q;EHD8O[6@=3 ^94
M!PSLC9M9(\.LNC#,I/B,G,'J9N+X,-IPU<:HP1@>8</C.OJ8-G\T:VY,1D@B
M,R>PB3UL(0LYGZ*M$I10?O(GU4-E_Z-9N<I89H]AM>SD)E]9/V#.SMAJ.>8R
MBRU!",JE@F:I9@JU^4%OKA&%/C3GV!X7N+#C[6[WO-K6^KFTPL5MWOY\VMLF
MCKCOK*VA%\W.0#N:T8)^=*,A+>E(4YK1M4.$G#*-4IM^U,(9!K6H*TQJ#(_:
MU*4.=:I/K6I4N[K5L&:UK%=-ZU?/VM:UCG6N :K3;_6ZTST-MJ]Y.FQ/ [O8
MPCZVLE5J;&8GV]G(CO:R<2IM:$_[U[O.-JZ!J(\<%)4N\$#J6\9]EQ&+\:E1
M93%5$Z;N=G/58 7KC,2Z6K&Q?E6L^";K65665B/[%;!__;? XZKDN]KUX([<
MV5X#SE>!\_\,X5NNF=$BON2"US5JC84L8QU;68Y;UN-=(S/7-'M9D:/-/YV%
MT<E3R_*ZP:WE,(\YV_H,Z$NCLW$X9YR=)\US2_><M7J&')\?1W1$V]SG2"<3
M<9=^Y^+VUND[-RYMF\[TJ5\HT[>3Y[9UO?5;<_WK/ 1P?P4\]OR6G;_W)7O:
MS;YVM(N][?]5.P;G3O>ZV_WN>,^[WO?.][[[_>^ !V#<V?[VPLO]\(1'O-L5
M/_C%)_[QCH]\XR<OWYU03]M@Q[S7-Z_YSG?=\YF?E>$A3_FSEQ[N[\7'ACML
M+Q#G1<0B3@>)R8@8&901Q;AWH^YSSWM PC&-.9;-'G^<QQ[['H__P_=]D /)
M?.,4&3C/3_+%*UX<1FHG/M:_I/9#2<KN3WF4H@S_*55)?E:6W_O;'[_YUQ]E
M\+O?/[ ,CX-DR2!:TO^6P:0E+_/_2V'ZG_^;4TS#5%T$N%Q/9W0_=W25=FA4
MUX!6QUP'V'0+J( 4F( 6F'05B($7.($;F($8@EWTA C$-FVA5X*<]WDH:(*@
M=X(JF((L^((K&(,N*(,M6(,P.(,X:(,T>(,Z.!/81FW7-H+6-H1 2(0_>(1"
M6(1*B(3-MH1)R(3/YH1-"(6?MH-6F(,?,0\;9E1U(6YWH0-WX2]7\!?G]DC"
MQV)3A3#N%F\/\VY@56_Y=F]=E6]EY1AU_]AO(M-P>LAP? AP1V9QTB=Q-9-7
M(Z-P?NAP?2AP7B:(Q5%83D9]@0@UDI@<'R=9(&>)F-AQF5ARG!AR,,)9(B=S
MGD5S@U9SI"B*J%B*A=9G'8@Y#JAS>"9UJ\.!&E@D5<<Y00=UL1B!#TB+M\B+
ML@B,PEB Q&A=Q7B,QIB,R'6 (,AI/?B,/!B-5PB-TRB-6/A0HR=Y Z:-IK>-
MIY>-W\AXWCB.W5B.J&>.X$B.Y[B.Z5A?U?B.UQB/U"B/UCB/]EB/^ B/]ZB/
M^4B/ R$/79 O7*A%XY9479 #(N8O810PAG%\N!=C5?5B[N9B%"EC%9E5,S9\
M-_:&/K8Q.T9\QO]W&R))1R(35]&'9)"8DH>UB"S)?M\7?N@G?EDVDU]&DS89
M<>B!DP:7<#/)']3ADV>69B8WE+(DE!)2E/A7?W&F?TQ)9S=29[L8=<.8BW]#
M=$"WBJI(BY5CBEGI@:^HE5[9BK4(EF))EF,9EF=9EI>3:9M&)T:8A/OHCW(9
MEW39CW7)CW@YEW:YEWEYEWK9EWSYEX+IEX1Y:E08A%/XA(J9F(P9A8?YEHU9
M;5+HF(M)F9&)F)9Y4X4)F-HV$'AA+T=%;F$X8DWU5"?F>RNF,.R6F@O#AEHE
M;UK%D7(XF_96FQASAWF(AT*6B'MXB U'<']X<2T)<>GQ<(7(F\B9,CK_29P3
MUV6 J)*'E'%5LW&;>(F:>)V=2'*>&)2AV)T"DHK@26A $I[DV7*G&#=FN24Y
M1Y7!B);I28&E)73R672.4Y6_Z)[XJ9;1=)]1V9^ZF)99@G4A.)B!N9D$RIGB
MB(X)RHX+VHX,2GKJZ* 2VJ#^$W@6>J$8FJ$:NJ$<VJ$9%*$5ZJ'A"*$*2J(/
MRHTG.J(H.J$FRJ(K2J$FBJ &.J,%6J,R:J,'2E NJJ(\"J(MJA#^L X!208#
MZ87\DI YL)#G]D9F5!N]]Z2[%Z4H1F-G^!G!=WS%!Y):BGS$%T@D"57.-TC3
M]YQD:GV0Y$C9QWV3%)-L^I*GU'XR>7YN*F7;_T=*Z@>G=SJGJO1*8L9*?'I_
M@&I_3+F4A I,_0> _W>HQ!2 R-BH_ F@[ZF?[>F?MVB 4GFIDAJID)J?FYJI
MG*JIH-HD(*AU,O&#-'JCJ)JCIZJJ.+JJKMJJL)JJKRJKL<JJM'JKMIJCIBHH
MCSF9DMFKP%J9ORJLF#FLEPF9F6FLR4J"M3JK%^8/L[ 7]:)%7F!%1LH7_O(7
M#(ENF5$9::B:K8E5[P:;;AB'MCF'Z(J;^P8SNFF'B.B;R;E6P!F)*[F3>M5D
MQMF;[[JO:C6</.F(CCBF DNOU$F)&&>=E8B=" MRVMFP89,BH/B=Y3F*@W:>
M%CNQY7FQK.6IO6AGP_](J1+XJ4?WJ/-IGU^)J?^I:!P[J2E[LB#;L2_+LB3K
MLBU+6\U()\Z:L\VZL[BJLST;C3OJHR_ZHT0[M$;;HR5ZM$*+M"FZM.\3*D'K
MCKGJLU/+LU7[LUA[M5I+M5QKM5U[)_2R143:A7/Q#EVT5.J0I-O:D(G1I&H$
MD7#;8N(JM]T*8RI&I3>&,,&WD3J6I1_YD4'FKCU6DOXVKX9+I@-+,_Z*?7KJ
MDG7:N*!4DY)KDY,[6/ZZN,Y9DT IE#_)G68FE)\+9_AGE&QF2_>W?VX&3$XI
M9S0[LR:[GN@9NQHKGB(+)5QYE9J*@$BGLIW:NZ&ZLK_KN[4KO-#$EG-23[[_
M6JQ>N[Q9^[5;R[S/V[S0Z[S4.[W6*[W8&[W:6[UXTJL7$:S'FKS(JJSDJ[SC
M:[[BF[[@NZSGV[[IR[W;RVN(L!<>=B]>\ [7"GO_4IJ/A+<M]JUJ.+<";%6N
MZ8;U!H?H2IOF*KCZ=IO\!J\0S*]SI9P3_*^9RY,I8XC9H:\<W#.8:[DW^8B(
M2[ '.XD%F[ HO+ .FUEAL\*>ZR(GMW(8"W/G.<,V/'-=R8K$BS>OJW.1XY_!
M&\1L$I_T";LE6Y](+%M"#+S#N\0[3#MSDG4X>[WQF[WP>U%1V[1)R[19W,4P
MJK1;[*%B/,9D7,9F?,9H?'>--\9<_,5M7+1O#,9:_SS'7@S'3AO&4GO%5*S'
M5KS'?MS'V.C&=TS';DP/;R&0=6%%5G2V_I*V2EH8MJ=&3>JV4%K)4AJE5.J0
MZ<:EG.RWGIQ\@M1':25\8>H<T0>=)'RFR)&FK-P;;?JXL.RX5(:G=!JGLMQ)
M=EK+>?I^NRR3?-JY\E>Z\R>H;W:Z@PI,2WFHRFRH Y@AROC,U/6Q3]S$D.:Z
M,@M=TJR[3KS-U,S$WCS-W\R!H^J6FID5W'(N?%S%ZIS.[/S'Z^S.[0S([RS/
M\3S/]ES/SNN]Q.J^ZUN^_+S/Z@O0_8R^ _W/X5O0]PS/LN(/2>5A]E*0_"*&
M^^M48U3 WHJ&:RBN!2R;'/^]P E\KB#CP.R*5A'<P24M,R,,B9A+B"8MP2?-
MG(S8&P$KB*A<<=)YTPM;G3JML-7IPIC%-1 [(S)\P[);L3E\U$0MBK,;SJT[
M.MG<U$R]LM9LQ#5[S3#[G]P<LT]]U5.-LEVMU=YTL]JET/1,U@E=UFA-H'4L
MQVL=QVX]R&T-UX*,QX1LQ^:X%7'=/FF-SV;-UWO=UX#]UX)]UH0=:OVP88@<
M;F]AMON2 VE;FA1]R1<9MP/,FA9YV1'9&3"&MWO;V2'YV5N:I8$[RD=VDB>9
MTJ@MG'=%RW(:R[U<N90;V[ -TSEYP<O9D_B1VZ#[PKNM9J3[VTD9W*@KNAFR
MNAK_ I55O=6X.'15B;M%[=Q1K3A8"=W@C-7=7-U9C=W7G=W<;7/&RVG.=L[8
M(MX^%=B%;=Y^?=Z#G=[LC=[NO=[OK=[RW=[RC-#?*]#X?=#YS;X!K=_^S=\(
M'>#[[<_S'=]'H0]W<2_ZLLBBB9"D2='<*I&K>=&6/9%MJ-FQ.6\*_-$>'=(-
MW,#^-M(N/>+Z>KBT;:\VF:_QVM(?'-,(!\(P7=,%A].3F,([;>,B]],Z3I1G
MEG(PG-086\- /N2SNSA,3=4]_,/6'=W=;;NF=<1(CL11WCA7W>3:S>1-+*!:
M1]\%#M]_G==US=9S'>9O3==@GL9HGN9JON9LWN9NCJ%E_T[F<FW7<F[F8W[F
M=Y[G='YY7=[G7/[G!A[H!8;G>Z[G1GL/"2X/]! 77'2_^]+(_U*&M+=&DVS)
MEB[9F%ZE<@3*G![:H-W)7QKJ9PA]8IK*J>W*4=/*C,NXL?S*:LK+J,3:MZS+
MM>SJKTWKK>W+?KKK2FFZQ.SKQ7S,NI2HS$SLSMS,^0?-RI[<WK3=SLY.7UW5
ME@K6NF7EUO[L5Y[MU[Y.XXR\XGT6)745P +H7N[G@F[NY4[NZ+[NZM[NY^[N
MZ4[%]CW@!$WO!@W@]M[?^/[?!"[@_%[O\1[P0U$/&X8OBHP7!KE4V>H7D&P8
MT,>: !SQ&4W &M[1''[Q&ZZN(O^^\2O>\8=HXB,CXS#>&RR]<"]-X@'7XHWH
MXJ:>N#->P@9[XSG-TS2?G0][\Q([Y&HCY./9\\]-NSIO-TN=[3.;<]2^Y-J>
M@5W-GE1NU4ZOW$^W[4F/Y>,DUB(([^S^[EHO\.Y.Z&)>Z&#_]6(?YUY/]H9N
M]F&/]EN?]5R_]EC_]FX?]VT_]Q0%D!Y&#_B2X%WD+^D0Z24VZ78;^'4[^!5>
MX1)Y^!B>D:*AD9[=D9[\Z2/I8\M7N)1/P2Y_^8&H\K.>ZS%YZ[,MVZ!_9;>M
M^2^.99M;2YW;VSRN^F-VE&@6W(%:J,.>?\9=^UX-U5+NPT-'W;SO9U0OW3X_
M]+X8LK__+_7&C^W'7_P5^-WD3-[C_?SBW0_8(OW.C\XY$>YRS_;:#_=TS_W;
MG_W>'_[@/_[=G_W^[H/Y?O[]GO[L_^_WOO[NK^_PS]_B+_"'K.!S(9I*)='\
M>YK^*_$ @< !"P<"#0XLB% @P84)&2I\\)!AQ((4$3PP:!%CQ8P=.7Z\Z#'D
M1P<;1Y;TB/(!2@<J6;K$N#(FS(LT9=:<F1/GSILR6?0L^1.FT(@R2P8UZC,I
MTJ-)<39]"E2G5)XVARXMVI1I4J):N6+MJG0K4;)BLYXM._;!VK)LE;J%6S3N
MS[EKY=ZE*S-NR;UV\_*]"UBP7<!V]1H^C%CQ8L:-'3^&K'A&_V3*E2U?QLQX
MLN3%FQ%[!FTW]-K1#TJ?%IV:=&K/JUN;AFUX<NC9K&/#KKU:]VW4NWOS5@W<
M=_#?Q8D?'Y[\<^?EKW/;EGW;=7/JT9WCMDU;^';CRKMS1P[>>_COY<F?'Y\>
M^ Q'B-H_0@2_O3]_ .C7QV^?OGW^^?WW!_"_^P($$ #^#*P/00,/9##!!A=T
M,$(()U2PP@<ME!!#"B_D,,,.-_0P1!!'U+#$#TT4$4423V0QQ197=#%&&&=4
ML<87;9011QIOY#'''C=<D,$@'1PR2""/M+!((X5$DLDDFR02RB6=I#+*)Z^L
M<DHKLUQR2R^U!+/+,(W\<DHSST0S3?\UUV2S33??A#-..>>DLTX[[\0S3SWW
MY+-//_\$U,TRR1Q324+%1/1010UE5,I$&\5R4$BY7-312B,MU-)))=6T4TP?
M]93233/]]%)10_4QU1U5U;'5'UUE]5598Z5U55MAO7767&O%M5==?>7U5V&#
M)7978X$]=MADBT6V666=9?99:0T-=E102[765$ZQ;;*++N8A0YYPR8#'6R^\
M1;>+*W)(9P9W99@!7AD<D.&!>0G"%Z%\6\JW7WW_]3=@@ <6N&""!Z*HWX0W
M^@E?AA=>Z.&()T8X8H<MKAAA@EAJN"6*QO*8K)#-2@LMDD]&JMZR5$Z*Y:;J
M+0EF>V62N6;_FF^.&>>6L9(Y9Z]ZUOEEGH?^F>B=?9ZY:*6/9EKHI9UNVBZ@
MUP)ZLGK7*LEJPF"[6B:ML>8:MJQGGFSL>LL.6VNUR6;[[+;3QL[MVN3&KC:[
MZ\;[;KWSSJ[OZ<Q3#W#Q!A>\</0(Q^YOO_%6O'&^]X9\\;L=GQSQP \W_'+-
M+><\\\XQ!WUSST</_7/12R>=-/GB8[T] /K9KQ_^9*^/]M=GQ[WVW&_7O7?>
M"100^&6'AY9X::-%WOCDBV?^>.6?;WYYYZ.'?GKKI<>^^NRIY_YZ[;_O?GOO
MPP=_?//%1[_\],EG_WSUWV]_???CAW]^^^7'O_[\Z>?_?OUMS8^"_P)(( $^
M:(#_4=$!"T1 !B*P@0MT8 0A.$$%5M" %Y20!3.(P0EIL(,<+. &1?C!$8:0
MA"<T80H?Z$$52I"%*P0A#$LH0Q32L(7_Z]_^_)=#')ZO'UT@ [C !8]SG2M=
MWLK!NM8%+ZW5ZUXF24A##B+%*"JDBA*I"!9'<I&)9*2+(#%)&$4B1C *A"4G
M(2--/%:5J5BEC6]D8QRE0A2<E,R.9FE*6) 2E9]$Q8UR_"-5!!G(K>01+%\)
MBQY-IA9&+M)D;D$*)/'B%TK6Q9*3O&1>-%G)P' 2,'_AI&'R8IC"9,:4E'G-
M;C3#',ZT\I2OA*5T@A,=5Z;.=)][3N5TN?\>7FK'EY)+W"UM.4S4 3.7P=SE
M<Z9CG5X:LYF40V8TCSG-9S+.FL0\73:%64QM)K.:DUO=ZN8#.]C1IYP!VD_P
M9JA.X;%3A^_L(3QY.,\=UE.>]HQG/NEY3W[J4UC9 BBJ2'4J;A64H ?=%D('
MFE"&+M2AUU(H1!LJT8=JJZ(!->A$+4I1CF[4HQB-Z$<%FJA^[M.?)<6G256:
M4I:BU*4GA>E*7RK3F+:TIC.U*4UUFE.>XM2G-P5JL_@!1'J,2QY>*-<1U:6N
M'+CK7?&*%[WL=;"&Y*NJ5O07%;6(58=TU:H#N^I$LIHPB%PLBQGC(EHEEK$^
MLG6M;>781N)*QY'_O>0L=429(^_8R)(9TBMA 1K2H 8UFPDV:(?U2F*QHEC&
M+M:QC87L6?SJ6$56]I"152S8FJ+9PPP&;)_M[-9 .QBT@:VT7IN9:=EF-K'!
MC;6A<=MJ8GM-:7ZSMM?!;75FN5M5\E:6W>3F-I5#R^6XDKC8Q*5M@3N>8RY7
MN,]%;G2#*UWG4A>ZT\5N=473GO8DPCW?]0<YPQO>U\4N=KMS)P?_8SOVMK.G
M07WO3G\J7_C.-[[WM6]^Z[M?^O87O_S]KW_U*V  #SC !S9P@@N\8 (W&,$,
M?C#U7NC"&%)81A.F8(4SO,X-U]#"'N[P#3$\8@V3F,,F!C&*15QB%I^X_\4I
M?O&*7:Q@!],XPO=#!!#%-<0B*E6)3<V!O&:FLG]1\2 /.7(5M=K5)4O1(F5E
M<AB_F-8MDK'*8\0R2=*HDS7>I,N$A.,@P^Q&.IH%KX7$8YK1#!6L^'',;P9D
M3B8[9S5+EK*7U6M>]YIG26XRDI@$]"8SR4E!'P:4?4%T)T%+RL64<M&QA'0L
M4QEI2E<:E:PL;J:MZSEF=AHZG_;FIK-[7>V6^K>GSJVGE_GI5;<ZF*Y6YJMI
M2\U?0I/6HR;=K6UM6UW+.M:SX2[K5M</\9K3O/A)9SJ?)R!E*[#&$+9QM*$]
M[6?3$Z0:O?9%1RK2C&J[VQW--K@#-6YRE]O<Y_]&=[K5O6YVM]O=[RXWMK<=
M;FZ'E-[WGG>^OUUO>>\;W_[6M[T#WF_S48O:-Y9VM1%^\(0O7.$-ASC#)>ZL
M?PL<X!=W4HZ#:%2D*G6IZW(J5.4EU7L=;&,F/QB_4&XPEJ\<8&1U6, @IC&W
M4JRM-W^863N&\XWE/&1U_1A:@+YGHNMY9BNSL\MN]I/")LWI38>ZS@+K],%2
M';%6-VS6L;[UJ"-MZE\W6M6U#O;-6IUJ23E[4[Z&VJZQ5K5M=VW<U^8VNL.M
M[G.W.][HMK;(]?UQ?]_;KFM-:L*+VM3FZ76HG3EXORM>\(O'=>0/+_G"4][P
ME9]\YC'?N7"V#A'^X ?_L<LKNW.VUW>F_UU^;)=>U*.>PQI2L0T=/ON(/WSB
MM+]][7%O>][OWO>Z!W[NA=_[X!-_^+\_?O&1;WSFORCV'Y;Q@I\?8ME#O_K4
MMW[VL;_]Z7<_QM?W_HQA+/[HEQ_\W]>^LY>_?N7[]%P;%Q<1N]!C(W8AB4T5
M^9 7AF0F7U')5DPR)],B*:L(&>B">NB">;FR,F+ !5S ,Y*K+=N)+XO .+-
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M]?$TGU3W_<B5.E0E,V$G5T0FG_G>_,B8ENG[A3)@'\21Z)](]#)1/+)')-4
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MW$(6W!FZ]6K?@7>=(>&%956X85G;XL<+A\7="EF''Y@A+D$R)E>0.Q7&6%:
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M >D0B&4EZUE[:-:THO6';%5K6]<:5[C.]:UU=>M=Y6K7O.*5KGS5:U_W&EC
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MXV:DNTQ1Y5"1XU*Q25;Q%%7Q%5D1%EV1%4EEO/^L9.C,Q!;/)+QV\;Q\T;R
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MT[!#"SF4#T,1 P1QL!,UM&[%Z5BLKL7IYO$"'C+F(8-&><CH8D<O=NPBARN
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M.CG633N^33S&NJVKNMV48U+QNN.93DPQSFN;!3OJMOE<$K83%$*NMIR].QF
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MREJ]*J^>\ZZN<Z[6RQL>XCPO8CX'XGSK!WV8!WD8N718!T%\!R4JW3UOGWQ
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MZZWZ".6%IKG^JFNPOUH'E*XLQ%J4/L$BNRJR0]U3ZZJ/W=2LM-(6&Q,_USK
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M!&NOWLJV^D,^3-VXVJ2U0&93F"3<[0RQRF2S3*M2.@NX @#_/WB!Y0G,N0(
M4[E,3BAEWNVD3%S-OUC,/="?TK!,YN7$Y+%,Y5T>R[PDOZ(,_%W>R-#?6(J,
MSHR,Z<7,S,1,YTF?PJ0>>Y'>R-+HR%9L[FE><3Y \4U-S"C%R,*L8G:>3EQ-
MTQC?98Y-V6@-UD0?T=R,T%@?<+IL4 PG97)K;WY?^/%+]1$KZ;RK<B:MXW2>
MUZA.Q2KGU8+8<FHMUC)GUVYMUK:-<Y88B<F@_-3#"[Y@?):MVJ:M_<S@^GS@
M_61@D6W@D=5M"8I/=^8M"X8/#=JM"$Z9 [XG"OHMC_D8#FI@F&G/\[Q/]_2@
M S60]F1/ D60_QSA!!GH!"UA!MD9_S1T$!3JV7[LZ.@^*H^:+NGFQDJ&X>H^
MXB>YKB4Q4NS*[NS2;NT&D9W&DSKE+CSADS,>$1R!DXCD43^,!SCMA>\.$2;N
MKCXM;SJ%4SB@4BB)J^[B$QI!INKR9/1J[V%N;V1R[_=Z+QEE+_AB;_>6+_F^
M+NN:;_J.;_B>K_NR[_I:I$TX@/$Z+_-6KUVD0R8]A^XZ0,BV1*12+SC,P"G=
MD_TV;P+G+_(2$B(@</Y"<!B1U[5!T^F6+NI:<)5J<#;Y ^\^,#BU UG@;@0;
M&WGA!#X(&PG[11=,Q1;A[P=3435NQ0'G$@*H [!Q13_,0SMTT:]>\ ]O, 8+
M,1 #@&&T"?]#B5PX0I1$J4,.U,D3IR-)\>,\NE05<U1)7;$5:S%+<?$6BQ1
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M3[$0+VB&)BZ1YO$HCV$KKV$;-O,&$_,L+S ]3S#3QFG:)O3:YFU0SV-'[_1
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M.((16(&:Y&DG:"*J]&FD!",M2".H]((Q.(.F)(,UV$JP-DI(PFNVM(.^IFU
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M\L?A?H=KKKO(-7/"W>YBZY)ET%SME$D>G86^?46D:M(7'GAQR1U7G![/1S\
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M7O# [K[0H=SB+I>]R'5O?-L[7^3"0WS<(X,\O&#?+H!O?%?HPOD$HCZ#E&2
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M/'-_]V77!Y:I!R&N=Y;L@M<;]V\7]X#'<^NQ% #C8GKH8LPTGP#+@0'S;86
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M2Q]]]]2G;S[X[(L//@#PBX_R?=XS*"'^;4:H_X3]Y[\_ /W'O_\),( $/.
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M\]CAUE*B(*:4/;&4'^:4(AZ>*TKB3E%BVS*CVRX5%XD$/I"!-C[ W'+$NLT
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M&?&/V_-4R.08Q'#YKX)C4^2\S/C(/L$-D>/C8ALK>,AY"4Z.KSR51#P5/S*
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M: =BVM2B=K6E9>UI6PM;T5HLM+,5[63)8UG,FK:VIB5(;P?R57S,E3TM/.Q
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M/U[Q$NQ_ .R_YEF>_\NP_3% Z1$@\5% _UE !VS !O0P!PJ?$4LQ!Y(R#+Q
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MX19ZH1B6(1F2[_F>8?K2D!*MX0ZIH2$6XAS"[_PFT1W:[Y-6(AY"HJEU$4/
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M*^(@-UA((AIR=X0\Y"(3B4@-?N6198GDX P7N,)9LI*4Q.0F-<F066 F,F2
MQV4N@QG,Y$ =.9A!:"Q$GMZ\YC6\@65L9EE+6M[2EKG$Y2YUV4M>[E*6L@'F
M,&TSG6+R1O\UVD& ,97)S-4T\YG1= TTIRG-95ISA]*$CS:IN<W[U/ ZWZS/
M,KU9SG":DYSG5&<ZV?E-=Z+SG>N,9SKW0\]X_F= ^"30@$JTGW[F*#PA"N@_
MVPE/@\KSH 5%Z$(5VM!X_K-$_ P0@/QIGXI65*+YG*@^.;I1CVI4HT?ZCT@!
M1-+\F-0^)%5I2EEJG96ZM*5:@NE,95K3E]HTIC?5:4YY2M.5PN>G. 4J2X<*
MTZ)JZ:A:PJE28<I4I2+UJ5>*ZE"C6E6K7A6K6=7J5KG:5:]^%:QA%>M8R5I6
MLYX5K6E5JU=7E:I3O745KKJ5K%H5*VO%%5G*:E5<[[I7804K6?G_V-4S\@$L
MPAH6L,4:EK%^Q=>X"FM6>\UK8@4;6)L\0Q^$_0AA,9NNH!'-LTZ#E[S^55J
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MW&U][TW?WK??X-<P >[@%C,R%\Y"1$,TMN#%5&%N4\QM ]AN!9C%2/-_.XZ
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MUH<(N'=)Y\=(@;K.B.!&(%&GZ8Q^@UJHB+I)O<>H\3=,D/JHCEI_N%>GNP2
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MT>L"R\.B$,PB1'"E :R560 S?IB%K<DV:+J'&8! ^M._&9C 9^HT#>R'62#
M%ARU(C3 (S3")$3")53")F3")U1"@_"F(Y3"=)K"4:O"JK'"+;RU4Z,V+P3#
M+A3#:0M#,AS#+SS#,AP(AH >B:((B[@(C= (CO (D,@KFIHIF#**/12*H/##
M/@3$/Q3$0%2*I,")HRA$IL"*EZ(*I[ *1US$L#B+L?"*2;3$2L1$KV(+M;A$
MK\H+3WP+T1#%T"!%SS!%T#A%430,O5A%M7(K5_R-U9"-O:",S< JS4C%4D3%
M71S%7/1%NH@-6?\4QL@H#:0B1MJ #5A41K:*Q5=D1N+(C>.P#N.(QNVP#NVX
M1FL$CVSDQFWT1FS\1FT$QW$DC^\PQW)$1_<XQ^? #W8$CW:4$'=4C@^A1P3A
M$.##QWS4QWWDQW[TQW\$R( 4R('LQPH!D7I4D'=4R.1@, 8[$0J+L J3R C[
M, W[$1\9DA#+,!WYL(M$DF99DA<#228!25[ADBEY%BPA$Y5,26N1%FSIL7%1
MDV=@M$@CLG=!%T%)ERF3LIYD,D0!%$FIE*&DE*(42J,TE$VQ%"O[%*;T%$^A
M%5,),U89LTRQE:C4$VM!%E\AEEXQ,65I,RTQEB89RQ;;2K.T)FB(EES_HA9
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M*,0@$G&'1@3B$8>8Q"(BL8D7PD<7Y$$&*?]*$1Y=2-@5NW"%'&QQ!EZ<@0S
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MVL=W'=8HEE=?O(<:'D: ] >!P%?-J5W9A1W:34B7<$F)V"+7(4*3(-@!W"(
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MRA=[2JSDRC;1B*2TRJX$2Z=L!T\!%3H[&SQ+%65YE5CILUJ9A6^)M7&*PUD
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M."^_/:_R(@[X*D?-Q5S.?2]WK"]#D*]VK(YY# \!^R_4'3#1/=W4+3 %2S"
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MPNF&%V!'W>BDR.1,6 Y@/QS-SJCD [AE;LPE5?(D5-K;7G(-P'C!Z7B-P3D
MJNV+NH6-:@Q@N1WFJLG + S@O"'.SLR-U[R-# R@JJ$5XFCF:A2.6>8EM_F-
M8^9E;D1EX>1-7:8-/ S@YYCFW@P(P,#E [P#3ZK.X7!F=<!#X.1E;-JF#-1E
MR 2(:L"#:(YF/]1F:\X-&:BE6#H <38':VZF9_)D(O3F P#FOJA.W\@,P+B.
M=@Z@K/F-;NY+XFBE R0"3\:F=KIF<#[ <C8'>U[G6=+-3J8G>!#.=]SG;=Y'
M?O(G\?0G\/SG?OKG@ (H@0IH@2+H@2JH?00H@_\:J(,F*(0NJ'T^:&NJYX5:
M:(9N)H9NJ-] W=.!:/E8'?R0*-65Z(B:*/^H*-<)$-CYC]B]J %1D(Q:4 1-
MD(S2* 19$ ;= ]W5PP8-"9#^*-U]4("-4#Z@$)*64.#YG1L-GAP)G^)%Z92>
MD90^WI5&7I9>:>==GO,I'_15'_4MTB)Q49E^$9F>:1:9EY,*7INV$>_!$0T1
MRIL4'Y52*9?P4"#M$2$=TA_YJ17U*: .4B$A7YHJDJ&R5Z(^$J4@&$#.2C8N
M9$(>9*0B9*52ZJ5.:J9*JHDU*GN=E_\)R2H<TVRP3:KT0R/0U2^E:C"M*ES=
MU3!AGZ?( E[9!B"XPSK_M$,[N(,>N(,[O$,[O(,[P(.POL.PPL,[R$.Q(JNR
M)BL\P$.R0FNQ/NNR-NNT1JNS1FNU9JNT;BNV4BNW?JNW7JNU+JNXEBNY:FNX
MHBNXCFNWKJNYIFN[JJN[TNN\VJN\XNNYUFN^QJN^WJN_\BN[ NS ]FN\3BN\
M"FS!)NS"(FS#ONO#[BO!,BS$_JO!*JS#0NO!4FS 8FS%3FS$7BS%'FNS(JNP
MFFRP_JH[Z"JNXJHZK(/+I@,7%%-<R8*K+-.HTBJKOJK.YJRKRL8JT(HUO"J"
M6 =I 59\K*(K*NUAP2)C.>W30FTM2FUD4>WWZ.+5\F+6,HXO?I9G!2.&< C1
M__Q7?_'6V')7;YVMV:Z6VL(6VW97VI9MW)+MW,(MW:YM,PJ7_-##/-2#<05)
M@)67H!!8<P4.]F$?@QGN*K52-X()?C5*/O!7V\KMV79!>(V7/@1NDI@7'=%7
M-_*L-=+7H'BC"L62H]Q#%Z#MVDZN [2#F%QNX+J)?-7)@4E8[5+8[=IN[N(N
MA'E8IFS8[X:8[P9O[Q*OHW*8IEHJ\F+JIB8O\RXOLO@#&5R!%SS+C$F+%N;8
MCO78CP59MZ15R8192Y;9D85O^7Z9F+%+E#TOL/##CR!"-,X ^LKOEW49DYFO
MDS'9R)S9F;49FYF9 T2:P]49G@TP IA* 5\'J6G*GO\)V@-L'[$E#:Z%2M0,
MB^L\I; L6]6D6:84&B>YCJF9FZ/!VK#=&ZJL&ZKUV[JQ6JD4'.SP6MAL\*9D
MCJ/%<)7LF=B@2K$QFZ\%L*_D@Z-E)8GY0[&A6Z7T<*IYV^PL\ 7GBKEQQVQ^
MDC^HL'F.VK^]F[%(L6#298OY&WA \2B5C<4EW*<LW,@Y',@5\:<\7,5=,0#8
MW ,3G<DQL5V:W!CG1AK;2C[$\1X?G=(E'1__<1\#LA\3\B ;LB C<B K<B'/
MW(=^:-2E*-:E*(JB*(M:\M:U:"83$(Q^W8UN,@.I'=J!LMNY78V>G0-I$-VI
M<C[,'9#J70@IZ=\U*9.VJ=__&9Z=6BDN#Q^6\K*6^O+E!1&79EZ7$C/GB=X6
MC=[HS9XRHY[K49^9BFF5WM[MN=$TZU[O 5^5$I^5;G,W[^F7'A\?>2GS/5\Y
M(Q(T@U$915\Z0]+A.J_RPO,[RW/STO/ZQG,]WS.(28D_:DE]?8D]WD,E&F!8
MMLT#<N)!=V)RJ,(GTI\U*& [X*JNVJJO^FJQ5O2Q>FM&:ZP\E((\;'1'?[1'
M:RM(C[1(<RM)G[1)8RM*K[1*/RM+O[1+<[1,P_1,A_1-ES1.I[1.MS1/Q[1/
MVW1."_5.#W5/%_5/'W50$_52&S53(S51ET)32_533[525W5-8S5-:S509S57
M;S5'_U_U5T<U59.U59=U5R<U6CNU6;,UN+Z#1:.LKJYLKN[J.K1L EXBOUA#
M*"9T7R,T;30"0Y\-7Q.'9JE#.^@!1-]JKK[#1*,L7"NK1J>K9(,K95OV1E<V
M9E_V9&MV9W/V9V<V:&]V:)/V:)NV9Y<V:I^V:*MV:[/V:Z<V;*]V;-/V;-NV
M:U=VH"VCBN#M,Q;7C_PM-4:*DM@)-AIO[V*C(H&1E_@?-(@)(NRV [B#F"#I
MHQA)YI[C.1+'/&JN_QG*_^$#(N!C,G:!HQ0*[,X)G!1W) %O/KOW/-LS?+\W
M/LMW?=/W?<>WITA+1\*#C87D2';!CFD+MW2O)$KE^(IO@O^3F8+3"TY2Y$1&
MI/WQ:,+40Q> [TO69$QJ.$QR.((O^(?KYOK=@TQ*C/RABU6R0%9*#<VP#'94
MY(,'&E?NC'1">$:^7Z.U):E<C7CF7VXHI@@S6[T-#.I*<.7,&F%VBF$ZS=DH
MYK^MSA?[2Q<#2*F.)W?8<6Y49N*P)X#T>'.$YME@[G9X@6K2WWI2L$7F!G1:
M5H2_>&XL2(CO"SYT1[24.8&$6Y03"*GH6W?@@W-^"F2R3ILWI)KOS.GX2S_(
M^7:0P97K1H$8.G:NFLP0S =WQ]ETY^O N6ZHS0IC9/@I)N;4<&XX>HV''Z G
MSV3=8O.D.JI_SZE33ZNK.JRS.OC_R/JKT_JMXZ+6ZGKD)'&U;;H3,QT(8N#[
M5MW5Y0\E%WN)9MV*9K*+:O+8*=",ZNBT+Q#95;LI _<%9="0UAW>%2F1% JX
M5W>2TG(UY_*YZ_+O]1 N^]XONWLO*Y'F!7,4@?,5&;/T >HZHS.:'FJ_^Q$U
MUW+ IY$U1RF>:C,>06D>93.=^JFD].F@-GPX?W/$.SPBC2FBEFDK+6H['V\G
M0>I\YW?(@_S(V[?(E[R+J5*=S-=UJ9#ITH,AX.PMV8I!^ZRJ[FS-\ZS-%T)@
MSWS/&@)= RNPFBQ&LZNU!M>S'KT\W C2"Y?2-WW2+[U'-WW40_W33[W5/RO5
M7SW39SW6_SL]UW^]U'<]V&O]V(M]V%<]V7M]V:/]UI\]V\/]VLN]VM/]V\^]
MW==]VN/]WNM]W[N]WYN]WD?]X/]]X0>^X;?]X2M^XC-^W.<]XCL^WT/^W0-^
MXU/^Y#_^XD=^Y6_^/"#KP98L1E-TRJ[LK;H#%\3&,3'@K=!\SKL^SL/^S-I5
M,M'*6^4L7U5'.I@^L*Z#ROYJL [K6QLKM1I]QF:LYYNTU'_^\2__YR._T3\_
M\R=_<#6_\D]_]#M_]5/_]6L_]EL_]'=_^'/_^(,_^4M_\6N_\:?_^D^_^K<_
M^Z/_^\M__-._^]<__-M__N/__L^__O=_\P,$/'CRWLD;^$X@0?\'"QDZ0-"0
MX4.(#B=2G"C1@8PN\N;!FS>/'DAZ]T;>RV<R'S]H_/3U:\G/'\Q^ &;ZHPG
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M H''!"GX#@FVPQV!Y$(""<C !I9&@(14) 0764#_';(T^E!%(PN!@S?)P!V
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M#=J@[=JJ#?\NS_=UNBU]US<N9PU^P<V@K-=Z"0H"(3-415!Y2-!56=5_^Q>
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MR@2SG,NW'.F7'LJ=B@9G5:K&P%9Q%:MR0#K2P5=]M:\(ZZO+JEI_$%O!WJW
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M 1KCZ_;W@$0&>][E"^1=OUU"V<%OW Y"(K[Q'44 SGO= 3(9__SZ_49A]\.
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M6=DD/_-+O_1C/NO$3C <0U4\Q2$UTIH%4INEV2(CSH'YT !$H#V#&8H(%)N
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M((O)R+()TT-Q%:YTE3-0'Q4IG#D:YS?+N<YTWNBZ;F6N.X?4SGWF\YS_+.A
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MAA%N6"&'&'JHH7G\N--%%V3(0X\\7L!38A<D=I'#%5VLDT,Z,\APHPPXLN"
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M9]3=%R( ;%[L$06_(_.OOA:,@"XH9;TN*\GANKLW^1+XNAJV;H<SO&$0_RO
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MVA98.2K (BS*<L[<S"SJ3+_/RLS1:I724DW<FS_OE#_PE);Y>Y;QM#_SQ#\
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MV&6'0HSTHA_MZ*@@)=-]U@V?#U,4P#2&)S"<R0G9.(_+5 ;5EJ',&TF(9\_
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MQ'2-(+6XU+64O#6X4'6CGDA4"ZJ1\HA5IW5AK_5A&[;A>;6FFG5CE_5C][.
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M-]9QC&.,3$EARE*:$M6G@@RJ1H5*R$E&\I*/W.0=VYC'3#;RE#'EY"I?D\C
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MY#A$%*T2D4:3KX*/Y)9C?KE)^-S#_Q=?+,4TUU.QW628Z:4+%A3JI+>^>NN
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M#\<KWO+RT+SA/:]ZT\M>\J[7O>U%+WSG*]_ZOM>^\;VO?O/+7_KNU[_]Q2^
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M= P.[DS>?6S>9 S'\5'>"/ .53S>['W>[ORR2O(."(#>/HO?_QVKW[8$#C/
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MO4[6Q4Z_S9[MZ9[O"9\H,Q\J2Y_UX3(]= #ZT8C_>5/]L9\2!HD <C0_56%
M+406_M,6AN$_?<1&A,056D0:5L0<3L0=ML0>KL0?IL0@?N$A/D0ACD0@MN$@
M^J!83*(E!B)6+"(F4N(HIN*<D&)?S*)?Q&)>U.(N5D93ZR(M\B)52\8Q4E4U
M0B-J3",V,J-:;>-=A>-<Y=4XUE4YIN,YQM5S#59@_55_ZV-S5<>-!/_)5UJE
M0B;D0\Y'1.Y'1=9'1AXE0T[D2%YD26[DC@QD2^9C/?YC?B-77ZWC3\;C;CRF
M9#JFED0X=KVFA*/)&!DHFYS7%JG7JLLZ=C(GF=7)G -*K<NYHL17MYS9BZ)*
MB<W8DR-FJ=S8*:E8DYV2N3QF91XYH].0B8K*A7(I@$79@K5*L_RYHB0I;\J'
M>U!+E^U)8)9+6_[E>U+8:&[:QFS,"P%,_'AG?BA:>.Z'HHUGH)UG>:YG?:9G
M>][GI"W:PJQGPAS,G95:RJ1,IGK0NGG=" Y<PAU<"?;:&5BPP672QY68'SW<
MCM&QN<)H6\&KPLI-5O&OOE+<B+G-P&*5BR;_SHJ&Z)>6Z(>.Z8B6Z9I^8-4M
MW8:&X)W&:;?9,/6DK1(#ZE,1:N9)T11<F^),%L]]F]9DO>E*L>F2WL2BS^6J
M&=[,%"1M4O<,T04N4"N-+RP-:[!&+P4EZZ_.TK0>:[4NZP8]:R6%ZR*-:QV=
MZRBE:[G&Z[O6:_-"TI[!+J46FKH&S@W;N^(=+_^<F14M,0QET@.PL-CLKZC>
MT"/MZKQ^*A:UEBYP4+EBPLU$4BC4T)3.*\%F[-W",<:N:-+64+%N:]9&Z[5V
MX :6[;<!4RB+PRFC,BO#,BW#P_994Q#.1#@3;CL=[CHU[CM%[N)&[CU%B3R-
M,Q=>X1CVTT:E[D=%_]3K5M3L/E1 =%0&JF[ICB%*W31)70F3P+0BRK1*';5/
M7>].=>_V/K55D^_XCN\S-E56.]7\IM;]ME;^CE;_7HM9O54!?^,")_ ##V5.
MSN1.7O &]V--AG &?_!#HK<*ES9M;59WR_!XP]8.WW ,M_ 05_ )=W! +O$1
M-W$25_%HVR-@ SCH6*9W)8^8I'$9<64U@>6(V^6 !1 N\=>- W)K#G*2)7*#
M3><CA[F3<UB&+>8F3W(FAW(GEW(H7_*3(\LIM_*ZS-@KC_*/91*+LE< J;@B
M/UEGACJ;BSH;T66%RO&J/-A]>A!?YLHWY]B/E2FP.SNP<^=YFF=]L&<_E_]G
M0/?S/R=T/C?T]<CGG^W9!/%913]:I66[J<V[2BE"F+9I2Z?I3/>J'.1;3L^J
MQ%L]]QL9^<2^(?07+V3!&OS"D;Z8RT7!'NN4VL._YE,^5)'UO,7T7)]I7;_T
M7??U7@=VQSK"S-:5*>Q!I='"8SEI;0E"G+$54M>\88%V=C'UZSD=^E._C%E"
M@,EVCT$$;&>5\WN\AA$;'G3-U>WIS^5IG4YWMV'W=X_MVK7" Z;WVO7=%\1=
M%?S=?<?W?J]>[25??O]W?0?X@O_W@_??@(>4:^<64P?>81=/^5W?X348])MX
MQ?G"I4[X$1S?BP_"^D-X2^'TW?T94$_![[U>A@?_&'I ^9:WVF]_0H7?W5L'
M4H17>6NY>(G/$V-/]8QW^ W4FF3G, K\09H/P]BV&WC/:=#\=4UO0PM^P]N>
MPSI,G]Z&'Q &8>_N[A#2[D'];B*&[K ';R.^81X.(1("(1QF1+,?^R0V>U5,
M15+\Q Z:^[B'^[J'^[RW^[W7^U:L(29>1K\7_&(<QL('QBQ&?"Y._"WN16$\
M_,,/HR\VQC(F_&G$16@\#&HD1KS0_,Z_X\^WX] '9= '99+,"],/R=,O2=7_
MR$L>9$LNQ]>7?=>G_=BO_4;"_7JT2(J\R-[G_=_?_> '2> ??N%71]X7Y-MO
M?=MG_MR?Q]EO_N5?_=2G_WYRG'[K'_U<35>!2^7NSXY5_GY6%O]YK<EXW9$S
MH>98-DJLXV9[O65;IN69E?-R'N>(W?(NQW*+0N?]=_*$O7\S!PA^T 02'&BP
M(,*#"A,R7.BP83]H$2="\R?Q8D2!^I[I@[:Q(TB/' >.Y%?R9$>3*9\19$FR
M94.&(T-^]&B3YLV<(&?R#!GSH4*</H'^A(C16D1__"8N':@OHSZ-43WFDVK5
MXU1]6;=>Y<?5*<&G4:=Z[3?6;#]^LY;R4^JOW]JW /KY\S<7@-U^>._FW6OW
MK]_   +;'0RX,.'!B0T+WLOXL>/(B"<KI@S9LN3*FB]OSLSYL^?0F$=W)@W:
MM/_HTJKK(?B&X/6!UPCJJ7Z'(/9KU[!EZ[[=Y?3FUK)Q(W"G&KCA&;MSOTZ-
M_#9OV>:.1W87?;EP[+T/S#".VG1VZ BZ8#8WG/<,Y)Z[;.=-_?O[^.KASY?O
M_#Y]_/;S\]<,F/%_BPEXF'^9!4@@@ 8J2-F!C2$XH(,1-CCA@@4R6"&!&2:F
M(8<;>MAAA\1M1UYB]<S0'G,@!J;=:R2J")AU*!;G(8L(?!@8:R+*YMV-'5K'
MW&ZTO;B77G:Q!B1T0O:XX76^:2A#>+C-4&1@5 )F99.Q&6<ED8EQV1>!7_)5
MI9=EAFDFF6".226;7:K9YIMNKBDGG'/&>:>=>=:Y)YW_?>+)YY]^ZBDHH(,&
M>JBAB1:Z*%Y=Z/A:G?1DB0 ]BKKI:)9]QGA>;B0NVD6->?X898N,^D,JDH^*
MEQTBI@)@7JH((,IGK A,2>A>,KIV)Z9(\NAJ.YRB.NPWB,R*UZJ]_8JK/XCH
M:JREQTJ;YY5H5GLFMFDN.22WVWK;+8CTR.,%/&2,"T\777CA3KI=7)'#.CFD
M,P.],LP@PP,LR,"" _SZZP "_;X&\, L#"R;P $C;'# #"?\L,,1%SQQPQ1#
M#/#%%3>,,;\;>]POQR%_W#'((XM<,LHDJWPRR0JC['++)[L\,\8TVUPSSC?K
MG#//._O<,] _TQSSQS#S3/3+_RP#G*_(3'OL=,D/*.RTU$MW7#4"5$]]]=1=
M+^UUUF!C/;;897]]=MAG.T"V VM[[;;:;+O] -QSURTUW57;K3?>>V?M=]Y_
M]SVXX(4'?CC@B1..^.**&^XXXX\WGB_C+%1^^=Z69XXYY6MKWCGHGXN>]^B>
MDWZZZ:F'COKJ:[L.^NN?QY[W[*^K7COML)\NN.F\4^Z[Y< /WGONP1<__._'
M"[^\\LW/SOSSSN\N/?'16S_]]=5CO[WVW2>?_??<A^^]\>"7+_[YM[..._OK
MNZ]ZZ:W+'W_ICR#B""+VXX\_/L_DXS\ ^_>_ 0*0@!OYWP%%@D#_*5 D.WE@
M3E020?^4D&0E%C0(!(7BP IR4((>I*!)6K(2$;ZDA"$$2D8N(I 4LA C+J0(
M#%\HPXA88X8VC"$.;ZC#'/)0A3XLR@X5DL*"#)$H1DQ(#_MA#8LPT8=" >$S
MH,&2*)($&B9T20BGF,4M:M&$!\$B&&'B13&>4(,XT0@641@4#$;0)D TR@IE
MZ ^D5(2.2@R+5$"B%:SHL8]\_*-6_*B5/&+%*H$TY" 'LI2H+ 4I=%D*72+Y
MEKK,A9)BNE!_ZJ-)_6PRDYS\I"=#N9]1=I*4D3E2>%RC),B,JC>N;!)_FN2:
M=X!R,R>2I2DG(TL$R$ _MGDEDH"9RM?,P).M=,]GAOD:XW3_$E3*K&4IHPG-
M:8I2FM6D9BZS:4UM8G.;WNPF.*\I3FY2)IB[-"=ST%$AR CS&[\!)92>R2#V
M-(DV";H0*E])RP?Q,S"_;%*E*-0AU@@SH.M,S#^!]*%=\@A<RIP1N+XET8A2
M=*(6I2@E#Y-1(FTT+QVM9)@^2I>0_L62&35I23V:4I#B!:4M5>E+63I2F;IT
MIC:M*4YA>E.=YI2F//VI3X.Z4Z'65):>0BD]@]G3H?;#F>T\YS KQ52D/A6=
M#Z7'4BT)U:JV1@9;RJI'T?'0J0)UINV405E-*BEANJ.HP40K47FZ*:M6M54N
MK0M,3V7.KY*T2HA )[3RRM&^5K2P_Q<]K(;N::'%*K:Q$/JF:<@ #W&9BQ[J
M>D>[V)4N=>2 L^BXU[UD( .0C19I,SM8S5"K,-42S&:L11C,6(NTE9FLMBE3
MFFUI>]O<XG:WOM4M<'L;7-[&[%]&*R[(5F;<Y"9MN?]2[FV=R]R-2;>ZT;TN
M=+,KW.WRUF36U2YUL1LRXS*-O,^UVG3+&S5_C8V]6^M7>^'[WN"=C;YIHR]^
MJY;?ANFWO_S]KWP#O%\!^[=M!88;?1',-P KF%]W^US 5!=AT$T8P@:VL(0O
MS#G!09AU]/,PB.$7XOF-^,,B/C&)46SB%+-XQ2MNG_IBK#L9R^Y],[YQC6F<
M.QW;#L<[]O]QCW,,Y.,%^<="/K*1DUSD)1.YR3 >\I-=7.(IJYC*+;:RE#VW
M/T0DXGY>_I\ GQ'F?$!C@&5FH)G-G, THYF!!^1(3S9(DYFXD<X9C'--\HSG
MF^SYB1?42 ?=*.B4"/J-1_1A$G481XHL.HB)?K0+B?C#0QNZTI2^M*5Q:,=(
M.]#.<H;BGRDX9PB>L-1IM+2A"6W&-@)1@V0>"J%1+42#P-".=OR*/O(!$EWS
M.M>^[C6O^=%KJ@C;UU3Y]:XU4I5",GN09WF*6MBBE'Y(4B],%91A'=M/@3(6
M0MS6MH0.NFUQAQN3Y#PW9..3HWJNAEC"<HTFD[4C<BH'5=@DJ+#_IJ.>4:FJ
MWY.R%7_^*N]52L:IG()FKZ*$[G N?)SI?CC#T_UM;Y-[XN,V-[@M7NYN7YSC
MB/VX84,N45V]N^0("*RW:N4BB?:[F(3)TLI5A&_L--2BL!JXMJX5&$FQ2$EJ
MTOE?G"4L@UXKX=N1$]")5/*:NTI,36=6M*+^]&E-7>I0KSK6KZ[U65ERL&OJ
MNDZ]SB:PRU3L9@\[VLN>=IN>O>SF:<]T1CJ+L=>H"V-_$]B3*N\:R;N7=Y\[
M2N=N<+[[^S7FJ O@59IXD.Z]\8^:4N!WNOB;ZRBM917XX\DJT\&+QZ[^ /Q<
MQ:/VT<\T6+5RM^&W/JQV;-WHPX%6UJF^__6H)_WG2+^][46N>Y!_2%SD,I<7
M,*NN=KG+7?("K;WPI:_2,K=C%I.8QB#V_.E''_K2KS[UKZ_]B'&L8-WO[F^Y
M&W[P#]>W1AO:T8*F?J&MO_WL?[_Z9YM^]-,?9^6_?]-H"[6KZ5__[TU;UG -
M>@&@UJ -VQ"@V2"@ 2;@ 3;@V\@-!#Z@! :.@15.!5*@WUS@W4@.!T:.!T(.
M"$Y.!X;@"(K@!YJ@XG28A+$.AVT8"[[@"E:9##J9C2$9DT69DM$@C^D@E-5@
M#N+@#?I@$.X@$/*@#1KA#PHA$@YA#Q*A$A8A%#XAEHU8"VZ.%0Z.YFR9_>@/
M(A"0%Q80G"V0&/\VT)N5H9N=(:F!6@>IX0>M6DVTX1J&FAQ>T0A=$1G1&A[&
MD1XBF@O5$*3]H:,%(B .HB 68@_M80O)&A#E$!,M447\4$],D05-D169&AEI
M$29NT1AMHJ$EXJ3%A$MLQ!VFFDX4FAHAD4.T4%+0T1Q-Q*81DK'E@ZZ5&:_)
M8J[9XA_AHJYUA"[.HB[NT2X"TE@D$C^P!20YTEM0VR35Q5#AU6-%'#0Z7#0V
M'#5"G#1Z4C[)!C@@P#Z-DFUL(Y+$$I)L8S=&TRV]!CBV!B)($RJEXRSY$@*X
M(S&9AM"AXW7H!VO(XWB@QLVY8R^!$N>!XS1:8S4.I$%>8T$B)$$NY$'_)J1#
M,B1"VN,X-HD\EN,G]88[OE,FA4<Z,M->)%0\-D=^M&-TJ!-\-(A8Z:.L>%R#
MY".[95QD\%Q(=@JWB15&SN/&I=1,AD?-[=Z+?)0S:E2& "51#J51$D91(N51
M"F5,!>5)K=1,.6-4WA55YE55LI14/B567N546J57QA58:IY8@E58DN586IY/
MG>-.:IY,WJ14F:4SJ:1<\H8,O"5:CI3>S>5$V@I6W:56321?(<+-W:2MG&4E
MI21 F25*(8)<'A5:CHH\PA1A%H=B>E3HI:-A=N56YH4V1H=W<&5&Q1-A-J5?
M)"53GF9I^J1$P23&49Q"-B1RF(MLR@,]P,,8_PC?NK0+9W%6\H46\S%?T=C?
M_ DG_-V,_-7?^8V?<N(?^6W7=XV7>(47=!V7<"*7=4(G<X;?<THG=C:?=YX7
M>'XG<[7->9'G>(IG>*9GVZ G>ZJG>[8G?+ZG?'ZG>K$7>-8G?#E7>?67>^4G
M@?7G@ 5H@0DH@!&H?^87@.XG?R6H@_%G!?IG@SVHY32H?5Z8AGG.A3(-_&0H
MA9(.AT[A#&;9E84HB(ZHB4J9\IU.BIK.BE).BUK.BSY C,[HZK3HVMBHC.H.
MCNZHCO9HC?'HC_IH[@#ID KIZQ#ID1IIWB#IDBKIC3IIC@:IE!;IE"9IE;IH
MC6;IZ-#HEFJIBIYHB?^*J(MQX19^F9@5T)GAPSVP&9FQZ9FU:9O!J9PJ$)S=
MF9WJ!)[QQ*OEZ9WJF9^5HJJU4: "&J&:8J;A8:(U&B$NJB$JVJ$5$:-AFJ0J
MHJ0FT2ORV9_Z!!NJH2ARXJE-ZJQ1ZJ :ZJ !*JN!ZD^HHD38&E0HVZ[I S[X
M6JSJVJS"JJPB&ZW>*JW:8JW6:J_-:K$M6UDP$EI$FS*V!5Q$$NGQ7F*Y)DM6
M'+2V9L>QYK-*Z\91*[8Z:[9.JU\0RSIJ*P <TVYHW*G(B$=RZV$XTZ/$W"A!
MB:K8TWV(ZVVDAW.X'FS0*VH4'NHU7LUEG-Z)2+4&++@1)+E&J\<1K,%NZ[7_
M@BNZ+FS#%JRU0BRS3JQJ5BS%>HB^]H8Y= >[5E3=%9:ZWF/0R8C/;8OCX=Z8
M7 LBM%SNI:R<9&.0N&S+Z@7A_9N[;<G530K.RA[/6EW/QI[/!BW0#NWL$>W/
MDEW3(2V=("W3XIW3?MW3WAW4SMU=R-W?61L F)[CV:RN(-[55FU=V&OCF4,7
MN(/G 9ZU>2W8?EXD"5[-,@?9M@/LJ:WBM:W5OL7J>>U;S(),/@K:)M[?RIW6
MM@=?H2U(&:[5UAN*G"W6WFW:GHJJM(-<]$,\B0A:4>WC4FW=[H765I[FDI[2
MW@F_JIZ,3,?/%BWJGBZ>U)[,MJ[37:S%<HCOE<NY_Z2+%Q#?%1C?O-3+O>3+
MOG@G]D7?PAQ,]EF?\18O\E;?]Z6,]S6G\RZG^&5G<DZO^U5O<5HO]EZO]L;?
M<%)O<'[O;NW? *Y7T_Q??!&@  ;@ JZO K:O [+O^RH@W*3-_"Y8W$C@@V:@
M_A*.!B[8"98@ /^O )/@ *.@ 0=P"*H@A<'@ L<@F)(H!#^P!+^8%#JA!3?A
M^&1P^F@P\FRP!W<P"$,/^H0P]7"P"),/"9M/"H_P"9OP$KYP%%ZPF(8I#4,P
MF7H9_X#A%WHA&9[AGHHA&)KAGO8IIDZ0&Q:QGQKQ!DG0&V[J',*A)5*:2W@B
MHU9QHUHQ%@?1'DH:*E*J%_\CJAP](J/%&12?1"6&T4MD(AJ#XBC.FJH>(A]^
M<4($*JR%*JKRH:8Q14'XD2W*8BW^,:SV<2_>XJX6<B #LA\3LAYY!2,I4EI0
MFQ(I8[5-4C-Z"$0^)&QF\FMN,B:/AL )4W^ 9&^(XS!9I"<]53358RK](WR(
M,DX"AU5]!^=Q%2VW"'_,LDAVLBY?,B]K\B[[<B]S<C#_LC G;&*@$[LJ+(6T
MDT8Z[%X,)EW^A5%Q6X;@\CY>E&A>!\I%U,R%!]'U2-C6,EU-,VFNE#2SE4BE
M,V%YW96H<Y6X<SM#I59J)CW/LSW+LU_F<UGJ<V96YC[_<S_SLS\'-$ /M&*.
M,T+_CQ5<HE-!Y[/>N9)!WR5#^90JOU(^/]0W&/1:-<GA\?,G:S-=A)YN-'0E
MB;1L$+183K1A0C-ST$8SWA4[Q[1@S70YPZY-[YXR&S-]2!9ET>9E999N=E8.
M]*9H,=]RZ<QK);5K+77.R)93(V?T1O7S9B=52S7T3G547R=U4B=X 2]T<B=8
M>_5YA?58B_5TF?5V7K5:5W5:E[5;G_58XZ?ZFE=ZQ75_SG5\V9>"HI=> ]A]
M#2A@%VA@$YA@%S9A2ZC])MB!+?:"(C:&45B&5A@&0G:&.; "7W8-3W!FSW $
M<[9F=_9FEV@,8_ 1CG9I5S!I)Z$,JW9J,Z%GOW9H@[9L_W\V;;/ EG79EH%9
M +TIFJI9G#:0F_KV#].IG@WQI_5IGAIW$B^WIXV:J6J0!]79J,9:I8(Q%5\Q
M=F>Q=LN0'-]Q=P,B&GT$GRKQ!Y%0%+_1IW8Q'L<Q>WNBK-%Q*7;W(N8AHI%%
M5LRBK/*JKMIJKO;W(?\W/O"J@!LRL.ZB5Q2C62 XM$W;(^VMLK)=R\;N34^X
MA'=(3D>L3CMSA5?'OT$+3/);=&#KZ$HL8T!)Z0HL ,!LYV$XB.<&OH8;R8%;
M-V>LR<D;MHKM 6AXAI,XP^HXAO\XBC^LP3:KD /YA2_6AB<YA2^YDDNXKG3L
MQ:J<AKSN80R+7EC'H^0<[JFRCO^4+)7?Q=OE6^H"0-]&ATM#75O6.(UC1],M
MG=".N=&^N>H*;=-"K9U++9ZW'82#;M2"U>+=;=U.KMYFKN05NJ"S[:$C[J ?
M[H,ONN,R>J(W.J(3>J17>K+6Q0RL^=;&BCL KMT.^K_RQJ![NH./NN-Z.N?A
M!JE?^J2ONJN/5.-)+JL#WD9KAZF;>N5>!^3-^J=/.I='!ST$[JVW>N?R!GG,
M0N26>JL_NN!."J7?Y=GE[:SD.I#<RIS'.;9C&\I^.>MR.Y.#W.P"'V[BKNXB
M7^\NGWC"5O)NW[H?;_"R^[N[.[PS[\@T[UI;=55C-52#KVEEK[]O+\"WWW$2
M)\%[[[W_Z[OXJN_3]-\ GJ_#FR\#1CS\2KS[4KS]TF\$WJ_&8[P%[F_'\Z_'
M%S "'[#(ESP!GSS)H[SD8/855B$6NJ!EPSQMFS9KG_9JNW;-YSS.[SP,H[;-
MMW;/WWS0 SW-,QELQWS+,S#+OWS2VXT6YH^9[G 0^W 8]C 0"_%QRUD1E_&?
M23<;03<9.W$<CKVIU>%YI_<4TW<,^6$?9O=%6$0D0X,U."+;)X7;;S>C-AH7
M>S??0UH3P?T7I6&H:>+9MW$G6K<@;IHK+OZJ@O<=7S<BIJ+D*RJGW9%3\+$O
M9KXBTR(O:GXB<_[G"S(@-ULQ.G(Q-M*Q2C)>O72##+/K S/L_Q>S[),21Y8D
M/*HD*=^D*>=29R()O'Y'-DOD;'CC3NJ&RYV&P.DCB8#&9#9_[]<^DN@;?@1D
M+K_^[%L_,6<_]F]_[&M_]W-_.16_+6?3Q#7_RFUK7)8D8[YDCW\C1<+5D'2S
M/RYE:B*E2R()T9DF .PE]/>_\YLD0/CS!T#@P(($!2( AX#A-X8(W D$T$_B
M08H&)5Y$.%"CQ8H9/W(,.7%D1Y 81:(DJ=)DRHTK7VJ4>1+F3)<V:]+$N5-G
MSYL^<_X4&I0HSZ%&BP)%NE1ITZ- W3UTR'!APX=5$4Q5*/6JU'M/.7:ARA5!
MTI3^F*;LHA7K-Z=FBY+=ZJZHV*U6$?_,2 N@;5<$B/::\YN5(>"W-N\29DA/
M!EZ%,L FC<KVX5[+@QW2Q6D1T5C'YFAZ5'F0=$6"+PVB/DUZM>G1JV&GEAV;
M]D  M&_/S@U[=^K>IW<'!S[<-O';QH475WY\.0 R\IX_IP=OS+LN7;RXN]Y%
M78[N,F: ES'> 8ORYQ&@=Y">O?KVYMNGA[^>?OSZ]^W;G_\>OWOZ\P'\3T#Y
M!E0O0 (1-+#  \\S+T '!8200 D;5'"_"OF[D,()(U0P008?M%#$$"$LL4(3
M43Q110=6;#'%%U4TCT48:8S1QAIQO%'''%EX $4?3P2R1"$;%/(!^8Q$TL$C
MRTNRR261C++_22E[I)+)*J?,$LLMKW2R1RB?U-)+(!WH4D8S642S3"739+/,
M,WM\,\TXR?3Q 3G?O+-..N'4L\\\ ;4S4#[]+'100P5-E-!#&544T44=;132
M21^M5-('9' T4T(W+;33/#^U,]0>1\54TU,Y1=535<LL,U17$X653EGUI+55
M4V?%M59=;WV55SU]#99548<EM=A?C4U5V567!3729RF]5%IH+:5VVDD?0<01
M1++-=MM\GL'G'G#S@09<?,Q]IEQRTUU7W7;A95>?=^<MM]YGYM4'FGSWQ;=?
M??D-V%^! :9WX(,+3OC?A0%F&.%](>:7'W_Y@;AB?2^&)N.-+=;8_^.*08:F
M'X]'KKCDCT4F.>6165[9Y99A?EGFF&F>V>::<;[9Y9!Y1KGGGWT.&NBAA=9Y
M9']2SCA??!^6F.*G,7X&9*F+)AKHG+$V6FN3J_88XXZM[CKLJU7F&F1]E-XW
M'X#7QD>??/A9N^VWXWY;'[?GSOMNN_')1^^^Y:9[7[0)[P=M?OI!G!]_$*=H
M\7YF>9RD?B8ZC7*.:LM\MLTU[YSSSST/'?3112^=]---3QWUU57/O+$#Y((=
M@2[JZ5PPQV!GW1_%$) =(N9XPTUXW[7RG:[?BJMG!MRE0@1YX'T#("K<9XA>
MMLYZCSUXV>PB'H%WA->-H.5YE[V+Y:PG:/^MAXB'WKCTX7]??O3G=Y_^^^W/
M__G]P]_>__AUU[H #E" !23@ 0V80 0N4(&=NQQL'IB:"%J.-@_T'D,.<+[*
MS6:"F.-@!0& 0;)TX8$EI* '-PB VY4O=AHT(0I?.!&[%$\J,ZA=#"DW&?9Q
M108IQ.$)4TB/V"& 'CX$XN76)T*&M..(3?3'#"[8.Q<Z<2)#U P5?PA#+&Y1
MBUTTHA>S^$4QAI&,ELN(&6%XQIM43B9L%,@L*!?',\K1'W!T8QWCN!(XHD6/
M%*'C'O_HQS[R\2* W",>"?E&01;2CX<T)"/1XLA&0A)RE'QD)">)24U6<I.7
MY.0G/7E)YB$@E)G_K"3VHFA*3W8AB@?HI"IA^4I,=H\LI90E*&/9#Q8N\9:S
M:(<5;?G)72J&A+=$Q JC2(]>YA*.V*/A*(,9S5\JD3"(#.0=[7A-#V;/,4ST
M8CO(U\HI@I&+8RQG&<F93G.B4((@_. [(=A !HZ.'O+P CR><\_K>&$[7;B"
M/W.0CO ,=%,R2)%\&%*>A+(@H0]1*'L6VM"((I2B#[4H0RN*T8M.]*+_6:A'
M/_31#RV(I",UJ8=0"J*2WN=""<I/?UX:4YC.5*8UI>E-;9I3G/K'I07BCW[Z
M<R @(6BHZ"DJ?(::5/8H=3U,18!3F?34I4ZUJ525:E6Q>E6M1I6K5NUJ_U:9
MM":LBO6J9 WK5]>DI_2D5:QL/>M3VWHDM;9)K75U*USE>E>[YI6O>/7K7O^J
M5\'V%;"%'6Q@"7M81.&53HS=:V,7&]E .?9:U8J6M3![6<U:MEJWRE6@/+LK
MT"(JM+<:[6EC15K5HO:SJ66M:%T;V];.%K:T-:UL:YO;V]IV5[PM;6]U"]S=
M<K:RQ<TL<8\[6<DF"J[>XI:VH$LN=4U7NM7ME[VF>R_M9I>[X"(8PR(6WH8I
M;+Q-&YAXT3M>C9TW:E]K[WK?.['X0@V^ZYT:T4Z67Y=90V;\S5K6D/9?K0F8
MP />FM@0/+8$JZS 2 MP?;\KW_K*5VK/@$:%)_^68?LN6+\%/IK,'MRR!_L7
M&@\.\<Z2MN">Z==L*D99AV76,WW,>'#Z\AO :#QC'+.-Q^:2VXU]_#8@W_C&
M..;'C/D!,L4EN1_6Z(?CGHR6*.\%=/P3WY7_5S\K9QE_6P:@_OJ7ON0 ;\QE
M1LZ9FX-F,JO9S&EV\YK]X4RY:(7.<Y;+FY-C9\?4V2JUP_,,^,R[0 ^:*VV&
M,P#>(6@]*WK/95%S/1B- #R?F="&SLT,%TUH=+"9TY/V]*$MW6E0BSK4GR[U
MJ$U-:E6GFM6'_K*75XUJ+H,9RZ\.LY;EF>MYAI#1&MPUYP;M:]>HYC6[(S1>
M8"+!87?D-$)L]+,CS>?_\X6&VC^!=*"5R1*:.%O1D9D)M-,2[4P_)-MPL<QA
MT.WM=)M[W>=6][O9#6]WQYO>:4'+2>XM;Y_D>R7\-HJ_"P))@0@\WX"62SL"
MKLB$(U(@TU.T.PZ9[XCW ]-X :3$_8CQA4]<X?Y(HJ 5GG&&:WS@'<>XG2-"
M\(M$>]HJ5S@ZQ WM8V?%Y"X?>2&G&7,$(+SD-\?W3'0H\TPCPMOC%OJ>(5/O
M=8L&@LMV.@>'S9I?Z[J!L.YR_X)#!GQ"1Q[TP(YUKJ.=ZW3G.P0ECWEDP%/\
M-+0^;(=H?MR^GK@[-#YQU^A[[+Y2E9YT[RG5^]_Y#GB_!Y[P?J?0AC#4H0R-
M_ZA#&F(\ATC4>,E#?O(JHOSE+3]XS?>=\XDW$>8_G_G/$PFIHS<]AIST5#"I
M/DNLQY+KN;KZ+E&52U:RO9AN7WO<[QY+8NW][-N4)=^_5?AFFNMDYW1\YB8_
MKHUE_EDAJUSI)Y?ZFS6N]:N/7.QO7_O=O[[WL_]]\8>?_-P?O_G+#W[TKU_]
M[3^_]K>UK41 ]UOO.E>\[)]_=^T?__ROUW6OBVG(ZV"PJV"PR[L,I@ =9@ 9
M< '!B[PBAF(LAKXXYFL4+&18+,4RT,,,C ,]L -MY@)=3 1)\,48#,12K+R6
M1KV<9KZBYKY&$ 0_4,12YL1:IL5*$+]B,&QB!@>]!O]MU.9BX&9PA+ (@S (
M T=NZF9MU,9N @<(D>QP#(?)]"%Q(B?*'H=Q$NDH@*B=X&GJP)#JPG ,Q; ,
MP1"5AFB4ALDA=(>;UG"''(,N2 ?26BD-W]#/6L?AZE -:0@/0:>5B"X/W5 K
MS$%T6,D.GZE\S' 1R; 1&?$1'3$2(7$2P["#4L@+X^D+N_"<.-&+$O$;QFF=
M1-&$1HF$.M&':$D-BTB=PFB%/A$.WS OT$D4N<U[;@B+=F<0"V,6'RCGO*>'
M2DB-JHB:7I$8?R<8&6Z04N*0E+$9!<X9.PX:D_$9*4D: 6F0 FD+K[$:N3'D
ML/$;36ERMG&9R!&7RC&:F"G_'<]1'<VQ'=%Q'<_1%Z5"!MPQE]80,(+IXX@'
M'NOQE2J.F]ZQ']M1%WFI'XUQ,=91S@Z2(!GR /"1'8.I(>=1(*4)$6'QF?3"
M&RDI%B62>M:(%4^1%T-R)$'2BS#Q)#>1G5*2$E>CGK0NG^!AG_KIGZX@H @J
M/( D[0Y*HBK*H33J)SD**#,J*(ER*(URHXY2*#LJHT#*0$1J\P2O\PI/*M6N
MI:IRIW0J*[%R*[72IJSR*X,J+(%J*J-R0(ZJJ80J+<URJ9"*+<&J+=$2K+QJ
M+N6R+K>*+N_2+M%J+ZG*K-:*+\>JK^@JKOQJ,-]*^1 K,0TKL1A3,17K,1MS
M,1TS_S(A<S(G,_J8:[DP<S,?JS/=BC,_TS/3[[6&JS2%ZS1_*S57"[=,4S5)
M$S57T[=B,[A<DS5A\S5KD[?8;UHHBZ] TS=%LS>%4S,ELS@%*_Z>R[D0<#F9
MACG_;[N6,P"ATP$#)@)9T+P:L 6]9L(F4+TD[#LI,#Q=<,*H1L/(IL7TB\1N
M,&74$P21AK],3&2<3#X=K 9+[#YGT&9.S 8-S =S< >[IL'N\SU33,*TD\(F
MYL+,LSR#9CUG<#YI\,,D%#\I-,"LP4+K,SZS!CW+1@-1K =-<,5.4,!^)L=,
M]&*@,$51=,=JC A;5,=>% J33&,0QQJ8S,F@+.-$#N!&(__J9LWJ:,U_3FU(
M8XU(6\U(90U)E;1(F70@$HTR'*,O/$,Q K'4Y$)*$X,RP.?3E =*>0=+VZ(+
MEM1)LQ0SS)0JQ+33_G$AMC1)B:,QOI0A-*C-UO1*[;0LCK1)W31/^71/_71,
M_U1/ 750!;50^Q10;:W6<$U1KXY1\Z?8B"U206=*I\+7)#7J,'4VO!04-R=3
M44,B7!$S+!52I>Y3!\+AP/1."0,=B&XDF.Y500+2L+3<6F(EN@!+(T+?G@A,
M7<@GRI12SQ0BVFU8=57IBG7>D)58C759D_7=>/19;0):?VY:SR):K95:^^U:
MJQ5;+P+@@%72M#5;,P)[L%1;T<+_+J0TW]2U6]F56Q?NX]IBX=;577LN6^U4
M,S:N6[D-2CG.Y_ ($6 N5:-4+G)57+?U8+-5(7]56A&V78/N5R&V+9)N*8)5
M8!5C!@H6*6#5)38VV5S555NC4T4V-CQUUX#T9+'.4)/T);EN.JICG\2N"];!
M.W) /,*#/-).)Q6/I<229\>2*[<2+'^6*HFV+,ERI [/\Y0V:1VO:7G6:1</
M](Q6]):6\7AD1W1D1BI$:R&$:['V:L'V:\4V;,EV;(OD1] V2-*62\#D2\2D
M;<<D]X!/]^AV;NT6;O'V;?5V^,[$3=3D;_UV2?CD^?YD3_R$<!%W4 C7_4:S
M<7?3<1GW_W$WJU0H]U@JMUF(!7.3A5DXUUDT%UE ]W([-W-'=W,]MW1#]UC>
M;W4AEW4E5_V<JUNB2__ZKW;9Y79I5UX2$ "?L[NDTW=[]P"I$SN'-SO9ZP&W
MLP*3MV,LT,5.!@-'-'KS<WIE$ 3_\WH!5 2QYD)=QGC?ZT"?YC^I5T"/9C[Y
M$T0WL$.?MT.A%WO)9CV/[&SDUT7C5V. L'[Q5T7M%T7G%\GHMPJE4 H5AW&P
M\-X>9QQ+<A1/$255LH$O<24M,8+=*1,IF($?V($ET8(SV( 0P>&*D9MFP!Q&
M-77TT"*5J'KRD'P^V'S\4($0H3%6F"%"F'8$Z)C@<(0#R!S"J?]Y4$=Y%G(/
M$:"%-WB(69*(C;B(*QB")]B")5@3';B)D_B)EY@D%3B!1=**FTV%9;@0L1@D
ME8=XPJ.*UZD+D*F&;K&+QZB#.=)W1!B-R8B,>:>-1]&&BR<47\B.M$B'GPDP
M" */-\B.'A:(BP>%&0F;\JB0KRF1^V@B)$F3\,B0&=F2NO&1L[&2L;&1.<F:
M,!D<0RX@/1DB09D?/UF40YDB2WF43;F3<FXJ9D"94AF4Z$&+,4@OHDF'\:*5
M21D>=9AX9( >4#D@;5B$=)@=@QF$0>.5 0F.?Y@KW,$PD!DBO<X8ASF7<<F&
M!?DB=S&2%0F;5AF;&4*'1=B;Q/B*QYG_BLGYG*F(B:=8BIV8$LD .[9.G[!C
M)@%*H&QV4VPD*8M2[GJ2HWQRGY4RH $Z*)L20)[R)Z>V:(\6*G_VIWP6:+L2
MHB4ZHBEZHJ^RH7TJHWO*I,Z2]8A*J-QRJ^#2HV-/+_'RJ_(RI5%ZI>G2+X.O
MK  3IOM2,._*,/^R,&NZ,HV3,GG:,G?:IW4ZJ'MZ,7]S.*>OJ(G3=2-WJ96Z
MJ9\E-VES-EM3JF_3-J%ZJG&3JJ^ZJE_7J;NZ=:G/J#/SJ(/S3F*7_A A.J<S
M>'^WNIJ3NMJ:=PW&>_]% *DSO8ZW.B%PK[ES/,'3K\LS?#?L/#VT9=IS?/5S
M0%%0P#240B>4_P/]TV<8U'VSM[ 3&SZ3AGC!]P4Q+$"EUSWM<T(;>[1#V[&K
M%\9R)K)+<$,+]&/T%W]G-'_YEW!FVW^CT+;O%W%H-'%X&T<).$?O3>3H3=F@
M;F1EPT>'N&1#%HF/N+D+"&4=%;I_]-8:=;K#4+H3U;JU.[NY>U&WV[N[N[K#
M.TC'FX&PNWZ<.[V9>[U/1[E)U;TOU;B7^[CE^[V-&V0Y%HV:3MN*>[_]F[AC
MHB2 HF-KM< %_%B5M5F9-<$9',$=?,$?7,$EO,$A/"@8UE@OO%T/ME_[U6 Y
M7,,_/+AK+N0T3N0NCI)*/,51?,43;D=UE,3;U<5%O.1DO,;GU<9C_/_&=3S'
M>;S%=]S'>YS&?US(@US$B_S%B1S&E3S)F=S(E_S$GQS)H=R:2*[*PW7"(YS"
ML9PH7E6_ ?S+YYN]J>Z\Q1LXM,X+H ,>O,X+P*X+8I;L:M;L=%9G'?KMU@[N
M\/S.];SN\ASO,'JA%9JA!3W0"3VA#9UIGS;1%R_R,(]#I!;1&9UJ(;WR0J_2
ME1;0#1UI'T_2-]W2)83TXO+33T_46R_U3%WV9$]*KNKU[%9N79WW6AW6I63X
M;KKX9AWX:#WXW+;YE,_YD._7EP_8?7VLB?TWO_K8F1JLD=VKDWW9E;W9H9W9
MI?W9I]W9(46L-Q,YYP\Y<9?_NMUV<Y=V_T__=X5WK7>7K=%=L]5= ;^KW:TS
M>270O?IZ>7501.W=0[D&L?7]M'6&LOV]LJ&71"%,L[MSO:!AL#F,W\FW0DO[
M?#_TX3DTX@$>P?+K?BU^?H]L"@&8"C.^< K'?C4^?FE[Y$L&<0*8MZN0'ZX0
MN+-0<A9)&-O(C<UYYF6^YLO9))6XG:$XAM19Y]?Y@H$>BGL^BH/^YX4^YXG^
MZ-DYZ8V^Z7W^Z9D>ZH=^ZI&>ZI?>ZHM>ZJM^ZZ^>Z[.>@M'9YGG>ZW>>YF_^
M[,,>[<T^[=E^[=U>[-\>[6'^B&"^[M/H[GW([O/^D3^R)M#(CPMY&6V"&2<9
M@0W_Y359DCM9\1-___$=O_$A_Y(B/Y,FGQPK_YFI^9=/>?,SG_,Q__,UO_-%
M'_0]/_1)?_1-/_5+?_51G_7[\?(YV9IBORCT&QGW7NWA/O=Q7XRP7NF!OA'7
M/)YC<IZW@R9M\IYS<D3V^9_UN?F1\OD%VOFC'_H!NJ"MGRDQ/?L'?6KK7*/5
MKJ+!WZ+#_Z6$]J&[?Z,O>OLY6BT_VBQ!.BY%^BWE7Z5/NOY-^O[I'_^)3Z8#
M<Z;]O_\!XH&#!P@<#$0@D*!!@@D+'FRX$.'!B TK/KS($*/$C!PW>K38$>1'
MC2)+DCP9$N7(E"Q7NDS( F1,C#,YUMQX$Z;,G31YVO2)TV?-H3H'$C5:]/_!
M4:5)ESI-.!!IU*13:U:%2C6K5*Q/MW9EZK6IV+!D?_8\:S9M4+1KU29M"]=D
M2[DO59ITA CO(T1[\>9[]O>O/L#0!@LF;/B9X<* %3=.#/DQXLGZ&%<>?%FQ
M9<;Y-F/V7!@:/\V716OF%WITZ<RK0[=6;;HR[-FGGT&+C7LT:MVB>_?S#=P:
MM-_$H0DO_OOX\.7*D2]W#MV:/VC3IPNOOAS[]-_:J7OO#OZY>.CCEZ/^O1MX
M^O.]U[=_[Q[]>_GIY9._G_U[>]+\9=?>_0R  L('7''-E=>/-<0IZ!UW^3FH
MG70/2HB=@Q8VB"%^&B)(H'L>F@?BAN=9LQL_)?;_HX^)Z/&#HHHILOCBBBVR
M*)J)-99X8HW]F,@BB?TD^*,_"O;CSX]$'EFD/TH2Z0\ 3#JI))1-/JGDE%%6
M*24 6&YY99=-<OFEEUJ*">:889YI9IIEKDEFFVA^J::6<;XIYY9U7GDGG'K6
MR>>>?O8)Z)^" @H H8;N62BBA_*9**.+PMGHH)(&^JB<D5I::9.7:IIIH9UN
MZJFBHCHZ*J2?GEHJIJERNFJHI+YJ:JN@SHHJK*K:.FFN>?:))YV^S@FLG;\*
M&RR>M-J9:*_%^JDLL<XV"RVSTO(ZK9[14HNMM=7NJFVVW'X[[+7=CLNMFVI&
M226XRWH;+II4HBOFNU:Z_QMOO?3>FZ:\63[)+[SS[NLOP/_V.W# ! N,\,$*
M&\QPP0XGW##$#R\\<<042RQQDO-JG#'!'#/Y<94>C^QOR$N63/+&3,X"\LHM
M*\FRR"C/K#+-&IN,<\HWOWQRSSO+[#///P<-]-!&"XUTT4D3S?312C_=]-).
M1PWUU%9+S;.4.=.L=<I=<YUUV!:/77'9&.N+MKWYJLUFN^RNJVO<N+H:Z]S'
MNMIHWK?JS6JA9,!#CSQ_!S[&.UT<[L[A7:R3@SHYR# #Y#),[H ,E3O @@,%
M99YY09YCKGGHFXL>>N>DF_XYZJ1_SOKJKH_>NNJP@SZ[Z;:7CGOMN=/.^^VZ
M__\..N>X"S\Z\<'WSGOQIR=_?.K,&R^\[\@#'_WPR$-_?/7:9\_]]L(;5#WX
MQXOO???FAW]^^N6OKW[[[+_?O5+9RQ\]_<';SSG]"L64_^;Z^]\_S/U/@ &,
MB?\.*$ $&C"!#%R@ _<'00 V<(#\FV !Y3>1"F80@Q#,W 8]V,&%Y ^$)(2)
M"$WHE1,:184<' H+2UB6K\AP+&"IX0QC2,,;VC"'/,2A#W?X0QT*L8= +.(0
M@TC$(QHQB4Q$HA.7^$0E2K&)4*RB"U/HE;[P98M^(4Q@H/'%,'IQC)T18QDG
MTYG%F)$S;%R,&]'81CA^YHVL\4Q_XIB9--YQCJ[I8VO_2H,:V:2F0X3\$'OB
MHQX.;6B1BFPD(QEY2! 9LI"4G*0E*UF@3$9G.\O)HV/J^!G:^$>0EZR/(T_I
M'$X*Z4*KI Z#6OE(5'*HE)BD9211)",=Q6B7.\(EC'JI#V "TT7#A)&+B/E+
M?LR"1?SP!XN(U$QH)@E)1X)2/ZQY-HO)Z9I3VJ8WNPE.)WU3G.'D)CG/:<YT
MCE.=Y5RG.]L)3W2^4Y[Q9"<][VG/?,Y3G_7<IS_["5!\_E.@ >4G00]J3SB9
M4Z& ,JA#!_K0@D)THA*M*$(I>E"&[FFAX]0HGSAJT8A>-*08%:E)2XI2DJHT
MHQU-Z4A?>M*5QA2F+IVI36N*_U.9YI2F.JTGS-+YTY(&=5XLV^90I534:[I,
MG$M5:E"=ZH^D(O5(,8LJ55U6I*K&K!]:O>I/LXI5KH:UJV#]JEC-2M:SJG6K
M;/7J6MW:UK*^5:YQG:M=ZXI7N.J5KGN]:U_SRM? ^E6P@!VL80N+V+\JEK"+
M/6QC$YO5:$+6L8RM+&4O.]G,/G:SEM5L9SE[5JLZJ:NC;>I4C2I:HMZTISQM
M[6I=V]#8;E2V'Z64W"2%B"YX 1YDD,=N#^<%Q77A"HO+03IF@%S)X6]W+$#
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M?OQS+__F[S_ZZ:]_U<-_^[=_RV5AS6. "2B  W2 "]2 &L9 #_AA#AA!*?9
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M2[5=J[5?ZP#XN;0  +9C^P[WHSWX,[9=4$$/_R2V2)@/#W1!33BVA;*8&OA
M=%NW>YNT&1A"V[FW;1M"#^2??%NW9XN"B1M"#F"X>]L/*^053/M"DXM%4FB%
MEGN%4C$+C;NT $IEVIFT2DB%2%&WF'ME^+"THIME8SL+,^$%]W"YHVNZLDN[
M.TBY-G2[5V1#<\9%B)"&: B\:UB&:^B&Q2M'QVN'R/N&R9M'=G2BRRNB*AI(
MO>&BTVN]C[:(6.JDG-BCW=ND9@J*X$N)XH&F(I)H?R9KTPM(_T&CXUN^W$MJ
MFNA*W"&_G 0D&?*CG2A)XAN*2%H<HRB+T7:+S<1, VS !8S .W+ M:C MIC
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MS\S\SCS-)FO-T3_-P4_]X,S-G+G-#N";B%#\XHQAW;_.NZDY[?QA[NG.K_D
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M&H/<4<@?B^3QR!MO]&?)'5M<TLDFF7PR1BFK=-)**J_4,DLNI_32H2[!_!*
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M1]YWN1]BQ ON>!L N@"]6!?[T;_VW.-FT>N= .\!Q(YTL8]M.18.!-N3L^!
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MXM)4V8Q)#8=!C+RHER82S2(ZV):9XME4HMIL6)-1HHPY32+J(MX832EVV-^
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MLN15$'-(^8Y)"?KP$ \69MA)7CG*C^+* ] @5G2*E*B("DK(%!M%%0?*!P,
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MQM0*DJ;7K3MKZB1*MN-'@C\Y'ES(D2'_QJM6X\*=*[<J5;%X;PH,JG>J7ZJ
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M !ZRCDG3A0"<8JFB@LJ7>'SZ'(NYQJ@.#5'!L(13\T 'J5 ]4U2=$R"F(O]
MJF?BZ7I\*A]Z3/6I6"VJGX9*GD =-:Q@W1-7UZ,AL<9KK5<]JUCEFE0GD54[
M[3@2 /K54_'4]:]ZI4Y@72,#[<!5!G25SE>) U?#-BFMS6EL7]$ZV+_>5#MT
MK6R!Y./3.6U6L@<8[%(Y>RC-"O:T?<W17\G5V,2>=J[C,JR/7$O;ORH6K;>%
M;6XAN]O>"NI!B_VMF[9*GL?J";1Q-=- C]..NV)G-,OEK'C: 5V@-A0YU^T'
M3QN+B(@BS+L@'4T7)!M1V:IVHAP-KT?3RU[TNG>][U6O?-L+W_K.-[[TO:]]
M-<I?_/H7,QNU:$';*> "=S2>!QXP@C&JX 8;F,'_#X:GA/F9X ?KL\($SC"$
M,;SA?R+XPQ/.L&;@>>$1>X;$%#:QB$/\8=#FB<7\8*V/N@!C?IJ7/31.<3H+
M1MSVK)C"TO4QB'6<XAZ/Y\<_OK&<+MQA1049 0[NZ).IR^$+C_=1%.XP<KDT
M8(H2]+_ZG<5HB4N/,.=7-MFMKD2_N^8TLQFWK^5MG$V;V3G;N<YX!NR=]9QG
M.O.YKA<#]& #3;)"B^P^^H#9.V+F!7B\K&8W6T<7=O:SH%EZ!BP8&O#$PP).
M3ZW3V@%UT3S=-%*/.M2?3K752KWJ4[N:'G"+==ID/39:PWK6N*YUKF^MZU[S
M^M?S0)JJ72WJ8OOMT\=>_QRR?1<\X%GNV<R&=N.BUCK"43MKV%::/C9W')5Y
MVW3=]@+8QIWM<I/[W.9.-[FKG;AK@XW=T[:VO*--;V<CSGGW/AR^J:=OZUD/
M?- #>/K^7;Z %YQ]S7.?P1>.<(8KO.$0?[C$$TYQAU><B08_8,81KG&,>]R!
M[BL@#;$W<NB-T.1%++G*3[[RE(O\Y22'.<IGWL*:R]SF,<\YS6_.<YWC?.<^
M[SG0A_[SH@O=Z$%/.M&/SG2E(WWI3F\ZU*?^]*I+W>I1SSK(6[YUEGO=Y6#?
M^L9#SG'Q7?&*CT!$VJ]8QF6V?2QP?Z/;N^+VN*^Q[G*W.][7"):WM]TK951F
M&/^3.?@Y)M+P<40D'/>.3;W#'2UFB7S>T5*03ZK%\ALIIT4R69'.OV7SGN^D
M1RJ/S9FXI!2K*,4]4*\2E,@DE5\I/%(J?Y;10YXD/<D)1VK?$[XC\YC)5'SN
M9YF6S-LE*\!/_M_S+A;*.]_VES<^5BK2D(I4\_K6] OAFQ],;WJ?G-]7R_?E
MPIAL(0M@MQ+8<%PUL/:O'U;O=[_ZYT\J]L?__O1'E:5&M?_^&X?__^=_GS*
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M.K19AK1+V[0:QF10R[-'Z[13JV'P1*T]&T_T, /(9;5-JZJ@>JEV6+19NV/
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M>@<?=>IWX]ZAFG]KF+E@:_W:]_/73WY\^O#] 8"?W]]^_?;KT^?OOP#U&Q#
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MNF[MXN[MS@(]I)OXJ!FNRFZM!N^P 2Z A:OPNJYA&2]R02SQ#N]DE2RZ(MO
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M$[7$LSS)\SR_4UI8Z[&\ /G<,P>-[SW_I )'1;ER<!:^I0OB<T^FA;C>DQ^
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M=KY*::_^6%NDMM1&JNH#Y3*+9ZSJ6OOAN]G&NZZXN<J+;[GZD@NFL%[LFRW
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M8(;SDJ(L)2K/.<@_JC.0;Y2C.[?H'R#V1Y[P#) ]_X//>]H34?CA)Z[ZB:R
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M+?B!+AB",#B"+TB#,5B#,VB#&'@S.I@S%KB#/MB##2B$$3B$1V.$ AB 29B
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MO.C"BW?"5[^='-3)88899(@__O4*0L"@^P?*'X']^V>!?_\!$'__XQ\![R=
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M/E&!G.JSL12=%<>TON<;W>D3W=(=7>PKP=1]L +<0M=M/PM,GM@M/W< H ,
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M]0DO;S=Y&V:4"-@UMSA;J[AW>/)\>PAXV[J!$PPR1_-S.W,'L/(T7P@W+S=
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MT!!?[0R-J'DJ E&C+,VH[-,<[?\>Z & %C'1(I7-Z $?)#6#)!53%TA2%VB
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ME,.HID7Z."L]QSNS]?V9]8&:+WM9'N^Y.J63]L-BEG+I+<^2*1.#*M$RF &
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MFZ,Y.M@Z.<B#L+--/*AQ&%=L/UB$GG.$0YB$%[>$W70]700]_R-#91:%"!!
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MIWJDAW=]MR8FB[(GVWH@>WDBR[(D"[.P,K.(,BDV:R@W.RLZ^RB40K,^N[-
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MB)!H^2.D'&D\ !6%\YM$B-"&R@-07;B11#J)@"B%5IB((>DX[N _C/C YSO
MWP2_T3,#;39%#0%#!RR)E'C!2$2^#UP^72#!ZL2)(EG""^R))VS"YI2_+DS
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M7;E^E0K6W]:P6L62Q6I6[=BK:-VVA;OVK=RX;.G>M9MWKMZZ>_WV!8SWK^#
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M\*D'GV?,%IMLM,]F>^V0UH:[[9GB?EONNMT^^YZZW]:;;;YCZAN?OO,9O'#
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MI4&MH,*(N]/F)G>Z631N3\O(3>Z&MX[>+>]X$_I(1L)WF^J]I'W?>TW,4Q/
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MTA1.Z8)VB$BD2SH9,)BQ<SMHL;I:L99171>Y4]6X>SNT6SM7A;NU$]5K:9;
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M3@[PSDGE-\M, "=Z%$OQ;3[Z.4-P5[9FJ5<);*;Z4Z;:K*?E6QYE\9OQB.A
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M.=+-D.%6!@NX#EC,G8L @8.[>/7F[<MW;]Z[?@/?I;M7KV'"@__V92$8L&/
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MDJE^J*GYBW_Y?[_ZAS_[K[_[MS_\7\B:CBF;IC_YS__[YS^'1#]TC&\\V2E
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MTA]!Q!%$TE]_?8^2@5]^B>(O997Z[ZG__E44PM_^_OFW/_K-[WXV*6!!DF'
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M'[[OZ8M(%UYT088\7L#3A;\%%[Q.%^ODD,X,,C@L@PP.L#!QQ12S@$#&&B.
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M?O_;7_T*&,#U#3"!UWM@_!IXP05N,((9_& '*UC"_)UPA"]LX0Q7>,/WY?"
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MQV]^W,)N_;DC'FB?!__WRS_^])^__>N/__MSSOWM5W__;PN ^2> ^C> !4B
M!VB  \ACT5,]B( _]],]XK,]$?@]^),^X_,^%4@^%W@^%WB!3\9D0\8^$OB
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MPMX.[AX/OD=V@!9\ &'_? BA?ACA?" A?NA##J26/-"#/(P!@20(@B@(@^0
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MHYI@Y",R9#0FHTO")#3*)#9>"-J@32+\&MK<0^GT#;HU&]_\). $);5-V^@
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M>WG5MUU@LP776VL#!N"=8H?U%9&! >CB6&.!U:=:;^MQ^.!A\]GVH(/OX1:
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MD B'T AC$ FUY$W<)+:*, F7+_E>Z[FDD ICJTU29 FCL G7A FQT J[\$S
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M0&G)EPQ4EE1IMP!4F8PIF1YTF"#402.40B?40FL+MS(4LJH+NSK_]+JN*:L
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M76"=^L!*)]P0^)!QLW /:B<2"- %LW"]%8>C%I'"$[?"XME]^J"B$_0_U@L
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MF=IF.[6N;8@PV9 LF3*G?=NT/=NR'=LDR=LIB=N[#=RLO;7$/=S&G=FCW=B
MO=R+G37;F(W3""AO'==*:8S6'3>J C=YTY39C=U3*97@?956.=X6MS<2X0^%
MXVZ)$V^-T[N0(SF4,P-DF3F;DY__H$,]U-/'C(S?;"D[M+,^ ![@ GX0^."7
M]W!UA6EPR;O@6,<1SH-$#[Z:;BGA%,[@FTGAS<N8HT.89AS*##%(ML/)XJ?
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M^?D2&C#'%+-,,LGLI\PTU[2&33;![*=-:/QITQHZX_2G'SSKS!-//>W\LT]
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M?.K/_YU\]M/_?GWLY_>=?N#;MQ__TS7_NV^ZW?Y;X0@WP+=IK5U@^]K*]K5
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MP/_Q;X#]J]_^# C  S*'?PMTH (AV, ()E""%:3@!>^'00':CX,(S. '-TC
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M\L"6@O=.WKNR8M.2-5OJK%BQ8<=^[<JU%%:M>._:I3O7+URW8^,&GB</,+S
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M\';WN^(-KW?+.][MIM>XZLUN;J_[7N1:-[[1A6Y]J0M?]SJWN<1M;G^72UP
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M'O!W$Y'H ##ZPYU></71G.F>1$ ^ABYUHS=<ZG-42,9_B/*0<YTA2J<Y/[R
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M[.;,\%XCYM[,U82F.^)/Z_0'? C-_]YL(=QD(R;Z3]L4" %-I!A"!(BH;P
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MXH<EOKABT?AIQPMYR(#'"WBZ>*>+DDW.09T<TIG!G!EDD($%F!U@8>:9$4#
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M8\.M]^,X.YXTWY'+7?FYDF=NN>:0<W[YYRVKVZ[HGI>^^>F=DRPSZ:ICWOK
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MHZC'K2B,&AF,M]C"@'R1?]R0$@F1$UF1@FS(#,F,C>R,U5A!37C(E/S(DLQ
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M@+%W6)]S[W'5VU[ZOM>^R*TOR^)K7/[FM[_W_2]^ >Q? @_8P )&[F<+C.
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M\''ZG>Y8QZ##/[Y[1KH*$(%H.\EOCT&5PQST1)\\Q3]1]*=?_>QP?T0PDE&
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MMU___/E?_W[KY[<__PTI=O5#0 &G=\  ]F^!Z6/!_1[(O@BV;X(.A.#_,"C
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M0 ]T0!6T<"I'<2Y.<B+G#RU'0BD4 /1A<SKG<\8 'D;'=#P4=51GYU['=5A
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M5X_C;=X0E]YDZ]_P#;@4;N :[I 5#N$.F>$@KN >CC<V%D$G3G >U./T)N5
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MQ=7W%J)N#LFH8N5,RE^.-9Y9UZ3]>/<BHD&2AFBMJW)IJZNXWIKKKKHF>>&
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ME;.$92D=-<J3X!*59J3D*C,IRU]^Z3S ? \EBZE*S/RR48M:)J,<U4RYB.0
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M01$4 2S _CM _DO _5O _Z,.!D3 !U3 _T.3!HQ "Y0,Q4 4T\@)R>B(#@3
MH/C ?F@0=JD)#NR'O"A!G"K_$XA@%\@(P7Y "A6$B*P2P<=2P:?P0)0 01W$
MB1O\"9O8P9T00M-#BW;QB2%$!P28P24DPH%0PI4HP:7H""IT0I0H#R8$AW:J
M0HFR%XB@!RLDB"Q$@(OHBQ+LC"H<0C6,"B*,E*KPK#.DBC8TPBP$0099%P+;
MJAA<POJ2"Q;D0QJ<PY? P]W""1)$0C;,"9F:P4/AJ"C,IP+DJ!F4#@ D0"]D
M"0+<PSIT0 P$J3&DCD.Q0P#L@BQ<"@-$BTT<0)EZ1#Q$AQDPARYPA_Z0P.5
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MB,15Y)1I0%(28@0BC)@Y."!%P(=)(,()+D5XT-]M((1Z"" '5F%[4(4J8>$
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MP\O1,#G17\720('7N&X6.]M4O!(2J'81G_*1%F7/2ZV40?F3JBZ32FV6)<U
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MHA6M2I6K81T+'\?*AZZ"]8Q1B5=84DLOU,@5M?:R][WPFAG7MH:U^3Y-OOS
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M^_/_\?TWG_R?D]R$)P(.T(!T>A,""ZC  R;0@0M\8 ,AB"<@W:,+[Z"'/+P
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ME;']HM9[95=^]3%.I3,\$U5DF[,[8[)*K3,M<S*$U34Z:]A/$[4G6]B#I=B
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M7Q 1G>>,\8LW*4T=72+&20(@+,4AC#X$J9 P.I*3P7D. C@IRDJ"LI2CI*1
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M/5!_'/O,HR?M7_LIYU%]PLN@FR71?6]D@"\8<1[6QWS_MW(*T07J1QRN07.
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M-,B["LH+6LE[O)OFO,P[O=(;O="[_[S6F[V(0 [8"KRO!;ZE"EL%.[XE.[[
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M?!'JAV&(#2)8X8 B/O@AA/I=^"&+*ZK(H8HNNBACA3=26..-.N:(HX\<6@@
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M8,HOF/-+9"[JMXA=VD\7]\_%(^R'R?SESY+ZX__^^A=+6W02EO^CA?\%H%<
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MYYQIZIGGGX$2.FBAB!ZJJ*",&NIF.EUT088\]$3Z3J1=M(.I.CFD,X,,G\K
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M!L1 #MQ _OM@#I[ $*[ #@9A[^L4& W-:AEA9,G %8;A%XWATE3A9K%>[%7
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M^7:2DI3L1Q?P"P]ZR(,>\, ONP"\CARH(P?HF($,9E".>HU#!N-P0#C_'NP
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M%$0UYL-#'F3\?-=U%P]#YF-X7T/R! 3V".0[3,\U3H]YMT/MA*M3HL-J$^5
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M;&G+/>J2C;RLI1\#^<M9!M.7>NPE'W<IQC(J$XS+S" 9F1@:1"2B,]14E3Z
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MF80[V^(NIKF/:4QDHOO<ZFYWNM_-;GBO>][NCK>]Z2WO>N/[WOKN=[[_S6^
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M^>'31_Y>/O+DM>O#[KWZ=^7,_Z'UD[_<.GOK^?1#TZ_O^GWLV/,/O^B6^^]
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ME[T$YC 364Q$RM&-R\2C,IM)1V;:\#C%&4XU\5:@8V$H0.SA3SX&M)YAZ0U
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MF3]PY\=S_>U,9PVC'UA77O.6<7Q_^[NSX7(= HR=H]F= E0=U+D=HE$8H7E
M2(M E6F9E)' "I0T26L92)L9"&28#@R;UDD=$ 1 $HR7!!S!$UR=%%Q %!1!
M 51!%\0_&0S &2S!&GS!&\S!N0$=SN'!R_'!S_&<SK%!&A1"(!S"T G"S?E!
M(VS")53")$3"'G3"PS$[*V3")Y1"+(S"(^Q"*M1!(B1!US'!&"Q"UCG#%0Q!
M!53#IT% X'E#W''#.(3#WYE#.SP>/$R>F'$>ZZF>D[F>/Y01[2$U4"-$\A$U
MSSL?13Q$\V'$RS,?6H/$^)'$_<D?6;M$2^R?__P!$UGC1$T4OM^#%.*3( =:
MOE)<(%/L!T3XH'?P@@R"AV?S(! 2(1(RH1DHAVMK(18ZI"T:(U\\HU],(V <
M1F$L1BDR(V.THF \1C)*QEXD1F9<1F6$QFET1F2,1FI\1FL$HSI2(SB*)F?Z
MQF>R(W$LQW ,QT$RIG1$)F%BQU]J1WA\1WDDIGBDQWDT.I[+QYW;1WSD1Z3S
M1WWL1X'\QX$,2((\2(-,2(#TQV"ZQW6LQV."R(=TR(:T1WH$1V@:1V\\QXPT
MQX[DR"6Z.FJ:)NY IR##CKD+N[DC$+PC,K4C$);T+O&:M,[B)H&:IU+9IU"Q
MK(/"D'VR28+RR<FR!O^_>A6(@BQ\\J?"*BF2LJA:<2B+PBCX>LJ%"K^$FJA_
M.BF,^BDF(:JM],J?8JFFE$JQ+$NMK$JRW+2($BJB:DN>(BJ:ZBJF&J"EFA)K
M,#8 F,NY="FX?*J@\DND8JJ\3"O7^TO!S*JZ%*JN3"J@(KV_;#W()$S!K*MB
MJTRXRBMC([;+M$S*W$S/[$S0U,PK 0"\I*O2Q"NJ>K[!6LWH@[["\BBS_*?N
M$TI7J4U_<!6JA"RK%"W!@S(OXTW@W*W>#,XFRZ_JTBZ91,[O4D[3\C(8>T[A
M),[AC$YW J\( S3J,D[M5,[MQ"_N5$[KG*_D',_E),_P+$_T/$_UE!'QDB__
M(Z&O]K25QON1^51+^J0\'V'/\9I/_73/^[1._V1/[0I0[RS0[/S.!TO0!%M0
M!V/0ZVQ0"$70 S70"%70"G50"WU0#26PYERGT^I0,@.Q)_.Q#WTN$#U1$T4Q
MX"I1V4)1WXPQ$N,_Z$PR&56S'_._,\/1_DNS'.71)8O1+)O1%Q72&J71(+6Q
M(AU2)#U2^V"S)75.) 52';U1'Z72$-W1*[72,,3!-]NS0$,T,+6P0Q/3,/52
M[/PS-!U3,_TS TO3,N6S"XU31RNP1LM0.V70.I6T.6VN/%V82IL8!3&\T,//
MS?L\$_&>0RTU0UQ4146U4UL]U8.2S,N\HM(2,\$J_ZW:O: J/M_K5%#T5+8B
MS+82D[@B3+H23=$TMEE8AP^B!WB@!WD8@PW:H&@3H7:@-G2XMFR3@6T;AVT+
MAZHSN'\;5H$C5F$M5F0]5F55.(0C.&=M5F@E(F:5UF>EUF@].&O-5FS=5F.=
M5FY-5I (UX4+5G']B'$M5W*-NI9P.*I;5W6U"8ES.J:;UZ>8#7N=BMFH.:$+
M.J+K5YEKC=08C8 UC8%%#8$]6(+]5Y/35W]E6(4%NH4=NH?=UXCEUXEM6(EU
M6(W-6(ZUV(3]6(,%V8(=682E6(@]69--V=I0BWMEV:9+NGEM5WB5689S5W.]
M68V8)N.HIO(H2?@(E_](#_^PZXZR<[_U<Y;[6(^BS4(6\[JXLZ>["Y"]NSO+
MLDES4I66W#ZC_0XDT17 RBU 351!91"4(KS(FRWL.UNP!36Q93Q$E))&1%17
ML[3XBE18&1_-XS04:<2NC!6K.D2JNE1._=3:*US9B\S>(US:2]S$K9/9TU36
M(US&):#D0T7F.T4'&D7-M5S,)<5-X=S/993F6Q@$F3Y4J;[J^]K#TUKWTLFO
M917&(I'K"S_P^Q0D^Q4HG,(LC#_VN\+<O1PP),,U/$,NS3"^L5$G+5[A;<'A
M3<,ZK,,];, [E,/GG9WHU4/L+9[KM1B/N< +],,)],.7*1F7D5X.I$/J_1D8
M;-[_,LP=I]F=]T5?^<6=]67>YZU?_&5!Y0U>_C7#_?7?N/'"W?W"+=1=+@1@
MNR%@LA'@*BS@+30[ XY@!_Y="M;"RKE@"\Y@!I;@"M[@"79>$&[?$_27^)U>
MFRGAZIW?%#9A%EYA%W9#XFGA]%5AZ$F>/$01A\EAZYD>\>WA/OSA[-G;MQWB
MN'U$(V:?(@YB]4GB]Z%$)?X?^8'B3*S$ =K$ /I$?^"? FJ4Q>W<5/QBSB5%
M,09C1F%%5R2##>H"+Y#%+F#5$**V$[HV&=!%%TJF:ZQ&;-Q&:=3&/.YC//YC
M/@;D.PYD0AYD0VY&/RYD1!;D10;)C?Q(2"9'1^Y&2L9(_TGNR(FTR(BD2'6L
MR$W6Y$S^9%$.95(6)(4LR(5$955&R%1FY54^95>.95B>Y5:FY5'VY%+N9%UV
M1U#&Y4A^Y$L.9F >YDK6R&[,QH;06:U#!)5<6M5Z6K*#VEY1NV<>IVBN.YC<
MILFJD*A-W;VS)^DCE9X\7=.%7=G4S<,ZYZ2T/G->W=A<*$WK$:6$S<<:O!_!
MRJHT2[(\2WT>2WA>-:Q,*B/12JX<2Y@BZ#(!2[#D2\;L2\345$S%U(5^3(J.
M:, TJL(DU4Q]:(;.*H>N:(C>*;4"MI'6Z)(>DU(U:90FZ94^Z92&*U-%U5"5
MJK*M%>L+9W+&VLB279Y^RMFTOO_8];X%:97;7-W:I%WIY#_I)%+J[*VD9E(L
M]9K_N[,G72>H?FJG;NK>'+.Z65,U];,-/4[]&FNQ+NONG%"T=E.SEM#L,M#U
M-$_[$D]V@D^ZENO\G+293$_N6FNW#FLSO5"U]NHW_5(R+6S!-FRP'NPSE9O#
M;NS$1FS"3C&Y05X=K8XJ35XLI6P?'5$I!3,U2U+0AFHGNVK2GE+,ME+-1EO3
M;C$H-=+65M*L?NW0ENW2]NPF.VW<7NW+UNTLS>W=_FVN_M\M[=_A1F B/.SB
M3N['ENS(7F[G;F[H7FR-V5/JED#K+A*Z-2^1$;V[=5M&+<1&!6]0LSU50[5$
ME%182^__2[U46@/5P9U<]XYOR=63KRHK8;MOSO2369C5,7A56$SC+JC5$1JA
M7%4A;5LA7_4V8 4)>VOP?7-P?8MP?IMP"*?P![]P":]P#<=P"\_P??/6;JW6
M;UU6$0_QF]T-%&=7FZ79%']9>)57&(?9&']Q6Y;E6L8DC/78CJU8'D=9N7CE
M&P=R(;?Q(:_Q6\KQ'E?9BUUR(P_R@\PX>I5Q*:?QF5UQ*Z]R+*_9+-?6;A7)
MK!-)L!-:\GL/G_59O(L_7G&6K2USI4U::3YS:N:[OZ,^H)1F.G_S;0)GNKLO
MM V\CVJ[U]40@)K*];)=;D[;T0I;^U34LLVH[8$OT<MN=I+4_TS+V\4[DO-.
M8N_V6[HMQ$PW$T-TDZN"Z%R+5%6K5(I6;_B>;T^%M5-7]9#./?D6Q57O/>!C
M=59'/LKUXC!67$VKC];$29N\IZG%OMFUZ;YRS<;JOJ%N=G2>Y]OENO(+)_CC
MLKNYFN.=/S6GOZDF;N'^]AE,;7'O4>,&]ZY)PP,481'$0*3)7]-97G='0^7Z
M0':O=YFQ]T@[7P^40'WO=W9'X1!FW^$U=^7V=H,O]X,O>(1?>(5O^&\_0FQ7
M8,R)>,/Q737O8(D/7HC?08F_PFK_^(L_X(J7/PB>8 WN>)0?8)47>9;GX)-?
M>9=/^#%L7X*/]X"W7YNGX1/6>1GF^?\7]OD9KAGE<9GC\>% _.&CWUL'&<3P
M-K7RX?0C=L1%9.)4VQ\GCF),I&(IKN+[\42N[Y3W%EVQ'^,P)F.R=Z!9D(<N
MJ*!E^^\U_J V;N,<@&,44B%NX\5#WN.\1^9&WGL]YGN][WO!#WS"!WS#_WO$
M3V2_5_S!!_QB]DAA?OQ)MF1BCJ9<YN5;WF6)]&7-YV3,)^4F+W(G#WTB+WW2
M/_W13WW17_W-[_Q>=OW,_WS.9T?*E_Q?MOW(K_W$?R*1W%GB^+INLO,\OV:6
ME',XGV9LMMIR6OZZ(W-M3GX]]SN_<PZ_XHZQTVG*^DF=7JAY[NE\ILV<7,J>
M[GZ?EBQZGJC_?4[_@H:5PTI+J$Q+J52I?IY_HW1_?YY_?BZ1_%?_LI2IC_YH
M@/#GSYI ?_T*$A1X4&'!@P07&AP8D2'%B18A8FRHD2* ?@#\?138\2. A!9-
M.HSX4&+&E2XO;CPI<F%(D"83EB19L"9/D#Y%[@RJ$^A0GT5U]CQJ5.C/I4F;
M]@1*U"G3CAK[];.6E1^T?M"X<M7W%9K8L&/!6N.:=:W6KFV]JCTK-VY<KW:[
MXO67%^]:OF[5IOW*#^Q@P80/&TX\&/%BP7 +#WY,6+)BR)897ZZ,F7)DQXL?
M]_OLN7-DT:5)\PN-6G7JRIQ;+TX+>[#LP[4UXVZLF_9J?:L_^T[]_UDVZW[!
MBQ,??CIU\LC-F3M/O14Z5N)IJT?'3GWZ5NW<GW-7+CSZ>.CEPY-'OAR]>?7;
MK:>__ETZ?._RZ\^WCS4_?_SPV_\WWWF?$;A>@0,:F""""Q9W8'''F78>A)%-
MF%J%#2J(X6S%C;8A<!DZ&"*((S(H8HD97M@A:!$:A]IDCAT'XV\S>DCC:S>Z
MEN-N..XHXVPO]ABD9: YIN.01@)YI)!),ADCA;U!N:&3@TW9HI0N%KEDEIGM
MAIF72&[)9)BY_3AFEV;^6*6:6+)YI9N@K?FFCW!&2:><3]YI89US\HFGG7_.
M>9R@?@ZJIZ%6(GIAH8A^*.%ZBCX:J:.3/O\H::64-GJIIIER2J*&GYK88&B@
M>AJJJ:66-BJ!JJ8ZX*C)O1IK=;*N-:M#^VEUJZT#8>6/=+P>]*NPO0X;;*_[
M&72LL@<AVVQ$SC)[[+/3,L3L53!QE!%(-'$[D[?;?FL5N..*6VZWY)[+$TT[
MK1MN4%,]%6]55,TR3Q?OC"$//?*,\<Z]7;C313M=J-...CF@,X,,"\O 0L,.
MC.- .!([  X"%UN,\<4(?+-QQAQ[O'''&E\\,@(?FXQRR"6O##+)+I\L<LLI
MR_PRS2S;/+/..?,<,\X^PZQRST(#?7/0-1>]<])#(TVTTTU#_?+'4[=,M=15
M8WVUUD!;S?7%%:__##;)8OM,=L9F?VTUV@B([<#&;;]]=MQ?S\WVQ0? C0#>
M<NN=-]YOW^TVW7T#3OC@?Q\NN-V&+XYXXXH+[GCDD =>N.25&XZXYI-COGGG
MG&<.NN>A?UXZZ:>/GKKHJUM..>.@/]ZZ[(G/'COMM]N>.^R[8ZY[[ZRC#KSJ
MI@\?//'"(W^\\J__WCSSSU\.O>O14S^]]7SOG3C?;&^?-_>#?S^VVN.'3;[X
M67N]===3/X*((XBTW_[[8>4#EF]?W:]/_63EHP\^^ML/+O?CAS[Z4;\!(C"
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M%]81I!G(8 ;E*)(,6$!6!X0# 6BU%5K!$:6VNNFM:HKKEN;_ZE8VU95)>$6
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MJXI4I#_T0[Y H:Z'*4#L8BXTJ:[I_T+ !C1 A_&'AY$8"3R]C:F8Z!$>Z<G
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MP1"O&CVO^LS21+S2?!(NT9S)R:XOQ!$N2;RE0KRO^9^_<:S/TL7:1)M<E!C
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M#"BB&9?](9H]V4_'(XZ.)&;J+V*B\[R])@(:IWZQ*'XB/9 ](ECA%GNQTK#
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M929)]CVR4I2J-*7;4ZGVN<?]_^^I-+\DC="OQ)\%!]>DIA.JVX#-[Y/S%6A
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MK_MD%U+0+2'G[7;)[R%SE_STE?T&=E4X_P)XW2]XWZ]X]4&TND!6Z $>QL!
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M(&JFE+*A94XS&T<1P;4".X0M@L8JV[$G.[(-_SN_T/3 D$RR=QNV790>9AL
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M3 4D( //!$ L,?" 6-K3D@AHP0)><( <G. "WQ? ^1D0?^^C7_^@(;\2V@^
M+$Q@ /=G0 EJ<(3W@V$(-_(1&\KP3Q7L(0]_N*<.RI""#QRB$!F8P23Z,(A
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MFC$NUE\.8*XQY@^VK&-\F#&N*&#7BF#/.NK\U6#4JF+J$&/J:ENF2LNI*EL
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MENH"$8V1%06 I%K EP*K#P6']Y,I''G1RE#1M8+/>E!1QU(J,N"LP4!!\5#
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M&[A4&SB4W;2435R7C5J.8UF"D]O#+5S$Q5S-)5S.O5Q,\]NP7;70!5W1+5W
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MGX@0WJ 0&?F_V@M *&&!J_H1)WZ->5 0>H! =- ''?X0OGJ-"BR/)UT-'.Y
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M$3URW(A1I,:/%TN&-/_9\23(D2I)MD3I,B5-C#+\ <B)4V=. #M]]OPI-"@
M?O18'$2'B"?/?#(%RD#D2"JB1U2G3K6*E:I61#D,SNBZ52S7J_-J/HT94VB7
MF6XULNC'%"A/?C)8$'T'\R*_H3H1K0R,P"_0>FDKRIA%&*>ZO0AF"*4GV"0Z
M?8MSZC-7<>Y/O9,=<,Z)2*V\T#GOR7LW[UWJU:U9JX;M.O9K>8+EAL9WN"-N
MO_1>?J1G&@#2MVI9(I^,]KARX\D=CZU*%=\]?/7N5;]>O3J^?/B^YX/F/?SX
M[=3/<]<'31_[]>WUY5.?+W[W^.+GB^_.G;Q]]NK9\[,>??/EL]]]\O7WWGO_
M^'E'W3VK/!BA=N>M@AX^S^!3H7C0R')/>++<QY^(SX2'WCWU9'@B>N2MMZ%\
MT 2H7H#AO?@?C"T&F"..+=:('X#0]&--D$,":8V.,O*(HY%%!AADD_SDN*23
M,%J#Y)$W1MFDD$P6.60_0?KSI9!C3CFDD&+Z0Z:48X8))IEHP@EFG&J:V2:=
M<*9I9Y[][-FG-6'Z">B?? [JCZ&$ GJHH8DRRJ>BBOXYJ)QNFME/EY<2F>F:
M6EI:)YMH%AJJH)5B2B>7=?*)J*J+.MIHGXJF*BB@L9[I99^T?HGJK;*VVBNK
MO^+D:["+_CFLH<4"X*A/AB;+K++/.ANML<U.NRBU_]?ZJJJE_"P98Y+>@KLC
MDN/>2&ZXY-J8KKCE8MGNMD#>^*Z\\6YZ*I0PWJLCE#GJ$^.]_>;X;[X"!UPP
MOC'VN]Z_"0/L'L(/.QSQCP#ZQT_%%U,\<;\52\PPPP0?K+#!#>\;<LDG#QSP
MM@.OK++)_+3\LL$HSYRRS#?3C+/-.?.\L\\U ZUST#T/_;/0-Y,,<LE)%]WT
MT5#&#/7+4<,\M=5$/VTTUEMKW;6_(V^LL<4-9[SPV!Z?G3;&8;.M=L9M<_SV
MPVNG[3" <R^]<=Y.HTQURP"OW _@^ HN==]7>YTUOV [3?'> .-MMN*3<\UW
MXI53GO#>)FLN^>:/?VXVY/]V6SRWV''K+3K988L.NM*7PVZY[)3'3OOLF.-^
M>>>WUYX[[[_;3CCB+A]>/,N$#VY\X54;SCR4R<,,_?*!2U]]\],C?[WUT4,-
MN/?=@\\]S/M.3S[@Y*,/=?KCJ]\^^^_WLW[\[L\/O_SWQU]__O;OW_^7X^=/
M3/FK%0%S54 !(C!-!OR2 O_'P#/Y V:$8J $(TC!"_*I@A7,E053A<$V>3!6
M(9P5"45(0EBY*E8HA-:CJ)4H%[(06]*2X;1B:,,9QM!:RK(6#X'20YS\T(="
M!.(0A:@3?^0C!^[H@CS(  \OP*,+[Y!B%]K1A77D0!TY2,<,S"&#+[+@BPX(
MAP/_6%#&,3H ' =18T;82!(W1@2.:SR)' E21P3<,8]TW&,;^?A&/\81D'/L
M(R'_6,A 'G*0AEPD(AFIR$9"\I&2M*,@*9E(2SH2DY'4Y"3Q6$E/7A*4F13E
M)DG923V&$I6C5&4I67G*3[J2D[(TY2QC2<M;VA*.,N@)+WOIRU_Z$A_K\"0+
MNI /8/;$*82,2E>:69:L/+,Q",B!=*!IS6IB\Q%GR24L$=#++G S(^9 )B]Q
MTQ//X)(?R$1$*S>#3,.DL@OD[(<,,$D.=?;D+.U$!SGS@8Y;DA,>F00-, %C
MR!D$%)?=3.1/?'F/A<X"F9)1* *6@LQQ4'25"]5H*C?:_\Z".+,K!3K/=5 T
M(11YR$/XT(=*65J@?*#4.M1Y:7_RD2.;"D@?W5FI2E^:TIENYZ4K72E.X:/3
M\H"GI?71J5$%%"/[$,@\$+H./>HQ5>Q8R#S<R6I2QY,?$4'C.S+%3DE5U)T#
M)2E=[2$06OV35AXI2%WSD1',A%2U^;5K;&G57.>VQ=?%P8AA./JK\ :XP+H:
M%H%#8I[FWJ3 NR)V@I*U50$!.,&Z0@V"=K75!@'561/&2H,EC.!H0?M"$]8P
M6J!]X&$K12?$TFE,3^K4EBH5V=$^:E:+55EE7?9!TZ:J67()+G ]R\#0?E"#
MR:7@:#]+6A'*<+@XG&YJ@P64&_]6EX;:E4MVH27=#.*U=&]5E[?49=[QHO>\
MZOU6NZR4U_<6+K"S#:Q?_0I8\>+WKWJC[\;JNU^+%4YO^@CPXOY+V/S>]\!H
MDV_$$,Q@!T-8P 4N77\-'&#_ OA[XIN>ACD<O@M_;\ A]O" ^0M@$Y<XPR=6
M<8I%O&(7M_C"*,9PC/L[XQNSF'HJYEZ-7PSB'.,8QC\6LH1A3.$ARQC(2B9R
MCBN\XQ_SF,12'K&3F6QE)%<9R^"[<I"U+& "R]? %$XPF1^LX#+_2+QI7K":
M";OF,D<XP6!N,IV9'.4.X_G#5-ZRE_N<913S:\Y&!K29 VWA0]?9SV.^<I8;
MG6A',SK_T5VV,8L-G5]!8QK1?+5OH3M=Z3 C6,R:MG2D!_WH4Y=:T:F&M*I;
MS>I7H[K5,X;UJF--:U?;.M>U=O&=^;SG7@,;RL)V<K")/>PG&SO9R%XVKP67
M/^\]NWO/GG;TJ.WL:F/[VMH><+:YO6UK>YO;_@@WN,O=[?C-@MS\2#>UV8UM
M=X\;W=QV]RS&5V]TVSO?^-[WNO7=;W[?^]__[D? .UAOXQ*\+QGT+,,7[O#G
M/O?@#I=XQ!4N\5FDZN(9M_C&PX1QCV<\Y" ?.<%%7G*2?URZUE5YLEK^K.O"
MW+HR;_G,N4OSF]L\YS''^<YU/G,B<K?>71@Z/,@@#R],<8I+_QPZ%K6(CAG(
M .IB-"/5">* @Y $.,MYCM:=TYS=.";L70?[V)DC]JU_W>QEYSK:S^YUMY.]
M[6M/.]O?/G>XJUWN>K?[WN/.][_[/?!Y!_S@!5]WPS<',D09SF5\ H]Z"F0&
MPFD\4)P"'&8^,YN9M\H,"-*%:SH3]%PY"]U+/YB@M 7OSTG'XNGB>ISHA3E]
M:;T_##KXF] > (:Y^SIR#X!9%&<C++",:.8^C\4H\SC#0:=:".H7=M)D. \U
M_=TC8LZAZ*;ZO5D\/=0NG-?W)/C5[WOARW]X\T\D]%1!:G94=%*L[B?^7#70
M7"4&5:CJ1ZQ:Q>J$Z(__D>;?4-5?4_\-X'NT2(ELQXE$"(0PH/YER'E\AX=4
MR 3.%(=L"(BPU7Q@8(4D8$QYB(^\57FYR C:R(BPB(V BP%R"I?H"Y88X'^T
MA[YT"UQE26"Y5\DXB9K8R0*9BFMU2KZLR:3<B1#RH \:20'%5J4HEJ@4%ZV4
MD)<PT J]BJODUJI4(;#(BJ0@(:EH"FUQ8;V421 2T EE(9%P"Z>0"9#<2PX:
M$ D5B@I181R:T!N"T*ZLEFE)81[*(;# D+2<%A]BUW91ER!VEQ]ZD%U=R;FP
MBR*N%[JLRWK12 BN2PLV"7S%RR5J22:J(27.(,2(38/ER^Z (L1LSNF8(MJ@
MCMO C=S032O_RHW=G"(I>L[K6([?#(_P^$[PY.+6B")^A2+P[&+O"",P_F+(
MI%DQAHXLWA<R#J,N-F,P$N/MB*+CM XJMIDJ8J,KKB(JQF+'>"(W@J/IA*,V
M+AHU+F/-_(WVJ*/S8(_Q$(_NS(R$D4XUJ@V%L>(]RJ,Y@MHO[I?C6",_GDPO
M"B3?#"3GE Y ZE>H*:0U,N2$->3%V&.1X6,V3B0YMN(UBAKH_..$ 61'<N1'
M[B-(CIE'/A@SGF-)GJ0O4DU*%F1 QN-+&F1&'IA)AF1-CJ1(IHY([DQ.WF+S
MO.-/XN*&98_SO&,['L^'#:6.L>/V*&53)N53ZEE4;EB>3:54ZL_Y_WR8^= /
M5FX8 '%E^61E5NZ/^HPE /&/6?8/6B*692U6 +7EF<S"9L'E 350!]5E!4&0
M<H'77MJE7MHE!SE78!Y7:1%F$Q9FHJ3<'[90(#+F(#9F(4*F=@$=LTPF$5EF
M$5UF9EY1%Q3=T0V=TE71T'6!%G&1%WT1.4S=U9U1.-Q21+CF2;QF1L1FUL%F
M;<JF;=+F;>IF;O+F;/HF;O[F;@9G;P)G<0JG<1+G<2IG<C+G<#HG<C[G<D9G
M<T)G=4JG=5+G=6IG=G+G='HG=G[G=H8G1.R2Z_%20[5>3M1#%RB$#+@#/J'G
M7/"2,N5F5&Q%(EP%5>#G5DP%(M33-W2!?O_FYU3L9WX6J"-(QG@^9T.Q)WB>
MQ#ND9^NADV_J@R_MA#YXISR99SY9YSR<9R_M7D+(@#K9QG+&)U (U'">*$ZD
MJ&TZP(K"TVS>0X0"P PH:'42D4-9ISF9YT0%IT7))P!@U(V*IX,6Z9%FW7WF
MYU'EWT]E!TE!J9/"U$RA% #2U'\4U8#P%%(UJ77PGX7H1WF(Z5#!QU.9J;@P
MS/]A1_NQ*01R502"J5"YJ58Y()R:QUD-((/TQWB]X%>I5 72R)DQ6/Z@9'OQ
M*24*%@Q2(I;4%FP9X5N:85\14-]4E@\*4*-ZH5PF5@-1UG))5E]B$&>Q%E]F
M2PH=9AX*UV'RY1;_JF',/.JE/FJ7#"$$K=9FA8P/;B+AT*7"U:%A&J9S ::G
M_N5OJ6IA"A<A(NMC)JMC,FMJ@1=C74DCIM>T2JM<'>"UGI<B+NJV8N*IN""<
ML9F@QIE,+MI".B2XCEFGO5F#A2LIMBN[GBNH%=FE_5>494^*%5M4XFN2V2N?
MW:O*4)J0$=JG$>R\RF/!$EB5D1JIZ=BFC9K"*NS FMK$)FRY0FRYRFN\8BS"
M/FRE1:S'@JR1?:S *EF_FBR_)AG%%EG%&FRZ;NS!BNN[KNLGTNR"U2Q@S:R;
MZ2R9D>NM4:6'Y6NS*5N/$>V0'=G*DJNGG5G2OJS+PJS%LFS4(NVB>=G1_U+M
MU#KLU=+KUB9DUG:MQL8LNBJMV)IKQIIMTV+MPIXMS$HMUZHMQ^H:KNV:W-(M
MI+WMW/JLUN)MW.;MWMK9L0DMLTV9KQ%NT YNK_WMT +MXOYLN$G;N4'NMT6N
MNDENY5+NY9J;Y6;NO'DEP'$NP/E;P(ENZ)+NOB5<_!B<7E*<:#T<K[INPT'<
MZ[9NPZTNRG&<Q]UNPJ&<R:5<[_*NR0E7RE&+\'H7MER7LQQOS?7<\BIO\_*<
M\_J<#V$</:P#9]+#T25=%RS=%651#CQ=U'T1&)U1<5S=^9DO]9'?^:H>^A*>
M^HY?^[(OXJWO_+ZO_-8O^M%O^L8O_MZO^^IO_O_"+P#;[__V[_XF!^XQ7NOI
M@SP@A4&D R)0WF4XA5K89^9%!W\B@@,,Q.=9< =?DR.0W@"_Q?6E'O]RA -X
M: +K1==!<.Z5'O&%QEF87VDLQD0]1#G8'M>5!O@!@#[DW?)QG?,MWF@D!P\#
M10!'Q(2&Q/41A6Z4W_8QQ6\LAT411O"9,!(3<!9[772(U/TQ*0 Z2)O*'YVN
M*03R!Y8B"%AY%5OI'__!7U*!!UH5(,(H:L>48'YP%0<B8(IP((54H"R0"(=(
MX -.%1]G"" 32" CLH\PB 6>H"3>,7RP""(KR9,D(AB"X;3*(+^05[RL81+6
M5K=\\@H&B8R(89N<BIK_6'(J:R(.OHD0\HH;RK(6MN&<*"$L%PJDQ+(NKTHN
M[^$5\O*MF,DJR\N6*) 6'G,R]V!LU6&D[" F>R$KR^IHT2$P[S(UQ_)D:18V
M.V$OX]8O*V8X*^LX-^NR1&:V<.$DJK.Y0/(BKC.[6&NVJG,+SDLEVC.\T)8F
ME@D0MN#J?,WD,,TH2HSD^+,WBHQ!3PQ!VVPX(G3;#+0G$C0M'C0T!F4T.J-%
M8TU 4_1&/V-'8[1$'Z,R"G1 D[1'7_1)<_1'CXS-D/3'F([J,'1%RK1#O^),
M4^0VWG0]SF(M'@ST%*5/5W10IS1 YR-.I^+=C/0T*O5!BG1("_10\R),1K5!
M_U)U,A:J4^NC/XKC5EOD1,YCY#0U3V8U2R^U,9;U5+MD5=,D5,..+;*U-$JU
M2;\U2A]E70.E3P:E4>HU4/LD4T*E4")E8 /V8._U.C*N53;N5M+/_2QV8]N/
M8Z<E9)LE69ZE_JBE6VZ6!$'J$BY0 M'E9W]07HXJJ/*E7V[0;QW78(Z0"*EV
ML9;J:_^*"O6AL8AS.9/S.9>S#E'F#/$09?J0;P,1<&/F< ,1(J@#$QD=/411
M]EI1%W2O.LP .H0O:LK ^*(1&;E1.''4=G\4=[]21X&W=]>21WVW>&=4=Z-W
M>:?W>(?W>I^W>L,W>YNW=KLW?<?W>\MW?9-W?M^W??_SMR:5)SGUDG$?Q#AT
M084*>((# 'TB$N:)GNB1 5+( !EHWH-7>%5LTWXKU#?Y-RW)0#T(.#KED88"
MDT#)=PJ_DT<!Z2^YPWXC^"\I4RDEU"81U"\95"0)>.>9-X1FGR2=Z&E E$2Q
M]XK[$E)T^)%K.)(?4DA1A4N1J0!NJ8=4:94&E7G$%)5[!U/1AU'MU%%M^8!H
MZ4@]Z9.&*9G:%%&=:9DB](VPWYN*N9>2U1O?J9QVX +"WQKCZ8:P"%+I^9["
M8"0S")[Z2%\QV#'^X+8TJ@BJU7V5BX(49:MJ*K3F=:N69*>R(Z5#F,\<NJ:6
M=FIW^JINJEYREFX]7+"2JJ?__^4)"2++_>JH0%;@R&IB06&E'E"GMBZAYHQK
M!4VN^"5JI>JO$NNGWZ6P!J:Q@M:RXG:R;U?RXARS?E>RY JF/R*U4GNU3BN-
M^#EZ:>M[+6I\S4NG8(FDQ]G8TI>9<1K<?NW8,NW3KKO3DFW8KBW4!BS**NZO
M >[AWON>I=JDZ:W5%FW?]MFL\:V/U7OAWON]TIB_WZW39IK;7FRI*?S#MRV7
MY1KBTBV_[YK"2ZR[BQFY.UC.XBR\?_S.>KS(^RV^%[SAZGO=HEJ@E?R[R]FH
M26S#>RW+%RW&TUC.8SS#_AFZ+[RYM_O+R[S/S_S0JZS;XGS2+YG-,SW ._W
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MEDX?ML(!*(UM^8'SXG<>'L][ 4 ?%CCU-KC2%$EW.66 O:,+])<>'O@>T->
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M$(&'=[B'?]B'@32=VDG#;4\P?IB?A!B@)(.<?/2;S@DS_LE';8^=5G1&'5;
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MWGUN>*$[7G]T]UGCG05ZUPM>]O)#O>V-[WO9VP_UV@N^];WD+>V+RUKZ5[\
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M.NGRRABL1F?=3#PS@#5=(&[BIFO6<^@1.^I^3NJB7NJH?NJJ[NBFSNJI[NJ
M+FXPF=("G90+U$T\G0_G64,XQ-)A!+4,E[,O*T"E0 \V:])<V=$'U' D5&]&
M!$9%V^Q!&T5"5')-^[-#*T4?][31KG DYT,0%+S+>47/,+52JW*<MQHBI[3X
MH+77E'/O3GJ07;:X2Q[%ZQEJB[GY3IIKZW/,$;?\CM1#1YKZT;9M-W=[C+>5
M_QMT5@>X=D&Z@ZD23P?QDXNZGHNZ7H?(L4MV8"NW%<\7(T'OIT=(RCO75?=U
MB:MW)\]W=]SR46?6JZO(F1B[-.^Z-N]XL&L7= V\DEU-/%^VOJN[P'NUE]UY
M/B_T2"_OTIEZVDO!XOG!]MO 40\@S6>>'DC!!BQ\VVM^$DQ^K5WU(+PE2NS$
M8T_U80_U>@+$;2)]B[+#S:>_2&C$<0_4><+4.DS=;2]0*=S!)3S!68_!@,_W
M0<S"/:SV]V>#.[A^B1_X'-SU3J_U?=_TXNGUDW^>D@_Y2Z+X>>]]U#?X^/?W
M%>SXHH_Y$VPFB+_"GW_ZA(^?-.K<ZVFCJ@V$K+_Z-?^(@XN_^JJ?^JX/@3 <
M?W=O?+_/OTN8Q)VRPU)8]I'RQ$N]_*G2A;ZRQ<X?_6/LQ=0?QF=L_=4__=B_
M_=H/QFRLQG!,QWPX_J+DV'_H+H]97WM<B)8)R'W-FJ_YUW@=NGD-\_6OF8H=
MR?F__XZL_Y/,J@ !P)]  /W\#40H\"#!A T9/C0X+X>[+O+(P.N2D6+&=5W6
MY4@W(Z0,DC)8F'00S@$"EBW!M?P&4R;+F#1G(JB)\V9.GCM]V@2J,VC/H3^%
M'B6*U&A2IDN=%H6J-&K3J4^E7J6*U6I6KEN]5@6K-6S7L5_%GB6+UFQ:MFO=
MEH6K-F[2<O/Z <"+=V#>O'O_^0+(]U,&(D>(R,A@Z87PXD2+"Q=.)/'EW+=R
M+;>EG/ER9<R;-7<&S5GTY]&>38<FG?HTS,>(&K?.=P_?O7SU9M>^;9NV[-WX
M\.G#ER^?/FCZ]/&#QN]X\N7ZA@</+CNZ<.#.B5N''GLVOGKWNI>J1Z_>O/#W
MZ'GGOKV[[//=VZ?O'1^^]N#0J$/SS?W>_E7W^J^'+\#U_-L//=[R.S#![0[4
M#1_[AK///MKJRR="X2JL\#KA\),-P 9I@]"XZXHKKCD3KVN.Q!%'5 XY%YE;
M4<7D9N2'GWZ@Z<>:&_NQ,;D:?71QN1R'_+'&&_G1,<DCB^RQ1A>9?'+)'6W4
MD<I^_Z[4$<LKB>32QR$-LE%+*\'T!\PML_0G3'^RY++*(96TLD<>O_PRS2OM
M-)-,@_8LLT\^M\0ST#_]O-.@@0SUL\P[W5021R65U%)//*=\D3@DD1L2QR)I
M'+-.-=4<=-!/%[USU#P%)?544$LMM$]^$N7ST#(+6FA/6F7]D]98=;V55T-U
M]=/76H?%5=B[^'S5(#=AE#%&9YN%]EEI9[0T6@HMM+"^::=5KMIJ7P271G%;
M+!$YX\Q=CMP6CTN7W77?;;<?=YF35UU]ZHUW7N7P#9)?>O6]%V!X!V;NW8+G
M/;?@<A5.N.%VT0T28H4)IMC=ART>&&.-[?5W7X [#IAC=O^/##E?>/D=66.4
M/<ZXY8U?;OE@>PVNV&6;87YYY9+7U3ECD'4&6N6/!<8Y8H$9?GAA<A->.FFF
M38Q8::B1COIIB6>>&&.9+YZ9Z*Z_YCILH\$>6^RLH\8Z[:2;KMIIMR5V^.JI
MXUZ8;KO7QIMFK6LN>NNRT<[[;*D!)WQPP=4N'/'# U>\<;,K_GEHD2<WN?)^
M);?\7\HO=SSQQ_?.V^O,6;8\Y9--+QE?U5%?G?364V<]=M=EAWUVVVO'_77=
M:=_]]MYS/\Y&TX5GF?B0C:\7^>"39WYYYXU\GGCIFY_3^>JAOU[X[.7=_M[I
MO:?^^^ZK)U][\[D_'WSURT>__?7_TV?__5GDMY&?6>J_G\?\[<>_?_W]Y]^5
M]H>G 88I?WFZGZM*Y2H&2BI9:6H@!!T8P60E4$^S0%:9,*C!"N[)@AOL!PA%
MZ$$2:M!6)3R6"6?UJQ,2JU=WD=6A",+"&=90AC<LB USB$,8[M"'/02B#H/H
MCUG4(R-=@ <]Y#&&=QRQ'4=41Q?4,0,94)&**&&! \:1$I8XH"9>O,D!PCC&
MH(BQC&0\BAG3B,:<J+&-;&R)&^,(1Y;(L8YT1( =\XA'/?:1CW\\8R#7*,@W
M$G*.AKPC(O>H2#\R$I"#A&0A(WG(22:RDHN\9",S^4A)=I*2GK0D*#$I2DV2
MDI.?1&4H_U,YRE66<H[KT(=?9-D76@:FCX-Q!#T0XX NM*8PCW ,(KJ &%>J
MTIBL/&8QD;E,93;SE,E\)C.CZ4Q'5G.3UC0E-ELY36YJ$YK>E"8XJ7G-:[8&
MF, LS&T4-!T*_>9!U<F'W.!FG =5R#?TP5"(('2?"^''-]WISBKJ$5#O%)0W
M^]&/>P9*H -%YY[2V0Z%-M1/?*RBH@4BJ$7Y,QO_5!0?S^"H12T*THWNQS;]
MT>AVH"$+V6BTGR_UC71D44\292A"SHE-/E"Z'9#>E)XKHF>WQF6-((THGS:U
M%%&38PU+_?2F)+J4HS"E5!Y-]4E3?=.;K"K5I;I(J4[J*I"XFO\CK#XJJV9%
MZXYTY*@<]<D:BF+36_]TUC/1-:UFU1*DU@17MRJ*3W+MJ[("Z]8S\16PAQWL
M01"U6%C95:UTDFM;L;2F(WV5JC,B*XXPB]DDP751B4*L8$.UUTC!*K!U BR@
M4OO9/;4J5GU2[$%@.UO&QM:VM)5M;7%[6]WV-K>_Y>UOQ52I:!671= R%[64
MFUSF0E5&-L704Z%;W.9Z:[G.#5=VQT4MJ(D(8N>"VX^8)EXHB16LYRTO>J]J
MWO2V=[U@#9Y8XPO?YHBWOO/$;]WFMM_P]E=I]C47@.6;+O*N=[[N9>][$:S>
M!#>8P0]><(0-7-X#7PW X"T7AL^E80K_=WC"'W9P@>6;7@*C3<(A5K") VS@
M^V8XOAN&,;OBYET:Q[A;,L;QC75<XQSS>,<V]K&/7=Q=^K;HPD4.WG>1O&0!
M%WG +#:RDH_<72!7N<=6_O&5J;SE+']WQE_F<I!M/&0I6SC%_RUSAMF69#*+
M6<M==C.<L1QG.L]YSNO:,)XUEF<B$[E([OKS>TL\L4";=]#J*O1Y#[UH04=9
MS7U6,:''=F1*1QK1EF8TBC4-X3-S>M,G]G2H03WJ3K=W25%B[ZF]E&H@+<]+
MKH:>D5XMZUA_K];-NW7T<#T])S&OU\O[M9&"7;];#[NJO"YVLI%-;&;[6MG.
M;G:OI2UL:D=[_T[2GI.;P@39ND9J%G%-%6I9I:QQ!\I4YB[WJDX%*'87RK5^
M->UHY8W;UPXJAK"]%;Y9Z,)]Q_"%_ :XO_NM$'_+ME<&1SA#%M*0A3_$(0]W
M>,0/HH\</-$B\/!"%[S01(H\\2-3#(DY2G(2&3@@BUO,(DLF<Y25YZ3E+KG)
MRU4><YH'1>8(N'G.:\[RG;N\YS"W^<]G'G2B\[SH/C\ZT(V^=*0S7>E-A_K3
MI3YTIU,]ZE:?.LZ%KO6D8]WK7*\ZV*\N]JSKO.MD_[K9PZ[VL;.][%MW>]KA
M/O>SQQWM=X^[#.3AE[_T/3!$'PP9QH$ %I!A,>A$!##)H(Z5X)WN:_]_?-LC
M__:Z3U[NE<<\Y#,O^<U37O.?YSSH/1]ZTH_>])<7/>I+K_K3BQWQYUP,;G:3
MTPG!TUSQ'$X\BZ-[?NC>.?SX3?"IDYT)Y92=P,F'\)]3G>(S2#WH:1! \=$>
M\T!?G=>/#S[MX\[D:Z=#&$7H@  $405]WST%I;YM'!K3>VX?0^QOJ/'?/W_W
MKS.G(:+G?8!:..NX_YUH1AKBT+^U:9("-+''8A1::Q+&2;0"G)(VJ:LXD1)-
M@< QD:!)01,U891LFY-5XT +U,!T$T%5&4%X.[<3?+=Y2Z%=&:T-E, ,7*"\
MTJZRRI2J\L#2.K?1>B!D*4$47#<%(L$@-+?_>%NA(EQ!8T'"?4NA8E'"?UM"
M86'"81&5#ER:XD(JX\+"9ZDNY7J6[O,_+TR^;<'"+9S![6(;_9*GQ=&;H*$<
MDHF<?=&<>XE#-QR9.8Q#GA&:TR$;O^'#SNE#T'G#SPE$/-1#.70=.SQ$WZG#
M1 0>173$1MP9U.&<T0&=-<2<2<3$.Y3$322=2:3#1_P=W9E#3MR9/_2<4U1#
MP[$:57P;JDE%/X2<2[S#6>Q$6BS%6L3%6]3%GWE%QO%%5(3%5CS#89R:8 1&
M093%7 09P%G&K"&98X3&7HQ&8Y3&:N089US$U$%$;61$U=E&;^S&; 1';B3'
M9Z07;(3#<-P<6QS'_W84QW=,1T@,1=ZA1U"L1WF\QWFTQWW$1W[L'>6)M>-I
M'8!,'^P1GX,,GX1\'_>)GX:$GX=D2(A<R(ETR(BT2(J42(><G_+9R%?QGOWI
M2) $()'\GY(,H),\H (2H <R();D( J"R0FZ()<,(9K\H K"216J29W\(!0:
M(9[T2132%1!ZH1RB(8$3HJ3D(:7\(:8<HJ9<RJCT(83 H(SP@B22AXT[HHV0
M(BG* 72P(I+(HI,SN2YJ"7+*)K3<)G'J)K7\)K<,)[@<I[2DR[64R[:LR[?,
MR[C<R[FTR[[$R[\43+T<3+XL3+\DS,0T3,4<)P3H GP@"+VHI4B2 7K(H__!
M>#U$$"89 $RV],R[_,S.!,W1%,W2/,S 9$S47,S51$S65,W6A$W4S,S60"CI
M,#[;0\/=LX[GZ#[;],WV@RE[6C_MXR?>W! $*1#Q("B%8D[S6*CQ0Y#GBS]L
M2;X%,2@#*:C_J$V/:BGK#*AZ0"F#NHUL<9#HJA"60I#SW+X%B:CQG"D,H8V5
MHJD5F:@-$9%Q:1<-.2H9 :O,RBP!K"G^Y"RUPI3RLL',BJH$_2JH^BH#O2O'
M0BNONJH'C11N@Q0(S:H?R:J\JI/6"BW(\JP*!;?2BJS0(D+1 J[$VJW!FJP+
MQ2O)RBJN2E#.VBH%19)N0RW0,JW54JUNHRP1]='_$L51-!G1'U64X(JM>DM1
MWT+2%652)P6N?&.LUAHN9HF1Z1)#+40NY[*N+010 (VN+WVJ&"%#+MVN+C73
MID&1_+*S-R,S !PO,P- 42LU*'NR.T4R,/,R+GO3,?-3K5G%/]4Q5K13)U.T
M.OTT1*731&74)7-3/I.S-ZLS26U3@X'41U,R2).T3;TT3JU$-KM409W42.VR
M/LTQ4QW4N\$O[T+540TR/8,72*4Q6+684 6TO\'46>VQ-:/52F554=735@U6
M5<U-8E757SU57[552]VS9HU59WW51Z54/@56:DW6:TU5;$76;.565Z75F^&;
M/0S7S]$;1QO7ORD:T<'5_W/5U9@Y5U-DLW=IP$FC5T]-L7B]59F!$GPUUWR5
MUWI=U ?SUT-C$E530%1#+X,UP%6[M5ES0%BSM8C=M8G5M8K-M8N56(O-6(RE
MV&J#MH_5V(Y=-I 5MFLKV?JYMI1%60G<-FT3H T,(38)02'T072CV1($%% !
MPD31614\T9\=+2*R-RD-N'\3N*(=N*1%VJ5UB%])"*>=H8:#N*F5.(+SB(JX
MB(SK@B9JHB>Z@AQ0!Y"8 9$C"7(@"9-#VRQ2B9M#C=50C;:%V]*(V[>5V[JE
MV[MUV[R=6[VU6[[%V[T%W+X-W+\57 0P!T2X"[_["3"2 <@@#'K( <*57+^E
MW/_!K=S"G5S+U5S,O=S,Y=S-]=RA:(W76(SYJ+W?B"?4O3W@PP[FZTWI--TP
M# [>',[?G#WAXSZ',C_G/ _QZ-WR (_>A;[]\#X!8<]VH@^.ZI#GZX_ST,[E
M59 !"<_^,*GT7+_;0-[X-$\&P2CVM)")NJD0J:E]4I$409$L);0'Y,)H"2I.
M,<>TV11@=%^VHD"SLI*UHD(YD4#S<M$/K,#_M5\ YD!R"T)QL\ 1Y38"-M)/
M(11)\=D'_MD'0F"8K<#L:E^L,B_WG6!WH]+&$L(B;5D?/3<8O%D(;J%<:2%<
M"990@<(D+,(HA&$7-I,%3"YGL<\Q#5#TY98TM<(O1%[_W<Q"ZN+A+N6O8BUB
M8B5&='W76%Q'9537=+49>!77T)GB<E57*297* ;$9-Q%>*3$063'/-3B*K[B
M2UWB3R7C-$;&0B1$BV'#T@'7+*[B5 S4(CY#8SWB8M3C-#3&*SYC*U;C=47C
M7[1&0DYB0G5%/&;3/,ZO0^[C0%9#/Z[$0IY&8=QC1#[D5:3&339DO %C)V[B
M+KZ=3 3E+^;B3][B4$;EW_'$?'1E?WSE?I1E?9SE6*;E6ZY'@AS(70[97LZU
M\4%(ZPGFBL3(BR3F8\[(9#9F998?^M&?CQS):#9)DD3)EN01 C(5"QI"F;Q
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M#ECZ3G!%57#[7K$GTS 9N[!AE7 OFW JF_ "!_!!$_!.[=0.)S$&1U0!)W%
MU59EG=9NI7 53W%7U5,AR[-*4S,9CW$Y7=02=[1E19@61W'_4H7Q$[=6%M_3
M(?_Q;F6R-.MP#L_7&L]5675R'H=R(4=5--S6*G_Q'H_6'?M6/XLT)F?R?[57
M0VLT,2?S0RWS>0US,S]4?CUS3!OS!:]O$8_S.(_7!F=PA558.4]85MOS/I\>
MAQ790/?EC6TV8'LV0X\VCS6V:4OT1C^V1V=T2%?T27?TE3U92/??$.Z4$?VV
M(/7T4R%AFQ7UFLU9#D:5#IXK$P9:X:(W*+TWI3W:6#?:68?U63<XIW4AA)-:
M@G.X7:?:7Z]:?]"'*+((>: '>&"BK>V")^H"L&V'D$"'DC#;DB-+M76\SF.]
M;+_VU-OVU>OVUK.[<+>\;]=V<<=V_W)'=W/G=G7W=G8']W%W]W*']WD_]WA/
M=WI?=WR'.AFH!P"XAYU;!T10AWNO=WU_]X)'^'Q/^'8W>'E?^(-7^(AG^(=W
M>(F'^(FW>*O+3,23/=KS^.A+#]WH^-GCC>)5O]M47=1%OMK%/I,?WMWUW7L@
M#_&8^?$(:_ 8:]H0^9+?>=GE)]W5C^\3^NL4J.9,/_:,/_+SWK.>**#GW@/Y
M7@$D7_3]^?=C;_A%V+597Z2ZY/W#SP,,X+"O00>D0(9U0!A\P4Q1P >$V4 )
M]1$>8+<?8 C$P1ZT^Q(>=9Q==0@VE0H.P''14%.K7YPMMU3/>[S/P9T]P0AB
MX<8W0AEVX?\8?N?)?V'(/V'*ZI'[[+_@%&_NUN$M]>X5^6$PU!;Q_7SS#N_J
M8F0C;N1+1IPG=AEWC$?9-^51)L4W%F1 KGU*M$1(+F5,O'TOOF5$1)Y9$TCA
MO\<V5GY3E$9)AD9)7F7A#^,VM&7>F7[>I^1JK..V:?TTW/[LYV12%N7=%__H
M5V5T[.1*5G],[GI+YN/T=T;T]\3K_\1XB?]KQ'_X#W_MU__^7_]@!(A^^O@-
MA$90X$&#^OHIY*<0X<*' R,>G,BP8D*,%!=:E)B1XT>(%T%N%.FQ9$>-(TVJ
M/+DR)<F7(2W25%DSYDV1.7?:[(G3ITZ@/'\2#5ITJ-&D2)?VY!?_U"E'A% %
M2J4*<BI6JED7;NW7]:O6L%S%>B4+=BS:LFG/JFW+]NVLM7'=SG+*;^Y=NW6]
M[LW+5R_@OX+]$O;GM%]=PX;[(>;GK]_BQH\50W9<>;)ERIHS<WZ<^++DT)]'
M0Q9=FK3GTZI3LT:\VO5C *]E^_,G^S9DV_UPU[ZM&\#OX+Z'[Q9>G#APY,:3
M'V_._/ERV])E]U/7!1X]>5[>=>GBQ5WW+NNZJ,N1;H:,&>5DL&?AP#T+! @<
MR)?_K?Z!^O?EY[>/7_]__O$'X( "(M ? OL=2.""!B*HX(,!)B@AA Q&6."$
M&%;HH(4=<OAAA@V&>*&(&X[HX8D@FK@B_X4M:NABB3"2.".*++YX8XPXTJBB
MC#7VR*../@8)9(Y%[I@BDC8:*>221!ZIY),_)BDEE$Q&.>246%;II)5=<OEE
MEDV&>:686X[IY9E@FKDFE6UJZ6:9<)(Y)YILOGEGCH\@X@@B>O+))S[W!#JH
MH(+6<\^A]-23Z*+WK')/H?C@DX^@DU9*J:283@I-/OGH,ZFGG&Z:::6#6CKH
MHXP>^JB@J=ZCZ*KU*+J*K/64(NNKD.)3#Z&]1KIII_IPVJFH@4**Z+&K&*LL
MI*LZBJBMB];S**OX,&NMJ;)$6JDLG'J;S[?0=)L//MJ"JRVVK>(S++CZ$-MI
MN] (.Z^\]=(++_^[WM+K$+\&6>.05_SRP^^_!@ULD+WZUNN0L PK-*\^#2/,
M3\$# _RO-?UDO+'& 4/3\<8 'VSQQP5W7++(%X/,D,8"$^QRR2MSG#%CUCS6
M<<TKYYPSQSO+S!C.0=M<\V1#:USTS30+#?3,3#OM,\W^#(UT:9/5!MG465,]
M6=5&<XRPQ!*__#'"+:-LL,I*>TTUT%67QIC47,.M]MQ)SPTWT%(_'73>?>,M
M]]5<UR9X;E8;7CCB@R<>...'*_YXXXL[7MMA+1],K[OMODNLL/'&BWG"^RX\
M>M@3@WUZY^&"ZWF]GR?L,.RDGQX[Q+7+&_'M$#.,>\2[^W[[[[U'7)#_\,5/
MU#OPP_NN//!H.T\R]"-+_SO) \%,$,S(5U_0]OP2?_SW!"%O//7A.Z]]^,R3
MG_SXW)N/??/PHT_]Y=Q/_[S]U]\?O?[]/[\_ *^7O_C5#WO@$]\!E:= \BTP
M@0Q\H ,G(C\)I@]^!K0@!9<W0>R-;( 7[*  +YB\#4IPA DT( 01J,(&KG!]
M+C1?^X('PQDN+X8LO&$*<9A!!:)PA\+KX05Y6,$AKA"(%/SA"9/8P@@NL8GL
MHV'S8AA%*$JQBNFS80Z16$0EFC"(1ORB$H58PRN2<8QFG*(,TXC&-5I1C5@L
MXQ.;J,,@:E&,=O1B0TJ(QSUF,(\8%"$? =G'_T#J<9"&%"0B"YE(Z!T2?QST
MWB/]"$+K09*2DJPD(R/Y04Q.,I.6W.0E_S<234JPDZ;DY"BM=Q'IK5)@K338
M*JL"2U72<F!5J254;(G+6^JRE[G\)2^!N4N+!;,JQ%3E,6V93+OX,F# 7*8S
MC=E,8E*S+-6TBS6SB<V<;7,6&>OF-W'F3: =1F^5N=LYTQF9=9:SG7!SISKA
M>3-U5JV<;B,</N^ISWQ:;1;WU(W@ "I0V@PT-P0]J$$3VAN%%G2A#FWH0*=C
M4(GV9CH63<Y%,XK1C5IT%NWH@CS(H!UXC($[W?EH%W*@CG:4!QWLD<%Z9/ >
M!XS# >&PJ0/ P2 %\?]TISXU4$^!^M,0!96H0RTJ4H^J5*$RU:A-3>I3E^K4
MJ4*5JE*M*E:OJM6H<M6J7<WJ5[?JU;&"E:QB+2M:SZK6L++5K&U-ZUO7ZM:Y
MPI6N<JTK7N^JU[CRU:Y]S>M?]^K7P0*6L((M+&(/J]BO_@D1B=@39'>%*,GR
MZE")0I:BZ)&KR@9*4YBZAV<O!5I\=,Y2Y HMJ5)K*,SB2K.5U16O5LLK5V7V
M5:V=;&PE^RM*D>M3[BKM9W7[+$,-ZE#-8NVB2H&LW):JN9+RE6I[9=S)FI93
MH\74MX!EVDUA+E3=[=SF=->0^'G0*?]S&.A$UR](FHY_L'1>61SY7EN*LFG_
M3@DG+/%+7_?2MRSAI-M]T=DQ\]HR:O_=&]UV9DZ<K=/ "/8OA#/VL?M2;, 6
MCIH\]ZEA?FZXGDX;V<)PM]ZRF0S$KDPP@^4I3PRCDYWO;/&*(1S@>+Z8QATF
M'&W<EF.N[;@T/7;H;A2J8Q\3.39"%APVQWNO=V67=:E[<NBB7#K:S4[*P++N
MZE1'6BF_3G941J^]B <VXN7#C50\LYG+IV8_[A"#$,&D^Q;IOC>WN<Y>;#.;
MX:SG//.9D']4)*#_+.@X!WK.A:3SG35BP#>?Q'LLR:6A,P)I1^\0T78N])[]
M3&@2#CK3A\1TGS_MYD.3>M2=#K6<V?M')<>9O&MN_R,;T1SK-*]Q@ZQ6=:M7
MK6E/IQK5H-ZUKT\=R/'JNM7SFS6R8:UL8S,;U\XFMJ@CO>E<3_O9Q6;OL;/=
M[%MS6XJV_O;[PFUM:H^[W- V][5++6U*FWK=C7ZWHN%]E" R.M[VCHF\ZTT2
M=DO;*(MFRKP#KA1Z5QK@ Q>XP1,NE(4C'".0YN55GB+QF@BSF;14BRXQOI6,
MO\4L'E_+Q]T2\HZ#O.1TD0LVN=*7E0>&,"P?S,L;(QB9.^8P?8G,7N*)F9V#
M9C,\]WG/.Q,:RGR&Z*>QC#\]@_37)!TV3F\ZU&<C=2 C]*'$62ASL!X=Y7#=
M.5OW>M<Y.AS;P .DB!AI%__>\9WPC&<=YD$/>EX*G_?(ASYU+RJ=U"2G.NU=
M[WC*>YH";Z<X_9WOA?<[X1,/^,$OON^"=SSC#:]XR3?^\(^W?.017_G):Y[R
MGN\\Z"_/>=%OOO2?)_WI,X_ZT*N^]9!_/>9AWZ#&ZLE/B$"6JZJ5>\SB'K;0
MW5:FH $J46G*5,87[7./Y2AIT4I5IBK^MI+5*%@-5[>Z]>RP0$<N:QUKNL[R
M/O>=12U'I2L?URH7:,_?6645JU"XGY:N0/LM)J]N<_EXQKFRW[I\98[+VJN8
MEYF,  *,Z:27E[67OXS-R9@-Q2C@P3#@ P[@V2S@S%R,!28@?$4@R_3,T7!@
MT_#_#,BDC=UXH-T0C0D>S0EZS8,US=>8#04*3=)L#=9L3>!HS0PFSM1$3MQ\
M30-6V8CU( 6.V NJS3SM8-$(F(-!#3ZA&!/JS-) S=]430U.#A5*CA5"3A5B
MX17J8.0X3<7PSOS=7Y9!F>L8X)<=X \6(.IP"OZQX>H\ QERV1GVRY2%F.T,
M3^[D(1[N(>_TX1F]D!RE4!05T/G<C_448O8$$"(N8O48HB$2#R$>XOA$(B%V
MC[Q08O!@(@%E(B=NHB<>(G]=CB/Z3RB2HB*6XGFEHGN!8B5J8O$44._4$"Q*
MXO',HBUJ4"O2#R[NHB=:$ C)5R:=SP!I3RZ.T"R6T1PE_V,6P1$@JL\!Q5$<
M*2,322,O_A L=H\E$:,N&F,UEM(V:N,G>B,T+F,@3N,;_>$S-N,Y4F,R8J,[
MGE(7<6,7V1$YLJ,Z,F,ZYJ,*C:,^VJ,Y_F,YTI$/]9$U<I)!AI(OJMHO!B-#
M+N0I[H\'1:0I*B1%$IM#DF)Y3:0J/J1&HJ)'<N1&=B1(AN(K[1<KB1)*-M,L
MF:0LJ:3%O63%Q60Q#=,TU>0S*1-.,A,VZ60T45-.]N1/7E-/6I,R$>5.:M.'
M/:$X)=@X*5B"F5.#U9B+V=A4KE/>V)-4^HT^16$1WM@_X5/@2.'D$)355!U$
MF25:,E1:6MU$6=W@'-1;QB5&5?_47&J478K== " V.DE/8"42&5'2:5=%X#'
M1ZU42\7=>K" #+A'3;E'."" 3AE(9(;(9"I(9=;'9<I'9D(F@VRF9W8F:$IF
M:%+F:%IF:6+F:6IF:G*F:+8F:;JF:<(F:LJF:M(F:[XF;L9F;L[F;M9F;]ZF
M;@8G;PJG;Q(G< XG<A9G<AZG<C8G<S[G9]IF=/[F=!IG=2[G=3IG=D+G:FZG
M=W8G>$IG>%+G>%IG>6+G>6IG>G*G>+8G>;JG><(G>LJG>M(G>[XG?L9G?L[G
M?M9G?]ZG?@8H?P:G[=4>9&W6KA179\56/N26@RKH:Q$7:(W6IYQ6H32H@DIH
M@LH6/KC_UO(IRCS<%F=-J(5::''Q7H1B*&CQRG;YEJ=,RJFT"HK:UF5]'[*L
MUJ\8BX8"WZE(2JE,EZLPZ'41WY">5KX8*;Z8J'89H'A-4)-"Y(CMH?^=VWP%
M&(&1VX25)(%Q#(%U:2Q5J9:>6($E)8!96'XE99:R&-; V--$)3<MS8Q=&(1!
M89RJ:1%FAE?BDSUQ&)^>TY7&3I2>Z1<*H96FF%2JV*'.:55BDYV6TS<M:J)J
MV(\%F9%5ZI!9:HY5':4"%*5V:J86F:>":H-53^ML%V]I5Y:5X92:(1HBX+T0
MZ>K(W^IPUZH>H-BL(>V(6?"4613QZK+1FK>)FZN%FJ45J[KQ_]N_$=Q,*"L%
MZ1LBG=NQRENO =NP71NQ%ARS)FNS(H5+N$0M11S%'9RX8NNVMANO_5JT>9J^
MK6NT%AN[+BM*P"NRYEN[-I*UWBN6:ANV;5NPOMJV@1NZ82F^SJN[UNN[NMN]
ML02^)6R]!JS#<AO #JN^0JS 5NS#,JR;0=LH/83&4NG >JS%@NS%ANS'EBS)
MGFS ;NQ'.%K'9FR[R42\QBS,CBO#B6NWM@3.+JS.*BS--IS/]BS0*MS/"FW0
MUBS1*MS#?>LM:9Q8<-S2DIS(F1S4OH4_K$75NL758D76:@5><*U<?*U79.W*
MJ5S+O9S+E2W:,D;,W9S-U1S."5W1"?\=T,TMTL&MW2H=WHI&W;8&:CP=T_TM
MWX)JTR$4;_S&IH;=UT$'XBXNV#6NXAZ'1(G=;N!#VGD!/%BN%W@'>'1'V[T=
M.L2=3"DF?-1=?3B Z\4>ZH[>Z:JN[)D>Z[5NZL'NZZ:NZZZ>[:YN[>)N[-+N
M[K(N[\ZN[P9O[LKN[1*O[@+O\/YN\2KO\2ZO\/9N\CXO\@I)@4(6G^!69P'?
MA&8O=!F7]7GOI>B?B>*HCDJ7]*G*M-1*\^7*MF#?^'YOK_2H^X8*OB1?]ST+
MK=#*K>@O\SU+;)%?]/WOM:@+ :<+MC#+9%UH&'K+N'"._<D+_15PN2B,E-ZJ
M^.3A>GTAD^K_X91F<,J<#?0L3,4T#0A'X/54S,B@\ 62S,^PX :VL)DZ(1.6
M( R"8!.ZL T_&!3N, JB8-R8X ]S6-WDZ5<F#L_0897=J@L"X 7"\ U"Y5,V
MH8)UC1<RV-M(,53VC=SL4U@ZCE@6L1:&,1=FX1A?X9HR!NHPF;FH#O\IC*K6
M(1PC8!J^:JJR,91M\!G&,1_>81_RL1_KX?>(UZ_RXSX"8K(-(R)G3R*'9"J"
MXSVB8R$WFS-&,B5/LB6?(R$+X[X^$@]=XTA^LDAB9$<NLCL243S643WF$!AI
M$!&U(Q=I43SB$2S/,D'6LD &I#]6\B#OLJSQ<II=,D#FLAB=LBV7_Q M3ZLX
M ALJ!_,C'S*P]C*: 3,DL^,JT^- WO(1%;,@&K(O.[,W=S,XTY T$[(T6S,V
M5S,L4VNZ6F1%)B0[(V0RK[,Z+Q(\@I(]QS,IY?,GX?,^Z[,G_3, I1) 'Z0]
M#XPJ29*6"G27NE)*GJ1+ M-*RN0N331,SF1%4S1/(M,T,6W*%25/[J1'#^5'
M(^51EC12AI/-H;3:'AAB,*6=OG2D0BI5(NK;T!-F<.6>$G&?[K0_-%U9_M-:
MGJ5:#C5;%K50&_5&3536W253XZ532U1WC,'ERD-@<@=ABH=*Y<#GOI3<R4!-
MW=1-;69B!199&U99C[59IS5:K_5BJ75;L__U6;^U7,<U7;MU7<.U7><U7N_U
M7.MU7_/U7?^U8 <V8?MU80.V82<V8B-58SU68VTH:DGH9TUVI#PH<<%H;X$*
M<%VH]EK?[M7H9M&H_T(V9Y=HBU(H:;VH:5>H:L>H<#5?^LY*^MZ*LQP7^7HO
M;G>O[^4HC];?K(96DH87K/IH_(XA!*>7L"(Q>&F.[2BW'$Z,_90D]TR,>:W,
M0C\/=/^@B>57?P68!\872_Y7=S]A9##8@=4I>,^8WA0J2T,E3=^I5,+T#KMW
M3+>3GG*E$;L8$\NQZ7C,>FD@%N=-U%PEWM1W@:>3H:I3HQZX5=ZT3C_XI'ZJ
MI?*8/DEXIU)X/MW_C7GAH9)V5G7]=KAL,![;JJNN8:K**O&EN(@G\>R(F2#;
MBZ]Z%YGMZC/7^#>3&[JFVJ4E&KD2[+[A6;566[ )^3PKDL@.^;D*VXZ7*Y/[
M^,'&TK'>A+;R.)4O>9$K.3)G^9&GFY([:XY_.98;N<GZZR9W&S3;>#B3.<6.
MK+.!.9$;TL%.N90W&I"C[)I+[)G?.)I#T9AON<6*N9U_[,1&[* +:Z&K.:'_
M:Z O.IO[>9N;*[V^[-'ZA+;"K),;[*3_N*)).:=ONJ=K^M :K:B'.JD7;:GS
M1-+V$KA>-*M+M-->G#!%K:Q/[<C5NM2:1=>2+5VD[=G"'*^;;<ZQK=K:_\7;
MUEC<OM//R:VR)SNS@T;<YJW1Y2W4+5W@5KO?6GN.#:Z0!?75&8?6,>[CAGOB
MCOO8*:YT= %*8:[FAL='N=UYG =7*V;HTH?=S0?>02^^3Z^^.V_T]GN^\_N_
M-Z_ &R_!,V_!2R_ [_O &SS#(_S"._S!^[O"1WS 4_S$-[S$)[S&/WS>T5Z?
M'"CY'HOU(=^HR"_)@TOP!3?*ESSTV6_()Y_+EZ_(XW;\30IKSXMW^2KN!(OX
MO@MQ']?X)==L+Q^0+HO11\JU)'WOB1^V,+#\-;!OB\H:0_V1/O"YH/@;2YF(
M43<2JWR7$4SIB(X%E]@'0X\*@_ (CXT'EW 32__8STQ@!<+]TI @%'[W=^=P
M"B)8##YQU]"P"N8]WG=@#?OPU-Q3#M)@%FI-R&#@VE\$V1!@VP^^@95@$/>]
M$@+QWRNE%(/,$G9^GI:Q&).QZ&_AZ.\@TY#J<LM?9[GA J]X'I=X&@;JDW4*
M'+8^!;-X[*LA>O4Q(/_Q'O?^% ER/ZXC-\.0*T)B)SKR,((R(QX_FCN_)D<_
M+3),).8Y.-\B^XAB*#/R1VY_]W._]C<_]2<B^8O_)2IR)"E_^FLS/HJ0^D=_
M*2-Z,1:D/-)_*C,S0)(S)C<S_P\__N,R0.C3QP^:0'X"!Q8<B)"@P84-'_*#
M>% B08K0*F),F)&C1(S_'CM:!#ERXD"/#E$N3'EP)4.7!A6R3+@R9DV:-U7.
MS%FR9<^=+W\ZO"A4)\6?1HG*-*H4*%.?3H/NC,EP*DR<4+%2?:HU:M:M5YN&
M_2HUZ52.$2=^M+B1I%JW(=^VA7OQK,BU=C7BI2N7K]Z^<?T&!CQX[M_"@@]_
M[!=W<<?&(Q^+C*R8<67'EB$K-OFXWV;-$CEO%@UZ-+_.I%&;+MVOXFG3K3?#
M!BW[]6S;M7&SGLU:]VO>K7T#_[T[=_#?_9!;.YX<>3_ES*'[>^X<N?3JIOM9
MSXY=NS_NWZ^'WR[>.WGNS<MG1[_>G_KJZMN_;S\??GWZ][/[PZ]_O_[\\_T!
M_^"__ 3DC\ #]2LP0 073)!!!2%\D$#^(*1PP@0I#%!## '84,,.0?Q0Q!!)
M#!" $D\4$)%VNGB''GG(@*?%+MSIPL9UNE GAW1FD&&&<F0(<AP9QG$@'",=
M0"!)!,!!P,DFG?S&22:GE/+)*J>$$@$KJ8PR2RRO]#+,+;\4LTLRQ^122S7!
M/)--,]<L$TTWY7QSSCC3K%////FDLT\\_0P4T$';)!3.0A$]5-$[$V5T43LA
MW5/01B/]DU))#754TTHG?1332RWU--1-/Q6U4U)'Y31354$]E5535RT555=E
M?7766%.M5==<>:6U5UQ]#1;885LE%M9BD3U6V5N39?]V65LA?0011Q"15EIJ
M\:GGGGKPH6?;>[SE5MM[LL7GGGS.Q0?=?-1-%UU\VF7WW7CI7;==>-\]EUQ]
MS>V77GW4Q4<???/-AUMRPRV7X'P:8EA@A@N"6)]\ &:W8H$#SC?;;^FI1]N.
M/_;XGE7N(7?<C;4]>5]_^S6YY)$Y+ME?>^?-!QIY;[Y79YK)W3EGFW'.A^*(
M];EY:*&+3MJFC682^F>CB][+(HP*JEKIJYF6C#+0"*.:+J_9(H@WY4Q3S!K0
MR*9.N<K&I@Z:MDV;+FVYX:8N;M[>OCN[N<WK>[R_TPN<[KV;>TX[NQ$?G#K
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M\441_XI Y.(7O8A ):Z0C#!DH1EWR+\N.A&,3M3B^^*W13E*<8YQ9&,8[QC
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M'0O:R8K6LJ3%[&91V]G4?G:UH6WM:%];VMB>5K6U9:UM78M;V.I6MM>JUK2
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M-W[J9^-LO'XUQL;F>6/RZ?X_WN-Z!/\Z%F0^%O\_'F3RYT?U#^3U1__V3_^
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MR1[5N)0\_N2/@1RD( M)2)SX QY/H<<\R*!(JKC#*DY9QU:^\A6PA$4&XW!
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MDB,D'GT_((G_0A820TKS^<,$148D1.I#.V!SSNYL5?3;O[4#5Z #)I%#F#O
MP7&25Z(S8 ($ G ("'XC*/"@08(#"QYDB$ APH8+$SJL2'&B1(@6,SZ,Z)'C
M1HPB-7Z\6#*DR8XG08Y42;(E2I<I:<ZT*1-G3)TL>:[T";,GT)\O_XG6S!FT
MZ,V=0XTN%?HTZ5&F2I$VK4IUJE2H5K,ZC>J5ZU:L8K5^O5HVK-FN9\&.54NV
M+5JW:>G.M2L7;UR];/FN]0NW+^"_+V4\0N0(D6%' !@W=OP8<F3&B0]3OE</
M$;W+^.KANY?OGN=\G4/7NWR/7CW3FE=O-EWZ-&O4JE''CEU/<RG<]>;MGD>O
M]^_>I8#7DU>\-V;6G"]G/MT[M?!ZQ(/32ZU;\W+2H$6'QL<==NO5M%./-[W*
M]OG3Z-67]LP<]KU[[&NK-TWZ/;[WH?GOAY\?//_Z&]"_[[S+!YI\#-0/- 7U
M23"?!_6)$,('\[DP00,OE% ??J#1I\,/1?\$T4,2H>$G1!1+!''$#RG<L$40
M'T11PA%#-%'%#U/DQ\,<?>2GGQ.!%#)('HOD4<@>]3FR'VOZ =+)?OQQ$LI^
MI 322BJ;?')+*:F<TDI_L!0S3'[\N;+,,\E$DTTQU313RCC5E)/..=VL,TX
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M+W8_NW664QUK,D?PB'?[X#>C2L>T\NVX5+ODZ1Z>OI^'ES++_-XW+YN1Q9)
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DW,J=[,JF#,NI_,JT',NU/,NVG,NXO,NA+,N]3$'9&\P! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img123481027_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img123481027_3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )Q _X# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M':)=:SK^K6.AZ/:*&N-0U*Y2WMX02 "\CD*HR0.3U(KSW_AK'X(?]%D^'_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?+OA7]KC5M<_
M:GO?!%QI>GQ_#>YU"]\-:/KT8D%Q-K=E;P3W,,C%C'Y9$DR)@ EX&&2>  =4
MO[/'BOP-KWB*Z^%OQ%B\&Z/K][)J=WH>JZ"NJVUM=R\S2VF)H6AWM\Q1BZ;B
M2%&<52_X8YTFT^'UMING>*-5MO'%OXB/B]?'$\<<UY+JY4H\\L6!&T31L8C
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ME6/[7OPDU+Q!8Z1;^+-\E_>_V=9WYTV[73;FYWE!%'?&(6SL6!4!9#D\#)H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_A!\/O!MI)X$\8:5H^B2:1K/A7Q$)!I]W*)2T5W%<BU>0-L.UHGC*<G'/S4
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M2<?P$T[X1R/\,-&TF'PY#X8DU^VOM0O;I+=;9;=I4MWMHT:0H"0"X )[@8H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT7EM'%!+'+!;.K-))'-YG*M@*HP_S8!^FZ* /GH_#+Q-#\+T^$D'AXKIHO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^WS_ /0-NO\ OJ+_ .+H NT52^WS_P#0-NO^^HO_ (NC[?/_ - VZ_[ZB_\
MBZ +M%4OM\__ $#;K_OJ+_XNC[?/_P! VZ_[ZB_^+H NT52^WS_] VZ_[ZB_
M^+H^WS_] VZ_[ZB_^+H NT52^WS_ /0-NO\ OJ+_ .+H^WS_ /0-NO\ OJ+_
M .+H NT52^WS_P#0-NO^^HO_ (NC[?/_ - VZ_[ZB_\ BZ +M%4OM\__ $#;
MK_OJ+_XNC[?/_P! VZ_[ZB_^+H NT52^WS_] VZ_[ZB_^+H^WS_] VZ_[ZB_
M^+H NT52^WS_ /0-NO\ OJ+_ .+H^WS_ /0-NO\ OJ+_ .+H NT52^WS_P#0
M-NO^^HO_ (NC[?/_ - VZ_[ZB_\ BZ +M%4OM\__ $#;K_OJ+_XNC[?/_P!
MVZ_[ZB_^+H NT52^WS_] VZ_[ZB_^+H^WS_] VZ_[ZB_^+H NT52^WS_ /0-
MNO\ OJ+_ .+H^WS_ /0-NO\ OJ+_ .+H NT52^WS_P#0-NO^^HO_ (NC[?/_
M - VZ_[ZB_\ BZ +M%4OM\__ $#;K_OJ+_XNC[?/_P! VZ_[ZB_^+H NT52^
MWS_] VZ_[ZB_^+H^WS_] VZ_[ZB_^+H NT52^WS_ /0-NO\ OJ+_ .+H^WS_
M /0-NO\ OJ+_ .+H NT52^WS_P#0-NO^^HO_ (NC[?/_ - VZ_[ZB_\ BZ +
MM%4OM\__ $#;K_OJ+_XNC[?/_P! VZ_[ZB_^+H NT52^WS_] VZ_[ZB_^+H^
MWS_] VZ_[ZB_^+H NT52^WS_ /0-NO\ OJ+_ .+H^WS_ /0-NO\ OJ+_ .+H
M NT52^WS_P#0-NO^^HO_ (NC[?/_ - VZ_[ZB_\ BZ +M%4OM\__ $#;K_OJ
M+_XNC[?/_P! VZ_[ZB_^+H NT52^WS_] VZ_[ZB_^+H^WS_] VZ_[ZB_^+H
MNT52^WS_ /0-NO\ OJ+_ .+H^WS_ /0-NO\ OJ+_ .+H NT52^WS_P#0-NO^
M^HO_ (NC[?/_ - VZ_[ZB_\ BZ +M%4OM\__ $#;K_OJ+_XNC[?/_P! VZ_[
MZB_^+H NT52^WS_] VZ_[ZB_^+H^WS_] VZ_[ZB_^+H NT52^WS_ /0-NO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M511T  X J6BN6MB*E>W.]%LEHEZ+^O,VITHT_AW?7JPHHHKF-@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-MI][JDOG7DT*8,K^I]/7 P,DGJ2:WJ*M3E%-)Z/?S)<4VFUL%%%%04%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJC^R8/\ GI=?^!<O_P 50!=HJE_9,'_/2Z_\"Y?_ (JC^R8/^>EU_P"!<O\
M\50!=HJE_9,'_/2Z_P# N7_XJC^R8/\ GI=?^!<O_P 50!=HJE_9,'_/2Z_\
M"Y?_ (JC^R8/^>EU_P"!<O\ \50!=HJE_9,'_/2Z_P# N7_XJC^R8/\ GI=?
M^!<O_P 50!=HJE_9,'_/2Z_\"Y?_ (JC^R8/^>EU_P"!<O\ \50!=HJE_9,'
M_/2Z_P# N7_XJC^R8/\ GI=?^!<O_P 50!=HJE_9,'_/2Z_\"Y?_ (JC^R8/
M^>EU_P"!<O\ \50!=HJE_9,'_/2Z_P# N7_XJC^R8/\ GI=?^!<O_P 50!=H
MJE_9,'_/2Z_\"Y?_ (JC^R8/^>EU_P"!<O\ \50!=HJE_9,'_/2Z_P# N7_X
MJC^R8/\ GI=?^!<O_P 50!=HJE_9,'_/2Z_\"Y?_ (JC^R8/^>EU_P"!<O\
M\50!=HJE_9,'_/2Z_P# N7_XJC^R8/\ GI=?^!<O_P 50!=HJE_9,'_/2Z_\
M"Y?_ (JC^R8/^>EU_P"!<O\ \50!=HJE_9,'_/2Z_P# N7_XJC^R8/\ GI=?
M^!<O_P 50!=HJE_9,'_/2Z_\"Y?_ (JC^R8/^>EU_P"!<O\ \50!=HJE_9,'
M_/2Z_P# N7_XJC^R8/\ GI=?^!<O_P 50!=HJE_9,'_/2Z_\"Y?_ (JC^R8/
M^>EU_P"!<O\ \50!=HJE_9,'_/2Z_P# N7_XJC^R8/\ GI=?^!<O_P 50!=H
MJE_9,'_/2Z_\"Y?_ (JC^R8/^>EU_P"!<O\ \50!=HJE_9,'_/2Z_P# N7_X
MJC^R8/\ GI=?^!<O_P 50!=HJE_9,'_/2Z_\"Y?_ (JC^R8/^>EU_P"!<O\
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M2_LF#_GI=?\ @7+_ /%4?V3!_P ]+K_P+E_^*H NT52_LF#_ )Z77_@7+_\
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M5']DP?\ /2Z_\"Y?_BJ +M%4O[)@_P">EU_X%R__ !5']DP?\]+K_P "Y?\
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M@"[15+^R8/\ GI=?^!<O_P 51_9,'_/2Z_\  N7_ .*H NT52_LF#_GI=?\
M@7+_ /%4?V3!_P ]+K_P+E_^*H NT52_LF#_ )Z77_@7+_\ %4?V3!_STNO_
M  +E_P#BJ +M%0V]JEJI"-(P//[R5G_]")J:@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*WTVS@M+2"*UM+>-8H8(4")&BC"JJC@    #IB@"9CA20"Q'8=ZI_P!H3_\
M0-NO^^HO_BZNT4 4O[0G_P"@;=?]]1?_ !=']H3_ /0-NO\ OJ+_ .+J[10!
M2_M"?_H&W7_?47_Q=']H3_\ 0-NO^^HO_BZNT4 4O[0G_P"@;=?]]1?_ !='
M]H3_ /0-NO\ OJ+_ .+J[10!2_M"?_H&W7_?47_Q=']H3_\ 0-NO^^HO_BZN
MT4 4O[0G_P"@;=?]]1?_ !=']H3_ /0-NO\ OJ+_ .+J[10!2_M"?_H&W7_?
M47_Q=']H3_\ 0-NO^^HO_BZNT4 4O[0G_P"@;=?]]1?_ !=']H3_ /0-NO\
MOJ+_ .+J[10!2_M"?_H&W7_?47_Q=']H3_\ 0-NO^^HO_BZNT4 4O[0G_P"@
M;=?]]1?_ !=']H3_ /0-NO\ OJ+_ .+J[10!2_M"?_H&W7_?47_Q=']H3_\
M0-NO^^HO_BZNT4 4O[0G_P"@;=?]]1?_ !=']H3_ /0-NO\ OJ+_ .+J[10!
M2_M"?_H&W7_?47_Q=']H3_\ 0-NO^^HO_BZNT4 4O[0G_P"@;=?]]1?_ !='
M]H3_ /0-NO\ OJ+_ .+J[10!2_M"?_H&W7_?47_Q=']H3_\ 0-NO^^HO_BZN
MT4 4O[0G_P"@;=?]]1?_ !=']H3_ /0-NO\ OJ+_ .+J[10!2_M"?_H&W7_?
M47_Q=']H3_\ 0-NO^^HO_BZNT4 4O[0G_P"@;=?]]1?_ !=']H3_ /0-NO\
MOJ+_ .+J[10!2_M"?_H&W7_?47_Q=']H3_\ 0-NO^^HO_BZNT4 4O[0G_P"@
M;=?]]1?_ !=']H3_ /0-NO\ OJ+_ .+J[10!2_M"?_H&W7_?47_Q=']H3_\
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M% %+^T)_^@;=?]]1?_%T?VA/_P! VZ_[ZB_^+J[10!2_M"?_ *!MU_WU%_\
M%T?VA/\ ] VZ_P"^HO\ XNKM% %+^T)_^@;=?]]1?_%T?VA/_P! VZ_[ZB_^
M+J[10!2_M"?_ *!MU_WU%_\ %T?VA/\ ] VZ_P"^HO\ XNKM% %+^T)_^@;=
M?]]1?_%T?VA/_P! VZ_[ZB_^+J[10!2_M"?_ *!MU_WU%_\ %T?VA/\ ] VZ
M_P"^HO\ XNKM% %+^T)_^@;=?]]1?_%T?VA/_P! VZ_[ZB_^+J[10!2_M"?_
M *!MU_WU%_\ %T?VA/\ ] VZ_P"^HO\ XNKM% %+^T)_^@;=?]]1?_%T?VA/
M_P! VZ_[ZB_^+J[10!2_M"?_ *!MU_WU%_\ %T?VA/\ ] VZ_P"^HO\ XNKM
M% %+^T)_^@;=?]]1?_%T?VA/_P! VZ_[ZB_^+J[10!2_M"?_ *!MU_WU%_\
M%T?VA/\ ] VZ_P"^HO\ XNKM% %+^T)_^@;=?]]1?_%T?VA/_P! VZ_[ZB_^
M+J[10!2_M"?_ *!MU_WU%_\ %T?VA/\ ] VZ_P"^HO\ XNKM% %+^T)_^@;=
M?]]1?_%T?VA/_P! VZ_[ZB_^+J[10!2_M"?_ *!MU_WU%_\ %T?VA/\ ] VZ
M_P"^HO\ XNKM% %+^T)_^@;=?]]1?_%T?VA/_P! VZ_[ZB_^+J[10!2_M"?_
M *!MU_WU%_\ %T?VA/\ ] VZ_P"^HO\ XNKM% %+^T)_^@;=?]]1?_%T?VA/
M_P! VZ_[ZB_^+J[10!2_M"?_ *!MU_WU%_\ %T?VA/\ ] VZ_P"^HO\ XNKM
M% %+^T)_^@;=?]]1?_%T?VA/_P! VZ_[ZB_^+J[10!2_M"?_ *!MU_WU%_\
M%T?VA/\ ] VZ_P"^HO\ XNKM% %+^T)_^@;=?]]1?_%T?VA/_P! VZ_[ZB_^
M+J[10!2_M"?_ *!MU_WU%_\ %T?VA/\ ] VZ_P"^HO\ XNKM% $-M.\ZDO;R
M6Y!Z2%3G_ODFIJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N.^*7Q*L/AAX;-_<(UYJ%PXM]/TV+F6\N&X6-0.>I&3V'O@'5\:>,
M])^'_AJ]UW6[D6MA:IN8]6<]D4=V)X KS;X6^"]2\9^(Q\3/&ENT6J3(5T31
MY>5TJU/0D'_EJXY)ZC/;HO?AZ,.5UZWP+_R9]E^KZ+S:.:K4E?V=/XG^"[_Y
M=S5^$'PQOM!N+SQ=XLF74/'.L*#=2CE+*+JMM#Z*O&<=2.^,GU"BBN>M6G7F
MYS_X"71+R1K3IQIQY8A1116!H%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY_;J2=A_W[XS4?VA2?P1E+TC+\VDOQ+_ +-JQ_B2C'UG'\DV_P #T>BO./\
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M?/\ ] ZZ_P"^HO\ XNC[?/\ ] ZZ_P"^HO\ XN@"[15+[?/_ - ZZ_[ZB_\
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M-_P/5**\K_X0'Q7?_P#(4\9^(9<]?[/CMK/\MKFC_A2NA7/_ "%(/$6N>O\
M:&IAL_7;(M?1_6,7+X*%O\4DO_2>8^9^KX.'QXB_^&+?_I7*=[J'B_0M(S]N
MUK3[/'43W2(?U-<U??'/P-8-M;7X9WZ!;:.28D^VU2*33_A=X1TS'D^"86QT
M,Z13'_Q]S72V-O;Z8NVST$VB^D"0H/T:BV/EUA'Y2E^L0OE\.DY?.,?TD<A_
MPNVTN^-*\,^)=6ST>WTXB/\ %F(Q^5'_  G?CC4.-/\ A[)"AZ2ZAJ446/J@
M&:[K[?/_ - ZZ_[ZB_\ BZ/M\_\ T#KK_OJ+_P"+H^K8F7QUVO\ #&*_-2#Z
MUA8_!AT_\4I/\G$X7'Q5U+OX9T>,^@FGE'_LM'_"!>-]0YU#XA31(>L6GZ=%
M%CZ/G-=U]OG_ .@==?\ ?47_ ,71]OG_ .@==?\ ?47_ ,71_9\)?Q)SE_V\
MU^":0?VC4C_#A"/_ &Y%_C)-G"_\*1LKOG5/$GB35\]4N=28)^"J!@5<L/@;
MX&T\[D\/P3/U+7+O,2??>QKKOM\__0.NO^^HO_BZ/M\__0.NO^^HO_BZ<<MP
M:=_9)ONU=_>[DRS/&R5O:R2[)V7W*Q6T_P ):'I&/L.C6%GCH8+5$_D*UJI?
M;Y_^@==?]]1?_%T?;Y_^@==?]]1?_%UWQA&"M!61Y\YSJ.\W=^9=HJE]OG_Z
M!UU_WU%_\71]OG_Z!UU_WU%_\75D%VBJ7V^?_H'77_?47_Q='V^?_H'77_?4
M7_Q= %VBJ7V^?_H'77_?47_Q='V^?_H'77_?47_Q= %VBJ7V^?\ Z!UU_P!]
M1?\ Q='V^?\ Z!UU_P!]1?\ Q= %VBJ7V^?_ *!UU_WU%_\ %T?;Y_\ H'77
M_?47_P 70!=HJE]OG_Z!UU_WU%_\71]OG_Z!UU_WU%_\70!=HJE]OG_Z!UU_
MWU%_\71]OG_Z!UU_WU%_\70!=HJE]OG_ .@==?\ ?47_ ,71]OG_ .@==?\
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M<@M#(T+H9(R1G8^5SGCDUTEE96^FV<%I:016MI;QK%#!"@1(T48554<
M=,5/10!\X>./V.K?QQX@N]3N/$<L(FGEE2%+<83>Y8_Q<GGK[5O_  <_9J_X
M4]XC_M*R\0/=P.K)-;26^-P(['/'(4_\!%>X45A&A3B[QB>;_9N$^MO'^S7M
M7O+J[JV_H%%%%;GI%:?3;2Z_UUK#+_OQAOYBL^?P;X?N<^=H>FRY_OVD;?S%
M;-%*R9E*E3G\44_D<O/\+/!=SGSO"&@RY_OZ9"?YK6?/\#?AY<?>\$Z"/]S3
MXD_D!7<45/)%]#GE@<)/XJ47_P!NK_(\WG_9R^&EQ][P=IH_W$9/Y$5GS_LK
M?"NX^]X2A'^Y=W"?RD%>L45/LJ;^RON.:649=/XL-!_]N1_R/'_^&3_AK'_Q
M[Z1>6?IY&J7(Q^<AH_X9=\)1_P#'OJ/B.T]/(UB88_,FO8**7L:?\J,O[$RS
MIAX+TBE^1X__ ,,UV$?_ ![^.O'=G_UPUUAC\U-'_#/M]#_Q[_%/QXOIY^J+
M+_-*]@HH]C#L']BX#I3MZ.2_)GC_ /PI+Q7#_P >_P 6_$B^GGQQ2_S%'_"J
M/B1#_P >_P 8[U?3S]#MI?YFO8**/91\_O?^8?V/A.G.O2I47Y2/'_\ A7_Q
M>@^Y\6+2Z_Z[^'($S_WRU'_",?&J#[GC7PY=?]=]*9,_]\FO8**/9+N_O8?V
M317PU*B_[BU'^<F>/_8?CM!_J]3\"W7_ %WM[M/_ $&C[7\=X/\ 66'@*Z_Z
MX37B9_[ZKV"BCV?]Y_>']EV^&O47_;U_S3/'_P#A)/C7!]_P=X:NO^N&J.F?
M^^A7FGQX^-WCCP[X-O-)\0^&K+P[<:A&$AEM=26Y9QGD;0/E'!Y)Y (^GU77
ME?Q&_9T\.?%+76U37+K4)90H6.))0$C  &%&/;/U)J94Y\KY9._G_P ,<N+R
M[&^PFL)B9<[5ES./+KI=VA?3=6ZVZ'@_[,WQXU^P\+_\(W8>&Y?%EY!(62&.
M]2"1$QG(WC##CH#G()YSQ[9_PNKQ=#_Q\?"/Q$OKY$\,O\C4?@W]EGPIX#\0
M6NLZ/=:E;7ENX8'SE(8 Y*D;>AZ'V)KV2IITZBBE*6O]>1CE^79E1PM.EB,4
MU**M[JBU9;/WH<U[;Z[GD'_#0&HP_P#'Q\*_'2^OD:<LO\GI/^&DK./_ (^/
M /CVT]?/T%AC\G->P45IRS_F_ ]#ZICUMBOOA']+'CS?M/>% I6ZTCQ+;*>"
M+C1I<?CC-8&I_&SX(ZKDZK91QN>KW&@S*X_X$L>?UKZ HK*=%U5:=FO-7_4U
MIQS>B[TL5%/_  /]*B/F(>,?V?99#)IOB:XT29O^6EDU["<_1D('Y5=@\?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCJ.AZ=JZ[;_ $^UO5Z8N(5D
M'Z@U>HJ914E:2NBHRE!WB[,X;4O@CX'U,EI/#UM _4-:EH"#[;"*H_\ "EH;
M'G1_%7B/2,=(H[\R1#ZHP.?SKT>BN"67823O[))]TK/[U9GHQS/&17+[5M=F
M[K[G='Q=^T1X?N;+Q;!IVO:DWB5OLL<J7$\7DL%W. I"'YL?,<GU]JX'P9X<
ML1XKTA-/MTL+R6ZCACN49R8RS!=V-W.,YQ7WIK/@GP_XBNQ=:IHMCJ%R$$8E
MN;=78*"2!DCIR?SJK;?#3PG9W,5Q!X<TN&>)Q)'(EJ@96!R"#CJ#7SE3*,P]
MNY4<0E"^B=V[>KN_Q/5]OD%91KXO 1GB$E[_ "QO=;-=K=+'._\ "K_$-_\
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M7_@7+_\ %4?V3!_STNO_  +E_P#BJ +M%4O[)@_YZ77_ (%R_P#Q5']DP?\
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M5']DP?\ /2Z_\"Y?_BJ +M%4O[)@_P">EU_X%R__ !5']DP?\]+K_P "Y?\
MXJ@"[15+^R8/^>EU_P"!<O\ \51_9,'_ #TNO_ N7_XJ@"[15+^R8/\ GI=?
M^!<O_P 51_9,'_/2Z_\  N7_ .*H NT52_LF#_GI=?\ @7+_ /%4?V3!_P ]
M+K_P+E_^*H NT5EV6E!H6\Y[K?YD@&;J4?+O.W^+TQ4_]DP?\]+K_P "Y?\
MXJ@"[15+^R8/^>EU_P"!<O\ \51_9,'_ #TNO_ N7_XJ@"[15+^R8/\ GI=?
M^!<O_P 51_9,'_/2Z_\  N7_ .*H NT52_LF#_GI=?\ @7+_ /%4?V3!_P ]
M+K_P+E_^*H NT52_LF#_ )Z77_@7+_\ %4?V3!_STNO_  +E_P#BJ +M%4O[
M)@_YZ77_ (%R_P#Q5']DP?\ /2Z_\"Y?_BJ +M%4O[)@_P">EU_X%R__ !5'
M]DP?\]+K_P "Y?\ XJ@"[15+^R8/^>EU_P"!<O\ \51_9,'_ #TNO_ N7_XJ
M@"[15+^R8/\ GI=?^!<O_P 51_9,'_/2Z_\  N7_ .*H NT52_LF#_GI=?\
M@7+_ /%4?V3!_P ]+K_P+E_^*H NT52_LF#_ )Z77_@7+_\ %5!;Z4#-=>8]
MUL$@$?\ I4OW=B_[7KNH U**I?V3!_STNO\ P+E_^*H_LF#_ )Z77_@7+_\
M%4 7:*I?V3!_STNO_ N7_P"*H_LF#_GI=?\ @7+_ /%4 7:*I?V3!_STNO\
MP+E_^*H_LF#_ )Z77_@7+_\ %4 7:*I?V3!_STNO_ N7_P"*H_LF#_GI=?\
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M?W<DCRRSLL5JJ LY)"*.%085<G:!DY /<:*** "BBB@ HHHH **** "BBB@
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M80_9UT\>4DSR.=[^?O2$("-BKA<(2V0 >RT444 %%%% !1110 4444 %%%%
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M\#O!>H>%;GP[<:5--IEU>"_N=VH7/GW-P#D22S^9YLA! QN<XVK_ '1CO**
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M%O\ RZK3_P")KPSQ+^U3\2M-^,]I9/X9?3Q;L+-_"9?S6N2^.?-"\L>"CJ,
M=F!.?5P^48C$-J#CHK_'%_DW^.GF<57'4J23DGK_ '6OS2/M2BO'A\3OBR1G
M_A2W_EU6G_Q-:'A[X@?$K4=;LK75/A1_8^G2RA)[_P#X2.VG\A.[^6JY;'H*
MY'@JL4VW'_P.'_R1NL1!NUG_ . R_P CL;3Q]H%]XVOO",.HH_B.RM5O9[ H
MX986( <,1M899<X)QD9QFK6E^*M+UG6]:TBSNO.U'1I(H[Z'RW7R6DC$B#)
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M/Q#\2==\#^&?$VL7-M"-"O=3O&T?4UADU">*[^S1[KFSE[)EV2)P-YPWW<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *RKCPKH]UXBM=>FTVWDUFUA:WAO6C!E2-CDJ#_G&3CJ<ZM%4I
M..SL)I/<****D9DV'A72],\1:MKMM:^5JNJQP1WEQYCGS5A#"(;2=JX#MT S
MGG/%8UO\(_"%M!XI@CT.#R/%$K3:O$SNR73L"&8J6PI.2<KCDYZ\UU]% '%^
M&_@]X4\*>((=<T^QN6UB*V:R2^O=1N;N40$J?+W32.=H*# Z+SC&XY33?@QX
M+TCP)>^#;30H8?#5X[R36(ED(9V8,6#EMP((4@@@KM&,8%=K10!P5M\#?!EM
MJ4VHG3KJYU*>UFL9KV\U2[N9Y8)5"O$\DDK,RX48!)"G)7!))N7_ ,(O"NH6
MNB0-83VK:+;"ST^YL+^XM+F" *%$8GBD60K@#(9B"1DY/-=C10!S%A\,_#.E
M-X;:STF*U_X1T2C3!$[J(/-0I*< X<L"<E]Q));.3FJU]\)/"FH6NKV\VF.%
MU748]6NI(KN:.4W<90I,DBN&B8>6F#&5Z>YSV%% '.>$?#EYH%WKSW%[/<VU
MW>++9PS7DUSY$*PQ)MW2DD$NCN0./F[G)+KCP!H%UJFNZC+8;KS7+-+#4)/.
MD'G0*&"IC=A<!VY4 \]>E=#10!R\WPS\,W%MX;MY=+66#PZGEZ9&\LC+ ODF
M'!!;YQY9*_/N_/FJ.A_!GPEX=OK>[L=/N4EM8Y8K-9=1N9H[%9!A_LT;R%;<
MD?+F(*0I(& <5VU% %;3K"+2["WLX6F>*!!&C7,[SR$ 8^:1R68^[$D]S5FB
MB@ HHHH *XKQ%\&O!_BO6+C5=5TC[5?W&WS)?M,R;MJA1PK@#A0.!7:T5A6H
M4<1'DK04EO9I/\SHH8BMAI<]";B]KIM/\#$\)^#-'\#:=)8Z)9_8K624SM'Y
MKR9<@ G+$GHH_*MNBBKITX4HJ%-))=%HC.I4G5DYU)-M[MZLR=0\*Z7JOB#2
M-;NK7S=4TE9ELI_,<>4)E59/E!VMD*OW@<8XQ5*;X=>')_&C>+)-*B;Q ]D=
M.>\W-^\MR<E&3.UN@Y()QQG'%='16AF>:K^SI\/_ "[&*319[BWT^42V5O<Z
MG=S0VA#!L0QO*5C4D#*H K 8((XK6\-_!WPIX4U.QO\ 3["Y\_3XWAL4N]1N
M;J*R5P PMXI9&2'*C;F-5.TE>A(KM** //XO@+X&@U/3[Y-'E633KS[?8P_V
MA<_9[.8OO+0P>9Y<0+')5%"GN#4&J?L\^ M9CO8;S1IY;2[N'NY+$:G=K:B=
MCEI4@$HCCDR2=Z*",G!Y->CT4 ><?$OX(Z#X\TC7F6T:+6M1L#;><+ZX@AN)
M$1A URD;;9]C$8,BN0!QZ5U?@;1)_#/@GP_H]T\<ESI^GV]I*\))1GCC56*D
M@'&0<9 K<HH X76?@CX.UV^U&ZNM-N$.I.)+^WM-1NK:VO&_O3012+'*3T)=
M3N[YJYK_ ,*/"_B.2SEN-.DM)K2T-A#-I5Y/I\BVIQ^X+6[H3%E01&25!' K
MKJ* .:LOAQX;TS4=#OK/28;2XT2UDLM/^SLT:6\,FW>H0$*<[5Y()X]S53_A
M4?A/_A'?["_LK_B5?VC_ &K]G^TR_P#'UYOG>9NW[O\ 6<[<[>V,<5V%% 'C
M/PZ_9STK0O[2NO$=M'J-_/KUUJ\<<%]<FT;=,SPM);DK$\J CYF1B"!@G QV
MGB3X0>$_%FJ76H:EILKW-Y''%>BWO9[>.]2/.Q;B.)U2< $@"0-P2.G%=E10
M!Q?B#X.>$_$MY-=75A<6LT]JME.=+U&YL!<0*"%CE%O(@D4 D ,#@$@<5>/P
MU\,F\GN5TB"-YM(70FCB+)$+%2Q6!8P0BJ-[8P <'&< 5TU% '!M\$/"!M=/
MA6TU&%K"V:R@NH-9O8KH6[,&,#3K,)'B! (C9BHP, 5UNAZ%I_AG2+32M*LX
M=/TZTC$4%M NU(U'8#_.:OT4 %%%% !1110!PWBGX*^#O&NK2:EK6D+?WDF,
MR2ROQ@ <#.!P!TK>\)^#M)\#Z8=/T:V-I9E_,\KS&8 X XR3@8 X%;=%*RO<
MS5.$9.:BKOKU"LF_\*Z7J?B+2==N;7S=5TJ.>.SN/,<>4LP42C:#M;(1>H.,
M<8YK6HIFASC?#SPX_C*Y\5-I4+:]<Z>=+GNR6Q-;%@QC=,[&Y5>2,X &<<5S
M,?[.OP_5=.231)KN'39%DL;>\U.[N(;7!SMBCDE940X 9% 5@ &! Q7I-% '
M&>'/A!X6\*:G87]A9737&GPM;V(O=2N;N.RC8!2MO'-(Z0_*H7]V%^7Y>G%4
MK?X"^!K34].OHM'E673+LWUA#_:%R;>RE+%B8(3)Y<2DG)1%"GC(X&/0** /
M.-2_9X\ ZM#=076C3R6=Q<-=M8C4[M;6.=F+&6*$2B.)\D_,BJ1N.#R:;\4_
M@AH?Q"T;Q*T=IY.NZII[6_FB]N+>WGF5&%N]S'&VR;8Q7!='( &.@%>DT4 8
M_@[1YO#WA#0]*N6C>XL;&"UD:(DH62-5)4D XR.,@5R6G?L_^"=*TZUTV"RU
M-](MF4QZ5<:[?SV7RL'4-;O.8F7< =K*1GM7HM% '*W?PN\+7\/B6&ZT>*YA
M\2.DFJ1S.[K<,J*B-@GY"H5<%,8*@CD9J/2_A3X8TFVUF&.PFNSK$!MK^XU&
M]GO+BXA*E?+::9WDV8)PH; R2!DFNNHH X2?X(^$;BUT^ VFH1M8VKV$-U!K
M%[%=&V9MQ@>=9A))&#T1V95[ "K^H_"OPOJ.F:/8?V7]A@T<%=.?2[B6QFM%
M*[66.6!D=58<, V&P,YP*ZRB@#D=#^$WA/PWJ.F7^G:2MO>Z<EPEO<>?*S_O
MRIF:0LQ\UW*J2[[FXZT1_"CPK%=07"Z7B:#6)=>C;[1+\M]("'EQN[AC\OW1
MG@5UU% '+ZC\,?#&KGQ+]MTB*['B-8EU19G=EN/*0)&<$X0J ,%,$$ ]1FJ<
M'P=\)PZ9KEB^GSWD>MP?9=0GO]0N;JYN(=NWRS/+(TH4 G"A@ 22,$FNTHH
MX;5?@EX,UFY:>YTF3,L,%O<107UQ##>1PC$2W,22!+@*/E_>AN..G%<U\2_A
M?K'B;Q"]U8:%X>U"T_LW^SX'FU6^TJ9$)):&X%L&6[M\X(B?8!EQ_$37KU%
M'BNL_ :XNOA1X7^&$365YX8M3;#5-3NY&6Z98I5E800A"H,C*5RT@V*Q&'KV
MJBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>nuvl-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-02-25T15:36:23.2191+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.nuvalent.com/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nuvl="http://www.nuvalent.com/20251231" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" namespace="http://xbrl.sec.gov/ecd/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" namespace="http://xbrl.sec.gov/cyd/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>75000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>75010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>75020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>75030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>75040 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>75050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>75060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity" id="DisclosureCybersecurity">
        <link:definition>995457 - Disclosure - Cybersecurity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>995467 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies1" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies1">
        <link:definition>995477 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/MarketableSecurities" id="MarketableSecurities">
        <link:definition>995487 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>995497 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>995507 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStock" id="ConvertiblePreferredStock">
        <link:definition>995517 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquity1" id="DisclosureEquity1">
        <link:definition>995527 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>995537 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995547 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>995557 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995567 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DefinedContributionPlan" id="DefinedContributionPlan">
        <link:definition>995577 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/RelatedParties" id="RelatedParties">
        <link:definition>995587 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995597 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995607 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995617 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/MarketableSecuritiesTables" id="MarketableSecuritiesTables">
        <link:definition>995627 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>995637 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>995647 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockTables" id="ConvertiblePreferredStockTables">
        <link:definition>995657 - Disclosure - Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
        <link:definition>995667 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>995677 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>995687 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995697 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" id="DisclosureNatureOfBusinessAdditionalInformationDetail">
        <link:definition>995707 - Disclosure - Nature of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" id="SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail">
        <link:definition>995717 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995727 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail" id="DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail">
        <link:definition>995737 - Disclosure - Marketable Securities - Summary of Marketable Securities by Security (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail" id="DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail">
        <link:definition>995747 - Disclosure - Marketable Securities - Summary of Contractual Maturities of Available-for-sale Debt Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail" id="DisclosureMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>995757 - Disclosure - Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" id="DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail">
        <link:definition>995767 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail" id="DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail">
        <link:definition>995777 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value of Company's Related Party Revenue Share Liability (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" id="FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>995787 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" id="DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
        <link:definition>995797 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail" id="DisclosureEquityAdditionalInformationDetail">
        <link:definition>995807 - Disclosure - Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail" id="ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail">
        <link:definition>995817 - Disclosure - Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail" id="ConvertiblePreferredStockAdditionalInformationDetail">
        <link:definition>995827 - Disclosure - Convertible Preferred Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail" id="StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail">
        <link:definition>995837 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail" id="StockBasedCompensationAdditionalInformationDetail">
        <link:definition>995847 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail" id="DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail">
        <link:definition>995857 - Disclosure - Stock-Based Compensation - Summary of Share Based Payment Award Stock Options Range of Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail" id="DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail">
        <link:definition>995867 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail">
        <link:definition>995877 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" id="DisclosureNetLossPerShareAdditionalInformationDetail">
        <link:definition>995887 - Disclosure - Net Loss Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>995897 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
        <link:definition>995907 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" id="IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail">
        <link:definition>995917 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" id="IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
        <link:definition>995927 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesSummaryOfValuationAllowanceDetail" id="IncomeTaxesSummaryOfValuationAllowanceDetail">
        <link:definition>995937 - Disclosure - Income Taxes - Summary of Valuation Allowance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>995947 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail" id="DisclosureSegmentInformationAdditionalInformationDetail">
        <link:definition>995957 - Disclosure - Segment Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" id="DisclosureSegmentInformationScheduleOfSegmentInformationDetails">
        <link:definition>995967 - Disclosure - Segment Information - Schedule of Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/CoverPage" xlink:href="nuvl-20251231.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets" xlink:href="nuvl-20251231.xsd#ConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="nuvl-20251231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="nuvl-20251231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="nuvl-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="nuvl-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows" xlink:href="nuvl-20251231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity" xlink:href="nuvl-20251231.xsd#DisclosureCybersecurity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:href="nuvl-20251231.xsd#DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:href="nuvl-20251231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="nuvl-20251231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail" xlink:href="nuvl-20251231.xsd#DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail" xlink:href="nuvl-20251231.xsd#DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:href="nuvl-20251231.xsd#DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail" xlink:href="nuvl-20251231.xsd#DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="nuvl-20251231.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail" xlink:href="nuvl-20251231.xsd#DisclosureEquityAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail" xlink:href="nuvl-20251231.xsd#ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail" xlink:href="nuvl-20251231.xsd#ConvertiblePreferredStockAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail" xlink:href="nuvl-20251231.xsd#StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="nuvl-20251231.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" xlink:href="nuvl-20251231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="nuvl-20251231.xsd#DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail" xlink:href="nuvl-20251231.xsd#IncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="nuvl-20251231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" xlink:href="nuvl-20251231.xsd#DisclosureSegmentInformationScheduleOfSegmentInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusiness" xlink:href="nuvl-20251231.xsd#DisclosureNatureOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies1" xlink:href="nuvl-20251231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/MarketableSecurities" xlink:href="nuvl-20251231.xsd#MarketableSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurements" xlink:href="nuvl-20251231.xsd#FairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="nuvl-20251231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStock" xlink:href="nuvl-20251231.xsd#ConvertiblePreferredStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquity1" xlink:href="nuvl-20251231.xsd#DisclosureEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensation" xlink:href="nuvl-20251231.xsd#StockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="nuvl-20251231.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxes" xlink:href="nuvl-20251231.xsd#IncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingencies" xlink:href="nuvl-20251231.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DefinedContributionPlan" xlink:href="nuvl-20251231.xsd#DefinedContributionPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/RelatedParties" xlink:href="nuvl-20251231.xsd#RelatedParties" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformation" xlink:href="nuvl-20251231.xsd#DisclosureSegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nuvl-20251231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="nuvl-20251231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/MarketableSecuritiesTables" xlink:href="nuvl-20251231.xsd#MarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsTables" xlink:href="nuvl-20251231.xsd#FairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="nuvl-20251231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockTables" xlink:href="nuvl-20251231.xsd#ConvertiblePreferredStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationTables" xlink:href="nuvl-20251231.xsd#StockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="nuvl-20251231.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesTables" xlink:href="nuvl-20251231.xsd#IncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="nuvl-20251231.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:href="nuvl-20251231.xsd#DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:href="nuvl-20251231.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail" xlink:href="nuvl-20251231.xsd#DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail" xlink:href="nuvl-20251231.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" xlink:href="nuvl-20251231.xsd#DisclosureNetLossPerShareAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" xlink:href="nuvl-20251231.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="nuvl-20251231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesSummaryOfValuationAllowanceDetail" xlink:href="nuvl-20251231.xsd#IncomeTaxesSummaryOfValuationAllowanceDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail" xlink:href="nuvl-20251231.xsd#DisclosureSegmentInformationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_PerformanceStockUnitsMember" xlink:label="nuvl_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NeladalkibMember" xlink:label="nuvl_NeladalkibMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" xlink:label="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityIssuanceCost" xlink:label="nuvl_EquityIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanAbstract" xlink:label="us-gaap_DefinedContributionPlanAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DiscoveryProgramsMember" xlink:label="nuvl_DiscoveryProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_OfferingCostsIncurredButNotYetPaid" xlink:label="nuvl_OfferingCostsIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_GovernmentSecuritiesMember" xlink:label="nuvl_GovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_Rule10B51TradingPlanMember" xlink:label="nuvl_Rule10B51TradingPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AlexandraBalcomMember" xlink:label="nuvl_AlexandraBalcomMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="us-gaap_AccruedInsuranceCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TrancheRightAxis" xlink:label="nuvl_TrancheRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_InterestAndOtherIncomeExpense" xlink:label="nuvl_InterestAndOtherIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TaxCreditCarryforwardExpirationYearStart" xlink:label="nuvl_TaxCreditCarryforwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_StockIssuanceCosts" xlink:label="nuvl_StockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_PreferredStockTrancheRightsMember" xlink:label="nuvl_PreferredStockTrancheRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="nuvl_AccruedExternalResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NetOperatingLossesMember" xlink:label="nuvl_NetOperatingLossesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ClassBConvertibleCommonStockMember" xlink:label="nuvl_ClassBConvertibleCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AnnaProtopapasMember" xlink:label="nuvl_AnnaProtopapasMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DueFromOneToThreeYearsMember" xlink:label="nuvl_DueFromOneToThreeYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RevenueSharingAgreementsMember" xlink:label="nuvl_RevenueSharingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_OperatingLossCarryforwardOffsetLimitPercentage" xlink:label="nuvl_OperatingLossCarryforwardOffsetLimitPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_InsurancePremiumFinancedByThirdParty" xlink:label="nuvl_InsurancePremiumFinancedByThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NumberOfTrancheRightsGrantedTemporaryEquity" xlink:label="nuvl_NumberOfTrancheRightsGrantedTemporaryEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DirectExpensesRelatedToProgram" xlink:label="nuvl_DirectExpensesRelatedToProgram"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_IssuanceOfPromissoryNoteToStockholder" xlink:label="nuvl_IssuanceOfPromissoryNoteToStockholder"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SaleOfStockOptionsAxis" xlink:label="nuvl_SaleOfStockOptionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_OperatingLossCarryforwardExpirationYearStart" xlink:label="nuvl_OperatingLossCarryforwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RelatedPartyRevenueShareLiabilityMember" xlink:label="nuvl_RelatedPartyRevenueShareLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ZidesamtinibMember" xlink:label="nuvl_ZidesamtinibMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityAdjustmentPromissoryNoteInterest" xlink:label="nuvl_EquityAdjustmentPromissoryNoteInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_FollowOnPublicOfferingMember" xlink:label="nuvl_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember" xlink:label="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_OrphanDrugCreditMember" xlink:label="nuvl_OrphanDrugCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityIssuanceCostsIncurredButNotYetPaid" xlink:label="nuvl_EquityIssuanceCostsIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart" xlink:label="nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ChangeInFairValueOfPreferredStockTrancheRights" xlink:label="nuvl_ChangeInFairValueOfPreferredStockTrancheRights"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ClassAAndClassBCommonStockOutstandingMember" xlink:label="nuvl_ClassAAndClassBCommonStockOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AccruedManufacturingExpenses" xlink:label="nuvl_AccruedManufacturingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ProbabilityOfAchievingMilestones" xlink:label="nuvl_ProbabilityOfAchievingMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AccruedOtherAndOtherLiabilitiesCurrent" xlink:label="nuvl_AccruedOtherAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RepaymentOfPromissoryNoteFromStockholder" xlink:label="nuvl_RepaymentOfPromissoryNoteFromStockholder"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TemporaryEquityFairValuePerShare" xlink:label="nuvl_TemporaryEquityFairValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses" xlink:label="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_HenryPelishMember" xlink:label="nuvl_HenryPelishMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TrancheRightDomain" xlink:label="nuvl_TrancheRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DueWithinOneYearMember" xlink:label="nuvl_DueWithinOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross" xlink:label="nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ConvertiblePreferredStockMeasurementInput" xlink:label="nuvl_ConvertiblePreferredStockMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SaleOfStockOptionsDomain" xlink:label="nuvl_SaleOfStockOptionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RelatedPartyRevenueShareLiability" xlink:label="nuvl_RelatedPartyRevenueShareLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_JamesPorterMember" xlink:label="nuvl_JamesPorterMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityAdjustmentPromissoryNote" xlink:label="nuvl_EquityAdjustmentPromissoryNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SeriesAConvertiblePreferredStockMember" xlink:label="nuvl_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SeriesBConvertiblePreferredStockMember" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability" xlink:label="nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TemporaryEquityIssuanceCosts" xlink:label="nuvl_TemporaryEquityIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_GovernmentAndAgencySecuritiesMember" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NonExpirableMember" xlink:label="nuvl_NonExpirableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NVL-330Member" xlink:label="nuvl_NVL-330Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ClassAAndClassBCommonStockMember" xlink:label="nuvl_ClassAAndClassBCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:label="nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock" xlink:label="nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ExcludingPerformanceStockUnitsMember" xlink:label="nuvl_ExcludingPerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross" xlink:label="nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ExpirableMember" xlink:label="nuvl_ExpirableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityIssuanceCosts" xlink:label="nuvl_EquityIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_PercentageOfNetSalesPayable" xlink:label="nuvl_PercentageOfNetSalesPayable"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock" xlink:label="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_PerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_PerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_PerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PSUs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Estimated fair value as of December 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Estimated fair value as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of promissory note from related stockholder party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment of Notes Receivable from Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, inputs, level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, par or stated value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred Stock Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance , Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance , Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant-date fair value of stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_NeladalkibMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Neladalkib [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_NeladalkibMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Neladalkib [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in unrecognized tax benefits, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of insurance costs financed by a third-party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Insurance Costs Financed By Third Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash outflow to repay a third-party for insurance premiums paid by the third-party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases recorded to income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increased valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities credit loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Valuation allowance as of beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Valuation allowance as of end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares issued, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Issuance Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The costs incurred during the period for the issuance of an equity security.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Contractual Maturities of Available-for-sale Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to Class A and Class B common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DiscoveryProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Discovery Programs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DiscoveryProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Discovery programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_OfferingCostsIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Costs Incurred But Not Yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_OfferingCostsIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future cash outflow to pay for offering costs that have been incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_OfferingCostsIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering costs included in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Fair Value of Company's Related Party Revenue Share Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_GovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_GovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_GovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_GovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Government securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sales Securities Due [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Securities Available For Sales Securities Due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 842 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of cross-border tax laws</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_Rule10B51TradingPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule 10B 5-1Trading Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_Rule10B51TradingPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule 10B 5-1Trading Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AlexandraBalcomMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alexandra Balcom [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AlexandraBalcomMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alexandra balcom.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Cancelled or forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedInsuranceCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Insurance, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedInsuranceCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax credit carryforwards research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TrancheRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TrancheRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TrancheRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche Right [Axis].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share Based Payment Award Stock Options Range of Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_InterestAndOtherIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income and other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_InterestAndOtherIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Other Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_InterestAndOtherIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of interest income and income (expense) related to nonoperating activities, classified as other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Loss Contingency Accrual, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Loss Contingency Accrual, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock (Series A and B), $0.0001 par value; no shares and 112,431,508 shares authorized at December 31, 2021 and 2020, respectively; no shares and 89,945,206 shares issued and outstanding at December 31, 2021 and 2020, respectively;</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TaxCreditCarryforwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax credit carryforward expiration year start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TaxCreditCarryforwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TaxCreditCarryforwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The year in which tax credit carryforwards begin to expire, in YYYY format.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of expense incurred for issuance of stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_PreferredStockTrancheRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock tranche rights [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_PreferredStockTrancheRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Tranche Rights [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_PreferredStockTrancheRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock tranche rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of preferred stock tranche rights upon settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Temporary Equity, Carrying Amount, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Settlement of preferred stock tranche rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification from liability to value of preferred stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value | $ / shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range of expected stock price volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedExternalResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued external research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedExternalResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued External Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedExternalResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development expenses from external sources. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_NetOperatingLossesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Losses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_NetOperatingLossesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Losses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_NetOperatingLossesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Operating Losses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon exercise of stock options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Elements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash investing and financing information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ClassBConvertibleCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class B Convertible Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ClassBConvertibleCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class B convertible common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ClassBConvertibleCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class B Convertible Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AnnaProtopapasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Anna Protopapas [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AnnaProtopapasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Anna Protopapas.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DueFromOneToThreeYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due From One To Three Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DueFromOneToThreeYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Due From One To Three Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DueFromOneToThreeYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due after one year through three years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted common stock shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding as of December 31,2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock to common stock upon initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RevenueSharingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Sharing Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RevenueSharingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue sharing agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development and clinical trial accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_OperatingLossCarryforwardOffsetLimitPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforward offset limit percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_OperatingLossCarryforwardOffsetLimitPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforward Offset Limit Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_OperatingLossCarryforwardOffsetLimitPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of annual taxable income that may be offset using net operating loss carryforwards, as a percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal (national) income tax effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Stock-Based Compensation Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nontaxable or nondeductible items, permanent adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Professional Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">General and administrative professional and consultant fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative professional and consultant fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of deferred tax assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities and sales of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement input, expected term [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Term [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of convertible preferred stock and preferred stock tranche rights, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Proceeds from issuance of convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of restricted common stock, vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total fair value of RSUs vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_InsurancePremiumFinancedByThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance premium financed by a third-party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_InsurancePremiumFinancedByThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Premium Financed By Third Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_InsurancePremiumFinancedByThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of insurance premiums financed by a third party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_NumberOfTrancheRightsGrantedTemporaryEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of tranche rights granted temporary equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_NumberOfTrancheRightsGrantedTemporaryEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Tranche Rights Granted Temporary Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_NumberOfTrancheRightsGrantedTemporaryEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of grant rights issued in connection with the issuance and sale of temporary equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Class B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, inputs, level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value Assets Measured on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance , Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance , Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 10)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Outstanding December 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Outstanding December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DirectExpensesRelatedToProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Expenses Related to Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DirectExpensesRelatedToProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of direct expense from external sources related to a specified program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DirectExpensesRelatedToProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct external expenses by program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_IssuanceOfPromissoryNoteToStockholder_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Issuance of promissory note to stockholder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_IssuanceOfPromissoryNoteToStockholder_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Promissory Note To Stockholder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_IssuanceOfPromissoryNoteToStockholder_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash outflow from the issuance of a promissory note to a stockholder.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in deferred tax asset valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in valuation allowances, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SaleOfStockOptionsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale Of Stock Options Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SaleOfStockOptionsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Options [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of Class A and Class B common stock outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_OperatingLossCarryforwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforward Expiration Year Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_OperatingLossCarryforwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The year in which operating loss carryforwards begin to expire, in YYYY format.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_OperatingLossCarryforwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforward expiration year start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan drug related tax credits, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug Related, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Orphan drug related tax credits, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RelatedPartyRevenueShareLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Revenue Share Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RelatedPartyRevenueShareLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party revenue share liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RelatedPartyRevenueShareLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Revenue Share Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of effective income tax rate reconciliation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ZidesamtinibMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Zidesamtinib [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ZidesamtinibMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Zidesamtinib [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax credits generated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits generated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in valuation allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value | $ / shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of presentation and consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwriters Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityAdjustmentPromissoryNoteInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Adjustment Promissory Note Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityAdjustmentPromissoryNoteInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) to stockholders' equity for the interest on a promissory note from a related party stockholder.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityAdjustmentPromissoryNoteInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on promissory note from related party stockholder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earliest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earliest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-On public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one stock option and incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Stock Option And Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Stock Option and Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_OrphanDrugCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Orphan drug credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_OrphanDrugCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan Drug Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_OrphanDrugCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Orphan Drug Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Other Segment Item, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of preferred stock tranche rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory note from stockholder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables from Stockholder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityIssuanceCostsIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Issuance Costs Incurred But Not Yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityIssuanceCostsIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future cash outflow to pay for costs associated with the issuance of equity securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityIssuanceCostsIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforward expiration year start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Tax Credit Carryforward Expiration Year Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The year in which research and development tax credit carryforwards begin to expire, in YYYY format.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other adjustments, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign tax effects, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of new shares of temporary equity issued during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of convertible preferred stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ChangeInFairValueOfPreferredStockTrancheRights_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of preferred stock tranche rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ChangeInFairValueOfPreferredStockTrancheRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of preferred stock tranche rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ChangeInFairValueOfPreferredStockTrancheRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Preferred Stock Tranche Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ChangeInFairValueOfPreferredStockTrancheRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of income (expense) related to a change in fair value of preferred stock tranche rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ChangeInFairValueOfPreferredStockTrancheRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in fair value of the Series A Tranche Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ClassAAndClassBCommonStockOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A And Class B Common Stock Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ClassAAndClassBCommonStockOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class A And Class B Common Stock Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ClassAAndClassBCommonStockOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class A And Class B Common Stock Outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value transfers in or out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-based compensation expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug Related, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan drug related tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Orphan drug related tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average expected stock price volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued manufacturing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Manufacturing Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ProbabilityOfAchievingMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The probability that specified milestones will be achieved during the period, as a percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ProbabilityOfAchievingMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability of achieving milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ProbabilityOfAchievingMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Probability Of Achieving Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedOtherAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Other and Other Liabilities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedOtherAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of expenses incurred but not yet paid classified as other and amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedOtherAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of changes in tax laws or rates enacted in the current period, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign tax effects</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of Class A and Class B common stock outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RepaymentOfPromissoryNoteFromStockholder_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment Of Promissory Note From Stockholder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RepaymentOfPromissoryNoteFromStockholder_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from repayment of promissory note to stockholder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RepaymentOfPromissoryNoteFromStockholder_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow from the repayment of a promissory note to a stockholder.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2023-07 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2023-27 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range of expected stock price volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TemporaryEquityFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock fair value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TemporaryEquityFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Fair Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TemporaryEquityFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The fair value per share of stock classified as temporary equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical and Other Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expenses and other research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical and other research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Valuation Allowance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. treasury bills [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_HenryPelishMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Henry Pelish [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_HenryPelishMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Henry pelish.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TrancheRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TrancheRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TrancheRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche Right [Domain].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the components of accrued liabilities and other current liabilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of changes in tax laws or rates enacted in the current period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Extinguishment of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently issued and adopted accounting pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of preferred stock to common stock upon initial public offering, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nontaxable or nondeductible items, permanent adjustments, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based award vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock awards granted, vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range of risk-free interest rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DueWithinOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due Within One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DueWithinOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Due within one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DueWithinOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due within one year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon public offering, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised Restricted Stock Award Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total number of shares issued during the period as a result of exercise of Stock Options and vesting of Restricted Stock Awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options and restricted stock unit vesting, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Nontaxable or nondeductible items, stock-based compensation, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement input, expected dividend rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Dividend Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ConvertiblePreferredStockMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ConvertiblePreferredStockMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ConvertiblePreferredStockMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of input used to measure convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sales Securities Due [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Securities Available For Sales Securities Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Section 162(M) Limitation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nontaxable or nondeductible items, Section 162(m) limitation, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to limitations under Section 162(m).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SaleOfStockOptionsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale Of Stock Options Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SaleOfStockOptionsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Options [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of note payable and accrued interest to Series A convertible preferred stock , Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RelatedPartyRevenueShareLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related party revenue share liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RelatedPartyRevenueShareLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The fair value of the liability pertaining to a revenue share arrangement with a related party, as of the balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of note payable and accrued interest to Series A convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value option for related party revenue share liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_JamesPorterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">James Porter [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_JamesPorterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">James porter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityAdjustmentPromissoryNote_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of promissory note from related party stockholder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityAdjustmentPromissoryNote_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Adjustment Promissory Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityAdjustmentPromissoryNote_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) to stockholders' equity for the issuance of a promissory note from a related party stockholder.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Description of income tax examination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrecognized compensation cost related to common stock options and unvested restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nontaxable or nondeductible items, stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Cancelled or forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of related party revenue share liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Fair Value Of Related Party Revenue Share Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to the change in fair value of a related party revenue share liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of related party revenue share liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of related party revenue share liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range of risk-free interest rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued employee compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average expected option term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-13 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D tax credit, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">R&amp;D tax credit, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, terms of conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Terms of Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock awards granted, expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of presentation and consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of expense incurred for issuance of temporary equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gains (losses) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">State income taxes, net of federal (national) income tax effect, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government And Agency Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government and agency securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government and agency securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of cross-border tax laws, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_NonExpirableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non expirable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_NonExpirableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non expirable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income tax provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_NVL-330Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NVL-330 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_NVL-330Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NVL-330 [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of common stock in follow-on public offering after underwriting discounts and commission and offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net proceeds from initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ClassAAndClassBCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class A and Class B Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ClassAAndClassBCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class A and Class B Common Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, by Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Term, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value option for related party revenue share liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued during period shares new shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon public offering, net, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock upon public offering, net, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred Stock Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted common stock vested shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock upon initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Convertible Preferred Stock To Common Stock Upon Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of convertible preferred stock converted to common stock upon the initial public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to Class A and Class B common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of notes payable and accrued interest for preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Settlement Of Notes Payable And Accrued Interest For Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of notes payable and accrued interest settled for preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">R&amp;D tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Corporate bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of equity issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ExcludingPerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Excluding Performance Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ExcludingPerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Excluding performance stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ExcludingPerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Excluding PSUs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options and restricted stock unit vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised Restricted Stock Award Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total value of shares issued during the period as a result of exercise of Stock Options and vesting of Restricted Stock Awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, inputs, level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities by Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ExpirableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expirable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ExpirableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expirable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Section 162(m) Limitation, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nontaxable or nondeductible items, Section 162(m) limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to limitations under Section 162(m).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Issuable Upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net accretion on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation arrangement by share based payment award annual increase percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The automatic increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year, as a percentage of shares outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Security, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gains (losses) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The costs incurred during the period for the issuance of an equity security.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_PercentageOfNetSalesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Sales Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_PercentageOfNetSalesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net sales payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_PercentageOfNetSalesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount the Company is obligated to pay, as a percentage of net sales of certain commercial products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of credit risk and of significant suppliers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Of Credit Risk And Of Significant Suppliers [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for credit risk and significant suppliers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Labor and Related Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Personnel-related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel-related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based payment weighted average period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Contractual Term, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_PerformanceStockUnitsMember" xlink:to="nuvl_PerformanceStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_NeladalkibMember" xlink:to="nuvl_NeladalkibMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" xlink:to="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_EquityIssuanceCost" xlink:to="nuvl_EquityIssuanceCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="us-gaap_DefinedContributionPlanAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_DiscoveryProgramsMember" xlink:to="nuvl_DiscoveryProgramsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_OfferingCostsIncurredButNotYetPaid" xlink:to="nuvl_OfferingCostsIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_GovernmentSecuritiesMember" xlink:to="nuvl_GovernmentSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" xlink:to="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_Rule10B51TradingPlanMember" xlink:to="nuvl_Rule10B51TradingPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_AlexandraBalcomMember" xlink:to="nuvl_AlexandraBalcomMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedInsuranceCurrent" xlink:to="us-gaap_AccruedInsuranceCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_TrancheRightAxis" xlink:to="nuvl_TrancheRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_InterestAndOtherIncomeExpense" xlink:to="nuvl_InterestAndOtherIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_TaxCreditCarryforwardExpirationYearStart" xlink:to="nuvl_TaxCreditCarryforwardExpirationYearStart_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_StockIssuanceCosts" xlink:to="nuvl_StockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_PreferredStockTrancheRightsMember" xlink:to="nuvl_PreferredStockTrancheRightsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:to="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_AccruedExternalResearchAndDevelopmentExpenses" xlink:to="nuvl_AccruedExternalResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_NetOperatingLossesMember" xlink:to="nuvl_NetOperatingLossesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ClassBConvertibleCommonStockMember" xlink:to="nuvl_ClassBConvertibleCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_AnnaProtopapasMember" xlink:to="nuvl_AnnaProtopapasMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_DueFromOneToThreeYearsMember" xlink:to="nuvl_DueFromOneToThreeYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_RevenueSharingAgreementsMember" xlink:to="nuvl_RevenueSharingAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_OperatingLossCarryforwardOffsetLimitPercentage" xlink:to="nuvl_OperatingLossCarryforwardOffsetLimitPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_InsurancePremiumFinancedByThirdParty" xlink:to="nuvl_InsurancePremiumFinancedByThirdParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_NumberOfTrancheRightsGrantedTemporaryEquity" xlink:to="nuvl_NumberOfTrancheRightsGrantedTemporaryEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_DirectExpensesRelatedToProgram" xlink:to="nuvl_DirectExpensesRelatedToProgram_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_IssuanceOfPromissoryNoteToStockholder" xlink:to="nuvl_IssuanceOfPromissoryNoteToStockholder_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_SaleOfStockOptionsAxis" xlink:to="nuvl_SaleOfStockOptionsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_OperatingLossCarryforwardExpirationYearStart" xlink:to="nuvl_OperatingLossCarryforwardExpirationYearStart_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent" xlink:to="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_RelatedPartyRevenueShareLiabilityMember" xlink:to="nuvl_RelatedPartyRevenueShareLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ZidesamtinibMember" xlink:to="nuvl_ZidesamtinibMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_EquityAdjustmentPromissoryNoteInterest" xlink:to="nuvl_EquityAdjustmentPromissoryNoteInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_FollowOnPublicOfferingMember" xlink:to="nuvl_FollowOnPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember" xlink:to="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_OrphanDrugCreditMember" xlink:to="nuvl_OrphanDrugCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_EquityIssuanceCostsIncurredButNotYetPaid" xlink:to="nuvl_EquityIssuanceCostsIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart" xlink:to="nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ChangeInFairValueOfPreferredStockTrancheRights" xlink:to="nuvl_ChangeInFairValueOfPreferredStockTrancheRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ClassAAndClassBCommonStockOutstandingMember" xlink:to="nuvl_ClassAAndClassBCommonStockOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount" xlink:to="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_AccruedManufacturingExpenses" xlink:to="nuvl_AccruedManufacturingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ProbabilityOfAchievingMilestones" xlink:to="nuvl_ProbabilityOfAchievingMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_AccruedOtherAndOtherLiabilitiesCurrent" xlink:to="nuvl_AccruedOtherAndOtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_RepaymentOfPromissoryNoteFromStockholder" xlink:to="nuvl_RepaymentOfPromissoryNoteFromStockholder_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202307Member" xlink:to="us-gaap_AccountingStandardsUpdate202307Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_TemporaryEquityFairValuePerShare" xlink:to="nuvl_TemporaryEquityFairValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses" xlink:to="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_HenryPelishMember" xlink:to="nuvl_HenryPelishMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_TrancheRightDomain" xlink:to="nuvl_TrancheRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_DueWithinOneYearMember" xlink:to="nuvl_DueWithinOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross" xlink:to="nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ConvertiblePreferredStockMeasurementInput" xlink:to="nuvl_ConvertiblePreferredStockMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:to="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent" xlink:to="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_SaleOfStockOptionsDomain" xlink:to="nuvl_SaleOfStockOptionsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_RelatedPartyRevenueShareLiability" xlink:to="nuvl_RelatedPartyRevenueShareLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_JamesPorterMember" xlink:to="nuvl_JamesPorterMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_EquityAdjustmentPromissoryNote" xlink:to="nuvl_EquityAdjustmentPromissoryNote_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_SeriesAConvertiblePreferredStockMember" xlink:to="nuvl_SeriesAConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_SeriesBConvertiblePreferredStockMember" xlink:to="nuvl_SeriesBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability" xlink:to="nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionFeatures" xlink:to="us-gaap_CommonStockConversionFeatures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_TemporaryEquityIssuanceCosts" xlink:to="nuvl_TemporaryEquityIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_GovernmentAndAgencySecuritiesMember" xlink:to="nuvl_GovernmentAndAgencySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_NonExpirableMember" xlink:to="nuvl_NonExpirableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_NVL-330Member" xlink:to="nuvl_NVL-330Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ClassAAndClassBCommonStockMember" xlink:to="nuvl_ClassAAndClassBCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:to="nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock" xlink:to="nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ExcludingPerformanceStockUnitsMember" xlink:to="nuvl_ExcludingPerformanceStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross" xlink:to="nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ExpirableMember" xlink:to="nuvl_ExpirableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount" xlink:to="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:to="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_EquityIssuanceCosts" xlink:to="nuvl_EquityIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_PercentageOfNetSalesPayable" xlink:to="nuvl_PercentageOfNetSalesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock" xlink:to="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RelatedPartyRevenueShareLiability" xlink:label="nuvl_RelatedPartyRevenueShareLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ClassBConvertibleCommonStockMember" xlink:label="nuvl_ClassBConvertibleCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="nuvl_RelatedPartyRevenueShareLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_ClassBConvertibleCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ClassBConvertibleCommonStockMember" xlink:label="nuvl_ClassBConvertibleCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_ClassBConvertibleCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_InterestAndOtherIncomeExpense" xlink:label="nuvl_InterestAndOtherIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="nuvl_InterestAndOtherIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SeriesAConvertiblePreferredStockMember" xlink:label="nuvl_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SeriesBConvertiblePreferredStockMember" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityAdjustmentPromissoryNoteInterest" xlink:label="nuvl_EquityAdjustmentPromissoryNoteInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross" xlink:label="nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross" xlink:label="nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityAdjustmentPromissoryNote" xlink:label="nuvl_EquityAdjustmentPromissoryNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_26"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_27"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_28"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_29"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nuvl_SeriesAConvertiblePreferredStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nuvl_SeriesBConvertiblePreferredStockMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_EquityAdjustmentPromissoryNoteInterest" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_EquityAdjustmentPromissoryNote" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_29" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_StockIssuanceCosts" xlink:label="nuvl_StockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SeriesBConvertiblePreferredStockMember" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TemporaryEquityIssuanceCosts" xlink:label="nuvl_TemporaryEquityIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_StockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_SeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_TemporaryEquityIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityIssuanceCostsIncurredButNotYetPaid" xlink:label="nuvl_EquityIssuanceCostsIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_InsurancePremiumFinancedByThirdParty" xlink:label="nuvl_InsurancePremiumFinancedByThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_IssuanceOfPromissoryNoteToStockholder" xlink:label="nuvl_IssuanceOfPromissoryNoteToStockholder"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_OfferingCostsIncurredButNotYetPaid" xlink:label="nuvl_OfferingCostsIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock" xlink:label="nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:label="nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RepaymentOfPromissoryNoteFromStockholder" xlink:label="nuvl_RepaymentOfPromissoryNoteFromStockholder"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" xlink:label="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="nuvl_EquityIssuanceCostsIncurredButNotYetPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="nuvl_InsurancePremiumFinancedByThirdParty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nuvl_IssuanceOfPromissoryNoteToStockholder" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="nuvl_OfferingCostsIncurredButNotYetPaid" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nuvl_RepaymentOfPromissoryNoteFromStockholder" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember" xlink:label="ecd_AllTradingArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_Rule10B51TradingPlanMember" xlink:label="nuvl_Rule10B51TradingPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AlexandraBalcomMember" xlink:label="nuvl_AlexandraBalcomMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_HenryPelishMember" xlink:label="nuvl_HenryPelishMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_JamesPorterMember" xlink:label="nuvl_JamesPorterMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AnnaProtopapasMember" xlink:label="nuvl_AnnaProtopapasMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="nuvl_Rule10B51TradingPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="nuvl_AlexandraBalcomMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="nuvl_HenryPelishMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="nuvl_JamesPorterMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="nuvl_AnnaProtopapasMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/MarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DefinedContributionPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanAbstract" xlink:label="us-gaap_DefinedContributionPlanAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/RelatedParties" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock" xlink:label="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended"/>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/MarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SaleOfStockOptionsAxis" xlink:label="nuvl_SaleOfStockOptionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SaleOfStockOptionsDomain" xlink:label="nuvl_SaleOfStockOptionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvl_SaleOfStockOptionsAxis" xlink:to="nuvl_SaleOfStockOptionsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvl_SaleOfStockOptionsDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="nuvl_SaleOfStockOptionsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_GovernmentAndAgencySecuritiesMember" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvl_GovernmentAndAgencySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DueWithinOneYearMember" xlink:label="nuvl_DueWithinOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DueFromOneToThreeYearsMember" xlink:label="nuvl_DueFromOneToThreeYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" xlink:to="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:to="nuvl_DueWithinOneYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:to="nuvl_DueFromOneToThreeYearsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RelatedPartyRevenueShareLiabilityMember" xlink:label="nuvl_RelatedPartyRevenueShareLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_GovernmentSecuritiesMember" xlink:label="nuvl_GovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_GovernmentAndAgencySecuritiesMember" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="nuvl_RelatedPartyRevenueShareLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nuvl_GovernmentSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nuvl_GovernmentAndAgencySecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_PreferredStockTrancheRightsMember" xlink:label="nuvl_PreferredStockTrancheRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RelatedPartyRevenueShareLiabilityMember" xlink:label="nuvl_RelatedPartyRevenueShareLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="nuvl_PreferredStockTrancheRightsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="nuvl_RelatedPartyRevenueShareLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RelatedPartyRevenueShareLiabilityMember" xlink:label="nuvl_RelatedPartyRevenueShareLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TrancheRightAxis" xlink:label="nuvl_TrancheRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TrancheRightDomain" xlink:label="nuvl_TrancheRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TemporaryEquityFairValuePerShare" xlink:label="nuvl_TemporaryEquityFairValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SeriesAConvertiblePreferredStockMember" xlink:label="nuvl_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ConvertiblePreferredStockMeasurementInput" xlink:label="nuvl_ConvertiblePreferredStockMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ProbabilityOfAchievingMilestones" xlink:label="nuvl_ProbabilityOfAchievingMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ChangeInFairValueOfPreferredStockTrancheRights" xlink:label="nuvl_ChangeInFairValueOfPreferredStockTrancheRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="nuvl_RelatedPartyRevenueShareLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvl_TrancheRightAxis" xlink:to="nuvl_TrancheRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="nuvl_TemporaryEquityFairValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="nuvl_ConvertiblePreferredStockMeasurementInput" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="nuvl_TrancheRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="nuvl_ProbabilityOfAchievingMilestones" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="nuvl_ChangeInFairValueOfPreferredStockTrancheRights" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses" xlink:label="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AccruedManufacturingExpenses" xlink:label="nuvl_AccruedManufacturingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="nuvl_AccruedExternalResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="us-gaap_AccruedInsuranceCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AccruedOtherAndOtherLiabilitiesCurrent" xlink:label="nuvl_AccruedOtherAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nuvl_AccruedManufacturingExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nuvl_AccruedExternalResearchAndDevelopmentExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedInsuranceCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nuvl_AccruedOtherAndOtherLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_FollowOnPublicOfferingMember" xlink:label="nuvl_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityIssuanceCost" xlink:label="nuvl_EquityIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityIssuanceCosts" xlink:label="nuvl_EquityIssuanceCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nuvl_FollowOnPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nuvl_EquityIssuanceCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nuvl_EquityIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TrancheRightAxis" xlink:label="nuvl_TrancheRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TrancheRightDomain" xlink:label="nuvl_TrancheRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SeriesBConvertiblePreferredStockMember" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NumberOfTrancheRightsGrantedTemporaryEquity" xlink:label="nuvl_NumberOfTrancheRightsGrantedTemporaryEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvl_TrancheRightAxis" xlink:to="nuvl_TrancheRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_SeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="nuvl_TrancheRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nuvl_NumberOfTrancheRightsGrantedTemporaryEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember" xlink:label="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ClassAAndClassBCommonStockOutstandingMember" xlink:label="nuvl_ClassAAndClassBCommonStockOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ClassAAndClassBCommonStockMember" xlink:label="nuvl_ClassAAndClassBCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ExcludingPerformanceStockUnitsMember" xlink:label="nuvl_ExcludingPerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_PerformanceStockUnitsMember" xlink:label="nuvl_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nuvl_ClassAAndClassBCommonStockOutstandingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_ClassAAndClassBCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvl_ExcludingPerformanceStockUnitsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvl_PerformanceStockUnitsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_CommonStockVotingRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_CommonStockConversionFeatures" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ExpirableMember" xlink:label="nuvl_ExpirableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_OrphanDrugCreditMember" xlink:label="nuvl_OrphanDrugCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NonExpirableMember" xlink:label="nuvl_NonExpirableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NetOperatingLossesMember" xlink:label="nuvl_NetOperatingLossesMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_OperatingLossCarryforwardExpirationYearStart" xlink:label="nuvl_OperatingLossCarryforwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_OperatingLossCarryforwardOffsetLimitPercentage" xlink:label="nuvl_OperatingLossCarryforwardOffsetLimitPercentage"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TaxCreditCarryforwardExpirationYearStart" xlink:label="nuvl_TaxCreditCarryforwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart" xlink:label="nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="nuvl_ExpirableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="nuvl_OrphanDrugCreditMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="nuvl_NonExpirableMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="nuvl_NetOperatingLossesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="nuvl_OperatingLossCarryforwardExpirationYearStart" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="nuvl_OperatingLossCarryforwardOffsetLimitPercentage" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="nuvl_TaxCreditCarryforwardExpirationYearStart" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_OpenTaxYear" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability" xlink:label="nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesSummaryOfValuationAllowanceDetail" xlink:title="presentationLink" xlink:type="extended"/>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_PercentageOfNetSalesPayable" xlink:label="nuvl_PercentageOfNetSalesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RevenueSharingAgreementsMember" xlink:label="nuvl_RevenueSharingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="nuvl_PercentageOfNetSalesPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nuvl_RevenueSharingAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ZidesamtinibMember" xlink:label="nuvl_ZidesamtinibMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DirectExpensesRelatedToProgram" xlink:label="nuvl_DirectExpensesRelatedToProgram"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NeladalkibMember" xlink:label="nuvl_NeladalkibMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NVL-330Member" xlink:label="nuvl_NVL-330Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DiscoveryProgramsMember" xlink:label="nuvl_DiscoveryProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvl_ZidesamtinibMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="nuvl_DirectExpensesRelatedToProgram" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvl_NeladalkibMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_LaborAndRelatedExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvl_NVL-330Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvl_DiscoveryProgramsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ProfessionalFees" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/CoverPage">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RelatedPartyRevenueShareLiability" xlink:label="nuvl_RelatedPartyRevenueShareLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ClassBConvertibleCommonStockMember" xlink:label="nuvl_ClassBConvertibleCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="nuvl_RelatedPartyRevenueShareLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_ClassBConvertibleCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ClassBConvertibleCommonStockMember" xlink:label="nuvl_ClassBConvertibleCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_ClassBConvertibleCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_InterestAndOtherIncomeExpense" xlink:label="nuvl_InterestAndOtherIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="nuvl_InterestAndOtherIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SeriesAConvertiblePreferredStockMember" xlink:label="nuvl_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SeriesBConvertiblePreferredStockMember" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityAdjustmentPromissoryNoteInterest" xlink:label="nuvl_EquityAdjustmentPromissoryNoteInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross" xlink:label="nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross" xlink:label="nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityAdjustmentPromissoryNote" xlink:label="nuvl_EquityAdjustmentPromissoryNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nuvl_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nuvl_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_EquityAdjustmentPromissoryNoteInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_EquityAdjustmentPromissoryNote" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_StockIssuanceCosts" xlink:label="nuvl_StockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SeriesBConvertiblePreferredStockMember" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TemporaryEquityIssuanceCosts" xlink:label="nuvl_TemporaryEquityIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_StockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_TemporaryEquityIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityIssuanceCostsIncurredButNotYetPaid" xlink:label="nuvl_EquityIssuanceCostsIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_InsurancePremiumFinancedByThirdParty" xlink:label="nuvl_InsurancePremiumFinancedByThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_IssuanceOfPromissoryNoteToStockholder" xlink:label="nuvl_IssuanceOfPromissoryNoteToStockholder"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_OfferingCostsIncurredButNotYetPaid" xlink:label="nuvl_OfferingCostsIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock" xlink:label="nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:label="nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RepaymentOfPromissoryNoteFromStockholder" xlink:label="nuvl_RepaymentOfPromissoryNoteFromStockholder"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" xlink:label="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="nuvl_EquityIssuanceCostsIncurredButNotYetPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="nuvl_InsurancePremiumFinancedByThirdParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nuvl_IssuanceOfPromissoryNoteToStockholder" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="nuvl_OfferingCostsIncurredButNotYetPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nuvl_RepaymentOfPromissoryNoteFromStockholder" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember" xlink:label="ecd_AllTradingArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_Rule10B51TradingPlanMember" xlink:label="nuvl_Rule10B51TradingPlanMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="nuvl_Rule10B51TradingPlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AlexandraBalcomMember" xlink:label="nuvl_AlexandraBalcomMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_HenryPelishMember" xlink:label="nuvl_HenryPelishMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_JamesPorterMember" xlink:label="nuvl_JamesPorterMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AnnaProtopapasMember" xlink:label="nuvl_AnnaProtopapasMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="nuvl_AlexandraBalcomMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="nuvl_HenryPelishMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="nuvl_JamesPorterMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="nuvl_AnnaProtopapasMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SaleOfStockOptionsAxis" xlink:label="nuvl_SaleOfStockOptionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SaleOfStockOptionsDomain" xlink:label="nuvl_SaleOfStockOptionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SaleOfStockOptionsDomain" xlink:label="nuvl_SaleOfStockOptionsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="nuvl_SaleOfStockOptionsAxis" xlink:to="nuvl_SaleOfStockOptionsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="nuvl_SaleOfStockOptionsAxis" xlink:to="nuvl_SaleOfStockOptionsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvl_SaleOfStockOptionsDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="nuvl_SaleOfStockOptionsAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"/>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_GovernmentAndAgencySecuritiesMember" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvl_GovernmentAndAgencySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DueWithinOneYearMember" xlink:label="nuvl_DueWithinOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DueFromOneToThreeYearsMember" xlink:label="nuvl_DueFromOneToThreeYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" xlink:to="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" xlink:to="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:to="nuvl_DueWithinOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:to="nuvl_DueFromOneToThreeYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RelatedPartyRevenueShareLiabilityMember" xlink:label="nuvl_RelatedPartyRevenueShareLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_GovernmentSecuritiesMember" xlink:label="nuvl_GovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_GovernmentAndAgencySecuritiesMember" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="nuvl_RelatedPartyRevenueShareLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nuvl_GovernmentSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nuvl_GovernmentAndAgencySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_PreferredStockTrancheRightsMember" xlink:label="nuvl_PreferredStockTrancheRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RelatedPartyRevenueShareLiabilityMember" xlink:label="nuvl_RelatedPartyRevenueShareLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="nuvl_PreferredStockTrancheRightsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="nuvl_RelatedPartyRevenueShareLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RelatedPartyRevenueShareLiabilityMember" xlink:label="nuvl_RelatedPartyRevenueShareLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TrancheRightAxis" xlink:label="nuvl_TrancheRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TrancheRightDomain" xlink:label="nuvl_TrancheRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TrancheRightDomain" xlink:label="nuvl_TrancheRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TemporaryEquityFairValuePerShare" xlink:label="nuvl_TemporaryEquityFairValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SeriesAConvertiblePreferredStockMember" xlink:label="nuvl_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ConvertiblePreferredStockMeasurementInput" xlink:label="nuvl_ConvertiblePreferredStockMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ProbabilityOfAchievingMilestones" xlink:label="nuvl_ProbabilityOfAchievingMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ChangeInFairValueOfPreferredStockTrancheRights" xlink:label="nuvl_ChangeInFairValueOfPreferredStockTrancheRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="nuvl_RelatedPartyRevenueShareLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="nuvl_TrancheRightAxis" xlink:to="nuvl_TrancheRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="nuvl_TrancheRightAxis" xlink:to="nuvl_TrancheRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="nuvl_TemporaryEquityFairValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="nuvl_ConvertiblePreferredStockMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="nuvl_TrancheRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="nuvl_ProbabilityOfAchievingMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="nuvl_ChangeInFairValueOfPreferredStockTrancheRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_FollowOnPublicOfferingMember" xlink:label="nuvl_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityIssuanceCost" xlink:label="nuvl_EquityIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EquityIssuanceCosts" xlink:label="nuvl_EquityIssuanceCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nuvl_FollowOnPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nuvl_EquityIssuanceCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nuvl_EquityIssuanceCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TrancheRightAxis" xlink:label="nuvl_TrancheRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TrancheRightDomain" xlink:label="nuvl_TrancheRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_SeriesBConvertiblePreferredStockMember" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NumberOfTrancheRightsGrantedTemporaryEquity" xlink:label="nuvl_NumberOfTrancheRightsGrantedTemporaryEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="nuvl_TrancheRightAxis" xlink:to="nuvl_TrancheRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="nuvl_TrancheRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nuvl_NumberOfTrancheRightsGrantedTemporaryEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ExcludingPerformanceStockUnitsMember" xlink:label="nuvl_ExcludingPerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember" xlink:label="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ClassAAndClassBCommonStockOutstandingMember" xlink:label="nuvl_ClassAAndClassBCommonStockOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_PerformanceStockUnitsMember" xlink:label="nuvl_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ClassAAndClassBCommonStockMember" xlink:label="nuvl_ClassAAndClassBCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvl_ExcludingPerformanceStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nuvl_ClassAAndClassBCommonStockOutstandingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvl_PerformanceStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_ClassAAndClassBCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ExpirableMember" xlink:label="nuvl_ExpirableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_OrphanDrugCreditMember" xlink:label="nuvl_OrphanDrugCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NonExpirableMember" xlink:label="nuvl_NonExpirableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NetOperatingLossesMember" xlink:label="nuvl_NetOperatingLossesMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_OperatingLossCarryforwardExpirationYearStart" xlink:label="nuvl_OperatingLossCarryforwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_OperatingLossCarryforwardOffsetLimitPercentage" xlink:label="nuvl_OperatingLossCarryforwardOffsetLimitPercentage"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_TaxCreditCarryforwardExpirationYearStart" xlink:label="nuvl_TaxCreditCarryforwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart" xlink:label="nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="nuvl_ExpirableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="nuvl_OrphanDrugCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="nuvl_NonExpirableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="nuvl_NetOperatingLossesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="nuvl_OperatingLossCarryforwardExpirationYearStart" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="nuvl_OperatingLossCarryforwardOffsetLimitPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="nuvl_TaxCreditCarryforwardExpirationYearStart" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_PercentageOfNetSalesPayable" xlink:label="nuvl_PercentageOfNetSalesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RevenueSharingAgreementsMember" xlink:label="nuvl_RevenueSharingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="nuvl_PercentageOfNetSalesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nuvl_RevenueSharingAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_ZidesamtinibMember" xlink:label="nuvl_ZidesamtinibMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DirectExpensesRelatedToProgram" xlink:label="nuvl_DirectExpensesRelatedToProgram"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NeladalkibMember" xlink:label="nuvl_NeladalkibMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_NVL-330Member" xlink:label="nuvl_NVL-330Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DiscoveryProgramsMember" xlink:label="nuvl_DiscoveryProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvl_ZidesamtinibMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="nuvl_DirectExpensesRelatedToProgram" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvl_NeladalkibMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_LaborAndRelatedExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvl_NVL-330Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvl_DiscoveryProgramsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ProfessionalFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202309Member" xlink:label="us-gaap_AccountingStandardsUpdate202309Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmConsolidatedMember" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmConsolidatedMember"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="nuvl_RelatedPartyRevenueShareLiability" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RelatedPartyRevenueShareLiability" xlink:label="nuvl_RelatedPartyRevenueShareLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="nuvl_InterestAndOtherIncomeExpense" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_InterestAndOtherIncomeExpense" xlink:label="nuvl_InterestAndOtherIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nuvl_RepaymentOfPromissoryNoteFromStockholder" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nuvl_IssuanceOfPromissoryNoteToStockholder" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="12" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" xlink:label="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_RepaymentOfPromissoryNoteFromStockholder" xlink:label="nuvl_RepaymentOfPromissoryNoteFromStockholder"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_IssuanceOfPromissoryNoteToStockholder" xlink:label="nuvl_IssuanceOfPromissoryNoteToStockholder"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="2" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="nuvl_AccruedManufacturingExpenses" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="nuvl_AccruedOtherAndOtherLiabilitiesCurrent" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses" xlink:label="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AccruedManufacturingExpenses" xlink:label="nuvl_AccruedManufacturingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_AccruedOtherAndOtherLiabilitiesCurrent" xlink:label="nuvl_AccruedOtherAndOtherLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="15" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent" xlink:label="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20251231.xsd#nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability" xlink:label="nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_LaborAndRelatedExpense" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfessionalFees" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="nuvl_EquityAdjustmentPromissoryNoteInterest" name="EquityAdjustmentPromissoryNoteInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock" name="ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_AnnaProtopapasMember" name="AnnaProtopapasMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_StockIssuanceCosts" name="StockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_RevenueSharingAgreementsMember" name="RevenueSharingAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvl_GovernmentSecuritiesMember" name="GovernmentSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_InsurancePremiumFinancedByThirdParty" name="InsurancePremiumFinancedByThirdParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_DueFromOneToThreeYearsMember" name="DueFromOneToThreeYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_PerformanceStockUnitsMember" name="PerformanceStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent" name="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_AlexandraBalcomMember" name="AlexandraBalcomMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_GovernmentAndAgencySecuritiesMember" name="GovernmentAndAgencySecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_AccruedManufacturingExpenses" name="AccruedManufacturingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount" name="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_EquityIssuanceCost" name="EquityIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvl_AccruedOtherAndOtherLiabilitiesCurrent" name="AccruedOtherAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_ExpirableMember" name="ExpirableMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember" name="TwoThousandTwentyOneStockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross" name="StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_DirectExpensesRelatedToProgram" name="DirectExpensesRelatedToProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvl_ConvertiblePreferredStockMeasurementInput" name="ConvertiblePreferredStockMeasurementInput" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability" name="DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvl_EquityIssuanceCosts" name="EquityIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_PreferredStockTrancheRightsMember" name="PreferredStockTrancheRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock" name="SettlementOfNotesPayableAndAccruedInterestForPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_RelatedPartyRevenueShareLiabilityMember" name="RelatedPartyRevenueShareLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_IssuanceOfPromissoryNoteToStockholder" name="IssuanceOfPromissoryNoteToStockholder" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" name="RepaymentsOfInsuranceCostsFinancedByThirdParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_TemporaryEquityIssuanceCosts" name="TemporaryEquityIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_RelatedPartyRevenueShareLiability" name="RelatedPartyRevenueShareLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_ZidesamtinibMember" name="ZidesamtinibMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_OperatingLossCarryforwardOffsetLimitPercentage" name="OperatingLossCarryforwardOffsetLimitPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_TemporaryEquityFairValuePerShare" name="TemporaryEquityFairValuePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_TaxCreditCarryforwardExpirationYearStart" name="TaxCreditCarryforwardExpirationYearStart" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_ClassAAndClassBCommonStockMember" name="ClassAAndClassBCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_InterestAndOtherIncomeExpense" name="InterestAndOtherIncomeExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_OperatingLossCarryforwardExpirationYearStart" name="OperatingLossCarryforwardExpirationYearStart" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_NonExpirableMember" name="NonExpirableMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_EquityIssuanceCostsIncurredButNotYetPaid" name="EquityIssuanceCostsIncurredButNotYetPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_ClassAAndClassBCommonStockOutstandingMember" name="ClassAAndClassBCommonStockOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_JamesPorterMember" name="JamesPorterMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross" name="StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_DueWithinOneYearMember" name="DueWithinOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_OfferingCostsIncurredButNotYetPaid" name="OfferingCostsIncurredButNotYetPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_TrancheRightAxis" name="TrancheRightAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_ExcludingPerformanceStockUnitsMember" name="ExcludingPerformanceStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_AccruedExternalResearchAndDevelopmentExpenses" name="AccruedExternalResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_ChangeInFairValueOfPreferredStockTrancheRights" name="ChangeInFairValueOfPreferredStockTrancheRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvl_NumberOfTrancheRightsGrantedTemporaryEquity" name="NumberOfTrancheRightsGrantedTemporaryEquity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_Rule10B51TradingPlanMember" name="Rule10B51TradingPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart" name="ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_ClassBConvertibleCommonStockMember" name="ClassBConvertibleCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_SaleOfStockOptionsDomain" name="SaleOfStockOptionsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_OrphanDrugCreditMember" name="OrphanDrugCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_NetOperatingLossesMember" name="NetOperatingLossesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_ProbabilityOfAchievingMilestones" name="ProbabilityOfAchievingMilestones" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_RepaymentOfPromissoryNoteFromStockholder" name="RepaymentOfPromissoryNoteFromStockholder" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvl_TrancheRightDomain" name="TrancheRightDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_HenryPelishMember" name="HenryPelishMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" name="ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_EquityAdjustmentPromissoryNote" name="EquityAdjustmentPromissoryNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvl_SaleOfStockOptionsAxis" name="SaleOfStockOptionsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_DiscoveryProgramsMember" name="DiscoveryProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses" name="AccruedClinicalAndOtherResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_NVL-330Member" name="NVL-330Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_NeladalkibMember" name="NeladalkibMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_PercentageOfNetSalesPayable" name="PercentageOfNetSalesPayable" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" name="DebtSecuritiesAvailableForSalesSecuritiesDueDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" name="DebtSecuritiesAvailableForSalesSecuritiesDueAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 19, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NUVALENT, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001861560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-5112298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Broadway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">14th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">357-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NUVL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinions on the Consolidated Financial Statements and Internal Control Over Financial Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Nuvalent, Inc. and subsidiary (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2025, and the related notes (collectively, the consolidated financial statements). We also have audited the Company&#8217;s internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025 based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the registrant&#8217;s Proxy Statement for its 2026 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,181,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 261,745<span></span>
</td>
<td class="nump">$ 145,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,110,207<span></span>
</td>
<td class="nump">972,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">20,474<span></span>
</td>
<td class="nump">14,146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,392,426<span></span>
</td>
<td class="nump">1,132,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">20,279<span></span>
</td>
<td class="nump">9,304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,412,705<span></span>
</td>
<td class="nump">1,141,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">30,158<span></span>
</td>
<td class="nump">5,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">61,013<span></span>
</td>
<td class="nump">48,795<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">91,171<span></span>
</td>
<td class="nump">54,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_RelatedPartyRevenueShareLiability', window );">Related party revenue share liability</a></td>
<td class="nump">73,160<span></span>
</td>
<td class="nump">17,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">164,366<span></span>
</td>
<td class="nump">71,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,218,407<span></span>
</td>
<td class="nump">1,616,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">2,353<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(972,429)<span></span>
</td>
<td class="num">(547,052)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">1,248,339<span></span>
</td>
<td class="nump">1,069,792<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">1,412,705<span></span>
</td>
<td class="nump">1,141,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nuvl_ClassBConvertibleCommonStockMember', window );">Class B Convertible Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_RelatedPartyRevenueShareLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of the liability pertaining to a revenue share arrangement with a related party, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_RelatedPartyRevenueShareLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nuvl_ClassBConvertibleCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nuvl_ClassBConvertibleCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">140,000,000<span></span>
</td>
<td class="nump">140,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">72,804,111<span></span>
</td>
<td class="nump">65,909,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">72,804,111<span></span>
</td>
<td class="nump">65,909,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nuvl_ClassBConvertibleCommonStockMember', window );">Class B Convertible Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">5,435,254<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">5,435,254<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nuvl_ClassBConvertibleCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nuvl_ClassBConvertibleCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 306,970<span></span>
</td>
<td class="nump">$ 217,774<span></span>
</td>
<td class="nump">$ 113,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">107,337<span></span>
</td>
<td class="nump">62,594<span></span>
</td>
<td class="nump">36,249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">414,307<span></span>
</td>
<td class="nump">280,368<span></span>
</td>
<td class="nump">149,492<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(414,307)<span></span>
</td>
<td class="num">(280,368)<span></span>
</td>
<td class="num">(149,492)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of related party revenue share liability</a></td>
<td class="num">(55,220)<span></span>
</td>
<td class="num">(17,940)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_InterestAndOtherIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="nump">44,735<span></span>
</td>
<td class="nump">38,316<span></span>
</td>
<td class="nump">23,273<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(10,485)<span></span>
</td>
<td class="nump">20,376<span></span>
</td>
<td class="nump">23,273<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(424,792)<span></span>
</td>
<td class="num">(259,992)<span></span>
</td>
<td class="num">(126,219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">764<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (425,377)<span></span>
</td>
<td class="num">$ (260,756)<span></span>
</td>
<td class="num">$ (126,219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to Class A and Class B common stockholders, basic</a></td>
<td class="num">$ (5.85)<span></span>
</td>
<td class="num">$ (3.93)<span></span>
</td>
<td class="num">$ (2.17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to Class A and Class B common stockholders, diluted</a></td>
<td class="num">$ (5.85)<span></span>
</td>
<td class="num">$ (3.93)<span></span>
</td>
<td class="num">$ (2.17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of Class A and Class B common stock outstanding, basic</a></td>
<td class="nump">72,686,749<span></span>
</td>
<td class="nump">66,408,807<span></span>
</td>
<td class="nump">58,223,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of Class A and Class B common stock outstanding, diluted</a></td>
<td class="nump">72,686,749<span></span>
</td>
<td class="nump">66,408,807<span></span>
</td>
<td class="nump">58,223,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (425,377)<span></span>
</td>
<td class="num">$ (260,756)<span></span>
</td>
<td class="num">$ (126,219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gains (losses) on marketable securities</a></td>
<td class="nump">2,412<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (422,965)<span></span>
</td>
<td class="num">$ (260,846)<span></span>
</td>
<td class="num">$ (125,694)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_InterestAndOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income and income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_InterestAndOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Common stock [Member] </div>
<div>Common Class A [Member]</div>
</th>
<th class="th">
<div>Common stock [Member] </div>
<div>Common Class B [Member]</div>
</th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance , Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,233,701<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 462,978<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 623,543<span></span>
</td>
<td class="num">$ (494)<span></span>
</td>
<td class="num">$ (160,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon public offering, net, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,160,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon public offering, net</a></td>
<td class="nump">323,534<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">13,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gains (losses) on marketable securities</a></td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">25,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(126,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126,219)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance , Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,629,896<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">700,561<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">986,819<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(286,296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon public offering, net, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon public offering, net</a></td>
<td class="nump">540,012<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,518,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">28,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gains (losses) on marketable securities</a></td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">60,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(260,756)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(260,756)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance , Shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,909,564<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2024</a></td>
<td class="nump">1,069,792<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,616,895<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(547,052)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon public offering, net, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,950,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon public offering, net</a></td>
<td class="nump">$ 471,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, Shares</a></td>
<td class="nump">1,672,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross', window );">Issuance of common stock upon exercise of stock options and restricted stock unit vesting, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,925,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross', window );">Issuance of common stock upon exercise of stock options and restricted stock unit vesting</a></td>
<td class="nump">$ 42,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">1,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gains (losses) on marketable securities</a></td>
<td class="nump">2,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">86,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(425,377)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(425,377)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance , Shares at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,804,111<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 1,248,339<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2,218,407<span></span>
</td>
<td class="nump">$ 2,353<span></span>
</td>
<td class="num">$ (972,429)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period as a result of exercise of Stock Options and vesting of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total value of shares issued during the period as a result of exercise of Stock Options and vesting of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (425,377)<span></span>
</td>
<td class="num">$ (260,756)<span></span>
</td>
<td class="num">$ (126,219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">86,502<span></span>
</td>
<td class="nump">60,579<span></span>
</td>
<td class="nump">25,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion on marketable securities</a></td>
<td class="num">(11,107)<span></span>
</td>
<td class="num">(14,669)<span></span>
</td>
<td class="num">(10,109)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of related party revenue share liability</a></td>
<td class="nump">55,220<span></span>
</td>
<td class="nump">17,940<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(6,342)<span></span>
</td>
<td class="num">(7,563)<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(10,508)<span></span>
</td>
<td class="num">(3,408)<span></span>
</td>
<td class="num">(1,428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">24,599<span></span>
</td>
<td class="num">(4,049)<span></span>
</td>
<td class="nump">2,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">11,459<span></span>
</td>
<td class="nump">26,862<span></span>
</td>
<td class="nump">9,641<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(275,209)<span></span>
</td>
<td class="num">(185,064)<span></span>
</td>
<td class="num">(99,739)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(1,057,766)<span></span>
</td>
<td class="num">(1,024,963)<span></span>
</td>
<td class="num">(459,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities and sales of marketable securities</a></td>
<td class="nump">933,689<span></span>
</td>
<td class="nump">451,449<span></span>
</td>
<td class="nump">315,959<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(124,077)<span></span>
</td>
<td class="num">(573,514)<span></span>
</td>
<td class="num">(143,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">515,722<span></span>
</td>
<td class="nump">569,987<span></span>
</td>
<td class="nump">338,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of equity issuance costs</a></td>
<td class="num">(382)<span></span>
</td>
<td class="num">(483)<span></span>
</td>
<td class="num">(856)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty', window );">Payments of insurance costs financed by a third-party</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(622)<span></span>
</td>
<td class="num">(777)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">515,340<span></span>
</td>
<td class="nump">568,882<span></span>
</td>
<td class="nump">336,847<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">116,054<span></span>
</td>
<td class="num">(189,696)<span></span>
</td>
<td class="nump">93,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">145,691<span></span>
</td>
<td class="nump">335,387<span></span>
</td>
<td class="nump">241,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">261,745<span></span>
</td>
<td class="nump">145,691<span></span>
</td>
<td class="nump">335,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset</a></td>
<td class="nump">798<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_EquityIssuanceCostsIncurredButNotYetPaid', window );">Equity issuance costs</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_InsurancePremiumFinancedByThirdParty', window );">Insurance premium financed by a third-party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_EquityIssuanceCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for costs associated with the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_EquityIssuanceCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_InsurancePremiumFinancedByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of insurance premiums financed by a third party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_InsurancePremiumFinancedByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay a third-party for insurance premiums paid by the third-party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (425,377)<span></span>
</td>
<td class="num">$ (260,756)<span></span>
</td>
<td class="num">$ (126,219)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table describes for the quarterly period ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a Rule 10b5-1 trading arrangement) or (2) a &#8220;non-Rule 10b5-1 trading arrangement&#8221; (as defined in Item 408(c) of Regulation S-K):</span></p>
     <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
      <tr style="visibility:collapse;">
       <td style="width:13%;box-sizing:content-box;"></td>
       <td style="width:14.42%;box-sizing:content-box;"></td>
       <td style="width:22%;box-sizing:content-box;"></td>
       <td style="width:12%;box-sizing:content-box;"></td>
       <td style="width:26%;box-sizing:content-box;"></td>
       <td style="width:12.58%;box-sizing:content-box;"></td>
      </tr>
      <tr style="height:8pt;background-color:#f2f2f2;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name (Title)</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action Taken <br/>(Date of Action)</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Type of Trading Arrangement</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nature of Trading <br/>Arrangement</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Duration of Trading <br/>Arrangement</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Number <br/>of Securities</span></p></td>
      </tr>
      <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alexandra Balcom</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">December 23, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Until </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 11, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">, or such earlier date upon which all transactions are completed or expire without execution</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Up to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares of Class A common stock</span></p></td>
      </tr>
      <tr style="height:9pt;background-color:#f2f2f2;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Henry Pelish</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Scientific Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">December 11, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Until </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 30, 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">, or such earlier date upon which all transactions are completed or expire without execution</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Up to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,306</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares of Class A common stock</span></p></td>
      </tr>
      <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James Porter</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">December 4, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Until </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 10, 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">, or such earlier date upon which all transactions are completed or expire without execution</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Up to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">390,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares of Class A common stock</span></p></td>
      </tr>
      <tr style="height:9pt;background-color:#f2f2f2;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Anna Protopapas</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">December 7, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Until </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 31, 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">, or such earlier date upon which all transactions are completed or expire without execution</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Up to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares of Class A common stock</span></p></td>
      </tr>
     </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=nuvl_Rule10B51TradingPlanMember', window );">Rule 10B 5-1Trading Plan [Member] | Alexandra Balcom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Alexandra Balcom<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 23, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December 11, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">128,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=nuvl_Rule10B51TradingPlanMember', window );">Rule 10B 5-1Trading Plan [Member] | Henry Pelish [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Henry Pelish<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Scientific Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 11, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">November 30, 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">116,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=nuvl_Rule10B51TradingPlanMember', window );">Rule 10B 5-1Trading Plan [Member] | James Porter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">James Porter<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 4, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">March 10, 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=nuvl_Rule10B51TradingPlanMember', window );">Rule 10B 5-1Trading Plan [Member] | Anna Protopapas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Anna Protopapas<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Director<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 7, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">March 31, 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=nuvl_Rule10B51TradingPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=nuvl_Rule10B51TradingPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=nuvl_AlexandraBalcomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=nuvl_AlexandraBalcomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=nuvl_HenryPelishMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=nuvl_HenryPelishMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=nuvl_JamesPorterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=nuvl_JamesPorterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=nuvl_AnnaProtopapasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=nuvl_AnnaProtopapasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Cybersecurity.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity Incident Response Plan (IRP). Our cybersecurity risk management program is a key component of our overall risk management process, and includes similar characteristics, reporting channels and governance processes to those that apply across other legal, compliance, strategic, operational and financial risk areas within the Company.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program includes:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity awareness training of our employees, incident response personnel and senior management;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a cybersecurity IRP that includes procedures for responding to cybersecurity incidents; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a third-party risk management process for service providers, suppliers and vendors</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not identified risks from known cybersecurity threats,</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations or financial condition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Governance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to its audit committee oversight of cybersecurity and other information technology risks. The audit committee oversees management&#8217;s implementation of our cybersecurity risk management program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives reports from management on our cybersecurity risks at least annually. In addition, management updates the audit committee regarding all material cybersecurity incidents, as well as any incidents with lesser impact potential that management, in its discretion, determines may be relevant for audit committee review. The </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">audit committee reports to the board of directors</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> regarding its activities, including those related to cybersecurity.</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer, working closely with our Vice President, Information Technologies and our Director, Cybersecurity and Compliance (collectively, our Cybersecurity Oversight Team)</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, is responsible for assessing and managing our material risks from cybersecurity threats</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Cybersecurity Oversight Team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Cybersecurity Oversight Team&#8217;s experience includes a combined 50+ years in the pharmaceutical industry and information technology. This includes software and systems development, cybersecurity program oversight and overall IT management. Our Cybersecurity Oversight Team has over two decades of experience dedicated to supporting enterprise architecture and over a decade of experience specializing in cybersecurity, implementing cybersecurity frameworks, assessing and managing cybersecurity risks and executing incident response plans.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Cybersecurity Oversight Team supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, which include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engaged</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by us; and alerts and reports produced by security tools deployed in the IT environment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our IRP, all of our employees are trained to report a suspected cybersecurity incident or breach to our information technology team. Reporting guidelines under the IRP describe how to report an incident and what details to include. As a first step under the IRP, our information technology team assesses the reported risk or breach and escalates it to our Incident Response Team (IRT), as appropriate. The IRT is comprised of the members of our Cybersecurity Oversight Team and other critical business function leaders, including members of our legal and communications teams. Following notification from our information technology team, the IRT is responsible for continuing to assess the suspected risk or breach to determine its potential impact on our organization, systems and data. Based on that assessment, the IRT may raise the incident or breach to other members of management or the audit committee for further review and triage.</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to its audit committee oversight of cybersecurity and other information technology risks. The audit committee oversees management&#8217;s implementation of our cybersecurity risk management program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives reports from management on our cybersecurity risks at least annually. In addition, management updates the audit committee regarding all material cybersecurity incidents, as well as any incidents with lesser impact potential that management, in its discretion, determines may be relevant for audit committee review. The </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">audit committee reports to the board of directors</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> regarding its activities, including those related to cybersecurity.</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer, working closely with our Vice President, Information Technologies and our Director, Cybersecurity and Compliance (collectively, our Cybersecurity Oversight Team)</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, is responsible for assessing and managing our material risks from cybersecurity threats</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Cybersecurity Oversight Team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Cybersecurity Oversight Team&#8217;s experience includes a combined 50+ years in the pharmaceutical industry and information technology. This includes software and systems development, cybersecurity program oversight and overall IT management. Our Cybersecurity Oversight Team has over two decades of experience dedicated to supporting enterprise architecture and over a decade of experience specializing in cybersecurity, implementing cybersecurity frameworks, assessing and managing cybersecurity risks and executing incident response plans.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Cybersecurity Oversight Team supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, which include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engaged</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by us; and alerts and reports produced by security tools deployed in the IT environment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our IRP, all of our employees are trained to report a suspected cybersecurity incident or breach to our information technology team. Reporting guidelines under the IRP describe how to report an incident and what details to include. As a first step under the IRP, our information technology team assesses the reported risk or breach and escalates it to our Incident Response Team (IRT), as appropriate. The IRT is comprised of the members of our Cybersecurity Oversight Team and other critical business function leaders, including members of our legal and communications teams. Following notification from our information technology team, the IRT is responsible for continuing to assess the suspected risk or breach to determine its potential impact on our organization, systems and data. Based on that assessment, the IRT may raise the incident or breach to other members of management or the audit committee for further review and triage.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to its audit committee oversight of cybersecurity and other information technology risks. The audit committee oversees management&#8217;s implementation of our cybersecurity risk management program</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer, working closely with our Vice President, Information Technologies and our Director, Cybersecurity and Compliance (collectively, our Cybersecurity Oversight Team)</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, is responsible for assessing and managing our material risks from cybersecurity threats</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program includes:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity awareness training of our employees, incident response personnel and senior management;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a cybersecurity IRP that includes procedures for responding to cybersecurity incidents; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a third-party risk management process for service providers, suppliers and vendors</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer, working closely with our Vice President, Information Technologies and our Director, Cybersecurity and Compliance (collectively, our Cybersecurity Oversight Team)</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, is responsible for assessing and managing our material risks from cybersecurity threats</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Cybersecurity Oversight Team&#8217;s experience includes a combined 50+ years in the pharmaceutical industry and information technology. This includes software and systems development, cybersecurity program oversight and overall IT management. Our Cybersecurity Oversight Team has over two decades of experience dedicated to supporting enterprise architecture and over a decade of experience specializing in cybersecurity, implementing cybersecurity frameworks, assessing and managing cybersecurity risks and executing incident response plans.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives reports from management on our cybersecurity risks at least annually. In addition, management updates the audit committee regarding all material cybersecurity incidents, as well as any incidents with lesser impact potential that management, in its discretion, determines may be relevant for audit committee review. The </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">audit committee reports to the board of directors</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> regarding its activities, including those related to cybersecurity.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Nature of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvalent, Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The Company was founded in January 2017 as a Delaware corporation. The Company is headquartered in Cambridge, Massachusetts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks similar to those of other pre-commercial stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of which are larger and better capitalized, the need for adequate financing to fund the development of its product candidates, the need to obtain and maintain adequate protection for the Company&#8217;s intellectual property, and the impact of geopolitical events on the Company&#8217;s business. There can be no assurance that the Company&#8217;s research and development will be successful, that adequate protection for the Company&#8217;s intellectual property will be obtained and maintained, that any product candidates will receive required regulatory approval, or that approved products, if any, will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred recurring losses since inception, including net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">425.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">260.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2025, 2024 and 2023, respectively. As of December 31, 2025, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">972.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company expects to continue to generate net losses for the foreseeable future. The Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the date of issuance of these consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Basis of Presentation and Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of presentation and consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and under the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nuvalent Securities Corporation. All intercompany balances and transactions have been eliminated in consolidation. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain prior period amounts have been reclassified to conform with current period presentation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair value of the related party revenue share liability, the accounting for research and development contracts, including clinical trial accruals, and valuation of equity instruments. The Company bases its estimates, assumptions, and judgments on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of credit risk and of significant suppliers</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company&#8217;s cash, cash equivalents and marketable securities may be held in accounts at financial institutions that may exceed federally insured limits. However, the Company mitigates credit risk by maintaining a diversified portfolio, placing its cash with high credit quality financial institutions and limiting the amount of investment exposure as to maturity and investment type according to its investment policy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant credit risk beyond the standard credit risk associated with commercial banking relationships.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party vendors for the manufacturing of its product candidates. In particular, the Company relies, and expects to continue to rely, on a small number of vendors to manufacture materials and components required for the production of its product candidates. These programs could be adversely affected by a significant interruption in the manufacturing process.</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents may include money market funds and marketable securities. The Company records interest income received on cash, cash equivalents, and marketable securities to other income (expense) in the consolidated statements of operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">comprehensive loss. The Company invests its excess cash in money market funds, commercial paper, corporate bonds, government and agency securities and U.S. treasury bills.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair value measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows the provision of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASC 820&#8221;), which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 &#8212; quoted prices for identical assets or liabilities in active markets.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 &#8212; quoted prices for similar assets or liabilities in active markets or inputs that are observable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 &#8212; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cash equivalents, marketable securities, and related party revenue share liability are carried at fair value, determined according to the fair value hierarchy described above (see Note 4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for marketable securities in accordance with FASB ASC Topic 320, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments - Debt and Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company&#8217;s marketable securities are classified as available-for-sale debt securities and recorded at fair value based on inputs that are observable, either directly or indirectly, such as quoted prices for identical securities in active markets (Level 1) or quoted prices for similar securities in active markets or inputs that are observable (Level 2). At the time of purchase, the Company classifies marketable securities with maturities of three months or less as cash equivalents on the consolidated balance sheets. The Company&#8217;s available-for-sale securities are classified as current assets as they are readily available to be converted to cash and for use in the Company&#8217;s current operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unrealized gains and losses are included as a component of accumulated other comprehensive income (loss) in the consolidated statements of stockholders&#8217; equity. Realized gains and losses are recorded to other income (expense) in the consolidated statements of operations and comprehensive loss.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When the fair value is below the amortized cost of an available-for-sale security, the Company must determine if the decline in fair value below the amortized cost basis has resulted from a credit loss or other factors. If the Company determines that the decline in fair value below the amortized cost basis is due to credit-related factors, the Company measures the credit loss and recognizes an allowance for credit losses in the consolidated balance sheet and the credit-related impairment in the consolidated statements of operations and comprehensive loss. The allowance for credit losses is measured as the amount by which the amortized cost basis exceeds the present value of expected cash flows, limited to the difference between the amortized cost basis and the security&#8217;s fair value. The Company subsequently assesses whether the measurement of credit losses has increased or decreased and adjusts the allowance for credit losses with corresponding gains or losses recognized in the consolidated statements of operations and comprehensive loss. Impairments not relating to credit losses are recorded to other comprehensive income (loss).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company intends to sell the available for sale security or it is more likely than not that the Company will be required to sell the security prior to the recovery of its amortized cost basis, then the allowance for the credit losses is written off and the excess of the amortized cost basis of the asset over its fair value is recorded in the consolidated statements of operations and comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair value option for related party revenue share liability</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a revenue sharing agreement with Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund IV, L.P. (collectively, &#8220;Deerfield&#8221;), each an investor in the Company, to pay a fixed low single-digit percentage rate of net sales of certain commercial products, which represents a freestanding financial instrument. In accordance with FASB ASC Topic 825, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company elected the fair value option. Accordingly, the related party revenue share liability was measured at fair value upon issuance and is remeasured at the end of each reporting period with changes in fair value recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The fair value of the related party revenue share liability is estimated using a discounted cash flow model to calculate the estimated payments that could become due following commercialization. Assumptions in the model include but are not limited to the following: probability and timing of product approval, future product revenues and discount rate. The fair value measurement is based on significant inputs that are not observable in the market and thus represents a Level 3 measurement.</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development and clinical trial accruals</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. These consist primarily of salaries and related costs, including stock-based compensation, for personnel engaged in research and development functions; costs incurred in connection with the advancement of the Company&#8217;s discovery programs and product candidates in preclinical and clinical studies, including under agreements with contract</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">research organizations (&#8220;CROs&#8221;); and the cost of developing and scaling the Company&#8217;s manufacturing process, including under agreements with contract manufacturing organizations, to manufacture drug substance and drug product for use in the Company&#8217;s research and preclinical and clinical studies and manufacture commercial-scale validation batches in preparation for the commercial launch of the Company&#8217;s product candidates that obtain regulatory approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and may be reflected in the consolidated balance sheets as prepaid or accrued expenses. Determining the prepaid and accrued expenses balances at the end of any reporting period incorporates certain judgments and estimates by management that are based on information available to the Company including information provided by employees and vendors regarding the progress to completion of specific tasks or costs incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent costs</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation &#8212; Stock Compensation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASC 718&#8221;). The Company has granted stock options and restricted stock units (&#8220;RSUs&#8221;), both of which are subject to service-based vesting conditions, and RSUs with performance-based vesting conditions (&#8220;PSUs&#8221;). In accordance with ASC 718, the Company recognizes stock-based compensation expense in the consolidated statements of operations and comprehensive loss based on a stock award&#8217;s grant-date fair value.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. For RSUs and PSUs, the fair value is equal to the market price of a share of the Company&#8217;s Class A common stock on the grant date. The Company recognizes forfeitures as they occur. Stock-based compensation expense for stock awards with service-based vesting conditions is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting period. Stock awards with service-based vesting conditions generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_2bc711c3-dec2-4073-ad3b-8876b685c8e8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- or</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> service periods and stock options expire after </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Stock-based compensation expense for stock awards with performance-based vesting conditions is recognized on a straight-line basis over the requisite </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">service period for</span><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each separately vesting portion of the underlying stock award when the performance-based vesting condition is deemed probable to occur. The Company reassesses the probability of vesting at each reporting period and adjusts stock-based compensation expense, if applicable, based on its probability assessment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records stock-based compensation expense to research and development expense or general and administrative expense based on the underlying function of the individual that was granted the award. Shares issued upon stock option exercise and RSU and PSU vesting are newly-issued shares.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Company&#8217;s Black-Scholes option-pricing model for stock options are as follows:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; As the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the Company utilizes the &#8220;simplified&#8221; method, as prescribed in the SEC&#8217;s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetical average of the vesting term and the original contractual term of the stock option.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; The expected volatility is based on the historical volatility of the Company and that of similar entities within the Company&#8217;s industry for periods corresponding with the expected term of the grant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant for a period that corresponds with the expected term of the grant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Dividends</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; The expected dividend yield is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% as the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Company&#8217;s Black-Scholes option-pricing model are inherently subjective and represent management&#8217;s best estimates. These assumptions involve a number of variables, uncertainties and the application of management&#8217;s judgment. If any assumptions change, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net income (loss) per share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, including potentially dilutive common shares. For periods in which the Company reported a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income taxes</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently adopted accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company prospectively </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9bb6efd4-414b-479c-bbd1-d6eec4dc4cc3;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-09</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;) on an annual basis, which requires public entities to provide disclosure of specific categories in their income tax rate reconciliations, as well as disclosure of income taxes paid disaggregated by jurisdiction.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently issued accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASU 2024-03&#8221;), which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the consolidated financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company does not expect the impact of the adoption of this standard to be material to its consolidated financial statements or disclosures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangibles &#8212; Goodwill and Other &#8212; Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASU 2025-06&#8221;), which modernizes the accounting for internal use software. The standard removes references to project stages and clarifies the criteria for capitalizing software costs. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company does not expect the impact of the adoption of this standard to be material to its consolidated financial statements or disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Marketable Securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables provide the amortized cost and fair value of the Company&#8217;s available-for-sale securities by security type (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.93%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.982%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.982%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.982%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,889</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,884</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">772,457</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,233</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">184</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">774,506</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government and agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,684</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">340</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,990</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury bills</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,824</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,827</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,107,854</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,593</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,110,207</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.93%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.982%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.982%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.982%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,473</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,309</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468,673</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">532</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">588</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468,617</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government and agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,783</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,886</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury bills</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,741</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,799</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">972,670</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">736</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">795</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">972,611</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the amortized cost and fair value of the Company&#8217;s available-for-sale securities by contractual maturity (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due within one year</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">523,630</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">524,421</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due after one year through three years</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">584,224</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">585,786</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,107,854</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,110,207</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> credit losses recorded during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, 2024 and 2023. Interest income for the years ended December 31, 2025, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="fn_4_fair_value_measurements" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Fair Value Measurements</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present the Company&#8217;s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.99%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.958%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.978%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.978%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.097999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,567</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,567</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,884</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,884</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">774,506</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">774,506</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government and agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,990</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,990</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury bills</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,827</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,827</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,567</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,110,207</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,361,774</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Related party revenue share liability</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,160</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,160</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,902</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,902</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,309</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,309</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468,617</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468,617</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government and agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,886</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,886</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury bills</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,799</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,799</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,902</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">972,611</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,108,513</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Related party revenue share liability</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,940</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,940</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents were valued by the Company based on quoted market prices for identical securities, which represent a Level 1 measurement within the fair value hierarchy. Commercial paper, corporate bonds, government and agency securities, and U.S. treasury bills were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. During the periods presented, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers in or out of Level 3. The carrying values of the Company&#8217;s accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these liabilities.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the changes in estimated fair value of the Company&#8217;s related party revenue share liability for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, which represents a Level 3 measurement within the fair value hierarchy (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:83.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated fair value as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,940</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,220</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated fair value as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,160</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the related party revenue share liability was estimated using a discounted cash flow model to calculate the estimated payments that could become due following commercialization. Assumptions in the model include but are not limited to the following: probability and timing of product approval, future product revenues and discount rate. Changes in fair value each reporting period are recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. See Note 10 for additional information regarding the revenue sharing agreement with Deerfield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:60.072%;box-sizing:content-box;"></td>
         <td style="width:1.001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.203%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.722%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical and other research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,235</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,555</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued manufacturing</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,976</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,511</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued employee compensation and benefits</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,935</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,452</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,867</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,277</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,013</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,795</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">4,950,496</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its Class A common stock in an underwritten public offering at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">101.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (the &#8220;2025 Public Offering&#8221;). Upon the closing of the 2025 Public Offering, the Company received net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">471.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting equity issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in addition to underwriting discounts and commissions. In addition, the underwriters exercised their option in full to purchase an additional </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">742,574</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Class A common stock (the &#8220;Additional Shares&#8221;) from Deerfield. The Company did not receive any proceeds from the sale of the Additional Shares by Deerfield.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,750,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its Class A common stock in an underwritten public offering, including the exercise in full by the underwriters of their option to purchase an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">750,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Class A common stock, at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (the &#8220;2024 Public Offering&#8221;). Upon the closing of the 2024 Public Offering, the Company received net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">540.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting equity issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in addition to underwriting discounts and commissions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,160,714</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its Class A common stock in an underwritten public offering, including the exercise in full by the underwriters of their option to purchase an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">803,571</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Class A common stock, at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (the &#8220;2023 Public Offering&#8221;). Upon the closing of the 2023 Public Offering, the Company received net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting equity issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in addition to underwriting discounts and commissions.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Stock-Based Compensation</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded stock-based compensation expense within its consolidated statements of operations and comprehensive loss as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:60.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.040000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.040000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,097</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,369</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,600</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,405</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,210</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,963</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,502</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,579</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,563</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2021 Plan (as defined below), the Company has granted stock options, RSUs and PSUs. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total unrecognized compensation cost, excluding unrecognized compensation cost related to PSUs, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. Stock-based compensation expense for PSUs is recognized on a straight-line basis over the requisite service period for each separately vesting portion of the PSUs when the performance-based vesting condition is deemed probable to occur. The performance-based vesting conditions under the PSUs have not been deemed probable to occur, and accordingly, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock-based compensation expense has been recognized. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, total unrecognized compensation cost related to PSUs was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which will be recognized when the performance-based vesting conditions are deemed probable to occur.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 equity incentive plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2021, the Company adopted the 2021 Stock Option and Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, RSUs (including PSUs), unrestricted stock awards, cash-based awards and dividend equivalent rights. The number of shares of Class A common stock reserved for issuance under the 2021 Plan is subject to increase on each January 1 thereafter by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the number of shares of the Company&#8217;s Class A and Class B common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#8217;s board of directors or compensation committee of the board of directors. The shares of Class A common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expired or are otherwise</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(other than by exercise) under the 2021 Plan will be added back to the shares of Class A common stock available under the 2021 Plan. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,244,716</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock remained available for future issuance under the 2021 Plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 employee stock purchase plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2021, the Company adopted the 2021 Employee Stock Purchase Plan (as amended and restated, the &#8220;ESPP&#8221;). The ESPP permits eligible employees to purchase shares of Class A common stock at a discount in accordance with the terms of the offering and consists of consecutive, overlapping 12-month offering periods, each consisting of two six-month purchase periods. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,322,110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remained available for issuance and sale under the ESPP.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the range of assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.26%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="5" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average expected option term (years)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
         <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
         <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Range of expected stock price volatility</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average expected stock price volatility</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Range of risk-free interest rate</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend rate</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.120000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">of Shares</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,980,047</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.93</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.45</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">398,407</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,544,070</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.51</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,672,786</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.13</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled or forfeited</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,690</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73.63</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,717,641</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.90</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.90</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">476,355</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,701,612</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.06</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.95</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">369,254</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of stock options exercised during the years ended December 31, 2025, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock on the date of exercise.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average grant-date fair value of stock options granted during the years ended December 31, 2025, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51.94</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53.07</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSUs</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s RSU activity since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:55.98%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:20%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Grant-Date Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">716,921</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.13</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">657,148</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.05</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">252,814</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.29</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,139</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77.97</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,091,116</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.77</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RSU activity above includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,935</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of outstanding PSUs. The total fair value of RSUs vested during the year ended December 31, 2025 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs vested during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Net Loss Per Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has two classes of common stock outstanding: Class A common stock and Class B common stock. The rights of the holders of Class A common stock and Class B common stock are substantially identical, except with respect to voting and conversion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each share of Class A common stock is entitled to one vote. Class B common stock is nonvoting</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each share of Class B common stock is convertible into one share of Class A common stock at the option of the holder at any time, subject to the ownership limitations provided for in the Company&#8217;s amended and restated certificate of incorporation.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company allocates undistributed earnings attributable to common stock between the common stock classes on a one-to-one basis when computing net loss per share. As a result, basic and diluted net loss per share of Class A common stock and per share of Class B common stock are equivalent.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.27%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.097%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.097%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,717,641</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,980,047</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,034,755</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,091,116</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">716,921</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ESPP</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,400</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,827,157</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,696,968</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,034,755</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of the Company&#8217;s net losses have been generated in the United States. The Company recognized income tax provisions of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, as a result of investment income earned in Nuvalent Securities Corporation. The Company recognized </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> income tax provision during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reconciliation of federal statutory income tax rate to effective income tax rate</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has elected to prospectively adopt the guidance in ASU 2023-09. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present reconciliations of the U.S. federal statutory income tax rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to the Company&#8217;s effective income tax rate for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (dollar values in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:60.98%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal statutory income tax rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,206</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local income tax, net of federal (national) income tax effect</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">585</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign tax effects</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of changes in tax laws or rates enacted in the current period</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of cross-border tax laws</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Orphan drug credit</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,137</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D credit</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,061</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in valuation allowances</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,819</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.0</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 162(m) limitation</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,316</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,413</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent adjustments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in unrecognized tax benefits</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other adjustments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">447</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">585</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.58%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal statutory income tax rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.3</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits generated</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.3</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.7</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45.8</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.7</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2025, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each year, due to its uncertainty of realizing a benefit from those items.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net deferred tax assets consisted of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,120</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,677</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,127</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,002</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credit carryforwards</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,361</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,117</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of related party revenue share liability</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,284</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,785</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,225</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,705</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,648</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,714</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">362,765</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">362,495</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total net deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">270</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">270</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">270</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the Company had U.S. federal and state net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">503.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">531.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which may be available to offset future taxable income. The federal net operating losses include $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">502.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which carryforward indefinitely, but may only be used to offset </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of annual taxable income. The state net operating losses expire at various dates beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2025, the Company also had federal and state research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and federal orphan drug credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which may be available to offset future tax liabilities. The federal and state research and development tax credit carryforwards and the federal orphan drug credits expire at various dates beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2033</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilization of the U.S. federal and state net operating loss carryforwards, as well as the research and development tax credit carryforwards and federal orphan drug credits may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986 (&#8220;IRC&#8221;), and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards, research and development tax credit carryforwards or the federal orphan drug credits would be subject to an annual limitation under Section 382. Any limitation may result in expiration of a portion of the net operating loss carryforwards, research and development tax credit carryforwards or the federal orphan drug credits before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the net deferred tax assets. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception and that the Company has yet to commercialize any of its product candidates to generate revenue from product sales and has concluded that it is more likely than not that the Company will not realize the benefits of the net deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2025 and 2024. Management reevaluates the positive and negative evidence at each reporting period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">142.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the years ended December 31, 2025, 2024 and 2023, respectively, primarily as a result of increases in net operating loss carryforwards, research and development tax credit carryforwards, the change in fair value of related party revenue share liability and research and development costs capitalized under Section 174 of the IRC.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits and tax examinations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any amounts for unrecognized tax benefits. The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b03806a6-1c81-405a-b304-d4fc62c72a8c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2022</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the present.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="fn_10_commitments_and_contingencies" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue sharing agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a revenue sharing agreement with Deerfield pursuant to which the Company is obligated to pay Deerfield a fixed low single-digit percentage rate of net sales of certain commercial products (the &#8220;Deerfield Revenue Sharing Agreement&#8221;). The Company is also party to a revenue sharing agreement with its scientific founder pursuant to which the Company was obligated to pay the scientific founder </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales of certain commercial products (the &#8220;Scientific Founder Revenue Sharing Agreement&#8221; and together with the Deerfield Revenue Sharing Agreement, the &#8220;Revenue Sharing Agreements&#8221;). In December 2025, the scientific founder assigned the Scientific Founder Revenue Sharing Agreement to Royalty Pharma plc (&#8220;Royalty Pharma&#8221;) and, as a result, any payments the Company is obligated to make under the Scientific Founder Revenue Sharing Agreement will be made to Royalty Pharma.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Revenue Sharing Agreements, the payment obligation in respect of such products expires on the later of 12 years from the first commercial sale in a country or the expiration of the last-to-expire patent in that country. The Company accounts for the liability with Deerfield at fair value with changes recognized in the consolidated statements of operations and comprehensive loss (see Note 4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The Company accounts for the obligation to Royalty Pharma as a contingent liability and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t accrued any liability as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 or 2024. The Company has not recorded any net sales and, as a result, has not paid any amounts under the Revenue Sharing Agreements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, CROs, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Segment Information</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is a clinical-stage biopharmaceutical company and has not generated any revenue since commencing significant operations in 2018. The Company&#8217;s operations are organized and reported as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which includes all activities related to the discovery, development, and commercialization of precisely targeted therapies for patients with cancer. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This presentation is consistent with how the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d7650aa4-5b78-4427-b72b-9d9f6eb1e03c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, assesses the performance of the Company and makes operating decisions on a consolidated basis. The accounting policies of the consolidated segment are the same as those described in the summary of significant accounting policies (see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The CODM assesses performance and decides how to allocate resources based on consolidated net loss as reported on the consolidated statements of operations and comprehensive loss. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c878b86a-9508-4bbd-ac26-41dc1d148b19;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM uses consolidated net loss to monitor budget versus actual results, assess cash runway, and benchmark against the Company&#8217;s competitors.</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The measure of segment assets is reported on the consolidated balance sheets as total assets. The Company&#8217;s assets are held in the United States.</span></span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the Company&#8217;s segment information (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.36%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.020000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.020000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct external expenses by program:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Zidesamtinib</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,519</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,110</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,878</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Neladalkib</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,446</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,778</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,894</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NVL-330</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,819</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,293</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,634</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discovery programs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,875</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,178</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,586</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,121</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,225</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,502</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,579</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,563</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative professional and consultant fees</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,033</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,854</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,423</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of related party revenue share liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,220</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,940</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,794</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,372</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,277</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,009</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,511</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,293</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax provision</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">585</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">764</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consolidated net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">425,377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">260,756</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,219</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:6.7pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items included in consolidated net loss include expenses for commercialization preparation activities, research and development consulting services, information technology, insurance, employee recruitment and other miscellaneous activities.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation and consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of presentation and consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and under the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nuvalent Securities Corporation. All intercompany balances and transactions have been eliminated in consolidation. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain prior period amounts have been reclassified to conform with current period presentation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of presentation and consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of presentation and consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and under the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nuvalent Securities Corporation. All intercompany balances and transactions have been eliminated in consolidation. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain prior period amounts have been reclassified to conform with current period presentation.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair value of the related party revenue share liability, the accounting for research and development contracts, including clinical trial accruals, and valuation of equity instruments. The Company bases its estimates, assumptions, and judgments on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock', window );">Concentrations of credit risk and of significant suppliers</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of credit risk and of significant suppliers</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company&#8217;s cash, cash equivalents and marketable securities may be held in accounts at financial institutions that may exceed federally insured limits. However, the Company mitigates credit risk by maintaining a diversified portfolio, placing its cash with high credit quality financial institutions and limiting the amount of investment exposure as to maturity and investment type according to its investment policy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant credit risk beyond the standard credit risk associated with commercial banking relationships.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party vendors for the manufacturing of its product candidates. In particular, the Company relies, and expects to continue to rely, on a small number of vendors to manufacture materials and components required for the production of its product candidates. These programs could be adversely affected by a significant interruption in the manufacturing process.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents may include money market funds and marketable securities. The Company records interest income received on cash, cash equivalents, and marketable securities to other income (expense) in the consolidated statements of operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">comprehensive loss. The Company invests its excess cash in money market funds, commercial paper, corporate bonds, government and agency securities and U.S. treasury bills.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair value measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows the provision of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASC 820&#8221;), which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 &#8212; quoted prices for identical assets or liabilities in active markets.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 &#8212; quoted prices for similar assets or liabilities in active markets or inputs that are observable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 &#8212; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cash equivalents, marketable securities, and related party revenue share liability are carried at fair value, determined according to the fair value hierarchy described above (see Note 4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for marketable securities in accordance with FASB ASC Topic 320, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments - Debt and Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company&#8217;s marketable securities are classified as available-for-sale debt securities and recorded at fair value based on inputs that are observable, either directly or indirectly, such as quoted prices for identical securities in active markets (Level 1) or quoted prices for similar securities in active markets or inputs that are observable (Level 2). At the time of purchase, the Company classifies marketable securities with maturities of three months or less as cash equivalents on the consolidated balance sheets. The Company&#8217;s available-for-sale securities are classified as current assets as they are readily available to be converted to cash and for use in the Company&#8217;s current operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unrealized gains and losses are included as a component of accumulated other comprehensive income (loss) in the consolidated statements of stockholders&#8217; equity. Realized gains and losses are recorded to other income (expense) in the consolidated statements of operations and comprehensive loss.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When the fair value is below the amortized cost of an available-for-sale security, the Company must determine if the decline in fair value below the amortized cost basis has resulted from a credit loss or other factors. If the Company determines that the decline in fair value below the amortized cost basis is due to credit-related factors, the Company measures the credit loss and recognizes an allowance for credit losses in the consolidated balance sheet and the credit-related impairment in the consolidated statements of operations and comprehensive loss. The allowance for credit losses is measured as the amount by which the amortized cost basis exceeds the present value of expected cash flows, limited to the difference between the amortized cost basis and the security&#8217;s fair value. The Company subsequently assesses whether the measurement of credit losses has increased or decreased and adjusts the allowance for credit losses with corresponding gains or losses recognized in the consolidated statements of operations and comprehensive loss. Impairments not relating to credit losses are recorded to other comprehensive income (loss).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company intends to sell the available for sale security or it is more likely than not that the Company will be required to sell the security prior to the recovery of its amortized cost basis, then the allowance for the credit losses is written off and the excess of the amortized cost basis of the asset over its fair value is recorded in the consolidated statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value option for related party revenue share liability</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair value option for related party revenue share liability</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a revenue sharing agreement with Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund IV, L.P. (collectively, &#8220;Deerfield&#8221;), each an investor in the Company, to pay a fixed low single-digit percentage rate of net sales of certain commercial products, which represents a freestanding financial instrument. In accordance with FASB ASC Topic 825, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company elected the fair value option. Accordingly, the related party revenue share liability was measured at fair value upon issuance and is remeasured at the end of each reporting period with changes in fair value recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The fair value of the related party revenue share liability is estimated using a discounted cash flow model to calculate the estimated payments that could become due following commercialization. Assumptions in the model include but are not limited to the following: probability and timing of product approval, future product revenues and discount rate. The fair value measurement is based on significant inputs that are not observable in the market and thus represents a Level 3 measurement.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development and clinical trial accruals</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development and clinical trial accruals</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. These consist primarily of salaries and related costs, including stock-based compensation, for personnel engaged in research and development functions; costs incurred in connection with the advancement of the Company&#8217;s discovery programs and product candidates in preclinical and clinical studies, including under agreements with contract</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">research organizations (&#8220;CROs&#8221;); and the cost of developing and scaling the Company&#8217;s manufacturing process, including under agreements with contract manufacturing organizations, to manufacture drug substance and drug product for use in the Company&#8217;s research and preclinical and clinical studies and manufacture commercial-scale validation batches in preparation for the commercial launch of the Company&#8217;s product candidates that obtain regulatory approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and may be reflected in the consolidated balance sheets as prepaid or accrued expenses. Determining the prepaid and accrued expenses balances at the end of any reporting period incorporates certain judgments and estimates by management that are based on information available to the Company including information provided by employees and vendors regarding the progress to completion of specific tasks or costs incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Patent costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent costs</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation &#8212; Stock Compensation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASC 718&#8221;). The Company has granted stock options and restricted stock units (&#8220;RSUs&#8221;), both of which are subject to service-based vesting conditions, and RSUs with performance-based vesting conditions (&#8220;PSUs&#8221;). In accordance with ASC 718, the Company recognizes stock-based compensation expense in the consolidated statements of operations and comprehensive loss based on a stock award&#8217;s grant-date fair value.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. For RSUs and PSUs, the fair value is equal to the market price of a share of the Company&#8217;s Class A common stock on the grant date. The Company recognizes forfeitures as they occur. Stock-based compensation expense for stock awards with service-based vesting conditions is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting period. Stock awards with service-based vesting conditions generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_2bc711c3-dec2-4073-ad3b-8876b685c8e8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- or</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> service periods and stock options expire after </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Stock-based compensation expense for stock awards with performance-based vesting conditions is recognized on a straight-line basis over the requisite </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">service period for</span><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each separately vesting portion of the underlying stock award when the performance-based vesting condition is deemed probable to occur. The Company reassesses the probability of vesting at each reporting period and adjusts stock-based compensation expense, if applicable, based on its probability assessment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records stock-based compensation expense to research and development expense or general and administrative expense based on the underlying function of the individual that was granted the award. Shares issued upon stock option exercise and RSU and PSU vesting are newly-issued shares.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Company&#8217;s Black-Scholes option-pricing model for stock options are as follows:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; As the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the Company utilizes the &#8220;simplified&#8221; method, as prescribed in the SEC&#8217;s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetical average of the vesting term and the original contractual term of the stock option.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; The expected volatility is based on the historical volatility of the Company and that of similar entities within the Company&#8217;s industry for periods corresponding with the expected term of the grant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant for a period that corresponds with the expected term of the grant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Dividends</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; The expected dividend yield is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% as the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Company&#8217;s Black-Scholes option-pricing model are inherently subjective and represent management&#8217;s best estimates. These assumptions involve a number of variables, uncertainties and the application of management&#8217;s judgment. If any assumptions change, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net income (loss) per share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net income (loss) per share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, including potentially dilutive common shares. For periods in which the Company reported a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued and adopted accounting pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently adopted accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company prospectively </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9bb6efd4-414b-479c-bbd1-d6eec4dc4cc3;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-09</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;) on an annual basis, which requires public entities to provide disclosure of specific categories in their income tax rate reconciliations, as well as disclosure of income taxes paid disaggregated by jurisdiction.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently issued accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASU 2024-03&#8221;), which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the consolidated financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company does not expect the impact of the adoption of this standard to be material to its consolidated financial statements or disclosures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangibles &#8212; Goodwill and Other &#8212; Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASU 2025-06&#8221;), which modernizes the accounting for internal use software. The standard removes references to project stages and clarifies the criteria for capitalizing software costs. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company does not expect the impact of the adoption of this standard to be material to its consolidated financial statements or disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk and significant suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Marketable Securities by Security</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables provide the amortized cost and fair value of the Company&#8217;s available-for-sale securities by security type (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.93%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.982%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.982%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.982%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,889</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,884</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">772,457</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,233</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">184</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">774,506</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government and agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,684</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">340</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,990</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury bills</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,824</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,827</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,107,854</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,593</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,110,207</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.93%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.982%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.982%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.982%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,473</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,309</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468,673</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">532</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">588</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468,617</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government and agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,783</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,886</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury bills</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,741</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,799</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">972,670</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">736</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">795</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">972,611</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Contractual Maturities of Available-for-sale Debt Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the amortized cost and fair value of the Company&#8217;s available-for-sale securities by contractual maturity (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due within one year</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">523,630</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">524,421</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due after one year through three years</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">584,224</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">585,786</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,107,854</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,110,207</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Assets Measured on Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present the Company&#8217;s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.99%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.958%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.978%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.978%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.097999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,567</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,567</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,884</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,884</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">774,506</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">774,506</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government and agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,990</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,990</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury bills</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,827</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,827</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,567</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,110,207</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,361,774</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Related party revenue share liability</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,160</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,160</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,902</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,902</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,309</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,309</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468,617</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468,617</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government and agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,886</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,886</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury bills</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,799</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,799</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,902</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">972,611</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,108,513</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Related party revenue share liability</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,940</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,940</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Estimated Fair Value of Company's Related Party Revenue Share Liability</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the changes in estimated fair value of the Company&#8217;s related party revenue share liability for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, which represents a Level 3 measurement within the fair value hierarchy (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:83.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated fair value as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,940</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,220</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated fair value as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,160</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:60.072%;box-sizing:content-box;"></td>
         <td style="width:1.001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.203%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.722%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical and other research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,235</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,555</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued manufacturing</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,976</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,511</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued employee compensation and benefits</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,935</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,452</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,867</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,277</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,013</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,795</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities and other current liabilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded stock-based compensation expense within its consolidated statements of operations and comprehensive loss as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:60.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.040000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.040000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,097</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,369</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,600</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,405</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,210</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,963</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,502</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,579</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,563</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Share Based Payment Award Stock Options Range of Assumptions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the range of assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.26%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="5" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average expected option term (years)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
         <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
         <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Range of expected stock price volatility</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average expected stock price volatility</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Range of risk-free interest rate</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend rate</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.120000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">of Shares</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,980,047</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.93</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.45</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">398,407</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,544,070</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.51</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,672,786</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.13</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled or forfeited</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,690</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73.63</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,717,641</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.90</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.90</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">476,355</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,701,612</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.06</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.95</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">369,254</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s RSU activity since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:55.98%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:20%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Grant-Date Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">716,921</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.13</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">657,148</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.05</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">252,814</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.29</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,139</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77.97</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,091,116</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.77</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.27%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.097%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.097%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,717,641</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,980,047</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,034,755</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,091,116</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">716,921</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ESPP</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,400</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,827,157</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,696,968</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,034,755</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present reconciliations of the U.S. federal statutory income tax rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to the Company&#8217;s effective income tax rate for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (dollar values in thousands):</span>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:60.98%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal statutory income tax rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,206</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local income tax, net of federal (national) income tax effect</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">585</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign tax effects</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of changes in tax laws or rates enacted in the current period</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of cross-border tax laws</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Orphan drug credit</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,137</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D credit</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,061</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in valuation allowances</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,819</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.0</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 162(m) limitation</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,316</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,413</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent adjustments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in unrecognized tax benefits</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other adjustments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">447</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">585</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.58%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal statutory income tax rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.3</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits generated</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.3</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.7</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45.8</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.7</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net deferred tax assets consisted of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,120</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,677</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,127</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,002</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credit carryforwards</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,361</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,117</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of related party revenue share liability</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,284</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,785</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,225</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,705</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,648</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,714</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">362,765</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">362,495</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total net deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">270</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">270</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">270</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the Company&#8217;s segment information (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.36%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.020000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.020000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct external expenses by program:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Zidesamtinib</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,519</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,110</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,878</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Neladalkib</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,446</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,778</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,894</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NVL-330</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,819</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,293</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,634</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discovery programs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,875</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,178</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,586</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,121</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,225</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,502</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,579</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,563</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative professional and consultant fees</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,033</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,854</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,423</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of related party revenue share liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,220</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,940</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,794</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,372</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,277</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,009</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,511</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,293</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax provision</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">585</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">764</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consolidated net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">425,377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">260,756</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,219</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items included in consolidated net loss include expenses for commercialization preparation activities, research and development consulting services, information technology, insurance, employee recruitment and other miscellaneous activities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 425,377<span></span>
</td>
<td class="nump">$ 260,756<span></span>
</td>
<td class="nump">$ 126,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 972,429<span></span>
</td>
<td class="nump">$ 547,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease', window );">Marketable securities credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate202309Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock awards granted, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock awards granted, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock awards granted, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 93: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 94: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 95: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 96: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 97: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3<br><br>Reference 98: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 99: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 100: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 101: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 102: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 103: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 104: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 105: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 106: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Marketable Securities by Security (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,107,854<span></span>
</td>
<td class="nump">$ 972,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,593<span></span>
</td>
<td class="nump">736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(240)<span></span>
</td>
<td class="num">(795)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,110,207<span></span>
</td>
<td class="nump">972,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">107,889<span></span>
</td>
<td class="nump">251,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">107,884<span></span>
</td>
<td class="nump">251,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">772,457<span></span>
</td>
<td class="nump">468,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,233<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(588)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">774,506<span></span>
</td>
<td class="nump">468,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nuvl_GovernmentAndAgencySecuritiesMember', window );">Government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">207,684<span></span>
</td>
<td class="nump">162,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">207,990<span></span>
</td>
<td class="nump">162,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">19,824<span></span>
</td>
<td class="nump">89,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 19,827<span></span>
</td>
<td class="nump">$ 89,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nuvl_GovernmentAndAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nuvl_GovernmentAndAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Contractual Maturities of Available-for-sale Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,107,854<span></span>
</td>
<td class="nump">$ 972,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,110,207<span></span>
</td>
<td class="nump">$ 972,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis=nuvl_DueWithinOneYearMember', window );">Due within one year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">523,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">524,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis=nuvl_DueFromOneToThreeYearsMember', window );">Due after one year through three years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">584,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 585,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis=nuvl_DueWithinOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis=nuvl_DueWithinOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis=nuvl_DueFromOneToThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis=nuvl_DueFromOneToThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease', window );">Marketable securities credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 44,794,000<span></span>
</td>
<td class="nump">$ 38,372,000<span></span>
</td>
<td class="nump">$ 23,277,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 1,110,207<span></span>
</td>
<td class="nump">$ 972,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">251,567<span></span>
</td>
<td class="nump">135,902<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">1,361,774<span></span>
</td>
<td class="nump">1,108,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">107,884<span></span>
</td>
<td class="nump">251,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">774,506<span></span>
</td>
<td class="nump">468,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">207,990<span></span>
</td>
<td class="nump">162,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | U.S. treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">19,827<span></span>
</td>
<td class="nump">89,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Related Party Revenue Share Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">73,160<span></span>
</td>
<td class="nump">17,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Fair value, inputs, level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">251,567<span></span>
</td>
<td class="nump">135,902<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">251,567<span></span>
</td>
<td class="nump">135,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">1,110,207<span></span>
</td>
<td class="nump">972,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">107,884<span></span>
</td>
<td class="nump">251,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member] | Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">774,506<span></span>
</td>
<td class="nump">468,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member] | Government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">207,990<span></span>
</td>
<td class="nump">162,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member] | U.S. treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">19,827<span></span>
</td>
<td class="nump">89,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Fair value, inputs, level 3 [Member] | Related Party Revenue Share Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 73,160<span></span>
</td>
<td class="nump">$ 17,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nuvl_GovernmentAndAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nuvl_GovernmentAndAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=nuvl_RelatedPartyRevenueShareLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=nuvl_RelatedPartyRevenueShareLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Estimated Fair Value of Company's Related Party Revenue Share Liability (Detail) - Related Party Revenue Share Liability [Member] - Fair Value, Inputs, Level 3 [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value as of December 31, 2024</a></td>
<td class="nump">$ 17,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">55,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value as of December 31, 2025</a></td>
<td class="nump">$ 73,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=nuvl_RelatedPartyRevenueShareLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=nuvl_RelatedPartyRevenueShareLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Fair value transfers in or out of Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses', window );">Accrued clinical and other research and development</a></td>
<td class="nump">$ 30,235<span></span>
</td>
<td class="nump">$ 25,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_AccruedManufacturingExpenses', window );">Accrued manufacturing</a></td>
<td class="nump">10,976<span></span>
</td>
<td class="nump">11,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation and benefits</a></td>
<td class="nump">16,935<span></span>
</td>
<td class="nump">10,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_AccruedOtherAndOtherLiabilitiesCurrent', window );">Accrued other and other current liabilities</a></td>
<td class="nump">2,867<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 61,013<span></span>
</td>
<td class="nump">$ 48,795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expenses and other research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_AccruedManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_AccruedManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_AccruedOtherAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other and amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_AccruedOtherAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock in follow-on public offering after underwriting discounts and commission and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 515,722<span></span>
</td>
<td class="nump">$ 569,987<span></span>
</td>
<td class="nump">$ 338,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nuvl_FollowOnPublicOfferingMember', window );">Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock in follow-on public offering after underwriting discounts and commission and offering costs</a></td>
<td class="nump">$ 471,800<span></span>
</td>
<td class="nump">$ 540,000<span></span>
</td>
<td class="nump">$ 323,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_EquityIssuanceCosts', window );">Equity issuance costs</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon public offering, net, Shares</a></td>
<td class="nump">4,950,496<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="nump">6,160,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon public offering, net, Shares</a></td>
<td class="nump">742,574<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">803,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_EquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred during the period for the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_EquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nuvl_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nuvl_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 86,502<span></span>
</td>
<td class="nump">$ 60,579<span></span>
</td>
<td class="nump">$ 25,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">48,097<span></span>
</td>
<td class="nump">31,369<span></span>
</td>
<td class="nump">11,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 38,405<span></span>
</td>
<td class="nump">$ 29,210<span></span>
</td>
<td class="nump">$ 13,963<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.94<span></span>
</td>
<td class="nump">$ 53.07<span></span>
</td>
<td class="nump">$ 23.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,502,000<span></span>
</td>
<td class="nump">$ 60,579,000<span></span>
</td>
<td class="nump">$ 25,563,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,600,000<span></span>
</td>
<td class="nump">$ 102,300,000<span></span>
</td>
<td class="nump">$ 52,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember', window );">2021 Stock Option and Incentive Plan [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,244,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,322,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nuvl_ExcludingPerformanceStockUnitsMember', window );">Excluding PSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share based payment weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nuvl_PerformanceStockUnitsMember', window );">PSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,091,116<span></span>
</td>
<td class="nump">716,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of RSUs vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(252,814)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2021 Stock Option and Incentive Plan [Member] | Common Class A [Member] | Class A And Class B Common Stock Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage', window );">Share based compensation arrangement by share based payment award annual increase percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The automatic increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year, as a percentage of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nuvl_ExcludingPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nuvl_ExcludingPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nuvl_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nuvl_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=nuvl_ClassAAndClassBCommonStockOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=nuvl_ClassAAndClassBCommonStockOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Share Based Payment Award Stock Options Range of Assumptions (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted average expected option term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Range of expected stock price volatility, minimum</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Range of expected stock price volatility, maximum</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted average expected stock price volatility</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Range of risk-free interest rate, minimum</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Range of risk-free interest rate, maximum</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Options Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance, Number of Shares</a></td>
<td class="nump">7,980,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">1,544,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="num">(1,672,786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled or forfeited</a></td>
<td class="num">(133,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance, Number of Shares</a></td>
<td class="nump">7,717,641<span></span>
</td>
<td class="nump">7,980,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable</a></td>
<td class="nump">4,701,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance, Weighted Average Exercise Price</a></td>
<td class="nump">$ 28.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">78.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">25.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled or forfeited</a></td>
<td class="nump">73.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance, Weighted Average Exercise Price</a></td>
<td class="nump">38.9<span></span>
</td>
<td class="nump">$ 28.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 22.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Term</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">7 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Term, Exercisable</a></td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Balance</a></td>
<td class="nump">$ 476,355<span></span>
</td>
<td class="nump">$ 398,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 369,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail) - Restricted Stock Units - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding as of December 31, 2024</a></td>
<td class="nump">716,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, granted</a></td>
<td class="nump">657,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested</a></td>
<td class="num">(252,814)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited</a></td>
<td class="num">(30,139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding as of December 31,2025</a></td>
<td class="nump">1,091,116<span></span>
</td>
<td class="nump">716,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding December 31, 2024</a></td>
<td class="nump">$ 75.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="nump">78.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="nump">75.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="nump">77.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding December 31, 2025</a></td>
<td class="nump">$ 76.77<span></span>
</td>
<td class="nump">$ 75.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">Each share of Class A common stock is entitled to one vote. Class B common stock is nonvoting<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionFeatures', window );">Common stock, terms of conversion</a></td>
<td class="text">each share of Class B common stock is convertible into one share of Class A common stock at the option of the holder at any time, subject to the ownership limitations provided for in the Company&#8217;s amended and restated certificate of incorporation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of common stock conversion feature. Includes, but is not limited to, conversion price; conversion right; timing of right; terms, event or change in circumstance causing contingency to be met or adjustment to conversion price or number of shares; manner of settlement upon conversion; and method of settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">8,827,157<span></span>
</td>
<td class="nump">8,696,968<span></span>
</td>
<td class="nump">8,034,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">7,717,641<span></span>
</td>
<td class="nump">7,980,047<span></span>
</td>
<td class="nump">8,034,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">1,091,116<span></span>
</td>
<td class="nump">716,921<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">18,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provisions</a></td>
<td class="nump">$ 585,000<span></span>
</td>
<td class="nump">$ 764,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate, percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Description of income tax examination</a></td>
<td class="text"> In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from 2022 to the present.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart', window );">Research and development tax credit carryforward expiration year start</a></td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increased valuation allowance</a></td>
<td class="nump">$ 142,500,000<span></span>
</td>
<td class="nump">119,100,000<span></span>
</td>
<td class="nump">$ 48,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text"> 2022 2023 2024 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provisions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=nuvl_NetOperatingLossesMember', window );">Net Operating Losses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provisions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 531,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_OperatingLossCarryforwardExpirationYearStart', window );">Operating loss carryforward expiration year start</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards research and development</a></td>
<td class="nump">$ 14,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">503,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards research and development</a></td>
<td class="nump">14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Orphan Drug Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards research and development</a></td>
<td class="nump">56,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Expirable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_OperatingLossCarryforwardExpirationYearStart', window );">Operating loss carryforward expiration year start</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Non expirable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 502,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_OperatingLossCarryforwardOffsetLimitPercentage', window );">Operating loss carryforward offset limit percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_OperatingLossCarryforwardExpirationYearStart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The year in which operating loss carryforwards begin to expire, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_OperatingLossCarryforwardExpirationYearStart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_OperatingLossCarryforwardOffsetLimitPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of annual taxable income that may be offset using net operating loss carryforwards, as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_OperatingLossCarryforwardOffsetLimitPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The year in which research and development tax credit carryforwards begin to expire, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=nuvl_NetOperatingLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=nuvl_NetOperatingLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=nuvl_OrphanDrugCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=nuvl_OrphanDrugCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=nuvl_ExpirableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=nuvl_ExpirableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=nuvl_NonExpirableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=nuvl_NonExpirableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="num">$ (89,206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate, percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal (national) income tax effect</a></td>
<td class="nump">$ 585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal (national) income tax effect, percent</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects, percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Effect of changes in tax laws or rates enacted in the current period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effect of changes in tax laws or rates enacted in the current period, percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount', window );">Effect of cross-border tax laws</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent', window );">Effect of cross-border tax laws, percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount', window );">Orphan drug related tax credits</a></td>
<td class="num">$ (27,137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent', window );">Orphan drug related tax credits, percent</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">R&amp;D tax credit</a></td>
<td class="nump">$ 1,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D tax credit, percent</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits generated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.30%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances</a></td>
<td class="nump">$ 114,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances, percent</a></td>
<td class="num">(27.00%)<span></span>
</td>
<td class="num">(45.80%)<span></span>
</td>
<td class="num">(38.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount', window );">Nontaxable or nondeductible items, Section 162(m) limitation</a></td>
<td class="nump">$ 12,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent', window );">Nontaxable or nondeductible items, Section 162(m) limitation, percent</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Nontaxable or nondeductible items, stock-based compensation</a></td>
<td class="num">$ (12,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Nontaxable or nondeductible items, stock-based compensation, percent</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Nontaxable or nondeductible items, permanent adjustments</a></td>
<td class="nump">$ 113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Nontaxable or nondeductible items, permanent adjustments, percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Changes in unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">Changes in unrecognized tax benefits, percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="nump">$ 447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments, percent</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective income tax rate</a></td>
<td class="nump">$ 585<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate, percent</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to limitations under Section 162(m).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to limitations under Section 162(m).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred Tax Assets, Gross [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 139,120<span></span>
</td>
<td class="nump">$ 56,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">103,127<span></span>
</td>
<td class="nump">94,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">82,361<span></span>
</td>
<td class="nump">52,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability', window );">Change in fair value of related party revenue share liability</a></td>
<td class="nump">19,284<span></span>
</td>
<td class="nump">4,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">14,225<span></span>
</td>
<td class="nump">9,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">4,648<span></span>
</td>
<td class="nump">2,714<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">362,765<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(362,495)<span></span>
</td>
<td class="num">(220,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total net deferred tax assets</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(270)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross deferred tax liabilities</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to the change in fair value of a related party revenue share liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrued liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nuvl_RevenueSharingAgreementsMember', window );">Revenue Sharing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_PercentageOfNetSalesPayable', window );">Percentage of net sales payable</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_PercentageOfNetSalesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the Company is obligated to pay, as a percentage of net sales of certain commercial products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_PercentageOfNetSalesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nuvl_RevenueSharingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nuvl_RevenueSharingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment Reporting, Expense Information Used by CODM, Description</a></td>
<td class="text">This presentation is consistent with how the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), its Chief Executive Officer, assesses the performance of the Company and makes operating decisions on a consolidated basis. The accounting policies of the consolidated segment are the same as those described in the summary of significant accounting policies (see Note 2). The CODM assesses performance and decides how to allocate resources based on consolidated net loss as reported on the consolidated statements of operations and comprehensive loss. The CODM uses consolidated net loss to monitor budget versus actual results, assess cash runway, and benchmark against the Company&#8217;s competitors. The measure of segment assets is reported on the consolidated balance sheets as total assets. The Company&#8217;s assets are held in the United States.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration', window );">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</a></td>
<td class="text">us-gaap:SegmentReportingExpenseInformationUsedByCodmConsolidatedMember<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Personnel-related expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73,163<span></span>
</td>
<td class="nump">$ 44,121<span></span>
</td>
<td class="nump">$ 29,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,502<span></span>
</td>
<td class="nump">60,579<span></span>
</td>
<td class="nump">25,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of related party revenue share liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,220<span></span>
</td>
<td class="nump">17,940<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(44,794)<span></span>
</td>
<td class="num">(38,372)<span></span>
</td>
<td class="num">(23,277)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">41,009<span></span>
</td>
<td class="nump">17,511<span></span>
</td>
<td class="nump">9,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">585<span></span>
</td>
<td class="nump">764<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(425,377)<span></span>
</td>
<td class="num">(260,756)<span></span>
</td>
<td class="num">(126,219)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nuvl_ZidesamtinibMember', window );">Zidesamtinib [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_DirectExpensesRelatedToProgram', window );">Direct external expenses by program</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,519<span></span>
</td>
<td class="nump">62,110<span></span>
</td>
<td class="nump">27,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nuvl_NeladalkibMember', window );">Neladalkib [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_DirectExpensesRelatedToProgram', window );">Direct external expenses by program</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">105,446<span></span>
</td>
<td class="nump">67,778<span></span>
</td>
<td class="nump">31,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nuvl_NVL-330Member', window );">NVL-330 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_DirectExpensesRelatedToProgram', window );">Direct external expenses by program</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,819<span></span>
</td>
<td class="nump">8,293<span></span>
</td>
<td class="nump">10,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nuvl_DiscoveryProgramsMember', window );">Discovery Programs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_DirectExpensesRelatedToProgram', window );">Direct external expenses by program</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,875<span></span>
</td>
<td class="nump">9,178<span></span>
</td>
<td class="nump">8,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,405<span></span>
</td>
<td class="nump">29,210<span></span>
</td>
<td class="nump">13,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">General and administrative professional and consultant fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15,033<span></span>
</td>
<td class="nump">$ 10,854<span></span>
</td>
<td class="nump">$ 6,423<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items included in consolidated net loss include expenses for commercialization preparation activities, research and development consulting services, information technology, insurance, employee recruitment and other miscellaneous activities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_DirectExpensesRelatedToProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct expense from external sources related to a specified program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_DirectExpensesRelatedToProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nuvl_ZidesamtinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nuvl_ZidesamtinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nuvl_NeladalkibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nuvl_NeladalkibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nuvl_NVL-330Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nuvl_NVL-330Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nuvl_DiscoveryProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nuvl_DiscoveryProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>165</ContextCount>
  <ElementCount>297</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75040 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995457 - Disclosure - Cybersecurity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity</Role>
      <ShortName>Cybersecurity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies1</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995497 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995507 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquity1</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995547 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995607 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies1</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20251231/taxonomy/role/MarketableSecurities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995637 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995647 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995667 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995677 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995687 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995697 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995707 - Disclosure - Nature of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Nature of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995727 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995737 - Disclosure - Marketable Securities - Summary of Marketable Securities by Security (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail</Role>
      <ShortName>Marketable Securities - Summary of Marketable Securities by Security (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995747 - Disclosure - Marketable Securities - Summary of Contractual Maturities of Available-for-sale Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail</Role>
      <ShortName>Marketable Securities - Summary of Contractual Maturities of Available-for-sale Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995757 - Disclosure - Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995767 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995777 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value of Company's Related Party Revenue Share Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail</Role>
      <ShortName>Fair Value Measurements - Schedule of Estimated Fair Value of Company's Related Party Revenue Share Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995787 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995797 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995807 - Disclosure - Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail</Role>
      <ShortName>Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995837 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995847 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995857 - Disclosure - Stock-Based Compensation - Summary of Share Based Payment Award Stock Options Range of Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Share Based Payment Award Stock Options Range of Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995867 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Options Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995877 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995887 - Disclosure - Net Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995897 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995907 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995917 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995927 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995947 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995957 - Disclosure - Segment Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail</Role>
      <ShortName>Segment Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nuvl-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995967 - Disclosure - Segment Information - Schedule of Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails</Role>
      <ShortName>Segment Information - Schedule of Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="nuvl-20251231.htm">nuvl-20251231.htm</File>
    <File>nuvl-20251231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img123481027_0.jpg</File>
    <File>img123481027_1.gif</File>
    <File>img123481027_2.gif</File>
    <File>img123481027_3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="600">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="13">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nuvl-20251231.htm": {
   "nsprefix": "nuvl",
   "nsuri": "http://www.nuvalent.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "nuvl-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "nuvl-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 272,
   "keyCustom": 25,
   "axisStandard": 20,
   "axisCustom": 1,
   "memberStandard": 24,
   "memberCustom": 25,
   "hidden": {
    "total": 10,
    "http://fasb.org/us-gaap/2025": 7,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 165,
   "entityCount": 1,
   "segmentCount": 55,
   "elementCount": 641,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 600,
    "http://xbrl.sec.gov/dei/2025": 41,
    "http://xbrl.sec.gov/ecd/2025": 26,
    "http://xbrl.sec.gov/cyd/2025": 13
   },
   "report": {
    "R1": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage",
     "longName": "75000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
     "longName": "75010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "75020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "75030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "75040 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_fed5ef36-c783-45d6-bccf-aedf6738ae46",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fed5ef36-c783-45d6-bccf-aedf6738ae46",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
     "longName": "75060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_1dad83de-cc46-4271-b61b-c56d9259a2a0",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1dad83de-cc46-4271-b61b-c56d9259a2a0",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "a",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "a",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity",
     "longName": "995457 - Disclosure - Cybersecurity",
     "shortName": "Cybersecurity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusiness",
     "longName": "995467 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies1",
     "longName": "995477 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/MarketableSecurities",
     "longName": "995487 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurements",
     "longName": "995497 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "995507 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquity1",
     "longName": "995527 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensation",
     "longName": "995537 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShare",
     "longName": "995547 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxes",
     "longName": "995557 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingencies",
     "longName": "995567 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformation",
     "longName": "995597 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995607 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/MarketableSecuritiesTables",
     "longName": "995627 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsTables",
     "longName": "995637 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "995647 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "nuvl:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "nuvl:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationTables",
     "longName": "995667 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "995677 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesTables",
     "longName": "995687 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995697 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
     "longName": "995707 - Disclosure - Nature of Business - Additional Information (Detail)",
     "shortName": "Nature of Business - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "995727 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail",
     "longName": "995737 - Disclosure - Marketable Securities - Summary of Marketable Securities by Security (Detail)",
     "shortName": "Marketable Securities - Summary of Marketable Securities by Security (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail",
     "longName": "995747 - Disclosure - Marketable Securities - Summary of Contractual Maturities of Available-for-sale Debt Securities (Detail)",
     "shortName": "Marketable Securities - Summary of Contractual Maturities of Available-for-sale Debt Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_249fe9c5-035a-4be4-bda3-5a7f5c5d842f",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail",
     "longName": "995757 - Disclosure - Marketable Securities - Additional Information (Detail)",
     "shortName": "Marketable Securities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
     "longName": "995767 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a35f2a79-4ef6-43ea-a2a6-e4132c6ac5cf",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail",
     "longName": "995777 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value of Company's Related Party Revenue Share Liability (Detail)",
     "shortName": "Fair Value Measurements - Schedule of Estimated Fair Value of Company's Related Party Revenue Share Liability (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_d099b530-0cf4-48be-a348-63560b2d2db7",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d099b530-0cf4-48be-a348-63560b2d2db7",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
     "longName": "995787 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail",
     "longName": "995797 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail)",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "nuvl:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "nuvl:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail",
     "longName": "995807 - Disclosure - Equity - Additional Information (Detail)",
     "shortName": "Equity - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b3cff3c2-044c-46b7-89c3-2f4680873e9a",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail",
     "longName": "995837 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expenses (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f59252bc-b763-4e51-83d2-54d4bba5a6f8",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
     "longName": "995847 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail",
     "longName": "995857 - Disclosure - Stock-Based Compensation - Summary of Share Based Payment Award Stock Options Range of Assumptions (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Share Based Payment Award Stock Options Range of Assumptions (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail",
     "longName": "995867 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Stock Options Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_995479a7-c042-4eed-b4f4-cb48506a82ad",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
     "longName": "995877 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_b5d7c4e7-18e6-4f91-bcaf-b360fe129db5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
     "longName": "995887 - Disclosure - Net Loss Per Share - Additional Information (Detail)",
     "shortName": "Net Loss Per Share - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "longName": "995897 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
     "longName": "995907 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail",
     "longName": "995917 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail",
     "longName": "995927 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "995947 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_315a253c-12d3-4e3f-8582-c49af65387fa",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
     "longName": "995957 - Disclosure - Segment Information - Additional Information (Detail)",
     "shortName": "Segment Information - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
     "longName": "995967 - Disclosure - Segment Information - Schedule of Segment Information (Details)",
     "shortName": "Segment Information - Schedule of Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASC 842 [Member]",
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdate201613Member",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2016-13 [Member]",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_AccountingStandardsUpdate202307Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdate202307Member",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2023-07 [Member]",
        "terseLabel": "ASU 2023-27 [Member]",
        "documentation": "Accounting Standards Update 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207"
     ]
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r130",
      "r131",
      "r132",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r206",
      "r207",
      "r243",
      "r245",
      "r246",
      "r260",
      "r261",
      "r264",
      "r287",
      "r288",
      "r289",
      "r290",
      "r374",
      "r375",
      "r376",
      "r377",
      "r428",
      "r429",
      "r430",
      "r431",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r468",
      "r469",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r520",
      "r521",
      "r539",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r809"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net accretion on marketable securities",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "AccruedClinicalAndOtherResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Clinical and Other Research and Development Expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expenses and other research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "terseLabel": "Accrued clinical and other research and development"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_AccruedExternalResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "AccruedExternalResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued external research and development expenses",
        "label": "Accrued External Research And Development Expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development expenses from external sources. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedInsuranceCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Insurance, Current",
        "terseLabel": "Accrued insurance",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_AccruedManufacturingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "AccruedManufacturingExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued manufacturing",
        "label": "Accrued Manufacturing Expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_AccruedOtherAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "AccruedOtherAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Other and Other Liabilities Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other and amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "terseLabel": "Accrued other and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r57",
      "r118",
      "r604",
      "r634",
      "r638",
      "r1088"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r6",
      "r14",
      "r472",
      "r475",
      "r548",
      "r629",
      "r630",
      "r959",
      "r960",
      "r961",
      "r1013",
      "r1014",
      "r1015",
      "r1017"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r1013",
      "r1014",
      "r1015",
      "r1017",
      "r1089",
      "r1150"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r130",
      "r131",
      "r132",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r162",
      "r206",
      "r207",
      "r243",
      "r245",
      "r246",
      "r247",
      "r260",
      "r261",
      "r264",
      "r287",
      "r288",
      "r289",
      "r290",
      "r374",
      "r375",
      "r376",
      "r377",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r520",
      "r521",
      "r539",
      "r540",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r861",
      "r871",
      "r904"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r874",
      "r907"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "nuvl_AlexandraBalcomMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "AlexandraBalcomMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alexandra Balcom [Member]",
        "documentation": "Alexandra balcom."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r875",
      "r899",
      "r908",
      "r912",
      "r920"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock-based compensation expense",
        "label": "Stock-based compensation expenses",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r378",
      "r388"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_AnnaProtopapasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "AnnaProtopapasMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anna Protopapas [Member]",
        "documentation": "Anna Protopapas."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.nuvalent.com/20251231/taxonomy/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.nuvalent.com/20251231/taxonomy/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r87",
      "r114",
      "r137",
      "r138",
      "r139",
      "r177",
      "r191",
      "r197",
      "r200",
      "r241",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r457",
      "r461",
      "r527",
      "r593",
      "r594",
      "r599",
      "r689",
      "r764",
      "r765",
      "r775",
      "r809",
      "r815",
      "r816",
      "r828",
      "r1040",
      "r1041",
      "r1105"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Assets:",
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r119",
      "r137",
      "r138",
      "r139",
      "r241",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r457",
      "r461",
      "r527",
      "r809",
      "r1040",
      "r1041",
      "r1105"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total Assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r497",
      "r797"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r857"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r857"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r857"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r253",
      "r598"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value",
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r253",
      "r496",
      "r522",
      "r523",
      "r524",
      "r525",
      "r589",
      "r743",
      "r797",
      "r800",
      "r807",
      "r1025",
      "r1093",
      "r1094",
      "r1095"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation and consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash and Cash Equivalent",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r112",
      "r745"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524",
      "r525",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r63",
      "r136"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r63"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r108",
      "r130",
      "r146",
      "r206",
      "r260",
      "r264",
      "r287",
      "r374",
      "r429",
      "r438",
      "r439",
      "r447",
      "r448",
      "r450",
      "r468",
      "r484",
      "r485",
      "r520",
      "r521",
      "r539",
      "r543",
      "r544",
      "r627",
      "r628"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r130",
      "r206",
      "r260",
      "r264",
      "r287",
      "r288",
      "r374",
      "r375",
      "r429",
      "r438",
      "r439",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r468",
      "r469",
      "r484",
      "r485",
      "r486",
      "r489",
      "r520",
      "r521",
      "r539",
      "r543",
      "r544",
      "r627",
      "r628",
      "r954",
      "r1016"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r147",
      "r161",
      "r244"
     ]
    },
    "nuvl_ChangeInFairValueOfPreferredStockTrancheRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "ChangeInFairValueOfPreferredStockTrancheRights",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of preferred stock tranche rights",
        "terseLabel": "Change in fair value of preferred stock tranche rights",
        "label": "Change In Fair Value Of Preferred Stock Tranche Rights",
        "documentation": "The amount of income (expense) related to a change in fair value of preferred stock tranche rights.",
        "verboseLabel": "Change in fair value of the Series A Tranche Rights"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_ClassAAndClassBCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "ClassAAndClassBCommonStockMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A and Class B Common Stock [Member]",
        "documentation": "Class A and Class B Common Stock."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_ClassAAndClassBCommonStockOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "ClassAAndClassBCommonStockOutstandingMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A And Class B Common Stock Outstanding [Member]",
        "label": "Class A And Class B Common Stock Outstanding [Member]",
        "documentation": "Class A And Class B Common Stock Outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_ClassBConvertibleCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "ClassBConvertibleCommonStockMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B Convertible Common Stock [Member]",
        "documentation": "Class B convertible common stock.",
        "terseLabel": "Class B Convertible Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r115",
      "r116",
      "r117",
      "r137",
      "r139",
      "r166",
      "r167",
      "r169",
      "r171",
      "r179",
      "r180",
      "r241",
      "r275",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r291",
      "r292",
      "r294",
      "r295",
      "r297",
      "r301",
      "r304",
      "r305",
      "r308",
      "r311",
      "r319",
      "r527",
      "r644",
      "r645",
      "r646",
      "r647",
      "r654",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r677",
      "r697",
      "r717",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r944",
      "r1009",
      "r1010",
      "r1018"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r179",
      "r294",
      "r304",
      "r305",
      "r306",
      "r308",
      "r311",
      "r317",
      "r319",
      "r467",
      "r644",
      "r645",
      "r646",
      "r647",
      "r776",
      "r944",
      "r1008",
      "r1009"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r274",
      "r822",
      "r823",
      "r824",
      "r825"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r81",
      "r600",
      "r676"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r266",
      "r267",
      "r739",
      "r1033",
      "r1035"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Class A [Member]",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Class B [Member]",
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "us-gaap_CommonStockConversionFeatures": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockConversionFeatures",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, terms of conversion",
        "label": "Common Stock, Terms of Conversion",
        "documentation": "Description of common stock conversion feature. Includes, but is not limited to, conversion price; conversion right; timing of right; terms, event or change in circumstance causing contingency to be met or adjustment to conversion price or number of shares; manner of settlement upon conversion; and method of settlement."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r320"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r818",
      "r819",
      "r820",
      "r822",
      "r823",
      "r824",
      "r825",
      "r1013",
      "r1014",
      "r1017",
      "r1089",
      "r1146",
      "r1150"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value | $ / shares",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r677"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r51",
      "r677",
      "r695",
      "r1150",
      "r1151"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r292",
      "r300",
      "r602",
      "r809"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r121",
      "r123",
      "r128",
      "r591",
      "r612",
      "r613"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of credit risk and of significant suppliers",
        "label": "Concentration Of Credit Risk And Of Significant Suppliers [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk and significant suppliers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation and consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r751"
     ]
    },
    "nuvl_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock to common stock upon initial public offering",
        "label": "Conversion Of Convertible Preferred Stock To Common Stock Upon Initial Public Offering",
        "documentation": "The value of convertible preferred stock converted to common stock upon the initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_ConvertiblePreferredStockMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "ConvertiblePreferredStockMeasurementInput",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, measurement input",
        "label": "Convertible Preferred Stock Measurement Input",
        "documentation": "Value of input used to measure convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock [Member]",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r308",
      "r822",
      "r823",
      "r824",
      "r825"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Issuable Upon Conversion",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r31",
      "r50",
      "r71",
      "r314"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate bonds",
        "label": "Corporate Bond Securities [Member]",
        "verboseLabel": "Corporate bonds [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r931"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r931"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r933"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r933"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r935"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r933"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r926"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r927"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r927"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r925"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r925"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r925"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r928"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r930"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r930"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r931"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r934"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r932"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r929"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of note payable and accrued interest to Series A convertible preferred stock",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of note payable and accrued interest to Series A convertible preferred stock , Shares",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities credit loss",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Period Increase (Decrease)",
        "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "DebtSecuritiesAvailableForSalesSecuritiesDueAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities Available For Sales Securities Due [Axis]",
        "documentation": "Debt Securities Available For Sales Securities Due."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "DebtSecuritiesAvailableForSalesSecuritiesDueDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities Available For Sales Securities Due [Domain]",
        "documentation": "Debt Securities Available For Sales Securities Due"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total gross deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r80",
      "r419"
     ]
    },
    "nuvl_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.",
        "label": "Deferred Tax Assets Capitalized Research And Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of related party revenue share liability",
        "label": "Deferred Tax Assets Fair Value Of Related Party Revenue Share Liability",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to the change in fair value of a related party revenue share liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "periodStartLabel": "Valuation allowance as of beginning of year",
        "periodEndLabel": "Valuation allowance as of end of year",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Deferred Tax Liabilities, Net, Total",
        "terseLabel": "Deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DefinedContributionPlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution Plan [Abstract]",
        "label": "Defined Contribution Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DefinedContributionPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution Plan",
        "label": "Defined Contribution Plan [Text Block]",
        "documentation": "The entire disclosure for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333"
     ]
    },
    "nuvl_DirectExpensesRelatedToProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "DirectExpensesRelatedToProgram",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Direct Expenses Related to Program",
        "documentation": "Amount of direct expense from external sources related to a specified program.",
        "terseLabel": "Direct external expenses by program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r339",
      "r370",
      "r371",
      "r373",
      "r785"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_DiscoveryProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "DiscoveryProgramsMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discovery Programs [Member]",
        "documentation": "Discovery programs."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r857"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r857",
      "r900"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information:",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Domestic Tax Authority [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "nuvl_DueFromOneToThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "DueFromOneToThreeYearsMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due From One To Three Years [Member]",
        "documentation": "Due From One To Three Years [Member]",
        "terseLabel": "Due after one year through three years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_DueWithinOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "DueWithinOneYearMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due Within One Year [Member]",
        "documentation": "Due within one year.",
        "terseLabel": "Due within one year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_EarliestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarliestTaxYearMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earliest Tax Year [Member]",
        "label": "Earliest Tax Year [Member]",
        "documentation": "Earliest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "terseLabel": "Net loss per share attributable to Class A and Class B common stockholders, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r129",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r164",
      "r166",
      "r169",
      "r170",
      "r171",
      "r176",
      "r290",
      "r376",
      "r445",
      "r454",
      "r493",
      "r494",
      "r592",
      "r614",
      "r754"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "terseLabel": "Net loss per share attributable to Class A and Class B common stockholders, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r129",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r166",
      "r169",
      "r170",
      "r171",
      "r176",
      "r290",
      "r376",
      "r445",
      "r454",
      "r493",
      "r494",
      "r592",
      "r614",
      "r754"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r173"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r172",
      "r174",
      "r175"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate, percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r788"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate, percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r140",
      "r400",
      "r432",
      "r788"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in deferred tax asset valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Changes in valuation allowances, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r788",
      "r1008",
      "r1012",
      "r1078"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Effect of changes in tax laws or rates enacted in the current period, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r788",
      "r1008",
      "r1012",
      "r1078"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of cross-border tax laws",
        "label": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount, Total",
        "documentation": "Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r410"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of cross-border tax laws, percent",
        "label": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent, Total",
        "documentation": "Percentage of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r410"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign tax effects, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r404",
      "r788",
      "r1008",
      "r1012",
      "r1078"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r788"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Nontaxable or nondeductible items, permanent adjustments, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r1008",
      "r1012",
      "r1078",
      "r1080"
     ]
    },
    "nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Section 162(m) Limitation, Amount",
        "terseLabel": "Nontaxable or nondeductible items, Section 162(m) limitation",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to limitations under Section 162(m)."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Section 162(M) Limitation, Percent",
        "terseLabel": "Nontaxable or nondeductible items, Section 162(m) limitation, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to limitations under Section 162(m)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "verboseLabel": "Nontaxable or nondeductible items, stock-based compensation, percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r1008",
      "r1012",
      "r1078",
      "r1080"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other adjustments, percent",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r1008",
      "r1012",
      "r1078",
      "r1079"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State income taxes, net of federal (national) income tax effect, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r788",
      "r1008",
      "r1012",
      "r1078"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r788"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent, Total",
        "terseLabel": "Changes in unrecognized tax benefits, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r788",
      "r1008",
      "r1012",
      "r1078"
     ]
    },
    "nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug Related, Amount",
        "terseLabel": "Orphan drug related tax credits",
        "negatedLabel": "Orphan drug related tax credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Orphan drug related tax credits, percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug Related, Percent",
        "negatedLabel": "Orphan drug related tax credits, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax credits generated",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "negatedLabel": "Tax credits generated",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r410",
      "r1008",
      "r1012",
      "r1078"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "R&amp;D tax credit, percent",
        "negatedLabel": "R&amp;D tax credit, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r1008",
      "r1012",
      "r1078",
      "r1080"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued employee compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrecognized compensation cost related to common stock options and unvested restricted stock",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "terseLabel": "Unrecognized compensation cost related to common stock options",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment weighted average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.nuvalent.com/20251231/taxonomy/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Options to Purchase Common Stock",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIK",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Disclosure [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_EquityAdjustmentPromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "EquityAdjustmentPromissoryNote",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of promissory note from related party stockholder",
        "label": "Equity Adjustment Promissory Note",
        "documentation": "Amount of increase (decrease) to stockholders' equity for the issuance of a promissory note from a related party stockholder."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_EquityAdjustmentPromissoryNoteInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "EquityAdjustmentPromissoryNoteInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Adjustment Promissory Note Interest",
        "documentation": "Amount of increase (decrease) to stockholders' equity for the interest on a promissory note from a related party stockholder.",
        "terseLabel": "Interest on promissory note from related party stockholder"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r100",
      "r107",
      "r108",
      "r125",
      "r126",
      "r127",
      "r142",
      "r143",
      "r144",
      "r148",
      "r156",
      "r158",
      "r160",
      "r178",
      "r243",
      "r247",
      "r261",
      "r289",
      "r321",
      "r376",
      "r427",
      "r428",
      "r441",
      "r442",
      "r443",
      "r446",
      "r453",
      "r454",
      "r470",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r492",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r539",
      "r541",
      "r548",
      "r610",
      "r629",
      "r630",
      "r631",
      "r654",
      "r717"
     ]
    },
    "nuvl_EquityIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "EquityIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity issuance cost",
        "label": "Equity Issuance Cost",
        "documentation": "The costs incurred during the period for the issuance of an equity security."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_EquityIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "EquityIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Issuance Costs",
        "documentation": "The costs incurred during the period for the issuance of an equity security.",
        "terseLabel": "Equity issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_EquityIssuanceCostsIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "EquityIssuanceCostsIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Issuance Costs Incurred But Not Yet Paid",
        "documentation": "Future cash outflow to pay for costs associated with the issuance of equity securities.",
        "terseLabel": "Equity issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r861",
      "r871",
      "r904"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r858",
      "r868",
      "r901"
     ]
    },
    "nuvl_ExcludingPerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "ExcludingPerformanceStockUnitsMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excluding Performance Stock Units [Member]",
        "documentation": "Excluding performance stock units.",
        "terseLabel": "Excluding PSUs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "nuvl_ExpirableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "ExpirableMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expirable [Member]",
        "documentation": "Expirable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r497",
      "r510",
      "r797"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r497",
      "r510",
      "r797"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r511",
      "r743",
      "r798",
      "r807"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524",
      "r525",
      "r743",
      "r807",
      "r1103"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r511",
      "r743",
      "r798",
      "r807"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r525",
      "r743",
      "r807",
      "r1102",
      "r1103"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r509",
      "r510",
      "r512",
      "r523",
      "r558",
      "r559",
      "r560",
      "r743",
      "r773",
      "r774",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r797",
      "r800",
      "r807"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r511"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r497",
      "r498",
      "r500",
      "r797",
      "r1094",
      "r1099"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r505",
      "r507",
      "r508",
      "r509",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r588",
      "r797",
      "r801"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value, inputs, level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r323",
      "r328",
      "r329",
      "r497",
      "r510",
      "r523",
      "r558",
      "r743",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r797",
      "r807"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value, inputs, level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r323",
      "r328",
      "r329",
      "r331",
      "r497",
      "r498",
      "r510",
      "r523",
      "r559",
      "r743",
      "r773",
      "r774",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r797",
      "r807"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value, inputs, level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r497",
      "r498",
      "r499",
      "r500",
      "r510",
      "r523",
      "r560",
      "r743",
      "r773",
      "r774",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r797",
      "r800",
      "r807"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r511"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r511"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Company's Related Party Revenue Share Liability",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r506",
      "r511"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r497",
      "r498",
      "r500",
      "r797",
      "r1094",
      "r1099"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "verboseLabel": "Fair value option for related party revenue share liability",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r511"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of preferred stock tranche rights",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r511"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value transfers in or out of Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net, Total",
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r1096",
      "r1098"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "terseLabel": "Estimated fair value",
        "periodEndLabel": "Estimated fair value as of December 31, 2025",
        "periodStartLabel": "Estimated fair value as of December 31, 2024",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r511"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r509",
      "r510",
      "r512",
      "r523",
      "r558",
      "r559",
      "r560",
      "r743",
      "r773",
      "r774",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r797",
      "r800",
      "r807"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1099"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value option for related party revenue share liability",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r286",
      "r317",
      "r467",
      "r482",
      "r517",
      "r526",
      "r529",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r597",
      "r611",
      "r771",
      "r797",
      "r798",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r810",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1090",
      "r1093",
      "r1094",
      "r1095",
      "r1097",
      "r1099",
      "r1101",
      "r1102"
     ]
    },
    "nuvl_FollowOnPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "FollowOnPublicOfferingMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Follow On Public Offering [Member]",
        "documentation": "Follow-On public offering.",
        "terseLabel": "Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r875",
      "r908"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r875",
      "r908"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r875",
      "r908"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r875",
      "r908"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r875",
      "r908"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r27",
      "r28"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r699"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expenses [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent costs",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259"
     ]
    },
    "nuvl_GovernmentAndAgencySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "GovernmentAndAgencySecuritiesMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government And Agency Securities [Member]",
        "documentation": "Government and agency securities.",
        "terseLabel": "Government and agency securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_GovernmentSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "GovernmentSecuritiesMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Securities [Member]",
        "documentation": "Government securities.",
        "terseLabel": "Government securities [Member]",
        "verboseLabel": "Government securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_HenryPelishMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "HenryPelishMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Henry Pelish [Member]",
        "documentation": "Henry pelish."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "IPO [Member]",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r857"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income taxes",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r83",
      "r86",
      "r593",
      "r595",
      "r607",
      "r747",
      "r749",
      "r750",
      "r759",
      "r764",
      "r1019",
      "r1021",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r265",
      "r463",
      "r464",
      "r465",
      "r466",
      "r502",
      "r506",
      "r511",
      "r528",
      "r529",
      "r530",
      "r624",
      "r626",
      "r702",
      "r742",
      "r743",
      "r789",
      "r790",
      "r795",
      "r796",
      "r799",
      "r807",
      "r1086",
      "r1087",
      "r1117"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r265",
      "r463",
      "r464",
      "r465",
      "r466",
      "r502",
      "r506",
      "r511",
      "r528",
      "r529",
      "r530",
      "r624",
      "r626",
      "r702",
      "r742",
      "r743",
      "r789",
      "r790",
      "r795",
      "r796",
      "r799",
      "r807",
      "r1086",
      "r1087",
      "r1117"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r400",
      "r401",
      "r414",
      "r424",
      "r788",
      "r1084"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r400",
      "r401",
      "r414",
      "r424",
      "r788",
      "r1084"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r140",
      "r394",
      "r400",
      "r411",
      "r412",
      "r413",
      "r416",
      "r423",
      "r433",
      "r435",
      "r436",
      "r437",
      "r596",
      "r640",
      "r649",
      "r788"
     ]
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationDescription",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Description of income tax examination",
        "label": "Income Tax Examination, Description",
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      },
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision",
        "negatedLabel": "Income tax provision",
        "label": "Income tax provisions",
        "totalLabel": "Effective income tax rate",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r95",
      "r137",
      "r159",
      "r160",
      "r177",
      "r193",
      "r200",
      "r399",
      "r400",
      "r434",
      "r615",
      "r747",
      "r749",
      "r750",
      "r788"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r397",
      "r398",
      "r416",
      "r417",
      "r422",
      "r426",
      "r643"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowances",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r788",
      "r1078"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of changes in tax laws or rates enacted in the current period",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r400",
      "r405",
      "r788"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign tax effects",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r404",
      "r788",
      "r1078"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal statutory income tax rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r788"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nontaxable or nondeductible items, permanent adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r1078",
      "r1080"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Nontaxable or nondeductible items, stock-based compensation",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r1078",
      "r1080"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other adjustments",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r1078",
      "r1079"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes, net of federal (national) income tax effect",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r788",
      "r1078"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount, Total",
        "terseLabel": "Changes in unrecognized tax benefits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r788",
      "r1078"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "terseLabel": "R&amp;D tax credit",
        "negatedLabel": "R&amp;D tax credit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r1078",
      "r1080"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r875",
      "r899",
      "r908",
      "r912",
      "r920"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r924"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r924"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r924"
     ]
    },
    "nuvl_InsurancePremiumFinancedByThirdParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "InsurancePremiumFinancedByThirdParty",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance premium financed by a third-party",
        "label": "Insurance Premium Financed By Third Party",
        "documentation": "The amount of insurance premiums financed by a third party."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_InterestAndOtherIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "InterestAndOtherIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income and other income (expense), net",
        "label": "Interest and Other Income (Expense)",
        "documentation": "Amount of interest income and income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r192",
      "r200",
      "r764",
      "r963"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Contractual Maturities of Available-for-sale Debt Securities",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r97",
      "r209",
      "r210",
      "r518",
      "r519",
      "r1114"
     ]
    },
    "nuvl_IssuanceOfPromissoryNoteToStockholder": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "IssuanceOfPromissoryNoteToStockholder",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Issuance of promissory note to stockholder",
        "label": "Issuance Of Promissory Note To Stockholder",
        "documentation": "The cash outflow from the issuance of a promissory note to a stockholder."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_JamesPorterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "JamesPorterMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "James Porter [Member]",
        "documentation": "James porter."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Labor and Related Expense",
        "negatedLabel": "Personnel-related expenses",
        "terseLabel": "Personnel-related expenses",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r749",
      "r962"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r48",
      "r137",
      "r138",
      "r139",
      "r241",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r458",
      "r461",
      "r462",
      "r527",
      "r675",
      "r758",
      "r775",
      "r828",
      "r1040",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r82",
      "r606",
      "r809",
      "r815",
      "r816",
      "r1008",
      "r1011",
      "r1031",
      "r1104"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r111",
      "r137",
      "r138",
      "r139",
      "r241",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r458",
      "r461",
      "r462",
      "r527",
      "r809",
      "r1040",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Adjustment",
        "terseLabel": "Change in fair value of related party revenue share liability",
        "negatedLabel": "Change in fair value of related party revenue share liability",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Liabilities, Fair Value Disclosure, Total",
        "terseLabel": "Total liabilities",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r1091"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r268",
      "r269",
      "r270",
      "r273",
      "r390",
      "r772",
      "r1036",
      "r1037"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r268",
      "r269",
      "r270",
      "r273",
      "r390",
      "r772",
      "r1036",
      "r1037"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liability",
        "label": "Loss Contingency Accrual",
        "periodStartLabel": "Loss Contingency Accrual, Beginning Balance",
        "periodEndLabel": "Loss Contingency Accrual, Ending Balance",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r945"
     ]
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Summary of Marketable Securities by Security",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Security, Unrealized Gain (Loss)",
        "verboseLabel": "Unrealized gains (losses) on marketable securities",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r269",
      "r270",
      "r271",
      "r272",
      "r334",
      "r365",
      "r366",
      "r367",
      "r390",
      "r500",
      "r586",
      "r623",
      "r625",
      "r639",
      "r667",
      "r668",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r735",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r770",
      "r776",
      "r784",
      "r789",
      "r791",
      "r792",
      "r800",
      "r801",
      "r805",
      "r806",
      "r812",
      "r1042",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input, expected dividend rate [Member]",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r1093",
      "r1094",
      "r1095"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input, expected term [Member]",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r1093",
      "r1094",
      "r1095"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r498",
      "r499",
      "r500",
      "r789",
      "r791",
      "r792",
      "r800"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r499",
      "r500",
      "r789",
      "r791",
      "r792",
      "r800"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r269",
      "r270",
      "r271",
      "r272",
      "r334",
      "r365",
      "r366",
      "r367",
      "r390",
      "r500",
      "r586",
      "r623",
      "r625",
      "r639",
      "r667",
      "r668",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r735",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r770",
      "r776",
      "r784",
      "r789",
      "r791",
      "r792",
      "r800",
      "r801",
      "r805",
      "r812",
      "r1042",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1050"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "nuvl_NVL-330Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "NVL-330Member",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NVL-330 [Member]",
        "documentation": "NVL-330 [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r182",
      "r755",
      "r756"
     ]
    },
    "nuvl_NeladalkibMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "NeladalkibMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neladalkib [Member]",
        "documentation": "Neladalkib [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r65",
      "r84",
      "r108",
      "r109",
      "r120",
      "r122",
      "r127",
      "r137",
      "r138",
      "r139",
      "r141",
      "r147",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r168",
      "r241",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r290",
      "r293",
      "r296",
      "r302",
      "r376",
      "r445",
      "r454",
      "r494",
      "r527",
      "r609",
      "r696",
      "r715",
      "r716",
      "r747",
      "r749",
      "r750",
      "r826",
      "r1040"
     ]
    },
    "nuvl_NetOperatingLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "NetOperatingLossesMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Operating Losses [Member]",
        "label": "Net Operating Losses [Member]",
        "documentation": "Net Operating Losses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r130",
      "r131",
      "r132",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r162",
      "r176",
      "r206",
      "r207",
      "r243",
      "r245",
      "r246",
      "r247",
      "r260",
      "r261",
      "r264",
      "r287",
      "r288",
      "r289",
      "r290",
      "r374",
      "r375",
      "r376",
      "r377",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r520",
      "r521",
      "r539",
      "r540",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r641"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r130",
      "r131",
      "r132",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r162",
      "r176",
      "r206",
      "r207",
      "r243",
      "r245",
      "r246",
      "r247",
      "r260",
      "r261",
      "r264",
      "r287",
      "r288",
      "r289",
      "r290",
      "r374",
      "r375",
      "r376",
      "r377",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r520",
      "r521",
      "r539",
      "r540",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r641"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued and adopted accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_NonExpirableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "NonExpirableMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non expirable [Member]",
        "documentation": "Non expirable."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r875",
      "r899",
      "r908"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r768",
      "r1020"
     ]
    },
    "nuvl_NumberOfTrancheRightsGrantedTemporaryEquity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "NumberOfTrancheRightsGrantedTemporaryEquity",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of tranche rights granted temporary equity",
        "label": "Number Of Tranche Rights Granted Temporary Equity",
        "documentation": "The number of grant rights issued in connection with the issuance and sale of temporary equity."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_OfferingCostsIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "OfferingCostsIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Costs Incurred But Not Yet Paid",
        "documentation": "Future cash outflow to pay for offering costs that have been incurred.",
        "terseLabel": "Public offering costs included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open tax year",
        "label": "Open Tax Year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r747",
      "r750",
      "r759",
      "r1019",
      "r1021",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "nuvl_OperatingLossCarryforwardExpirationYearStart": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "OperatingLossCarryforwardExpirationYearStart",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforward Expiration Year Start",
        "documentation": "The year in which operating loss carryforwards begin to expire, in YYYY format.",
        "terseLabel": "Operating loss carryforward expiration year start"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_OperatingLossCarryforwardOffsetLimitPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "OperatingLossCarryforwardOffsetLimitPercentage",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforward offset limit percentage",
        "label": "Operating Loss Carryforward Offset Limit Percentage",
        "documentation": "The amount of annual taxable income that may be offset using net operating loss carryforwards, as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_OrphanDrugCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "OrphanDrugCreditMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orphan drug credit.",
        "terseLabel": "Orphan Drug Credit [Member]",
        "label": "Orphan Drug Credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains (losses) on marketable securities",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r6",
      "r78"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Income (Expense)",
        "totalLabel": "Other Noncash Income (Expense), Total",
        "negatedLabel": "Other non-cash",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r863",
      "r873",
      "r906"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r876",
      "r909"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r876",
      "r909"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option [Member]",
        "label": "Over-Allotment Option [Member]",
        "verboseLabel": "Underwriters Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments of equity issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "nuvl_PercentageOfNetSalesPayable": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "PercentageOfNetSalesPayable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Net Sales Payable",
        "terseLabel": "Percentage of net sales payable",
        "documentation": "The amount the Company is obligated to pay, as a percentage of net sales of certain commercial products."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_PerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "PerformanceStockUnitsMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Stock Units [Member]",
        "documentation": "Performance stock units.",
        "terseLabel": "PSUs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value | $ / shares",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r304"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r677"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r304"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r677",
      "r695",
      "r1150",
      "r1151"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Preferred Stock [Text Block]",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r294"
     ]
    },
    "nuvl_PreferredStockTrancheRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "PreferredStockTrancheRightsMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock tranche rights [Member]",
        "label": "Preferred Stock Tranche Rights [Member]",
        "documentation": "Preferred stock tranche rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r292",
      "r299",
      "r601",
      "r809"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "nuvl_ProbabilityOfAchievingMilestones": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "ProbabilityOfAchievingMilestones",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The probability that specified milestones will be achieved during the period, as a percentage.",
        "terseLabel": "Probability of achieving milestones",
        "label": "Probability Of Achieving Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of common stock in follow-on public offering after underwriting discounts and commission and offering costs",
        "label": "Net proceeds from initial public offering",
        "verboseLabel": "Proceeds from issuance of common stock, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of convertible preferred stock and preferred stock tranche rights, net of issuance costs",
        "terseLabel": "Gross Proceeds from issuance of convertible preferred stock",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities and sales of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r587",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r744",
      "r746",
      "r749",
      "r750",
      "r777",
      "r778",
      "r811",
      "r812",
      "r813",
      "r814",
      "r817",
      "r946",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1038",
      "r1039",
      "r1116",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r587",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r744",
      "r746",
      "r749",
      "r750",
      "r777",
      "r778",
      "r811",
      "r812",
      "r813",
      "r814",
      "r817",
      "r946",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1038",
      "r1039",
      "r1116",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Fees",
        "negatedLabel": "General and administrative professional and consultant fees",
        "terseLabel": "General and administrative professional and consultant fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r764",
      "r826",
      "r1148",
      "r1149"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r120",
      "r122",
      "r133",
      "r137",
      "r138",
      "r139",
      "r141",
      "r147",
      "r156",
      "r159",
      "r160",
      "r241",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r290",
      "r376",
      "r445",
      "r454",
      "r456",
      "r459",
      "r460",
      "r494",
      "r527",
      "r593",
      "r595",
      "r608",
      "r653",
      "r696",
      "r715",
      "r716",
      "r793",
      "r794",
      "r827",
      "r961",
      "r1040"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r269",
      "r270",
      "r271",
      "r272",
      "r322",
      "r334",
      "r365",
      "r366",
      "r367",
      "r373",
      "r390",
      "r500",
      "r561",
      "r570",
      "r586",
      "r623",
      "r625",
      "r639",
      "r667",
      "r668",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r735",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r770",
      "r776",
      "r784",
      "r789",
      "r791",
      "r792",
      "r800",
      "r801",
      "r805",
      "r806",
      "r812",
      "r820",
      "r1034",
      "r1042",
      "r1094",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r269",
      "r270",
      "r271",
      "r272",
      "r322",
      "r334",
      "r365",
      "r366",
      "r367",
      "r373",
      "r390",
      "r500",
      "r561",
      "r570",
      "r586",
      "r623",
      "r625",
      "r639",
      "r667",
      "r668",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r735",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r770",
      "r776",
      "r784",
      "r789",
      "r791",
      "r792",
      "r800",
      "r801",
      "r805",
      "r806",
      "r812",
      "r820",
      "r1034",
      "r1042",
      "r1094",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "us-gaap_ReceivablesFromStockholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesFromStockholderMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory note from stockholder [Member]",
        "label": "Receivables from Stockholder [Member]",
        "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r858",
      "r868",
      "r901"
     ]
    },
    "nuvl_RelatedPartyRevenueShareLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "RelatedPartyRevenueShareLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party revenue share liability",
        "documentation": "The fair value of the liability pertaining to a revenue share arrangement with a related party, as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_RelatedPartyRevenueShareLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "RelatedPartyRevenueShareLiabilityMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfCompanysRelatedPartyRevenueShareLiabilityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Revenue Share Liability [Member]",
        "documentation": "Related party revenue share liability.",
        "terseLabel": "Related Party Revenue Share Liability [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/RelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Parties",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r650",
      "r651",
      "r652",
      "r700",
      "r701",
      "r702",
      "r721",
      "r723"
     ]
    },
    "us-gaap_RepaymentOfNotesReceivableFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentOfNotesReceivableFromRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of promissory note from related stockholder party",
        "label": "Repayment of Notes Receivable from Related Parties",
        "documentation": "The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "nuvl_RepaymentOfPromissoryNoteFromStockholder": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "RepaymentOfPromissoryNoteFromStockholder",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment Of Promissory Note From Stockholder",
        "terseLabel": "Proceeds from repayment of promissory note to stockholder",
        "documentation": "The cash inflow from the repayment of a promissory note to a stockholder."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "RepaymentsOfInsuranceCostsFinancedByThirdParty",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of insurance costs financed by a third-party",
        "label": "Repayments Of Insurance Costs Financed By Third Party",
        "documentation": "The cash outflow to repay a third-party for insurance premiums paid by the third-party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r742",
      "r747",
      "r748",
      "r764",
      "r1113"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development and clinical trial accruals",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "nuvl_ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit carryforward expiration year start",
        "label": "Research and Development Tax Credit Carryforward Expiration Year Start",
        "documentation": "The year in which research and development tax credit carryforwards begin to expire, in YYYY format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1084"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r859",
      "r869",
      "r902"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r860",
      "r870",
      "r903"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r867",
      "r877",
      "r910"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs",
        "verboseLabel": "Restricted Stock Units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r73",
      "r605",
      "r633",
      "r638",
      "r648",
      "r678",
      "r809"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r107",
      "r108",
      "r142",
      "r143",
      "r144",
      "r148",
      "r156",
      "r158",
      "r160",
      "r243",
      "r247",
      "r261",
      "r289",
      "r376",
      "r427",
      "r428",
      "r441",
      "r442",
      "r443",
      "r446",
      "r453",
      "r454",
      "r470",
      "r473",
      "r474",
      "r477",
      "r492",
      "r539",
      "r541",
      "r629",
      "r631",
      "r654",
      "r1150"
     ]
    },
    "nuvl_RevenueSharingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "RevenueSharingAgreementsMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Sharing Agreements [Member]",
        "documentation": "Revenue sharing agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r808"
     ]
    },
    "nuvl_Rule10B51TradingPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "Rule10B51TradingPlanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10B 5-1Trading Plan [Member]",
        "documentation": "Rule 10B 5-1Trading Plan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_SaleOfStockOptionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "SaleOfStockOptionsAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock Options Axis",
        "label": "Sale Of Stock Options [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_SaleOfStockOptionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "SaleOfStockOptionsDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock Options Domain",
        "label": "Sale Of Stock Options [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities and other current liabilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.nuvalent.com/20251231/taxonomy/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of deferred tax assets and liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of effective income tax rate reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r788",
      "r1078"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Summary of Stock-Based Compensation Expenses",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assets Measured on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r338",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r373"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r75"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Share Based Payment Award Stock Options Range of Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r70",
      "r72",
      "r73",
      "r115",
      "r116",
      "r117",
      "r179",
      "r304",
      "r305",
      "r306",
      "r308",
      "r311",
      "r317",
      "r319",
      "r467",
      "r644",
      "r645",
      "r646",
      "r647",
      "r776",
      "r944",
      "r1008",
      "r1009"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r763",
      "r769"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r177",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r760",
      "r761",
      "r762",
      "r764",
      "r766",
      "r767",
      "r768"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r196",
      "r200"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]",
        "documentation": "Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r196",
      "r200"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "negatedLabel": "Other segment items",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r195",
      "r196",
      "r200",
      "r764"
     ]
    },
    "nuvl_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A convertible preferred stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Stock [Member]",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r956",
      "r957",
      "r1044",
      "r1048"
     ]
    },
    "nuvl_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B convertible preferred stock [Member]",
        "label": "Series B Convertible Preferred Stock [Member]",
        "documentation": "Series B convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_SettlementOfNotesPayableAndAccruedInterestForPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "SettlementOfNotesPayableAndAccruedInterestForPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of notes payable and accrued interest for preferred stock",
        "label": "Settlement Of Notes Payable And Accrued Interest For Preferred Stock",
        "documentation": "The amount of notes payable and accrued interest settled for preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation arrangement by share based payment award annual increase percentage",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Percentage",
        "documentation": "The automatic increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year, as a percentage of shares outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share-based award vesting period",
        "verboseLabel": "Stock awards granted, vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares, Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Unvested restricted common stock shares",
        "periodEndLabel": "Outstanding as of December 31,2025",
        "periodStartLabel": "Outstanding as of December 31, 2024",
        "verboseLabel": "Number of shares, outstanding",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding December 31, 2025",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Outstanding December 31, 2024",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Unvested restricted common stock vested shares",
        "verboseLabel": "Number of Shares, Vested",
        "negatedLabel": "Number of Shares, Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate fair value of restricted common stock, vested",
        "verboseLabel": "Total fair value of RSUs vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of expected stock price volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of expected stock price volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Range of risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Range of risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average expected stock price volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r338",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Shares, Cancelled or forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant-date fair value of stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning Balance",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding Balance",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance, Number of Shares",
        "periodEndLabel": "Ending Balance, Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Cancelled or forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r343",
      "r362",
      "r363",
      "r364",
      "r365",
      "r368",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock awards granted, expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsRangeOfAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Weighted average expected option term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Contractual Term, Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Contractual Term, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance price per share",
        "terseLabel": "Shares issued price per share",
        "label": "Shares issued, price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodStartLabel": "Beginning Balance , Shares",
        "periodEndLabel": "Ending Balance , Shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r115",
      "r116",
      "r117",
      "r137",
      "r139",
      "r166",
      "r167",
      "r169",
      "r171",
      "r179",
      "r180",
      "r241",
      "r275",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r291",
      "r292",
      "r294",
      "r295",
      "r297",
      "r301",
      "r304",
      "r305",
      "r308",
      "r311",
      "r319",
      "r527",
      "r644",
      "r645",
      "r646",
      "r647",
      "r654",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r677",
      "r697",
      "r717",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r944",
      "r1009",
      "r1010",
      "r1018"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r51",
      "r54",
      "r55",
      "r100",
      "r107",
      "r108",
      "r125",
      "r126",
      "r127",
      "r142",
      "r143",
      "r144",
      "r148",
      "r156",
      "r158",
      "r160",
      "r178",
      "r243",
      "r247",
      "r261",
      "r289",
      "r321",
      "r376",
      "r427",
      "r428",
      "r441",
      "r442",
      "r443",
      "r446",
      "r453",
      "r454",
      "r470",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r492",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r539",
      "r541",
      "r548",
      "r610",
      "r629",
      "r630",
      "r631",
      "r654",
      "r717"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r178",
      "r291",
      "r292",
      "r294",
      "r297",
      "r541",
      "r587",
      "r642",
      "r655",
      "r666",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r677",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r698",
      "r699",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r717",
      "r749",
      "r750",
      "r821",
      "r1147"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r178",
      "r208",
      "r291",
      "r292",
      "r294",
      "r297",
      "r541",
      "r587",
      "r642",
      "r655",
      "r666",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r677",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r698",
      "r699",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r717",
      "r749",
      "r750",
      "r821",
      "r1147"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r872",
      "r905"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "nuvl_StockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "StockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Issuance Costs",
        "label": "Stock Issuance Costs",
        "documentation": "The amount of expense incurred for issuance of stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion of preferred stock to common stock upon initial public offering, Shares",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r31",
      "r51",
      "r54",
      "r73",
      "r285"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares issued",
        "terseLabel": "Issuance of common stock under employee stock purchase plan, Shares",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r51",
      "r73"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued during period shares new shares",
        "verboseLabel": "Issuance of common stock upon public offering, net, Shares",
        "label": "Issuance of common stock upon public offering, net, Shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r51",
      "r73",
      "r644",
      "r717",
      "r730"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Issuance of common stock upon exercise of stock options, Shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r51",
      "r73",
      "r349"
     ]
    },
    "nuvl_StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Stock Options Exercised Restricted Stock Award Gross",
        "documentation": "Total number of shares issued during the period as a result of exercise of Stock Options and vesting of Restricted Stock Awards.",
        "terseLabel": "Issuance of common stock upon exercise of stock options and restricted stock unit vesting, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock to common stock upon initial public offering",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r51",
      "r54",
      "r55",
      "r73"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r51",
      "r73"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon public offering, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r51",
      "r73",
      "r654",
      "r717",
      "r730",
      "r827"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r51",
      "r54",
      "r55",
      "r73"
     ]
    },
    "nuvl_StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options and restricted stock unit vesting",
        "label": "Stock Issued During Period Value Stock Options Exercised Restricted Stock Award Gross",
        "documentation": "Total value of shares issued during the period as a result of exercise of Stock Options and vesting of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r54",
      "r55",
      "r66",
      "r679",
      "r695",
      "r718",
      "r719",
      "r809",
      "r828",
      "r1008",
      "r1010",
      "r1011",
      "r1031",
      "r1104",
      "r1150"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r303",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r318",
      "r321",
      "r467",
      "r483",
      "r720",
      "r722",
      "r734"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r554"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r554"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r554"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureEquityAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of valuation allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax credit carryforwards research and development",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "nuvl_TaxCreditCarryforwardExpirationYearStart": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "TaxCreditCarryforwardExpirationYearStart",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax credit carryforward expiration year start",
        "label": "Tax Credit Carryforward Expiration Year Start",
        "documentation": "The year in which tax credit carryforwards begin to expire, in YYYY format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityByClassOfStockTable",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Equity, by Class of Stock [Table]",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "documentation": "Disclosure of information about equity instrument classified as temporary equity. Includes, but not is limited to, description of share, value, share authorized, issued, and outstanding, redemption price per share, and subscription receivable."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r292",
      "r294",
      "r295",
      "r301"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Carrying Value",
        "terseLabel": "Convertible preferred stock (Series A and B), $0.0001 par value; no shares and 112,431,508 shares authorized at December 31, 2021 and 2020, respectively; no shares and 89,945,206 shares issued and outstanding at December 31, 2021 and 2020, respectively;",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r291",
      "r292",
      "r294",
      "r298",
      "r387",
      "r389",
      "r603"
     ]
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Equity Disclosure [Abstract]",
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_TemporaryEquityFairValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "TemporaryEquityFairValuePerShare",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable convertible preferred stock fair value per share",
        "label": "Temporary Equity Fair Value Per Share",
        "documentation": "The fair value per share of stock classified as temporary equity."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_TemporaryEquityIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "TemporaryEquityIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Equity Issuance Costs",
        "label": "Temporary Equity Issuance Costs",
        "documentation": "The amount of expense incurred for issuance of temporary equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityIssuePeriodIncreaseOrDecrease",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of preferred stock tranche rights upon settlement",
        "totalLabel": "Temporary Equity, Carrying Amount, Period Increase (Decrease), Total",
        "verboseLabel": "Settlement of preferred stock tranche rights",
        "label": "Reclassification from liability to value of preferred stock issued",
        "documentation": "Change in the value of each type or class of stock classified as temporary equity during the period. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r292",
      "r295",
      "r297",
      "r301"
     ]
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Equity [Line Items]",
        "label": "Temporary Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r294",
      "r295",
      "r297",
      "r301"
     ]
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liquidation Preference",
        "label": "Temporary Equity, Liquidation Preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, par or stated value per share",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred Stock Authorized",
        "terseLabel": "Temporary equity, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r294"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred Stock Issued",
        "terseLabel": "Temporary equity, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r294"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred Stock Outstanding",
        "terseLabel": "Temporary equity, shares outstanding",
        "periodStartLabel": "Beginning Balance , Shares",
        "periodEndLabel": "Ending Balance , Shares",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r294"
     ]
    },
    "nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "documentation": "The number of new shares of temporary equity issued during the period.",
        "verboseLabel": "Issuance of convertible preferred stock, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of convertible preferred stock",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1045",
      "r1046",
      "r1047"
     ]
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Redeemable Convertible Preferred Stock",
        "label": "Temporary Equity [Table Text Block]",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_TrancheRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "TrancheRightAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Right [Axis]",
        "label": "Tranche Right [Axis]",
        "documentation": "Tranche Right [Axis]."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_TrancheRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "TrancheRightDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConvertiblePreferredStockAdditionalInformationDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Right [Domain]",
        "label": "Tranche Right [Domain]",
        "documentation": "Tranche Right [Domain]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r286",
      "r317",
      "r467",
      "r482",
      "r517",
      "r526",
      "r529",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r597",
      "r611",
      "r797",
      "r798",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r810",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1090",
      "r1093",
      "r1094",
      "r1095",
      "r1097",
      "r1099",
      "r1101",
      "r1102"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one employee stock purchase plan.",
        "terseLabel": "2021 Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "TwoThousandTwentyOneStockOptionAndIncentivePlanMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one stock option and incentive plan.",
        "label": "Two Thousand Twenty One Stock Option And Incentive Plan [Member]",
        "terseLabel": "2021 Stock Option and Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r130",
      "r131",
      "r132",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r162",
      "r206",
      "r207",
      "r243",
      "r245",
      "r246",
      "r247",
      "r260",
      "r261",
      "r264",
      "r287",
      "r288",
      "r289",
      "r290",
      "r374",
      "r375",
      "r376",
      "r377",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r520",
      "r521",
      "r539",
      "r540",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury bills [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r779",
      "r781",
      "r783",
      "r797",
      "r1115"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r415",
      "r787"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r181",
      "r183",
      "r184",
      "r185",
      "r593",
      "r595",
      "r757"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases recorded to income tax provision",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "verboseLabel": "Increased valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "terseLabel": "Weighted average shares of Class A and Class B common stock outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r171"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "terseLabel": "Weighted average shares of Class A and Class B common stock outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r171"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "nuvl_ZidesamtinibMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20251231",
     "localname": "ZidesamtinibMember",
     "presentation": [
      "http://www.nuvalent.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zidesamtinib [Member].",
        "label": "Zidesamtinib [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715-70/tableOfContent"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0001193125-26-073317-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-073317-xbrl.zip
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M[>ZI4I.FCT7:#[K3D7BWIUCANEV3P4F,Q0)V.UR3[0Z8M?".T[HA"V0%+'8
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M-6\8E:K[UQ1=#$>9&NH!W>%TIE;6K?EP/E-/>.R><(6I.T2G% :+#8D$_&'
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M(!1Q-M56"< MKD@8I.+I3N3@4JR0&>!"9K=J*\<EFYGA[4F@HIJMO-,-Z!F
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MRY>S_I#+G8"SYU)- S&\ 4BJBP?LT;BY"*'A6MR5H:M6BRP:KBEH!4(^N@E
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M=@P5O0$@@4AGRD9"JQB+3UICC!#$HS9YG(=M7-J5 !W.JBM=92-BQ&4KBO6
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M3.&J*U]BU4R%],8+<:CDLV: A!PI276VH#7S.L$1N>^V.#OI[8\WE_^M-P"
M\.G3O_\*?>?[\3\Y%? ?'-+XV6,'TWH.\DP)J-4:K3)< )UAW)@LBNP4&\/#
M%A9V3J)=3F:2S>YB)]$\;)]D9W*0E84LD NV]@#_L/E/H-$B4V^?7]H/S1K0
MUER.YUD&FN2R,08T:S=*%MIXLT,,2#M9#G2Q!Z /:OX3Z%A%%$25E@^J4Z\;
M^# *69PNR.:RNKVH&P1=H UQPBX+:@5AB]/C/(!]B/8_Z8/@5%9LG][RR'2U
M.J-4*1;Y]E&? Q@_>O[3Z7,5L<&QWDI1^3?/;TSK.2$U1?R>ISV3<M 6R)IS
MV2=9<U9P$F^Q\9-<M-4U*9>S6*V0PV%UTL;$?M+V4-#L3T62@Q@CVW+:)SD8
MWCG)QM'PI)P=Y(W.'!9#$5P01','T-E#L>M[].)_6RH_V_Y0W51^5C"'?/XC
M:_BA9'XJ-B-5K14K^B$.Z)!<^?_, 9V>\VM3:*8]QAE5VAA*>^@'W?OY1N)/
MS=4!0@X[ T.&?1I2M+D8QR27"[1/XNPL2!OV!$.PY0#^SZG'#_K0\IQZ\)$I
MBVN*S3D%MAXX,G50K9\'J1;YFD97.$0P!/EOG9TZ5+N?QV?RM"IP[ S@0,,#
M-_X]9_E_A^C^/4_[_T)T/S[M]O\'T77N_M 8#UCV3XUWVD$'.*>0-;I2JY?B
ME2(ORMR,>,68P33@7]3X&9S]1_S(>N[0)P-_B/FCV@=A&DYKBM$56V>XRGZ4
M..KMEL5<A:[HW:!C<EMH/Z@UZ& F''3$N'-^&=A_@'G&((,C!TY/'TH4_^?I
METY^Z>273G[IY)=.?NGDET[^K^IDT/>_OV*D1M/':F-/G_'M&X/3 8_GG#@1
M\P;"F*FKRV0:[ ^+:K'7D2:3HM8JA,_=G<YDN_MO,O4R#33U,X$F$\U42Q'2
MFVC_#$P \W17C4JF'] GSYNZVI_/3O+'N[M-_QD-94J5FLG4%3?*5M8(;HSR
MA499UFJE]OV]1OGHG-0N]^K3+E>, 1KED>VRT"F?UE.G4SZC7685E37*[3&7
M6(5MEQ\VRI<TZIQ1[ATVRA<U1$XSRL\9Y9/DNB(:Y<_:;16.KII,?0:W[]<X
M)F^4+49Y<"5!>(SR-)-IP&#AH'+NH'*-:];:D_(42WJE_0L*W:<PIW:#+I>S
MV\]I,E>K38H;0J$K;+>GJ)1H53>9.G/NH:/:O.TVF&P'77;[)&@R>!"C_N7#
M?Y/:LNV4/L)[9-8U8N/W]PY5K[C(9'+N,WCSA^_OY>:93&M^;S*-?.G[>R?]
MR60ZPI#;ZJ<.FL^(MKX<]&,Z(L=,;C/T._HO*_P;=%!_D]MPW[&G&^W\#DK[
M-TZZF:)LI'C=5<,FN.Y)/U;B_W;#0X_C-(+CN0IG9&[=24/+1%4PQ+U_@Z);
M5'].B/_-9C^BCEX;-.R6;TQ'GS/9=.131YMZO[?1U&?88:;>,Q<:3[J^DUMX
M8-+4MKS4"6]W]+Z'NGZ*VNNJ]EM5%'K:>8A$-U.O-#K/VF9IZFL:9#K"=+3I
M6-/QIG&F4TR33)#)89IJ.L.$F8*FF"EARIC.-C&FO$DQ54R:Z5S3;TP7F2XS
M_<%TG6F^Z2;3+:9EII6F.TUK3'\S/6AZU/2$Z9^FS::MIFVF':9W3'M-GYB^
M[.KJZM\UI&M8U[%=)W2=W&7N@KJ<73.ZL*YP%]&5Z?I5E]"E=M6[SNWZ7==E
M7==TS>_Z<]>RKCNZ[NUZL.NQKJ>[7NQZO6M7UX==7_3JW6MPKZ-['==K?"^@
ME[,7TBO4*]'KK%Y"KW*O5J\+>UW9:VZO1;UN[;6ZUX.]GNBUN=>V7N_TVM?;
MU/NPWB-ZG]A[4F]G;T_O6.]L;[YWI??YO6?WGM-[4>^5O>_KO:'WL[VW]7ZW
M]^=]^O49UJ>[SZ0^4_OX^U!]F#[E/N?WN;S/_#Y+^ZSN\W"?9_N\WF=OGV_Z
M#ND[IJ^Y[Y2^@;[IOD)?K>]%?>?T7=QW5=]'^F[NNZ/O)_WZ]1O1;T(_1S]_
MOTR_0K]9_2[OMZ#?[?W^WN_I?MO[[>O?O_^Q_<W]I_>/]:?[U_I?U']>_UO[
M/]#_F?X[^G\VX+ !)PR !G@'9 >H WX[8,Z Y0/N'_#,@+<'?#GPR($G#YPR
M,#:0':@/O&K@+0/O&_C4P!T#OQPT=-"$0=,')085!OUFT-Q!*P<],NCE01\=
M=MAA8P]S'88?)A[VZ\/F'O;7P_YQV.N'?3[XJ,$3!WL&SQQ<'WSEX"6#_S[X
MQ<$?#1DR9/R0,X9DA]2&7#EDV9"'AKPZY+/#AQT^^?# X>SA%QQ^P^&K#W_F
M\#U'##SBY".0(\X^HG7$G"/N.N*I(]X]<N"1XX_T'$D?>?Z1-QQY[Y%;CMPW
M=-A0<&ALJ#+T\J'+ASXV=.=1_8\:?Q1V%'O4A4?=?-1#1VT?UGO8N&&>8<RP
MWPV[9=@CPW8<W>_H"4<'CBX<?=G1MQV]Z>B]PX\:;AN>'-X<?L/P=<.WC>@]
M8OR(P AYQ%4C[ASQ_(@OCCGN&.08[IA+CUEYS#/'?#IR],@S1G(C9X^\?>3F
MD5\<VWTL=JQT[-7'KCGVE5%]1DT<A8_21BT<]<BH=T<?/7KJ:&;T[-%WCGYI
M3*\Q$\<08V:-N7G,QC'[CCO^.-]QI>/F'??0<>\>/^+X,XXO'/_'X^\_?M<)
MPTZ8<8)XPA]/>."$W=W#NY%NN7MN]\/=>T\<<Z+_Q/J)?SYQTXE?CITPEAK[
MV[&WCWUEW*!QSG'\N#^.6S]N[TDGG!0YZ=R35ISTTLD#3W:>G#_Y^I,WG/SI
M^ GC4^,O'K]F_,X)(R<$)K0FK)CP\BE#3CG]E/(IBTYY[M1^ISI/E4Y=<.H_
M)_::"$_,3[QAXE/F7F:[630O,#]]6M_37*>IIRTZ;<NDP9.028U)*R:]/GG$
MY/#DWTY>,WD/<!*0!:X&-@#?6&"+;+G%LA4\"@R"OP7O S^$)D(,= /TG'6(
MU6N]P'J/]0.;V<;9%MI>@(?!$?AB>#W\M=UAK]A7VG<Y3G+\RG&C8XOS:&?<
M>;GS'ZZ^+K?K M??7)]/L4^I3;ESROM3)TV5IBZ?NG/:A&G<M%NF;9\^=CH]
M_<_3M\WHGO&K&7^:L>WT$T^G3U]T^AMGC#N#/6/Q&6\CIR(%Y%9DC]OBKKA7
MN3_U3/&<Y_D[VAOUH;/13=A1&(7-QU[UCO4*WA7>O3[8-\OW=W]??\A_M7]+
MX+@ $U@6V!MT!,\+/AP:'")#\T-OA">&*^'[(KTBP<BUD9>C)T?5Z)J8*1:(
M71M[)3XA7HZOQ?OA<?P&_"T"),XE-I##R'/(Y>0G"7?BJL16ZA2J3JU/'I&<
MF5R6_#2%IJY);4L#Z?/23V1&9<3,/=G^V61V<7;?F=B9UYVY8R8\\Z*9SY\U
MX:SF68^=/>IL^>QUYQQQ#GW.7;_J^ZO4KY;_ZBLZ1B^B]^4"N1MS>QD/<SWS
M#GL&^T=V%S>=NX9[FY_.7\/O%*8+UPJ[\J?GY^3?%3WB?/&#@K]P4^%3*28M
MD;Z54_+MR@#E5\J]ZE&JI#Y</+[8+#Y=,I<N*FTK3RE?5]Y;"5465[NJ9U7O
MJ1UM!%,;ZZ?4?U]_O3&C<4/C,RVIW=4<VE2;&_6)^J7ZVRUOZR^S^LQB9JT_
M]\1S?W/NZ^<AY_WY_*[S<^>OOV#<!1=>L./7OE\O_<V@WTB_>?*WEM]>\]N/
M?Y?ZW7T7'G?AKR_<_GO?[U=<=/A%E8NV7#SUXILNZ7.)>,FF2ZV7SKOTF]GL
M[,<OLUPVY[*O+F<N?_P*\(JY5WQ[)7_EIJOL5RW\0[\_J']X_NK3KUYZS=!K
M6M=LOS9R[>H_=O]Q]A\_ONZ<ZQZ;8YMST_6#KJ]?OVUN>.X]\TZ:]X=Y7\W/
MS]]\@_N&VV\<<^.E-WZZ@%WPS,(S%JZ\Z;B;+KOIBS^)?WKAS[X_KUXT?M&<
MF_O=W+CYK5N2MVSXB_,ORQ:/6GS9XJ^7J$NV+266/KS,L6S9\C'+KUK1:T5]
MQ:Y;9][ZS]O0V^Y9.6GEGV\?<?ME?S7]M?[7W7?\ZH[G[PS=N?XNYUTK[S[Y
M[AM7#5LU>W77:GWUWC7Y-=ONR=SS]+W!>]??-_6^56LGKUWRMQ/_=L.ZX>NN
MNG_0_1?>_^T#K0?V_;WT]W<?%![<OOZ<]5L?2C_TW,/XPYL>"3WRCT>]CSZT
M =GPP#^F_^-OCTUY[-['G8^O><+^Q.J-\,953\)/KMIDW[3Z*<=3]_S3]<_[
MGI[V]/W/G/[,@\^BSS[Z7."Y)S9'-S_]//7\"UMF;MGV OO"SA?E%S]XJ?'2
MEUM__7+?EV>_<N0K<UX=\^JBUTY][?9M]FWK7D=?W_@&^<;6[<SV=]ZLOOG5
MC@O?&O+6G+=/>'O93FCGWW9Y=_US]YF[=[Q3>N?+=R]Z;^A[-^XY9<_=[Y_Q
M_L:]Z;T[/JA\\.V'EW]T[$=+/K9]O'Y??-^KGRB??/GI[,^._6SIY\[/-WR1
M^N+M+[6O^G\U]^M3O[[OF] W+W^K?/OMMWM,A_?L99K8O[?CAV^WFBXTTHM_
MFWI]3[V_HP//>AYW'?SDWZ1O_VX:.J#7A0/JO;N&FGH-[>H]M.O;ATWO&^&-
M =:&/A#<##QLP*"^_?KWZ;EKVM_Q@8?]^@_HVZ=WKZZ!1YJZ^K3'T:?O84,&
M#^S=J[^IJU?O/D:[H0..&GCBL*,'C1V^IND"5XUHK'9HUX]TCD+&W?7LW==M
M3CY_3"I]+'12XKGZG(LOF7O//P(X[2:LGI.7;"%M+^3&EW]3@Y?N%(=VM?%Z
M]^U_Q,!^?7L;8VE?#NW3]T2P'X+31_4OWS&V,JQF_PWD)G+7W#FN>NU=1P^'
MC[GZST__]AGR=XD1#RY:;_4\M/?F9T^R,2CVP?8_GDR]P7+COWW)-+BW,>&A
MO8>:3C>]MNWGX\9?Z!?ZA7ZA7^@7^H7^9VGDVL=>V=EX\N%I3SRR;NV>O]UQ
MV^:WH]P+Y2_>NO@1YV.OW?"*&KOF(@G^<-Z-]E/G+-Z\:L>*LP.C+QB_RAS;
MEG3O8G<^LFO'W>>%'->N79I9E7CSUF>M5/7.!3=>;7UGR2)P[HX'GWA2FJ*2
M+BGV0&/N4V<O'SM_G'*FSH][?D,DC7[(G+;(=>6?C#%,.6_!E^1?5EE##\R]
MS9.;?]V9FT\]B[KUB7]NO>9A'%HP[USX[3NONG7/'>/6Y;X8/I2\/:9,.5]]
MBWQG]<[Y=SZ=>'BCLIX9\L']X]2O-_7=<\H_/_SBY=(> <1NRZZH;8D,_VQZ
M<WGADMD3;^JW_([%YXYIO?STY&W-!7O_M]G^_P7M5=]8>].VPY_Y;,^G$S\]
MYO'[KC\Z__&-G^4>>W?-YNNKJ1</>W?\,=3?R2M??6B-?-2#HQ<^/O+QU7MF
MV%V[1JU:F?A4_$*]@-KH3<56G;7UV<>&WN?:O>"Y#>&-OM"#2W?K0R8 KMN\
M[XVXU3>)7"W,GWO%JA@&6O_YS-J-9[YZ_HZ59$.[[,L!Z]EFZ*H=G]RH;"IM
M/77[>]413U ?W'_WA[M'QC+7_KV\<,KC_GVSGWCE#T^N($Y]X_ICI\PXZ9[F
M!7?)*U,KYFV9>-F63S^?4OZPO#WZV,J6G;Q__,0KEC.7K(T^^=9]+Y[5;]X=
MU[^RH_#0X]0;C[ZP:$IC\WTY<<$E%W_XVQ<;DS8\N>*N!4O4I]Y:O>"&Z9L^
MKF2>O(IY_-5-0M4UVGGK$^^RT+WGWOC)G<>.7GW"KG/O\G]^_/W742??F%%?
M63C\R9=616Q;%S_\,&H0,WKL.-8];KUC\MEO;%RP=15%O73[PQL-VC1L-=_8
M>)O;.HXP.-S+]N7=5)2\==G.Q&9PT.R;J&.V5OZR8/T)]=@3U*M_N6IM[>/G
MKP)7[=US_PS;GC/+SZR[Z=B;,O97&C8Y<M&[N^?-'CK!N^2O;[X9.,%6MN[V
MG'[%NJ&C-G@O?C_Q^N5S9HV^]]S3WA+FC'MPX7O3%KSPT,+<V><?_M[O+G%J
MRZ[=/+[Z19@>F4H]^O3Q;[RYW3IT]-+;1ZX?>^KR2X17+WMLOC:.^&0=8S[N
MTNW,"=7AW%&KSSE^)?KQF8O>=KW:I_+9>;)TTN&5B?">G7\Y[Z9G/KI/.2^\
M>20Y=?D5=S]5N>#.TL)FX?A1VX\_X8V7UUS_].V/I,:.E5:E?M>X:M2E6R^>
MD%VX:ICS]<2V]Y=,/^5_6[G_Q^GUU<===LYSI8QRL[SI]5572+W=FU)3[Y!=
M4](S1QQS;-01*8Z;\P2[Y#;/<>Y;)Z4"MF<@.SQ\YM*+][RR]GKILN2R^2LI
M)XJ&-SYE0Y5YYT^>N8:_=&UCN;@JS%BM0X<.?<(Z=>RHI9_/GO74C<@C0S:5
MKZ?O"1==E<'1.ZY<\^14:N;OSQZ]90)Z+O3"YO)IUX^^Z<T5^][$]E7-=WQV
MP3&_3;_UP%&WJG=]9IC+JU+;7&X8X?A\2NG#:[='7UAT^J29<\F)=UVR-O+8
MCBDO*H/F/C#WE1T3-SRVX;+1X^_=]6)L,NP)+MP^==&>_FM5S]K'SWOTP]5;
M'_]RU>K[1U9&G_S6RM,'8N\'9IRRN?X22&Z!QXSF8J/P1Q/+\).J-^W^2JW.
M>>/9CS=>=-WUEZ^\J7!9DKEFG/S4=')J8>&\>=<!2W?/O^BVN3<^?W-C[9HE
M<P36!X,C,?#I,#KMR$^G#9SVX3E?D+-.^@K.?7,W/^"UD2WK@L^/?7]]Y,&%
M?V3OSTY]9E5IXZ2HP?<!S^S9\OZ2<]XCAWYYU\3,RR=^FOAJU5F[TY^NB47R
M'XT^Y_!W1EX:G'_>/>_.\1S1N#\TO/6JXT0"G7/;2_:35Q0&#AT^#8\=-F_<
M<)PZ9M$7> OXT^<OKU+W#2N\!U+WOC9LY,-?7/,Q9YWWMXOXR]_R[FA4DV^/
MDA8M6[Q<6,0,O(C[8$G#+LV:,>&:%5/>//49^[N?O3!JSO;8TBL?VWZB-/;.
M2[\U%8([-RR:\,WHS93_["7K;9NO> ]JK9H57"+LWCQU[;5W+1YUQ.^^K*P3
MEEW]QA?C=ZQ[>NZ:V.^/<TQZ=&@JDJ!GO+'LI2<WCI]UV)W;__3$-JAVYPM;
M!WZQ^3[KG<V_G3WBWJ<#KY]SM/71*V-CBMY_//*Q:^AY?49]<_8WR7=?W$A2
MQS#7,$=\<\>3X)W9J9'G/OZ:.34Z*[1._898MQD'P9=O=%!C[MXT;/3BL3/O
M^&#6K_^W#>=_E/J<H,_6/_JD^D)Q0W;\L%,V;9_Z^PU?4HZR8S2_\RM\^8Y?
M[7Y*V'&\6W9-F['@)!+>..>*?&7>TH67OB-BHY])S"]]:^J]^XNWDU^7]YU[
MX9=3WB@OG_[(Z/$KW]TGOK5<.W$:MJ$UX_?/WX%^S<2O^GCGW/7S/JV_-WO6
MU<.II\+%_'6O+9G_5/-5^O-="YY\^;=?G7[LEK7#UVF_<WY=E&Z,_>:\E.NY
MVUYX<-([FOWE?9K_TS4GS[_C#_<.NV76K\X]TDQS6_^\]_ZK_X1_:^**8S:-
M5JD+MTS[LK27633WDK<?;2Q=-VOVJBM/O/V;3]XZ5FYD;QZY9LQ6<.^2Q<OF
MO;7>/J[VAYM_;3KIH\<NV!5Y]]J]FR_[XNFYX\ZE=V[2WA0>&.CHU\*O^3S_
M?G#S0Y953H-!XT)KS[E_P06KPKX]&Y<)I8M?(3_<K"UC7GUE.GSS1N7<J;?F
M3IZ8-_57GOWTMA6>Q\:3R8V91S<M?RW_F^77/+UN--7RG'_YTB^>OWGGCEUO
M%"]=T+HCNV=V\Z-Y@Q?_67J,7SI[V9L+T[LN?>V$K8_OV3DF=-O>1XOOW#<Y
MM]8Q_8_%1?>\M?+21^???,/(1QW/@E,S.QY=\(PTVK'TD3VW_HY\<NTMR@/O
MC+EOQY:/8[]_#UIQR\/3G]BR[87J(C3VE;K\BNY12P;Q=][SRC^VMS8X[KJ*
MF*XM6_/RAW>_W;^Q^6;IN)G7#\5<QWD;]0]N.G'F9\^N?N[CE#7VS6+K[R:.
MN\;%L'=,OP8;-_JDBO?-<RO>CWW@N[.H["?35VP>/GW0A40N5UIP[6%WSE^V
M<N[*2R]=Q(R<NW78L/MR>NZ<NS[[^G];F?\'Z4'UDVD;OD0__.:Y9^D]UC^>
M0G_TZ<[0!=0;3XI_E<^]:RUXY1S[Y#5_>;"P[J+XG(<G7[S]M OO!H>&%PY4
M'MV!GOWJ%0^]M'*=]MBN3Q8K#[]N1/2S9ZVJ?NR%JYZ+;RL??_6?LA_.O^*%
MQ6\^:GO:T.27E]QP[6U.\LK/+[KL_MS]>[\U:<>]N;AZY3VY1[YY_K-!']VR
M;/P1@4WI;^J.TRI3O&9-]2]ZZ9C\/__A?G_+'6G^F>4[7]UYVA/Z30/5^T_8
M=IS9O_LMZUR^^O03B>;13]V[J'PYLY6Z_,.'B9OON>SN26>FW^$^)%TS+WQW
M_;R]NZ^JSZ3!8>^)ZUWC"]*;L>'M;TS\'[82D^GX!Q_]ZI6U']Q]=6K#RY\]
M:[JFN7C+G5==D_5OF7KK9>ZS5\R A!8UXN1]A1V[/SE]]Q@EYOG'[C(\<\FR
MN9]\_/X^?>*5>UX5+_SRPEF^-V8<N?P&UYD+SPEM4"Z[UNJ+$=K6FXYY<(.2
M>.X/4?O;T\==,WI(L/'-^!?.?NWBVSGVRJG$]-NPUG9YPD7W$[:/EY]4N'9<
M=F5-=J]][N,QG\RSGE7>\L2LEG;^W<4EFU]\$GKNJQ-?2@WYX%R2 <[9O$^\
M8O7D,$9.NS]Z^YD5QQ>O'3'@T>6G7GS7&.K"_V6=_!\CW6&O/C#DD]<WO+B0
M>EL-/M>\_:J_GH;]0_[RRK-73YR]Z9-[I>WE#_P[[IWWY#G5X=?ER=FS5N_8
M-0:<OON*<Y*Q<3<^!SR:&J>NO7?V&C+,3'_QK4MVS%L_;L[9X3VS)BSAWH87
MWHO=NF[J[N6E*]^L;OP09:R/#8&G/;)NYRLKN)FO':-KTK-B<T)K]S%3KWPS
M?-R9HR_"+OD4"HV1-LRSSWSX'9B7\W>PU3M>7GN2%0C7#QO,+BL:BQ _Y[9]
MU2E?G]7Z]/.)$QZ\ZOA[MDY_O'3Y>=?A=T3+QXB?JOON_-OT\-/>7>MF-LDW
M<.<CTU^ZX\;I5UA7+=WT^0/OS_S+&L'Q3>CEQI5GO-J8=?MC\ID7O;W@L7?7
M3JY\=<GS][V:<LR]JSJN=4%O?.FNDRHW9Z^(7G+)[U?D'KE\U7*96[KXE=G,
M@,5S+[GDRDNN^,.RXEO 6[=3<S=NH9[8%[52)$Q9G[6N/@O]XOXS#+YV35@8
M^M84++(W773K.<]?_N#H[4=XJP^,F_Y9X![K,Y=?_X2OE5QY[.^7_=VH.>JL
ME[[^^)VOE^=.;W"AJ1?.V'W3G!7K0L=_LFO7;<<STNNO,$-/)7L@OY!NW "_
M6YW[B6O,AE742FG^NNQ;]TXQS]P<7;ILWQ%O/ARFI][T4F$^/W$Q/_'21_\?
M]MX[J@TKW1=EDDG<[6# IA.#,:$;1*_CF&)31+ 0HA,CBNFFBDX2%XJ1,&"*
M $$,1H"$P" $"%%BTZN,A>@"TZM$%0B0Q"5SYIR5G#GOK77NF\RYZ]WYB;7T
MS^;;>__V_O97=M$M;2'C3M0'ND-566? I<* =_AW(O[WY4$/BZ]&Z70%@TT\
MA)-6M^QA%>"5)("U#J^SU;-@9%/ PA8^/F_,JGPC'N)%S*2\X]3Z1LE I*LZ
M[#D:MQ&UY*XA,8'!/E1?QDCAM)&?5V5>JT_TOKZJ3HM+R[<:1=&68/"3&\;K
M*TS8(_-9O'/4$6_OC"T79;<L\^8'KU#V=&%(C^=*KE<ZK/U )O1@/K,T(CI9
MS>";WMA XW[K\!SF,(-HM LQ8MGL <7L9RSZ_6%\[2__1S7D#\*?MA=4^574
ME#V"Z\OG52)ZPX.%%+*^[5<K@ZX\>+8?X-(<W#=?]0!EMMUXWR-MP-W/A]B;
MF%RZG^N#*4/G(#%>9Q-G  -7%L$@8X!S"*^%"0!0(RF5Y=!YF'S<[TP*9VQL
M"NT'(MI@NGW#-,4+(GO9"EV3W)+(%T,?3?,ZR([RO2,W;%;7WE*H'<WBB  P
M&;ZEF-;&R5\33H  L/V+-1GU6"[.>@KU*J[6TF4YTW[[NK=#.&JD[]$VT%=;
M1&>,#0;0X 1N18?!9MH;S;#8Y0.5Z983'F6I ]D^$1FII?E8]*?M;"\/,5.K
M8A\/Y!@*\%V7:F5SQ7S&!X09=5QA;3AF,^MTF2TT']JC"W=1]]9M)HNSH/Y@
M*WTP<+Q@8V/A/7\6MF(M:@2ZKI,Y40GIX:O)A>;F0CU4IN!-#7W7$1DY_\;D
M_>7T$YZ/>>,RL]CKS.+;)JRVH?S-;G+<U8"+>\72.T/3F=CG#WT>GY8TR0YO
MC=4YC45R4FG(!X.S5QI+%S&;#[J:&Z-\37,F6#"[=C.;#_\V/+T/\9&QT3>^
MA)Q))R9WC[B\G2K6RUSR"3,.$>BWV6[GHD2[PJ 9'\K*8@+M\,AZC4"*97AI
MC 548OOC_NH1(MYL %1 "72JSBL."P6KD4,\605V^6XP"W-U%H7T38D#J\ <
M\[*U&!I >5&)Y<O^4*!7)_<EMFA]%7(?7 G$)+XDZ)2?'6:90$4FG.8E2)BX
M2Z!I[(R:ZYG]9>-8IU3!(2HVU-.?@B>%4W4;?>KY)(Z"1.Q?I_3. VQ\%[8.
M5A>V1Y#S5>'/$G&VR#(,E1GR[7)U[ZAD4:D+SL;&)?GI+3JV3LD2.TPU[CX-
M[BRBTC\0%1A6UGW6^=W.]=&R3E#+4+  2+\G!5H46>I.CUT>6/N?4Y8_"G<W
M<P)1A9X%KNH[$W7Q[MS(2$;QS>2J+X*RS"5"M%-:UZ96\KI)4LW8<UW\:=PK
M#GWWH8IK"_>_[AKS M_W_/%=8TNS2CC-P%3*< W"][2K <X\R@&1;21%[W8V
M:EYIGR!"LLA=1S86%NW'1)HI%NXTW&=D>#M>B['#;MN<>1\L/L^F/4Z>",TI
M^'S>W/ZB1O**9,.DF@RMHO']XJ&4NN/P7TYXG%^E[;VNOMIGAI*.GJ@/?_)>
MQ^1'"TAV<:_7X\GPIEN5!572O'/TG'& G'*B5IO]G# ZI2/.2AK19P/EWPLC
M^J(F?<;YZG)*^-^\%OCW?F>0I4]X2C1KK-ILE==-OH=O)Q1KSZ05L&].":V:
MF"\6-\M#+KX?_G1:$JY$CSL*XU)5)$BJOTG/1?][>JXZ\57YSW^3>GFW>,=@
MM@O&J8?TF5NGZU?6P_-P*< [?$6AQ#OK:P4G/.<C'IBP;KG)L<0I[PHHP5'P
M%K1/(A).->DM)AJ.-T8^E)YM41IE60&8J&L<&Q!@UK'P/#5.GZ_&ZQ+JT?N&
M5$<;P'+*<>XP3,*KTZ\%:STF,0O7QP0TZ.[*%?.-[:A&Q*;?O_XQS6YK;PWN
MER[KZI.OG-\#A<G#-UJ-(JQI")<-F.>-,BW=.OTSB3I(?2CV)=7K[%;IG"]J
M^HL>)MY@I$F["%.2<;:L+/D%]?K'Y$)K$/>5U(47<6-3_Q/3\P^$8 +M()96
M$2Y;A#Z8JE?X/O11P#OOH\X2OE% MV-'<EF2M#[ M/.(O1_X3B^M0_U-4LX1
M,/-%0#LOJ3.L%L4'&MD\O*1#!?<'8L/X651@-R.PX%ZV%&0TM/ER5_9P)25
M9H32TMCD /4[@)DJM)G&J[A& HC<E>OZG32L<38=^E0IVL7 8@EPX^KN]&I*
M&O=:7\Y4=<9]1\3/>'[_X(^C[N:/L6\0%K@&UT_FA0G'NI30Z4HHJ$T=!6^P
MB $#ABR.N/1H32M;Z7NGEDFXH'2DS]MN,1B$%RR$8W1\4NVGB@-8Z_WJ-7C/
M@4D-):=J?5+X<M8 UM8C/5K#CRQ54M"1M!BRF!M9$D7<#,;F+X+!:W9IO+Q/
M_1)M=P& %#HR_O.C_V#KC]$7'A[]+GCD 6R^Y*?46J4V7&<9]9W'K:B2B%9P
M0]Y:.AENPS&1O'\&#&;Z8(<_K<48I@U7$Q,R^LEXM"9KJ+&2T;-JKR<QD<J[
ME4_)6N<$WDO="[!@J9RVU&4"=Z GITD&B95_/E_I\5%;[IKI\^YH<>_JB(WU
M<76/F#<NXBW5S,GY4.WS=)OU]:]#V(HVV\4",=*1Y8^(=-6*0-!(-:)W==(*
MV\<WI!7J-LR6F;AR.>A90ZD5:8%Y-L6G.N1\@*D>I?["JV/,K<<I.D,6@U=L
MM64;_ND3^8_#&:.%%NMYA-!'?'Y:G^-(>>?1-0(XP*N.0]%%C(:QW<5B5(Z!
MYK)N!/>"]N2TMJO:'@40]30".5@][M"O#JH=E=]BFUSIB@D'65CT'Z6=\'S%
M\@RQ]T/EXK5)KQRK+?PQY8F)3"^N="DYI[Y9PN7+9:WZ/JR+.8!8MSVJ^VHA
MYD)Z<YB-75[T"ZU)Y:N*2 =,:L*-FF_3)(L(8^6\CG*.>H;C;\@00+O 0Q$V
MG.\06ZD[',TPOMON7&845M.D"P20^B 2!<DRK4YQI?) KMTB]\%R[*YN#[NO
M6\3KUL[EOH=^2W4TBF:T/K*N149!/<]G[R/.PO^6+I5:?M[4]LTW8Z\16A,C
M)83,7H\:#=D^=_I00(=N.5I2:C>8K+")VBG=C>P?B>+85RSV,I;D9L @@&%A
MNK:DALE*Y+N5R%_^@\D_(!CZ&[AOK=2]BZH=O'W'?C*Q_//6/1;ZN=U4*L*N
M!.[ 6H"F"8@F)R<7/-D%JU$M*#9&%)4ZF=#6<(83/CBOS@?SHK;? LRGHJ)2
M=^N61GL[(V>J3TF-4?K]+\<&\K')_MG\5'?_?J.*@+C\N.>L4HC\C;[JQ,+#
MY)[1CUBIT2)>,=#3G<.4@-7=:U71K@_U!QUB+:!%UPO/A$]BO%$6J7P4VQ I
M0=/,%+UF%0J"-UR*9@%I\6RL!]2#IPBH2>&INJJ<\BQT"W_VL+ZCVYM48YOG
M3&W>K')@&=7&O<('(V.S5I#^15Z/9XUF#,(GJ:@%1:'P-4(;*,(R7SV:,LU(
MV7^14Q_7V1^%GP4!>ISYGME8&5OS]8F(Y>R0OOXGZ\H?A3^QLNQF$??1:6EW
M^204:GKWNT2M.ZDA"VD,&U_!SB(,!B,I>38EW&3'4U(%-1#$[FB>GZ8>6[$.
MX,?^ <J-E:%E?6KN^"I/X<&O/JKBMMM.>!C^NZ*KA0VTKGY<&FOJ#"[9]?-/
M>5(F[GMV3H;CC%),6(@P0MOI%7U20L@F%&10+QY%JK;\KK+A1:V_O-FZ1^T4
MP'YEO"9.#GD -JW,62HFJH,414B]FR<\C=,<6$) <T]P@:O?3R63MDSG,Z++
MLUI=WR;WQ5K5K.;J:T,$4J)]U%_>C[*ISB2*^CN&5]RGKH>N"E_+?CVVHQ-6
M5N2I)U?J'Q9!#2Q8ZH6FWS!=U^%BJUQW)C+'*R5CA*4\^%FU#(1?.%4/KP#0
M86C]EJD_RD2=CL&@[Z12/*BG+6=4M5Y%2-"0B >ZGH$7W QN<Y.1^IE@OS:\
M;2SO*M(8Y5!:",CL6Z);Y@_PCP9$RK2*5NNK$#Y^),!!=P=!A1^5I_J65FE@
MON<J S8!&.0BNBS7*TLZW\F+%J<I2=C6@SOH&7=%2*9"NSJDJD'$N/-*)AFQ
M?JQES-[Z3=^;<A@,+JGL3ACP*LE79,)O(#3Z/G-H;G"5 >2C9:5_8DP%1[94
MFKYX]$((GG9])2DO+*9$Q*=>CPD:*19"YA3E> K(#]> Y6>Z''%Q\(9)=<=7
MR\D#CKR&Q\CO"ZX;R$)A:_+@[YZ/!I#  Z0TM:FD]V[0<X@-,T[?4O!A'[]G
M3?8WI*Q*%73C+3ET&8HB8**B0KEZE-JV\<_4AS\,GRF13GAVHS?(?6U"\2*]
M>7TP _?]/^.??@)J92&BTW!]GHV6\$(/N%]'\CQ;K#8M/=K%Q6?'TK7]Z+%3
MM/Z#GE E/BKSJ*@")V91H!LPFF)-25 ,&0+JPOH#3=2Y2D,-4<A2=5=7[>=]
M-@_53\.2;Q"Y:!7XD&ZN9&3BX=Q!YA(/>P098LCNVC^,W?\ZX6G#J$PXP6])
MR<9$.LYBBK=VU^GIH>#,J*_91$X8S%3UB7B!.JGV\H6/:DJXE=(^KWF.V9R&
M54-IF!B-$%TBT*X76+'.\05 7E*6.3HR,=&-]:-3XU;$N]K*=W_X7;^O1BZT
M[J'W[[-\.CB/^GE;;N]YZ>X 9I[F/='_IB>F%E;B,YOCD']:D+>$5C4#;)U
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M#;I3AFW"RWQ+W-*BQ?5F)XLP#,V85X\P:G!)90B0,OM,!5"-8OM.C%3CH@U
M8>EB>#7R17C74;VF4XF,257">(E)7W:(Z(NM4I/W"ZX6^M:B?PDSD!_PK":D
M)>&AA>-D[$:L9<LJNL&PVE+$=,TK(MF;[*/RE'F;E2S3@:I_/%G7))M3N+.=
M8@\2#6H3?=PF(IE\2T.K"(YS#^KL++87]?.1LNM4Y_T57R5;#(!2Z$CG6FOC
M1DE:0_(CM*2DY.W$Q'%>7I$B[1M;[[([';J=VD>:'3I-Q42O+LB^D_?,?:+
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MN:2&28?:/>)QM5Q$QO!WF7IJ@GLG//70XHP/Y7P?7OC$@%[US/O*/MOH,JU
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M>JUTOK+KV9#I"<]$.$S%J3GI<<)$8X?3?52IZ'.S"L5Y$;E6E12KK:(HFL
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MRW=JA_.% O#[A!H:A?%I8,9,89D\Z3'0D[/KWP;QP5P?ZW:(.E(9)D_EG6C
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M&)ZB]%4W>+V96%SU7GO'+ZI9O9U2W_1HD8WIJSCA-HR/L^C^Y7^WPO_>UL4
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ML)PS@8!GHS,Z-!K"RPH1@Q"48;_+ELIBMG26U1W2C3Y6)#8?+N8]FWXOU '
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M5IYSV<6M['D&6(EAN-:<2M:MG%:@R'7 =00.<P8PYE_J:-F3W[ T9 0SJSW
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M'*"0'DD.>UD3GRB_8.9'7RD,RF[I1US8#O'9\;CP:(AUH*7?K\R(X'1<7MI
MQE72(D9RK=-='TY?A3YHG%-:89CKJ_5SU48W(22=MV!5Q;,97GIS@6N7=L\
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M92HH'6NV<$^2:"8*EA?/$[*=YR(JFWM@EF-1J<Z1P]7-*3";G=1K 3S\'<U
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M2[L6 N[IXKI=!3:9LP6$AS3#A0B'YN@V1P'G^#.B:?=BGI?=I@6IU6]S+?O
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M3OEABQBBOMSZG69:S 36WOUQ)D!C+M$U ^=E/5R%T".6([QLXX>).-/XX>)
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MO(C?"D;^.=KBD+C.9#9*Y;E?]YE--N6,(V_:\&@\'MD:*S[GK?;7#>PR0X0
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M53EI\8KDE9P P81JZ;KF?[RJJ[&*P8W1YP%0'(,TZ(O+"GDU9ADX>./%9Y3
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MK4+V(Z1<_EU//I5C*_N=126) [V"R84XEZG9F6[3'[+%)5,F"5@)4--03UU
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MW1Q3C]EH^'$?\9T56-N,(^:7/]N]M+U_^.8+C[C18=,IH,ML+?^CW%1M^2E
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MR9OQXDIM7WMY]Z<9&BZ?H][>&#55P6$8*KJ>\@]E^4%IL0](P6),&[703Z<
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MF;VPSP%DVS2U*S$[)B4]01["XKOC+:.,'WO.<P6+2XP$LXY*Z2.S[W9-JW9
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ME-7H:,63G;8 <1[G31!K<11[<CXD:"_EEVKNXW#]$/%;.H0Y%!!KR' > UG
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MPK]&:80E3_-KE>>U'+C&=8W=+MSOFPD]7RF1\MU9J+F*#?VTWJ=)NI[]W2E
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M7[AUAT7+_!^N5)Q[S,F 96\DC)7@G#-Z!S,L@"_I@KDMR6[#REF^I=;Y8NC
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MM(9:1.1&>KA\ 64N\/6P4T!7W[';*6 FIR98Y!0P=0KX]GA!9NP,GO$?A>]
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M\!0/:AE&1444PEIRB!@WIV5TK%SKE^9A=EYV[KMF=@WA0#_L?A:=%%;2BL#
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M!MC[U4<W.L3X&T'PE4$=.N=<RE[].__RYUN2C/<_AHI2F"=<Y7F0!XNHZ5.
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M,06T9(]J_&:SWG+(0)-1N+2T&@CD%1<W'Q>I.%83RK'R9@C8XC%Q<6-\?+=
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MQQ#OA"J3^K=M5G,/T.AVF7J^2B="D*(M4=$6[T[A2P2!6ENW05ZO/JW?R)O
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MO@2O\$LH3M]5.;T&(:@+-$]GR!.AL&FRS4)&X/12!F+KHO>R<R6"%#KS)JN
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M/&FGKUQ<;ZMM!;-:M2H1^#T-#_AZ*VTPP/JFU;8F8S0\DAJZ;B-JKG+[.^Q
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M6AG;V[EU3G%K\60PX*]M=Y82/JL24/]E>HX/IZ>CXEHT^>/57?+EP^-.&#,
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M'2IQIUI!Q&5(W2*T44%IV79W_X'Y89YYGGWZ^@_.#^_W^9SSG/-^QTC:RX(
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M)YK 1Q;M/[34(^8[VK'64A'F5%F/GI3.('N&-#[3ZC@\+IU??@_O5QTO;FM
M+46Z;ONP3!9:]3KB]']'T/D7%,SP*JK]L<G6'I.V&G 5(J^&F#JAZ_N%#C4\
M!OUJH>*:S]"Y],&D-P'Q:*:F2GG'S=H!<UKA/V0)0&,;D_%N5\GK%*Q=,'M
MG*3^H9#MT28R>=,?(JF(/[@VFBIRAT]P+$0R8XZ1!=<RRT 0# X=6N/=B^VR
M42N;7IZ-2%"C/Z_2]"H@^J4Z+N64F;Q,J7S !XVEM=R4<BAQD+AQ+F(DMP^E
MZM%%?;= F8*,DVJ=](9C;]MIZJJ;8[;?/T:HOM11?!SSX=%"2^J"@ 1ISG1
MC<3,WC#E]>T9O(NW1LQ@"6+NR]O/>4>#*H+>I4"1NTK0JK82#C5U,N5;7?=T
MB%U&1)!!A/?Z9']2]3VDYF(R_;>=]K5"T[+"&7QI_[PDW"<CX1;DI<HM%$Z0
M%CJE I?E73S]#3!#W6M U0C 8M/^>T]K ,WNT%8NQVH,+5 ^ F>'E#(X=$91
MK+C!F6,PP0G\3SZ"!AQ.I'PJ[AY82-)_]&>+XX_ER\H(!K6L9<F;!XD=?N1
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M*IO]M$%!L5;.5MB&,NH(2V?H_WS7^LQG/O.9SWSF,Y_YG1S>%?T;4$L#!!0
M   ( /(T6ES%^[IBZNT% /SM!0 2    :6UG,3(S-#@Q,#(W7S$N9VEF'%=E
M5%1K%!TZ)05$Z6Z$H3N&[@[I&)"2+@'I[N[NEFZ1CJ$[I;N[=!Z\[\==Z\SY
MSCX[[OTQ4C*2/+S&NUB;2/<  !0*!0"    8 $@# ""O/[Q50"  " 8 TP!
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M.57-B.?-J%4+F&)6AP9IB..G>E49@L:LHE2MJ\:LB86^<B:DFTRH$2/K9F'
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MG>Y(4G3\_.%1#G,VB$&4)JA\*A?I5(96K-F**Z<F<XPLH(2!S^HD"+=,EPF
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MA3[P?G_,#QJ*@5E;"M]U#U('%#'$JFS".9X;H,P$8CW>QT4E2Y*X,-^JO<W
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M='WWD^:%+\[8RWKI%T34WCS;ZSJO#T0^T+]J*C]<SGTQ,A<+)!% N$,P<"
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M-*BJ+FRPA[)K8N4D=A#,Y2L1MM*'Y\"8N7B1[S/]*%UJZ#$PJLRB21IQ0#L
M:)!U.( %=:2C ];AE8QH1!!YX5 YR#A$C0 R(ERZBA?_.EB4&=QN*<-KR,>>
M8D6"R*\F\."0#!KW1(0PKRM;,Y].A.:6FHC/97PB95J\<"CJ664&-/M4]KQ
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M]9=55 K_)89 .0[5QQ%3 S&(E$-3&41@108J]%B""UY(T$KW4?28> S]]^%
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MQV<05 @1_,<1N>5\7A9], B'<?@5XZ=P=:AP'"@0JK-41$A4,88(6#@02H8
M2T:(@Y@ H-."< %Y@=0*[S #!DA\!Q%Q$8%E3,9^5[%ZHS%C_' /B1>) !A5
M5?81#D<:@@"(=.(L8>'_!6"C&&I4%M:51J26/A/113GQ=B,B-@?D!1"H6A9X
M%=9U0,^W0!KR(,"((N4@:.:3B'+(C,T8$G#BC-&H;S*(28,P1 N0!8/0"JW0
M#VSA#]W8"H.0!0M 0PM@15?"@M*HCNO8*=1(@X R _! &_T@"(^G:^ %>J^A
M5>F5C_VX7EAAA.Z%%?TP;L_&$$(6*%W0?3<!>RL!A1+1D $888"R/LZVA:L&
MAA AAG_25/=@6P]AA@B A@^AAA0$$06)  YPBGCUANSHDB\) &5@AZLS [:6
M"'ND03%6(;.0 S.).18P Q;P !40E$4IE$0)E$DYE$'Y *-#AYH#>-\'.GBX
M_Q"9&"C(> ](=7^K\I"B-AKK4!;Q%B@L, ."D ^7^!$(61[T)HHC894K47%T
M4FJM=CT8N22WXAG=0H&49I 36'@#H3W+6!"_-9AKA6J$J9<'L8 "L7L,$9CE
M%C\P*9F3F1!71YF7N4R",(.8J1OIR)F?"9K#H9E80I"0^(D01BB^5E+"IIK^
M^&MDN!M#$9JSV1NO<2FTB9LU!V,^EA5Z*$JI)Q!/Z9.=Y)1^B!'Y4 '^MA E
M"9M5T0^K0@X)T4JG&3Q!,AHJ21:M8)HBF1!M617T]U58XD&]&"$F0I@#48M0
MYA5NY8H$H3T8V7?C*6ZL=FSG29[%!4&&5VD=HICPB?]1 -)\NY6; WJ!B""8
M!(J@DR((!YJ@8&&@6_9[O $O,C*A<3(:O,@I1X$C+XD(FUDGL^"(U'D0.]B#
MHJ</Q":$.-F@*QHI+<FB+PJC,0JCQT4J%VD_",!<V#)J%Y$NU[9IA4F,"Z%6
M7(>>+C$^Z^&8:><MAAF@3#I; JJ?Y4EIBTF>>_D@%PJ9?2FC6[I7B3"27 JF
M<K*@8=H6GLE7%<I:?\(>$D6AOG(?1N:*P<67!KEI%,F8@#(DPI(L]#(#KW(D
MM!9<", >]$(@*(FD$K$JR"@0]>!V3\ID5<A\+4%HB&"/M :G22&GED:G'(EV
M3=*H $"IXR)4#PHJ_. .2_;_1B3:&BV%HFN0".%)IK%Z)2XJJ[5JJ[>*@1""
MH;CZ%FO(J[]Z3%X*K,-Z'*1*K%DAK'N5:12Q$@M(6Y86=J/!=<+R*L\*7(8&
M (_FEW\96T62=X+:#EY I%7:=];*G_;IJ+.8I%;:K(=9EP!@KIJJJ=,JK>9)
MG_;ZKN?JI/&JKY$)5,8J.:"Q7VRU*"IZK ?K';2*L O+L WKL \+L1%[&<DJ
ML17[%@!KL>+'H)(4H=VZGW?:GP11=@_!>,+%EW*W$BAKI?CJK_]SJ \E+CMR
M=]MJ$'V7@RV+/MK"3S/+EVQW>;%VH\/R5BE[LNY:*YKJ5D [5(CP;QGKM BJ
ML$\K_[532[55:[57FZ 4B[5;*TQ-R[5<^*5?NV4W.QI]5QMD2[1Z=0]>*[9M
M&X=1Z[9Q*[=S2[=U:[>2H[5W:[=,>[=YJ[=_>TD\!KB#FV]P2[B'B[B)J[B+
MR[ACT0HYT+AB*[AVZ[>1:[F>@@]L>[F;6TR&R[F?"[JA*[JCZ[0K1KI/FP^0
M2[F:>[JMFR7YP+JN*[O\XKFS:[NWB[NYJ[MQ:+J[N[#Y8 %]&[:^2[RVH0^J
M6[S)6R>U&Q*^.9S/"[W1*[W32[W5:[W7B[W9J[W;R[W=Z[W?"[[A*[[C2[[E
M:[[GB[[IJ[[KR[[MZ[[O"[_Q*[_S2[_U:[_WB[_YJ[_[R_^__>N__PO  2S
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MC=(HW0K1 !+1T IJ+==F31!; =-T/;IY BH@6K(ZB(]":$>OBM=YU=.#/9M
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MJADD01N\01R$$ O8P!R4L1%TMQ_LP<@+0IV2AR81-$&Q$R%<,A-4*!3,MHT
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M;! R,49B5**:$8AK=!+KP1^!R!FR_^ 0\=",-JD>'XH<!"B.[AD+IS$+X &
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M?D-C2/R]V/PE2,E-'=!0WXLQGEZ@WN\AFJ(-7XC(G.E%2]_!2,LEB<6%V9]
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MQ"&TS< "YE (RE C#F )"MT)YF,17AZ!E%GN.1DB^@>EH0@+)AR^O*/)L9I
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M!E8<9ZY,^WW@$]$C( G@-<[<EE1E#$;(7#J)"EH(.Q89_PPV&9!T8,Q9&8'
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MR9KLR:)LRJHLQU9 OK8LOK[L [SL#+1L!= LOM)LSMKLSNILS_+LS_ILSEJ
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M/H YF[/,XFS,LK/+]FO,KFP\R_,\TW,]V_,]XW,^Z_,^\W,_^_,_ W1 "_1
M$W1!&_3&?IW_SP Q$Q<Q$B_Q0SMT1+\K0Q_Q1$.TPCBQ14NT$K?0 PAP/NC#
M&X?T_(XT2(OT29,T2IMT2K/T2KMT2<.T2L=T2\_T2\OT3=,T3MMT3O/T3OMT
M30.U3@=U3P_U3POU41.U2#^ 1C,U1S<U\SAQ0S^U5#LU(RWT15?U$&^T5D]U
M16<U57/U5WNU_52 [(@U1:-UYG@T4AMU4KMU6\-U4<LU6\_U6]=U7--U7MNU
M7N/U7A.U1Y\U5H?U8 .,1X/U88\U8G/.56^U8@NV8S=V8DMV6D<V97<U4U9
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M4,0-37PP1!)5])#%$5L\44,42Y1Q11=MA#'%%VG4,<8><[QQ1R!]G''(@]9
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M-/5#;+_;L)8L']24BU+]H0!<S)-EP)T<O(35#9>\(;T ^F850S9%^<9S!G3
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M.*>M(2=*5].-V9"SQM]T+3IF),Y;V@B='=$1.O(1D9**6*4X_H;_;)W) 8<
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M _^,WD;P@?DMX,K*XG*DR:8&7R )>N0-99S2<9@:-A(N_)1PB6@P"$,P@>7
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M'B-L+%RF"<I.,S71(EC".4F$>4L<83KON<(0SO.?[1I?/D_8SX6NLY[[?&A
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M1S:\\N-FP=@RB"+;PG,&J(M[W</,P-@U,155I@8II^;9>,12W:0V[F77S'A
M:DUQ;%<F^)0R8.:,&V;;! 21X;=/AC<^5-F%TRA>G#>%8;DD9Z 5WG$0"H
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MA1\<P#ID "ATPF"DP[V)J!]L3J3E)1_*O6&ZP"=\HCJA1M8Q9'O!G7AF@68
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MOJRN<JAM#653WUK7N::U0I9;:UY/.=B^[O6LCTUL9/^W);_*-O9S$N$"U]2
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MJ$N=ZQ[G>(=YSGF_^W.7&V/ ]GWOAQ_SX!M?^<C_/928+?SDQRL1+RAE7UX
M<.![K-O,EW[TG;]\[7__^-X/__BQ)(B@DS^/Z"''!V?QCAF0]NFA0_!#%!QA
M1 ' 3/U>J;];^C'],'!_%%,:QB[R]WEBPDZ" "8-AQW\$#X\TGB.<E/U5A[K
M@U2@ V.BASP:=Q1H9%J/<VA9178B%Q,D1S]: 3X)B![ZTWSKAUTNQRHOV'W@
M1X/B_V=^.7B#Y]<P0T=$,T &+B@Q/OA#ZD<09/9S25A8:*9#2+<3_H"$.E1T
M%3$B['$H9>4/$6@?5]!5!D%B80)%SV5@,I!*:Z0/%)0C+$%WU&8Q7!<D(XB#
MQ;(E.5$/D%-.8#02/+(?Q+5,E#<#,C #Y=!/)O%X%E%[@"B(B/B'@?B'\$%-
MOV1X7[%J)U<?*R8[J@,5@', 3%00^B$4KL86\)&) \*)/&B*.EA^.XB*-IB*
MK1@EL;2*,%B#LAB'KDB+IYA7Z5>+K,B+M_@RB.!MJBB,MEALFO@V"(%CQQ2+
ML\B,HV@AD;B,NVAJZ4>,#2-OEF:!4!>"]D84^&<G)Z5E__\782OU"" EC<V(
MB]68CKV(CC G@]&XCKXXC.QXCO48C_35#U&(+3.@=6;C#Q:@1&X'/U[@94E(
M6 S!A./BA'"10WR%$!GFB*XU"^F"60"0#XJ%D1FID>E"#@LQ576G7O<P5.'"
M)747,@4''RG7CFO!3%4U=ZT% $%&*[JU=^8"B2LA/WZG$H78$'=C>\_A>;M5
M*Y,(*)5(>I@H$II8BI[X>JB&.S()$K$&>?1XC_8(CU<YC_*HCF8%C%7IE5BY
ME5FYDF%97(A !E8IEFC);EVIEE1Y)002>C>!@-.T.15"<0=13/*1@:%E$/F4
M45Z7$/Q3'E.)>*\630IRB4&B8WC_F2Y3B1.O8TZYIT4/11!3I6(-<7GGY"3<
M5$$S$)<(,9>F4Y?K5!3T8&!TF9.?HA)^&8* R1!?5&=SN2"(AQXJ61"FB3<S
MDII"J95NN2E=Z9L6Q0^<65KS9W\1@7_ET@KB&#WE.);!"9V]*9W/.9UMV1/O
MF)9?F9U@&9W4Z9W6^9W:29;="9[E*9X,HCI24IALH6GVA!2( #AUUB1U2':U
M0R*+B1/Q:12[64&!%Q*X63QW^9B>HHS1M(G_V7I709]Y\Q$ A "?B8PR8A#P
MZ5_0B!%$.9[5>9X:RIT<NIT?:BK ":+DN:'AV:$F.J(9 VCF>:(LZBO<YZ+C
MR4Q09SEN_W,ZKZDXJ',[DP-:0#&CMS1.'3&($S%.=SFC0@D108(0B'=+ 14D
M$YB!#RJD<UA-[BDP 402FG,00':CAVD>H!E!.SEZHM>C@M,E0(JA_523@LF@
M!]%/+HFE*1J>(HJB>Z0/71"!]5<F;W(]$/8(^B>G,4JB+5JB@NJA,H&=&5JG
M@QJHA>JHA JIC1JIBFJHB\JA8U2IF?JH;C27-3FIC$JIFQJJGWJH-I<(/@:J
MJ5JJJVJIK:JI+0&,KRJILRHJ,"JJH)H@9J&D$1%KF.=,1+(2MA0@.880&>B?
MH^5UQJHEP.H1I>,Y0>FIP=HEWT,A@%DZ$%H5Z=00"UJ;2<IYO/\*'R8' ,8X
M@0# K1+*@6F8G\1Z5/]QK-4J541)K@IQKG1)JL%'I[)J1_W0!<<Y$;. ::YZ
MJZRJKZHJL&"9J 9;L 0[L =+JPK;L OKL*/ZL Q[KQ*+L1&KL1>[L14[L1!K
M?*?:L11+LB#KL1G[2HB@ RA[LB-KJQP+LRT;L\1XK@6JJ#7[L1JJLB5KL3+K
MLSR;LT'+LB.3L#T+M$-KLD<[LDG+M$;;M$*[M$XKM5 [LT^+M%-[M53[LU;K
M,");M5@;M5JKM%5[#RL;MEFKEB*+MF?+ME\KMESKMD^RLW"[M6 ;MVU;MV]K
MM$6KMWV[MG<+N'G[MX*+MV-+N(%KN(G_2[>*:[>'Z[B,Z[==FP.%N[B5V[B0
MB[3X8+:(:[EUJK:4>[F=.[B8"[J1&Q:M$$2B6[JCJ[J<&[JO:UY\R[JP.[NF
M^[BM>[NTN[J[Z[JV2[J]6[O!R[NYZ[N6"RW#^[O$*[S >R^:N[S*&WV?R[S3
M"[W4F[S72Y7Y,+FXB[VZ:[W<"[[>:U>RB[SA6[SBV[WGJ[[/F[[L:[[NB[[O
M6[[Q2[_K.[^SV HK9K_?6[_PN[\'D0^;6[T#W(K22\#RR[__V[[W>U_Y8 $+
MG,#^*\$,3,&!1+X17,$'W+\9#,$:K, ([,$3C,$C',(<#,(=C,(V=[PDG,(;
MS,(G# #ZD ,B_US"@63 +?S!+ES#.XS#;Z4/%=##)JS#0?S"0QR<%UPL/&>0
M2\S$3>S$3PS%42S%4TS%56S%5XS%6:S%6\S%7>S%7PS&82S&8TS&96S&9XS&
M::S&:\S&;>S&;PS'<2S'<TS'=6S'=XS'>:S'>\S'?>S'?PS(@2S(@TS(A6S(
MAXS(B:S(B\S(C>S(CPS)D;S(1JA:2$S$/ S#1JS).<S)-'S)GYS)G2S$HES$
MI(S)FZP1*WS*I@S*J$RY_% !GAS*JO4(DRO+KES*M\S*JML/#]#*NXS+JZS+
MPQP3ECS+HTS,N8S,RZS,S2S,S/S,SOS+R1S-U9RAL^#+TGS,VAS,X__I#P]
MS=-L+K4,S.4<SMMLS:K[S>+,S>8,S>S,P\;<S>@,S_5,S_<\S_GLSNU\SOK<
MS_N<SOX\RMD<T !MSP)M?.#\SOBL2N3\SP^]T A=T,I&T ;-T!#-SQ$]L?)L
MT1)]T!T-TA@]T1HMTA]=TA=-TBF=T6[[ /UXTAZ-TBOM1@HMTR8=$ZU@RRH]
MTC4=TSM=;C0=TCIMTSP-TWO;)B;DTT.=U#VMU$T-G9_0#R\=U$0]U4M=U%7M
MU%>]-BU-U5+MU1$-U%F-U32!TV.MU4+-U&G-H4#]U5V-UF?MUB_#T6UMU69M
MUW2-P]$ "IF@";V@"9E@"L-@"L1@"M&@UG?__=:('==UC=>'K<O\N-ABW=AP
MC1 /D$J.G=A2<;R3K=B,G=F?#0 5$$6<3=J@[=F1/=>F+=FJC=F1S=#*L-=]
M_=>9X->94(8 H RF  J#'=B\K0RM?=K!O=JN3=G#+=R'#=G'7=S ;=RF(MJL
MO=P]L=G0W=G-S=S7'2P58([47=K$7=W8W1&I[=W=K=S?'=VM"MM\7=NT_=>W
MG=N[3=B"3=B&?=[D;=WUS=WY/=[Z38/)?=_F#>"WK-W\W=33O=\'7M[VW;HY
M *C4S*_^NA#.^=\*CM^H?=1KE> $#MX4KG,-^4/:ABO\H$0Y?1 )V<6I*Q&#
M50$/4 $S8 $SX&46_Z #,T[C7@ $7H#CVZ'C^84(9=#C/_Z-7*'7ZOW7O3W?
M&Z[A%9[A"#[A21[@Y^??".P/IS (5&[E58[E5Z[E6<[E6Z[E#,'A83ZP#.[D
MGFS@2X[F3<[DVZP#0FC"PYFGG@+A&^&-_@>H:I[F2%[3XIWG2H[G?VYS'JY#
M(%XL(IY$)&X0)L[%*#YF.O3BCYX#.A#ID=X%.D"0E[[CVU$&9.#C/FXG_! -
M_1#J4>T/I;X3G\ /8K[F?J[G??[DJ_[J&S,#;$B[L^#E6+[=*\,/79[EI@[K
MJIZB.8 /9?[.9P[HK([LL3[4.C#LF]P/B."@V:BGW3B._9<JS@GLQZ[LB__+
MY]H.[%U !CF0 \SB!6863%Z0 U^6+#E042>#)NB^+##N==D>Z$I$Z*-BZ$2$
MZ "@Z--2!MBEC]GB*&:97UY0!O2@#\K0"M# #\H0#=' #PQ/WZWN[:;(E,1^
M$T02K17O0G=CFQGL1*7XZQA?6X,P UYPZRG/ZRK/\BOO\BT/\R\_"+E>7;ON
MY12/\T7-["1?S\:>\]N>[/3NPCHP0*^*".9 ?TF//'-.$'5N[=7NIZ/-\S\O
M]&/9[50O%HCE/T2AZ!?D#X*N+"XY$]YB[@WE+72E[@^0NBC1[\@BKA-!9OO>
M>3JT]0TQ[@(?$0'_ &*/];L&]MYR[R63[S^T[VW_ORS_KDIZ+RT;F!30  KP
M[=NFD-LML"R731'\69S_Q?>-T@KSYS9%KQ"8?Q^1TI[ ]%0!YASIT#\\_8RQ
M)IFV<O$CKQ :/RIZ!QUC*J;U(?)1L21#@49OOQ"[OSC_X7P>3Q2X][\A#RD&
MLIN;3Q!4U!%!^2JQ=IE1,2\U>3? ?QW4;XD9<?T<7_(S\ 4Q3_XR7_[G;_XN
M/_')%PV\7O7O'VQ$/_4>[?-!#P#1OHW ])W"1!%U$[Y(!1#E  ST-] @P8,&
M"QI$A #! 8<1'4*4.#'BP84),V),B+#C1H4= 8#TJ%$DR9$&RT6D:/+C29@O
M9;JDR7&FS9HA;^K,61+G_T^>0'T&U:GC'M&A25/N5(K2:<R:+"M:G$JQHE6)
M6*5*=+=4XR-$B1"M"3NV+%FQ:,VF/=N6K=A'_$SVZ^E5J-=V6QUZ:0KUKCN)
M#OHRM8NT\."Z3PDK3NS7\$:]#N4=ILSXKN7'CA%?UERY,^;-F1=_)CW:=&.#
M:M>H/LVYM6C4L5W+ACU[]@/<N7%W&:C;]X.3B7[C1D1S>.[!7H[S3JK\>&G:
MH4MV.?X@A^?%SH=?#UJ]N&+AQQ-)QQZ]O.W:Z<F#/J^^O73MU>7/IU]?]_6-
MX>WOG\_WIH[]RDBJ%6(TR4237@Q$$)0K'G! /C)0 FRJKEXCR(NJQJMKPJO\
MX_],AJLTQ"B1#&>Z)S($NF*/L7188@Z]]:"#\3T:5XQIAHAF "DOBCRD+"^)
M9+ +$1"U$G*C+BP24B@OK&I'(1P1**>XPV; "JF'IM(Q(7JR=$B@H7B,"$RO
MZDGRH8X0P8I*D+JTJIZ@SJ1H!H[HB9(J.MV#S"+3[D3@R9> W,O&A)J,"-##
MU)0H3T('BI(B*F,T*,HI9?+S )@$10 1IS \%+N&6(HTI"XE@O,C3[-"@)Z:
M0H44IWJD8M6FJT8=2%-1+1QI481P/54C7@_S,J(C/ZOHR48YTM2+%8^M448]
MH974O&2CU;7:I :9P8M3!NGV6V_#!7=<<<LE]UQSTT7_=UUUV^TVFF>OE3:E
M?LP]15Y\J9T7VWCUS7=&?@/>=^!_K?6W)QU^!9C@@Q<N>%J'&S8X8HJ#FH5.
M@1_NMV*(W8NU(DX_2Q4!&12M*J)?%QJY'3\G&M7-J88U522M2A(4(D0)J@@
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M[K,&B?"6[E,]GLR%6^]PC"CW[_S^<#"'\2\7\_<.\_W6$QU@OC(G\Q</U1F
MP35_80!/L1R#$SG+C ,;EB=)ICBY,T53+QP"&D8+TZM9(OV"B4(JFB0O-(<X
MDM:$&@N?E%L#$S^IIRTZQ?<@IJ8(K=FRDS?AB1WTK8_X\\A@2H/P=/Z;H$-_
MB3SG,B2+SH@PL^C*DB71)KYHF_^2@16I$$;/R/,#X",0!S!$_\@S.HE8+'3L
M.O$$O'"?2;15/_6UR9,<*SI2;[-L\J^IQ#-7R@$8%-16:$4;(W2.2O$,_<0T
MA;X 9W,OC_-HG'&Y+6^QM@SIKHP<!XH==Y[J /*S/HPBEY$E]XT6]/%-?7+[
MN?&<,'C.J/+?"(FW(A^]4?C<N%0H)_@8;_.*7W>+'_,SQWB.-_/;T8&(8W>-
MO_C[[ (XS_@ESH'")K%Y(HGLPK9*\R^>X/"< 32G])KK(K!G3ZB*T':%J)V,
MX'!,+XDD&_HUFXHXTW.%&",JVIEK)W#;J+'+$,I;V?6$N$U7SPA542Z1@$W*
M(*>E2"?_H[?Y4]3Y,;EZ^5.RC'APH)CV]*H(X*N,8P^R^++ZA JM)D)&!-<9
MD*$A9*R;J<CZ"^)Q>%J[@0@H =MZDRC*29KN8WW$$P_WW7:*<E]Q#S4I-MTK
M$X\(/)2HT1$,CS_\X51W3W;W\/WWR=4<IZAWHKCWDT#]R&UR@^AW:Y)<RE X
M%<QNBD^(AI_<>#\(V+>/GRCO[Z$EY6'OC0]]D5]^E&_^CB=]Z(=GD!]YZF?^
M\>P"6TQ^FE5Y48*GN_!ZK><QC+"_JQ\6W(,R2!__ON^($$^4J3-T68&;?#IU
M\^>)HB]_IS^XP>&A*#L-56$T@ #@#P  +P@.(CB L!Y!@01G_R!,B*AAPX$4
M"=:+B$"&0P :#WBYV)&B%X41Z8TD*"-AQ(H4$2J4 1%FR(O^#$:<8=&F2(?M
M-);KN;,A(I,?$5(<ZO)B48THE:XTBF ISH,'9HA42E!K2D16#V)M*!7!4Z%"
M-2+P I5ERXY>889-^O)K6KE9 :R,R%!D.8WM4B[E>7<P@"Z)MIHE;%<PX\6.
M S]&W! F6K9'T8ZE>QFA.\!;'R%*A&A-Z-&E28M&;3IUZ43Z9EF<E4\UZ4<$
M^:4^'-DS[Z&4,6\<RG5X3W<:)3>&K!SY;N**E_=.G)PY=.>-?R.4%_TY]>[;
MIW]O+EV\/T3I'"!H95T\]_#5Q[]OO_\^/OCYS&G3E@_?NWWW_/?[%V!_ P)(
MH'X'UE>@@@BRER"#]#48(803_O=@A0YB*.&%&@JX8(84=FAAB!]N"**!)([(
MX8DJ>LBBB"N:V&*,+\I8HHTISH@BC#?NB"./-?H89(]# DDDC4?J6*222+J8
M)),Y-ADEE%/^^&253F(IY95:"KEDEB;J,!&71GZY)95=6HEFF6J.Z66;:9+Y
MYIIQGMFC87"Z66>>9O+)IIYX/IA#(G3V2:B?A>YYJ**&,IIHHX#.N5]3$?WU
M:*20RIGIGY=B>.>BCK:(7429639J9:2.U=EPH+'6JFF/O+;5+(FX2MMIB, &
M@#ZUZK:I1U__W0/ %:+"U(6(QK5EJ::(8@HAL=HIZZNTS!&+ "+1,LOILFSB
M=UJSV6Z+[:??CJOMM.6&"RJYXK*KKKG@GMONNNZF.Z^][Z(;+[WZWELOOO+^
MNR^\ ^=+,,#^(LQOP/TJG+#! A<<\<$-5^>%F!0_S'#&"W/LL,003[RQQR$'
MZ.G((*.L\<<JSR<HR2^GW#'&*\LL\LPPLQSSR3GSC&478N*L;;6E#HWJJ1JI
M*M0C_% DFZVUWEJK/@3-$O5JH_4*+F7!VE45T0>9TTI[R"(5W;"F'M19B<.2
M>H50B0"'$- -S19U(K,@E@]Z</7#4UZ4R= *UP(E0K9F!VWXK'M1_Z$UP^!)
M>?T51\WMC?9,5LT 3S[]S**/(&=OQ@+>GB'BCA>FDYU9%ZB??OJU.M\,^Y;=
MIM;SSC73?+ONL=O..^Y![VZS\+G['CSQPP-?O/+(RWZ\\\DSWWOTOS</_?/5
M8R_]]=I;WWWV]5E,/???&^_]^.>+GW[YB7J1]?3KHP^_^LJY3/[RV\___OWF
MYX^__/_OSWX7\A3_HE2TH\5M,Y:#Q^A69;6G70V"B6":/U@5P0>Z+TY;2] [
M%'@0!Z!$)(:;BMDVHS;WL*TR;E/,3$CUEXM4S384$8149C"U..&$5.M1W' B
MQY::; AN7^M-Y;#3MPVU$"V"V.'A#O*Z^/\%T':T&PT4]6=%_T6Q?P7,(@"O
MN$4O"A"+8*RB&,OX13.&\8QJ3",;R;A&-[91BW'L(AKA:,<YD4$0<KPC'=^X
MQS_V<8Y<!)$7R,#'08X1D!0SC!\#><A$.E*1D$1D'25923D5<I)::R(GOU:J
MS.7*'X+H2Q.3EA4+0C"5I9$A;A[HRMP(#5@Z:D4"$7*ZXY00;0@XX7Q2B)85
M@B<C<=-)8'YB%0<<\3TCK&&PAB)$'8Z'ASTAY5$F%Z\BTL58$.H")]4234X^
MT9*-]-44U_#(2U)RG)I$YSK5R<YWNC.>@FSG/.%93WF>$Y_BO"<_\]G/??HS
MH  =:"23DD>"IO/_GP5-J$ 72D]R91*A#Y6H/9_#2(4R=$YOT25'2:A/ASI/
MF!^9P0L!0(^25*:D(.W/6#CRT8Q&4A"&K&B&#J@14!*D'XA@7"V)94J;H/*5
M5QM=W:!FU AFT$O^V""7]'$Y8OU'$*%KX'B2B)9T> AT8V%!/I0RD/4\LW%@
M[203B0:MMR4P*%>Z!P*:*11LLD6;&^+FU[RIF&J%<Z48G=UI\D/1EUX1$0\8
M+&$+:]C#(O:P0*2I7AL*T\=.M+%_W2MC(5O9R%H6L)?=K&8[2UG/.A:SHN4L
MR,BP6-*&%K6332UH5XLBF;+VL[+MW45CFUIJ'L2E(B&:9)Z**HI8U8,'_]D+
M28P6MXL)Y*D\;8E%-NK)S-AU,FSQ;4J?RLF4T-6X)+R0,7\H'GI\Y+0 J&$G
M38+<@?3T<&'9B4BUBQ!B4N0G1E%K1YZ*6V)5ZB+E/55<,CM;QL!6M8Z!RSN.
M*$IR(%"XST5:;X)JU'Q0[8)'524LY=0/IIZKNXASCW'<BYUW$*0+I,*JA?)A
MM!!2J!4>/EQ(%HP B$!&FF-+<$?ILMCAP-4D<@U/=M$2W<?X8P8K1@#3;.M:
M )33R)+]GPX2FP,!0S81B>VO?Y5<Y2-?><E9WO)H6ZOE+O_WRU &LY7)C&4S
MB]G+\3+MF<?L9C6CF<MO[DF TQQF.4^LMFU^*?]XC4O2N64E<O"UB7.':Q8-
M(X"^ID*Q9+P&$J9(19M<071^(8W+G5!3(2IU"%JX<M^R4&2YHT)NA8XBG\JL
MQ2@EQ31E2BI?A-!7*9J!W$V'4V@$$/=7;+&)H+DR%L0@FKYRZ?2=XXR< ,-9
M(+-X!W73ZV(/_C0I#EY-D4%#80E+.!]4+?.<N9WL;Q<[14G><[B!UV3$/IDX
M@DTLNQ.[G':W>[$S2&R8""(:>!-V*5*F=T@&@@@OL%L'B%DWOMU]$7;/(&M>
M\,*\!RM7<'N[W!*/.,7)77$[7QS/$[<XQS'><8UGW-AF3,1I(?YQD9O<XRJ_
M7YU!?O)N?TG/*T?S;V[_#*!?1^=O^Y4;<C)-8X3(VC+$G?3/-3-T  2[)XC6
M;7PM$^M;HXK*WVEOT5EB3>1T-R8\ 6]$A&W29YMJT^A5\'RI,BJIXSS5"%GU
MUVM,M$J_W(_(WKB&9M&.'%<]50V^U2,&TLIKT^9N*7?YS&%>^,&#:]R'IWO#
MSGW8="OHWUUP?,$GHA5VVP?@BAV.P6U2\,\3-@=:V?=AI>Z9'.![!C-%O.$)
M[WJ4,Q[V(6^][.,>>]KCGO6ZO_WN6?MOV\^^]\ ?_N+;T_+:%Y_X$[*8\)/O
M+[='&OFOQ]&KG2U/1&O7^5?^?>[=I ]?0GOOH]L5MG.E?>FCO_O!YSV]%#_]
M_^9#B?*%A7R@$UMRBLB?L)87">;W@WK#/MF_ 6 7B!=7$-QA60GI&9;I&<C_
M&1S\I1\$JI_R12#[K=\%4N $GI\&OI\%9J $=@_)?: ';B (DN#TU4,!GF %
M9ES[F" &EN *<B +CB"D((+ S>"XS((Y[%)O5(WYY> +UN 0QJ"2N1\-%F&6
MY-]@T1]/."#HL=O^'5QB]4?#02%BD9I%*. 5&I84,@447L03<F$'PB 9$J$9
M)F$:HN$:(B$;!J$,"J$:MN$<CMR.O6$9TF$<NN$9U0,.RN$=8ID+PN$@XB$@
M_J$>YF%#W ,.(J(A[B$AGF$B%F*<'*$C2B+QT5N%:/_>83T<)!ZB)S[B)(+B
M)7ZB*)IB)%IB*C;B*H[BFR7"DY4B*K+B*<8BERPB+89B(.95+M8B+_HB*?ZB
M*BHB([;B+,IB,2(C+B)A)1IC+W89R5VAZ@'C- JC,E;C,5IC,P:C-E(C-UZC
M,W[C-A;)(\"B.&9C,F)C.MJB'YJC.CX6\Z$C.'KC/,9C.\H)/A#C.>JC.W9C
M/?:C$?:5M_!C./[C0-+C/LJC/Q+D0AZD02ID0R8D0MKC1!H,.3JD1!9D1%[D
M1> C1C(D[,"C1T(D17ZD2#YD0[1"/FZD1K(D28YD1A8/,YZD2=+D2KKD3-HD
M3.ID2>8D3[;D3KZD3][D),[_ I4%Y5'BY$^^4SZ4XU#VY,2$Y%,FI5,J)5*>
M(E,"Y51F94U6I5:BBTQR)56*Y59*95B295>:I5">Y5BJ95M:95G"Y9@495RR
MY5NB)47I@P6DI5TNWRZNY5^ZI5?RY27F)6 .9F#NI6#&(UC2I6$J9F)"9F,B
MIF0>9F4^)F5>YEUJ9EU6SUQNIF-&YF>^$S]40&ARYI-$I6A:IFF")F:B3S^4
MYF2J9F:>IFNJ(V/.)FO*9FWFIFWVYF_R9G"V)G .IW#N9G$BSRP\@&\:YVHR
M)\' IFXZ)T$4TG0V)VTBYW%64G1JIW5FIW=VYQSAYG5*)W:&9WFBYW.>IWJ"
M9WN:_Z=[IB=Q"HARLN=[VF=\UDELRJ=U5N=]UB=^?J=_^HL_+.=Z[J> DN=_
M$M1X]HD@<.&#0FB$2NB$4FB%6NB%8FB&:NB&<FB'>NB'@FB(BNB(DFB)FNB)
MHFB*JNB*LFB+NNB+PFB,RNB,TFB-VNB-XFB.ZNB.\FB/^NB/ FF0"NF0&E8%
M():1#A:2/H"2,BEA(>D,/&F4+BF4#A:55@"5/@"4:NF5<NF6>FF7@NF7BFF8
MAJD%:*F97BF:SH":FFD.K.D,N&F;OJF9RFF:PNF=QNF=ZL"\S<">NJF?]JF>
MKFD.^"FA]FD.N"FB_BFB'NJ>ZH"A/JJC0NJD1BJA6FJE(O]JI3YJIEYJIVKJ
MY!$JJ.J J%XJJ8[JJ4Y>JJ+JJJIJJ[+JJ[IJK,(JJGI!JM:J#BS<Y"V<%^#J
MK>[JKMHJ >;JK0IKK1IKL2+KKRKKKIJ6L3)KKC;KKW9!LR(K&1"JLD9KMCZK
M:7%K(7EKMW;KPH'KMWJKN)+KN**K3!62NN81M[+KN[:K3,EKO-+KO-IKO>+K
MO>IKON9K&<AK&2 "(@@"P HLP<I4P"("&03LP0JL:#3LPCJL($1L(@C"PUIL
M:0@LPFKLQG*L:'AL:X"LQ];#QXHLR2*LR0:LR:IL:(PLRY9L:-S#RR9"S-+L
MS-ILS>*LS<+LS7ILS.*#SMKLS_K_;- 2[=#>PR.T0B+@ ]+.+-*VPM+^+-0^
M[2/@P]3FP]16[=+F ]52[=.VPM9J[2Q4K;:UPM>*[2.0K=ENK;9=+=O*QMNZ
M;2O K=K.K;:]AMN^1MYVSM[J;=_R[=_J+3_LK>"^!N'.@N$B[N JKN R[N$Z
M+N<(+N3.@N12[N-.[N5R3N9B[N9JKC]P+FQ,KC]X;C^(+FR4KN>B+NBF[NJJ
M;NMZKJS KK+%[NN.Q$[8KH<0:( "J($FZ('R$8/RKNXJJ.\.;^\:K_ 2;_(>
M;_ R+WP6+_(NK_,J+_12;_,B:/5*;_3^T^TB!^UZ;P.![U>%DNN2+^N:K^J6
M+N>,[N:N_Z_FNN_G5F[D6J[\TN_E-N[].B[^)F[A*B[_^B_@ K#?"C  LZW9
MZH/:FFW9%K#;,C#<PBW:SH("BVT"0_#8<NW5CJW5:K#4<G#7+FW90FW3)FT(
M'VW2&JW2%BT*G_#.LC#/YNP+NS#/MBS0SG -KRS*ANS)ANP,MP8/WS#(<FP0
M8^P03VS%2BS$&O'$0NP2"ZS"!JP3,^S +JR_-K$1\^N^8O$5:W$6[^NZNNL7
M>W$8M^NYDG&XDK&YHFL9J[$9:ZNY*NNT#JL7C,[[ &_V8N_U6N_NVG$>/R\?
M3Z\?:Z\>X_$>$_(@&[(@(W(?%W(B__$B*_(A/S(C![*VU#$D-_^R)4_R)4OR
M'6\R('-R)(.R)H=R)I/R)XOR*9>R)ZNR(Z.R*:<R*[\R)KLR'0=D[8SR+*^R
M+.=R)\,R+O?R+M\R,+>R,,<R+^OR+R/S,2NS,3-S,"=S,P_S,\=E)4-S,3OS
M,E]S-?LR-D<S-UMS-VLS,6]S.$LS.&?S.9MS.G_S.H\S.K.S.'\C-;MS.ZLS
M/;]S.=^S-]OS/L,S/O.S/_>S/@<T.0LT0!MT02,T02OT/ ^T;\IS/3<T1!_T
M0DMT0C/T1%^T15<T1><S1_^S1G=T1GMT1(?T1HOT29MT2D/)0Y=T2W_T2&.T
M2K\T2KLT2<^T3-MT3L=T3>_T3?,T2/O_=%#K-% /-4P3]5"PM%#W=%'3M%(?
M]5,;=50W-5/C]%);-51/]55+=55C-5=O]4]_M5-#<U)3-5AG=5>;M5>?=5B7
MM5BO]5NK=5RG]5R[M5S7-5VW=5YK-5SC-2O3!L"FAE>A]5T3MEX/MF&S]5[;
M-6+S=6$K=E\?]F,[=F13=F)7=F,S]F)+-LWXPU^?1E)9=FAC]F:3]F5KMFE#
MMFB?MFJG]FBC]F2S-FR[=FQG=FNO]FS;9@39V]78=F_+]FT#MV_7]F\+=VG3
MMG'C=G 3]W(/=W,CMW([]VM']W&S7]3T1-0D$W0_=W%+]W8SMW=/=W)S-W63
MMWA_=W>C=WEK_W=ZFW=XK[=ZMW0_N$I/7+>K;%M[@W=^L_=[X_=^CW=_P_=Y
M![A[_S=_&WB!([B  _B"'[B"RV/5S#=]2WA/ #:U)3B!._B%Z_> ;SB#:[A_
M9WB(8_B(=WB#DSB(GSB'HWB)?SB-_)U 3GB,R_A%5'C@ :&)L[B(YWB*>[B.
MK_B/JWB0]SB/XSB0#_F.([F1%[F0+_F954TJS7B42_F44\2$"17@77F66_F6
M8QN6<[F7=[F6A_F7BSF8FWF9HSF9J_F8L_F9K[F;MWF:Q_F;RSF<VWF=XSF=
MZ_F<\_F=[[F?]WF>!_J?"SJ@&WJA(SJA*_J@,_JA+[JC-WJB1_JC2_\ZI%MZ
MI6,ZI6OZI'/ZI6^ZIW=ZIH?ZIXLZJ)MZJ:,ZJ:OZJ+/ZJ:^ZJ[=ZJL?ZJ\LZ
MK-MZK>,ZK>OZK//ZK>^ZK_=ZK@?[KPL[L!M[L2,[L2O[L#/[L2^[LS=[LD?[
MLTL[M%M[M6,[M6O[M'/[M6^[MW=[MH?[MXL[N)M[ME-YNJO[NM<W(EC0Q[[[
M*N5PO(L&O;O[O..[R=K[ON<[R/*[OO<[O >\O -\P?O[P-<[PM^[P0L\PQ/\
MP3M\PD?\PD-\Q3>\Q3_\Q6M\QG.\Q&.\QV\\R'<\Q8<\R8_\OW^\R8O\RJM\
MRZ-\R;_\R2M\S+,\S;O\S./\Q-O\SN=\RO/_O,[W/,P'O<P#?='[_-#7/-+?
MO-$+/=,3_=$[?=)'_=)#?=4WO=4__=5K?=9SO=1CO==O/=AW/=6'/=F/_<]_
MO=F+_=JK?=NC?=F__=DK?=RS/=V[_=SC_=3;_=[G?=KSO=[W/=P'OMP#?N'[
M_>#7/>+?O>$+/N,3_N$[?N)'_N)#?N4WON4__N5K?N9SON1CON=O/NAW/N6'
M/NF/_M]_ONF+_NJK?NNC?NF__NDK?NRS/NV[_NSC_N3;_N[G?NKSON[W/NP'
MO^P#?_'[_O#7/O+?OO$+/_,3__$[?_)'__)7/KM;__7'.,W'2NT&!O=R?_=V
M?_B#__A_?_E[__F+_[_YIS_ZDS_[JW_[KW_\P__\OW_]N__]R[_]YS_^TS__
MZW__ P0 @?X$ B XL.!!@PD9(G2X\*%"B0TA5IP8D>)%BQDY8O2X\:-&D1U!
MEAP9DN1)DRE9HG2Y\J5*F2UAUIP9D^9-FSEYXO2Y\Z=.H3V!%AT:E.A1HTF9
M(G6Z]*E2J4VA5IT:E>I5JUFY8O6Z]:M6L5W!EAT;ENQ9LVG9HG6[]JU:N6WA
MUIT *$#7OQN7[EV[>?GB];OWKU[!?0$7'AR8\&'#B1DC=KSXL6+)C2%7GAR9
M\F7+F3EC]KSYLV;1G4&7'AV:]&G3J1//XO<(4:+8B&#+MAV[8&[=NWGW]OW;
M]^S:_[,3Y9N%&OGJY*J9LU[N7'GTYL^I2X<^W7IU[-NO=]?N/7MX[M_)BP<_
MWGQY].O/MU?O/GU\]N_IRX<_WWY]_/OO]]?O/[\ ^?N/0 $!'-#  A%<\, &
M%70PP0@9?)!""=.:19_;9!L.N X]]/"VX1XA:$(+*RP110A3/%'%%EE\T<08
M5Y3111IAG!''&G.\4<<>>?S1QB!W%-)'(H$<$LDBDSQ2R2:9?-+(*)>4TDDJ
MH9P2RRJSO%+++KG\TB01B?N0S-]H$RXV?;RTDLTMVUS3S3CAG!-,.>ND\\T[
M]<R33SO[Q-//0 $==$]!"R7TST,539110QM%U-%((9UT4?])*Z7TT4LUS=0\
M?C9$LTPR0XRM'TPMY?345$U==5-56V4555A=C?756FF]==9<9=W55EU[Y157
M8'T-]M=BB3UVV&2%7=9899ME%EG6^OG4ME![0S,1-9_=-EING>T6W&_%A79<
M;\D]U]QTPT5W777+;1?>=^5E=UYWZ;W7WGSCQ7=??>OM%^!_AVJ%6D2L!:#@
M1_SE5V"&'5X8XH ?ECCBABN>V&**-<Z88XP]OACDC3\6.>2.2Q[99))53IEE
ME.D5,Y$/-41DEI9/OGEEEW&V.>>==>X9:)Z%_GEHGXT.FNBDCRX:Z:65;AIJ
MIJ5^>FJGK09M%N)P\VTXV8Z+FNK_L*^N&NRQQ2X;;;+5/GMML]U.F^VXWVX;
M[KGEKAMONO6^>V^[_;8L:PUY0W-$O@W_N^^\#U<<\<43?]SQR!N?G/'*(:?\
M<LLEUQSSS3/_W//0._\Q:PYSZ[I4T$?GG'756Q?]]=5=GQUVVF6O'??;=8^=
M=]M[S_WWW7T?'GCB/YI6N(*T_MKXX)UO'OKBI1=^^N>KCY[Z[*W7'OOMO>\>
M_.O%YW[\[\OG./#9$#XSV_/=)Q]^\^,/?_[WY;^??OSMSY___?VO'X#Z"V#_
M!O@_ 4:+8.S34*D*V, #$O"!!H3@!"5800=2\((6C& &.;A!#V+P@QH$X0A%
MN"SDV89:_R3LH I#N,(2NA"&+90A"VGXPAG:L(8QS.$-=8A#'_80B"2CEH9V
M6,0?\A")1@RB$I-X1"8^T8E17*(4FSA%*U81BU"\(@$UE$(J:C&+7Q3C%L<8
M1C*>T8QI!.,:R\A&-+I1C6V4XQOG")@A$@>.>:RC'NG8QSCZD8]_%&0@";E'
M0P+RD(-,9"$1V<@\=9%]C%2D(R59R45>DI*8G.0F+9E)3W)2DYT$Y2=%6<K_
MW=$VIB1E*%FY2E>.$I:JC&4K9_E*6=Z2EKBT92YYN4OR0+(VNJSE,(59S%X2
M\YC&]"4REZE,9C[3F=%,YC2;>4H%XI&:T,RF-*O936UZDYO?%/]G.,FY37."
M\YSC3&<Y*03,V+!3G>B49SSI"4][KA.?\[RG/O-9SW[NTY_\M"(JW_E/@PHT
MH D%Z$(/JM"&,A2A$'5H1!]:48I>E%;N3(1$.6K1B7ZTHQ@-*4@].E*3EA2E
M(DTI254J3X)N=*4G;2E+:2K3FL84IS.UZ4YS>E.=]I2G/_6;1H/J4Z,6%:E
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MC#+")%(U!7#3/)(BWM EH/,?$:PF_.P(P_(K3A(AZ $$X6PQ_1 EK/.YIA$
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M5O^! CQU<&+?L=8$HB\1]@(!<PN9-4*]%5EAE5<5S#/K$#K0LRC#[6,G%=B
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MTQN]U]N]*P"]XQN^YUN^ZSL'XON^X?N^+6 &\KN___N^ QS ^SL' KS "=S
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MQC!L,\QA_F&5)AJV;8=%O.$2D_C$(4[QB%5L8A:C_WC%,'YE!?3QXA;'N,8
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MEU)8-R1H]V7]-7A@!V98\H7?]8'3EGJO!V=W)VZIEV6,YR1I6&;E!GD(@&X
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MF<=FTG@*5L5V@@A\R8M>4*ZQF\NT>[JSV\NMN\NO^\N^/+JZ/,R\+,S(3,S
M++O)?,S*;,S!_,S-',W.7,W4?,W,+,W:G+?Z5D:X/*>"ZKOHRJZ_2\[C#*_E
MC,X0%,3[8XJ.=\1L-IQO5B9]9B0=.2=/*?\#Y 67:W*5DK)_IVR13MS(5JE?
M<Q)E?2PEL+?*2(+0[U.!'Z>8SW5V>@AVZ0AGP[G%$'DC[GP ])B.E0S&AYF6
M?A+0\[M5=F; 4'06@IS(AXR29O-0+SW3+6W(-2V3]S@FLJS19K)^@O)L "EO
M1=R_- )R>'C1)/V1<GS2DK+4"I@C1LW*9*8D!=>^"=V*3KV11R*_3.QY2R*=
M"KC1IIS$9VR8T@7)@#+$J9C*[#@#:]?)95S+5JQM9RG&8JTC:0AOB(#46LTE
M],#5!K9P5%+527S5<\V^Z,:_C=+)D[C)'[=_@-)ESMN!*MW4["774#*'F?G
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M];>?_>\W.M-5^T;XKY_\][=__MV/__WKO_[]!\#_$T#^&T#_(\ #-#*U0\
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M1+V!4[_R%0%1N:A(*69-OK9MH1\UE4&S.5+%M..>D$5I6A[Z38D:EBF6]>9
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MTT>[4L-5R;ZN(,C>VBPYO#ZY,$B\V+YV$S9A>\#5$JVP<#=HM K T[]+DD@
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M8-E>D.\_K5J2%YS[@XC_.UY49-/A!&&*"*^YBA2\1;#_KCWU+]'S>E.38P^
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M2N$(AN 5VM:4:5T6>B$6@N$&?H8%!1I:],.[Y4LB$(7WR4:9A1\:MEWY!9B
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MU[9+*_@.V';MUZX:@UIHA6+HA48HVTYHVL+MVJIMVT:)LVZL?7"B1?_T!*E
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M*I3%6E43V[ 33[$_6)\%8=][9*]HZ%-'E%WTDM/T D#UIL;U;L456U .E"D
MI,.3LL#4/H47'%HCLD7$>2@_2"<+0*=9?.:DO/$"N:_\"K(4#S(5%S)LV:\A
M$_(BY]7^SNW;RFW<TJTD0_(D1_(E6[(7); B#X@R7FZFC&Z>Q"@JG;"D26V^
MCK+GCK"=G&LX5LHP#=6<M"ZY2HZ4/FF0ADZTT@4IV[*E**WKLD0PI7+K:F/0
MGAPC&P@.$Y8^=($Y_\Q .<R ,T.S-$?S,U?S-%LS-6MS-G,S-B>BE^;#(^3#
MBCP"8(3S.(>S.8LS.:LS.I<S.;MS.Y.SS2+S,J7R-U=QR@'O(?-S/0_H<.FI
M?LB;!<F:0N"#0X(Q:8@Q&<^&^DZ%;EK0&ZF$=>+*?>57%Z0#?1WL&RM&&_<E
M"P@J8<#9_$78?677#,B -;- =MV72[* 2EI&(/LS)^?S3-<T36-5(M_T3O>S
MRM1#!1AP6!*P4/]O4?OO40^P42<U2&TR3]MT3SNU6RBS8?5P51OL52/L4 SQ
M$1-Q5W-U:;:&@73O1>CL>52KKX(F/D,UMD&Q/4;U6Z^UU/F#0?Y+I-8'1/^S
M[%6T0E)T 4++Z4+[M6B8<5= ;SFYITWD \'.(3BR!#D@ CU;QEC?B1[+ASX(
M@AT;,R];A -<P7;&=$W&-4X_]6B+=FG/E4Z'-ER3MH'\]",'(R97<FR_=B;+
M=H;:MMLV45.G]FZO-F]S!#^$%E6W[NMJ]C!GM6AZ->TFMYB>)D.PEU^(&6X.
M[7J I];FG5DS+M?>LV^WVC[W]G>;-G>+-WBK=GB3]WB;=WK#!6J?=WNK=YK<
M U /];$J]0'7-U$CM7WG-WXO]4GIMGN7=X +,G#/E57_L('W91"KQ%8K]U<W
M[#[U0SNVHSOI [I,]WM4-0+ EV6<M78;K%J3FS__Y,,[:'0IVW!;MZR  SAZ
MJ_A[K_B+NWB,M_B,.QU[RSB+XSAGQ+=KWS:/XW:/4_)LU_:/$[D8_?>-PSB-
MU[-.%99Q W,O.SF7:C42XRY5G>9""&2#EXN8#>1H7CAZ1#E+K(-#<T6'*_)V
M8]PPPS$3>S>2N[F2OWF.QWF2RSF<VWF=SQ:0X3F=\SE'X(-\WS=][[>@][=^
M%SI_&WJB(_I+'?F=][FCSR:3&Q6"4SI6 _&4&S'MOJ.:S:[MBJGN L L>/J*
MX$=,2.+>6;H#;+A;F#ELIC6M@>N:FS>*0WJM[_F<X[JM/_JMZWJN\SIZX,NO
M[_J*#Y>/&WN0 SEL"_FR_R<[;2][HPN[KP\[V XC5H4YE \W8\/NE$LX/Y0I
M>V7ZJ-ONG8EZE7]Y>@R3)&*Y9/?L\@I%J^M$Q/%RDQJ%O,M960, NW?287.Z
M@X/J0#AN3[3"O ZW@D,%FJ=%^6;[MI\%HA[C/GGFD^/GJB^%,5X[I" N;+;Y
MJQDO:<AZZZB&&OT$7>^F4<@&P5W&!9V3G.K #'Q\673\:*3X5YS\7,3\ U3%
MS?/+3=1\]^UF#IQJKPM]M _]M!>]M"-]S."\T1/];@]74!.ZHD?]HD]]U4/]
MU<]W66YHTC<]T\=FM=-5I1^XI8.FP8_L1O##<H=[IF^XJ"?WN6^&J?,$(A3L
M#_]3IU/ NTW8N_"DQ=ZS"KZK&0_C94[@9A&+K.7T[$\ K4^I^TV4K\$V_L%_
MN%7@;-^@O$T\/IM</E X_,$ZV$OD V"&*UC$NC_3.K>)U584MFB(O$Y$K\FK
MQN9GD 79?$*[V5OD@)>]1<W#Q<T/Q6^VODW(ALG2Q,W/V\X???)W/==[/?,[
MO_*GS-(___+3>#X\P+$K>[,/.?8[N_8S>Y$[%K0W/_1/?^EM_:0O?'&G?RJ;
M/0!T^MH_K+@_0EBK?>Z6^J1$/D]8_"NQ@&<G9G8#! !_  @.)'@%0<(#"1%X
M0^!.(,&(!24:!( PH4.%"*Y,].@/T<:,#%GHHT@P7R+_1"IGG92A$<&!&2<]
MEIOYL6). %X6CE1XTV)0@C$9PIRG\R/#G@T?XJ0Y\!Y1GPB$NH2Y5".BJC@1
M8B79TNE$J4P5(GJ*=&M:M&O/M@VKUBW<MVSGQJ5;565>E8]6RO5[%[!=P74)
M_R7X '%BQ8L1ZXB+B#%BLULC(_8R6&[E!Y<+ \X1V8N.RIP[[]0,&)%HS3E*
M)ZI<[W1I@9HO&Y[H);9'V)H391[=%G=DUFXU/\ <6+9MY<B7'W>>G'GTY\VA
M3Y=>'3MU[=>W6_>>G7OX[]W!CQ=?'CUY]>?7FW>?GGW\]^WASY=?'S]]_??W
MV_>?G[\ _^L/P $%+! ]XPQ<_Q!! AT\\$$&(VP0P@HEM)#""ZW+YP%H^,E'
MGWP^U,=#$$4$L<001TSQ1!)';)'%%5^4T40:541Q1AQKU/%&%W?TL<<8>80Q
M1R")_%%((VT\,L@BDWS2R2B1E++)*:VL4D4 'N@'PPF][!),#3,<\TLQRR0S
M3#3-3//,-J5[P,TUVR*+3ICL+ K/J>Z<B@4O^*F+K[P0"72E0@D5]-"^ .@G
MT43W6BD?"^G$![E\9M 3SRO\$<H=.N7"J,ZF; /USH[@\F)/IDRM:!9$9@G*
M"Y\TY2\?=V9(U2'!0DWHJ+9NS;,AS@Q#!%>V7@+6&P><^U5/073%U2PUI8U3
MS4<3$?^T-S:U9?"WXM*"+++)D-*,C/=H>V\WQA(A*#C&AC.L7<:B^ZRRF^:B
M=S'6!N)-N7.;BW>QG(JK!SER@:N7KG3EG79;AN5T&&)J)6YXXH<KCICBC"W6
M&..-/>X8Y(M%YGCDCTL.F>2435996@517AGFEV4^F6:6:X[930Y;Q*=(GG_T
MN4>@=^Z9Z)^+#OKHH8U>&FFFE6X:ZJ>E'E%HJI.VVFFLH]9Z:A"K]OIJL(W6
MDDN<;3[;[+1G1GMMM6]N&^Z2X60[PK&N M8KD>C$:H9W^C$($7,8@J@MOAP=
MM%!$$S>4('X4QQ9Q;"-=<"Q*GY,';SSEB:A3F#Y5"D^(1LW_?-6XNIAJ*7C8
MZH?OZ1(1_&[4,]<U;P1ZQ0EVT&7??6^\A=7I6+V]Z<*Y+FH_X/<YCX_V[>95
MQM9:Y]V6Z+?#8@L*7,;$I>G<!*OO#N#$A*(-WMS*_QXM]$VKC#E_I0L_,8)4
M"_>Y[JN"_X'A<,J>,=*DCYMN 9S>  %(P/\=4( %5" "#9A !B[0@1%LX 0A
M2,$'_L]E%Y1@!3FH00MNT(-HXM#7E#2D)9W0A"DLX0JA="4FO1"%+*02#%78
M0BS14(8NC*$-<<C#'<X( !4H6P=!6,0/'I&(2 SA$HV8H;DI43R[DB*N\,0"
M0?R)(/.XE!0)YY1&+<Y:B^/+JP#@_[C(B1&,D9M<@29UGG0@JR@S6(>GZ$*J
MT,G&CB,IW5SX$;PZ.2!20D&(1F9@F'Q0T1Q:T0FQX/@L8-U.*+F;BCG"Y$<[
M$:\T7<!5\IPR1>8UD8GNL1:V0@FQZD5D8!7AGV*VYY'BO#(Q]J*,^J#SFZK,
M;S&R9 O^,HB<&53F73K!WU84MIA6IL5]SN'E:K!C,*<L$Y:(F0$G2UE-4%X3
MBME,XC:MJ<UN<A.;X/1F.+]93G*><YP$? !8S)E.<;ZSG?!$)X!&R#5[BFUK
M^.R:/DC8S[#Q\Y_^S)H^[PG0@1HTGPC=IT 3RM"%!A2B8Q/B/.-948I>U)T6
MS2A&GRA/VO]ECG>$A <[!2$#N^F.3EVLBN'2>#A"@24?+FTI&->X'W]43C[Y
M$%Q(&2*7G9YTCW)A2.^"FC"4:J0+0J%'3 I)&'R M"ZM.!X"/CH52.8D*K%K
MR.0BY$>L8-(PQO-=5??VR8V>U2G0BYQ&$71*B_RR,I-996*.2;UHII(XM+1-
M,>GJ%EX*YJ_UJXQC<((OQ>AK+>2[2S)+\]>YLE*PH#G872F+6+2R%;,8]>AF
M,WM9S7:6LY\5K6=)&]K2@A:UXV+G:$W;VM2>EK4UJZ<.:SC#'](VAS>\K6YK
MBUL?]I:WN>VA;8$[7-\25TE!'.)K71M;Y\(6NLV-KF&V]%RQ4''_*N00!)?\
M,0MY,&N*<$R(2G7R1<@=2A^OFL6UT'C>F2:BI@&Z*4PL5Q]$L$"\5#$JIA"@
MC[_H([Q%M<L[INBLZC!23T!A"X)#Y4BKTN6G>P)/I^!BR:* -3":1!8U=>+)
MZ6)TE(EC+GG<FA/#+J8>CWU 7:T7F7)Y3[+5H>R,-W,J\P6&EV9='XVCN5A;
MOL]\)UZ,;9QY/X39A9>Z_/"2I=OD$5OWR4R.LI.A7&4I6YG*5]8R?M:YY2E_
M&<M@]NQL%5I0AYHYH@U-\T,/>F:"OKG,<'9SG.D\9SNO&<T276Z8N[3%A8B.
MSUZV64B((@-%#NATA<[RHJ-<W26?]"?P_]B40 11#I#VCJ?C90M+W8LMDP"@
M58]K[ZCS$E_[W'0I];6I6*?BEUG@]WA=^%-5 G=4T F8,'DD"@O(^)RI(L +
M6^F4\$!'5J, )BJ_#C9=\+%%C2R[+5Z]</&.Q^&3\ 1ORF(T.M4:*#'+IL0T
M@:;VPF*_\Y@;,RKF\8VOS>ZWJ/L!!#L)+M?]RMJD[\?*9+=KF.F;&!M9.($I
M3J"W+6B#%QSAWU8XP1=^\(8GG.$1=SA29K#:B5\<XAA_^,C(;-S@_E:XN_7X
MR$5>\N*:/.0G5WG*60[R&"F7M?7(+ZX4/)X\'9JSA-X3M-^2:,\!IG-%08NS
M&=*.;3$8NTU%M/]/E"X0GQ?].C+W26?X&]Z1T"/C62_31!_MD')LMR#P('K5
ML6OUIA2.U(::=:C/*&JW&PI2%9HO0U1=H6;_?##\&+O9O=%4?P@"4[AV-7Y3
M)6_H!)WL=_1'K*R.<X-(\:J +7O9R1MM7&%8,!K6D[4_<E^^(R"0$F];B/.R
M<;J$&R?C[NLL76PNO=(%?R^V#5PE"_#()&S<9SF-<N"-S'PWUMT#$3)DRUT9
MV0OSR&'AZY!%;WJ--Q_ZSY>^UJ-/_>D[W_K9Q_[L+:[]ZF__^^&W#YGOW&8\
MR_G\=4Y_^=5L?O>W'_YLCG^>D09SSZ).QQ:1^E@,;Y%V@$X&WD)W'&__GOYO
M(Q / <KA+A)M*?X" 0\@)TRJ=0AC_Q1P/'2.(?J/31@P(9J./O:O)\IC;S#/
M^ZY//KANT?C!"TQ*JUK0UH@-!L_.B]H.[A*A;#@M[<+H[1+ATT)KJ<#/!(.P
M!%LC<:)'_(JO?Y!#]5A,2^I-75C/"3>C"2-# S&#EW3 ]J+0F,("?PBK.8HC
M_[30,FXC^"KBE:!P,:Q-]68L_XX0"(?P#>/0#>=0".6P#ND0#O'0#L.BXN[0
M#_-PNF:A%<K "W; $ OQ$ UQ!Q!Q$0TQ"!+A$08"_/*A NX!N5SN$C/QN#;Q
MXS2Q$SF1Y%8.$T$1Y48Q2U#PFPR0+ CP+);J_Y(*8N:@#A9] E7$RP,CT.PL
M\".>+@ MC1:;HTXDXDX [2F>+B$<,!@! .E$!3GLI W334](4"[J8>]211>#
MPAAO<2JJ$ !\48I442-$\!7GHM60 AP1( "# D^PSAOW1)%8$%EJ3C>J$5BN
ML2+6<1FI"G F#RG:D1FAJP*P".'Z 1'@,?$.TNPJ;R+,:U &@E'>*P?/Z!&X
M2P\K\@_WL)U(3U'^L!YP*0>P4#H2@?840\D^@@S$T+(^8@T1)C62L#MT8"03
M@QL[DK)T( >\P N>D0L90P>X<:_HK3'.8B4CPPLE(C06HR<#0R3I30?\1R)H
M4C%@,F&&;S6:<ET $?\K,=(BLW(KM?(BNQ(LOU(LN;*T^I LS](K.6@0$Y$M
M&[$M&1$N%3$N$_$+6F'A*-$2T>_]Y(\OZ:\O]7+^ /,OU6\O_=(P!?,P";/^
M4'&>O"(= \-NY%$5%^(QGP*E[-$5E0+S6(TIL$X=1<+QC)$HW$&12)/W?"*I
M*L+/.C M./ 8@0[3R"(UG^,J=')87# ARJ$-4:<?\V0VG4XDM)%.-%!O,!/3
MQ%$S[4)OMF(RT3$IIL(X\P;G0# A?G,@>),F_!$!K/.H9D!T$.$[1<(Z":(+
M[)$@[H88I2L'!%+,9D'L8O#78A,F%-(@<) E!L*,=I &]R*]TM(_PQ(ML:G_
MVS8R0,?R/PT40 ^T0!=401LT01\402.402%T0@G"+!U40C$4/EK!+3L4$1^Q
M^Y9#'Q)A+COT"QY!T/#2$T.QY5:T%%U4%&&T14DQ1FET1C_Q%/?,G>ZD,NNB
M3B033WKT,U>1UNZ$(C(3(?$..,GB%I_C'#TS)Q#0&]!"-)'13@! 2N71(&HQ
M2>-H/+K (.GD&F].+;:Q(K)1*,RT(,:.Y_0O3Y S(Z0Q)\J1)LY12,E4)\!K
M>(J1Z88T*\IT.._1)UB1<[[1-@,M!WK0]/K!"_"K2ZN./@DB4<!B1&LP[1Z!
M/2E40S=54[=%([,E0SLU5$>U0DN54TGU5$'&&\W3_U310N>T5%0I9*DHLU67
M#!&6PB</I )C-57IXT)Y%5A1%3 2P4/E,D0KA!\(42[EL@RNC!+K(3'9;S"E
M-5K7SUH+$S&S53&G]5K5+(@RU9W.<3O_0@*%KDX!4 !!LTB++2)FE2%8U2_0
M-#S<-=-.*CW]P37URRX>4%#YKQF5XE#=(S)G438!%2;ZSS6%\V!54SR)27?@
M-";DE"*6TQS1U4\3@A5GX*OX5"H\T#<--@/[M2<(E=::,TXO+E&[<A;<P0%P
M$])D<*40AXPJ5:;@ZUB%%6=K56?C9$!!=6>#]6=SME>!=FB%]J*D=.9F $K_
M R;@E5>?;FF#ED(0CV3E(_\?DX,7JR-0W6+_PE',N!0!N/%)T0,< U9JBY8/
M;_9LB;93]:%8#1%<'686OF!9#U%MS>E99=04671O7]1&^[9&<91O]99P2?%;
M/PL#,T)IG\D='7;JT@)/3V(9K^U.HC9>^Y0[JO0N\L0#-7=?DW$B\K%JS[,H
MS!9R$\+HGB)Q&V).Q;0W!Q4;,7=BMS8BH#,GD)0L('9/R1%T!P)W'>).83=/
MQS%VF31-73<[(U<@E#=-VU0B_#%Y1^)>1RL'3&U!]:$+""^_(A4 'B$?6J)5
M7&K6V-9HRW=M%^13T59]R?=\VW=]S?=]IU9,#Y4>--9+TY4I!J-IV1=?K\Y]
M*Z3_4T;600@M;\8S+NYW.:C6<8DT^C@S5_]C,DT7+? $?BDT!^KV;3.X1#<8
M@SGX+3L8A#]8A#4XA$EXA#W8A%,8A5>XA%GXA%L8AE]8AE4XAFEXAEW8AG,8
MA:]R].;29RTJ'W* 'JH56[>5B /3B+656I6X6[FUB)=8_0[WM/(5-YL4)V(P
M=9=771?I;E0W3']M%V57-KSQSSKCB\\4/H.T4*]B+5!'8O-C=:?*<B7"9&/3
M)Q/V>!<V>NV8@!,"8@_@C0'GUPJ) X.7@4_"?D\VC#N6.5_07RUSBU4WC1."
M&]$SRW3 >@^T%=K! ::">P6"[:ZEU_ZW@DN9E,NC9^-7_Y7YEY5->95=N94]
MXARMXQ<G>"3T]UU5"?%F((L36$^[8([3+>ADP'F== 8,DI<EN"# DTE[&6K1
MA!Z\H!V/N9AEHQV(SC2E Q&N>22(N9?O@IF;-I#7(IK%F2(46$# 5M[ ZX$]
MXDJGX^GN=>Q&5S?,%4&N&1Z)N9TY90:F.9LE+V31A1=YKFQM[I9G!DR90I_7
MPE9@HAV462# $[QL8GJ5R1L?^BQL956!.?L^\H9K&(=#&J1'^J-+6H=)^J1-
M6J15&J57.J5?VJ5CNJ5G>GP-:!;>LEF;*XB'^&\+5W#]]J<#=W![FJB#^D:'
M6K< 8#UC^95/N:F+5@?JSFC[H?\+WH$M9B%NGYJIMQJ63R)]N=JIP5JKNSJL
MR?I $SD!H\BAG]*1L4+'7) TZR&AK^*-F[-'Y1HU3[<A"K+0$$&N36J?;U=,
M,8P>.-,A@AD NK8#4ZRPR7@=ZWDC! .M>WGLN@!ARS4W&;JOQ9D>MAFEU()>
M&\([_;H+&EH6/<(KHI:;I>+=BA,1.GNU8X>>E>.Q+6)_)1M7HPZ!B4Y(D0,$
M!<2P,0_!#!@ Q#6989N*V<*!;9FIVH+!*-.O)7IYGH,Z0\JL- \!OIEC%R*8
M-6\&NG:TJ;'5,% &+#N< =8M8L>\"SNV3YM3%/I6B^ZUC0<H7-,Z=6Z<H\NC
M87JF6=K_O_G[OV4ZP/L;P M<P V<P ]<P1,<@UO!B&9A+D<9;X7XB)T8B:$8
MPYNXPC><B9]8P]%/J;-:K$?<K$F<+*/:Q,>ZK%=<Q?&B"-<JQ6.\Q&><Q66\
MQK6,=O_EMI\S?PF#>*E4>G$"\:K9_TH7D@\931ZWP_18^6H;%Y\-9'M[,,!1
M3A%0+MX9LGM\.90\O7.9)ISQ,837/'"WD159+8:<.NR$M]&C:P,$28E<LPGI
M<G/W?IC<3V%5S)T"Z2#Z8@$:=1?0?^O<GK?"'Q&[?YEB>O-<KQUB>A'0:0FB
M:_,[Z[I !P;<TA'\TA<\TQE\TSL=TS]=TT&=TT_Z"[@)@Q7U_Z*">!Y\&JE;
M':A=7:A?7=9CG=:/^H1"W,9;/-=W7<M0G,9U_==Y_7R_.MB+_<:/'=B17=B[
MZ9&K [OAE8)]W,M;6]&*EY!L0@;Z^9BU/=O)6$L1&$+ LSRWW2:X/"(P>[:?
MF=:PHF(5(K])6Z.W?6.%7"KHN1W?6BFX P"YG=^Q':V]P:S8&38%^#Q $%;7
M=",,O9"U-K<#.*!YUV4'F3KRYKL!?30[8Y>K8KF/7":>@N@,G8[1.SNB'2ZP
M6[L7F;N= KO;>3(#N8_OE>0!(Y+7&&/_0G@6]^%RX (\/=1[?M1]GN=_7NB#
MGNA%O>B!OA%KNH-NVD1%2]4Y/(FC/O_#/9SJ+_S#I?[JI]Y;4];8D]WKE_VY
M=. >P+[KR5[9Q3*5S?[KRY[MS][MU]YAP'9*O8..CCQ7I#VSPURA%YG1TP/<
M!5;-__G<Z;QUO=;B#QM_$=\@P*LUI^*AHS;2,QK)"=W(W7G0F2/FZ5Y)SWSR
MHP-INU3*M5BTK0.=(5WQ=#LCNN2\%3V>,=YXA<G.^[7O[)ZJ"*.@1_Z@3V6M
M32?08?_AR[PA7#[(^YSJ.K_T2\.S]83/-:L+=M[HGQ_IHW_HH7_ZI?_HJQ_[
MKW^<VG('G#X'5KVH8=W6:QUPQ]_\RQ_]65W6E1K5VQ[NWU_MC4CLX]_]Z?_M
MHX_8[Y\F8E+_FNQ?X88/('(  .!O($&#!0<F/*@0H<.&$!E*7$CQX42+%2-F
MO*@1H\>.(#F*W$CRXTB3)4.F/*D2I<N6,%G*7$GSY4R;-6/FO*D3I\^>0'D*
MW4GTYU"C&]LA6.H- ;VA,Y@BD#%R*8*F,9LN+8<2T=(#4R]*18"HJ$:KWF8$
M)=E%JKN3,JXNO>@. 5@$,VA&E?NT9%VM70JZ%7GWJLEZ:+MTK'NWK,ER:!%%
MA/Q5[="V=L.:9=A%*P*N+>,VWES8F^*;HI<&MNCY %+,8-]FE+O5*.*O2',#
M0.09],&O2QVW',NQ2^%Z&*T>L$P1<U.J*RG;E7Q4(5H$,'E;]4UR_R_8O@\[
M6T4>4NG7TR2]9I:-T+EFE+ 1L&_X-_AFBNJ?5]]_7[?,+A?LL(,7 @Y8(($"
M(FA@@@<VR."#"T:HX(0.2E@AA1!B:&&&%W;(X8<;AJCAB!Z*6"*)(*)H8HHG
MMLCBBRO&J.*,+LK88"O\^=>?0HE ^(6.0*[E4CXYS,-//OK@<Z0^^2RI)))-
M(ODDDTXN&6625E8)I9942IFEEUN"V26689(YYI17HLEEFE^:R6:9:HKYYIEM
MQNGFFGC*F>>=>O;)YY]V*@E #OH$F:.0B!ZJZ(Z+&LKHHXY&FBBDDTK::*68
M7JHII9M:RBFE.MSCZ:B9?DIJIZ6>:FJJK/^BZ@ -0/*_ZJJOJBIKJ[#6.FNL
MF":"B*Z)Z/K(KK;2>FNP1WGQP+'('GN2L<DV>VPB.27B[+'D$83(M,=ZT1^V
M#TS$[+2XWO0MM\YZ$5(.Y*:+K XJ7:NNNM!^A*VVP]8K[+WA$JNOO?GRNR^^
M__8+L+\$"TD/;5?- )Y&>WG6#GQ206=2;UU%S)%V3#'G45T/GY5QJ?G9]Q#&
MM(GD65,+$^2>5"EO=#):CZ&E<4-QG8R>0_61%5UD&H6\5+4+W?;90S.<3%UZ
M<9%TG<XX(ZR5<#/Y#'5."&=4]'B(T(-(/5EOW377$0F=EDH-S[63V)'6?'-#
M!WN6D1<G*WP1/5<S=?1#</^/E]S''#E]]T#F^3VI>Q*7=UWA*H_%%T=Y_VQ2
MX*:U.]AL-B^&,'=-/[TS O2&?=W H"O:A0XPTEAZC:;;>/KJJK>>^NNHQ\XZ
M[+/+[KKMM-]>^X>S!,QI*Q7Z7F\^.AA9)C1M(G]\\LPO[_R8RD/?O/3/7QF]
M]=-C7_V2UW.?O??;(]F]^-^3'[X^XZ-?OOKGI]_]H(6&+KS\GJ[<^4$UBTR_
M0F6W7+# EW+:_^8'0 (:$$@Y0T#'"CC AX2J@?MC8 0/.$$(2O""%,2@!3/(
MP0V2RE>[XA6P/%C!$LY$!]-BUTG>E2V82&M:0-L-N8PRKF9IA S<TB +9RB2
M&>S_D%L"&<D+?SBM>(7$A\ZRC 9-V$$FDG")4&QB%)\HQ2I2\2?&65IF(K8:
MH)"L-&L#@'1BV)'4^ \BB"B-<@XW-80T[&^*$IH:$=!%N2#.:JV1&7CR=\:)
MJ.<N>7E)W;:8L+XX!XX%.1A8[F@1H6%.(RLC),I8,L@YKD<FTLFC#(0S@]'8
M1#H'0.1+TJ@WMB',DJ69F1BMLL"4=+*44(3<&FL#$_$ 1W&/O!@@N_,54=),
MDMLYFG=\R9,O)@8D653<<O:8F3-B+) A<20Q_?%'IYR$;JB$94G:]IZ6,$:+
MBYRB$P<RNMWI[IRY2R?NUFE.=;:3G>B$ISOC^<YZTG,'_XFX(D@20:$RB+-3
MQ!/$G@)5IX+"R:!T.JA"$\K0.3ETH A]J)\(NE") BJB$*UH1ANZ438-*A_Z
M;-0WE:E%,@)0;-T$0.#N(L%DRF6<_RS*2!%@4D:U1I56A*D!U\A(^?D,FC&U
MEQ=J&M*<!E6G14TJ4I=ZU*8:]:D0%&&O$/$K(SI5J:["EA)+0D0=I&2(S3(I
M#W-20V292R-E198$T_J K?H'7<[ZE+N:==9/H1!<5V4J5/6*U;WF]:]^#6Q?
M!\O7P@*6L(<UK& 5B]C%)O:QCHVL1<IYSWE:5IZ8M>=E-9O9RG9VLY[EK&@M
ME,_ EB%#CV!LI8@GC_6YS[6P;?]?;*E'6^W5%GRW-5]NV;?;U\KVM[V=K6V'
MB]LF?;2Q.%D94!/B-.RP!!&4F4%-NR"#0;:#F"\K%77E,I^#T$TKTK54.QK6
MA3X&;0;YZRY1$%$SN05LO!F3C?W8DK]-4NUD+_&"=,HQ3=WH5W\2J<=VP=M*
MF\#W*N6-FCL:]YD9J-<E?T&O1+(K$P'G#R\%!@DB E<.YBP-LJ0:*G)5"V(2
M2];$(RZQBD]<8A!.E5<LCO%/N%63>0%@K \!:[)JRM8'6+4D<'762'"(+08&
MV8:<0F*S/J7C8Y%!6#F4,8JGO.(42[G*5+ZREJW,Y2QW&<M@WK*7QQSF+XLY
M7%ZPP&C_0<OFS[IYS6\.K9S;#.<ZSQEU^0QJCRCTA=Z9V2.L[:B@)XI10FO4
MT!Q%M$4IFNB+'MK1C6;TH@L-Z4D?]+ADILDL^]::F\T4E$L!:C:5^;=7,H5H
MK2%:858*3I\!DVF_+$Q%+NS2/-)RPK,\Y8<7PNH+V\4R>>S96+K(DEKG.H_=
ME>4M=4U'YHXZ8?1AMK0CAYHM5E(U"3'UM%G9M&>W!HXH7;8F)W(X8#[%V]V\
M-DF7DN%MB]N:9]Z1%ZA3YDS_V=[XKK>^XWUO<4K5Q?S.=T&.G*P?>\3&!2%7
M1II,+8_,M5PHP98*2=+C K)5,@7Q@A=R<-=CY6"H_1T(P8\E_]=IU352#T^6
M5_L=\'VS_.4"A[G+8T[SF=N\Y3B7><YKOO.;][L+(?<YSW5.]*6V8D2S<&(K
M@J A' V](X$&+G%U.W7>5MVWP95Z<;=.=:Y;W>M8O[IPP3[VKIO]ZV=_GPY
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MDB5-GD294N5*EBU=OH094^9,FC5MWL294^=.GCU]_@0:5.A0HD6-'NU9 0
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M/_%7::SYS/<;W\J0Z]_Q+OJ^+]ST84+XZ$]?^M+4G?3 BOB1?7H52&O6+/_
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MPFJ^L<A'<I1 NM Y<XQ'_P0@Q-DCC8<L1R<S)"0,QUO<15;<2'(Q,BFD2+4
M.BG+BDN,R 1,OHMD2//;I2U3/G(,OJ)[-N2:0S-$OYJ<HQDP1%TJ-)Z[R.2*
MR(KK28BD/D)T+>HCRNZS(]X#N5;K1YIL,D?[O9FD/25S2F7+BJECR9_<LUDS
M+"C#2K#42DXT2N.JJ<O@1W/D0XXBPO52-%3T!_K[OBX N@*\R7H\#.4#2 !
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M?@;H?Q9H^_Q>' G?4YV4-E[D0V9H_U#I O9=:$4^#J,$4(ENE0&VZ(R.Z+K
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M+%*UKN4/;^LJ3F62DK3='4>YI,MR.#9;PVKPC#,T0Z^:8^N_8$S_)<UJ%X=
M*=U2[=LY(=;PL/Y2PG9RIV8VPVQ59V*^+H_)%H:+Q(7RWJV'(+?EJ8!?^95'
MJ]#SG8QR($_)NZ9LU&;TU&[T1W?T2(?T29?T2J?T2[?T3,=T>69:+3D%4BV5
MV)X9,Z_PYB,T\#SUJ/@]L.83Y5N*2%5T)+G(OUAUPH!QJ6;*\X!QC^4NM%XV
M*PWL/"?P")1+5VN,&6=((W^=+@CO9"'U87_V0*??7-5?LPWN_?6*1!#DI= '
M"7T$]9R%KBANY>@'4J=>XMU9$J+HZ"X5C)YM=K=;0< (+SAIDR9I>T\,?K"
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M/SO/DE!T^>1S3S[X#(V(T3?&I#///O><<U0_2QTRU3_CY+3/0/>%SPSF8(Q
MO["2]S4"5*;'=<4!;TP>UCQCAH_"+EW1!<V6,8T;V=X(0K31]R#-C\1R"LYP
M0R3+-WC@A"N>..,.+^YXXXA#/KGD@T>X(H4S6.V/BIA+2(9VG7M^8IB7>_X
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MF8R.M@& /DY&QT34;4Q8>9E)].$U,Q:%7.*QV65H9$8G]D6102223(R$1@1
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MZ9V)JR:1V+CB";GI._^^^8N_<7&YZHN^_^N_ :R_ #S  KR_!'S !DRZW%O
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M70%92_['3_V0#_WK#__!V?[E3___A0W\%WMTIV%A4ZC]7[<LF0<0#P0.' C
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M[Z2_.W%\%\9=>*)TVR&9W.[J&:QZJ73WX>#&O?]1PJMOYPO-H!)V296Q7^M
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MNPOBL<%!Q WBQ@4\Q[$#QIN<O!';/$@<QY\\;F7\.9"[J+%C?,.['D+X'KK
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MGA#^QV&!9"8&GI6?[;8C7XUQ"19-,6:F95-?1N0D:G9]-"&B!SJZ8%^^W8B
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MPW6$%R[5EX)J5W:U)RVT%W8ALSQGUWP)2#O_7&-Z,C-_"W-WV=*<#]0^F3>
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M:9K^;9L&[N$6[N*NZ>,.;N0F;N4V[N0.WUWF;=V6[NA67J#>[=N^[NR>[LE
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MT'I_F;(66P( C.I%^9O6^??&33))BX9^S+Z6P >&R5X)T6K%F4D^T-+%O!T
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M:I@F/OG%^Q4BF) C4!97*,('FY+5IWPA!A:*V=6,8PT%VSO%37PG?'1Z1&Q
M)5FK-@+2$'%AG=DEQ+G324E[=&)C=5CDO#E6B\8#D_V>Q=R5GI +-Q0HB!&9
MHXT,YD'$.1S$R[W.T?W<U9W<LV)+L6V#X3W>Y7W>Z;W>[?W>P6UI=V__EA37
M@-,":N-";L\BILCBZ-AV\O"V,+SV^.0M?1.>] AW<#'C;(<#< WB."CCX->B
MY,3ZWZ56+JYNX 43T^TV;'/*+" .,@JI:G^OX<86,P#W<='B]% .X*<E_.B"
M,AUW..ZW+;Q:^.A:?W<C+E2*+B38;^$V+@H;W_UB/OS\Z?\<ZJ4^ZJG>[,A
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M\^.6@_:B*PJCF=JBF^JIF@JJG1JJG$JJGRJJIUJJHVJJ5<*@JNJJJ+JJL0H
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M6\$/D /YJR:(D ,&[+[S2Q!>T, ;C,(G7 $Y !(9W+\0_RP6+ES!#5HE\L#
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MMW<_G2\]O]<]P3<^Q7<^P]=\Q_=\9>O[I)=[L;=]M9=]X]=]'P5AWQ<UWL]
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M@T9(A$>8A$BXA$ZH_X10V(11R(14^(12R#A,-H566(5:V(57R&.SH ]E0 9
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MPS7\PYN#"%+K2/]#Q#9IQ#7<_[5F2[9GV\1H"\52_,14[,30H[9"G,5!O,5
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MM.A2HDV1,GWJ5*E4J%.C7K6:M>I6JEVQ_W+]ZC5I%WYAS6H5"Q;MSWSK'!Q
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M\KG#G.<4:1AZHS_&*"7$36W2:V@F %R+7> #'5E&&?JY)34A6^_/:MH162-
MI.=Y%?$0%]U1_Z$K84[= Q+5#JQK( "94D3ME%D[)@K>Y43T>4>U.KOIE!&6
M5*A?^A,)1@@*AA^]5+KE($CI9?[LE!59E%*U)OC=PTYON;9ONP3>-9(ON9*/
M.+B/N[B7^[>;>[B?N[H7(F*GN[N3NY&+-(JO.+VW>+W/>RV^.$(^3F8+YJ;
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MBW<$6[0$.<0<9ODTU$J/TH7LY)8\*X0&"\*O^(F4XVE!7-F4@_F43XE]BU9
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MWJEKF'N6J:&=#+D#8900]FH.@U$JQ"B49.IVZX&J0H2L@G-.&VV".?8*Z4#
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MZQ<LN*(;]6<02#-AV#<F$;)]#5$LAY4LQ?<@_-<C9/)\,=4K#R)\1"*"$7)
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M#^*)#F* Z&(6HY@ABN@A'_A_!B&*E*@@O]<@CK(IMUE2:\2'ZYM29.(@%"B
M^[F!<D(GQ)<^#P(I+%J_%\<@L:*B%1(E GP@27.;DSB(#-(T6K(AQ@LAYJ@A
M"YB_)6*_TN)8#U(TX-!]T:&' &"'1$JP=[+"E3HN'!PA(*M]_M<@J\BJG6C
M-[6"#M*"6O7 #4)^M7C 5=(A;1(U1_JV5PRW6*S%6<S%'#0P6L,//_%,M#>G
M9BB&_UX8A62(QF>LQFULQF7(A6G\QFL,QU\XQVX<QV*8"#M<OB4RPGRL():C
M)0N\AQ'J?DE\@N"R(!3(@(]GP8X<@ /\R.#'ABZHP^R+R!-"?KB*(  LH :A
M5H3\(/2VOAC,O\,++(0\I*G:P@BRB>" #Y3<P)OZB <2E[:<R@JRRK(++*J8
M)D?<QROB#Q40S,5LS,>,S,G\-<68O6]JO=4+S=(;S=0KS=5,S=?\S-:<S=@\
MS<T1H.3RM*-[=@=GE^%XL"W1/ -KJ>$6D0  O.4!GF QENW8D"$ACW_W/;UC
M==Q8%NM&+B[;E[GK//ZX@9TT/:IK%F);CQ_)/+!SM9:+L?]VAY"Q49?_/'%M
M:=#%L6]D@6M6AY >RF\ X&P' +#)9M(3X6XT@M(G/=%B43Y >QM;Q+'S3&R4
M-;DT"VHJ&Y(1/;*_NT:9675/>QH3F;7W.7@4%T N*;P*^ZHRB5:=Z7'R[,_Y
M7,\MNQ+9T\Y*MXRS\ !HN\5?W<5A#=9C+=8Y <U!\0C:W!5Y^[>#V]:$"]=O
M+=>!&]=T[1>EP<WT6K7(<QN?U+N@5D!H";1]IT>>2Q+.=A)(W6]C4FRBJ;"1
M*;DO"X^16]C7AA+T%M)O\7?RW'9G9=EUM+'"9M@K:G5.1]B'/=H%@=B#V;.7
M"]BH_8^B[='=3-O.D83;C-NUG=?_NYW;:NW;O+TVM6D@XDK<VGJNQUVNQ>VM
MZ;K<YIK<QOW<S:W<Z.K<S$W=TXW<UIW=U<W=V!W=UPW=U1I!JGID M5C0?)8
MY6RK;4E,0ZID%\E-[]EGKKHEYK"A/.**VN1L1F8EH=I-WZP0SHH@^PUK1=4X
M AA8&3Q,4A5-C4K>>@7@[ZT0RW3>'^8F"EY05%5/!/A,#B[A)\56!^JH1B:/
M-_7AF@?>&SYE]LQ,%4[>451,"HE^!3W@+XZ>_JUG<&6).3SB5FLYEYI2-JI9
M^0U/.\I-MPIE<0A-[QM4-F[4W4U15@RF6RJF5$ZF5FZF7*KE57ZF6<[E6W[E
M73[E8EZF_V,.YEX>YF=NYBGTW7S&0L*5XG%.$L-,J():J':.YW6NYX/*YW>^
MYW[>YWD>8'LLYVUNZ,0I5^CP),G&N!R6T$Q.K%Y[K(C(301.$):R8:SBJG0I
M4G&XZ<?TE\1DP@-!;R)!/\JF8<+4;:X-Z0,QNUF$X.LM5T-2ZHYGBZU^$,5*
MH1HM=2X.*);^$>ZMZ2+%Z;CN#[H.R2I-ZC6VGH6NW8>.G,/\[-,.Y=(=WM7N
M[-B^W=Y-[=RN[=#N[>%^[<6]K@;RV[T-W.>NV^C.[NON[NH.[^DN[^BND9MT
MNJ]!TQ,:FAL9%^4CU#R\S]&ST5_1/9EM'A7=>./#F5O[=A'A.O],].^)F-2G
M@=1V9'@T?NGH2=$*_17X_*\7_46.K19Y!WC/LT<MW<_IDQK^;-5=X4F**RLA
MB[#CK6\R#\IFU_!DEYKC]\YEX8 Y'_$5W?)H=T@@KWD/CWCR(<[1X18_;W7C
M,Y:QZ^H8_YF7 ],B[3M2'W!CM]33IM)%F_-6"XU6 I1E3=9G;_9IC_8^:+?5
MJ \_,3#JGH1U[=9V;?=UC_=TK_=S?4-XW>ZL.6PAS^]2Y+6M*[R<"]""K_$1
M._AEQ/B?*MM+C:I5K_@*4>P+O[2#C_4ACQL +OAJ^?4 V?,V'/!VA*"%5'6
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MS,JN),NP+$NPW$JS5,NT',NV]$JV%$NX=$NY7$NZ1,NZ?$N[G$N^W$N_U$O
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M5G(]5VM%5W9=5W?U_]9TC==VA==Y[59[#5=Y?==[-==\I5=]Q==Z!=A_Y=>
M)=B!55=_3=A]1=B%[=>&+5B&%5B%E=B'/5B'I5B,-=B)U=B*W=B(Y=B,_5B1
MO5B0+=F1A5B2/5F+15F675F75=18ZK8N?#1$(0,O1<N;I5*<W5F=[=DGY=F?
M]=F<#5JB'5JC!=JC%5JD75JE;=JB9=JG==JDC5JJG5JKA=JKE5JLW5JM[=JJ
MY=JO]=JL#5NR'5NS!=NS%5NT75NU;=NR9=NW==NTC5NZG5N[A=N[E5N\W5N]
M[=NZY=N_]=N\#5S"'5S#!=S#%5S$75S%;=S"9=S'==S$C5S*G5S+A=S+E?]<
MS-U<S>W<RN7<S_7<S U=TAU=TP7=TQ5=U%U=U6W=TF7=UW7=U(U=VIU=VX7=
MVY5=W-U=W>W=VN7=W_7=W U>XAU>XP7>XQ5>Y%U>Y6W>XF7>YW7>Y(U>ZIU>
MZX7>L4W2$X+$+SL^[_U>\ U?\1U?\BU?\SU?]&V\&<"6]&U?]VVD&=P]VX.]
M^96]VKM?VLO?VZM?W>-?^<7?_05@^A7@;GJ$/WM?!$Y@!=X+)UQ@!WY@")X,
MIJ391JQ@1;3@1,Q@1]1@#-Y@#^Y@$+Y@$>9@3LF![R-A%/[@$6ZH._Q#%WX_
M&/;#&.;#&8:_+$KA$,;A%<[A%FI@'O[A'0YB':[_JB7-0B.F0BV\0BNLPBU<
MXB1F8B5N8BF.8BJ&8BM^8BP^8BQ$8BUVXBZ>XBO^XBK.XA6< =0BXRU.8R_F
M8C968S!^JPJX!Q[4P1Z<XQ^L8SRF8SV^XSV>K5D8)S1>8S<>8S$.XS869$1^
MX_7)@< Y9$5V9$*&9$,>Y$E.Y$B.N9E5X2'69$X&XDWVY$X6XE#^9%$&95,N
MY:DRX5,F958>90R)8QJ685F.95I^X5D.-G[( 5=>Y5U&Y59.$$;NY5_V96$N
MYH/BW@A.9F5>9F9N9F=^9FB.9FENI!QXPFF^9F:.X_XEX&W6WP'V9OL%YVX.
M8''^WW+V7W3F9G,FO0/&_V9W?F="JX!&AF=ZKF?BFV!C)F9>WF=][N=A_N=\
M!FA^%FA_#FCM4^6"'FB#KN <N(=:KF&(ON6(?FB)OI-9T&6%SNB$WN@S#&:-
M)FB07FB._H\BEN1 ?F1*/NE+MN1*1FF65NF67FF7GFF9KNF8OFF8SNE"UFF3
MWFF?[FF@CKEJMFF>3NF?-NJ@?NEXT^8\YF.GMF.H;NJH[F.IKFK;^6.:QNFC
M5NJDSNJBYFJD%JP<J#BP+FNOWNJS[FJB1NNUOKA,_FB1#FFXGNN1IFNYKFN\
MOFN]CFN^U@V$WFN[[NOZ:VB*+FQ;-NR)/FS%9I.+%FS SFO'9L2QCNS KFS(
M#O]#9+9GS=YLSNYLS_YLT YMT48D$QYMT_:]AA[G;R9GUEYMUP[GUH;MUU9M
MV>ZFQCYMW,YM49ILW>YMW_8Q?+;LQQYNRKYLXR9NX2YNY#YNY6[N2_MKYV;N
MY)8QPE[LBD;LZ[9N[*:[QIYNZ?[NY3ZPR?;N\([N\J:_D@YKLVYK]4[K]F;O
M]=9JM9;O]Z;O^/YJ][YOMK;O_.YO^/9O_OYO ;>?T@YP \?O 4?P __I'*B'
MJ7YJJX9PJIYP":_P!_><VU[P^59P#M_O#M]P#U\YWJ[O#R?Q$ =Q%#?Q%-?O
M9'EK\#9O&"?O&']Q&:]Q&K_Q\\9QD89N&\]Q'U^Q!M__;NT>\L0N\NQ^N^[6
M\1Z?\1^?H?%6<BAO\B@?L,S^;2N_<BS/<BW?<B[O<G0*9B\/<R9K<-HN\W6>
M[3.O;3-/YW-69S:/[7'.<#%_O!F0B79.7WS@GK28@7;B"T3@'K/H@GF"C#^O
M<X8P!T$/I1&?<T9O]$4*[BE?<DF/=$J7<DMG<DR?]$O7]/GB\4K/]$\?H2 G
M\B,O=2$W\E.W:(QFE2Y("#-:IS:"]5=7B.\!@'=@(TFIC:/ ]=5P=89P'N6X
M]5GGB6'WBH%R!S=*=E@_"SF<BR[(CV2?#F1?)^QH]5A' -M@BUDO%6LO=CC*
MC5W7B&=W#;8@]JQ87]Y !'.7__6$0/?6@'5@9PYU'R-VUPJ+>O)-#W5]SW>-
M2F\65W& _W>!!_ 2'_@$/_& )WB$-W@-3_B#7W&%A_B'=_B&9WBA _."CWB*
MS_B)M_CI(O,(O_"0'WD*%_F2)WD+SX<,KZ[H82.>>/ES+XAIAPEK6:.7K_6!
M@/D^;Y>9AWE8YPDMO'6?=WDR6HAO%^/N^0A[2_IOP)V<$7HR.HMF@7JI6)>6
M7PA?62,VDOK$NOJDH)9YEPJG?YZB+WJ<+XBP)_J?5PF#T/F,2?NAAWFU@.(<
MD#")KWB-]_B[YWB\[_C,<G%^!_7 YW3"WW?!/_S"'WS#3_Q!Z8(31OS%C_Q0
MZ3P=\/^",K!\+PB"S,?\,D"$1$ ]4R?U5!]]T7?A)+\AJB^CY1#VAV"-I#>C
MZ5$->-^.U,]UU$ $D2AV!$ CB>IVAL O>N?]#WJ)5Q]W^4A[W3?^XYCY5Z]V
M6%>--1KVG.#V>E<(V-CUXI?]K8>-+F >VUAW!%#*U'B)>/?UA(CWX0!_\2<-
M\I<H?(=\Q8]_^$>J*G=T^[]__,]__=]__K_F+IAG@  @<"#!@@8/(DRH<"'#
MA@X?0HPH<2+%BA8O8LRH<2/'CAX_@I0XJU49'4&\[/!R,HA)E"I5MDRYTDLB
M?/IN0M.73U].G#IYW@2ZLZ=0H#Z'!LV)]*C1HD25-H7Z].?_U*5.DU+%:E6J
MUJA9F5;UNO7K5;!=PZ(]J]8LV[*S<H2TZ X!77!T&\ZE^^WN0$1[ZR) E_ O
M KOO(N8MS+?@/02$[<:-W,6N7@21+RM4K!<19H8S*#ON<I&NXL./+2]\I]FQ
MPRZG"38&_4W&0])V[V%T;1M?Y<4$$<D6_?LT[HBV2=>;*!O!X8;'Z2;O+)V@
MCGS3KV//KGT[]^[>OX,/+WX\>8V('B%RA.A\>L[^!KX7&!_ _/KP[\O'3U^_
M_?S^]__7'X #"E@@?P<&B""!"AJ8H(,+/M@@A!-*6"&#%T:((84:6IBAAQM^
MV"&((XI8(H<GAH@BB2J:F**+*[[8_R*,,\I8(XLWQH@CC3K:F*./._[8(Y!#
M"EDDCT<&B2212AJ9I)-+/MDDE%-*62635T:))95:6IFEEUM^V2688XI9)I=G
M)MG%(V:&B2:9;K+Y9IMSREEGG'?"F2>=]3WR4DHR^>G23'^^=!*A,Y6!"#]*
M+:I3H_D\&BFCDSI**:262EJIII=NFBFGGWH:*J:C=DHJJ*:*6JJJIZZ:*JNO
MNAHK-&_9>:-J!Y#VS86J$7; 0.:0ABL"B!A(E[ (N'/BK;GR-X.QI-7GK&,(
M)%=/KG?9MVQO"!PP0W)5=K&MA-8:.X- P#Y[6+;3/JN7MQ/6$RZ[W%Y+FWWM
MSGMLL@$B(O\#O=L>(%R!_?[+;A?^2/O7P;86G)RVK#V8V%\DRGML?#,<N]>W
M&#;,8\5T(9*8L 0BTMO"\I5<L#G*%OP-9SMNN^^&#[OLHVX(O+LGB]75JK//
M/0.-Y\]"!ZUGT4,;3;3223.---+LJ=>>>@?-1U#5^EE-M=8&7?U?UEQO75#7
M WXM=MAEHXVUVEZO37;;8\-]]MMRLUVWVW;'#;;>9N^=-MYTWQUXWGP3[K?@
M@ ]N>.)S]\UXX8XKCKCDC?]-^>&6+U[YXYI'COGDFU\.>N:A=R[ZYZ6C#KGJ
MG*].>NNCPW[ZZ[*S7KOKML?NN>ZF[YXZ[K3?'GSNO!/ON_# #V__?/*S]\Y\
M\<XKC[STS?]._?'6+U_]\]I'C_WTVU\/?O;A=\$/]]"C?[[ZX7<O_O?MPY\^
M^_*/7__[]-^_OOVZSY((H#O$Q$\!--0 45)  !K*"V6P"5(:>!4'<@6"69$@
M!1]HP0A><((9K" &.ZA!#W+P@R(,(0DW:$(0/I!6^ON>Q'P3N!9:QA_7PMG@
M"+.7YC@.AGR;@0U1,Y!YD6M>ND+9MGI8F>BD[V;3^ANOZ#(#&"+K-T6<X;0V
M-I"$4;&']A*($HW(+K'Y2XA9I(W9IFC&T%3/+[D2#@"PB+.T-5$OC.LB:GHH
M&-1="XG5ZR)GZ*A'->I%8 /QHCE>EC= _W[1>#U4U]80.3'CP9!8^9L? '*
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M2$]I4>]/FI9(<%9K(V+XCF3N>D2I]H=(,A-@W8X>8 L V6__V'9MRX_^W'8
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M3G'\9PT.0PU^7(T3EP<L%HV.@9W4#-TM>7V&=V)YBEC_KY9-)V;ZRI&"VF8
M(-X!J-<%  !_71 @^*8003V#!P&\0W"@H3N("!4R5'A@AD%_ RDV_(91XL*&
M!Q!]-(BHHD8$ D$:-(>RH;F"B"ZNY*APALR('V?P1."SY$N%/^O51(#H9\:3
M"LV57$D5J%6G4Z]FQ5J5J]:N6\."'?NUK%-$@LR*54O6J]NU;]O"G2NW+MN[
M<?'2U6LWK]^]?_L"'BRX,-_#@1$35FPXL>/%CQM#GBRY,N/+D=4B>H3($:+.
MH"&*_CE:=-;2IJVB-DWZM.NJJV._5CV[->S:J6G?WJV[MVW?N7\+#TX\]7#C
MQ5DGE\W[N'+DT)]+9PX\.G7G_]>7X[:^?7KW[-R;:Q<?OKIW\N?-@T^/_;M[
M].OCOZ?MSQ\T?M#Z0=O/3YG___X1HPPQIB@CDW#VZ8<??OI TR TRNBC3#X3
M*@.A*<GXQX\^\[4G'C_]*(/AB"(F8PHT$?772R:]?*+,>.IU"*.',<(G8WDT
MYCCCCCCRR)YV+Z'S8X]$#FFD?#8F6>.2.A:))),^/MGDD3=2J>244D99999.
M;NGEE5J"V:685D(YIIEE8ODEFNO10P:97*89)IMKJ@EGG7/:2>>=?.[IIYZ
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M+<T\+^,8MR# [:<^Q[4,Y@J436A\HA>@0)QQ!SQ< A>WP @^L(+SFV &+]C
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MOO'+O? KOO.+OO;;)-@9I#_:O_S[OT,:P$(ZP/XKP 5,P*]2I.I;OR]Z+^@
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M?\B!;PU>K\FM@5#"#9(!,2&L.HNLR7T*X,2V@9@%<F@A?8B*;H6K2+(MT7"
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M5_QB5L*(VC&R=G,M_EPN::N/%L-S%OG0'(M$+)(^'JB.N[DCB#<,@"ORN,/
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M0 D^1)[JCS=F!4=RHP/4 \(X #H@5!>00TJ^SW2 Q4F*J8DAP$IR*1/)(%0
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MMNB&5C!8!&Z!$BY&U'-B.&YA^#-\-@BVVG.+ND?L1NY9S*= NR<_IZY!1RY
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M"%&84)E*TY/<A*J!JJH,NK IA-3C5%5="U7]5YE\).*%C2$K8]"*B+,B E,
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M!7<55[&H4%N56AOK68OBZ4C5YV;@-?$$7C6C4UU"58SZ*#!#5,&!,YRU. '
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M&%Z)" 1[*X1!6U<9Y"?O&"*]\<;_;O[K!L#]_4^  >Q? 0=H0 (J,($,- T
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M:OF 7,YREQOXY2U[><Q@)K.8'UCE)(<$C,<A"8D$A$2)]/@;-C[(&!L2X_*
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M'C_$2QR%><<4>A>C1..$"-:'COUX4>415/5U8B<%CNQ8CNIXC=3HCPEI2SF
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MB2C#HI &*9P(=0^3]5V=I ]FTD=/"9W%B9;&&9WI*)V.:9W9&9S5N9W724L
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MV0W_< \/\0X?<0XO<43#8P3G;K&5L:+5D78J6JX6"+_>F9X\6J<^S80HVHJ
M\1_E\<F8'*)CNLL,+Y?A\18AVEOV:^>J!R270ZC;P:+E)+PV'-@1\MJ&\0.!
M5_D@)]_LCA>W7P#P<:N[ZQ:O32@7.M+*V@+1KJ(U5[I&\JGC<?^H<>^[ZQW<
M55G_GJ]>5'.S,4T^WV9D+EH9. \FUW'9B?()L<G.R.\%QXEP!O!&-_ $9W0%
MKW1*OW1(M_1,QW0+W_16^]NH1.W!E5. AF>*BV"'+O5[GMP'6#])-;CU*XB%
M<[BG&&A^]B-;MV!LZ=RV_%RK/&[<,.B'"^C5+O;6/G919^UD-_9E1W9E?W9F
MAW9GCW9J7TPRL/)J;W9ME_9SF85"^8(-C:-^R% MX0>0!B R*&IU3VJC;O=U
M5VIW9W=B86K\W8UYTG+U*XH"L>N!2":Z\]%W6MK'1KN!]Y#<(,WYY=_1LT:'
ML$_** JB0VN9"R3>^*?=3#Q[UU'2&PMMI+NPT]J!"/*6_Z \3(HFP.XYUZBF
M-E0+6$;SA@>.KB6(F]/W'60Z@)\(D>]K^9T\UUP_&LWJ/,^,F#?-YGKYDR=L
M]*QV+XCU;<]V;G]ZIX_Z::>_!4:K<[:8$-;NBYA@<ZQ@O8+A@L!@#(Q(K]^K
M?]G@ [PW$/9ZC]E3!!0(Z:Y@,M!Z@XA[N_>"N2^8XJ8LMS_ ',@!>0![O2_[
MJR]\PS]\Q$]\Q5]\QF]\QW_\&B8#589\RC_\1XA'" >9";>>?#C*,(9C,X[C
M.DYC.RY]TC]].4;]T4]]UE]]UQ=]'<H!'KI!8JY])Z^N3/Q%V/G$F3S%/I2;
M<8R;<7S$A8!ET[%FRME]47Y%___J27"PFF.,1:W>'$+&QHLPQ4NT<R2\PWZI
M^6S<>2Z4&TL6".S7R9I\14X^Q#6\FMP?&)OD92ZT,5H>PE<$>5P&_N('?^C<
M1=#QZB=$?H  (' @P1G@$"#\AH@@080'$<P@6*\+.@3?$"( 1["+0X1=& XT
MA_'@/9 F3Z),J7(ERY8JY2UT*7,FS9HV;^+,J7,GSYX^?P(-*G0HT:)&CR)-
MJK0EHD>('"%J^G2AOX%5!5X%D'6KU:Y8O6H%R_4KV;!EQYI-BW:MV+9GW:H5
M^^!!A;ET'3QX>W9N7;X.O'Q%5 $O7;L5Y'453+CO T1L!1M>C%CO8+YV<[ 5
M*,^OY;S_<?5^#HTV1^>[I2L7YDQW\N<<BR.??MU8],![JAFCQDU81^:XIE/G
M[2T<[G#0Q6D;)ZX\.7/DSH]#7_Y<>O3FU:=;IZX].W?LWJ^#W_Y=?/CNY<>;
M)Z\^/7OT[L_#7_]>?OSV]>?;IZ\_/W_\_N\#N-]_ @;87X$#&DB@@@DRB*"#
MQ9%1SX(/3GB@A15BV."%&F9(H7EE>!&$%SN,&*(79?33X5:S?$&BB"*2N$,B
M*M)HGCY=D &-/OGPHR.//O:X8Y _"@FDD44B2:220S)YY)).-IEDE$]*":65
M56))I993<GGEEEYVF6687XH))C0 Y##+AAY.]XY%&!V T44(_\4I0V@BT8G
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MZB:B?R&RGXMF7 ;_1/!T%BG"BHYGD8]$D$'&0:#Q4'4 P!??I( 2U(<&F?Q
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MT8.O'D/]U%-]](IYQX.\OG^\UF<]UG/]UWM]V&^]V'>]RKT\V8/]V"^VGNL
MPAM\PL/]V\N]H!=ZVL.%52HC9>8:H=CB 93PWSF&H.D;]&D+IP* YE4?XZG%
MX\4$WCMF6+1>G="&5L)>68(E886>5R) 7":>(9W=;'X>6NQ]Y1F2WX-&:2J?
M_X3$9KC47>%WY.4MII_%1-_+L/6Y9D08GMJ5/=K$M]W[/MH#O]HG!AK3XZFC
MN_&G.[LC__*O^_$W?_([/[DSO_0___2;._1CO_6K._5S__5KO_([H;]'O_=7
M?_EW__:3/PCJ>1<PN[(W>_L?N_O+?_S3O\4^^_=S^RKF8F&%XBT"WP\!A#L
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M<B2%#257\B15,MA>DB5ALMBZH $[<F,0(7VH(G8:#@#N <F(:R#<31TUHH_
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M[]=^\]=HXQ=_]Q=^_[=^_3> IU9_"5B ^]> $]AJZ[=Y^;> %QB!(?B!'?B
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M]O?W#I+&T+:9NV:N)3G0\?%$#UTI#S:2#S+R"/IP]-*?*$5-\-8OZG8..M
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M2>+Q1^+)2KW*R(^IJ1G +^WXJ:";*;&DR7KTQDI4R[9TR[>$2_AROK@T*BG
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M"I]M#*"=VJ=ESXP U9]002/\FI.X3[JH4 HAF]016N/43U'%"3Y\3\"C0ZU
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M;^\N;_0^_V_Q5N_V9F_K$DS<Q@)1!+:R+IPPMN_<SF_<YF_=WF__1FNSUN\
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M6@(\^\.,"5G=<OW(0PX<<$U[3<)/EI_<-2:/C$N,;W)+]"?E_'39.KKC_DD
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M5HM*.Y)[:K/<TGX.O)K$N3(MS'I;X<:5.Y=N7;MW#2+:*5 O3X[^# (N*!@
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M$WH^,*/&/-TXXCG,@_##$?]#4/[H%<-[A!2 [TQI0G8%T:+)+J8%U!Q((8J
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MF(]Y\A-_F.S')\/G(U96D[#!YAYZ-3%&E&D8F_$'9_W=V7:>N:XKJ.:D3T:
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MGGBSH7G";(GSGX:3-]<V+4E).1T($>R3G>;6=*"QG0 6@/13E;+S<C[PG60
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M5P)NT:Y'(1W4+E>IG3NZK?W"L;W:_30C1Y>K1_3;KT,'( .L!Q"(9=?;,Q$
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MZK@3U\1.6 '#'7R--<R\H>2]C>O#ME3""7'"$*'#]&E438R-0FS#%$Q%B #
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M "SKFCOJH4@2<JKJ/MP%U;O$) &^C_(1Y?M$J)[4K1C<#6'J'X'L5$/KIQC
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M9;K4J5&$WW@BJ-<4ZE.E5[5FY6JU*U:O8<&.W2JV+-FO9]6F96NV+5J<][S
MI;O6[=VZ;^WFQ;O7KU[ ?0/S)?RW*:(N@A47'FR8\6+'=A&1:5P9LF6TB'I.
M/3I5JHR,[Q <F.INXF8$,TS.D,KSP R'YCSS1+30W532[Q[>WJS;-FX$OD\C
M:*V:X@S2/7\FW-EZ=%/B4\UAY!U=>,$9KFDK190\>M6%.[6GCC@;M$31WDUC
M1]TE//">QYV_CCT;06V$U7/OGGT]X7CCV(L. ?<0$F\TSRY3\#$&A4)LP<@P
MBQ!""?\KI/#"!BW,$,,)-_2P0Q U- P11TA$!)%'3$1H119;=/%%&&.4<48:
M:[3Q1AQSU'%''GOT\4<@@Q1R2"*+-/)())-4<DDFFW3R22BCE')**JNT\DHL
ML]1R2RZ[]/)+,,,4<TPRRS3SR,G.5'---MMT\TTX<7PP3CKK!/.>,>S4L\4N
MG /'/@3^5&Y%T9Q;CT5T9F.QSZG 22Q&S0(%5- !86.1)TI;1 T!327ER45&
M,7WTTLW0:5$&3"?MC\7J_M2MQ42=<W$&2OU$X!X;8VU459ZJ(G1 ! Y=,='-
M6$3$UDUK#:[%2)5-%35+5WR64U)EY;/640DZ=M=D5]U3SSG_OQ5W7'++-?=<
M=.U$T<1U2PR10Q'CA7?>#^6ME]YW[]4W7W[M[1=??P,&>.!]!2Z8X'\/5CAA
MA@UN&&&'(X9XXH4EKICBAR_66"NY-K8X8Y _%AGCD3TF&<-P2P[Y9)-;3@@1
M(%26&6#X@/6NM8=DTZZB2(N+*#L$.8T)T)MY"I"A+FY^U*!01UN:H*0]>[H@
M^$(#]M"%=+894(E0]<ZB;5VS-**>:SZJB_&V[A4CK4GC&5J)=BI:[$(YTXAH
M^XYF6NF&FCY@:H& QCGNH&V>H6Z>9G99PT1&57SEQ5F&?/+'*Y?<\L@S?[?=
M$TMTM\6%5@P=(]%='-VATD$W?775_UMG\?2'4G^=]=E=E_UVTG-'7??8>8?]
M=]IQWWWXWHD'WG;?@T\>>>.5;Y[YXJ,_OG;JA9?>^>NAG][Z[9>OWGONL>_^
M^>_)#U][\=-'?_WRLV]_?/?/?U_]^=F7_W[P\S=?__CYA_]_^N%O?P/L'P$!
M:#__!3"!"#2@ AO(P )&\(#UHZ  )>C "T)P@A;<X (KZ$$.8K"##_P@"4.H
M01&F$(4K+&$&6]A!?,1,A2^<X0EIR$(;YA"$.S0A#UVHPQX&\8<^'.$0A5C$
M#3X(B34D(A./Z$0C1G&).,1(QZ0(Q2G>4(M O"(5F_<.UDBG"[YJHA<EV 5T
MA)$GYNC"._^6\T30H7% 8U1@/9IFCL-U\7MV+,ZAG/.-L:T.C,YA(QGA^$$^
M&LV/G@FD&;/(Q4>6\77ZR)8>(8E%3#HRDUN4Y"4U^4E.'M*3H;1D)TTIRE.6
M$I6K=)^)2N3*GV".<I>CI>9D><M:SM*6N<3E+GVI2V#V,IB\).8OA7G,8@[3
MF,E$YC*=J4QH?@P?.GAF,Z/)3&Q6,YO7'$OCMFE-<&(39N'49CFY>4YRK@5H
MR4%G4M;YJ73&DR#>-*<\Z_E-?-Y3G^W<)RYAR;ET!52@ R5H00UZ4(0F5*$+
M96A#'?I0B$94HA.E*)&F65&,9E2C&YT1)3GZT2U9$:0C)2E!U>C_*6!1RI!K
M.JFS4+K2DB;)$96,:4UM>E.<YA0 G .H/?GY4Y\&-9] ':I0^UE4I!Y5J41=
MJE&9^E2G1C6I4)VJ5)N*,'SDX*I;I2I7K=I5;M(3K%\E:UC&656T>C6M8X57
MS>8CG:*ZM6;34:LS^>&XM9:UKFS=JU[Y^E>!\=1S;QQE85,9258B5I6+56QC
M-VG8Q#[VL)*-+"@ARUC*8M:RD]UL94GIV,YJ]K.9!>UH0UO:RZ*6LZ9E;6I)
M^]K3PK:UJW5M;&T[6\_6%K>BU2WN\J$#U>:6ML,5;G%Y2]SC&C>XR64N:F?:
M7-GV%KG+I>X,\3$7Z-Y6NLJ-[G2[RUWM_WJ7('9$%2'S6%U0DA=8>/3/=K.[
MV\9ZU+WHA>]WWSM?^](7O^$%;WWY>U_Q^E>+_QPL8/-ZX+XBV, )9O""'>Q7
M""LXP@V>\(,E?&$*8]C"&7Y*5CF\81!76,0:-LA=27SB#P_DK"E&<8A;/&(6
MQW@O)I8QC%U<XQ?G&,?W^F>*/J=3( =9R$,F<I&-?&0D)UG)2V9RD[^5#ZTZ
M6<I37K)\J8QDD5Y9RUOF<DQIW&4PAUG,2.:ICV.IXQNGV<9K1C.;=ZSF-L?Y
MS6Z&\YSE7&<\TUG/R?RMG?V<YSOOF4%B%32@EQG#0B<ZT(O^LZ(S]PB\-IK1
MAJ:THRL=9\&JZ/^_^@WP?@7L:5!W6M3]#36I1PU@4Z<:U:OFM*I;S>K\QGK3
MLO[TJ5]]:UJ7&M:SYG6M79UK6P/[U[WV;0YP3>Q@(WO8OMXULX_M;&''SL3/
MUC6UDPUM]EVTV=6.MK67S6UE;_O:X,9VN<DM.GY$>=SK_C:[Q=UN>+];WMZ>
M=[=I36 565K?D]ZWI/U]Z7_W&^ #%WC!^7WP@".<X-N$<L(=OO"'PQC2"C?X
MQ:99<8AG'.,;ISA-)A[QCH-<Y!H/^>8&"] QIUSE*V=YRUW^<IC'7.8SISE"
M&EYSG.><3.G6N4:UW7.@!UWH.N+YT(U^=*0GJ<SY+CG'1^YTDC^]Z5/_EWK5
MHWYUJ&>=ZEC?NHANKG6K@YWKCX[TV,UNH=^*7>U=9WO8$3R+LJ_=[7,_>]L!
MG>D?G]O=].:[O</=][_[W=Q[%[S>XPWXP1^^\(0/?.,37V_'&Q[RCT>\Y"O/
M>,HO7O&1WZ$^C*WYR5L>])???.8Y7_K;\9STH<>\Z%FH[=7'?O2S/SWK4=]Z
MW-_^\$7/O>U]+_O: ]_TPW<]\7M?6GR[2^YUI_ORG6_WYS<?^M.7?O69?_WH
M8Q\EGK=^]KU/_;W,0MW?[SX T@Y^\FN__.O/E_C1_W[VIU_^Q.RQII-^?_SG
M7__[YW___?]_ -P2[@M  MP_WBM =/DY!%Q _P;,*?=K0 B,0"Y;.N6#/_6[
MP/F+/PO,0 S<0 _40!#LP!#D0!$90!+\0!%,P:]X0!5$09DXOQ%T01F,01ID
MP1.DP1;$P1M,";PCK..C/>/3O=\#PN(KPA\,/B(\PB <0B1LPB44/B,40BA4
MPBADPB=,0BG$0BNL0FOSO"G,0B?D0BW\PBVD0O<C0S0<0\&#/34,0RI\0S"\
M0C>,0S&<0X%@03J$PS+,0S[<0S],0SL$Q)TZN0+;04.<P1Q,Q$/4041<1$5L
M1$AD1$F$)A.,Q$><1+FS04M\/AB\1$]T1%!L.TW$Q$TL15+4P/K+.PE<159L
M15=\15B,15F<Q24Y0/]:O$4IPT-<5!,%W$5?_$4UZ0=U T9B+,: HL S.\5/
M-,5E5,90=$9F?,9FG$9IK,:M*SIKA$9M7+!1I$8/[,1L],9M#$=RFH5H(<=H
M3,=Q9+L>;$,Y?,<ZA$<]%,1XK,=Y=$=[[$-ZO,= Q$=^E$=]],> [$>"!,@_
M%,@RY(<*V,>!-$B&/,B"S$=+$D:(=$B$?#8VC,A_E,B'[,B+_$B-E$**Y$B0
MM,B0K$B2/$F/5,D92KYD%$>81,=UG,F85,>:I$F9O$F=S$E_P4:;Y,F?U#%S
M#$JW@S*@Q$FBW,E\&DJD;$JE=$JA2D4?-$:JK$JKO$JLS$JMW$HWZ8<*X$K_
ML,2HD0Q++/$PLCQ+M*P174Q+MFQ+(T'&#B&#!YC+"G  NIS+!ZC+NZ1+N\Q+
MO-1+O^3+O<S+OJR ORS,PQQ,P#1,P0Q,PE1,Q&Q,QGQ,QUS,Q*S,R*3,R;1,
MR;S,S<Q,SM1,SQS-SBQ-T33-T$Q-T%Q-R&Q-S'3-SX1-TCQ-VE1-V41-UGQ-
MW8S-W9Q-V^Q-W+S-VLQ-WBQ.WR3.XQ3.WS3.X 3.X51.Y&Q.YGQ.YUS.Y*S.
MZ*3.Z;1.Z;S.[<Q.[M1.[QS/[BQ/\33/\$Q/\%Q/Z&Q/['3/[X1/\CQ/^E1/
M^41/]GQ/_8S/_9Q/^^Q/_+S/^LQ/_BQ0_R30 Q70__\TT  %T %54 1M4 9]
M4 ==T 2MT BET FU4 GUS,+,4 [5T O=4! M40@]40Q%41)5T1%MT0Y]41&%
MT1"=41--41M=T1MUT1C=41IE41FM41P-4AWMT1S]41_E42 =TB0UTB)%TB,E
M4B%ETBAUTB:%4B5]TB6ETBFU4BF]TBK-4B[54B_=4C M4RP]TR]%4S)5TS%M
MTRY%3WJ8F':T++E<3 <P3#O%TP_54[[D4\+TT[H$U#O5S$'-4T(55$0]5$4U
M5$;=TT5UU$;MTT>5U$C]TTFUU$H-U$O5U$PM5$C]5$H%54P554XE54\-550=
MU50MU54]555]55:%55>-5?]:G55;3=1.Q553U=56Y559]=5:!=9;W=1AS55B
M%59D/59E-59FW=5E==9F[=5GE=9H_=5IM=9J#=9KU=9L+59H_59J!5=L%5=N
M)5=O#5=T'==T+==U/5=U?5=VA5=WC5=ZG5=[3=9NQ5=SU==VY5=Y]==Z!=A[
MW=:!S5>"%5B$/5B%-5B&W=>%==B&[=>'E=B(_=>)M=B*#=B+U=B,+5B(_5B*
M!5F,%5F.)5F/#5F4'=F4+=F5/5F5?5F6A5F7C5F:G5F;3=B.Q5F3U=F6Y5F9
M]=F:!=J;W=BAS5FB%5JD/5JE-5JFW=FE==JF[=FGE=JH_=FIM=JJ#=JKU=JL
M+5K_J/U:JK5+'Z0OEXS+#Y7,LR54M%U;M6U;.V7;MW7;M(U;NIU;NX7;NY5;
MO-U;O>W;NN7;O_7;O U<PAU<PP7<PQ5<Q%U<Q6W<PF7<QW7<Q(U<RIU<RX7<
MRY5<S-U<S>W<RN7<S_7<S U=TAU=TP7=TQ5=U%U=U6W=TF7=UW7=U(U=VIU=
MVX7=VY5=W-U=W>W=VN7=W_7=W U>XAU>XP7>XQ5>Y%U>Y6W>XF7>YW7>Y(U>
MZIU>ZX7>ZY5>[-U>[>W>ZN7>[_7>[ U?\AU?\P7?\Q5?]%U?]6W?\F7?]W7?
M](U?^IU?^X7?^Y5?_-U?_>W?^N7?__7?_ U@ AY@ P;@_\F-TX.12K=L8 =^
M8 B.8 F>8)7S2@J^X#I92PP>$K/<8 _&17\8Q@\>X;:$RZ-\2A0^815.RA6&
M2A9^81>.X8&SX!2&X1IF,*:\X;HS2AMN81WV87O)82#N82*6862:4Y-,XI14
MXHULXH9<8BAV8I24XI5DXB>FXI*,XBO>XBGFXBK6XBX&,']8R"S&8I8\8RL.
M8RCT!]CX8C-.XRPR2S?VXC*F8S0&XSE68Q%B8SBN8SV^XS?&8S_.XV<KVR$V
MXB+^X40^9$5&9$=N9$AF9(>A84E>9$MN&2&^9)(#1TVNY$?VY$S^Y$X>95'F
ML9,S,Q).955>959N95=^92098_]8GN4IX6-:SI&;NV5=SK\'V&5?ID43)N5(
M%F9/'N92-F9D+F9E)F9F)@A*;N9DAF:#">5HQC$OE&9L/N9#GH5>UN9LKF9P
MMA D%F1 MN,^+N<_/F=U)N=U#F1W-F=VCN=W3F=YAN=Y)N1!SF?.&V-\1N=^
M;F=[#NA2ZN5_KF=ZQHBOTV> /FB!+NA[5F@Q[.:']F>(GNB%=NB&5FA#_N9E
M]F:/#F>.#NF/[FB0'FD%>V:33NF29@EN%FE XV&5)FF99L9S=.F9CFEL9N!?
MWFF>[FF?_FF@[K^O#&JBOA&)+FJ"R&6D7FHQ.VJF?NJC"V:<GNJ5ONFJMFFL
MIFJKWNK_K-Z*H>9JK?[FF@[KH[IFLK[JL\X^B09KM&[K91YGBS9HC&9HNIYK
MNZ[HC*9HO;YHO*[KOK[KO9;KOQ[LP(YK@B#CPLYKODYLOV;LT2%HPEYLR4YH
MQXYLP:YLS);LRQXMIP9LS39LQ=YLT0;M9MOHM.YJMDYMU%[MTVYMMV;M%.YF
MU7;MG%QKV)8JLWYMVKYM%'0 WMYMX%Y&G89JXBYNXSYNY$[N<QEJY2YJIR[J
M 6QNZ1:RYYYNZP8SJ=9M[9[M[?[M[@YN[@YO[R9!V1YO\Y9AVP9O?-('X#KO
M[WYOM79O\59OZ8/KT"9MSQ[M^][OQOYL_LYO_+;L ,]L_>[O_P('\/\6\"U&
M;/\V\ %O< 0O0\@F\ >/1\J&< 5W\ 2G\ W'<-7I[ R/<!$/<1+G< U_"-.&
M;_E><?I6\1:?;Q>/<1@G*S*><1;78=]^\?5N;QWO<1EOL?3^<1^W<9 ;[NL^
M<B1/<B5?\B5G<":_Y>H.ZNA^<BJ7J"BO<BS7J>PF<B'O<B[_\AL'\R$/<S)'
MBQHO<R]/Y" 7\VMB;S9_<S3WJ;%.\S&O\TNS[Q,?<1/7<P_O\P,O\>KAAP[_
M\ST'=$+W\PI/]$%7]#ROXPKH!T-G=#X_=$K?H0E']$6/PTHL=$[']$;O]$H/
M2! '=4F/]$S_=$__YQ2'<SMG=157!O]04(8XG_56IW4ZE_$SKW5=O[XY=_69
MR6U?M_5@UYPU%W9CWW6I,O(L7_:L-(5> (5DR =FGW9JKW8 >'1K7^5H6>HI
MSW9O)Y<'F(5O'_>,VO)CO_5AOW5BR(1G3P93D/5TC_=SEW=D=T%LIW=TM\1B
MK_># ?9Y_W=^!YD9$/=\#WA\3W8S@R531_509_A2)_53?TAH^(1>H'AH-P5W
M%_2&G_2'3_6%Y_B(_WB1AWB''R!L)WF0+WF53_GN"7>6'_ERVW2/1WF8W_B:
M[_A+&GB;IWF>GWF?W_DD7G6 +WBBGW%GUX1>8/>+5P:,E_:B'_J#AWJIC[][
MG_JGMSZ=OWK_HO)W@[?ZJ*^+ /EZK1?[<%)V<C][!M2'I%][I+]X=W][?4![
MN9][GSYYNI?@K.=V$;Y[OA^3'"#XO@_\8TQX5"9[KS]\3%2&7D!Z=F?\80
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ML1.UR/56V@@@_ $8.! !@F\&$1$$('#AP'H&#\X8V-"A0(,($3#L@E$C0X<
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MT"YJ[GHKJ:-!$CIUBK!3F68B6JWZV$Q%4B0OBAL=U?MN==.]3J)<>]\#H^)
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M_\E$?N0KWN-)CN1#ON0K'N1.OE'J2J_K4%#\T X.L,H.1\O]VN6>XFT Z^4
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M6PB-,;)%VZ\]L)HM6Y=5V[0-6[B=)+:5V[I]V[LUI6S_M5B)K=B%Y=N_C=C
MW5O!]5O"?5C '=S$+5S%/5S#==C'I5A /%O&A=R^;5S*C5R?FUK$7=S.S8J!
M]=S*Y=S+#=W,Q5S+C8E\L%G1=5S3+5W4=5W2E=VCPUB\;=O;M=NXM=W<Q=W=
M]5W=!5[X.MO?[=W@Q22Z)=X!?-GD95[C;5Z!F-KBE5[>I=[?>]/$N=KLU=[M
MY=[N]=[OW<Y9.%KP)5_P4=WR11W;1-_U!=KS9=_W9=^L?=[J==[ZG=[YQ5_[
MI=_[U5_FY0>;S5_^%>!KB=[]I<#E[=\$'N  '@KW9> '5F #5A6]?=W19=W3
MM>#8O> *;EW8]> ,_N .!N$1_Q;A$L9@$^;@$\Z165C=%';AV=7@& [A&E%=
M$E;A==5%&W[A#8;A&=YA&2Y"]P5B%.YA'2YB(N;A):W="(;@!6;B)W;B*)9@
M*)YB*?9,%J[B+&[B4W%@*O:_"LB@+19C+];8+K9B,C[C-'X4GH7?-G;C-X;C
M.);C.0X>+*;C.ZX=(<9CRU'?/?9C[=2'%O[C08Y5^45C+3[D,59C14;D14[D
M1W;D3\)B1J9D*C;C1HX\,(9D3*YD6[WD3N;D3?Y:"C[B&R[E'_;A4U;E)!YB
M4V;E5'YE(XYE)&YE5);E6E[EB;5C6Z9E6,;E62;80+YE7T[E'.[E84;F8U9F
M5\[<0/_.96).9F:&YF7F99-:8H A P=X@ >H &WF9F_NYFT.YV\69W VYW)&
M9W)6YW%FYW->9W=NYW2.YW>69WBVYWK&9WK6YWGFYWO>9W_NYWP.Z'\6:( V
MZ()&:()6Z(%FZ(->:(=NZ(2.Z(>6:(BVZ(K&:(K6Z(GFZ(O>:(_NZ(P.Z8\6
M:9 VZ9)&:9)6Z9%FZ9->:9=NZ92.Z9>6:9BVZ9K&:9K6Z9GFZ9O>:9_NZ9P.
MZI\6:J VZJ)&:J)6ZJ%FZJ->:J=NZJ2.ZJ>6:JBVZJK&:JK6ZJGFZJO>:J_N
MZJP.ZZ\6:[ VZ[)&:[)6Z[%FZ[->:[=NZ[2.Z[>6:[BVZ[K_QFNZUNNYYNN[
MWFN_[NN\#NR_%FS -NS"1FS"5NS!9NS#WNO46",V%ATR^.8*J.S+[F;+SFS,
M=@#-[FS.]NS0!NW1WNS2_FS3%FW4)NW39NW4;NW5=NW8ANW95NW:?FW;EFW<
MINW;YNW<[NW=]NW@!N[AUNWB_FWC%F[D)N[C9N[D;N[E=N[HAN[I5N[J?F[K
MEF[LIN[KYN[L[N[M]N[P!N_QUN[R_F[S%F_T)N_S9N_T;N_U=N_XAN_Y5N_Z
M?F_[EF_\IN_[YN_\[N_]]N\ !_ !U^\"_V\#%W $)_ #9_ $;_ %=_ (A_ )
M5_ *?W +EW ,I_ +Y_ ,[_ -]_ 0_P?Q$=?P$O]P$Q=Q%"?Q$V?Q%&_Q%7?Q
M&(?Q&5?Q&G]Q&Y=Q'*?Q&^?Q'._Q'??Q( ?R(=?Q(N_P$D7(A+*_<*%L>=[F
M=7YR=HYR<)YR<:YR;KYRRW;R+8=R+I=R+Z=R,+=R,<=R,M?R+D?S+T_S,%_S
M,6_S,G_S,U?S.6=S.G=S.X=S/)?S.N?S.^_S//_S/??S00=T0A?T0D?T0U?T
M+&=T,V_T.']T/8_T0)]T0Z_T1+_T17?T38=T3I=T3Z=T4+=T4<=T4M?T3D?U
M3T_U4%_U46_U4G_U4U?U66=U6G=U6X=U7)?U6N?U6^_U7/_U7??U80=V8A?V
M8D?V8U?V3/]G=E-O]EA_=EV/]F"?=F.O]F2_]F5W]FV'=FZ7=F^G=G"W=G''
M=G+7]FY']V]/]W!?]W%O]W)_]W-7]WEG=WIW=WN'=WR7]WKG]WOO]WS_]WWW
M]X$'>((7^()/=GC.]H4W=X:/=X?7=X@/>(DW>(I'^(/'>(O/^(;G^(?O^(C_
M^(F_<XTG^9"O>)._^)+W^)4'>987>9<_>9A/>93?>)FO^9:O ,CN(E(&YFKV
M^6>.YI_O>:"G9J*7YJ W>J'_Y:6?YJ,O^J%OJ%U.^JF'>J9'^K<3YJ>W^ADU
M9J?W>J5O>K"_^BS]7ZK?^J\W^[!/^[$?BFL.Y4A^^[@'Y;D7Y;K_AWNZ[]U^
M &"[EWN^GPAG[GO)T^2[]_O"%U3 Q_O 5_Q%E6Q"=OS'A_S(E_S)7U6II_S+
MMYRRQWS%Z>/-]_QOY >G_?S1ITY#)OS37WS#3WW43_S65WW7+\E)?OW9EV+$
MI_UM&_S5UWW81T7-Y_W?O_V,Y/FS%WNM5_NJ/W[B7WOC9_OF9_[G1WOD=_[H
M5W[I%[I92"?J3_[MG_[BKY'0[_[EC[FN]_[R%W_SMW[MWRB]/__V3W_TK_[X
M#WNW!W[6#_[[M__\WWW\WW_]MSS9!P@  /P)'%B0H$"$!A,>;,CPX<*("B<Z
ME%B1(D2,%C->[,CQX\:0&D=Z%%F2)$B4_R93GFS)\N7*F"IGNI19DR9,G#9S
MWNS)\V=(?CF ZBSJ<R=2HT2/*DW*].G2J!7Z074:U2K6IEJK;KW:-2O7L%[%
M@AUKMBS:KVK)KCW;-BW;FOPJN(U;]RY<O&_WVLWKEZ_>OH#_"BX<^#!AQ(,7
M T#DR#$B1(\@%ZQL^3+FS)HW<^[L^3/HT*)'DRYM^C3JU*I7LV[M^C7LV+)G
MTZYM^S;NW+IW\^[M^S?PX,*'$R]N_#CRY,J7,V_N_#ETV;-F1*]N_3KV[-JW
MB^XWE#OX\,HK*!1O_CSZ].K7L\?>CV[[^/+GTZ]O_SYMR9#U/T[LG[%BAOTG
M(( #!GB@@0D6N/\@@0TBR."##BHH(8031GBAA1E6N"&%'6+(X8<>:B@BB".&
M>**)*9:X(HDMHLBB6].IZ.*,+]((8XTYXKCCC0+.92.0.O88)&!3#2DDD4?R
MF"232#JYY)-*2GG6CU$V"2664UJY9997:MDEEU^VQ%]DC_5W67D5598F1&MB
MQF9$;J+Y)IUSVFD9G'G6B>>><O)YIY^!JCEHFX3&::B>@"+:YZ**%OKHH9 F
M^B>E@DK*Z*6.1KKII)9RBNFGFG;::*6D>CIJIJ6F>BJHJ(:JZJNLBMHJK;/:
M"JNKN=:*ZZZR\GJKK\&:.NRJQ,9JK*[ (MOKLLH6^^RQT";[*[7"2LO_[+7.
M1KOMM-9RB^VWVG;;;+7D>CMNMN6F>RZXZ(:K[KOLBMLNO?/:6YF,]\H+K[O]
MULOOO_L*;"[!ZQ8<[\'^ZIMPP PO_)[" "]L,,4(5QSQP!?W2I[%'6/LL,0A
M9^QQPQI/3/+)'YLL,L@CJXPRRRN[7#+)[\V<,LTOZYPSSSC['#/,-P.]\\]"
M&]TRTC(G'33(D#WF-")A>CFUU%6#>;685&.M==96=[VUUUR+'3;98)O]-=IC
MGZUVVF6WO;;;;'_H#W5PV_TVWG+'O??=>%79-]]Y!PZ D7H#?KC@B!N>...+
M.XZ4S8-+KOCDC5?^..696TX1U&3B]SGHH8L^_SKII9M^.NJIJ[XZZZV[_CKL
ML=>6K^RUVWX[ZY'COGMO.5#%._#!"S^\ZO[ 1SSRR2N_?.MD>JXYYIM+'SWU
MEUL/_?739U\]]MUK[SWWWXL?/OG;FP_^^8G/\D#ZY:/__OCM2QXY_.['#V#A
M\M>O__W]V_\__Q!#/_\%L(#[.R !$0A %CG/3%$KVM*(-K2>31""2KL@TS H
MP:-ID((<S" (-QA!#X[0@B$D80=-*,(45K"%'USA"56(PABZL(0U9.$+9PC#
M'>JPAS+\X0UIF$,@#C&(/'04[8JH1!LN$8=,?*(3HRA$*$Y1BA\SWA&-Z$,M
M$I&*&/-=%<.8Q2:*<?^+9!RC%\V8QBY:48UM9*-!C'=&-Y81CFA\(Q?S.$<[
MTO&.==3C&@&9JLXYT( )/.0"$6G(1#)RD8Y4X",5"<E)2K*2C:3D)2T9R4SR
MI&Z:Q.0F0PE*2 Z0DZ)$9 7X\<E5FG*4K#QE*VE42EC2TI6QO&4M7\E !WJ.
M>;[\)3"#*<QA$K.8QCPF,I.IS&76AGW,?"8TF2?': 83C-2\)C:S^;II:K.;
MWORF\)PWF?[8,I>X+"<Z=:G.<Z[3G.Y,)SOC^<YVPG.>\JSGW=B'3WKR\Y[]
M=-(L]^E/QZ7RGP*U)T(/JE#!!=2@#AUH0A\:T40VD#)\O*@@_[C'C/JQHWW_
M_"A&-RK20(X4CR75*$E3:E*5HG2E+FTI3#T:4I;*E*,@M>E,7UK3D^Z4IC<E
MHPQ^ZM.<QE2H.C5J48G:4Z5A$:E+32I.HQHL(SVUJDZ]JE*Q*M6A;O6H6?TJ
M%X\'59YJE:Q@-6M7Q\I5M+)UK6Z%""$ILU"(SG6B=JTK7B6:5[KJM:]\_>M=
M_1I8P*93GX+=ZV 36\^&$O:P0RIH8R.K6,=*%K%[@8]E*3O9RFHVLQ'JW#@?
M",[1DK:TICTM:E.KVM6RMK7!=(!K8RO;\<SV=?FK+6YSJUO.B'6WOOTM<$\C
M3KEVMKB</>YFD^M9Y1J7N<A=+G2;&]WG2K='AJ4N_W:=J]W,8;:ZV<6?*K_K
MW>V.=[H&=*9YTUO>]8J7NA4]4UJM>M:WJM6K\2TK?>5[W_G:MZW]S2]^_RO@
M^A)8O_XM<( 1S%\%[[?!!S8P@!<,84C!5L()GC"#'WSA#5LXIQSKL(,C'&*9
M497#(\ZPB#4,8A6?&,,NYK!87[SB%--XP#)NL8E9K.,:ORJNY&0O>=L;Y"&K
M5\A%)C*0CZSD)#/9R$TFS'61[.0I2UE#Z'WRDG^2@_!6.<M=QC*8'W1E*GNY
MS&'^<O1 :]'@LKG-;GXSG.,LYSG3N<ZQJ;"=\PS<WNIY/=;L,Z #';P/"[K0
MAC[F<'],YC.;>=&.1C.D&_\=:493^M&2OG2E9Q1E3%LZTYR6R9@GW6G"<?G3
MIO8TJD<M$HZ=6M6M%C6L&?->T>[8QCGF\8UKC6);SYC7..[UKH.=:US?VM>Z
M'K:QB0UL9 N[V,U>MK.9#4-G_KK:QXXVMJ&M;6L+A-#7WO:W';SE9W,[V>8F
M=[C3K>QRH[M1A)9VMMD-;W"O6]WGGK>\"^+CJ+VZWZF.];_][>J $WS@!@?X
MP05>N4T7'.$.ARZK&Y[E<2=<XA:ON)$CCO&'7YSC%5<S? \M\I&3O.0F/SG*
M4ZYRTE![Y2Y'IK=?_IP_R[SF-G=.S&^N\YV?)]'\[KC"@P[TH6]<Z$4GNL>3
M;G3_I5=W!K-8.M21KE"-,[V]%*\ZUJ-^]'M27>M9ESK8^3KK>-N[W?<F>[W3
M?G9ZKSW?;#<[W/%==KFK/>YH;_O<[V[WM],=[RR= 9OZOG>W$S[O?-<[JFY;
M=\$SWH/C;OSA(U_XQ2.^\I)7<?X@/WF_<W[PAM^\YRD %D#IO_^S?7]]ZZ4_
MO==3'W;4KU[UIG<]ZR/T@*>WOO:OEV37;6_/'.A#][#_O>^_5N+;$S_VQE\H
MR&G-\^4SO_G.?S[THR_]XP!^^M9?G>*OSYNK:[_[WL=,]K\O_O$+-[3/"W[Q
M@9]^]!^?_>IO__KC#_\O._W]]G=_XH8__[E>_?[R]__^*8G^ 2#_ >+?_S'.
MV%V>Z(&>YGV> R[@ W9> T(@!4J@Y3'@!49@Z%F@ G(@!G;@!H8@#%7?!Y:@
M!DZ@!YY@@(4?"HI@!IK*X[U@"E:@"X)@"]Z@#(9+YN4@#MH@#_Z@#P:A"9(+
MZ17@ 1YA "*A$28A$RZA$QI@$Z)-_4'A$RKAEPP@%:X3[V6A%79A%"H&%GIA
M%7XA&7)(\I$? .1 #E2  U3  U2 /-0'(JQA&[YA#B@?,,TA&[IA!=PA&OXA
M( :B( YB,#D=(1XB=X0?(JH&]RVB(Z)<(SZB)%J?SY4AVGB!&S[ &SJ )I+!
M2" ")G+B ^A '!*4)FZB)KY;DV4B*K[A_QB^(A=:HAC&(BS.HBW"10[0WBW6
MHBPJ2!CV(B9MX2[2(C$.8TH4%"\F8S$"8T\DX!!:$1ELHANJ(1YVBAZ*8A^2
M0=O) Q]BHP-HXZ&$8BK68<YE6#>.8W<)H1*=HS3.H#O6X#/"HPJJ(PWV8#S:
MXSS>(Q#J(SV^(SX6Q S\3CX.9#WN(T'Z8\E %C\NY$'&R1;^(T+VHSP6I$1"
MY+/UGT%2)$-J9$-:I$=>8!&NESBVHBJ^!!N.8RK> ^.,Y$D^@"=6A#>BI!?$
M34O6)*?5)#8JHS$RXT[J)$_^I$\*72X&Y3(294X@8U&RDC "95+VI._%8*?A
M R*0A"H9)5,ZY?]G\5)H,0\W2F,[CD8WAB4>0D=7[N$F@N-ET&%8OJ%*7L=:
M[F$QO64;3B)=UJ5=WB5>&@?-Y25?[H9"]F5H+"5@#F:;1:+RZ,,\R  "?$,I
M9D8^3,8C""1A3B9Q5.*2L>0IEN1*L&)-MJ7;8&)FBN)+9L0U:B(I-@YGYF28
MI68J6J5K-N55QN9K8J5LJM-0PN9LRB94UB8C+65N_B9N,MIN%ADBJ ,"'.<W
M'.<\D(0^A-9DT!YPTF9TVH0S=B3-R ,ZHB*PL.,>_AR(E:4W@F,#<N=<3J1)
MD6<Z;F1$JJ=YMN='5F1&KJ=UPB=]LN=[VF=\PMU>NF=^WN=\XB?;_27_1PZH
M?*K)0_8G@M;G?RXH@?*GS_AF@O)+/\"##"0G<A[G8I8BG.1#(D#-8R2"/LP"
M@Q8HB3HH@)ZHGX2DD[&D:OX$3J;D2KZH2RJ0C&IFEM7H=.9H<$KGCO*FC^HH
MU]PFCP[ICY[$</9H_4 HD0)ID5K:@6;7/73!<1X AEHH E I BQG1S2GAY+)
M(_3>DB*IF'+$&2X/>(8E:<AE!8RE0-Q#6/IA0=Q##GBE6?8AFVZ&G-(I.<+I
MF9ZE9I#!&FXB-79&GM8I.=9A#C0FH:JI-,(I^.DIG_VI6D*J--ZI9EPCHV9C
M:(1BIGXC:42CH78C6JHI99:JJ9XJJA)B+J8J_ZN>AF&VJF"VJJR65JS6CC\@
M@CE@*#A4J:Y6J:)>QF-"AG,**V3,@F3.*K)^AF6*9$UFIE*P)EMV!$D^P'?,
MZ1N&9BJ&Y@.IA+5":VKF &BBY(Q6Q#V(ZS2"1+=BZ[6*ZVAN!")@H[I"JPY@
MA+>J!':NZ[2:ZRE.I9'FJ[_"8;\VJ[ZBI'>&1+GBJ\"B(B+4ZY@VJ<,R*<0V
M;,2&Z5@(Z<-*K/L]Z<62CY*>CY0N)@($E5+@*H::P[:NUSN + *0X,8Z;#W,
MP(76@XIH+%[I0SNH[)7RZI3JK)9R!)<^QK "+;$Z0HA.;,O>7W4VZ,O<JZ&V
MW*J@9\%6AC=.8[<>:O]VUN1W;,K!-JV>7FUX%LK"3BVUP@G36FW7"NJCO*O7
MKNU7E@=Z0DK9HB=)FBVME0>HBBU.GF/6MLF<YNW<0BVG]*W9<BWAEJ=_*FV$
MCJB)*N[AEFCC+B[B*FCDHNCD,BYF[.?C9F[B5B[GNE2M0J[C9J#&SA$ZX&QR
MRNS U(/I(HMBJBR_ZIMB)N<[A(P[E&PUWATB6.DW4,>VU.Z%_BX"F,,,O$,7
MH K)'J<[=.[@^:[IEJP,S*[E=E'L8BCJUE''1B\ )";PZJ[.FJZ&8@:'=FF'
M.M"'>F@^!-[FAJ[DJB_E^IJ*,A>+MJ9/U*AG4L3<FFM,WN^X9H07Z&^-YF__
M2[:K0FRM-W['1"#"_<[D2,SIZT9$V;)K_7H!'<KO0^#H10BNN<+IK<8O*BIP
M0X0MNY+$&M9O0TQP*S:P0E3M.)XL0_@O +\P!1\MQE*L#-.PT=[P#)N$Q>*P
M#6=L[_'PX'0LB.0L\";O63 OE<ZN4:@NEBYF0TSOE';!5:@N\!X0S!(Q"I_$
MQS:QE7(QAAX [VI$KNXL A0O%5YQ%W=O$U=OJ^7N%X<QB= L/^5#%[" &M\Q
M\&)ISUK$ST)-:#G0'Q/K(U1E#@-QU)6I\O0I7((EI-[IH;ZE9^K;(W_E971!
MJ&[B6 JN7**E983M6NYM09#!)(-R:-SM6EIJ&CK _UB2ZN5><J161@Y,,AMR
MLD H,BD'YBASABB_)?C)L@/<,@*[<GDF*S$7LS$?LYR]*C+/ZN?"*IC^!B+L
M*O#N*CJPQG%*,P*4!O/*KF58*35C1NE::?5>1LIZ,S[$QST@ #9_PVBH<_>N
M<Z\B9U!AQC67K&ZELS>_L\[R;C*UKC1+\6\T\^@@0CJX\S3K\T$CYZ]:1K *
MK4-[Z=!"M"XN,ZHNZXHFK(UZA+>2< MC-$<OQ$97A I?JP%?,,**ID80<+:6
M=$)@\+H6+$TL;+Q^-$XP[$-$8P:W1+B2)$4$JKAF,4PP;6BV1+YZ<)L.+$P?
M1##'JR$7LE/W,%37L%3KZ/\./_54 YT<1W7]Z, SEP@5@ZQB<K%8= $7 [11
M "\;UT07P[$\;3,"*'%-?+6% C4 C#'.FD./(O%Q6D0Y?W$VBQH1._&+9/4B
M]8,[.  9XZP7)W8:_^X>4T0?!RU$/[1D/T(^B.A5:_70)2W[CDS<:F>U "Z<
MX"V>!8I+=V><!+/8O@IXCJ-X=K+?Y@";B/+:Y@ G3TIK^VF\O&V<B':?^'8M
MRVVBTDK7@C*<5"T?@K()FV6[!@IO:^[Z@JYT0W?[3G?Z6G=T4S?V;K?R:O?!
M1*)W=W9W7W=X9U .Y -YI_>*C2X3?:R%4@<:'V?=U@DB,*\YS#, Z.Q\ZUM?
MKZS_$;LQ<K(UKKCW<9KQO;A#?/LW"_-*/73!>QLQK+A#ZWY#%\CLJ*#UL$!Q
M\!H*]R)  P=+%VBX.53XIS2X77_#\T;XA!_G#+C#[>+,.\R [I)XL"!"[,K
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M>M_LJ8NG+Z_^.7OCZ^&WC_]>?GWZ]]WGGZ_?/G_\^P'L+\#_!"R0P /]2W!
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M,]!)4&@UDB4C-B<M+L@](OU'2&M2(CV9=&]1 A)JJ:0+(VEQI ^-DLV*!)8
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M N>"^?+RDLZ/HH1/O?CS6Q!LO?AB03\T4("4^@ @3C(T PUD>#?T':HV1 _
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M%$W^,$U9QW,051$YUA,[1HXY=!#\L'2QN3=.)Q)VN#'SX !E<RW_+B<G+/"
M$M$.J!D3<MDX+R>)[)*'HZ.:#X%<)Q<3CV(6JL.9"U%0@O,.RRD17B0V>DD5
M3RD3F(@8=;<7A;@0<T$[+ "=G>E*?1<9'HA\K<=>#O  #U !#E !]"F?^'F?
M]3F?];F?^>F?^/D !/F>LP>?!7I]R:>@!TI]"VJ@#YJ@#.J>#2JA#AJA$/J!
M%:JA&(J@&<JA%/JA$RJB%LI[M$BB'8JB('JA*^JA+)JBAA6-(7JB*MJB:P5B
M+SJCAC5_SD4:A[B$"^&C4:24.D$9C\E\@2D9T =^S2@9@3,27?"4>>02X%=M
M2$H16*BD,.</U?8F WBETZ50V]$F#.D:_T&) !!)$3H!%<QG&V::?63I$$2Y
MI&Z)$'M1&4&:<L1G;J#AIL1'EAOJHBZEBSBZ(6VR?81R6<RGJ& J@0A!?H'2
M64!F%)!:?I6J)^Y7)/"G5=W60<VQ?V!*?#1!7'#2?^(1G+9"#I(J'KBCI[MB
MI*&R.YNQ+%4H&IS:JHJ*E,)"+!#I&Q@XD<A!#Y'5#I+*#_DP#U\WHH":52$8
M&3^)@EX@H-'*G](*H-7:GP": ^JIK2_)K36YK=[:K<XJKM\ZKN%*KN=JKND*
M/#.)KN#JKN7ZKA;SF>H*KZCDD^TZ2&<#A0CAA+K#$J?Y#79II@?0!7YIB0&[
M$7BI%ZB3G'N!=_\\UW]E4[#\FCMU%J1Z46K\:E!1T1"\61%XIQ/N$%V(T(1>
M&1BOBBU@J1+<Z:0=Q66O6F<'*["FPYU+L1=4F!!L*11%,94#.*0A,9DH)Q'>
M.;,N&Z^9-*\25Q'CH#8U-I4#A88X9G0]=JD(05I$QF-9.S=.!Q.VV3'^$)Q-
MYBWSP&10.P.L1I0Y,67T,D==QP_T<C@ FQ6/PES&.6=D5B[X (EGV%'HX+7=
MF77@61COJ$SDR1*N$K7?(*GUJC.AV)X9&3]D8)_Z2;D!:KF3>[G_60'9ZHJ9
M^P"<"[FA*[JC2[JE:[JGB[JIJ[K'8Z*KZ[JO:T$Q"KN6Y@4)>;H= 4+_ 80/
M_P=&!,F,X)"KP_A!MLN,DD&4ID*0%$M"]OB54!2\EN$FS,NO(Y092FDJSVL5
M'_2\B$"]DN%;X""]T'.QX.M$>U%OG -"^6<9(?1VTSLXJ3%S'F09V:L39,H0
MT0N]RY89]$M"I]8%Z6L9T >\J<&_*X&Z9(!;&-2^^B /QS*-N+9&>*1KXQ>;
M2C>.LLE-[J<]$0@/\_!SYH,[TF-9ZPB/,@ /&IP/U]G!')R\T+,.7= .7?#"
M,7QLT=/!KH8."0Q6:N2W[2L9,RS#,"S#->P\\M!M$)QF/MP\[B#$0/S"]:8\
M]6#$'CP/*RP/MIL\8.L 9!0.5S#!I+N1S8JO_QE'!M(ZGV9\K?UYQM-ZG_VY
M0HS[%_>0QO3YN?0ZQG:,QT>KQW"\QW?<QWG,QX'LQX+<$XC @X \R(F,R("<
MM(3\QT9SKXO,-2T[=1BK$?WZ% I[$9:)$)K,HP>!%GIGLPL;F3HARE<:LENA
M6_N*%E[YM#4;E(69LW1!G-JBE&*+=6-AEPRQG7,F$PY!R8 9%U*WRVD:$K7L
MA%='EQ4!I\H;%#5AI/W7LELXS+HLR8.$"%[ @OI@:WPKMXF;FE.+=/KP=:V)
MP:V)K #7#_"DR(_LR"_(GBU,J#*JK/Z1 _]YK9P[SX'*((C QI.; _M<HP)-
MT#1:T,E*SPG-SSG*T/_U;- /C= +[= 1/= 0W= *7=$4?= 7C1"MB]$;/=$<
MG=$B#=(?'54(;-$AK=(F;1PWFM(L[2"+NF4+-1ENXAK1*QO,.*5"(;T',3EC
M:1D_O;.KH; @L1J2511*JKZ3P:6EZLP?X;.01=.HP:K,1AP_&T5%RA3!N]-/
M*AEV>AE&>F[!3'6Q@=,,\;.QVA V+5ULDA=$&AM<.M42#=/0@0B>^-+K@0C
M"*HR?:O=V!J/>BA)T1 "H7Z'S7ZHI3EY/=(K3=>/W=AU#=/,*C3M#'+W;*V?
M^\[Q(L?4JL^6#=K7'-KN/-J;+=JG3=JH;=JIS=HE8\BK#=NE+=N9=->M/=O_
M,@,$[1O;"/.T\++,9]I/">47"85/6CH5;<D2T^RO8.&Q^XH0REVS;%T4PET3
M9P,8RLT4XJ*;BJ&S%>&5E+,58MW5DMD3%]O,EFBR/DW=#^&P$_';)JO<@4G,
MY:U,S:S:-%/;*9@/73 LE?S-IAG.:MAC#RAD<JBU>2./NVW;]\W@EN2X+3R[
MZ7//E>L H#M%7>"YGDL&S.//F)L# 80(%%X!R#/A&8ZY)WZ?&YX\\J"Y(OX
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M*8;74_MR"*TFI:BT?%>\YGV K=8+7O7&E[N=6Q5W!Z5=]OH*N_OE;W_]^U\
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M=FNMM]Q*6RZYYYJ;+KK8YE!NN^SFL&Z\,^10+[WVUO_;;KWPZHNOO_G^"[#
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MC;T'^>[OG?:] O[_9(#_7S_X_P6#_U\A^/\E@?]? _C_H,'_1PG^/RSP_W&
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M6"(.W&!,]AE0(JMP-94(8];UF1[53TE8"6J650A>54'.9@L-ALFD!"SK%!M
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M4!AO]> K_O.;-VB-;">-F%N];"?=>R>]W^=:^^:O,.'>1,$WE;;:.5#:G$&
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MUVTF7738L!9&>!;U-*_FN^#I&1FQV#?^@ML.P-!/W7CECG L7H=H-M@L:GM
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M\9U:K5<HH_<7'KYF!K[W%R=K;6>W%0)J-!<ZM&%HPV%XXA]HH\/=\S7E\RW
M+.*>%2!7[NAPQNCLBM>B]FF[S"5^YN0G]0FGW D^1'_S7$KJE&FV3*HD8FIY
M_!F^S#F_3)H&8EKG59H10]I@?+HU0]:H55R\K$WX+(9"G66^OXR?C= !2[1
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M*&>,<T_/ AJCH W-GUP[6M*61E"G0<U&4GLGX;:H3XQR2V=NF\_:\.& +\Y
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M^EG#THL+4V0/0-PX_6&)D>N?W"L]K^BWK@#%3-P*-&G$.Y&Y"N)"K]N,5 0
MU+E$5YHMH/LYN_#%4_F,4;G%T=*+4ND,,)F-6*1#H\M%V/@"8JP3?: -900
MHFN--[23>H"--_2"9+03=(P,+N0'U!A'=3R-4:2Z!\!&4/0X>MR-:9R.<40=
M7_PZL0O(YJJALAN2ERF1_<H/A!3"Q&/(];LB 8P&[FN_L^LO_DJ3A-24AUE(
MNIN[6<"UO7.1OFO('\&OP#M)PDN$1-";AR3)*SN_QO^#R2ECO/&K29LL0IQ$
M0L[32<_C2=#+R23\29_4/)Z\2<J;!:K1AU98RGN +T0@ T$H T& 2JFDRJF,
MRJNL2D& KWI(A%9 RF]L)10ILQF9 7RP)$2HD1D0)6[T,X$*1DH2OK)D2SMQ
MAQJ9!TN:!3EKD1G(AUG1)AJ9L;#T(Z&$ELE[)66!LIF,/ '+$Y<<0HI\/P:,
M',J,-O_[00NL3 2<3,MT0,WDOQX,37+RS,[DS,UL0![,3-5,3=;$S-84S=>D
M01;D-1FT*%5S$1;XP!6$P13DS=VLS1;L3>"D3>$LSM\TSN \3MB,F5HCSN5\
MSM5T3>DL&HZ\$(>,3%0RPJ#_),KM)$);B[,E9!UPBYVKHL(J["ITPT+UU,)V
M(R4P+"MU*4/Y'$,S[(A\LZM]ZS?\_+<RB<.^NL<Y<0?!&L=6 *Q)/(I@S,2?
MD!-2%(I[-,0%+9-5Y D&C8H'A;@#C<0R(<5:E-"LR#A*I(H$!;F9&$42%<4-
M98M@7$7*$KE-U"R30PL3_= R\0I;Y HYZ;  &L=PS(M)S#G%@,O4@@HYL;EC
M3(UQG(66H\/% $5W[+G6NL=P3(Q]) TYN0?8&!/5F,?8 ,6OXXNAP4>FZ]*A
M$T>H:XT66\=W/+K5.-.J@X!Y+(X<[2T>]8TJ%0YX%*YJ9(^!5"X_S:&"7 _K
M/$A"_QW4(.Q(['1)B6Q)1HU,F3Q42(5,(X*;*;Q-;AE)C53(0K4UDR2\-H(O
M[4O41E4_*GI44Z4R4S5*5:6\PMS)[@1*5XW5GGS5H=1.66W56;W5#%M57EW5
M6;#+&9F:5 (<:H+'_APV%9N'P?RC>5#+W[,3?!BV>DJE9IV1C0F5N)D1%D $
M \/5:SO,,BF_Q42_4;U.4CU7[S)-T"S-Z8S.SP1"=GU7TCS-=W57=YW7.K/7
MV-S7=N57Z/17?>W7'6Q.@IW-YNQ ',E-$'3.Y&Q8AGW8@O5-AXW8X:18Y'S8
M?K78?Q78C>W8?C)7D&T[[M156\U5D_U)]Q $*/RVU_$VJ_\:-ZVZ'1EX@*X"
MB2Q4MXC80K$<JR\<JRN83Z"-JS.LS[R20_TLVI;@4;VZ*SM, 'ALT.^A0_))
M4J>06J!8DZ,(4P%!4 ^-T"]I.*K06@!9"ZA8T;2@Q0$ZNO2IB@RU+!/%N!SE
MQ9-XV[8PV\I2BU=$BSE)!!9]@!F]"K2MQ#*Y11H5$,(57*W3C"2%TKPPVPNZ
MTR%MC4G\N0<(QB=]#"=]1M:ZQW)4K<:X4[NXQJ_-1C:5NAI5.LSP KB$C\[%
MC#FI!YY+W3)=4X^+#=%=QM<H72L]7=F(4]08N7R$T]D5#M UCGX4KGKTT.#]
MK3>-#JM[WN:%@$!=@TW55$/=2$3_1=?L=4@!#-F7I+*+I,E(?4SR#:8; \GA
MVQ&&!+SX6LF*ZA)4C5_Q/=7YE5_&M-\FZU7][=:1/=G^]=;_#>"2!> !%F!8
M'9W]36 %GA5B12AC%9"];!%ZJ+QVJ+X8::G]K589N=8[2<L9P4M2(N#. U<#
M$=?' ]_R%545UEYY55=X;;. #4U\?>%UI==XM<P8SF& W6&.U>$>YF&/!6(?
M5LZ)-5@CEEB(/>**5>*+U=@B1F(GWM<H_F$J#N(9K$Y)W24#KM4#%F$NYF*S
M:9UO$\\HO*HIC-D'.+<T3K>;'1Z=93)]**MXFX>@K6.BO>,VS*ME?<2BK94)
M'9\'#L6K_Z65/Z90-,G:,N':VO5:,1D*J!!;^"#;RNW:JUC=3\'17%S;2B85
M2"S1%"4+  45J,4*NV7%M\A;JPCE3^G<K-ACP\7D5^[0Q#6@4EG'QO70QRT3
M9/1<J AD.U%2!<I<QHT,7WY$*M7ESE#E3U'2U=C34%&-4FE=OE!F.YE28E;>
MUKA=^+#FW1W=+?V4+Q5> Y%FUQ5$V !%;H: XMV-8K:3J'MGZ'7>Z'4Z>)Z,
MZ:W>3,WG8\GB[>UG$HDB?A[?<B79+K:VQ[0V1* =3$U4(,$2C@EHB$YA%HYH
M)2JQ#?/B!:8DC";H+Z95C^;HC_;? A[I@B;IC#YIE*X3?C G&?_I KJ$#WUX
M/1F1@7QXZ58"S!GI OW%:1F9@6=UI6%C+P_QAU*+,0<0')ON7Q(6$!-^5(I>
M8>]]ZAF>:A<>8@BD:M3,ZA;6:JL68J^NXJX&ZZ^V8K(.:R8FXB2&XK-^XB56
M:[=N:[ANXMD4:[HN:X#%8NO%WNO]F"T.Z8T6Z9(.;(]Q#W=0/:@D8]>!0C,V
M3RO<G?7$6=]Y3YZ5['CC63GN6;*Z;,K&[+*:;,OV[,P&[<Y>$3N6S_M$VCQ.
M0]5.[>PA"KZZPX6+;=B>;=EV.(L+4=R.N--SK+OM;5,^T=_V;?C)K 0@[M#J
M+!A%/<]:.=$:9LVM(",-H.B.(%X&4I?_<V[L/J#IKKDQ1=WN_F[O#F_P'F_Q
MKF=Y/N_E1=YY9E[T/J%[WFM]SLA]EFB\CN_ZGF_[QF?\WN_]8I3^UDB_[FN0
M]F>ICFKZ)O #%VBH)G !!^R.3FD(KY._GO &IW"3#O +CW -WW!G:05W0%86
MF8%.)$=G)3W3"<R:=*H&IB8O.,M0"1DC:Y&<:0^PT=892(<6'V$^$S<0#W%!
M<+'Z#?+[G=^F1N&!5O")%B:NMF$FK^L8QNJMCO(;;G(:KG*SOO*QQG(GSW(N
MW_(H_O*U3NNX1FLP?VNY-G,R#_/FW'(VM^NZN6_YCG,XU^(,=W ,%^P[?_#Y
MZ <O.!W484(R_R;/K"JWVT'/*V3CQW[/=2L>FZ7/TG9T2)<)HEWM_:QTU-[/
MIFWMVJ9M3M]T3_<KL,6+W)8XW48YWJXXX09NRUIU5;\XXQ;US=HLY18@YGZ@
MZ[YUZS9&[M[U[,[UY_9U!-KNZBYO\BYV8C]V8T]V9%]V9;>-]X;(.==O.9?V
M:(=O_JYVO<[VO/9O;@?P.K=P1DKP D?P(Q]W)*=S/!]P.U?WO^9P#@=W/8?W
M/)]W=J]P=[]W#N\9&;#@&W$ >&@]6KD'?G\1&8!D=TL$9)V!5A($<T O'.DQ
M@R<5&#>TFE9J.ID%>4!6<AAQVA-R<AURQBQR\35WDI=H%X9R'.YR&?\^>99?
M\AI^>2M7>2UW<YJ?>9N7>2E6<YU'<[8^\S%WV#:_^:#'^7;%]KP6=WO_]J1/
M]W6?CS%&G9:M !5 ZK^J\IR=*KR=0O>JQ[Y914\W1C_T2/_Z1W^KTZ;T2R][
MLJ^>3$_[3E_[3V][MC\LN#]UBIO[6=\+W4YUO ]NO6?UWB;N5W\,Y$;NNM>D
M6@\M8,=U7D<M7:?NR/UUQ^_UQV_\(Q5V9J_\9K=\S+]\S<_\W7KV"C_Z_+;V
M:1=]HR_WI8_WSW_(TZ?WII?W>E=ZV&=Z7,7W"'?]UE_]UY=]W#=9VN]]! -+
M01@(9)H!$ XD.#NH;?WI#4L$&MD:77$/%;%4:>(QY?_W%12)<1C1:=8'E59P
MOIENA:0&%?R-R?$?5_(O=W%/?YA'>2H7^BIG__5O>2FG<OBO>:*W_Z'/?_S?
M?PHL\Y_'6(  X&\6 ($$#18<F/#@0'\(#3I4"/%A0XJS(C*\:!'CPHX6/4H,
MF1'DR(\F19),>;(DRI4J6\)D*?/E3)<V81:DF#/D3H8]$_X4&-2AQYQ"C0)%
M>A0I4:9*EQIM&O6IU)U4KRJMFM1I5JQ<OT[M*A;L3B]=O @BXV4MV[-=NES1
M,2/'E1EV9SS R^+!7@0/$"3P"UAPX+^%!QLFK/COO7J(ZM5;C%APXK^6)U_.
M3'FSYLZ</WL.#7ITZ 2=3?O_1?U -6O+K5.[C@U[]FK9M6F;SAU;-VS=OFO_
M#@Y\N/#BQ(\;3XY\N?+FS)\;?W!<^F_IUFM?IYY=^_;NWK^#YY[=]';RV,^;
M3V]=O7CVZ-?#;Q__O?SZ].^GAV#?_0/]Y_N+%YZ  Q(XH'_9'7C=@0M:QZ!T
M#@+X8(,32E@A@/HQF."%$V+(880;9O@AA"-2*&*))%J(HHDI;BAAARZ:V*&,
M(-(XHXTUXGBCCCGRN*.//0+YHY!!$CFDD44B>:2221:)2"*(K &EDU!N%199
M55HUEI5;9GDE5%URB:687XZI%9EGFIFF5V&BN2:8;Y;I9IQ:PMDFG7-ZJ>:=
M=N8I_R>?;.K9YYZ! NHGH74>BF>A@QK:**./"AKIHI(BZJB73V&:J::;<MJI
MIY^"&JJHHY):JJFGHIJJJJNRVJJKG\YRSPP(T%JKK;:R,(,[@NCS*JOK.'#K
MK>L<Y"NJ5PA[ZSRE\N,%"\DF.\,57M!3K+&FMA,LM C(0ZFBH[HS:[(L=-'K
MJM;FA&Y!Z@+ KKM/O:M4O$C-:Y2Z$M&;U;W[ZMLO4_RN6U1)[0I<\$,$'UQ3
M3#0Q?%.Q T-L,+X1)RSQPQ:GBW' %7,\L<8(+^QPPR&3K+#)(Y\LLLHEH]SR
MRBFS_+++,=,,L\TSV\R1S#O7C+///-\,],\]"UTT3B -E?\TTDOKQ#1/3OL$
M-:1-)?IGI9!.FO75WEK]K9BSN*/#6FFM=5;9.G2APQ5TW7577GQI=IC<DLU=
MV62-/1:9W8==QC=I?XL6.."#"UXX;92]=IOBB3-N6^.X.3Y<;XM#5[ESEUN>
M.>:;:]YY=-.!SM]\UYE'>H&G"UCZ?.ZQOKKK^[V.7^RMPU[[:O[1_A_N"@:H
M(>J_ P^>[Q_RSJ+Q*R*O8H@A\KZ\A\[#J/R)TQ\O??74QY@]]$PNV3WWWWL?
M/OCCBU\^^>>;+^2444;YY!I>=QU_U?-;JC7\]&.]M?WRUZ^___?W#X#Y$R#7
M\%?  /)O@ D\H (-N#\'_F^!#T3_( 0).,$]72N#&MP@!SOHP0^",(0BS FR
MML4M=HUP5+.HA[B@Q0)$I/ IB)"!"6?PCE'1HX30DH$@8HBJ5EQ!6\GJP@4O
MU2E_M.)9.VR%F4I5KXS)"UY2C"(5\_4O?UDQ*@#3(A:#PL4K@O&+8J28QSIV
M,3-"D6AJ#!K(SEC&-[HQCFF4X\;@.,<[UI&.;<3C'O.(QS4.+6B -)H@"QG(
M0Q(2D8-<I"$3Z4A&*K*1D'RD)"L9R4NN3&E-V^33.!DU3VZEDZ+\)+XB6$$)
MFI*"JFS@*M?5#R],:VQJ,4M;U*:V'+3-;2WP3-TFT\M?"@9OD*';9_QFN&,2
M+IG(7.;A_R('N6=2#IJ/BR;E>'.<R7$NFY[;IC:[R<UO"D<[NK&/Z<K3'=4%
M[W?H_,_LVFF[W,'3G;)[Y^IV1QU[HB<1]/("/B.TSG0"]'3#&VAWK)<\[)'H
M132"4?.>Y]#H/?2@UYNH1"MJT!E!-*,+11]'T]?1CWHTI" =J4C#MSXIN<^"
MJ60E2QGHTB+"=*4OE6E,56I35-[TE#IM94UQZM.=MK2G0)UI3GE*TZ/"#U-5
M\R%3F^K4IT(UJDS51Q>4F*PK2/54L]#AMF; CQ#FHPLFI-456D$J)-+0A8CH
M1U9'A8\6)DL&3#1JIUH!+!-> 85:G6(6[=7%HG@QL( =[,$$6_]8PI82L7HT
M;&(/BT8_0K:/DB6C)2G)1\I>]F.8C>QF)ZO9SS[6LY8=[21+6UG38A*UI#TM
M:U/;VM6Z-K:PG:UJ:384F&ERE*$D)6]WZ]NEZ!:XO27J3^E:W* B58*S$ 1;
MFNL66L9E;7-Q&U[PLLMB$G-OV;V;8X:IW;@I,[S,'*]X2:,:Q#F3FJKQ@EES
M4@\O3#.^D;/F;[#97E;Y!E/P/4ZF]OL;_8(SP-[$G#CG.9YS(M@[F KHZ!I,
MSP<;&)[Z5$HB(!Q/"^/3/%YX"C_ZZ>'L3!A57@"/7DDUBQ))9\.8FL6(^^.%
M$.<$>S#6%#\CBM$6>4BC-]YQ?SIUXN/_?>$I7RA1D%=<XP>\6"D'G?&H.MR@
M>SQ%']Y+58V5Y 5KW6/$)47?5TU591!!62E2!E*1E;SE,X/TI.VC$G"[1#4W
MPQFY197S<8D[5*$:]\XR?7,HX]SF/@/ZSW;.,Z'IK.<Y#]K0A4XTH_&LZ$<;
ML:V2GC2E*VWI#E+5JL(BESK@XNDK?#K4H!ZUJ$M-ZE.;NM3OZ$<3CXB(<HP5
M5](2!#U:P0^-:&H@_&B%8]HQ TV/M1R(:#6HT%I#5",[U<E>MK)3O8ZUD@H1
MYH@U G+U#D3H0RI5Z\<LYN&%<@BQAO2H4ZJ>N#$Q,G:+Z?ZK8QOK;G4K%HN=
MG3=H[<A9C=7V_[4Q$ZV]^:U'>H<6X/T6^+]EFV^#ZSOA"%\X;17><(8?_.$2
MCSC%3YO;X5(-XQ?_+;KC'<9U?]SC':^SHQN=W*'Z@Y9D:PLMTQ9=ME'W 3)X
MP"[[ LSO^G*[-\>,9,CK\_+^O'#G3:]\_6(NI"2N'A0.52+H*[G.*5W,FM.O
M::*N%/\^!\#=I'"7/S7BX##9ZD_!>@+N&ZH6LS- HV-RI] NG;#3F#MF!Q7:
MTZ-B4M6]R?/I^MGK<W=F?5AWW&'[C[T39B5GY^]&<7N!,#7FZ\2=HM;3K_04
MJA_% ^#(&^6QY7M\]0>P'0!$%G*)XGY1)&?J])8_O%'&O#W]H+ >:/^V$=]C
M;".Q%R3TF:KP[ &4*=G7B/4Y<3V/RHP4DB(_I&I>7Z#Y+&CG'YKD)U]TR:L_
M?4B7'/I^UG[SMT_]ZYL<T=87/_C'+WWRH__\ZH_^I=OO_O?#/_Y(H2JUZV__
M^\>:!7-U53\2\8Y?XU\ 6ELK<-NU#$1:!6 "*J )L8 7')VH:$4_9!FP+6"L
M/8 [$& $E1M?@=S(O1N[?6#(M1N\C2 (%ES U=L)#EP*0IS#^5MFH6 ,KJ ,
MJF -PJ"]55P+ZN#$.5P.\N .^F 0]N 0 B$1_F F28UP_5;&<5P'.J'(/6$)
MAM_Z?5_ZI<E%+%<.G,7*F8U9H,TMU44NO4W_7_2-SIDASNV<,?%<T %=&[)A
M9@R=-!&=93Q@3B3=V#D3NU33'BH'[A6$/DS=V-5>NF".UG$3ASV''Q8$<; =
MV1$'Y@% TPV'.,W=(J[3)2+8@@E((X8')$JB.3V 'EX8>GAB>[!=A=T')-9#
M[ PB &B8)J*'?T B/XQ.X)&'[FT*+8;'B@4/)&9>05F'+P*814D'Y5&/,(Z*
MEN$8YST%[P4CIMS#@Y#>]2#CU3%(IA!C]0C?'W;>ZF&*,T)42;5BC2CBE\T(
MNYQ9'2Z>D&QCJB3?.Y;/\J74\WE?]V%?^>&C%58A%=ZC/MHC/?XC]PF:^45?
M0>ZC0?8C/TXA0B[D_T$Z) ;)7T1*Y$129$5:Y$5BI*DPI/EM8!5%80AZ( F"
MY$>*9$G>H W>&PV>Y$I"EA#^S NFY S*)$K"9$T2'$NZY!'FY$X:(4\6X4_J
M9$\*)5#ZI$YNG!(B)1,FY5$J95,>94B:( @:BD@^9$,VT$4@PK1L(<L]5W3)
M1=N\3<V!%QJ>8<Z1I=V4X1NZX5JJI>*@EQQ"DSJZHFV48QX^!1_N1N4H(B!>
M#M4!!PKQY7(88C8MF'&T(BWZ1B,J![Q41^@X6-I!IFG (GAPXB[*"R;:3BNR
M3BGF4S/N!R):V'K 8GZD&&@:F#^]';P0CW5@8W?(922>CB^B(C!NAX;XXO\]
M3-[8G9Z$8-Z7Z9CV<(AG+L^G#)GDC=Y31&.$M&*[(!1"M2,@ B=O9DIQ;MXR
M)LDXWIYNX@@Z@H\P.EGW/.>0&)]1P&-Y=H\\LIE JJ>?$615MF=";F0^*N2D
MK&= UB- 6F5^OJ=^RF=\^B-__N=^"J@&9F2!&NB!(FB"*NB"KHI_JE]'0J4(
MCB044J@41NB%=N!-QB1-:JA-XMM0VH2'JN2&LJ2(SF2):FA1JBB(KBA1LNB+
MNFB,!J6,MJA1)J%3WBA3ZFB.5NB$6BA)1B6 SJ<IS0(BB$US(>E9O-QTV<7;
M6!?<;$8:EJ64XEQ:LN65MB70Q:%ZS:'1/<4=?M[_,XEB7K:&<^QE(%Z=<2AB
M0?P7'FZ=4MR:UQ6'8EI.-6H**F+F@8$B+N8$XU4F>)"'G>Y>>PAJGU)8?72*
M+IY'H2+G?2PG(L+I>F18\=RB:O83:PYC=Y28CS'>=C#JYZ%8**)*-A)C-V:/
M@@BGC;UF05"G+)9*BZG(>(8*\#U(.WJ*DUG(IFY*=78C=H)(.>X(=RX)GWX*
M;H)9E(GG@MT(@/5>LUX(>KX/?M:GM-[GM%IKM6*K?6HKM6[KM79KMG)KN'JK
MN(+KN)IKN:+KMZHKN0;:@ 9H?[HGO,)GO-X4@]KKO>)KONKKOO(KISCH4GW*
M%08IAO:H24JHP1*LA7;H_\*R((DZK(FBY"!!+(HV[,0^+,..:(UJ+(S.:,=N
M+(UR[,=Z;,B2[,C<ELG>*&ZA+"@A9<+ZZ,LB+&/1ZY"622),R\J53<O!$AB"
M)5[,W%Z0X90*[5F:991BZ=%FZ3)M:=%Q*5PV[=,VCM,-F(!1[=06!R):;=4N
M1X&IQSCIZ=>6$]@R6('D:=B.XMG*$]J&YMI&V*22DRT6S]C*+8,15&TVIW'B
M;:E&)XXQ%*_N+8_E[6Z2JN 2;G.:ZNM9Y^$ZE+,R+CPJA;$V;N1"Z[J>*^6F
M*[MB;N5F[N5J;N=R[N=:;NANKNAZ+NF"+GZZ*\VJ[K_.+.M"9+_";NS*[NS2
M;O_MVJOK1MH1447,%NS  NG!^F[O F\88>R)7FS%%B]-_NX8(6_SCJC%0F_)
MCBS(4N_T6J_(8J_T9F_U;B\2WL3)LBR._JCPNBSOMEOKTNLLX(,6HL4L=6':
MN!S,]2R46BF5%JW][IR5)BW2\F]IG,;_.BW3"G"77I/69NT!&W "([!R<"U\
M>*WHJ%T$0^;<?D?9INT%LZW:1A@&;W![9)C;WD[OB+#@47 ) T_=(LC=#JX*
M5][?KJ;B_B8,5V?@LG -T_ -ZRWBRC#GN7#DFN</^_!YN@]*I>?IEN[H(O$1
M*[$1,['I.G$2-S$4/_$23W$4XV[J7K&\"JF#H@JQV>[_%X-Q&(OQ&)-QJ63Q
MF"C55 ;O^+(QS*ZQ&P]O^0YL\E+L\]+Q\;8QPMYQ]#JO\5IL]P*R]@HR]P[R
M]19R(!-R(ALRP\EQ'"^OS,YK)%/*0,02DN:LR]E2+C6I7HSE_0ZM)Q.M_O;O
M*.^O;;PE'!+P  =P*C_= BOP*[MR+%-M ]/R?83M+3^F"1.(!6<P!VOP+_MR
M,-\3A*$FA93.I>IR,A,("L=MX>)P"^MP"D?S--N8#:_P,UNS,U^SWU)S#/<P
M< 8Q$(NSDDRN%)LS%9^S%:MS%;-S.K<S.L/S.KOS/,?S.\MS/=/S/5\N%J.O
M)/.S/VOQ/V]Q/T]A&1OT03/5_QFO[CXB3%]!D4.?FU]Y)/D^,D5[W")5=!Z_
ML?G"\87N<8H><D@K,B(O<DF3]$F+M$FG-$K+:$UF=$=#\D #=)5<A%G,TB77
MTMI(ER;3'"]],OY^LBB7,BGW[](",-2R\BJOLM3BI2P[-2Q#]5,WYE1/HMA*
M,"\K,RY?M3!W<%<#<R]G\ <3,]R&:E:;=5FOIH4T<S:SM7'N<.)6\UO+]39K
M<UVW-5W?-0]W,S?']3?O=3B+E#<O2#GC<V'KLSTC=CXGMF$O]F$K]F,S-F0[
M=F13]F03M$!C=D!K]KMR]D+/M&<3%T*+]FC[BD*;]D%R=&IO]&H[LD5K=&N_
M=B/+]O]+;]%'-RQ+J_1(K_1NZW9OY_9OXW9P\_81SK9KO^QE@]] L 49,!=.
M*RD8XM(FRUQ/8Q?1 K5U]UQV#_5V(ZU1<X8J([52(S53EVE4F[=4GS=4US)5
M;S4H6O591V:"?>U7>S57T_=]UY,'[P=95\@QP_=_JS5:H[!=8[-;?W-#"79?
M_W5>,WB!X[6#JYY?*_B$)WB%\[6%ZS6%;QYA6W9C>[AD?WAEAWB'@WB)B[B)
MD_B)JWB*L^=F@W9F=_9I?[:,RW2-IRYIXWB.GPJ-P_CZJ39LP[1Q_WAQQS9M
MLS:1![G"]G'$#K=P^[:3 W>32_F33WF44_F5[PR2#WE,]SC_4%T$&<323>LL
M)L]%&$KWST+I=8/RFMNO4!,U=[^A=Z.R>(-WG9/IG6-3>C<'NSAB A2FG@,Z
MYZQW54-P?+NW5L,W5N,W6-<W[&CBHK?M6(^P?Y,P@)\U,PMX@S_X"L\U@E_X
MIV<XA&LZ@6\ZJ9LZ6\_U@J>ZAH<ZJ'/XB,,ZBL?ZBL\ZB]?ZK<MZKM.ZKMOZ
M0.ZSB_,XL"-WC _[BPO[C,^LCBO["+'?I04[L2-[M&_QE@OYD1LYD%.[DC]6
M2\ DE'M[E7\[EH>[E9/[N)L[N+^6EEN[<1>[GLP"/:"-)==2_)IYS 4M=N,[
MFY>EF\/YF[NAG)^RG=-Y4G,I>0<Z_W/P.7HKO +[)54_\ .<Z24ZH*;DLG4,
M(@J=CJ+;]\8S.J1[O%AW=3'W-Z7&K:5G-:8'>,J7^JC7<*?G&*C#]8*+^LRO
M/,V?NLVS/,[KO(B\.J_C^JX#?:\'_<\+?=$3_='[?-([7Y>W>]-+.],__;';
MN-1#?4$O^]5GU;.K;FD[_=1#^T)F>Y*+?=C7]H>*.[J??=J7.]JOO=J?N]NS
M/4FK.[:O^_E&?5+8;'.Y[YAG\OQRLM'FNYJK.;_[>[^WI9Q/TYJ&"F+&ACL8
MF66P%Z:L8IFJ"G*H2I^/:6*FBB3ZAKH$9F[@XM=Y3L,3>NE'O'Q;1R4"0"O\
M$]MEAR*N8O_PJ([B9ZHOLEAM7)GDPX=<3OY\^.+NW^5[V#[:Y7ZCFH<B*FH"
MX([N?>)Y:";)&[/)2S]MIK#=6G_-8W]"27C?]FVK>W_,5_/.WWSVYSSYBW_Y
MFWK/#[W2&SW[(_WZPW_[GW@1Q?_[RS_5X__75_W^Y[^QZW__ X0_  ,) A!8
M<.!!A H+,B3H,"'"B!(A&I1HD>+%BA4O=O3X$61(D2-)EC1Y$F5*E2M9MC2Y
M46/,C#,7RJQ)LZ%-ESL]PL3Y4"?0GSR#3KQY-.=0C$B%,DTXBR+4A5(;4GUH
M]6E4K5.W5NUZ]6O6@5+]425[5FS9M&@-LE7;=FU<N'/?UG5[5Z[_W;QXZ?+5
MVW=O8,"#_Q;V>UBPX<2("3-6W'AQ9,B3'U=V?%FRY<R8*7/6W'ES:-"C/Y?V
M?%JTZ=2H1WOE^MIU;+"P9\L6:WMI4J>YF^KV?95?CBYD!)'Q<AQY%R]7=#"_
MDF-&=.DS'K1XP.(!@NS9$VA'T)V[=_#?Q9</?YX\^O'KS7M'O]U]?/CSY=>G
M?]]^?OS[]?=_D. ^ +43\+_M"*SG(B\,7% [?2ZJ9SLO>"(0P 0NXJ? "C.4
M4*)$-$P JX&\^###_T($8,020;Q(Q?\229!$#?FY*,8'53RQQ1AS_$\E!0%\
MH$ $)=*G0""-+/+(5BYJY4<CA40(PB.E_^PH$2FMO+))()\LR$<L'^#0)2";
MM)!%,1_8DJ NS710(C.!!+.E,8'LJ,@7"TH$SK',O*A*)!^ P$T@ ?5ST"L-
M/1311!5=E-$K"SWR42,C%5322BF]]$]+,\6TT$XU]9333RL%U%-21Y725$@W
MS3155E<UM=177:6T55A%#15767,%5==>>?WU5E^#!7;788TM%EEADR56V5<1
M2021-:)]-EJC%+JV*6RMS9;;;;U=2EMPNQ7WVW#-'??<<M%=5]UVR7TW77C9
ME=?=>.V=]]YZ\=U7WW[I_3?>WXP2F+>!>SO8X(0!YG=A?_-M&&*?=I.88(H1
M+AACBQ7FB"B4-/_.N"B0E?J8Y)!+'MGDE%%>>6*56V:Y8I=CAOGBDU_N&.><
M==Z9YYY]_GGFFX,>NF:9@5;)9J(W/CKIHFE>>N00W\)MZMJLONWJN:B6FNNP
MM,YZ:M94(TWLLE<[FVRTQU[;[+3=9EOMMN%^6^ZZX[Z;;KSGWMONO/WF6^^^
MYW:ML-FN[9HVK!7_>O&J&S<:ZHEGZ4('+XA+S@OEE',..NBB>X Z&:J[CC[V
MU&O/]/143YWU]N ;C[_8_9M=]MIIOYW!^2C,_<".6AEP07>HI%#)#H$_OD#@
M-53^PAT3R',@#S?L",(8H4\S1AQCM!.A%'6<42(26=21?.?-)U,B[\__-Q)
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MM-JP5$K1D#B[E-S("$AS=$?'0IQV[]T6K"7IK<)*!SO;]#K?]":[4TZY,Y_
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M%S90&Y9A.>X]6P0^09%1.351*E92'35C(752.[8J*U7E+E7,_(\7+=9D.Y4
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M6WM%[KF]4P3_6[SY[M:EJZ^^GKI[].'AEY=/OO[V^]_QC]=/M+___P &*."
M!!9HX($()JC@@@PVZ."#$$8HX80.VI??A?MA>!Z%'';HH8(69BCBAO/%9V*)
M_RB&2***]/'7HH8OCACCBBZ>&.)[[0VWT7@[8M?C:S_*]EV0L?$XY)%&-K0C
M;4PNZ:20138)I911/EGEE%92J6667&+IY95@;OFEF&%V6>:89I*I9IILHNGF
MF7"N^::<<;99YYQVTJEGGGSBZ>>=@.[YIZ"!]EGHH(82JFBB>0*YVY*. @?I
ME)'R-FF4Z<EH8XTIZC?:%3*1(9-,77A1:A<Z7)%J#E?,X.H,#\ JPP,L/("
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M!)8'2+X_BTJYS1.74-N]]1,W!=.W3=NV+=/#+5S"S90U9=S&%5PQW3W)X=O
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M(LY+WO'RD5WK5@\CSW6* J>+E.B.UR4)7*!X*YA<^%%0@N%S+WL?"%\'7K"
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MI;:5_6AU:_O9ZG[XOU_^9(TK7?&?.<&"FO^?]O_^_V^P^@\ "9"PC(W8$/
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MP:J]RFH!K,$"*RRO,P1KP0S 'FMLK\DZ>VR!YOUP*K//'HOMM=IFR^VVUU;
M;04/@"ON S.8^X #Z:XK0Y3X+7B(@?S!B:"[TO97[[SWTHMOO_R*L<J"L>AK
MW@,(&.S P0H;_$###C\,<<023]QP_[[V<5$NQ1IOS+&\Y(DA \<BCPRQ@V)P
M\4 "#A_<,,L,M[QRS##/_#+#"-AK",H+'ZSNSC:OZW/0/_N\;WHA]PQTT@LC
MO?302C/<\[]<)/PTSTXS#?756O>+ ])86^WSUU6/[;'1/XN-MM9A#SW#._+(
M(\@\<B-"3SWU(')/>/F E8]W_/!#6#^ ]R-XX(#_[=;>2N$V=MH+([6W6R+I
M(UCAAUWG3V*+S7+NV@J[V_3..0">N7;9;4?XX7%]!14^:I]]]0Q62=X=X:=G
MM[EBF4<V"^^^;_[[[L /+WSQO1-_O/'!)W\9\\$WWUGQT%L7O?.4D8;9]=%C
MS_WVWFL/?O_VXG<?/OGC?W]^^>B;S_[Z[JL/?_K$S<\>_;SG,X.$@N#9A1?]
M]W^%' 0P@#,H(+I"Q@*;)0 !"U1- QFXF@=*,((4=& %(6C!#&)P@Q/4X +O
M<3>[A1"$B!!A"4EHPGJ@T&XG#"$+5>C"$<:PA25\X0K?8; %ZE!A"\PA#W_H
MPR!"4(@]'*(1BXA$(!Y1B4DD(A.#5D0%"FV*3J.B%:N(Q2MJ,8M<W*(7N_@S
ME?E,C&%T&AG/R# T'DR-*4NC&]?XQC;"<8YRK",;[QA'/-)1CVU4&1KK<;S&
MZ",1[K!C']WHQT,F<I&*;"0C'^G(2$)RDI*L)"4O:<E,8G*3FNS_)"<_Z<E0
M@G*4HBPE*4]IRE2B<I6J;"4K7^G*6,)REK*L)281D0A$K$&7N-2E/.A1"GK\
M,ICRF <QC0E,9)9"F<P,YC*#.0]@UB.:I9BF-*DYS7I4<Q[:S.8VK]E-;E:S
M;ML,9SBOB<YRCE.;]R!G.]N)#Q72(Y[XF&<]Z)FW>CP%*4CA2CX2 M"%"#2@
M!!VH02$2EHAL1",,7:A#*_(1B$(DHB9Y25YB<E&8G,2B+NDH1G<"TIZ(U!\\
M$9Q0>@(7L'2E*48Q"U/4\E*5&F2E+V6I5KJREIQ.)*=CZ6E;? K3GR+T+F^I
M2T6/BA>DQ@6I*?FH2&ORU)(&9:K8,8Q-_PBS'=U93W[MBU]7[5>:^GUUK,,1
M:UG/&E:TUB:M;%VK6ZE3G.J ]:UR-6M;X3I7O-J5KG$-WW40DSKN4$XM+77/
MO]:SH :5S6*+]5?1<$:PR)HL8 MR;(38U"0,M6A%).HLC#S;HC(<0D0G"NV(
M2OO9$.%H1C9J+6O=X:/8 DFV0HI1;6=;I=QNJ4F[M9"8LF2EX.H62V8J[IFT
MY([C%HE,RC4NGC#[W.BN"4]BHA.>ZJ2GZ^)I3Y#JKI\&Y2A"B0F\Y"W4I+[K
MW?1>BE*2\I0.$O6I][H75/(ME7WO2RM&<>I6L)*5?_O+JOX"V%3\_:^!N3 L
M7OEJP<1J,*^*]?\L'21K6="J<+,292UFZ2##WNJ6ASL,XG$=ZP')(M>YSO4P
M=2'-'(PUSX( P _(FJRQ_WJL9&ELXT#:IL6&P,'.J+8PD@E98_5!\9"//++R
M8 S)3.88>;@0LH:I3,HRJYG+KEQE+-/L<V:[HMA"!T8J*CEI7GL=F,^<-<]]
M[&AF3C/L//=FV(UG:F"+,YKK?&>RY0S(C6LSGMVLL!R\#6YRFP?=6)@WR*EE
M=92SW5\Q]VC3&4XP:FG%WI#2.3L#.LV":*FEU2+825].TJ1.3&+<1>JLHHXP
MD_[;8"M]:4'DV7$,NT+K6O$=R@UFU*;6ZO)^C3Q@*R_8Q!ZVL:=7F:W_*KMZ
MS*:>5]_'56B3]=G4CG:UIVWM;&-[V]+N]K75JE?>(2('^N.?_\X]0 'FH( G
MG@$"I=A!#EXPWO2>M[T]>&\(@E#'+^ZWO__M[WS(4#I)W*$/#;Y$)RH\X0QO
M8L.!*!R LZ<>0XNB$J489INQ1Q\9_Z+'.Q[F!4G':?68.,C'J/%_4WQA:$2.
M;0JI1HD#G!^&W*,;2_YO/NH\CC@?S<H;"<=$!MV0M"RZ+8\.R9Y[Q@M(KR4_
MV /SIB\R$>SQ B39,PM6BMR1&Y<ZUZMN]+![7>QD'[O9RX[VLZ>RE[O<92[7
M4,QCREV8R(P[W>=N]V<*$YA[AV8ZK?G-P />_YN$=Z?AS:E.;[:3G?1XISSC
M"<_'W].>^(SG4_2)%,SO\Y_ZZ&?G.5]0@C[DH EUB.@CDM"'JKZA$VT]1UR_
MDM?+_J)&Q2A3.6I[F@ FJB'5R4BG:E*J"K^I._4I6X+*EN3S5*C)ATM2G4^1
MTK>EJ$2E_4OZ4A+=>[2I,L%]][>_>]^+'_C"%TIA!J=JW$G/V]IF/[>_#?^U
MMC_^X;YK7<%]?_OW-:_YYRO_][]7]>=_V),\D795KN8=,(4/]00?/,9OHZ%8
M/%9C,H9C%&@Q3_=BLV!C8N ._K,D&'(A'():H)5:)'A:G55:(V@B)JA:KE4C
MK 6#+RA;23);-4B#M_]%)3E(7+S5)!7"6UTB7#H8A,[57$587,Q%A&4R74OH
M)M+5)MBE77P2A7\BA9'27>6E*.&EA>1U7H6B7MYU7I4B*O%%AO-57V>(7VE(
M8*-B*P'F7V[8AFMH8+8B+,4"+ SV8 Z68!4F8<K2+'_X+'^X818VB,WR88<(
M8HA(8B,&+A:PB.!B+I"88DJ# [E2( KR8C%V8Q*X@16XB3KR@)X1@?H",DK#
M9R[39*FHBJO(BJVX,5,&,; (BUIF95EFBUMV<F3F9[E89G5&:[.VB[^X:7]&
MC'T&9\!XC,-HC)I6C,+X9S+0!8,6-_1@:'5S-XFV-XLV.8%S.[VF.<:C5:G_
M!EB%\QWY8&E0 0_*Z(Q TP4+B%.55HZ")3A_4SF'XRZ#X6KS^&J)DQ2$=0]=
M@(S,N"ZVYFFY5H]8=3JE4VP%*&P,N9 -*6S()I'/0Y'$,Y$669'K!W_SQY'O
MUY'N!Y(;Z9$C&9(?27_]1X""0&YDL#]I\C_^TP57H ,#Q&XG]@#OIC#XII/R
MMI/UUI/Y5F_[)G-#292"1$/U@!L[A'!*^4-+"4$.!Y5/M'!1.94($(H H ]4
MV7 + D4'$W&CP7%!LW&M('.),$54-QKM\)7_-G(8^&^M,$6A^#-%"0"S\'$*
M4W4/X):>07-D=# NEY8U)W([AP +DG5Y9#!H.1IM_Z1TCT%QA%ESBBESC\DP
M:SF4< ET#]"8 ) F+Q9UH&0;'+>7_O:9C>0.1=D*E+29G-E(EBESJ5E)0SF:
MC5&:*C.;$F=UCB29CY&;C(1UCW25E*DR^L >D[1Q5\D>B?!*<OE(N\F9KIF!
M:2>=:C>=U4F=UVF=H,1VO/1V=N>=R$1-U,AW>==,R>1WYSEXV*2>X)1XY)2>
M?R=.[ZE.BU<*]&F?C5>?DE=/]'1/_7D4EI=Y3P$- OI2H4=Z!HJ@ _40&"%]
M"\IZJP>AL$<1%#51+5&AM?=]MJ>AW==[)>6A)P6BP[<7Q<=\,L53^*!\.U5[
M*VH77T&B"^H6TU=]2H5]X/]GHQL:?A9%4ASZ44XE?E*5$^5'5>=75>C7C;I#
MDB)9DDEJDDV:I .(?P 8I?]'I0&(DE<JI?I7I5-*@.&(.H(SC_S84O/PB0 C
M<ZM@@8Y%@8=PFPO"#Q/X(.[P#O#P#G4*#W?J-O @#_ P#])83+\D-X#:IXA0
M:(0ZJ(4:J(9J:(F*J(<Z-XSZJ(ZZJ))JJ/*@J)5ZJ9 ZJ9;:J)P:J9ZZJ9E*
MJ9J*J9TJJJ!:JI]ZJJMJJJVJJJX:JK":JK'ZJK5*J[<ZJ[E*JKMZJ-18JK[*
MJZ@:K*QJJ[HZJL<JK,A*K+@ZK++:K,7ZK,RJK,XZK=!:K9M*C7V:K7#S-GJ*
MIWO_2J=T^@[NT 5UV@Y=T"Z;2%D MPJ.T(F<*&.&T*;L$0MJ6@@^]C+N0*YR
MZ@[BVJ]SFJ=WNJ=[VJ=[*@A^^C8'VZ<'F[!_RK#<NK!^&K$-.[$0RZT4>[$6
M^[ *F[$<N[$.*[$="[(8^[$5Z[$A6[(B:[(CJ[$HZ[(&.[+P<+(P.[$R&[,S
M:[,UB[,?"[,-V[,7:[,^&[1 R[-#R[!&VZU%J[0(B[0_>[1+*[1'6[!!RZ=)
MVZU3*[57VZW@VHS!V&;0*(V%:D*)!E-](Q*#0SB1UFL/B3Q>VHV!Y6JLTU+X
M< 4"N8YIDS_M.!4+F!3NLH!["P\&U+7).+@/< 5Z$SF,_W:0HZ8=W^B0QO:X
MD0N1;'ML&;ELSI9LS9:YF'N13KJDGZNDH>NYHLNDI0NZ)BE_7S4+7;"2>')N
M_Q.3,RE -8DN"70PMON3N<N3N^N3O N4"""4="F\H+%"\,"4Q_N4R5MP2^24
M5>F\#_>\3;2:+X:91\25%>>572>6H<E%Q,F].^.<G'F6R3E%T&F70R.70K.:
M/W>70V-R<'2;-(>7MM$.@@EVB$E'"_)S9_2^=K0@9EES <Q&WCL:3$='JQF6
MF9D X:N<=32]1\<>L)ET)I=(JUF;?02=O<F8><E*!.P9C+2:?1E)MWG!GP2=
M#3QU]^N;MI%UH8C"D>3!CV&<W/]+23$L2*;$G(H4OAJ\PK:1G=@)Q#\LQ$%,
MQ*RTG6[G2W5G3'VZQ,54M4I,3'P7GL,DGN@9GNLI>%<LQ5M\GE7LQ5A,>/$I
M3N_4>&5,3Y1'>?T)H  J< )Z>00ZH DJQP=ZH Z:>@^*QQ'Z4!0Z>T=UH=X'
MR#<*53_:H3[!$R$:HL0W5,IG?#&Z.M:G5#+JHB6JHM7WR)$LR) L%QG*R8&<
M>W]1R$"!R.>'D*6,I$AZNJ9+NJG,RJNLI5::I5#ZREQ*R[-LR[*,RP)8?\F6
M:F@+%"Y*6$E13^X!K_SA",-;E+, )C.6+X=@C31T#R 4'M&,"'\KS%9A%(JC
M%OVHS=W_S,W?C%/@O,WA3,[C;,[>7,[H?,[BK,[MS,[OG,[PO,[Q3,_S;,_N
M7,_X?,_RK,_]S,__G,\ O<\!3= #;=#^7- (?= "K= -S= /G= 0O= 13=$#
M'3DMU3IZ\[=XLT+T0#? .@]Z6K=<P,S]$0OSBLSL$6-P"B!0]C-7T*O<5#<>
M;3<T34+1?$\XC3?AL=/W4,T\G6@_[=-!O=%$#=0\7=1(?=0^G=1,O=1"W=-0
M;=1#K=14[=16+=55'=5-G=57O=5/S=5A#=9CC=5B7=9D_=5GK=9IS=93W=9:
M[=9Q#==S[=5R7==TW=51'=1[_=1\/=34K-,Z7=/U0 _T4+@!_WDP,S!H@.JK
M8[N 9<L=:'NDIC:YD-N0I?-HB*$Z^WB.<UNWB*V.9@8ZH4VXRWBXD+,WN/8=
MBYNVJ6;9G&NYE2VYE'NYFVO;G5O;N*VYG:O*H^O;O0W<K?S;PAW<&SD+5] %
M_>.Z+YG<,GD%-6E YV*[#X"[&\0:O8O=OZN[V1V\*>W=,':42:F\XXV\RVO>
M4@F]Z:V5ZPU$-MP82'2].]-#T)G 1J2]6(3 0[/#Y4N^6(1U09.^)->_[;LS
M _XS\<L>]>N7!C.8^)LRT-D8N0E'WUW #LY'[FW =83A%L[ 0J>9'$QT(4Y)
M$4Q)T"F<>@EUL;2:3+=(#<Y([LU(M_]YXC&>XA7<=8]TPLVIPH=$X@\ X1+<
M2##^=6!92?E]2CF<PK;!PX<DY$/LY$4,Y4\NY41\Q&SGQ$S\Q'@'Q>;)Y7KG
MY>5)Q5.\Y5_N3. )GW]W>/5I>/!DQOJ)QOPI<&NL3_X9H'7^3P3J>7%,QW,L
MQW:\R J5QX&^4'P<>X6.R<^W49GL$J%,R$'QH4)Z4N)7HHU<R8?.HBDJR2E5
MR9?\?!J%>RQZ>QZ5Z)_,4=IGZJ#,>Y!.I*0\:JX\W*Y>W*\NZUV5RUBZI;>L
MR[8.R[=>Z]5F@..XV0DHIN.<%.U$S/9:TBPM+\X<S:U3MJK=-_GX-X=C.9:#
M.NGWZ]DNCMK_CNW;[NW=#NY'&N[<+N[E3N[G_NWFGN[H/N[K[N[M#N_J'N_L
M+N_U3N_W_N[VGN_X/N_[[N_]#O#Z'O#\+O %3_#W#EBMUAWEV-G%[D)U$ZB"
M\-DWB0,D[8G)_J[G(0;F$&?N(#>$3=@]?6L&*>WTN&O5[LNBAO(JG_*!Y?(K
M__(M#_,S+_,US_(W'_,X3_,Z;_,Y[_,[__,]#_1#+_1%S_-''_1(3_1*;_1)
M[_1+G_2#48YR>Q3W<-B;!M-_*IZ&)D+A\=A\$]FL-MFO3?:S7?;AV&M?BK:Z
MQFBPEM%U>[>B/2^@78PS( C8_&FTHVO5+NX*6;D8"?@:6?:R7=FZ_PW;@9_;
ML7WX@K]5L>[XQ WYL![YLS[YV';<[^6ZKPN3S@W=YX*3U&TP&G3=VNV[VTWZ
M00E(%*[ZGB%P+41PY W[!\>\L\_>T8O>"0"8=%F]203A+^::]5U$+$R4U:O?
M5<??M@' 0O/?Z,L>612^+$S@!JZ^_J;@[OO=(Z=&+@R9*C.]$B[ <;3A-F>5
MR!QU!PSB:.3AC#1T*M/CD&3BCD26PSO!2J[#WNW^R?QRBN3=+^Q'.WQUM@$0
MK1(\&%C0"P"$"1,29*A/8<*"# L^!#"+XD6%LR)NE-AQHT6*'@DFNNB%8T2'
M%$^*7-F2Y4N7,6'.E%F3YDV;.7'NU-F3Y_]/GT%%(DJ$:(U1HD;ES2LU;RD\
MITRC-EU*=1[44O*P:I5JM12]IE^K@F5*]FM8>O+ KBU5;QY8MW#?MIU7CZ[=
M>_3NE<J[MZ]>P'_QU<-';_#A>X/S):ZW.%_C>X\=0Y8<F3)E:(ZAZ8N\.;-G
M?:!%A\XWVG1HU*=-\_/,.C1KV-!BSY9=FS;M?K5SL]YM&UIOX/IXZQ;^VW@_
M?;F1*T_^N_ERY\R1^TNNSQ^_Z=BM:[^>W3N_Z^'!;U]>'#GL?.C5RT[/GK=Y
M^.OY%9\/FW[[\\[?[]??/___^*+S[SGXI!,0.@0)-+ ?['YKL#ORP)-0/'_Z
MJ7 6"_N9Q1\ ./3_,"$.$0JQ0Q!+%-%$$D]4,4461W01Q1=7C+%%&&N4T48:
M;]0Q1QYG]!'''W<,LD<@BQ3RHA$52A)%)9%TDJ(E5VP2RB<?BK)'D/S9\$)_
M+NR'00S!Y&<^!N>;11]]\CDSS5;R8=/-?-K,!Q\YX\SGSE;03$_/,\T<4Y]9
ML.,GS$$SQ)#++C?L,,LLC23R2$@?E71(2AVM--)+)[5T4TPYU;134#\5-5-2
M/2TUU%-'-7555%E5M5587QV541$9[5+#6PD-M#X]Y<1GSL$0N>>>>A"IIQYZ
M$*&'GGD0F<<I9YUB5MIGU:K666:5S98>9(TE%I_$(OL5GS33Y#50, W-_]5#
M6A>5L=%:WY6W17C=I7=>%^O5$E\0]?67WWCO%3A?@.TE>.!^"]X7X8 /7OCA
M=B%N.&**)[;8X(HQOEABC1=EM]://>Z88Y(SUI+=7+\<=#XW\<$'@0<<> !F
MFF.>^>9UHK(VVV*+=9E.-P$=LU ,M\1U9).3WEAIC%'>T&BH548WN3_7M'-.
M7X$5%UQA!;FBBRYFF&%F0PH1HQ!##!%#[!FZ@$<0>!!Q>>MQL88SSS3[I'K,
M,#54%]&2EQ8<Z<$#)WSDA!DV.'&'&7>\X<<7AWQR65.UW-7+8\V\<LP[U]SS
M21/YN@LRO##]]"Z\ /L*':Y@^W46'HA]]ID10/\@ =MSMQUWW7?/G??;?Q?>
M=^*#+QYXY(<W/GABC3W6VYZ?KZ?Y8WNF7OKKK8]>>^>YKQYZY]^9&7?R@R__
M?/-I1G_\]-EW/_CW<8]???KGMQ]^_.7/O_[][]?_9OP!\'_\ V !:W9  R80
M@0M48 ,9^$ '1A""$Y1@!2D(LX$@,(,%W&#-.GBS#880A"/$( D94D(4GE"%
M(DPA"U=H0A?&$(8S;"$-7QB1$N)0)#F\(5!\*!0@_E"(023B$(U81"0>48E)
M9.(2G=A$*#Y1BE&DXA1GDI2C'*4H:ZA*5* "#ZZ \8M<><I4TE(6M*2Q+%T<
MBQK%PA:YR,4NR,*+7OC_$A@\_B4OAS$,8?QX&#].9C&*L8P@"WG(TFA&D9_A
M3&E(XQE',E*2D:2D:E)SR=9D$I.NJ<UK?'.;3X9R.*/T#7"(PQ\ ,><]"U+0
M@5I)G>DT!T*SY$XMO;,=\:B2/:]QTR[=\TL \8<?[:F/; )4S& .2)BV(>8I
M!Z3+!*&R0,]T)2L7U" &Y:8[$F)0A<)CH4%QJ!\DVEPY06?.SZ63<^I$YSK=
M.24K50F>\V12/:5D3Q;1\Y[[G!7($K4N1.$JH(?RFY<&"E"!'NUDDI.4/O.)
MSRM%5)X0G2@_)4HEC,8SHPZ]J$8]RM&*/M2B(>TH2#=*T9..-*4B96E)4?K1
M_Y>:%*8JG6E+27K3E;J4IC+E:4Q]NM.?VA1*%#L9U%(F)C'YR4Q\TM-\S-54
MIJ));[NB6KJLFE"CBNQAY^0J.[OJSG:&]:MB]6I9P3K6L?Z+7EKR6U+M]#*;
MT6P&<7M+LY:5K.GYS&5X$QK?_J90IAE.L($E;.&,>E O675E2=U;7X56MK.E
M30Q5^U.9A*;8OA'TL+AZ6L@&:UC0'NZSHHU8Y+9*N=,R-+6K56OC4*LOM)J5
MK&>5;6QI>]O9SJ@?B+B"ZDIW.M.EK@NM:]T,7,<VV267=LK3'?":J[SD'0^Z
MTY5N=9D7O>5%-[O3+9_ONIL^](47O.,5;WG)2[_RL?\OO?UCK_[<R[_W^@^^
M\Y5O?0-(0/R^SX+[O2!__=M? /]7P %.H0<3^,$"VU"&-63P"QN\8 ='&,(3
M5G"%:ZA#CO!0A!CNB(:M6$40?UC$(2;QB$U<8A2?6,4I9O&*72P3+")EBV+T
MXE7D\0X;CQ$J\B"C/*RBXQS;V"MF2<M:YN*6.=;E+FWAUAW]8D<]$J:/A0%D
ME?]X9<5@^3*&K$R7MXQ(S"02DF-^9)DM>69,IEDTG&1S)D'Y9E$:AY3)I/,T
M4ZE,:B;(FM6$!BRC0QY ;[,[_6%S+X?)2VDF&L]U5G1^9M-,^3B3T8LF4*,#
M-&D]'\B6$1*/9L5IV]R"6M3_M24U;D==4YT*%=4X775.60W/L,)6G3T%:JU5
M3>M;!S75NWZUKGMM:UZ[6MBM)C:N@UUL7P_;V+_.-;"9?>QE*SO9R':VM*L]
M,*)J=;/;!NC)_JEMU)XZU*4>MZG)+6YTGUO=YF:WCYY6T)75YT[CXMJPBA6N
M.6$-354M%. 4-5J %Y:TH0TXR+3M-&]C%:'<1JQ O5W4A19\X!.7>,4%7G'3
MMC;C"M/X:SFNL'2W.^3E)OG(7=4/+_36';\%KG!;EP/7'5=LRJ4Y<VU>O.=:
M5[L[I^YV?7<]GP>=Y]+]+OJ\>U[S)AWI[1NO>O>WWOBVE[Y2MV_4K3[UJ^LW
MO_<=_W#7">QUL']=[&%O(()5:& -6EC":J?P@]G^=K?'?>UNYW#=>[CAN[]8
M[RWF^][]WG? _UWP@2?\X%T<8RT:!8PXIC&->0SDQM\XR&#T2E>(K):O'%G)
M2%YR7YSL9#SR4?1:!N1C")GETT.&D%[F\I>[G!E$?J:29DY-)-5\>S3GOLV>
MA'/OXQR;.D/3SI<FOJ7WG.D[T_*6@W:TH9TO'V)&'_K01S0PCTF?W\?Y/[KA
MOO%=:6GO([^5V>2TA#P-@'%^:-TE7[_)V__^VT:;VLVF/[2G+7_\WU__U\X_
M__=?_V<+0&L#P &T/_\[0 *</P-,P/YCP/];0 @40 64P/\&C,",8C^1@S\,
MW$#WRT /Y$ -[$ 0G!642:QX Q3A0$&I&AITZ3>'^[?2\CB*NS@:)+@:)"W/
M@D&#@Y@<M$$?G,$?M+@@#*R-4QS6^C@C[#C54L+5$D$G#$$H_$#003F5^ZUW
M0!W5>;F8>QV:6RZ<N[GER3FAZ[FA&\.?PZXR3$/NVJZB6SJE>T,W;#HY7!^J
MJ\.LLT.LR\.JT\,#&B"M([NQ"T1 '$1!+,2R.S!$3#NY:[NY:T1&?$2X<\1(
MI#"[PSM+'*%*-+S"VT1-[$1._$1/#$50'$6_0SPL8B.I8*,PDCP:"XNI,*,T
M,K(XH@LYNJ,Z>C)<U(OIF3)>'#W_*I,R*PO&0 *SUBO&SN RV8,],9L]2:H]
MT["]W,.]3=*D3JK&W;/&[/,]4 H.Y3B.XJ,T5)*TX1.^/9NE2K-&Y^,E3U)'
M=%Q'7QHF^XA'0CNF; PE4YHS<0R_<\2T<>0SZ% ^\ "G\_N0$2S()Y3"*!S!
M"J3 !V1(!+3 "2Q AW3 AYQ(B%Q(B<S(B-Q(C.3(AM3(C@S)C_3(B@3)D13)
MA#Q(@TQ)ED1(EUS)EU1)F=0<6_&8ACNLB#,9QKE!(01"G^Q)H.1)H1Q"HOS)
MH?S)(G2M)41"I3S")&3*F8S)EH1)JL01E$N=E3,==U =KARN*X YXV(;&>C"
M!& ![>H=_[0,0S!40YTC0^$!.K8T0[DTNO$Z.CB\RS@T+Z=[+ZCCPSO\2[\,
MS#W\0ZXK3#\T1,0D1,5,3,:L(+-[S$3DH$F<S$6D3$FL3,R\S+7+1 _KS!T2
M1= D1=$,3=(<3=,L3=1L(E.<,3):HZN8/%;T,2&#Q36"(UJ\S;CH/"C;33WJ
M16#\S5\,SBDCO3]2!F$T1M8[1MD[QMC3##.#1FF,QC.[1NKT#7>L3G>,SDLB
MQMB+3GBLQWN4,_'L#>#KQW_<QUY*#4Y23T.CQD*[3O>,ONK[3FWLOE*R1WO\
M1GX$/W#T1UG:M$[+$'(:T*F,RJHL4 2E2 6]R)-LT)(DR06U2/\)-<D'1<D(
MI= +A5 &K5 'S5 +W5 /[5 0'5$)/%"I/%$335$#7=$$5=$6!9+6TD&C+,J@
MI-&CK-$9S5$<W=$;[5&"2TH@E<&F9$(BA4HA#5(49=$D?=%(X0>P 2XOV$KA
MRL*O%!N9&TO:,4NS!,.T5,LO_-*Y=$OI@DLQ#=.V;$,T9<.\7%.\W$OT>CH\
M',PXG5/ E-/#O-,%.LS%W-/&[%,^[3K(5$3)%%1(S,Q"7:&#H(A6,%3+/%1'
MQ<2\\\P,^\S3K-34!$TO((F$X >3N%1+_51/#=4@6DVCR(HQ>@>MB$VL0"-6
M?:.S6 O,8XO<G-7-X\T\VD5?),Y@]$W_8<0'94!.UPM6Y$S&YSPS9M1.Z416
M926S2=H,YDQ.U.NC/0).7O7-:9W6X PS<EDS-ZO'\F2E9>*,1KH'??@5<C77
M<EV,=#U7=?T5U<!.;)Q/;]4^_,3'.3./?.S/.Q._51(0Y<.E@.02]"/0)2U8
M%S58)251#%58#9W0AEU8A_W0B!71B>50BPW1BV58B858CGU8C]W8CQW)@QW9
MA"U9)D78DR79E+64(M51'W59&XU9F)U9'I79FJ79BT-2IQQ2(UW*I_Q9G@7:
M<Y(UE"U:E9655M"!U&FYKJ12L'P=+%6NLCS++JU:,'6N,HW+Y"'3MNQ:,U73
MY$G3L&53LE4Z_S<]V_1I!8Q86[9%""^ GWJX"'V(KT2]B':8'TU]B%F@TSSM
M6P/24S\-W '+6X5(!,$]7+ +5(P85,9]5$;%H+I5B$753 B+V[9%",W$""]X
M.\M]"'YX(7=8V\V5U ZCU-(5BLM%B'J B<A-B$[="+6]"'=@"2]("0!PB=!E
MVWHP'8;(5'YX"'WHB,Y5B,_UB=Q=V]W=W('P7> 552/ZW=0%@.*]B>'=5)QH
M78AP7E#=WIL@U35PQ2YRHR([BU8=7V:1Q5?-O%JD(]#SQ6IUWUYE#-/[5?D=
MQBJCW^3,7]=+QD5:1F+-/>A,5@$.X$0ZI-43UOJELCQ:8#WZO+RX1?];7#+.
MH]4DFZ,F8U_!T#(U:[-^11#KA*3(,&#5&^%!"N%V=21W3=?-2&'W; WY_"7@
MJ]?QG%?RM,_@X,]]'3\=OB9MLJ6 =4$223^C-=DA7EDCCC^*'4"K76*T1 2'
MJ@>KC=PKL5IZ6#4FOF+;<>)F0P0LOF)4>]LN1;:J182.ZF(SUATR?I(SIF*,
M;:D96&,F+H=>ZV*4XN*TK.*,K=@VUM@D#EF:.MH0@>.T=)2J[8).$>0Q)A4[
M1F0$.!)&OF(M!F0BEN0CIN1^$EJ;?=F;W62+>.3<41HP3DO"\N3>(>/ 6F1$
M7AI2MMI(UF17SF2;U=F6#5I:EN6>;<)*GF3_'+D'KF3:*?7*IV6;+)6=J>72
M1\;:J\U:9?9:K5UFL!4>L2U;:89#M*7#]='<.JU>A)A;!  )O<5#PDV(O:W3
M_-'FZ'V(>O!#<V;;NZV9<[Z(U2W$=TZ(> :@>?Y<=YYGA:CGFEGGZ#7<F_%G
MMD4@@;[<"-/GBYA<QQV)BP"A<$8(A;8AS>7<BRC>V'V(B+ZPN\/>T35=SNR(
MDA@(C)A>@PAICVA;?7A=G'AHU54B<R9IFF!I %C=%+-=A5B)@H[>*GKIG>#I
MFL!>A.!>H=;>E_!>5"1?L7!-I"8R\<4\6JW%WL167KTR0SI@TR-APJ!?U,-?
M!-9?16I._F7691UK_V:M).=D)!&^ZEQ=:^#\H_>EUL'8(\"(:\/((R:;H_1%
MWZ?&S<UKB\[CBU(HO68LI>98SU]I#"R3UN&L,OEM;'!Q#!,6%Q2>;+'FUDBK
M3\P&3QO63\X^ON? IL\V$(#TIG$24/4K8M2V9-76Y1T!65RK6NR]R#?NTAD8
M$=AVMMMN2'J(XHP-9;04XRY-XP&$XB[%XV2KVG;H8YDJAZJ5 0#<[:KUJ2YM
M!U0N98RJ[MPQ;C[.XXYU[3Z>D8ZD9.3^JD(^Y"[U@B&IVAF E-D>Y/:#[CMF
M[=26[]7.Y5N>Y9V$99S5;R&LVG7P4=_NG5$^;\-1;\%I;[1\98R!;[2D!_\%
MYV3^?G#\/E(*]]E:KO"=M>5)(=KZ]L#=75HL_&4M?)T9&.8MI=I51F8O_=IF
M9F9G;O$QC&:[G&8:U\LY;!]LUD-SGMMU'N<\9&D?MU-S;N<[A5YT+B!S[N@'
MNFB$WF< 8G*V5?*986F GB"YE2 H;_*9EJ!$J(<S25U^MN>&1KN9 >HF!R&@
MSFA$3>C'98CC58C9=2&;3HC@;;")KDR>7F<U%Z$WUW+7G51 9XB+2 01,G+B
M%72*4.F8\ )#9]N3QH@D\FF<6-L6F_.@%HDDAPEO5@@KDG29R&F$'FI1)^J(
M\%ZT"%_9!-]4[(KR18NYD-5:S<4,SM;2LU_$MFK_Q[YUK29A[O3J9U5&8!<S
MLD;6]50-1^H,TNAJ90?6JQZD6[]UQ2X,7'1@OY[@:K]@;)_%\U5?OJ[@O[Y%
M>CAKWB-LUTB,NG:+!YZ'#,96JDY@7E^]R';.%-[6#6[ARY[7S+97?24^SU:.
M![&E/@/X?_4F%_PW^CYX^Y[OD_5N6_/DY"[  &=EB71X5$-PZQ;1B,\=X$Y+
MX9X_XH[O:/-D*990!N^=AT_ =JC:*G:IZ4X1[,Z=1 V1ET< [=;C[=YCFR]1
MA$=(4LZ4\M:45<Z=CJ^4-2Z'2.Z<DM>=FD]9#M_Y#G]Z4)MP"\_O_:YZ"(?9
MG@?EJAWPH#=EPUIC&6CE_R%,^NR6\ @_>ZO7\ N?>@R7^@QO^UO&G*9/^!&A
MAUX.\:[L@J^4.;$Q\38,^B56<<%_<<)W<<,/4QFORQI??+-MNAROKQU_+S,'
M@+?%VXL(<CKE:?;*<H0@Z)">("I'7- ?] NZ\M&GB"H?,--/H#YOZ05:7 C"
MB 2;_;-[ (R@:1CB_#VWL,GW<T(WH3N71$F'7-%]1(Z>3+L;]$ML=-$EW9B0
MZ3AG"'^&:9_P=.I=6^JW(DN_74PO"4UOZ"BR?I<0?]J%=%(__]'T3%/OBE6L
MO#9B]<H37\VS8 B>]<76,F;O]677_Z\N8/_]?X" EN]>/FCZ!!I,>'"APH8,
M'_\ZC'BPX$2#!.L-S(?Q'CZ,]3H.!/EQ(TB.&S5J[*B2'CYZ]URZ+/6RGLR8
M+^_5O$F/YDMZI7S.^RDO*%"A1$L1G>>SWCR>-F.V?-E1ZLB4&!$RY)=0J]9^
M^K1JI,ET:=-Y.G5.95F/JLJJ!-]2Q!<W+L2ZT+0>Q'MWZUY^^;CV#0QXL.#"
MA E[[?H56F+&^OHY5@RY,>7%E2<_AN:/G]?-G3GK\QR:WV9__4S/\@= -6L
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MM]C $T3P1Y3101';!3&+U"%5V$)$!S=XPA[&HUVJW) ^1A++ABPDE[>LQL)
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M$Z-I@O'UPH.=6 X#'Y\I__3"C.!+_6,VGRK/)Z41 <IE[!L?_<57/_B71&3
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MJ]-X:+GN : 5S>(5?N$(C=%TJ-'Y ;W\F2*E&VXM+;NOB[H^/J%#KM(N;>1
MGN2IF^0B7?_3-*V*I\C1:S)1!=>'FVMMR)CE,Z*,XBLH+\4IU'/7E&S9E%WF
MFM(W4PW6\[O6#ZS6;?[4;)[6<-[FEUWG-B77<6W;B[WGN*W8?7[;?HYXNHTK
M@ZYW>IG)&_OG?![H@-[HB^[HBA[IC/[HE"[IAP?7=EW;=KZEEC[)0LF3DTWF
MHA[JI!Z4HNW&LYWJJ+[JI][J:?SJ:PSKK!WKM#[KMA['L*WJ3XGKK"[K%08X
M>#[IG7[)A[[;>-7;P/W;A/[)X6,^[Z-^QCW*B/EBBMD/9%! CPE SBU _*=
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M>R/S<TLW>[^XM"/_D\NZ;#_VT[__LS](2I#]T\M+6C,<W#(=_^PD WD41+-
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MY+FC_^5M&#M&7H.R8RDTZ((>J!A]&!II'CX6B>>)GCWF8^G5$8CNR3\.Y*<
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MW_@>W.#V23A^LZA'#NZ7O_WU[W\!'& !#XA !3+0@1!DX8E1[! ,'K&7+08
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MXH(K6]U+7^*Q=GH<<U> 1:NSTIYV\(,%6N$=FWC"*KZOB'UMWQ6/^,4'7L"
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M^6692'8H8XAIGK@FFFJ^J5^<<L[9&R*)(+(&GG;B6<H\??XY#SSRO#,H/.[
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MA5QXA0<(AF$HAG(2;?Z$)Y1B;6FH;:AB;9?R4/_R\&X"%V_UQF_6<E+#$E,
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M.&XRC9X;_ZCIO:'GBYZCN7Y+IE/'O]$%QN7KNB$#%FDYG^\;P 7YS#&VJX\
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MLL>K.=352E1L^:TN -5A$5,$6#VT2B\@?:PFU0JAY"_F@JE"A2]/%0O5:1\
MDU17K1=()$HGO=5Y:JZ-/-*RJ]6M((>%Y*U6M=7#XLO=.]5DY9N7A)KL:9\L
MC4G=RM*U-)WGJCP$&+MX$@0GG=7)"[?*ZX+(<XJ@X;S!6];5FE6:9->>U/\<
MI(1'=!T5SUO+K^0;49$';^4HQ6/*I:028P4+>:#*@?7*F@2+>U58^>17S!,5
M=76:9B4NMKJ"K92<QQ-75]U6(PVNB#S5*U42?X6;:+6[K]C6ILB*DX2NLA"O
M]3%5=CQ2(<75'HW$>8O&P=19GNT?Y-N7Q$RPY6M,QBQ:"3/0R8Q,REQ:I6W:
M[,N@S-0^[PLQSJ3#$8L)FQ"(I#B_TVRQ*U _U70_%H"*JGC-W3Q;M$U;M5U;
MMFU;MWU;W Q ):*'!<RR![S;XCS.-&O./J20OM6V$;04$L0'%FDGPVV1[90S
M$U%/&V70$>DF_>S!6I,3%5W/9F-<R4W$($$N,K3_7#SA)@RE+B<)W4PK0U Q
M"%9A0\I=71^DS\D-W<V=M0Y%PP%U0J05T,<\6MTM( 15PV4;W2CDO%^*W1\4
M3QELM?U<-/^,3R%QW5,:%2=9B#%A$X=P0^L5/Q JMF/#B6!+-CQ,DA,Y-$EK
MI0F9T4<;-3F[)09%Q$"1UYI%TINU-YJ]V?>MW_DMTGM+4DC4WYU=TDG<W_@-
M8,!<.@ 6S)Z5Q)'3.(]1*@5NN 7N*08V4_\EN@26X#I=4SL]X/XUX GFX'Z3
M6;*X5 T>8:(+6;$@K '^7YQE-_O%7P'^6'SK*WAU85+!1X]M81C&81V^WQQ^
MMW)]O(151*7\DR%&6"*&_UB-W5=KTAPE'CPF?N*'7>(H=N(I1IXFGE<DKN(C
M[A0C[F*!W6(=%6*'%6,RAKPD/N,LYN*(76,TYN$=IN$>AN,WCF,ZGF,>3>$.
MWF"',C[^ =I9&5I ]I+%'.0"*F3+;-JD3>1#GKZGA8FH%;'.G%JL!;])7HEY
MR &N-<WR"ZS 8C_W6TVRM0JX'652+F53/F543F557N7\ZDT!7(,^N0=$R WB
M4 X)/$Y',1!R\EL*F8]UDD[!O<[J_*;J+$'SK!-X<EQE!MU%?-W2C<]F^Q'6
M=685G695"C71?=TG:40S]!W@]5UX41_!Z^;?[31K(N<TO%UUWMW<->0/I5Y#
MOO_==X[G U6FWB508G+F_!S#9G;>:?Y/VFUG#[7>$"51[#WH[3T3 ]UF9)XS
M&=TV\Z7102,1]3W$I<S1( X5.79CCMYHC\;BCH9A_AWI/"9A EO5'P4H.[8Z
MD];CEM8X"\[@"K[@F9;I"/;@^JGIERYIGL;IG?;IGG;IH-99E"[@3R3I 9YC
MI#YJ^@WIE?[HI[;B.G9JJG9A-@:5(-91J)2\,.[JK/YJ, ;K'[YJ-6YC*I9B
MM#YKM>[A*W;?>(W7<GWKMI;K(B9K,T[CNRYKO.9JL^;KO8YJP*[JJ89JP0YL
MPL9CH#;@/DXP/UXP!WOLHB5D0:9G7UMDRV9:1<9L[-O_OI&0VN[[;/&[6M'V
M!](4!$T6BJ]-;:7XY!<*Y:L091Z2%$BI!U:N;=N^;=S.;=W>[5*6VR;B-'[P
MHS.K!T59CN1DSA ,)!%4#\!E;CL#)^Q$7.VTSA6)W&W*IFAF4" <S\ZMPF=>
M$CVL;A$YP7^V9EDK;_N$9H:&8EJCDF^&DG+NYM-UEDW;T'*^DNBM$OMFPX6V
M9R><70F;9X'6; 8"40\-<%WSWNJM[ )G9WQ6T$\)YW,.-_YV\ 5/Z.LU: T?
M40Z?IIE(T5"SPH@>\3U#WT%QS_9LYHL>X\,>;!>WW[F>ZQ;/WQ<N:IS]Z:6R
M\:6V<:5FZ:'6:2"_YR G.0S&_W$C'VHD3VRA5O(C9W(E]5&C)B@G1VRFIG(=
MK_';VG&5+FPNGW&_8V]+C/$7[_(Q7VOW]>*Z3O,Q]NHCWNKV1?,U%^LO'NN^
MWN*\-G.ZUN(\3VN0QG.[[G- =VLQ_VLZ)_0_MW._)G/#+G-&7W1'5W1.U+<D
MKZO%/K[&1LP_AFS)AKY-MW &1^3+!G4"?V12[^P/BV30MMK0/NB>*$VA.*&C
M4&T6<HK5E H<@^T=DI19  !>[W5?_W5@#W9A'W9B]_44D^UZJ(>*/*)B)W9^
M2 2R&/8>"O:/X6VU78=@![G]HX=@;P=K_W8<PG9@UW;<$7;:9HMV"'9] />Y
M\.W%P/^5+PEN]) 4>C=N-5N07GY.1.' $6PU#A'F&13O$Z_182[X&\D3S(7/
M^K1<SE7Q9RM!A_\FZC3=:)Y.3(M>9OO)_]YX",?O!P_G)KQOD7_O"J=L>_;X
MD$]GW2U0>"X) ]<(%%5P.+QPF(<FFK]YF4_H"U]GWG5, ?_YZPTVA.[PH2_1
M['7YT6WH;AMQB58TI__"]_1.[_1*C$9T<:YSN#[TN.X[&0?S0-_S9AYB1@Q[
M/??R?,/R*,]RM \H&K?RE$Y[N%_AMU]RNC?R(6_RP93RNI]TO.][OO_[*;>:
M*T_JM=?RN%_J=3,Y(!46'H=TL_=Z08?\/?=SR3_TMW[\1[?_ZCJ/:[)F<S@G
M8\^?<]''XD+7:]._\Z\?=#Z_>CVW?-4/?<@O?=0_<ZVW?,RGZI_<_-S/_$9W
M_-ZW62KW^W[C8^+/]$!>O@%Z,.47:)X/]<P6=>AO9.DWDU2'9%6__A%%H4P^
M"K!E(;&U]2#2]68??_(G_^Z8;16;/V&/R&%?=[BHAUG0!V.O!W3T"OB7_UY/
ML<JB=K*X_U]_=H!HAV @P8(&#2+B-PL 0P#Z$*T[*!%AO84- <RJUV4BQXX>
M"7:I=W$6O8\30R:ZB)%?(I,N7\*,*7%=(GT-]64DN$XE0WXOZ]54R5*@S*(?
MO=!#I'+60Y?T> (@:K)=0I4XZQGE_TC/(L-Z7K(6[**P(<F-6KD"\&J4JLB+
M5\$:I.D6D4NH .!^K(EVZ$NJ_*QF;(EW8-"&$(O2M,GP[<"=/'T.)NBWH<*2
M ]M!U>=2[]*D$4W:+<H6,-;(ID^_1)0(T1K6JEGWBSTK=K_9_?CUTZ?O7KY[
M]^C=J_<[^&]$PNGA.YY\^3U\O/'US@?]GK[IU7M7SYZO.K_MT+IS]\Y/'S]H
MN<?G3D\^W_CR[;^3-Z]//?KXX.&CQSW?_G9\^KS?EMLL^@6X7WVY^:-?@K<-
MF."  BJH7X,*28@;A0SVDZ _&2K$X8,=,FBA;1=VZ&!L)'XXFX8><KCABB^6
M6%N&,FZH8O^,*M(XHXDUL@@CCC_.:".0.Y9X8Y#] )#CC_[4Z$^2LS!9FY-2
M-OGDE%!:62654F;)Y998?GFEF%:2&6:2 $0))I1:KNEEFVJF.::;8SI9)Y9U
MHGDGG'G:V2>??\[)HX:XR><>-/H<FBBBBRJ::'F,(FJHI-\56NA^Z1%888B;
M7HB3B/R,ER*HGH88:J:F8HKJ?*.*"N&FI';:*JFKNAKKI[4^"&NNN1;(JZ:T
MZJJIK9RVBN*MQA)[;+'+*GLBL\E"BZRTSTZKK+71CIBBLR)NBR&QW8*(HK/C
M>AMNMN2:B^ZYY:Z;+KOJPOLNN]Q^*Z^[][:;;[SX[JMMO>+:JV__P/T2/+#!
M_!XL,,(+*]QPP0RK2R_ $/_K<,+]2NSOQ-1R?&VU%6<<\L4C,RRRN1YWC"W*
M*ZO<\L?!XBKLKK<&J^IM-K.::<PQHSJLSRE_'#30S]9<M*RBXMSS@$K+G'.I
ML-X\:]2^FII?TE([O>K55&.]]:E=&TWST6*3_2K280?HM(5>IPHVUV,_?;;<
MGS)=-]H4,NWRT"P+3??=S-J]M]Y\"][WX(<;GGCABX-K,<6/6RPCAK.=2SEM
MEMLF(^::*\DYCY9_WKF@HBL99Y.GAXGZFZ:GWOKJJK/^NNM,^O-Z[7%"N>;M
MN=/.NYZ[]\G[G[77,\,57G3AQ3O(>]$.__)=7)'#%3-03ST+,[#@0/:H<7]0
M<&C9%;[XXU^4CW'UU(.(/-VSW[Y=7[UD5VF206590> # %E,?SW6D5+P%P0J
MLY (_C#2D? 9A'\C*4H!S7(0QZAD?C)YBEWX <"!=*&"!\D@3P8XD0(>I(!T
M.<CX).(%J @F)B?,C$04 Q7]%42!%_G,05:HDA0.)#03L0L-$6##!7X0*A*A
MH$JD0I ?7L2(!FD+3W!($/&-L""8X2$)PW=!!' P?!XLB M5(I$I6H4C,FR(
M1)1BEUDH$8)+V:$0(U/ +4I$)&D$ #T<R!$!LM$N]B-( :-20[MHYB!=%(I$
MQL@0B621D <QY/]-/LB2CQ QB7GT8D? Z!8QMK%]FLS*:UK3FM6L 5U1R\U_
MJI.<X-0C*<*IAW.<TQM76B>6TKF.?Z#CGWS,<CK1H4XM[^-+]IA'9\!:$+!(
MB1\#Y:,?WBGE,0M$S+3!#5E:@]6&7G6>8HH,9B?#D(.XY2,6<9,?+BK2.&WD
M(M$524A'VE'I1C>D=I+NG?)<9SI[U+DGK1.>J^N2[/84J'_"B4URVJ>9"KJG
MVY7)GPH=*$/)A-"'HFEX$7WH[X9748@R5%"=.L]WQ-,H2'TTI).:%$>O:=*O
M%6B47YM;VU1JM6FZ%*:C2FG6>B7,:,[,;&7[6=-V!K-9Y92G/L5I3Q7_1[BC
M@FQ>2MTF4[-E,J<N%:I-;1Q5*_8PQV'UJD^MJE$1M[BM)A5R5QTKR;+JK7EP
M1 ;R\HA8S"I6!GG$"V1]*UW=:M>YVO6IS0JK5/O*58T!%JP;TRM?D=K5P^[-
MCA+Q*E)_RE*>!LYO+)WFVR1KV;CM-*A?9>SA_N8T=7C$;2L=;=MX=06.R&-I
ME!WM2U4[M9GFK+6D76UI9_M:S-8VM[2E+631QEO5/A:XEUVM;'&+-\]&UKC"
M5:[:-GM<YVY6FQW+FS2A:UCK<A:QU]VN5_^:,;R"5UZ2ZY#E)C?>S9DW<YM;
M[Y% QSD@N7=)[HP=?6%GW]G=MY_UQ6_J;G<Z__]*B7=,\EWO@#=@X/%)>!3M
M!_28M[SD.:\+T(.>\:HG ^P]('LL&(@#-AF9[Y$OQ"(.7S[09YQ[N,/#*L[*
M^^*G0RG6CR/K:(6(>YC#3,H$CP:QBQ(1J6.#B$7$BD7 B,F7E4@VI,?WPS$"
MD%SD&THD)4UL#$\V@C^0,!DF3+P(#&?RPBH^^<4%D3*4!X)$AC@1 5L.\T6B
M2! G^[$@:^Z)20;)D!Y_N2-JO B8+\D1$'+$C"I1+)G9?!$)#D30%QDR%[-\
M8YY$1LPPV7.8)TF62L98SGF6\:9CF&4X!Y(CEFPD 0W-D#T&T-$$*;2IT[+B
M5W^DDZX!Y;;:(QUZI/\RE:U\3G1TB8]=)^>5K&P.=?ICRE6F4CK2><\OW:.;
MCO['E_PICTG)4\SX5/M PR30>IR)4FM#4V8M:M&QRCGN<)K[G$12Y[K'S4YV
MB].>\&9W/.6=3WK/\]WW#I*8V,1O=^Y;HT,RTGP%JKI_SXF?_0;HP@/*<(4G
MM*$)3SB>)G[1B^/)3QG'N$7]Q"6$?GRA&EU0I7P94I""]%&4BA2EWE-2<(,;
MI3)O*6SS0W.:OY2F-M_M;8'EJZ'>-.B8<A50,UM4H@)=ITKWN=&3+E3I<G=:
MWHWJU*?*UZK[U:IE#6_)J%[8[/8UZD-KW%X'Z_6Z<CVK_DL[V[?N=K2__:[_
M<6^[V15RVHF0([!G9]S5^U[WK&L7[$=E]$!F(/;#"YYGR%V\J B/ ,/KMN>2
MKVG6EOO<ICN699EG;G+7)MJV.7X&Q"7N^B8B@ZJ-_K6R77WJ8]MZU*O^]9_G
M.>79=OG(U[[HG;<\[UU_V]L#O_>[;R[QAV]\J"<^^,1//G8#[_SF0Q_QST?9
M7^DN=W>=]W+C*B]Y)??>[\.W<_'U7+WSNU_]FC_]_$7_^@O\W]4)&'BZ(_"!
M%4Q@BRIS!A)6'O.2)^$K0(_T6-@,7!@+9!B'P5I6@%BK,:!=],/YI$_Q). $
MIEH#-@2BP1A/H!H"6 0_$)Z=W<42A8\^ %!( %$%_YY@02@:EP51EO'/+-@8
M'V79"EY@7N $6,"9DLD@I/49ESF>F3U%#.Z8D2$$^6!@46A1:9B@^'390,P9
MFD'2@'@$(VF@1P#2#V*1' T15"A9^#!:(AV:I3T& /41 +C9$_%$J)4:#TX$
M#0( HYV1$!:$7#":&_X@"$X$"+XA01B'4;#:2-"07)!:D[&0("&01/S8%V7:
M$ J0$CXA"RZ2JFF192#%^*CAHZG$%2$ I37$!@Y$']$04##B4LBA3J0$%E*@
MA\G:)[&&;OA'<[#2*K72L 4;L4F'*\$B<RA;+?7:+&T'>QA;,&I'>&2'+942
M>_#'+N9#,_64U&!;S T=T_\IG339E-Z<VU3!R#AIH[O54[MY(XW$F[YE([_A
M$\ 5'#KE6_G%T_D%W)>0HT'%3CNFHWR5CL+-5\1!G,7%23X25#]*7$6%G,9Q
M'$5IW$0-Y$$*9$("BL.9$Z'<#+2MW,E)I,J-5,OAAZ6<5,[5'#9I),Y$HTKA
MG$QI).YY)-80735*8TJBY$I2WDG^2C4^'=(AW\NDS$SRW<9HU=X)%F!97T_&
MW4Y*W]@QUDDHA S(Q(?,@$SD'5BA%5S,0,$TY6FT%;HXWE3*"SF A55V2%7"
M"^'-PRR47DS(0\(8)5PDA+Z<H5C.W6"L V"5)5SD'=EE%^%=03]@I4Q\Y<JD
MI4O_K,->(D!=DLI@B$6M^,_'W"58"(*UA,I$ &92QL12IHI@?HT@@$5JV5;N
MW6'/J=846E[4=$074%9'C"6K".9J=40_O.5+&![J"1=KNEYK'F91@&;L.:9,
M\$-M&@3/,>9XX*9+D$/LW59LRL1L^EYJ&@4BA WA*<1'U*7R'5]P%9]-(IYT
M,E]06F=U8N?T9>>R^"3<>>>Z9%]Y?9]L@!_Y;4[HS"/"T2/[L>?YN:?ZM6?Z
M =C\%5C\T9_\!0]!\HD_M$,.) \\]!_S ." #F !'N#V(,"&I:))! <$GE@$
MFM@J.:B$HD\$-FB%/NB$7FB$;JB%0JA:+&B(BNB(DFB)_YKHB:)HBJKHBGY$
MI['HB\)HC,KHC-)HC:K8*G:2*UX';^0B+ K;+.[BCBI;L15C+@TC/H#'+>T2
M+/EBM/TB>""CLTDI1D(C-M$',IW4E7)4>VS;SJ23-X5CF%83P8DI-V[C-YEC
MF*:G.*KC>LKCO:4)/:5;F[[IP<'G>\*COZ7IFKJ)>NYC^^$C/$:<0 VJ/G;<
MH6Z<0H(<0B(JH^KGHS+DN3FC>W@4RCG*I;(<RXW4,U);E6:D2()J3$T>V\A4
M;L6DT*GD2^8>U^@<1[IJJ\+J93I=]&TGX6#=K?J=WEG=W^'53J8=4-:J3I8+
M*JH5LI@$Y!E+;R80N]S=3"A,Z/^EBT>,IKXH:T' BU\.A+H8)T)P';8BP,:8
MQ%E*S&=NTVF"S-IMBKE^)U!69=D]B$>(ZU)5*T%H9[A:B[<V9XK Z[7@Q+9:
M:^V!%F,.3KL22T<$36&V2L!VQ&H&RP]>EL(>Q!5X#7ITQ.QIYJJNE+\.A#KT
MW+P>A#HLUWQT!,B>"L0:!&!*7K-^;&6!WD><GJ=8C<DFT.BU)LS:["QH[$ D
MIFNRWFW\X,M.'F5R!,I^UD= WFHY+.SE+ (D)N?9[,T8[.I12$?L;&C&&N-=
MEG-B+7-YZ71Y5K(\9]9J%K\BG7::+:V>[77NZO6Q;=N%I_>A5WF>Y_>98YOB
M:7RVWYW_ZFW>SJ?[!9A_X6?]$:3]]8D_Z(-_>@& +H\[".B$10_U7)B!;IB&
M)>B+;JB-8F[F:N[F<F[G>N[GUJB+@N[HDF[IFN[IRBB.@I)]Z 8P.NDNXB*3
M\N+L_D<N^>*0,H=SE-(M'2F4_I*3$J/KEIRG-B.O<.JEZ,."],V*6!.8R@HT
M7>.(I)N:<N/ Y1OUINF<\NGVUFGY$1R=UJT\Q:F=,MPY^J/!N:.>KI^?HB]#
M-MS[!NI"Q6]#+:JB.NI!W:_]ZF^A-F0_0$."4&JF2J2E4N2E5F2G(K"!*+"H
M;B0#=V2I0O#DN>0$FV0%LVP$PU9(.G"H-G '1Z-,HFT(RR6O_^8JL*ZM"3<,
M"N/JWZFM4/*JMZY,86)+SK;EK9Q&7,I+5)81PW3$5VJKC)T+O@KK-@EG0>3K
MK93B$7\+# _K:4SK4X5E:JCPO\ P=_JLP0(-N4)7SI*LRG@LL@Z(MSXQM%PB
M0JAD%(?098Z'T$Y$LIK&#'3QSZ"Q05QP/ZBL0<0Q<,WQOY+JS>RQ1PB"[-5Q
MSISFJ"@G/\BLSK+*'1?$;_K>'W\B:4'RMXI6?K!Q(;'>@+0KS][L:_+#)4<L
M)[N6ZWVQQ3(R04 F94WRJ.+$*6_L:^%KV(X'*L*$//0LJ!0Q01QQV#HM= Y?
MK?YRX&T>36)>V89P"R-SL$J=UGUG=_]&3N7 +>>0)WN-7S6OH_G>;3;O+=YR
ML^GT[8&]7WT"[GW>GW[V QD<#^-Z@1<PKH3]G_3D0/40( %FF/9T6.6RZ.6B
M[C[S<S_[\S\#=$ +]$ 3=$$;]$$?A.JVXG\P1;2U[G@ KY+2KC'JDF\ !W#4
M@R_ZKC#RKNM*-"U)VY2Z'.LB<#)U&\PE<+8ML##15-=6KX=8R#G-VXF<:;I\
M$[KU"/9B+SK:&YMN[_B"K_=J;_?BFWK*(U"++S_^Z?D:JNNP[^PH=?O2U_P2
M:E/+;T ZU%4#Y%;O+Z1Z',>!8_\:2$1::EF+E %;Y$BG-$IS\ -O\%MW\,Y)
ML 6C:DZEJES_QW5;Z_7/T?4TCFW7)K/0C/ Q*[,+ZRK@'?8*'W9@<TSC]#"U
MM.NSZ/!!)(O'#N8)>UU'%*M4>>M ;#:Y3+9!O(O'?NL09\LD+PMJHPP-M\HJ
MIZW+1+:MUDM'*/'$+&S0=#9VE2("Q"NRY#)(&,MM*UTB YG0-6%8?*UHFHUJ
M\_+ME;$*HLTD7\UG"K(:>\HF/RW&UA:VTJ6JS*LK(P#)LA[5BA:Y]K%HCC+J
M@7)NUFQ[>S)I>[(H@PIQZVQV+^9'P-ZH^,_K2?=JP7=^ SC,]G=ZVW>! Q=X
M0Z;6^O+6*KC8+E_?!+/7@C!W#?-?O_:%$S:&#[:OSEV'HQWWQ6V(_YOGB(]?
M^"*U-N=MBG>SWGYSW]JG@04N?B8810%@A+'S\_A? $X/Y&(/]MCS0"CHBNHS
M0A-YD1OYD2-YDBOYDC-YDSLY6"CT&L26Z^9#*SQTS'%ID?(:[W+Y[M;N1\?2
M,%)Y2$-D=U#JF>.'20>P?"#(KQ"3\6I;N%EC-WVP\[(TF(ZI3.?T4!,)G^^T
M]?9T4,]CP\%I.5YS6 <Z]_KTB>?74=MCGD*U5;_OG?*C44LU[,QOIDNZIKOO
M0G[U_F*U.;_)-6ZI>"S3 *.Z !_P\:KTI\*U6^?UJW,P2?9UJKHD7N/ZJ\Z<
MK??UJ?HU8[OK%+-P80>E8@M[8I>P:1M[/_^4XF;?J[HRBPQ+2V?#!"+\U=*B
MEEVV8<B@Z\10NT=H#,(>B[A#2VC_*[.0-DPX.X3@A>'1ZFY+Q!A?R&_'Q+I/
M'_> L; 42+I/1&)R1*_3,G2G"()3"[_[YMQ J]=0+6;&!')ZIE-:]R!7S203
M!-"ZWGHC$NV92L*+5L 31-4^"'V_;&4=MR[+]\G;+,;#1'M3O.DA,E'B#+3B
MWL*SGLJ_1.P-B,&;A,6C'GD3^,\[>',+W]=J5X0'/8/_-=(_>(8S/; 3NX>W
M+=3#"XA+\WC2[=7/[:!C\S:C^(JKN#?;#OR-,XR3,X+A9^[0@_$X&/-$F([+
M<X]KV#W#Z) _>=W_V_W=XWW>Z_W>\WW?XWV4LXJU-30R.C1#KP=$$_Z8_^*7
M']LK$>F8/_232GZD]$>S==245IN6<EN<LS1;7],S31N;4Y-AU;1?"=Q+,Z].
M"XGS[GE.7^^:?F]2@V\XZA.C(WKX$G7NMR\]B6^CFY]2<_I2"S_YNN\].K54
M __#Z2/R"VJH,^KRA_7FEWFJG[6J>]2F(G"EM/I,8;E>R_KWQWH&8S!>?Z2J
M4C!?3_C-C3_8Q"KN$5W2-[VR)SN&M_"R8W8SE]6Q.SW],Q_6[7_\ P2_6?SZ
M"21HL.# A <5(G38$")#B0O[Z8M8\:+%B1HI<D3H42%(@B(Q;LQX\>'$_Y04
M5[9$^5(E3)8R/W9!<!,GSBXN1YXT^;.CSX7\1!*-:%0BTJ%%F1YMFO3I4J=3
M1Q94JL\J1ZS\KF8-Z;4J5ZU@*Y+=VE7LU[1AD1(%ZW9MV;5PVYZU^];N0+H:
M]^K-*]9LX+A_Y:(US/=O7\!S$?MUS/AQW<B-(5>6;)GR9<6%$0L^K/8SV[%Q
M#896?#IQ:KQX)T]>S?AU7;*EH]*F*C5F[J!0:?8&:OOW8]S#@<_4S=-X<N3+
M?2MOSOQX[WXSIPNL/NMZ]H3:K6_WWAT\]N_BPW,G?SX[=O3JI_=C+]Y]_/?R
M^_FCC]T^_OCYZ^_W/\N?_ )T;T  !3R00 0-3/^0P04=+!!"!2-L,$)_'@SP
M0@LA!-! #3D,T$,- 0@1P!&QZ^(*+[KPXAT57>P"Q1RNF&'&&6:08086<G0
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M8M4GV<@V]MQK(3=B(<ONMXI;N<T.=[=Q)VYYQYMXF:TW<^QMW'YS]MNX52W
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M-EQRSJ_&AV]]9M"Z'+WO 9[PP.\!&W!YOG8'<'? 3N1O&;PF/6]]J&8]\"[
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MR[N\;WJ])9V]_1@;C1J_=[>^BUK3Z7MX[QO3D;JIG[J_F_>_]?NII9? 55W
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M?Z7H_WZF"'^GJ(JIR(KREW+T)U<OZ(*S2(4X)XL.V'3^EX#\1X"\N(NYV(O
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M]1:$ZRWBAR;N8BN621E9!JO]MU@'MQ)UN"T%A:F=:EWG==3W]=3'^M6':H?
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M0P"@#.?JJ!G/J">.<*Q0(NAHQS\"\H\6R($.NH,J/2*R0A))4" 5I ,F[A$
MK1"$#F;02,S,H QR),\L$&&=_%PRE JR0!<2H8](MJ(+%1!E9G1PCWY%$D*V
MF84@O#"#5;(REW^K@!?*\)!$<E(0H-0E,8O)H!DD_Z(?BLSC,F7I3 HQ,YK/
MK(B'0-0B*4:1BE.<(C!S<Q$8O>D@,[(1+/?E1'/*Q$?AG-20)I(/+[1IG?+$
MDS@-<@5$H#.??VJ%.R:800S6\Y]!DD$78F4N>#&*37<BE0/64:Y4O1.@[$1
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M/-/S/-N3/=]S/>-3/>?3/>6S/FUMT\)O,"4M'?=3//V3/!72.[OSQ[+M'73
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M Y^&JNFHGI(*JJFBEEKJIJ*R.JJKL)X:ZZRRUDKKK;;FBNNNNO;*ZZ^^UOK
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M3^]Q]^?BW^GC__WP_X_WT)99H:7O3T+)A$JANW>K^I=B'?\  4 @ '\#^<U
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M)SJS(@&E 0S ,!/  B3 -JNS/&/ !73 !H3 !Y3 "*1 6^(U1I,47MNT#>3
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MRI3-RT1..ZU3.IW3.,73/;U3/8T?+_B[8_Q-AGB \@$<U?!3YO&']8$\!'"
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MZ1<,Y$ 0)$':2L#<BM+;JM()K)D,?, NC< %'-.,\:V(;,0WC<$]S,,XO=-
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MD9V_9/7Z@,!FUGJ=/19H3WNEL'<=V(F=,HW=UR5*F ! ;!&@VD%'A/D2;3F
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MS6E'.I+LC:!A),LB_PFSC!(2/Y1TV1OY:4Q3ZD^8OB3:*IT62J(M[7U"V]H
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MN(2K3>AO_O"D_B9+__0OL_B/LQJELVZ.N6"IZ+".!:O.!:^NNL#+NF906KP
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M.)X .9#F29X$69[H>9[W2&2!MF.[IHYXZ'+K69_J>9_IF9_LJ9_VR9_XN9\
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MT(,=1,#_\)<($'Z0@3KYX$$L6,(.:O A+$QA"<^5$Y:PL#'^B.$#&W42&"(
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MO./-7B:3//!Q4I2<2: J;0E+8X(HF2(Z43%QZ4QK2E-&,3HGCM:)HWRJTYU
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M>]S[7H(1O.#M-?C #E;P^L@'X?%)CWT2OG"&UT=%^"EP?/1+@/UBH@_]G1
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M7!EE#973#"]O1=9EK3QP+<W/LDO5.SVML4S);-=TA5>ZK,S3VLN^_+U2E97
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M>1$V4#RY%/+&>>,M,E@S^.T3 #-[+4.\;R/^.,8RB-6.XWT_;CGFE0ME+KI
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M2.U@B$(7>J2$&BE)2#HRDI2<I"4S6<E-8I*3E_RD)CLI2E!ZDI&9^5"' !U
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M?MBM+G<)IS_B0D]R1@5?<ND[C_3A#[_NL^YEN]+>WN[7J/1M[T?]D;X9B/?
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M+) ,)-CE"9=195AF3F54.F6[CA[KA1]8@AYE;EYA5N6]EF5@[JMC\JN^]BO
M_JO YBO!^FO!!NSXB>OP515@8F5<YM[ [BM>IJ7!\N7Q=4O*B07MZ:M8->;
MQF3-1-_ (JO_3,\,!.QCEM?!"NQD%BQ;3D]@TJM40N7,MNMF+B7.;FM0.M>R
MBJ;I$"NP:D1JTEA3L&8.X%B.':!6R*9M-JW3UB9N1NUO\B;53JW5^F8&9BW_
M%AVG<78M<HX@V#8G=$XGV8ZMV3ZG&IF9VEKG=[9M>+ZMV\8MW,XM<]AG>5ZA
M>N*GW>8MWLJGW[[GW\9G*=UGW^ZM?NHMXA:NW-)9?ZY2@3XN&1JHY/9(CB#H
M&7:;,$FH@D8HY\*AYV)N@^IH'(XNM85BC'9HDW[HK@5IC8ZHC<;BZ[*N[)[H
M[*KNZ<)H--4NM&4*/>D)@ZJ:A6)H[H)HE+8NC1[O[AIO\B)O']KNAZYH(39I
MZAKBD%;*E.)B-"YC,#;C,QXC+S+C]H(;,5XI,*8IFT)C+E:CP2E<G&KC2DU?
MS]9?_-KD_-8OZGACYX2.Y^2I_L9JJ^(J "-.MRJL_U]N#*HN[%S:C&*)T,L2
M,&0^UJUF*F0B, 3+1,Z=9*W*BV1Q3Z1J3JD6<,]EL CK:J^.,*^:< D#K6GZ
MZL^29K"N\ L;:PN'9@S;K_S2,+8BY6<*T XO)<F"*Q 3%V&9Z\T6,;-47T=N
M;,TNL;ONY$>&ZMI\GA1/WP!K#_A<9<):G\%V:L@6+!0OW\J&<<6B[!A'+!F?
ML1FGL1BC<;["%+>D%!RWU/NZ<<29)1V_K[;<L1[+<1Q'7!P;6!_/<4NQY%CX
ML1P_;"$+LB$OLB);U,2&12!',A]/\K)<K"3_WN!0\AS7' ([,/=ILB2[U#D"
M,BB_<;0D[!=WC\4^\;AVU?\:#ZS,QK+Y,?$LGZLM!S$/=R9HWO#N_"H,#P12
MS!#1)H71(BUL'B#3/JTR+_-L2BU<7&UP0G/58FTT:VV4;:W79C/7ABUS=O-R
MEBW:4F<X@[,XEW,,PB Z8R?=KO/BLK,[MS,\PZWASG/BDB??VO/A*JX^XS,]
M[S/A\G,]_[- WRU ^S,6QC-"'T?C<N$8!BB.4*Y#3ZZ UDGE^FZN6+2=B-HO
M_8CF=O2#=N[FNB'P7J@=BF*IV.[T+J+NOBY+*V_LNC1,,R_MCFB+WJY-PRCK
MMK2O16@F$E.&GC3QSC3RZO3NSJ)15Z)1#[50"W7U+C7N"G52RR*E8"_"6:-5
M5S7_5N_;56MU^DXCE5+C5L=;O2T<-LII'0=FG7*CYC$$-\ZR1-PI7%O$G=).
M7$=$7;^U7.<U_>*P#>\U+_LU8/>U8/,U8?_U8!MV80=V8A^V8B.V8S<V9 -E
M+NNP+ANQO=ZRY1DE9=<I9E^V91-Q9H>V9XLV:(^V:9<V:M=>:;,K$\.K9JXK
MS<8RRLHV;+]KO+)Q&;^R;N<V;^.V;ZMQ;P/W;^\V5M[QRNXQ(P=R'I=R<E_4
M1X7R<\_Q<SNW'T^W1EEW(T.W=C-W=F/W=<.Q=X=W=8^W=),W>)LW=9>W>I_W
M>J<W>[^W>\?W=[?W?,-W?7.W?4=W?F]W<_=W=G/W<@]W_W 3MW!/GRS7-BUG
M)FH#\68O]O/X\F@.;0!V03'CV(X=,P(RLX9O.-1"X&U*,XA3\S17LP5"F618
M\S9KLXHK)QFU^#B?K3G#.#G/.&RL[3FK,QV]LXXG-(_ON(_W.(_W<T$/^4#?
M<Y'G,Y$3])$+^9(#^8\_.7$L]!I ;D13^:=1+I83:*B1&HU8+N5Z>45O])9[
M=#F%M(/V$NA^[N\.4X6:[E.G"2PZ+Y N-5'7>4PO[U(W[TWO.4[G^;/Q;KG9
M29RLN1SV*)P']4K7Z%'#$U(W.J/7(J2S]"PJK^[VX9O/N4,UFZ87W%AW^C5>
MRJ?_&UF#>D1UNKQY>JE_>ONJ%/_$_?=+F;* QWJ!$SBM#[BMRWKPX2MMYWJ]
M[KJ\ZOH4\[J]_GJO!SNQ#WMLU[*R([B[)OAK/SMK-[NT+_MI-Z5T/=> 97MW
MP1>V;_NU<SNX6S9G?SNY;U>WGWNXFWNZVZFWJWNY5SOZ=79JQ_MG6SMI(YC.
MUCN]W_N^F_:Q[_J\LQ^RVRRS4WNT&SRPE^6T,[NQX^NMS_K#USJN1SS%3[S%
M0_Q8(C>V:'R N[K'=SQ_>WS(CSQ^E_Q]^S?)G[Q^R_?*J_QWL_S+N[QXTW?+
MUWS,V_S,[W?.P_S.RSQZ^SS-W[S0]SS.H[S)XW'%8[S22SS!0WNRDS:#YSO\
M'3:$M[#_(,B0:M*05."0,;\F,B<@A]MF/= #(G1AV"N@,W_X,XMXB)/XB+^]
M$IFXW _GBM>]%R4GWG/S-\LXW[^XW\?XW^>XX)_9=1:^DQ\^E-,@NP! ^R&^
MX]-@/;0"/_2$1NA#(K3#X_=1(E#^3B3"W&Z^NH1,FSD.YZ=,YB?^Z0.YE(LA
M-V4Y1$MT@+Y^EH,YZ\N)1F]YEW/YF%^TF-\^FB]H&IHYCH)TYOHT2:N*'5ZZ
MG*^NG\NT4C\_M)FH2O.Y\%;_I3._BLZT)>YTZ_?T2+>Y];\BHKNN2U.B^3OZ
ML$1Z5-,B^S?_3$OODTYOB:Y_OL$ILHSZJF?C_>?_P_4___\__T#,ZM>/GT""
M!@OV\Y=PH<"&"AGV<RA1(45_%C%.U.COXL:.%6=QS"C2X\B/'4FF1+E2HLJ6
M+$/"=!GS94V:-V?FE+G3ILZ>/'$"]1GT9U&B1X<F%;K4J-*> G%"32D5)=66
M5D-B]:>5*=*N.;6&?3HVZM.M4\]637MU;=:V9T,"8!MWKC^Y;NGBM5OW+MR]
M>ONZ#7QV<-:Z4O$>KJLVZMO$>A$3YCL9,&6_A?]>MBQXLV.XBO4RW@K:;V3#
MIZ>235V6]6K7557#;BW[]>*KL6_/SEW;:].OOWT'[SW<*7'@QH475WY\>7+F
MSYU'1SZ].?63-D%FAZD](W>-WL%?__\N/GQW\N?-IQ^OOCQ4]NC7N__N_B-]
MBO;E9\=_7W_W_?_]"W ^ ?L;T, "$:R/0 4/9#!!_AJ$\,'\'*Q00@LIO%##
M#./SKKH/H;-.N@_=$LU$VT([K+05XUH1 !=A;%%&NPBK<<87900 1QIGT=%&
M'W/<$0!!O.C"BW>*3-+(+KJX(@<GKYA!2BE9>$"&!ZID 0$M$>C2RR_!#%/,
M,<DLTTPSZZ&G1QW9M(O--M^$,\X7YZ1S3C?CQ/,>1.I)$Y$KSNPR 3$'#;-0
M, ]-U$M%!5W4T48A14!1.]_T0M)'^:ESJT<OC9313D']=-!1'26U45,O)575
M5%E=U=5687W_558$'H"UUE5O93574G/M]5)?!P66UE^)#;;888U-=MBXWM2'
M4C:5%;;69W6T5-IC'[@3 "^4]4);?6KU-5QBO96SE3?=3 398<=ME]UWVW46
MW6KAK7?--S.]T]U]ATWDSEGJK?5<.77DUV!XY]6Q'7[7Q%-'<!%^%N"#*0[8
MXHHQOECCC#G>N-]T+6YX3G4[WM=A-CTN.>6557;77SFM9?G=@7VDMV69;\X9
MYYUU[IGGGTM&)!%$UB!::*+KP2?II.E1VNFDE<EGZ:>IGIKIJJN6FNJHK59:
MZWJTYGKKKYU6IFRRNQ8;;*CSN0<?L<UFF^U[I&[[;;OAMAMLM_>N_YONOL&&
MIF[!"<\'&GT(1]QPQ0]/W/'%'V\<\<DEKYR?QB]'/'-H-K_<<\Y!_USTT*'I
MA_3140==<\Q9I]SUQB&/'?;9#9>]=MH+SUWVUWFOO/?.3P?=].%)5]QMM;].
M?NG: ]_=\=Y?3SUUTR^GOG1]AL?^>N*SKU[[?O3QOOK@1U_]\]6A]UW]W\D/
MG_/O^1D^_H0.@JC#_> ++R*'$IJ%H?_Y%T#[:6=_ SQ) ?.7P/<LL$,*;*!)
M(%@2"8*$)!043P6WDT'LA A$(^+@!ST80J2(13>HH<T)=X-"$Z:0A2MTX6A*
M"$/>R%"%-&RA#5](PAGJL(8\O*$/<XB;(/\VAHAH*:)I9,B9RBS1+R=*T1.;
MB*(H0K%$4@0B#K%X12T*,8M<W")QOMA!$8U1C&4$(1G/:$81JG$Z%ESC!>$8
MP9FX<8(:O D=\6A'#&Z0CP_T8WL Z<! ,G"0?P10A.ZWH WQ!T.,7.0A)^1(
M#DF2DI#,SR4E9,E,;A*3DX2D@SK)25&&DI255&0I$6E*5*HRDI]\Y"DIZ4 V
MSC*-::PB%3U31-$@$3(\NDR,?GDC&_E22,/$$9!XA,QC%K-A<2&2D9#D!245
MJ4E/>M*4I'2E*V5I2X'RYC?!&4XOI>E>!$M8GC253FVQB1]]H@>?!,$E<8[I
M4%^J)Z?LR2E1Z9/_GXVBUK9"Y:5RS:L+D*J'.M%9T$LQ*T[\4%>7BO3/%ZT*
M ?EZ$\!4=="3^<A2I$+$1B7JCXY*RED;1<2EO- .<P*@6 >MF8X<BM(NO P
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M*^99J#O=L77_[-D3AEN5L=5-BD? NQW?+K(W=*\<[^WE[YYYS&,>N$8;[O)
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MD[S2DSRQ_U-[S;,ZP7-\K>MI3,_T< ^YUG=K<J\ZO?<Y#><]#8SZ"LQ^AZ]
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M__(UW_(Y__$]/_,['_0_/_';N_0-2/%1?SQ\%#PJO B!D,=>O$NNG-)BOTN
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MNYHL;Q+/^UOSIA>]0!R>9U[(21K"-WDT["0H[RM*_-HWO_S=KW]#^5_] GC
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M>A>4CDL>C>F[$1C5(]26'94B34&Y)-+50].@3MGHD])*@>J5#1QW8>JO:MG
MTPX-[.K5USX/?0!>, ^NO@XKA!3=TV;(!P"B+AC#OF8#T0[S0V9BS7P#$4.G
M<T+4N^S3/M5;_=C.7M;:3M;([NVR1.P]G>UGO>CD;M8$K=7C+NXV/=;@'ASK
MSNU<?>Y3[=:";N_UCN^!GN]P/4)%6M=T[><!CY$#G-<%O]=\?O &'ZH"/]@
M[Z3_[:CO$>\]\A[OZI[L[]Z4#MS MB[KM^Z4F@WR%4S!QG&K7H"5&EQ,'/P=
MY"%^")#:K0WS,2_S(MR6-0\@NXWSC,F7.U^M.M_SD)G=0<].4DST&6CT1$_&
M2=]J(,CT(N[T)3[B)A[U4__T4E_U5 _U5Z_U6<_U5M_U6._U80_VN(;B:^"U
MHHSVI*7V5"7*D]7V:]]OH,Q4,7YO9^_*N>+D/ZZX4Y.+4>XRN%S,S7PQ\U *
MA"\/I2 /[R /[I#XBP\/BH_XD'_XA$_YA6_YA*\QF;\QFJ_D1^[YIACF90[F
MKS*W6>Z*> N+B[7D2T[F9N[ZK2^+?9_W-*XJ--IM-P7G_VDUY^]RC%S#HUV#
MN;@U=4WW-TK7C>.8\ ^OS_<N\?KHZ,.!Z-$O&\]/Z-6_Z=?_Z!^=Z97._<O.
M1X[!_=LO_MK/Z0G]Z1Z/2\9^%J#^T!W?&YT^&,)QVQXDP1 ,ZVAQZNA?'+2N
M_]6GZLP#$ #\S?(GD*#!@@,3'E2(T&%#B ?7(:!8$<$!! LU/IS5SN+%BA$5
M'NQ'T&3!DB,U?L3X<4;*DP!@-IQ)\J1-E3)OHMRI,V=-GC][ O49D^C1H4F%
M+C6ZTQ_0ITZA3I5:5674JU2S6CV)M:O6KTK#;B4[UFQ*KVAAJC7)UA_6M 3A
MNITKE^Y=NWG?XMVKMVY?P'\%\_\=[)?P8<.) R->K+AP8\B/)3.>[)CR9<N9
M(V/>K+ER9]!1^]4=S;9TWM-]4XLFW=JT:]2P5<MF7?+T[=JQ;>?&O=OWK-[
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MD 2_D/P^DL2R-"F_+(,EE5P_]6M)EGS)09N_^'L_F33 F*1) !Q G<Q)GA3
MG@Q H-Q)GQS*;T+  ZS),Y-)F#P3!20G!EP9G2J:BII*BJI*JKS*$-2T1>-"
M?&(T+\0TK@S+,2S#$(Q!$-Q*J6G!2CLU?4G!M@S#?A%#=3)+$:3+&/R9>S"%
M3X,690@;75LV'H3#'CQ")12XLD)"**P;(#1,@F/,(CQ,QP0.G8A,)4Q")DQ"
M*FQ#S<S_PDECMUS3%WYY2Q*<-+44MW![M:?2EVO3!WS(-F93FZP:#K.:S0I#
M'/>J1UJT1]W,31FZQ\3(Q5TL+_0"1N DK^#DS5A$SCWDL _+.8!\3DS\.GY<
M14BDSNFL3NR\SA#;"?HX(P!2Q>Q$(_#43O&T3@1*1+#P,/2\*[W:S>1\3]^,
M3_>43^4LC.)<J\JX3[J;.[C;SV/\3V($T&'$#FAL1FID/&4TT +]+W!LS 5M
M4'><1B2"T :C4&:,1V_$4 W-4 Y]C@CU4'A41Q%]QQ']QA#MO \-1Q+=T&Z<
MQP&U,#V<3QGE..$JHT=<(W\TQ4O,.H'TAT "/N%32 XIOH=$_[X'B$A'PD@E
M75(F;=(FW<@EL[XH%4DJ)<F/K-(KM5+O,TDNG27Q^]+P6TJ7'%,Q%5.;-,J;
MG$DU/5.D_$FA#$HWC5.B?%,ZE=-G0E,\;=,TY:4R)5,C:4IQ>JF4&M0&C,I"
MK2BLD4H(M,NLI,"L[+8R9#5W\TI%J\MQ"[>C$4%(HTO2S!=W\=1U"=6X'-6W
M?$M':U007!J\7"J!F99K8QMF<\)B@T):34(@C,(?;+9:;9NG:$PA;$);?4Q?
MG49?!1R!F,R_6<*R H B;+8JM$&P*55/%1O05,-19<L5)$T/W$K5W)<JG"I]
MNZJ .ZN]L8UR-48\/$[CPL_Z;-?WU/_/_HQ7_AP/ 477%YVBU'-7^ES$O>+7
M?!P[G\"<T7&YC2!8TBE83*Q.?5Q8&V78\]S'AZ6/&F7/L7/8LFC.NP*Q\E38
MADU/?YW8?B4[BAU9R/A7^)S1D]57E-U7EBTA=IU7W#1.F877>1W.>PU0G(6O
MPN.-!450;$Q0%W5&!8V\%"5'$RW19Y30HYW0"FU:^2I:J#W1I9U:$$5:%:7:
MJZW:%<5:H]5:KBW:#K7:KLU:LAU;LXU:L05;%N70H+U-8&Q9E>W8B"4*'*U;
MVMO1RD*$*SA(&@N^0FK((CW2(Y5()RU<PSU<Q(T^*)52QL72D<Q2R'U<R75<
MRCW)E;3<E,S_7,SUTS[M7,[]7#;%R35-2M$-W=%5,SB=4SNM4]5MW=1EE3PM
M7=(]W3V=7<^]73(%U'**&96:&9<Z*7H 7D,=WJ5BU44M2^0]2TM57D9U-W!;
M7DVEEM$4RPTL-3$$55+%7FFE5BW$WC&DWF^)RZ>RPL!<FV@#3%TES!^40EEM
MMAU4WRALPG#EU:KZU<(LUEX55CJ\#63%#IFXS,N\U6?+S*CBWFCMWH1JENG=
MPFEA2P4&575AS6 #S*L2USB,3,,\5PS68 T>UH*SURN*69H5X94M87DEX1,F
M3MBH5Q;.V91]8<@QV9!M19&=X<W1BX"]X=%Q3M#AX1WNX4ZT6!D>_V*0)>*/
M/>(:-N(D+F(FYE<3AN$GAELHCMLIKF(I1F&85>$45M=ZM4T7;N%[[5FA9= Q
M1MNM]5HT+ELS7EJN:N,T/ENI?6,W#K@S5N,XMF.KI9M^^RJZ^=H3W>,YKF,]
M]JH]-E=P'&0Z!F1"]BJL[6-&?F0Z-F0#<^1(AF0X3ML[7EL,;=MTE=DKCN*_
M:$1][,Z,U5&[!46\%8E6V-L(Z5OATY"_S;%$*I$4B<B*<(#$S65=WF5>IJ3%
MK3Y@UM+*C=QAGEQA/F8FZ]+QNUQE_E+<?>;/A6;T,UUJGMUJ/DK9Q6;:C5W7
M9=W7I11NON;:U69Q#F=KCF9TEN9T_E-#<__*-1!4WCVJF%$JWX6900TIDMHI
MJ"Q>EAH:1*U*3!V8@&;>Y(5>1AWHF8K>[UWH>L)>;!55:85HA\X76=M>-9RW
M*NP'93,V]*5":>.'C1ZVCG;?6'76UXS5P5Q?E<95ED9,6W5,^UW,8JW##TZ-
M'+8)_NV' '8;CCXVSNR:%&0W47WH?C%@C%8V?+M@T;C@O>FWQFSJV%3D1(Y-
M8JUJ$#XOX>SD$>[#E\6PK>9B8L1B,(91L-:N3\;')EYB)*9AMJY8MR;9]2@*
M'8YK@'UK&X9K*CYK^%3B]LQK4/9KP+;BOQ;L0?SJF=U/L?YBQ;Y9QH8P(A+C
M QWC=I3L3%YC.:[_;,Q6T4">8T0F1ZE&9-#F;-&NVM F[=$.Q])&[=/FX]7^
M[-9>Y*F.[=1F;=.N;=6V;=J^;=W.;=YV;=SV[=T&[MZ&9$HN[D.V[+"E[,A.
M.'75ZRMFSO6\#[JEO5+L1^CT1%9&R" =OK_- 8<T4B2U"%SN9?(N;_,^[QSY
MY4Y:;V)&9F-N;_A^;_G.OF9&R<VM[W569_W.;_XN9STU9W(^YP ?\'$N<  W
M\/].\&Q&\ 4_</C;;PCG[PBW;S'1W6"!Y]^=9Z.B9WKFW7O.<)3"<'XNU!$G
MWIGJ9Y$B:!6W5(1V0&U]\1?\0HF>\>SEWM!,S6FM\1J_Z%_K<6VCMX\._^F-
M7K9DJS<A[^B3%NF2YL%=;6GW3=^5%L*P2LR7GFD,MG+1Z%\+NVF=[G*^84)G
M,]]E>ZH#/N!U.> ;_TP;[-9NU4RT@<.D[C>FEG,ZW[<Z#[C45FJGMNJQ[O,N
M.NP[;&R;#>'%!O0L#FSG-CN^MNM%Q^NU9O2TIF&Y=F)$'^Q$KW1,)VQ-O_07
M-FS#7CM/1VPM/O2K;MOX*G0_#V.@]=FA_=GZNN0ZAG4_'E'AKG78GFU;E^T[
M'VX\O_,YMW-@[_5@_W5A+W9B/W9?3_9A5W9C9W9D7W9H;_9H?W9IKW9JOW9F
MYW5<O_77KN2R3>Y5!^&8Y726%64;)65/-.6$U?^?6:B05O8">'_E*^AN1'I(
M6I;()$5O?=]W?N_W%U'O)'/O8AYX@2_X^"9X_-;<A+]O+XUPAY=PB']X./'O
M!E?P;;9XBK_XBM]XC>]XB8]XD/_X6J)P+R7Y+;/P=RZIE$(JF>GPBN'PEW_Y
MB(%Y@W'YE1)QE I>?2YQGD=Q5DWHYC7H2OU*&&=HC )#:55SI<_"I:]6I[?!
M76/Z&[Q"(O?QU;3"(D^;(==,D#9R] 7,(0]I\RW?*'_RD6YRM,\WQ0S6.K1?
M^L7R_?7@@24))M1IE-AI)2_@BV[S->_[7=LV'^=Z,7_#"L;V:1<K"[8JP[=V
MVL0-.RQU/O=@QA1T5*___+(F]>(D=TN_H$:_V.@V.4A_=)+]#!G>_$S7_-,W
M_4U7?=0W="Q^_5&'_<OOQ5'_3\B^?:+59'!W]5:_//V2]<O&9.&/=>3V[."/
MCFW7]=_F]N57_N!F_N=G_,.??NFO_L6_?F?/?NK'_NW7?NOW?N[__NX??_$O
M__ G=FU?[5G7/%/7.R]N;M:W1W/GSND.Q>L>14$@)(2,=QN#Y0VI=X"0,4/&
M Q8.#") P"(APX8.'T*,*'$BQ8H6+V+,J'$CQXX>/X(,*7(DR9(0$YQ,^1#E
M2H8L$;R,Z7)F0IDU:<+$:3/GS9X\?^X,JG.H3Z%%B0)%:C3IT:8Y4<J$.E/J
M_TVJ3Y-:E1H5ZU6M7;]Z#0MVK-BR9,^:38MVK=JV;-^ZC0MWKMRZ=._:S8MW
MK]Z^?/_Z]5J5Z];"4PDK58HH$:(UC1<W+E5/,N7)EBMCMCSOLN;.DC=_]CR9
M7FC*I.N!1BV:\CW6KB>WAOVZU#UZL&W3IM>Z]F[=N7L#_TT/GV_BM8T/UYW\
MN'+DSIO78WX\^O!ZQ/%9KS[].G7LW+]7!^\]_+-\V<UC1U_>>CWT[:&9SP?_
M??SY\N_#AZ8O_W[Y_?4#N-]^_ !(X( !(BA@@0DB:" T#O*3#X']2/A@/@-6
MV(\^$VX(C88?ZM./AQUJR*&&_O!S8HKZH"ABBRRNB/^BC/S,.*.&L\1(HXXH
MSM(/CS[RTZ.,0 H9I(_]%"DDDD?.X@\ 2S[9Y)-/^A-BA__I<X]_6@+H'W]?
M>JG@@1B:&&**09[98S]&KJDFFV^Z&6<_;:8Y)YIMVHDCGGO"F:>?>/X(Z)(_
M^C.HD84FR221BA)JJ))R(KIHI(TF.NF@ES[***::9FIIIYMZRJD_GHZ*::E-
M(GJJJJFRBN2JKK:**JRSREKKJ[;&>JNNN?)*ZZZ^]MIDC[8.JVJQJ1[K:K+"
M^BJLL<U"2VRTO^(*K+758DNMML%N>VVWV7)+:KC>C@LNN>>:F^ZWZY;++KKN
MJMNNO._.&R^]]]I;*Y.G[BO_KJG^/LIOJ .#2FN__R(<,,"<,DSPI_K&>K#"
M!3_<\)+#*HIQI!I?O"G'&&?Z<<<;>WRQD2"?;#+(2*8\;,L=KQPSS#/+['+,
M+^-XL\XPX]SSSBC;S'+0.0M=--%']XGTT"<GW;2<1.,)-=-/._UGGWS*B;75
M65_=-==?;QVVUF-[+7;99(.-MMEIG]TVVV^O';?:<[LM=]UTPXVWW7G?W3??
M?^\=M]1!1YVTRCS7//+,)%?LL,430PZOY/5.CJ\_RUZ>.;*:*YMYE)E+";KG
MHX=>NI.DGVXZ *#?DT,77KSCQ>NS>W%%%[9?D<,,N_-.D$$('622\,,37[SQ
MQR.?_[SRRS-_T4L-/8\3]"HQ5?U2UR?F%/;:9V]]]]M[S[WXX9,OV%>#&8;^
M8>F?WWY@@,'_OOSQTS^__?7C?[_^^?._OU_J ]!]5PF@^0KXO0-J#S*.<0QC
MUI"9!ZZ&,Z51C6D@^,#3E *#IYF'!B>800]*\#*QH<UL1LB;W-QF-ZS!S0E;
MZ!L7!N>$SYF.=+2SG/#@<#PZS,X.Q</#\UCG&3W$H7O44T3VY.,>Z;$/$[WD
MQ"Y!$4L+&M.#JN@@+'%)3/S1TCWT@8\P59%,81QCA#ADQA&!Z(P@JM*)K/2B
M%ZTQ1RI:DXQ@I*(:T4A2A]H1'PM%J#U6RDA1ZL<@!TDH%O]UZ(I::L\B\?,?
M1X*)00/:D)GHI#=+PJE.F(R3)OT6.$#U*5" E)2C&#5*04&JE),ZU))02<K&
M4>QQLEQ8Q"AG2\O=,E^5TV6N,.?+:2$+F,K")3%Y6<Q=(C.7$EMF+8O)3(/E
M,IG'C"8UIVE-8V)3FMFLYC:O^4R(03.6CANG.,L)RW,^3F#FG.4ZR8E.=V:L
M9"&39SSG:<]ZXI-QBP*:T7R&N'_R,Z"'$^C2"MI/JB'43X,K6N$2JK2#*K1J
M#8UH0B=JT:E1-*,7!=M"%WI)3WX4<"'])$A+*E*3DO2D*DTI2T?J4I2^=*4Q
M;2E,:PJXCK;2GP2E&4]EID]X.DS_G> <JC:+RLUG$8MSSDHJLY::.M&MSJE1
M?>I4JXJZJ?;(=5YPA^RVVE7<W4YWO-L=061P$ <@X*S-6RM;V^K6M\(UKG)5
M7O1\,KV6X+5\"-3K^,#GU[W^M:^ ':Q@"RO K SPL(@A8&(-B%C_]2^RD)VL
M9"M+V<M:-K.,?>QB%<L^Q_(UM($5K4L4^)@&6C"$$$S-!U'300F^MK6RC2UM
M*S@:V[8V-:R5#6])V%L3LK"$*XSA"XM;PQGFL#L_W(X-=\C<(4+WA^D!(CZ4
M@1[K(M$ZV)TN=^GC74@^48I:5- 5 \2E))HG2P)J)!?'2\8IDK%"9?10ADA4
MWS*QT8[Z_P51'.^HHSGJ%X]#$G ?1_G'&06R4ZSL$0 $B:;\&NB+\&DD$IOX
MW2UJ$4*4U-.=,HFU3G*8DQ^>*8EM2M-$@1)2H50EB]_9SH1)S*C7E'$W:TSC
M&Q\UQS,&V"Z_*52ALM/%1.6Q,ILYY!T[T\@_UK&-F8QC?/F8EN$\,N2B#&4C
M!QG(0'VQD(-LY2IC><M=%K.7R?S3Q:%Y96=6<YH5IV:=8K2C57OHT08:YSL;
M]*$;92A&]RSGBO8YT(03-)\';>A"GSC1)9:IB1>MZ$9#FM&2?O2D'6WI2%,Z
MTY>N-*9G^F>%#C34B?-IFT5FYBDO&<E-5K6N?*E4T6U.2ITSG?^SL'K56].Z
M'[6#75>YVH5? SMW5QCK0&;P.[0&;Z[*7C:SF^WL9T-[>'7]R5T=,NW18INP
MI#5LMKFM[6YO.]S8X^QG&VMN<B-@=0!8][KUL=G.@A:S\L[LO/VB;G8#0!_S
M9K>3ULV/>I_EW>5&;"+XP>]$G!O>"8])/?"M[BYX.^+B_K9B&GC:R*@VXZG-
M;6UOZ_'95I T(O_@R$M.\I.;_.,=U^UOA=ORE_\FYC"4>7&:8_/C=@<Z./<A
MSY-;7?3XG![7';IV@7[$)=8GZ?2)XI<RC*#XL#>]46>DU,$((09!*$-:GY!\
MZRNB#T'CC2L">W\#3".S YC >+Q1@8O_I'8=)5B/"F:PH5HTQBS%)XA&U#L2
MH]Z@"SUHPVD:_"8)W^$0&Q[Q(_8PXSGM^$2+$L4+]M,JYUYF&#LY\ZS6_*H[
M_V3/!^O+HE>RE*D\^BE?_IRI!O/F44WDUJ?K]*"'_>=O)?O5?S/+I<<]Z:^5
M^U./F<NI'W[O6=]ED2&?GL GOO)IIM.>YK/4RL<S1#\]43I3'_N /K3U"=U]
M[DO4^^$'__81O6E-=SK]CS\_^]6/_O6[O_WPG__[ZR]_^]?M^P 5M=&@OV8W
M,Y_I<5[M'96K,96QO%JMB0ZMX1I5H4Z/((+MQ,[K^-JOR4Y8#=M8"<2Q'5NT
M840]T ,B1$<]_X@@"(K@/9!@/9C@")9@"+*@"KH@"K;@":;@"LH@#-+@#$;'
M.Z"5!WK$O>$;Q#6$%] #$.*;/R"<#RKA$@I/PSE<@UV;0WA!OSD<M3'$$ZZ.
M%Q"6$SK<O\V$%W#A$:X;(E2/%ZP;%1YA(@@A2]3#+#PA&B9A4B "&J[;+$R<
M$;);.]A$.V"A/VBAQ,5$%^#A&3ZA%H+;2_ ;OOUA3H!A(CH<&7H%'KJ;9ZU/
M)0J<)5+B)6IB)I*%/C@<'1*BOM$;78@A +3"6)CA(.+A&B:<(T(A)L8;+%[%
M(&YB+-8BQ15%&#X<(.+BQ/%B39@6 V'<QFE<QK$<"'E0;9G<,J+<!__-0RD\
MHSR\PSR\@S1:8S5BXSS @SQ 8S>2QC..' 6)XV[Y%F:8D,N58VVD$,VUAG&4
M G+!8\[1T TY5]!%5\_UT'8)779U5Q%9&'@QG1.U!W5174$F47HH$=7I1Q<Q
M2!*15X%L'7T1R'S-5XF@4=A9"=EE9(B$G1RA'=H5&('YU]N-9$B&I-PUS(.%
MB'SEQT$*D7014=]9W8;DPYKP@SXHWN$EWDX67D_JY.*)6./E"8CA'_UI3>0M
MBBM12NH1(.WMWE-BGNM%I0!*I?'Q7E7>'E2JGCM=)55Z95=JF? M7_%]F>T5
M7U/F2U9.Y>JA95N6BUI:)?"!I5R.I5C:9?#_X64 ZB69)=\]U67%]&5//=_0
M0-^H%28^:1^BZ=^G)69B^MGX*29D+B9D:HU'H91E&F7\:69F<F91>N;]@>9F
M?J9HAF9GEN9H<I1DYM3/\%^=)<[_T>5:#N!L'I,!(N !QIJ3S-I3*:#J-*"P
MV(ZO\1JP7:"P$=L&%D1!)!L32@0(NN$G]F%TOJ%T0N=T H!YM. B,N=&#*(0
M0D0JBB$].(0N$N)TMH-#@*(JIN<Z0 1Y-AA#M,-SIN?E.,0<4N<1:F>ZS>=]
MQF%#N&(IXIL=.D01[N<;YJ=&N"<_7,048J$5)D0?'BA?):A05*<=,EQU&N(!
M2<D3RB$H6BC%/6=Y_U;GNAWB 0UBAOYBNHDH "RB3##H$]:#3*CG?;);C Z0
M>Q8HOD'B5=BG=4)G%Q <@ II(BZ<+&:%+CJ)*+(/C:XHNW$B%GHANJ%/D[(B
M9_WGE38I -0BDM(H37!ACJ[;&@JB&-9#+H[HD)YA'%ZH&+)BBI:HFWY/,"H0
M,=)I,58&.<(6;C$C,SZC-EXC/+@#H+Y#H+K#H,+#.P"J-"8JHA*JH19JHP8J
MHUIC-X*C;(D&.9XCS,W<IAK7.]X</7ZJ<\AC<CV7<N$C3-[C/O9CA2%D>C7=
M0N8=>!P=(_5C0J)7%&41UD$DUTUDUZF1&[G1V)%(L)9DE8@=V^&1VWFDV/_9
M"(P8Z[)":['V$2E1R1ZQ$7VM5ZS&9*LV2!65B)G<I.+A).&-JT_FY+GRI%!N
MTE ");NJZ^&Y:U":9MD@9;T:F#FQ)6UB"USNY5WVJY#-I6SZZU\RI5;R*UD2
M+%<JK,#&)<.6I;X>+%:>I;ZZI<1:[%#]:\8F[,!R;%YN+#H%)FPV'YN1+ "&
MK/3YI?.1GT8-9O\9)FL:U&/"S626G_YYFF3B;/F=YLZ29L_.Z\^B9M#R+- .
MK=#ZK-$2K?LMYFKN'V$Z+4_]GZGAJU96[.S9F+/D9M;NYN?T)E0UH%4MU:]Q
ME1<,9Q>T0W'F0 ;VCK$9FW(NQ'9&A'/Z*)K.Z-S_NJ(^Z. ,P*U(U.V9 L!Y
MQBT6LB=%R*<B5L28)N(D)D07@&)$;"B[B2=$]&@05H3!96G?LAL9-D3A3B<]
M1"A#"&*!SD*9C@2.,JDJ2@2$4D^U,83IVNTD!L5TPNX!32Z^Z>%,U&X=^B)/
M?*ET?FA36*[?LJA>G>CN(N+EYNCM'H4D.@5X'EQBB. L>"+=VNA-O.B(\H.:
MT@0?VBWR.NG P1N7*JF1,F(]),+T8NGJQ)LGTB'Y%@:5,M:#BJ@7-@7W?F*V
MT6+X].ZZ*:_U("XADNY2)$(;!N]^!K!+<&F;&F\OOFGYR"EJV6D$URF==M">
M.F,W*BJD#JJAOD,''^JA_RHJ-@+J!T?JHH*PI#(J"5]CGS:C!1NC9V0J"1'7
M#+,CJ!Y7J(YJ/)[J#OO<0-8JU GD0;)'J1+'K!IQ>^7JECBDKHH114:D1:X1
M1UYK%*<='U6QM*Z=LW[DL2)2VA'K%N>(@*&DC6 KK!ID%N%#AE'2M]HDN);K
MN(;KX,6QN:8KNM+Q'?]D'MNQ'M<Q41;M3'ULU4:LQW:LQA;RQQHR(3],P#9L
M(P^R[DVMPR+LQ3)RCTWR5QHLQ4+L)3/R[QWR)X/LR)HL*.OER9:L*8_RT[IF
M],$L*Z>R*VM,R^J9^-5LG+6F+&??9>8LRQ[::=(L+T=FT@HSTA+S'Q^M,0\S
M,O\7\S$S<S(W<Z8M[=/<<BN3VBG?925KLE/69@)R\P$62]=V+=@Z8.D(0@Z,
M[7!ZP=G^FG%J8-NR@-ON;7O20XBF+YC6L\/U@PW"0SP+3W>&A'L.[D0D0I-6
MQ'0ZA!$**$CD+@!X9W.Z(ND:#SV?X>=&Q/^JF^)N1((N:'JFKH&NKO0DQ(2>
M!)<.KTP@@I!NC_W2H0*CQ$+_[K:E9_7FA"KV;P/+*"BBZ.[^9XL.%O.6X1MJ
MKT_O(1;*-/8X;[^=XO'>+P,#EOARST+G]$M(M/H.12N4HIO"+_GL-%'$-/XV
MKOZZ8DWKA$4[R0'+;Q<&!5D#@%G#1 +#Z5LO<%\]\##_QK $VS5F=%P+4VHI
M_"FACO"CJC"BBK (0RH)![8)NT,(K[ W>J,\C%RE0O9>L_ WGIS*31"F#A<[
MUC!OV'!GPR,.S^,]LL>J(B1I+X=PB.IWT*H/KS9Z*23>Z8>$B5=\]6JOBA$4
M<R1_Y?9&7C$85[&-%-@=;3&PMI&+$+=OFUVRCG%P6TAM-_>(W"0;CQT_S#&:
MS+$;ZPEVD^L><_=V>[<EE>N=A'=V=S<><_<R3UJ]@K(V#7)8*O*_NG<BRS<B
M_V4G<W(F4W+IS?<UXS<F2W)^3^5^6VV,9;-_.W)]ZS=]D[*"YR4J[]0J0S@N
M6W.B.+@H!^8J1PW3_K+,NFR'_T?XRNZ9WFPX+1/SB(,XH2ESBC^SBCMSBZ/W
MB[,XC*_XC+NXHT6SA\LRRKIR;$9.@5>MMF#M;FJM4WWS QJY;R)Y/IBS%P@"
M.JLS!LZ VFZ@.R\G/X?T/'<OYMZSC_)#WEKY#X)B0W<$0&M$$=(M%2KH1 3O
MF??A0RRTF%?$0 LO0C^$2M_G+, Y K ODVKN1VBT13!N@T;$Z:9GFH\GE$9A
M0J0B'4;NM'D!^GJOPT7U4"RTEI<T AQU'F(//5-A40/6GF?Y5X_65O.B4..$
M\Z;IJ7>OA<*H3#PN]2[%HUOZ+H8;JL]Z61<%I--T B"I3:SY]^X5Y\YY^_J$
M(R8UJ/^/J%A+W%03.^^&]?6H-5NC1*:_H8"2J9FR*5S;-%,[!0+,M0-IZ@1K
M7%XK(Z568V+[=0JC\ BO>V*CL*.^0SO\]6&[NPE7XS;N-673@SRP<&3K.V-'
M=K]+]L +_+]O$&P<(Z>J$,+_5J<BAPR%ZLW1',-?-@R#!@QY-D$><=7!:A>U
MEVS#U]7=MM==Y!0/ZV\CM]H!"4D&V'%?J\D;]]=)L<M_<1TAV!C7G9W $76[
M<1NW<7;_/,\'_8?P/- 7_7?SL7GSY'BOB+@Z/=*7=]+3>/T1S5**&38#^(%?
MK(!S_<(:7]<O>-:W=W_;-^IYO>R)"MDS.-B_]]KS^-C_=]O_1[+<T_V.AWW*
M'E\I!13U<3B'?_@K1ZV%VUDM$SXP,V8N%WZ(ZW+BDWC1FG@PRWB-3WUI@I@?
MOVN+5S[>6+[D<W[D>WZ,@_[DE\V-__W+ZCB",^R/^_B0PYJ0;^W6+B!O?BWI
M](/9=M4$IC/:#IN4%]L[I]7;?CD"R.VP$WKQ6R=VPB!%!__R<^<@(D) 8_H\
M<S3S4S_U)[JU?;1=@;2V<WM<>_^V<W_X?W_W@__XB[]4KZCVGC_YL__ZN[_Y
MPW_Y7S_K2L^WHV-=BSO(6?9M478&"ZJ\ X2[=^[DO8/WKN#!A 0-,E38<.%!
M> P+RH-7T2!"B!KGE>I(3QZ]4B(__WHT61+E2)4B69YTV1&FRI@S79)<6:K>
MO'HX5>;<>8\>4'Q!2]V;)W)G2Z4\D>K$Z30GTIY3I59E>M7GTY].[_$$VO4K
MO:%"ZPW-5[;>67QI[ZW-=R\?-'UP[\U]:U=N7GYZ\^W=JP_:W\!]H?73M]=P
M8GV*^Q4^[-BP/WZ1^4F6;'A697V6*W?F_'GRYM"7-R\N'=ET8LBK_:5>#*TU
M:MFG15/NY[ER/\FS=//CO;MW9LS\^"TF;KSX[>+"D1M/?)RY<GW1H4_V'5KX
M]=O9N5OOOAV[]_#@EXLO__Q\\^_3Q8-WKQW^=]_]WO.N3W_^=OS<]WO?_U^_
M /,;T#X"___+[+?Y_.DGP=\8U.W!!1V<$,)9_)&PP@LC9%##"3O,$$,)/Q0Q
M1 Y+M/#$"E5,D<4-*6SQ11=7='%$$VD\L484981QQAA][!'$&X7T$,<BAPR2
MR"-)M%''))U$$LHEGY0R2B:K]#%'('G<<L<N?^1R2B^U%!/,,;$T,LPFKS23
MS3+=)!/.+^-L4T;>Y+R333M5U!-#/N?3$T$&#0Q4/T(-%+# 1 _\\\\' ^73
MT3HE;3!2X !E5%%#[1R4TTP[7=334$$=%5$ #SU5T5(U-75344M]%556957U
MTT)KC1765''=55?^[OLUOOYRG9578GLU%MEA@?4UV&7]<U995)__;9;:8Z.U
MMMAK69V6V6ZYY3;9;,7%EMQPR]46W7'-73?=<]5ME]U85YWWP4(=;1302/.E
M$%(\8<P18"D['%C@@IDD^&"#FT1X884'MG!AB!_V)V**)[80 (LESEABC"WF
MV!^0.>X'D2N\./D=+[KPHAV5N[CBY1RNF(%F&6:PF84'6'  @9Y]_AGHH(4>
MFNBBC2:Z'GH0J>>>>I9.>NFFGU::::?K@;KJJ:.V&FNIKZ;:ZZZY!OL=GH\^
M&^VTU5Z;[;;=?AONN.6>F^ZZ[;X;[[R/3D!HOH/V&VC ?Q;<9\)[!ASQPA4_
M?'$$$F<<<L<;?USRR"F_?/+,+=>\\LXQ_]\<=,\Y_USTT$D_??3435>]]-91
M7QUVUUE_7?;8:;]]]MQMU[WVWG'?'7C?>:=\\+Z-__OXHA%)!)$UFE^^>:]X
MVHGZZ:VOOGJKDKIJ*9LPFFBB@21R9_SR-YH(H_01HD@C]#6RZ'N'WID'GI26
MLM\DFUK:WB;ZY?$((2_)WP!I$A/]#; IU(.*4\8B%J(8I7M34>!6*/@4[5$%
M*PN<H%:*PI4'!L6!9"&+6="B%K:<Y2UWH4L*Y8*/N  &,(*1(5\00QC5*"8V
MJ\'A:'C(&=O@9D&?$4UK2!.;T^CP-3=,XA(;H\3&&!&*/+1-;8:(&TI9)CCF
M:8YTI$.=\B2G.O_H88\8UU/&]HQ1.VC,S'FNDYXNAN:-9(1C&)VC1CK>9CCU
M:4]\OH6H/A+HCXD"%[RT%2(%S0E-5PJ8DJQ$)4<B$I+^BF2/%IFF2BH23)=\
MI)HVJ<E&?I*3H/1DPT29R$Z:LI2,#.4JL_0F2;Z23K!T92QI.<M_H7*5M9RD
M+7?92UGZ4I<_\E.^^A0A?.WI7JT2E#)MY2I,D>J8CTJFOJA93'Y-\U+Y:B8T
MF?G,;7[3F^'LYCB7&2]WG;.<X"2GME9%2'7-ZUWQ])8?KQ5(80&2GOC4IR#=
MB<Y^VA-:^[PG/P4:4((>=* )798YS0G0:CETG@6M%D,-JM"'YM.?\J3_J$2[
MM=&,?M2C(1T6/#-5KVA2<U_(O.8O68E+AKW483%-V$Q)65.8TE1C%].IB#:6
M4X]U+&0?$^I/_=$*DZTL92MK61=>IH,KR(QF-Y-JSG;& KU=%6E@P^I6N=I5
MKWX5K&$5ZUC)6E:SGLUPG2L>\M@:N.2M57C!^UU<Z3I7NPX/KW+-:UWW>E>]
M_I6O@/5K8 D[6,/V%;&";1Q<&;M8QT:NL7F#GO.<Q[PU7 ^SV<,*!OEWDP*6
M(GX+$6U&1JN0B\P/M +$7TIF<MK1%L2 G/7L32(($M:F=A[K\Q]M>=L_ LJD
MMQ;D8%@:.)8.*K I"1PN5S2X6>5F!;K--<I/_XA27!"N92C834L)2[A"NMAE
MA7F!H5[(&\/ #*:&B'F,$M7;1-. !K[6B6\0.S/%'+(7B>[5;W[YFT/_OO>]
M4JSB9WI#7WZR!XP)5L\<O[A@.3XXC69TCQWSV$8[NO&.&59P'!W<X3A&>(_R
M$7&(0SQ0$B^TG\@"SHJ-^<I1OMBE,08F+UEJ)ABK\L:6E+&.<;QC3/98E<&T
ML8]/">0T"9G&2#;RFI+<Y#CEF,DSEG*-G5SC?E7JF)9J,9:)F>5J?KG+RGS4
MK=9)YG)*4\PFW5<TV;QF-^OKF.I,ISCG3$Z2<E.D&F6GF>\LYQ3_6<_C@NB@
M,6K1B"*THH &::(ORO\K0G/TT8CF(Z,/;>AM%9K2D3;T( ,MZ4IG6M%Y/B=$
M15WJ4)]:7GQ6,TI9?657^Q+*,K6IK&\Z:YS2VF%VVBF'),;3H>849#T%JL@T
MY@ZF>B&I*G,9S)XZLYI-56<.L&K/IGW6MW7-VMG6]K:YW6UO?QO<X=9;6LG]
MUL>J]=SE5NRZ"YO8=K/[L/!V=[S?76]ZWWO>^9;WOEL7671#-MWF!OBW)_L\
MR\KV@K7E;0$O MKUJ0_BI'7M:3\+$H7?SR2P??CY*%(3"7(ON-V3QVUA$L#8
M7ORW!RS)4K GW7ET!;LA/*YS,_@3KT!E>LV-[G.9"Y;J7K<L8D&+=DV8PGK_
M@!?IWW6A>,]K7J>C%^J&::]CT@L9VLP7B+G!8GQEPU^I(W'J3O0Z$UD#8/N&
M9^L*TKK:=87'28]QB\?AHMPU3&&[2QC$Y('[&S=,][[_?>]UQSMS1JQ'PS>Z
M\(@W=:H594@JIY+'D8_RXRD_Y"476?*8_W'F(;_YR2N9I:V$-9$[KWG33QGT
ML08EZ%E/8]7GLLJM1WWLK:G2X' 9]]G,_9:'N7M*C5G,=.YSI^M<_.';&9M\
M5KXS[;S\Q2^:^*%N9_2I#_U>:1K4D,:TXK/O:>QS'_R?#O_WQ9]X[V^__)$N
M<?<W_4_TDY_\SS<7_%%M??G7GZ'T*FE*^6_[VKOR__5J30!Q[=8*T-8.\&$.
MIM=XS6)\C:B$#=A^C=@@9AYR *E.1ME6AMEB)JJ@K:I\IMK$+:NB1@1+T 1/
M$ 534 57D 7A1MW<JJW\[05E4-_LK0;QC=]PT 9S\ 9[D =_< ?KC09C,."(
M<.!:D&T*KK*BQRI03N54*^->HN'\9WZFD.*L$+:N\']H8@NGT"6Z,.+<QWW2
M9R1"XB:P!X%"+N5^*[>Z<.74<+4\3N&V)[JH"^:NBQXTJPXY*"NF:[DJR _W
MT \'\8.$ NBTRRVZ2X46L2Z^J[R:#A)ER(;6B^R^;H?.3HCFJ\ $C#$JT1/W
M2^Q"D>R@*,#.[H<2Q, H2?_65(2> @_PO,@58Q$69Y'!8G'N  ^//"R,\HX7
MS>_$)@T8T^_]\$_.@$,_:*_TDA'V9H\9*P\9G;$9+8_SH)$:9:\:GU$51^_R
M5@\;NS$:O?$:OU$<5\K_LLP<P^S,V@S.@N_->L\=L2GYF,_XJN_^G$_.CF\>
MY9%6[(\8Z;$?^=$?.XW^M(\@SZ\@V^\@#6K]QF\8$Y(A'=(7#T\8(7(@#=(B
M$?(BV4\C)^H?C:4B,;(> 5(D2TW_#J356.W_P*Q2(BG'!M  71(!"3 F>4T!
M&Y !*^8!?PT"(1!D)&,&3"9E3F9EF(JIF"T'.A!GHJW:0G %L0T)GY)H $ J
MIS+_8ZA2*J'29[Q 'ZR2'[P@;69A*Z=R%NJ!:-K!*D/&*JLR+?W!*X4F+*<2
M+<\2 *:C'MI2;=8A$=8R+6=A'5(P+0& '[#R!#'&*NW2;1 A+L6R'8;&<.K!
M*O7A"/VF'69!*A,3+J42$6!0,WO&"QQ3+ZD2,DMG,JUR%MKAL#KS,O4R-'60
M-7TP"%L3"&'S-07NWVIS!HMP,\]-,,E*"2=KMGR+X;9PX\:P"O_'MH#K"8'3
MXX+3(UQKX[(0.MO'(=AGMTZ.YN@0@Y0S.4_"Y-:P"=E0@# N@NA0YQ@(#RNH
M#\L3$)D+/=FS*+RB$(L"#T=(Z!+1+>#BZ+Y+Z5[H$05C_[PDL>KPRQ)+L3:R
MCC) (S-\R#3XH2\(@T'](A]BR$$G%$+5RT+!+K]<(Q>+2#Q6C.VD<=<@9O5:
MD18?3!<QK,'X+NYPT>].],(H+!A_T?Q <B-'<A]OS_%6Y)#"D4>MT4?!\4?'
M,4A[U)9V%$>W#$B35$B5E$B%]!U_C_>BE!Q3DIB6U$JK%!U?;4K/<1W3D1WS
MT4O#%/C$])G&%,W(M/GD<?IL-"#9U$U#$DX[4D[;-"0_LD;M]"$S,D8EDD;S
MM$\C$O%D5% E<E#W-!C_%$\G4D\5%5$;TM/B-$\7\M *]4WGM%('!1[3K/]2
MBDI7DO):4B9A4E1#-507$*@<,/]D;C*HALVG5M55%\0+@%+9W,%EBE)FH.K9
M9$ IS69GD- I=Q,JN\ R 6 6@#5H\O(LB_5LUN$O_2$JY7(QWP99J9)BBH9:
MJ=(P?08LN\!HY'(J$T$$_S(PAT8OC36L"!-;X:8RJ9(RU5(JP75HO&!8L[5G
MW'4JO?(V 0XQFU59<Q-C0M-G/),K\U5R$.%:Q3+@VG4U75,V&Y9A'S9VAC W
M(Y,V"=9B*]9<,Q8!>O/@/@L,I7-\2FLZ2TLZX:<X42L.^T<+3[8BY <CZ <F
MG',,H7!_LI.WMJ?BS/ XE;/B$ ZX>O8-QY.SN (^#=%H9RX0W9,0;6X] ?'F
MF%8^C5;_Z.BSZ/#3Z(P.+_Z3Z9[N00MC$MTK0)F(BN!K;(&(BKZ.0?4!'_0A
M0M>V;=DV']PV;N'6;=66;=4V;1N4;8MC;_6A;Q_T,.*.3SWT18P4\PC&)@_P
M]B:,.I[#<0/O<7,1%F]Q12N7<G-Q[AYW\"A51AL5(DO-& U7=)N4=']T='6T
M<%,7=5>728?4=8M4=7-4=C^4<,O)4CXT4&[W]W"7=W?WBI 426D7>$NW=9/4
M<+_Q=&572L\L4YE74V_O2:%W>;4,2JO7>:^7>K&72W7/3,O4>[^T>],4S_"1
M?.V13BT54B]5??\T?=L7?2TU4>/743T74$6,?DV,4#&*<_/7_U#K=W_[MW/O
M='X%N" I]7XI+7TK\G_]ET_?]WR)CWR;EU-5\LI<#TU&]25)-8,W& %U#551
M%0!4-=AT4@(UAF1@)MEH=2A?)F:<+:IT50:DS6P08(:;4JLTE@6%=2^)9EHO
M,UJ!QBP/%@#(-379M2\1H OJLFUZ>%T_TUO/\EF%6(JODH?7LE\#MET/]HK9
MAAZ>^&ZR.!%^.&CX05R)F"NC^#*/IHLM$V!_I@OL=2Z%9HV;%0#HP6>4!FB*
M& #H%0':-3'I56#9V&>Z((OA& "X]6V:6"KMLI K<XOE-2WY& '(V(GO]6S\
MV"H166T:4UP)MI&K4I-Q4V)'691+F?]BC= V,1:5+W:557EB4[F58_F5TPJ'
M:YFK.#9Z2BY^PJ<=>#E\R(>T@ODAAAF8Q9 @5K9E(V(CY&%DSZ=DEQEEFQ,Z
MY? ,CP+D@C8\@XOA/NL-L;,E2 XYTU!HM<>#?(X^@6*#!I%HJ0MJOR)JW]F=
MXSD^W;FX@JYJ[Q.%\#-K'U%K)31L+W1 ,7&(!OHRK"B+% -"82@?YO9MV[85
M(C0?'GIO(3IO^59O^^(P,/H5)57%GDR#B4I$0KBF5I=$:Q%S6_1R45JE652,
M3CJ/ZHB!_13%'KCQ#$1YB?=*D>QX8W=XC_1W?]JG@[IX<[IXDY?W>A=Z/R5\
M;?>9=#>I???_J=&4J96)Q8"ZJE^7J)&7RHS:JK<7J<?T'LMT>K=WK-OQ>T=E
MJ;DW'J5ZJ</Z2]UZ?,\:KN=:^,QW?4>*IMTWKQW83>5WK^7)KQ<UL.EW@0N;
M?V,:L0T;@ ];L6>4@ 5[@&5:LAGUL0\X4AD;L_NWH=!/K^TO@I_W3"<82U/O
M@C\:@V<2M4]; $TUIT"X54>8J$2&061U951XV5JX Z=*AGVFAFW9M[E-ATE3
M:/95N(\&DRTYCU-SB^6&B3D&;9AU+=%X7<68;9J[6H&&DL\27M/FC?48 *A;
M:+I;D0\V,X&&D*=XO.'2C*ER7(6F7)'&N]-;OH<8:.:8*D-YO0U9_[\MTXZU
M]6 E65N'%;_79KRW^V>.6RJ5=5[;Q@NR>UCIV[_A>,#;1F#96VT^.60F/&Y8
M>99=F91/N<-E^<-A.<1?^;=/',71!I?70&9=5I@S GR<&7[JQ^&HL+74APJ3
MF2-6-L>'DWU>U@L]=CFK6;,4CB9J]INAL&<3[F>S.<E1CCSUT'KHT[K,&9X_
MJ)WG&<NOW,KI^1#IH6KS6<RWEI_[<Q(1X[SZ@4*MCD.QCC-0$3=0@T&E3F_E
MUL[O-J(I&J(E&J/_-A_ DJ5A-#O<[EAJUX)?LB<Y1*1KC:3SSG)7^M%95-(%
M%Z;'0] -&('Y>G&Y6DLX_:H_/:MYVJIWQ/_32UW4A7K&=AJK<?I+3'VJ7SUW
MSSJM99W6P?>LG1K7F]K5AYK55]W7<UU\Z=K609NLWYK.;A2N9WW8I5K8P;39
MRU=-[=K9ZUH?__JNK;VSLSVR*9LCJX_3R&6P*UO< S6S$[O<&QO=SUW=%YO=
M(9LBMSW<)SO>N5U1T[W= QC;-7W/U%2"3VJT*U@;G42U39O@.5BU61OA23@G
M8WNH!*$+4EC9E@JW.Y %9H"J9KBW4USCPRJXV75H*APN =Q@BWB]T7*YX\:Z
M3UYHH!N*\[LJP5MM4MY:]9A>6=XR8?ZJB)LJRSMH6)Y:71XPI;LJ^WMHD-4R
MY<:^IQ+GDUN1R5+_76D^: (Y+34<;0K<:#!\ZH-F7>D!P!%@*X?UY'7^6MLX
MO*N2[$%>*ML[;48^O<D^:,3;[3=>[N>>[E-\Q3GNE_.^(4*6XTP6?L+Y(W36
M#*,".4>.9L%S"W&+QH$6\(F<#W\3\I.KR8_<.VONF@\_9<799['3#NO3\ZN<
MR]_3#D/?RZ6VRC^?N_ Y/Q>1S+F6AJ)NO6SH:]D\P#*Q,ZZ(=M-(.>J<;M5V
M;EUH;8&_]QV:HOWVSP-7ZB+=P30;V54]DTQ;MC&&IC9]/5)ZPY!?[K _.;1?
M^5T:<B]]W1^U(T/WU#]]UWO:_,O?TXGZ_+M:_7L==ED7_4G]_=O$U6.=_ZJI
M':UU/?_[']:_&B#XS>HW2R!!@P4'^D-H<.' A/T<1B08L2%%B?XN:E2X<2+'
MCQY#9@0Y4F3'DBA/JB2YTB3+ERYC2GQ8D:9"A@/[X>RG\Z'!G@=S[IQY$6%1
MFT&30H0(M.G/IT*C\H2:%.C2G4LI9O7)52G6KU*9[K1*56Q7LF'+JDW;U6S5
ML7#/QITJU6E=JG;IZLW+%Z_?NU'Y]06\]V]APH,/*T[,&*I@QW8?!XY,&;+A
MGI+I9L9<>;)ESZ U=Q;]F71HSJ51@Y:\62!KU:]=PYXMNW9!VK=MQ\[->[=O
MW+]U Q\NO'AOXKQ-FPZ>7+5RY+N?VUZ.7/KQZ?_.LV/?WIQ[Z^[@F8N'3OZR
M><3G%Z=OC+[]6Z1;E6J=#Y)F2ICW91+T=Y___I'^S1+@@  6^-^! AJ8((($
M,JA@@PM&".& #U'HCX0"8GBA/P#LER&'&P(0XH7Z=-&%%RB^X\6)[:S8Q14Y
M7#&#C#/,P(*--C[  @((.,#CCT &*>201!9IY)%()JGDDDPVZ>234$;)Y#J)
MZ#,+ %B*. L]74CIY9=@ABGFF&0F6:6 6=;C19E&MH,(/UD",(L^B"A)3T%Q
M8CF+FEVR660[58H8YYR(M--D%XC$*1 ]?C;*)*#Z"(KEHF$F<B><6')(IYJ.
MFGEIGINNV>FHI)9JZJG_J*:JZJJL/HE((HBL$>NKL;X#CSOPV.J./+:^PVNN
MO_JJZZ^X%DOLL;Z6,D\I]##K;+/0*OML*?4X6VVSUU)K[;;83KMLL]]*"^ZT
MXY9K[3S59FMNM-U&N^R[TH8KK[/A8HNNMNWBJ^^X\,++KK?D!AQMMO7<>P\]
M]Y2"3SWXT+-PPPL?+'$I$B.,,,473ZSQQ0T?W+'#%G\<L<,,TY,/P_7D<\_)
M*JNLS\K0Z!/SS#+S,[/-->=C<S_0[*S/SCI#TT_0_>C#LS]&Z[-0T0LU+9C2
M_&#4T-0W923U;4G;S(\^^NB<CS[X@)U/V/B,+7;87^O,M=I:_RSTSUD;S<_6
M_SK1_;1.16-]'7CJD601?@X&+B& ':*Y7^$0BF19W7+;[7CCD#,N^=R14XYW
MY44S?IR5XZ6VWN=22024Z%3K1?I-H5-U>DUZN76UXG['#OOLKZ/TMTRW8W04
M[;O;+GM^P+<4/.#XY6[\[[TGCSKOR_M.>^FUEP[13-)7O_ST0V7?%?776\^Z
M\^#O;I]1UXMO?O/*ZT>\^NP/W[[P\,L^OESTOV<_]MN3S_I5;<WEUO]K:5T
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M<S%_[(=^ZV@ZXS>0""F0"FE5B- %,U ./W( /#(#ZX (\["0)+$.7?!(0'(
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M9N:[:4QI[N;H?_[G)"["B7A>YW8<'<]91HNYB.W;F9Y(/7B$'NE3*^V2#K,
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M:)H!S;I!&7S!"-2/G&HL<M@I25,U"T1" U3">JL/@$H=FINW!G274GDL2D-
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M3+TRH:#',AM54_6A_CM5?%S57'75A:U8@\W7?STK>,75!6981A-@!V;@<AU
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M48YYIIEMIJDEFV'V\^::9LZ)Y9U:RIGFGFOF^2>??O:I)YY[EC2G/X0JBB@
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M;,JEC,JGK,JI3,I=(!)^J#NPG'&Q/ .T;,NSC,NRK,NUG#L_H;.&[#N&W!/
M/ /E\ "?7#]>"P#RP(F,C,F6[,R//*%'$;B'6UW+-:+ Z+C63#."V[A.=XR"
MJ[CM.$-8)[EKQT(5*EY2@5_IE<YG]QG9R':(<8WP]1F- 8ZC*J3B2'R:NKH#
M=GQCDH^4!Y2F@9 #+54>QDZGFV'C]F*.-[QCE'CY,1Z^2Y'#"[T09M'B%C97
M-'EQ*F!L.A]35;VOQWK>\7DCK699"M&#RI%T2J>!(V,Q+:C7*[[$.<<E>[XK
MJ7N0&KE9=JGMR[[-%[]%'7?SB__4RI3/>[=?0<F__&O.+9Q+J;JJ;8:KO$K$
M.QRO69W$78W$7RV#YB?!(ERL;YG 9,W5/HRLVPK$XPK64<RO37S$8:U24JTF
M48W7W)77+JS"?3V8;0W8.*S5@QW8/RS8A4W8AZW8D_G7^<HR Q.NP%9KRIJ7
M\PJP<'W9<8TP)"Q/9D.$5ZR$1@*E"CO:6OR[#LO%837&$TO&6VC&AP/;O/E6
M:]S&M0V2(:O3N7W3.1TZ;ZBROXW'#">'K ,/,0O(%7>SN#-9&\>=@?AQ(Q'-
MG1RWG S-TQW=U=W(U*W=U[W=UNW=V>W)R%P_,L"U6MNUYVW>Z5V*_M *J&BV
M9'NV98O_"&1P!3T[ UT@MH)PS C0!4A!!CJAWJ3X#C7A %D+ *XLWO*CS,QL
M/]R-G@YP!=T-WM]=<].\!O6 X7BKMQ?ZM[[H=8AKMU)17AV>HM3US<((XBE^
MS=K%HBCZN"N]72G*=MK8HU0AS^D\S^QUN7N+N3C^SI[;&3^:ND#M=CQZU$[:
M#W6'CFZJ>20$XYHGNP"-OTP>IP?=>KB;TL+RNQ@=O3#-Y039TF".'Z/'NUW:
MT2H]TB#F>0&VO.X88]J+1V^NYA4]TS5=D6!^T26]8BYMYXFJDKJ-V^,K9.(+
MLFWTT^^;?%$62J 1)91ZJ9GZN?LEZ?2;U*$*=WMGI-RE77?M_]=3W>F<'L3X
M5WZ5IL%=S<.);=B"AL2439AOG=;>.M>6MMAU:==K\<*(?7VNCIA</>LH6.M3
MA^K!CNN]3NRI+NS%?NS&/NS*GJYTS>Q/C-E0K-G3?MDD/,6A:379EIJC*;!!
MN,6FG=KAWKNK7;&LO5:QO;%IO)OZUCBV#9QO/"1R#.B\;;(H:\?WKL=W[+((
MASNR0SO(W8<:!XC=B5D)2HL4OLD.CO#2/>$-_\P2_O *[_ )O_#8'?&FE> B
M0=X&3HH<WY\!_O'K[;7M#:#O_=YD, ,&<=\F+Z 1C@ S0+;_G1/\4(KIT 7H
M38HNSQ(%7HI>D/'PPP(+3A(2?_%'"_\/'<^?$$_Q$[^(%EZA3;'A? OU?5NA
M?FNA3X^AO)C-O9@DT(7B@IL72IPK6'=!8,^Y^>7.[*7VH5NY]+#C.9[.F"NC
MJBM=]VQV[[5"FNMV^0L;"1;EU*=V=F>.2MXE+TFZ_ RG;=IAD8L;5N[XRWN\
M<=J0QZ$W7IYZT9N]V4O3EP_G1?2F#RF[ZD&/>F[Y5\Z032K0A">0\'[28UJF
M>4[F?"[[U_N]A(K3NKV1)\N2;S2IYRB-\;7HC1[\BUYV0"[4\.NIL?1*EAZ[
MZFM?3OWIMA[]P [J0GGKTL_7V2_L;PU^<YGLW[_LX-_KNA[K?!GK\-K"IZK7
MZV^J>^WIV@__ZN]/Z]>O[*O^[+_.ULC>:T+I)O0O_CD,$/EFZ>.G;R _@00-
M*CRXL&!#B PE/ISHT&)$BADO5L2X46-'D!Q%?ASIT61(DBE/ED2Y4F5+F"QE
MOISITF9,FCEOUL1ID-_'GSX?!IU%U.A0I$*5%DW*=.G1ITVA.J4ZU:I4K%&U
M5LW*=6O0?E###NVG;ZS/LF>+IC7*EJS9MG#?JN7G5BE=MF77\EN+EF]=OWL%
MU_T;=K!APH<++U8LN)_AQWPCSYI<&?)ER9@I:ZY,>;-DSYW[>08]VG1HROY.
MFU:-NE_KU;!EC_8W>U9MVJUQW];=._=OWL!W#_<=W#AQX;H]#[]]_[PY<W^W
M 42G+KTZ]>G/9\WP\LY+%R_NOG<!?Z7+E1Q79JQ?+^,!"P?P$<RG7[_^ ?OS
M\>??;[___?P0^(^^ ?4+L$ !#U20OP7]:Q! !B-T4$(()[2P0@P)?%!#"CF\
MT,,,#>Q0Q ])##'!$5$L4<43$71Q0Q-!E#%&&EF<T<8:7TQ1QQ5Y;!%&'(-$
M,$ BBS3R2"23E&$Z )ITDLDGF_0G2BFIA#+**:GTIQ4C65@#$3)F<("^&;I(
M!)$OSTP33434;)---\E@83XOX+3S2S*2U)/(69Y<)T!U^L0RRG?V1,"!+)OT
M LE\!FU2'D/GN_))?Q A\AU'G;PBOQS>7/_SRQSLFZ'*)O69(<!$2,V44BO=
M 9(%*Z>$],?Y[G$R42=;<6<&\=RYE<H9?)045R?Y04 &055E54L ^AE3QBLF
M_979*%L1-D<@KQ4R6V[K\_1.?/"Y!Y%[Q$4DW'OR05===M=%-UQQV]4G'W7G
MK1>?>^O-9]Z"YFUE7WSL#9A>?/[U=]]\_FUWX8(1+BBCA!#J-Q^$] D8WW37
M+;<>?.JYAQY$/.9X8W$[+GED<2U6&6.+\[FGY9?3E=GEE6%N^6*:+[8Y8&@D
MSJ<L?GK>5^B@'_Y9(:"A2;IBH?5INF>"CD9H:8J5-@NNLOP!+*RLMR8(ZJFO
M[DOKKLO6AVRLTP;_^NJP"^(::\FT)GNQN563>[+$$GNM,+_LYL?OO?P6?._4
MXOZ;<,2U3HVUN%EC'/"]YRY<<L#01CNMJS$W^VW.*_=<K[]#5SSTPB?__.S3
M@3ZZ;,,AM^TUQQ=WW?#2\89,\<1;SWWVQ7N'W??B?M]->-N0.ZXXXY-'/GC9
M#D?,[:^9GM?IZ:&I_GIH\K%^>Z>UIYY[\+\7G_NAF3:__*HEMCKHI-=V'^FO
MWV<?_J /BCABA_"W'R/]H[;?: !&+8 2$Z#_"DA !%+L@/<SFNJ,QK^>1) G
M'"$*0RK8E GJ1((:S.!..(A!$'I0A!L<80=)")$++L6";@-+"UGXPKM<_T6%
M(:2*"6?2/X1 <($ZA-C_#)C  2HP@3X$X@*#>$0C_E"(]]O?1'!8P@]>)(4G
MM&$4FVC%*D+1@SCD(@^U2$4LAK&+3O3B%?-7QA^>,8M@_.(:W1C&-L*1C7-\
M8QSM2$<YFG"*>^R*#+WR1S\&LH^#_ HA 6E(0182+7)9)%X8V1='1C(NDIS+
M),42EZK8Y3"!R1MB/,F83H+RDXT)I6,X<\K,I/(SJ[2,*EM)&E:&!C*N<0UL
M0F/+V,4FE\Q+3B^/YTOE 7-YPA3.<I1#G6,Z!SO7L8YVIK3,6=2C"^+Q0GB^
MXX5VC <]ZF'/#&0P _C()TG:(F>W>F1.6IUS1__HO%$YU_E.=<8SG?-L)SNQ
M!4]ZWE.>]<0G/_>ISWQNJY\ ]6= W?E/@2)43TLBEK*FM:J'+@M+B>C2I[[E
M)HS>Z5NA0L ,,FK1.$5*I,D"P)^2- -^Q.I)B)A3@!#UI"XP*E.S,I2TI&2I
M(STS5HNRCPS*T"89:,A73^+'J1#J(I4"@*<U@A6S:!HC7S44 *Y:YY(D6HX9
MV91)]U#GJ"(*@$WQ"!Y?!4!"#6I/LQ94K3'ZUJ=$)JY[9(QA F-7QLQ5KG&Y
M2UT&2QC !':SOQ(LL'MUF#[F-1!^&;:O^F)LPRPV,<CZ56,F>RO).';9>UPV
M7BSCK,M<UK'/UB.TH3W_F6=G]C*,F;9ZYW.:^AH8-:JMS+/X&EAKD>:UHJ&O
MM55SW]9P*S6KY25SPW4@^N87-N%:[G.B1)WFTK;)NHDN<GJ36][N-CK6;9*4
MUZ7=[[S[.O VKG:XXVY? I<ZX@8WN,-5+NC"4K?([8YTIVMO<XEKW<.5][N[
MU!UY\TL[ZG;7OY/;7>(8![Q= H=XL0OF+QW<X 8OF,">9-O3KC<T['D/?!I6
M6?;"]^'N\:S#XJOMTUR;OO3%3\7'75^%Y;<^L$&#B&/L(1EM7$0<+Q&).=ZQ
MCI.8XQFC,8=U1"%0C"S%/";YCD1FLI+Q"$4:+_DE?$1RE8MLY15BV<E-WF*0
M_W_L8QY_.8"))2"9%6AFR!80S8KM\0-OK,8MTY#*AYQAG9]\YR8_$<]QEG(<
MHVQ&0*<QT$.N\<.4Z.9"PUG1@]8SE_?<YT='VM&3YK.D*\V2.6?YRG3F]%0T
MG<A.(U+4B@RU(ND"0TA:LI*K;J2J6\WJ5,/:M^[EFW9+>>M1XEJ4NV8E*GOM
M2E^_4MBS- VQ8[F:6B+;N[=4-G@3;!P)0WB8#YZVM(%I3-H\)YG0:>9ULO/,
M;F>G'X*XPC6] YYLDF>;,^"F-[TI@W#.YUE$.NA9!YI6@N8;W_NN]UKYC=9^
MZSO@_[[WP T.<(07/.%'7;B]&:YPB#_\0PQ-*D0=2O\J?:SC60?H0CVPQ"4+
M>>FB&OVHI[P0+ 28B>0KQY-(];0?7)ETGS) A%0392H$L !7/'U1HR1*TVMI
MM5([\@*U & L&M6\6$:]U@QL[J1[)"*H!TCJ4H/4U$$]545#%7K%)?KU&=4F
M5A2-9TH="H^$CO7B!)>XP]VNUK9ZBF#JNFMFX3JRN))KLWL?%U[UGBZ"\75B
M?TWM9/MN][C6X^\,F^UF"7LPBPG>89(U+64_%C+$@W9CHR79YD\;K]-67K26
MU7S.9%OBBM46'ZGG1\!0:UK3@XUBQET=VX!;W-WF/L8/,W'YHN?[MJD-,-!%
M;W+K(K6?$09M8QL^?9V?%[[_+?_6U7UO?+DKN>DB1K\#_JYXNX_@\3Z.<,T7
MKG/-5E_SW]=L1=E^Z#"'7/OZ0\7"9?]_!T?> W_?^OWE_WC[OW\"PS_PDS "
MK#8#)"9J0\#AL9OI@A[=N[#OX;#MX3">H<#NL1Z_VC"<>;T*1#W=ZIGM.;&B
MB9X5@[$7<Z 2[#$A^S-!.S07)+0EFK$V$S,:#+,ANC$F6J-,D[-+ZT%(H[0?
M]$&4:+1$8S0A"T(DM+0D' D6A$%$ S,H1*(UF\(SJ\(T2RPL]#$J'#,H]#(Y
MFC-0\S0: L(AY*$8W*$WVZ F7$(A?*,F?,,5],(SO$$ZG,,Y7+063 DB9$,^
M5$(__R1#0&S#2MM!.PO#4=LT0R2U1"PU1ES$0-(DWY(U2)S$OY#$1XK$5J,U
M\^HD3LHU3^0U72.E41HV8"O%7SM%4CPV510-6LHE9DLV6-PO\+.V!*Q%6KS%
M W2F;=NV;WN.;_M%:(H.=\@!\/".<].F\SB/'&@/=V.!]XB/>=N3@XNXMQ.X
MAO.W:6P[;+Q&:Z3&;?3&;M3&<*Q&MB/';#1';BS';]1&BC.ZKTN$L)J/+K"5
MBQ,ZD*L0D2LY?423F.JHD0,IE@.3<^00DI*YM\.4IW,2GE,0>L@4?5 KA(P5
MG$HG%A 4J3*'_! $?WB %"F'I.J1JCL1K&,5K?L/KY(JKO\"1QP1.RTANW0R
M.VE!.[$B*W4<QW5$QPZ).S7!*[K#%\&BK;JB.[FB+=!#O+R#%WJA%X,9F,::
MGM5#F*6$&9<QRKP*E\'RR<;BJ^F9/7ZA/)G1/).Q++NK+,NC!\HZ2\TB2[EZ
MO=!++9D!K,YZO=&;+=/3&:(!KO-I&[S\O=S2O8J9O>.2&N*B'\'DG.&"O\XQ
M/_0*/M5IS/EC+TYDOD],-=:1/M IKP"C'$\,# #L3&<;P/ *P+^@/OO2G.>S
MK_/2/O=KG<H1(-YZ3/E[O]KCFO]K'O\3S=L<OU$<L,PL,.X3P )4L%PTGF@;
M3N,43KX9"ZAY0 SSL/&Q0.>TG@K_Q, .\YX,S!>VA$M]49D/9*W>&T'P-$'"
M/,$:A,,T?$$&0D\Y?$+V5$\TM,'TA,_V)#0\%,0^S+,_M,_\E#+S+$+W]$_Z
M-,+S#- \O$_]S" :L\/YC$\M;% N?% U<U VF] RD] *#:(KVL,3(L0:.E ]
M;(@%7<__O$,!!=#^K,\3M30-9<(X'- $#5$7;5$3E='Z-% ;[=!"/+)-"\0;
MY=$[ \-#Y%!'#%(BW8I/*])&'#5*>C4FC;5.S,0GM;7)#$4JG5(K-<54S-)@
MFR57DJ726,6B:,58?$5= DT&*Y[CM,4TQ44%K#9MRS;L@--N\\5@I(SS\ )X
MJ"9K*H]D_T0/9OPF9XRWEI+&=!Q(FSS4FDQ40U740FU4E5Q42'54<6341Y54
MG)S42.VG=GR2?%"'^IC'KG-'LIJ.>_20? S(,Y$3.OE'5MU'/,G4*#'(FP21
M+NB'25E("5F'4:V4*W@6%I@!>B I ) .+9E(?\,4:K$Z<O*ZJ?*"<O"F5OBZ
MAQ))E2I)!>&Z>A2/H*J/<D@51RD1EIPH>())8I')!T&$>O342EU73-T0G403
M>J@'D*D'>0V9>A69Q7,7OB.7S,(\Q4N\?&6\PG,\H&3*#11*?OU7@N6K5E L
MG#BSBRE+?SV9TA++>?V8S,J\T)L9MP3+N?Q*E/E8J?2\V$L]P/_JSLE[+*^\
M&9\QS/?[3J)IL?1KGZNY'/JI,/.!K<'LK?.;-=3\K==:/_(#,$T<VDTLVMW\
M+^ !)=Z\':7=O_OSOM#,G=(AO]+TV?:"AOJJO\%Y6<><'\V!L995OE(R,/_C
MG0"KVO?J3>QB#,\4L/Q#TV<+SEF4V]Y90.%$0*K%+0N[3A'#&< %K.P)7-HZ
M6>YLRKBL*^W\V]5"V=8*P11C,=[[6K$E01OTB!1ET?<DT1&%4?DL3PB]T B=
M02?,PQ45PBGRT2I:PX>ET4'K44',7 *=W?Y4T,Z]W=F%73:47085T2T<7> 5
M7='-PBNT0@HUW@KUPAK=S_SD7=>]W=__K4-$0]$C9%[5]5 H:]T8W=X9'5#=
MW5$>U+(<%=\Y2EWLM=[P140D'5)%7%\D/=+VC=\DE5^KF,1+M%^\J+7(W-\K
M%450[%\MQ=(M%6#0Z-)B^U)65#;?(5,R_4Q9I%LV5=,VG6 )=HYB0B8YY39P
M\S9FFI+1*+<\K2;Q( ]U4\9V^R9 A<;Y&%0DR=1V9==+C>%91507EF$:MM09
MIM07WF$;UN$>KN$<UI9V$-90M;@BIA27-%6 7!..\JE61=65"Q,?#N*%8X%^
M!.(;AF$JUN(LYN$M]N(N_F$<?M<U2+R.Z=>XFM=ZC5>08>.)Y4ETT3N\P[NA
M)+S/,F./N=@Y_Y;CA+T[N#J\PU,\>OW7O.-)O/)C,_:\L)38/,:\>?58SO-8
MRKICV#-DT)/DS2M<3;X7E>7.3I;.G*D\U#*SI5DQ%Z.?IM&9I]PM]@%,XUH?
MY./9M+F<U,$MR'R_6;;:Q+2]]RD_H_UEI_5?XD-:NGG;J#UFJ/5-J>4OW#S-
MMZFOK>7?4P;;]:)9^B,=JE5FW$2<8,[FWQ2PVGQ:!Q[G,RUG,X6VS\1;='8<
MU:"PV*).U1/<T]-.#C3<$H/ "=Q J2R\4![E>,:P[H3<W K/R;7<W?LRY2W1
M[.5>ZMW<!0U=Y(WH-!->B49HAS9=]/W>&WI>VN7HT]7H)&-=[_5H,__TW"@$
MW?]LZ)SXZ.8EZ3<S:9@^WHFNZ.BE:0NUW=+-Z=[%0<]5:9=P7N[%Z?1<L]*E
M0A\ZK A-:(QFZ(QNZNL%ZNZ-ZN6]7D@SWZH^7ZJ.("%U7_KEZOG]:O8%:Z^6
MH5.[7[.6)/=Z+O[5W_ZMTO\E8%0<X+B&Z]4PM@0.4P4N4[UNX+GEI0J.8,!>
M4S>]8&4J[ VF4V?*#FD"CV*\IG0SX6X")W!287E[.1P.XR\68RZ>8LSN;,[^
M;"P&[<L6[<T.;=,>[7J; 8U,2".VN5(ED5--$T'@R)1;XB?&$S$I;=3>;=WN
M;3 F[=\^;=_6[."^1C*.X[CJN[HC9.6V*ZS_K$+$JD*ZTJM_;BS2:N1XG0=$
M<.-!YM= ABLU!AF A>.[ZIB /5@\QM@\1LM%QJQ''KU+!EG2(CV1566Z7$NX
ME"V0K5B:2=E5!LS>LRV?\<O(C5GO5!_'5$Q<3G"UT5GC6_##+,R;-<V>S2Y.
MW.7ZDTRW;5NNM9U%HLS2S)SIVW#[>]O<]*_9<9VX34Y;?N:AK2[!J0NE>67S
M@V6>)?&SU6;=_#_55%M>,W&S?6"_%O*^+O)S5F=UUC_LPEF_HKP.%-Q\>7)\
MX1ZFI$XKEQZO#$I^KN?";7+J<=P -S$2%/#EE#T5W-S7=>H/>E'TG,&:GFG2
M%6JE[FBFSFH[_] Z_Z?S0N/<W-TSEA[I.V=SG99!&GQSF3YTHC[ISZ5#GU9H
M1U]JJ7[T05>BHQ[JFX9S1+_T"27>33=>3O]T3^_"/!?I2,==2^?"2F_8Y$UJ
M5E]U5X?N]VQT2)=UK*YU/W/I4M=SD-YU->=U3!MK8.]J81?K80]K8T<U%XJA
MI'"D3#KKMF!K:!=FMQ;F )YK:Z_V!+9KNVY%7%I@5S1R)!=L"@[L<4>>-]7%
M#&Z6Q.[@7H2F?D $\VAL=-.F]$@/]D#AR6ZI:#02X2[NX<YL@/?L?B=N@@]X
MX"YX@>=M?U]XA!>H&9B'78V5UU:1?-P4?[3M5+5X@Q_XC5?XAN?XA/_WD/]G
M^(X7>74DX^0^EW@)O,+*0JV<.^1&8X*U8Z"T*YN7%\&"^>6VU_#F>7F]5WKU
M;I57;H55V+44RNL>2XRE!_7.//A&F8ME>JD/F=+[RM,:6<?;;_JFY"W'>>KI
MK-K2,=WBRL %OL$<<%5NW.-J<,;4V;:1/9H%S]F\K0J//Z_9'+=7:Z&E,&C&
M6K)E(6+N< Z?]K7.<&-.9N!$\2!7?.ICZY]=6]D409D]3)D%YG!&V\G4S4XD
MVA_G<&]., 8\9R(7?7*NV[R5';PQM-PCW"@/L<65Y^D4GX!>_98!Y:,'^]<'
M: +W2\C=_::QPI:WZ3@74?J<WC3'SU$O:5,G_IW_9O0,[6E)_W-;;VF>AG0Y
MO^A)E]Y9C_[J#<0HB^GL/VE#'_]0+U[S#][KUWY=YWY S_7:C6FDUG[RAU!0
M/__Z[W3[M^E*GW.H5FD^;WZ R,=/G[Y\L_0-/%CP(#^!! TB=%BP5<2!!0<V
MM)B/8L:'&"4Z['BQHD>2"TU"%)D2)$.6$5LRU <3H4R:,6_:S)E09\V=/GL"
MQ?E3:%">1(\:33I4:<^419="?2H5:52J4YE:S8IU:U6N5[N"_2I6:T)^9<_*
M-)L6[2RU;=FZC0MW[MJZ;^W*Q4OW+E^U_?+^11NX[N"V_?05YG<X\>*XC07G
M[?LX[63#_ Q3OJQ8\U_+_YXW?^X,>K3HTI?[=49].C7KU:YGJ8;=6O;KV+93
MPZ:=NY]NWKYW __MVY]PV,2#'^^7?/EPWOZ./W<.?;KTZK.B7Z>>W3KV[MJ]
M<X>>N_OU[>7]F4>O'H#Z\^S/7W_O3[[\6>YR=/'RSDO^_EZN='%%#E?,4* ,
M,QS(P@,L., @ @]"&&&$!TCX((457BAAAA-6B,"&$'YH88<A>CBBB1B>J&&*
M'*+8HHHNLOBBC#'2".**-L*(XXPZUBABCC[N"&2/)?Y(9)!&#DFBDC<*R:.3
M34*)Y)-21KEDD58>B6623%+9I993?EDEEV%Z.>:(,] #@)IJ^M/*CUX@L@8B
M9/]<X8"85YJ)IYY9YLGGGEO^"6:?@/I9**&'"AKHG88FRNBBB#[:**1E*DHI
MHX@D$J>FF:YQCZ?X>%H/(J$B4D\]])1Z:JJH>GH/(OB F@^L]\@:ZZRRYG./
M/OC(NFNOO-)ZJ["QWH./J*:BBFRI]]0#*K/+)JLJ/=*J6@^SH((ZJK':!FMK
MK_G\:JRQ]] S;K/GBGLNN>2>RBX]S#*;J['RUD.OO<762ZN^\^)[;Z[W>JLK
ML+@*K \T#>V*,#0%[>JKP+DR+)! !R-$<4.'#81Q/AIC#$W'"./#\,'Y&(S1
MR"63/#(_'M.$,6(O+Z://XJ]?#',-V<<4<Q_'3;SSHC_T>SSS1SK_++00H?&
M&6>4 7V894B3EAEF21O'C\^:S4PUS9@='?36I"GMF7)6CUVUV6,3EW79:\^<
M-ME9T_QQRAFIS/+*/]M\]]=.6]VWVG^?!G=J@H?=M]E@GUV:U(:O/7C@C[MM
MG')L-R>YY9-?SESFE6/>N>:>#^>:W WS&O+ P#J<>NF^A@S-K_DL'+O(L\]=
MN\$,F_[OZ0$3S+K!WS9L^\G#*UP\R1)?=#S"R(.TO$;.ES22]"%1_Y'U)'64
MO5,SA476]DI]WY!0X:_T44OF8T_^^.NG?_Y+[;\OOD[JP^]3^&-Y11;^W7-%
MO_WNRT][ "Q?_*J7ONL%D'K<__-?4[S'/OY!L('S>Z $_U<_ VH/@08<B4J>
M%[WF?="#TQ,A"#N(DNMQ4($71)\%6UC!%W(/AO&380!IR, %LE"%)MPA"$<8
MPA_Z,(@E'*)&!FC$"2+1A52YX0QQ^!".$/&))YRB$$EH12#V,(LD=-])5,)%
M G91AS:D8 SU9\;\H3&"9U1C&O?GQC6^L8UPG*,<Z\C&.P8E,GK<RQ[UXL>^
M\)$NC $:9,I2F;@YAI!,&R0C$]E(0VX&DE-#'"5-HS5+5K(VL[F-)CO9FTV"
M\C1MZ<UN<%.<4R+GE,G9S>=::1W,@2<]WYEE>&HI2UO&$CW<.8]XU-/+^+1G
M/<($)O\QY].>?G0A/X+@#S/S R !":A YD#0#!3$(!9 ")L=DA0W(^5-2TV*
M3.(<5#?!6<YQ5@J=CC+G-]493G*V$Y[LG*<[SRG/>L8SG??<IS[[N4Y\TI.?
M_Q3H._U9T($:U)X)S2="&WK0ARK4H1&%*$,ABBE-R8E3I"I6MUS%T5IUE%NC
M>E:HL!6L;Z%T7Z+"%[96FJYG62M:,D7$M))UK5:!E& Y_2BL2H<KGPH+I:4S
MZ;5BRJYYG*H>\S@JO,IE+71!-5U2[1=+J<HO<?4+=0/3U[\>EKNO.HQ>)OT5
MR(Q7,H],C&@K QGIS#J\VX5,>!]Q&=XV5K&Y&BUH1?M9Q]3_:M>[50QO39.9
MUWH6-Y@5=FA[*QS?%!<:PC:FL4N;I&2U!KBKM:5MH]&L9C$)N,1!#FVBO2S;
MWK:TOMYU8AFQ:\PNEE;$&E8TGV4<W&;K6=->\G&?^6QIST;:WP9N<G\3+N=<
MN;GC@@ZYK3QM14B6NWV=-+JJZ]7"6@<[VMTN92(K7NQ6AK+LOJZC\CHI6)V[
M7;FB][O,*ZORVIN\]Z[7O<U3'A8]R$,-YC"_!=1O#<O8Q/]"D( )Y*^ "WQ$
M !Y X;\!KG"_"A[P@E?BQ/XVF(QVC",>ERAA"&.8B1F^L(8[O$ ..S")8Q2Q
M?S><8 :GT+Y1K&)]6\SB%Z]X@P8^L8,![&'_$D]XC?[3(09C?$48_UB++;YO
M21!LY!$KT<8@1LD7H1CD)[M8R$".,I1A[&0IJN3*$T')E4V<9"_3D,)BIF.%
M<VSF,J-YS&=6<YK)_,8^ O*/<)YS(.5<YT<N3I*.F6S4'NOG/F<RMX(.-&@X
M^4E/&CK1H3PTHX5C2E*B,M*78Z4JBVMI\\"2EK?<="XUW6E<BF>7OG0.+TD]
MS&#2Y]2I)F8R_>,._B03UM L$#5EL* &V6F;$JWH1'O-ZU\'=*'!WO6P*5IL
M7Q\;V !=-D&1S6QA/YO8T3;VM)W=;&5?.]G:KC:VH9UM;F_[V^+V-KFE/6Z)
M7E1.&8U33&E*K6BM__2F),U6JT3ZT:K>E%BVTC=TQYO3T_U4=_3&*DSS+=YA
MD???^U;IN% UK:76M*G+BJI18YHN@.7KI4XU>%BIJCN(:;6K7;UJL_3EN]69
M-^2F"Q[I6![7A*4<8BFC:VK7JEWSXMQ@?MUYT6SN<[NQ=K!=X^O08/;7H$,M
MMI!=.L\&2]>]#=:R?7/<;AEK=:XE]L]*?QK8-%NUR(W6M& W;FG3)K/F_IQN
M>/.8:BLV=,AB+6QE0UQL%BLVP36-SUNG.^%\JUO*I>W2Q!VN;XFKW-!E+KB)
MU\UAD_=3?ON;JRKWG>MRM[";9S?SER]9=[N+^>>&=?(HU[Q;2X]6^#I/OO^I
M1[WJZ8OZTTO9QP><?09I?& QEOC&1NXQ?FD_XQ;6>/<$OCV!>U_[XP<?R<IW
M,_/3J/OE*QG'8-9O&%D(?0:#.?<'OO[O>5]DV9MPRN&/?95E7/[S3Y'(U8^P
M].^WY"]WG_I@-#^5ZS_E^X,?)%K^O0S7WT4D\U@1)9C_S5^3<1F3(: 7'6"6
M?=#^H1#YV1\$"M'^;9_V21^;86#SM=F::6 &<B 'N@56A* :C6 >L85-T)F=
MJ6"<L6 *MN"=.5(,&I(B84;3:9W>71VA8=(.(MJB*5H/ B$IU48IB9)O/!IO
M%&%P**%PK!+G4-KA60YV9!JH42&G>=H5XM)X_!+_>8P:?!B3%Z[:%XKAJNG#
M#%P!,^U'?K2#K V(&=):@N":KLFAM94;M9V;'=8A'9I;'G;;'OHA'OZA'@+B
M( IB(?8A(1ZB(88;'RYB(";B(S8B(D:B(H);)=XA)5YBDZ0;(I1!NI74)PZ<
M1\G;L11<O)7<P*D+*1Y+M135O/4;2[6;LLAB4LGB*(X5PHV4*7)+P 45PY64
MQ54<N9C+,#X5M!@C,.9;QBDCQD6>OIUBQG%5=/W4R7V<5[5<S#U7[Y@.W9A,
M-_9<S?S5R;S<RKT<\<C5-])<QAQ6:_V5T"'2SP@-S;56S2A69"U=TN%@TN#C
MH%G2W%$=H?6=#BX.#U*-_S^&%G!]G3\RW6'E#3VJ%<OL73_V7>/(74 29-T1
M)-_]'6^I#=7U5ME13N&-'>(-GN MQT:^!D,B#UB%G#0"G#6N3N7]SN;)#DUB
MESE^U^99GJ]4'LB]CDVFU\D@CU!"#^L997R]7E*N%^P]C^M)X%.JF/'U6 5&
M7P+%Q/#YGE02'_L)7U9Z)?;1'_)IY5=ZGUCZWE:")55NX%KNS_-A95>F91(%
M(%<"H/5]6%7.)8J%9?Y%Y??U)?Y=T?BA'V!&()2IWU[^Y50F(/<]D$LPH%FF
M6&'6EU,.II IX&4ZIF,R9ON]WV;"7V/*GP$^)E3Z96D2I@^-ID;LWVH64&=:
MX/^7>2!;=N!L?F"=O> *NF!N#D4)\@4*[N9OFB!NVJ9N"F=QWN9QYJ9HZ%EE
MZ6 .9N1L%)H/2F<0_F!P'.%U)B$2+N%V,F&EI1(43F$48J$55N&GD>=Y<F%Z
ME!H8!E,QN4=[CJ$NE6&LI:$7K&$R/5,;&@@U7=.#Y-H<.N(D0J(E,B*!!JB!
M2B*"8F*!9J* .JB"#FB#0NB#2FB%,NB%'JB%9BB&)JB&=BB'+BB$;&*F<,JH
ME-PH3EPNIF@QLBA,L>*)NM0K0MZMX!N,.@N,YF*KB$I/\2*]D=2SW JXX$,K
M.!>1!L_C'5QXB54LD@NTN(N[S0--->E33=6\4!S&M53_E3YCY E<O[TD-3*<
MQ?&4K)2>>Q&E[8#>-K9=VF'C=@767H&C6A5=SN3-QIRC.MICTBW2.[KC//(,
M8TF-05[2TO%CX2!DV"7DH7;DU5'DX61D;<7=W>$6VGP-G3K=F^+I0.H6;3DG
MH/*CICHJJ KJ1W+DI+8-2 [7V&VDX7F.XH5D;R$21IQ>7+U.-NZ.2_HD2];J
M[UB73M[D>>6DPA3$KJ[.Z)5CF:I742+ELJX>L[;>"#WK?$$KD%$F99HF:1[9
M:]9E@TEEM]H>67HK6#[@N*8?7UXKN1XFND:16<+E\]'F'>E>7L8?5\HK6LYK
M7+:KO6YE9/*K8G9EOZIK8I+K_VF2)L$^6;5.J[0J;&4&&6NF)I9EYEN:*\!*
MIL%6;(Q18 +6*V=RK&QVK&=&;$0XK.RAIOXMH,D^[)99Y<FJIL;:955Z9LR^
M:VS2[$T0)W(.9\X:Y\WRK,[B[,[Z;,\"K9SQS7*":G,6JMCTXW0V&M/:!A%:
M9W:.DJ11[1(VX:29Y*69Y]:.)]>69]=ZVGH&TQ;6QZF]9S'Y0SW@AQ? 0S,Q
M$S0%2 [L9X+<FH, Z(;B[8?F;8CJ;=_R[=]&*(@&[MX.KM\6+N!2J. F+N$N
MKN$V+N).:.1Z*.1.;D7IP"8"0!>4:")XU,+EXHW>J(H6XR?:8HNF(N@RJ4W9
M*+Y\+O_IXFB-[J)/">FP#NGL"BE(@>Y&+5RNM.*[/-Q1)5641AR3JLO&O0LP
M2A7%)6-+-2,TBMQ6$<O(%>_$W6*N@JDV L\X7J/+G1=@T:G%$$^QDFGMV-Q[
MG2F;>F\].MTZ.N2;VF/3V6!BP:_\)A;4=-9!1BJL7N1$\F_^]J_?N4T JX8
M7U:AG>H!FVH" W#4I*/*;$S48!;2VAW4Q:]C9=T%VV/2-BJI)K"J^IU(OBKA
MA?#?_>EJ=:F_T2CD69675B,UZFIY9>]-EI[G@9=UV3#N "M.%NS"3F;"-J4/
M,V40*Z6R$C&5(:QEKJN[PNQK;FR^SD^XEB7)0F"ZEJO 5O'_N5XQQ1(9ON+>
M$GLQ5"AQ]LV0Q!;?%>MEP&+Q%M_KO&IQ$N\K8J;QQ.XPPUXL'1OL$3?K#\]Q
M'/>EN)JQOZ(LQE+1'ELL%6-FRTY/QA[R%VL8FX5Q6[Y?\FFKQ&KK@Q58EZVQ
MOGYL)0-8S=;F6 CMSXIR*)-RT)KRT([R*:<R*B=G/DKP<S*JT\HRHDTM=D:M
M$DIMU3KA+H.GYG@M>H+MUPHSIVFAJ:GG,;%G,J.:JO4#(@!(?NS'J[5:W$;3
M&U;3 \@ KF&3-MVMY"JN-S,N.#NN.%/N-U?NXQYN.J/S.I.S.K<S.Y_S.\MS
M/-.S.=MS./.3 VP*(@#!FJC)NLF)_[30 U+5%/6.J4^%E.O>H@IKW#%.:9,^
MW*D,-"+,PT GE<-5BZFH*$^%8N@^5:NX"L(I7))VR_0&HTT=[[LU%3%BU;:<
M=*F0'//>6S4V;\-!"_-";S3JU)CJ2LZ)XW1)%_GJ,#=B*DZ*(ULY%S>^ELT0
MG<])3$/*8Y^V;VL!753'3 3+5J=B'7/N;T62S3]ZI*(J, <[JE9/,%<S:O]&
M#@0S9)\::EJ[,G2B]:<FK48RGD361JD",%FWZN+U]> Q5\2,G"\2W.E2*2BR
ML'2);W7]) Z#"U"27N=Q7D[^:E 2]5D9LAS;,0]7$1X+\5(.L6>'-A"7[%BN
MK*S6T%O*+/]>6O( H7$;6W%FQ[84T[%L\W%I(I]:AO%NNR9>DC&]EK%M<_%O
M1^9P _=QZZ6]:M 7#2PA._=F6Q$>1VL>3W=U6RR+V;;*ANS_*40!LBS$"F#*
MTM]U/S<6C6QXAZP8J[?[??+,ONLC]_9ZQS=O;W)[VW?WE#(KJW)^KW)_\_=_
M[S=<'!(LUS6!1R=USG+3#J$19N<1<N=W=B>$^_*$#_,O6W@P$[.H'?.&SX<Q
MB^'9+G,QO8<@#(@7F'@:QAI^ZB=_5E,<^N?=PO,]CW,]X[.,EW.-X_B,V[@[
MT[B.Y_B-^WB0 _F0\_B.Q_B/%_F!D@'F^G.3 \ ^RXGGDLHLSM3_8?^H2;\;
M];;H3!5T02/+1;L;1HMYF).YLD0T/4PTF@NOJNCNP?&.^*K4DD*T2I]T4SWI
M\ HCE1YV\LHT0RMCGR<V,_(T]L:YQ_7T=VEO4ML.4J8I\%1U:B$Z[AC/6O7<
MT?E5\13UQ\!IT\4CG\)OR[1,_1:66<^UX1AP!_-UJ:KJJJ,J2B;JICH.J^LU
M!WLP_2J=GNXCU.$ZG^II!1,JKX]Z66>65I/UJ??&K"-[UBH7<Y4OK3:ZFQ/V
M*9*T3HF>4/%D96N>#!.$4<_P67D[^$+QR_HQ9)8W>4.W$?NPZGWV;+,[N+8F
M(X?89[H[N\)Q<=?[>)<[MN9[8+KQMSKQ_VFOMGS[>P5Y'VS?ML$C?!3_]K@K
M_!\S=Q;C^[F;>QVONVB#MK.2]L43L;5.?"*[[$-\4<A_?')_=\?O.\47<B"C
MM[C3M\>ZO">_O([-]\S?-\R_&7#Z=X#K]\[G/,]7JL\/9]'NJ=$6.*D;O8(C
M?74JO0]"K2X_>(1#/=EA^(57^-1_1S%[X1:2+7R6K8BKVC#U@R"<(30S4SNT
MVJP1R-RV.(3\YQS.LY&_/9(?N9 G.=W//9'??=WC?=S;/=_O?8__/=P#OMX3
M?MX76PZ,J),KOI,#-"*42NM>>>ZVXNHN[R^Z*)=G-.8C547+ T5/=$43=.:7
M.9N78HINU.0;M/^WV*HS-IR=UWF[_:Z7Y_GD$^/L1Q4L%E5+__F].2.7*K;T
MLG2^^&0TNO#)P1SI#/_VFB.E>R_XC@Y+'O]/YQP^I)[WMN.GYXW%!%TZ.J2G
M>W^>\FE!6B2Q(SO^OOKY(VKZ(_"K"S!8P_K["_O<%;#BS"_XW[JH\Q4&1QW^
M__K]1^31 P2_?OQF"21HL.# @OX(]F,XRV'#A_T41H0X$:/$?A<U<KSH$"1'
M?Q0/]M-GDA\T?OGTX=.7+Y]+F"[QQ6QIL^:]F/ETWL/7\R?/H/B&\MP)[>A-
MFC9GOF3*M.5*?2KU3>6G+^55JUBI;K7*4B58K52S8LUW=27:LV;5SL+_JL_M
MRKAPS<9=FY9M7KPOU6J]NY9OWL![ 1?V>[BJX<12#;-4')BOX\.2*4>VW!CR
M6<F+-U^>G!DQ:+U_^XZVV];T6[MS5ZNNZUHN['RG1Z/&>YNTX-R#%1,NS3OT
M8^'!B2\V+AKY\./*?>O^O1MZZ=BX:4__6WVV<]W8:0,WWCQY\?#+Q2L?WQRW
M].C:QWMWOQZ]>?GEZ9.WWW[^_?SA.VL&W9^QSS#;C\#ZWGNNM>GH4C#!Z[9C
MKT#]#(P0OPDME/"[PEK1;4/J4O/PJ@07S"[$UTH\<<$468--11971/'%%F%T
MD<89;901QQAUK#%''G>\\<<>@?21R"&!Y"=$_R3A4K*@))U<\LDFH9Q2RBJ9
MO#)*+*G4TLHLO=S2)"M-&BC),:\TL\R3SCRHS)*65$B@-TN:,R$Z$;H3SCSM
MU+/./DF"J*) &Q(4T$$-+131/Q4E=*-#-WJT((@DA93222<=R=*0-,5TTT<Y
MQ=0?4$7=*%121YVE5%1/397555TU%594965U5E!GE=2?60'(E5=4=[W5GU^#
MY5788GM]QPMXO$"V"R^:;?:*+J[(X8H9JI5A!FQ9>( %!%AP (%PQ1UWW /(
M#=?<<],E=]URST6@77'C1??=>>&M%U]U\V5W7W?U_9=?@/T-F."!#9:W7X0%
M5KA@A@^F=V&(&Y;XX?][([9X8HPKMI?CA"EV&.2/1=8X9))'[OABE#-6>6./
M37Z9Y9)C/MGEF6&N&>>4<UYYYY9U_IEGH'T.FNBAC9:Y9Z2%5KIHIH^F>6FH
MFY;ZZ9NCMGKJE[U8 Y%$$.$:@+#%'IOLLLT.VVNNTT8$D7I^NN<>1'R*FZBX
M?:I';GS<OCOOO?7N^VV\Z[F'GK;K*;R>PPTOG)YZYCF<GGD0:9QQQ>F)''+)
M+V<\\LD53QQQRS&_7/)Y1N^<\K;O\9OUG_0.7&_"/:?<\<,/7YWPV.G!G1[=
M>8_=[<$1)YSXW857O?6[A6)]^>;G=GYUU7L?W.^>C'H^)^>-RNDFH'3B'GS_
MG*(Z*ZROQC>_?'RD2G]]J61J"7[UR4<+&I3(JI^K ,U"Z:2W^!^S?U=!23X&
M:#^U ' @)F&( N.T0#4QT$P1U,<"]U1!CRAJ(A7)R 4W:)&(C"0C(.R(!QDB
M0I%\$(4A)*&='L*/%K90@Q)QH44:&*<$3K"&$,1AF'+XIAWZ\(8)^:$#@]A#
M!QX13VZB8)^2Z"<86G"%%XPA!V7X$0YZ2H8C"50 NP*-ETS%*4OQ(DM<@I2E
M+.4>W1.*]]:XD^_Q1"EQK,D9O^B8K:#%?THBDYH$J,>WT ^08JF,?PBI'N[4
M!I'I2:2#0,3(W,0',9#,T(7^4\D!"0B3G+$D)@<9_R  ?7*3]I'D@3XTHA>1
MR)2R.>4J5?FA1_8&EI&,)88J1$L*W9*2N!3E+$DY2OCP<CVU%*8NAUD?7SXG
ME\8$IB$Y!*%DVO*9Q83F-/D32L]H\I+8]*0TN4F@#A7FD(3I#HG Z4QJ$A.=
MT4SG-(^Y2[]\TR_A)"<K3X3*(-VS2$+2)SZ-M,]\\M.?_03H0/]94($:-*!4
M4@V7&/JE+FW)H0V%Z$3%!"8^ G%-0F0B#_G41(]V%*06;.*B',4HDY84I8EB
M5*04-:F*6*HAF9)II31U*9I^RE,YM6*J0M*J6/E453]]55")"E2CXLI6O$JJ
MK$BEJUX1ZZF^@JI4J3HLIO\ZRPON\,)6G^6%:$UK6C.8@3FRE2UN.>!;X>K6
MNYS65JJY%6M5L]E<D_96N\85KG2]FEZSQE>YUA6O=_5K7@$[6,$6%K%[36Q?
M%_M7Q3Z6L9!U;&0I.UG+$E:RF*VL9B][V,QZ=K.@[6Q@26LO%I"A:U]+[=E8
MVUK7FDVU:_/:Y$ZGN<_)CGK 0][BD <[N D.MY_[7-MX"SK:VC9TR;6=YD9W
MV^K%Y"=RB][Q<ON\N[VM<H]K'')YFSKA\>YWN15O[JA+WM==%[WGU9OS@J*\
MZU97O?70'E"8UY/NW3=[[EVO?6GB/CG"KY-D].\<XY<6_ &P+)9!8QP%F15!
MHJ__??.;'U?^9T,+(YB+]/M?_VYXPR7VL,,VY' .Y^3 C4+QB2?LH I7K!$3
MIC"+491Q!Z>XPA?#\(<(-**($?A 'WOXPC^.DQ!UW&,BCUB"1![R1^E$PY"J
MM(HSCG*+J5CE/XG8P0"&GQF_6$8M>YDF\8-C?H=2YC>>.2DU&2-4'D.6/UYT
MCW'V8X++5[Y"!KB;RI2E>OB\2&8VLL^*5&0OUUDA4&;SFI[!\YT374@)+;HX
M@GZE;5)YT'K2L]*9;I!M)CU)3Q-:G:$^IZCSK!W"P#,QXT3U2U;]RSU_NM"Q
M)K6L1XVA=I8:U[3.]:QY31X ^=J:C';TKF&-ZI48FYR<_W[G:)#=ZE;WFMC1
MUG6$VGEJ9I=21-DVD:812E!+)]3;X.[VN+\=;G.3.T=,6BB,U!VE=5-4H@^5
M=[SI'5$>MDFC3#[QOO7=;SZ1%,H!!_C 3RKPE3[JI0B/*4UGVG"=4@JG5NR4
MQ(=JU(I?7*@9+RK&@;546DWUJ<)R*K",5559N:,+7=5J5U,.5K&^7 9G3:NW
MV,I9FXOVYJ5M;,X-J_//^CRT0!]MSXF^<YP?7>@\-WK2D5[TGSL]Z% ?^M*E
MKO2G4QWK5]=ZU+/.]:U/_>L(F %JU1;;UYX=[6E_;6S97O;9"LZYNJ5NW'\K
M7;@+CKC&]6[B=FM<O5O.N7;W[?_JY([;U;61S,$+;N6RNUSIA9=XY66<X15?
M>>"YSO+I5;SQS!N\_;;W>O%%_/9"+U_-CSZ-X0LS'5>/$]*G_GQ=T4Q95F*_
M 08R?F*FXX/E%WM Y@_XM*^S@0^X/^-GV<X&WG ?DPQB__5/B";N8?27K$-^
M/QDA5R94]EM\XQFR>,KA1Q3WFXQC(CJ_QT64() YZF,DME_ZZP\R]>4/_^J+
MM,8%]V#^Q2]E*\-)+<RGC*!B  MP*EQO]P , =V( >MF)W:/S4*CBWX/CP3H
MS2R0SB),T<XG'UH!TCYP X5MFQ M/R1-V4S$D4[0!,TIV/2GT5QPV&(0!D>0
M!D%0!&W_L 9#D ;=R94P3=L89-M^,*"2S<^*< 7!8]KT#-:0J=:D[=5>0IY4
ML --;9FH\ F#*0F;, N=4 NA;0N_T O#$)IP$ >[L-B:R=H #06ET-FN+0VK
M$ G%D OG<)U\Z=G<L-(8B=N L-S0[=SZT-T <9_:3:$"L1#!C1#_\!"KY-U8
M(Q'K#=XB2A(CD1+G#4WD)-^P3Q/QCQ,-+J4([A/U[^ 2Q:463E),D>%2D5-L
M*E,B;N)ZBN,L3N-D<>-F,19CL5::"N1&+N2BRJI^4>1RI1^D!:N8Q0O:P5FD
MA5JL!>9FX%N>L>:BL>FZ#NR\SAJK$1NM[AJU,1NG,>R\<1O!_[$;F8X<JTX<
MN1$=SU$=RY$:TY$=O_$=PS$>Q]$<Y]$=4<8!9L +4JOL^K%KU X@ U(@!Q(
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M<B6W<C,7<S?W<CO7<C]7<STW=$&7<TE7=$MW=%,7=5?W=%O7=%]7=5UW!BQ
M!U#K+?43=_.S#'02+H;5=XN56(U5>(.7>']W>(VW>($7>9=7>9OW>)TW>9]7
M>J.7>IEW>JVW>J$7>[=7>[OW>KTW>[]7?,.7?+EW?,VW?,$7?==7?=OW?)WT
M5N.W5&UU?F75?G7U?C.55O67?SEU?_VW?SOU?P4X@ ?8@ L8@0%8@0EX@0^X
M@1.8@2/8@248@B?8@BL8@Q]8@RF8?D\U?^L7?T/X5M/W?4N8A$^8?<67&)6E
M658NY9R%6G+@Y<K_B@6<$:VJ%0',55UWF(>Y]5UTN(>#6(BQ%5['15[K%8G?
M-8G]58GS=8G[56$=%F$A=HJE.(JK&(L-]F&UF(HUUHLY%HR_6(Q1EF%7MF7/
M6&;1V&33>&?5V&7;^&9M=FAS5H[CF([OV([S.&:)=H^OUH__&)"E5I"%=F>G
MMF@+.9 369$7V6G)%FW-MFS=%F]']FTE^6XI>9(/]Y(UF6\Y>7'_-G(;MY,'
M]Y-'N7%/^9,3%W(;=Y4E=VU;V7-?^7-EN7)IV95+UY9A>99QF9=CN9=WV9>#
M&9B'N99_N9B%^9B)^9:1^99I0 =D,G>CV6PVLB%G(X51V'VQV82OF9NS_[F;
MM]F;PQF<QUF;R_F;S5F<T9F<SYF=T[F=U]F=XQF>YUF=Z_F=[5F>\9F>[YF?
M\WE.Y=>#11B$ ;I6.=B@+WB#$5J"<Y6@&7J@'SJ@&[J#"UJ@(QJB*5JB/]BB
M-WJ?_=FC.QJD]=F>9R%:F@59C+'E8CBLR@I;8NX9Q76(8WI<?YBFPP6F<UBF
M<SJGC[B)F?A?>UI?[=6)AYJ*G?B*CYJ*D=J*NYBIQ3B,G]JIHQJJ,9:,69:-
MUQAEL=JJS9B-8;:KZ[AF\;B/YQB1"=FL@;:L?Y:/&9FMV]IHR?IH#5FMW9JN
ME_9K=_:N(]EKM1:2']F2'=EN/=F2!?N2][9N#_][D@GW;D&9<!F;E!$7E!/7
ME%.9LEDY<G4Y=F&7=35;=C<[LS_;LT.[LT>;LTL;M$G[M#6;!E#+)*7Y/C]R
M-D*ZGV7[HT5ZMFV[MF];MW.;MVG;MW'[MW<[N'L;N(M;N(V;N(];N9.;N8?;
MN9'[N5,XHRL:HR_:H3DZ@P\ZNQ6:N[?;NQ/ZN[4;O,=;O,N[N\G[O,T[O-/;
M@J^[NCG:O:%;OI<[NGM[%O(A![K*&)$QI:<E'6#N ;1%YLI5IPN<K8"8P U<
MP=65IWVZP1\<8($:B0W6J)/:PI<:P[/XPK%XBZ=:JC_<PZ&ZJM&8JTN\9*U:
MJT7VC;6:K,<:K%]<9UW_7,;1>L:GMH_K&L?_&*[1^JS7.JYS',B#'&S[&K")
MO)(Q&<D#>VX)6[ -=[$ENY2C7)2EO+*KW+*O?)DG5YDQ.\N3V<N[',RY7,RU
M_,O'/)?)/,S1W,R-.<W/W,W9?,V9&7)I8'<[L@Q<>^U*LA^:>[[YG+[[O+X#
M'= '_<\+W<\/7= -/=$1G= 97=$;?=$C'=(G_=$KW=$O7=)G=+HWW;HG.E77
M&]31NX+CV]-+7:/?&]5)_=15G;I9G=/AV]1#F-(Q?=8SG=:'-!&B!:63T5E=
M;H:UQ1GU]:877!J!^*:'?::)7=G7M5V7N,&#.L)]NE^)6HHK/,.56L.O_6*Y
M_QC$NSW$O3VJ1_RK5=R-27RKS[UEP_K%U;W%>=S==QS>TWK'?5S(ZWUIYSVM
MZ=W><3RO_7JON9:O_YK(C?ROCYRP#3NQ$;NPX_9O%[NQ'_ZQ'7O*49GBJ[R5
M"W?,4UOC1=NT.7[C4=OC0Q[D1[[C2?[C0?>92Q+/QZ8DAZ767][2;5WF8?[6
M:W[F8Y[F;][F<Y[G<=[G=_[G=5[H>Q[HBW[H@_[54SW6D_[31=WIU?OIV3O4
MH9[JI3[JI][JJQ[KM_[J_=?5.WW5=S7HB?[H@7X6Z"&_F777ORJ&?]VL9."&
M<1K!EUU=Y]ZFZ1[OB]C9][ZG(9RHA=I?*7S#L9WP!__?\*6XP\']VQ>_V\7=
MQ,V]W*\:Q5>\CF.<QM==CR^_W3<?D6\\CNM:KO>=WN.]Q_/=]$4?]?^XR 6^
MX%L_R8]<R3.9X9L<RB<^E&^_]JU<]V49RW7YS>5<S8/_][=<^.&\^(%_^,O\
M^(D_^=O<^)L_SIG? BY2FBF2'XR>[+-_[+<?^[F_[+]?^[M?_,'?^\.?_,??
M_-.__-<?_=G__-\_0IE^Z<&>NKE>Z[M>@+\>UL.>_UM]_O<?(/S- @# '\&"
M PL>%$C08,.$#A$V7 B1XL2'%R4JQ+A18T2&'4%^K)CQX\*3)5&&5&DRI<N5
M+UO"G"FS)LN;,7'2U&DSI\__G3][ ATJM"C/HT&1$E5JU"6B*UZZ>'D7M6J7
M+E=R9+TRHZN,&5]9/&#A@"R"LP[.(DBKMJW;MW#=LI4+=ZY=M7/;YHW+MZ_?
MOX#C)H [^&QA!(<//U"K6.WBLX\11)Z,6++CRHL'9[:L&;/GSJ Y6UZ\F;1H
MTZA'JT[->K7KUK!?RXZ-.@%KVY)Q/]B=FS3O![J#DQ;>N[?MX\"3(U^N//EN
MYL]W.Y]N.[IUZM*K8Y>>G;OW[^##BQ]/OCQY[=JYI^]NOKW[]^5G@)?_G;YW
M^]SQ0]BMGS_W_0_, . #  HHW8 %(LA?@@LV&""##S8(@8$13KB?A00:B.&&
M&G9X_Z&'!(9XH8@DCFABB1E"H"*!*@JXHHH6M@BCBS'62..-,^8HXXXVZM@C
MCS@"Z6.0/Q9)Y)%#)BGDDD8JV2232$+IY(U ()*(E58>I.667&Y9!I:/(/)(
M4TLE96:9:)*I)E-LGKFFFVVF&>>;<L)I9YUXTJGGG'S>N:>??>89Z)^" FIH
MH8@2JNB@C!ZZJ*.-)AKIHY)":FFEF%*JZ:2<7KJIIYUF&NJGHH)J:JFHDJKJ
MJ*R>NJJKK:8:ZZNRPFHK321Y9%%(N8JTZT@E]2ILL!R)!-&QQ2+KD;+&)NOL
MLL\V"^VTTE;+[+718DNMMM9FZ^VVWW8+[KCBELOMN>&B2_^NNN:&^^N[Q<*K
M:[STSEOKO;3F.^N^M^K;+TNS")*#5/),554[46&EE59=@?5 6(N5I5=@%%>,
M5EU^[67QQAQ7?%A;B3$FLF$C5T8R9"53UAG*H97VV6DON]QRS)Z9UIG-L^5,
MF\X\[PR;;J,1EUQQ0Q?]FVY'^S8<=LA%UW1SS$7=W=/003TUT],Y#=][ZVV]
M==?;A8T>>&"#[?79:*?=7G\!_N??@0Z&&.%N$,I-H=T*5HAWB1J*V/>')V[H
M=^!_HQBXX2P&_B*/B=/8.(R/+UYCY!<R[B/EF%^NN>6<3[ZYYYT[_KGHH4,^
MNNFE2TXZZ*RO3J,785YY99>T'W3_9>R(],HOOKO[R_N_P/\NO._$]VY\\,4C
M?_SPRR?/O/+0/R^]\]0W;WWTU6-__?3;9\^]]N!_+[[WY'=O?OCEHW_^^  3
MRZO[P+XO?_ST_\KN_>GFOZZ[]?K:_[#SDY?_[#7  @*P?O^#GP /N$ %)C"
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M)6-1Y>5#*?.'Z35T0D=^XV=T2[=T3J=^BO@SMR%_2N-^D#AU5U=U %:).R6
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MTB9=S"6-TB<MTBK=TBS]TMB#S'7KS/[ZMS9-OS<MQM4LTR*7TC#=;VLL%8)
M:"'TL 'LCS'7F)@:SACZ%@HIJ@T\JB';4>E<U8?HSEA]HBH:S_3,HJ<[LZG;
MFHT\UO\ 778"[1ZZ]K-GO3:7/*R:K,F[ZYNI^,)**LK,^HK">\JFK)Q.F\J
ME[R40\N"_<J#/<N$?=B&S2.V+#LN[=..O=*/W=B0/=F27=D_;=F1?=E>QM,1
M1-/+',V@_=FB[=FD/4XY3<U]NV>:W:;^L+\>!*D@U* .FI@0.K&8BK%,S3'C
MW+%ZC+D?NKGJ'-Q539%9[<Y;[=6EJ\&P.G\T>[/[[-SZ[,&_NJ/^_*/_/-UF
MO=9F1]!.Q8!%&L-$.\,,7</&V]<0C;Q0.Y0=K=$9_</N7<3LO=[O;='M#=\0
M -)9N=J4K=^8O=^9_=_^'>#]/>#\7>  7F5T6]JA39<XW>#_.DV?ZWO:G#U!
M!V[@CF6X#<N@DBK'E,IH"36Q"#!SN)W;@+';"AS5**ZY@@C<5KW.2??BQ?W.
M*0K/,%OC&?S5PJ'(K+E_CDS6L:G=:V3=V WDXJ&;M^O62%[0?#1(1 K#WQW*
M4$Z<HYS7Q*O7M7C#?FVM'EC8L8S879[87Q[F7+[8^5WA9B[@%D[@9Z[F:+[F
M:?[F;A[G\#GAKR7-"C[:=I[G"Z[G>)Y[$K[3@-[F4?P(4 $/9" 5RM?-+R>Q
M='Q=)#Y1)O[4'+K'O[WB+2[<GOFY,K[I*JNRR+W<&VSCVA&C(:S(^0S=LY:S
M1([60M[CE+SJ YV 0_KD.(G0GNSD_\Z6DS9,W@[]DUD>M=8FW_8][/0M[,7N
MT?5][/&-[(F#W]T)YX+.YM(.[=,NY]4>[=2>[=:N[>"9X'Q^YPS^X--,YWSZ
MYZE]O]B^[8J5#X?[0=R,F'-LVQ7[Z!KKU.2<XIBK7BY#U8 \W)H>XP /SYX>
MZ@2/R%-'JSJ^R&)]W3VNUK#^B;.[J[+[\$7>UA/VUIT<DW.]BG1MU\U*Y<\:
M\K-HWGX].%J^BU[.Y2J?\BP/YBN_>&3^[.J>[C1_[3;/[3<_\SE?\SC?\SK/
M$^3.E^#^[42_YT;?YTCOV>8^[H&^\^+I#_R0H/D(72W'X0<%AS%'[^-5N9)N
M7O@.?ISKXO^7CJJ"C'Z<_L['?>/)W=4PVMRG3J/2?>HFF:,0IL)I=,*L^^H4
M/YO<W>2VWKN CU4+[:2[_M#C7?*41)03/=\;S>R.O^R0S_C)WOB1OSK.[O0^
MS_,_O_F:W_F8S_F?[_F9'_K1Y.U'/_1^ZN"HS?00[HY+__K],_JR#RCL3C!3
M/U =!, =+A8?_A@BKO4ESO5>3^DJ3JHLWN^=2]QG'_ 7O+(<#.H&G^,'#]8*
MS^,^WO!#OO?M,78.K_U);N08?_$93T?@S?$&?==2COYW5^7LCYPDC\,G;_(H
M[_(M+^;U__+V3_\V%O.D/_NB#_H  4"@/X$ " XL>-!@0H8('2[_?*A08D.(
M%2=&I'C18D:.&#UN_*A19$>0)4>&)'G29$J6*%VN?*E29DN8-6?&I'G39DZ>
M.'WN_*E3:$^@18<&)7K4:%*F2)TN?:I4:E.H5:=&I7K5:E:N6+UN_:I5;%>P
M9<>&)7O6[*R(;"VZE0@WH=R!= W:]8=7;UV^=_OF_0M7<&#"?@T#/CPX<6'$
MC14[9OQ8<F3*BRU#OCPY<V7,G35[YOQ9=&C2FTV#/CWZ\-RVK=^ZC@N;]6O:
ML6O/5IL[[6ZTO<WR_AUVUI4N[[P<-][%B_(N7:[D>#Y#^@P9U!^PN.X .P+N
MW;U_!Q]>_'CRY1$D"(^>N_KSW=F_=Q^?__L#^0CHKV]_WWY^_NCI^^]O/P '
M%+# _PP,\$#Z%N2/00 9A'"_"">4L$(*+[0P0PP?2&#"#NW[D,,%0R1QP0=&
M-!%%^TX$44061>SPQ YG/!%&%VVD,4<;9=P1QQIUY)'&(&\<LD8CCT0R2263
MC'%))Y^$\L@FC6RRRA^OY!')*;&,LDLOOP0SS"]G,!*"$\FLT<P'T#Q1S1G4
M?,!-..=,\TPZU[SSS3KQC+-//LT$5$] XQ2T3P@*#7301 TE5%%&'87T44DA
MH/312BD%]%)*W]3T4$SCW/133#G-U--.2075U%)1'5744$]U5=5467UUU5AI
ME;556'>UE==9;_\%UE==>R7V5V%K-;;889-E=EE,$4D$6FD?@58WWZP-+EML
MMP6.VVN[!?=;<;4-E]QQO34W7737+9?=<]N%]UUYU8V7WGG=M3=??/>ME]][
M^P7X7X'U#9C@@?TU.&&$%RZ8X8,;AOC>O6[["S?54,/X8HU+RYCCSW #N6*1
M5QNYL9!)1MGDDC=.C>.354YY8MMF?EGFER-6&&>'<WZX9Y[!FH6?')1+SHOD
MFEL.NARFFZZZZK;3[CX6S*.Z:JO!8\\[^/#C>K^N]6-//[&[4Y#L!,\FL.RT
MT<[P000WU#!NN.>6NVZZ582PQ!7Q?E%O$5L$_&_!2]2Q<!^!]#'+&ZW_5)SQ
MQ;ET?$O%Q:2\<LHE?UQ+)BWGO/,SDV33R-!K'/US)$-WLTS3^63=3SW;M#-V
MV%E_O78Y9;<=]]O_S-W31G_W/7A!AU\T>$,1G31Y2"]M]%A5285^V.AKG?YY
MZ:^G'GOKL^=^>^^K!U_[\+L?_WOQSR<???/39W]]]ZM'A-IHYZ]69_M]WCG_
M^W_6'__]^^??_P3H/P(&L(  1.  #;C !!Y0@0UDX ,EZ$ *1K""$,3@!"VX
MP0Q>\'\V6YEL0DBQF,&&91UK60I1N,(3MM!C+U2A"V,(0Q;24(8UG&$.<=B9
MFHFPA"2$61!!^$.:>="('-1@_X:S'*.103GN_UA.<W30G.=<@6G6D<%ULG,U
M+G:1/%FKS];:TS4QAJT^8.//?-BF-@2MS8UMA&/9'-0VN]7Q;G;$XX5")"&_
M]1%O?NM;B@(72"L)*7&'0V0A'V=(Q#6R1XBCDN<D.4DI;:YQD.-2)#5'24YV
MDG.E6Y/J0KDGU,G.=7E")2E3.3OD_>EXD$*>\8KWRD?%4GFWC)2H#-6I5#4+
M6<[Z93!S)4Q<%3-8RB+F,7TY3&8:TWG.1&8SE0E,:3YSFLFTIO.D13_Y=1")
M1_1F.),X3G"2\YOG%&<YU8E.<Z:3G>MT9SS;.4]XTO.=]Y1G/?6)3WOFDY_[
M]*=0ABA$$]K0H#J\8?]".=-#( [4H04E(D-WJ-"&^I"@%<5H$5/63XX"M*/_
MS)D_D"8(HS&1.<YQCM*8]K0'9'$[W'$  F+J19I2#8QD#*/9OG9&G7K-IV-[
M(QN%NL:SS3%";KMC4O.X5*7FS4-\@^H@_SC5P!$ND5<U'",Q>4FN9LZKCM.D
M)\4:)LR!-9-G'6M:0;?6T['U2* LY2AI)\K7G7)/=F7E[G)'.[WV]7>\*Q[Q
M@"=8X<W2L+A$K*)8U;QHEL^QZGML^R+[/LA65K*6I>QE-9M9SD[6LY@M7_RV
MN<V ?K2T'D4M2$^K6M.V-K6KA:UK6?M:V<:6MK>=;6YMJ]O:]A:WNP5NMQ[_
MFE&)%G>$&KTH<H<[T8,R%Z'-I:ASI1M=ZD+7NL_%[G2ONT+C1O2XW4WNS7[K
M6][B;Q;-40Y)BW;2*D*G:=;!3GRE5E/ZCN>F8\1O&7.*TYWV-XY$#2J _QM@
MI#:(J0=N*H(MM$>J#J[!@=R;5%O4I E?2:L7QNHB-:Q(#EN82#U2*UK56M:M
M?K7$80UQBE7\5KJV6)4OGIV?\#KCW=EU4*Z\G6)AN>-:\EC'B4TL\TK5RVM6
ML[%%AN8RDTS-)6/SR-E\<I25C&0J0WG*5F9RD4<;K6Z2-[CC!7-Y !Y X;_%
M_.4Q>]G,829SFL]<9C2O6<UMAC.;Y?SF.;O9SG&F<VZ6*]'_ZF:WS]K5(7CW
MO-T_%WJAWT6T=Q4=WD0'\<YUQO.C<^,%XA1MO5&LX@RL*!VGS2"^4?O.3.L[
M:JWM%[]H5*-_QY;JGZ9QP*\>*H'IF&!:*[C6265P504I. @[6->ZIE&%LYKA
M#G<U<B4^]N1$O&)F5W*3'U9VL\<*5[>*KMJD<S$K25=C;NL.QGL%MU_YZFW?
M 7:P@47WN8%'RUP".9>+-?)G-ROOSH+6WO.^=[WQO6]]]YO>_U:?:.DWOSQ+
MVN"11CBD%5[PA#-\X0=_>,,A[G"*3]SB$L=XQ#5><>%8=-"+_CBC0>YQB +:
MY(;V,Z%5GG*6GWSE+F\YRDTN:)(3_[?1 [WXQ@\^"W=,L:3,B6(7IIC233=-
MBU![*:F5SM_\FEJ__C6C&@$D=5@+.-957YM1*U3@6]O:ZWCC8X/]&&%>1[5'
M%1Y2L8G]2+9C6.V0!'&*,2=M$AO[Q"*>N[3U+LFX]IVNJZ2Q*;O=NAS;F-V'
M/ZPLUYUX=P=Y>4.NLI2SC&4G7UGRE9_\Y8UL><YGOO.8!_WF/4_-+0N<XSK/
M^.E5G_/5IY[UKW=][%$_^];3'O:VEWWM=7_[W><^(R&7F<R%__+HTMSF,2=^
M\D=^?)$W'_@6Y7WT?5]/?U#:"X(@ SR.8U+TMO>*6-2B3,6_]/K>]^FGYBFK
M5]WJJ6/=_?]7E^/;OC[_KM<_U[ZND83Q/W8'!WOMPW8[9!- NR- :#/ O1.K
MNC- !41 3Z*VMH) %HM U]FVU0D\PH,QO HW;QNW<2LWP3*WPE(W$23!6+*E
M=D-!(8,W: (X?FM!?\NW%Y3!&*1!%ZQ!&+3!6A&X+>L]W//!'@1"Z?M!(0S"
MZ1M"(RS"(U3")&1"(G1")&RGYV,^*52NFJO"*;1"/E,^F./"X4.^+^S"+?3"
M, 3#,33#+"R9)UQ"(IP%>!B:[;LT*E*:Z*"..L0.EUH_\KL:\W.Z/H2ZGD*/
M]H,_JR-$68N_0S2P^J,_6[L__N._7H-$%*&PMMLP#P/ 2DP[2]3_Q$SD1&=K
MP!&S)!,K0 ;\Q%*D'+\CI;_+P#NYP+H:/%>,G1LS01]#O,6S1<5#P<:#O%V"
M/,H3O=!KLE\4QF DQLC[O&$TQM$#QF1<1E_$E=+K,BB4QC6<QB:L1C6T1FK4
MQFSD1FSTQFL$QVW\1G$,QVZ\%BK4PC(4PW54QW8DPW?\,^.;F3&4QWI,PW(<
M1W.T"#(@#J"+0Z);FO?"0_GBCJG1PZKA0Z:+.O13OYX"*O9[OT+\+ZVCR$54
MQ(N4FT8TNQ")Q%_;OZFZQ)#<1%$DR60KR5 T14]20%*,MI3\I&NS0&R;0)G4
MME3DP%9DQ5<4MPWLP-[QR70K0: DK%K$_T5=Y,574L%CFL$<Q,&F7$JGO,&G
ME,JHI,K-VL&!T\>LS,>MQ,>N),>OU$JO#$NPY$JR%,NR',NT_" T7+XK=$M[
M;$NX=+Z2.T-WK$MX9$>\M,N\O$O!( C'^$N_W$MWE$NT-$S<$@2D.0ZB,2E,
M"\B5:JFC [6#-(^$;#J%-#54\ZE A,A!-$2)',2*1$2,)$T[TDB/=,2-W#6.
ME,21=*0 O,1.?$U,/*0B6;&\8[:5', %1$F7]$TH0<6:S*M5O"N=)$X<BT7#
M2[Q9[+'F_+%<A$[E$3(BXR5E1$9G9,;KU+QBQ,[NW,[LY,[O],YE@L;Z.<OS
M-,OT5$OT7$_U//],]V3/]VS/^93/^HS/^X1/?4''X^I+OO3/P=3+ *7'FS.A
MP*P+ [T+!,T+!7T,N=S/_*1/*/0'1+@"+Y"'[-N^DZ(BHKNB@<R.I*/,[[#,
M\]/,$G5(LQ%$T%31K)._T;3(%RW-IT+-U:31&9U1_Q-)D93-W33)'NW-WQPK
MW7PV% /2RGE "412:YO U+')X712&3/.GMS)*26WGQQ!PL)2H"1*HTQ!'8.R
MJ61*,(7*,*W*,353,453S+I*TK)/"&W3"'53_(33.7W3.I53.XW3/*73.V7/
M!YU++ 34MR300$U' ?U/0P70_DS40U54%F+01UU4,"Q,/M73**P'Z&#_HG]L
M+SIDFCL,/P0 4<H<43^\3(8T5<Y\2,^,R,]DU5F#T5>]M=/\2(_LR+)#N];<
M4=B\JERES=E4.Q7#S=L,11]M298LTF.-20MD4N'$R>.$10R$UE9BSN<DRFFM
MUNC$UDF9SEBA3NT\QO#\5O 4U_&T3G MUW$5SW0]QO),A#VM5$IUUWC%4WF%
MUWFUUWK%UW?55WK=UWM=0C\-/D85V$A%U()MU(MQT --#$@%S--(6$+-5WX%
MKD3HQTQM3#GDU#ID*3SL#E$COU%E.A-5M1--T595U=!LT42$U96-45EE3?U+
MS1OMO_]#I!T=11[%V2%%5LL14D\DTIT=$YB4_RLE35*:I, FW:MFC;$HY<FF
MI5)S"\$LO5*AI,5LM=JD_-(R35,RY=HSU=JO[=JM-=,U)3A_E5BS1=N(3=M^
M5=NV9=NW/5NWC5NXQ4: 9<L_%=2X'-2\Q=N#'5B#_5N_)5C!!=S!?;E)I5NY
M+9A\>$/M8TR@DT/I*#JG.;I/U4.0+=7S6\C-)=E5]=R3)2K19-G1W1"7%3O5
M)+N7/3M*?#N:Y=76#<!.M$U@-<6>)5:?73:@]<W@/-HG'3PH%;S@C=94DL6J
MO45K74[CM5I+>3SF[=9P)==F5-=SC5YOI=[IE5[HQ5[KI11VG=OO75OP5=SQ
M3=SR%5_S#=_T)=_S9?]?]=4MNZT-PI7?P*5?PR7,O;68P&!8T6!0_/7?C5I?
M]TV@O*C0+L#0XX B]'+,HN.TRF6!R20US!4CD375];-@5P-=DPW=E(U1TK5(
MTTW=&IW5$;:J''7=0[K=%+Z[EM3=SNG9GSW %G:2(R7:&C9:HUW6WDW:* 7>
MX>5 I_WA18%:J0W*J1W!+5W>=],E[13;)@9;KPW;)W;B**9B52%;\T3? -;B
M+.;B]MUB+^YB 1;C+Q[C,(Y8^.5;-'[8-+[;@+7?PH7C^7UC.8YCZ.K?A9UC
ME_E?,.;CE)B%ZBM@+W!<[B,.[^M0!X9@FI)@4M5<0.S<5%W1SR5$T>4Z#^[_
M8,$).QLE81&N54.Z55_5Q-A$8=9US;@S)-HM1=O-6=Z4X58>VAR&9>%]UAY^
MUEH&O,+#Y>-57N3592[5UN95E.JL7G/-WNO5WF,VYF0NYF7FWF8F9@CPWC+N
M8S*F9C.VYFF^9FG6YFK&YF[>YFQ./36NWSK.XW(FYP!=8\G8W\BX8[Q=XV_V
MYG.9A2ABHL4DY#EDFC7QM,A\J0=>ND7^PX84Z,Y$44G6X )#:$M6:%R3T1'N
MY-.5V1*F65"^V8H^R6)U93%Y8;S+:,NAX1M.UJ'%864E:1]V4EL.XI26TBK-
M,2)V::H]8L9+XDE9P<B;8BC&Z9O6:2GFZ2JFMRMN_U=X%FIN'FIP-NIX/NJB
M1NJE5NJF/N,VAFJ(U=NI=N<]IN.K'F>L-F>M%M!V%LR&/6>$W6.G3NJ!<")!
MMEC(!<C)M</*K0]%3@]&)E4*1M6"SF"#CDA*7NB]=JH%@VC\>^@0GL38'643
M?MU2)FRX8^$@K=UA7648#M:.EC8:CN57EN6<=-9;OFQ&04Y<Y&7/5EY?SJ5M
M)>U>W-YG1FUT169F3NUA5FUE=N;LC&:BINVRMFVFKFW<OFVRUNW>YNW?SNTW
M%>>MSNKB)N[CWJ%T]FIVQF.,>>=& ^[=1HJ\$(3&O=CE&#HZG%Q^=FNLL1J
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MB#\D\E(R-3%XH8],Y8HZKU5NDZ>MCC'-3AWLJ!KJ RC0X>CAH8FN=WI#"#V
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M$A&)Q$1IQ/P.QVB,$VTLQSH1%#\Q%$EQ%$W1$U%1%%$L]!(!!UVQ<&8!'[S
M'!R@R9+L%FTQ%Z,,%W=1%Z&L969@FYSG%>&&G!H"G3IO]#@/S4!/&9LQ8]8
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M*0(>S-,]T[-_^?=_V].9$*!H$$%/\5?49B$?F!$_IV9I$%800 &"5R] ,=1
M,U1 +8IO&]04E*&#*?8$*V>SY.Q !Q2A9@(M']0@0]9X6?C01%1Q939Q9?B
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MA]6<(F9 RGC<?^-<QWO&'-QZ-> Z\2 / >B:S/OQKGM<S@,]\KJ '\G<'[Q
MS]>S'0R9,X"9SA%@'3JTD3,"'HX)/1'AFR@=2 L[: F[L4\G&@!0 *F2LC_'
M:PV+DVF;MVW;:FO[U5E=E,FCDUEC0D7=;;&4*@W8(C*PVWP!LQXD&IK;*T$!
M&H3\V--\%NKA+1^7F'=P+HT9<[L[4H_0X2XU1\P[FL<;X[B]4]?[VZ^9A=K;
M5+GYO1ES554UG/-;YLRYW<?YW1&<R[](G0^<G>7]_WC?69[A>0_W?9Z)U9[U
MF<*7=\('WED-OI^C=: ->N$E\:"!\WH_?*$Q$3EE7*,QVJ(S^N(M/N,Y'N,]
M?J.CQJW3O" _>G_W>J1%6JXA>T94&H3;_,?\X9]2[T(AUL^PD4Y]>OH<>!EY
M_LFC''&$_1K%,:%0>)([6LOO/>DE):I?WL^=ONFA'ME%PLP/;:M'_NH] JRQ
M7CW(.N7UVNM/7N5GI*TG5#;R'.5GI,^CWM$ 7>S=_NO5NF9F !\FN^X;&=%+
M9JW;01] G3T>?>4CW>Z+]K.=P]+#/M.9-O$)7_%-VR+ 9R2G@WP6WS?&%K>[
M)Y1CW=F@S;9/F9]\5CQF\O]N!1#<HJWL1P<#85EYDOMCF-LKPQ(4.'3KI3[+
MLRDN$[6V@C"W @Y2(>BW.O?WG]F9MWWXM;WXT=MTPSWY$W/<S[V;Y[O<M[!0
M*K._7]5V/9._KW^_M=^_2;/[>Z[ 837>VU#IT7G!_YW!GS?J(%QZG5?"!1%<
M=I-Z.5S#(9[^YS_B\9_BPRY\QTY\67S& >(!A($S!D(02- @0@@%!RYL>- @
MQ(<*)59,Z-!B1HP1.5+<R/!B2) 3-78<>;*D1Y,?4XI4B;*E3)8T5]J$@"A1
MSIV/<OH# /1G4*  A!8E:C0ITJ5#FQYUJA0JTZ=4HU:=:C4KUJU2NU[MZ@_>
M# 3_"+R1+7O6+%FU:->F?>LV;MNY;.O"13L#D5:O>[_Z[0N8ZU_!@?D2/ART
M7S1^Q#3U<JPI4Z;'DC-%GGS9LF3*F#>#^@0*E"!$/=>0WJFSI\[5IUFG1LT3
M]FO7.1/-*CS8L+]HC3=GODP9%+%3_7(;QXT<\7'ER0T[7P[4BX4'U*M;OXX]
MNW;M7:![;_Z=N?CGX,N/#T_^O/GT[-&[7_]>O?SV\.O/CT__OOW\_/%73;1=
M@ (*J(,^L_2WGW\)+JA?@^SUHXQCIC"(H(/Q^=,%"V0YH"$+'"+@88<?A@CB
MAW+9=6*)(JZH8HLD:GA%/C\E-4L^8]V%(EGY5,BC@A92_^AC4XAHF&**+,Q0
MS@PRS$".DD@ZV>2249I(%XYW(># %?T R:5\_GAQ5I5RM<-/CS1V(6::Z_S(
M9E '5O4FC5#%"0 \8::I%B+\T.GFG'X6%6>@?<+YIYR$'FIHHDCQ"6BABSH*
M5#31^)(++KY8BLLRD#:*Z*.=1AK-,M$HLTRII(IZZC+*;'EA/\L4@\LOF%Y*
MJZ6^$$-,-/SYHPPQL^*B"3%"46B*99-D<FPFH"C39I#.=FEFL] ^*RUS7G3A
MA2!>;/O.M=YVT<45.ER1PPSFFON N3(\P,(#"+@+[UGNDC7ON_+>FX"]]"*0
MK[O]\FOOOP('3+"_!0-L<,((V_^K<+P.,PSQPQ)'3/'$%E>,\<4:5YR Q!V_
M^_$#(8=,'<CPEBPRO".KS++)+J=L<L<RISQSS33?;'/'U-F\<W4ZI]QST$ /
M_7/1/A\MM'4_#\ATTTX_#3742R,]M-+931UUUEIO/> ,V7F-'=C7B6T=V=69
M31W9!Z5KW=IB%Y1VVVFO+=#<U;F-]]UV4Y=WNGW#[??>@ _^=^%VAW0XW(@O
MKGCC$3DN$.2,/TYYW95'%#GFFEO.^>:>=]YY29EG-+I+))D$4>JHK\Z1ZJVS
MCI+KL<,N>^VTW_YZ[K/K;COON.\.?._!_RY\\0:U)MNTRE<;;?-?S2*67 ?<
M-;WTU%__;WWV<U4?(Z/+._\]M4Y%TPHQH&C66?J<K0]<^\J:PIIJL,D?OVS(
MUT\;_;'ECYIMT/;3F%ZHSS&261:KP,<\\2EP6M+A&M=T<)L$AF^"$JP@ B^X
M0 MF$(,4Y* &._B46?1#A"0<X0@]B,+O ,B!4--!/KSWP1BF$(3[@5!D)B3#
M#>H0,+-XQPRJM[TKS: X7*K1C;3'%@3L:(<YI*$%AX2]N6!)2_#A!R)D@  @
MLD6+9P%B.YJ(%>^)<5/^N V8NAC%=NAC4(IBHZ?*B"8NDD6."%C'&#_%J3;F
M\8UO%%0>_5A&-D(OB-G3$R /*<A$_E&1@5RD(QL)240^4I*1_V0D)0,5#5C5
MRA>^V-(EW0C*/8+*5*525:A8):E3C:J4RA@6'X%2*DYB"A>_HA4Q1(5'2+X2
M )G\5;!<::96&$L3R5J6/YPX0S F<YE,7.8L!)&#+I!!6]CJ%K:N.:X<7&$&
MVSP7V]K5KH/MBRSY&B? _K6O@2E,G0MCISL/]LYU'BQ>_Z)GQNZYL7SB<Y_Z
MM%C(&+:REP449M5Y&<I(UK*"WNR@1%LHSHZ6LX<:;68]H^A#*]I0B_+LHM?!
M&@L%Y-&/?M2C1A-:21N:-*I93:0L;:E+7QJWL,F-;7JC*=_V5K? W52G.05<
M3^G6MY_6U*=YPUS@C*HXRR7U<DKUW/]2,Q<ZITHUJJ#[G%6KBM63=(YT6A7)
M3&X"D["^9*RG*ZOISOK5F-1$K6 E*UK7*E:SIC6N;VVK7.'JUKF*Q'ZJ068S
M_]K!L-PH1X2U4I'P9-BYH ,1S/2K8YD"(5.8[S$"1!]G+/L;RD9F6?J 1C^*
M,Z=$\&^T\^.K:4F+/]GX+X'* (5FB6&*5C96F8#-H1<J %.F0?"Q/")A/A)Q
M#YT@0A!DV)9QCZL#;&VK"SKP0G.?ZUSC0K>YUZ(N<XT[343<8Q9EXFUM9YN>
M,@:7N,<]+G,%D0ADS@(1Q4VN#F: 6]QR3;XSL( .DINM"(+WN_SUQR.TY=P<
MQ+<Z\G5I@>W_FUPR($*__57/"G.;'1V4:;_>K; R;=@+'%*8MD442V'E@H A
M+M"(8?JPCKS"#T%<(5Q."I$,6/#B&:!#FUV 1RLH/(MY>"$=74B'DJAT)PXY
M:<57T!.'N0+%P];% 5TXH'_X,=C$)G$&.^K+"/.A743(0Q#=>D<7U!&N+X<9
MS"MNAQ?@@8AZ\(.(%CRCDL_B#A@B:!9H,C%;UM256="#Q>A0THLY%.,DD6O%
M^)#S=^ZHQTBZ [%Q0<0)'\G'&2%ZEXVT8CMZS,T?W^E.1UH2D;U0:#)..I2Z
M)/48>;-)2VF*@ZY:)2E%I2NIA$J5JHPU+Y>!JUK6TA>E != Z+^*QK1Z24O_
M35B*&*"UCS].H0EB*GL2FH#&D3<,[09'^['^0,05O 4/;[GC6]<*5[G.I:X'
MK N<[%*8.>ME;GBJ6Y[L;N>ZW?VP>LZ3G_3N9[WO;>]\_C.A"#5H0ADJ4'X+
M?&8QDZC!(QI1C)YTX51CN$D;KM*(0WCB+"7IU21>-8Q3?.-00YM-R_:UD,MT
MY#M56TQU:G*>!G7E0P6JX R'<I@3[N4T1]Q19SXYJ.9\YY+K^50U]]2K"CVK
M5>6JZ-B*=./Y;NG#8[K2FP[UITN=>%1W>M6C?O6I6YWI]T.-A:?];.A +\IS
MC.(6S8Y&)*9]0^TX9MB_3BU_1%:SOJG[ .ONVM#P_\/6S9F%/AXAVM*B=G^"
M+WQJ#[]:L"L>3F5L/ EG]';;3H?CV-EMY+N2B"Y0?O,$GH$.!/$( X%6VE]Y
MQ ,*_%(=)&B$K2"#@%F8 [U(<!;X<#WJ.3\@'22B%8;FH0XF;H%"6UB\9/ X
M[J-6@2X@XH4<?.;DCP_]K<T@$6Q>/-R_9\-,:)CTUU=/#W^(]K.(N(@V*O':
MD[C$,NHC0^'/8A3)<H56%!$?@B"2^]5>=OQO2/FC1V:2"2E%3.9D]B$/ 'AV
M9^$ ]? 7LW %#G" !GA^$7@G,M .AE1JHH0(YM!^=,2!&X@ [H H='9_$$@6
M=N0F8M&!^@=$(58/QS1JD_]D2?5P1"0X@@]H@Q(((EY@28*D?H@P@S6(@RDH
M1631!=LE:3L(@TE828X4#:&P:\L >:9&1KNA*JS4:WR':*Y22KF6:K5"2[?B
M:Y36++UT*<)V*\6F'ZW@"\HV3,S2?=9W>=P7A^7A=]%D7/!07-\29H/V;> V
M;N5&;O=B3N6D+^+T;O$$;XF(B(OX;O84;_@&B?D6B?BT;P%GB00U4/U&4 "G
M4)JH40ZU4:%X<!PEBI]HBAF%BE-C42NU>2$5?1UU<0\GBRB5<2EEBZ^(B[CH
M<2G'BS-%5#C%<CLE5"7G<BH'C,=X5$(%=#_75%2UC,[8C,\HC40W=-6X59[#
M50O_H8U>E5=X=5=V55=)UXW@J%??*([F2%?E&([IZ(WK.([GZ(X@<5IO*(=P
MV!2"]6;YR&C[B"(.$&KU") UU%J5\1MVAUEX1PS\$(74P@_Z<WB$]Y"S87@0
MV3\,1H] ,D+S, /V9W[ZF"-A4F0&<I'G<5O19WGV^!29EXNO6 %>D%[/9GJW
MUU*J)Q_Z0 83%WL,4FVOMY)<8P&,A1RS\'L09@&\YU?\4'P]"6$5( @6J1_.
MIY11^374%Y!S*$,8MGTCB9(TXF%2%B;C)RTDYI5GD0@ <$5CR8]"U)3UP8!I
MZ9%HJ19=,&'?]7]V)H ,8D7V9V)DH8!9P8 .")>!^6;O_^"40J*!;XF8:0F"
M?EEG:+DF]W %=B:8<\$"7E!ES/&"922#'>F6G9DCE2F%3Y&!#I"8DIF8E7F$
MN929JSD4R]"%JV(?J62%I20>H2)+73@KO,9WM$6&LT)L/-(/:SA,D[ L5KF5
MQEF5QSDGX/(.9'!-QG5-WL:'X.8U?QA.Y;8PYX8OA=ANC-B=A]B(\]8PDRB)
MY4F>YYE0 /5OZWF)F2AP 4=PHXAP!J=P$#>+#D>+^(F?K"B5V*&#4?%@(Q6+
ML'B+%M>?N+>+(C<V"@IR)-=3OG@V;N.+Q?B+QDB,U5&65^$%,4=S'.JA,\>A
M-@<Y-W<Y/J=S)LIS)<J,3&6-+?^:54<'H^^H=5BW=31JHS.*HUFGHS6:HSRZ
MHS<*.UVW&EJ9G/4X=BKH@4@*8C/0E\A)I#,R*J;P"9!A=^SC&Y0E'/RP*A0F
M/PXII%_JI6%Z6K51F$_F!1RY:6FJIFG:!0;2'OG@!5<@ T)X@_E'@T)X).\@
M(TXJ& T$?2=9I$*1"!MZH-&7 V1P8QUD>A-'D^3Q"'ZZ<3FI'X/Z?(7J0,GG
M:(0AE, G?#%DDSQIJ13G!?70>YHJ")4:JKDX?=47J'S:/-F7E:[:JF[B0W3Z
ME:RZ(&*I?]Z@)'>:I "H#J4Z)_. 14'X?FE:IT!8=C*0J<M4ESB()4W&(/I0
M?\8:)DW_.B<-F*RV:J?;FA9=@ \8>)B^JJ2^NIA]%$?M%T[DRJX'* -+)$I*
M>$B;^:O>JG^@.4G^D _J0)KM"JWUNG:5242?%*\7:+"G)DM?B O%@(6B1H6S
MJ2JL<K"2DFN5@IN_X O%0"JI0DK1X$ED-(::Y)MH2!^\H0FW<+(I"YNR^J0L
MZ[(SY)S9DH?6I(?B,IWH4IV ^(CH=A;Y@D[@^9U!JXA .[0["S'R!B]SF17F
MR;3HR3$>\P!*NQ3U\)Z8>#+LN8E1NQ54.U&I"%%>.Y]=*[9?.[;U:;9?NY*N
MB!U=T5)ENA=>H)]'\Y_6XC2)L$;($:!1([7/0:@LY+9(T;=9_S,#9/ <O7BW
M4W$/?7,/6/%@%.JX+0>Y%WJA2+6B.A>-E\NBEINYBX.YU.BY+HJ-H7N-VXB.
M,FJZI8NZ\:BZZLBZ[=BZY.BZL0N[LPN/"S&/+SNKWX6/GCF9IMD%S)>[W2=W
MRF *PY ^!RD9[N,8RQ*&<.@/@R>1$0FF8^H:B><L_'"FO)N/;7H8U98.O0N^
MI0D712BL %F2?_JWBJ>2J?J*%K"6%A23$-:H"QBXFR>I[8&4\,6^+]62+SDG
M0YE;19F^"K)>];N_E&<!7E"^-'*J!ZRJ5-FRRHD?6!G!P3MVIDD68 D^NJJ]
M&;QB[H (\Q#"B)!MZK"1'7P #K"XA?_1#^@PF4<"#PIY&/V@8L6*P0C09,WT
MK$IVEVSR#G>REPBPPF'D0TEB#C-PQ$069NL +EUP:5ZV;5'<Q$>L(1AL%BP@
ME^/A9OLH#PN,F8TIOF1Q)"N&9B(LPEZ&#O-BQ6'2'<?!FB&X:*:I%P0;2:G9
M2/UP1FLLQMPD",![@?V0".]P!>30KWH\ _0 2&+H/+UY*;G@"[%6& ];A:@B
M*5<A=Z]RF[IV*;@"A7XA*:\V*I4,0J%22[^)'B8++"B+LLPBP17LRK@+)/=@
MAP#F!30;G3:;:=YD+N063@G0R]R9G88HM-Y9M(GHB$?KM%H+&(B0S,WL, H(
M%8E0B5:[M)S_R(GNV9X/L+1A*Y_T28KVF9_@K)\9JA3W4(OGW)];\5'^&Q_U
M.S6'VQ^"L!W==1]4RS0#O!<!FJ .^@#IH0\?)Z%#11UB-XP"P;9"Y056P0\R
MQ] ="J(X!]%%!3E^@:(5K:*:B]&<"[J?FU5&5Q&E\[I ZJ,C+=(EW:,F_:,G
MK=(IS=(#\:7L_,JMS#Q'ZJ_=:JT&. /P'+QA%PVG, R9<7<#]!C#< J^5L%_
MUW5B"KW3BUK6FR#8JR'<JJS*VJ9R)@CD<-/V6M-3S:V'[,7[!:FX!ZAO.*@.
MG(L*#"V+*K]:T0H&S'GW:QR ;-8;]Y-P L P%7SX['V(<-=S#7T)_[S 4.G7
MQ[>J.RW3P!DAVA?3@?I]4AUBN/HC'*S5Y"![06DG6FT6,B (/-0.7'T7E W9
M#S(/_<JMS;I!.SS5T3J \S$+\E#(-XW%]-Q8^A#5[;<.Y$QI9A0F0@@/B1R:
MB2*"4ET]%.C;CY0(57S3(4:8!XN$2^C<(FBOAM3<EX0/[&?3U^T )BBOB>0/
M]W CCNT \+#=JBEJB>&:M>2&=_3)D[Q*NM)(MHF;"LM)N,3<A (A$*L,HOQ!
MRU#*)'L<P2EL*0LLQ+;8!0[+!\X># @N9^8MMMQMY$*=2B)N.OO+]4*(//NS
MPTRTQ,SAX3F>"I/04[&W1[&ASMS,(>X4_/_@,-.,S5;K;R^>M3!N405WMJ78
MS67[S:>(XS,#@G-B-6K;BDP#S57AUE%S%/_,GP\PMU+QSR>5%0;\,UF1M]21
MH?PPY=?1>T5.'2->1M '0TO^%%J>'3H(%83[%0!]<@6=-WZ14VT>C!4*YX\[
MN<I(YQ"@TT+A!4&GYY6KT1F]YQR]T4*7C1_=52!!NJLKN[6;Z.Q(NXRNZ(U^
MNH@.Z:D;THX.$[=[V(;=3+NKQQV<(W&6Z30T*JY%0)4U&95QD,+1"AYKX&YB
MY?83O109Z[/^TDYM(5#MZ8;%O4XA#V27ZV'\ZU52F6N$DN=[?&-MG.L[V-%G
MF>(3O[DUOT*Q7C+_>7QPG16/NNR4EP.!TM<N)<!XF939GHNXI0.+RQ>"+>X<
M5]BMKNE[0<$(SMA=J8^//6+E%YA=H-=>T>N(V05] 65O^:X,,@^=B6>GK9=2
MUL/YT0^(T Z^;IHS( \<=AMH@I8L( CAM<4FUML;#,;[&&*76=ZB.:Z2R0(R
M?.XA#]R=+<=[,MV*1,-8A,$"2]ZJ66U7()@YG9G5X@^NN4D9NYM!$2KLG=\>
M2[$BBYN<5 RPQB:7#+'+(+$2Q-^;9,HLW!BI'.!;VN[PSNY;OQ5?<FW;DFW/
M^9PWZX<3'HCMED[ W.$:SO8+<\QO?V^,=154BP!DKA0J3F]S#R_8ZA=X_R\Q
M_>$.!,7W>/XNUNPN7NSW(3/XT1%10VX4@9\ *#X8&RJ*0:/7E.\]2/,>A.I1
M7+X5*MXT8.Z7#P#31&'/+F6@DP^+LIV2 \+E5_XTN)WBVW'G0-%Q#'HV"FKN
M57&3I0\4O7@WM0\ Z2+[)"ZYNY\4-TF,7;&A,O?5L_#0;O,%[:$XGF\8"RTY
M"MP>B0N-!W$5K1 10XQBH(O6F.G1&T$&R<$[WI,()+W2[M_2* W_\R__]3^C
M+\WUH>X@-(W966VL+  0^?P!(#BP($$ !A,B5-B0X<.#$1=*=$@1XD2,%3->
M].<O&C]BFGIIRD329,E>F4JB!#7LU$"-,3G.M/]8<Z--F35G(4K$$]$CGSU[
M A7JDVC0GTB'*DTJ--&LG#>E*N3GA06" PBT>M.*M2M7K5FW=A6+ &P7?;,*
M\G/7=6S8KV3CPGWKM6Y9L';-RKT[5V_>L@ADY)M*LS!.PPJ]6'C0V/%CR)$E
M3YZL VIBS(@U'T[DA?)GT*%%CR9=FK2@S(<G/C+=6D?#68M;SQ:= Y%,?60>
M5*#=V_?OWA5F)/(W2P?PSQ;P7=Z<<^=QY-&E3V]-G.,L08RI;^=N>G@_U5'%
MIQ[?G/QY\^DG]E-&TE3Y\.CCJX=?G_RL=S/P\MW;=09X^YJ;)9\9W +,+P0$
MX6>^J1"AJ[^_M)HAK9K_'.3OP*ZZH"^S663P:S^M6$"+P0 1N:HO%-U2<446
M/W3QKAGJZ4@^V/KI1Q]^\,DGGT1TQ*?'?'[T$<@?\['J10@1\((BM3*"R@NW
M0-0+GB:+8_)*)PN:I8L('\SKBLNL3*A*,K4T$P!]"NRRR]O*'/-,,>-T4TXM
MN<000K$0X6=./N%4:Y9Y'$@1PRZ6\Q-.AJI,E$D/[[RSG07?S')2V+"L%"-E
M?,%%4TZ)B:8@?Y991AE1HQ&UF&)\^6535G%A55-B?%DF3AK/\XA447&-)IH9
M PQOF5<W)0:\\-C3!)=CC_6%&!)KW?#99J'U=5IGH[666FFKC>FY+KSH%AYO
M_\/MMHL<KB@WAQG23?<!&1Y@P=T'$( 7@03D[:K>>N/5*MY\Z;6W7X#_%9C?
M@?TE^&"#$PX8X843CA?AAQ'@1R-W(GZ@)B@MMM=B?9SLV#Y]-%8TO8P3B#<1
MB^IYV&1Y37;'60<?8!GEC51N6>;&O*B(.095-MGDQG[F&5L //OY@8_EJQBR
MH1.]QS$OK*,HD<F6)-H@JJ4#&K*M'Q@9(WX<VSJ!F8*6;.N8LJ8M)\KJX4CM
M1-*"[1[/MM/Y(I4;BQ1LT#0*N[%[.-+M@1D>@^ !J3'*N['#":?9H;H;?Z#Q
MO1W2)Y$9#O<B<(N>SMPQ")*6R O=#O_B'N:HUGS:6?\F_QR"RJM]?7+70_>X
M67T.UYUVW44'^PO> _<; N)YC_T@+SPCG@S4"TJ$^,R+)S[QAI[7'7KBKX<@
M>NVYGQQ[Z<'O/OOOMR<_>^_1/U_\\M-G7_WPS8_???G'GW_]^MO'GW[^]_?_
M?@#:3X#E8PI1KJ8M!&9+@==*H#_@H::\1- O$JP+!2&4%P1T 4 )9. "L<4>
M4*1D)"I9R4E40I),$.,4GSJ@!SE8GZ,4)89&*6 -B[*4&_+D*2T$VY$L^,,)
MSF5$ &C%B2X8Q HB\8A)9.(2G0C$M\Q@'E_CH:^\P)ON@,8R57PA1!+1A2R&
M48RCL0 BFO8LUF"1.Z]!2';_QE@:VV@$']IY8QW?F ,OZ(".VU'.&1G4CT3D
MP(Z#)"1E9D"&!<'&C85DI&^^TT%(<M&%DYR/L7KQGBY24I*13,PL'@C%)/V'
MDTPBD(&4B #"1-)"H 2+%*E($$&P4HFR;"(M+S@#PFS2("::92]KZ<LG(N *
MK2#6'Q%Q!1794IFG7%)\_ $E8%))DUL*9EW6L2A*85,A_8"@+P71,42%4U*7
M(N<LVE'-_NB)BNN\TC&!R94K](-6XF3= TW91"5IDD;]\ 6G6$6,8HAJ5*GR
M9T%?)2L6CI*!N\+5J$KU*4T"RY^Y\ 6Q<L)/?R:KHOKDJ$)UF4F/@O2C':W/
M+*[@_P5XD$$0R1.7M[I@+IBB2UV%:]>[WB6OFS9L7PG;:<-\6K"?,JQ@$>L7
M43=V5(TEU5ZO1*J\7J:1IFH,$3C)V%$?]Y"0114!K[09SI#*LNNPS#'R2B1$
M9G$SM'I5K6!ETM&.9K69A,RMC;D-1[QPM*#1Y*YB$]LK 8"(L?&UK!%1&\XD
M<QW0E TR;K-(R*I&DRQV[0'"4ZQD'W WBM0---1#R-]:XU< >%8RG(66("13
MN,B@%C*%@RMA'X,:B@R.=H0C0^<(M[J+W$-RC?O<35JW6\"]#72-R5QC;TM<
MWD*@)L<EG'"9^[K/'==\C1E>[:R[O:L2%KJZ^QQI$\+=W?]E-R.EXQWB+,*/
MW>T.LQC1;7FU%Q/P*K<BJGN?^+@7/=+.XK[PJ]]^[<M?__87P /^;X$%;.
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MSUN_]+I7 "B_UER^FW#9\LK,]_L<BHU-WFFFC% =]VK:]RL?]YJ_S=0)J&7
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MPI>69WXPZ3-<9?)H^NJ7:>FW??@W""%]_^+=:8!+TF8[Q8N3]&DI:FBS=(
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M$:,5T2!VB[GM8MOP VQ=2ZJXC[I4<G=L;&^$*K.734)W/!O%^6@-$7DXDB[
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M1^E@1_$@1_G@1^W@#P8A$/8@$0IA$0[AQ3#5URC?ZR5?2:E4LHU7@.&76+#
MT,6>,IC")^!4%Q+#*6Q;$QZ?&-X=48U;L)T;&IYA4ZT;VE"A<TUA4\#;\<W;
M>KD6'((5OCFA6?5;V#VA62#"8B'@(#K*P77/7146Z^C<L%D<6DF<$XI/(_[_
M$L9Q!S^0 2%BHEPQG&H=2,BA565AX1A"XBC*E&>QW!^B(AFJ(BFF(BNNHBC>
M1RA6'H,IV"Q27@O9HN+!UWSMHGOQHGSY8C#VXC "(S'^XC$F7BWBXC(FX^3I
M8BXJ8S-"HS-&(RRRV'<40X:14861F!551WK AR^4ARN2HS6^8BN:(QU9B!=
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M_HLDNY]^YO/'W_[]_>\?@.X3H/P&F#\"'M" "0P@ A>H0/W5[X$%;. $(\A
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MC394H 3UITA-*E!<&#6A,+5J3HUJ4)Y*5:Y!M6U6M9K<KAJWMVUU;5]%&]G
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M@)LHK;#(VX<.>&W<G"((,V+LO-RD9((/,]#DR8AA[8 (]: /^M *^=#_"OB
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MIM9KU6X]IM-;Y.B@^KC3<86)N[O:ON6M<WN[>,7SHQ7W0,1HZ'WU*W1!Y_)
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M_P1#,R8DK[&S&7BT>JE93=K9>JDEF\7C0TSB4^KC3/IC5!I:.48R.>X3-F;
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MWF?\]G=^3V=^WN?]7G! -8M^\ *EF#B16_@9J#R&=WB;L6__?G '+_@&I_B
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MYKI/KRYF,&]=ZUT'N]?3+E.QAWWL;<?HTN'>\*$;O>@F V8.U*.^K/*YJU<
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MEDRX [[6,SZ3ML&&-JS)!&C+'B5J222?"^N:MFS5RT582A+9<G>8>:D@>4(
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MR/;,IT5M(Y%Q]WS#@A%8&%^HR\@:\?RS_?PL()?_4PP%'J_V<=-1IW^Z<#]
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M.__U[=Z[8P</ =$C1(G.IS=Z%2A[W$?ANX_?GOY[^??KS[>?'_]^__H!["]
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MSC#C%9+N_?^% \#N&&8Z!/3?=PP(OP *1SWI,<_J]N4O"0)L@A&DX 4MF,&
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MKWZTXAZ(*&P]#(L(Q!XVL8M5;&,ARUC)/G:RCK5L9"G[6$5EL!_RZ((,NN0
M/8U6AUP:(SQ$JB]_Y".SEZTL9EW;_UK8SO:UD[W'HB@XBWF 2;14G).FCH2
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MEBEKY>=.26F@$]H5VO73Z%\6:$%V?LZ*&)WH(S'SGY<"]39;!#>CZTKO^ >
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M%WL1&']Q%X<Q&(E1&)'Q&/EK_,P/OI31&*&Q&*4Q&:,QW_0!D_XMX 2._ZX
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M@ IOV39OJV=]][9]GW5<P15^Q35^Z7=^[3=<\5=^\Q=<RU4],/=R)?=_!3B
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M8XN--3OF;#CQX=&B2X<6.2M?CBY>O/^0@4>&M6PO771<R7%[AN[=,A[T9O$
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M2O_@@..'?W[YZ]^7X+L*1AAB_NNB^&  +FQ_!_N+Q038,01Z+($FH\S)<O9
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M],'\'L +4+ JB(7]R@^,T /_AD7_L(+_O,C_+]2/V"!0+(#P5FB2+Q*AL1(
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MUF$&&IJB.50S\->A0[J=>Y0SA/>A_3E'J72A%?J:R3F<[=: QQ1Z 7BF97J
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M<#4:87SJ$")B=Z#?6)0 .J B&J(D"J(F2J GJCDQJ746A(R0LWL0ZC7TZ'R
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MQNMEF>J4G I_SEN55VFJ6;1_TIM_[HR5O6&]7:F]^"RK^LR]!.B]X/O/PN&
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M<5W_YI"JIFH2KPU>LHT217';ZJ6LS,WR4)'BG+(J490J550;4Y3N<DCB2D[
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MTSS;$SW_'S0-HVVDXA.#XS!#,]1##RY$]W,/Q<H/1Y3<R.U<D$7>="M!5]B
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M@I*3^ZCD*$SAZ%(^ZM&?+ 4H)WK(&.C!E:NHY2PK-<L_4\+2F-9%IFZ9"%X
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M-EU !!WM)-X DQ=5ZI24H- K0GBL-TWP<*][XTLI2VFJ4]XE5K#":^%B71C
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MVYMP6Z_;NJGC.K#+B;IH![8,BKXUN[A\2WU26[BTR[P\W+V<.W_R2X0"J+8
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M\-(NZ /;WJK10]3@LL5D;=4"=A!QS"SX$""XPSJX0SL<]CNT V-W@3N\@SO
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M7;9(ELTLD(RUP$0<24J;38"UP(,E(95I2D,BK7BZ1*;S'$I-&^+6>)Z$I_4
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MR($D2(A[N(G3%XBRN(5TJ(IK2(;DN(S#.(F2F)$+N8T2N9.C.9D"1'Y@K2Z
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MDO,Y+VPZF_,A^NLZOW,[HW,\J_,\L_,Q22P^4U,^1ZP^P[.]TO,_VW/!^O-
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M;KF/C$L//O7<DVX]^+3[KKKQN@OO,_(^DX^[]M*;+S[XZIMOP/<$# W!^?]
MHT_!"A^<,,,*-US/P1(7'#'%$E=L\,(:3\SQPQX[##+"'XL<<L(FBWSRR?R@
M+/+*";L,S<HRQTSSS#;7C//-.N?,\\X^]\SSRS@+/3/1-*=\=,M)PPPSTDZS
M+/332#/-<S_06-V//BM;?7(^^&Y,<M@-B\URR!-+#77::*^M=MMCLXTVPP,C
M/+?*2D>]M-(W6[VU/EC[?;765^<C<SXO&XX//X@KKD_BBS]^>..,QPPYY9%;
M;CGAFF?-C]_\9#W+Y_R$[L_H_92.6HC]Y&A2CAI1=!%'K\\N>^T3T7Z[[17I
M'GONON^^$4/"9T1\\,53-+SQRB-_O/"(# 5]%\G_(P3]@]4CT'SVU]<D??;+
M,T33]M][3]#SUG<_OC]=C,723L$CTDY^VT4__?3NS*\2^0#@KU),]6=?'?9A
M3W\$3!_S#/B_C?0.> Q<H ,+V,#C/5"!$JP@!2\(.PMF$(.XBR '>:?!#DYP
M@R1LG0E9A\(3JC"%+%RA"JT'0P'.QX4"X1],:N03CZR/?Q&I2_7R\B(9^<-\
M[*.*BA:C(OE=[X@I2HL/K?,6%HUH( &<GVA@&!/5#4: 4]'B%$4$1B^&L41C
M_*(8STA&-)HQC:EIXV[<J"$XVB:.;ZSCA*;3G@SA44!\O&,>U0)(W 3R-H/D
MWV%2EYN^6$^0M!GD+-81_T,;5J\=C:RD6JJSO4P^:!V()&0E-<G%^34%D;)Q
M9#^4:!U+,E(V\[ A)3U92M;8D).#G,'U9A#(/9)&.]?S8QWI"(!,<D6/H*GB
M#\N(3#4FDXUKE")G3L1$%>'P(3>JIHUHB$V.P(-'9/B1C[[9A2$5J4A(6I(Y
MF_2D)TF)!6-JISO?"<]XRO.=:2*3F>X)J#GEDT]X\A,_TR0H@/*S4(ORIT$5
M=5""'LJ?"]T40T<%T5)%%%03-95%*XI1B<IJHZN:E4<YVJJ/A@M<)!VI24N*
MTI.J-*4L7:E+6PK3E\HTIC2=J4UKBE-M(>)<Y.HINM[%+G4%E5[R@I=1BXI4
MHO\JU5_]^I>Z\C$PC$GU8ATSV%0M9K&H4A6K5MUJ5<'VMI&%M60>@UO;J&:T
MGZ45:#]K*UO?>C.\H35O1<N;69OFMKQ.3:]WPQG? H>UI G,:U[5V%C)1E:S
M*O:L<$T;7A?[-+GE2Q]UZ^M<+ZLWH'$N<'TK7.3PH0_(@5:TH94<XDH[VL:I
M%K2L12WC'&?:T'9.<;/0FN= )SK2H.YTIMM/&%M($A&&$(0?_-T(A5M<#Y(0
MN<LE;G.-.USH)C=V511/3*8KD!V^Q[D$B9 WC(C=C83G0>5X;@,A=!?S&D2[
M=]$)<1_T$O=%L![PK6]\E#(#YA*DNLLY+G?_*UWU1E?_N?H%,($-[-\ %UC!
M"!YP-A\,7 A+.,(YK# UKVGA:<8H+D+D< T+<]T-!]'#041O_T0<(Q,3A8KM
M70F*-U,AO#P3,M T9GNSB$1H#A$^!FIF9* 28_O^QSJX9"-\#NEC-1)SBDMN
MLFJ .<<HYP;*4Y9R'W6)Y3]JV1_]J4]NNKR@+^\1S%S.99CYPZ!.WF>0:V9-
MF[W,9C.76<V W,^;PQQGW<+9SG6NC_R"?-\6>PC/;JXS) LSY]/MN<]Z;K2B
M&SW>L2R:T)-^M*7]X=W#K/D^RJD0+3?-:$7SLL5%OG2H0?V<"#$ZT:@^W:&'
M_.@.L:0=?&YTH@N]P_04FLZ\_^YCC(>Y1T7*&MARK+*Q=;/,)#,3F3JFL;.=
MN:(9=WC$U)ZFM;]B%&]J&YSB/-*1DG1.)T%)3U.ZD@/FB>YTJWO=[*[GG>R)
MICOILY_TGK>]Y8WO@PH44 $M*+W[W5!'/52A&:6H1@V.\(L>7.$)+SC#'^YP
MD884I+F:>$<IGM.,WW3C&N\XQS_N\9"#?.0B+SG)3P[3<OF4I^T:ZKQ>[M28
M-[6I19TYP-P5L7LPE:M7Y1C&%O9SK_:\YV#KV&'/!E:Q*KUK?+6;7(?66+=*
M/>I4G[K5J;Y7R#9]ZW;[V5\#"S.)X6M@7S/ZTKF.]KU>?>U53SO+J.99N\K=
MK9NM.__A,/?:O)]6M'I7+6E;"_C8PM9QBLN:X?VFC]#UH[>,=_1O*4/A"4L^
M\I2?_((KC_G)N_")8REO@MDK%0<'\WR7OXBP\><.T?L#E5)IRH'5)\/HPE"^
MLSL]*"490R,*U\8Y*;WJ!1Q>X O?]\%GKN8SC_SC*S_YS'_PC5)H36E+/]K4
MS_&S28Q%$E^_^DYQI?6=F:#Y4<60S39C)-$(E4R6)=F=X3QT>IS,48?R]L)4
M-A>1S'YE/MG*3BXVLOF_?\?6?[^495>F9:;D' BH@*H$2Y3F@+<&9PQX9Q#X
M@!-H@7)V9Y:6.AG(@6:F@:&V@8%$?Y%T>Q[(@:]6/;G4:AW_Z&BHADD/8H(Q
M2$HLJ!;"](&ZI4G> 8*,]H+LXP6FUH)U%G[54PZM%H(SV _N9Q/^@()_<8-/
M^&;R!QT32$I;]AKU-X!Z(85#$8#_MVSZ]X5A^$7E-WW?-WW71B/8-F';] [=
MQ"/@Y"/=E@/E9$Y,(F[J5&[LIH=[R(=]&";N!BCPIB;Y5F^$N&__]D_^=HB'
M2% )Y6^-B% .)8D"%W$+5XD-9XF9B(F;:"FP4BL6!XH5)XJT8G$F9XHHAXJG
MJ(JIR(JKZ(JM"(NO*(NQ:"L[I7(JERZY*%1'M52\^'*^2 \VQU0X!U5/Q7-"
MAXQ898Q==8S-F#&%!8U<A5C3>%B+_X596==V;*>-V<B-._-T6@>.: =WFD4S
M?P4Q4$58!5-V/U>-9Q>.:[6-?T5W@J-62>-T<P=U-F,X^/AT7B<X_7!WDR.0
M?$>0@M=W@^=:>Q=;E%-X6I,/AZ=XB<</NT61J]89";$ZD#<1&=D0'+E\']E\
M(0F2(RF2)9$50F8374 /ZT=%73"$+<9"WB5H$>)Y(<%Z)M8%UY40]( >*.EZ
M+@1Z02%?#X$(]9!K\ 5>("%K*L&2 !E YK\H=#\TB4+\%6BRUI0D:94E>97*
M%WT7EF%JF(9?B2->&9;:AV%<:98O1I9I.6+<%TUDR)9N:89L"8;*!A0@5H9-
MM'THH6*OE']R(85!_Y878)A^,\D<7A"8LQ$_4PE_ )@:[N<6C%D5WO46NL1[
M0NE'4ZEB\>5+O4%FG9EF:"9FH0F:H[EK>0::>8::I5F:M?9HK#9IKHEGK+F"
MIT:;06B;0(B;LWF;NIF;M=F;N^F;O"F<M;D^[U%JPTD:F4D?PMF$T?&;SZF;
MZU,AP4F=NYEIO>F8XP&<NA5^019.?88(Q4F8*M$<T.F;0P8?QUF=IG:44J&;
ML F?;?9K<]8:\#,#W0E?HU2 F]F%63B7?4F7;9F7> EM:%EM8CD+;/A-0,)M
M1C(#WU:',X!.X[9.6')N?HBA&:JAZ0:(]":(][9/(5J((@JB(XJ(_):(^O^F
MB(\R<(L2<)QXB1"GB3(*HS,:HS=JHZ0XBI^XHY[HHQ)'B[,HI$%*I$-JI$6*
MI$>JI$DJ+CY%+BR75+]X+_T2C+UX+U-Z<\/X5#HW=,E(,,M8,6!:C$3GI4$G
MC=%H=F2EIF3SCOQ(5]W86/((I]NXC6UJI_;H6);U5F 7-NF8,>V86%LWCFRW
M63-3=__XCU>CJ('%IU.W5O 8=?MXC6]JJ.7XCW<'D(6C.(RC.9MJ.)VJ.9$3
MJ@PYJIN*=YOCD(<'D;G%6[K5>*WY>'J!D;.JD;):JP?!D;E*J[;:D1SAD;N*
MJ[XJK!LYK+U*K,=JK,D:K,BZK,J*E<\Z1",X?\O_,90Y(JV2E)0C05_3RJUV
M 401%I37"CTS\*W:"D,0IDDG5)GBB@!9":WOZJZ:MY5H.);U.J^,@4,>*1?Y
MRJ_X2J!W*: %^J]O*88 :K#_J7_9A["9X7T!.AFXYV(.BQGA0X(5BP!%1H!6
MF(1<U&/$,9B2IK&X$4IXU*V@A&15V( IB[(KBX$MVTDH>X$OZ[(+N(..=H0J
M*(,XBX3;:9X\BYP]"[0_*[3K.;0^2[1'JV<W.6M%ZVI8Q)PP=&F]56=2:[2S
M()YC0;6M&K2G9H.\:7M"\8,_2T002[;>L)Q(FYO-B3^TAK:@MH46NQWEJ9KD
MP:[S1VP&R$=4YH5[>[ %_[NP 0J7 PL8]'JOVO2&VR8D1C*'Y:0D=IA.YY:'
M67*A&TJYE6NY6]*AF6N(FTNB*ZJBGQN)B_B(H^N(I1N)E(BZ+(JC-<JZ-.JZ
MJVLJ/XIQ/*JCM4N[3+JDN8N[NZN[O<N[O^N[P0N\@6*+3OI35HJ\4IJ\OA@Q
M6>I4S;NE3T6,7-HOT&N]8UJF!R.FS;B]S.AS7P6HU.B.>8HW]TBG5/=U58.^
MZENG;GJG[ZNG_:B^YIA5WMNG2N<PUCBGEKHWB?HWC+JHBKHU^WN^W^BF._-U
MB-I9I,HY#YFJ#]R0F^J0LT4X$ RJ%-S M=4YJXI;%/FJJ$:??2NQ(WR1((*1
M?O^[KR:LPB7,PH%QPK>:PM+DKS),PVG1KS4<PS8\PSJ,PT/$DTHB'DI2#EZ@
MDPB*8?H*PTG,JSS,Q#WQP_=)9.U@F$N<PX5KKV5)N$=\PTVLQ 0KL $+L($+
MQM1FH"V2Q17FQ6$\H&"<QFT<EV\LN"3\MR),QW-LQV+HG\<F(GF\MP/8&WK+
MQX&\GX,<LE>&".=1#C>9R.UPLH2,MV3&GZ*Y:Z3I991\9G-;@:L&PINLR6WK
MR56[M:#,M*/\R:%LRJ0LRJ6,RJ>LRE.;RJ[:@EE;D; <M;%LR[6,RYLFR[M\
MR[K<RZZ<R\#LR\%,R\-LS,(<:HBP#N;D%S+0!>MPML7_C,ROS,K4C,KQV<FV
M%K.63)^1C+?>#,C]><> N\9B3(9D/&TP(@B'R\Z).TYTV+@2>H>0RT[F9L^7
MB\_Y;+F:&V^=Z\\F6J(!38C]!KH$';HKVE!E\J(+?;JM"[L/G:,.'=&O.]$3
M);L7A]&A:+L778K#*[P?[=$A#=(C+=(EG;NW^*3'J[SO0G/\LKPUY[S"6*71
M.U59"KW/B[W$Z(QDNM/9>Z9)MZ;ARS:3BEEU=;Y[P[Y^E=0 /,!-C75!XW;P
M^S2/1:E[*L!E@S%E9UAEY79X%8]*77<!#,!C+=:+2H_EF-25>G4&?(_FB]9.
M?:@1[, ;;%NJ6M>(QSEXC7AR_ZW!#FS7'"R1BT<Z'RS+@%3'*%RK+KS"BMW"
M,<S8CXW8O K9B>W8E4W9ERW9EBW9NSK9F8W92$S%7;S%52S:.TS:GHW:N:K9
MJOW9+QS:2PRLL7VKL@W;I=W#KPW:N3W:MLW%N+W;OFW:O'W:N0W'MQTB8CS.
MARW'D9W<S<W<S[W<T:W<T^W<TEW=R2;(;N3-V^W(W%W(+"NSO)::$4C>#@B%
M.7NSZ5VSY[VS.NO>ZLVS\%W-\[W*]=W*UGS?Q!RTO*S?LZRUQRS- ?[?TSS@
M N[?!\[? %[@"X[@OVS@"4[@#=[?$/[@^&WA]+W>,3O>F1S>W^S(X>Q_U W=
M!FO.Y?]\?69YQ@.QS@S*H.Y,)/ <;H];H5LRN512X_J,XSG>;O@TB/\LT"@*
MY"<JY*)KNI!HY*0[B:J;N@Q=T4TNT4].T0C'T3T*I!LM4B2-Y2:MY5G.Y5ON
MY5T.YJ]2O"@-C%%:YB_MTEI:+]7+YM0[O=(+Y]=+O<K8I3UM,6]>Y\_XTWH>
MU%Q]IT1-P%8-UV]]U>E[U'TEU5'-6-A(=X2^,@$#,&176.VH=8.*OOY;UO\K
MUH##J(FZP(:NU$CMC7+7UO'[I@G\Z7C].;?%ZHMG>*ONZJT.Z["NUW8=D;>^
MZH-=S!\<X88=:I%A:9;A6Y4L[),Q["-^W<F.[,MNW<PNXLW_#NW/+NW*'NW4
M/NW.;NW9CNW;7NW<?NW=#NU\+,+9G;%]+,[^1^X@7N[D[MT>_MV.[)GB/<GS
M7MX4:.\:+INOR<D7;M_\GM_]CN'^+O !S^ 4SN!$:_ '?FH)S_ .7O .+^$*
M'O$1WO 3#O$5+_$83_$7S_$6[_$ #_+ZGLT;?N^?V>[@#)GJ_NWL5^)?C,YJ
MJ<[LS*!2'$Z*"^.."R7T#"8WKA(\C\]%R2YUH>-#WT[\W., S;E([^-)/V\&
M[?0I>M )K>13S^10#M%6[^11KO57SW!3;N6SZ_6W&^:J6 ^SP!#Z(!9C_^5K
MGU->4 \9L7C@8O;9XPYJ;_>MB-+%_XMS+*TO9AZE>P\O@"^,,F?3.0WG.%WX
MA3_G M.]/,WXCE_GRUATXIN_BC[5>GKHA K6:,VG3/W4DYKHB6[I4U>H)"/I
MDJZ.2!>H^GOH9*WIA@=8L0_[G3[ ?S/HM__YB&[JH^]7B/J_^E Z61/\P)_K
MJS[\$7G\QE_\PK_\Q,_\'3PZ$QG]'KSKU8^;\KUFP)[]O\[]CN?KI!$:JR,8
MXC\8Y'\9Y@_LX:_^X[_^Y=_^Y__^Z<_^V@[N*T__]N_M]Z__^<__];___@\0
ML_P!Z">0H,&" Q,>5(C084.(#"4NI/APHL6*$3->U(C18T>0'$5N)/EQI,F2
M(5.>5(G29?]+F"QE9IRUTN;+FCAI[GR8$Z)/H F#"ASJK^A1H4F)*BW(=&C3
MI3F=3HT*U9\_J FQ2A6XU:I7GV"U9JTIMBS9?F;3HE7;ENW;LW'7RO7JEF[3
MNG"SYKW;=^Y?OH#Q#O8;V#!AP67Y%49<=S'@QXX9%XZ,M[)BNI?3:O;'V7-F
MT)!#2Q9=FO1IRZ-3FUZ-&C/KUZXWJX[=VG9MW+-AZY;=F3;OVXF%'YX\7&]8
MLE>3FS6JM'G4Y]&10F?HLSK/F#>SOYS)?:/1B. EBE](WJ#X@>G/ U"?GCW[
M]8*\O//297Y]_%VZ7,G!?\;_&60(< 86'F#!@0,10! !!A5L\$'_!QYL,$()
M':SP0@PSU+!"1.JYAYX./PP11 ])%+'$$5-$<<436S3Q115/E&=#&FNTL<$$
M+LRQPATE[!$ ( <*$LCWA@QREBX8['')!A_ L<DG&71222BIE#)*!*;,LLHM
MK_2R2S"U%!/*',<LD\PP$3ASS2W9=-)--=N4\\TYXZ3S3COSA'//.OET$A$A
MBWRO'C_U1(#(0/WQ8DL\G6PT42+=:71++R %DA]'Z\ST 4N+W)114)VL%%%2
MC10TT5E"5?5/4P.MYU-8006TU%-I]0>157.-U=%6;265GT5WS=+2?G0U5EAD
MCU4V66:7=598@WKMU8MFJWWVVEA]Q79;_R<3:358;K/4IU937PW76G3/53==
M=M=UM]U-$7D$D43HM3<1>O"I1U]^G\EG7X#QR7??@07FMV"$#U:8X'_U;=A?
M@!NFI^%Z*+8X8HP=CO@>C3NN>&.'H?DW'VA"'IGCBD6N&&6+65:99)-3)GEF
M:/01N>:;;2999YQWSAEGFX,&>FB;^2$:&J.+QCEII)=NVFBHGY8Z:JJG;KH?
MJ[&N>NNFE?:ZZZ.%%CMLLGD>^^RRAV9Z;:>KUAJ:MW5>&1^(Z::9Y[M_]AGM
ML;GV.VNX \=Z<+CU&=SPP@\_W&C"^]&'\<<+9_QJJ__^FNW+G<[\;\<A5UR?
MSAR?A9]^%B/=]/_21T_]=-51=[UUU?6!G75^?*O==-]XBVSWV'C?+7?BC"LN
M>.(;,W[XXX57+J[EYVI^J^?'8IZOZ+MJBB&OL+]>>HB@U_XA[[7K;CORQS=?
M?/2]4[_\]-E?__SWVX????KGMU]^_./7O_[\^=___O]AYSH]$:!S!OB3 E+'
M@ M48 .C<T (,O"!$K0.!;$S'>DX!X,;U& 'H0,]Y'S0.2#D7@BCPQP4+F>$
M*N1*]?XB%;L(+S'5<V'QD'=#&=HPA\G380]Y^$,<^C"(0-SA$(/XF=\U!HF]
M66)P@.?$)N;FB5*,(G"H^)LI6E&+6>1B%;N(12^&$8QC_)T8RVC$(A;_D8;4
M8R,+3[A"$4*'@W+T( ()>$<[^D^/X[&(>=K#Q_"<1Y!_1,\@X:,>^;@#/_2Q
M3R/WTY_^ $A  BK0@1*TH!MAB$*9Y&0F.U0[7TF+7*/L5"E+U0\8S:"3JV1E
MG'BDHPN%DI2DTH>57'E+)MDRE[C$TBYWJ:4> 9-+P<22,,]TI6/6"9E]8B:>
M"O7,9AK*F=&$Y@/&94H@24J:AK+5HJJIIDZU8YJ^ZD(UNS#+2WWJ3)D:E2BQ
M^1Y0K;--_)#E0*CEK%FYLYX T":\]/G/5,'*4@%]5T'A95!W>0N=I#PHKVJ%
M4%C5HTC],%=#\?DM=<T"HQ;E*$0]VE&0?O1<__>RU[P2\8Q^/2P?'*M;2Q^V
M,'X1+*4,VY=+,V93N]WT8CGUV$[K-K>/.8QE(),94$>6LIC1;&8RNYE2>_94
ML^D-JFD3&N; QK:H*>UO6Y7:VZ+F5<IQE:N9^QK?R+:WJ?H,K5$U*]JLRK6W
M.8YP0IL92Y?J5*=&=:UI$VOE**>XQ 56KH(5'.(&>]BP^K5J9+VJYAJ[.;\>
MUG"@(QUE;7=9WMT.,YJ=#6<QNUG@X<YWH>U=:75G6M*>4;6](:(0TZC#@_PE
MMME#S&RW)Q?;UB2W_8AM;V_+V]_Z5K?!K0AP WC</?8/@,E%[G*=JUSH-C>Z
MS*7N<Z5[W>I.U[K9Q?_N=KVK7?"NKX(.'.\$'<B1\J8W@>9E[QS;6\?I6(4K
M5'F.?%GXE?N&$+_SC2$,CX,8__+WOW()\&M;>V TNE;!"#9P@AF\X.%Q1HD)
M-B,3R6CAU4+QPAK.\!4[O,4*<QC#(Q9QB3U,XA.;&,0;EB*#"_QB $MOO_9M
MH7N+$D'RAI>[.Q:)'P\)2""79SV$? ]ZBAP?+RC2/HS,SR/Y<P5)#JB2"(H0
M)AFT22Q?:),0:F67'_3)=X9YG_\45#Y2)(\M>UG--NK1@]J,I6[V$@'Y%!2A
MY&Q++TAT(/S E3"_E C2H:H>X++EF+Q4C]$5B1^#YI*ATX3,=B#B2'8VTY;_
M.J31B3+ZFSE"A.$"Q>=R4C-+74 $/8^DCSYO<]-MDJBIYMPJ7$$SSG#*U#H[
MI<TRT=-2X)+GI&CUJEXA=)3]U)6>235G2Z4Z67064K%VY0YR@8M=O2+VIEI]
M*F4/ZY2,<L<LK@DD1%1[68C6-9'XS&AT>:'4B/)VMIGEC@[]:A85%6E$;450
M?SZTH8@64KA!BNAO7RH1Z#:60A,E[6UA^N#7*K7"@411A,/+'0:?=T@M7F^,
M7_P!\B)IO? %TX(%%:4R)7E,#5;RB=54I3I5.4V%VM.,!549.T68Q'8:U*"F
M'.8[QWG+DMK4EP%=K6D]VM#92M7')KVO2P<<T[G&_]BV$EVO4I?JU(]^]:-A
M-;*)99K<5AXRNP7=Z#^+NE85>_;)21:P:A>L806'=JDQUJI5=6S7ZW[VP?IC
MLIWY[&G]GEK CU;PJ!W\WPL?>,*S>,4?_F*#'0_AQR>OP+NE?&TM;[WA8MZX
MS?O>YK_;71U_GL>A)SWH33_ZTX]/O7C$\7M37WK4TV_U,)E]ZVMO0=;C/H^V
M7^_M<TQ'X&<P^#:&;_'C*'SD$S_X)-2\?O4+O11.CS!KG'X;I>]@[$<^^Y#G
M_H.]O_WO:U_\A@EQBLV_>!2C7\6-3S_[UU]^]9_?_?(__&A%7'_%(_[O[\\_
M_.>_Q?"#,.J[/N>)OC<Z/O_E0S[>R[W?BSWS\3$([",))"1#*B0*1*3\N(]&
MJ@\GBZ3_F"0",1 JNY$TJY 2M) U\Z1Z "4R$[,6M)5_.9$D24$:7*4WLZ4'
MB3-=8I!.L3,E,;8@,3A::8<E.2<7/)54V4$67"A+X8=;$D(@N;9=DQ,O>,$A
MT0<X280C- INLD)>$[5I<I)H>0\L'#5RD36,VK1PZI9;"\-M:J<B 9<Q%))$
MT!0[;!13P[8\J350<;AT4A-H:Y5F8;9+*39R:2AJ$Q9;J<--V4);B94J9$):
M$3<G&;,XS!4_E,1[TCA&R<-$:1=)D\0@03@D##A!P11*@355B41'S*98"<6%
M0Q?_*1PS90M$42P2? ,5* 2 6322B,LX8.1$83R6CN.X@5LIG@J8G_HZG!HY
M@?$I9E0INU*Y::2;F>J896PYGEK&H<+&KRLJF.FYF O'NW*9D:DZ=!R[O4*;
M=52;NS,[IX.[>.PKJ#LKJANZO,FK=+S'J3*KM\J:R $KG@D[F@D[?  ZJ^.K
MNYO'OVJ[M3,LB"2<R1DKI7.LLLNZA>RJJT&<T+$L_%LM^TL\PQ-)_2O)CS1)
MDCP\_F.\ 7NA&".PEW1)F,2MRS,NFQ2NFR2NS,O)G12NAO"\V_K)BP#*S!/*
MXA(]I(2]I'P]IG1 I7S*IEQ*IXQ*J)Q*JY1*K-2]!=P]_ZWLRN$SON0S/AH;
MRZ<H2_J:KZHPR[2D"K18RYEL'AB;29F<R_Z*R;H$/[P<OP!L+?_KR_[[2\9;
MHI",OY$L3)0TS,$\3,4\2<9,2<=$S,=<S,AL3)"<3,N$3,+\/\WTHKWTB[BD
MR_R2L02\,:]TO:NL2IF(P$!:S2+[,?<P,B*3CPUD,D=Z,@\<$!DP$!&\) G)
MLBN;$. T02VKP0T!,TML12:<MQ8Q!^)LSE:ZP5O205R"MD[!)2 \E44I- ;Q
M1',C)BH9)3#9153\,U,1)R[9Q4 QSV5RDB44DB^<DG;XM3LQ12[\)CAT3S!4
M-3!4Q35I0_V<M?Q,@!X$4'52E?\RN<Z!B*=>! !4Y,-D8<5209=D"Y5$-!9"
MM$+VX*@*_93[1!2!\A5Z$\,-[42*6K:-HI0I1!?J_)5=X4X@61=;%+--7)=@
M2Q92RD4.;15&#!7#"5%50<]?!-*,.M%-H4\ T =%K%%9$25*#$8G'48HU15C
M[#AQ/+EM!#F3*SF1HQB8PJDMK:DNC4:7^U)OU$:=(],J3=.;0\:>,T>FNBNA
MBU-UY,>+E#MYO%.&S*JD&YLYS4<Y;:HW_=,Y3<AVC+I_=!NW8YJE>D:7\Y<X
M34A_Q$AXO-/&B4B'E)S F4BKJ<>R&II!]52RX:I*=9R.Y+O:V0RL #PH2M7$
MI$S)Q,S_5U7,E6P__^M,O42CSXRARJ-)S>L\7SU*8'4(HAS6K*1*8SW-8RU6
M9%U696U6U'S69.T?WS/-K:S6TIS6T03+;/U*;@W+;MW6^E)+N!1-<FV^<AU7
M<TU7T!2PO.R^=K55=[U5>24_P*35>IU5?#TQ5]W7RXQ5?H75?_77?@U8@AU8
M@P78@Q78P+S7=VW8 2Q -S(A<$U :STO:(T)U0RR"MS8"W1-04($_5BD#-0/
MVX2R#Y2RW=02&CG!E1U.YVP0X\10Y(04?6B1>5#9E\W93H+.XY3.)4%0 )A!
M7T* .00W7K*2!>6''ME%'WS"<O$S!!!2[502(\V398+0(&P2_R.\MU!SPP1P
MT2))M57SV@5E)O0$@/],PP -ITP<B#+T6CF13VGJ%4K3STKT3P>-IRP!6KW]
MD^J<%+_MV3\$*9DEE2;EE%+!44:I0DCQ46O!6O;844<!VWY3%LCU!\E5E;;=
M-\&=A<-]%B551)IMELMUMVLI756!143Y16MIVU]L6].UMEI!4ETDTB>]W2C-
MW54I1I.:FVRTFWLXF61$QF;\NI"[1M\5TVV$1FUTJ6HD4R_]1NG%&.%MTY]3
MJD#%*ZGR4TA%NG^$K#S%T[BK2+IZ*KS*WC\E5#K=Q^[%.CLUNTK54YMA5(-T
MU'RP7X0D.Z2CNTF-Q\9YN[5[.Z:K4__V+>"^:1N-]!QHT#M2O1U3)4D>JK""
M15@*WDR&S<Q:Y2\DRM66O$O9JDG:XE6C%-:A+.%@'6%FO5AGC5863N$67F$7
MCF$8GF$5KN&F+"_5ZST=9D!JO59M%<LY(LNS3 ZT#-<AKC$B3F*T#$VY]& G
M[F H9M>]@%<J;M@<\LN%S6)[U>+6F&"%_6(O#N.$%>,*)F,P'F,T+N.$S5<,
MMF(=XF I=KYSG5@?YF$:3M:,%3+6Y"TBZV/7! !ZR$#:Y,"2C3)*VLTJZ\W@
M1$'?5&3A?&3BC-E;G%E$B4$2N0*=S60U^Q$RXX=$<(<=U"6@!>6CC9-HNR4_
MBT]3&<\X20O_P?T2+9':1\N2PA5$JT4 +R@W=_*F.KG06E': *V320ZE]S1E
MM87;-_'/#AW%OI452C829]O#>;JW;1%<4F)=9-NV3QDV#4U.@F,68M&5%1T2
MQ]7E28[=;-:G!K6T6JXS*(W1"#V7T,V5V25='5T5(VW!S.T6VTT7UU65.$.6
M<7Z/=685[,1=A-9=A6:4*?4X>K%>;NRI;A2YF)(8+&U>Y77&XL5HEEO>CD93
MFW.Y,UU3;533B693[4WI O[40GW'B@S?Q=I34/6ZDMEHD\E?EE[?G%9?]W5'
M^$VLN'F91E4ID<%?[M5? CY4N(NKAF1JBN13G2:ZHX[4_LW4P H=_P<^556E
MOPLSXU:-3#:V8)9TXRJ>5P;[U5X]U^C;O!"681MVZQ=^ZSN&:[J>:[N6:[QN
MP(KM8;W^X;[^5K_V5L&FX^5C8B-.U\-.[+668\1>[')=URDF:\DVZ\F.5\N>
M,"[FZLQ&OZ]68\\^X\_VZC0&;=(6[= >;=,N[=$.ZPRF[%M]6.B+V!(*;'#=
M:QS.ZSTV)#W6V(ZU0(]5#Y"=S9'M0)/%S1"TI$1N64C.I!-DV562Y&<>9B#!
MAQ0A94V^[E623C>#)5&N%:&5LPN-M3L#VZ;=Q7;(,USTY&+"$EGV3C4!VJY]
MDF3"D_5$$VLZ963&Y4Y!Q553W79VE7$Z9O^[!:<AG$]R<<(P_.]'-)3+!9)O
MRA1?IN2ZA? F--!#F>=>.Y81A9>!TA7&)940!=M<N=Q]-I9E9M!-:17%7>A=
MD19T9I9YSI;1M5Q5W!01A\0:7]*#/JA__A3_9H\7%Y=:\5$A9?&$/G(HY=V'
M)MZ5JMXF3UZ0L6DI+T>/7M[GS>B,1EXF[^BZT;GH'>J29G*Q T=!+?.=1D>J
M?FGQC<=.+=_YQ2DOMQBQH[JH._-/=?/];2RW:4BC6=3B+1F<IG/OS<CPE4@
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MNAM/&453/U$M;Y)"A P0@"J^J6E44-*;D/3TTIXB5:A4*MY/9<#4N_TT1UY
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M5E%%KPDV8)$795%&8=0B<%1O:]1'_Q9P U<Z@)1P@7%(CQ09BU1Q$Y<[Z@$
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MH*$TRF6_<K6CH]D9R"T*R\<<I/8\ =P!R^<Y&W\_T+47^;_<S2_$^N=M0;P
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M(#XW HY+KC3GFI-^LMEF:TWZZJ!G[G@":;?3N>@ Z,/ZZZW?[CH"O9G]M>[
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MEACGMG2%+5W&XA:MN$D\^[DJ;$2C6=0XQK40VHQK6>-90/G&B!BF'HP1C%\
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MET(6EWX9F'Q)F&1)?X@I?DYF0HPI$ "H9JG&1!?QF&@F$6"69I5I95L6_Q(
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M?RE,-0ZS0,$D)C*-6<PZ,G..XV+4IY 8QUH-L9K4O":GL@DJ;&Y3F]/T9JN
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M&B$3[HZ]T=N]12$43N&\5>$36J$48B$57B$7:DZ^D5L2-N%B#2$0DF%C/=;
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MSKF!B,>]_/'1QSVB[-"__3GWE8-?>/'5G]]W^@^R'WC\^;_?__W_IS\!G@^
M!1S@^ Y8/P*2)W\+A%_N+**[]DU0?1!<7P3#D[\*7I"#Z;/@!Q\80@K6CG8E
M3 X)3VC"V:60A2N<74Y@"+O3B2Z&I4/=#&U(0_\=YI"'./3A#8&XPQ\*,8@]
M+.(0C4A$WRQ1-;_!2Q.9^$0I^@4OGXMB4:R81:5H$8M;]&(7P2B9+XHQC)X;
MHQG+B#DTDI&-K7$B%>'(ERG*,8YNO*(2DYC'U\5.A2ATH>T0*#_KT(\\SB,D
M(:^7R.UACY&*Y-[S\%,?^. ' /2A1Q<$Y!\ \6<_!?)D@F3P@ 4Y*$8\,N4I
M48FB4F;H1:U<)8P@=")9LHB6L:PE+%7)RE>J*)6]].4O@1E,88;(2%DJTH^0
M&:1D$LM+87)F,]?4JVC^RE?5G*8U 27-;/Y*4-OL9J6\.<UOCE.<Y0SG.<&9
MSE)9RE2M:N>JX/E.>;+_DYZ:4M4\[>G.>G[JGOM<9S[CZ<]^ A2?_-0G0>F)
M3G(JU)SJ;.A"'<K0;6*35M>TZ$0O6M%L(D)9Q_+HLL05KF]YBZ0C-6E)42I2
M:4&K6>-BU[I@"B^9ULM=-)W6ON;U+W\AS%\%0YA/]174AR6,J S#&,2&RC"0
M;<Q@(BL94Y]:,I*MK!Z(.UE58Y95Q>D,9T#SZM&^"C2A-2ZL@RO:XXH6M:89
MS6M6"QO7(A=7MV8M;673&MC>5M?)(::N>04-YBXG-[T)EF^%!1S<J#96EQT.
MJUO%F6/%ZCC(N34P2^L*8S#+.<UF3C"9O6QG0?M9T'0N-4@T[1%1B\?3"M%U
M_ZU5W1_[&-L6GJ0ZQGN?;>.'6T9:AW?LX>UM'^G(1BY2N,4E[G&#B]SA&M"!
M"&QN_418P>C2%H,=E"UL@2L1Z&B7.=T-Y'>A"][\"5*\M0WO><=;WNR:-[WH
M9>][UQO?W*+WNGZTKPJW*T'L[O>^LR5)#?=87P&O)"?^-3!__RM#UP;%=:E-
MG1X=O%H(JS;"%=[A'$F'X=EH^(UT]+ =H1AB#M\1Q",6<1TWC);4F!@UGAG-
M9CK\8LO,&#(P'JV+28MC'=^8QS;V,8T_\^,: UG&0S9RD)^"X15#QC1+_G"*
MGQQC*.\F-[>Q,H55NV"A'+B_+MRN=<C[G?D6<I# +?_D> [)GC0GE\W+;60D
MY3/)\]QC/P#Z#R<'Y$D#@9)!I(P0+X<9:$$/^D.NU.6A<V1H0B^:T8UV=*"+
M^:5C*I/20X*FL)Z)Z4LS4].=YO2G,PWJ3<M)FQHU-:FIF5%44W35JN;3JYT4
M*UE7=-;_-&A $9KK6Q?4UKT>Z*X%&FM:#QM/Q,:5JTO=:HPN^]3'9K:R1>WI
M4$][TT!"UD<[JE)MIY3;)_5VMT-ZK9"V-*8U?>F[S%UN=.-TIP<+*D^/6M1X
M,\QA18T85.>=,:<N-:K\!ADT2J8RJUK59BWC*N/ FG">G57A00,K/B)+5J.E
MU:QLI9K7Q";7B\-5;';U>,?_0>XVD=^MKR,_"MW:R)*Y 8YN*R<?R_T&\Y73
MK6N#V]GALLI5GB'\J_R8+%SGNCG1!G:O1;><YI!>.34NW<(3=KJ$H7Y#+1=8
MP<8A7N\B<G7<7D3KY+,(\<#N._ IU[AM+KN;SYYVLJ_=[,O[GM@#2$ /3E>_
M@)3N".N>]^J"$._5S:]\_S[?]@Z>??7;( ,+KT'G+EZ!C&^@>IGK^/X9\/ ;
MY+M[]TYW+NO=NGWO_-U!;_<NWQ? 4T<PEQ/,1].K_O2O9;#KMXSEIS<]ZK*O
M_>QM3WO=YY[WN"\QBJ4<?!)/F?C"MR(4N9AR%S/]K\MW?O.AG_PU3I_YTJ_^
M&:^?_\;G6W_[209^]+T?Y>$+_\3B+[_O;Q_[UZ]_P/SE?. 1KV;YHP>1;$>[
M_=4N9T@R+Q]UUB2>.\E ]@Q!%F24'H %;"D!'VT!4TG1 "V7(/ !'W"6%) "
M<<D"'?"6)) !.; #/? #GV32+*W21+ $J^T$I0T%FRW9G&T%4^W96A#:(&H&
M'ZH&)2JB<) &;U '<_#7?.V@@$W7?A#7@K (AY#7?- &>W 'E9 'G; )H? &
M62T&J9 %K? %M82CKNW:OJT+N^T+38H>O' ,Q8VER&6FSBW=T!"F\L5><JK=
M]D7>DBK?YK .Y;"I\+#?]FT/1T8/ 8ZJ!HYP!/'@!K'A&/^.XLIJ9_"!97"N
MYQSG$25.:3:N:S@.Z"SQ:D .K\SFK3!1$\<&;D;NXX@N^<@&_$#'L&:.(#BQ
M:J!FL62&L0SNL0H1X11+$B5'Z'"Q;3P+%W>Q%T.+%W?,QM!O]X:Q]WQH]=IO
M])*QON +>'H+/7ZK[:3Q_J8Q_ZCQ&JUQ[ PHS$2/(SA/&5$O'%O/@K[L(\I1
M\,#L(<[Q',&Q]=;1NR#B'=61&YL1_NA1'-LQ'Y<1'_<1MDH/]OZ1_0)2_0@R
MA0;R(*M.(!.2(!&R&!TR_8@1(LV/Q;[O_(IO_##2(LF/(B>R(CGR]SH2,&(L
MQTC,R5B#)(4,R8ZLR%2R)5GR)5'_DLAB<B5GTB5K$B:#429SDB9%PR1ODB2;
MK"<WTB.)LLJ,$B0?LB$#3,OXL87L,3RFP[S(#"K1;/X,R2JS$?^H!\XJZ3SX
MP4#L;)/R3 "O@,\,$$(04 -!<"W9TD,R4 $W$"Y%Y"W;LB[M\BY1*=+T<IE,
MT)A4D-I2,#"C;3 !DS#_4@5EL JQ,#&O< H;$]D64S$=,]5J#=9<Q=B$K=@T
MTS)GA3$C\S%A$#1=<#))$S)+D]D*,S4/4S!5,UBV\%BR;=R^)=RHA3;!\#:]
M<!YPTS;!A=S6$-W2D%UH*@[A\ W=S0[I#3D7YMZBBAZ<RCFA"F2FB@_U4&"P
M*N *1ZMF_[$0=Z[A)*YQ$-$5NXIP#N=P("[A:K$5%^X1IZ8]OZ9I?FYJT(:N
MZ&JN/+'D0/$3\3.,2O%SZ.:,6LYO!BL5 [3EW":QKHIE&FL["=$1Y=.N?G$7
M=7&S@''H?)&SH"\IC3$B(Q(9/=3JOBZ[GO'MG!'N2O1$A4<;4U0KJY%%L=%%
MLQ)%PR[R&J^"Y$[S/D_TOA%'+T]',\^#0F]'/:]'A31(?]3RC#1'OW&!*@^!
MFM3P/"_^Q$SQH+1*@?1(?51)FS(DBC1+>[0?48+J6$\AQ[0@$4PI/Y1,EQ(@
M%U(I.71#X51#Y50BY_1-,\POPJ].Q>_XJFB+/O(B-9(I^E3[3/_1+KBO4*FO
M^PCU4!D5^Q25C7)Q41VU4(DN41&U^OZT-_BT*)$24#,U(Y^(3H^13<MT2VOG
M_>2G\ IIS:Z2_F#T55M4_XZ'0,(2  F$+,VR00ZP O&R5UUDE]12+H45ER;P
MEC#06)$5T>*26'VU69WU64ED+TDP!*F5-5?3,#W-,T]S-$VS6T/S,[DI"I=P
M7)^0"<V57,6U7-'U7-6U7=/U7=D57M=U7MWU7+=56[V56[^5HEHS"SOJ-<$%
M-P66#+M0#+7%8$L!816V"\?M#-7P88.3#6VJ%-CMW8[S#HU*.3468_WM8JB3
MWZIJ.A-4.V/1L2 +/2&Q9PR'$1%N94/_EN=2MA9C%G)\SCVO!C[E,W(X\>,J
ML1/G,Q3I$VC[D^3\:A0!ZR<*E.4(*^;L9A452Q]@<60#T60=CFB8AFLVT4(C
M=&NUMFLK]&LEE"?C5%3MU+32U$SU,;O2$?.\[!X%KQZQ;KM&-$9?-%:O<?):
M-8$>CVV)%$OK#DP!UU0#=QP'-VT)UR10%?*>\H_@=DBGJW A5W EEW#1E%37
M5$TG%W,M]VPK5W/U]'.1R,3(-C@^-5!-MW11EU,]576'DB\L8U!=<G5#\B1'
M<B=MLG9[3"=S5VQ3$B=W]W9_UW=]+&R!MW>3+GA_TG9/@\E:C#22UWF%$GI!
ME5--<LIT0S< _Q7J.'<A,S<EY/&\IE+,HA(J5955J])NZ19ZN#*2^L$+KJ!6
M-^E6/XD ^XQ,)"18H35_'XTN^7=&^E=_ 3B [U):1[" ^U+2KK5?%3B!&=A:
M'1A;(1A?]S5?)5A?+;B",5@R*;@%$P$ *LF#*RD1-'B"2?B"1]B$17.!'UB%
M(9B%5?@UM3 1>G,V:7A@;9A:%O99$/9:<CAA"3;<SK V'39B?U-=*I8X+18Y
MZRTY[0TYGT%A. :*HS-DIG.*^[!CKA,0M;-!QS,1O?-D<&YE!=%E#:>L9#;B
MAB8^WW.-:W:-@^ZNX%AG@Q84Z5@4U<9H&^..]9@_F<[E@")I^4;ES/^&%;M3
M0:>69+M8LIHF:\&6:QO9:R_TZ"AT4@\5=,N6]ICRC[KN=[A.1#WY1#LYZT)4
M1G5K1E>4E+T.E4GTE%G9E%VYE&$YE5M9\OZ'D\T'?>3N1AUWEY.T;[5T)#J7
M&?UVF'_9EXV91Y&9EYV#29VTF:VT2Z&9F(]9F2/W<'NYFDDHF+6Y3:TY3+FY
M3+<9G+]Y="UY;"_9G-&YG/,H=97O4EO7CC:UG1N5=9<HGBUUG@V5DO594OE9
MGO?9G_OYGO\Y4HTN^P#ZH 4ZH&6W4]]YH1WZG/7H;+N7F.'O2<^,*C%:?-,7
M5NMV_["G?=_W/^!!+ -P?AG$ !'P?H=5@)__]7\C$'\5[5AY50&]0!\^V(/3
M Z=!6!]FH1X0X:6'5498>J@)S1W$ Z=GP1U$A*=SFFY$>$.\H*FE&H2G6J>5
M6D..^J:U.J>[(A&Z8%K]DDFZ !&J>JL]F!_J8=ILNJS9&H3Y 4FZ8*MG01\\
MS0OJ0:Y/&-6\0*?/^E[GQ OJAJ_-FFGJX:E=D*K=>C+KE5[E=;$=>YIF0;#;
MX;'C5:("6ZN7L!T0FVYZ<+ KF[$_^S0O6ZHS6)ON6K)+&UQ=N(%C&&!Y\X:]
MI8=E&X=]>&'%\+9K.[=Q>[=UVX=UF%MTDUN">%Q<JEQ6*EV*&UZ.^ TIUCB'
MZJ?H$&.C.V/Q[3D)_Z9CK3BJ%C00N=B+O0H6PSB\6?9E7>8\UQ.-SVJR+.YI
M;/82=S;CV@JOWBJOZ'L30XZ.E0X_>=IHTT;I4 ?E!G2P# .N%+%P#H=B1!9E
M3 8[%_2\TY@?L/9L.FN_(]FR>)'")QR2';G"?]$R4N,FR3G$,;F;1W1MN4NW
MW)8=:8>]3+S% 2_%85QQ8YR^-N^$_A9+L3G'^3&<"_?&<U3'NQG(R7'&"4]M
M)SK(C]QPE7P9>7Q[Q?G) ==-C=')+U?$TQF'V-GWLORAIW=VN?QT%5I3_]E2
MP5PDOZ*,GM?'MEPPFO?\TEQWC5=YWYQWX;S.Z?S.BW=">XS#,53HA-?.\_\<
MS_^<>0D]R-K\T.DY*+N<RAC]RT55HI&\.+[WQ,%7*LN7?#'=5=&7H^]#5I\#
M$=Z7/T;ZSL;2I OP '<U+5>Z5Q$!8'Z:J#^0+C?;K 5[JMNA0^@2UG7=E^YZ
MJND:1/;:K#F$UHE]JNM!0WI]UMM:L(^]6A$@LHM=V:7=2SHXVFN=JIN$K;W
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M"3%.C<KJFTJI#-5/%55$*!ZKC#&L#+\:FQ[I03^OS!ZP_,R"&$M9K57OX4L
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MX!)N^_\H8M?J;<7YK5RY3S"_'(PV7>7F16'(:(TRG8Y&;C53,S6GUF18KF8
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M2;2C_DMHG^MW&P:3(C%?#8$(0VD2+UI>#%&C$-263WD2H@FC^DE]3UFC*>I
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M""ZWN0^)3G-]^YGS>60CVTE?;\ K7O2A+U7CQ<AY.6*^]:+7..!3[WNY"]\
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MEDL:Q"*0W+.3<0+(FU!DBBCYHD:JR$7[/?J&:J%T(2U"PD/KN8\R9.%+X(R
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MG$8U]19W_.W_FL^(_+T9F#_]8QH^7^F/?OWGG__GIW_Y_2\ ZV\ ]T\ "W
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M 5YJZ7\.ZM,AIIURNNFG_82ZZ:CUB4KJJ:F"JFJ#K0JX*H6?RKKJI[:6NFJ
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M?P/(0 IRD(0LI"$/B<A$:B8VL,G);!0)R4A*<I*4K*0E4X.(X@AGD\'93WG
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M:$NT9TM81(/&A%1T:(66: AEA8RF:%5(15YP!4@A1D?1#F3$%$R1#D\Q ^6
M:6RT:5L1&7%T@6^(-W4T>G#HAG,8>*W6:;"6A\3&AWWHAW\(B($HB(-(B(5H
MB'^82<9F;.:V<_IA'K1T;:P4B>Q12],FB=71'8_H_VV.N(G+1DOHL6S$A$R"
M8B!3-R \MV[PUF[R=B'HIGN!PDWY)F<["&=#6(M!F'  IT\,=XL%ATY-LD[
M^(L.9R08]W'_=(S&Z'"\"% <YXP/]XS$2%$9)5$698TJAXT558W;J(W=>(5M
M(D4:Y2'UIFR,4G/G.',RAW,X%W,]QU)!U6$&$H]+)W00QG\BZ($F2'0"R(]
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MZ;YEVS[O8Z5H"R9I^\&R2:KP6*JJTK9LNS8C_#:YTZHG"C<G%*MR@\)S0RO
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MEO_->/;N>(__>) _6E,F3[UXC,%HY84I*H;R90O\*9-JY5;FN5(\Q?JLQ<Z
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M)4P $E_>M)E2IS^>/G,"W1FT9T5^5W)T\?).J9>D7;H</9IN!M5R,V3(8.%
MJU8$7K^"]?;UP%>Q7LEZ-8L +0*U;-V6'1OW[-RU==_*39NW[5ZX>NG^M1L8
M+V"^A?T:%IR8L&+$CK_6 R"Y_Z?D=7>_4@:0V?+A69,E:T;013/HGEW )@Z+
M.K#HSY,1(=CY6=_JUIE[TJZM6S>BVY)GZ5Y7&G2]VI%= ^"\>_ERX<AS,X^.
M@/3LY:.I:X8-5C9U[;NY4SXM?3SY\N;/HT^O?CW[]N[?PX\O?S[]^O;OX\^O
M?S___NH1)0*@@(\ F \_^NB##S_YZ)-//_STHP]!$<X"H3X/1OC@@1%NJ,^"
M&5YH(8<.>@C-@1VB2"(_)AK(HCXLKKC@BB/VP^ ]^MR3SSTR0E-C/SU>".2'
M%TI(I#]!@GADA$H6N:212$(YHY$6*BDDD$M2F266!'$I(3\:%?2EF$=RN5"8
M9'[I)?^8%9:Y9D-B/@2 F6PF)*=-<L8Y)YP0Z=0/GG[6R<^=%?TYJ*&$^IFH
M0(4B.NBBB?;)Z**" AHGH8%.FBF?=4(ZIT68;JKIGPP5"BJIC2I:::J'LNHG
M48:^&NN=LD+J*JNOKEIKJZT^NBNDM))FJ[#!$@NLL;,B.RRNHZ;Y8XTQ0O.B
MM-%2.ZVUU6+[XHK:4@LMM#_.:**5&5Y9+H?F>D@BB$."Z".1[;Y[H;KQPELO
MO??:FZ&(^/*[[KPTQLLND0+G>V^%^E)HX<'Z+#PAPUH^C&7"$D?LY<065^SP
MPALKW/'%'%^,8<4B@UQQR2=[;'+**%/<<,H:>QSFQ#)'3//_P39#B/.#(-,,
M<\L0NWRQSRI_O++112---,9!*\URTR]#+734&4_-M--7'_UTTEAOG3776H/]
MM=A>D]TUPB.7'?:^(??;=L%OAPCOPB2O/3*1<]\M8LITGSWWWG^'##C:@1,>
M-[UUB]PNXHB['?"]'9ZM>+V+3U[YX99+?KGFF7/^+N6;>PZWZ(V/7CKICZ,.
M+^0#QSN+AZV_#J+KJ\^>^NFFXWY[Z*!'OGOGO0-O^._"^UY\\(D;+[S>D2^O
M////#QZ]WX5/+WWSU6-_O?9];V]X]MR#[WW:8YNM=OGDZYS^S>OGS/[.[<-_
M4/P)O>]FA0_=#U'^#.WOJ9O_^R^ _Q-92$8(B)$#6N0C(U$@2A88DIFLY"8;
MJ<E-*"B3H5B0*$+9H 8[^!,.?M"#%3Q*4I:R%'<T!2HYN((*J2*#J\R !0_@
MB@.6HY8;U@6'@=%A8GCHPQP"<8=![.$0?RC$(Q(1B49,(A.7J);C8 <W1$1.
M>'Y(CR@.9S)U4<UJU,)%+%+1.ZOI318!P!XP[D8?92S.:J"XF?H@@HIF; \6
MH5.;Z]Q&C%[QS63$ Q8W9M&/_ADD(0MIR$,B,I&*7"0C&^G(1T+2/X@@4( J
M"2#6<8AUKFO0@CA9HDP"3$;I F7S-#0P%5F)1YUT$3ZFI<IHM1(?.FJ0M@SD
M(%N>"V#.>O_2+C_4(A[EDI<]:E&2(%;,+5&M36*BF#+1A,PRL4E-:CH3QJ"9
MIBXYK)G2I!,T%=)-^8'S3)YBUJ-$Q2E'J>I0YBPGGQ#%SD@5<(#L/)6FW!0I
M :K*GIR29Z@^9:E_IO-2[ZS50(42+(.*\*"T,JBBEA647)73H0S]B4*352R*
M)C2C&-UH ;%9HE5N*ULBO1:W2BHND[[26ST2%[C0):5>7@F3 5/1*4$YRMC=
M-$4V)1A.<Y>[U86RIC@=DDX=ISK>62]\?!/?^;*VU*<*KGJ)*V7RD'>\4G9O
MJ>0SG_IBQK.O>C6L/VLJ6<UGUJVB=7QJ+6M:V;K6LT;5J7%5ZES_F8I4JSHO
M>E.%WEZ3FM>^ K:N4+TJYJIZN\\-#Z^*12Q6^=K8OSXVL(XE[%WY =2>ANBR
MFI4IBF2Z+MOI"ZB6K:QH2VN[ ]7NJ*HU*FL_NUK7MI9A0_4L9V7;V=3&UJ:P
MW:UM-3E;W%+HMZ^K'7&':US4"O>VR04M;77;7,PZUY2*,^UT#T==SUTWM-;=
M;G6[BUWN5C6RXITL9,DKV?*B][SJ'6]ZV;M>\[KWL=^SZV#A.C.PWA=^[]NO
MS/KK/O^VKQ_UHU^8\K<SB1"8)9[JGX+Y"4 '^R^>(S%@ A'8P LS,,,A04E,
M.-)A"%ZP)17$((E!.)00HOC$%10$4I1"_X:DH/ I48$*56#X0AG2T(9]V?%A
M>-P8'S,FR)<9S) 74^3']#C)/U:RD(GL9",'!I   $\9;R,>)"- C7($ "*\
MN,4OL^8KS@'C')F#QRJC63)L1 T?R=SF-?^QC,JA3Q?:;.?AT$,W=;1.&.^X
M93)KF3J"C"2A"VWH0R,ZT8I>-*,;[>CU",B2E*P9^V3$(%MZ<D.,DY*F\^NO
M WG27S1BD(ED>:,<W8A:SQJF+V=D2Y#B$I=!8A*YSA528#H(&MC<UTNKF28Z
M<9-*4]I2SZX)IV.C"9Q-6O:NG>1L:6;3V$<"-K)-9:8[X;-4>9H4.AF%[8&B
M\U2L M4]1=4I@/\^>%7[U-6UV<U/;>>3W)3J$ZGDS6UUUW/=ZM25LBP*K(;Z
M.^ $Y?=$^SVL7]U*X!<U^,(;_F]Z4S.7OQPIQ:]UZVYA7*7?8BE+/PFE78(\
MIAGZ5TY59/)0GGRFK]6=3T^G69+SE*>CPYM;:VY?I=5WOB63'6+#6UCJO?5K
M0QN:^R@MUH?)+V%)5]K0JP:TH$/=YFV]^=2K'G6J7]WJ4G=JWN16M_GRW.MB
M;UU6!9MUL[,M[79[6\];7KJV$X^RG!/<8G\>][O7G>5ZCRYT^WY9N^<]L8RS
MU]_W;GBW\VNS*^<[XG_*W((I/K; ?6[D&W_XR@(>[H'W.>8[+_C,8R[_OM #
M.]K]FO.R YVNJ:=OZ4F_^M.K'NM;WZ_1/0U@_OZ7?4D7IT &[) ]I9O!"(8P
M\?UI_'23A,(:D7#R-ZQA!T*_@2!>R8=+W,$,IMC$VA?A]K/_$GS,("GP>+$7
M8@P5%1Z%*N: (0MBN!4$L #^M7%B$>NO1/LW$?_TOS__\]___?M?  )@/;A.
M=R@' (J%')T&#W$1:GA9F%V1;]#& Z:&<13@;<P"/73!G#''.B""&E$&/\ 9
MH]'#@621"#X%(W4!&4D&PXS@H\%@#,K@#-)@#=K@#>(@(DU2I$5:W"28?K&>
M=I%2I]',3CU.RL4(J752+"6(*OV2$A)3%'(:_Z;=B*FYDJPY&ZO%5+,UB18>
MTS0A!!?NFC/Y6A8FR;!U83$E&]+Q7K51VYJXX9NLH36!R3?IB3*]TSB=6SL5
M%$3AF_&1$[]]6S^EVST-HIT(8JZ$V[HA'SZ%$T!)BA\F'$$M5"4JW$(!W,#!
M4T%)E"4*"T)Q%"@RG"=6E#MYD[ EH4F15,5AG,6UHKBH5$O)HL<QTZ]E"1G2
M6LFAW"[J8D[5EA'R7>51GLL]GM^1CN8A(^AY'N>]%WJ!'3.Z#6.MGM9Q%7[5
MWC4V7?D0W=G-GNQY(S6"(S=^HS@Z#>P%H5XEXS+*'32NX^BAGNE153OB73H"
M%CNVC3 &8S&^G3)^GO\ZSB/AP8YR"61 $N3B8=;D25=N&:/L+.3=+%<FX19R
M#21#3N1Q_:)#5J1$^A;M'&1'<N1',E=$]A9$+E=Q9>3#G"1"CA9)IN1#Y@WM
MK.1W>9<0^H[>9%=F@1=-ZB1.SB1*^F/@B5Y[P==0"F5>2550GM=1$F4S,F50
MNAX\SEY7X9Y^W5Y5YIZ \1Y6 IM6#A]7"M]7.F)8%E_S39CSF67T/1^&G:5:
M=IA+3) $C9B(A=CU69_WV:6*<9! 0(47P$-3E%\*R=@*Y8 +L9_[=<5N8%F3
M0=EB)N:1 9EC,AED+MED*F9C/IEE,N9C7J9F)H:4A<9F*ED#AD65Z5$%AEG_
M#J)F:JKF:K)F:[KF:\)F;!H2#P8()1G(06;-T"!/C'A<Y*&(D-SF%$I<*L+(
M,*&4%,+(+24A<<*:P&33QU73L*$+R$';F$@;M$5)N3QG%C+)&++A&W[GGN#)
M=6ZELMDA>';3>#XBH-C$>B)BN:73O.GAO1FB(JH;MK5GM@FBO0'B'L+;?^I;
MMHEE?*Y3O)G3(H*;?5[B@AI<KR2BKSBH12'<*#*HPU7HL0#%():)LTS<*GHH
M*[HBMVA<Q_5:M#TBLBV-O/ B42&ANJ2<NQ"54(F:0EI>XPT>V8U=V.&H;*D=
M7M'</^[H\/SHD'Y=]XA-UP4IDNKHDI+C6V4CU4@-_^T]J=4\W5@M39-V8SAF
M*9:.XY9Z:9>"Z9(JZ>6)SHV6:8YRJ9BJ'9':W3.NJ>:1:>+%:8U&(S\:EN45
M'IWJ:4/R%IWBHYP:Y)\*:D%BI#X68YXJY*!2Y*$RZN@H:J(V:IW^)#W:X^;)
MHZ4"Z=PM)7L]9:>^HZ?&7CFVWJ>2:JARJ99*I552);7YWOS\GOTL6*R.Y8 V
MHH,QWZVN95KJ:JX^$%RRA*]2'T]D$/;A)?<9ZUUVWXB1P17P)?DYA5\&YA7,
MP/K=V -@18[5!F,@H/YQZ_]UJP!^Z[9ZZ[B"*[F*:Q*!49>%*Y@9!@MBAVBR
M*P52H&S2:[W:Z[WB:[[JZ_^^\NMN[* E51*F">R)&*7VI,@2=M)M<M*E):RE
M!=6*%J<3UI*KI>*I-2$4PM0 "T#TOZH%DQG>RW9&)X<2U1;RFKIL87:22W=>
MIW>.H3B)H1M>TY3 (1X"7QO&+!C*X3;-;'G2*G_"9WWZ[( &HCYM&R!:6Q]"
M7!Z^VQW.Y_'I)R12HCJ1HD9E:"9VV]-:K:-$;2AF;89BJ"AZK0:]B9,P)RN&
MU(>BU"LZ88G>(LU2D\,$$XNN:(O&[=SV8HP"XVS=+:+Z%%+*5U;=Z9P";K[0
MXZCR5:66ZCEJ*9AN8Y2":>(Z[JD2;N.*HSEJ%>3:'.6Z5Z4&[MY)8WH9KIVR
M'>AFZM^NG/](S@Y-F:Y+:B1+$FIP/6J?\NE(%BKK+FKI>N1&XB[M6J3NKN[N
M^J[K$FKO"J_L#F_J#J1)]A;R*J]%+N_Q,J_O:F3S)N_S1B_T$N_U&F_N6F_V
M(B_O8J]+[F1"AF],CN]-BB]/ON2D\B/?;FK[%F53NB_\OB_[SJ_[@JI=H0]^
MJ>I4\N\/,H3O>66"=27_R"K3SJJM6ICR[2I:\BH#>QB'07!<Q@1.R"4%TV5>
M%BNR'JN*)0*S"@+YF9]3H-\,H(.-6>M6U)#\=1%G8F8+L_ +1R9H4J9D5B8,
MS[ ,UW ,9Z8.NS /^QB\GJ9I"K&\]FL1&_$1(W$2*_$2,W%TT.;_OPJ5*&4:
M$D9Q%+-2@N1#+&4Q+06GD P,<.H2*DFL@I"HBY0:CDS+R9KLK'U<R?I(%/Y(
M=T;)+<4QS*8A&S_3+58G+J*HRL[LRJ*G+?)Q+3X;RO+Q&@;R>@HMTQZBO#4R
M?<Y;IVAHT>8L@1IH?Q;HOA4B\Q4MT4YROKV;*<(3K$PB*>N*0UGH*9<RAA++
MA)IR*L,R*\NRA"[=D;C:V9HMV:(M,?$2&%:;1W$LIX%QW<HM,3^L,??BC"KS
M<]DHFD[CU>UI-.N=ZXP=-:_=-;,ISHWIFW[IXR;-E%;IE5KIXH(-.%NI-TMN
M-UMN.K,S.B?N4VWSW?VH8N&+F29/-B?6_^;NK>AB*CYO[LO5[NQ":J#J<T'[
M::3"[NL.(T$S]$ [-/ &-$0+M$13M.Q6-$+>KO=F;T0O]$-W=$(C]$<W%Z5>
M*DF/;DGS,_VJ5TW&;]^:ZDLC[N%B[NM%;N6J<U3J;^ZMZK$!L"(G!%CBS\X>
ML $?'ZXZL%H>]0)/WU)+\+#6909#=;)*]0;/0@DY*[2F4%34V O)P EW10VE
M,%AHZ[J:*UF7ZUF?:UJ;M5J7=5NC]5KC'Q /\?S1]0HW\5WC=5[K]5[S=5\/
MTK_2)F=YL:VERQ)R,:B92.R,%JC9TA;+4BM!8<@>,\6$4JG-DJFEK18Z;$X5
MY\:6X1=C\8T\X?]+#;/:,A,:>NS*IK8>FRC.SJ&Q<6<O5\D7^O&TD6<<^O10
MQZQ0$W6I5"V"$G4ACA/0BO+2;K*Y%6BM!O?2;B)$=2+4)LO71O?6%EQU/_<G
M;NW"23=V*]PIKHL9ERV(ZO*+S&(>OW;(O>VXK#'<(K/=^N(QL[=[RS=-P3=]
MOW?L8FI?W6\^/VIGJ0[, ;@TI_2 ;TY-&SA-(W@[K[,[+WC:U)=^TZ^;8K-,
M'SC8S#148OA3YG=D?:[Z&G1("SC+F30] ^1J%2_U3F_U.N^)@R1';_1$B[1S
MO3B+:R^-:[3JIOCWMN2.UWB.2^^/HSB0JSCN"KF/!WE);B^.S[B.]_C_DK]X
M^>8D^D)Y3Y[O^5:(:!&XIM;O7['TELOOEZMTF+?TF!?E?M=5_HK5_JKY5@+P
M@1G83Q=P_@B?<M.Y42]? R-UGB^P6YK$6U8PB%FPL#[U7&IPH>.E/'1!C#'%
MLT;K5L>0M68%6"- 6--PI>.PI>_P#6=Z#FMZ#W>Z#7-ZJ&.ZIXOZI<NP7!.Q
M73M@7?MUJ[OZJ\-ZK,MZ:ZK%$]OFB8C<R$9(@F"Q%D-VI@TVWA8VP]*BX3SI
M;'\4@S"A@D2V<@Y3+RDG*HW<JN&:9(_2:(LL>A=[;7^LKJ%VRJ;LMY,)=$9;
M+=KVN5.3SKXAS?KRB2*RM"W3'E<GL;WJ<"?M_[CY"H3V-L\*:(0^Z"73TQ\2
MQ"=7\FX/;<#O6\)?K2LS?(6Z\BRK\L)?Z,13*,/52CA-B&:36BZ']W&2-LH6
MLLD24QG76AN7?,;6K8RJ?##:=WRW_,OO5("KG*2JZ83G:#S[J<R[R\Z_"\GQ
M_+2WC34S9)L6Z<US\XXR^$TKN-)O%3E3Z3<W>%G9=(87?9)^#)):\\9@/=9'
M_=+?7,V;^=&#?=77?(B;_8<+N#W#C4)C=(O#>#XV-.R>O:.".'['[N2U?=TK
MM(QG-(SC?=_S5MX'M(W_KD73EN![--Q+GMWO_8@[?NBA]/MV.)B3.>7'=.57
M>-A3/4Q?>-)78YKK]/]4[IZZ5S)0ZP]OT[DCVKD"X_F>1U"ORB7U_:I38_!4
M&[KM1S55XT.+F1"T/L4(2RM7QU"DQ]^DZYA;L_5;(S]<+W_S*__S)W_T,S_T
MQRNKH[KUL^NL:__V<W_W>__WCP<% C; +CNN5Q=B-\@6$_L4XSK!HAS"$KMP
MWC= /^'%DO>U+V>T[^(OQ=*M\3+A 02T?OGXZ?/'KY]!A/H2\A-(,%]#@0P-
M4CSH3V'"@QH77JRHT6)'AA/[D<SX$:5'E?PPKFS)4N'!62SYS;S8D:;-FC W
MQMSY$JC/6?UN8IS)4291FDF9_G0ZM"G4FDJE#@4P]2J ?EJM\M/*=>O4J%3_
MR8Z]6C4LVK-DP?KK9_4MV[A@V\Z-.Q:O6+UH\\+E:]?O5L""O[[U]_6PX<)<
M$Q>>U3CQ8\2,%RLF;-EO8\&2MT:&3+GSY-"6 7@6S=FQTIX8'0YTZ% ?M-BQ
M8<NV79L?P8FM*28LB1%D2=?0<K_67;(U\=TDE_MNKH]W[H81H5,OV)#B=>C9
MN6/WOGWZ=^G@JXNWGOU\>/+:??=VWQ[^^X7PY_>N'S\^^_?NM?>W_G^Z6<IC
M*!\!QQO(0.K:.[ W!??S[3Z&(NQGP@KQLU#"A([*4)\-*=1POH4V'%'$$B$$
M\<0.0T210P]-Y/##%E=4,4426;21QAQQW/%%'F_L_Q'('X74,4@B68S1Q2-?
MC)')&>F[$$KYHGQ2QBDI2A)&^VIT<D8LL6PR12K%U%+*,L5TDLPQPTR3S37Q
M>Q#.!??3[[LW[8P3S_SFS+,[/NDD3\/U.A34P$$+*A0[1+<KE%%"'>W/4.X4
M/?1120&-5,],KZPT44X7O7123#^EE-1(0SVUTD9+115254T=]=5586754EE;
MG1576V/=M5-=>ZT5V%^%S5744H<U%E;O^*%S6?F8?=;9:,]T$T8NP[0VRVNU
MK79;,+G]UMMPL16WVW'-+1==<,]5-UURV7W7RR[E'1))$W="\=Y\C](7(7W[
MH5"GH0#.Z=^I9A+8X(2'.O^8+(;[*FLOB/^:F*B[+(;JXHHQWECCCMW:V)^/
M-0XYKH5)?LSDC_U)V3"3&7.Y9<Q6EADTSFPVC>:<A^KB"B^Z\.(=G[UHIXNB
MK^ YARMF6%J&&620@04'6$   0>HOAH!;ZX^X&JMJ>:::J\1 #OKK;LV.VRT
MR_[Z;+;3=GOML=N6^VVZXR9;;+S5SGMNO>'FNVZ_[0;\[KX-#_SPPA%?7/'&
M"7]\[\C_EGQPK.?&6FS,+:];\\TSOWSST$4?G?3233\=]=157YWUUEU_'?;8
M99^=]MIMOQWWW'7?G??>??\=^."%'_[VSSF?&Y%$DE_^D>3QT2>??)Z'*,'I
M<J/_#:*"7AO0/_7&*RX?Z*\G+GSR]<'G>H*@>ZXUB"0JSGSRC<-^_GMFD_^A
M[R/2;?SV>G(.."FQ"'_RMS_><"0X D1@ 0$XP 2Z)"9"R0E/*"B3"I[$(S:)
MX&H(%I2;!.R"&H3@!ROXE*7@Q()%^8E05#/!I*PEA5CQRF;20L.UP/ I;(D8
M#M4RP\7XT"ZIJ4QI*@.7U#P,B3N485<"4\3+T.6)F@$-$4?CF,]4\8I6+*(4
MJTB8+'Y1-%2D(FK V,6VT 0D\U,.;90#/_A)!#_,>1__RN=&Y2!'('>\X_J<
MT\>1^%$XW /0>M(S(#G=Z9#\<9#WT).?1<*)08CDDR0I_SE)2\+GD0/!3R8Y
MN4E/7K)-.5*3**\4(1\9"96G5&615CDD598R/B."I7M:F4I6WM*5N+1E+GFY
M2U_6$IBLG&5[/#1,8Q[IF-F"4S&122UFDK*9<<+0*)]935->,Y;8I*4VB<G-
M4%82G*!$Y(3$6<YP)A*=>/K3.O=42?W0JE?G450ZZ]0G>IJ3/^W$)SN)":I'
MR9-[A@(H@^8IJD#=ZGL"[><[/7506EZJG@65J#_YF4]-W;.B&'TH0S-J3X_6
M$Z00%2FSK$0M)GUSFF@RZ333M"YWO=2E,6V73+\5KRVERZ95TFF];KK3)?U4
M2;T,IE#[9:-[T8A? U,JORPXL/^H=%!A#8M8$ODR5:MRC"EW$4O&1-95KGZ5
M8RQ;F&%$9K*QP@QE,D,KSFY6,[:^U:UQU5ED^B&(HP4M:#\KFM&0EHZES: <
M3H.:U! 0-=*)#;%S2VS=%ANWQCY6L9%EK&0=2UG(3A:SE<WL937;6<Y^UK*A
MW:QH/4M:T(X6M7'KG.6,IUK0'0^VKB7>;&E;6]O>%K>YU>UN>=M;W_X6N,$5
M;FN)&[K6(J)YRE-N\B BONIHK[G3.Q_TG%L<?517?> 37_BR"XT$7>]Y^,C'
M/<:+#_**=WK1,5]SXP?>\;V7CK,1K_W(6X_IXL]_?#1D;Y[SP) LR(#X/<X?
MU_=& OO_%X$;1.%2,+A@$?Y7@B]!BH(]>$$.2C@E. F.23B8X!&6D(1 V8L+
M<_BP&V(EB#1\X54EUN(55Q7&3TPQ75 <&*JZF,4OU"H3;3@8*(Z1KE/$&9!/
MPT74;,;(2=[BDD=#1KDZ&8NGJ>%-%H2_-P[X@">!8X%O8YO[O;>-84[.F)N3
MQRT',CJ#U)_W"IE0\?0)4F\VSYP)2>?N">JB^#RGG_2YYSM%<K_J 7">0PI.
MEJZTI*+492UYZM.@*CJ:)T6TF5#:TT9?&JB_7/2FB=I+3#\ZIY^&]*BMF4U+
M5UK/J?:SJB=Y:&5*^M6NAO6L92UK4'8TI']:M48)[2E=P7-3_QS=Z+"/M2M7
M'3M7!4H6L8"-+&<7"]K-CG:JEDTJ95M;5=<6*+)_71UN;YO9WAZ5MA.4[6^?
M.]R^JO:T$1JL=4O[V\6&MZ_9[6YD@>B=S:(/M+I)4DI/>EKO&B6M9UIP@=,4
MI@9/^,$5CG"'-]S2F<[IOHQ:\:)>?*D4QW@.G3H5@+TE8@P3><A)'F,D[MAC
M6\4J6#W&<J\^YN4G&YG*Q#HSF,?L9FO5^5R?#%>>QT4?1_M97H5FM*3EP*]+
M"VS3HM9TJ[&6LH*3>N(@-SFK5^[J4V=<U;'>=:T[CG)?Y[K8PT[ULF_][&#/
MNMG7CO:VRQ;NQ?6<<>DN7+O?'>]YU__[WOG>=[__'?"!G_O@H4[XU:YV><M-
M;G:((V[C:%>ZZL,N=,&7/@/?&7O3Q8=YQSM>ZF;7.O@M<!WK>!O2T^9Y]DO]
M=.\!/D JL)$C 8X<#YP_ ;?/(;,/C_L@_&$,!S"#$WP@B44($Q#^GH+#]Z#L
M'9CAX4\XQ!0><0P#1A7B>V7Z2HQQ5J:\1!UV18A _(H/<^Q]$Q-&_#(VHHJ]
M?^(>\IB'4.7QB]4O8S%Z,8QE%*/^\1_E* Z1B_8OC/J/R$A#_ZYH_CZB.7@O
MRP+(C]0(-[J,C>A'S/2(S/#HS&@OD-!,S3J0D3XPT$:JSV)OT!3)D4[0!%EM
MUU003P0DEN+_I)/>(Y-8T,]<K=2VJ=,T+0>'"IIZ\ :[*=%^,)EXD @Y30>/
ML AWT B34$>2:=9HD,]64 JA<)Q,#0>O$ BQ< AM;0J[D I9#==$R@O=B=B"
MS=W2J7K&+9[64 W;T*$6J@QYS:+F\ WG\-G2T-K8, _;< _[4*'&S=P 41#O
MD-[F+0R%K=<.<01!BIP4,1$7400?41+I,-82C>#^3>!0;>#&I:4@CN$^4=1"
M3>+FQ=%(C11#\11',>) ;0DY+:E>4>.:JL1F<6%*3JI,KOQPT>10KJM4KN56
M#A@[9JS*BJQ*!N=*QC-VKJU^;AF;T>><L>=>Y@IRX&?@06C<06BF_U$;_ZII
MGL;I#&MT3JNT4DL<R]&TSI$<T7$<U]$<T]$=V5$=VQ$>WU$>Z_&UXJ[N"D\?
M#T_P^M$?_Q$@ U(@!Y(@"Q*XY&X?[Q$A.0NY$B_QL@O._L/RN NZ#*3QK VZ
M!"U+^L-\PLOSPBLC4Q "PX>^\*$>.D_U*-"-CL-]6/+Q0B^_J@R^<(]];&\X
M_"=".HSQ<-+#4$A%8L@E5F@E>C(^5H/ &K#Y+BS"A/+ZGJK"4HC"?I(IH>^$
MD*\HI._X<K'[MB\7Y6\K<4PM,*/'MF_'O/+&S*+]4 Z*,F,M$= MBPPN+^/(
MI@C)VM(NY?(MF^P A6PMK:\ECM* 8%*_'O]OC0HS B?0,$OO-2H0 _?H@/J+
M?3Q0D-B,,@,*!.,,ST:JS3;3SF(/,S\3SC[J"R]Q#$=3G4QS$RVQUH(P%5FQ
M6S01-@$N-FNJ-4UQ%6U3IQBM%960-U&IT7 $%54SG!"1#]EMH(Y3#PU*-'6-
M"E<3$TES-DMS$N60.I=S! TQ#I5SHCJ*5M"MW0(1VP81W,*3/,?3/+W3V-*M
MWG[%.\DMV<#S/!TO/G,#/LM-/-$3/]4S/[N-$-M-WB!*WTHIWXCSWM;SW0H1
M0;_3#/MMFP:T01\T-:7%/O)--?DM1*[CX4 Q0Q>.0S?40SVQ0UTS-X/DJ#0N
MXS;.1&&Q8*KOXQC_ID6C:N1J$2T<1BM/CF*R*AA?[A=_4>94AAAO+JV U.9.
M9DA?1JV.%!J9\1G?:A;@@1J]P!J)SNB.9AJ9QFEFX!N?3G0:B^S>;NS8SNO
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M_U!$WR.4C_?GFX^^]_J0W_Z!*TW74D3MQ0^_2GQ>&__[TYF_D$+J0X@ &4)
M -X#'_7(1SWP00\%(E" ][".=%SB'8LX1R(808\%ZS-! C8D@S#9H'LV6,&4
M (@F3CFA!@74$Z6X\"MPR8I-S.-"%=Y$*SA<2DU>^!:Q?*4J$6O+5LABDA;*
M<(=&'%(1F:/#)/KDA5(I2U-NF!00#3$MCK&+9PC#Q>68C(A:/!EA<'.;TYA1
M9J'Y8LG$.!HV_X*&C'#<66V,0YPYQG$XN3EC&?&(-#N:,39+(X[2DI.T-'JL
M)QG!8$QBLAWY5>>1VZF.([530>Z$1R;C"2%Y$KD13N[GD_T!I7Y"2<I1FM(_
MJ,R/F/3G)U7JKU#8FA:=8DG+6=H2EK<45)>\9:YQN<N7\.HEFJ1%RU6U,G_(
MW)8LN50E>NWKF>[BES2AZ<QH4C->V!2F+FN)RVY>*Y?6XE:*JK7-<HKSG.94
M)C=3)2M;^:I7PUH5LH U(CVULU>SPA4^?_4J>R(+G.H$*"Q1Y4]V!FN?"-4G
M/>'I3F(6JZ$0A2<_)YI07MWSG?;9E$9UQ=&,=C2?%@WIKD8JT9("B_^D&!7I
MK52:4I2"U*44Q6@_6[I2F)KTH">]J; ,RM."^E2>/57G0H<ZSZ(&-9XX3:JP
M(KK0AY8(5?R JE1#%-4L355(7T(75'^Y+FQV]:M<#:N\Q.I5LH)UK&C5ES77
M6LVT"JQ?^7JKCQ0V([HZ[*X2RVO%]/JPO?HU,'O-2\5, ]B0T<RPA#VL8A.[
M,3>J\;&)25ED8Y:SRKK,LI1EF3\PNUF=X8PU/;/9ST!+VJ0)K9"!5!IJ5SL<
M>N2 :E&+&M5F>[6LS4!K79/! \8VMK*Q[F\'H%MP[S9<O!7W;<=%6W+/MEP$
M-/>YPHTN<:5K7.HBU[K*Q2YSM>M<[D)WNN#_K6YXKSO>[)9WN^?M;GJ_*][V
MDM>]YH4O>N6K7OJR5WFF@QY^][LZ_I;.O\@+L( '3. "&_C "$ZP@A?,X ;;
M#L#->YZ$\SMA -\WON_-,(8W/%\-=YC#".#>]K#7O?8)\'LMZ6#[TI>0 M[C
M? !LL?WD1^/WU6]\\,/E?>*W'WXDY,4'3&"0%1+CZ_SO("\6L@(%0D'N7% E
M#(F@)!<YPI189R'ZP'()HQB216[YB4742 IOB!0DYK F*(0*F*D(1##ZL,T]
MY"%88HC#-V?%SG7&BQ3K'!<S"Y'/1UPB3[A,YR>"L8H]9,P:(?.9PH@&-"*+
M\Q6WB!C+M%&/<<2,_V,WS6B2D6:,O"DC:FQSG%(GQS6DKF,?;V/I5)/ZU(,$
M)*R1DVJ]J.4\FGRRD[TLP13W>I(3S$XEPT-L\1C;DU+IY I+F4IFB[+9IQ3E
M*NTYIC:IR=KA)"<ZMVW.;J.SF4*R$E7%'6YN<^M-VJJVM_-5I'&[&V '@S?"
MXEVP>1.)W?@V=X0"ZLULZ_O?ZP:XP /N)8=:*-W+_.:T6U1/C[8*W08G>+^5
M1-"*QW.F,T5JPPV>JEMVO)NP<JD[7WJK?$;JHY-"><E3_G"2MSRFL3)JK? Y
M\IK3_.8*C7G(9Y[SG=/TYRYW.5*7RM"B-[7?_%:XTJVEI:1+R.D6W[C4N?^Y
M=&;Q\I?:#";6M^Y6LWJ]ZV!7:UO%3G:Y7M/L;)6WVNN]=GJ[?=YVY2M>_SKW
MAXDEL)'>#,@6V[&,D6SOBPX\9$=&V<G*#+.'OZSB8=;9F]7,LSPKK<]..UK6
M(DVUF+^\Y@.ICZQ)3;96ZT)ML:8UKLU !C+@K=CZ.[WH4:_UU8L][&?_^MJ[
M_O:RMWWN<4][WNN^][L//O I%V$*&Q_"^F6]@Y?/_.:S !'^R(?K9*"]&33_
M^MC/OO:W7SSD5UCYJ -_\87_^_+[_OS7$['V2OQC&+^XQ0&$?SY8G+[YLT]\
M-EY)_?K#8SAQB,KS$X WIAWWEV(:U!)8EH#^PV3_P>9C6<: 3M9D!I%E #1E
M(G2 -%803H1F5O9D)J1F' B" *(>Y,-"S5$>3]%$6+08=Q9$<B9%;#9$7K%G
M/G04;78707$6=T:#/#054_%G302"1A2#=%9F.SAIG 9IC"99A)<6/^%&C99I
M:91I@R=X4)B$4XAI?[1'P.%J7"B%8+B%=_2%J$5(@&1YEV44/D%"'<AKNO8<
MPN9KDM1D&3ALQ[9)RX:">9A(T'9RT49MTN9*R71,B2*(A3B(KY2(5.=OBBA0
M"<>(P_2(3I<D5Z=UEIA-7(>) X=TQ"1/BNB)BZAM+%*)FEB*I'A691=77P=,
M6 )U W5Q3 5RQW)4(\=/_S9W43('5#^5<;'X<4M'<1'W=##BBE/G5+AH*O^4
MC#YG<LMHBT:7BZ_XB;(8=<]X5#"'4C@5=-=H4MI843;5<S45CD"WC>.X<B5'
MCMT(CN6HCNG(4NWXC>Z(CO+HC=Q(CDJE4_B84T1%B]7X4QK7CT!555.GC_=(
MD#L%D/]((U?U5%2UD.IB=5:WBJ@XD1)9D6%'D1=ID=/$5JD(5QZYD6T%;WTU
MDG57DG(G=Q2C:'C7%8.E,2V)6!H3DS#Y=TE8A95E>"J363J9>#O)63X)>8U7
M>4'9,T0Y-)2W>6B8E*K5#U?S>54C>J)W!5=S6UMS>J>7>JOG6^&W7M[5E5SY
ME?_VY95A"98>5E]E>6$?EI9F"6)HN99JV99P*99G*9=L29=O:9=NF9=QF5[C
M)W[)]U]^^7W<-YB#.0/OX!4 D)B5 0"M,'WK-V*(0 ;61YB469F6>9F[XWW'
M%YB;"9B>J9=XN9=C.9IS299HHW[IQWY$]F,+Z$'PYT'E$YL?=$KP0S\<U"Q-
MMV/[!XH>D8$C%#X.&(<3&&571H%:MFN5]!!(9D 5*! VA&LT-(1KJ$(>"$(5
MD4(E:)T<6()""!5_9H22)H3A^8-ZEH.2MA;E680OZ&9]%FA8Q(-'>&LA>)UJ
MUDE+M(;W:69/Z&9!Y&E<9&E*:&MOUAA=]$:G@6JB]FG_A&>%E_9HFQ&%9Y0S
MK)8;K=:%P)%'?!2&7N@;LM:A=)1YI7:@HB&?*Y1!&30>Q9:<C!2'P.9KNI:B
M>(BB>A@5YH%L'.%LI31MQE0GU89NA/BC/!JD=]*C1"J)13JD0CI.ZK:)$M>D
M9R(C3BIQ4'>D47J*NE2)4$)N[49V6\JD2->CP8AP2'ISIQ(FR'BF;;*,-E>F
M#4>E7AJE;QI.^Q:F9IJF/*=SHA*F' >)'K>+MXBGZQB/]/AR@_J.=ZJF.)>+
M&%>+B0J/CBJ.A@IT+!=TDSJ/QWBHF-IR?WJ0/U>0GLJIT%B,G"B)>DJJIKI.
M<CJ,I1JGY9*)5IJ1L%I68X=V_[.JBA]Y=K;:=O:FJ[S*=@DS5R9)=R>YDGEU
M=XI6@WZ7K(VEK'W'H,YJDSB)DXO'D]2*>*$%E#E#>=J:6D@)HDK9K=V*".G@
ME* 7E5EC6UM3#E>I>KVUE>='?N\Z?.8'K_0JK_$ZK_9:K_BZK_?:K_KJK_;:
MEY\IL.Y*L :+F0A+.RS@!?R0F,6AF Z[F(W9.M27FB)&8MGC!9.9L!S;L1Y+
M/)H9LIPILI_YKR:;KRAK>Q;[F*KY?C%6?_3G8@$DF_23?V(B@.7A30(90K69
M8[(Z$?SS093DH@019:U99 I8'49+G)#4@ 8A01"B;%)19?79@2Y!M;U)0<\)
M12HX9_\^*+5?RT*)ED1XUK7SV8,O&)\PA(2(P;9CNX)KNV<JN&9T:Y_="6:
M=F8MN*"EP;<18VAVH: 4FJ$1.D9^NZ"&5+B:$89V!* ).H:,^[ARM&K*X4>Q
M9C1FB)2:MAS3F6N*E*)N.+0M.KITZ&56)J,6D4DU^IS(]H<.!Z0Y:HBPNZ.
MZ$^L=+NU2[NZJZ.\*[NXN[M5IZJG"DYP"J?$N(A2VHF]BXBAN*J.V+RCV*J7
MB)&F*+VMJ+S2N*FN@HZ,RHXQQ8SF*%.36JF-FJ?:>[S$&XS .+S3B'&6JJCO
MBXV@.K_Y>''Q"ZG<6ZCW&ZB/RK_U2[_>J[\"?*F2&KXF-[[_!KQ1K[N_D=K
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M4IBZJE1;2"JN;M6K,QP5(F;UJE7%:E:KZH*M;)6K7?7J 3((E@.,52R)'>L
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MLW5;NW79)Y=RO(7R*I_R**?R*[?R+.=R+/?RL\UF;A;S;7;,H&V8H0WG+G@
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M[45=_9K7L@5.VX$'++<%2Q=N#F9PW!K<-KK)UFVOK;!N+8PWQ.6V<0\>6>1
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M$>NI$1<^?9-9F"WQ)+(9X_^WXP<XY$\Q_,@#*>[/HVHQGQ'0#%S! 2&0&,O
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M[[G_OOOQQ2\__/.51[_Z]-E?W_WMVX?_?>WI!S_^^LG_5U_^_?$W_W[[YP=
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MPS#'G'1*S[!*US!R_$$><B!+.6<<-Z=+OS1,2X<%QK3*RA0<#1@?PS$?$?B
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MFY6L=.5TO%V=6^XRE[/LY7J >6YAFGO=Z-8E/=Y#AOF\XS[X629_^ .@9\K
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M*WNP@R8D\PY_Z$,>(H@E,0$/&-%839,D&8HI9,A!8@CE>1S9B3K<\T"J&!%
M:T307,R(#LVH36U>DR(G-+0UV_E.2-?_\XZ2MD^D[4C$]+R$/E5Y)5S6Z,:U
MS&:/;T%11.$(&\>NI9:+!(PD,5M(WO"2E+,VS"T?Z9=AH@:7NQS.='J]Z]?.
M.C>E[+4I5REL/Q[2E6%19*M'J6OA!,<QSF9D:F[-:E=GTI8;2TYS=-O,;^-V
MM^-^9F)^ M$!M;F,XR%C-ODCQF]V,][TJ:-_Z,T>-Z,'/?6N]SL)-*$*_3M
M]@2XP &$H4T=')\+/^I.;9I4GCI5JF'=TE"I.G&OB@E7#U=JQ[EJ5(\3*N*G
M8FK&2][2@&:4K,Q:^;0Z&E24F[RK,:=Y49]*5(T[55>]LOG.4373K7)\Y$.7
M)\.+#G!/Q?-3_T@'5<*5_G0*+5WD6#TYS[-JI%P)7>1'UX?4I9ZIK89]J3/O
M.<H!:JRJY_SJLQ+[K:SN<[BW_>-K3WO=R:YVL[J\Y6AM:[3<NE9[R57P<24\
M7 W/+<KFM5GXZ@Z_"L_XU3@^\@!K/.4GS_AO8=ZRA-7\X#//>=!#2U\/LWQI
M14OZSV[6LZL'+>H3-K'4FK:ULP\9[6'KL=M')F4SFRWOG^;[VK:L]^ F=V^-
MCYV?,2>XRQ\N\XM6W*8)UVD]VYK2N%9]K&7?N=.%[O:Q:UWI?E_\U15$#MQ!
M!KF!5_W?O5O>9K"W\SZ@<.LUG'L#[,#^+1#_ -1__AOH?P8*P/W['_\")" !
M!, !-, $[#_^^[\&/, '7$ '+$ &I, )5$ $S, (U$ +A, .E$ /Q, -',$/
MY$ 1+$$2/$$5K, 5O$ 6?$$71( 9D* B&S)$0"(F2R$FDK(H6Z(>1+(:RL$P
M>R$T8S<N&H\KRZ(@0B(Z:R(QXZ&<"#,ELZ:78#.F&*,C3,*<6$*%>*(GN[-[
MF <[:P@O C2,T,(L]+(;0J$E) \WO"(R>K.5V(\7*D,RHC=-.[A[4@J:. \A
MVHES0PI![$-Q&CAI$C4_2L2KH"@^@@T[<@U!HB56TJ-$G(M1$Z1<>C9;\XUL
M6S5?.K;8.C9-NJ1-M+9&VC91FD15_,3>",7_U  DMN@TLCC%7ZO%3!R.6BLV
M4MS%3^0U4C(V5R0^812W80RWF\$V1_0/E[A".;R)+71&:)2)?7NW>7,/^;!&
M>]/#2\M&_'BWG?"F?J,T=U*Z>]I&"2E'0ZPTHU,X=6PX=W2X=P2KB9O'BZM'
M>>PI!H&H?'HH?J00??2G?PS(?O2IB;(XL%*YO..[A$0[>Z0X>6Q(IJ+'ARR[
MDI(YG:NYD ,YHHM'>'2XI3LZD/Q(CARZNXM(F*-(M:.IH(,XN0,ZE+2[B30I
MA&0YB71(F[1(NBO)1L$YF+PYB/S)B9I)O1,KMBK*P"N\H]RKR8(LQ1(LR>.K
MRX(8J$RUJ)R8J3RL_XBYRM>(RK["2JZL2LACRL3:2JIT+*L,+:U,/;5D/=5K
MO;:$O=.*RXR1/=)R+=:JO=<JF>&3+>'K2V+\2V.TF>0;+N5K/L-\/N)*S.2B
MOL5\FL:DONN+3*_I/LD,O^NZ3,O,3/!K+GZH&_03+_8;K[QQ/_/R&\)1+\.I
MO\7IL1IK31US3=9\3=F,3=K\L=FTS=J$3=S<3=WLS=OTS=S\3>$,3N+DS>$T
MSN($3N1<3N5LSN-TSN1\3NF,3@(C R&3( "@00C:(2;;LGHXLBY3H>\,PB14
MLBH[3QR$(49+,NXLSQSBLO7TSBF$PO/ AU:P0BL\HNX<POVT("AB(C'$L_^#
MJ(< #<\NU$$G;,,SG+,SQ*)!,P\%=5 A5$(C#*-\H\9*FZ9U4P]4BR94DR-K
MPM">XL-Q)-&D&-%+I+902U&W2-%.O#85?=%I&T5*0@Y<%#9<TK8;W5%BPE%,
MHC4@U<7 K)E/DHL/K8I@RD7?@#;+&(RYQ+4=;359,ZUL,[96##:] ,SB&U(M
M?292BXIFW% C;,-GW-!M4B=SDC<UO;="U,9L/"=OQ,9P-,=UA#I.L=.$4Q"F
M^X\ZC3H[33H_'4EXW$F@M,F:Q#B,)$F-W*>IT\BM<U1(A2E)C;N7;$B&?+FA
M+%2 PDE.)95*D;NVZ\F,H]2<?#M0-566U).O^]/_/KW30'75@&/5/8W5@FO5
M5)U4ER2YNYN[43U5M_M54@U67^55C(P4*3%(A:1)9:U(ENM4K-/)BZS4:&6[
M:1758M7494W63-4[H_2\I/Q6;QV\Q%.LL!R]<3W7S2/7R+*\=$57<VU7>%T\
MQ7O*=S57@0D8>PVM>T4]?)6\?:U+UW/+SX)+*@T9NJP8VKO+N\P]DP$^EN'+
MX(O8F-G+B2U&P?2MPD1,YU/,P^38Z;,^Y8J:X](^D7TND^4^S1R_E,7,K?&"
M*_""=X#9\&H'N^$NO$F'\O(;TYR_PU'-^P)!H#5!& S!H0W:%"Q:H8U!HE5:
MHT5!IVW!I8W:IH7:J47:_Z-EVJ25VJRM6JR]6JWU6J[]VJ>UVK'MVK(56ZK=
M6K4]VBXHLD0  +BUP0C"LO2DT"7CLCDS4+W]3P+U02GK,C(#0O@T3P4MPG6+
MPS333\ ]0@@E-# ,4 (=0QEZ(LI5B"B2LH'XPAN*T$%#PR]*HS=4P@--" LM
MW3>[)M1UQGH0HWO(T$<T-4@\4>^HIG%Z77^#CTACMJ-PI4("I+/HW;9HMDZ,
M1$M4M5_R1&+3C5&B426E46,ZCF\34E_KT>1ETNJECF(J-^DH4E*#1&>S+%8$
MCA>E-G,;7_/=-52L7F#+WBYM7RX]QK@ TRBT6_KEW#<$HW3"7S2MQG!BTTT3
M1_]P[-\Y=2=Q;+BPJ"E!3>".5& &)DA#Q=:8/-2*PT<*3BJ!],>!S,<,KF 7
MX> ++E40EN (AN '-A-G3<EKE3@21E81]DEI!6&ATCJ<:E1<;6!!9<=T#,D%
MKF$4?F&+.F%K1=4>!M9A]=2?:F$DIBJA+&$F3N(1?N(F+E1B ;RT.KQP14K"
M<DJEE,J&T4HO[F(PYF(QSLHP)N,Q_LJR],HT;DLV7DN!94LW;F,XUM>X+-C2
M,EB\5%B[;-B\#$:)!;[WW=+=&DS$S%CDZ]B-)1K'#%E&9DSOHTQ(7EE)WDR5
MI62671M^>%GPBMF85;_VXZYTR('R*H>=1<WU<B_J9,[_Z53E5(9.5GYE5X[E
M59;E5IYE6ZYE7(;E6];E7*9E7OYE7P[F71;F7AYF8^8Q+Y@@1(!;9E;F1.#!
M>8BROD6R+"Q"',1;-LS"+ K<\!10/"-0>I '>IB'<0;G:,8SOR5<,VM<&**R
M^43";2;/D###O]U!,*SGR\UG.FM0&[*S/$,(>N!"-)S?!XWG!-5F,E7=.$1=
M<E*W;*I"V2W@1MS=3QLGJ7")-I5H[WTEV3W$-Q)>VD!$OI+%9<-$25K22C)>
M*:TV'_U%&_71Y1 V8&SI'X71\[TV3OR,7,/288K%DHY1]"VF;7/2*=7I7@*F
MGO9$7;)28&1JZ=UI+06:0+;8_Y3IC@.!1H&.YW;.YL\-TS#-WS4-:_]U4XL.
M)P%Y-(F.$72,5 3V.!U^54"%5:>K5;@V.H3;87XB5"BNR25N83R181Y6U,"F
MX;86[+P68F&U.I/<:Q+V:ZU"[,<F8L6&5AA.X;7SN4^%[%LM;,+V2%E]:[EN
MN@;)TX*K0M(..#T%[<W.56)]5LV6;-A.[-C>N->6;5L)8KS;DB7>[8]2XH3J
M:\H&XN"V;)[4:RY1N6ZE8N6V8BQN;G:M5WJ-[N>.[J[<K,BJ;GB%[NG>[G)]
M8W[];HKI5X(=;\C;U],[;].+XX%=&/)NK+G,8[N,[Y7I&(:=[]^[[S_&[XJ%
MV*DN9/_"1&0 U]@ ESX"=^22Q;Y')MG)/-FUH<Q+?O!)EAIWZ"Y.%J]/OIN<
M/2_ ,66?M;^T!=NU/=NP'?$0_W 1+W&R-7$53W$6-]L5=_$61]L8)W$0K_$3
MM_$7EW$8WW$=[W$:OW$@S_$?-_'KC* R8&8DS\XB>[(>W$'Q1%QK[D_V]%S_
M!$]W;D)HEN9_;G(N+T/S_'(L%T]U!B)W,U/Q6% KUUS)Q7(O1-#-+;0DRZ+R
M *,MDK."^-S[G?/R^,.+#N"62-TPDC02U4-FXY2TEB.S]@E0@X;>C>A'9%'>
MA<4.33:*\FB5/FEK(U]@6EZ:WNEA:^IBZ]+LM<7KO21-Y$7_7RSU6[P+%H4U
M6BS?("U?*X4U:7O2HUXU2:1%HOYT5.=I]NUO8%^F@:D/_21H0HMS9&\A*#=S
M:K3&;Q*G^(AV2T/TC&8GV]U#BC9A&.'@C<1K;V]'D+1AN_YV@&QL<V=L$_;@
M#6XH=N_@=O_@>%SW(<9M)XYB=+=W?&?A0M7W>Z_W38ULSF;K;W]4<I^GC\1A
MA$]M@_OL&<;@:J7L'[;L$[;MSM[L(O9AL_-M3-56CN?MC??XO1N22PWY<\=W
M?\]6Y#ZKY/X[YCZ\I81N,XYY-%9CFB?+FE?O,IYY.?;NG>]YG.?YGW]+]KYC
MHJ]C/-;CA)5O7T<FVFIZ0:;JXS-D_T-.Y !?9 -OY 3WO@5'64N.< CO>K 7
MOUFXAQRHFTZ>&_:SV=$LK[[Y&Q;8\,2)>V ^YKDO9KNO>[PGYKRG>[WO>[[_
M^[OW^\ '_+T??,,O?,07_,0G_!J[ K=-<LAW6T1 A"R3"+PMB!^4HO-,(ATD
M4"WWVR/K<M!W\C#_9M,O9W2>,A/"_',N9W(^Y\SW<OGDHM-=1CK,P7M>\[WU
MYP&%W#P#0GY>3T9[1O& 0\:-1GC6B#E?=FP2B?JT]K.N=F(O?D?38$6_W4+L
MZ$D71!LY-=DPM4?'H[FP:;R015P_+.2-:4L2)E/_=/>=7OBGZJ<F]:9.I6"?
M:6BJQ%HBWO_S[W_RQTJ T.>/7S^!^@HB%$A084%_!QE"G,7/X4"'$@M*')A1
M7T9^'3_VTSC1X\B/(RMZ#)E2H\I9+5^RC+ERIDN4"?E!XY=/'SZ>^>[Y!(KO
M)]%[/_'5.YKT'E*E1XU"#2IUJ%">^J!=S8IUJU:=5W%^W9ESJ]><8LNB/4LV
M'TZ=;=F:Q5GPK<ZY;/75Q7LWKUN]=MWN92L8,.'!A@LC%JSO\$[&BQ-#9ESX
ML6'*@"TK=BSYL%Y^?CM_[LLWL-W2H?.9'IT:]>G5KEO#'NU9-FC$G0??%AUX
M-F?;OC='UDTX]V[<PHGS'GY\.>G:K'7_/<W[M>K8SZ]3QRY].^W_[M>G.T\>
M?CQS\>7)[W8>W?OZ[]S3LU>/WCS\WO:5WZ^L>3AFK_OU3_8?90,J9M: !BJ&
MCW\+-L8@@0[^)YQQ]=%7(7KM67B>AA2&-V&%N/6G3X@AEN>AA_.AN&&&[L4'
MW6FSO!CC:##.*.-U--YHHUTX[JBC7CS^Z*-.0 YI779'&BF?BTOF6*.334))
M(T=!>H:CE%;B-66565[)I9=;@JFEF!)Y-A='_)3Y$)D/880FFV>FV6:<9R*T
M4#]NWEGGG&LFQ">;=@):IZ '+701H6T.FN>ABRK::*",/NIHHI%2.BFBBQJJ
MJ*$7D81HIW1V&BJGHQ(D:C]WCGIJ2A+5_[2JJRZQVD^LL[[Z4JPRM9HK3++N
MJJL_O/Y:$[##"EML2,0>6ZP_P2:[K*S^P.KL+- ^&RRUTT8;+0#/:LOML]M.
M"ZX_XI+[K;GAGCMNNN6&"RVU75SAQ3MD=.&%.UYTD2^\.5R1PPPSF#.###.P
M0+ #+"" ,,((,-RP-PT?X##$$C,<,<,/5TPQ A8C@/'&&G/L<<@37TQRQR:+
M#++*)6?,\L<NC]SRR3*G#//*,[^,<\PYUZSSS3T#C;+0- _-<]$[(_WST4H3
MW;313B=ML]0^3QTTU$P_G7745'-MM=98;^UUV$M737;79HL-MMIE7\WVUVZ/
MW?;9<J<-]]ISO_^-=]QYUZWWW7T#CK;@= _.=^%[(_[WX8H3WKCA#,^0""*2
M/X(( )=CGGGFE$\^.5-+(87//??4@]0]]"!23SVHUT-ZZ$L5U=3GIK,>^NRE
MXWXZ(O34,\_IO?\^S^Z]K][[\*SKWCKJO O/_/'/\[[\ZJF3_E0^5$UE%?;8
M&P5Z4LKOKCL]]_@^_O+DGX[^^.4G?_KKM+^>#^Y.?4Z4]_*_#[O^1>G3/?VR
MR\]^ O0? 9'2O_[QHR<*/* "P1*7!Z*E)T+YB54>B!#4P,4M8^&) ]-2EPS"
MI1^"$>$'Z?(<:%QP+BA\B$,:PL*#K+ ?,32("V68D(HHQ"(3R2&=>+C_$1S^
ML"0G$2)*< 43FAS15T@T(JZ(2!*10/&)0PQB$:<XQ"BBQ"10A$@+N;@0' ZD
M(3NDHA<ILL,PEC&-8#SC%]EHQBUFT8E4E&(<HYBKDK0$CTQ<(A^5Z$<[X<5
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M(?_Q(S]T0YUU)=3RL9FW6[=V@SMVC5=W0Q_TQ[EX?]OT27_T@U?U@WOUF[=
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M^YR;"[H+.9JGZXZ>F[JENXZKR[FAJ[JQV[JRR[JO:[JP:[NS>[NNN[N^J[O
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MUW[ZN1__^,\C7/# J;A^S$2@7D&H+6^7CC JL'JR)C/ ,X*R,,*RIM*R!6S
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M>2611QHI))=A.IFEF%9N.>:99I;9)9A>NMDFG&S*^>6<;PXX2Q<Y=.&%/&3
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M_>]G>:L=![,$S1_FA$]PJPSL,EK7!?^;M)G^:YZS3%B8E#D+FL^$YO___2\
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M%U9\V)!B1HL;,4[D^-&C0XDC+Y+4&/(DR)(=58I$R3+EQ4>('"&B2=,F '\
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M]OY>_\#ER?K7MYC@*Y:][4=\OGXS?/<%G'%!<>QC'@O?QOT+_K4FGO$A*_^
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MAZ+=7)9S4<^ASXK^^=EL:=)I'WKIXD4>F7E>X'5I_8YVEW8YUN50EV/&#!G
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MEG+$FX)$FYI$EXHI2YPI2I3$2L3$37Q$F?+$2P1%3M1$4OS$2)P!$-LI$-/
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M6"]-MS35OP4*6F]_T/0E8\HGH&3R28&9(%@')G5DHJ"#"T)8!QT.TK'')_I
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M/@#UXZ\_ @7$C[\#"TS0P 89?/ _!R.$,$ )*Z1P0 P1G)##"SL<$!\9PD&
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MMK99O3 ,O0!54.4WB<.!BN.!206"@R."'MB!N#95O2!L#\@?2.$/B) #%?
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MST$]]$,,J*B(F&A9T: ^AA%KQJ%QEP4-_I!1>X-8F64]&N<9Y;D_205 PU-
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MG9DXS@/A/B]L/PW['KE!PY^H"<0@U] PBIH%L>%AGJ4QQ$"E#*8 "K7V"9G
MV-_Q'4L\G_-YL6IEU")MV53-TIJ-V68Q"U=00?) #Q\KLD37!1]TH,*5H!HR
MC=2ELALBC:X=V]1(C=:HH-RHC3P;)-XH).!H).3HVT-+R$^B7NG()5*2M/;H
MCO#_M=SVI8_-O8_0;8_O-=U*&]V Y";_:) -ABA>2Y"'DI"+HI"E++:8[*3E
M+;8N=I'EO=Z;;-ZJ/-Y16GK& F-\:Y+UK9+X#;BL7&2">\OY@KA2N91/V913
M6> "'N!0:> )?N *3N ,_N +'N$.+N%$V> 5#N'9\LXGD]4<_A?<UP[@E[N$
MUKLC+N*'5I8F#C4.8 [T0+U8K1J7I@\AU<[J3./K[,XX/C81/!#7"ZNR2KY
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M]77@!;13]-LM*MS3'K7K:-WOY=Q.&_]/*_]Y7+3U3^WY-6!8>[6-O&!:RR<
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ME&%,4:;''OE1AA]H^ND11A:/-#+)&9'$L<=^ O0OROZ4ZP>1'"J8",N&M'R
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MJ#)9[ XD]Q- )'D_.#*%(6$G[ L0?["23QD5.G% 3GK +XG 2YI ,*E 3+K
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MZ*W3JP[#!T^<<,.TRVY[Q+7'GOOMNPLTPSU#\?,=[[D[$+SKK(N^O/)9U>,
M3A#/[CONTTM?_4WKW -Z__*GCV[2]=0OY#T ^G2A>_@H==$\^8?3@_WN3G$_
M^=3MV]]]4= 0 Q;_7J5U/T4<T@^TL&49R[@+ NL2EP.V)2]IJ5_]8.(/90"F
M?Q8,"S&B,1FCH*4K8'&,+Y:1&.9-!!J@V(QF^+%!_)&0A>QS(0!?V$)^]>,Y
M9("'<F[HG!T>YSG7R<X,N..A#9TG/T9TP!&3B,0E*G$\363B$IT('@38AXI.
MY(\5D8C%+1J1BUKL(AC9XT4$49&,8BPC?AR$QC6JL8UD=&,:*81&#M$Q0C&B
MT(D"=,<X\I&-;_QC'^&(QCSND4-XM".%ZIA(,-5Q1_]Q)",C"<E)-HB2CZPD
M)O\OB2!*@@F3G?PD*$,I2C-U<D^E#"4I1:G*58(RE6,ZI:#X-"@YT8F6?XKE
M+?F4*"\=:E&!LF4M#25,1!&S4*)"U#&[E,QB,G.8NP0F+G_)RVDJRDJGLN:G
MK+DI41E+59W:)JN\*<YPDC-4X#2G.+>ISE2M\YOF9.<[O\G.><JSGL:BYSWM
M>2Q]XG.?^?RG/P/:SX'RLZ  )>A!#2I0A2)TH0E]J$,CVM"),K2B$*6HL8;V
MKGG!L*,SE*'D /:=Z!F,I+8S:>Q0JM*2EM0![I@?2&,H4X_Z9(#0X <Q2O:8
MFC'M$SUE&LUZ43)0W"QGCNC91G>6B)TE=:E)?9=3F8K_B*C&JV\T!0 _EC:,
MIODT9CS]Q##T8;2KDI5>_M":WM"6UK6JM:UL?:M;XPK7SN$MK6:S:USO6E>Y
M\G6N??WK6V? MX_.='FL.:QLAM,:Q2*V-L!9;%EC&MG"2I:PD[VL92&K6=/A
M@ZUZI2MHR897S\T"LY4]+67)EU64=2:SJ 4<[$[*4MG2-J6SM6UM<8* &3"D
M(_[@A\!RFQ0']#:UIC7N#.DA ^$R%[?.76EMP2&/OKW6M1^9A4F8FY"6D' F
M3+DM GABW>," !'?I:U3H(+<ZK)W*-$@S%>6 8WQ:L0O:U%@ J.1EKRLD(8
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M1YXN6) 1Q";)DZ$+>K33,)_]K@S3RC&)K ^>+A7JZYT9JCQ/S#*/!&^&=;S
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M/)8D!X\H%0VITP]$="$'84QC$NTX2$D*LB1-000?:[B0?I"A*XY4XR,]"<E
M@C*2E%Q*#BXI1#=F4I6LE$VJIN-*62*RE1"A1SG8ETMU8)*&_,#E^61T'CL1
M!!]4RB4PD2DD!Z!C4;4DR#QF (YCIF^:ZSN/.>@APUE>A7S)!!*%0-B]+U7S
M02NBB3^,Z4URJA,\TJ20G3ISCW54R9K49*<]J1D.**VE"]*\)P*2Y(]^N$,&
M]33H@\(Q@WFL$B)?X@\^#WI/](%#!O*XSBSH,4^(KG.CYY.!.]ZW34$I@QB7
MZI,O/B5"0AG_BJ6'0F!RE+&,2HEJIGORA:%HJ9E07<H7I+J5,O2GO_])9T<,
M=:91D2I2I>9TJ559DK'($"QY> $>Q[+J%;J@K!DXBZO/(M>TR&6M<8F57. B
MJUG+&M:TCO5<;44K6\^J5G21=:[BLI>YJ 6OO-HU1.W:ZU[W!=AV@6RP#%.8
MR0R;6)(1-F0?BY9CZP6MCD468))]+&4G>UG(;C:SG>7L9SW;V- F5K2@)4EF
M0W(SU9Z6M:EM+<#DLEJY0,NUL\U:O6SK-&@![F]LXRW;B,8TX0Z.N&<K;G!Y
MEK;B*M>XS67N<P7GW.A"=[G3)9S>L,LW[?9-NXOKVN-& ]Z0B/=R_^,-[WG-
MF][RKA=QY!4OYQ@'7\\USG2;JR]]X7M?S-67O_OU;]WZ"^#_SB# !!YP@1$\
M.P/G;L&X:W" '5R[!_\WP@J6\(4MG&$&8WC#&JYPAT'\81%#F,04+K& 0WSB
M":-XQ";V;P0MR%09'[6I(AS?+['TIB+IF$8[+F<76%1C(<]8,P2!!C^(@;]>
M#%"H3-Y?D_$'"F7T8U'AFX4%LX=E#6:9@5QNH)>O!V8/AAE[(Z(QD>7G#WWP
MHQ[T>$<7T-&=AV8+/!VJ\WCF+*X9M&,>4<&'"9.*9HB !#>%UDU2@'CFHQ*Q
MAX8^C:-W$VG<!*4+B/@SAA2M&7T\^M"Z6?\-B?KQ"$9VFM-ZQ,M12U@/'9!:
MTJR&]&!R0(9P6L>/KK;U:MZ7Z<Z<$!&K;O2M6UWJ8.,PUG_.)#_($)AAOQK8
MS!:VLTFRQR'K6M"9?DYTID-M;0=Z/=SQ<8W0PRE6ML?.3NKQ??HQ#QSWF-UQ
M<I(ZQ*TA?KRCW#DFT[?Q#2 6R(-%V\8(A]KM)!&%3TKON7=]5M0B8_+8W?:N
M445+11,?M<GA^6ZXCL%A424Q*> !VB<]9C >BYO[XG*")RWSD8Z15[SC;W+
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M3/^GR=1TR6!0H,"NA/*A>GYP".?4".VT3O&TS&BH]Q:$XL9*1<X%4$-$11#
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M@@^Y=F9RD88C(A=L*/<>8%8@[F$^R2\1K(XC\,$+_C.Z!.%A,0(?"(T^I4]
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M =TOU@'+': =YOS/01W3_YR(,T,A?.30O6.9N@ >YKP>\N$>YOPO% 35_P_
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MU%$S;7766&]=-==4?UWT(X@X@HC88I--7MK E<>VVNVUO;;;<+^MF4WE2'8
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M$0'F^$E@\GB6Z&@FCU<1)>Y <\-8HF66FKF' R2R2DT^Q 'K.-=BU#8+>LP
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MUN>>J6&MO5Q9/ZK@P_7W#K@D4.:D*N++*E:JFI6PG-^OZ(LV^L"2$%X1VRW
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MPYXAVY&8?L "IKW"1^JSS68;;0C:CAON?4%ZQ&RXY=8[;[[Q]GONO_<.O&_
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M 1&JY%O'LHH)1*ZB&#+>9;3Z97_/*AWJ(4SFTI=TR2XK11\0H3_,F)'\LK(
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MJJRNZBJDK<(Z&2)=>"$/&?.0 8\7M7;AJZ\Y=)'#%3G,D(,,,R KPP/+LO"
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MKKZX7+ BC-G*7=NUC-7E6\HXK]BZK6[Q7?K)C^QU7K[U"#DP0P#K7G_G!5Y
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MF?.'=7" )I>1>5#SJJ[R-8^A69AS.>_R0H=H/^__\S]''HJ^85#D(>$TV"Y
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M3N)A1V53J?%D%OI#IU3E:'3!// #/N@#/I@F:O+#/:SF:5J)/,C#.LR .<B
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M/ P\L*O#CU4E.E@\Q\.[P??VM-SY=?['2I<[O)]\%Q@\90@\.MBFG'\#O\_
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M>O3LJJEW7QT=.?+OXL&7+Y\=??CM[+&WUSY^??SSYN6O)Q_]N_[\_.?75_W
M?P$*&"" X!4XH($*)LA@@,@AZ&"#T44XX( /5C@AAAINR&&''FHXPX<BCDCB
MAR&"..")#ZC(8HHN!M@B_XPK8AABBS6^.*.,.N;(8XP]XNBCCS*J."2-,P8)
M9)([WFCCCTP>">634D9)Y9165HGEE5IFR>667CH)9I-(+@EED6*Z>*.9$$BY
M9I1MUKCFFRO&R22=<\X P0-T[HEGGWS^Z6>@@ XJ:*&$'FJHH'HJ:@&CCN[Y
M0*.02KIHGI3&&2F>E6::)Z:7:OJII:".*FJIG)Y*::JDHKJJJJ:ZRFJ>CB R
MZR.(V#JK8KHFQFMCN_K:ZV+"_KI7/_1 ! Y8R:Z%P+).1>1L3]%2-"VTRE[+
M;+4RK$,6L-X.&RRQXH9++K"SY%/KK;2JFVZ[[+Z+*[SKQDOOO/:Z6R^^]C[R
M4?^YPOH#CPS.5MLLML\6G"VU\ASE[[A7 <#/. Y(:S#%"5_L0#O]'O1P61S+
M]#'''B=$Q@,5F(SRR2JGS/+*+K<,\\DZ@#SR7"&+W+'-->?\L#_Z(-+%RT+'
M3/301A=M\@QDY!,3SCSG<W342*O<Q<Y.BPSUU%I+_;(.&U\--L\TZTRVV$Z/
M;38 Y_[LQ0Q<;PVWRUV0@<@LW:8MLD']Z!!WWT;3@_?->9]-.,Y&^0STVXK[
MS;C1.2S==-B23TXYVI87+G(_LR"2>..>OYU#W9<;CKG@IN\\^N"D4PYVZJ>7
M[?I!_"C3BR;*H%XZ[JNKSOOK@>O.NS_M7'QPLN%T,53_PS;[(\_$U!J<+#J(
M" XN7[[[O(X#!!,L%EFIGU4/1 @73U'WW^JJC_C68AQ.OXOET\7ZY*\E@\;*
M%Z2/._//[P Y70R$&$28XS7CLQCYUH&(C0FK'_-0W_XL)H/D^4H?7=B>5QP@
MCVY5;X/CFL4ZQ&=!:\F 'AO41_8&5C&*O$,?#",,_ P(P^>U1A[Y\)7/U)'"
M]4EE>HWQASJT!ST9%LP=^K@;!U_R#I_$4'[@P&#DSG>_P]6C"VDIH!";"(\G
M^L6$5I1?3R+2#D0843$F!*(7KRB#A2T0-2$<(A3?R,$H.BR.;[Q>[F!WQ]_A
M<7=VY"/P^L@QH'5!'F0@I#PB_[,9S5RA"YZ9@2-' TFNG&8VJ*DD)2]IR4QB
M<I.:[&1J;I-)4!I'-94<I2E;<\I/HK*4JUQ.*\>S'/W$LC\"\L]^;%D: 9UF
M/;LD#7)\F<M?1@>8Q!RF,>D#3&$BTS[)/"8OF>G,8BKSF<NL)C6O>:%F!H@T
M$0H1-Z/C30O-B#0A0DXXRSG.=)XSE^N\$3FA],XOR;-,5"*3/7]TSS'A<Y_Z
M["<]GV2F+J&)GTHB:#X+ZL^#*M2@#$UHF 9ZIGE*]*$!K6B;='31'%UTHR?B
M:( \NJB/=G2D(BUI2$\*TC=YM$\E96FA[K2F1L%T!C(-E*1L6JB;ZK1/.UU1
M3VG*T_\:_72H0?5I48$:4Z$>E:A)-6I3D0I4IT85JC5EZE2M6M6E:O6I6%6J
MJ)R:*;!F]:M4]>I5MWI6K@:U7O&B2PN/ I>W8L4J<76K7>N*5[KJ521R[2L<
MYP@28Y4#+$WI26&?<K##JB6QA&TLLQ0;%@1(3ZYRK.Q?+4O'S!+D7(F0E[X^
MZ]G0YDNT]R*MOAX!0,#6Y!WBZXE&G+<6V#Y+MJ]U;42\,$;,[@HM0;'M4GQ+
MV]Y>T+49<XEJH5BR )U,N0-:+LJ8"]WG2M>YU'W S"Z+7<VJ+1]DR$%UH_O=
MZ39WO. EKW1U(+KSZ2.\[#5O>RM0-<VNU[WT+:]]Q1L@KQW_5[O9W6T^$.$%
M'9RHO?<E<-+0FXB!5'86@L@!?A]LX/=:MQ[[K3!!?N;=^D)8PQ'F<'V5)D'^
MBMC"?-$<(KJ[L@)[6,7W1>\L= OC_L9XQ(GI!^TR<3L:RWC'(_9'%YH"V<)V
MH88C?HQA'7LP"L]8,8C8R9$?&Y$9U$,A_PI?^9[\K/^16";Y$%^0O6+<Q&3O
MR[&5GF7[T>6N0#FV(7X+/KA"9L;* !$*_I8_WB';.'_# ?/08EW@MV;&RL//
M2_:7/\:,Y->R8![DTL</%XOEUZ(#'][3U9OUC-AOK(,E'.P'(L:1Z5"+!5RS
M2$>B0\VM'O=C>) 6=6H ]U>_YO4N_\)3,V-CFPX>_H4?,\#T5^:<VV\A LZG
MC@@+-"@7W@;ZM>W8LK,+S>-G1QO:.JYV6?I!AKD=DI"6P<QE+L/(SGPFDKF<
MI&I@,YO8J%LWZ4[.;X0#;^7(V]W%"8YSX(T=5[XG._S>M[_=XYWWW+*6!"_/
MN>\#GX3W&^ *?X_![8,?_.!RX@3?#X+B Z$#:7Q!&>?XQB5DH N%7$(5,E")
M3KXA(A6T0BK?$<I?GO*8HVBA#CU3D2I:SYS7'*$\Q_F4?/[/H!\T30*=J-&+
MCG2 WJE'<CJZTX-.=*5+O><-35+4H4[1(]D)3BZ=J4HK!2>PSPGLF$*4V1-U
M]K0KZD]DU_\4V]_N]E5Y*NZFFGNGY([WNN?]5';?5*AB!7A8";Y5A']5X4\U
MVEQ16]K67CRTC041WQY,\I0'2^69=?G)6QXLYI@'D1D/>L='VQ_GBM>L9M79
MTZ\K]>M"?>M7_WK7JU[VKV>]ZFT/^]DC@O6VXI>S?S8/1-!#^,0?OO&+C_SC
M*S_YQ)^'@AMO9Y(L?_K,IW[PEW]]1."#RJ$WR^80<0_.@5_\X>=<^<=O?O*K
M/_WL1_\CH ]_P/QW'E[PKMM@QMP4XW]J,] !9&X5;-7C:>UW?@6X?NB'@.=7
M0X/A.P.8@ =H@ 0(@1!H7+$C>O'7*_S #YQ##]EV&?X'@CD@@B/_R!E=X']D
MX 5D,'SX8#=;-@L9EG_BI7\O$X/5M3)D\!$8V%_ 5W]'4X/C-8,L\X,_Z#(Y
MX'^(P#35 TA+V'W",@L_0Q(IB!DZ,((5<']6&(19*(,H$SJ$-FU?J(3 HX.+
M,3NU<SL7V(0DU@_K@'F;)Q9MUC#XT 7AX(::%Q'AL XYF(8TT0^LU8;9(@-9
M1&I69H<'8S[QESY7YH8.T#Z)X3.#]8>&* .?9UGTP(:%2#'J@ @!-$"1:%OA
M, .P]D9:@1J9UQ/V,T$55(>OE4%H2"X>U%IUF"PCM$'Y<$*K6#[K0&&9=2R8
MN'FYIED!0S"2)Q9Z>!@^%%R>B  L0&<5_^9IY("+:X$\>\@7CZ&,UL*,B&$3
ML:B,H"B*_-5EU^@4X]",A]$/I2B+". 68TB-[.B*8-B.\9@7CR$9E&%(WY89
M[J 9ZR!NZ1!)HU$:G\05EJ1NZ6:0M8$;!:E)L4&0H-1N!)D;K!21J@1OYT:1
M%HF1QG%O%KF1]?$<'DE+ R>2(4F2]($?S31-Y8&2P<22*FD?] &3+RF3,4F3
M,UD?#^<?.(EP-7DA]!$AY4$A&=*3XM1-0CDC0QE.1?E.YL1.+O).0'=U4<DC
M-S=0+"=S1C)S54=S*X<C5KF50/>56BF6.Q>69#F65&=S.I=T:_ET6M)T2Y<F
M;QE2+#67*Y52)/^%4GAYER9EER1%ERK%=5O')UX7F&AGF'1R4XB94XO))XD9
M5(WYF&655),IF96Y4Y1YF989F9G)F9OIF9CYF9H)FJ,IFJ79F:1YFIIY>Z\W
M5[/6FGOUFGQU5[ )5[0Y5[+IFK6)F_+H5OF #C[A:Y$5::(FG,09G''& J$8
MF_#XCN[H*_S0>^^B>J976M,9>])9G=GI+M:I>]2I+RWHG.')F^+9G.-IGJ*G
M.?IP+AN(8I_S ")(!O7 #^JIGN5IG\R)G^29GT1A-_VI.90%C]PEA!O&8AMV
M,F00@.=98D\X"_C0.4-3H!U6A/$YGRVAH/J96?U91/3)H$RCGAYZ+AW_*J(?
M.J(M>)\8>J%Q86.]@&/[>:* Y0\YX&NOX1%OQ _SH XR4$7'B0#IT \)BH9O
MIHBMMA3M@&S'&#[#J19:!FWA>&NW%F9\08A*ZA/IP ] "D7T0*5-P0+R<!C#
MEF=(Q@(+J%VE5FQ5NHF% 6C%"6E.A*+'F#U;2A&+UFB/]J1'Q@(LY##P8)P7
M!(??(@_+]A12QGV"8:9$RJ;*N63S, -RFA$RX Y>^!>R9IN4U61]:FR,UA>7
MZJBIX3Z Q4#0B*@8D1K3J(T[ZE@9DZ(ORJHNZJIORA@-84B%5!GX"&Z9X1G^
MZ$BB81JY5$H(J9 )>9 3N6Z^81OU%F_TEJS(_WIORI%O#+=P#0>M_P:2%*>3
MU[H>Z4&MT<JMU"IQ-TE+-?FM(TEQ(WEQ'X=Q']=Q(,>N03ER&3>4&G(A%3*O
M,&>O'M)R]ZJO(I*O9KES*D=T5#EU98F65.>550E1!4NP4/E0;<F6#^NP$0NQ
M7,*P_IJP%7NQ;L(F&ZMU71<H'0N8=P<I:D>RAVFR)8NR:_<H?L(I+.N8I>*R
MC^)W=,=W>_=W-TNS.&MX.QMXAT<IUME6K0JK0^LP^J ,RF *>R #$[%$7>2T
M;=2T4"M$4=L644JT0EMA_ !:H\6UI=6U6^NU80NVZ?((3(.U9^NJ3+A'O?-'
M;;NV:JM'<6N!<IM'<_]KMZT)GLL)MW?K1V_KMJP#N($KN(-+MWU;N&SKMXE[
MN'OK-$'CGHNS,KI6MY-KN'P;/ "@#XE #SWX.?WG!4CX1(Q+N*-+N8B[N']K
MN:)KNJF+NJ4[.:RKN'-;AK;3NI7KNK6[NJ4K/,0#0>:P#NG0#NGPNSD@O,!;
MO XA Q)315%[+<>C9*]Z;4O[0-3B .H0NC6SC6<D/X?X>PX40HSXJ7E!#[+5
M1LTV8_S 6E([:G(A0 341N"P+?TP8L(XM3+D &:6BNJ+04<*O8;Z0=H[/K-(
M0F1TBP"\+-7+OQP4/LM;O\:F9=J%"*+ZM-0B99*:$,BHO@@P#K &?_4 :AG_
M; X)W([#-L'2B!CQT\ !'(C^4&WZ\ XS@ Z0]! Q',.B\1#IX'EZ<8YFM#_)
MLHZKVK]!K+I#C+M$'+NWFQ?T)P^(8(^TBAF;D0/\Z!F\"I"FX0#FMDG'X4E;
MS$E=O,4.^:L7*4JH1,9B7,:D),:HT9%J?!NV-$OE6I(5YZO/=)+@(4TL><=W
M[)+6E)+.M,?8Y,?1%,A]3,@M.<B&W,?;M!Z*K)3BE)3@U)1,N93JU)3O9,F4
M'$^4++$_IY8+>Y:>;+%2F997@K&@K+"?C,H6:\JBG+";C"6E7$]RF5%Z2<M\
M6<MY:<NYC,N[W)<MU<LOA5,S55.*"9G%C%.HB59C_Y56RZS,S6Q6SBQ5T%Q6
MT?S,U4S-USS-V=Q5V+S-VIS,UHQ4817.8R7.JL)6ZS*;NZG.RZF;['R;[DRI
MZ]S.\_S.]!S/\.PM&GBTRF!<&]@..G&F/"JHHQK0IR8#\W /A1K$5XM=Z?FU
MI@71#RW18AO1MZ*>6,K0&0W$&HVV'+W0&PW2'1W2'_V.^< W'1:A'@9?%BS2
MND5ZWM,T .K1,SW2--W2\+BB+6K3)(T5/X:I=_K3CGIK""Q',($/^4 2\- %
M[= %Y@!)Y'#%FS20.AJF:^8 5AHL_D"( \VD7^BDOF:U91&H!$T174 /:,8/
M3(,/:;V>:LW6^<#6:\TT</_MUDPSI<2) .M B6;Q9K:FI#.P,);%J&3M%'-6
M/6LJIX,VTX?FUZY&I\#B: 2D9S+P#BP=JTH!U+_F?',$IKZVPKQRJ)GM$^X0
MUG+$,+/@#@0DIRP0UO>L-PV:$L(W#_I8PS-0#C(PD%&M25PQI&P:$553C2CL
M:UU@S^F,SS2F;)FMJC>]T\U=T^9)>IEACU[ ;9EQJ^'62(_$JW8\QL(*K.QV
MK,2JK/.&K.3M2OBFK,\JK>O=K=/J']P1Q^,*<=41'^W-WMLJ</-MDCO)W^0J
MQ^EJ<>HJX!Y'X.VJ<2)'E!I7<OOZ<OW:E0_N<@R.<@Z>E:I,4%()RP.;RJ<\
M=0'_JY:LO)4@/K&N[)9&)R<P<N(CKN*<W.$;;LH9CG4VLG4S !1 Z[\%LG4B
M=G07=G WLB?+XRE[*&TGLBRKXT*NLB);LWJ'Y$>NY#H[LT;.Y'T'Y3:;LU/N
MY%2^*8G'0SSMW&BKSZ; SZFU$(AC:@!LBM'HB^)8YG^X+6FZY5H>$D_(G;5W
MG;A'>ZNI>W2^>W.NYW=^G8_@"+;2$I;=YH/^W,Q=Z&YNZ(E^ND=LNXI.Z,&"
M"!FFA3:XA91.Z3JP?8Y^Z'0$2(^.Z)_NZ= WNV<(ZAM]B6E^YJF.ZCTQ66]T
M#S@J ^1 U4V[ZJM8O8*^67<=B=R[9(D8C>![&/R@/\-X02Q U>/_0-7&CAK(
M7DG'GNS.KDEI/@/SH- *T;[B"+]]-F+UT [$SBSDP,& 04'>/ENM6.IJ\[^I
M+L"U6,!G#JDB'"[WD ,,_(<.4 YG?5F(4 ZJ+8MI).C(F.9\5NW[Y0_WX$"7
MQXABE,_Y\ [M<-MLE$.J'HW$'1=R2.Y?I*G-O<-E_@[G[O&AONGM^!B30?*2
M,3?OD$B<X1E33&Y6[$G!"O/#"I$+N4F[L9#=;?,4J1P9><:IQ//GS9$:Z9%O
M7!W^;?3QK=^'O))YK/0VR9-.#_5/O]]3#ZXY&:XR^9-&"91&&93Q"LE(:92/
M+,E'2<DR\I0?GG5*1Y5K/Y40WO8OCLH'_WNP%J[A2')U<$_W'*[W>)^Q+4[B
M*YXEL@Q0@.G+?KF7O'S+AZ_X7%?XC0_,@_GX/6Z8+PM5Q'S,EV_YEI^:FQ^:
MG(_,GV^:G2_ZH._YH4_ZHV_Z967GZ%S<N5G/K^_:L&_<K5^ILR_[KB_3UV9C
M1\L/T< 84^1D02W\A"W4Q1\4+- %]8#KFKYX_>"=V+F=V@G]T__\U=_GU]^=
M]?GQ(<_\V]_](/_]W._]X]_<_ "#!(K^*,V%E1;^[4_^X@_^[[]D.9UC\)^&
M,2K0HIW_6%8.F\U!&P@0Z! ,/# 0P3>#!0<B)&B0(0*%!Q,ZG+APH(-T_
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MX!UG(^0.^VC(0B[O?(M49".=Q\A'.I(C^/$"?>0C#R]T@0SOR$]^<J ._^1
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M!WF8!T2HAWR@V.OR!^.RK:5Y&J8)&[S;N[O3.[KKN\_VN]#V;-$^;=/&FGP
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MZ[ N?U@W?_0_?[0>?SV=N?:'TSV-?_>7?_AW?T 58?^_SW^OX <!XP>2H6*
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M^G";NG"C^JB?NJIW[NF*KNF^NJN3KJS#>@YXP2-843\4:;9 .@#;4TC)@SX
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M1(,XV?L-SWP1Z131R2>9H5,(DZ4:8K_)@[12C:DX$^L#\<Z,)S\7E7]V*CX
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MVR-7\B?,TR;74R>'\B>7\L8\5*>B0^<>(']6[N;F\N/V\BW_<BP7\RXOH%F
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M3L(_O_SU3UE_85LF>O^:: KZ**/^MZA$%>I+,XH3]0R50 0>\(!U<J !$:C
M"4JP@A2\H 4S&*@ *G"#!,P@!1VE0!%"*E2D,B$*2ZC"5:60A2ND'@E7!2,7
MRI!:,_35#16V+1UZBUFS:E:T?F@J70'18$8,&!*+&,0C$JQ:"-MA$Y-8,"DR
M<8I1O*+_%;-8Q2U2,6!/_"*_]B7&,))QC.GZ&,9VB$:2I9&-&7-CQ%+6JCC.
ML8Z.HN,=[<C&/>*1CWKL(R#_R+$\ME&.A'RC(5DF1Y$UQ&,E:V1$.,;(23[R
M(9&T)"8OJ<E,<G*3GNRD)2M2D43D+".[.Z7O4-F[50(OE:YDI2I;"<M7RK*6
ML;PE+7$YRUW:TFIA6T>.^%::W92&1S*81V<PQ ]T!'.8B)D!/G*YDKPM1I@(
M6,?/^L$/><R F+UQ)F(@,X_);"@TU?1F..G1-MHAHFS6_(TNE>:/YO #&KWD
M93SS*4U\[O.>_M1G4>H#'H$>B* /DA!"#1HAA4XHH?I9Z$,;_\I0AP)HHA:-
M*$4+BM&)\K.C_^PG0'MYC\AX81XC^A 9E/<A%*VHI2Z:GHS8M+[NY8A\1,H>
M^FIZ)/#E-$I08A]0J^33H0;52D4-DU'+I-0]^:FI2^U3__[G/T05L*H(O!-3
MZ_14IS)UJ@CT(%A!^+\"#K"L CRKIO#DJ4Q5BE-M)2&HW&K"2:705"8<U5UQ
MI=>]"E%;?/TK8'%%1"UV\8H_I!48QX5%+BZVL'WU(;<.V]C)'JQ;ELV6&<NH
MV<QR=K.>[2QH/\LO'EZ66X2E+!0?EEC3LI:TBA47&CLV2-B>L;;EBBUN:?NQ
MBT'2D1K;K6QY*]S@$D24.+L92)/KT?^0QK-K63.)<Y_+-9A$M[K4O>YRGPM=
M[&J-N]/=+GB[&][OBK>\Y#VO=LV;7O1JE[W272]\VZO<CXXWON^5+W[OJU_K
MUC>__%6O?[UKW_^ZE\ #%G" ^[M?!"]8P09.,( ;'.$'2SB]%KYP@1E,X0UK
M&+NSH,<\QF:XLXV8;X9CP0S<P3@)9WB\_8"'#$H\-QE$L\43[K""(4=BQ#B@
M'0=V\$K"YHXNC,,!)99QXG@,#AFLHPOSZ >0HWR2O&DNR8Y1!XM_?&/H]D,>
M,;8R8M;1-@Y+V<9FUO*9(9SF+*L9S6[.+W/G&^?LTIF^=I[SG>6LYSKCN<][
M?AJ9MRSH-0?_FM X'O2;V?Q<>3B9#"8UZ6!.M#P5.0]Z,*4>W,ZGZ?)Q>M/?
MN\<JD-3I4<^TT]7#7_RR9[]4LYI^ZU-U_E ])Z.ZB=9GY2  <_TF& 6*UPQD
M4P,C2*-@#UO8"X1@L1]8060O4-D*9#:TC4WL9AO;V;]^]K(1Z"@(;AN!-8PA
M#+_T;7%3CX;E)O<-TRTL==>PW=NZ86CCW=J&,?:T]JZW$5?K6M;JF]Z%O?>_
M\1WP@:.6X/?NM[P3/EIZ(UR-"8O8LB N2$+ZD>*!M/C$*Z[QBV\\XQS'(R('
M"4<[AKR0(K>D(Q<Y X,XDN4-<?E"8,Z0EDMRY367.41H;DF%O#R2_SR/N<^#
MOO.@W^PB.O,SG_^,]#PGO>E,?_K2HZ[TJ3M=ZE6G.M0]([QR1(XW9P-GW&8
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M3$*B3#8B3;[D3-ID3<9D3N[9+(Q4Y* 3W#E .72!/.@#'>Y./W2!XO$-_PL
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M]:XI__HBM9$N=9\F=9XZ]9XR=?HVM50K-55?]51GM55K]5-7=5=C]8]R!#V
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M[<<^'[-^@S/X[5MRSK#DT3U\PT.\\$=\\1\_\2>_*,^".ZB=<<![$<XRR#J
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MT)^_Y\S!3V?^EOO@O[J_4[^,VW'[A,O%QS<NZ*![[M"S7W\@R#P ,MD!G"[
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M"D*R3"[D2.X]W3,^IVCDY),].4Z[O @1++(B)W(__;,_ 50B!90_!_0_"S1
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M,F3LN.BNJVZ[Y[H++;SLOHO2O"G%6V])'>7;T'BJS>O >:J-1"^^2&6(;\(
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MFIF9R-B9F^F9G"F:H4F:H&F:GXF:HWF:JIF:I=F:_ZOIFJPIF[%)FY?I#XA
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MZX1$Z.1.L*/.["S)ID/)311$I //[CQ37$' 0!M  RS ?W)3-(U3G)Q3F(Q
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M!-E6L,5<1445PR6?/%7*)J/<LLHNL_RRS#'3O++-5Y&<L\8ZU]7S73_[W'/
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MS>4=__WG/?W5!L(?>O,9'_[?7_X77Y%0WN*/RY'L/^,I?O_OO]\E'B  ^ -
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M9AGFEV*":6:9:)*IYIALFND((F\F N><"0VTUIUJY7G6GFSUB2>??_JIIZ"
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MXLSG<^'+H06)+GWP+A^_A33U^<.7B"!3K$UAPM3*=2!-C@N__Y(M6U:EOK
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MT4,WS732+"L=DLE4FR2U2%6/9%)A=/9U-4DG720#HF(7]#$+,MW9S\<$M?W
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M5AN"?.$%S2G%&6MI!@8:QN&KME:OG99F-JMN/6MJ2:MO5?^KLT*KM5)K:\Y
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ML1M7Y.>/T8:@",A_YQ=:RQNA^F>?,\1"[*<@)H*\]Z$B%Y@B&H);VRN!*)*
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M;L7I6*RNQ>GF\0(>,N8A@T9YR.AB1R]V["*'*X#,08899'C 2"0=8.$!%AQ
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M1Q<&K%)!O-?"J@JR&>*I4ANS83[RI2=I/54F65V5#+CFPJ2.-:UW(FO_K61
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MQ;'LRT]L"[, S+!JB[3,'0 XWF 99;X$"[Y\9$H$:Z_>RK;Z0SY,W;C:I+5
M9E.8)-SM#+'*9+-,JU(Z"[@" /\_>('E"<RY @!3N4Q.*&7>[:1,7,V_6,P]
MT)_2L$SFY<3DL4SE71[+O"2_H@S\7=[(T-]8BHS.C(SIQ<S,Q$SG29_"I!Y[
MD=[(TNC(5FSN:5YQ/D#Q34W,*,7(PJQB=IY.7$W3&-]ECDW9: W61!_1W(S0
M6!]PNFQ0#"=E<FMO?E_X\4OU$2OIO*MR)JWC=)[7J$[%*N?5@MAR:BW6,F?7
M;FW6MHUSEAB)R:#\U,,+OF!\EJW:IJW]S.#Z?.#]9&"1;>"1U6T)BD]WYBT+
MA@\-VJT(3ID#OB<*^BV/^1@.:F"8:<_SO$_W]* #-9#V9$\"19#_'.$$&>@$
M+6$&V1G_-'00%.K9?NSHZ#XJCYHNZ>;&2H;AZC[B)[FN)3%2[,KN[-)N[0:1
MG<:3.N4N/.&3,QX1'(&3B.11/XP'..V%[PX1)NZN/BUO.H53.*!2*(FK[N(3
M&D&FZO)D]&KO86YO9'+O]WHO&64O^&)O]Y8O^;XNZYIO^HYO^)ZO^[+O^EJD
M33B \3HO\U:O7:1#)CV'[CI R+9$I%(O.,S *=V3_39O N<O\A(2(B!P_D)P
M&)'7M4'3Z98NZEIPE6IP-OD#[SXP.+4#6>!N!!L;>>$$/@@;"?M%%TS%%N'O
M!U-1-6[% ><2 J@#L'%%/\Q#.W31KU[P#V\P!@LQ$ . 8;0)_T.)7#A"E$2I
M0P[4R1.G(TGQXSRZ5!5S5$E=L15K,4MQ\1:+%$ .54P)U4"&<4,RI$*:<4^-
ML4:IL5$%$5J5W52QL;_ %D9"F+Z6RW!EU;/84$VRE5%^54J.Y!O_E2 7\KYF
MEV49UEZ=Y'ZYD".[4%0VEA I,EG!EA\_P&/)Q-,8\@,P6&.MBFG9Y)UH<DNT
M9%J=9"8+44VNU7S)Q&8IS)U(F"G#3&/- "2/7UH^P"S7)FO5BFO5,5C:EC#O
MEJ].U6[-96<%$2?;E@D[5S)[UUP>ES3_D759,]M(EW4)T3475X$!@&#Z#2^?
MUU[B7SF3<UX%$8!=C(!QCC>GYH*]<?]ZN7)+9*;G)%AG0MARXG+]_8V J3/L
M"-AIVM [,PU^9=@?>2USY;/B\#*%98Z%?6U"@^U$2W1%1_1%<RW;+*")(<)\
MUD]V9B>2=6=(6UG@>K1VTJ>:;9E]KG1+AR=+\Z>4J2=VTJ=Y#ME]EL_W@'0]
M?+3>UC3YP'1^<ME0@YE* Z@/9L]#N)F;Q9GF)N&<)6@_? 3H-NA7B.Z5$FJ2
M#'$0$_%69_!7>W58=S5+0!&0R, \4*D:QFF-7-I4P!NQL4!X.,5X_%L!)P6?
M^@6.T)M1M"*;DN)J0*FFR<"NQ1N-@O58<W5B'[9BBW45S@AIR  \%"R?=4&1
M]@4.1\5C']S_#+0:4^ UKZD#58RH>20'/3U%JMWI6T9%8 ?)!"_V:U<3EBYJ
M5BNJE]KVE0#JA!0J;==;F:+I;^<V<%>(CS:C/!0+@>B#\K(IO5D(<>M;GTF(
MBGYH"$^(DI8&.<A#,QG(+"CC6IM&P)F(7_G;#&AW<)LW;S?J;>^V>@OJ>@\J
M>]?V>\OW5%PU8R-:/8"<FE JR;D)G,")RJW<5U$QJ!*XJ(8JJ<)CS9EJJ?(<
MK#JXT<5JA,^JA->JTMGJC0"+KF(XVY'KT^'*M 8KN!XKN9!=P""%O78=]A5,
M57V?2!JDW76XB'<XV^&K2,[XU!W63:S*4 )%NM8=NNHKOL:6M70>_XK_RU $
MGKZD;-==S+^V1, V[.4IWRP<;/$I;),S17P=[,5X[,6^WTU\'LV$7K)N[,BB
MG^<AW\_Z3$:"37(VS4X\3<XDY\D^YLO(N2<S!?!=# "G1,SZ^<44W_$MN<[F
M;,Z >'(6W\<>#K'^)L^@CHKGC?:93'Y%;>F@'_DM^J2?CI!CM.*UG]1*;'I9
M+45WND5G]*F3.JJ'V$:+[=E"($]#X-J>IT^S+:VO;?3 K4KS(/# #]\VSZQO
M9][6>GS.+=Z:-$^7 JQ'(-K&8-O.X)IAC_OL>N.F8%'KS_ $80!-[H V!)PA
MX;<[M1(V(9Y1M13:][G#-F*G.[HW-EF\[_^[QR_ZSJ_ZRGLGG=,*@V__2J-I
MN,,E]74>(N\HU<,KMK4DZ8,8Y1$A*?<I\F%KF.(?AO:NB:*0JWN[ZU FL7O%
M:WS&-]H\5 :?2\4,+*.S+05=9V)H7\4PNJ(/^X0M"8E;_-(FW@4?5L6_+P8[
M6?S&K_O.YSS'8ZCR.H )>X4_P.DOUL-4"!LHTKQ6I+ TEM-.#.-?X/Q6#$<Q
M]OM5;%$BSI/.]SS/<_W7OQH]=(&Q(K%"E=P2QXD3HV/+93$5N_T4P[T_QOT^
MRKW<E^H^WGT]TOW>ZSVE_./?/^2K!OY HLH9/Z3A(WY#RDI$ M&QJHI96:6U
M$$LBV7$?);=359+_/C35#Q5KN6XD9W@!(/MP9:+D*!L6#?6#)-LD/#Q&NJ[5
M1>)+@9G$*8?R)J5^K<3FDU\+;6[+8.5^OOHDL5YKK? X9%55U8ADW,F^/LP5
M4VK68#T 8(ILOLA,7PY86.[R(6WE6.:FE_^RQ0HS;7XS6J[S11;S ZBV3,3E
M]]?E,%],^E=F^YOS#/2E_P52XRF,/$@_W/3?#)0640#$O0<#9SPH.)"@/GZS
M$!I\P \  '_R'  30.R_'APXRU]$C0 <#MR8,2(\A >]?-RHCV!#?1%!1O22
MLN$#+RTU\K/8L.!&EOY@.H1H$H"7@_P$PL2HDZ/%H31=*AWY4&?&GC-*1D79
MT2'_4IK^!/F,JK$H5J=3H9HDB^\KQ;$&0=)\2A:NV+=RXZZU._=N7;Q[]?:E
M^S<O8$>(!B<B?+A>*7KSZ)6J1R]QO57WZ-VK=V_R9<V8+7?>_)ESYGNC+XO6
MC.\>OGJH5;->G1IV:]*<*]>3_#CR9<BZ.U>>7)LSZ,NI7ZL>[9DR;<NW(3O6
M;9LR]-WWG"?_C3PV\=&LL\OF[KU[^'SX\MW+!PWU>?70U)-G_WZ\^GSG]4&K
MKT\A-'[\^NGG;ZV??OP1,*,")3JP)0,3U&A!EAA\T$$#(SQPP@8IO'!!"1'$
M$$(.'?S0PQ M'+%#$D$T4<0253QQQ119?-'%&%&<L44:_V&T4<8:=;QQQQQY
M_-''('$<LD<B@312R"*5_'&6?):DL(MO$)CR@"D1D))**]&IT4HL$:AR2BG'
M";*=+JT$\TH$9$C1'WZ0S$B>-+,,\\PI97@SHBCKI!.!+C)R1\XOS9QRI2.?
MQ-/01)-4%-%%'6T4TD,E97321RN-E-),+=44TR07PE,=0?D454X_5_3'2S13
M7=-'/><,](!U;O1GI3?C)#55,]><$9%74Y6'TTN%#9;837/44,%A-\R00V0W
MK/!!9Z5MEEIFD[UVV6RAW5;;;K']-EMPQ0V7W''-+1?=<]4E5Y^CUC70'%@'
M%=74;_E1=<\K9WAW!GQ]K3=<6O_3+;>+4?T55)V!_9G!8#/-41CB=\GE-EF*
MG_7VXHHQGM;::*OUN&.+.0:99)$_-CGDC4\VMM.6E35Q%GFZZ((,>,B0IV8O
MNM!YYBZNR.'G&82>00:B'Y#! 18>8"'IIA%PX.FHH9Y:ZJJIOMIJJYG6&FNG
MK][::[#%GGKKI<F&VNRGRXXZ[0?87AMMMN6.FVX$W*[[;KOGUML!!_*^V^^Y
M W\@\+[=)ASPPP=?7)\&O;![<(@055QQ8P7R&_.E'^ TG\PQ=Q+#QQ'/''+*
M2[<;T406KVI!I3-_I\1\7$<<TED\7WJ68/V>7>D3;==\=\1A!S$LI>]95/.!
M6&"=P7S_E$=(:;3PY ?QYP<Z'D21K*_^J ^3KQY\OP<2?Z!"WV0HIH;@Z?"J
M]-U__\V7&NJ>PO=GNG26FQ"27M+TD0QK(.M+G?L2X;CWR>1$[7-?@]"7OO7]
M2"@-:0N#YO( \S%(?OHK7X<T>+\/)4*##X#450*SED)=:"W8NY#VZ$(_D "&
M+S#T2PEC2,,9UA"'-]2A#&-RD,$,YA&(".)@'M,8R1AQ%8G!C&2"TT31/+$S
M4%Q-9E!C&7Q0$8M6',TSJKB**DXQ-$I,HF.26,;(C-$V8A1C%*THQ2^^$8J3
M*>-RG,/$RY1BB77$HVWP*,7C3)$[6L0'%[W(Q=00<I#?\6)J_Q9Y'EF8!QJR
M@,\SU$-)]CRC/O29CWW>DTE.WH>3_-"/?T39#P !2$ $8MG+6%DLE[FRE:N$
MY2QE6<M7!@DH7]$*4BZ4RUS>TI<="B:(>%E,8QX3F<E4YC*9V4QG/A.:T>3'
ME, QKVK2J1W(?$>@KADH>CC3']RT)NBBF<QP4M.:79K!+MFIDU"A<U3 B@B@
MX"E.R?&2*<04YC[UV<]>\O.?_LQG0 DZ4(/B$Z'M'"9!FWE0A0+4H;J4Z$(C
M2M&$3A2B%[7H0P6JT8QRM* >[2A(*_I1C([TI"$E*5C2.2IPR-.@!4- -[UT
MS7Q$-$'3G&E+$4#.C:84)/V@J96&.O^EA(T4$47=:9]*2DM@QO*6487J5)U*
M55M:5:I5U>I5@30/HO+T&XBXT3I<.B@W%2D?91W53[BJCYKRU!TZ@H<X^70G
MK-YUJUGEZE[UVE>\\O6O1)*9S7!66#*\8V8\ZT(.U,'8'!0-LD9CVF3[UK2Q
M459MEM4L93F[V:;UK;.@]6QG*2M:THX6M:=5;6HW:S;.NM:RKKV;TB8[6]NJ
M[;9)RZW2<%O;WNKVMX'SJ4:\0%O$L: ?S.R'"C5RW.,B91;#6Z87@B<#X"VM
M*M#4A]^LR]T3;H2Z1T-<=\7+W?&.-[O/S =Y'XB4\HZ.#,5$2>9XV0^V)E,D
MY,W<=Y&)'Z3_Z!=QO)P%@,W;WHW@8W1'>^;OS.N ^")%=>?-W'V;20:_%<2Z
MXWL 6I!"D0PC#L/)=:^&,>R0"XNW(">6@8B?Z6&'6+?$\M0)]6",8AO7N" E
M+F<$<SS0BOQX!KE;9OZ@FV,@EP6:1BX(AYO)XY&D-YDRU@@)1\)?E\#EP3.^
M"S[A0N%B9O BO*2+EP% AKN0>2I0C@B54X(4?JCYF%VQH5S0+!<F;T3.>/'Q
M#N?<YQSRT,]\_G.@ 5W#(0H1T4143',6DQAZ-.<QR>'-=9[#FTEW9C;"0<YF
M1)-I-NHQC8Z!-&22.&KF1*8RTP&.'"7=1$T#1]72D76EJ3/K5IMF_SO%T76N
MOT,<U_PZ-N0Q#SY80VQ(ED<]QV;/)N/#'O?H8Y.@Q(\HI^V?_MC7E $:D#\D
MAJ>1H:QD*O-K7@-;;G*?&[#H'G>ZV;UN=YN[W9.:Q<$.)F,+L2!?N6*43.D]
M)5-I%5?Y]O>;9."K,XGU0(#J-Z'@_6YU-QSB#Y=XO"?N<(I?W.(+NH>\&H8
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M0S'40S?T0S541#NTSW[_"!$,PT0=;8P>[8Q0[=1$[1)A5$9AD=,XHX]T4=-
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MBZP5H9%(9&$TX>9(E+\"A-*_/ZBM$S_[-ZS-3SU_N??6K_?8W_?7WQ#KFJN
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MP3U77'375;?=<ME]U]UTXZ5WWG,100"!;_)%X !^]\W7WW3LA1> >?CU-U^
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M9G7J?)68H]2MRBE662WJL$YJHR9KL59J2YV%?=5JK&88[5J7KE/K=G5K=W&
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MY<,0PT.R>J:;T9$=+7&*" 2=13&\2W&\SSL54VL5:_&A*<EL[OL8BW$8]SO
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M6L4.WZG>^JT]YTD/_2D^ RX0'5$0(6X1(6JC#$H_$>KAYHFA^O#A!#3B)JY
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MI&>:T55:INLOI1NMT1S]_A?M_A5]I6F:_NA/__)?__D/__P?_W8*$ ]D/'!
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MWXI+W&(6O]C%,=[<Z@)CD-;!>'-CD(S_9.A!AAXC@@R($'*0A8PJ(2="R(A
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M=[];W/!^-[FO_VV!>>? WO7^=K[QO6]_5Z#? +<WP"LP@VL77)4%5[B!&.X
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M+\U-+N.M+KW-WJCM+_L-,,&-WPHS!P3NWP+N,&> X R.,1]3X1B3X0K$)'
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M)4RA!U&X0N)U4(0O2E\(&Z0@&L;PAN+1T/S(0R,P9<F'7?JAEX8HQ"(&\8A
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M>9_G,S[YF3X,LCXTQ#Y 1S_S@UT"BEUY9Q\#M#\+Y#^8PZ ,Q$ )"J'[<4
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M<&>>B7R><:?(C<S(*@JC+!JC,C1">7?)OOBXFJRXBML%=O(-"!#*H"S*H8P
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MJDBAJM6L%K*K:W%J8YZ:F$*2]39E[4U:>;/6W;15,2&5#%PI(]>XT-4L=GU
M2.Y:5[[NU:]Y[2M@_ZI7P1:6L(>M#&$?H]C _G6QB85L:ACKV,96EK*7+>QC
M)1M8Q [6LIG][&1!BUG1EC:RD3'M9E6+VM..A[' >2UH81N9V=91MH"5SPQP
M&Q?=AB2WNS5+;^$CW-_ZEK? ?0!QCVO<X")7N<UE;G(!JUOH2K>ZU)5N2+ K
MW.U.=[G6S2YXN?O=[FJ7O.>][GG-N][PCO^7O>YMKW??*]_XSM>^]<4O?,>;
M7O[&M[_[]6^  3Q@[_ZWP )V;H)EP*(5-?A$]'A1*2 ,HPE+>$@PRA&&B91A
M(6D8PQ&648<WW*1Z#.M)OSHQB4T,I60YB<7(JI*R\O&L7=5XQM:B\8UMO*TP
MB:M;<@+RG((,9#W1R5WM6M>@E(SD)2^Y7NQZ<I.9#&5Y$:I>F+)RECFE92QO
M.5/\")6MQ.P/,(_9EV5FIJOJE*T6&RM)OGKSDUH<9V/5N<UWMG.>\9S+'><#
M'WS.9;5\[*U!:PM;-2;TM[0E9"'3BU_[&C*CMP9I;:KJR?YRDRQCF>DW:1K3
M^=*F+[NY3U+/L]3_^C1UJB\F P0<@&BNSEFK7SUK!'1!U0"8 :Q7)C)=LZS7
MO*;URA"!3W@B(M:__ABL;8UJ<78AV41K&K&9+6UZCOK,_9CT,_5QCT.@S71A
MBP7"8B&V;WN[B>=V6[G5IFYRHWMNX30$N\,F[T+0VW3B;(2YPR8&>8QA'F3X
M-^L01[G)':[@B#AXP@E..7NO;0R5*P/$61?QU56\<O-V-]E21[K8N0YV'R]<
MQW/7[G2/S7JO Q[Q4*YRW^4N=UY8M[O%4#OCO<YY-X\>SJ%G\^CM7'KZUO<8
MQ$>^[65/?->3'O365SZE>\%X&2>W]<;G]*7#SWU>0.#]!(A  0I0;O06_X,!
M=6"_L2]0[%E_( 5'6$$,QAOJZ/L!V]EN0KJ3T.YTQWC):4=W%'*P[G\G8<SU
M#D(-QI" -D0\#A6_PQCN\(<Y^*$/)=]#P,J@B [@0LGIILIQ"Q[HG@<]R3\O
M^I@W IU]J_?;4Y_N5=[-W&)X"U9L*R$VEM'V:FQC!=XN1S?VWO>_?T##U<;[
M$85HCL>OS.J!+@;1 G*0=R0]R?GX?.KW,?08OZ)<2EF64B)2DG*!)$I&O^]R
M2+(LX3=_^B.)@,&3C0M:1/_ZU1__1PI?;%>$_R//K__Y>_^0KLD!?U&(?F"E
M K0V9O(73-.V/[N'+N _^8/ +G@6?."'?. :;/^#)3*KE5890(6HARS:/Q!\
M@"Y !-'K LO#HA#,(D1PI0&LE5D ,WZ8A:W)-FBZAQF 0/K3OQF8P&?J- WL
MAUD@P!8<M2(TP",TPB1$PB54PB9DPB=40H/PIB.4PG2:PE&KPJJQPBV\M5.C
M-B\$PRX4PVD+0S(<PR\\PS(<"(: 'HFB"(NX"(W0"([P")#(*YJ:*9@RBCT4
MBJ#PPSX$Q#\4Q$!4BJ3 B:,H1*; BI>B"J>P"D=<Q+ XB['PBDFTQ$K$1*]B
M"[6X1*_*"T]\"]$0Q= @1<\P1= X15$T#+U81;5R*U?\C=60C;V@C,W *LU(
MQ5)$Q5T<Q5ST1;J(#5G_%,;(* VD(D;:@ U85$:VBL579$;BR(WCL [CB,;M
ML [MN$9K!(]LY,9M]$9L_$9M!,=Q)(_O,,=R1$?W.,?GP ]V!(]VE!!W5(X/
MH4<$X1#@P\=\U,=]Y,=^],=_!,B %,B![,<* 9%Z5)!W5,CD8# &.Q$*B[ *
MD\@(^S -^Q$?&9(0RS =^;"+1))F69(7 TDF 4E>X9(I>18L(1.53$EKD19L
MZ;%Q49-G8+1(([)W01=!29<ID[*>9#)$ 11)J92AI)2B%$JC-)1-L10K^Q2F
M]!1/H153"3-6&;-,L96HU!-K019?(99>,3%E:3,M,98F&<L6VTJSM"9HB)9<
M_Z(60'M)0X/+;$DT'SLT0@.7NQRR)-.7(@,R17N3>5&7>WDT1W.3<^$'PS3,
M?.DE;F(F-#3#QW3,R$PGCF&9RA2:&7"'8<L81*B'A]JU6/L&&: V1+!,T/R8
M+G"'BZD'1 @:TXPU<X#,C/G,V2S-79/,@E :H@F9IDG#WJPG5T) ;5(3:((&
M?,"'O"FH*%*BY12><$,HUU-.N7%.A=$'N&E#WR$<T6&<@3N<R$&XS5FX@8LB
M0P"=T2E/BT//RJ&WO-&<] 0YCPNY]V3.DW.YE;//EL//WM$=Y1R#Y#F>_W0>
M_W2>[B'0Z8FBVC$ZHPN?!2VZGGN>[U$Z!AK/^G&?^?]YG_R1'ZW['_^Y'_XT
M.P+JN@]]H!%=NZYC3C' (+F[H"Y8T;XC(!?U("4RA!\HH0YZT0VZ41E2H1M5
MSA"J(<7[T2"]H1]E/,B;H!G0(22=/"&Z0\M[&X8"@.ADSBE-MYY!/2F-FU>9
MF"M%&]@#P?^S+>^H/=R[O3$EHR3:HS0"2(,$I?/Y@QQ /N>3T[A(HNR;TSM-
MOA9JOLDXI#YMI.Y;)#?%/VH:)31%04(5I25Z/T1-5$%EU$P"U#O* 40 )BU,
MIFO3&JZI0#^;L4=U ./4MDD#M3)3I@+D!QR<I"[0AXM9&XIAB$N2@54IP&O[
MM*ZIEC\[5$*5!U"%IFS*)C3_ \XKC$W?O,UA-=9B158U5%9B7=9C;=9D9=9H
M==8QY(<N@(A_ QR*JHB*N(B-ZBAT "D[7 G+*RH]--<\1->86BF6:*EVG:EU
MK:F:.JEUO2EY9==WQ5=U5<1SU5=ZQ<-ZQ:FIJ%>ED@J"=0JNBD2L2MA.5-B&
MG2JK@EB'O:J'!2OMJZI07$6TPMA/; U67$9G!-EF;,9@/,9A)*W6"JW3ZBS#
M2MG5TJSJ@UD\E=F8I=F9G=/9P-E9]*.<-5G=(-F?]=F:'20["I$PI:W*(%K[
M,-HX%9&F9=JG-;ZH+;ZI=5JI!:_?L@_LPMKA"A&M/:ZL[=JP!=NQY5JRW=JS
M_=JR_U5;M&TNLTU;MKW:MY7;MEW;N8U;NH5;K\5;N]7;NZU:JHW3$SD1[WRP
MB#1<B$1<$+.1#F-<C5Q<Q[T1(!FQ%*/<$E.Q)"FQD,P1.5L6E-P2&6M)T/U<
M0#.TF"PTO*S)U+5)(^/)UO7)UW7=V(7=*&L7H+PR/KFRW.4R2PL5JZ079K+*
MJ0Q>-/,E2\,56IHS/),S-U->/3-./8->XTS+M"1=0/NSX3RTNHQ+1./>[#W=
MKOFQFB1,(5.T\@W?2/.T3E/=.1%57MJF2IW6^(56R,RU8/N&G0E#9_O,&3"U
MUIS-7IL!:6,U9).UCTE#__VU 28:V+Q-_?4UD8FV9Y7@</\B0EA9%1K$E3];
MA;PSN72*!?N[/N4+81 6O>E,)[=KO^CC8+(A)Q$F-W?P-X#SG=8)S^\TN!I6
M.,,9X;2Q'AIV3Q]&A!1>X4)X.-41N?<\XOB,3]53M]2YSY2[3]VIS^7Y.G<;
M YS#8@?5'NUY'9^#'A<>8HR[XJ$;T ;5G@A%XP?]XC &8[!I!Z>[T!#54+3;
M.A'=8;=1GSE.H#I&N[7+N@@:/S#F@A2]NT+V.T,F("$6X1<Z9!QU9!O]NPXB
M80X> \6+H<8;TALJ4L;SH1E:TLC[H2%J4AP@O;U9&-2;Y#9.Y56NM]-C8U8F
M&U-6I3#6J_Q#6C<RT]S##Q5V83'_($C@NV.PX8*_;5H\#>1RLU.A=3XF+H3W
M4^;%\--$6F5+^M/O4\'\^])'4N6U8;[^RV8=_.8V)>%NON9R]N84Q*)@-@1J
MQF9TSL$')"7O<XT9H-1?.L(A%$)F\M4ULT%\<$!S?F<'Z$$+S#08!)A\KN!7
MQ>9UF 4C;-51$Z9K?H<.](=\7I4$Y&=]^+-Y:.>.#D$9N#&"OL R@T%[=L*3
MAL*41NF55NF6SL*+$=:8YD*8GNF7MNE\$M;YU>D)EE^>WFEI_6E]TH>&B(BB
MA@>+P@@Y]*@Z_ ARQ4-^W==TY<-#',2J)D2KQFI$1"FDB&I]A6J!;8FH@$2P
M'HNQSHI._Z1$2<S$M/Z*M6CK3@Q%[NL+4+387^Q%7M3%NU9%SFC%COU8GBW9
MP 9:Y]L,8.2,S,!KN\[KO!YL9 S:9(1LQ\93P&YLD?WKRW[&S*Y&X=AL:.3L
MSP[';B1'T1;'TB;MTWZ/=9P/=4S'U7;M F'MV'[M]IAMP+5:J+7MXD/("?$0
M>^SMA 1NWCY(WQ[NX#;(W3YNXOZ0W"9FW$[MUH;MV@8.P6TP!DM<&IG(ZR82
MBZR1CFQ<&\'(BSR2'C&2S+41D#SOSCW)]59)+^F2+G')E9S+\J7)U<U)O83=
M_);=VF64H_3OI23*_PYP #=*47G*4#GP3D&5J%05JG3PX'T56O\!F)R,)F(I
M2QI#RRDA2['4%6O:\.*\< Y72QI;RVD!-$&3R^[=7F[QWA0W7[ST2TK#2;Z$
MDQ=?-#E!3'TY3!W/\<+\RZQ9)G0:*"@E\H-2*((Z\B)/* "HF:'Y& :.&H*J
M!YE9J(9Q8)Q9&=&,<H9"A]FLF8D><H,RMI')F6$CFI/AWR4?J-QT\EV+8"3?
M<B./\W(*5C(33FTK3NA,F\U3F%C TK'A<S^GTK7A<XP1]#_'FRE2&#UO&^N1
MB'\+N,2I'.YL',F!',L!3TO'THT3G?,$XM59S]E)GT__]"0F@T$W!">>8OUD
M.2@>'"Q-'_^4]>B9=9W3XE.7TBOVGN[_"1\%-6.BPQ]<G]*PL[IBEQ\X7KH0
MU1_\@?4\SI\"FF-H'U$^7A]43[L4;5$+:N2^P])!!KQMUU$5@G4:A2$@S>0<
M,M(@2M(@ B)1MCP9X *V*?2#.'14EV5K"'7E=**ZX5)$7YM5?9A\BYM%M>6E
M92,P*E-=?H I'68U;:/BEMKH'.:D?>;'8$XTLEGJ8_@MBF;_J^:.EWA/S:0I
M'521EZ0>S563WZ2+5_GOD^<[HF?X)8A?NAH[5\"N^3/C?%0)O*:N"35N.D('
MC*2=":=6/:=A&OIN^J6LB:7CG3&D1U3C]+.N^4%_(4#XS6F?UGJ@WOJ>YOJO
M]_JP%_(J5W.R_T]R.0_SLH?SM#_[LL\':Y7A;*TH.&11;\T!<&UJ&0BI@/4I
M>XW7>V4IJIY7J=9#?S7\HT+\D>HIQ4_\QB^JQW?\Q#?8L;*IJ*)\AT58IY+8
MB'W8S<=\SL]\DZA8G=JJLM)8T:^-TR=]R]9LU@]9P'HKQ\:KV9=]SK)]S\)]
MELW]E4TMUG+9T0+^WG_9X6]9WS=^XC_9U>+]VP]^E$W^XR]^Y&_^WW]^Z1?^
MZ(BM[#]:[;<MQGJN\"HNKHVN[R=_!1/_\P__]/\N]3<P\VI_\3HP G-_!)M_
M^8?_^H___,?__;___B\O_P>(!PX>S'@@@Z! A <+#BRX,*%#A T-2O]46#$B
M0XL9,4*DN-%CQX<3#SX(6=)DR9$G5::TV#+B2X./$#E"-'-F37JEZJW2R=-G
M*9U"=P;=N:I>J7M$E?)DFG3IT:=(G3)==<\JUJOXL.*KI]7KJJY?[SW;BJ_L
MO;/YRI:M=[;KV[3/\MU;2S<?-'W0UNKMF_>O7G[0!!,>;+@PXL.*!?=;K+@Q
M8VB-)TNN3/FRY<R8-VONS/ES9W^6K37V1UKR:=.34[,NW=J::MBD8?,S[:^?
M;=RP==_NM_LV<-J0_^;#AR\M\N+'ER-G[KQY6N/0C3^G'OTXWKM[]^++WCUO
M/K_9\WG/OMV\/O* U_OEIR_P7\'P"\.OS_[__OO$[O7STZ]/_G^#\>-;/[CA
MY@\ ""H( (,(-LA@@A Z&.&#%5)XX8092KBAA1IVR"&&(&8X P((?%,B @>@
M^ TB'[H8XHL>4F@BBBJ6>.([,.J881<EVDBCCRWN*"*#*:Z(HCL,=G&BCT?F
M*".4$O9HY(THUD-DC%@B\B.3")B#Y9 (]A-A;?W,\M]_W75GB"&%M-DF(VY:
M$Z*;=<;YIIUUXGEG(2%:LZ>>>>()9YVQ1!D+GX .6DBB@@9Z9RPAQJ*HFX:,
M,0\9F-)#QJ:(D.$IJ(@@HH:HHY9*JJBHFIIJJ8T2NJBKAY0!ZJ>?SEHKK;GB
MBNNKCP;:*YMD".OI_[#"UEHLLL<:*ZRCE%(ZQB'&;BKLM)Q*NRP97F KK!?.
M-BNH(=F*JRVYXXK;A;'EHBLLNK["^BNCEGH!!+KSUDO&O5W0BR\0VNJ+;A=>
MZ NOJXS"*T; _PK<KPY=--PPO0\[_"_$$R\*[+=L1DRQ#A)[G,/#(#LLL@X@
M&U(PRH$B7#++(+O<,LPORUPRQC4;W";".;BL<\D\S_QSS-[:?"<7.NML@=%(
M'YUT#A7D@+33%<P0]=152UW!05D[((,8!,]I(<%AORMB(^Z:#6@C+_YY\]D9
MLPVH+!W&XBX7 CF @ -Y#[1W0B?Y75(%)P4.N.!_ RYVVSD8OCCCC9^4\O^[
M...P$N4M69X0WRWQ_;;;1&/^.=^A@S[Z0)V'C8/HJ9,.>MZ8"\TYSC*TKK?=
M>K>.M^UYXYX[WFW7; @.N]LNO-[$ZYZ[[I&WC?K=R#>/O/'/VPZYV6+(?CST
MSD>/>^VKBSX#(@<",*:8X\]2YIG]!*@//OK<0T_V\?-N'/OOJ=]/;>B3/WZ"
M.1B/R(("&"%'14B "((?\=;!/S'=YGSX4]]^U)2/X6FO@@Y 1%WP01A]W \W
M95I@ 4-H0!&2<(0F+"$*3ZC"%*+P00MR88A>2$(8:DB& J3AAFP(IBAEJ8=#
M\B$/?RC$(!)QAT8$XA&'F,0B(K&)%\)'%^1!!BG_2A$>74C8%;MPA1QL<09>
MG($,P A&![" C,TK(][0:,8T-@]O;'3C&=LH1SC2<8YVK",>[ZC'//)QCWY4
M(QP!&<<ZJA&-#RCDW0XYR >X49$(8&0B#=E(22:RD9:L)"8?>4E-9A*2G!S(
M)4&)25&2DI$)X=XC2YE*4X+RE*YL)2Q9*<M5TO*5L[1E+6.Y2A;8DI>Q].4A
M$P+,80JSF ,AYC%'!TR^\7*5R71F,*&I2UQ2<YK6O.4U<XG-;6ISE\K\INB6
M&4QQ\I*<X/P<,H.9S'6JLYWI?*<QW1E/8I:$GO*L9S'QF4Q\\C.8_>3E/T\"
M4'\2=* &%2A" ZK0@B:4_Z$+/>A#&PI1AU)T(/VT*$$Q.E"-5BZC#>7HY0;J
M-Y$V=*2+(VD_36HXC/J-I1UMZ>)<>CF8KM1Q-KTI3G.JTYWRM*=]^YM,?TI3
MH,:TJ#4U'$H)JM*_);6I'=UH0G%B$YI0%2E6C0I2AJ)5HDS%*%=1RE>38I6G
MA'4J1QEK5\$ZUJ^NHJU7<6M;L=+6MX1E+FS)1UWA\HRCO,4M=E5+79ZA#[L.
MUB^&=8Q^##.<Q2HV,Y&AS&,](UG04+8RHJEL:2RK6<Q<%AJ=_>QF/2M:T+HF
MLZ*QC6=AD]K3JA:UUI!-<$B3F]G^IK:F*8QV9%$7:&"'MW4)2UJ RQR\]K:X
MN__%#G")&USCXD46<SF/>O2"%^D2I[K2?:YY[!+=[1SVL/(QS'P0"][Q=G<]
MWSWO8:RA'_4N9D"D,9"#F*A$)\JWODO<D R I-\3T?>^+S+'D:J$@"[8UT(
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M\HJ'KRB+KPC8@MT4M7BR)GL5P5BR8N&OC!BP726PRJ$;:T5R!3K) H0_!81
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MG;-=JIB-0PH6(@"0]2)E76M;V?I6M\85KF55!5H=YE9#C$%G9PG+4%XR$YB
M4; R"6,B!@O8G0S%(3YARE^9TA*9/#8JDU5)11A+6<P^]BI'N4IG69(00V3%
M+:,=K5E,NQ:SB$4B8S@+5]H2EM?N!;9GT<ML[Y(8,N V,&0 +59TZ]O(0,8S
MAV$,8WYKFMPB!@B]-8UHFFN:T)P&NK9!C7)C8UWLLD8V)'IN=JT+F^#P1KS
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MVB451$&*6L$49,&)>O^HB#+ 7'G :-&H5YNT6#.8ATDV9".V(%0V![&JGT*
M S"J)/2I)9R!IAK"CW ')9Q")IP!7WL')%1"(OR(IWJI)90I&4@91&!"*CS"
M+U0ID.K"E?I"<]A"?7FU70DU>C*7>X"3A.@PC8D%#@$4/K1#/PP30)P0#7&(
M6#"907P',C")L.BKQO*KG+ )2'Q$2<2)R$*$@CB$2I0LI,@L3I2L2]3$3MP*
M4<2*4?2LK2"(O"*MTU(+5FPM5TPMTA(+N" (UGJ+O[@+6]0+78R,W#(,P3 ,
MC @MR7",X#(N8AS&8?0+94PN9:0,R$#%N8BNT/@,T: NZM*N\?J-;-2N@JC_
MC6W,C6U<#?1JK^-@K^. 1G),Q^APK_VR+_V*$W;L+^FH+_YJQ^^HCH,0@RY@
M#WYLCGZLC_IXL(!D,(*T@/VP#PI#R  !D )1&FYS@#_PPP[;&#T<Q#X,1"OY
M0T'<0XW,R%4(&6O(2!*)NCIILAW)$1M#R1_1D8?P 1][29A</8T@LM=;O;1#
MNX4@DYMT.[);"$?922B;,J%<$]6Q,@?(B"V0N4T9%CPIEJ:L$RMQ%*:<2CY9
MRJI4%P>("*FDRA=[2JSDRC;1B*2TRJX$2Z=L!T\!%3H[&SQ+%65YE5CILUJ9
MA6^)M7&*PUD JT>;0SPC2TW) ;=LM&49M%L)M%KI_\%N24P T =$D*^+\()Y
M>!;$G,QON96[U!5>81524Q6G-$L'^*1R<14^>Y;#E+6#\<'31!B/&IC5[)C4
M],&(H9@?E$W6I$W7O,V*J<TMA$(@[$TA],W=!$[>_$WB)!E_8#:<2<1$Q R?
M84Z?68>AR0%TT+:D^3:,6RF$RTZ%T\YT\QK $;>M.96U*\[A=!A^H)NRF0'O
M!!N^^1OVW$[X')S"41RI49S#Z8)@TP?+T9S]I!S,\<_,T9A9@+G.X<_8F9/4
M05";HQX&#9_:T:".<: &U9X)%9_;63N3T0>?@SLOV)BV*[R; \)9<*"W:Q'I
M>9W]$9E\J% 6O1X,;1D2Y?\>X)&[]J%1PX,['.7)$@71'14Z_$D$C6&AHO,?
M'RW2(66!D%"8#PV@_VE2)A6>_<$8$4(@C]&'+B*A%+681# A =VB*_)2(/48
M!_K2*_52+")3-)6BTJ.B(&/3(5I3.&W3.'U3.:U3.KU3(1(B,]W3,NW3-.73
M/X4AW_NB,4($YTLC-QH^14U4Y6O4ZXL^/G*D[..^Z)/4[0,D3/TC2]543(U4
M1NJ^1AH_35*_35*_3R(E]1NE$9R_$V15&&15@^(_6=4_6GTF_@M :)*F_HNF
M7=557XTF; I6;3I :SC :2K6;YHFNT1 %&P5"R1!:!W!$7S6$O3 5N4G:ZU6
M6HK_U5KJ5H;"O__+U1H<5X@B)V,5IU=C0'N!-?(4SF##N;KSN\DKSWC]"$/M
M@G?0J94"AY6: 7.0@7>X*:X;V'D5O(M!!'?H@NF,*7Z=3G/H JJ"5[N25X.M
M6(J]V+JSV(S%V'KMV(G=6)#U6(D=V9B!M70=-%0J%U0Q!+B:R+H3"!,K,9F-
M69J5B(S]"#U\J[QZMI18B5)QQ,#R/>#[/<$:VJ'%"94((YDPA*] K+]Z6D[,
MQ%!L":8%1:N=VJ@P1=YZ"E+LVEC\6M0*VU:DAZJ%Q;%%B]A*6]I:6]OB1=R2
MBV%DK=WZ+63L1=L@+KP=KKL=+N2B#6?L+L!U+L$]C6M4_R[;\*[GRBO80%S&
MO:[B^,;R(B\@."^_/:_R(@[X*D?-Q5S.?2]WK"]#D*]VK(YY# \!^R_4'3#1
M/=W4+3 %2S" +$@(RP^$S \*F[ *:,B'E($-8ZM"O%D+F5GAK5GBE8BZNME8
M8+$K*\G92TGGQ3$>4\F15$D>DY$@69(8@;TG*8@MJ!'2T]&;'$F@!-\M$5\I
MN;*A1%^C3-\^F;(W(8BQ/#7Y)921G%_[79&"V,K[E=_\W=\TDX$NB+,XF[-1
MX;>V5*<]B\M7HS2[Y"K2S"A=<C1U"I;][0(]$S56B[0%;N &8==]N0A\85>3
M[:ITQ4R]=%9UNH=+NU\\0Q8,9O\6:&'@=IWAX*1A>G57&\;A&MYA9"/9@N78
MCQ59@M58(?[AD UB)/9A(FX01&@'9TN):)NV:I,O;"N:;7/( UD1C6NXARLX
M+^YB]P2<ACLX]R0;:+A9-$YC-5[CF\TD>UN%+MAB+08W%9%C.[:X.\YC/-[C
M@7L'-LY8?=CBP\&X07::06XYCS,YILG8?F"YF'-DE7,YCDOD28YDIJ&YP\'D
M2SYDWWE1NZHX^H%0N\H'HR-2HEMCPA.Z#JT[(7V> ?GC-<8'JN.=JP,[L%MC
MK\.Z"[/E7>[E6O;D$.D'J:LZ8G8ZJ"OF8S9F94YF9A[F97;F9M9E:)YFI0/F
MC_C06O;_95W^NEZF9EYVYJVS*S+PYFZ69G,&.TZK._!QYHPE/'+FYG2N._T\
M9D9^YG,NYQ>9NGRVYH^0Y2719WP.:( >Z-HC:,PS:!Q"Z'^FDAFXL"9IZ"1Q
M$8CNH8E^:(>6Z(LVD8K&Z(C6Z(Q^@(WV:(6&D9'.YX(^Z8-&Z816Z85.:9=>
MZ9=^9V26ND(E5,%:U$5-OIQF5$2U/N:#U$>=5.=[5$D-:D22/NBC5$7J/O C
M&THR/U4IO_+30/:S)VUUOVMUU:R^5F[]UFZ=5;"NU?P+5UM-P8DB0'(U5AJ$
M%AQ$5P>\RW%B5A&\IPN,5KO^)VKMP'QBU:LV06TMJ%IJP5@5_VS"ED&S/NQ(
M.VP;7.L%S$$&9$!<V<$15DS9O.$<OFP>UF'+SFS,WFS/UNR6><,>;):\[!51
M^I4Z[,./!)E8L,B.=&V,A.V-E(A"Y)A5Z)"">(<Q0 F46$3)BD1*3*S@!FZ=
M4(E*E%JC2&ZB@(JDN%KGQMJNY2RM\%K1HFZN,-M7%-OL;D5;K(O1H@M9Y OQ
MWL5=W*W; JZZI5OA:@R]76^Z9<;DL@QEK*["I4;[EL;*@ W4T,;(A5SP\L;=
M"'#?R$;?B-S-A8YXG(X$1_ #'UT')UU[_%P)AW#IZ,<*]T<,KP_XB%W8E=T&
M.\@ 44C<;>B)SC $P>VZLNW9OL@5?_]MCHSMA?C=/-R0$HD2YJT](*%>ZK5>
M("D$,=BQF QR(2^2@P!R[;5)*#D['^=F\AU?'D$2)R\3]47?HGR3,:$RI?S*
MJ_1*+O>3)?=,+2_++0?+0.GR,3]S,4_S/6&$*P_S=#'SKNR"M(0S>IBS4KFS
M3\('?F 5/FN6:*%,;_&6R]P55BD74AO#SD3S%)$!T)S#$VX6N8P6NOQS>GF0
M$0%T:9%T/Q>7$SYM?< S2P%S+K=@P60URYP7DPWTUUQUU)Q-5]=-6&]UU;3-
MW,1-AXGU6L_U6[?UV.1L7__LS@;M8!_V'?8'1%@'R%3.G?D9Y\P!Z"0:ZLPP
MC7//A:OV[*3_=L$)&_;4]O"\A_'\=2#D![6A!S%^3W-?3W2OS_E<]XW#G,9A
MG$*A.P_M L<)'8594?[\S_[<=\]Q'!,1T-I14'^G'8%O40IU4(1_!WD'@'OX
M4-T)TXO9TAFUT-_Y]YB9A5)F@5564O0ISU2&'NQ)TI)Q>(0_>!19^) @>9.7
MT=>YT1[5N^%9'Q"MN1SE45/.^",M'HC_D%:^>9^GH )RT@$BG*WC>!(*>D"-
MH"@MF"F5H"KUTP/R@A?UAWR@=RZU& Z"^J17>!#!!R$-5+ _4[%/>K+7>K,/
M^[)'^[,?^[5/>[97>[@_H)H6K##":3?2:3EBU.7;^T"*5.<[:N8[_^H_HCY
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M/#CQX<:+(S_^.Y9NW;P!Z$O.Y8$#Z@X0.,A>?3OU[@^^?Z\ 7GSX\>;+HW]
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M.J?):A99*Q "$G&J!W"LR@)R-'<\;>E?(Z!SFE*UKSU=7F'O9M+$!G7F9O>
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MJO1#(]#5+Z5J,*TJ7-W5,&&?I\@"7MD&(+C#.O^T0SNX@QZX@SN\0SN\@SO
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ML$$RQ#RX<#Q.1$.^$$-80+R0IQ\TQ$,X! T[Q"$NY3-$A UC)$1&I$<<XN)
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MAU=>K;T[]^^85[?>'KX\Z]G:6]-^[8\?;N&]>^N>;[L^?7\ ^@' SW^_?_P
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MXHPKGOCBCC<.^>0N^I-#%UW,0X8\9'31N1==@(YY%U?D4+H,,PRDND AL^"
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MD ^O.,6/O# A2AR0%U[( B]<*!\K3",/!^1$%F2106ALHT%8, LMJK%!<GS
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M U1 ?#@>CO$1'RFC#F,S#J,;ZM$0P^E!NM'!#HN;:^NB( $@&93![#' R+%
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M][W;G>]X][O>^R[XOP^^ZX:/K'[UV]\!#UC !F:\3G+2OP3[K_(.-F !D\)
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MU<:8S&"*3&%R(6)NX=#PF[\EYE+YS,$9G&1&)F5"IF7*C+XMG!9N)M)TYL=
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M]+F'/_AQ$7WDHPM6[#J-O'"/64!D%K7Z[MW#ZX"X%Z0@=<\'WEDDDKP/?NB
M%^_A#9]XPB-^\8HO?.,A__BM2[''/08RD86<>2-C"LF>2O(E.:E)38:J5*4
M9:I>E?I5JI+UJT?EF&>9YU;.LLQV_B6T=EGFW..>F+N$IN_I?*[>!Y]>W9J7
M\8DO_& V+%G)*A8M:;GG=JUSTH&NIS\[32]%;_]AAYY^-!U=??$G<Y_ZO'X^
MT5_^])?,TIFV=$"]*6JY[%K>]<_UO.E_?_OGG__X]__^_T__!+#_ +  !S
M_PGP  TP 1D0 1UP 1]0 26P 2&P B<P BE0)@2+,NZML#:C,SXC-$;#>%!#
M-I!'X"@KX5+0?A)N>Y#CX%@P!IOC>[!C.C[+M&I0X'#0.]!#M4:K"ZSJK.X!
M-_)!H_K!>PBGIMY!-^XAI?1!!WF0Y-@#LYI+"D..0:R0@+"0N9:K"X?+"Y6K
M0:1+@L2PNF3.NT#DA= P@V0H16#(\1CO\>3P[6P('BZ*'W1(QVH,I6YL2"C*
M"UZ,OA)!I&9AP^;.(MZAPRZL3[@D"3?J'LS$#B5*OL(D[<XJ$=/D'1RQJ!*!
M2Q*AH@I13S1QK#I13II0HYXPBU0Q3.!A%@B130;1HO]"L4SL4*16\189$1=U
M,1=YD4,."1$&Y1<AA<C@ ?,P+Y(<J?.2[/.6;)-"I<E*A51 :<I4[U5RI<NR
M#!MYY<NX<1MA3_9J3\W4+,WNK!R[C_O<;,[4,?G8<9S,L?F\#,OD\1J]+,Q.
MR1S[3-+VI=+<[_@<YAVE)2#1<=&Z#UW0Z6**;_P44A_=Y=+8KQ\[K?U69M &
M!F8J,M1D1B (A]0RL",Q\",MT"-#$B0O<"1-LB114B13DB15LB59\B/?K=K<
MC=UH<B9M$MYN4B9Q<B=ULB>9K29WDB,C)]O0K2C-[2B-,BF1<BF5LBF9\BF=
MTB>7;2JI[2=STBIY\MA.TFK_;D??=,>P]JTS^BT'B*>Q "ZWGB<MF6<M=Z/@
M6, M91 &8V/AC",N5;!\-*[B]/+B^'(OT2<OJ<,+VF((;0,1*&(6WJ,W0$(?
M>J,)&P(/ TCD4JZ!5N[D*G,R7RXS"ZCESA""8DZ$:.Z"'-,A(!'KK"[K3'/J
M?"[H2J@B\&[ROBB'J*CI(N+INN2'/"B(;.044<)'KDXDO. T': (,>((F8@C
M\B$UD2@VN8Y&-+"0'H V+R(1J<@2?\),W@LJ2A%#B),A9E$VK20[I2(1F--#
M1A,BR#,.U1/PO, Z)\(?]J@[%P(^\4@Z&6(](P\_V0@VZ; YOPX\H3.*<O&*
M?C&1_WILR!RED2BE\T"O03TEDT+/DTPOE*J1E%I/&U])EE0I0V<O'&N/' 72
M6G3O]H"O1,6E]U!T'56T'=4E19W)E]Z1E;C1]2Z41FT4'!=F^*B/(??IF_#I
MFA F(-W1^Q+M^PPR_!B2G0QFFMZ%2=?/_*#T2:54_4C&_7P4H"HR_C*R7Y M
M++;*);=R:[9J3,/JJ<S*3,\J3=%T38.03;G*3<F4K-2T3>GT3>LT3L_T3LM4
M3^443O?43@$53^<T4/]44/VT3_DT3PD541=540TU40?U41OUI\!T)</T4BTU
M4RMU4U\24SG54SM54T/U4R4B,@;K,C*C,Q K!!>+!%,#LO\ZZRYEU2YCT+0T
M2WM\,+1L4+1X=5=CE59'"PIW:UAE0[:*-;* ,*64=5DGBC!;@SCA*[5X<Z(0
M4[6F]2">D%A9Z[><R[>@ZUN'"[K D N_,%S-];D0Y%H'@C"CRPS'D+K@E;M6
M! WC%0X53UF';KWH0U^?I+SR\%_I0Q(G"@^%9%]CC$B\@%D/(A0#D4.4%1!3
M3#P=ZCN%1%T'HA_Z<,$H3 ^31&$'@F I3& =2KZ61&0G2A^"DT.\ !\L*L,L
MUF/A*T@^418Y]D->%F8/ F-K+$O:TZ$2 1,5<6<U=L<2#!XV<5F_L\!FEEK[
MT&0/(FAK=FB%%FH/C&JE-FJM-FO_,U9K?Z3R?@P1AK$4&L48@RP9+>ELEW')
MU!:3/"G*5F64K/'*M'%NZQ%#8\_,: ]O/51O!=+0@A0@XXQ%5Y1= #=$RXQ8
ML*R4[L'*5"]67 5NJ9$:%=>4:B7,[NQ(E10B,^;,8LER/;=S05=(B=1OR^4@
M[^71=M3/DG3\+DTB/<UU83=E+C)+^6'4ZJ)+1154=3=W>9=4?7=4@7=W?U=X
M@[=WBW=XC;<HRJ8F8A(KI;(JJ;)YHQ<HGU=ZH?=ZK3=[&T<GG;)[H?)[O3=\
MP7=\Q;=\R5?;JI=ZG7=]I_<JJ9)X'Z,K.1#?>N<#NV LR[)X9HO@^%<N_7=6
M@X,NN:=Z_SZ+?!S.+_LR@1%X@2T., N8.H#SXX!#'PZ3.5S1(MQ!/PKH/!4"
M,C'S@R\SA&%.,STS,VON,U%8.:F.@P6B-%'SA87S@]JPA6#D#</+-2&//P/4
M0Y;N/NP36X].B+(."!]3(R#1ZH!3..63(&;!B ZQ(2A1-?D. (X8ZLJ3!70"
MBWYX((!V0S*BBLGN0]YA%D!V0RSD(V:ABTU$[OHN1Y8X+@ /C8&V1-AX(!!3
M/_'87M%HBU$B%.7HC?W!C]V(C_TAC_-3C^<0D?%3A__3C,7ND6G$:W_1D0SE
M&,N6\\ZV4YC103&IDTAO0BO4REAO&U^/;E/I&Z./S/A6E=?L<O])E)=^ST5+
M=/@&-_A<%%C I1Q3F1RACQXKU'&K#')9A5.&69A;)7+C]AYUJ70G[4>EM- X
M5UE 5YJE670#-TC)Q707LIGCZ9VF]/RJ-/LR[2$!"DOASRZR=".U,GG9&7G=
M^7CA^6<0P1U* P&^87D0P!QFH.G>&7[1H@O>80;, 9_O&0$$N@OJP3#CN9T7
MNI\9VB01H1ZZ !WL&9_-00;>0:']V:$YNJ$]>J.=0GO=%WOCC6HBN@MDH**7
MYZ(SNJ-!^J4?.J9)PE3GUP,G8U5!0S08ZS1.\ 17\*?_%UB%PP4Y2Z@!. IU
M-:ES\%>7&JF9VJF%-3PHJ@N"M3;>N"[_@"-9:[,'+39;H7H'$U,VWD$^^8$Q
M-7@+@\L*QYH@^J$T"P@+]>$>CK;NNB ,[9I<D8LW$V((Q]#ERK"X\L$Z[\$+
MU!!%XGJN[Z$+W+"&UW@6)!8 RCJQ[^BD"B_NEMBQ_V[QX$$?Q%,?VOI#:G%@
MW2Z].JRBGI"BIM8Y-0IB$TP07S%*$O8.<\Q*3-8?6)MKP22EI!.BO*2V 2"*
MX0ZF^F2F*/9+$C9E:61I2S5.1JJXP80,;+L7ZP0>E'OM>C&T!P)E'2 6F?9,
MN'MBTP2['6H7R5NZR_N\S3M(?C$8"R7S+%D9,?E2TA;T-OE!GTRSWK9QY196
MYK%N_3N6ZI%#_P$<'%-9'/>VE?N6^12&ST2WE@DWP5?9P%%)'ET%F:4,]=Q6
MLT!I5#B%PZ4Q&C^9]#QYLZ ,]18W;Z_YS\(9FJ,ESS[7'F&<6""\2-/12!$2
M=547(5=WQSTF=B,2(E\W9ES&(@>*9@Q'IC\:R6$:,69@>0H: 0Z H/$YRIU\
MRO$Y)0:ZRI<GRF5 )^I!I:$<G^OA)6;@R:D<S,_<S*4\*NJAR<-<R]\<S9.U
M)=X!S9=G!H@BSI^<):P<SM.\S^T<SK$<T-7<SZ4< >"JSO]\RP]=S^?\*;I@
MT>-\S&/BRQG=R1%AR9/<I0<CR_6<T E]!F8"U/F9S"7]U \=H;<"$?]2NM #
MW9Y%729>W=5I'=3E3:2SLGUSG:1'&M?3M]?55]=_/2C1]WS-5RD]O=8O'<WQ
M/'+<H=&C?'/*'-27O="[@!ZVC=4_O=JGO-D?9]O!'=4-_=B-?2F'_=S9E]=W
MW=?3O=DT?2;X@3*Z@ QL6M]^YWZ%ARS_3;?4TGG8\BW[%WH"WJB'PQVTYQXR
M&*A)ZX$9GGX4^.$9F($=^#> \X&90Z-+-3?$DR&\H.-\@X4A.^16;N3:XXUC
MHPLN>"2HFC(IV"$2D9 [?H%ZMB4\F#-!$S2'0F='Z#'K(PD90N<Q:.9= C*;
MZ+M;PH6Y<RA25H9 'B20VXH ^2'TS>GZLXK_+ B0.<3H[3@W@2B)51.0C1-"
MW%,B4E:%M[CL85B&=T0CND#K!P*'^)@Z=T0P$7&TO\[MJ=CNR020G?M+\!Z,
MJ_Z*.23E)8*0M)X2I[@BRECO880V[YA& )D^ORCR_9.0 ;21&=\_&7GS+Y_S
MTQOS!7^'6:! O]9L-Z^2Y-OS5)^3U]891WR8J:Q&97_V9(_ R:S FV^50=3V
M<JGW8?3W9WF8A%]P;3F6(49$H2_W>=_UJE%RASG*3D^4[B$93N\9-EQ"K[_T
M0EP:K[_ZK1%O(XW2[ F;6/Q9:A_&S;_%171TRTF;<9S'X2G^O9E*P;F:_@F?
MPCG(R_F<SSDN./W__P$"@$!_ @$0'%CPH,&$#!$Z7/A0H<2&$"M.C$CQHD6*
M!2MV5/BQ(\>1#T.*]$@294F!"+XA> GN94N9,5^ZA"G393V1( 7.N(F@9DL9
M)WL"0 14Z+<N14\:I)D3JDVI,U_N7(D5*=6D47':),K3J;NM")J:93D5YTZC
M$(-V=9L6;E6Y7-<Z)>AUKE*R,!%A50F8K6 9>;G&W8L37>"['=\B9IJ28#VZ
M+_U&9GS69-C,ESG_%8QYLVC-I#N/-EWZ<^C4BSVW/JVZ:6&^E%^R/E@;@;N,
M&1W[/IS3LL;AB( ;GZL8XT#:B',WO[I1>?3IPWE+KW[=.G7MV+=G_^X]?/_W
M\=S+@R=_WKQX]>C7IW_O/G[[^>S+'S>L5R;Y=_E?SF?^FU["L5><<P&:PUV
M^"U(%73TP?>@?/5!.*&$%%YH8881;E@AAQAZJ*%Y_+C311=DR$.//%[ 4V(7
M)':1PQ5=K)-#.C/(<*,,.++@@ P.\ BD PC\*"210_)X9)%(&LGDDDXJ"662
M4C9)Y)-!)GEEE50NB66170[Y)91/3CGFEF9:>::60:ZI9IM!.M FG&P"Z10
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M0'_\3]'CNY_MZ+>X0;]O=^NK7?WP%[K\?9E_ N2T A,(ZD^+.H&,3O2B3^W
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M@\:ZX'>*-UEYM(/GR':\??_KX:/+CUH&]\%/BGCRC]??^_#]3X !)"#W!FC
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M+=B^UEF.71>XWF5;W*XK7O[@![QTRUO?]G:WX9(7;^EU7'N9)($'=.!RG<M
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M#S%R'VL;$2$N1HD*Y9,9%=J1-ZC4RDZV<FZ?8+@E-\$* E #&$2>V\520?=
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M]4\:!= :W<\;#9@.W5$\&[ N-%$$R)][4=$!+=*Y<2Y$D $B!=(CY9Y$PR]
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MIHN\M?@Y=Q6ZIML+Y3!8G?B7I$.*\/^)R/(PU^<)C^ZY.KJPV-UI//CXUHV
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M=JVX>N98CN2HCNV8CO"XCNZ(CO(8C^]8C_AXC_<HCOS8C>$('8RR*/) #_
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MO='FVU*]#:874[[?$3?H&08G.\\N7.Y[4G=D./I:&0A'>V=^,Y5V\J"SO1L
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MCS\^S^3C/P#[][\! I" &_G? 46"0/\I4"0[>6!.5!)!_Y209"46- @$A>+
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MK'7*77.===@6CUUQV1CKB[:]^:K-9KOLKJMKW+BZ&NO<Q[K::-ZWZLUJH63
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M1YF4LS=[N;5;O?5;NB5<Q'4%QC5\RF5\]!=>"/!=W-65Z/5=80F68ZE>9.D
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MDND Y;4*:;D*V'</*ZNR+@NS+RNS+%NS,:NR-INS./NR.MNS*KN9YO=^]C>
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M0/FS&GHBE"J(6,YJ!-.E>?H&,,UQP#P!T 7&,.95DXD57O(QSWY<U"[NG!&
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MSB?-T>20#C(ZD3%B$3.&4C-"XS,F(Q2M3A!-8^[<#C5F(S9R(^ULHS=V(^Z
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MZK'O^;HO]IDO9;HO"^B>5?0#]$9?G!"OGP" ZE%OZLTO@SS?7<!O4/!>>#J
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MX+G6$OI+;,U?/W_\^CV6/-FQY<J8+VO.S'FSY\Z@+?OS/#IS:<VG*Z<631J
MZ=:O'Y^>S5IV[=&W:=O>C9NW:M+ 8_<>[7JXO^*SD8M6+ANY\^;0B4<_/OWY
M: 3?$&C/KMV=]._4M6,7G]V==>K@NW ?OQW\^??3V<O_A@C]<=S.\3?73YS_
M_>_NS">>?P#X)^!V"*"3GWL$-NC>8^@<.$-U%/8G'7D8FN>@/P<BX-U_]A7(
MH#\!KL<=<HB82%Y]"X:XX0PJ:F>.A2Z.B!Z".':Q87$E8MB=C?D56%P]'9HC
MY'Y'__;G(W8Z A#C>" .>6!]0%+8!8Y02ODD/0]V:9]Z2W[C)7QC5ABBF62>
M6>:::K:9)IE8<M<%FM#=$Z=V<[*)W(%Y'F=.F#*X2>=H*8;)XJ#)/7:G=[+!
MN.2,B1K'''C+\69?I9):.NFETV&J&VJY;9I;<* *]YNIMYU:ZJJJMIKJJZ'%
M^MFLLM9*ZZVVQBH9KKS6NFNNO7[VZV7#3E:L8\=2MEFRS'+6[+)W(I"GL9@5
M&N>TQ&;VY#?84FM9M',^V\^5?"J+F;B(1#NAN)9MVRVNUL[W+FAA>ACL9.2J
MB$ZP/6(Y(["=K>;;;?1TR*4_LVBJL)Z(OMGPPPQ726.0+O\F>9^0^%V<,<8<
M:]SQQQZ'#/+((@/PL<D>H\PQ /RXTT477LA#ACQ>O/-R%RZ_O$X.ZN20S@PR
M "V## ZPX #11B/@@-)*)[WTTTPOK1W44C,]M7A48QVUUE!?W?764M=S#SWU
MB+W*/6*3;3;:8Y>=$MMJOYVVVV?/O;;=<K=]M]YC/^WTWWX'WK3@11,.^."(
M%Y[XX8HWSOCCAD>^N.2.4PZYT8 G;;*0FP-P3Q>8.^!./OQPWGGAH0^>>N!.
MJ\YZY:N'GCGLM,]N^^NWNYY[Y9/WSOOOD$\>.^JX%Z^[\<3G_H#L2R]// +.
MIQZ]XM,G'?T#3%^?/>;8-\_]]D7_=P_]]]Z'GWW3XG?/0OKHGV_^^^NW#[_Z
M],L?__SVUX___O?WK[__^5.: _0W0/D5\'T'O%\"N[=  1+P@0:$( (EN#ZC
M+=""],.@ ]=WP %RD('+>T '0SC"#VY0A" TH0,\B,(3EK"%*R1A"F'(PA?:
M<(8W="$.=[C!&*)/@^$#H@(I",((&G&"1QQB$HN(1/[][XD!=&(4 2A%_#D"
M$5=,!!:WJ!6=Q.2+7NP*4[A2$S&*T8MH)&-88))&-N+%C7 <8QRA <8NUI&-
M=Y2C'NDX1S#Z$8^ 9,H?!1G(-NKQC%W,BU*:LI>F*'(HD(S*3B1I&(6XY9*6
MS*1&JN(6_\ 492]F-,G;2E&/L['$)":)"3[X"):MT-&1.8%E4F"YR#'R<2EF
M_.).=.G*5NZ2D7TIC%_<PA5>?L6,:I3C2,("2TFFI2R5Q&1#Z$+-NE1RF7M<
M)%^V.9AN$D8AW+1)(RNYR7XD9B'\@,RNTOD8=LZ"G9!QS#LMX\YZRK,R[L3G
M/>FYSW[,TY^3^6?"Y)E/QQ0'H 8-Z&0..M!^,'2A"DUH/P4*T7Y> "E UK^F
MH1?E#$8CBM".-O2C''VH1#LJ4H=6U*0C/:A*3[K2E++TI2Z-*4K1,U/7+.D
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MF&PA"V"W$MAP7#6P]J\?5N]WO_KG3RKVQ__^]$>5I4:U__X;A___YW^?,H
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M,\,I%K.0)SSG_(Y?S.D6NKRE+6U1#V&6HQYZ J:=AG%G/G4C%M/@ S2B"4U
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M+:E:D,.;Y,C3_M?!_U_T_QC]SW/^A-D-E5J%9^B,SOB,T-@,!/0,91I FFA
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M-N"(N)2&C,A/=2"+/&"&*,GY)>!R2!4*/@E4K:!4654"EN!5)8?ZZ4:#Z!^
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M6WO#99?<??,UU]]^ ?Y7X( !=J#@@P=.F&"%_S68X84A?ECBB"F>V.***WY
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M5:MFE:M8]2J='MFFL%Y2K'JZDYT,A:@NR(,,C_+".]2**$I=809US90,'K
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M>K_/ @4>_ C^ >&/!9ZW3QI>.7QWX;\W!<OWX,>EW9\O6]3_;T\R?M_S-T\
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MIR(VRL(1HO>)X,_/]RP?M/KY[N7';[__??[XT\>_  GT;\#Z$(0&P6<45+!
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M&H1!&WS!R5&=S2$='MQ!'\1!'<3!&;S!(13"&C1"(CS"(EQ")6Q"%!R>X8%
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M%_]%S,2>V$0B6G0NYR-"'M5DA&5%YHA3C/]76T50QO$N;R& <(#  0N! KT
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MT4,IG.4\H.5:IB5;NJ7:P>7948C9S65!'=1 &=2%,%39!119ZF5?,E1,E51
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MRY?AUW?_'AY@:'NV:WOB^Q> T3I_,WY_-U[C.SZM,9ZO0=[B0_ZL*UZS"\R
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M)Z]++; BK]OK*OC0O,HJ#?N:\S,X ]MS,CWS'"S0R08=]+M&%XTOS '_R[3
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M>_WV!8SWK^# ? D?-O^<>+#BPHO1*G7<6#+BR)0G,]8JU:WFMIPSR_4\-C0
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M\ '-^ O-'>M,]$/!9UB%F4A-LUE-U&2;UAS [F.=XH&(!&PR!'0R[,DR"91
M+^/-+[.RW=3-+[.&URA.+ -.X\Q IJ"( Y2( V0S$[0Q-UL):%@)T"S-RX2S
MR*2SGVA!!>2'H7">/<,XZIFW'$D1#G&Y))1$)&Q/]H2Y=DLW^:1/=*O/.>$T
M$Q&1]-3/_D01=K-/]XQ/ ?6+F3N//C&/!/TU!470!2VV!^T39,LYG/.U"(50
M/L'06+M0#;70#LU08=M0$/50#OU07@M1$QW16C./7F/0 W71:$,/&"4/:$.U
M49LY&BW0]]31 85/ NW1']U1^Q12_ 10(CVW_;2T_S=!4OQ44O]L4OY,.2A]
MTBE=T@FTMWP[3WZS4BV]TI3KTG<CDG[#4G@+4R<9.9 CN28Q.?-4N#/]LRIQ
M4S<]N#A%$Y*S4S3%TS?-4SFMTRR]-R^E4DPK4D$%T@&]41DU4!(ET0G5N4)Q
MU-Y@%-_P#7GP.4JQE*/2%$[I@G:(2*1+.ADPF+%S.VBQNEJQEE%=%[E3U;A[
M.[1;.U>%N[43U6MIEL#TRJ[LRZV\RM&RU5S%RU^]RV#]O>(COM K5L1#UHB)
MO&4UO&7]/&#=%^,;OF$UUJ>AFFM-E:QA&:SA5I7!UF^UUJBQUG$%UW(EUW,U
MUW1%UW55UYS15G9EUW?%&?]OI==M?9H(^QH*6P7GB[ZQ&9OI0YM_31N +1OL
MT[^#5<R[Z;#NLYN\6;_[<TP24\'SHUCN9,ST6TS8L0G-M#_)@;_U$0GY.1\2
M+)_5:1SSRUC+*3+MZ[^6_;^6K8?%N0C\2< -1)XI$Y,(U%GE8<89P:<]NT#U
MM)$\&XCG68B)^$ 5_%B>\![I1)WX$1W$B5J(?5C"41P6O+/[>0@8K"B-2J!O
MA*B0$EL<[$(LW,)]7,(>#,,B(B(BZL=%;"2X-<2U;5NT'<(HI%LO+-NS-=LN
M/*5BPL<DLL=J"MQ1S$=B*ER^_4(.FB)_9,1'[$. E-S(I5P^M%R!K%S,O=S)
MW=S_S.5<S07=SQ5=S^4BN87<Q[6D+S)=QWW;-&Q=1-0AELI$3GQ"2S1<VKW=
MVPW%3SPF4-3'W07>W]6EP!W<XJW'XW5%Y(W%9?(FY35>;'(GD9+>L14HZHU>
MZ]VGL;W!Z@6HZ:TH[^5>[MU>8@S'K@W;C^(H;U3?AEK?\DW?;81?]X5'C6+?
M]Y5?L#7?_*6H^IW?\[5?[ 6I[J5>YU7>Q)TEE9+=!)Y;TNW<!@Y=%M*IV\ I
M"%X.2DU(H!LJ3#$J3XE(IIK(BH0JDR3)K.M(C!Q)$3;)$E9AM6)AE%RK%VYA
ME91AP%I)M[(KF?S)GKSAO^)AH/3AG@3B'*9)HB1BH;3+_R/.2V#U2USMU:IT
MXEU]XBB&XBF6XJCLU2L&S"S^RRUF8LXB/+9\RS!VRS&F2S*>RS-&+S-.XS)F
M8S0&8S5^XS9>8S=>RSJ6RSG&XSBFXSO68SSNNR4&9%WEXD"^U0.K8EK!5^9#
M!.=;A60PS("%Y+.A/L1$6(75OZH5OTR63(ME,1 \L4T>O]0,"5%V34_63HZU
MS.S\")$=3?0139'%3!0[S==I3=A\3?YK&Q6D3=Q4P-K,S>T!,Z+U96!&3F#^
M32M+"^2$D.(\H>1$"#&SAIHELQL3P9.(SNC<,?!19<Z$,:PUL_ DBN?9G^/)
M"F:4DG%>TY.+T@ --4HK5!_=4?\!'5)"G<]YSD\I%=." ]0_]5,G%=J6>^>
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M^;<_^LWO?C8I8$&28< $(E"!)TG@3&P200A.4()& 4I-5B&35?0D@\_8X%1
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M+VF20FF4'0F122F0C"2*$96/]8B*\HB-4WF,KEB,N A8O!A869F+B.65A@4
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MUN>S04LV/_NSV6>TT@>TV/=\WL<WX*<V;P.UWBFUX#FUH6FUFYF9E]D[F)F
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M5:6/6Q$6L(,M;&(!JUB_,K91NGKL+'H5V<F>2K*WHBQF';O9Q9:*LY?U+#]
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ME2J4I2DEZ4M-&E/ZV&>F+85I366:4Y3JE*<^/2E0<?I3H38'I?V!Z5%EFM0
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M>(M6XP];_\,V?C.,=5.,>&,U202,@D,XS?@WSLB,SU@5./0W, 1+)I1#M.1
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M[, 9C,%!S*1#[*1%#,1$?,1&+,1*+(/N6[XLP%N(X"A1_%[)8J;7Y:96F%V
MVJ6>0J;F]81?ZJ6N$H5DK,5.F"K%18?NQ<9>W,6?@BJ]PL9W6H;%LJ=UJE[L
MLBV9NL;N8H<!UE_>%<B ?(?QDH?Q]2WVPH?=DB^ J"\ 4V$(XZF'2#&+2*H=
MEJHMXS$R@ZPC0Q"L:C(9<3.A6,D.HP\*<\H)D\JGO#"I?,FBNHE.HXFSK#:F
MV') ]#/C"#JO6:]+_T$WN?B+P0S,PTRM74,VV,J+PKR+;^,V@G0W>5,XLAC-
MTAB-U3PXU'S-6VN3)BF1"NG-X#@ZX S.[KB0Y.S-QQ.1]%C._L,_*#E [[,_
MG6G.\UP\_-C.!?N1!"1!^ZS/^Y//W0S0[RS0MT30_X.1"'F0]9C0F]F9]ZP^
M_TQ!$9U $FW0%<V9#(V1#AT_\&Q $^G/'MW1_1S2-$G2-[G-DFG2*-V4.SF4
M3IFU1+32)7W2D$G3&/3238O3.R1#J&28/7W3/VVY.1W40$U#/(V87UF6B734
M?[G454F69[E(@20W4DV7@V259S1'@CG5A$358D357SV8=QG654W66EW68_]M
MUFF-ULY\F%[IEVIYUF(MUDT-F'5-UX6)USYI1#&=TC+]F!!=T/]XT1K)C^<X
M3+L,3&GWBMF$3*39FH^MFI#-FI%-V9/M#_"0 ]Y4F[<I3N%T3KNI3NC NRB8
M>K@AG,9YO\>)VL2AG,UAO*GMG-(Q4,S)4 0%G3$EG0:%GAAEGMYYGKP-W+/1
M#HFE?.!94@[@#AC"HK-0>K[MW+W=PR 5P,_=GCU:4]EYG04:5$[%4D#EHCAE
MG3DE4U0EWORIW9*QGPFZH#'*4RC<H._]5.Z #QM<HFD")N^]HVHUH1;*5<G-
MWC4U"_< WPQZ(3<JX&N%"&:B(6GRW15*'%N2(1O_,MUWE5AZ1:49RE,C/%0<
MBMP5;E=> %BOU5F0-<-P\E$NNA^4!:$C_E@EOB1>   HSL0SGL0UOL0VCL0W
MSEI2NJ$BSN$^#N0\[N!#;J7\3>2X%<6^U8-57*9?FL5M^J9B3*;D)814_J=@
MC,91?J:Y\N1H',?HU:?QHBV-.BG:4N;4,N5Y:L?*=8;A9:=K/H2!:N:"6JCI
M8J@2]BV1^J@)YJ@+M@J5JF#T]><.1JD.%B^:BN@21F&#2&'Z<&$91JJV6JN,
MF*NG2C.YJF.KJNFN&F0A ZN[6LJAZJFC_JFA'C$>1JNT&LND&(ETNW4,X;&D
MNV2S+G;N.JY:IJUDQJQ?_^:LN=[KT+KK9:;KXMJM;E:WB(OL=TMGCUMU/VNS
MXN9HSQ;K"_NQR6;MJS9L#-NQU:ZR(WOMV_[MW&YJTOYGT.9MA4;NZ7[NAJ;N
MZ+[NT?[NU![N\R[O]0[N, MK[J[O[![OX&[OXE[M_5[NT&[N^P[O[SJT/:OP
M0+OPSI[P# _Q#@]O5V=U0DWQ"U?Q#*?Q&<_Q&._Q1'OQ(!^YD#NY%,?L76OQ
M#;>U(U^Y*$^Y1>>W>2OS:SOSR=ZV<&OS,4_S-&^W'-?S/W_L,Q?T-:_L-Z_S
M.6^XKD[T1A^X3>?TDHMT2;_S2 _U3T_R)\_R5KNT']_PF@OMG-OMQ2:Z8Z^Z
M9?]/NF9_NJK;=G#W=G3G]JL;NZ\KN[%+]W@W"_+P=YIANYS=!>04&NA$&J+-
M>(QG@>1Q><*;>8F_>8>O>8P_'(C/><DQ>OL$O96OP D\O<U;VIF_^0L\(K27
M4 [@@"4Z(>(I@/Q@OP,*?2FB?08H'^09?.*1OR7*^00:??\4??8+^N2;O<N!
M?.UKOLV7(OO)?CB2?]$''3%2P3O8!?W;??J0^MIA?J(W^O,AP"D^^D;BOBI.
M'U9R_+HGXS4250YHHB+LP])G4\X/ #L\)\CG#MR?(CSR_?2QP\)/_Z@%__2!
MPI_E^FQQ)_D/$  $WG/ P@&"@@<3(C3(4&'#A1$A3GS_6-'A18D)*1K<F)%C
MQ8\.0VKT6++C29 F+6;$2+'E2I<L9<:D"=/F2YPS;^K,6;/G3I\\A08E"M0H
M0J01DT)<JK ITD>('"&*&G5JO5+TLF[5JG5>J:_RP):"]T[>N[)BTY(U6^JL
M6+%AQW[MRK445JUX[]JE.]<O7+=CXP:>)P\PO,"#^W[%VG@5UGNK[MU]O-=Q
M8[YV]>KUNK5O7LN5,7.V6Q<TZ-&6*4,N-=GU*MCXGLFF7<]U:\F26^^^'3DR
M[->]>>/VG1NX9-NK\-6K+3O?[&?Y[CF_EP^:/FC/L5O??MT[O^_AL8,?#PW\
M>6C]K(%7SWY]>O/IK:GOQX]^_S_U_OKYFX^_?_[]\/.OOG[B(T\?[!*\+I_M
M&%PP00?UB3 ^! \\3Q\+S<-0PP+YL6^^#_'SQ[[]2-3O1'[TFR5  %+L!P 6
M]_,'1@!F?-'&&FG$T49_>"P1Q?KXJV\6?0@LTKXC^TER22.;1-))):%<TL,H
MD:1RRB>SK'++)-/C9Q80"QS2OA3)'#%(,]-$<\TRV3RS33C?E%/-.-7\L401
M71P113[OW+.?6?1T<<4^"05TT!A53!3010V%45']'F4TTD4EM31 1S%M=--(
M$2V414_O-/3/3"%]45-*3974T$!-;7720UT-E55.3U4555MA7;7675W%==10
M20U0V/\^_R16U&'U3/;$98?ULUEFCY4V6&I-99967V_5%E9LN?WUVVR]#?=5
M5F>MEEMS9547UFG7+===3--%=UQPQ47V4WSOU;===L]]E51!BPW8SX&-+?A@
M@1,F6&&#&49X88C/)#A/(">VV&"*\8SXX88W=MCAC"7&^&)!0S;QY#Q3/G3-
ME=ML6>) 68[9Y9E%1IEDE6W.^6:=->YYY)]+]IEGHG=.V>4Y\:N9Q)EC?IEI
M,IUN&NHQE8Z:ZB^QEOIJJZO.VNNIN_YZ[+#)YKKELM/FVFRPUU:[;;B_1MMM
MNN-^FVV\[]:[[KSYWMMNOP,'?/"^"?][;)CM7%KLQ&4^.^S_N0T7O'#*WX[\
M<L@/__MIJRON^'..!QWX7]%5+#W6>5/O=O5Z6:<WW%YM]6=%&F74\=$=;[]1
M]QQW][UWX'/_7?C@>2?^>..3?Y&>+MPA8QXRX.FB"R_<F;Z+=KI8)X=T9NA>
M!O =D$'\A1!@ 0&DT'?@&_711XC]].,_J'WZY7=_?OOKQ]\!>NZQC1[WW2^
M AQ@_ *(/_,5,($%/!\#W=? !480@A-\8 71-\'Y8?""#\P@!S=XP0Z"$'TS
M$@@)<U1"@9PP@OI(H0E=V$(8 J +#9%@#(D4PQSI0X(6W&$]3IC#'7[0?%U
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M9Z"THM%AJ76TPU)]/"-!,O5.><J#'IP:2*=B@@]/V1,?GM+'&D(:JG_T(U0
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MH0L^""^X_HMCO%MR!_\"!GX#1HCLA[W,T[C#G"7("_$/%_'\WW_\[W\0_W^
M<,#" 0*!! T6')CPH$*$#AM"9"AQ(<6'$RU6C%APHT..#3TBX)@PY,&1(@62
M%)FRY,J-CA"]3 1SYKQ2-6^6@O=.WCMX[G2^^^DNJ$Z=\DH=38ITZ=&B/7<^
M55KSZ-2E1GLRS<K3J%:D49?BI&=S+,Z:8L76*Y7VWJI[I=BFC:MVKERQ9DNA
MQ3OW[%B[>N_R7;LJ[N"]>ODB/DQWL=S&A=FZA;P*7SU\S_)=OEPO\MM2J]J"
M9OO9[6C/H#_C^SSY<V75J4>[9GWO&67+M3-;SG<O'S3,O/7UA@;\M_#BP/G_
M%4=^/#DTY/V:0WON'+KTZ-:>][M^O5]V[MG]<=_^O1_X\N3#]^.'G)\^Y?F&
MOQ<>7U\^]\#INU?>GKF^_>S7\]-/>P%&%^!U_/@3('D*)LA=@PLZB.""X,UR
M'@ 68NB//Q>"Q^&&_0#P88@7C@BBB!]JZ"&'()[W8(,('BA@>@*J1V.  ]J8
M(XX[ULCCC3T"^:.0,MXX8X $SAAC@2_Z<R"33A[)9)13IB=EE0Q2":&6+F(9
M883E29@@F&-.6*:8_51(9IIEKGEFFQ*^26&+<+9X7IQHSBFGFGFB&6:8?-YI
MWIF"_DDFH8*:R>>A>.[9*)N 0NJHFY&RJ&>EC%YZ_V>;=M9I*:*&*NJGH:)N
MZ>>7I8Z:JIFD#LHJEF">VBJHL]:YJ:5KXLKIK;IBFNNNB-J*J7G!:DKIH,;2
M2>NQRA:ZJJJRHNJLM,LFRNRGS4*;K:O/;CMMM]IR&ZZWXH([;K1<<AOKJ^>N
MBVZI7KX;+Y?JTKLJO//*VV6^]^K[X"S] LROP/ONBV"7!@^,K\(!:_EOP@HZ
MC'"?5W(7L;]96@FAQ!ESC'&6%D/\L<@43RPQR!6/S(_#):\<<<M'OIR>RS#3
M+'/-*M\\RX$N[PQSSS+_K'+0.ML,=-%"'TTTSD8OC733,R?M<])#4SVUU4\/
MG;/647/]]-9>=PTUV&.+7?_VUV:'?;;::;--]MI+L_PVVFZW/;?=-<==M]PA
M%UWRQ22O[*[@[7Y;N*K_2IILG[<J[FNOO#H>>8;^K.EAY>2AF+F*F).HN8F;
MEYCBYZ.76/J)G:-.^NFJIVYZZZN'V(4[],Q#!CQ>=.'%.UWPWDX7Z^2@S@SI
MS""#\<8;!%%*RQ?T#?,..+\12=$3]'Q(TF-???;7:]\]]]];'_[VXGO/_/78
MGZ]]^N>S</[U[;N/ /SNS\]^]?,K)/_[]^\?$O[5MP,  MR0 /71/P340X C
M*N#]&N@_!^AC@2-RA_SNIT " D ?#M3? _UWP/_=0X(;,N#_/.B_+@SP@@ P
M(0?_12A +^"/)#$TB?Y"B,$1HL2#*=PA#-\G0Q\6)(([G& .NP<_![A#A4/$
MX#U^F,0;*M&%*30)2I;8#RK"3XI%/"(+$+'$*$)QB/7X(0(0$<8>8I$D890B
M&PE8Q#52,(U!C&(<MTA&.R+ A?>PXQ.5B @6T%&&#!$D%AWPCC9V82$1#.,?
M";G%068D'U;,B"/;QP\I_A&2#ZDD)S-R$8U@))2@'.4G2^G)4XK2E*E$)2E9
MJ4KE43*6FY0E+&=IRUKB4I.Y+"0O'RE'/ *3BW<4YB^)&<QA(K.8R3RF,IO)
MS!R^Y"6/0,0T7^*7JL@#'C[9RD_>092OP",K5<%F*0[1_Q6JD 4L3($'.MLY
M%J6X<YSL3&=B[@*8Q4AF%9YY2V'DPAK#!(8Q .V+8O)"&,%$II\%%:A!U:+0
M@_(SH:+I#&HRXYM58.8UIDD-1UV3#-1XM*(<I0U).VJ;9X!TI"(E:48M^@Q]
M9 :F][F,<:"SG/7P!SK3V6ETJ.-3[%P'&DT:#U&M 9[Q-"FI1M7.4:VSGO[(
M!S[WF0]4^W.?_5A5.%C=*H  U!T#>4<\VQFJO+QSU!9I"'/ER=Q:-R>Z%&E(
M<W$-$5S?RE:UFE6L8:V1-6K4' /YM4;J(9!@ SNDO^8(L7T%+&.SP]?'@A4]
MD?UJ=]!CV<I6EJR9U2MYQLJPA?\ES*P,,BMI'43:3^%54&E5[:?2:MJX=FJU
M:&TM;3MUGM?*%E&OM2UL<7O6M?X6K[X]K6MG2]S:LC:VR#5N<IO+7.:N-KK
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M\]1=#YSGL*&6G7:?O=;G=<3U081T )[V^G.I?O?YGM9[=V=VS',/GFY$:D>
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MK 7)"Z5$ZJ)Z0SZY#T'I$Z3H,Y\B%*5,S)[&Z\/N4\B ; \]*[102S\U*ZI
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MJK520]5:,75#\1"T#M5)411$ RM(SY1<L6S*_!-=ORQ=I7%=PTQ=!?0_ORQ
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MU*O)?_S%63S+-YS+PXG'CES'P!Q5*[S#+7S,@9M;(;R.06O)UKN]KWL_XYM
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M8BGUK%)/*?? :".+,^9HXSTRTMCC*C:NTB./_SKJB&.+-R8YXY$S"@GDDZ4
M6:2-,Q))(Y(OOCCEECNN4J.0/(;I8Y5>^ECCDEBFR>6:5 8I9)11.GE/,D+B
MLTH^=SZ3CYY\[NEGGWJN@L\S=A9**)^#XIDHH'\NNNB?>^K#IZ3Z0%-II?Q8
M"DVFG&[J::;]>!HJJ-"$:FJIHJ8:JC_6K-JJ-:S&VD\_L-8JZZVP0D00KKO.
MVJJO_?##J369ZF,L-/GD<ZFREAYK;+'Z=,JIL)M2*^RH_-!Z;;7:9MNJM[/2
M&NZOK,[J3[8#H4N0N>'VNJY"%>U:$4DGU6O2O2)E%&^^'>V[KZX FZONM]T6
M3&RVW J+\+4'8ULPM_\-1\SPQ-XR'*RXX *;<;G #D2NNB ++'*Z[([\[LGM
MIERR0BNCW++*+,?LLLPPSVQSS3CWRJ[.\-+L+KSS[CRONT,#_7.\*2,M-,I(
M-UVTO$<_#3#145>==-!&7\TTUE!K[35$ 6>]]-=BL\RUN2Z?#7;):M/\\MMN
MQWTSVVG7K?+9/,_M\]Y;]SWUT(!W[;3@@?]M-=4]-YTUXF/#K??C.#N>--^1
MRUWYN9)G;KGFD'-^^><MJ]NNZ)Z7OOGIG9,L,^FJ8][ZP":'[+')'YM;^^RM
MW\ZQZ[O#WC''XN(>//#D_CJ\\<6/:SOMS.?>/._(+_][],(G/[WR'1^/??#_
MW%-/O/3:7R]^^.1;W_WVU)^???KLHP]^^^N['__\ZM</O_WRXT___?SGW__^
M_@L@  >HOP+^SX "1" !#PB_[U7O?0DTGP0A^, *.O""WLL@]C#X/-]!KX/2
M^Z#S1BC"$LJ.=R=D'>]&%[H66BYO/=M9XF8HN,4MKG!.XXB\/F(O'N*+7C_L
M(1!]2,0A&K&'_](7$I&H$G\U45]/[%<3IRC%?OF#'COI@CS(  \L9M$=1.G"
M.G*0CG6DHRE/<4I4'#".-89C+ =P #C8$L<Y8J6.=+Q+'->RQSSR$8Z K$H?
M!QE(!/3QCGJLBP,.R95&6L61D'RD)".I2+@X,BV7_YRD6C(924Q:\I.5#.4F
M0;D7J?C%E*7DI"0]Z9Q'"J>1K\2.*UD92U&R<I2VU.0M=ZG+7MY%+KI$I6<N
M*4S-0+*8:YPD,I=)268JLYG0?*8TCQE-2FK2FMB\IC:SR4WE5-.5WX1E.+TY
M37"64YSG)&<RUVG*=J*3G>]TISKE"<]YQO.>]LQG/?=)SW[BDY__]*<^!0K0
M@0;TH 9-:$$72M"&(I2:Z5RG.2%*T8E:])T75><V-]K-CG+TFLZL*$9'JE&N
M/,A!*(40AE*4H7F@*$/RZ)!,/42B$4T('A+J$(94M%,,::E-65)2F]A$U#0%
M]:A(*E*9K+2F'J$)J3]]ZO]0EWJE,XT)1D.J*E"1M**D#E6H;!*3F(#T)4$=
MZE&, M2@\%$/.X%)4&TE5%S7JJ=[.(I09MU3HNQ:5S\A2U/YT!2F-%4L3PUV
ML*1*+*JD52IB-59<KQK7KG)5PQT:CH;P"MG"%A:M9A466J#U[*8ZRP]]C,JT
MT<I6:ONQ6M,B[&+9>BT_,#?;% IL5[--%VX/DEL Y)8B&[F(< D2DIO$I"8P
M"2YO<2NRV1+,M:R]%G1;>S'JJE:ZU<VN:K7+VF#- KJEXL<L8NN/\(XW6+1-
MKV91N%O=NO=<[87O>W,KW_K2][[QQ>]\\\O?_?K7OOT%L'O'VUX"#UB_!I8O
M0@S_C! %9Y8A!7[P0@8LX0;_=K@39G!#+KS<#'.X(!_6<(1'3&$2.]C$'^Z5
MA2%<XA;75\+NHB^,9QQ?&.M7P#B^L8X#+.,:^_B_._9O@G^+8 0WY,@L7C"2
M,[QD)2<YQ%!^LI0G?.(#\_C*0,:R@HNLY2#GN,M@SK*8OSQF+YLYS&1.\YG+
MC&:0,7>^MWW=FU$89SJ_+G8C.V]MF^LZ/?>9O.CR<Z!C>UX0HW?0WD6T>!5=
M:$'/RM&&WG.D_WSH1P/:TI6>M*(IO6A,2UK/H":TJ!--ZDZ;FK:./O6H]ZSJ
M4J-ZU:$N=:Q-/>M:P_K6LL8UK75MZUS[>M>_[C6PARWL_V+S^MC!1C:QE6WL
M9#M[V<]N-K2G+>UJ,_O:T<8VM;5M[6Q[>]O?;G:D&XUL35L:OH.>\WWKO&8U
M%YC+5@9QAQE,Y"DO.,1-SG>2EZP1BE@D)1,)+D<$ O"3%)PERC6NPI&[<)LP
M_.$.C_AQ)1X1+WH!'F0 RCN\,)2B#$4=1\D!4T8N ZB8O)5HF<H!LC*7LX2E
MY3!WB\N]@I>: _.7.,]+6_XB&+\$9N>)*65A@@X;Q11=-JTYNM(_DYJF,_WI
MIG&Z:48#&M5$'>I57WK28Z-UI'N]ZV#G^G5PXYO:_*;L9/_-<(S#=@2!9^W!
M:3M=B"/+YL!][@8*D-OS3J"]^_]=[]^!)6\$/\_!:X?P[#3\<Q#?3L4?A_&0
M/[SD%S_YQU?>\9@OO.83O_G&=S[RE ^]Y46?><Z;WO.G9SS?5__WO@/>]?"Y
MN^SM3ONZVSX[)SVI2GG*^Y5FB$,WA:GP*^1[GK*HJ\@WJE>9A%4R.?^J.A(2
MEZ"J?.:3]4U;&I)3E__5L)8)3'2JZE+'7]8:68GZ1<U^69WD([+&:17)H"ND
M^I2G !E YK_YKU50=#*K_ ]E?T3Y?_[S)RF!12F&]2D%R%B*-2J+M8 *>"KE
M @WEDBNTLBZ4Y3%0 RLXE(&5A3S;P@^.]2S-<BF=!8(@*"W6<H(.PRT00S'Z
MTSLFPT(S)$.' _\T121$4&1%..A#)^,[&.,PJY4P'7A=FQ4L0?@P+!@Q%X.$
MX+*$ZN."N&-G4&A;K0.#48AG4_B"6'B%6KA"6<B%6P@ZE".#D\,T81B#9O@S
M8IB&-G0TF,6&;MB&<*B&:'B&,42','2'93B'>@B&J=.'?/B'IN.'@?B'>$B&
MAN@UB).(:S@U=@B';_B(>5B'.^A"D[@Z@UB(?*A"4@B%5-B)70B(J*.)E.B)
M6[B))T2*7IB*HFB)K%B%=_:*KFA"(>1!M#B+MOB$M8B+%,1!XS-!%J1!))2+
M3LB+Y;.+P%B,O[A!Q]A RVB,ROB,"Q1!TAB-O3B-"G2-!!,]&=.#VGC_/MN8
MC<KSC4D8CMY8CMUXCN38C>C2@^M(,.TXCAICCNE(CK'%CO,8C^B(C_?(C?L(
MCOKXC_P(D/X8D %9+AOCCP:I/0<)C<A(C+[HD(_6C,DH/K*HBQ8YC+J3D2 $
MBZ9HA;'8D:V867+HB"0)B28I-?9B63881"Q9@RUY1"^YDBXYDS Y12 A13=)
M13I911AQ#UT 1EOD$T,A%&$T1F=T1DZ11B?G36]D1W3AE%T!E5LAE3>G<U5I
M2(GT1UII<SGG1WBA2F!)2KSD463Y46692YWD2ZMD3FP!&ECAEL/TEITD3Z&1
M3'59=>ATE\,44ADE423EER45F(#I46.YEEUY_Y5J&99H:9B,J9BX])B%Z9B1
M*9:)29EI>9F-:9FSI$RTU)F<^9G'1$OC-)A\^9<.I5"GR5 /E9JLN9JNB9JO
MJ9JP.9NR69NMJ5!]69J"J9NMA'B;&9J@^9N9N9B269G$J9G%B9G).9P(H" *
MD@@+$ITLQ5(\-9W"=R'$EYTMU5/5V5/'5WU"Q7PZPE3=5YY(U55!%2/F=R7I
MQWWMF2-997[D!R?K69_LF21(U9[B.9]@0I\^XE;ZQW_(TE=JU59.XE9S=5;\
M=U9YI:!WE0_WX%<#.*"7<H"$=:&,U8"I BJ.U8"1]2H4&*(TI(&7)9.2^%P*
M(UHD.((LRBFD95JCY?^#TH5=VU6/LF60. J2[D9E'Z811=02!M=P$T=<(DDR
MLA5=0HBD2MI:,YJDT\5=3RI;LT PYD5>WZ)>?&:*ZK:E;"9G7LI>7^IF8<IN
M^<5N9-JE.YJF-T9C[\6F+_9C;^IB*3:G+%9E6X9B1]-C;0JG>AJG?MJG@)JG
M@IHX@8JFZV:H;19@;JIC9VI?C=IND,JG;[AB5+9D*C9#E!IC=4JG/+JI@ZJF
M//:HB8JH8\J1L<.E8 JJI)JJ8LJJ9@IGL.JHJ]JJM/JJLOJ1'JFCNIJKO&JJ
M1DIGGW9IYC9NC%:LX:9KG):LF[:LKK9JKW:LGD9NSD:LLO8MW09NP_:LXF7_
MK83&K<'FK=M:K>)*:^ ZI>,*:N5:KK"6KN>J:[ E;.]JHZ46K[ %K=A*KS:J
M9_BZKZO&K_/:KZX%KP$KK]AZK0;+;0AKKP>KL E;L V[L [K:]0ZL;%&L<(*
M:5&(JK4ZJZ-ZI_%FIYQZ;_LVLDQ&LOYVLL-E$41:+PGGHS7I$D%:7#)+<1 W
M<38KI HW"_DP%!?W$T%A%!XG1B$W<DVQE"C'%V*Q<E4Q<TP;<W31M#+'E59Y
MF%0[M58KM5@+&#ZW<S_'%T3'&D*'&$.7&5=7MEF'=61[ME,G&FR[MFZ+EVUK
M=6H[MVF;MF&W=7C[=6.W'&EG=G[;MX#+MX+;';-W_WMT]WJLA[BME[BPQ[B.
MN[B0J[B2V[B12[F3^[B76[F8:[F<N[F>J[F@F[E'.[ITYYPH=5+:F7S?V7N]
M]YVNZU,]19U<!9X_=23,)U;:1R;RV21;)57I>25.DG]6]9Y4LGU<PB/@%[S]
MJ;SXM[SC9R1JXE6Z"WUM(I].\GU>DG_P5R>"TJ"1,BEII2@!JE?AFU9H!8#/
M((#IF[Z"9:$(N*$,B"H:FH"H\H 1&*(@FBL 8"L580WY@H&QHH$8N+__JSC$
MDZ((;%@O.BW#PL#5,BT.(S$5,\'8V(4J1#:$HY(MZ2\WR"\>#$0VPX$4W# K
M.,)'>,(CG(060XT8Z9&HN/^*E1C#+SR(-(PZH.B'F#B2=X@W/.PWC5,VE<6(
M06S 0ES$.0S$8=,U/ZS$2*PT3=S#=^/#9B.(-ES#5+PN:M,V5WS#7'S$0XR2
M)*J(3#S&1@S&5K/$22R)7&S%GP-#C@/#,US%<KS%;%S'<[S&=VS!HZC'K2B,
M&AF,M]C"@'R1?]R0$@F1$UF1@FS(#,F,C>R,U5A!37C(E/S(DLQ UHC)U%C!
MFZS)G/S)GAS*F3S*G=R/\$B0HES*J@S*I-R"$CG)EHS(LES)D3S+L4S+BOS'
MN;R1N.JK,LS'.!R))KF(1%S,80PX-&FBRAR3S)S,S9Q$.7B33)2#5=3!3L23
MV)S_+_R0 T41E/0 #U\41EV0%#. E$G) FH$%6T$%6\D2'(T%U*)1X@4SUGI
ME8BTE83DSOJ,E?O,2/M\SYCDSV=IEMHTF<=YT)!IG FMG)19EZG$%\SIF< Y
MT<+IFQ:-G!B-T :]T%<K%\7DT'$9TKLYFKQ9TB1]TA'%FP0]T"R]TF9ITBF-
MTB(UTC%=TS-MF[%YFSA-FSK=TSG]TSP-U*0IT[E)U*9IU#3=TDKMTF<)TS?M
MU$6=3KF74HAP(3B%G=O)NMSIG5NMU<8'NZH+N[_[?%92UDYEO/@)GO IG[O[
M5>)9GF$E?FPM?MS+5F)UG[ZKUCL"U]4[G[@+H'2U5Q)*_Z#DRU9K-5<)&M@.
MNJ![)=AZ\E>5,J&'9:&(98#SVU@9VJ&M\EC(0X&2=4/.'-I%FI J6%HN>MHQ
M.EH0'"VHU:1+"J47$UX8DZ.9IJH>*V+*)7 "A[,U>Q,K>V='.ETTVETU2MS&
M':7$_5WH5:7HY5I8RFK/[:H<.]VV':G4;=VJ.F0=YK%D1JG>76'@C:?RUF*X
M7=Y1UJGCS=V%JJGHS=[N'=YRZJGHG:F+^JG8?=]:5M^$JJ@=B]]"!F\@:V\;
M)M_?+=X%_K$A6V'^7=W]W>"QNN 0[N ,?MT2'N% 9JN'>JN[*FF]W.&VQ>$7
M&^*D9K$C#K&0=N(B'JR5UFHL;O_B#_OB#!OC$3OC+B[C-4[C,([C-I[CQ3:P
MP>;CX@7DRJWC1'[C1L[C2+[C2E[D21ZQ)*[BG3:L0W9N%%[EZKW=]3;>]#9O
MYRVR)?OE3@;F^I9P*'MP !<2+0NSO$VS;'ZSO?WF;2X3 L&S&*=Q1@%&0[$.
M0[L4:+1&)N>T2HL 2<MR45OH3^NT9H'H65NUB][16PO17!OI8COI1D?I89NW
M=ZNW9ENWL<'IK>'IIT%UH"YU="MVF&[JFI[JF;[J>YL<@>OJ@]OJLNX=A2NZ
M;U=[I"MWM7ZXO/ZYMN[KG1NZP?[KGW=YQ4YZQSYZREYZJ-?LH+?LR<[LS\[L
MP%[MPF[_[<0.>+NNZ[C>ZW$'NE-MNL0G(K+[U6%][K-K[K/[NNA>NWU-UE3U
M)>(W?=%[NS02?E!"5+F+56VMGF:BO<(KO'&BV,[;[UL55682)_(^)>S'O-N;
MO76]H $(OHV"5XI=V(S]?Q)?O@+8OI]E@.]+OR(OOX\%@9M]OQ\Z@>U"6?T[
M.(8SP-)\+P$\62?3C0]\\R;HP B,@B7L, H3P4>X03K:B<.LP3^:S?B"DREY
MHBH\A#_?\U"/POS(A -YC,*XJ[Z,]1X.S''\RZ6XQU__0L)LPUZLQF5_]B69
M]GM8]G:\Q6A_B#J<QW)/QW./QW1_]SDS]H=8]&/8]W$/]XT(__A[^,9@KXJ%
M#\? K/6;V/6H6#.('_9>;_@AR?64#_F,WZM;#XNZ[,>\O/F![/D3R<BU3,NB
M7_H/F<H.Q,JK?/H"9,NK?\KM(XZR+X^O+Y"P[SZSGX^H?/NY;\J];_N_O_NS
M_X[U&(_$?S'&3X_C**_NN/RT;X_)#_S/7_6\/_W5K_O4'_S93_NN;_H49*X=
M _[!(_Z_0O[?3SWF7Q#H#XR[/,B"G/GPK_BC.&=FK_;V7_1@K$,ON\RBS?_[
MW\P T<^?/P ""1HL.##A084($1)D"!% Q(D5!TK$:'%AEW9=Y)&!YP5>EW==
MW''L<B6'NASI9LB *8,%3 <L'(QS$/\.03@'X!#\](F@YT\'/X4&+4H4J=&A
M0ID^)0K5:52J4ZTF/9!T:E:H7*MJ!2L5:U@$7(N&/?LT;=2U3MNFA>M6;ERZ
M<^W6Q6N7[56Y>]'R16 3JF"J@M<:GHHXJ6'"C!>?;0SYL=#(E.DJMCP7<\W+
MG35[AKNYKU[29 &?-AW7KUJ^;T>K+OU:MFO:K6W_Q<TZ]VK>L6OO]GV;A=_A
MFHD?-YX\-''0;C<_;R[Y\_30T3-SONXXNW3LW;5[Y_Y=?'CRV\UW=VX=/??T
MU-M7=P\9^7+ESN?;K_];]_[>L/W/OHV_X(#[3[_^ "10+D<063 1!A^4IY0(
M)Y2PE'DL+(7_'@PUO)####<$\4(1/^PP1!(Q+''$$C6LIY067RSEGE5>G#'&
M&%>9448<[[D11@U__!!(%ETL914;9>011B5K7+)%)%VL\4DD<5P%GV2FQ!$?
M'.O!YYE\GNERQU6D9#)(,UF,<LPC;:31R1B3T5++'6^4LTHP[_PRSWORA$;/
M+K_L$A\NP1Q4T$#O/!10+_'$<T\O]X1&GSZ?D512?B*%YE)+,;VTTTRAZ>?3
M4"\=%51K2+4FU'Y2-755?_I9-=948;7F55L',NA671UJJ%>*>(W(5H%@%6C6
M5?GA9U1D,]6GTV:9[3399O7IIUEID:T66VNSE;:?;I--%5QO_4E6_Z!RR;7U
M7'[29=?<=M'M9Y9A%Z+7H8KZN3??@_2M]]6$S(75GW!5_;9:;PV^MN!MJ57X
M8%#YF67@AV=)=MV*R1WW8HT#5I=CC]T%&&2,158W78Y-)OGDD$=F>=V576X9
M97AC?OE=F$NNF62;=]:YYYF'_?E=H&_F>6:B?3[:Z%?E;9=ID)U6&FEAA:9:
MY*&GMKKJH+/F>FNO8;X:Z*[!UCIILXN^6>6HUR9[;*S91CMNJ>=>.^RIV_[Z
M;;SWUEONO.D^&W"_ X<;:;5QICEQQ!<?W.;#'T\Y<J,AGUSRM"UO/&>V*;^\
MY8\]?_GSC>,=G>*,14<]=-5!Q]AB6$UWG?_TTV6'N%S83:?]]HIU]Y;WVGO?
M^'?7A6\=]I&-WSWXV\/U?7G@GQ<^8NB;3W[ZW9FO/OKLI==^>NRM[_W[[L?G
MWGGR*SY8^/3-9_]Z\,]_G_KXT<]^??JAMS]]_.O?GO_]_X<?_6"7/P'>3WW^
M4Q_#!JA ]#%P?@ <8/\>&$#Y45""%IQ@!35XP0UFD(,?]& (,3A"^>7.=M6C
MW?%*US',:6YQA\M<X0I'L:8=#6HNN^'2AD7#>.W0ASH$8@^#Z#2G_:N(!CGB
M0)+($'P!JU^_NE=#HK@O*%*Q(/S"EQ6S>$4M8M&+7?2'O+HP1GC00QY>*$E)
M.C+&=:PD!^AXR4O_:&(3.G[%* CX!E$.8)0\"F6//^DC6 +)E$$2I9!".:0#
M$IE(L332CH]$C2,C"<G42.6.6KGD'2UIR>)HLI-W_*110OF33I9R,:(\)2E3
M&9A5-@:5I'QE8&)9&5:JTI:UQ"4M=3D96=[2E+#TY2R%"<Q>%K.4HD0F,8\)
MS)HDLYG,7.8S>RG-XE"3*-'$IC.CR91J<O,KW;SF-\-)F7$^TYS51&<YTTE.
M=IY3G>]LYSK=&4]XSM.>\L1G/?-)3W[>4Y__[.<^_1E0@ [4H )%:$$32E"&
M'E2A#VWH0AT:48A.U*(2Q6A%,TI1CEY4H^*\"CC;Z4UV3K,X"UK0(Q"A_](%
M72A"*@*1D(@T))J>R40R3=&)9"K3%@W)26F:4CW&I*8L4<E(<TK23(FDI#49
M=4Y,Y1&6BH2C&QV5JO=(1I; 9*<X/4.KBLK3HL)4)2I%M4PUA=&3J)35H<[)
MJ7@B:Z"X&M=%A=6NE*IK7>=ZJ#\QZJY_S6L^)J4/2F%J4YOR5&)!)2K&JHJQ
MI%JL/R++*H&Y*E6UNNRK++NKB0CL(KFJ%:XN$EH 6*.SI VM9PF2VER)C5B7
M/=:RD!4MVF9*MK>-;6YMJUMLG4I<M'HML5BHV941B[C'%=MGE?LK7VGD(0JY
M2&>#U=K/#<RZO<4NN+*;6]]R]V#&LFYP@5LL\?]6=G7#->YPSY7>@+%W6)]S
M[W'5VU[ZOM>^R*TOR^)K7/[FM[_W_2]^ >Q? @_8P )&[F<+C.  -]B_PFJO
M@H&&JP@#&,+OI3"&\9MA!A.8PP';<(C[^V&#\%?"FB5QBD5,7Q4[^, N[O"+
M2\SB%<O8QC'&<8,OO*L(?_C$U)UP@GT\Y 3?V+5&7C",E9QD)B.YN/"%\I.E
MG.,F4]G)5L;RDJ^LY2Q'6;^I8]VL6"9F,I=7S.<Z<\#23-Z5K=F\8U9SG,=K
MWEBQN<YT+O-XZWQG\,J9SV8&])S[;.<\_UG/@]XSHA4MWD0S>M&"#K2A)5UH
M2CO:TH>^=*,QO6E-=_K_T9[.]*=%'6I2<WK4IBXUJ%&]:E#_5M6O#B]P71UK
M6*?ZU+5F]:UU;6M>YSK2E2:TGX&-9V$7.]B;)O:QD[WL03.[NL]N,[19-]_S
MYG>]7KZVD7=\Y+<E-[FB#?*WWR9:<N_*5[=Z8KJ=N.[FLINY[U9W<Z/[7(K,
M&[H6N3=$\BU=C63$WQ.AQSH\0@9YT ,>8T@C2KK@1I>@(R;DF.--<C+QGV0E
M* A RE*4\A6-6YPJ7MD*64 ^EJZ0O"PF]TK*31[RDK><+6:Y2\SS4I<#&6A
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MT7$ON,.$75A'%U:8CAG(@.4P! G,_ZTH,@<@>R UISGA<-Y@G3M@YE7Q^4&
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MXC+S[4 %"T300 <;9%!!"">4T#(*+[1PP00'K)###0VT#D01'10QP@\Q!)%
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MO7(6K<48;_(8X?,]C85:Z@JU= 1M_"D_ 6H_\]-M$(7A",IN%,J@$JI %XI
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MZ;MF -[RBLJL1$&.CKC^B[.<T=TNI"<[Z]W>;;40X6XCR['@1MZLBW!5!=Y
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M9;,W\&10%HLQMU%-D*N]571:A.N]^[M6N#LP&9S KT1C_N2[K42Q5)2)=03
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M+S_S+1_S-,^D-<_S*YJD)__S-9KS.-_Q'V_T(0^E2&^B&#_Q36_Q6^/0FQ=
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MP[LKQ)D[Q!W+_K']WW45X%=E9$6E7(1+$:,26+G5L5!9%;8($/SZ]?,GD.!
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M?Z9]]J%IGY_UY7=?_7S2KY_^^>WG'YK_T2]^^*M?^_K7/_HE$(#^LY\!&_C
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MY0@ ([>JL6Q6ZPBP=TTO?NKZ\.S?NX^OGFD_D_X6UL=XOU]^_OO[_1<@/_X
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M6(@E(QA:*7B"8/B%8AB"-5B%&GB!+?)<SO^UAIUR9OIP#]4U7;+R*M@U*ZL
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M^&L=^4L=UY=]V,>_"% / EH/ GR' DP/!*Q=!YS !CS !1R@"/S "RS!#JS
M%=S $3P/B,5^WN%^%/K! 0B _F=_(.PF!/A_5%B&*GR%!=C"!_C"+IS"5VB&
M-JA5FW(B)8(B1;@I25@IDW(I/]PH0.S#1/Q5?:(H2'PH1ZS$33(H3)PH3UPH
MC^+$4YS$5:S$,&R -+S%*ZR%7#S#72S#7AS&62C&4O\8PU><QDNLQDULQ6O\
MQFT<Q50,QU#,QE!"*49<Q) 2Q)8BQ'Z,A#Q\PX(<5H/\'LN%"*!RR%&!+;YR
MAZ5P78\LJ-B%AWN(#[L"B/G J.0%B(F:7M8B+=$(+= 8,^_R,MI"7Z7,B.;"
M+0*VK/S%+/AUJ6KFK)+X7_G5,FVSJ>IBB; ZJ[DZ:#E9J\QK/4C+DL-,M-U6
M>LT(,LYK,=5;,=L;S=H[S<$J,M;<,\Y<,J9&R[L<:3O3,18CS>2YC.ZDK<98
MS;(:R^/B7M,XRE?38^7:RHSS-?3\-W-DCWZ$SW/3$';$C8,S1O[\CGT#CX:C
MC8^C.([SS_=XT  ]$PF]SPS_'=&%@SFXDS<4_9"W$SNT$SHMF[S<-D!!^4$;
M_3H<7=(DG8_!\SN_@[O @](N-#P@/;,>G7D\B9.H>),SG=,=O=/("Y0UC=,\
M+=-!K=,]7=18>=0.&99=:90DE)1^T]17R9M(/9527=54[3D4&=58G95<7=%1
M74(U9$)=Z8XI]$6DE!!=I!!BG4FRA-9F;49-!)EQ/==B]$1P7==5Q,]Y'=>3
M&4AT?=>7Y$EM/=ALW9=O/49\39EX5$>,S4AGY-AI!-F+]-B4'=F5K=B.F=F1
MB=F;K=E]W=F@_=FBS=FC[=FDC9EH"9>J79>G*9NNS=J!W=JXB9>T;9NY.=NZ
M*97?__/3P&F<O?V;OKV<R&F<T1E-SIE-R"V=S[G<R&V=1Y87W_08W?G<V3N^
M2G-.C3'.VFV>Y=G=ZB0/77!/HP$/^\2^_Q10 R6?M3&_"26A%+2?]P??[^V?
M_ F@!PS!^'W?^BV@^<W?^VW?_AW@ #[@_0V@ TI2_.-2$EI2"WY2$_K@3EC"
M%>H !E=E % /$7ZA$_Y348894:8/'MJA.N6A(9I7(EJB**Y41@6G.LKB=^I;
M+?KB=4JG-$ZC-8Y<-FY63M4%%EYE_1#C,@KD-]KB;MJFB$!E'MX%;%KD3*ZF
M7WJE8#JF4A[E5 [E5IZE58[E5PY;3M[D0<KC'EX9/ZY67?]0#QX^"^+GY;_1
M!4A.9;, XW$:Y'$^Y# ZXSF.XWANY\,EXT).(H?<7&JH%N32R-H%J(5>*I3<
M7<4B+(NZ+)HL7N:E7I JJ8ZJ8-YJC;+L8YJ.Z3+3Z<R*KI:NZ;>\Z=GH8:9.
M7YD.B3PFJJL*8<JZ,!36ZK8:J[%.Z[9ZK*Y.ZUL68[P.8[KZ%:[J,4CFJR\6
MK+[>%],*-!96%R/FZ\V.[-!>[-)NK,3>ZZDZJ[FNZK@Z[,2JK4_V[;UGX9<A
M[F'>YKMW[-TJZN#J9>Y\C>=:9J/ZB'F#<NW:<0-[[_V*[U9;K_K:MGU'M5/K
M</0><_3^<_8NM8'F>$PKL0;KL$?_^_#('/% Z_ 1S_ +3[$7K[0N4;-+$;*=
M9VP@__$B7VPC3VS49K(<+[2N-HK #K,>S[(C.VT>^_(Q3_-"S4LH/[0VF_,K
MK_/TUK.J!LQ+"_1#7\Q%#_$3G_$^B_$6W_1,__0-?_!B"[<L9^^$I[L[E_4>
MA_5;+WA;=_5>3[EB:_4$G^]F'_5.K_ ZU_7Q.GA?#[F2&_=PS[F7>[F5._=K
M=W9Z;W9\_W=O+[> CW:!O_>4B_>3>_AW7_B*C_B**[I4[W=;&[>2'W:3#_EG
M^W1CW[O!R[9N.W$UY[6<G_  G_9*3_0J/]0P/_,A/VS/RS"?)[VD]\W*_*O7
M6_O>*\VW_T_-W[O[LP>^X)ZMN&?.PL\9_!8:\$!\Y+V^_190RL=\]$F_TR=]
MVZ=NUM&_W/>_XY?]OD'!K<+]#!R@W6_!X=_ XP_^WU_ YW]=$HP(Y.#! 1A_
M\2?"_T?"(4S"^X< [M#A^K__'3X0]8 / ''  0($ @DB&%@P(4($_0 \A/C0
M(,&!#B8RK(A18T:.&SUV[!@1(K^%'2EJ/)DQ)<.5)5%Z;'G0)$R:,VV^O*F2
M)@(6.GGZ[,F28%"7.G,*Y<BBI=*-3),NA=HT:A>1#_MA=(I3J]&M2+L6]<I5
M;%B&^:H"Z%+SJ\RU,=VJ'0M6+MNX=,G.?>ORY%ZO?/7V!?Q7L/]=O'#O$D:<
MMZWAPD?!4JUZ->6[LP 0)6:, ++(JXXQ>X[Z5.IHT:6QAEX,>BA0UH=C/D+D
M"!%LV++]\?/7SQ\T??GRU;NWJEZIX/56!;]7#]^]Y,N=WUN>#YITZKRG7Y>N
MS[IV[OJX7]>>?;L^?M#*GS>?'GWY?M;8NS</OQ^_\^35WZ?_OA^T^>?I\[>F
M/0$#[&<_?KSCS;[U^!&P0 ('%)#! "<LL$$+*<2PP@<WU'"^"SO4C<$0<[NM
M0'\(/-%$W$9D\382=8.11!%+U W%&&]\,4<<9UQ11W_\ 4 W(&$,4L<BA_SQ
M2"6%7#)))I]T,DHDIVR22BBME++*(G'_K)!&+U'D,$03A23QQRNU9!+((0%0
MD\T@W6S3H3;7G!-..^6\4\<!UTM/N_+\M(Y/0=,SD#]"#6U//P#W\] \!OE[
MU$-]&IUOEDD9O-1222N]M)],._UT4WXTQ91344EE=-1.(9V%P4A'=37560+$
MC=96Y]NM4EI3]?#57GE=551>8V5UUV(]I+7$6G%U55EGDVTV6F:GQ4W::E6<
M5LQKM?621VS%!+?;;)WU=EMRL3576F[+%?=:6,=5]]91;75UUDJ;I1?7?-V5
MMUUQP^V11QE5'+A%@0V6,6&$%W;18((!+OA?B;T%^-N)+:;XXHHWGECAAC\.
MV..0(2:YVX@#_W[8Y)(/]C=CES&&F>.792ZP7Q%MKKE>G>_E^5V?Y05ZYY^%
M#KKGHM_M!^>DXV4Z6Z6?;GI;J'E>FNJIAS:::*VSYAIKKTD]&NA,8PVU5+,]
M-=5L5,M&V^>VY7V;[+3C/A548=D>N^Z[]S[;;E7U5EMNM_/^FG"P!1?;:,+?
M]GMMOMN&W._('Y>\<LHO[QOSR3/G?'//+>\<],\U;UQTTTE'/?341U>]==9?
MQWONV/]6NW3 &;]]=L=IQ[WVW!4'_F?##2>:^. 3%_[X>H=7ONNPM_X:^N>=
MWWEI%V^N5F601>:>X15;51A\%L5O6'SSO_\>1O/53S^W6=2'W_WXD_^>_WWY
M[W=(2/OS__']-Y_\GY/<A"<"#M" ='H3 @NHP ,FT($+?& #(8@G(-VC"^^@
MASR\  \O=,$+[NA""-?1A77D(!TS.*$,5.@ %LB@)TPY"$*^<9 9$N0 -#S(
M#0E2PX+@T(8^[.$.<PA$>MQ#'VYZ")"2"!$E(M&)380B$Z6X1"H^T1_U0$01
M@9,.BN@0 36TB ]+ D:9D)$B9I2A7]#H@#6N4291K"(<G:@/O["%($^$B!T#
MH\<8+J2/,>1C($\R10#0<2B /"0B81C#11X$AH]T9"03R1-)4G*2D+RD(Q/R
MR$UJ\I*=7,TG16G)GXR2DZ;<9"I#64I6!H7_E*X\Y2M!V4I/RM*4D(&B9##Y
MRDKNTI>]!&8FA<G+8?X2 8B HQ>,24QF+M.9P6PF-)]93&E*DH76Q.0U$ZE-
M2W+3*=D$)S8)XH4C+M$=W0SG-J<936JVDYWO7&<\>XE+)NKR(/4@I#_PX4YC
M>@&.LY G/ROI#H<@49FUC&5"$;K05294E:U\*"QG"4N&TK*A#*W-;&*ST3%5
MR#K($0YQCK,*?!SG&<^13G2@H=)\/",\+@7/=F0*J._4M$_XN0^@SB,?0O%T
MI^]!CT[CPQ[UP <]B5K4A((Z5 #Q T,I4FI3I0JA $UU0E#54&[:HU5K8/6J
M#LJJ@TC45;&"E4)E_]TJ6;FZUAAUE:Q;1:M;3Y0C,_VH3#[BDEW)M%>]]E6M
M=07LD<HD6  "]JY\_5%7IS17*ME528Y-DY0&B]C#^G6L<XTK5[/ZU\H:%K%L
M2M*<0AM:.]7)M*6%$VGKQ%>S$G50K\4I41F%*-K.EE%5%5!2*24A^AB(M[^-
M4** ZY[A]I:XPD7N<95K7&0Q=[C-+:Z$H!M<Y4YWN=%-KG&UB]U=5?>Y8 7O
MA\(;)O&6E[SG!9%YTXO>\9J(O>IM;WSA.]_WUA=9Z\6O?.T;WQ2%"T4STYA6
MP]6E&1&XHP.VF(%AE."8]?=+%ONO>R$,HOXVJ,)@FK!_,_Q@FG4XP  &<?^#
M0^SA"-=HPS,JL8-1?&():]C%'+9PF"[<8OI2>+\UUJ^-\XMC'M_8Q_F=<8Z%
M3-T=_[B]T@4KDHD,W%@=-S_]B96K>AOE*?>JRE*.,I1_]60J9YG+4P8SEK7,
M92N+^<MF#O.8TTQF)D^WR55.,G6OC-PW9]G);L:SF<NL9C2+F3Q^3O.?M2SH
M)Q.ZMX;&U*$5G6A&#SK0CP9TI!TMZ4)#FL^7/C.FU[SF/6?:TXO6=)]#/>E1
M(]I3EJXTI4&=:E*SNLM;GC.;Q]QI6NO9UJ,FVZ:]'&M>[]K+6P:V=.T,[%V)
M*+C&+O9]8Q5G9!/[5\SNT+*/'6T/0=O:TXXS@>S_A61[@5?%+?ZPB,7-,07G
MJ, 1N]&8\+KNO+;;1W6-T6*O--DLG<G>]<8WEO2-IGSS6TU9BI-J'XO:T[8I
M'R&D!SPR.(9W7+ +(&P'"7.@CAR@8P8JQ+@+'3 .!X2CXPX !Q!Y.'*1EUR(
M! GYR1&0\B\>).3 @<99FAB1F1.2YC+'>56 E _D .><**=(RDLB=)D0/>AU
M1/H>DSZ8O53QYCJ7.3_VB ^G=T:/";D(UE6S]9>(!$@D60M(/C)VL9>=[&<W
M.]?KHIBUJX65+'$EW/42=U6JA"AR1PE1)(J0O;.P[GT'O"J[4/,@!3Z4?C_\
MW2NB>+Z#A/&(3XKC)=^4_\D/Q"Q.1$OC*;_YR',>*Y7_O.<7#_K1BU[SG4=]
MZ%-?^M6?7O6O9SU69$YZU\?>]K7'/>1AG_O']Y[VNK\]\#6_&21:'?%>?TA:
M@N][AM 3(IUA?N=+B?CI2]3I -!\]?^^_<1S?_IXM[M)Z+Y*O.]E_&T_BFQD
MDXB-VH9B^\$'<$0ZG)X_!Z7X4"E+GU&=ZH1GIO__CC])$*$20#XAP$")K004
ME/\X$-BZ+]QB0/7X#PA)LI]R%/V@$*;*#PPKJX]YJPUY$1UKD1CID>Y*L(BQ
M$8\!P1%<-WBK+!;,J\!RMWCSMQJ\MWV[01OLMQR\P<YBMY3!$<_:08!KH#B1
M(/_4HJ C9"!YTRRCRJF;@BT'/!3;LBI%R:W><A3?@AQ(@9W5.1W7Z11B 38N
M%$-AXQ5C&<,T/)LL7)5#VZU?X4(T-,-D,<%E$;84N<,ZQ,,]Q!=J^;9EX98(
M \1G09<_-$1!/,1"1,1%5,1&#$1'),1Y4;9MBQ!*W!<\[!=HT9="'+%P\S"7
M.9E07)EQ\\12[,13Y$121$69$47M81D0:\55-$5X@9ETJ<59_,14K!JIB1H:
MF9[H,9I]V3:@$<9B#,9CW,7^(L:<T15FE,1DU+8^A$9G5$9IO)IJW,1=',9Z
M != Z+\QQI\11J+IQE_L%;@)0R\T1]<1G"X$PW-4QW;\PM=!G/]TE$?-F<>S
M2<=WQ$=)<<-&,YU]/+6^\4=! Y6 )$B -,C("4AVS,=U9$AW5,B'Y$>(=,B&
M7,B)M,B*Q$B)E)QZI)O .95X3)M?#!OC <:2%$GI04GJ44F3W)IDQ!Y:'$6'
M\9[NV9Z97!CR09_P(4'\61^>K)^?],G<V)+].1*BA!+^P<$!$B K4<HEC""G
MG" E?,JIC,I^R $0XB .\J"&@SB).Z$4PK@6>B&CX"$O*DL@,LLA4KFT_*&U
M/(@B.B(YDLM\HLLXJDLWX8=[T*)[F <90 BV#*.3"\R60XHV4J/#+$S$'"._
MD*-VX(LNJ(>"DDNK6[JKL\S*Q$REVR/_0C(D/Q(DH?@C1/),OB E1D*DTJPD
MTU2DT_2EB7)-4ZHHBKJHV;2HVMP[B&JHB-+-W.1-W/1-6'(^-M&EW;3-U[2E
MXU0HVI3-XH3-8X*C+EC.@(*G:A*HZIQ.ZY3.[*3.Z[0D/,(^[<3.[01/[AS/
M> K.W%!.XTQ.BQJ\*0(H]8Q-]4P(.;K-^B1.^^Q-_/Q-^$S/YF1.6U(_C<HH
M!IL.Z!@ID"JI>S@IZ%A0E9*%_?,-WO"-_9L."!4/FRI !*0I_'!""\S0 R1
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MFX*]6Y%M1,9T+W9)'!A1V\US_<Y4/)IR5*5,)V.F+'#F2K.L)8_L['%UZ,(
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M'!#$Y23D&PDYP'.,B! D(D2)"& B IP(12DF\3E3M.)SZ'$/FZ"DBX3QHFO
M:!4QLH<]6E2' ZXH$36FL8IK=&,;FWC$(A:'CLU1XG$<@,?H[-&.>11C.^IH
MG80,)HR"C/^,7Q 1G>>,\8LW*4T=72+&20(@+,4AC#X$J9 P.I*3P7D. C@I
MRDJ"LI2CI*1 ZO$<%I12(ZU<"$)$TLE&&M(XKLP+*FDYD%4>1#,E000K;8F
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M'ZP& Z,EHBH03#90A][L @]#+_PO!=_"2U!P!050!3L#!F$C!EUP !E0*;K
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M.^+&PI$()+DC(@%VP>2202)@X7=(!HEC@+/ B&07[B#2HG4,2HGD?BQDZ2(
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MF9 (&9".'NF0+I&Y4>D0B2#M>.F;KNF=+I*?OI&@OI*BWHZC'NJG/NJ_"9/
MR>JK[NJY">LX&>NX*>NU+C'0,C&W#C&YSNM7Z>L*TYK!_NM&.>RUN90+PY3'
M+NS GI:**9J:">W/ONS$SNS OI;%KNS8GNS;CNS=/NW&SNW?GNW53NWE#N[>
MKNWH3N[G+N[AGN[M'NW-'N_./N[F7N_L_N[YON[WCNO]ONO^KNL.LYM'0NL%
M?R2^3&D:8S8UPYR?!C3,N9S.N3,XTYS+^VFNQC32O#1)<VO3?&O;B?$1IYX3
M1\[PN3;L.6SK@_]Q\BF?_7GRZ%E)>X,WEDLXCB.@_IDZ#OJ?J!//%IIM/B^A
M!MJA#JHWG/MN0P_TN>-5?&/T00_T$#H[#0JBPK/T9D4]O'/UOS.Z5S\\U7.Z
M-@KVJQOV*OKUU@&CJ5L]U"/S;J/R%/?1'KVD<:^DT-"D4-KVVO,^6BJE\U1*
M6:JV5-KWK.3W?C^F9FKX8)I @R_XK%3XB+]!8HMT(O1!D%]"DJ] B(KY>YKY
MW"JHG?^LG@^L?NJLH4^XFU_ZFH_Z'W-WQ-&TX]18"& .P_WZB@7[2-3;MP>N
MUE /U[I8Y?KYMT_[P<]8R-8/9^WZ/_44Q^WZCF4?P2K[S!%(O;_\T[__3?0
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MP(0P0-< BF9-"-4H#84VB'O"PH/&P^5PZ8B>:-*X9Y,P0J!8I6CF$I-NZ;M
MZHD>Z:&>:JFNZGJ&C=MX0>2PZIK6ZD;$:HGNPT9<Q"'<:K/V:D=LY_"HHN]H
MZP]R:[9^:_"(:[K>Y"@*Q2L:#\KA/>&$123JZU@,[+\V']4I;,)VSN/\Q0G1
M+=_A8>U\;/#<3L@.S]$9'P^!'B@V8BI^'DS-+AZA!WC01O B$F\$1W%4K_0R
M1RE!Q_822 +$Z,R09H7_F)-JAFW9W@EZE,<1G$?F \CO<^V"_&W?;K&#/)3B
M)DCC;ESEAMS'1;&'?.Z/U,CE;NZ(K&Y0(<S#S&[!?$F2[.Z2]&[P_NZ>T>[
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M@B-5I2,YNF/2I,OCU(JZY0MZ?0J<G%FZ;)P]]L.A@4NTG.-XF K!@<LW'(Q
MUHL^K@P:>D<^<@L!^6/2L,PXZL^2*62B557.5(P^[L^I1&3% "2I %M!(D!
MNB-W6"1)>@L]M..L7&2\L&2PO"31K.-&7@NN^(]Y.-RQL(RG[$FGT.- ;$J;
M?&2Z1,OW!(K.%.2RX8Y*VECJ( ^<S&2]F0\\"F7XK(_T@,[H.&546HI#PDS>
M/(U5GLQ63J-U:219/AI:>J57UDV@"0YDR,!%RD#DC&32M /KD.2W\5970F77
MS.3E8-=N%>5 ',Y@-MI+1B-:[A9U%:9 >,Y@,B;_9-RE34HF=MV:39Z,6SIE
M8UH;6/K+63YFYTSF95:F0EZF6*;F;L&E1/XE=K7E:YXE;,JF6=HF5GK/]-RF
M]*@/;IH/;X[/^:@/]:1/;OZF<?JF;X(75H$7>L78<#JG4S7G<MK/<TYG_$1G
M  TE/PX9=ZH7 M6+52U0 TW0@)4G6)FGB*EG>HI05XG5!85'6.65?)H0'-+=
M7,V58AF6?B(68_7G?@H6)6X6CP31*?[(/4C1&#31$T71%%71Y76!%G&1%U&H
MY\E &9W1&?G15*HEAVJF3<(1/=0#'7EHB:KDAWKH'=51Z;"1\?11(B%2MTA2
MN,QH(UD2(4G?C4J2(V5?_X]V7_C]J(^BTBJY$I$::9 BZ?<=*2IE%$=A5$=5
ME"]):4A1Z91::95BZ95J:9:&E)-J5)-Z5)A&*36Y15%,4IGVQ)EB$IJ^A)H:
M!IO"Z9K*Z9O.Z2+%:3.E4U $4YXNE)ONZ2_QJ3F9Z:"F*:&VJ:'>J9W6J9LJ
M*ITZ:J-"JIANE*2"Z9A.%)=N::9BZJ9JJI9ZZ:=*:F(D1B(H1JDBU:D&E17.
MU*K&5!-N!C[ 4:PRX6V0QJH"U:W2AA#F*JHJ56_X8E/5EB[VXK#R YOXC+%R
M%7EFE:TD4'RRIWR&70;-)QQ.ZUY5ZX'(9PK558,,UK3B$'V64(+ 4+;BIW^J
M%?^ HNM_JNNYKJNYNFNZ\J=B05;?119I@=;@W>MFA=:^FE:_ZFMF82MSM")N
ML-8K&BPLRF(M%@<7BN%W255I\AO$>N;$\A9Q]5MTY=;U9"PT6JS$>NQJ3IO
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M71.WW1,K<133'=VA$!7;'5_YE;S2U;P67KTFWN ='A@C7AA;5C[D0#LTGA=
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M>Z,(T\,\SE<_G) *IY":[4,*K?D_\@.;^2,+L]D+JQ"<OUF<N] _Q+"<)R1
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M($VI2$]R;)6FA*7ZT____M'.__R_I'_W<XG_9^(E 1@F T@F!8@F!DB =3*
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MT/F)UL.ES\.HG\.IO\.J[X5&7,2-_\.R#_NN'_NT#\E*_,BYC_N(O,5/W,\
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M9!]T1!]U/)]VI"!V?,=SE,=TG,=UK$=WO"!XS,=[C$=Z]$=[_$=\S"!^W,>
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MA@BW<#- '((W'^I)=3LW),J'LX4&D.BV@&,.>F,[M4,)7W(BA&BE;LNWEB#
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M.%?"T = !YUV@.5AY51!'W-MW?.HG1TV=]9;[/-U'>;A(7-+UW3*":%&]W0
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M7[OWW@H-7%<LT*R)F=XS#&"Q6+J!$1%UX,[P7P2+'0CE_V?XP.;._>H)Y8P
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MHO&+O_SD/[_YTX_^]:N__>Q_O_OC#__YDXC['O+^_;=?__T7O_]QQ3T 4I\
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MHC[^(T'N#S^2HSM:Y#E6Y#QZ(P7%HP=Y(SQ^I$>&Y/"\T.J8) N=Y.B8$.F
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MS+FO<U*-.-&ISG'>Z<X_3>>=T\G'/*DC'3\=ISGV;(YR0D6I3M5N/>)Z#](
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MO.Q-;WO1"]^H"=:]](UOX^;K5_7B-SKK3.]^_]O?OP8XL .^S7[?RU_% 5C
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M9>9E<A9GPFJLR8JL;<8B;E8CWK-4XQ.MR:EGSRF=Q&FMV'JMSJE5]R! B@9
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MKKA3GO[@0Y[;Z0[EEI5.LJ-36?)1T'S8KN4 F;,_J3IGKM#^'L!:-E2^0KN
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M6$&S8) L&A0+!S>8/WV()1\BA$8^2$C"_FG_$$@6[,RH%M@5V+R%.2W4S5A
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MA ,!:+456L$1I;:ZZ:UJBNN6YO_J5C;5E4EX18!>^7I7O\+UKW(-+%T':U?
M'E:PB"6L8@V;6,<N]K&-A>QD)5O9O!;VLHS-K&/CVMG&>G:SH-WK9TD;VM*.
MUK2I1>UJW^H T+K6L+#-K&Q12]O6OA:WL8WKJUK+6V'U]DG M15P#R!;*!67
MN,;%DG*Y-*[B7NNYNHINL:9[7.=>%[K8E:YVJ<M=ZV87O-L-;W?'^UWQ-G>Y
MZ47O>J/;7O.Z5[WP9>][Z1O?^L[7OOG%[W[)>][^_M>\ %:O@-=+X.H.., )
M1O"""ZS@!C,8N=M-[H1_6^%D"=>XM]7MAF>;VPYSN+:B%?%I1ZS:$K.6Q*?]
M!L<VUN+_CM7#8_JX!\AD3&-\E.QF4]O9SO*1X[JTK,=&\S$#<7QCD84L93TV
MR"PJ@M'KO(3()J,Q-)*69)WI^&9;>QDT2S:R*;N,@6'&V?PR"A'V86UG3).C
M>X!F48VZ&2+%;-N/ 8.V&Q[2S!R]#T?U'-*+=K3,DU-/VM:\YHWV),\Q-8^A
MZ\-F1QMNHR(5': 5C9^1[EG2+%7T?QP4TTX#+ZB?WC1(/SKJX<F4J*D.]:I_
M6E,.F;JFJ.8TJUFTTQ6=Z-8M A%00V1K7O]ZU\'6];!S7>Q:O_JE(:$S_*1<
M-"\KC6M-HU_9J%V_^UV;?]BNVP%WC&4ZBUDN.P[WN!USE\L,_Z4OHFE-7M3M
MFG6?)C7QEF=4<G,;W=";-_F^2;VEPF]_Z]LV 9_W..NY;X#OQN )A\G!E^,<
MA"]<X0^7^+WM77$H4_SBS6GXQC6.'):@Q"3.(<['H;.<B5N<WP.7=[O9_6[5
ML!S>*I=YP05.\YD3?)PQA_G+UVUSG^<\,Y^IS- S0_3-&+TS10^ZTH_.=- @
M'>I.CWK3J9[TJD^]Y>[6>M:Y?I9_1QSC_M:YRU=.]M5L?>S]9CC*UYYQMW\=
MXG$_><D[3G>[BYSC=[^(/Y3#]Y3X/>]XK[O@*\+DZ"C'\!=)_.*U4WCM/)X[
MD;\.Y"=_'NNH9T"8M_1X-L^?_'B^/O^@UT_G 53Z 9U>0/IA4(02U'K6OYY!
MG6;]A/SC(9[VVD6YQ[7NB<U[8^\>^"V:Q59G5*,N>"&K.[I1#H D)+ 6J:Q*
M4I*MG(0L2UT?4X>:F/8K1C'L2ZS[W/^^][,_J?&+O_S;-W_ZP[]^\)_?_>1_
M/_OAKW[[4VI43R*8_A?&?X<Q[&$"$  'T/\$D%X$IED2\%T0< $!1@$/T $;
M,& B$ (GT (?\%X8L (Q<%\N4 (Y4 ,SD )%T ,W\ -/T 13D 1!< 0[D 5+
M< 5KQ0!M9?]HL/]L\/\*D !Q< ;SCP?C#_WF3PCE#TU8C,4Z9L9F[&/NP6/R
M00GU <FV#-W_=,PL? S,:@9EO$S*;BP*P>R&WFR*WF=HJ,S9H$T,GPT-Z6=^
MJ UGD ;:KF9O"LC:UN9OZM!]HLU^Y(9O".AM$JA]^L;.'LAO%H=S"O%S-"=M
M'B>C)&?;$F=V#N=RYB82/P=P)K',*DIN,C%S*$<3.]'-%"<2:2?61N=XEF=P
M6NH31?$45Y$4;R=XDJK53/&FE,>F;$<6C4?5A@JINN=[CNI[=C$7B^H7AU$8
MBW%Z@%&I*B09?3&F'.<MN*;*RC!^I&T-ZZ?:M U_]F=__&<;LQ& !HAI#HAI
ML) <AZS;(FAG%B@=A8D=HZD=H<F:EFF;V(D>W:G@[@D?Q>CFE"(?_WM('Y_B
MEHBIG0+RG :R(.N1(,%HGQ92(1O2H!8*GQ@R(AVRYG!.*_K1)C!2GR!2H1[2
M(SL2)!-*(C52G!*RG.21FJ0)'E5RF.(1FQ#R(.U1)F,IG6#2G&ZRG'(REUY2
MA 1R'E/R)&MR)F/2)(72)QWI'=4Q*2UH';]-*=T1*GDI)85I*E^R*E?R'9LR
MS)[R@K3R@[32*U'R*,<2@8R2*&.R(BNR* T2)\VR+=E2)]LI+?>1+G]N+NUR
M)/\Q(_5R)>JM) XJ(QN*)!UR,"?2H0#SH9@(H@IJH@@MHAQ3HV;AS2CMHSRJ
MI$3J,D>*SS!S,TNM,T]*TT81UD;3IF3MIO^"$35I+35UD36%RC6/<7R4$?>@
M*C:U)T?D 1'D@1ZNZOC<04=XI*O281V<;ZRB[ZR@1+2V1#G99#G=I#G5Y#FC
MDSFGTSFI$SJM4SJK4SNO<SNSDSN_TSO#$SO'LSO)$SS-4SS+4SW/<SO[2K-6
MB[(V*S[AT[+H4SY3;+A 3,,^C#]#3#^#ZS_S\\(LC%DPS$ )U+<&5$$+E%P:
M-%T<E%T@M%TDE$(?U$(C]$(G-$,K%$,[5$,]E$,_5$1#E$0WU$1!]$0/=$$3
ME$%7%$!=5$!;U#_[<S]GU$9K%$=?U#YWU#TCZSY_E$<Q:T>C\V(N)A$P!DF=
M$&24= GQ(0F)!@K_<>S<#,X?[.PHO$W,@ P*;>S+@@S<FLRCVNQD1J8)GY ,
MM>S9W!!^QLQJT-1DH/%-:\;,5*G-Q%21LG!,Z2P1+TC-]":1SG%.$6UR. >D
M"-5PZC31'--*S>:BQ#318.H2!PT,%]'/)A43VV;-_N;.XDR"\DQL,G5L0-5*
MY>;0X"S22 VE0O,6D^W11+.F4.JE7E,U9RT63S.H8(>F9K4U5U-69Q-%=E57
M9158?4W8B/7V@.U8=<K/EFUH/F8,XV=^HE5^IK7:J@8;KS7;\E!OL/0<L_3'
M=();J?#;IK#.P*U<R\*2A@)=B2)=W0DN:"+MZM(BY?4NYQ4O[]5>\[5>__=5
MY>!N[OP5X^A58$<#8"VR8)F#Y Y68=LN)U(.7_D57MU58MN58MGU[+CN80=6
M7S468LUNYTKC73<V9.<R7@=C2J].Z@)#,HAN2EO6+UR69:UN,CXVZ6"VZ%8V
M95%69V46ZY".9G]V8_&R9'D.[8BVZXQV9#E6:3,V[-H.[@@/:@-/:@=O:O6.
M:J]6[ZPC([:C\KJ6:[\#;,.#\SHS,S>OST+O\](6;>,C\T;/\UY/]1 $]N1V
M]6(O0V:OIQID5GV5;WW/;X/O]WIO]V9!'F2$1KS@JI*/1[J ^7XD!YZ/K,Q*
M^I*$5X*0""T7<X%0<^^O_MJ/<^D/=(<P<S]7=/\WUW-/MW-3-W0OUW15%_Q\
M$'9K,'9O<'9S\ =U$'=O5W==$ 5C4 5Y]W=#$'A]EWB'UWB%%WE;,'EA\'B5
MUWF9=WE?4'I[MWFA]WFGMP)[4':WEW:YUW9K=P9=EW5)=WR[KTA;C,7*=$D_
MIDG9EVB&K![K-)O(T4VU,&F@U&:,PHU\IGY*YGZI[$S-$!H%V&CRX1G45 VG
M-0VA1FK8AVP<.!RWS0^I<0[=QUJU]0^]AA /<14-47/ 9EL?IW)(U8,'=78\
MYX--&!$SD1'W\(!>6((!D0\%:,YF6!'KT! W&'DNIZ9L475V!W9.^!1!AQ6)
MV!%7)W<>!(A/1ZF )QG_5Q6*6S&*CV=W7K%YF(I\LOA\M!B+T\>+E[$7PY@7
MEZHV8_/4G)& IW':K)%_+E@;O1%;NS&  (B.W]ANO(9/6X8K67(IHY*/_;@G
M75*;@+*30*F0"(F4$GF4ULB028F0XNB/Y(B1_TE_/ZF4!/DGR=*8,&F1.5(D
M)9F+T"B4]TB42YF43YDO.YF3?R@O_=&3S8B?/CF29QF2:UF60_*5/]*2'5F5
MW5(L,;F/L7*:-/F7KVF07ZF;C"B7W#(N;?(DK9*8Y6PGX9*9J_F8@1F0LUF8
MM_F/5Q(IM3F3,?F;N3F8N]F<R[F8TUF:J9F=F39HJV(M ?(LW]*9M2*>W_DB
M_U/9G?E1GPT3(W%9ESE2, =:,0LZH \Z,8^(H!6ZT.#,T$S55 LU3#O3,ENU
M;,GV,S,ZTR"-;3BZ&4ESU&8*5T'-5DM:6$^:5U/:%XUQ&9O*I9\*IC^D'KH
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MG>J,)SOEZ4YZPG.>^*QG@QP@3G[NLY\ _:= '>1/@@;4H .%4$$5>E"&)O1
M!74 1+LT4255E#\7E>B>,LK1C7JT3AT%Z4?1%%*2CI2B)[5H2C&Z4HV*]*4F
MA2E*9:I2FK+4IBZ-J4YGNM.:]O2F/\TI3X?J4Z("E:<-A6A2E;14_O\T=:%*
M?2A3I>I4JD+UF]?,*E:W>DZM=I6K[_1J6,%JSVKZRE>/0$1:?06O?<5+66]-
MU[Z:]2ZXPNM<Y#(*NO;*KY T9*^1.U==&>8N<(6$<1%[UKP6^PQYT6M><GUL
MQ*0U$,3RP[*(-=G"*JNX@FCVLPK3+&5'ZSB( 6QQ H',RW86-(JY[#6JC6W.
M7MO:D=7V9;!-F.(R&UK>IC9AN0WN9H2;F.#.EKBS+2YME<O<Y#H7N= =[G*?
M.]W+6#=GV+4N;+2+F^-Z]V9,"V_.FO9=Z7+WN\<U[W&;=IWAC#<[2TN:?*G&
MWO#.M[[W/8Y]J_->:W"GO]T93G7@ZQT"=\?_P -.L("G,V#C*+B]$$;P@B.<
MX  7^,$&GN]P>TNXTPK.8!\V;6E'W+@2@]C$J05QBE>L8H/Q]K A^9=)9NS7
M&J?$QB?),8UOS&,=MRLJ!%N)D"7RXZ6D92I(/HJ2#_.2([_%*G*)LDL8QV0J
M"XS)>WDREK5\Y28#&25$'O)$BNS7(IMY(4YF,IJYG!8KMYG+;IXRG.>,,#G7
M^<Y=CC.>W[SE/G<Y,%XV,I0'+>A"!_K0@,ZR8-C,Z$4[6BU^5C2D#[WF1U>:
MTDON\J4W'>9.C[G'.]9QF<4<9%&#&L>AGO&9,^V4JR19*JS^LJR34NI4K_K3
ML:Z*KF]=:U3[^M3 _R;)KTU-[%0/V]A@QK6R>QUL9!?[V-!N=K0]S>Q98^75
MKF[?M7.-/6RW^MM6 ?>NO1WN<H];VT!,-[JY#.AVL[O179:TO.$M[\(@AC!8
MMO=B\!UO?=<[WP#O]YY7AC./V?8S0=L,:Q'N&IBIIHX05\UV/3/QH4G<XKJ9
MVM:ZIC3D,$V_;UN;R-W&MJPU>,+403F&O2/@ U_8Y02FQWK@41XOP",]L&Q/
M.W)@R_G41P;DX&5_]!,.5/WHZ+>"4JV4KJNF,_WIKW)ZU*$.*ZE7G>I(SQ76
MDS[UKE_=ZUE?.MBY_O6RA]WJ9]^ZUL?^*B;!RNUP5WK<VR[WNM/][F^W>_^J
M6K5W5QD=3'T/_*K\KBK ?ZI3H-(4XA%_@% U7E./7U/DS33Y+U4^G([/_)P:
MOWD]<5[RG@]]YT</>M)37O2E3_WI36]YU*]>]:UG/>9EGT[7QQ[VL\=][3L/
M^<SW_O>@!_[I%1^JQ1?_^(/_NZD&+WC ,__YSH_^\O4^][SCO?K8I[[V\8YV
MLI]]K6H-OZ^D%:U[D9_\R_(6M-1?U\F-I/S?PEP"1QB_\YO_7L@Z5EP3^]AD
MW<-8^' / 3B Q;)_#5,O_?(W@-41D%,NZ"(Q#2A_%_$W/&87+I9:M+80E%%P
M+=-P"X<S)Z,Q>%,P!(<R(+.!>-0:HZ$T?<1P+4C_,RB8<"?(6B!S@1PX@RTS
M@S*X6JXE,@7'1PMG2%7S-1]W7T-8&P^G<5=S22,7<EISA)=$-$M8A"4'-YX4
M2J=DA9G4A%C#25YXA:6$A:DDAE@(2*'1,2,1.!3889O%AF[X81Z&8B1V8BZ&
M8C+10>[G?@PT0GQ800ET/BH$B!XTB#W40C:T0]63B$&DB.JF.D44/,@3B40D
MB4;$B,R30_9CB=-31%CD16'4B9_(1:!(19 XB8MXBHV8/<:#;H_(1.NFB:CX
MBM"#B?>#B(58B[=(BR:TBR_$0YD8B_K3B[9HB"A4C"8TC)<HC+G8B[Q(C,UH
MC"P$C<X8C<]8C=2XC-.8_XW2N(W6J(W=R(W7Z(WAN(W(J(O*^(M?88Z'B(V^
MB(OHZ([P2(N46(J5:(KU>(_T2(^D*(K\Z(FCV(^AZ(])Y ]51)!(9) #69!B
MM)!(5$8)V9 ,F40.^47'@Y .>9%J]$9LY$8<F9$=R49R%!<AF4=[5)(O:(8G
M&4@F24@IJ4A[I$@P>4B'Y$@SF4B4!$DVF9.-I)-:PTB9Q(2CI(6H1(9A6)1#
M:91CB)18B CH(1[R8'.QM$KO84NXI$L_-W2_Y"8E4E9DE4_WI$]@^95B*59<
M^55F.59G699HN99JV99>299OV95A"9=S*9=C:9=T>9=I&9=5A5!^Z5!_&56!
M.?]5@]F7@'F8@HF8A*F8AIF8)6540E54DGE4DQF9E'F9EIF9CUF9FXF9G:F9
M+?69HAF:I(E3HVF:I1E4ITDFC'E5C;F8C@F;LOF:M.F:MOE4N$E5;,F7NUF7
M>^F;O:F7: E^X.<K;G57\-<O<[6<S&(L<F57R4DM@V58U(E7U"EK"VB=\((/
MQ2* !6@LBX4O]C(OLB" JX /SS" _Y<O]D):#M,OE-6>_X)9$&%9_0=9D\59
M^BEB% A:O_5;,&:#.^-:S15;KT4Q%@$9=2B@!%IP/$@RPJ5=S16AS@6AVZ5P
M/)A;L"&@TR4P'"I;($HQ=<B#G;5;!>I;%7I;X,5Q1MC_HN>UHC\3,B[*7B!7
MA?B%&TU#A$>S7S=*HPYFHQ(683]J'4!Z<D**<D.:<D2ZI$%*<CFJ6KME8G%(
MAR(FI7 XAX<CAUK:8BP&H!D38R%1$I/C;&0Z;64J;:#&:\E6;1EH;:_&IML&
M:W*:;7,J;KLC98_F;DRFIW1*IW"*IL6FIF[*;8E&;P <0.._AEIE=)9GAQIO
M?N%G?&JG;YIL?KJFE#JH! &IW!:IYA:G?8JI=;JIY'9NGRJJG6JI?QJHI%:I
M;;JJ9 :HMA:JG.JII2JJIWJF/I:JH+IDM;JKKCJFOKHN?Q6FPLJ PRILO7JL
MIJJJ9KJL/2:F@.JLEQ.LQ#JMQEJMJH;_JZP*J]J:J=PZJK&:J]ZZK>':K<!8
MKJEXKHTZ:7R*IW?1KFU!/'QA& (WK_S&;^\:</6Z;_IZ;RL#@QXS&1Z#<#4#
M&S&C&@ZG@DF(L KK&G54<;=!<5 8L1O'-(Q$A3X*I$Z8L1B[L4=:8 ZF22\7
MLMF!".N 'N51'J^4'NW1!3P''S. #C\7=#+0'_S! @CP'S\R(S'2(KS"LSK;
MLSL;M$ [M#];M#Y[M$)KM$F+M$3+M$J[*VG'=F)G=MY7M6M'M=?'=] W?5RK
M?%Y;>%T+MLB7*61;)\1WMF6+*6:;MH<WMFO[MFIK*9(BMY0"*74[MW9+MWJ;
MMWF"MG#;MGX;_[> R[:)1[C&Y[?-%[9:*WU?N[B*F[57&[58.[626[E.>[E+
M.R!GA0C!LKGL=RSP%[KY-[K%TIW.^7_ZIYVB"[KD$G_'N#G6*8'@*8"TJY[<
M&9YUM5C=R9T$B \&F(# 2UB*55B# ZW*B2_@R9[7Z5DR\2_P63@/BJ!E=C$E
M*((U"**2FC$@JG )YX,/IZ$=Z*_6*S,T*#,ZTX/BJX.?L10_N+TLX[ZZI;TX
MHZ&AM8,&EUXI*+'TM5\ZBH2M8;Z[P84B)[$:5Y*_\80:VX2<Q+%.VL )O(40
M?#9@>)26M$=0>J5OF,%J^&%K&&)8BJ4OIKV6$X&9@SF=@X>@8\*?H__")BR(
M$C1#Z!/#[?@^L(BN-2R+-FRN.+QNYA./6)'#VM.*3Y2/KEC$0VS$4$3$.EP]
MZMB.-_S$2QS%0+S#[C,^Z_B./5S%_"/#,&Q ?5B.4NS$L\B,UTA_Q0C&5^S#
M:3P_9DR(WGA !41 <'Q" V1 <CR-;3R.UMB';EQ!$M3''53&@>C'+BR.A@R.
MA[Q#KXO%YZC&8KS&8PS)DCS#C0S%4SR/2"S$29S) /F/ OG) 1G*GBS*G9Q%
M$WD\I\Q&7T1&J.R1KKR1K_PT=#07(9FP#$N2*;F2*IG+O(R2+$E(-*F3,'F3
MQ"S,Q1R%/FE)#OR%$9R4%.S,T$R4CU&R3DG_!C>''K+D'N[ALKI4#C^G'^ ,
M3'DYSGA9SK\IG&X)G.F,SKRYSN1\SN\<G/'LSN8LS_5,S_!\S^V\S^9TFU:5
MFX7ISP$-T*U)T+%9FP<%FJBYT"0E _"P4S+0!0JMFJD)F:MIT17-F1GMF1L]
MT1C-T$CUSR(]T"-=T"5]T )MTH5IS_G<TBS]TO@,T_S,3)N;5N#'G.FW?SA-
M5_'RG7!UG'Q5G=E9$C\VU(&EG+MKNOJ"@+G[5HL%#;+06,K+-P<8GU/=AGVC
MGR)Q@%Q=6?^YH )!U?N)H@KJGQ\:O]CKH9=EH@P*OQ3ZUK0EH2)JH"=J,=>E
MH0>*A,^573N(7'2=_Z*RY=? M5H7:(."/:$JNEWIQ:.,/:.-S5WVNV&,/5[B
M%5^6W:./C=F.G33]A:0J9V$NUW(4IG*DW;%-NG*E?=J@C=I'BK]@_<%;FJ6!
M4Z54"MNUW:4JUEM>:EH-85FV^MO,^FS(^JK4IJJ"2JO&+:Z:1JZRFF9_MJCS
MAJB1!F^<IF96@:VMBJK%;:F,.MU^IF<F(]V**MY\-M[F'=W=G=Z25MW+O6S)
MO=W9"M_'/=_87=_R;=_*UM[Z[=S.W6K]#:Z\FJRWJMWN+=P#7N#(#:ZS&J<!
M'M_$C>#T#=^C9N# /=S!7>$4?N$:;N$<GN$=CN'7>M\BGM^R6N*;JA6PBO_B
MS,W=)DZJEURN<J$5[+JNZ5JHWJW>].9O.HZO\EJO/?[C]P;D^R:OE$$71;XS
M.=B^/RBPU-N]!^N"0K.P$2?E&.<:#@M;4I-Q6JZ__=OE%OOE#QSF#.R$1IIA
MJ;URJPUS(NL=LT#-8T >\I"R.8<>/-<.5/ESWCRSO>0??.YVW1>Y5DNY@?[G
M@@[HAE[HB$[HBJYVB<[HBRZUCSZYD6ZYAT[HV0>YUI?IEZ[IV\?IF#YWC4MX
MCAOJB4OJ6VOJA?NWJ2ZXJ_XIEU=[PF=Y,N ._    ) /L"YY,Q!^9" #N3Y\
MP1?LP#[LK1?KF&?LOU[LPJ[LQ'[LR^[LS9[LT,[_[-0^[=8N[:V>[8=KN*C^
MN*4NMN ^ZIL^[IU.[I]>[IT^Z8/NZ$Q'G.*'"*.+NOKP?\YR+'1E[Z3KG*Q[
M?Q+HA]>)+<"3G0O3@-UR[\<Y\%;M5@I?@.V9@$Q=6 WC\,_95X(C\/SROHVA
M$10_.!V#H-<[@B(<K44]?T@>,BNXL$+(O29?\O*K-$MN2/D[&T_^@@M7L$Z^
M,3./\R6/@DE>OOGKKRI8-5X#YI>-P%R#Y>LKH_3EP&,^24=?P;*A-5,8]50_
MYLPLP1$LE"5W]5HOS=&LE%-(%PNJP5-*]AA\]E8:VZ456H4CK?V.PH,<R(6,
MR'3_C&A,R2^>]U0<QIQL_X]*O,E''/AZCT.-+(\_I,F@^/>(7\J@O/A\SXYW
MCXQ:C/>4+_E!9/B#__A3W,1,3,9S;_>0'_J,O#V%[_EUK\>H;T.+?/J'_(VN
MG_JL'_NOW_JP/_NR7_NX3_NZ3_>1+_J.W/OHN(J<[_O#'_R8+/B.CX^,3\J-
MO_RC_/P/&?U+A)#3KY 0>?T2&9$4B?T669&M;$;?WT;A_Y$:6?[D?_ZS+,N2
M(<LC&?2[[,OO'_\N*9.)1/^+9/_#7/_&O/\[V?\XV?\  :"?OWZS!O83Z,^?
M0(8#%R)\J)#A0P 4+4[$"#%CQ8T7-7[D"-)CR)"SW'5QYT4>&7A=NG@YZ7)=
M%_]U.=+-D(%3QDX6#GJR0(# 05"AWX@:#7K@*%&E09$B:(K@:=2I2Y-:A8J5
M*E.M79UR_7HU;-:Q6\5*!8OV;-6R7M62?6L6+MNX;NG>38MW;5Z^>_W.[0OX
MKUS"=@,7;INXKF*]@ATC7ARY,>3)AH6:=8!9L]7,G#>'[0SZL]K0I$<C+8WZ
M=-#4K%=?]AQ;-.>@Z1 M!, QGP/41'G+0/0(D:/@B'+(&,JZMW+6OI<7;<Y<
MJ//HT*=+3VX].^_JW*]KI_[=^_;GX\.3[UY>??KJIF6[GQT?_GS5[^O+OT_?
MM?W]^/OKA\V_ "4[S++'#*2L0,84)' P!!\,2SCB)!S_#I%\+H0F'WSRN0>?
M#3/,1Q\0]=DPQ!))O%#$%*'1)T06]>'GQ1CU@1$:?FJD<<8:^>&G'QM[M!%'
M(47,448CB7Q11!YCO)%(#%O,A\4,I8P22159?))&&Z6<<<LK97GFPBJYW)(?
M:YB4LLA^K%FS33;/A&9--)4D,T8YXWRS33R9Y''/,FV$\TXSF0PTSW[6) C1
M@PCRQYI$\V1ST4/SQ+/-2=W$]-"!''7TTDD9[5310QLE]5-3+14U5$@UC135
M54]=%5(["_513UMC?3170U,%M51?.U6(484<$K988H\ME54W?S4V6(<2BBA:
M:)L=UEEKJZUV46R;U9;::9]]_S98:"N2*-QR)1+77&G3/7?==LEU-]YQV5V(
M7GC'1?92-N/<TD<[^P7X7X'_1+-@@ODUV%^$%U:X5GX=KG7?.R>&<\D?^<3X
M8HTMYKC/CC/^>&./1P:99)%+1OEDD?T=F64^7?X19AYE!K)CFF]>.688:^YQ
M9Y;[\3EGFW6>F6B>@2YZYJ"53KIGIGM<$FFHG^XG:I^7=OIHK*7^&>N7A6X9
M[*^')COKKIOFVF>K9UY[:K.OIAINL]NNFFJZ[[8[[[G1WMKKF,7^.^2RQPY;
M<),-3]EPG!%767' ^89<:[0#+]QLH\^6_&C*?WZ<Y\0]IYSPST=O_'#0FQ8]
M=-517__]=-=I)IUQV4V/G?;2:\?]=MTYWM'CWIG\?7?;;\Q=]N")W_AXY4%>
M/OGBAX?^^;&;9[WZUSM?W'*J+^=^>^^U!Y_K[L/O.W+,SQ]?_._3CGM]N=E_
MN_WXYX>__O?OUYMKO/?F7_^J_9_;_]0F0+;]+VI0JQL"W6; !#+P@ 8LH (=
M.$$V2;""_RO(!2,UBU9%JE'*VM2H>A3"@8SP@R4480I1N$)_F-"%*FPA#%_(
M0DW%4%(V9-0-=9A#'N[0APHQ" ^E!:YW$7&(143B$96(KR3.ZUWUFE=(T,41
M<4'1BA6914O>,09YT$,>8WA'%\(8DQRHHQTU0<=.9% .-?;_9!P^<4 X'  .
MK#S%CG7$XUCNJ,<\OF6/?NSC'P492$+RT9" /.0@$UE(1#92D8YDY",E&4E*
M+M*2D+SD)#/)2#J.I9-O^>130DF440:EE @X92JQHDI/KM*5K30E*6492Z%\
MLI-SG"4N::E+5++&EK[,Y2]K&4QB[E*8O+SE,6_IFV4"4SS-'.8SNP--7?JD
M"_G@2&ZT"8!\3#,H,Z@0<1(1SB[,@)KG]*8TU;D==*Z3F>ED)SS?Z4YGQI.>
MT;1G/N>ISWKNTY_]!"@^Y]G+:!(4F<XTJ#*+F="%)K.A"'4H+0DZ45&^$I06
MK2@L+ZK1C&[4HQW5)"9%&E*2!I(X_^(,)R)0M*$.L51#*L+'2E%DHA:1J*8Q
MS<>,<AHDX/64IS^]$?OTX:\=X6BG-$+:4']*IR(AKZ8CPI**GN2B*VDH2F,J
M$HV82J5[6#5#'Z*3X,K4(PUBRF1:!6J_R*HGWDW/IS.[H,;^U\%1>="#(\04
MI!B%U[*N-81^Q>&BZ'H0$%JJA8^::UU!>$)7)9:$C?54F]:ZUGUQ3&*5[5-B
M=_4JR4+6L"[L86B[9<2$C':OB^5'#D>%+&PQ<8D_A*UHVR7;@[C6MJ3%;1-S
M^UK=]G:(4O1(N4@2W".6$+$2V]'!&A:P@X752P<S6'09QMSE_BMB ZL;4'WW
MUJ(2U;LP4O]J4,%[MO ZK;Q)_6Y0@X1>HIUWO.TE;WSA"[>ATE>H\<6?><^7
M7_O)K[_TXV^ _2M@  _8P 5&\'\5/%[[-IAI]3WP@B-,8 DG., $[!F&@:9A
M"G>X?1#6KWWG:V 0L_?!\CTQ?%6<8A;K=\4N;C%Z/6SA"=>8QC?NKWMK7.+W
MLAC"X?UQ>H%LXB [.,0G-K*,D;SD(P=YO3UVLGBE7.0I*YG*0X:RE;7,X"H_
M6;U=!G.4Q4QD,G/YQ\2[\I:K;.8R?SG-;(8SFM<\YS?36<AW]C*6W=QF/?=9
MS74&])\%S>4C%UK)AB;TH16=:$9_^+Y);C2/I8SH25?8TC->,(?_-?VV3:>M
MTT/-<*@W+&I0C]K4I4:U %5-ZE6?NM6I9G6L72UK6,]Z%K">!0)!G>M5\YH?
MO@8VU()=M6'_6M@C]+4-DSU#'#([M2Q\]F&-.VUI5SO:U]YKMJF-[8)P.XC3
M_G:N"1+N@Y![W.5&-T%*^VTF(H2([M8M<#,BW)'4NR/W%@F^A\L0>N0@)2N!
MAQ=>$I,NS&0=-L&)3I## AG\I#V569"#(GZ@B2=(X@VB.,8MGG&(:QQ"'J_X
MQSL^<@:1_.(FYWC)57[RE:><Y2]W><Q?TYH!Y<?F_[EYS7&^<YWWG.8_GWG0
M^=/S&<Q#F[C)IFZ #IR3%J?IQ"'#.I*3_W.@TP8[Y\'ZU;4.GJV;9^L JKJ
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MXLY[!$T5 PUS0%7/\NQ2Z3L?^NP9.+47/]52K8>_G6>7XQC3Z*SB,%(L"GS
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M7,_R;$_U=$^:8L_WG,_XA,^[.$_[#,_TK$_ZO,_]]$_YY$\!!=#\Q,_^U,\
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M4<,\M=5$/VTTUEMKW;6_(V^LL<4-9[SPV!Z?G3;&8;.M=L9M<_SVPVNG[3"
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M,3H ' =18T;82!(W1@2.:SR)' E21P3<,8]TW&,;^?A&/\81D'/L(R'_6,A
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M1[_%&OV9A?PZS;R3?COMEQ]/_.O7__[\_9<(?P"4DP!=1!$"&A"! )R%.KH
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M"0.+L)QP*942"@,H"J,2@.*$@*@R@:[R@ H('KJ@W2!(@BB(@M+M@NA-'7+
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M]6YW=U'/=WDW>(%WYH:W=XL7>7<N>7-7>)?W=X]7>:.7>8E7>I_7>*^WY6;
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MXJ/<!A2@ 5<QP':GV]PK1"(%X6UN)7+0-4V$(+KO4>[_>2,QBD\,. EU&'"
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MB9SXB2VC3#!#,B,VBC*3BJ5H8UT #SF#8SSC,S6S#ETP-$-V-$FS- [@-.&
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M)F]3&9,_]' (=$0:EW! J7$$=W$,%Y92A$4M5Y8IAW.6UW*PX4(+]4998H7
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MC.N")FJB)[J"'% 'D)@!D2,)<B )DT/;+%*)FT.-U5"-MH7;THC;MY7; !I
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M95O&E>>$AX:C&_&TA_UT3V6Y3_B$EF9)EF>IEFEY'FJI> ?UE@U%EPY5E_Z
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MPQ^_>^ZE1W_Y]3EOWW/UX\?^_>[K9_]^]_&'?Q;X\Y]%('[P+T__&R  "1A
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MXL1?>\J/_,J??!,60PBFX,%?[QKF81\.?= ?_<]_>\ZOG,L_G&3$?,S_5_O
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M'[[WXX._/?GGFV^]]NM_S[[XZ;^/?OOERZ\^_/3'[_[^]?.O?_\ _)\ \T=
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MY@N_Z?N^]!N_]3N_]IN_^+N_X2N__7N__ZN_ <R_XPO !2S !TS Z#O #)S
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M#?YS:!P*H0=V@-\<0V&UIM3"FG@.EEFV(P1<1@L7'+)NB;@8^28ER[Z*DG:
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MD9G^2X^)/4!F'[0!C![F9^%\%"%,R$S:^[H:ORG,1<BK6IFZ%_-#KK'CC^E
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M_6, :W'-@"9O3V#-YU,B%VLONVSJZD*E3HGUD;4ZP8MJ0 'R0(G'Q9#0A<9
MN',<OY.%?+@=,U+=P7%%S=[XICN"WL]%WF5)L*5%&='K/5002*/?L^!9X3F
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M[PJ QN^BD4( ;KT[.R@1*Q=N3#O> 7D>K/-FX#D(.;HL+Z-5CE0":/&= U]
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M8!3<;?7L%842K.?U^^#+MT^; RW\]0'S8)] +"3V-C"/KJG2Z\3'9(>K:\?
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M/Q&Z!.'\M<059]\TI2J1H:UPHR]$6%FL5TZ[9T-",2EF09A>.C=,L9YHA]-
M1BC ^KL+&-T)77D^*[V-2)NI#BN:WN]M[2UQHTY>XE&F!]1)?:ZV#[OAU-H6
M3\&L$ \4F.1 B.MCNH/);H[#$@^3X1"ZV+UY!KXR+==T;T;DI:);8T=I]6;R
M*:.KBE<I0F=\*DF7@-05I<0N96(!F@^N\-$!-JSP8"J@@-/R^2,%?P7L'^ZU
M"R(I%M@B>S3F6ZOL:[S4"TT%GH-:HC]F%#"$BV.%J,S&(B0W,[4:FYJ%6\87
M?G@5S+Z)5RQX_%"C95E.K(]*>DDR?LY@X-RUO9<3NUC'R:J0>%4P@WD(X=NN
M24LKO[,=<^:Q\^#:TJV7)=],10;+<U_)?(./,'DZDW@R5U@2R+R/^#U35/FZ
M+KLL^,QHB&,&U/+S<)9-YD+#I&M>TX9^8U_'.@P93>V.G-;D/IQH+@S@(/'0
MAKXJ(H,MX:"HZ!%/Z,/TR+ RLV11]1_;&6-2KY$J@PY%)D'SF<__U"R"A&?.
M0 Q!?YU.WS=$4L+"'_OMV7=H2,<'MJ_;!AMEV"!ZKF;97\I27VA=$%A-<N>C
M/FZ$?SH#4?\F,*V])"#.0+U:^>^/>T=0SX6J\S[>*'%TX>]1]BC+%1X5M+BL
M2Q[+W]]W 7%:&?W'PD;![P_><JSF=Y7"\.HD]Q]SKK;U*VV?+D4+_M$')\,W
M3B  OG=)EQB]^12V-(KAWO'U46S\L$B=\#BI5OO*O)@4L,1WU_CZJSB7WI2=
M8E"XLA%\ KN<'%J0Y/YY9D?'*_O!N7\=..FR;YG[;[O3O;/R7>OBWK;=&+L9
MS4'1F@KO$ [U=>I=4B2RP\UF]EPB3Z1&NP_9'>TWKDWSN75E+'%E1S;4?W@M
ME\F&E/W^T3I$E>(WIUV2=[[R#/DRK/3WH/[,.B$VI^R7K<:.9%5G)V9\84G<
MC!^5)X!45+UU[=5#I<-8N1; !.^$C"]@#H"PNCKU^H0%<S"\NR?15U?4\.SQ
MJ+:Y.%MN+MO EKY0^/_?[XX]M\C@<9)=D<L&_U*.9Z6W1OS]UL^HE])1 ;HV
M^"<V<;5<'_[;8^4&H+XL"0 QQ><!!E:&/K9+".C!6=;Z<%LMHEL"?--DG9/R
MG]H\!-Q6Y@MHFJ-7"1DQ2J\<;&Z].'XL]27FWJ9.5)<KU:7/1S 1X<*V1S*4
M MI754],%7SOI<S-4=L7QG+2IQ8F72I/^<>.FD\?"U]<E/F/A=RC:]L;,X:6
M7MPDS!G(TR==@?4-G?>38O;6OB<&O?#Y4D"N+T(=Z'>KVEQBA#(]F@O<B5G=
MC:<>"_$5O&TN^-E)J]Y,XGE(;L6]2TF0X1<1.84O]$(AC!T6+#U[@!E='&*C
M\ QT'\AU,3BX7G=B.0=?EHO,6\?_G*WW.P/E#,T//WI$9B?&Q=W!V;XLA,$?
M'40HM:;][K?A>=++E)1YN5+EM,3E5<[MLG<ZQ:\_/W[BL^#UGH5G @[&@:/)
MLIV=A#-0W!HQ-N>CEZTZK;;/.X52Q.8P_]7!HY'W1F)7!V6#K L"UO/7L>"H
M:CTADN9W$B3D*=?43O%-OX<OV 1N_!XWJ]?98=RF??*$CJHD<.\VY97?ULQ/
MC*]>+8^<O1PY:EY#8L@\ R$J&F[3*&V_@ZR7S)!I!L^CBM7I&SK27ML9Z$MK
M)%#>;@2R)@]$DT-=(E><420;\#]E_RG[3]E_ROY3]G\ZV><0-KC#>[@2H6JZ
MLVK1Q<B'F4O<_-/--Z;/FU0%6MVCMT$2*Y2/4!C+I"5A(%#"5H/=O-SG$*)0
M'5=:EA>LS=;_5>^77A7R\0S#4\),'U1PTHS(C">SU3!PLQMA713U)\R2N#14
M\&DLVG<CER7L2N)Z:H*JI1?+ !2ANJL]V%/2<=3>>AH:M4^NAA.QJ'DYS+$_
MYE-CQ1GHRCK:3EXLG/6&LP&KCNKC?KU[(V8Z&B(KOO.'D!B292DPBC[06D(^
M:\[VW8YXH"+39W*-7B>*7B3ZJPCB2%K_-%;Q Y"C&EKR9W3E'7VV;.J7EE9J
M(@/%H2E92I MZ5X:S[:0RLV&L8:3, $!V([\SG<33M;J22-!$$WHT<*?<]+Z
M2<&WJJG9_.@,=!,[B$<@-:;542Z[9*-RF<(N^X-K")GWE/_+X$%=,9M.75L_
MO^S#X*L7Z:PMW5QUJ^"!'43;HJ<?X(KC<8A F=%,O7IEV9+9 MLW9$?P@5W-
M_5 ["T'=&SM_%+AW'W1"#2^ENUOBSD!1HS>)=DFJ4*H-]D?9!R7^)3_ZIQWF
M^?006K4'H.P_;N=-P/#'4DKT<X,KD1<@4-9-J\C21:DG$:,LA"@M[7 #ZOM-
M< 4"]\(6&PS9[_@V7X.H]5<P,S%16R=W)XJEK45WM/0)4VAOX//OZ$BFYX/M
M@%UAV#&J!9U1XH]<=,DX VE,K![F6J)1KX0% 6_.-.^FT<#RT>'I&C@Y<'$P
M6$%T?X]7>&K>RNC)W0JM\><??\].T!MGKR+JSAEFO;Q,(0+TOP9:=P5@9R#T
M&8BY(6B29/BINW0N*>8OLZLU)(;S6?\/*COZ&\5O[U7/7DE#K+VIT^+_.QH/
M$6A0HEPJ3:6TQ"EQ6KRDC2E1RGF".80_Y3_.6!=\X9.FU8RQ3"[S2Q7J1Q?0
M#IR!E.7>GH$2JG!!RM*D6FM(?.Z>2'[Z+RA+%Q?,'YO\]O6O($KMA-865.Y1
MI@:=II09BW3^TXGO=A^VO;"-&#WOR$N1QW<V?E6?,D.]K6L(Z9G!QTI39.D"
M-*&Y%\4CE7*(>_CA-*?PITX$R[B4',_XFMM0W*1L_P<AN1^J+AR6A+4<VH*2
M68.R'U_:W9N;DL1D#BAKK)RG:M7D)'F*;0>\,@?W0X]R[A3QAU9!@U'[P'D&
MYES:;<1YF^)_%=Q>7.QV\U48GAR;=\*4_,SPO!A/9VVV<O%OC1 I8%Q'H;R
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M'63!/9J;]+H^DQU\*Q9TV-_)PIG8TRM,ZF-/6ZZC=.).1OHS]7Z^<2&/Q H
M-?G0;_F)4U6GXH>Y'?MR<.'-WX='2G]/D!H3$?2/NK0GQ:8C+CVJJ+Z1O.8$
M//OZ;F_0\ ?7>2I@>PB^7'._L3'VVY)V&,R].4J2/O7Z!QO. ! SZ)-7M>,/
M1/K.R)Z39*%KXO%?];(;JF2A9=?*\SQW3?T_>HWJ/Q[E6AFM95X;YTY\N['6
MM;WZH7W_II%J3M U7X7!23NZ<E(($%SDN:.G,I8@9,O0F!6W\BI[[>=IA1[X
MYJIJ>Y6YZ^NG]3?'UU^O3Z13MHM']5JXJI;X&[O)G^=?:UU_?\C4")V!8LY
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MHN_<[]^0P(E!7\(GXR;H.E)F),=$>4._<)B]Q 5HUK'A;4+C:C1;8%/4!)^
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M'/T:@QO654/K<_3*)ZR/&4 EIA*[>1,M2J$_'^63@5>BB(;&HY;,E.98?M*
MV .,* 'I>I^XO\G+*NITXEG;AWXF"DUXK9#W0.<:< P'&, F&'^S:J4$;I3D
MG?1/WM-_F/]A_O<W/P__\XJK-_[J!DNDPZOY__"M(;\OPMU*(KB#AXC165S
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M4UW?*+&2NH,,<()#9RM_-,E?/"IX79U_;:4&[/0FL@L+$>]M=^CN7HN[I3Z
M,\:$#Z$VHP7JF^I'%&X7@B>DS!\4>%% LOX7D$ W -5S3&VE"Y=I 64==&2)
M9'J!+JX)G9]J2ZJ*+IY47B[I=!N.Q9UJ5FHH&0X3"#*);L!##F%DX$J##[+Z
M8\&9^Q:C.6,YZXA>2L,%_S6=*F1)$HK[;>\\F!#ND_MF^=M>^+?%#7ID /O
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MZ6 M4SLZ&CKJEPQ.*W+7I;!GW>A$^(-Q]Z@Y+[H8"YHAB27?E"^58U\3^\C
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M>#)(L^]LHP:Z 5[W^DFXKYF<>LR-TE+92R&G><J=*('5KE^>Q-@;@%<C@<D
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MEQ#[HR"#"#,#*.8,8H3R/%!%!$YQ@K^);P@9&%J?4.@"OV6"MFF.]Y ![BP
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M;6+B,^.2^WSGQS2>/''-'__BX'#"L"8%6ZKSA>:$^H J\P.U7T>">79 5(!
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M@ESP< CR!W'3NNUYYAX.JPWN&H5,X"SW0QIU[+"PB-)CJRP=YA$D99Z]$OW
M:[BN0I6:)?34!6[TI,HK-S)P_*2V5ZER0I,#(KUVT:WIB7VCUEEPX@<R(!11
M]T!^XW&;EOE8:LU^:+E=LOYA^N$1?M\)]X*"BY"L%6*W2>PBYJG;.Y4&I63
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MH%.$FWF^D-9T\Y:\.:(R)+QO\*Q]DH9,(EN,N;E&3.2;!"VPGCH[[P]JO_)
M-<Q6Q+IG1OT>E1=+1=^[]"=-M8,68OT2GKJ?R_NRE1Y_.PV$0*X43Q.,,7D%
MX;MEGJNM<Y 1,Q7K?2V_I_SU;Y:N?[A>HMYW[4N2F$')4RIJ;FL,&?@BC)E#
M'[Q0D)#ZW!A]#Z/XG66HA^!S?)7JYKW=V5BYL+E1V"R$WM?UBYQ:+$&K0HTZ
MU6I.44]1[C:0,MMS6<6W+%R&-?Z@?&35(^O8>[I'F((8SSA.A\&9Y0-M-R:)
MYE)LS[DWVB>^/AOH88JJX(P)K4ZZ>"/K)4,+*S8V>L[4M">33B=:KQ;>D/#-
M(9OZ4=KUYML\YV-B5=6R*Y1P?IC5K78Y\9@],/N$MH/'G%.\8E\B\U#[:$T)
M0]NY<UAF%Y+)^87[M.I[WT%5JFD.N?99-S]^K(GJ^S;6R?'AFFEKMIZDD4[Q
M>T\ N'Z+N^TOGW:7C(:=<VB1^"$NJ6U!73\DSL37+BC1MBAV>\*8W92:C4>6
MY](\@P"5T! Z-4R\B:?0-_^\^PA!_M&.FE)>PN535P7P&B#9J6LT\]*J4_,&
M+>RXZ&S?*OWZ(6>[A@B]VK"GO)7#<'PT9YS@V\(W:@KVWS.27G^FCX]9;$+L
M>P[MR@:?6[O@6#,1Z'\^J[&HA]<GOE/T42QGK==CSH4'VB]>+#?>GF-6BBCM
M08LS.L'8EFJRNEK3+5XHYK\^WRHIL<J">KEC_HE;3_JZ0,RU;AVSPF_S5/7-
MN&Z4O/R<3>V8SQA:8T[:_VF:EY_LM@V]9J?L8^_3G[@RL/!:($%H!-D!/COA
M:W0/"]HOGEKAR.UBCJG1Z78_T%/R_N"F6KI)!H2?W$F0KKDUX=9FO&H(/D6@
M0KT_DEM%T'L%7'=Q*9B\FW.@T^@^]#VL7_"XEF2"?/TXVV.-[F/U2#I?EBU4
MU^O@,\O^KZ=\QJ[G-[IY*/C1<W8GVUJQ*3+Y)8;-,KQ/N*$-^/<$&F&*?6V<
ME@S(P"N_1CQ@6=6SG^B%L!LG]=?V[M2Z+3@C-[2K<=4HK4Q&DQ'8 _SY_.BX
M#;[ALH6J]"$A]L"OMBKQ/L+'ZRTS>)XZ]2O(%/EZM)%$<&T53KT.=.&[0<$3
M^_(EA0==KMZ2. :CN$LPV:J-PU-H,X&^6=K4%X$WB65N<V 0#GD_5&.H>J$Z
M093'V.#XM\[O$FVB/YR+-;4D/UP\?*C[YLO'8],X.[18&+KW_I)V9=8JE^8,
M<UU"E][0ILA3A?S'.;<O8G-O/-63 515)=)7G+Z2N/.0[;!7$H&:%R %N*>*
MHO#7-/))]OF(L 5CFR9/64%.IML<M2+OZZF$869_F2?7$WG0U!%2&_+&PR)>
MT<9P(@?:U!3?BK]<F\!'=\G.68SY(</G68]^:@ZYS6@'M"+WCA;"V.+;YM7P
M)^$^86ET)ZCOE-Z0G8W"]C\/9OLAHG#S?U5WGD%-1M^?#X+T+D4ZTD1#E]X1
M:0+2I :D2XFAAQJ*E-"[@/0N':2$7J1+EQH)-32E)X 8%&'YS\[.OMK?OMF=
MV7UQ7SXS]YESO]_[N>?./0>KI)JEVZA'"<(U_2%L;(^U6+8UL[DR!^VB *?*
M[%%HZ_@W#[$%Y0R%G]:M!(^6!LZ()2AD]\;J.>]((95D6T\T@.E)GH-39:G9
M74P@E-C:$^&]@BMW]B_F9M]7K5;EQTAUT%QP2;_76MP"!Z15-F7PK?;@!R9*
M]#<\+C>R81)9[[N!$#^VI&*Q#[)E<]6US9SR5\0QRFY2HCP.I,F#!;RS(6S7
M\O/R]K4NVE+Q,/7Y513*X@N'?E?:B;4"Q.[@._XX@9/S6;];=A'E+>"&H2^*
M*F(;J[PX>V'.0\U319<(U+&VB7S..'GN!^M]LW:U39<",\.4K3,N7#^'&KA_
M<G&;?9/;%6"3LZZL?+9.9/"T0Z!8OWYOM4ME]=DV43]J-%*""D[K'UO"&(A,
M=/N5_XH8Y,. ]%YY]6T@NET'0M1U+PAI:BL9;8^-WQHI;8CGG;U8@=#^T3I-
MM0 &;&M]USZG9%.."9?A$)(9!@021F"5!D.X( :"ISLMN=H)>D&$-2X2D:U8
M:LW4TO87-A^)?HRL4\DSNT>&//$'CTK!YS5[\D]TF]9'Z=<2+A,5NEA)2AYP
M!33^P ]T,^CP4M^=P4,[VV+[8F :6."P;XKS#57''*-&8_-2AL';1EKQ-,O5
MVKRG7R<E:T(!8QP2NC7E(QG8TR]2?K\E<S[E5EH<R(;$NMM2+2/UV UUSF36
M;T(N(CFY[>H9B;4= $&"_TMZ>RWE6Q7D(M&=R#4J)O[.-J/$@[@?=:#ZY((S
M7#:<'Y];!SL24;MQV&IB4?9@IO@KUT)K&NURW,F@S)470*9?SD.EOS:9 F:+
M*8R'RLE12.GG5_0F:;TKV!O80@$7==PESR:8R[X3^9TL]UKG%DUY6-^79RK&
MN6\Q#M\"*%Q05HC>"/(_CDW?WVVPJ*-\@B+@T_^6[8:;S!H%M'@66L]4[V+!
M 2_#7'!1W<,)[6G!*T@CX7^P]LZ&9._('Y:0_\V#E:%-/SGC]V*)AI/)_.WU
M<P9N 0:>E6KB)K< N]:6@JT GE2R:@U6YZE'*#+JL&/6/(?7F;< .IBP-UI0
M=6C0V*PE6&$G[DP[I@P.<J%&EZ0Q&G"-I0$2*NT[/"C1!52#O5R8#7@W;RB6
M>TA$_;?%IP9O[XJQ2UO!G;@CP;KB-M;& )MPCHS G1]ANI[,R"@H1%A]#J:U
MI<DP\'N876GN%\NQQ*JL.0A.T_\@M=^S27#TTW;2 MZ)) >]O'!HV2%SZL)4
M8FL2OBNP:D7;4:((V*&3JA-S\-"KK)ZEU5,/TS!T9[HS!EEZ\VYN:3=RT*Z_
M?,45JV:3&-&GO"\*Q(6R'PH4A6D2)"1@.NOJT_W^JAZZ5 \Z2J;U4H9;J;D;
M,^,UG6DDEJ^=71>;OU<0+5@T>K[(AWN_7=7+/UIQ@#]@09CJ#2D9IB-W0WCM
MR#>/,DC1<8F;+9S]V-NDYL=?J)>'E%C@!N8'FC9*<.$'LZ<EC<3#":0KVFF$
M@!E\'B<BIOZZ\2L.]$DET3$C6M?=HG5Q?NC/278P7TFZ<]NWNJ[NE%I)[%5*
MU5E)XO-LQ4W(I)E[0_W_.J-="^)@<NXLC)/0H[2P'E5$E ^3(UMC2$0$BC[^
M9K7G>2+GG4>MV<_TW8>6^\E7<A'?-*H]6=-(&"_F;>)F7_(&C4\B^S#$YQ9P
ME"^IGIA?[L*&VNR2ZQ X&LIKIKW;E!BRL*7]?T9J7&S!U2^/ SPN6[/T[#W9
M\E<KS<14O69C'-^5VG#G'4M/ U6'^FBO9=!D'1"HE7(_E!G4M[S=ENG"<[[C
MCW[]VD1,KL40$$?&EN 9IALP7<56.+3!X.\W4$"%@",'WE NVO8M2K!HOC"I
M\G3SIHCZ#""";(CGJB_H$_I)S@9I+<I+V<$<L53#8*?[><P3:D[!4*J/MDF+
M(>/P1^$K*%7/Q C!/1LG^3#?3KVA6P#Y(;-Z0]5PU;\"I,;,94Q?.$CK':;K
M%A!$-UX?X<Z9P<3V3 ?S8]B:#%<NG#-C$.3MZ-:615*%FK+!KGSFT6WU>6['
MR;&.UQ8Q0X]^H_3MUT0#O%<1.]W\]H\,5K&X]'WI&KFNRZ=^/^:*/+Q'CE _
M)YV4HN/'G-O?NAWM7:IN9ME96CK:X"?3[F0'6E4JLD2QQY-+?U]4K]*O=46<
M*K.%PA6%_$'#?S+JX/G!7D(GQU-K)6_V?TO:G="$.[S_E$A0C?]DG&$SXMML
MQ1W%GC343GTRNP6 W^A1'.7 TE6*-Q2:7B49+*P2PXH1[^^WV=C7>0;2CUX+
MWG'#'Z)8\==G, HT3T?2A#Y)(Q3482_2ER*W,A29_"QL)J4K_*3>=P1IBA/=
M5"(]R!%.2DYHF<AW8PD0V&Y%,/BEKEN)O&T3K='>(_HHS>=$4(,-OQ<63/6_
MZ:="^"H;;26L@93(MYM&CB] HV-/*\[9NK=9[:1Q/%$#82)%@06OP%26.!7T
M'43;S0\B43XS9:CU?/6'MKWM49F;75\=SFF5=TY35S*Y>=B+[)M*PF3RN=%+
MB:6C0;3Y>@9M/9$KJZ!#YI[U4O+4 B985ZS#&W65+SNL[$ E=9P$6I!P7K^M
M9?Z$=,/E[LAJ..%=N;JJD_F1^VN<%H\37+0=;?\4K_\ CPU!AS?D[[1YYTYL
ME_?G*-M<W.W?N]]]0D)9S-N$-PO+S!LQ_9=6%F2J&GKW0T98AO3Z5=159WT&
M*W9Y-2!)OOPC_P<($=B!ZQ?1PVW6)<1_+B1A2A6,,>U');^_."76+1^75ZB8
M;&-82K6V?&&?:IX-FC3'SWOV8(+=(XC<CTZ?B,,%4Z&, ';\RMTU+VZG.;#X
M]6_'3K/<W-XF76<BP\=D__O;HL5>"IRU.5;W-)8W_G7K4@.7IIO0Q3^O/Y-C
MS.1/4\F_MK.'07E^\2#=U0!>.16#5%2'LB$9+@'T%U/ESQ0R?E^6SVT\-Z.'
M69&\^&ZCR=E+_$7FRTA(*4:U/Z<@"WTL<]%1!X$IFE\,S_\BRU5O\_T[S?Z$
M/GN&IXMVJ)EU-U9AC0XO'MU 8H8SE)D;#WX%_0BWKW)M,]VQ5_*9X<XXG/4L
M^/4XNAM8CC.&TL\=AXQ+D"U#65+WY*ZR:/.^W@)$I<?8" %']\'_.3G":GS:
MWT?LRD[6B_GPQZB0:L.R9VTJY\VK@G<-CW.&.MO?,?YP\SR.(^J_!5"*/^CW
M^+/[K^4GK7:PZI!%U((./N$N;WY6=9+G@>P#JSHZO!%<!/HQ_%IWZ_V6W-=?
MTHA&\.6C@(I#J=9WG&M=$_\FOTIF[B1X*3\NUPW%M VBZB-<RMX,!@>YNW@(
M'=<+04%5PIP?6*.3]LN?/=I)8O70_.EIY4B'-_#FF@KC> N(OOC'H"OD?R0@
MW->R^5>QU)N\Y)3G7W&Y%D$RGY;<<NR,3*D![C$:XJ2R(&ZE!:TSTNXC%A)$
M4%$?,)*B6;S"WGB9II"L)&PZ2=>?Q 'VNI4P?[4Q2\67$]IU7BZM="N5X-^_
M&S=O ?,RGWQFV#Q3K03_@Q(MZV;N]G+R-6=%KMFR^=R_4D-28E8''N4+XVZ\
M*?S>[=*.Y#0JI,HC_CL_JDO"I$%*X>L/FSZG]5-V\!5<IIDA\FZX%]Y&?/6?
M?!<NE5?)8O;^?<9F C4Q8LL]LI<)Z]O\R15YV=;H*NM  7'RK'#-,A$D@/S.
M@,4:,3TD6@#(XEE%T>&-K<*$,+].X3O?&FQ[%UHNVT%%4 K#@SW_<D/2;N\Q
M;FTFPZ+P!!$O=3'OP@",7']@=)0;3,ZS7%<R&^HO?.+GRJ@8//5%AE9;*7OO
MJPH^2]ZVZRW Q[[[SA""'Z-;X\N"ZU1=.Q.D/"1J+U$CS0&5_3R0WQ^&/8$5
MG/;2TR1L)(1M4;TT.%!_YP=9>+:MTHK@<51^2UO;;T;X$M75+E4^=TQZ$2I7
M'< 6Y2O^'TV-2/X&\*W _8'V)9\Y[&4\>^6^Y],6M"UU O5&%Y<(H9'+*3)G
MZ-L-B3]HT&1IJ=,%*?BN+GT"/NF?; #VT;%WCEFE&Z'2L>L:Y\>/1X90XHR&
M3'I9V[H:.Y.4*"NRRED$7Q[,UJD/ZV64I&K)O09H\9#_R5OF()=7O&%;N "V
M-R @P@;Z;=2N?\H7L=(_C2LR4&*4Q/PJ!/=D $A3-8#'V34#)FHF6F**<OM5
M>U?3$DIRH:QCP<VQHVNYS28(GC)N_#R,,03P=82$\&Z=*K(XW]!UQ^T-;(,$
M:1_. :=";DZHVT?DJSXY;/I<^1];Z=+A)4/1;'SGPY**W#GS(<V.[KSE/3,?
MMQT,Z86Z5%!>Q@&<J4E N_]PN5ZKV<U4NH*+,$9R(9P15H;K<J"NL@(UIR2%
M%<"@K>;Z:B5103?IRMW2HZ*$46 J(FV:VV;A'146%DK9%'F*/ M1G?DK,R>]
MLY_#A]*(.7=V6',0-=>LF(*.(N=.P<6HK_,MX/=^MFRMI=[X_2)CM$1):G:;
MS=1#:21\71;\^)E-.*=B"Q=49N'3 ]FZI%+&.TZK/4 &)KCE81BV3,GR\HY'
M_"_H"^TQ1OU_0K)JOFM46(XQU+D*N/-V+-17M*>MWB/@<DKYVABF^;V6Z'$2
MN.-NIAL4,+YO\MP2\?M>ARFC#N%R0>8PU4J]=S&,SM9\6BBQ(@\\2W)R'WKV
M;(Q]/TJRD;#<I:S%"V2IL(9HMIJ^])U7]-.F;Y:!2\GE[KT@<),^ +?^GZKS
M5<\Q>B.(K8AN."[!S(3UH05;TP3/5D/?J3KN*FHNMRIK>T:D'EK,5SQMVDUL
MV)NS#G*AD:D$]O5+7;$-TV]O8)I#!&X!LPRW@(GJ^3MR:"#'"A\;88&ZN!D7
MAQNF8'G0Y^90DJQSBYU>F?/G9Z/A2:4 7YM7P9:*!C%#DD7;)7VCC%=2N/T]
M3^-1P[+TM,!; +1ABOOX)7 T>N@TGL?IAJ[MQLJD\%K7V3]HBVBH3@/4A%A4
MI NUWY\;IPVZ!> TCRO.'G1=N7:\"R3=\7_:J-O&<4W)<9W:.:3297X+V!2[
M!7 WMF OWP=O@T^)!RM+<4GCB^Y.G_G1F0R<1.3J2TR.TR0CZIXYB')<C?82
MM >LV=QYCF!CUBSMC9Z GEEH#L6(*5-\L DQ],R[0X4?[HS^0 -DB Q,$\L!
MO[%^B'N[HM8[CV?'L OK*I2=Q2Z^55OY1>HE:KDX,]2'T^JFQYZ.*++T=,X[
M=$"8S3Z%J\.#7!0GW-(TVFW@)I31;/WU^&5_:>.N1B^C%[IU%+E5P>@U)_W&
M]B8,8@E!GU^WVJ@AW_I;7PLQ2\D1"!P]OR>R8ZP VIJ\$6O%]B5<--"X6DA%
M"[1,R:G-Y_3?[T\[VR_---$TGR7O?QO.ZQ5B->D=YH5W :^J CFC'->+ QZG
MN[B0S8CG:K]3,YSTP'L,8 =,/5-;$I17+?WNV@G;</[<&RY7$^";L<%2Z?A.
MA,"!VD-9XIQBNFY+D&B$G1?S:[&^JLP9E14.!?9_ EM<=_9,XZS29/*Z9+\<
MU2YKED$YZT,<OV0-=E[6U%G#E##M\]=Z5<ZM[ 3S"+XFS%(Y>S[/N6;OFRM>
M*9%GZG%A]TVXO;VDZ?!^23B!0SCGNV7NMZ R5GT]5]=4'4E2SGGFVC5GE7?2
M)A7STL-(&O+$ZT!#ZT\60QAPH>9(A+9FV2*TAFST\V(IHU3F)98ARHT'D9'A
MB&=L#78C9R%XD#.&%3<$Y]A^$_[%9G>YH8(KMZ^PT!8J]_S!6]N ?^02$<N6
M4>91O]-)T65&DP/X@VH\N@:5'; _7NA6</?; S/[B%I:@0+<Y-MWUW;SAR R
MWU?O:8Y*UVD^ OG;QVK3JY&2=?ARDGL-I>EUR$AL!I8O+"DQA$BNKNCR]@PI
MTC:GR=C9U2=P=3SZD*1"X$"CS*%L8,U[N/YTZ88.1X;NBQ= '/L9+T(+J=YH
M5_*5A@JN2M'> MY*3.KN=-$E.S163+Y_M=8?3^M]7$@!(U[*9&?!4F,U8H1/
M'W^FM>;=J^"=0IR_C%OISB;C 8$RSI[;T'9'Q $NXOZ[M$.'4=,]I:KO4(S1
M2FBNU.^Q1L>SJ"MEO(@L(ID?%>5.AB7E1#)O)IH@_\8DP2__J].C9-?)?TE<
MN/LG?X/,+2!R>XOJWP.EZX:56P!6XOS'L%Y,[[/HT9P<W8 JW%N572?MMD6F
M.:JUQ^K/Z4[^KE)M_6HH&/W1(B*>H4$BUP5FTN@SY^F$=%P$A%(A1Q=]/FS6
M-I25"M64.6Q872J.E?3ZX;BW3]GTT*#6-LP_9(+^FW8I9."X^FQ^[-_//&-?
M#E-')X,/9VVQ#<D%SDMZ\/77CF%.-VMM<NH!TBM3/NCF0.D<@^I2B= 3W9NG
MDDY"0+Z&J+JGKSQ@?1OAUZSIUN(^.;^3Q3G(_2-49B6LU.4$]:S2-%M^.J@/
MG3*'3W135'M,A VY\>"E#^LIQ?ODNM.C<&[:/9V+B[59GU%7;G[/$ZJGNEC4
MR?C[97Z4^R./:3:UE6*5'O0R^X=<FD,R]U;,G-TV>;0A8FKX:F+4*N1)U8,%
MWW^",S!Z0]K'X.WZ;([8ZQZIX3?,F)%RISIXPL>A6 '*-M)2@E$>1X>'(U[*
M^V_0FX5&L];<MX !M6T6LQ!6_PC=#N0QTGKQ&%*&A*Z9'2W<+*5+G5R4I3D_
MBN%7-^I@\R <G#!50T_Y6>!  67#6SB8L<M6-L2]2#O[5VFU,^H(.[SG1FR)
M:!9]_K.$_W-7NN W0##>%A6]2PC#S=3-0N=?X<O$(PMHP\G:]43LLT9%?<\\
M]E> $[!%K_&B.+P/D_7E]*$E+MUXX9>NTU"@\=3!Z@&M%E@\'3C^')0I.F#/
M61VSZ%'\GJAR&GN:</U2GJ,.=_J\$UF_C5@BT]@"YAO7"A"X!-,W@4#[50(U
MLJ&U)BYI8AX@ 4U]O%]K].>%,87ZV()T;*E5X3#S4F*E_UM0KH(0A91!YA(+
M__$Q@V-&B0G9DXS\>/'W[8 G5D7)=CB(GU_E'1 B%M(EIJ[_2-3624QDB6G:
M&)JO5/'DI2^%/3E48NKF+EJW!JT>2-$F*K1:6RZ[(*5,EM[)UIX/LVC0&$P0
MV;RF?H4WY2O9IK\!4O6&B/LQG'/>B=/FZX&ZZA-6:I6O7-TUE\X,@YL<T<-S
M0TW$%<PIN1Q8[-[89;+41LCQ<KW1EW3G/GH8N-JYDZ^QRJ6 8%8<I#Y;VP*:
MR'\V+44E^3>AE"?AP1AQM?=#BCS6"&6.Y[/63W%20X&_AQH>P)[-2[C3@.^-
M;R%!\#-=V4MM[JJZNO%1\MI9^J>:^MJ/B$[)T1^9F27KZEV4R%M.&?IB?_T]
MMA@=B2]7%X)JY3 V,:ZKA)NUO<MZ:I;-II/-O3=0">"PG+5^7#>-<,)$CX8H
M)0^CKM<?S4(/T?8/#M(E:CV'_<=;I]R[)E+-1#ED,_$^/,%[;>H OP5LT=T"
MZ!'!&D.!(]&>Z(EE 9\NB))^&DJ. +[,]Z#;H%TKOCNR4%PVY2/KVS"%/\W"
MUQJVY5.^66G:8+;RXMZ" S,>D#/Z?I/.,*P[L2QCK9V<5D2EH4"H0=YE*Y%(
M'9O9YKAEI3?8F1Q5U.& @;?Z'-8)[;QXX]([T\O;+MSQ\MY,FRT+"[>H__PP
MT6@A)JN\OJW*U>(^<F!X8?->@.!0<T";4J]HL7[]"IT(X!Z>(2E6F>/E?F!&
M:_,G"U<&KX"E+(\RS%A+_84C>07!/3'BS83%ZBO3 =/ I)KJ_1OZI)D1YH+X
M4G_35P4L>E2'X7/V"G/-/4/IVG[D28PV+Y3?2#"QF)("5VZ(#F5'>C"CFIW(
M7>U$8YUOVAY9U'I[,7O^B]F;O@D=QBSA!2P>Q\IL:_]UHJ0?P]T"AD+X,;]Z
M<G'V QR8+&W@YP+A8^G:[A1 _V38R8P\Y<=ZX1L&I^'D/URW@"NH12A6(J^:
MOTONW\QULEBOO0:5P7S>6]3QJ[*LC8<(7$&_&JP!&W^9@DV.$H#4(MQ)J0A=
M*3S)QW8/:=:U!%1B;6,6(!S",O(8T0BK]7ALQ99PK/A/! 4+6C[P4ZX0++>]
M6_==/#\1$^HK4Z"/!#N*!?S[68:3F=3C^Y,[=3Y5"UZF/0WT[(YMKSO]-%J7
M"#NVIX@&WW!_\Q'4,TB:,49:O)XO2F5AI'AHN"G"\AJ=A1<S)LTDT;\"T\)5
M"0YI"??/\/%YL%OC7@J";&8>XP6,EGL7M@B''2OR7!OCP$5K>H*YNO:U$^Y!
M;IZ"93\%V9^DA%/N0HT6G%*_+:7F9&ZD6V?_M&WTP?KY+&3TY3Q(7INB#TT]
MIMBJ$Y0W983G'#(O9.I5EC=D7J_4QK,H'D'0^>K/"@+M$#6[&]&AM/6_-A(;
MA&/)+4QCKZ4V)_X*>H@[;B<YUQ]_G*YN%V0I-B<43=%D [(A;@',9LG1S$NY
MT'J44@P"&/1V"?K/R7_A9I%@SMU*D">'F,M2?0)N\HK1=F<QOP)IG-YP1WF8
M+A=PU5KPQP._QOVEB F_<R%6T==7*B//I1[C)R'.;]YO43BA(2/Y5'$V6-VL
M> Z]!4,9MSMW_8DZPJCNN>O/,;2]_6Y%IT$U;J5H!V!"]<:YB>N]5WR:.]19
M7U,%EKW)AP9F!4:FK:QJBPL#Q3T8SM#$?D]K7Q8!;7X OA$M7)A^#9' %L:F
M#YBNR\^Z_5KYF&Y!P1CCAO!M:DP3#<F<@$#*RYIJ&X\IR70:&_MAC=+U-<-&
MKNS"F+Z19)JIK3JPVJ*\E*>?_2>U"E=#5+\3?4_GU[*A6@:-C/S8 'Q6L4A@
MHP?>14; =.%?%7]NH_DZ"7YW!/]%;L6+>...;Z>;3;RK7 \\, (OR:B[XO'2
MESKUHDV-K&&*F.&IR3E+2]URU!A/4Z.3K^@3@:$SK<<\.5=!:K/7(.A?NI57
M4 AE*&5_V;]ZB)"NF%D]7UN<NYAF[_QE6E%3J= +Z^'W$7  !VCYX/.&U?K*
M2!:0MS1FQZ7.,?9A!KFD'+\Y(14O"0#S2OT)ZE,%N&2_+3#J8A]L[T*VJB=?
M0<;J6IX=>P0@N*$_9RC&<@\Q9A5(MB&6W"]6@JV'+832V09US"^ZP#7^";VO
MCFHA8TSX\'=)'F"-K:F$7G;WF!"*UD5H_!KI^1?3/QO+[E"YW&Q(O:U-?).?
MMW 6IY*X8UQ^@HBJ"">'A@L2X]H9C#BN+8#436J+&]HD?OU"+RV?$"Z[&'=E
M/VAJD=E<7Q%5VHS-K"CY&<(RG[.^,HCZV?)!%\J4>L*; VIW2'=;B\GV7R!D
MT;C7"J/:4J*^UD+"J-"%#\",DM\227\;=4,XC,P<%A['G1[-GG0T9S4Y+G-Y
M2.5)K7T!_ ;/,.S+AL9>;%!96ET%CI22MS&TKH,*Q:1;KZ(]6-2E&@C"O4?
M=KT^6(W!68Y1#GC._9D8Z.&*YL6:A1Y"L0B[WAU4Q,77D?PN$C_YHX@=@'QJ
M.F"['HR*JH##I&&Z=</N5$/:MP JA1V_DS8_!LUT.QD^(F]6S^[\0;SWY'@
M#A,3OYANU0J<GDK?$A24W+3?2HT8GOS+=*E>*N!;R;/I"\BYFK#&ONI *VB,
MO"&;[U:I5K6Y>3SK4PD%3K1U=LX?-Y2HYTX4&$ZE^-T7TK*Z(I(>[!4C2R;2
MP)(-^ 9^*@\N7L<QG)M(=I9?(!O LIJ?P],FISA-390>V>$EI!#J H*!]D&4
MY8[N?FXWCMW8VL9>XM5:,4HJ[HCUBH9L>0;DC2Q&*0EZN/' ]8_"!GSTNT^E
MS^$59+-1&ZRY:_Z&WB:=B6E"*H^5'D_]/MB?Q6BQ5\K5] P<N%Y3Q"8W:*$[
MU6*A>Y3IPC:UVZ4K./F>";966VS,,VFCOO%D=0'O0I#^;"8\A,NU@!2C-!#*
MAHNP6G!OD5N3/-5=RMG:_Z0JQ%.P#GL6?#W(Y:Z@RO]UJZ=Y\X/LZ#50D.'W
M$*.1U:%%B62%S]O4PG&7[^-<^AM0>]/7I.WX3O?"Y*K_;]3B_M^-\79,?3)T
M"V@5")%<UWV[Q- &_U5*^#HQZ67$C6=Z4H5LB_$3Z:,COO15_I*XU&Q)=OJY
MBQD:5]0QHB&C^J"QGVUW]../*3-58OB<;SU^F_*S N]A>] U-R:JA?U)N,)=
M6(9I6U#=.B=C/D?$;Y^"2%]IC6^G%W0CK=4 GB$L. 6T'JE_.)NW7F,'Q [X
MMDG[<$U][\0 [RFL9U[SAS._B*RP],CVA_D0<G]A30SO:01$G-\6L[C=G6X6
MZ_ H_Z.HS6[;/6)#8L[ZV00;4[ :P,-D Q_&!*G2K<R7/?AA6+ $9FIPE]#N
MRMX--R;%RJ>]G)R(>DB04L'KH<6W>X?/PJ0'#)T\%+8*-<ZM S-Z'9_[VELZ
MP@'%+^S\R\Q)-\GA=B1,,O)(>S6 -P,'^?6S<BDX:D8K#GE#,\L_3_#J@/-<
MOZP"@)ZXYV7MR9,Y_<H5\7M C]25H;.G&V4?M0A]^ M<Q=65(Z.[ZDBJDP:$
MQT9G?A3-V#_Q_FZ@S/HC$B834&1U..,9I#"%6-N:<")'IEM>4=>*\JW-I:D(
M)>U0*KK]X.G<_L)\?ZFJ_D#LNULW4F!N4#]].B7@&[]-5>)W2R*WU_@S;S*^
MS2JS=F_<3= 3@NX*\$%D4E%69'U2/_LZ<>^*CY4:](/=''A^<GU5+<O17TCB
M[_MG_614KT,+8I\)E,@RZ,B1HT^QO9EB^6JRFGJVQUGVA-.&U12B!C"9K^6:
M.Q(\0KL4\%.K)WK+S3P"V.^ECKU5/-)2F#+_'YTNX[",_0U$N :S]D6H%?>Q
MZ6\6V%C(O)@;JEB#=).2CO*^;XL)?:7!D$9:"UWFI8O2Y,_BF#IXE@))>T]]
MKAY&5/[QYA3'%Y1/IBQOX?<ZAP_3LU<-?)9A)!.T@?S7-6YQ3_?GH_@KC;1X
M9YT3#E[GF\LLI$-.UFO'%N2!Y0>]G',273764J_G3!R;"B<]=TDR3/0^L-6E
MU/Q^/R(];)B+1D8_QI;Z-^D^Y</B+[/)G$I)G0J.C:GK'+M%I)&,,HW2S\Y:
M,!6X]C57#-X"A$:>B)N?"%Y<O6@U^2V;O_H-1=W?2.[^Q&PA1:SRWN>'G$E
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MR&DLPT@J$P[. [!*H?IT+6$[S_FGLJB+*9_R]8?1OHCL-K'&*L8DBHW&7HY
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M(:6*&('U%IEQ2<),1+1GO##ATF>:/G?!.[.RQ)-C"\*_PSH>NN9KRQT*5GX
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M60=I]A[+\A4'0:XNLV%Q0OT__Q1[-'I?.;7.]/047FH#;C8<P-NF^J##@5$
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M$%(MFQL&7HY\;>1KWXZO69]+!@O3#I<2^!I&DBE+ZNAPR6^\"J9A3FZ\44V
M(<)7RDYC '*=P)Y<HNH'HX&^A'MXXIR4Q7E]VMW=!$U0VZE9_XY-(+6Y&Q@<
M[[GO;YN@O4W?=X_=^\"MTYL_B.I?^_ M<^V>[#Q0U!/$ZQ3:OA:[.5!B&%I(
MXN.Z +B;(4V>$#1(-UU&GU(3BVWZX?W1AJO[X#=?H;?IN?>'80X[7&#UJ98K
M%P?+9'V;Z\J+1:@30R@H?,2G>!K,A$=THB(1!GZTLGH$UF.U S1Z4I27-YS'
MV8<L$Y7M0^L]FOO]9A;_K<Z05QX1MG+\>79_B6LMV'^,?5MKS\ ?9QM']!L
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M!\L)YIXU?6;L9_OS:$LX;CK;V96DA^;9675'=ZE&(^:]HJQ7NXM93TXW#[R
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M(2,CTE9@*;83#GS--Q*MUA29^M)K-K+-MGRXA/HN._>EKC7<9("?1BC&TC^
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M[3\BOWR[7A.+H$>EC_P$>? [^<JQAOF*<E#=KW.X.NZ^+I&"\CK?J".IVS2
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MY*G_'^WKC:L;I'=J5:%?_[6BCO\[_K]OQ_)G\#\B(Q^JR$C([/^F+?%XOP3
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MN'#)Y()+8[MW,\C@DM#NW<XWN!_VYIT[IR]6&K7OQ\;<0?C'QTWPHLD7=F?
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M!UWY0=OK\Z.>D1Q)XN%-ZI):78@[/JJO7&MOHP*'P,\!W,B(R GY^ $&V%P
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M&5!72&DXU1D&&2/)@:Y:NBK$'<[)U1V4>6&\,E#;L^9HRJ;\06Z,*#K*N$_
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M@]\@C*E67:6P&OQ'W "&LR<E];\,$,MKAX6E\4BM4G ?7VY[B^:51$@S4/:
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M@X5"Y&P-7[_]4&P+S?)R+(5X55#02((KIV1$#[20C'1[&1$MOV/1"BI?N$&
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M@@D;YC$C+?/[+I_9-6 FM87LO)E K,E#%VR$4"IN(@U9L"PY+R50Y2:TMJ
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MM<:Y@@""9]TSR KGMYP9FWQ'Y_P2]E,*.R?JPWS"2B*,6X0M^;58>'%WPL?
M'9(Q6*982GK>.X9<D8V%OQ)I658MHU3(L*],=,/8Y&ZY@D$JCXHPUH=)4+QY
MBG+AID2&\LL/!A$R\L?"3^<ON(]$677HAYI2W\<QU\M$7K7OY+_T8=I"7M-S
M@JPN@5^"=6)'6W/BN!%XZ\)__47.W)^T#V$=W):[MCDHEY.8+'B)DXI+?W-#
M6-$<S@!.!1(H*+MW(#QEHE,G_NGBJ>=&_ZV[@];HAM9*CM6\:"'%)?EEK-%6
MV3:BDMC^=0#R:!XF\>]$K2&O8)=PS<_;9K$.'L#A'V"?/EV9A(LWU'4\:Y!
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MM !3]JG<"J26HA16%J%V^E(DQU_]\MO+-Y=7OZ6;Q&HM*V!^P^MVK?L@P)W
M@3-5"\O0!Y^D#!MZMEC3'JIO"C-Y_*H'#9?[93Z/V-G/'3O[]1$[>\3.'K&S
M1^SL?R,A[CTD[>_(O<]^;PWHCK&H6_,A.*4L@?I[.*76A53T$.VG[GZ]M*M*
M9ZS=>XF$O/@V-?D25BOS+826@2971GIR"E$FI,9(;>-D*%UXY-M"JDCJB81)
MZ;7,)G>MBAWI5Y&4HWA;7 <,OT&5,FW,EY2G_!;U-B3XG6AVQ@@*ZFQ* B.
ML)J^1@$2CNF#%S^?_4(IW75!N(J,79E<(4GD"H1!;[G>E,4!6#[=):@Y03)J
MYISB'(BT)8ZT3=UZBDRV44H$?Z.X?AC-$S"+[W[XP?&!9'=?F]2CXF)_10CR
M)H)0WK@:R,%/ZR>Q7.$(CGV;#+<>-9WJANN[7J0T6-S4=[E)2D_B3T/?&J=#
M_.:TL5NLBPTC#5@EY[[#&()73YNS:,&7:NG8$5^;D+U*ISQ'A^C-9&B57PC8
MH.V"\@W_AX""I=9U)B\\!:=:_/0ZQ5.Q$4UOHP,PA'B^5;<'J,!NQW/.=Z1?
M*#1YGN_";#PP)+:'3GPPU0], /;Z IB 14A0+(-8B-()U3G#Y(?P:1<LK PD
M4SRE0TBO2(=R'5,57@D./!0.>1A6[[O\!B>$9IZ#W>54(>5.D(3AFP1?7#KI
M]P/KP1 RH#>>GI]EP_531=J'_W?LQ>#S+(W AF)W.N?"4U6K$"6O/@,#^XG
M2<,FAWWH_=CSRHRI)&A5]+N$R(@94DUKEV$G*G=CG'R2F"D-I#.YUV1_R;:[
M<=PIG,Y**MGL@+(D;]/>!+OT;\/GT/%.[3<5$826%9<H8#AL',PJL>5&9R$"
M501,F#WMT;9%ISYQ9U3Y)/^>Z1<4^*+60*Y(7[#=09^#49FMDWYAW51+_3B5
M.@M?IN5+!UC\.GD>U(P1838"<VJ+\ )J3AMV>74;XD?/(_/:"2)W#A=5J&44
M(5K+WKNW.AH;G!Q]N>G*&&O#&T"-(4X%&8$J6!?1E!WZN0 M=4CBY43$R-T=
MG(2]'Z(_T1$=?%G:^G5-[%AX (6J=KZ= .BCB%J(R\[-QMC:7[]Y^8^7O_PV
MNR8"<2C,06>:6\COD#S-%8\[(%(*P55+9"J2R#+ /9$/I8?(8$X&#SF"5U&9
M902N NZ9.+WY!F(3B]C-XEXHK=N"6](!K@NV/%=$'79 C[H>8.ZRI+%$48#B
M'Q;IH,?]%T[+ GE,Y*YY>3:K5:$-,/SWR Y&OWV<AOF56[8X%B7VR)73B@*$
MLSD8,;O@.2S[JC#R=%I@S%-@&!RI#PW6EKR-6JMY@^KUT%!8185;$RWNS!CW
MAQ(+R=&'B[5-\">Q8M2K4UN5)/M')N \[)LJO\=Z"UX*_P?2V+H$VV+%H@*3
MS1@88T44)X@FU63S@PI0G=LP\C!E.R:%/9]=K7-DD67=37IU6218LIX@.PKT
M%)AU]\&\;1S@7^RBYO[I*\%T+G:@^52\+XR.)VB7'9.0PTI9S+80$]HIBFUO
MVQW#CG#5_?+527Y<.!/;-K;C45$GN)6EAKCHOZ*S62MBM'4Y'<2M.HKYQ&DA
M_%>*]'6&JM]*LL+%_;@9LY PQ&^3K$)_-D5'6J#_R6R?SWZ@?L9E.$0HDM#,
M"0SO@S87.R[!4L<,RV1,XT 5^D1EI&Z.,N7"B;)WC077NH[<K8DO-0<%CUE.
M26.($W/O*E--'#JYVJK\H ].R0F9$, ;95.$0&S>LBY&BIT[? -\(*F'ZV(9
MMD?8VMH:?_ 3]TE.KM]M]<0)>5-T!3B=7S)[&P@B@S-%_) CEEX]JZPR3TU4
M*G3!LB3Q!]BI8H6=, K@]LM@:! U-I[V?2^Y^R#TUA1K<-S ,.NYIBAFJ2IP
M4M]2MFYK3QH\-<?T*+YJ9#1>-IT:Q7RYH;A:73F#E.ZY%KX@7$5NE"6SU:>/
MPP="DA)0;LW:C%*Z7.]GU^#8O'Y[?3H!AR/BQWIYUJS.%,5A%?Z62169%^JF
M):R"PB:&=CTB)YBF*1)7ZANDY#DS:+O7P<5Q-R\8;Q/19?X^?-%(T>ZA O)#
M^-)AFK383'G7C.(+YK-'7"4O5@O_G68L5,.'SYJ<<M.@9>.BKN_MXZ9"NS6E
MJ1FJF*+!,SOQQ($2GK<E*,"9(CX^>E2C8$Q=\.<K0*IPQ(1O@[&AC=T@=M3Z
M,D%L\DLG%2$Y<:PIW=963_$1?'WBM>JI28L8"X%# 1!',*HYO!H"->AO%WEM
MZY+2YW&'U[*2SG"8VHI]>XVH@[R#L"4IOEFD?EM\'##&HH67O3W7ZLM.LS+?
M+8A68&$G*J'Y1W0"#"K@2LHH4RJU!DG*/8"XZHY=+/_]Q_XQ@1\F6) NZ0$&
M 9R#/!*38+DJS@CZ$@Z5FFE).Z E.1 84E73=LBB@ZO;FX&4O 4R(<GE3K"^
MZWPHKIO8+W\.HO7+T4:T;N-/6HL]=-J 7V,,A0K8#"%8FL7R@QR88K:Y;#.D
M;I"-+4,$%5IQ84XL!<+0*,"B(CUHGMI!PR2%'WP9;*E'%_Y.SK+8YC:HX!7E
MUEK\XE,=OO/[R7J]))A&;$^Y\N9.+3$Z\\CV[X8+VQW$&?>EV!KM)OB&D=VC
M"U656U,PRZRQE>KM3'EH/8.5$<QW.(NG3\0N-K4/[I1F^2[CIA*?!H\A^:F.
M4'_(9>0=W+MXP.>*?Q\7*1KELT16-)5@#%=:WB?$ N/'TL _#CQI4Y>Z7".P
M:Q>ABJM+GF7BZ>*YZ7#L['340U!NE<Z3=6>&M<O'?Y7?A0UV%^7D'!BA(P1I
M3KG22ZJ\GUW%-"M#!/ E-0%W:TDGK=@UBGU@'$-/^SZ64N98E>Z5C2Y#1*=T
M,K.T;IZ82_OOL $+R']@\0PNH4L[>3=YO'L<'+E'XJD'4[NS/.O4!'%?,7D4
MQ!*^X[SROKF"WSF )"@\ W3C"%T,56Q#F]^[+%#VH84? A/EBZF\LHE8]:;=
MDA%%+MF)^A&1F#0ZA^L?K'=SQ'5^AKC.;XZXSB.N\XCK/.(Z__H047"1II[$
M2M;=KMC"7T(U*O@M(H%J;%_Y7)I)H#D1I2&*]\5FJYE_G/3@>$2!VOQ%$AQ4
M! N'H9!QA M-"0_GU>TYC-G!;O/$44S3D32X.Y&,C2Y#+KIS&D%%="A*1\KW
M0ETQ5&L&EE1C+4NV\D.RDXUG3+T+[NVE B9UR^25MA1J!*V=,#%_8Z-&Y/HZ
M^.(?(QG&M77QO9;@RYF+\S4,6M,RE+F1AQ_Q'4BY0\42E[,WW* E[?'=8;?W
M/N*\EQ96O&![EY(0,A_+OT4 3B4O.,HWUMI$"=P78R!BP1$R^58,O):HG1K?
M;<584Q?G;R7IXJEE(Q]>HNK,)*Q^7,-N01N<YJV8(D5JK"EH,"7-<$=EN/CF
MC(S=F2BLX\ULW6F9Q >#Y3(9",!#?8Z%<4:7[[ZG/#1MV]$2BN_PXORK_SF<
M%871W 6'B_WH[]\5Q38,K!IZFYB3!R:!')9O+RZ^-H_%>8;II?Z"9_V39N3'
MO"/IJGSQSI_!AQ0"G\^N+-$4NROIJ Y+"5Q'M,^FGT/H3.]'-+4?DQ6W5+B4
MUSQ\MW!T.ZZ=>:R4'I4;[7+G^P8+&Q2+0,&;F9=UDD*?A%-+ME+@J0,Y'*ZT
MEG"5&'##U:#E2,R."S^B2.UEJPF0(@!GY36YP2RU^_E-4M5L2;>:\:64J8+"
M4$9P$^*I15T2S_\9A/"<+<P<6OY=3:E=<G@;,$?)W<[C28G@F/_W:"2/1O*C
M3= /- /*'KL312.W<\__*BJ8C\MD--P$L8I->_.I!S"-AK$_81T,_XE*HC(U
M5" %:QTS=D%5? IWA"Z(^_=F0@Y#&)*)D>7WB2TF+2UBCP#%V@:X.:W7PVD3
MF6-'$^/;TR(N KT4Q?O2NDN\])N5&)&+!QN=T?TK"H#9%_9,],!JL\9!(97:
MCNI07@J44"HFRSPIJQ%_)RA"I0CHPGO@KJ'\1C'QY&>VI/5= /JQ6@E+*N$^
MN%N0ZB:,RZ=+ KS4-EUW9LP(.70KHMY#:F&/!O9H8/^_00Y5B7&PH [!G,XN
MIQKKNM3]W*8/0'XG5?[(,';.9"8V,4-C@T!],_K^G?*=I(Q8WJQ)@FE?1=0(
M;DWO<%GF-W73E9WT/8"UC0D>2<2#33OSMR>M-98[*S<"0Y/Z+/=5JQ\W?/ D
MCA;\75>^)S;*W1K\/-14+H1>3Y_HWU&4EL#YZ+<=S<I_QJQ<+A9A:;3<F6""
M2(=D7%[X%):&9NJVE>U^D"_9 =KDB.@><,B"TT+?+Y3R"]Q#C)XD<8WPE55?
M); .B0"'#E&4>>6.'#@PD(H8S_#4O+.6AR3:)RRJ(F^U]6&H[&(H:%6-T/9!
M@C@,*3*M#6(2QQ)O2N41=K:H*PU>T3ZR+,:X=$T=+GP_(W%T!1A0M+_S] @R
M@S"XH\=([Q9=8;V98QH+0[DM;QGG4;9DN5LF=PX>[;Q<BICQAMC3*OG' +UI
M(]GE[QC^2LF*Q:+I:YX2I#G1+MWF;6R;3FH;2?+"$@XB\5KJG2L*WND!J1FI
M9D<R+AJ(^^;N,M9KZ15(4DU:#C:\=^T3OB-O&N"EJ84GJCP/KR""L)Q%&9/!
M@MJ#.HSD P:/R=/'1 IX<E#!K/C\<_BO32.%L4V.AOBJFW2L+=?O:[C!ZC][
M]C]#&_7_O_3_JU$_ZE53,X_NIEE27VKLNX"= Y&;RYU/O@PJX'E#/"6:1T1Z
M%;4CJ3:4*S%$2)2NWMSSY# 5\ [NWZHD^'GCHV"FCT3UZPY&D$DCIP9*I8V[
MX"(I"X%AS+9#-F$!.V)9V\^MSZ#!>&GOWWOOC,&*$3GJ$FW+\]GK,*P&9/(_
MOOCUS64TLL4R+8F$.+/'7I ITK8VF2/R"I=M?@=X_.13KJ:4RRB%NRF2/@C6
MNW$XMF2"^1D(!(<G)D.WNM=6"114Y52  ?>GB!V!K=S"$A4N\] E9XIH1Y*X
MM>ICH9_%>^BN(<TKL@E)HL.J<L&:JO":!=$I_<CIB\O/'E_UO;5#@W%_R?+@
MA3A(-2.K2W7O93#UU+I>)&^ /B48GW1U2U.O>SQ)3$>5%9-5.-<^W]]D>[GG
M5'8$&0GO8^S37DG[I=^$EEZ5US'CG<=6&YTJ.F/0F9IPT/*7%99MV>LKTJ<$
MM#?VGT"XKQU];$!&D;22,<WN6B)Y14*_P+U'S:K3U?E':M%?HZ7NHV$1TEC5
ML4GE(QC3:A*BVM,T8V]GPD/5S3;@#(-C,WE<Y[LU&6>VB!LP@X%U-$$\-Y19
MHXF\N6=A(P6,L*L5J<A';GI8OR)^LZ ';;WT3OB\"LY"\&#$N\5Y LK6="RN
M/V_J(:A60IVQS4:D!\WY,;D@L8<$*2[<-!*YFL4-Y. @I=HV<ZC@4J8R7[!E
MU7C%(,[\/JCE7_C$ %"5Y$-)X'-ME&)_DI4Y*&VJ0AU_<M"\E&SE@'LC$M]3
M1IB5A19EN^@W'70Z14$-(.OAM./L=01!$QTFT4?=Y_:%A2=ZJ07E?\RT\(I>
M&@AK1, &T@ QX?AO-GYY=8_3E1OAR$+Q"DE$ !]8$EVR9%T42"Y0/^^40"$;
M$H%\B0'\;U[WE!D.?_AJM'4=TFNPBSW+S;[M&6;;OI_BGWR_"S7&=&[SDRZU
MH- DW'0'7^H=\$L=GVYXL'5DQXN-F"AVAH6VLU9T+I&*H^'[$,R94V5H:O-S
M(4\4H?'/678NHL"V!LB%YHX#&(I;J I!.K\4)%0FY!H\4]0VYM*[H7J1M=&*
M+1T7VNY^*[609LX:D<.)M3%!UHLCW8'<=?E  YJO/TV^X2.L_3.'M7][A+4?
M8>U'6/O!P-J/=9%C7>2C%^2;@M75N=J_O,T!#5"_^Y#J([-_DH.V#>N::"TD
M&K]"BH"X5U*O].G7+ATXG9^+SL@^(+#Y,(KO826,]H$I TSDTJ>"DMHPG+P!
M*)$!>7EZ6> &Z9!0X(@6'D8HG(RSG92V1U6@0*UAT7/F\3^/S]$PV2F'31=3
M_C RDOE$)D;%,;K"$3FV>N@EW*=3+/DC90/8)Y7GT>'3>BU9'(,+49LII \X
M-N+3\R+@ LD$1D!BN*EL@S%[Q&)4(V#+#;H_8G&JFRZ3'V1#P($T?+P5-KBO
MGGQU,C\]N3@E=:9'2G)%3\XTT]3"34G8I!""I+NM1JCM$"O!D%E&4,8) Y+'
MY9D=46J%I*K-V:,A39(DA!,**_M0$^9=D0).A&-4-+8XW3YXW4]/8U+WZM)E
M CNGEIOVCTA-&EDJ7]TD3:-P+1*@FKS5Q>A696>_\H!FR8]Y-"%J29)X(0:(
M3"O)/DI7Q:8H64@(P(G)Y51W%PQ\E9M^$P.">BWA5"58)(FD?U#^&C^60ZK;
M"G*IKTCOE60(.I-'H#*)95&$8PK9-+J"4H$I?T0"?J#YT#_2D46O>1N9,ZWL
MT8SI-OR,2YWBKA 9ALC4S?2$NN+D-W(BI,\6/U.Z0F9H($L^0]#!#))$"XO%
MSX_C^#N(T-G=\&XMGPQF#:.T$6K9Y'$:K/%:W*U[Y^TE!!5NX](FC<?J/E1-
M)-ZSE2%>0:Q?V6L_E[4/DHU]!@ 2&5%11>T'+V#S%8*/@I2Z^"+8TUIRD&)M
M0MU!QI%)-(6*/+)VP.^CS_N.60>=K-N05Y1P#;PW!EL;JYH2Y%;CY5FA':<@
MY;W&R%>K.V"8U93X!'HVV$,T4>*"2H>-LIYI C?6]0L[@)IV?!C)=G<'R$1Q
M50OU*$348LLB4B12ST3AUTWP4?LV\C=J8AWU7.[_L[T]9G#U(]BM"Z/4M;'"
M]D5O>B5\0N0C-QL[.L&UGG XID;)S$VDZB7KA&J1#<JI)*IT+HW M0YUY-;N
M7,EVZ@# )C@(,W3Q[.GJXL"]SL@815O_1Y9Z9O?AD3J?EUW7;X14DCJX"(DH
M>!/7\Q;!'0:880F03#XVH6PI!(X, HL;#.D.(S^D)T#VM2D7YIJ5,ZF7+"4^
M-KT%ZISS"M=02]@Q=-N39<Z9&FO GVD>KFHJ9 .?UA$TYQT\0T$5>N]&Z)Y0
M#C=PAZ*\]T3O*X 58\.,,S'GLQ=T+I+E6I I8M)L&,[[,_&X)D"82=:B$(:H
M/:Y_/IKHGO,!0@]=]\CQ#/"%P4JUBZ(;4J.R\ .W'.+8]CK-'6JP:KLCXB]%
M(\(1B+,>U<>M+2<<1*IY0P\C:CQ<*'.'Y@-/G* 9%21 Q*RK?.$W@##-AGDO
MW&XP/;;4KCB1V71-"#/$B]]_5"5B"\].G/1LA@NORHY>Y'V1MU;<Y?JW78\&
M$_[TMR^S9T^?9$^>7)Q&JD0/VO3'3MK#B7/8*4+05R%D;UIBX1Z9*XF2/&QP
M0O[VY9-GV;???D?'=<RTD:+JHBV9H,2?NATF3E2-K?"9+RG'"QQ=W8O\#UJE
MA..$K89R[BDXV1) /)N&4O,8@M@YJ_ TH;0DB)C)*#,UV0Z/3OL15&JS=4%$
M9)G\<B?OG-M"5#(V[0V9YVU;,A5=6==A >^4 BY>0U\',H[=AKR*.4D/D,<K
M:QS@X!TYLVU8Z9!>3T#AR9N'>$':^/6HSBUUY<0Q[6"]8OK4;<&JFFR(<834
MRMA)JTVZ(.&"^O>6"P2=402M(D0U?AYL=&QN-5->\(P=7$*+VN:_U30X ,[A
MT[ 0T&>(C,/0P_=J#*QEPR#M>BJT[DC26.$)CK4XCQ$3F#%!F:GW3>35"*A)
M9CC"G:3K8*G P2B7@?'3?Z.]*6:IZ35!,VL#Q-C4>(VNB&WO_4QIC]",Q'U9
M!+H K"6\ZC>DVX'9_)$@'"=O?OOQU.Z1J"BX2/$W-3QD9F;A)WS-N<NN>1YU
MY#GTQ=6LV2%&95&146X<^ZB?-'![QLYZ.RW<=YZ[H&SO7?SU2:"-N:##V\A2
MGP710U[=4ZQ)\9H0KH1S%$C[R;.O=2(4@L@W?$>G69_GG/&V;\CNR]0,QOL/
M=;+\=.!QI)TX+GGLM=C\HBU['3N/_=(ID5A+ M@SIS4SVCRV;+!4VW")\9%*
M[IRLTY*5C79)$(ROJJ=!;JUZ'U:QF!X #];_X ,'K3RP8U> .XFA ^GGQOLX
M+?REL2L[]XIF$G,DWA?/4,2]@5:V8VF"$'!NP3P_-+03R<BXV/@KW6A10#U0
MC-BT](V>!4F6_$%M!=:I\F3A/941]4+E3INCG/J@R"F&ZY()9X]I<&>](7.-
M#$7TI@3RB/Q58?$W#>B D1JKZ 3K5(J!*FY1',DYLW'^:;RNHU13,?R:9JJ'
M*:F204.K<I.[LSOVHR:O0DJR.3(FFZ8J%CWEU%6($B#8V%$Q.8JHJ627Q6S(
MR3FH$R8P>1F?4IZ(7PKNWV5,4:HP'%5^$ZLAH^*D&DYD2?PD)XA 6Q<BN)RK
MYIN,5:SW<IAS=]5>EK_ !+)>%;LCP?JS9*?O!^#!4@5$^T3"T]] :"%N/I+3
MZK;"E=79/&"]9%)-9]%,X0 $)Y!MJ8EX")5?\!/.B_M& A<.C^BJ>%./U/J]
M0M]-+4D_3I$D3=_I5 Y8^&.,);U):7H%1ZEQ''GY#0KOED6^9' _1QDBW\V0
M[5TS8./ P1;QO4E/G5-5$Y.;"E4Y]4X-I7W)<=<<% SFB)?]S/&RWQWQLD>\
M[!$O>S!XV<=SFEODD+CJDZJ-Q5!0FIWD^Y&:M9W HK5@A4P]/GO6<R VZ$'V
MY0_<G$D;)^6-4]9C .G&2GE]6SBY>J]J/='C6M8Q6Y+JHXYXI._5N1BY,%.,
M8])I%-8@%YEM8.E3O?KE!2[QT]7$PS$H9%?<>#G[J-&5%BMBB0BE#FG;,9%3
MNH&[.95'2&@Y_*&Y+XPG)(J6HJX57A:+(44U/DS#HF]3/K7WVX( G-+,2!E+
MPJK6A>;75RL61N88EQ@U\+TV;%X$TZRN.R-T-OX=7UJF=1;47*3:]D@]]-B*
MG[C>"FD>":U0$UB]X !7,KCK<AL32R'DK$G7M4I+91"UB="H9-%9D<]J:;(L
M?^%R52YI@$6.O,*#!9-]M\\36I6XCR*,@[O7<@\T(6!PB38WAA-3>3A70;YD
MMRJ)#>V&L$M,U788_""+2'<J%P6$G;'&N=T0F R""/'CY[OT:JJ)R-F:^!J
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M0I4T,25>+1G>\@ -LF1W?S=*8S]2@S>**A23FHI+YK,W+U^_E::Q42U;/AQ
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MDB-'CK8,0:I+F8IVA:NT7J+,12I<3;X3R V+ #F-+QY%E/=\W!&YSR#ZUZN
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MS7=S9=YE")_"L4VSG92[S4@F*WDH6^]K8+;]/U0$JZKQ%NGXT-$#P\Q/7!G
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M,X"F$% /'T&&$IX]F+!V]#J0^ZH2Y=7!7-(%=N79NW+Q;AXL9A8,3]45JH-
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MF'%I-&P++ +UZZRC3&+9I@*#(O':VB$4;.296]4* Q #& U">-MA\U0;L4/
M)/>$TA7_=RRA.P*XB?PNH; E$@B_R77=-_+S8N A&B+&Z%3B;?["HTM*%WM.
MKXMG3U<7#YU>/C/]%V',+A7'2E/H"GIA!E^+"L&UH@3%^7_Y^^/T!09QLC=E
M#C4&0Z1Q5+(%;_.V+$1F4#0%IPOY(U@-P!4J\>D.YX=B$@(Q4PRGIAF(MG^*
MKK0H:M\57HS<(,VI@+$!.]G$TJ$H/[(?"-)GCXBYX!U*3N'IHT<\'8'\59T]
MI_,N,]5.NNK%-V<;3L&^_#W3N%^,O;(PC::,#CEX+G$^\(Z:KDCOC!L:5([N
ML ?4BG!F?,"$I2K)#X_&2T[4R\'Z@+I'67O@M%"$\I!!TTX"I"O(DEL0*@ ?
MUUBADXYD8S+GE LL"Q6Z)'Z^.8LLG<_>IGD9'A/]%ZU/8C3?KB4F(<BN32P6
MX=!3C":!801Q7ORYZ@:FFHV/-)SXYZ0" ,_@%R_[-AQ:89 O=3=<AL4Y.WGY
M\O*471U%19 ?T=3 >OE51PBDJ!^3K#!^P[$!0S E,>,M'D4T0D*FA&U WGVZ
MP;+8> )22(25ULR4CU1M;BG%CXQZ=6_4PVE'4.H ,]\=(29OV2&)SM!.^N[9
M.[,_#QPUZ<@C#?IF*9$!,H<FJT'.Q,"03:!]QT/;P-42(74&C8&9<T88-323
MY((2G+B5-[3G>N!ZG3*,H58K!5?:WS[JR1=UU[>34F?H+:WQ(-Q7E",D  (E
M..9%!82QC,@UK_V180BI:LXR-IJVXX8BNY@N,YW6SV#;'PCT_Q=RN'7+O=V%
MN.6Q<K\G,]'Q3."P"3L;3-]+;E#:<%_DKG"8=[@6,>R'[[02%XSJ;8MU@5Y_
MH1H&ZRU]B<2/ :,^GR6W/Y$NI29,\/MRH3\XM7'!.YJ;X63 Y43@1*8R'-#;
MBL_9G_Y^C3I" >DFX(WI2'W!8*I@S"Z>//GRBZ=/OGAY-3L1V1ELJ#LB4>6@
MHQ267.O[M 3GE,.A5<+B_":<_FV^+)NS45<7!>\=9:70X8SO5/F\ %.K5F5/
M1]G4>N*%99S91>8@G/_:67%;WC:931HA^&N"Z=F;S8A*MMPU .^1#E.[Y/^B
M:%B%IX(;4MY*0_V"OI+.-,UMG&TMLI!X$Y'?8LZI;-"K3[T(KFHX,W+Q@HE1
MEB)/45?3LHYOLAN<IWIPEK$0-#4EF@"F\<6^O[985=IA\:N[!]-RJ%]PU9Q9
M>,LTLMP:R9J5WOD\>)MQ(/;V2M_.;W!OCJC'SQSU^-T1]7A$/1Y1CT?4XU]N
M>GZ->+UG3[VF#3F<@V,FZ:!X^?MI\#9G7SW[^HN+)T^_G)V@\OO;F]-)L3/-
MND0E%RW)E<%3&-XG\22?ANO#D]S[K5,.ES'BW][,\G*#ZGQ'/ OAC-+@NR.R
M\4U56KX@25%EECX8L8J,\PGQD<YGOQO_/GSTIB%(G38$,BF!^6$6KDZE*%"!
M)>1;TS+33_H-*6<EOGJJC1 F^#6G'KFM"VE=Y.;F:1Z!68( '" !%*U@F><6
M(_[?0!4_)V(FYO'@1/$F7])]HUSE\-V\<M#*M_!%,P$-#F<2Y"L5%X4HRR+)
MV9>O&0X5*\Q4(4PG1"8+M2S-*@[2M[+N_+1$MY=I+0_?Z?Q43>FH'E,=F\J
M(8@('MW"9LU1@0G$ZWN03\D>8I(/6S5QJ=^&6,065H%DS):T;'E]"Z(LO))K
M?N\(!_)=/L\[A9<]C[^7<&?9+'HCD:30*]@0:I'B;6V45VZ7V< \[HWM08DT
MI!8H'7$(PM'I%?9<%$%<)G-B<X/23Q4OW2"F+FVA74G,9]1BQOUK=\P$&>(M
MT :^ F>J<@7*W@B7IAE-GF.PR#,!U+HQ\7?I>NF,2>91KJT&",];599?W+._
MZ"NC_44-VMPX78]-2U(6F#)S5@.P868B<;,(ZSH,>G@_G:ITKCI:(HR."X\&
M,M*]EZ ^6'#,+8M\28O;ZT8;19M?8<FK'CR ?_-L0=NF*N*^$@*C8K>F[:9<
MMI$$RET\+C)8WE355;+?<5W4&M]3*Z@RZ]HS2U6JXP<VF2!0#D&-6#"EP:+P
M%*BQY^1#;)#_[<TC-IGJ9"BK( M0BR]3%._+;HA[4/2+[BQ?DF3W)U8RQU4R
M>Z>Q#WOZ6(N[#A=(EV39#;T'(&>FOYEX&!$N--QVV6"DWC(0,)IVG(%V1C8"
MLZ#-M8Q#3 JZ@WK.>*2F^D0^4.H\4;(?;@\"Y;&%D=<A- XQTT5<5Y%.TL%Z
MAEO5<X[D3*;+@>$V7*IYK!SB9(7+PM;/)&9/G#YZ^\!U)I7F+='[#==C2D>B
M<02G'%_VRS:_^HV0JO3ROI^M=[MM]_T77Q3TP6)W7FSR\X+JE/1_A_]:#B2[
M^-J*^)?^M#[XZ?LDJ_KU'D1#XM^=O+Z\[$X5%\&0:^D1B?)L77,FU..4FFRA
M@0IBH:&-__? IR;D634O0*060Z[7/:![;\)RN:E+;3)[4?B+ITYJ!,GP8> X
M6*9BR<1A>)POGT[\Z?F4HRMVSJ"C3QAZ.7C9AX4Y(?ICUN*41I/A >*#8!4,
M# <C<WY/N=P)1O[5(KARQ/+P][)8$+(XA-^E] O^TK1W^;T1&]&#T!&I+L5+
M;G7:\\RLO+#MJXZJY0ZY472RLMA+E*.U@#;G+HRAMEJE5)Z*B,A(=#-),I=5
M(*<P(?GREHIERS/:6/GVWMW^1"%81&"CGV<$. ]S'L[X,#7V*WIA.+S/(,15
M@+G*+G5JO!M.J))3%Z++:?56U:!T@0'T[#0NB/,@,G4.*O;SJW]\<?GJQ=N,
MC,:"'/&H<5?3D;4LF(L'MPR_%[4)#J&:<K/IZ\)=U\F?R4?WW2IA$+HMA4Z[
MX*:L!]]SLQ63M&H<1D]0(D2-"(\O%8K ]*(<&QX3K*+T$8(W+ *ABZ^#C\<)
M-S#0(4I-]L>=@NWEO*=0EZ"Y@'BQ$@G7RWWN;?I)N"^*E3,IL%FUE)G4EQ7B
ML*IWN/!9L.)^ZX5YN""EP/P^3#!+P3+>L5F\"Y:IV2*(+VH/Z[EKR4.$*6[:
MH?\2\Q<-1_R#H!NTE?@'0CPPLO#[Z]ZE#&7LAM*#O+:-8L!7L''UP=+-?@\7
M.KGZ^?7UZ?GLTO.SQA"3X4%S,6#N+N%7\.,5^D5<6+S6^)G'6Y0>D&E&"P7?
M-PP*_!>(2MVKLY>:N6(\@?\U D*&@WZ.Y 3;)UU>;A%%H-1'O-IX%.?3<Y%L
M@:=?C5\]O?0SO/_/H%;]J4Y$):LCA"GEJX3Y6#M]@H<BDB;F7TQ!.JA%5-IU
MPVEF #9_-,7<[PJ;XY:VPXTZ2Q/79&Y9I*T$38S=M6BVEGZ9M!/?^W?IBDC4
M&W16A9#^K&#"9DSLUM61DLKYX&U/EL@1DC['>SU#Z]'WE/DD'W^T N(KN#C_
MZG\.9T%@-'?A/.(*\_?OBF(;!E8-Z["8DP<F@4IYWUY<?&VU/%<S32_U%SSK
MGPR5]KC;AT03$$[)3BM>R^GA9CX]96W8*^ZZZ:O@[!2$M$Z/Z:F0P>"7J[W;
M$XE5RIS=%SOI7TW"$.JQ<5?*5<Q#9*6PN\DG$^<@*@E]>)M+.<L]Z&+=P/](
M8AU%\K<%,E^+(OV4J/:*?"FF1=V<P8DS*$/$PP+0"_[?HZ$Y&IJ/3T-PM-^Z
M:/] K8WTIFP>&' 6O4>X6JPCGMJ!J8+VB?@&X(!_:)."VG$27VFY%E?XPW[-
M=VISSF<_6G >[ QU3 J_S)Z(WAIBP/C/2BR4?69^5Z<IXAT=5E1R!1YRK*PS
M2;\4RS?H>^1&+LSHOPOI@JG*I:L*A$'=<%.H/>F^/(0/V?=/Y:3I>CS^;HPP
MT?5[%KN ?7I.VKR,U6FWWIO^R2R\M"K' ]B%M&@2TS3AZN\*U%>32B1>8]F]
M.U-%F'E>8?U'\A6NJ AA>-Z5N*H[QPQ0+$L/9,1AOPFR.!-,.F<<"M(/R1<'
M(O[V4,/J@:36KQ1I'?:E]K(>T;N?-WKWV9,C>O>(WCVB=X_HW?]&C[]KG$HD
M-3+R-KT&X,DE?3%L@*=?2CM5G@)ZKP#H_>:" +U/OIR=$#_:AD6&@X<XQ/Y>
M/'GZW1=?#7D8]"I?/?F&KO(U>1K^S-M36NX^*I5]>CHKB(<3(AP,S/-=L;&-
MZ4&GEQ W]JO8.NR) 0V# %880\ZBACH!:0-ES;X[GL_>]HP]BZV_<O!WVJ"O
MJ7=7;/&]_">1"R96O#ZR:G9*??DG3T\3]\^NS;)YHB0]JF%1C:ZX5195+?>A
MB)3?U(WZC@7Z\$/ LRS >\(,7A"46U$M#OR%F&DM/CV?G5Q\S(C":R+MN5E?
M;\+_ZMV)!8G[_5EQDB[W[/0!\H'!+-L2<,!FD+7N7P)6L#&.676PQ;$N-S0Z
M)(\X:<T$,$WM0@'][KAN$J.\IM_A[.S,E0^SL68 EI(9YA,R;A@E. UV)<!\
MO&3#S'QY^M%10?(2V++>"FOBR5>GPNA%3+S5?9P(3:=%X3P*:\4L>P4%#C%E
M*^V9;,;\T,.0PN;'[&>FU6 .+(-T>69+KD.%';HJ@;V8C]@2D^NM@\M"U5A'
MW.@N-A245--1%<9I4M\TLORI9&P=P/5RSX\C0[ );H;YNBGY#?%47'UX(KC)
MF$$"T+H+_M5]00VN*JV$'H P)L"FZY[5M,H'8D:5#4]7 @/D)B-/T).M4CD]
MT'<MN0KNVDPIM3SQMF(YCR&HA@2<K.X.&;F<>-347*= 9]0WIW#:'W6.'$;
M^QE@R5ZZ\O&5]T\.?@(_B<-V.7M]&87.W*$DC1%<HDYJ[G[2E( 7%7A78ZAA
MO&<=2<LP8 BVNJ^U<T:-<&IW<6K(&:6I'.ZI8-X!'DU- (8JV;TKD(:2;^
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MT842M7B_)QDK[;8MGXE!G!DWED*?;1,XRS"XPMN>/-\XQI@?8MT*=GXONFG
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MV#B?X<%0WIQ6=?G'T0&M27'8T1VZOS YCUBK!1R#=W?'D $XB=-'  EIZ0@
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MWN;"#'6";#\?"3MA;M^@&^Y[P60B7>N.]TY#-(PE'Y]_J(9$M*7A0]J"H$3
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MFC^'XME+*WY%@G5Z[BI2#/=>_/SJ]+ZE47P7F2(7F?M>!(HZO?J@:;_*_H)
M@Y:V@/<NM(J-?/5I=5[FH#U^O:BW\B]<XQ\YXCH^<DF^19.:M$^_UJRBJNPY
M4@55&/,T2MF4Y$T"1;D@%F3P=7A>-4DMXQ-9NF:^8_ U"7VB&:99]K;"2*UF
M?[@Z]>#'?Q35$OA70:/R'TY^%&G@Y-$S-V]X>]C8W<TS.B:GWXJ<:FX]YI!6
MB*C!XFJL%V"Y(*XZK]H75IDI*Y2K>F1&? D)JR+4;#[/:R-)!HE3*L0LI7TA
MNA^JS\ \YR&Y !K,)I^Y/FNI*H6G>M\3]6^D0QMXX<9Q<*!QT<\\YQY.^ZN(
M@Y2"B8?9O=?/^1_?G/SI!-W_0=CIAY]?O+IO,BV4Z"L.7>4:\4&7!Z#/\U0A
M115ULX&A- 6UY8'F*$_*EZR7[#X(,R;7@)I.LHR!:7%D*31KZ8X8BD=0.SP+
MSG6T_73._#E[/-.)$2:L]! ,#?DYYU5AP^.*I7?O^:N7]T/\R1"87 D3= &A
M;V7,J6C><-_(:!R*<K7UU4O&>]H(1IP6LRK;;SDM)9TYANICH/CE.,D2NZ/Y
M.J E"/%(2%C@H'@1"87-, _]*A#6WGOURN9;Z%]PHQGT1@-G?[9[-+>A:M%#
M90C:)RYN_+X'O)#-9\>N]/B.T&&[<AB]E4/Z[,EI=B\"=(ANE8(EWMB)G*D[
M_!9VAS^>NL.G[O"I._S&=(??'9<&Z2MOG>->.IZ@9I]!FWDJII5!V80K\IRM
M*O%;H5@Y3K_?PM^5EC@XU$;.$QOA,/=M10]T3I-CSGT\Y,Q$[3A@#SK[^<7+
M3+8+V>!-46D5+Q\Q\=\L7>(1V->4K"0X '6W%3 ?)IS$.XRZ0YNND3HI?9F>
M[98XP+$6_2+B([A9G -UU671U J(9_W$R; ;LYM'?M[=Q=+]AS/\O2BIXMM-
M/FXEAZB)(08L\SF,)W)17O(]OA>=\@K=D^?:@=32Y\A4SP*9G]P;9K9N)2:Y
MR/^=-TL\;$I*?Y53/$G![#..%9D*JE;HP\KG%5;=EMN;@'3I$W2M%G\OZ_)2
MHH).@!_#K;C]K\S7:[;"_L;QBR\NW#J E\T+VM]SCIJB3PN*Y<XC&3,&4+@+
MOT($PO442-O%BL($GYFW&G?1+ 4S+&I'CE=)B@LC*Q3AB5TY4X1<C7: +0"D
M.8D. D'N0$ ;LT!K;'/^O2J^HOIGU^SZ-?K>77U7%O,T?MAU9 ^:Y*6P:R/;
M+V_"5;:YDN:2V@^P[/'EM;E@IM37._ZD%$/D"N[= ND]W(J^1?]A?*9_.&NG
MP&=HT[LF9>-E0#=KEJ#ORZA"<5F43 +:\*):9XATI,3=):N\*&$2>IVMW#<^
M=N)NB1'X(LJK8(\J0]XPFHQ.VD@"_"0O*%ID.EEHW:AJ*;B ,*M7SIH_:%.7
MTE[,8JF%>HB"HSVI=PZ"PUWC%\S.9S>Q&IV-MDC)DT%CZ-8 "\O/P:*PC7J$
M3.X8A];7&:^<=2+[]PRW8?JQ6$%'PLLYM'?%@OZ_ 3ET7JRCQI:YS"HT##*B
MC]+)\;19@UFZ#DIER(_JT0I]&3R64?ITHXBPHET_TH@<9V>'KS3Z+7GD]28'
M,*:<69<WS+\=T EG64BK0#P44[+W_GO.H.BTO?<6U<)=G-&2\3F?A4,>M=&V
MM)>WZ0Q_<4?NJ9TMJ6=QUOLLWZ"Z>CM6Z,OD>OLS'=_R";W(E]G#AS]P-'3$
MWDVDFNA;4F \>?Q8*&O1A2J)0SL8"FSJS\:(P\0W8G,GK=)HSW4 4775UCLB
M=1.W!J"[I6 \0]: 31O'5.QL->=YY=E#?]6$;J):^8D;!_!35VVM8L?^(\94
MQ5]@C2I_L_YU#.;0QAJ+@Q5;U<9?86RG+-RE4_V@AQ=56S[?Z3.07K> [9:<
MSR]@8PT]7'N\R2_$0G-3B)S+X=XI=AMHMEJU<$LPAS?V46N)/,Y^HY]@O*7P
M368XY_ILI#Y!E2[<Q)#['[G&$6YUA4F8"T,.CX7,8X<+7J7S/V^*#4]<:F]K
MP+S/8WN@$UUF$<3D)3;%7S U+B&0P/45TU=!\FB9"X:0@YRN.M7]2>#@GX?]
M3/@E$I7%\T[T4/%88"2P%1;I.WUT\A$6'5<0 Q:PC@X6P@\P?'M>DWTKMT]M
MQ-4+V4)^E49 @R$GWKTQL+B!&KC+YPL;RX+N+O.2?<7XD)#$NZ7J5Q;OKM*E
MY/P7#A:?N%R J3!TRB-[8:>%.89>!\ZAZKFMA#/+/1_S#AC ZZY<^$+O:*+L
MWD/IMT8\'Z5ZL8DWO#46!YV@TTF4LQ>_W19?Z+/GL#J#LS?%ZF/.K.;L#//*
M:\%2VEG\,.O,4!MVG$"A0]MTQ5;_K0,[,T]/SVE\385LW7DC30"LQ%&)MS^:
MXVWZ1?*S&]JK1;&!)HV2D?@RDV%+]S:^'GJY[;[L$]#MUF+?H<JV+"/VE"(4
M]5:F$USB#/(80@G1ZSOKAF !"\7E4>VA;K?UXNV1)("3D#"_XOF@*R<S"7B.
MDB="NR9ZUN0K?IR Z^L.09"]->XBA&:2'/"17P^>8$ZV8,54D_GB+0)!NN^%
M*S?1>R:(]3-6JD?<^3)#%*%L\EC:8N5BQA5I\PQFQ"ZP5%H0^HJ,]88(<B87
MB7[>NWW+HK70,OHXA5F8B%N\S4J7@Q4OSQX_.+GW]CZZZT#*EZ$8RZTZK2=G
M7_"XCHF!HI#3=2YSFW>E\Q-2+)%ZZXJ2VP1,8C%TO:@I'N.M(L&P.CO"2E%"
M4<0XTZ%?^!9UYAG 8XTD5/)-%PTWLU2(:R%VG:<.C=9[%KJ8US+^!2I '>%%
M4B'PA/*/B6^KK@K>PE6T* W[YK'X\VV7M4V1D,CU71S?B5U)C@K6XTNCK>+3
MMR68?!X-%E+DT,FJ/?6=_+]A+Q&?W),9==_#=_(GCK*^NQ\MY?^59=G_EC'P
MM!K.=4DN=VM=%.^*9R-+@X\?E?F.[BT?D<<\>?#@^,%_V^<1N^2;UOVY5<#8
MM,;)W_M??']Z %^+QWF60_EGNX!]BCZV] 51ON'C1\??_7=<PK62)-=PO]GW
MM9./^<Z#XT</_Z![/7Y\_."']W[O?W^S;0;+I]5NEK8YZ6.T[U?+(Y7=%?]O
M7'8CW!-I;< O1L[$X)G3 OR#$Y39]5=2VZ9?7,(7(U]*+R6';M +0Q_T-7CK
MCMELI0TALX-G7])*N=SP"]?KM=GE<RF$:YWR7_.U2\KPV^776WL1G >/OLKJ
MCRGC_:O]L5T.7W-Y[YAHGYY/DCU)]G^B9+_4=J?1]?\(@[T@T5PMOK[!IH^.
M;?Q-.3/7W=1K[>%?<SS+*_"#42#3S+*7%\=/CK_$B;KAJWIC-=$-6K=/4S+7
M6L=O'_R'K^$D>S=4$YY=%&XU3"S,(CP!Y&B$5*EN/I?1NRE1ZEW:ZM/2O:.]
M;/+LI[Q<U.M9]N*GTUEV]O+T#AZB2?G<",/W^.%_^!I.LG=#M:$8OF=<FD+M
M5PT?6[LWC8#@?39S-\5X?_P&/W'HV+_(7A1EZ4.\6?;7*=";=,X4Z$VR=_/7
M[0O8NU_<><_6O78+-+ TNRFTN[V;^R1O2E<!0FA1S++3XU^.7TQ&;E(T7RNH
M^]-_^!I.LG=#]: 8N2=1?[>:NBF0N\V;VA0M/2(&=)X<9V^ZID(\]V(*Y"8]
M\_4"N1_^P]=PDKT;JPYAXUXHHNEGMF]3\/;';^C/KFIVV=/C[*4#X^34C#*I
MEZ]KVA[]AZ_A)'LW5!.*:7O-0TJ I+F>=:-_8%CE)@]<?O%YH?&&QMF-PE@%
M+#/3ARR96+-KLCW-1YF G\?]1\R'L18@"9O$KT'U "8=[4VBJV,",L$S?\!<
M)(;,G&]GV9/&%JGW,'\'\(._Z\Q@Z)-L J,ZG6Z:HA0>'+JJ81DSZQ$C-0#0
M1Y\X#'X:-/09\X3LY$KANW*M<&6%LU ^I0</\=>(W^3DN^1%&"OJ,J<7!=5>
M#5CY?)L]KU8@7-G%TY5KL$$U#.PG_*;I6V,Y1][[./OM4F$4,.\GJ&(,1W3R
M.-NYO.G=[T*!OHIYI\. 2@,V/H/O)VLQ^%J\HPU=,0JR 'K!/6V%:P!OD(YL
MMTPQP*AAW27<IV)N"#DW2O8G?.%;CB_\[80O/.$+3_C"$[[P'ZYZ8DNY=?D:
MF 5+N'B1 U#"X<@8G^;(P'E2>!_Y*GL=\6\70+P!YV)6U1[/TD I?GUR*@3?
M/*L_B^ G%8846/\QS\+9;R^?_^W-JU.&^-O0Q9RGUES595DLNC*GA]VM-Q>T
M"+.L70.$17Y>[)B70_\FL!GT')7_I7[ =6_=NLAC7D-S/#R? MT)P!4"I1$<
M _)#_NX:H(>N9_2E!4A5@7#:HX=8J(MVSSY\?X_7>.:]NW%OD7PBN\3 W_N^
M[]%];^3HH))4]K5 +S_S= J#/676EV2G I)J[!/!Q3J.7\0S6  %\J?CTV/&
M50+\:[L% >I6'=:R=.>>M^+GFOS&,P9"PHWQ50XU!%<1D!2+Z!K\UC^1SUE7
M=J%; I'SQ2.V_=WXMR-J&W;.2O05Q4,GQ]D+<M#E_;(YW/=6P@8*E21L8*@;
M $><%PL#BBD4]L7CD0$H#%!/A:L"?RB=VZU;7%3 )P:XR[)CB6-@FH:#(+JS
MHY/@LG_6@JGW:T=ZBF.[]L+M"9I>_\__E_T471IH51JSJ;:([KJP/Z1Q(9_M
M%QSJ"-U9B+^&X9:LH[/3CR>[RMLAMYFM$D/4"":2XNI(@"SP-/3[0<0;[4&L
MNY0=B1VE!F>SP?N?GA<UCG2L$5NO+,<U9;+-8P\/+1_VUJ/'F4XQA1N6:>QM
MM]*43:N]S=_YEY\-WOYI3IXGR*0KE@10RG&Y.#PB[[QY%;SKI#TNLA<D V*A
MGM.S@UWZPY9!L'GP_OF"F949WI$,P[DCK3A8U,0$C0D50^*=/%(>OM+M>E?(
M_@+>SNM8LO$'6Y&J:.0N#[Y/]I".)K"#L'P_'9ME,&GSR-:_5P!&;)6 \P4Y
M=?GBHFO=%A"$IVOZ=BO)&UR'E-NH-8AO"P(!0"?EF5"G@A!IT\W)FML&(Y%2
M5.F])H/RWG[WVV%1TMY4M28=Q9!B2CY&F7?K@C:1'"W R&U()^D1(O$D<[+(
M9^\[TO=>/WEY>K^GX$%O7H='B_7[:SKJ]3"7^,1M.CHF?U%(S3.2Y=:)E9-W
M?_[2?OD^0R 0;;A7R>NED+5"HUQZ5F^FY[/7K")Z8OK[_F4YJVDQ?MDNC^G%
M]4/W1S.H(F31-NYYP_\[7V]^'+RC[$U%+^)O/52R0&ND%X4O@6>F?=!M,,LJ
M=C9LRDR5S:%<:.\*#V)+#1=\GZ6^QA:^S"'@8]L( +BM@4;F1JV< -)N0%+=
M;)6+6<#@#&;-OPTB?8MLP/VP#3\*Z*&86/H)/ 4@J-AK#:,]A)#1UGBZ1*1X
M_2:Y39/37WA3LGN+ *QY</ON'S1'GE"\9Y"\6(KA>V#D!H&/P&(24#6NBF9-
M2F"+2.;%XHQ40>4JE;=G17N1_?++R^/L->>=+<YA>]:/<U@B7E_E=%[64#!J
MF69BMHY?'+^F5^</_9PWEZ@Y6._%Z\5%79?R01\$18P942S%X'CF7NBRB+E/
MKAR95#.<T-_ZC-V*HNBW\8=^H860IYBLX/Y.^-MA_D:Z5KT1Y"K0PX<#50SM
MDEYKU #M*>OH:8EIEE>KO# B^3B2R^!=E_&3'#3'*Q1M],2!E+@)M]"2&+Z#
M(SSCG<I>>X?_S/^=+-$O9S/Q]W9:%1L);?C[81'Z>GOD[7"T_H>T+D[0:6NT
M%*1;_M_'!YWT?>JLG]OY3JS*]9_Y+V4]IPM&C_J+RY=^45KZUO/UFC3NT6^5
MJ@UZVJ<OGM!V-W55SX8F/SQO0&.&E^Z:Q=OL;^<Y&5,Z*NMVFR_IZG]Q]$&)
M< ^_I/@\)X_3RB?*D<'<6?;J7-XJVGL-ZT2YP;B1/BN8.IQ" +)9BT)?1>_J
M$WH QCW2'-;:H7J8;R_(^IWC0B?\9S#YCIZ/<8>@!5$)/=U8[,5$%\$3"'7-
MUWE5KPI^>O(#_KU;N^Q>8L'D[V*_3NX?A[T>VB#Q*)>NW%P48WI?5!>N)214
MH?X\8BR>OMO"#R!S/%F#:[:.WPZCT&OS5(,0<DL']#!</'GAO=J1<_963^]E
MKG\J.P>\[&U$W6U)(TY(YW; @;,O6,+@T,@W_;R8*8T?^FDQG^^&@+?*R)V
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MA]F]GY^^>KCGBN9WANYC@[R=!?D+2$<DJA1X%SREH; 1!4=TC&C7-7N@(_Q
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MS6?=O!=*33ZR=LX ]R,ZG;[OS#PO2LK0&-@:4[T,KGM+7,&OA&)X34(I]JR
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MB(SMOLK[-#<[R><GRJ<G>N .#[ -<0>TZWMQXBM$M"I&8N@)UECS'J)#AE-
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M(#G[6=+H>:)?;[LUC.YN XI%;-)(H>T0(G0>635N,8</PI**MG/>:V/JC!Y
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M:VE)U-H:J&!(L1CUII%N6)PCV@0E@J=GLE&T-"!H8!.*@D>&Q6[$Z!@FH60
MT07H$9?T%$<6@YX>)S;-D4N/5/+(K?7/^YVD)^#L?)MX/IQ,\Q>-[C7^QH,W
M' 3NX^N'W+VJ7G^S)7!"6-EBJ#'Z^!T]VV>FXI,*;%1XC5IP*?(M> LYBU@A
MI&80E:N+VI>7>->J5D1$(U_UO 5FL[I$;OQ<!H4LESQ>Y(6S!05M9FA1-.1F
MM<P4%B8TYNF@#)URM :WN)DW*V*%Z9$OBDU</$R[>C7'#A^:4RF#;\TET:$*
MC;[OBWXP-3RL%AEOG<1#6D6';!BK@)Y>T*3"Q>G"VRLD&SKMHT#BL<*8=YDL
M&/F')/7:N)ISWRX=1S:?S,KKVJTOSUT5X''@3*93TEZ2I&T>YUHX*/#E/7Y@
MMK=<H_E7A_OJ] &^?]YHCS5;V;2FH,YGI#-[L0GG;#SXZM;W:X]EEK:M*U>Z
MMU,SY=1,^?F:*1]-S913,^743#DU4_[AJN>?KMY@B/_?XAH7PPZV7)O5HMF"
MF8Q]_M-I0*].6M(S8?YX&U=$;%K&4,[+T,@BLX255D3'T*OWM5H8PUB$M#WH
M_PM9\F'+WVHV4CO=VR<V"RV%O;X[GD4<I2_S[9\HLCB=7]O7\V??MMX_^ZX6
MUH^S%^0%(<<LCQU>U5Y3!]C[X2Y?QS<&2?,@5Q8X.;ZLKZI!?II]/EO_.# +
M4C.**(XML-<0YCQ\J=_5&-<[!K1QL\@E1;5/ZT%1^UU4@>,2D-^&I!_AEH1/
M7Z%/%MZUD0STNAFM38B[B!@#<PS-0R>=Z(M+G?XV]UT*5)(FIJ,VGE0/4YSQ
MINY!#F$N1=KM5L&6T^K+ZM.;+J-B89]A\/U-YK=$R#Y[H<WJ/H=Y0/J0$7$U
M6I+ 83(R&J=5LI K5Y9'VIY:#OI1W\\"<H  9)YT# ,L82\MI:%8>JT/M?:!
M/"'RB<,\(#H5 *$._!]%=>$TDQU3@5B9L]^'%ME!YI*0F4?#];&N)RW%Y.>C
ME<K0=7'P!">86S;]G!C_5=V,+.H-(#+14<WSCA1$A5R=P8WHD,48N4E_Z"0T
MBD[( &)0WM,>?]!L1-^]-E;+J!'Y"),5??N P$=IN1%ML\Y30BSZR%K@ANSJ
M>Q@O]IK9F?21VY,S'(7EZ*'6ZB;2:L![(45*BI;;(/M/_BR_K,44VM-P%M2W
M^5;DD \W*L?1%$==%VU@L=G2]KY><P_71;>&MM-7T28OR=J)0O/U?0]7MI!.
M#*[]6LXR_ILE)$V_>M=0NEW3I^#R6O(,)BP!WSL[K_DOFZY!KYI^1K@<VB =
MI;M$ET%\95O8J JU2)/6!FO C5X&E<:W][35B?6( #.L2>L03)%X-V)391=,
M 0FO=.GH#64]$Z>^<1$\Q!S]S*:KK<']@X34*\Z$)UR#G$36-#CZD&L;>I(9
MFB((XH'3>TU>F;NKI\5";G<;;=?@WH$M_&E0>+/99 XRBH&WVZ8(11/NY C,
M/B-2J6,[(NJ-ZLIK$;K!G1HC"9(M984\:AQB;L+6RNF,J(S&IA%&0AX#Y9I;
MNT'ZGP17<5FX*XHKL8>?7-JN!U!GQ]DOQ5N'"L=,Y'EF.!]'[2(?%!\.V"1N
MXNS8S^3GCS4]CX+RNC3G3B]L[52#!PK)@LT^7U5F#7A#MV@L[=J%VVP+C7\N
MR;N3!M6X4J/UH"HO=UYILD>K !O6^<,Z05%IENI%CPF-C$?P?B'(X^;?0N=)
MKDD'*+SB)/ATEQ)+!)E0[2C0&.-))7DH!H$B^QZU((=7T3P26:L>^7A![C1&
MZN3F,IF+EP@9" HKMD#.%/NTO$2-</CL:ANM9]8D=9;BT9)7G =$H4"PR7V-
M"VP:V_>D,W@&^4*4A0AKJ6(^=$L@K84GMH#8M-NQC5+R.9_CN=[6L!9G;"V/
MJ96W40_=FR&.V(%I;ORIW=:T5)NF6$C0SDW[41,EDHY%96X#,DU.,P)-HRBI
MM"X*=L1XJ4U^507W(LYB-*G&NQ9CF:4RN%>@V&IQ.LI*7$^N9#A,NZ%M2@>9
MNNNJU+MIX9Y74F?'J(06Y24L1+293BPQXK^=JJ(:M1=V3DPZ K;NR+9OC0EF
MF 764^YI($=F'*)NY%[S^&S@(R,?Q6XC\!#TSJ/D,KTORC#YA?S&I]XQJ,&N
M;ZVZX9R6OXH'\7K-[#[P4D\!E#680L[7]2"CD)#;D)TW! 4#NY)IY_$C'Q]O
MKOQ))U[;-><RJM#DRT+'H'$"+B@$$T]Z)]</8P+:EJ&0#A*XF$**?>?0VR =
M3=:2[-&E($?2^]KC:_#ZI*NBSK-]=8O30/6)UF&RI*W/:'KIP[U@A&F1EG#/
M>(XKCF!TS\4(LY=F4H I:OTG-W/#V8&35&Q]P\A@9D"*0-HM"=S'G<[31Q/%
M<9NCE$]B> +1P;.Q40A-:MU5O71:[:Y->:E!E4TZF:=X'<;M)"NGOL\8@39W
MO#%XZH'"VDB"WIIAZVB*\/J.0$)E-T;L_H$DXC+E8<.S2CD4[NRJY8:>UD9:
MT5/'O"D]+Q@CLB['%F*N)A@(X(J^!Y,WB[!?#BBRN#%,^7IE;# "[#T\?VXC
M>E,!8@!)'09[]OOZO0'8L1U*2[L&1A%*B^9^>D0>5KF^4!D^*&,3<^?Y*1!D
M]P!<W/*6;-M7*$X^3]W>> I[%HU6\_KK]/3,=E6W0.9I/2)!MV'01P56!73X
M>Q+["03(P"OQ/ <!"S>,282Z-N<E>@DX/L;PR*QV+TY#']YG4'*Z-#_UEHC-
MYS[MOX6&7*W]1S$LQW Q2&FO+R&!RK0]\S(P.V0F16_TX<;VB>3,Y%%TP[XI
M^T,"A#2$\:^&KTP=IU/'Z>?K.'T\=9Q.':=3Q^G4<?J'JQYD$P*;9:D^DG9_
M2-D]X.4'G+<+BMKJAN,V2\=R$"PP"GUCR:#E7,C2I!LS9"93KQ+%S:)D>X@9
M98[6 U!PO@GY\[Q9<A2\1JT&Y1:X'2%%UE5:Q>%#*YG%TN#HDU+H6+<==U.-
M%4%YTFV83KQ60X/D$;2%5)P<"34/M#GX9&+_EG?4\7R3]C3*7H_)G"5MI!-$
M4!1X[346 9X3@\$-$[\R(H^11#Q.O,X3O=E$;W9 .+6K6E+BH52(FFZ/D<2P
MP@1_23%X MO#]5)X$PWF)*(?*J(AJQG34&($PT]7[X-'G<1M$K</=C#1+)Y+
ME[/'2@HU$8/;W,\2/ G=)'0?*G01*%N*/!58E*K0?]J;2!OXWQ%P*[.731(Y
M2>3'4*H'\%_%>W<RI.C]Q'\!_E=&H/9$F38L@^F124U.0OEI0MEKEQD1*NC(
M2; FP?I@P5JB=]N L+6R&O!U.>NF>9<8%&S3S<MB89A5S#/J*ID]J7)2F.B/
M+MJ\W3IIX3QW-9 ^I8%$I/B.\X(_#4R)29%5FYUY.T83M!63?.QK2@_YWYF6
MPBT%%[B4 JET68:DY0CMP"PI[":U7,T,+UV[:(HYQB?+UEW)B 3:<XO6($M?
M89+PF8B0(9:V4M8\OK'%V;LCAV_B#M^J1E<6'5\9)8XF.[D-/9KO_K!> /;6
MTXGP)@ ;Q'W%!M_@Z_RWMFOK*V$3C"V_G_,=S/R'(LP'#/V#\==5Y]N+W2@)
M2C)W'55V#'"$&\\"DLF@!VU<@ ZU!YIJ"Y?:"PLR:$6+U&+$,RR(([=$TCY[
MQY!///KUCP&0/U9NF*0ODH=9-$F'V?XV'N[W19W07.BIZ(:S;#)\BF)1*QUK
MAX8%.,+;;=Q,\PGO#(JR(H56!AR[D>ZCHC)@TP1N/QPT13/WAM,S'>@]I>=[
M#9*,Y#VX\) T()\GK,0,/LA##O&0/X"[A:!Y) 0-#&8CSH'OZ^<6>9D]^"==
MN.5Z:(\06EKV4W"@<#(;'1Q4($Z45N%:R(  1B0C8(-C W_MRX8.@@5 "]B7
M1E(]_3O&B#I"*;#J%,N9I[G8=8JA394<'8]HT(W<068#?,FT&+>MV:UD%E<8
M"\:YS:(LE)]4PH6/L\C!L['$<N<'?8>8%W(O976+F^@.==U^TH'D$1'=ISU3
M)#(UP3#P@:]I&2TL26W>-/65:T:&:#*F:;^"M2_.@8^NN+3TQM+#';&=V"BV
M.)2",TTW#$?H*F?5I>5B(8 </:9!\".T*1L=#_MB(RS[D$</T"YAOM,UX%&7
MBN"J:-9I^_R>.?26*95TY'(;&@OV]T^.0FE5C!UZZ21X,-3A'LG7^R_DJ<)H
MD]*^3$%3@<:FO6EEIA6K#K-Q8,PP>(K[37F$P'+MV<5O]KR9[II- L@"Y"VC
MI[E=K:9>47#NJ#'WJRV,B9#2EPZ37PW%[Z\LP'PJ /9,=_'RU5.P7="C_RIL
M/*B&2\9( ?/Q>RRV 3<P[X2?!#,*/OF35M1E3"L:5)G)F5R(Z=UT"1IM=#T>
MO2O+ ":Q\4]/HA]S47"5(-3N=2)/AJP21'Q/O+'G4OP!,7^Q@L%\%SVZ/OC6
MGMMA:4O_<H*+;9J\91S E6L:,1!7.4@#$DY$M"W[CZA$GS.XCDATBP.%@%LD
M.V%(Q!"%^C1YJ@W%+'M<C(BO%7F<?+E+#5V4KLZ7.K7)*$]AB:)9)&_$^"YY
MJB/W[ZXZ.:)>Y\ZHZS!V[.D_AS><NW/@-B&V 7M&@FL.<$1LN1.F.!+<[->Z
M.CK#\Q4<Q-)C @8!'S+$<N!;L_8,D^Z!J1:#]OX)XME";QKD'.%>L\%E@(55
M>^V7;KW_M[)2BOWL74&M8T]YAYN'9\/@O\HK>:/DM\@Y'UT?R=8! P3SZ:P"
M]B^5%=MTO;PU-=(,V8H(&KJD#6KUY!@YP.\R>^H?)H:+-Q["\2JR8&>&]XR.
MY0A'61XIL^?Q^&GVLLRK,*:J\4OX\)D'FU>=HPAX(0S-[;#&>^</KCV]QR0W
MWX#O1(?,W^"NVIWWC8U%6M;HINCX]-I=_#F(*1DUY'CZ^^S]B&11RFID7YEK
MON)NXM@WE]RK<3Q%75UU?,365HL9L(76 LM6EG[PN0\.6S'.A&<SD0/JF\H.
MJC(V:&%TLG&;;NLY)/)F/1M?[T!MR#0I],UUT<YIR9;*.AKEA;VM=14S%TG$
MN# J;=H/7#)"GA^%L)V9ZQ9-^CEZ2F8^O)N'XK2/\;<7HPKR8N@\%A7N<^[7
M(J\#]V!_<^PT>W0+9X^^G6:/IMFC:?;HQLP>3:T54VO%>QK)/@5;FU/61<OD
M\J$A5R V9\B:BJ3Y3.QA./"IZVR2X*\BP4Y((Z*ZRQ[$<<&J[Z..SP1B$8QV
MZWKI%%0WP/=:"@7FOBWDL1C9#\"+$MOT"+ZW];MBH;V;_ITH< ( 7L,8-UIB
MX"H/R+X8O.<0Q$S=&#0-4WAS:2(J/G2MFX[?=/P^YOA%V2_)0RP].TL*$19-
MM89B)OK@FSI?BGE ;4T,AL!A<Z>/"V!1G 10$$RY!SK2LM&\^)5D:_P1F.1[
MDN^O[R!!40^I$;GL,!@?WP\B-\GR),L?(\MI,\\X&68,NNU!]TK4P7G")$+9
MB['TDKX$2V._MS5NT+3UX6=L.@K34?C0HQ"Z:4([9@*_67^J5!X*);1<R>WI
M1]J%DW%*,&8DV@!TMTV:F20("7C@D^A/HO\U/!JS#M:8)^4U&T14)'K/VN0$
M;W[AEEVC-4HF@5EYJ68<]@4 _0KK_RYH:S#.G4PX-HKTZOU[FP>73I]DVB3B
M\T)KT&0HIM/R)4[+!YP2)0=@K-+\O*KA1/'IB!IW]M=;)^F=I/<CW9S0QBO]
MS(6T/>9+DCJ> ^^T02^0%8[%!=Q%(NTCXMUPLZ'G=-E]!J]I&A&>!/UCU?1@
MP"4+'=GB97PZERQ.4\)!; ,O\=EHD--G+RBI<7'$O7>,XXY/&C,SA0[L#:9H
M0*#!9+'XKY!4^!$MSYG4(S,8T"W*%(XUMV%G8)]5[5V+2>$] //JE')75"HC
M(PS8UR"[OB7M9U]AA/2W_6PR,@86#^M>I[06%^9Z,!97%ZY"<6R9Y24/EC3*
MQSXWDGG)ZGX$XXP8T50N<ZMN&)&=LG)!J*Q\-R*E,_]'DU7)$3#'A1]#2C'G
M U.E+\P+]U!8N\J=2R4&'9G,/KJXLVV1S_</_R GT^,).2!1H1IL0+F#TNX>
M:KP1+IDO*)Y^YLRF(;AJT72;[4RFF;B%>$[KP$-TS+274B&(X,6_A#+%$(7,
MX^'!6QG>289DZ W"9,OAE1POC<OT=]ORJ<A+!IK@GWE.Q0F':I))D]I+GJ;D
M2#&S*J83<)R],;ZI(X,8Z3V-'%(>*5":!QLVI*ULNF)KR\+.2D3V5RG]N38W
MMP,_7 F6XE,:#J\)9.FISLA/+IAIH-J%UG\FXE:B,&RJZ8M.48OSQ47A+A6K
MV$*$T$H0*10SML9T,M+&;5.O(X8O]%E[?M_4[*6VDP<Y&F=DDZZ*Y_[*XBT:
M+6RNJ(G:Z?VLSZR_3?V3RC+6'IH8S-N4495#(_!ER=&JH)'.=T8S^2IM<8K.
MKAY9Z[._=$A5"9(UWBDE>H2@VLRW2;%?^]8%V4]?CX>^F4D(O*^7+/EXC.3>
M7']O-])Z@@?C[A>1:1VLB9WDZ[O'<GGN[81@08Z96,SF?OK#E/A-=1T$A4#P
MT_"@W1;\J.F@+[WZ$]J!+W8Z/=C?'W$Z/\/!N:-6.H8\., ZR%2!TJ@26Y[0
M/-(G C-V+\_-1XJ@)<'!,/*_97AK_% <9P?<U;G-9"T/F&V9D2Q<@G?@WM%B
M-G/6MN]7<'*)W5>A9_RLQ(IT(,1E)D-/>D#X"%-.U]'64AD(+(2<3EHN%HU
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M>T?=FN2<B:X N*K6BB%#=2WX\@/'!\%(WFB69:^M3EM<6J>@M]H6Q>*LF+"
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MM52T8AQ"J$\]8B9,DQI8CU3VDB-IZ)D9=#"^LIX;^F*CAZ7=\$XX4S_&E';
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MN5L<BO"_%&C-KN=LBY\Q9%=,$(O\K,T"P:3&?3CYL1#A55:&H0HY1N#IUTO
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MS'Q%);/^*2A<"K2AT<EVK%&WB W P&C):N:0[V&NX5^\MOE@\M"*9'OAF%.
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M'4/@9-1;YK#6+A:9Y\,;"Y.^3]K(V[97=*N>1S1 =F[ZOGG?!V/G!=GL6/N
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M8(U\V[V*O.^G/*N^M.]IW@GO#P'&J#8T0"+I,= 6#7$[A+TEG ,K ;FLN/"
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MCK+6TRF%&Y$G4W*K%AT3&&2[/H$W@U&WX'$0NZ7'\5MW\NZ[NMH",HBCEZW
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MR>E%ZYZ76)BLU?M\6P@IEIF\QL$X^J400M7)6)^JBFV-!:@ELF">5^SLDE(
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M1(:\\;!X@=LH-*1U7&B NS'$%*"V]YH*P^5SLK1ZW*D23DA.\<9+DXL>,:O
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M.6M4VKJJM*HS>=7(H/QA3Z89-7@/48-_GU&#,VIP1@W.J,%_^]9CA<GGQ.J
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MEW)W$5L)IE'V=E<EO_GD77;TV#P/0!8 K%!&^0VY/(X $*P3SM%9=U4X=Q.
MN1.]S$?O<+'XH7Q_Q]68J>'+QN"&TO9-TXO7_83U']V>\I';2#YR&ZM<T/YR
M^Q8A,SQ<]X#+N+6/U1XW@&S\B)O7[G#MY@N+;)2H\-.6\,MS7/[#4^0<\7Q$
M](/6-]&]J4G?&_SOSK/P/@HU19WA3![99L9A_1LX%<G0D!=X;K3:J[H);\7K
M?%L[+F5#G(F3V<M#(>D><5U9PK3&\"[.]NL5)-M!AW5P0OA7#]2BW['ZJ/?_
M1X%]TZG)6UU_%;"@U+ +W(F&I;B67"-6R73[=5$(33#QSE.SL:.(2+,#B8V6
M+7#>TH<>XO]\'5<7R_#6X9OOAWD&AX8N1EKGTM,A[<4;7&N*1<%U?L>DW&](
M4T@:E#<%.Y@T;RG%0OL1@_/"7XFXD0MHS((;\8P$':P+$=)HT8RAP.OQJ4[:
MOG7<)N;4@Z=OFTC6 - \^60O4>MX=\AD^@4[NA7?UB5N^U?UZ5#X30 !CZ>M
M!7LN&U>O3#<CV>X?DNUO3V<DVXQDFY%L,Y+M2\*6;ERJE^LG"&8)P#+M(TDU
MA9.]%_([-.)=A[.E(@0ZMT[D^W">=M7J*N9UJ)BJJ=8\O &D>8KJBCA?5!7,
M-,SZ-%9*Z!19S7I@-E_F)&*K5O," H(?9; YDH0J_,UA<._?#D]+-54*;%PB
M$AUH1RXA">%4'<-X^L$AG/3*MZ,0*DY^-?622.491%5Y7\,"<&F98">)E'2$
M?4MHYE-2"BM$#]X^X6I0K]H4[H*#O"VEJ,VOG(W[D?2TYO#PKQB<8NXRZ)&M
M;8';95PBA4>/6H)_K5,-'M<HFF:O-<'#]7EM(4ED#X30 6D1E,)C4NB@+WI5
MQ+$,@R(3Z]HAPL!0UCOFD@#E/!X+'I977$\,K_%:/5[Z^/LNK+[%SZ1DDV/Z
MBZX1MQCB )&<W'B6"<HF6>9E5^[6B_=5?;,KUN'5\RN*''#W*>26FS_-AZ_#
MX-;;CL,/OW[6K!AP7+PO3LER"5M(T1YKSM1(NBB9)W6:#_Y=4VLC3S73UO/P
M;R7XDOU!7%EXN:PJLB *-%B^ZL@Y:-.RT Y0[9&6Z_@H4,ND,GN\"%H7*W*;
MK4@+$PTBR1ONL.V,C LF @W $$MD0G:W=N1[A+Z-<EZ"&'$48VTLFD7D#S^A
M)!==5[.@3T:)4O@W@X#NO!S+\:H8)+_[L9XCSAH)^PXJU#$2??A(+PGA7KSR
M(9R+8B/!W?!U^D$>\KX.TH%N]O*JYI1)N$7LDP4]Q;F%<4_2*E\.IM$C^S(Q
MX ,EK]"WZ:>J;IQ<,+E6@V\7'\+>V8+L\A8J_:P/H\#!ZW^OSZ?R#GUHWD>B
MKS)I^8<5*T<BVXRUH]X/<_G<SM^;<;0:I37)Z_NU"RX&=6UR:B15[H$>O9X6
MY#ZFZ5DRBE82=>Q74UUY3RAL95Z(/,L0AW/6E%#B_,2?$\D-T]J,YX/'/!3F
M>/%F:L6G7/X]DM!N<JC C96'F,F"&B!,^S$%$ Q>C7:I37&C:>%G3Y]F88Z=
M$$<;<>L)BHF3=\/K::&G=[DX)]PQP"!+],MZHCO6K1M(D#%V+FS=X;A=72FA
M@J///0I=@^$F28F$B:BQN(BBN4T>XR?R?-B;=E354H)B/TO&6'$M].51X\">
M$W\F\^FN>K&8!@U-;6EDFB/XGXNPD,;Q.^<N- 3=G(%<MVGK__0NW"_I#% V
M0XNO&[_;JGPA$5J"825.:B]P>YC[W\MTP8W/+SDY1SB6"Y8X(@_0B$F#4=(7
MKAWO\[#_F?V535>)H#81#+1]>@):A>3!Y1]B],/A7=<6S9--B#QN\I+X>WH9
M[W(<\2&0FG;RQ2(4'F28,',N=VS*)NP( *'TN+%M7XQ"TB7?I5]^R"8J="0"
MSB/* ?2X#W&AV_[ N?![C+&&V5:FYX)7^X[ 9A_M^O,L9^;;'\G'0&D&WCSR
M#]1*@V>( JO[PNT](F5+'@U4YDA5C(#IX*8FG4EB//!"W\*C%'N-_,M) 2",
MT5=/1;4N7.=%U]0'X2[@_T9#_N!GLM<@^!)EP/*#7F:C1UY:K!BI;YUQ LM(
MW,/-8HJ"VB$X#*L+K]36/",RD,GT^6H)%Q'*!]MHY**^6QSP24;TF_/N_-V<
M=:7@2R_>)P:..T.\PX1J\6CS:-PR;@K.SO!%;CE;Z;;\]R<.%NA6X)H[;NA[
M72485>ZEBJ+8GFD9CC_A_L,$=TP#'VEITEJBC)/OG$/^.W5U!*6BRYTGE'$:
M?OM,?!:3US*TP-EW%!>([D+.FH/7:9$R!6\<I5E4N97]H)*XK,L!! =6B%-J
MI41-26O1S5E,.BU>-F*<R[W'=4*_T:PA@Z8&&&<\_I0;/EXD'UE ?3.W!70F
MYC3L">]H1Q-654P;>;O6*P+(Y"HG#AFB^2_@E7'HPQ9G'TI6>%^7A5'!+IW2
M2W*\N%?%%L'PJ7XHTSJ C5H#'0')N:Z'8'J8V2#C(_]LIXDG\29'&K_DB3M;
M$RN4Y_)0X@Z'DR3P*->/\*O/X$/:!@15BBP^L/CW16OI8;"UB\8G<JH2*:QR
MSAUQHX[98M,W.P81\@#V3J1HZ[9=.DO6"XA%]WP3O[*JHN0N+@\I\LDUY#]'
M@17\%W=(-R#J3.F/? /3R>7(+<EZ%[@&^K/%I1V_>!B'7H/- SV?7W*J@&!W
M(;ICWDQN0QBT.>S"*MG:7BT(].4I,JEQYX+(0')I*SARF')#30^MDRA'3_(K
M8Q7SNX#C8TON@&"Q'XADC(3U:551O2 3<H3?4[MH[)MS!XCPXZ>B#B/2#1-*
M#Z37W%XM-KOZIM4:&DI&]R4K]P62N,_%_IQBJF?.DVQ)3*6;!HU.H4DN.%^N
M*<K]LFM:H4F=3.+^)G[)+S!8#Y2"TB4WN!18[V.FO)?:Y6QA[+]A(XG=["#@
MK3HP1(;%:[9V70S4I62KDH7,#''ZH4F3X\FXVH;CNSVUQV*_B"U>X]KE6A"H
M589C//R8*HZ%[2=X$"L/;2QZY'PY"W8I$X/;VEQUTB+=$_1A?+C3IE'.&4&<
M7S09FYXHN_R&JK"4NZ,KMS(";JR: OW9RJ2BD;8H!=4'H8^)R;U,-.&T @A'
MRR0.D!F$>I;F $0^R?$/KX.S1CDKF@"IU2D^H71,IGP;KEYJK;(O9<B8\W2K
M2:>L%8_,G8HQM*KXV$PEA,YI LW0R'L.C?QJAD;.T,@9&CE#(__]'-Z:96JI
MR$/XHI7AP>CP>RT)B-><)M*6XTN2)EUC-3RG\YJE6((_L>=*LX ?OV>L$;Y"
M/WL1SC[VWM\4E& )W@;_\W*%.SY[^M73Q2,2FM3\%&=]7K^^?'[Y>.#"92,^
M7$8N7(%3'[SUY)>%RYF_IK$J'_K:0 @(%5$3BJL'&A0?=\IP!,]EC&U\,&SO
M\@^+YYU@&/^[7K;N#?]C\8C^'#YX[$C(^?9" RY,:K& 3DD?I*N55.V'&(K3
M+7Q@A"JHC1H<%ATB>=RN$J9J1E12]4USRAJ^WI.P]'=HV5I<!O,A8!U-XB$_
MA<%\0^U4&S>%SZS^!(PDF//R$_-0@K3L&LI%4KIK6G$WE2=0^N:.W1&'"1P_
M@0&X[AANU2/Z>173$#P"9MC?+]Y'6+ZH,0L5W&LF$_1HM3X]/MWF9;79Z;I4
M4*.][;-GBT<OWUR"5.:RVQ(@MD>@[TCL;3S"[:MB6W,;[JZ^02MSN9)B<21E
M;X_@8JBVNS##P>%=%6<8]=D+]]C7"',"6H6$2PDR6]:B!MM*+W]D_@[_<)XV
M1!%U&&+PEY9. +EM"WT!A3OHZW$D$>( 5ATR]D:B?:\X/;T3OGQ-9XT20B1Y
M\AP$.V&LJU(8(=MD3 :_WH5GJUKY]5=_UGG_%HGZL[],[RN3,5V:8"T1DB&K
M&TF (WVV5IP,!TPZ/,CP_Z*Y^)[A_13>[9MRN_BF"#94DIK3-U1Y(=M[]-,W
MWWS#5O??7;A'L+F_.IN#3CU 332]Q8=B?]"D^7KDE6'U>V[JSI439#S!33],
MOVD#%(M5O2(:S@:W!Z=%^[)O4*J52>F"O(R6%=[5%I# 5JUT!OJ3,&REKE7<
M]<0(]0.BTB4 ,:#[DRRJVS\BN('+-2LIMH>ES=G?%9'SNA7,V/%52=T-=7=\
M4F^>'()G77#QAZ$<((^K2+\!K8OKQ?__#%BMG%?!,@Q)58DF+$W@PSU66C@/
MK2.8/)/N2',9+DEAF//45D8OJE <^R.(-G.55"MZ"0K);4@VYU88=IH#<K_T
M^%3'O(=4#3/8K$RBF'Y-=TD8[+!;BZP&B)](:XMK! GDOI?*I9W'!L0 M&X!
M2(?.8'1-./RVJX=%>HUL6GZJ:6M-NJ_I_4QWT&G8MR#BI9'A-@2=8GO"@1GP
M VH:L)-#?5E@+J6$I_+P"WR+'+O\J-(U2-N5*G3F.0>+VY+=?^Q5^072ZN^N
M;&^&0#7,D@^:OHM0]E+1HUEHG)UP_X2"&C;"7>28VW[6.1QLJX[_Y;A.A!LR
MG"%6N<<SQFQLK[+!,K+@W;WJ^PJ6N+TG9O![^/QWG./H,YV;0X*B=LSKZHWB
M7:_^H%$"99/#0L=WTNBTK(@M NA^ERRWBH-TQ4%PJ#TJY>=&9%.].^*$2\>+
M#DMPK[+7T^152QTPM$]3<-%'$5%/V-9:9_@@<?+LRC\F7V1WRD,6#/TL^W$F
M,3<%5 ;5;L>\<.952$X]_D>YGO7@OOQK!X_XI]6Q%H6UI]GB^^_?)M1,D*"$
MR%?.TH&+IMN!^+^^829Z[9\1\RP4745>O6"Z<Y)]@E7_Y]._+%ZR_"7^_5I:
M<!^]??GZ,7HQ\4<GZ^:6MO1NT-'Z/*_R-?5QBM.,E?A65J<\$[-E4J?<6OPX
M?6CUJTOW)"(+EUP?C14[H?7J7= M59-"@R96W;S?-G5WP A0SHF"0;E;OE(&
M,*S]\-((2E[E&BOIL.=557=@T51P$A,6<V>J2S+)NP)^8;"*DZ>H$<5(WH($
M\D=&Y8AJ 'LS[%6^U7U$#B;A[QXG)H^4T.0(";8*1'E23RT;>D^[/T<PZ&_1
MU%M;J X7:FQ']"24[5%?#M2>ON6C;.QR+>4ME:5Z%5S"<G,:2J*GS=MH&SV>
M^.C0RT1V/S$I&0:DVJ*^ID"H]%(.)46%C =Z'/]D6::O_I9)INDH<2JA.N4D
MPVH-*Q%3%HPES-CKL+Y!8KGXAOZ?LCCRY+7)(83CQ:A>L50! MT*TFR0PI ,
M@IX]FD9CM\$+'[NLD),9R2FZ_AI[1 N, (?JO0/M=1YVJV_<N::??8N#N&"Q
M57DX32?*[4.$3I,3TP-?^U1V*\E\7,NJX=O\P'TS73R.A3V898OE;])%2'^.
M.8,#87$%6F]"?)K7H9V?-V .B&CP3W&%NL2Z<@.J+&RFW24MKYXHWQX9$'4/
MX137PUPFJ;1H7SQQ:+_W)%W+B)3&)2?69U8)&W1PFU^]97"SO8)[>.*ANPJ1
MXQ,$X[S8#[G([83=H[_44%Z/.:N_D=W18<]EK:_^JM_C*_&7_B.S/WQ#;S3R
ME?]D/_?9T_-?^SL/97&JJ_4@=_U%,\F_4.08[&;+LK\:>L3=F>0S@\]_O#TA
MG/3!>B)D9G6$0O79##3'UTYTG1/MC*H>2=>2*V"LI>-X>U,C0EZ:<L_9X*Q)
M<]%:[#RFO4Y:V:%R)/H??.M# C?E=+6V?-IDGLE5?WR:.E$>]XZFG$XM/U%Z
M.!+U07 *=\3?R/LZ#I\(&7/4&>%=**](+7TTPJ3%P0V ?>FVY.[+$[N?W)GF
M(%:B?EN07\6]<^%W;1OSX.Z E3+I/O]0[KL]W5IV+:V21I5<%&[?]1[":Y7T
M_0. [V-2'?TENDR3':.5O>A;7R1RIS.URF%.M,2&!,XGYMJ3]/H#/?G>68O6
MZK1B.$[BJ*F78(.+KOK7F)8?W1ZDX2(RI B/2LWK4,I4BI]_)O$T\TC_"H_T
M+QS:QG"6O7?#?<<F,GL&V:X'7B6VV*<$L2R0QQ%?%"TGUJI?<<$LTBWZOLYU
MF2\+0#]7P96JPO'[OEQ7Q4FW.4FO7!4=B5F7=+H&GRM<1[HT8^J+?;/P-/P0
MU/2S3[I5PNX7U@C9Z%<8A[_]<;,N,PSR'L(@G\TPR!D&.<,@9QCDETA=Z]$F
M.)-7;UW>E/(<?$1+=C<$>[YU .>E<L6,A)36;DJHQ_6XWY)I3\*/Q!<O271Y
M$M)T!7+,.;\NPO7E<R5>(1C-MN;0A8]PA\88G.3_0>$=9:=+HE$CJU'AV98B
MPJN:"SWFQ4A&2),XG-<RV"=2=?0 #FR@K>"]<E*POW"$-J<L@N;2+Z1>>2P-
MZ \IW'I?7(4-TK+JAOA<J^N?\CIQPHFR^!U-[!+_#I[6EE[[J/FK;#*SA3F)
M+((T09?K8%DEQ#0HJI0'T,0N50>/Y;%C<]$>PSS^AKRK(7A AC)J:H_ZD&X>
M)%_@VC1+4D#:UEJ'<WZJZ#)9&,<%!19,2IH<N4]>,D /-.1(D!XW(#P2[C8J
M['.$JZ0,(>!%',L%&DI[:D665BI*-4+!J' /+!7FBJ@67<N2?5C3VE-F]7X*
M,"ON>4;L3[U>X1O5,>V+=K+H,I^NYPN-88I^41SKV;Y(& M6 "=<1.ES33P]
MQ51S[&@?+&=NAFVS#]2NPK%S&1;T3K;Z6,!XUW3[@]*#HEM:82#P?60>.()I
M-=M^A-K"L3@(GMT*Z@[=,$X)LGB$I!==^C%'A?AO!J5#@<>R]Z[*9>)\:Q9"
MCV$O/[[?X,#AY&)6A%[R&Y$@:2G@W<.AQ4G(RBDX>XT:E\D77*55JQ8MU?E,
M<B*<8N&\+%GFU<J:41TV*@T<KVI:;/FJH62Z,3*;3(LK[R495X&TNI1[?[<>
MAOZNC")91AKD<4 &Y?6%@I:L5O5C).-%/TYDH)AT<%\'%X4JZB.5;LG"Y?BZ
MIGZ="5!=T[I60R@1=I)(H(=0@YE7U#\,3W-=M$<3MKGM 2!H>U E=WE;W0%1
ML6"\&UF:M767W,V0[X0YC+Z8P#]P?EON+.QNVB#Q,/>3MXX5)4.FTL  TWN+
M<V3[VPRVA<OX=]XA8)SB1I[UUL)L*4%ZN3N-[T@F6MO'2@WN:]O=P"^3_2_J
M(+)^81C/ZW!(KI](QOS1J^]^?*RY9K VMB, I\$K,#8J(K2Q0_&1K^RL1C5-
M+KK2-;XM*WG;_IOPZA_;),$R%PFT ?H(?D72DSR>KX^E5LV*@_^ 1T >2M/B
MAN&*._*2D!;;;:'ZF4)YTWLZ<"ZP%^)%KFA^-YMV: ^@9(,GDSZOE 3#(B<
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M)-!%+1DRS:/\:%)6&*[$ST*%!BO%AI0)@;-%(U28/2Z0HVS#"[<4>]%BU7V
MYT,M3>3Y!H]@Y&J@W*.#0;A0F2J8BGG'*^6@;W57/&]/E.&0VY&WM-MQMS''
MS1TU'+-AGJ8(SHGNHSO@ZFFRU>N>^Q+-6K=8?9NH@Z75&JT%]\I\,X7<?<=.
M_7G&3LW8J1D[-6.G_H@T"K^PW(()/*S(+7,!3H0Q@&-C=1**V.#]41\H]RL4
MJPYL[?PGE^6BPYH:3PHE1PB'*F5@R5<+?M!6?&W,#OMVD)_56X$W6"^."PCJ
M @SYJZMS-\PF[X;8,[@T'3=7^5X(7#0!:?"!K0/"A-4^&-N@0 8O7OLP5*>-
M!I158.]ZUH_RED=42 ^Q\4!3+$S60$:[IXS" ?YYM!<84&*1"Z,HUM9L3][K
MX#=]GA#RYWII2*XDW!06@R#P@(MM?X+F61WOT-.H?N<8ATARXKK>74<V!E=B
M#Q-QQ43Z/>.ESSRH"$+,O;L(_;9+U!@LS\0#N6W3^!)C2XZ00[ZL1#(NA."-
M,=> 9'*%(=&/A)#NJ[___6^+1]^_?'U)C)!4^J486<K9/O?-"5DG;C*RW+EK
M^\B]%P++\IL.(FL./"D3S6%V*ZV7AO@TFH*8=- X-LUA,4M?IG<*+H<,MOO:
M*L1;M!M>A0"W8)U=^IAB ^'/ICH.'5%0E6)-QN1) %R)IJ<"03+T&#DRD([C
M8;TXN_3<<:_[,KYK^=@45];$O<@USXV_[W!<5(81:0&!1DH\/T8JI14'E+SX
M\8:SE6D8[]Y 9CVS*><X:<FEY_#>V&(QU\GK)6.5EI?!A!Y>2^KA2[PI7?YH
MO:KIN*V:$,Y6R@?)B%D14;%!)YHK_#0OX>F%AWQ"?3W(KG&C8GLH&S+@\$IA
M\PZ+J05?C -\K(N#@'@D--_DFI1-Y-D8PX@S9T,]X_$!K<N/]89(IIMSPTIY
M'C/)I.5)>)(P@'!I1U:/I&<P&CT3S<8,E&=73U35[*+E30;*X3V9_!FSW,3%
MBA3%YJ.>N)>P%!N,>CE%)?*7//_#2R;6&*U>[D030?LBB;\GWU1R>1UE*7$3
M- WYBS0!=5#U:MF-J;S5%IK3L)45,Q(Q"6GVAJGQ JV/&*)>]M/NO(0?0W2>
M!J.HFII3&;HFF5\CYX2D5*S8?%97-56B$U2'5JPEG7_)HHJ9Y[E#[@/'#<ZA
M<1<.-L ;&'5Q#E>^)D.EXDHGH9X.4FOJVF(Q,!?027HCAF,$'B9*WOH-@\A7
MX&$5ZT6J=:M\3'9^VLDIV@Y$VR)[$!U!8DVI49@.;VYU=6S[0@)I#VB=L2,K
M,!YNX=SBW>QA^G/2!DTILZQW./=B#KAV8^<#_YDV8B*8UJ'5OTPM;OXCF2>U
MB)_B"J3D+O2+/#;Z3UB%=5S-:5K1O#?&8/4KZ_H#?JP,!LZKOFT+VN'5;)VU
M*E9G?#.,1BU',_W/F9RG'-=C9[-C,.OYC)&^6#>9]HI3Z;VER.35;1:#'NZU
M)_]4Q=,D%!,%0VRLR"9S^3WJF[BQ@6<GQ"+N[448LE<6(#T36M^^K)ZCHNJJ
M56%BP(W1.FE![</@8A&V2T9=1>: \Q%&..UW>:D +Y67O"[K7=[;@2+^BJ\G
M@T%>(>RZ6,OTC8:NB>*@>H>;X(FOPTC2<V8QP8S1:)6LD'+B3WB!")Z =!>K
MM>,L]*RF'*2BBWJ%63%E' B;3">H'\ZVE7J>?-CK^F8V*=XJ[ 0ALTF0]F1&
M1+7/=Y-E9Z[#BY\A]([B3^S?^@?';HMOZ<>OQ8C>6&BU>/2/;U^_>:PG%#,Q
M\ZK>%G2P'Z[@K9CX6[B+9%S\E@G.F;IZ$OYJ 13[P)%N1AO>%=<"]B32?CSF
MW+;DO8/N0.@B8U:FGQ"04*Q_4WNN,Z94%*9&>O-B5]\XA#V6T+.O7[.KI25[
M/\K]@;/-^-HQ_?IX5(8\Y0,-'T8A)1P%Q<.&L'_3%!_*_\?>NW7';239PG^E
MUOJ^.4M:"^18<E_<[2=9MF<\I[OM96NFSRM8A2+10@'50(%T]:\_&3LN&9D
MBI0L6^)AO71;) L%)"(CX[)C;RZDQ $C5U)Q+GR9<'@XH>P63;]8^3DH?Y3V
M;&NU3>*5/XM!;483/&<T&4QCZ8L$]45?I4>WG"52Y L;E9[)(_#)H59I$UB
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M+D+N?OH(;X9%Z''8WH=VL/\Y.YNUOSD.Q)XK'1_0@UPD]"!XZXPO(4CQCCR
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M4*1!V>JJ)CQ;3S_G'H,K>A8.#I*LBER;,I^>BYOV\/#4,[O#=]D2'DY[QTK
MN=%R*9BT8T[UW2$E^73'!DG);8*KOX8B6<;^F07;<D-)=T7.J.H8#ZCAT/6\
MPC(5%ZS\VT7>@%.;+3]>F/&53A&=4W9#R9.!V4*Z7*DQ9&=N..N)A,.YLIDP
M)ZE(SU29X[&/Y;!2GYM5B*E9BVDMF.O JT2934NUU.KG$!!Q(#,!S!F;JFRA
M6V8%*:*"3<%DM RG,W23G+>B]Z6PXZ1:J5/YA0M+&'H7_H:VU]CZ&38N_%.5
M3-">HQ>I$?976JJ<YC9VK+CT)ZAB*[P>=*/3$F-@1N8G5<=,!V;@,J9S4Z9I
M1N:O!>#$I%.)OR<:8>3=%1N@31.]V5G''#"J.]1O!ZKWTD[;=2@<\8BM?PTU
M[T(=>\?>E<9BMCME2%8@MC/-7?K%\T*41B+(MEA(9V0*VV_W9&1;I*5X%)\&
MJ63*9X'V!"N'[TXRY+F%XAW--/A&(DQW?X8(GB&"'PXB^,<S1/ ,$3Q#!,\0
MP=_<]<1(H9BE'4@C^82_B$M7&AX(NT9%IJ[YZS36>^;E0E5V\$1^\+PP#L.F
MUN\2NC[@6)@* \PC8-N1EG[,*@I7\7+2NRX(EH :\3OC7.@3<2 YDMBE)=((
M<.*NVMU-MP-G#(,=8YV>4JSP)STQR0VJQK@TV"2]>15KI4;)38FIJSIE^48H
M0RQ1HD.I7$3-0IGR!P<<2R9(>XV]N_LB[SEE#?J6E)(G9RW1&6E<_HX0I()/
MBO1)R9=,^3@6KW^I6E1:;D6=62:Y-QXLJ(,V6O1GL%J!$-'H!2Q"G NB$:XR
M'*O:))'PF,ZA%2B9"RD6O3JJB#&LJP&OBP./6:6:JU!A&U\P6X;$G)MJ6[6;
MV:+M9 ?P(BCL*^R%1PBY_0A\4L2/*&210HH&"H&J/=@+YH2=WDM#?'CXA[4\
MDMT-=]62BK'WC_C%ZQ^_'PJ5-9#!.:D&<.9L)8U=/5@#1^&S1- &JHGY+DX*
MS10YE"A7;H@GSF^>//N $%NQ7K6-H *K;C2%GY!-" $7G!O_:/,.=A).L/B'
MS)=*;D.()-.C6#+F(7>(/WWSNEA]^_6K8O7-7U]Q?W)'V"_P*RI$?<J6>EPE
MW,URKE&E>I2$/FEXS/.M%LF=3$F_WEFR7+\>H[JH0\<Z6'8R:L5<.6U78RMW
M]B^"1SA5)&)LG$"6HW(S:*>+;#1VGO53H$R><UII8;/A@+"YY/188+<[L"P5
MBA?HX_(*%<YT"M.2'0K&9&Q,,4]+X;28/&MNDZ#W3"/'RE!O[,43&JVP+=8L
MVD=W,[:LBYLN4?CPKN-0@IF[UX92B354,E^*M6YCI]3=_>PJ/V13R"!N5+JR
MS27=WL18$-9%)!KQ1/-?98UU1?!,F7:CORY5>HOG,9CW83Z^!6$.PU(4M .>
MX(0F&-$X7(ES7S*Z3G ^F"]EU2@"FG)/50YP!KF\%G=ZG(.DOA\#%"G6X6*#
M8XGM=-Y<P!;5@5 ZR^OOQS>J=3D*-VW%-4J$1129B8&P82,^E@UY-$+9*S^C
MP=$K5?!AWV-+VI?8YF,;S@^X53H#$/>&W3X(<W%KH2!]:L(H.DF%HC?6M*?K
MXXS4<*AV".]PF?(T-[-2R.:TM 3,X+$*-12XB7 /-!(>IZS'P4)PC43#QRB8
M)D  =2818 HM0-C^M_S,Q#3!M*_,4,7!,G>HTKJ]#!CXP>^EV8)4619)1ZU-
MA%0H<T8Y]I=1W:;,K2G;;:2-Q1MA_QU.:YW(^3#<L9'_-O+FLN=4@MTDA7@8
MN2P]&);@ALGL0&;O6B_A\&DM'Q<L\IF$]@,E#7/L/E,N,(,YJ"C'ZZ[OQ_TA
M)+4*GP&QTK?@I8*_5TIDTK: O'M_%#16^,&:/VZM'7II*1AWCL V*3%8YRAO
M3J9=^0%S?.$DL>.H4$XN^JMYRNR9&2!R8]4ULOP)T?QLI4)8^E?NSC@HD/-0
M%I?;5DZ2-Z%Q"U^\>R3V^Z&SFW<SSF^5M&?6[KI^UNPF%.P\G_HP8Q0B2/K>
MR%JO4>+@D OBM7RL(3^+DBIHXD&E#E\'%]X1D!+!)(6/-1/^7M>W @_4"+Y6
MR5D8TC5788Z0GS6IOD)IDKAIUAPY(M!_%4R:2*2\&>B&;J*6E,)!O=MMN"B:
MX?IK/DXM9D"!3&J$\- )NL$MG0<R#BK*D$#Y 4RD]2)]I-55U[W5#4OBVAK_
MQ60(!T=9]\B+M@UL1#$X%LEL);IE4K=:]#@0D]W6-M$G(\>&'P\;<CA2Y,-A
M,_JNC3)ORH0"? [K59CUUJ!DNJTCJY*0F0'&"SHJ"="'- 2AKRA=F5+61U<]
M)432'RK)?/8J)\*_K&IYS&V]B-J,/'UQU\K=BN&;0+"7&$=$W'%$'I,6O9*S
M_#LM&CJ.1/6/\1'BU )9R>7J1Q#6*HXCY/'XDEG,'<=R$0S*6P_&EM?RC<PN
M30RNZNX0A8X1GE.8$EQ>B.'791/M4^FTD#*L(NZ=;;)I-!AQ208Q #) .*G!
M@#VHXU0+!TE8B@:ZQL6,% :=@+&^/%\?2.!VY!8D(0]1AK IR=!,0_.+F>##
MY>I_<AJBI40YSP E5K40UZ6!+IQ'B$:O&X.%?;Y*::3KV(V2G)).X0UY'\WQ
M"LVVX80]!,]*3"FG(6,N$/2ZJ>>TFI1?+H=U; %8];!K<GHM%[QH;SNPO57
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M 3.LH1.(5F["*).+N_@9XO@L&,K1"=[SWCOOO??>>U'[.B$[C8VXOI91$A[
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M;9R'-GYSUV.:L7<F%0NV"ZHKR1@T2YMVA VHN%C$Q[;0&\1F2"_5J.3TI)#
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M<@IQWY^5O 4.)G-71];3%I7<F_B1K'0:E<#7(9LY>EA,Q!W.XCUE^$F GD)
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M/L9Y(GK$C(FM["3&\@[US=4S8=@.J2S>1;CB/ZBP'/Z;^;3IM\/S@AW5,:N
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MKW]X,G9^IKA&P%PRN4*D#IMS>B97<%*CO)@OQ^O.P'.=3$6>Z('[)@G !H@
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M>*\A): 1N^[JEL#BW._H&$!5H=RW [ NN<UVYI&PMKQ2/+RCMZL\V%33"X$
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MLI6#&44FDC +X68XH+MC5>6R6L%3__A]^-^QI?1AX)&D!8E8J?1'KC3!XK#
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MTD,C/'+,7R6W$?&%M'B>5N)4N(O)1<*W&LE3Q$&Y8]!!Q&G>FJN.CX<1>+@
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M3>PI.#,(ZC&3%0)KB&V'HMR602A:LQ5AU!^9HW)@\WNBR1\)[\\57:M[FJX
MHJWMT =$C+I^&;J"V8C06#T#HJI!_E+JKV0ZV3ED1>;?'LD0]V@#+11JUK%2
M*&;!%C+SMD<0&S^S*],KEVM-JF6#;NVTXYQ1NNB8=7EI%ZM<7$P8$YA'W2'F
MR,Y8O147:;:5O(Q O/&];]3]?#W^#H0=+P*"V?UK$")H0*GA&_KT\X[C _+Y
MN7$'F227L?:V<MSB#XW\+@]'(GL2B,#*<Z0S_C .UF@T!F-4,6F=T7; 68"I
M).$7[:ZL4[-89](Y:%U";MCWZ_.<\>UVW2<"J\UZKV' 3# V8R?RY&.XF',H
MQ/P$,[_]!-0KGL6YTV"=Q%9R8-$Z>@8-FIW/&02%:BT3PBEW :!2GG]/SN&7
M*5'%O,G#\%#B)T?@[%+D@Y?(I,JWJ&5I-]ZNTD#@=(Q<MY_7X1M9,2Q6C/=G
M;]I+=LJMYP0<WQVRJ*0I WW[T351N]-&,6Q@%O_524>Y7<"_,+!#R%1W;I6&
MW<&'R3VAGI\U-<V2^,>Y-Q+GF>^H:V12\2#A-/;@>OKWY#!\AHJ=&" _2IY3
MB><,JTY=S8(37)1ZL]YNN@[S3Q$QNLR4O_I$\&R386YE*)A2+[[J;/#?56;G
MG+\>4IM3-RDO1S(FGWYD Q(]U&3X\"RM=89'Z#8AK$IJC*1=EGBDIB , ;6S
M.9NN/*.TH]N 2?V*5>,3S'F#,V(HB9UZ T5+"^NE,W=U&/JZ ?VIX"%CVEO'
M\Q,LEU.[,U2PFFXMU=FV:ZG%1%UF26A+8$EFN-<<@UZ%M-E(XM:@!YE&)!@W
M&:2NF#1^1_VA7WN8<'][COL[GG!_$^YOPOWM$^[OS^,/[78Q;N9A!$'>;2RW
M1^%SS\ P['6]C!&1A&]': (\OK.O0Y[D7>OG_)8K[@8N-U5W!T1XPR: &]]K
M-@PT1I=D\&2(8'S$@\@C'*[PMU#R X&W K.:VU5MYJ:D-9'0K .9CZQ\3Y)'
MS3G9F>](9N>X?/LWH'*@8P?2[<7K^.#QR=-_^WK$7=9S:54G6\2_?31F;9=6
M]NT&[<L5&P'5\^SX^(G3/8&.CR_UM1QNZK/1I# /).IQ4481_8[\4J;%)X$T
MM*"HZ*3((,/-LJ -2-DF/=RTD#:K0.Y#-G@D]I,S##4@BK>"$_<"OO(JQ5'
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MKO<3\O* _S!8-</:@UX!:6TRTG$B>EZSE#LW;W33J&#J0HZ*!@#U((]APTU
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MF12M72MV>FJSFMJL[J_-ZM'49C6U64UM5E.;U1^N>F)K&!I!<EX\"%K=]-F
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M#8 Z19O:8%EFLY^9>EV#VPI)0^+)C:>&N(K-YIRF;]#LJ[0IELN@ SA,$-D
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M355E5PYKJ/EN:AR?!/$^!#'-S;\ZANFVW1H(78V1>(C()&*3B-U6Q'RXW55
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M+Z&%X'>M8[( 9,4&8N#=:/6PJ\<\"XZ3[WSL-1GNR;NY;_OP=[:C&?08;_N
MH((W' >S*9C7Q#X*,/5BC:4QTS=I<A-5$*7HF 4HW]9<$-_4UJ16O;C>PJI;
M+8"Y6_JFPK@5\,6;_W[]<G[TW%ZER@T15=7564WD+ ,R-'085Q])ZQ+4VL]1
MY&>:*TD+OAY.QPOO2BLE]A! 8(OVW(!/Y%_V:.LSZJY=V/NX?1 E(B.8J[9;
M4?M"M;0*P.[>S(5K] DPIQ"I6\/EJ_#;[@!P)J'WS:[BCF>J]\JW>Y=>EJD3
M=?CN#7)D6#O1R="MJU0@Y2'Y7'S\W#NF'G\ (JW86L-;U8"6=PTI.@I$E]Q:
M:A]B@^/9N%;\*\6+F_1T?Z(']R<?H O#%V>1V<F;=P6-W_6"HEG"RZ(%G0.0
M^7 AI!\:A!3*E^;"<:%NV&I?JV@D^$+D;#$/D.,Q<,^6UY<8&E8%'JZ[9N"_
M,DH:@16F, 8>AWC$74]S!O1L\ K(EY8^'?3"Q)*KK\"_,$/66]BJBA454F<)
M?71+I!GT))7!D'%NVUDPJSM?VU.X$W36X5]F"J5MB5Z%<K;\@;*#8_J-:M]7
M+'>09Z*",J-T^#-XJD U<TG;:DL:WH7W457(:%?$.+!,+VJ9D$1-3!$/'":#
M->1/BL'42" :>*RR'%K,D+JIWYCOB6ZDT4H(5 C91Q@^>[SR.FA4#'MK;>@I
M(_*"RC[K#!D  (\^(*?8D/HI*(@  QXIG1Z?4]B8YJ@5V/V23G7?PA78!<6R
MNLC"*K8+FOI,<9('<KGSBW?@VMC$TZ0BOSOY23]5O*$:11SMG-6$0K>BF%D#
MT\FIKI'OR\_ ZO6FQP&%!:JC"EUHKXC%JU<=F&&!.B@[F7.LB)JC1_OHU-&>
MG,0O1"-E7T$%^'^9A#S7B=V['A<-#3.K-L(AYGF\Z,00?8FUQM$WE"*!R#+L
M<07-+&*67P6Y%=S006.M1;ZL]08L?0C:$%)9$;120-$(P[(JX_&-8P^Q)R_^
M<Y!,N=>X3![_VT"9R/Q.__[L^2D:!=5!1[B];A,&Z&448ZI8^+@36/JNVNBE
M@4D"LS7TP&@ B[OQ'[X?_N&J*^O5+NJ-(U<9%Y99\A]U:];GR5OKD)?6![?F
MYJ>#EP>SY.VY_1\O(;7JV=[[]"#YY[DQI6GDK[-147MIK,DHC%6(/]GPG4NM
MQ+EC78=9\N/!6_L]<4;#K5/^$!ZBREL+9P%.]*;8=!LN<%!J"H&$EUU6DN-B
M/2,*!TJ]G+$#"1^ODI=HWY 2IM[P1+*A<YLZ.)"OJ/22HF5HQER>ZA?JS"4F
M7S4EX\'HN8.WD6(,IR3914J:L[02PP@+6F>=2\*'&'DX9N3MVK<# G_Z'?5^
M^N+W*OV5[&VS)F</KG/5IK00R7%QNH+8K&54N-T>XD+LJ"DD*_">@_&XQ/=8
MM])+55O+U_BVOTAHI5BEJ27"3UMI(ADJ](TL\&Y=5)2VH>**U!6"$??!EHV=
M7;_U9+HU3?,-%;1:=<9DV65!5')!K!+=DJ[+T4<%EV;*INA>PV$'JAKXA>,5
MDZLF/AHWE^47*24H1AZ5OX\UJG-M]9KP (_>+PY5#>$54[RZ5=&MA$]KR4LO
MXA<A_C<,J'HJG$\S%Y*FC"B!KR(]W1.C\06\!4AGCC0X%;J2:/#?X&2H5U:O
M0WZOP"SQ^+58N_=, G<\7D")$?/@V%=&&&O+8E5L=GY$EB"'(G1F'<UMH$U$
M1^Z)4'P.3V)TF\]%BUEC3%4%?C44.I1F]PNURLS>;\XF_"#YV5["2D5)"4UF
MB*.)?U?)A)@>D0OH;4Y=$S,120G6Y:XS[H-L>J)9("5(<C$+_5-JK($P2?)>
M@B[NKI&PAZ'49.),+FT+DC*'0T"&E\D",9F0Q8HB/Y1J^%LS5J7VZN?%HMA(
M@R.>KPU*..,;&A^+T:>5![$2!@.(6\V2;HT_=Q3FZ8UF_ LU_T)W(K&D_0AV
M@(S+Y7F]"C_K[(OW%.&%,..GL!;#6S@[ _7R1O9OW=G-:'G=[]EQ2(Y.'N0/
M55?\\)LP3YW:MZ%7Z;FBR*S]EA%Q]#)Y=/"<7-WG]O^\O^NUU7#P4GK\C+UU
MJ^.B+@?K-[70GM#:+A^#)1O*6N5">Q@N$SR,DK2GI%"Q##7>Z!N$CY851/1'
MWAO+)(IJR$R1_1^\(O<=RN91.H3>L*N$2M)4$\V*257?>5U?<F*:;?$:>;)P
MH3O%[4'O</BW[(])G^+?N*J2W4HHELP\E,)WM$B?+@]CB%CER_H'EE^U\]>@
M,Y.=F.*IC6(_VBB>36T44QO%U$;QU;11?#O^MCU4R,'59/MXR,,-[;@OB8W:
M\=.>S?3MWI\C6$J^-WY*P*Y 0-+UY38("69Q^@%C/N#E4>Z2N&J.#O]M--JD
MX1;  G4;_DR3E*:].E1TI="%T5H/D>SP'(P>XP@GUL3982I4GV=RB-'H^M;!
M;<',AVLZ!_?)@W3<P85'=.D 7@O3CT/:<[NH>7LIR%7IF,8P#DFX!;=8C-YB
M3V+8+Y#8>,7H.!X12JYIBS>7[1@8BLD"6",/5N@:N\4$UPD/F$]DA6* 2QT?
M'A\E[^E";]8.R_"Z@H>$L_VVM'OV@#Z%?S[49*Y'WW&%V2=5PL*,D]&1_.+H
M$(^P#B?C._9$4.Y;^9[Z.K462"39P(7J>.J&)*<(Q, EJ!)IT5SKH 3PB/B'
MB)<3_XSINF:[:\4S0)122BS<A,U9J:$! VWK+*R4N=ILJF 2'KX! (S5>"F"
M27EH-_*C-2!_CJ1:LBX%_*YXT!.G"00R$?P)BC&H9D=*,Y5TK)RY(+5\:1B_
ML8);.2">)A3(I;F7!<YZV?N%<;@"@DG9D\9H%PJ\24,(SI*U!27&8W"LPR6X
M<RHGW_%/](HY2));>?4+X3-ZAF(2*YH98NBE:1@+2,#P!K,T#0R4C:H1OXN=
MZ)G_/<QLW_>Y?CNF@*%:9S*TRQ7T ,-@VMW?V17@:1^B]=<>-(X4GY5<B ;_
ML:N*#56ZB%>,FS)I<L5FNX:0J03H.)%96-IFL!C$Q][-8YQ\0D22(- !S85+
M/D7/@K4K5"Z/;,Z  KCW_(.BDH=%.@F.,2&3\1@Q'OTQF3P\5W8L9E*R;W/5
M0_-:5XY*[U< >UT/P3(P,0*^Z#A_&./'^TG@::C:->_PG36#9"/''0'>YALJ
M==40(31*QJ#%N+(&;5RH/)\'3B45%GK,QT-FF#UYD_=]U/YAG:Z2[;$,X%GB
MM#64\K]D+"\'EYNH0\+MH+24M,[347I5/GK2=)K:-X(_H+3=U-T9.BOLD5H4
ME>NL$5=*[3'N)PX&80;LDQ#\>;'QP,=VENP8C$8%E[(L4F?C?:=_V.!/'ENO
MH(,'82=N1'9U^11%"HA"E]E$'A,M-?2-!O:!8N:%4<=HUB.9%[YO&N/&N'+9
M*_6_0C=&\0,1M)CS''P0KH!(<+(CD[H:UFUR@AE?]F(E;Q.7Q6^PC#RV+:GM
MFSL+=2A]S[I@=6F5MT)Y]!0C+L, 3=#NME*$L<(6U@8%=1IE2-!L$[P0+'-V
MS9<"DG2=LS<ZB53WR,,]H^XH7K5KIY8F+K?7.BVYST;%[,*A:5)?>R!=F,SG
MCX;$1)\HVB/D5.Z,<I4KTI< A% *^+:*DR;=DVLG>TQO@D6XJP+0<6V5])YH
MV2]@+_\I)[&',&NE#U%/H7=8\+K;00@Z$S*SOBMNHUR!^@4Z7.- 2H6BQ@XF
M:YZB:*-J^Q&<U7UY9_?NA(YM[N786[*1(R+]H,/=*Q)E63A([ LF,"12DS0)
M2O,=]@4,,Y2<-V4%Y$>4C&4BN=GQ?=HL4JMCYF]^*\V6?Z_FY&6=Y_-7#1I9
M_HF\[OM-@Q[3=P:X??K4VZ;>2,:3OPG;;S]I_]]TE,?+;<3F3%3-?2SR*YEB
M_?Z'%_37G],V3__50^9KNW92II<\B[PK X-!%6J:"!@.T?*Y\#.DI"O78B!O
M!=C#LJ99E-A9V";Z:MC*Q."(X"62&AR\O5[K47 0Z @*(BXE$%U+$T]]IHAS
M,<7*2#L7H7'^*<V@YRGMUWD1]VYX6=$8Q<S";@-"B%2FE":Q2EZ.(] $**9K
M;ZP QJY,&L'L1 F['!'U-XQK!A9F<A()/(DN**:Z<1-R&S Q%2O"DB*<D^LW
MP0BJT,NJ@^9A-^M$JCA^->&1^$:U4W2Z1L0 FXA#$=9B!CZ4F!<(1^#!(<O8
M$""GYO>^9;G# 6=MP$!=0)A)NK18\NCPD2JHH3HZ2/ZA*!^\05QG-K9(1]7%
M !PXB^$Y[QU3 F"WJI6X_RRA=J22L,UMRP[J,L#TV$M603E+VAS=U1C.[6_B
M-'%/I<G: [T=[$-0-1K3S)P DL=N)7A57Q]3)#8;PKWA:E)!JZN;KY1*+IQI
M%0I_I2\-45<:<'FSM2R:%4^_E;/.[SUXO8 J+L VM,N,V7-S+FU\_%:LA,^=
M7G188:^;]N3\?@&/D&.%(('H<N&7)OT($?8C''0*>=">2DVKT8E*PT/5;JT8
MK#CDB\6J=U$?V',I59WY0-NS.L>_5%B[9C3U1@F;D<Q;6$,?!+&:RN\U 7=T
M[&>A=SR3<<0R*GI*V6MDP>8TE!3JVY"^E3&A(B=C*"(A[T@>JHY(%=L@,3.Y
M'V+6K[D&[:8KJZH \%4U'4N.^U/++3PWUX .CQ#VJA@XN0B>$],T6BW C\LF
M[?(#PC3P=?G19^AA9QQ&<EY?LD^<&WB/ D]F$887C$29$IC4%1V%U'I:C)<E
M[VC1ULCSS/I=\8)0#N[KL+0UV19RM319M$+/IX.$+*7S!(VO%('[= CVN2Q[
M5V[ID0P%^Y)XF^">$]SS_N">SR>XYP3WG.">$]SS"\ ]Q0,)+;$:W;[-#=T.
MQS)$3@&QJ\$=Z+&[<)=GNHF,*L59BKA!$D50;L$%%D;\#@,'PSI,#<-19V'B
MI*7@=E @BB; $N%*Y,/!%X;I&O/AOE%?EV.F/J>);HLZML.(9Y<?N2OXX3*(
MT;!'G&&*AW:XKX1#H=?)<+=SL)@*:J0/5BIK9BP+HAUF[\.J3)@!*2I*=CCZ
MD[@S-V*6B,CN9BYUIPUE(9.$O;@KL//:7')(DKW:;B5I:*0F*8#;B0\N4.!K
M-]R?Q\EB5\<<&=1=[(T$?R&BD2 GMBOT4K&],@("1T"V\4IK3W;],\3(O62>
M8(&+.B^R6U1C*//O0L3Z9F^*<MP2+6[5&@@;@CO?I(ELK*(7-#P8$0NCE/F2
MFH4;/ .:$,9[*@F5EPGAJ\2P.*==19VUDD75W-Q,L%(P6CBYM&1K77)4[5?V
MU1*TCS\CJ@D90[%25$'@+6P3 +**9>&!OU)7XNEZ*[>75C'0%BY,69@+V04:
M!GG]-M9CFCW^S%A$#S'(3'%QSR%]$+MK4TD4BI/ (9K_-D_<!ZH#[,A<<"*<
M7)TT$U3.KUU^QL<.J'TK36C6F$M-3B@'EVE7"H,=?8<"1S!7L5?(CMS")T]:
M*F)XQ\^ZA9OTH[&.FBN2",.,=RW1+U\T]@A!J7*2G7,PUF<OB-%!%2H5"J79
MF\JDX*WIM U] [(=07*O3;WFTTM4@!A)[:&S\$V:8#29KJ;G3BYNEA/BI&B<
MY;J)-PQKPONG/"2A9[L?,OQE8!V"A \=+ ^F!R/Y61K"@JV&9M  ,4<Y-)65
M+E!WA$7=#4V!J/>%DNUS4)>/N;L[J4P6)B*+GX6\LS,/#V#5,2"U#8CSY'O]
MFW-GFW)Z7!BNE(V_=V9%X.:-0 C(]LE:R8:"S&KCR(L @,</_@MQ2'B 8MU0
MM)(4[0_6=>B&3.YA]=_7@T7:XE*=2TL[R>-V$O;B'3DIF=.FZG$?"B'S&&)[
M3^3WRV@/I5K%K\@]6X/?$:;& #-8C_1*MC5Y3(T!7Z.O') A, JCB,MDWWA]
MC$YK!=PS!<@IRN,TP+Y@WA;"+U^YZ71PI6N8$@*; EQS&Q,G<>P[0256$C@F
MI>6URL,5]J+-?'E4YNW:K0HI;-QYH_/*4A+<EI]#)IM9F6%8VN!1],XR1HCR
M&ZI+3IT0]?@E1::(;A5?[$D7;@/B.8.NN4!'.8D+%.6>R-P7./NG]EW.X8U2
M;BIH3U8G[@I"))*)Q19@._KG2U.B@\H ?B?$;IZX;^;I>#55D$K#ML#/N-0J
MUE7P1<,)/S'>;.;% S>P5V[;G1FJ/::.^QPL8?="@T4YR;%+B%Q(*2&4K*!8
M?]T;BPS.8NM)-#^O8+GH.J;7C:_ #,B(L,&GB%9NZWA0LT-K@L>-.PR1MCAS
M7<;F;Z'T3?.HIGE45QS9-%G4:$\-B5K%Q.9,*K<Y;XQA$:(>X^:"F]S2LS."
MXM'?YQAYP8T3TA5#TLZTI&6R,NA@=<DDOJ7Z=D2ZQOQ]Z!!'ZFV:ZS=)\NTE
M67D3R=&,>&N2U#5!<9O2I8TS[?<(]4X.:P_5ZJJE8Q=!?&M]FXH8)VGFE:#!
M^T7028PG,;Z]& =E&I9#JC\ ;\B2U@X8H)'6M9M#M)8V@!/H](AB%T\G9 4@
M_&DMK<Q,N>T3PV PIQ+.A3"\HN6!B;:#(0S^^AO,$H/G@XD2DQ:?Q/_VXL\T
MXO <X+%')4O$^Z$^]N3LG-9?24<V?])QN4HWZ/ X3/(YR><]J&=498VGK!U5
MO)(6MU\C]<JI9U*2JJTCA0XJX_6&Q)@+8YKRUQ8>355Q_$>JV34BV0O:(%FH
MG4F+!X,4X)&7'!S;S=Q<UG,*V'D>I?5WKJ7<U7$'5M$CC[XI.6]&2Y!<6<BB
M/!VVZ;#=TV&#A'X&2:XYTT3'2=)+8/D:^/T)4VOQAP42DO6H%Z_+;4Y3PZ>#
M<->IX0HOW%YA9M")"5BOT*LTCI;,L5HX-KW\BC !0"A,T1R; L3@2XJ6^S<)
M25^$B:/M"$3E2.D\H4N/HFX\>_Y-CC6/.G6U@?7X\$1W[>\RWNY%4#/Y,;UT
M*+2-:!Y7.'E 1 I_?_'C0Y<B\4W7Y79^CG%6[M-A*8;\%%.=I<1_0-UO0:G<
M4R!1KVWJ)[ZJ2.@H#4_QFPJH2$3(#:ZB*]"Z@J%9ETATUTT(S"LQ9Y=3DCQE
MEP:07%:H&AP]_K<Q%3_CB>("Y^-M\M^GSAP.8V7?"+O@Z2GQV++8<X5$$6!I
M9:YZY*XJM08QNF5%ZZ-MVEC4+&1< I-?'DP-9?O=4/;\<&HHFQK*IH:RJ:'L
M#U<]@+^XT$2-XKV4YHDJ[HK2O#6U$6)# (EM;S 15=<5X<,%=F:E'M;8I:^(
MQA/PM"[@]4&TNW6<'''K&5H2"!4?# WTXP+C8' X E4X\L#E'$T0+!0A3]AH
MW_>$)T4M4S $P+B-C8C<$TS(%^H)$NGA[A-(H3(O H_!/'($G:AEB+3Y+0,<
M_8+07_)Z]2M$M4QI .47USX*DU/]A-LH.24GE% ^'HKI6T,8J)^0<<U(C'K!
MG"7!V/)?NYSGH?GEPKYU&R-DAQV3D\?C:SE%V+ 7[#BC]T22/@>ZZ"K-H^TN
M,MB._>]+HS5>\N,!+^9C"J:BDAIN-DZ*N+_O!22.O(%SE"*:[>[(2B$,UXHF
MDDNT6M*)UI@5*ZY2/"@><HN0(=Y8TEDNW>1E-EE0W=K-M%^8\[1<SNS7Y?OR
M)8 T&M6DN N6"X\1_8U+$B/]@\[! XE;WEG9M ^:=T@O7/)A2"N7:M"1,NBH
MJ)N5V2&D]/0JI4R:F8PH:%KV=>M.&^9@CFJ5?:NF@>WL4^R;+O$:J_:@N+AF
MR=SUU@KC7]A>(XU=UIRD!? U=;9IJ),57&%X-QD&A_0Z^(9R>)X2]H9C4'N]
M7SN[27DA\G)A=)8O-(NQ\2L4C]"G)I5]O!QJ-#=+^YS@KV64HUT")PA4J%^1
MU+[5?7[(5+N[_NP;O#%D<:NOB<H6@1)V[]/W]@5P_U.FVQLV)%YWYI=VB\X5
M8GKCLT_'-9[UN$L9+$U.R1:[I4SC+?9(A.\?!^\/X%#<4 U0J?W"P9E!5@:"
MJUB6N!.JN<,6TGM\)2L>OL8HL72=Q(<[R@>/,Q\P1*C[;'7@C3AQGKN+F8OU
M(=VX:_1KQ)Y7K\<:L$<N)C&DG2O ]'9R?9&^!0#@W+-:AB!)"OX[-YAUA@Y)
MY@)GERWT#Y6YH,JCT4^]^U^FU%8I*XU8Y4+!"/NA%+(<]XB&A*%TXNC]?:-&
M_$I5HGNW0X054WN5V%(.>H5YLB%99-!.Q'U"O;%FN#(9&I5:GHA+9KK?4"G"
M9Q?F58C]9!>0CUVWP!L[DHLFM"_L4M*M%4N\!9]"'OB9MW0L([\R9++S2&C>
M"ZR]H_RL;\=2LM:QZ\:N .*[!#6%,TH3LSXCOGY[<;1E+[MR)N!^'NT[W)X^
MA24-F(X,U_L.P9X:3AQ 2JW^1..2C@^/#WG;].3V7V)0RJ.1Q(V:"YW3(&[;
M3O4+"DEQT] G([<A@\'4&51V.OQNF<K@X@M[/G/ZY=%W<MDP=I8V!.C&D!8X
M)=?J\IP3YXP $*M$ZLR@[UZ&%^PX26ZTS,Z3!N^T<WS)7247Y?[QB.1VR,G:
MFSGEC1Y)DIL-^.&*^[MI2G<XRQ@6R ;50^[7X9-!WP?/(TPA>!>\J%L$ *JQ
M;N(F!!.BX/+EQ7+)7<Z^.SS@F*2J-@\Q"%]Q/$J,7SH)21I5ZV NB]R(%58'
M0D+>LF:^!%16_ W(=F?G-;;;J1XJ/,II);)KO$&_7AV45<N@ GA=/=9\?I#!
M8;ZE]3LZ_E3SEQ0YU]9_.5K\TE4LE";_Q6KGY?(7FKQFG^@+)$UN5A.T"X_(
M#H.GL6O^!!K$S[[TY.A[\"?KAN,0+9%I7WW+%-@_U[WY2U2[*7[#MW[N;(!=
M9/2*7_UR=/SLV9/LZ;.YR8ZR^:-E>CQ?'!UF\\=/G^>')T^SU!SE?Z%<J7W2
M=ZC*O/CET(9XAX?IX?QHD1O[G9.3^>+I(S,WRT?'V:/#1_FQ2?]"$:'=@6W^
MMQ=;=&>P,=N^*]J//[FNI;="F]):#7U*I-3VV5X+>9?]YVF5TX?M/S^<@\2^
M_6#7\3UJ-7])3)NE:WN/3=.9OSBVY?QT<],'^^7H9EG[>U4/V2]9N!]?LTI(
MCEY\U6?_((E$:T\.^V??EFA3$ARXY*=XX,%[GI^SW8\-^UQ=[=)2+I&4(^W'
MSTET1I,&>QCT6EI_[ZQ)5T(]P%']F@>%* _-DBD(4\1:,_K@&5V*>D\OTJ+4
M.$S3%?#T,:U5V(B%.=%Q7'&RZJ;+(I14.WB.UU5&RTK>T=R(5J< OW[W]N&M
M;H!+?S2<8[);[0FJ=4#VR#<SFD#(CR7K:VVD6J;4U=I8/]#:I=9N DU!T0 )
MZ;K*" @_&':BA%LM9VS(K:1<$J4)TZRI,<> 7%L90N/3+,%LM(!+8##JA)XA
M!;-5"!&25MH]43:?X>QP$8T%F4PVCR46T="\/^W5S[JQKVU,7VPZ#F_>NY$V
MN,8'':.UC;5Y\LI>SES6S<?DP<^OWW](7KQ_1<EBY/)JPW%603,XE$<"'4R<
M3$16.NO*5*9T\<'2V\X<OE8I]OVT1/(:9]SHI)?5J9>Z"N;5/^LH?UDGYZ9<
M(Q)1SM&9;(M.QL$9&#E7--#'7 0#8T=)7W9Z;D^SD\?9<9[-L^<GQ_-'1X^?
MSY\]RW/KE#UY_NC)\\>Y>?[HWCVW=W5IWBR]-;FI-W:3Q=[4&_N3G*3;J_.I
M\7Z"=-]4NMAVN3$_K2?>5(TUI$@>TU&BFOK>R2RFUY71A]"L:.#/3.MG;2V:
M.D7.B("5ZP9IH-<?[$\715-76-O4NC.)]^U;=YR<;HQ5D5:N*K [E41%2KYM
MH?6*E200D@='#UF8AUHW&(CE',M9\N"8O^ ^J_R2+-T/3AX*^;0XTY@*%EV[
M$'][:D^;9/Q.73G"6HH1S 3Q$/6JA6B&D%%^'F!_>PI24.YN:N>"8EA:KW[>
MME;.I*>"A\$[<HF^G(^*[5\C;_2:WTY]!?O75W T]15,?0537\%7TU<0O+U;
M/,-?*&T@<;@TA=VXY$.Q^#W?]\8Y@,DOFORBJZ8912XV 26H_7'3V%,54&4%
MP"/UP[VK[H<]$^[ 5$4=LBE._OHDE[>/27O%EG=O=5*)E#N"@1P"U\7P;H&!
M[8H<)TZ'O9;&6UO.0:+_T.3+YT^>6@/]*#N</\J>+.:+[-GQ/#]ZM#QY\N39
M26J>W'NB_P.:'=[:1]^^P<QAN%FG52[(#"F<>/!&F9[]A6>+;ZPT_F:WKOC-
MY',J!7PMAY/:-^:H#(UFVC,"EX$";!ABM]UZ71:*.[VP@4W=>&>['_C>'3!Q
M[_B(7>%[Z)U]>PP86O\?>U6??EP?IR9]_/0HGQ\>Y^G\T>'S)];-79[,37[X
MZ/C)XV/K9!]_!D05Y_#+[2GUE)K\3?/.S<WZL?AHRNV'NO^I=S3QODFKS:X3
MO$S+]FLYPE3O%05D<JE/$(7(QZJ^K'H&=,-PL=D>'-, <QM,;.?6%'2DP37=
MX1W,@HDL*_=VI;&8,;C $0<CU$J2!1YFUOM\TD7X7X)S!'/H'<^(@">VL_&)
M]=3&-YQPOR> B3\8G?5WAVCI%W?O32$]>?XD7YCCQ_/,/#V9/\H?'<Z?+QY;
MC^CXR<G39X?&')X<W;M"^AZT3V^6+[5WPWD1NQ #7T(F/GUO'Z4GZ='B9#%/
M#7PS\_CQ?/'HZ&A^=)AE:9[E3Q^GB\^SMT X@V3:O&G>=XM,?WKGBU^OZN8&
MN_XU*, WXSQAVF70CE?L".5#[;96 ]'O:GW<9-E5F9OV<4YMJ4"!28,?-1I9
M);=)W+X%WP5=6)QBJ+1)(IPYN?&X)3)%W-PQ>EGT*(W,BG*(PU0;17=4)X>8
MD#VP:C=#,3TZ-@OSV"JGQR=+>X#2)X?S9]FCHWE^?+AX]/C1R:/EL^S>#Y $
M+O: O*87:I_%0YK>-.YHM<%I^IKTUI?LKNP+N%"AM&[>*GED@<3J1*@1<$D*
MBDTPKJ65#4:L(])KP@NNTJUS(FW;C"[A+&W8?<(PB'$X2^ R <]I["?A;%7!
M7[@FBBXC'/75&O,UU_6&8;S*ZN$'P!85*1*T,C:&%^SH#P-*7L'X$4W#8.$7
MA;EDQ?%Y@I'C16;2XX69/\^MQ7^T,$_FBQ2I_^='R^-GR\/'B\7AYVSOD')&
MN^-0O2.9^5"31=N'+,+@!;+,2]/XT(;M@9X.C@_910SFI:;3,!9@@#45I=B$
M9CL;+\:! /OHW#VV8=$R/7H\-\=+>W@>V].0'I^8^;/#9]GSQT^.#Y]G]^\X
MW_SPW,RGNX=M>/;DT#S.K.8X3.TC/3+/YZC7S9\?F>?F\?/%LSR[?Q]WQ$3_
M*=W><("725?]^/OS6(631_F3IT?YT?R).;:";=+G\\7RJ9D_>?SH^%EV<IP>
MF:=?4+#WP!"\."_,,GGELAQOF)A@EJ!?@=I6,(:^W+)+@3?YW\@IOVU,2[[&
M+'D=A!*N!:(PGO9 0^=9KRT"?W_A&4,>8'(V3U,'?00->XL^[PZ#O4VZ>K@'
M%FF&_J(^BC/5[E#?5:&'Q'E\04IP-!FX!\]^D.S!(M]<(V04<:^;8@72+_<B
MN=U-N0NU4>QF+1!,#K!&:08M7]8'X%/EN*_BR\35?<;H$N8F]U#*^!O(-70E
MICVW!Y])Z^;YR9.3_/'Q_.C9R=/YHV=F.7^6+H_FQ\]/GC\^6C[-\_1S% 9T
M+W_ P.Z-W;ZP?^?6[L37*G(NJ>+GDD=MD$2-;5__X\/_*<S<.N$<,[?M^CON
M;RBJO&LWS;;??AFD>Z0'S3<QULN-8^O0[LUH7'%/.$6F?<:)A%3.P^L/@?QS
M3^:U1XVYV2YK3#9.<Z; "O8A-WF1J>..6J:T5@8=&>"P*="^VLEST"53N6#O
M>C(PC%" Q*0:KF_FTUID!Z.U+[6EKYWM4NBC>0+B.[._V_ =!V">,JV"KKEQ
MQ?EUEQW^<!4=:%.S7&H4*URYG,G(-B!-(CH<(V13*RM*1)^ZXRWY7(J.0KQ(
M:;A]LC*IGWNO8QP65J*6Q)E*1MMI\Z$B_TYL.'VFM-M-DCB>F65^5)V#Q#W#
ME&8M9S*5@-DOP8@)U&[79'&TZVV$MPJ?R2A896Z.ELNG\T6V>#9_=/(\FR^>
MVUAKN3A\M,@>G3S+%^EG- H>YO$#QC"8?4C"&%[I'OA)8.CL&,&5I*4AHF$Z
M1IPUXJXY)O+TKFI=ES ?A%W,U4K%'7-[4DJ][^U\&W"UPJ=[_>[MC&<Q]0"?
M5/,F."C;/-YP<%AUU/ "QM;1Y##T@M#9RCUV5'P0JQ\D[QQ+ 36#EY3X]?QM
M  #F,G4#A)'A4BI_3YYX8U5;#A^UY#$[K" /DE-X+\NB:4$R:=;QU6?7+5&,
MK.3-^=X"G0@>E<RK=?E*RK 7?G\';!%D.1Z\?O?A(;.V^Z8C3F+;OR!V ],"
MW(I<"<J" <W7!:B!3G=-IPYYX,IZI4D9FN65=N\>1/H@W)ZK55=ILS_MB_7Q
M7]FPN;[$%\$$JI V&9UW]:[.9/\_C,6I JU2&F@F2"#F5B=[O>W'8'BM&U *
MUM<<I @A)92Z.4NKXG?IN0UY0O)TDQXDWWOJA703M#3Z]:(H88^%\!GLD'K:
M^V WPUI.,UJ P7,K52[7-)BYSDK&F;E!<O@3(&GW2<UT_ O$V1"A\=>*'GG]
M51,R@3/J^ !$B[*-WZ:A^J>ANJ;1&9QTSV!J W.#6YM@M=B_.NM]!;, K$I1
M D5K^U^D*^LCYV=FEOQD#[0]HEUK-LA1V'LLK,6Q[KJH.S[\X0W!TI,;>X--
M<'.A6J^,R95-& 3&7;&A;K* "1-)MX"UFJ^IE/1"852ZJ9S+CF)'HLU<V=,M
M'*0.>69X0ARQLNHLT2])TWCR"UF(7X+!#5_MF<>Q.OFJ#_[!5[VZY$=R!M[Z
M5_V->M"G+=/+9CQ0^.1H!N+BQT2Y2Q3"P-@R1%Z(]EUNG?VI]=VW\#X/[Z-?
MX"S]TJ9+L]G^ @1&6;?HJ_EJC_!7?3Z@7QX=)#_! 7U/>YJ\]'OZC9Z5GV7F
MA(T,K/6:IB7N.ZO!\<1J,+$:3*P&7PVKP>?<6M%+[#' G_FE*+Y6U^#MZ;L/
MR>O77]";>OR+_?!'L_G%!HF_-*XG[.MUIN"O/#[ Y V[:@IM?2>;*P2_X/D_
M/]A0$U7)=X)=?!^,,?B)9T50&/P:@\V;Y"U/'>(:*G\WF,.Q)Z[0Y^]ADE&(
M(8CIG8.1(AWPH4ESX6*@4B2_#-K\_=C#SU*0A=Y,3N/15%9J\ZALT&Y7]LWI
M-)>?__'?/^H,%\>JV^;IOY*_E_7"AF3O:<*,'@;M=UD84[D1['R//&D+%$W_
MH[._.7Y.H=\1DG7H+R0$<]$F&_N .ACF,@7)KI9,5_ZTU3N>1> *])?O!P.X
M$%N"I(#;$F5)U**SE0\9&<XV'3.6F7^7D3/3(8KR%Z_,HND +3MB(7[B!-8Q
MX?U6('%AY?QQ<NXWL8%_2T6I>%3<Z+G$23J^^;>_[YT$P@A5'>59/%VUX!ZB
M@4(X49?G]4HOB^+EN2DI_RM*H*J1[S!.#S3Z!VOSC-GH[U'RG\X.B\K+ NP-
M5?[MEB!XS"&F% +&55JQ(L6[3HL< T$Q(DJVR/5HA?+/QH)+H9E9\PP">UFI
M()1;F7[ 56V>2(RF*E<86':5E!B@X:4^8%):/!6YEYV,MPK <H+ULCL8CA9W
M!6"JE=LOU#P2M-H48'W=8 [IULV]C)]-ZQ.U/5O&R,JPEH/DU*]+*[!2\*UU
MRWBX,TVLTPMJ"60%9)P, /--8&[)PWY6-Q$R-VML')OS:FY^P]@#FK@EO?*#
M/OS11OO96)O]C,D[TVS3 1%M>& 8?UR'D<=<]VYSK=X4/E!?@U^FO/8=CT2S
M_(QUQ[7/;5(_?/[(2"=O34,.,D[2W^W-SS_K[N#37ZDZ CB$U<HZV)(S; G*
MF/4E84;(_!$H-_C0V#A7>SX_>$?X^Z(.$!JOD71('HS][2$/G/#?1!\%<A.F
M]RWW^X<,"(E<9MQ]4$)A_ L_1-'25'@;4*X,(WTN[#%D ,4R^1]'AX<ZR7.G
MXZ&#FP4_XZ?18OJRHU>76V#(<G@'IZJHV(I9)8/%M>=@3!'5>/6+@1+DH1[=
MVJ[1NC7VY!,L!Z@37H=4CBJ#GBU[#S(.!#I&Y1B3P2MA(J&AHN'8'#R:U=@"
M4O'0%]'+UT@"/]G287EV/0K#[DHIJ_N@E6<K#R;T+MPP360_,Y[LK*6PP N+
M/KHL2N/&;;I!OL$03RS"S9^FSJ>6C!P<0!H)*FF']S(Q].B9OO]P:C7O)2^<
MYB6&S[,PP?!Q1A8VAN9 $AY>BGJRMW;!Q17SGF>(QZSAU^Y6H&*KC9N*XF:H
ME/2V/:JAV(S<EE;*-[RMB?CD+.#_\W\5*RL:3?9__\7^X^CXY-&SH\/CI[^<
M'/RZ/OL+0 [C?]"T*^FS)X>/U[]])WGDDZ>']H>__/6;-W/O##8Y>9^6++H8
MQ(A,G(&SZ<5I/YR"SV#T&E=7#X)&PVG%8+2WU3+DFQ=(0N8,&T[RSLU(1>M%
M#23C!6WL8LO)FE.B31 8JAY,T<7!>]A]P!W^QQ?_@=^KNY:@.P(7A6=?]6YF
M=<TKJW62H\/Y?\Z2_V(0D_W2\,__A0=[(;"CWI^?S?]S*JSN>V'U9"JL3H75
MJ;"Z3X75/ZL[<J,BWK?IC&!P8Y&SC9?MH5A @JK 71BZ)T-/A*+B-]FF1@PL
M(?!X7/P%Z]I/OEHQ10'[R5<-"3Q(_M]W!E3()C_X_R87;<]=M$>3BS:Y:).+
MMD\NVB>>#6\%G_[B&_@(*M]1UO$7^\MRVQ9?-\KKZ4$PNMY!NUZZIZ ,QJD\
M"6$#7$7LA5;$Z#/O? 'MC2N@[4FQZA8[2U?^&XI\17;+\HQ/HN?Q]J;!]L)5
M'"DZ2GY]C R\/:^[,F<JS)1R2?9;OVH?KZ/' M,"E"UEK?T=K"G:<)TR2N%;
M+]90^[%)R3,U96MX#B*5-/JIL8/D?;TRFDP/\^5Z<G/WQ9T/C\D0!'^R*[[F
M?F'U-KP;/2T:A@'8DB9KXBYAZABA57<0*RW,ZN4,844NTR:?EW7]D>L=;G]D
MU,Q%75Z8@)'#[C2#]0B_B+0;T;J@T]P^=?"T_5)[P#<PLZND?D9ZA70PCPZ2
M[_O+RW?M_FG,:K^B&@07EH<DDUIQ]KL-H"'=\_0@ 7U%\DJ+TLO1S<=C^/HW
MR61&0I@7RZ5I0N)[BF.X-YX_J/WZ>!::"P\VFX)RKC,MQ>UZ SUANL&1^N.C
MHZ]4V8,# 'WC?SJ%?-/8G* FUKDH0%10P@4_,\FBJ'OT5%3#Q>FIK3@Q?#(#
M+0YDS*XQ*XATT/KO9X;XGJR.2M<%*XYD;3_G>8XSE$<;@O24  GAAC@YFY!-
M*S=FS=1/8 XC[7UN5H5CR++_Z(@T:LXEXKSISF34.(-H"-ACOU?5%])&O"*2
MYKHT65<:45LI(7!D0+DKG:;%BK2D75P&_8W?E<6JV.B<";!2"70F?E+=QY+8
MMBY,E=BS"@7&._,G-/PWDK,?@\VS:I8K21[/Y:%;LEM%=5XL"N;B9\820B\^
M*![J)\!G:6752M),R2&L,FR8G<F^G\JN<M7I/44M1N^"!0"7-]PF[B^)ES]\
MP3-[?[^ UC#Y)6'\904!B,#^9D1$B&"%'DU03BK&)#&MW:4R;7HB0^(.VA$2
MR>5R+LM/<V+X3X@W2P>#%U@AB2KV&$0TR=I4!@T*P4ZE 24B?N8%4NOMAKBN
MK-4@LRLS7JQ-7),%QJA":\'M+D%"<D<_C1M9NRPS8ZQG1@QMLM!HIRYC]@ Z
MMO8=Y 6SK!-T,-[*\""&;SV]J M[[JWEGM,#,^A_]_;D>0/O@C=%GT(!+7D#
M%;&JH0[LVQ!Q(.Z95B"U1&'"KH0R^(5KY"M ;8&-=?Q*K&'L(2E6H(@9>8'!
M]M@[M.$]%O8]+L'2@H4(F9[U=_&_KN)T::B!$JNXZ25;3Q4CQ'31](*9XC)%
MJ\39:D]TTJ>X G>,3EZH8"9[XR9<EU+Z@W;N?Q?6JJ8K>RB+1?+@Y__^<?[X
M^/#A5[][G\?%I- 51%JDQ9E\;>.UWBSY?72WB(UX8<B+9W<&$>K G7KWYCVN
MN:GG=975U@":Y"AY8'][]'#..2"@L>MJS@Y0A@$495>=B1]F[_?^Q8\O'AXD
MT3L#A8O]EKTM;G T5R4>V.;=CI/J6OS*Z:,,P#%3G0D4A8WU)M!'H7)'CML:
M16O&FPN0.#+G5/+@Q<_O'\XU&!]3H'WUKM,SMFP5:4D=$>2,^A]XUF2S;6I$
MF"/>R(,/__FZ[>\5#*1,(\F3?QR\1[!;Y[2<E[!OISE4/D79B,,>O'IY^C#Y
M'DELY:K\( :8=U0(P=0XNPVR:XY?/?AZ:(I:?H%M"^VS]=J3!_K[A_P.G330
M&T?K!]O; 'I#W5MT1_=:+VNZ+ P:3X2C/<(^\([7C0T5JM !]^L?N>V>6)O/
MH01.W]G]F!_Y([$A@I/",>W-D33O[(63,VZQ>TO5TJ._'EN/PCH>!9=^9DAS
M57,KL::<L0<D+'H:YOL^AG;3Y=8'N$C+CH.U2-?0(!K[!E,$1E6M?B"\QDC0
MG("-R9''[).)23:=%1;K-;VLB607S7P%'!2EEH)0RX,E1&/(.2#\>M<.5<E_
MI!5U7AT?'A_;\T78Z.!7T#JGW5EGE:S]\61VDYOPM4W5@,<^3XX.'_FG?O#\
M.3_=+'D\\G /OU$I?ETE[\UZPY5VWNA+5/.KNB/QX"PGO>M@P_D]'-_L9<^"
MY!5M *D^9V&L[J3636J*6ZT8S:TWP%&PIN_M\<N'N GP[BL;%! 5=0IL^(/_
M>OF0D=NW6A..J#-VB WY.'&DPEQ G%V3, =7B\[9?1PHH*+3%0^:;REO4CHH
M=)+5Y\3L&IJ(A6=E5-6-OJ6YV/T@*F4BMNS<?Y?L@MJT>,?T5O01LA?AUFA@
MXN,6[>NG;;8;82W'O$K_S__C^.3Y=Q?4YO17NS+[6]BAN=J>L7W1U7VCA^][
ML[G$=L<GD*3E/SIX?4^45.O1R>- WE M<%HNTK\W%'\:CD:W<)Q=_LB[=[0N
M+NJ--F? ^/=/0/\5W^)$N&RYV$5=I[./ R4BO2S17O'2UVC'JR1)&:T:B7]I
MJWM="?\@$1*>MFV=%;%;]IX,J]VW'^%+O^ S16BD?]9-B4DIE?8AV&\%'^+3
MI$,J#'@3TVSKZSWK>MV5X;WPN]XJ:4 E-[1;-7?T]%/VEG,2)FTE6Z&Y'[B'
MSJN-O0;>(^A9Y/%^LLZUH*X>S?ARR'RH7#FR_ <OW[Q[*-I]WJUIS+#.X7L"
M_V-SWH9=G/;A*R0OMM3>R9=!W_(W>OR'9[!L!=R/H-(@OJD@4GP ]<3H2>^I
M7=;BJ@YVF6+[9R8'9?U!IA@ER8IZP@Z2'VS$:5_UF50!XB5P4WST/JU>ZJWC
M%H(:A25]@21A3,D BA^H(DE50/OKGHY,K;7"D2(_X5%H^7*V:GV5*0^]8R/'
M?,MO5U!_KB]"K:N.6YJAK4NR&-($ABPP[L*1,M/><9C\,\+D@2$9#8O3'&G9
M6P7'NR)BI_*<;CKJQ;TR;S=8JN,]25OQA%*:N)4U!;6O\\/] ],]7QGJI=/<
M>,IH!,HQ4@.>FJNC9\PP8:77$>.6G#]'X9Y=K04R&O%QOUI*[V+]-<F/%Q@X
M>&G@XE$D&C?/CQC_.QY[[14U 'W8K2Z7N#[MS00/W7-XZ.,)'CK!0R=XZ#[!
M0[_9DM;/=I_RM/RH)9HGCQ]_PP4M,<>[*EK5R&;=L)YE V&KU5KX:.5VM3ZW
MB]-"S(/3'__S8;^>D 0OAE+I5 *:*^QAD]@O_='EJQ<_O[^O*A47!E#6T_+1
MT=^_PX2:WVMRKNRV\KN(/G.,SQ@@,>Q',*L(3T__I)$KF*PF7^9.[**)OW]B
MOV^%JY2/80^#,EBTYU'U"T[B'U#9PBO=5<UB D)?TMI9S<(SW:R,-;S=-QK:
M417KQ_]\\]\_?.DR5J!@;EW$&I&>^ZQA[=H?G[]Q%2S]&5K'D0MR'NT.=_"E
MK).3H)1U='*DM:SCJ985IBEZ6_X)I:SQ-W+36A8EKY"(>DP%J_]Z>76-:O<!
MO&V1*CA%5CRUJN2/W5A9*<?@3* +P_*2\$V2,=FNR7!=77$RVYO4F(;PW+":
M1(>*J(&6(Q6D^/#O.//8)T9_ANE+U3-*D73=E6![L-0XR?'MGBMF+1O6BL;/
ME-W0T_]]^DY>_DE?K*]_[3=(+(U8<!(XO?>8+6/C-4NL$YG7*^!=A>*0E2Q_
M<O3$!<<*OE\GKJ10T<!)S(70,$M!!_E6%PTA\K=+COYVQ"27=$;"RX:&CAR4
M'U[\\//[TSMV=E\ 90_T/TL33>@-A./)P=-[DX[1:;9?2E0?.+_X8;BC,W"(
M\5_01K7N-IQ?M<NTS@J%H:AWG&_;(BO2:MYF>'M6/H5T--;TX@-9"499KT;_
M E#J!0.+KQ+!2+;(MO<XAA]9>Q$+?.\T[!)[5WVL\G5=<%&'IH,;:A6:+QN#
MN9'-16%%.GGP]M7[AU[??U\6A+H <R'H1/&D+P2O]XZ',#[X_O6+=P\/P'U1
M0];]G=SX<C=W7&\S2^QM_%V861"!2MVXKI!HM&2Q,@RH!^FH/34,-N!B(_OT
M6$7P'1RXZ-/UXE>)"EV1LJ'P-?K46#%SMON[+]^\V[&X8(=Y?6R5OU$[<<IA
M[@\=9C;:Y;RO[9F0IH2?:'!\F;RI,N;6?%%7M'5P4Y3]8Z2B/RR#4A$Y=')N
M8B!"]SBINTU;\"CZ'AA!:RT['+(H2LZ-53#<:&GCFAUE4^>:69&I03H,1DU*
M'J#HC](FAZP]_,Q8M'O]@TG#0=HRFB G"A;. 5 SBI5-:4DH2RMWI6E\&)U&
MRW8GF9U,*^9@I'0@!56$Z%V(<C'VF-AW7Z^V"++(RJV1E^%D#V2PX5P1M*"L
M%M<98XJC.;3?YCD:EEO'\3GVD2EINN-<W!!!,N+]#L Y>AQVH7-B&W0E\"5<
M] #X<OSXY!.6?2/<2YAFB%$OOE1[<AAA7ZS^GT N]RO,MP*ZV.BUA(\&3TO*
MWI\2)_@;.+FF9-3MP2^/'MU]$5$2,Q;*(?)%^*(??])LU'L?A?IM"K2.0T#_
M=$FMT<2]8._Y\\M3JWX,Q1)12H@LNF \5O8P:.>_ED<2?)/ 'XX_@28!J%[_
M1$U>ASG>5E&.L;$@C@%J:8KP&&CIUI6+4^89'_A22G> WFNE@UZ)MR>[\?6K
MOJ^E(OG?/\Y/3@Z_^NWZ;*4(JEN-E1]E9V;C!4&N39@U?%XTXIXU]:4]&<S_
MX?W0X^3!O__P[OCA)Q0/Z]6"<J4JX3S\' =6N1,DR*#NX0I^!6X9=*YS0F'C
M)V]XUA+ZI/G-:H!C\/JWAK/$_KNT?/,;M1*Z&X[W/U,S-:U':W*^J3HN8 8+
MR#O3ZTF7_1&M=%F4^9S2P=?N]8,?_OX*"8.W]C?J*Y)"(^7)0P.H1BIO5N]$
M4+M%4Z<Y\F9G%*71OD@O9)%=M7O8&P*YHBE2B"0P['YK/XG *&Z@W[B R0L$
M].WN^U%D)),.@CY_K0S[_<'3]Y%^8#!8][>#W H?[XI/>GKZXMW\YQ>OYS^\
M>??A10^\'@/1?V+^B]2:B8!>0.#K7*PERH^12'O9-5P\8@0@-E'>ALO/.$A@
MN17.&_K1D1$$AU"BQ ,:>4&N'<"%4H$8:\UD1+\FA?C9:.M1PW4HP71EHEW3
MUZER$\7AU@)9P6?WWRR79?=;0F\NJ-%CAB>]%/NX,QR;!GOCN$/"!_:=$ V.
MNQ(%\76L5TI#K;%0TC\M=56$2UW5N2G;09(J==P)7O:MOD/0"XZ47OI+$TRX
MSZK(#-W%[0S?@HN+E$J\B+A:?JCL/S==\N##_.7_RGEHR;];43*_F=JJD]]K
M>\(:R9<JIRLO9N<R6$*+B!E%1_90S;?MRWW_*:,KD[H<>4QEJLA=DLW7:5_\
M_!Z2'ZQ^ H[N.W#TR00<G8"C$W!T HY^*<HT[Z%P98Z20!IHB^&QWLF;'_[7
M""HD[0&CTK\>+>X,C1+LCX=&>0-ZDS0 7*@Y^:SV!X$)]9D1Z1OJ,/L 0_I"
MRQWX&7%..4\@=R?W&<\C@5.PUFC'@CQQ_#M$=,&S4ADF+C\PK /E"F&Y0N&&
M;Q.Z&KZ YTN2\2Q&R:L@OS8#_!.C#4U3_![]56CR0,EH@$P4MW:F=9DQ3 ER
MPH#%L#.C_MV4]KCQ@-66YA%M;;1H?;UT]>T.5A#Z%N%<HXA&D%C4%.=D/>8^
M1!+.I WZ_64#0YQ:U:N8A[F+ ] 9\U<%Q N*,KV([PQU9&::#00-:0E5DE)<
M&\Y==6D;9#^V]N+PRH;]75_O>_T"Q&2>;'IOB,D^RQ%X3Z."F0@D(V(,NT*:
M#0C9]5S0!7)D:*F\E#.C-*9MMP <2R)X'!)A(S;+)2,0JY 5VAX<^\?,T.!B
M=XJ(0#"<),P:71GY..'/9R2TK6&+9-0Q@>NY#*:QZUN417O.AS-/X*C!.=/F
M66#A2N2C.H:8@#)U2YA1>ZB+&HC_,QL\_Z[?M]=;+O7++YC6-9S%:T\L)SN:
MM"#PLPSOG<&<24V>4)&N_9/VO\$&J7%DXU=?<$Y10 6<: RXL)#9DVY2KTW\
M6Z-R@@Q<II<&_EE)]K8^?8&OMJDDB'CTM/V"-#,84'=?F*HS7-S07''+<P,;
MGD0CF&B\V3W1.9_+EECIA&.;1P?)>C:)5=[H4QF=S8U4O#I;5M?KUKO-UC?0
M=B"[(#<0B?+LG'@NR6/:Z/?#,=7G)KT :X]@C-LNPY3795=&IPU#7JE>OQ:.
M[^8C%]580D#&BC<?XN\ZZ]8V[H"RL:+L=C<JS:(2!G4&EE"'00FV"=-V'QT_
M/GB4V/=2$M[K?QP_.3QXIC_3+?_'D;5QQ^Y7VA8#&P@6=&#L!F.-&&I 7V?^
M)6%UMX>IW"K5P<BW2/'E9-VSK%MUG($&ECLK>#KP\Z?'?KWT9*!?9KYX$HM(
M)O WHC3550_'G OE?F5"QGV!3'D5.>,4*^6D,<]U*0.&[8K_%I[%(%3%=(FY
M58F;N2F) 9T.QCJ(5J/\7.^TCB;B*$/T'9W+.2[?_@W5 /BV@Q/LC]#QP>.3
MI__V]1QI6<]EW>2<R_K;1V/6=FEE/^-#^W+%1B!I\.SX^(G+&@39F?A27XL"
MP[^*B@M2$MO>R,"2D+H2BU<K/E]"N3_^[R2#DPQ>(8,J=X3&B"P4<UV[N%6]
MP4G()B&[K9!1XD]01,6:WAQW6_6=DT1;<$/?Q<M@/VB1@&<2R4DD;RN2UNW[
M&/G7XGA'X6]/.B<YF^3L4WR\15>42'=2(#\+H[Z*ADMMFF+1">7HLDG=N!A\
M-XSP.*O@D@DC:I1Q)QF-JN6HR7\?$Z4Z8)EX3FU6MY,&G23[]I*-65^&?45-
M?U'WN$L\<N)/YQ$*'?XD:I.HW3Y(V0!.M9DEYT5C9+8ATLEAN4@#XEDBK:W+
M(IL%\C>3_"E+9:AY>^E=*VHM,D#E)*F3I-Y64K70,6.P0SZC,2?(2%*^%N,M
M72[ZFA*(+[JLTPW3,%D1S8E5LE$0[,>JOIR?UY>3K$ZR>FNMFOVK@S[%W,[*
M"D>&Y+@4EG;XE%:2SRMT-Q<V&L)O)K&;Q.Z68L?>HB$*K&3=+4H:!4$EW8,Q
M<?JF"II42@QKP5>5@KNJ1/6;!Q=OBA(%,U]P++>N@6^T6D!%R'I!?M1((H3R
M(%1[[UTQ"$/KRCAFNBL*CL%$8RKJ@3,0R)S0?5MV%8/W/%NS3+I&^$RE?P^-
MH%)]U[0=FU+IS]&1T ?)/V@W:#H(D5I098[&9KIM#>N"N[=XAMH>^CMHW;ZV
MR$$.WSU8EV8O4^FB<J588S4MH?J6!D&WO6YN%AN-E>@7 5$+=?W(TU!S3EG@
M;CW?=1:G#.Q[8!5.;FU#G44T:9G*HMCRA;%B0K5.\/.D&%';>P&$+B P)]R3
MFG>0#4)ZUAB9W RY"*Z?7)Z;BMXGDZ#X]A0 $UMB;T3G25D.JNX[%B&+E1XN
M%%BM=L@V/(%5@1E@::E7I#MDKKJ]E3WAF(!-W!><<68>#%0W,.0L]*KL[C7=
M6EY<K=,W6E?5Q\\7->"K]"-\.NJ/0Z/,IH>QX9?B0+0T3XW09!BK88^Z"6_,
M4'##HZ^7C(\E^A9CS\@F8>5HO\QPW6S+OUF62 :I=) WJ3O0EO5ECFXSZ4Z3
M+I:6:# 2)LO(K )J738(O:ZL><]-6F)&N\RAI>*VE5MT?6&'4ANS-_3*STR]
MMHXI3U967E#_4#)"G KK!-XE#J"T*99+^CI+47:>$ALI]HE\65PRVUKI+RX*
M^K:_1U?1=D"_X VDU!IO]ZO(-HSB5;G13-H5;P^1HSV7&-VLW4K+ )@<[WVX
MTR2+]BD;HEE@C=1NF.-4SB[O.DYBMI%IZADU4]8!W,A!L)8*-"@+JQ-R8&CI
M5"S3HI14G^CD 'DB9[.2803^<$5GC\>V,^K(C6WWG9!6]V"!532X?N::FZ&_
MO2:C60<JW>Z$A2^\@4ZC#&)'S\I3<#'%VKH<N"RU6$&?,)QX8^*B3FB(FA$
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MWV?NY3NX37IJ;]^E0[_WVA-N "0^KLZ$P\#YPV]62'0D 2<!/PW&)#J2@).
M'S%C'B4=J07-\;6@46.)P$4S<EY4Q@T?S811YD8E1GPJ,F/"J^DM_'8CQO"'
M^HI7PA@5/"E&Q?1VWV&I4]0-SQ%A&B1=#RUF.E3]L-V(J.^;CD/=B2E51:!Z
MB'0E4!TBJ-JA&7L$J@2J!*J'2%<"U2&"JAN:3D2@.N"T/ 6)!AHD>H\0(.II
MD\G'?L7ETM2^:8P%3:\Z4F5+Q794;/>\7=5<?[ </^Q2NT/C^4$2D2";V)<@
M>PV.=R/3M?<\ 88@FR";()O8ER![M7;SIF?3>1;JYD+'6!YO74P1+]+%I(M)
M%^\N[V^97D0AKR&DL0B\";P)O F\5]X,QS+=D&)?I\'S@R0B03:Q+T'V6B5A
MEAD%]F!9?MB8??!E8Q0&VZ2I<2+RLA)-&&S*O],$KV/5QH.DZZ'IVM/0I)[C
MF6'L$+]26(I0]0#I2J@Z1%1U_-B,"54)50E5#Y*NA*I#1%4[\,S(HI.  PSI
M4&73LY_L:\(XQJ0J;XJZ*,>#1B%2D91<&;82I>2*W R?"IE.A.$'243":V)?
MPNLU.#X,O,&R.^$UX37A-;$OX?5<DT ZMW>@82ZJ7'KF,-<',35&94V52B>A
M>ITS![$H*V?)2 Q;^6X*13_LFY.?3/&CT<.>XYMN.*AY['>VXY2T,8$Y@?FA
M<3*!^6# W DL,_0'=8R/P)S G,#\8#B9P'PP8(Z%7H$SJ/-])PSF;9P,?N#P
M]D."T^[9#SWN2<B;%3?X]G^!?YOU_"F[PG\_=U[G(_&=944ETFE1@@26H]GU
M^'56U),1OSW'ORZPUID/3(+/UZ%&]<&_9O6TR&^;I<BO,C'.7D_*NI#WEH/]
MBAL!C/D=WQO?I>71[RNR6? (I1[8&(TN^@HE3\UOFOLW185M[V(<+]W!JS;*
MJY==C$?%&)8TY=7TG,^FY>OY/P#]U<<3?BE4P)?Q'*APSD??^&W]^L5/#6L\
MCU!PXZH2^5]?_,>T3/_ 1:TL*-\4LR7E*%,WSD1:5EQRU@R8N<(75EF EGTU
M%9)1F7[=S49]03S!J95OU$==G)??+WUSJ"^%IY/'!;G:KO@\;0/7$9W!0%XZ
MXG6-$@-?UU^2_\+OHGIQ%Q'])03?.3(])0NQ!C7EG<^+*3PT78.^OXM:\"J]
MDL,W,G$C1N7D&OYDZ$:$<[F-K1,*KWY^4JTF_%?"R,O1J/P&EQK2M##JV36L
M'QY4&^6L,JK': <WJ(PIW.@6KJL- &R1&6]%*JX341FN;1J.Y?CRZ_"#9[PL
MQG!Y.:OAD_K5>8_TTL#1BYA3$E)<I1;0<(&TP9<#'L3+&4!E.=.7J/>T+>O,
M^K&Y'N@[XI-:G-=BP@%RQ;SHR^^]6$A$8DFW&M9[WMQ@6891/= /SB+GQSZT
M-:(JL>VG^[YG/]=WK#-OR,O;[)5\S^K]-^C%;O(=]\S9S:8]E'B/'LR[+\.F
MY<GX1<Q[UHGR)Q-S(J(]1#1@7_S37U\$+[9/P$WJJ9:3.-H2A;L U";V1=]%
M67T+_@<4O_%N0>\_(R-O5DZUCYTX5HC8%M7VB1#.#A""N(ZHME[=(YE? \4)
M(MK0P)7,+]P"#*^0K45:C^" X$#!P?JG$0D." X(#HX1#MY<\?&E($ 8C'_W
M2/NFU1V\+3ATIWRN[:TL&3+@B7 U'ZV0Z$QNL='39<6OS_>J!@:P$X>L%X9:
MP'GX]@G1D02<!/PT&)/H2 ). G[$C'F4=-Q#PQ'YLEB:.YZ>@R^\WP8D<_7/
M9['SX]SRK+M5I@?AR/W?(A,UOYX6XR+9]P&R4X3ZYS@)-DBZ'NPQQZ'B_G:;
MZ,:F;^^YS=<@V?99)9\PE3"5,/58,#5P3-NFZ1^$J82I!T17PM0A8^I+Q_3C
M/3?:."JV'<Q$)8K\[+PU[8AG?/25XCZD3\G8.VTU:EN^Z7E[[CY([$I82EAZ
MLLQY+%@:A&881L2MQ\VM!*7'1=>C8LYC@5(W-(. H'1'W$KE/$<8U/G'K\QU
MGY9D(M5)JI-4YX&K3L<V(RK@.79N)2@]+KH>%7,>"Y1&IA.[Q*S'S:R$I,=%
MUZ-BSF-!4MLU?8>RC,.)YU"1SL#C.6^+.BV!7FWS#)HD35KTP'!I*,QY-%K4
M-J-P_::5Q*T'Q:T$I<=%UZ-BSF.!TMBTJ53GV)F5D/2XZ'I4S'DL2.J801P2
MLPXFLK/^R OJB/HD ?C[F(]&9<JG(GN\&RJU0*4&:@?4^(L:J!TL'4G B3$'
MR9A$1Q)P$O C9LRCI..AYMBW!2['F&/_)*JZ'(_%B%5B)/VWE\4X'<V0+/#
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M!QX.[<A0.UCD(-(-%G3)4&L*!RQGS<%49)4=#4*0548 L0) K%E61 !! $$
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M&'Z+WSO"'M4;NC3O'SFJ=!2TV:Y+,U[EN)>:36@[WIQ%=-?ZFLR J;F>=?J
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M7)^B;'LHK%?BH6HTN,XQJQIYK)> 1975G:PP CI:)$ JGL F'DB!T;;!^N_
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M]Y9UQPKG)'IW/I$4,W5S=3BBIV*TVKC[)(QABWX/7?U"2E]+*&PPM9*[+@,
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M@@OL'27H%=3#7YM%-I[]Y_5?JKOAC>R[H%96"<%41?ZL8G*TT_SR=!QMCD&
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MX\NGC$-^@GGJ\BC)12A8$(8!\Y(L87'*(Y;ZF66E09;EBP623PKMOQ^GY;5
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M5G\[/XZSTM9AHX*N;DFN^J&DVW?8 @Y*Z6"R^]!<<# P&'B@!@:Z #2#@<'
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MNC1,;R +"C[9$&@4".'^H[!V[P0@!""$85@-* %\A(,%]^ I 7R$0R0$\!&
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M!-6A;%"*4=2&(BXM1L9@AP+AW :)K>?\WFON7RUIJSWHW9*TWF7.NGL?_^Q
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MQI%7S*:(N<1LJ^'3K^O9\??KR?'S6?3_LO7DEVG3[*A615 !M2HP3$%& )^
M3_#* :Z#@BO0*>"SS_C<@U<>#0N648<T3AIQ%A)RA!(4:=#61,E\V&K#>IN"
M<O#*#W280N?VGE>0M\LTD+--#*5S^VF<-+8E@/BEO(Y0. Y^P9 (!_P""+,
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M- H&6^L(#SQ=[1<4RHKAY:(P4K?C7%?2ERW4?M3LH*!/"3S*U@(_ 88IQ)F
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MSWD=H:T]N L#(AYP%R#Z K@.":Y IX#//N,3Z!3@.B"X IT"/ON,3Z!3@.N
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M=AUG1SC.FE=_+>KYV8YZ#2A0#E .4 [ )^!S+X)A&4TN48V,21YQRG*PP95
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MGXP,%2.),3@<,) A= 5\ CXA$PAP'11<@4X!GWW&)] IP'5 < 4Z!7SV&9]
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M.%"+>*(..:&SQV$CQ8ZE'$2'^TD KSCK74=9.W(Q*!\) [N]P8#M69@,-52
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MA543Q,[E8HLAB8TFDG=N6T0^6834EZ7AR=.S[M.;SX:C[#-)7[;>P7IX$T5
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M]+(L9I=V,U)'=XO&5XLF7PV7'COYSA/C+8WP&!"+\(B1!))#")BU4'@%:43
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MFGV<1(W5WW8]2[;+;]I1 (D]TK;W8Q\?O)WULKS_5?7#<%K/&O]H.K"3W,U
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M0H,*0\S.H.)E/7TSM3ZY[5KW'XCUF).4"1P!FZEHLA/+@='1B%96>>VLXCK
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M^+:69E\J_(/686'TDLTTA>-P]V=6H8$Y2'JR#D_L:?$%AB^2X.+@JY!R_Y(
M%T%P($'PNC/&_V2FW_[E333(BR0XB20X+7;LBW)?!QT%*,X'*/XZG=1U!HG?
MQUUY0?[X5ST<UP4T"F@4T"B@\5#0^-LDU5X5U"BH45"CH,;&,J2&FE7NJ%D
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MD[K<-Y.;&S^U0SVJ;O6MG_8A7Z>75+^0#+1>TO:LL\N><>:8%L8&X1EP6A-
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M TNH]8Q4#WR%$P:YR3R"<[^5C[-NTOYDJE^V'B(D= I##P2Q/NHA(JH3FFK
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MK=0R,N845FI.MUP8J=7L.J[)^^OTMV^^*E-D+MQP+5T52U?%/F@A7C#OD!.
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M2<GAR88$%I,V-<<=ST/<'[EO:^]QN1BMET?;HNV>E?) /8566 0L3CWN0S!
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M.4_Q0IC$4*1>Y(@H0 FG0+HH+Q"$\1=-,$5;;6UL:KX6=$A=!3&@F(DD7BB
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MG+2+3AWYXT[;JO/-Q!WN6[4G*A^S+^M6^H,>CC*8[+CLO3'X<_#).Z*MT]H
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M0#&5P$,)//3*?2B!AZX#YFXX"\I*$SA&4@B&N',4.9\4PE%@;R)1)O8#SN:
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M2@#X]&A;P*VCX'9+WTI%69+:(BF$S*-*&#),"^25LS0?ZW3\224.>X">!\:
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MSI42U%DG% V'+.K/S6O@NV'Q$3Z,=1F%6,2UGX0L+E5ATH(I#:8DY1WETJ!
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MF(_BKVFK+COW61Y:-QP!2\:ZT3:_P\-^R!KMFRK6WE["%\VF\W@(9LE7=S0
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M&8?%4*6ZL4!^R,IM_8*WDWIOQYKY&:7%''FI\EU Z/1H>W),>MH@A*,*7-J
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MC:2'L7[U*"'9IT2<)O+#YN4__]]OZ#>%B'O&_4*X0K@BMMTE8B%<KRK/RBG
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MN+R%UL:1:JV4!BJ7U];@B[;6T^*=FNS^8@&@94"T&Y0;#?^,&=ZS5LGPM;7
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MO=L"J&7U;P"0RB7OLTY'[]/-5AFK@1PH3%!5@)3"OQ(#Q7H DADKC62:*ZH
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MA+*Q-Q,N<7QFPE]13'RPCCRB5LC9BT4=Z=">VDF+6B8S*2,BX!9DI%9,PB
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MD&XT99O=+1S2S9#<\&[.XZ?==!=9;:RL3,(6&B@_T$7HL29!C7%;UR1HYRV
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MQ.IO^MY((!.=3,M)40EE-Q?;/06+C9P@_"O3.H7?/UWSD<Q9Y[LYT=!V;@>
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MX)Z&*S8SCR!^/-&K,*YX%;=HV[S6'QO7^F[._OE\?LW6>79!9C?GM\?S2_8
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MM34=F[=(2S-;8]X* J@K1SL0-7RLC8-^TW(6CCDH6_O+&$9+U[UH> "VYG$
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MUA+TUR$"7%'7#%C2UOU/3<S 5XQ?43&>P-IUU2IM]Z,Y.++^$PU2O&/ Q?[
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MR]7AQX_O&ZZ W .3 "V4!A($XI*FXUK)NZW=Y PL<*FT&VJ[MMX__;--9A^
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M: =R4RR7 (YN;@I#TRW\J58H7!(G$(&:TGU@WA5^1I>0?X(UU[S[%!V C-9
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MSLY^;'1R<SI(WZJ4<!*R<PAB$;TDH706W:7W"_G7+9._PR#V.";CC%U?,<0
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M=I1?A0O $1//[&SBX&@NFD@'B)D(:)/O5CKSX%#'KK7G\>ZW CYA>$[R +7
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M_[IG^(,,_LG!W\NP'ZL%:>J3E7M7/ADE)7E0EOP*7BJ@!?:*)_U :&/,4CB
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M<X*):^_%<1B1_'U=]5P.Q:I4)B>46WV]X[* P D!G)UJQDK+55?ELBM8]X1
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M[Y;]Z?=Z2>H?D\CTLNO>#7)(F:!AR2%E8>4/1!N,RX*Q\015X[1"YE> >J)
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M(M\-WWM-G*O ,+I%OK <WH01V VOT$O"V#BW>&LIJ2'U&7AB:20'P^,%Z:.
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M^'_ 6H=5^M+7/[C*.EZ4*E+P#V9YHRTSQ@"X8HNK0(W*;XS?.B,"ET^"+L+
MU5G-K%AX]8)7/BTX_#H(L.B4Y?1&@:KJ%ZB=SV0@%:TDRI2(08WXP#)#\A2S
MMAP3Y*MK "&CL+*O1B5[96P 'E'BX-?"S:UEPV\[FY'BHIVW]9+)*$H/--F)
MY(NM"EOF5&#P'69#JUKS8\;R?@FG 5,N_\C#PSZL[K&"082&4P*.969=(9S(
MJ)YM)4]-T-&4)%^R3$B8IBN)5I"XFB@+&0T/*C/H1ZU^0(QCU]^W?NI2#8SH
M!E"^E;CT JQK#RNLF"^]8M;.?9NP^C1)>6- 6+/SE9 >&$AS91M_9=PRPV-
M6"T+7QSDT]>)3DUF(2"_U;JBNH]%A _YF42&D,IPXYA0#N1-S%J7XE_IG\.L
ML# H9DS(44D)).!H;/^].=RUFERRZ'PZ(-M&V8-W56XD#_\D513(7F:*LKK+
M@&2O%3$/69QH-=H;HAFRB&\'TQI06NIG7:U*BJSB&"@RHSWXD8_H\?A4(_N#
MU.J+[] [\C\.YU!EOLN'E4=6_K#R8>W5Q^F+H \'S6>@RIL+9U#=30P5FV+:
MVQY9,?/4TDJGM$+J@,4W#L8]2L#H]P#E]ESD7AR_QN#"S-*=@M<U^*Z(V6>(
M:@%1+$1U.&3?@5B,7?Z-E5-\Y'3!90W(#PR4OX<O8#[RAU7QD57VE2/<Q%P:
MNH(*9@%FJ<";-[DU:70J?@/U[C98;TGY-'BK\*NP]0X^*O_T!'5Y@*-_/;C0
M_<K%DDGOF#/Z18@L+S^P*C[Z@?UK\=T5_3#^D7YZ]<\DPD_:SO'C\9/()T11
MA;45>')*C!Q*/#%_C0L\I1F>G GQQ+C\H2G: !-+[O;/EQF=&81!6#6F9I8-
M?87=\EHXF<5K_&INVF'*SH9=MS 79TO_8<)L9UX'NJ%./T$'NLE#!+7"5@DT
M2_=[R*O"$@8?UI>B7=/X/=J*.,@UYEXD)-5[9P"F]@'D0G5)L&RF5)G9[.K!
MM=I#)-G]L,C)=T0=/<R>8%(SZ'C^"/1'PYV!2U>$"&59ALGQ*H3B%\,*04 L
MU]\P$F(7Z\4D0(*N.K9U4D=OC^MI^WKH;>IQ/7I#C[)")HGT)+H+NG(2YQ)Z
M?_?O+$5K8S)KKF#15;;JV-?@*HL/Q83+]$O0(0CE*],68>7:IP617P,&+CBS
M[(>L<<AT@E"M?DTN,P]B7F7Y&LR=,TZ6+UQVQ9N&E2FT+\,R*7Y:TBW)XLID
MT2=$^.W'GS]]N?/V'F4+-(9V] #>RGY*+VFVI17>T^_W?UB5VQH[N-<61%;R
MF4+,JK^3UP5K>D$%8QY8O!KX\HNOSQU/M:=L703[@XW>]2#'$,$%?$')-X2"
M541",8EUJ6P(3G>U^OT+;6/Q!V*L1WF/8.G(+1'/J-G*.1S\8^X?</&<./&V
M13/R&.\QQ:KZL=[@(H:$M$.$X+\K=6"I )A9N(C?H B8:B2TE2<>9^'%59(8
MW;$@L!(6\5*EE5#' TE,ACL__%8-):O81<>W&XP.<KN!M(Q'4S>03OCB"K.7
M:?(^=?A!\G*9\CPLA)5)WR:^8[@>)(^[_, ,8,[I0IS,7A2"R9S Z;0X@+PN
ME'%UO,'?,G7Z*F\YL@Y<O.&]E^[C6U(BA$3@]*^U3C^V^CW[N3_ ,W!5:7*2
M?Q/N2/'5$\<%OTH&2DAR&T4+_G_[TH95]J>>.K4B>_Z9) C@8Q?'R]#=/^,%
MK[\GB+9&NP[PJQX-BCVLYUY\R*7+2A(&8:10;'=S]>7#"C:Q^F>YC16SC^G\
MUTS?J+][R5NCY5]<E;"J#0*+I@J?L;X!L<GT-8"'*;<=Z7&Q[ J7_V(1PPD3
M8'M^?<-[Y#1(C!M*4*.K8K%7K"/CW69!YJM\QX#^?,_C1N7T+0FT#H(4RHIB
M#@3)8[0SM?,ZJ! XM79R0J.=:B6OF!EWR&)R'1+&Y)!=@9!-MI6W7<?[FC<6
M?1:!+:70+K)2:"M>-QVZH56^H]7#0A#(2RO'NAR\(=N2G#Q:YR8H*E1EP6/)
MFY/@!_B(E= \D(RJ: X=\4.-5IG3R$KG[+PH3E:N0]Q1R-EBW0=+#_@DCLB)
M/M @M)*8F4^'98>@"8R[S\[W6Q=JR^X\:@"CQ;J&67?!=%1==467->%:+)L<
MYZ^(-O_I\0/;0IEA^Z<)9S6MA8'L%2\84PL'PF_:U+(I-5S1BG4:TB+RVI"3
MY$+HVCN'G9%$!V!E*=$AFX&N4!&#5/%B(K*=($^8R-L@CQQG/QST2EC]E,D>
MP"7!+^ _O(4!&L08R3(KLL[(K)")4]H<O #*0 QT@.?Q2MERJW].X+;6"$4E
M@[(*RJB47XHNFQW6[9\<OZBBTS>?JQ07H&H02E9DT;QRT*E PQ[(0T4""C!(
M,0'I<%H@B6L8 ?\%"=@)@&NMPA??(T8?XD!PCEQ!L$0#I-"@"))E22H-)"I
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MBU=B=9IT!U8@'5-)C/Z=8@"NW[-W2ESN6CC8"E#6F/^YGI]"6'!I"L)XQP>
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MZ])$Y0<K\#XX4CL/1#$7*]YI!U8@G66-HICM^AA+-A[$H9\WG6TO7" ;;PE
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M5MM00AH(!('FI,1@@A#$BQSPGR#AK6M[987EK* CIE =";[(TG^DGJ'J4"O
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MU7@::9E:F1.OJB[;G&F>R%7*V=A6Q09HAY0[>7@+ \2GK?KOQC><&9\V!R\
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MD 8!2[R18!S&IP&Y2G&,!=M;%__B[4C#>\@2PX/Q/Y_QMYTD[D0*>CYD$9K
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M"Z\P^PW<2ZP^.UZ0YT&3AC4EHV_C J-]S@X.H4(6U;*T8V%_UORC:-KQ!3D
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MR8!QK\B\Q_]-^T5G]:^\$%HO1LB)T16B_RO C<8/6' E1&WPA/>@,<$<$%#
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M-XILC=FW\/9I3Y\Y>P#.'@ -0?Q"$?H<TB\GM+MQ0_JM0Y6:"-9)R9G256+
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MU3'&MGK.FM<1#G=7+]NO*ZZM7/CTD-*]I8=>W'7^_@Q17'7_3([AVN?M1?"
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M71FW+<+_+;*</=-HMJZ]WJ#759/604/!)_SX4?+*O('CC4'28=TSNI^5+/G
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M!H?>QMN180<\+Z72K%P4^>!>?(!#F+4?[G; \W(C',VL8G OUSX[X KC%0]
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M)J$:H%[8#_2;Q! $4"?LQQ%.0CE =; 3IC@)V0 5/WX@Y"34@]7W1#&6DZ
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MB4X3)2B\#7!"+D59@Q5NT"9:"Y]LU^CH5&F.V)--5*<AAR\-K$/)6LPVLAZ
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M'<6UFI^ #'D?]ZSC;QR&KX$*W4CI0Y2T8C_H]'1&%IE)'?8M(*#=QFV9-T'
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MH&VX:-6UYI@(0$.@(0ZT[QJM OOU#=US^B<_J'4,!9YBJ&6_;+WC(38O@(9
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M<IX^PS IO.-]>IX^$  35301F\Y0]']20+5=C)[6^ ?'C7T'ID>)4G4&T=<
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MBJ#<,H@H,KI')Z^K0]>32)=I[)UONS0I&S;O03W?E/E(WEK45>J3),J&JZE
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M+ XFUM+(?@R9/#B$I8T\.I*%,EK"O&9]P#'P XO(Y5F>>=^ 9%*.(DA8D'H
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M"/SH5?NZ@%5$=^'5??%O_W:>B=]&V5C$&<Q[#1Z*PPF@Z_]AIMU@VDM@!;\
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M;E(RUQHH(IL>E>R_ @)H,$S7+\"A V+&0ERLR\<8P584.5X&0;^!@;*EZ*N
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MW#&,U/%G?/2G*LKZ.(V!P8&H<5HG,!ZZHEHSL?'3\<GIX68OB)2R:=)XQJ3
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M,ND>15Q#MD*OS-0B69N\O;='92J9%C,M?JHBC _4R1L68-?-3!%EJLCE_"7
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M#GVJI_2%0BP ?"W\MR^.AT&Q-P+5I+ 6&A>SX74IN6 _K%RFB]7=@D=OV.9
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M%K&=@SL\/E!$JUTC(>RPJ^"O\0 >?K5-K7M>=SL%Y\=!_M=.+_#/?]IYLWW
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M-8+M^U+"QU:2=G8:!^M/;Y3/J4@ZQ<C:+5/(W.DSS1\ ^O;KB;Q0EMYMR2%
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MQ-I,$CG;QU\74*G_"A $W^_M?O#Q]](4>CCS"Z&!6RH%U,H,]1#8SU5"[04
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M.L\B%9<PM=!IE)14]1N/1*<"3R5)<$?C6;6!P^%0P[L0CI_A+& ]?B]BP\Z
MTYHR&HF)_5TDVN#C Y5DE[1AF9@L.,O%S5YJ>.\ :%0Y^!U8NVWWDQ*/-SU1
MOP9N/""6+2<.RU0 AFPV)M#33&,YPVGT& @VKF 6UDO$B80N#%)")4!FB'*%
M,_4(N%.=)=7$RP$:X&$P-;WX KL1&;BL6U2@?8@G#,]F=-9!946#VPL&6WB^
M/7"%W6G<!596EQ<2A]&SU4^P.GRA?[%1$>!$H>D\A6S4AE]8)=9VQSW1"A!.
MJ:O].(77W;CUJG;['>G(G+AO2L"3@+B\Z7__:-1%W)$!K8W4W%47R6/O/#Q@
M4I%(0YH3-4E>)EG22>RX,IP:MH6/;X&ND)7N$?N6G>WM_O:W_GG872(G1NT;
M-9$@2*FF[$WCOEDPGT\UD&J@E<5LWT_09A?W+_PV5"V\$.ITBU:%VPV\Y[A7
MK_O?__#,[WSV3>[M]'=W;S7V:T:&]+=W'LW'9^=:!R?I'5.3UP*(7\%2]R"X
MW=HFQQ!]NGA'ANV*W?)')955H!S3R^YCX$NFE\\=8L((_H))+,.-X<9P8[@Q
MW!AN7U&\80-2%XZ&X<9P8[@QW-;(ZG,BQW?,(EH+&*X:[K&]A^T]'3D.AAO#
MC>'&<&.X,=P8;FSO6>.C8;@QW!AN#+<ULO><ZR+A")\5P#ZV^(B[)2I_K42V
M,./OJR1)+B92O=1D%4[Q7K$4[[UG3/'^\;M!%L_^^N\_?C<JQLE?_S]02P,$
M%     @ \C1:7(+^APZ3 P  QPL   \   !N=79L+65X,C-?,2YH=&WE5M]O
MVS80?N]?<4VQ(<%,6Y9FQY;< %W3;,62($@";*^T=+*X4*1 4I;=OWY'R<J/
M)6LWP%T?EH=8%.^[^^X3>7>+UXS!Z=G'2WB7.K'&4V%3J6UM$ YO+H[@E]N+
M<SC5:5VB<L"@<*Z*1Z.F:899+I35LG9"*SM,=3D"QDX6WN%[@]R_AE/N$.(P
M"*<L"%DXN1U/XFA*+X;A/)S]$ 1Q$#R@=+4U8E4X.$R/P(,HLE(H)6[A3"BN
M4L$EW/0Q!_!1I4-X)R5<>YB%:[1HUI@-O<]7B\*5\N05+ KD&?W"P@DG\>3#
M[RR,AN/%J%N2P6AGL5CJ; O6;26^/:AXE@FUBF?5)BFY60D5\]KIUZ*LM'%<
MN>03$RK#31PDK,'EG7#,X<8Q*SXAX]D?M77Q. B^2RIMA6<<&Y3<JYP<M'0R
ML>Z#]:["I!2*%>CSB8/A1*@7T8L18>]]I));^_:@Y 1-M7+TJ=I?6J,Y^&N(
MR<L>J]XN)V2; Y&OW"YUYG1%>;9[.2^%W,:WHD0+E]C M2ZYZ@V7VCE=DFVK
M!9=B17%\.CZ(Q_=Q4BVUB=\$[5_2%,(ALQ5/,:X,LL;PJ@O7=&(LM<R2!V[S
MX83(?8Y/NW>'1OF/J+3"5MI&9*Z(<^%ZI8C6ATTAEL)!=RH\C@2NOJXD$O-G
MBOR]!GM/^?LWXVF0_,MDQ^$7XG\FWY3BHMGO&6CY[4>/]U1/?(73.165#"ND
M?[2\QI6PQ!LSN*J74J14)E-=*T<.J229\C]4\*43\T_UV[=<OR&D.\6<!E<@
M")5J0X6QJ_O++1C,23>5^JW6PK1:[@RLH\[@>XJ%PTMMAQ!%$?6'61@=#[KG
M:30/I[OGXV R_[%_/HZ.YP/@*NO6LTDXGQ\!^3S3IH0;-FOW'GGUZ.@!, ^C
M\ D@\E]=UX88^LH.&5'+X R7IN9F"YZ%;T8#:(0KR,A6F-[G[6704G28_+Y)
M/<J/G%_6:RYIL>M8GHK'8IYCVW45VM9.^#NB".Z5-EJ"7J-YY+4C2%]G^'7/
MW92L]W9W]WWV1G8$OUY=_ SGYU??LEI_J_Q_TM9I-8 +:OH\+6J+SMG_HQ#/
M;NAC$9X,2,^&K%SBAF7"^.M'<Q!E4)<JR82M)-_&?O?Y'.;G.9%O>P*M%:,^
M\84!K3!]^)VL0DF:RQA5"./:B3)YND$NN]<57R%;TBA]QWA.%S#FLN%;VPZ/
MBY$?56G&';5#[I]02P,$%     @ \C1:7#_\:5>["0  1$0   \   !N=79L
M+65X,S%?,2YH=&WM7%]3V[H2?^^GT&FG9V!N')) :.MP.I-"..7>'NB$=*;W
M4;'71!?9\I'DA)Q/?W<E.PF0TK30EK3A 6)[=[5:[T_[1R('OP4!.SH^.67=
MR(HQ' D3264*#6SK_*]M]G;PUSMVI*(BA<RR@(VLS<.=G<ED4H\3D1DE"RM4
M9NJ12G=8$+P^((&'&CC=9D?< @M;C=9^T&@%K?:@V0YW]_%&?;>Q^^I?C4;8
M:,RY5#[5XF)DV5:TS8@)1\XRD!*F[%AD/(L$E^R\&K/&3K*HSKI2LCZQ&=8'
M WH,<9UD/CD8V52^?L(.1L!C_,L.K+ 27O<^!KO->O-@QU\BP4Y)<3!4\909
M.Y7PQ].<Q['(+L*7^54GY?I"9"$OK/I-I+G2EF>V\T\@LABNPD8GF,#P4MC
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MH9#"3BE!738L+2@.;0Y(?BVX1KI0+;HDX:J<4%[H'(%L7$(=1>@@3@%7-UY
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MBKTF.F3))\DD[J^_E6)3*+2E]'7:\ $2:9]]>;36KB7Z#X, #@['1S"(+;_
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M5+=F_L!Q_JA;LW_]^ ]02P$"% ,4    " #R-%I<K_3K+RH6 @"JI@( $@
M            @ $     :6UG,3(S-#@Q,#(W7S N:G!G4$L! A0#%     @
M\C1:7,7[NF+J[04 _.T% !(              ( !6A8" &EM9S$R,S0X,3 R
M-U\Q+F=I9E!+ 0(4 Q0    ( /(T6EP<F20,<J 4 &&?%  2
M  "  70$" !I;6<Q,C,T.#$P,C=?,BYG:6902P$"% ,4    " #R-%I<D?V:
MW]^I   %[@  $@              @ $6I1P :6UG,3(S-#@Q,#(W7S,N:G!G
M4$L! A0#%     @ \C1:7.-<"X%QSP0 >&XU !$              ( !)4\=
M &YU=FPM,C R-3$R,S$N:'1M4$L! A0#%     @ \C1:7%VL4UA,1P$ F>$3
M !$              ( !Q1XB &YU=FPM,C R-3$R,S$N>'-D4$L! A0#%
M  @ \C1:7+<4^1H620  HQ0$  \              ( !0&8C &YU=FPM97@Q
M.5\Q+FAT;5!+ 0(4 Q0    ( /(T6ER"_H<.DP,  ,<+   /
M  "  8.O(P!N=79L+65X,C-?,2YH=&U02P$"% ,4    " #R-%I</_QI5[L)
M  !$1   #P              @ %#LR, ;G5V;"UE>#,Q7S$N:'1M4$L! A0#
M%     @ \C1:7!VD76+("0  1D4   \              ( !*[TC &YU=FPM
M97@S,5\R+FAT;5!+ 0(4 Q0    ( /(T6ESB/,]E8P4   0A   /
M      "  2#'(P!N=79L+65X,S)?,2YH=&U02P$"% ,4    " #R-%I<&_%/
MTX8%  #=(@  #P              @ &PS", ;G5V;"UE>#,R7S(N:'1M4$L%
3!@     ,  P [ (  &/2(P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>nuvl-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nuvl="http://www.nuvalent.com/20251231"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nuvl-20251231.xsd" xlink:type="simple"/>
    <context id="C_804b901c-8280-4ee4-8d08-720119428cfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nuvl:RelatedPartyRevenueShareLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_84e19387-66ac-4596-b28a-643c9b3fb129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_87166674-75a3-43e1-b506-e4931d232803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nuvl:RelatedPartyRevenueShareLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_871a772b-11eb-4b5f-8988-87609b488c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_89ef94e8-5fe8-4da1-8b41-06e3cb2b86a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8c05b7a3-8cdf-43a6-a7e8-093ffb97f438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-30</instant>
        </period>
    </context>
    <context id="C_8c5fa58b-cce8-41df-a7c1-f605951d05f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8d3a377b-6ff7-4302-9183-32b0389e7d83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9197732a-6f19-4a46-a09e-bbf59e2e5565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_93016deb-ee08-467a-a576-f8fa9b49422a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_93b7517e-8570-4d83-b09d-74c6833d8f47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:NeladalkibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_93c55488-e02d-4971-b17c-5355e98cdfa9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_995479a7-c042-4eed-b4f4-cb48506a82ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9bf007c6-b63f-40c9-9e02-abfd50766d7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_9cdf4307-9ead-4afc-bdf8-f81ea96995ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nuvl:ClassAAndClassBCommonStockOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-28</startDate>
            <endDate>2021-07-28</endDate>
        </period>
    </context>
    <context id="C_9e99d067-33f9-44b7-ad37-2b11d6b976ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:ZidesamtinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_9ed360b9-2aab-458b-bda7-0463d9f71263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9f83a502-9a23-4e89-997b-59b9c16ccdcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_a003efa2-9b6b-4b5b-8e24-3f682b981042">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvl:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_a35f2a79-4ef6-43ea-a2a6-e4132c6ac5cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_a45f72dc-0315-4ee6-825d-858c0027d5b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a4c171d8-3da3-4eb9-89e1-62dacc43ee28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a59b2dc3-40a3-4254-a8ce-3b9d4e32e2ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_a7c68923-25e9-4e81-bde0-d29cb0d28c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a88ce5aa-19e3-4d4f-ad4b-227efe228c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:DiscoveryProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a9763b57-1db2-4f46-9ff1-ae604892960c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_abcc8928-5878-4175-910a-b88480310852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ade98c0e-cd81-4850-a29e-7a084963f5ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">nuvl:NetOperatingLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_aee1bc3b-ea55-48a0-b0ff-337c01baa3ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_afdd3fb0-ef69-40ad-bdc6-6e7c62bedfaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:AlexandraBalcomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b31225ef-7fb3-476b-bede-da08638f612a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b3cff3c2-044c-46b7-89c3-2f4680873e9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="C_b4f67603-f7f4-4146-9b75-51864e400238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b5d7c4e7-18e6-4f91-bcaf-b360fe129db5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b91245ac-3eac-4609-a0fd-52cfb27df07b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:ZidesamtinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b96b8a89-ec86-4975-9a70-f67d031a9eca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b9cdf8b1-21d2-4c81-8860-bfb22facc2be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_bba0ffcf-7930-4541-851f-def4fb4b8a99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-19</instant>
        </period>
    </context>
    <context id="C_be9e56dd-5d09-42b5-a3e0-25987a1ec13c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c2cf0b0d-1d62-4db0-b62f-ddbc77d261d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c5190b6e-fe0c-4289-8dbf-a33c66c7be66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:HenryPelishMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_c6bbbfaf-9812-4257-bac4-0186503112d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c712640c-07a0-45da-b2b2-bcb02c4fd3e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cade3bc7-f32f-4684-8800-eec9caada9bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_caf3d18a-ea80-40be-9716-306c4b3b915d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cbc6ed71-c5cd-44a8-8b33-02e5252b1e57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cbcb2363-568f-4092-88ad-525c58d12120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nuvl:RelatedPartyRevenueShareLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_cbef92a0-50ca-4971-bfcf-4cc694bd98f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_cd8ca3b9-735d-497f-8b2f-206e366ae9a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_cdabc5c6-3cd2-4eb9-9dc6-41bbf0db7742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_cdbd7a9d-c51f-4155-98da-a38460114f3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cdee423f-13dc-4cee-9db9-89de0a74a37e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ce0c1f70-1e86-4aae-bde4-2bb3ccddfaa6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d099b530-0cf4-48be-a348-63560b2d2db7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nuvl:RelatedPartyRevenueShareLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d47345ec-2ef1-4025-9501-8c6905454377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvl:RevenueSharingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_d4753189-18cd-4f14-9c1a-96a8faae97b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d715c616-aabd-4724-8a14-e0643645f7fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_d76a48ae-1458-49f4-880c-993e1969d630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="C_db861eb5-13ac-4eb3-ad97-2e20abffc3c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dcbf0a58-6a1b-4202-9cdf-1ee677e03399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_de369d63-3940-4ffe-ab65-7d8fb85e29f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e04f47c1-ee6d-40d2-ad63-924abbcdd776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:AlexandraBalcomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e1e6998a-a42a-435c-9db6-9c17a1e2d9d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e20707b9-ffb3-4b91-af22-0d9378f431f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e23cc770-0e42-4f32-8905-235f71ad32fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e296d935-9d7a-4619-b857-c867a08d6bf1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e2c0f06b-9e84-41cf-840f-bb816b9bcc96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvl:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e4d077ae-e343-4a79-ae30-25df3168dd9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e5c11e44-2976-420e-8d41-594249e44ff8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e69823d8-ed01-4d08-984d-1b2999947be0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e991fd94-9f04-42a7-9ea3-29c75a8aa6ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">nuvl:OrphanDrugCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_eb77daac-31d6-4c33-89c6-be1bd2d47291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_eba66bbe-f103-4138-86da-3992c8897615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ee20e1d0-82c0-4f31-a59e-df781ca5bef7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:DiscoveryProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ef0a437f-257a-4262-a85f-63baab8addb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f2bb14c0-23f4-4a61-858f-bd386111223c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f4890ed2-89d0-425e-bad2-ca3f8727c10d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f59252bc-b763-4e51-83d2-54d4bba5a6f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f899193c-c2e3-484b-bdb4-f0e98446f558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nuvl:NonExpirableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f95ded5a-49e8-49b9-b5a3-63dc2b4d4aa1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nuvl:NonExpirableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_fed5ef36-c783-45d6-bccf-aedf6738ae46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0000066a-157e-4f4a-ba87-0eadc35447f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_01cd509e-be11-4515-a517-f7b5049d7dd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_04cf2475-3d52-4702-8abf-c08e477d27e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0750e3c9-8640-41ad-9503-347848c2d04a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:NeladalkibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_07fcdeda-4594-41d5-be5c-795db943ad90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0b6fa2d9-3207-4641-a3d5-2ca8fe718b5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0e122157-f19c-4bac-ba06-7e7e26e67d60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_0ed9a5c8-bc77-4159-80cc-631b58767dd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_0f57ea6c-80f3-41df-a06f-6bbb78d913d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="C_115fa72c-632f-4dc3-a356-8cde960ebdc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_116dea71-ba5e-4119-8d49-e7ee6561f1e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:NeladalkibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1199f4a9-3a4a-4346-9b3c-1e5dfe502dce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nuvl:RelatedPartyRevenueShareLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_11b35f3d-891f-4171-b4d4-acada2917088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nuvl:RelatedPartyRevenueShareLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_12c1df21-95c0-4db5-83c4-037d4d91afe3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_13717a87-7c59-4d14-9edc-e3677683fc0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:DiscoveryProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1933430c-8e7f-4e70-bb06-113d64f132d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nuvl:DebtSecuritiesAvailableForSalesSecuritiesDueAxis">nuvl:DueFromOneToThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_1b1f7158-edca-404e-aa34-c73afe046033">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1b7c2420-1c2c-4ebf-8428-9cac99f1ca29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1c1aeab6-5cb0-40f4-a1b3-94770256e0b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1cd91e04-8d02-4ef7-b3c0-68167cbe59fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1cd95e71-e453-489e-afd8-afbc6cfad37f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nuvl:ClassBConvertibleCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_1d01bc0b-7ded-4bd0-9911-fdca86bb46a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_1dad83de-cc46-4271-b61b-c56d9259a2a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1e086995-98e4-44a7-b73f-1985518eb0f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20130f2c-c4db-45fd-abba-1f8188d4bd9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">nuvl:NetOperatingLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_21c5a8f9-d69c-4f2f-9b56-7302217a3a00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:NVL-330Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_22a8e1ba-3f11-4756-a8b5-7e71665e826e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_246b0188-59cf-48e1-84da-c53c20eff235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:NVL-330Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_249fe9c5-035a-4be4-bda3-5a7f5c5d842f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nuvl:DebtSecuritiesAvailableForSalesSecuritiesDueAxis">nuvl:DueWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_27e304bf-4878-4185-b218-ef61b37c5fd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nuvl:ClassBConvertibleCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2e334b49-451c-4916-9273-f6e7d4df64dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2eb94656-ce71-41b7-8316-033ff3cd4fea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_2faab416-a590-4339-bcf2-a0d2b4d28bcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-19</instant>
        </period>
    </context>
    <context id="C_311675e3-d4bb-45f1-8ba5-f59f04c6601e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_315a253c-12d3-4e3f-8582-c49af65387fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_35482e0d-c33b-47c3-848d-21781d777547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_38c713ba-cdc7-468e-8239-8bb281da925a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3b2c84ab-d113-49df-ac68-ee96b2c40bcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3b49c627-bb81-455e-91fc-cab076e3df66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">nuvl:NetOperatingLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3d1f51e0-4a93-4b50-a43a-e08057aecfba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nuvl:ExpirableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3eba6714-0731-48ae-b4f4-7f4ce2c35d2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:ZidesamtinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4012f4dc-f825-4c85-81de-f4ed79e455ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_40396d26-77ba-42d0-a54a-49ced53d5b71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_466cca9b-97be-4208-8bc1-360fd88d3e92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nuvl:RelatedPartyRevenueShareLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_47a42871-276f-471d-89af-7b2d8728791f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:JamesPorterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_4b2153d7-580e-498d-a2f9-c607f8bbecf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4b81bd74-b327-44d2-baca-063efd69c11c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4c059091-923a-455f-b4b2-a218c67cdf6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:AnnaProtopapasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_4f8e7dd3-78fe-4d02-b566-4230ae65335a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4fff95ac-8ff6-451a-8631-2a1193c942a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:HenryPelishMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5375c9d0-2105-44e2-b95c-e77a2e65b0ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_57e49bd8-5824-43bf-b177-9a36dba04b3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_59caff5d-8166-4377-8ad8-d90aab14d4f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_59e85967-08c8-41ab-9f65-d108262ec6c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_5b210e3a-65e3-4ee7-b4af-e26ecefa2931">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5b2c061b-d1fc-4fbb-80d8-2da875f202a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5ced912f-8b63-48e6-a3cd-afdf5cd699b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5ecefa5a-caed-49e8-bd54-e1b9762e2e0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6094352e-f262-4238-af9a-9fad395992a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvl:NVL-330Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_62eeefb2-1e14-4bca-8787-bc752cc63c08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_64c133f5-2609-4c1b-9738-f16ce3dfd8c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_651bca55-01de-4bcf-b62d-18da05e75cbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6656ba66-9dab-4e91-9c45-bf8d51c0b1f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_66ccad61-3ba5-4582-a264-afb3cb89f898">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_69edaadf-ec5e-4f6b-a8f9-bf8b5f259318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6b6f2b20-abff-42cb-90e5-af03ff62b7f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6c8c683b-7a90-4cec-ad1b-80a3610a19bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6edd2b6c-842b-450b-bfa3-6954cfc7acbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7026295c-45c4-4065-af2d-da1e39b72fb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7113a74e-6c90-4126-9b38-7b6f500f4532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:AnnaProtopapasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_72818106-430d-4e9d-ac04-dff4e3f376f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nuvl:JamesPorterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">nuvl:Rule10B51TradingPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_739ac674-8392-417c-8c4a-3fc04e811f6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_76fd5dc0-bfbc-4e89-bf40-514de9d64090">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_794390d5-c9fe-4091-8a4b-34dc63c137c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_79da2e27-729f-4d64-9d13-dfa7ed04d4ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_7ab55318-ef2a-434f-8bd9-380fef2ea246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7afb1013-38c2-4d5e-b701-12fe832c3317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvl:ExcludingPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7ba5c3d8-bf4d-45c7-b12b-5b3d1c87d47e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nuvl:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_7ce3ca05-ba69-4be9-a104-7719ff79cd1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nuvl:ExpirableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_7d73a6a9-9a14-4d7d-ac5c-0d24cfad2b78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7eb103db-61c7-4a1d-bd4c-ff51a5d2f879">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvl:ExcludingPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_7fb5a364-b725-42f1-ad2c-b3730193541d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Segment">
        <measure>nuvl:Segment</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_b805326d-b0b8-4b7d-bbfd-39a4c67c2a5d">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_81256ce3-959b-4b93-84e1-a8e06ee0a849">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_2960a5ae-7bfc-437f-b348-7f55e9e1cdbd">0001861560</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      id="F_0d2d81e3-69a3-4524-9293-717092943f94"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      id="F_8f9dc6b8-8eae-47ed-8d70-8d9905e57973"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_eb77daac-31d6-4c33-89c6-be1bd2d47291"
      id="F_2bc711c3-dec2-4073-ad3b-8876b685c8e8">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_9bb6efd4-414b-479c-bbd1-d6eec4dc4cc3">http://fasb.org/us-gaap/2025#AccountingStandardsUpdate202309Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:OpenTaxYear
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_b03806a6-1c81-405a-b304-d4fc62c72a8c">2022 2023 2024 2025</us-gaap:OpenTaxYear>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_d7650aa4-5b78-4427-b72b-9d9f6eb1e03c">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_c878b86a-9508-4bbd-ac26-41dc1d148b19">http://fasb.org/us-gaap/2025#SegmentReportingExpenseInformationUsedByCodmConsolidatedMember</us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_3674a9f3-5752-449c-bece-cdde11b798ae">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_4948668e-974b-4713-b1c3-c22059b58fdd">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_2747a553-19fe-4305-b088-8fa9b69b964b">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_2d10611d-fbc8-43f0-93f7-e2f269ac43e1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_b7a660ea-42e7-485d-bbdc-db2334f840ec">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_77046829-f83d-4874-8aa0-be55f67acbf1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_3cf87df0-8518-4d07-a7ec-88a9375ba518">001-40671</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_8b34456b-d6a6-4da2-9a9c-576f8185e782">NUVALENT, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_4f8e5431-1b03-406f-9624-bca20749257a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_f6587e63-92cd-488c-93bc-fbe14bd00143">81-5112298</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_efa60fb9-2e0f-49a0-ad7f-72d100abe0a8">One Broadway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_264d9065-3d0f-456a-918c-5f7ef414053b">14th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_8245a999-a394-4844-bb23-cec6976b9c4b">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_ce52a3f4-bd55-468c-9b91-ef6e99a33b62">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_c661d012-4c9c-45c1-93e3-4a6ca140e8e9">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_983460da-bf98-4afd-ae20-63b0fe0cdbba">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_b67257e7-21c2-4de9-b625-9824c65ccea7">357-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_a66cc186-5a5c-40db-b5a0-cf29c33a28ab">Class A Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_394c0d4d-b0df-491c-b6f3-d79fd7ad008c">NUVL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_6f38f4d4-f177-44d3-a1fc-3134f229c726">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_d6eda7b0-7d23-4acb-84c6-0b3f007afd9e">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_2744adc2-48ad-460c-8677-14d1053beda5">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_f1408c37-d233-4e28-b09e-e2efde675610">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_4d0f6da1-60d8-466a-9746-560b1b06f0fe">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_228b6e9f-1232-414d-b3b2-e9d7b654753b">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_5411d3bd-6bdc-429b-8da5-896e5f4d379e">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_9e68e42a-7829-47a7-838e-91b82cfa0639">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_9f642ac0-1e8e-4eba-8d76-83c9ab6231cd">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_0061c33f-b4b3-4d8e-b9c1-828c76a013d0">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_e6d8e33c-047e-4295-8b67-7c355000ccd1">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_cade3bc7-f32f-4684-8800-eec9caada9bf"
      decimals="-8"
      id="F_d61a867c-2866-4e40-960e-ae0c1254f83d"
      unitRef="U_USD">3600000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_2faab416-a590-4339-bcf2-a0d2b4d28bcf"
      decimals="INF"
      id="F_0905edc2-8692-4335-9400-a9817deb3ff3"
      unitRef="U_shares">73181747</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_bba0ffcf-7930-4541-851f-def4fb4b8a99"
      decimals="INF"
      id="F_c4abc14f-4730-4fe7-ae96-8c3b0d3a9406"
      unitRef="U_shares">5435254</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_719a2515-b4b3-4cf6-9e57-0153287862a6">&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s Proxy Statement for its 2026 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_12886c78-ec1c-4fa2-b10c-579d037cae1d">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Cybersecurity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity Incident Response Plan (IRP). Our cybersecurity risk management program is a key component of our overall risk management process, and includes similar characteristics, reporting channels and governance processes to those that apply across other legal, compliance, strategic, operational and financial risk areas within the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk management program includes:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity awareness training of our employees, incident response personnel and senior management;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a cybersecurity IRP that includes procedures for responding to cybersecurity incidents; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a third-party risk management process for service providers, suppliers and vendors&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;not identified risks from known cybersecurity threats,&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations or financial condition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity Governance&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to its audit committee oversight of cybersecurity and other information technology risks. The audit committee oversees management&#x2019;s implementation of our cybersecurity risk management program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee receives reports from management on our cybersecurity risks at least annually. In addition, management updates the audit committee regarding all material cybersecurity incidents, as well as any incidents with lesser impact potential that management, in its discretion, determines may be relevant for audit committee review. The &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;audit committee reports to the board of directors&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; regarding its activities, including those related to cybersecurity.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team, including our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Financial Officer, working closely with our Vice President, Information Technologies and our Director, Cybersecurity and Compliance (collectively, our Cybersecurity Oversight Team)&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, is responsible for assessing and managing our material risks from cybersecurity threats&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Cybersecurity Oversight Team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Cybersecurity Oversight Team&#x2019;s experience includes a combined 50+ years in the pharmaceutical industry and information technology. This includes software and systems development, cybersecurity program oversight and overall IT management. Our Cybersecurity Oversight Team has over two decades of experience dedicated to supporting enterprise architecture and over a decade of experience specializing in cybersecurity, implementing cybersecurity frameworks, assessing and managing cybersecurity risks and executing incident response plans.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Cybersecurity Oversight Team supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, which include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;engaged&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; by us; and alerts and reports produced by security tools deployed in the IT environment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to our IRP, all of our employees are trained to report a suspected cybersecurity incident or breach to our information technology team. Reporting guidelines under the IRP describe how to report an incident and what details to include. As a first step under the IRP, our information technology team assesses the reported risk or breach and escalates it to our Incident Response Team (IRT), as appropriate. The IRT is comprised of the members of our Cybersecurity Oversight Team and other critical business function leaders, including members of our legal and communications teams. Following notification from our information technology team, the IRT is responsible for continuing to assess the suspected risk or breach to determine its potential impact on our organization, systems and data. Based on that assessment, the IRT may raise the incident or breach to other members of management or the audit committee for further review and triage.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_7c35c2dc-c932-4159-88dd-1b694695de94">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk management program includes:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity awareness training of our employees, incident response personnel and senior management;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a cybersecurity IRP that includes procedures for responding to cybersecurity incidents; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a third-party risk management process for service providers, suppliers and vendors&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_0edf967c-54c0-4c6b-bc82-d14f36683ae6">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_5aea571d-02da-4096-88f3-ed0426529d02">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_696dbe25-ce73-4d40-9b5d-b263780ee031">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to its audit committee oversight of cybersecurity and other information technology risks. The audit committee oversees management&#x2019;s implementation of our cybersecurity risk management program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee receives reports from management on our cybersecurity risks at least annually. In addition, management updates the audit committee regarding all material cybersecurity incidents, as well as any incidents with lesser impact potential that management, in its discretion, determines may be relevant for audit committee review. The &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;audit committee reports to the board of directors&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; regarding its activities, including those related to cybersecurity.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team, including our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Financial Officer, working closely with our Vice President, Information Technologies and our Director, Cybersecurity and Compliance (collectively, our Cybersecurity Oversight Team)&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, is responsible for assessing and managing our material risks from cybersecurity threats&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Cybersecurity Oversight Team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Cybersecurity Oversight Team&#x2019;s experience includes a combined 50+ years in the pharmaceutical industry and information technology. This includes software and systems development, cybersecurity program oversight and overall IT management. Our Cybersecurity Oversight Team has over two decades of experience dedicated to supporting enterprise architecture and over a decade of experience specializing in cybersecurity, implementing cybersecurity frameworks, assessing and managing cybersecurity risks and executing incident response plans.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Cybersecurity Oversight Team supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, which include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;engaged&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; by us; and alerts and reports produced by security tools deployed in the IT environment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to our IRP, all of our employees are trained to report a suspected cybersecurity incident or breach to our information technology team. Reporting guidelines under the IRP describe how to report an incident and what details to include. As a first step under the IRP, our information technology team assesses the reported risk or breach and escalates it to our Incident Response Team (IRT), as appropriate. The IRT is comprised of the members of our Cybersecurity Oversight Team and other critical business function leaders, including members of our legal and communications teams. Following notification from our information technology team, the IRT is responsible for continuing to assess the suspected risk or breach to determine its potential impact on our organization, systems and data. Based on that assessment, the IRT may raise the incident or breach to other members of management or the audit committee for further review and triage.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_4a3a1b3b-aec0-4e55-b411-10ccadcd75ab">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to its audit committee oversight of cybersecurity and other information technology risks. The audit committee oversees management&#x2019;s implementation of our cybersecurity risk management program&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_42ebe525-53f0-4a60-8c41-d20b45434f8c">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee receives reports from management on our cybersecurity risks at least annually. In addition, management updates the audit committee regarding all material cybersecurity incidents, as well as any incidents with lesser impact potential that management, in its discretion, determines may be relevant for audit committee review. The &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;audit committee reports to the board of directors&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; regarding its activities, including those related to cybersecurity.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_2bcea2be-9d5d-4be6-ba78-e91f28f05bb0">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_5afffa15-e2fd-45de-a23e-808c956209c1">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team, including our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Financial Officer, working closely with our Vice President, Information Technologies and our Director, Cybersecurity and Compliance (collectively, our Cybersecurity Oversight Team)&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, is responsible for assessing and managing our material risks from cybersecurity threats&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_5860e5c6-b0ae-44e9-9469-91e9e59b8dcb">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team, including our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Financial Officer, working closely with our Vice President, Information Technologies and our Director, Cybersecurity and Compliance (collectively, our Cybersecurity Oversight Team)&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, is responsible for assessing and managing our material risks from cybersecurity threats&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_34d671d1-6e2d-4ea9-bf7e-65428c32a1e7">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_dd363d52-1837-48ef-8af1-293951f7dda2">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Cybersecurity Oversight Team&#x2019;s experience includes a combined 50+ years in the pharmaceutical industry and information technology. This includes software and systems development, cybersecurity program oversight and overall IT management. Our Cybersecurity Oversight Team has over two decades of experience dedicated to supporting enterprise architecture and over a decade of experience specializing in cybersecurity, implementing cybersecurity frameworks, assessing and managing cybersecurity risks and executing incident response plans.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_74ee1ff7-bcb8-439c-b9c6-fb04bc438dba">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <dei:AuditorFirmId
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_45eba015-3bac-403f-8f75-8388c9f3b8b4">185</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_2af0d644-f343-4dd7-b31e-4031b466b87c">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Opinions on the Consolidated Financial Statements and Internal Control Over Financial Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Nuvalent, Inc. and subsidiary (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders&#x2019; equity, and cash flows for each of the years in the three-year period ended December 31, 2025, and the related notes (collectively, the consolidated financial statements). We also have audited the Company&#x2019;s internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control &#x2013; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025 based on criteria established in Internal Control &#x2013; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_c0966265-3e7b-4029-b79c-bb90d6bb0e0a">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_6a911614-176c-4ade-a79c-505bfd0fd9f5">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_363d662b-462e-4811-ade2-88874626a9bf"
      unitRef="U_USD">261745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_8c51eeca-b102-4e17-8c98-63a29d26ad82"
      unitRef="U_USD">145691000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_aeacf3a8-100b-4e9c-a631-a53d19a2c9b4"
      unitRef="U_USD">1110207000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_8d4a5fcf-9f70-47da-80f6-584910cbcd93"
      unitRef="U_USD">972611000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_38ae861f-e306-422e-9589-b53140ccf38e"
      unitRef="U_USD">20474000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_b32c9144-cb0d-4c4e-ae54-d42c0cdcc95e"
      unitRef="U_USD">14146000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_e450f521-445c-469e-8911-f268c68e45ab"
      unitRef="U_USD">1392426000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_1b82157a-b365-4518-b24c-929320e5b3f7"
      unitRef="U_USD">1132448000</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_a2a75ce8-6b3b-4005-9b2a-088a662e781c"
      unitRef="U_USD">20279000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_0c6a297a-28f5-40a5-9b12-3b5e3c4f0200"
      unitRef="U_USD">9304000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_7dc29295-7c85-4025-879b-4e1e8c3fab65"
      unitRef="U_USD">1412705000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_49802752-7abe-49e6-b4bd-ad94c58366cc"
      unitRef="U_USD">1141752000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_ad5104ab-9df6-4ec0-97bf-d233cf8bf697"
      unitRef="U_USD">30158000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_5bbf03b1-206e-4b00-9a2d-0b712d09c6a3"
      unitRef="U_USD">5225000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_5770a79b-b74b-4744-bc8d-15fd96a546be"
      unitRef="U_USD">61013000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_95b639ea-7ccb-449a-99d4-bbcf65be96ba"
      unitRef="U_USD">48795000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_b6196e69-5a55-4f98-a80a-fba39a4802cf"
      unitRef="U_USD">91171000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_d409f04e-9a0c-4ed0-b42a-e1ad8c72b0c0"
      unitRef="U_USD">54020000</us-gaap:LiabilitiesCurrent>
    <nuvl:RelatedPartyRevenueShareLiability
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_3939cb7a-5673-455d-a091-39a09546d937"
      unitRef="U_USD">73160000</nuvl:RelatedPartyRevenueShareLiability>
    <nuvl:RelatedPartyRevenueShareLiability
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_4f972c6c-9b8d-46fd-936d-3ed5168d1d8b"
      unitRef="U_USD">17940000</nuvl:RelatedPartyRevenueShareLiability>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_245331b9-67c6-4502-acaa-de2300226adb"
      unitRef="U_USD">35000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_99c7373c-d972-41ac-ad0c-c38288d4234c"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_5f969cf2-65af-4b6c-a988-43193e100598"
      unitRef="U_USD">164366000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_08d1a415-42fd-49dd-933e-7133e2749001"
      unitRef="U_USD">71960000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="INF"
      id="F_b5137dbd-2bee-4f33-bab9-981a77934593"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="INF"
      id="F_b6b6629f-9404-4b91-9f8d-abe22f481ac7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="INF"
      id="F_3f57b05c-1895-4a92-8eba-8477e6c1d6c0"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="INF"
      id="F_68fda303-cd15-487a-b347-cd1c9cd5fd16"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="INF"
      id="F_e70c6d8e-3e8c-4355-9cb8-a607258883a6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="INF"
      id="F_11247f71-c30d-40dc-baf6-a721dc5fb1d6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="INF"
      id="F_454d048e-d4ff-46c9-958c-01b8d2f936b5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="INF"
      id="F_f4f62f90-7ac2-4a99-8b18-474afc912dfd"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_a7590693-7308-45e2-be7f-abed79d96559"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_2bdc6541-76b9-414f-875a-efed4b15515b"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_66ccad61-3ba5-4582-a264-afb3cb89f898"
      decimals="INF"
      id="F_82c94d2b-f519-4166-ab14-c5b88157378c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2e334b49-451c-4916-9273-f6e7d4df64dd"
      decimals="INF"
      id="F_d30f65d0-530b-4ddd-9419-cfa1458edc06"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_66ccad61-3ba5-4582-a264-afb3cb89f898"
      decimals="INF"
      id="F_b80750fa-f1a2-4195-9a2a-a34ff9e3a7ba"
      unitRef="U_shares">140000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2e334b49-451c-4916-9273-f6e7d4df64dd"
      decimals="INF"
      id="F_a63945d7-9be2-40a9-a95c-c5a5e229e8b7"
      unitRef="U_shares">140000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_66ccad61-3ba5-4582-a264-afb3cb89f898"
      decimals="INF"
      id="F_b5135710-f796-4217-a0d2-a90e7b70225c"
      unitRef="U_shares">72804111</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_66ccad61-3ba5-4582-a264-afb3cb89f898"
      decimals="INF"
      id="F_42891881-af08-42b2-96e2-c5188459fa77"
      unitRef="U_shares">72804111</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2e334b49-451c-4916-9273-f6e7d4df64dd"
      decimals="INF"
      id="F_9051b9e4-bf93-4220-b542-e5cff2ac4374"
      unitRef="U_shares">65909564</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2e334b49-451c-4916-9273-f6e7d4df64dd"
      decimals="INF"
      id="F_a377ced1-06ee-4dcf-9210-b7adf038b187"
      unitRef="U_shares">65909564</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_66ccad61-3ba5-4582-a264-afb3cb89f898"
      decimals="-3"
      id="F_02d23299-89d9-4ba1-84db-44ee4ad93ffc"
      unitRef="U_USD">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_2e334b49-451c-4916-9273-f6e7d4df64dd"
      decimals="-3"
      id="F_9d827361-773e-48ed-a661-7510b12addd1"
      unitRef="U_USD">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_1cd95e71-e453-489e-afd8-afbc6cfad37f"
      decimals="INF"
      id="F_7cd53bcf-795b-4290-819e-a71527fff858"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_27e304bf-4878-4185-b218-ef61b37c5fd0"
      decimals="INF"
      id="F_9def3d76-e2e7-4fb7-9cc6-37fab6491137"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_1cd95e71-e453-489e-afd8-afbc6cfad37f"
      decimals="INF"
      id="F_55f10be4-19cf-441a-ab40-aaa592751ea8"
      unitRef="U_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_27e304bf-4878-4185-b218-ef61b37c5fd0"
      decimals="INF"
      id="F_a3610ee8-50ff-471c-b40e-475933d8ab36"
      unitRef="U_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_1cd95e71-e453-489e-afd8-afbc6cfad37f"
      decimals="INF"
      id="F_71c55276-7ed9-4cac-9a68-7395a50f66fe"
      unitRef="U_shares">5435254</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_1cd95e71-e453-489e-afd8-afbc6cfad37f"
      decimals="INF"
      id="F_c61f328d-89f3-4e8c-b0a3-f8e525b0411d"
      unitRef="U_shares">5435254</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_27e304bf-4878-4185-b218-ef61b37c5fd0"
      decimals="INF"
      id="F_29a10f7b-6eed-4dda-9f9e-21e29ee7da43"
      unitRef="U_shares">5435254</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_27e304bf-4878-4185-b218-ef61b37c5fd0"
      decimals="INF"
      id="F_d49cc454-4a35-4930-be54-e0427b5ab994"
      unitRef="U_shares">5435254</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_1cd95e71-e453-489e-afd8-afbc6cfad37f"
      decimals="-3"
      id="F_b0a39f25-dc34-488e-b19f-6492d37013db"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_27e304bf-4878-4185-b218-ef61b37c5fd0"
      decimals="-3"
      id="F_3cdfd375-ea57-4b02-950b-274aab0bcf26"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_7da1318e-5e92-4d11-be0f-ae9f02db1cb5"
      unitRef="U_USD">2218407000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_a5bcd61b-9171-4aad-bd34-62e4d273b774"
      unitRef="U_USD">1616895000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_b28fb97a-d175-4671-945f-4b48f549a8c0"
      unitRef="U_USD">2353000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_de25dcc5-5ac9-4d43-89c8-70381ec3f8c8"
      unitRef="U_USD">-59000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_74692fc2-6084-4ebc-8944-00a26b1b1242"
      unitRef="U_USD">-972429000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_ffd598e1-e4b8-4eb3-9782-e9b164dda3d8"
      unitRef="U_USD">-547052000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_c798898b-8011-44ef-881e-ff7ba676205c"
      unitRef="U_USD">1248339000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_98cca7f3-efb0-4dd1-bcad-099566fe5913"
      unitRef="U_USD">1069792000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_e518e438-6b9e-491e-8e4e-5f9088b6f0ee"
      unitRef="U_USD">1412705000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_c43c941f-9109-415e-b7e1-a5b023444f73"
      unitRef="U_USD">1141752000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_26b54445-839a-462d-932b-246152a531d8"
      unitRef="U_USD">306970000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_19049f73-bb26-4af1-ad95-b2d15e138e90"
      unitRef="U_USD">217774000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_67593c40-dae4-4e36-9bfb-5e89bee8078c"
      unitRef="U_USD">113243000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_e04a645e-c2ec-48e4-a2ab-db26e03922cc"
      unitRef="U_USD">107337000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_ff556f41-79de-422c-9a3e-ef46f0ab5648"
      unitRef="U_USD">62594000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_51cb3d8c-b2f0-41d1-a694-6cfde0b7e6c1"
      unitRef="U_USD">36249000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_bf0a6fd4-5cb2-474e-900a-b02474346ccb"
      unitRef="U_USD">414307000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_0fd197c3-9468-413a-9f96-1e7e9dcbed1f"
      unitRef="U_USD">280368000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_a705a07b-5dbc-4dd9-9b2e-bc99194c1fce"
      unitRef="U_USD">149492000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_3a8bfe7e-6776-4bdb-9ca8-c5d00c6ddf48"
      unitRef="U_USD">-414307000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_666b461c-c88b-4b17-9dfc-cbacb2adfefb"
      unitRef="U_USD">-280368000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_3af188c9-11b1-457a-88fb-c319acf2913d"
      unitRef="U_USD">-149492000</us-gaap:OperatingIncomeLoss>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_1d95f02d-51bc-4c01-91d3-92f7400aaaf3"
      unitRef="U_USD">-55220000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_d7daacb6-a7f6-4f62-ab43-ee74d703530b"
      unitRef="U_USD">-17940000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_63bb86b9-3de8-40a8-b66f-4278f7450f10"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueAdjustment>
    <nuvl:InterestAndOtherIncomeExpense
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_6c9c8c5c-8ff2-41f9-8a39-643819bf9ec4"
      unitRef="U_USD">44735000</nuvl:InterestAndOtherIncomeExpense>
    <nuvl:InterestAndOtherIncomeExpense
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_ec4c1bd4-0136-41e3-8f22-d599787f793f"
      unitRef="U_USD">38316000</nuvl:InterestAndOtherIncomeExpense>
    <nuvl:InterestAndOtherIncomeExpense
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_2405ca8e-8723-43aa-ae29-7096404759d3"
      unitRef="U_USD">23273000</nuvl:InterestAndOtherIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_bd74e0e4-8e6c-4902-9b35-610a18a6f638"
      unitRef="U_USD">-10485000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_1bc1f241-c099-49b8-8a16-eacde8e96321"
      unitRef="U_USD">20376000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_afc1b2b8-388f-494b-8667-16864105c0ae"
      unitRef="U_USD">23273000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_10ed102b-2f86-4903-be3e-b289bcdc2f8f"
      unitRef="U_USD">-424792000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_170b9fd4-01ea-4d58-aed5-a82907786d05"
      unitRef="U_USD">-259992000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_4421dca0-c603-4cac-a554-01961440481f"
      unitRef="U_USD">-126219000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_7922d2e1-957e-42ab-a119-f5f2a2ddc531"
      unitRef="U_USD">585000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_cebb7278-aede-40a6-89f6-62f2aa1d241b"
      unitRef="U_USD">764000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_48961e08-0f0d-418c-bf6b-3039653342f7"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_37e3aec4-6590-4fb3-a6b5-c646a98fac95"
      unitRef="U_USD">-425377000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_3686687c-355c-42aa-a06c-febf00ac1ec4"
      unitRef="U_USD">-260756000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_7916baa9-1f67-4aa4-975e-41101271ed8f"
      unitRef="U_USD">-126219000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_9ae6be40-dba7-4f5f-89b2-e35d26b8c1e7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-5.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_c7e05491-b652-4cce-8bde-e032b5e8e7f0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-5.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="2"
      id="F_eb869057-70fb-4eb0-ae5c-1b5007783e48"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="2"
      id="F_33dc9796-8c8e-44e8-bf1d-25197c727fb2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="2"
      id="F_367ad345-c183-4c6e-aced-ed0c2013339f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="2"
      id="F_bc515826-05e2-40f1-9045-44fbaff7f7ba"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="0"
      id="F_147b1b66-ad66-4b19-bf01-c4970d2d868a"
      unitRef="U_shares">72686749</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="0"
      id="F_1cc8a7ed-e122-422d-9e49-277feb03dfed"
      unitRef="U_shares">72686749</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="0"
      id="F_b88c7663-f747-4665-a645-0f0eb762782b"
      unitRef="U_shares">66408807</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="0"
      id="F_3b3bbfaf-0d93-479a-9dfb-1b6abc0f696c"
      unitRef="U_shares">66408807</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="0"
      id="F_d54317a8-1a79-48bc-a3b7-8954c24b4f98"
      unitRef="U_shares">58223339</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="0"
      id="F_1baba27d-ec44-47a7-ab82-3b17bc41fc96"
      unitRef="U_shares">58223339</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_903ac264-bc6d-4fe3-93c5-f39b840df7a9"
      unitRef="U_USD">-425377000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_dc050254-15cf-45d8-ab71-ace3f9adce6a"
      unitRef="U_USD">-260756000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_79637e13-3ec7-43ab-bada-5d479c8603a1"
      unitRef="U_USD">-126219000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_a25947ae-2278-4178-b493-d649a411d183"
      unitRef="U_USD">2412000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_909edf97-ef2a-4a92-a47a-22818e92511e"
      unitRef="U_USD">-90000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_ed6372a0-d9e2-4729-a6af-74668b665c25"
      unitRef="U_USD">525000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_43163eb9-7a7f-4bc8-bf41-55214a6d9a51"
      unitRef="U_USD">-422965000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_836f9335-1bea-40a7-b905-d93abb4d200b"
      unitRef="U_USD">-260846000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_ae558ee3-f91b-4a91-b311-790c4952e0db"
      unitRef="U_USD">-125694000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_fed5ef36-c783-45d6-bccf-aedf6738ae46"
      decimals="INF"
      id="F_26eab8ca-b36f-481d-b702-242be6363819"
      unitRef="U_shares">51233701</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_fed5ef36-c783-45d6-bccf-aedf6738ae46"
      decimals="-3"
      id="F_07836f21-249e-4a0e-8cbc-aa0115aca573"
      unitRef="U_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_7fb5a364-b725-42f1-ad2c-b3730193541d"
      decimals="INF"
      id="F_cad9f159-b315-4fa0-af78-d2d82d98942a"
      unitRef="U_shares">5435254</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_7fb5a364-b725-42f1-ad2c-b3730193541d"
      decimals="-3"
      id="F_d6a4793a-147b-4ace-8984-6c0abc40af06"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e5c11e44-2976-420e-8d41-594249e44ff8"
      decimals="-3"
      id="F_7cf4b24f-ba7b-4614-b3e4-f695c56977f0"
      unitRef="U_USD">623543000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6656ba66-9dab-4e91-9c45-bf8d51c0b1f7"
      decimals="-3"
      id="F_ee31305f-4814-4374-8ca3-44b88032c061"
      unitRef="U_USD">-494000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_db861eb5-13ac-4eb3-ad97-2e20abffc3c3"
      decimals="-3"
      id="F_9e2414d4-5694-4d72-bca8-efb2344d5c2b"
      unitRef="U_USD">-160077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_eba66bbe-f103-4138-86da-3992c8897615"
      decimals="-3"
      id="F_aa5ed29c-03d8-44ff-a324-dc64ccd7ed18"
      unitRef="U_USD">462978000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9ed360b9-2aab-458b-bda7-0463d9f71263"
      decimals="INF"
      id="F_0db35670-3c98-46b9-b25d-7b130f74cde5"
      unitRef="U_shares">6160714</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9ed360b9-2aab-458b-bda7-0463d9f71263"
      decimals="-3"
      id="F_d3f6e2cf-43ba-411a-ad7f-fa443c0ec856"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0b6fa2d9-3207-4641-a3d5-2ca8fe718b5f"
      decimals="-3"
      id="F_9924d34f-098d-440d-b301-f405a6b7478b"
      unitRef="U_USD">323533000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_b6ff31c3-5552-4cd1-8c6e-a694b5da0300"
      unitRef="U_USD">323534000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_9ed360b9-2aab-458b-bda7-0463d9f71263"
      decimals="INF"
      id="F_8d0e3843-ec50-4019-abf6-74d9b456f05a"
      unitRef="U_shares">1222294</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0b6fa2d9-3207-4641-a3d5-2ca8fe718b5f"
      decimals="-3"
      id="F_8cb84d7d-c7a0-4844-a9c0-97d3b24b8a50"
      unitRef="U_USD">13793000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_bd23352a-9450-42e0-84ba-db3127ed1140"
      unitRef="U_USD">13793000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_9ed360b9-2aab-458b-bda7-0463d9f71263"
      decimals="INF"
      id="F_28d656b0-e892-46a0-990b-d144ad60ac44"
      unitRef="U_shares">13187</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0b6fa2d9-3207-4641-a3d5-2ca8fe718b5f"
      decimals="-3"
      id="F_4d1f8fff-88d9-42fd-98ff-4a2f9d6a0490"
      unitRef="U_USD">387000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_7640a2c7-c305-4474-b310-b83aefd9b967"
      unitRef="U_USD">387000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_1b1f7158-edca-404e-aa34-c73afe046033"
      decimals="-3"
      id="F_a259ac58-3a63-4d8b-9ca1-60170a64b62c"
      unitRef="U_USD">525000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_e93da32b-80f8-43df-b121-e2d8a9e63cd4"
      unitRef="U_USD">525000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0b6fa2d9-3207-4641-a3d5-2ca8fe718b5f"
      decimals="-3"
      id="F_3fb9a1a1-52ba-4d21-8122-e3a93074a145"
      unitRef="U_USD">25563000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_b4100b92-d00f-4fbb-a972-62f805a7ad40"
      unitRef="U_USD">25563000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_69edaadf-ec5e-4f6b-a8f9-bf8b5f259318"
      decimals="-3"
      id="F_6e9dc22a-5a4b-4b31-a510-0acb6fb2e901"
      unitRef="U_USD">-126219000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_28180d79-5319-4f30-8bf8-f28e3b1b1324"
      unitRef="U_USD">-126219000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_8c5fa58b-cce8-41df-a7c1-f605951d05f0"
      decimals="INF"
      id="F_21675a97-8c3c-4c73-a5d1-53be86ec78b8"
      unitRef="U_shares">58629896</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8c5fa58b-cce8-41df-a7c1-f605951d05f0"
      decimals="-3"
      id="F_e0f12a75-1a76-451a-95de-d0ba404da2dd"
      unitRef="U_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_abcc8928-5878-4175-910a-b88480310852"
      decimals="INF"
      id="F_3071b8ef-c222-45d1-a71b-646a0bfdad05"
      unitRef="U_shares">5435254</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_abcc8928-5878-4175-910a-b88480310852"
      decimals="-3"
      id="F_d41f0ff0-67bc-42ed-8361-38436beb0c80"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_739ac674-8392-417c-8c4a-3fc04e811f6e"
      decimals="-3"
      id="F_b13e14ba-99a4-483c-b7b0-780b30649a00"
      unitRef="U_USD">986819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f4890ed2-89d0-425e-bad2-ca3f8727c10d"
      decimals="-3"
      id="F_54ace6c5-d05c-4664-92d9-edc2ad8ec34b"
      unitRef="U_USD">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cbc6ed71-c5cd-44a8-8b33-02e5252b1e57"
      decimals="-3"
      id="F_84f9c287-ac44-4192-b883-db102f6e100f"
      unitRef="U_USD">-286296000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a7c68923-25e9-4e81-bde0-d29cb0d28c74"
      decimals="-3"
      id="F_6878d696-3193-4727-9813-d74b9301f514"
      unitRef="U_USD">700561000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_59caff5d-8166-4377-8ad8-d90aab14d4f4"
      decimals="INF"
      id="F_c629f3d4-108e-4916-aa31-a8683db8076b"
      unitRef="U_shares">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_59caff5d-8166-4377-8ad8-d90aab14d4f4"
      decimals="-3"
      id="F_28cdb97e-0848-41f5-8435-6c2b262a8b43"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_6b6f2b20-abff-42cb-90e5-af03ff62b7f2"
      decimals="-3"
      id="F_b04e0f0f-d4b4-4e54-9760-15e3287fff1c"
      unitRef="U_USD">540011000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_ed4b50c5-a6e4-4de1-9db8-a55fd4821b34"
      unitRef="U_USD">540012000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_59caff5d-8166-4377-8ad8-d90aab14d4f4"
      decimals="INF"
      id="F_44e9a578-9dd7-465a-a1f3-6719dfb03ee4"
      unitRef="U_shares">1518096</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6b6f2b20-abff-42cb-90e5-af03ff62b7f2"
      decimals="-3"
      id="F_9f120395-81ad-4021-ad79-d7bd69e95af1"
      unitRef="U_USD">28834000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_f2b3ea39-c031-440c-aecf-219a03384531"
      unitRef="U_USD">28834000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_59caff5d-8166-4377-8ad8-d90aab14d4f4"
      decimals="INF"
      id="F_c69fff74-a7c9-4e23-8898-21dd1be14110"
      unitRef="U_shares">11572</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_6b6f2b20-abff-42cb-90e5-af03ff62b7f2"
      decimals="-3"
      id="F_7c6c41bf-b022-48ea-a19f-66ed491e5065"
      unitRef="U_USD">652000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_44f06978-9a7a-4d28-8a4b-ec2c0be364b8"
      unitRef="U_USD">652000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_cdbd7a9d-c51f-4155-98da-a38460114f3d"
      decimals="-3"
      id="F_752b9913-af4c-4e09-9622-c6e865ac590b"
      unitRef="U_USD">-90000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_ccef38d4-d741-43c1-a645-cda66e1f8087"
      unitRef="U_USD">-90000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6b6f2b20-abff-42cb-90e5-af03ff62b7f2"
      decimals="-3"
      id="F_3eb78cf6-780c-48c9-9619-074daaa2f705"
      unitRef="U_USD">60579000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_78f8e8a8-355a-4e37-ada9-651f88250824"
      unitRef="U_USD">60579000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_e23cc770-0e42-4f32-8905-235f71ad32fa"
      decimals="-3"
      id="F_f9a8ae5f-b90f-42a3-a1a9-fe47b5597783"
      unitRef="U_USD">-260756000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_bf058987-ae51-4d62-84a3-5cff91b2d082"
      unitRef="U_USD">-260756000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_4b2153d7-580e-498d-a2f9-c607f8bbecf4"
      decimals="INF"
      id="F_44b7272e-d1e5-4dde-a9b4-4f91734c2c2a"
      unitRef="U_shares">65909564</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4b2153d7-580e-498d-a2f9-c607f8bbecf4"
      decimals="-3"
      id="F_d85b058a-009d-48d6-be77-f1e5b2e780a9"
      unitRef="U_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_38c713ba-cdc7-468e-8239-8bb281da925a"
      decimals="INF"
      id="F_a32fbf28-99fc-423e-a475-e9c7c4afbc88"
      unitRef="U_shares">5435254</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_38c713ba-cdc7-468e-8239-8bb281da925a"
      decimals="-3"
      id="F_32cc4bdf-eccc-4e5e-a65f-e82f1b251c44"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_871a772b-11eb-4b5f-8988-87609b488c50"
      decimals="-3"
      id="F_ca10883f-6aa2-4809-b52b-bf01cf2b9cb0"
      unitRef="U_USD">1616895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b31225ef-7fb3-476b-bede-da08638f612a"
      decimals="-3"
      id="F_b935ad26-60ce-4881-811f-58ee132f096a"
      unitRef="U_USD">-59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3b2c84ab-d113-49df-ac68-ee96b2c40bcc"
      decimals="-3"
      id="F_4b5c83d0-82c8-479a-892c-9a891678407e"
      unitRef="U_USD">-547052000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_56be793a-f658-4a44-93df-be7d21dd2f49"
      unitRef="U_USD">1069792000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_76fd5dc0-bfbc-4e89-bf40-514de9d64090"
      decimals="INF"
      id="F_d6f9708d-68ab-4125-a625-36539e5bf359"
      unitRef="U_shares">4950496</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_d715c616-aabd-4724-8a14-e0643645f7fc"
      decimals="-3"
      id="F_a4a23997-f77f-4d3f-a748-d49751ea69a4"
      unitRef="U_USD">471787000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_506f3c2d-9473-428f-ac1b-c1f76d5e44b4"
      unitRef="U_USD">471787000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <nuvl:StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross
      contextRef="C_76fd5dc0-bfbc-4e89-bf40-514de9d64090"
      decimals="INF"
      id="F_a8d5b0d1-0905-42ba-868c-cf151cf999f5"
      unitRef="U_shares">1925600</nuvl:StockIssuedDuringPeriodSharesStockOptionsExercisedRestrictedStockAwardGross>
    <nuvl:StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross
      contextRef="C_d715c616-aabd-4724-8a14-e0643645f7fc"
      decimals="-3"
      id="F_12a39bef-113e-4289-b8b8-4cb61c068117"
      unitRef="U_USD">42037000</nuvl:StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross>
    <nuvl:StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_0d275d91-c232-4a34-8759-360f49e0123c"
      unitRef="U_USD">42037000</nuvl:StockIssuedDuringPeriodValueStockOptionsExercisedRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_76fd5dc0-bfbc-4e89-bf40-514de9d64090"
      decimals="INF"
      id="F_7dfaa887-684e-4061-90b3-c08484d2bc6c"
      unitRef="U_shares">18451</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_d715c616-aabd-4724-8a14-e0643645f7fc"
      decimals="-3"
      id="F_cfaa3d5e-dd68-40d5-a8dc-c856ef10bd9d"
      unitRef="U_USD">1186000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_dd96daa8-010e-4d76-8875-0ae453d217df"
      unitRef="U_USD">1186000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_0e122157-f19c-4bac-ba06-7e7e26e67d60"
      decimals="-3"
      id="F_1e2e7b3b-dd6f-4d4d-98de-3cf19c352dd0"
      unitRef="U_USD">2412000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_14cccc86-d2f1-428a-8a4e-04bf64e4500f"
      unitRef="U_USD">2412000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_d715c616-aabd-4724-8a14-e0643645f7fc"
      decimals="-3"
      id="F_20be84d1-656a-465c-aed8-14400a6feb9c"
      unitRef="U_USD">86502000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_f4976d9d-d3ba-4f27-834d-827ffcdc0960"
      unitRef="U_USD">86502000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_89ef94e8-5fe8-4da1-8b41-06e3cb2b86a7"
      decimals="-3"
      id="F_82c83018-ec62-4277-8921-5d306a91e0dc"
      unitRef="U_USD">-425377000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_bc4a418e-176d-402b-ab3e-a1b6526c0f07"
      unitRef="U_USD">-425377000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_4f8e7dd3-78fe-4d02-b566-4230ae65335a"
      decimals="INF"
      id="F_01683ca0-7e61-4f3c-ae32-a1acb238ab31"
      unitRef="U_shares">72804111</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4f8e7dd3-78fe-4d02-b566-4230ae65335a"
      decimals="-3"
      id="F_c375cefd-e227-4ca9-95ab-de2aecbcbeff"
      unitRef="U_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_de369d63-3940-4ffe-ab65-7d8fb85e29f4"
      decimals="INF"
      id="F_390af39d-126a-4b54-a43c-5697437bb7bc"
      unitRef="U_shares">5435254</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_de369d63-3940-4ffe-ab65-7d8fb85e29f4"
      decimals="-3"
      id="F_d48fc5c6-156e-4e97-b3f5-493ed705d0d2"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cbef92a0-50ca-4971-bfcf-4cc694bd98f6"
      decimals="-3"
      id="F_0c2a0c64-f16a-44b2-9997-e2154ee69611"
      unitRef="U_USD">2218407000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8d3a377b-6ff7-4302-9183-32b0389e7d83"
      decimals="-3"
      id="F_739a1b93-ae77-43ee-acfb-cb444cffd7cd"
      unitRef="U_USD">2353000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b9cdf8b1-21d2-4c81-8860-bfb22facc2be"
      decimals="-3"
      id="F_2be77ea6-677d-4f6a-b908-9cf94756c45f"
      unitRef="U_USD">-972429000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_d96a9239-1877-4f3d-93f4-53a3204f33ae"
      unitRef="U_USD">1248339000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_f9deed3b-47d5-40aa-b0a0-aeefc9b5ff3e"
      unitRef="U_USD">-425377000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_53451094-8fc4-4a8d-bf7a-c41b9c743c1f"
      unitRef="U_USD">-260756000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_ca6f4021-4607-411a-b709-82b60e712090"
      unitRef="U_USD">-126219000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_1710f28b-7a29-4dcb-badd-bf350ea0ab8a"
      unitRef="U_USD">86502000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_8981a07a-def9-4778-bdc8-2301c075c525"
      unitRef="U_USD">60579000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_6d98375b-2ec3-49e5-83bf-16a05981bfb3"
      unitRef="U_USD">25563000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_0ee1b927-0ad9-4471-876a-31142b653999"
      unitRef="U_USD">11107000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_64b681c7-5650-4065-8ec4-74ac1b1e6afa"
      unitRef="U_USD">14669000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_cc1e3faa-b3df-4992-ad41-d43a964c37c5"
      unitRef="U_USD">10109000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_b84aa55c-47b0-4e3b-9b5f-9b980797de52"
      unitRef="U_USD">-55220000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_eb5a9b66-ffac-4175-aab9-ae1e76e177f2"
      unitRef="U_USD">-17940000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_60310df9-7178-4c0c-bf3d-3aab3f383e07"
      unitRef="U_USD">-0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_550d3044-6d2f-456d-9dac-d0cfaa692f03"
      unitRef="U_USD">-345000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_c4d8047a-8398-47de-9a1c-28f9bd93a560"
      unitRef="U_USD">-0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_fee24038-4bb7-4bf0-b067-4581a94271a8"
      unitRef="U_USD">-0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_0a7e07d2-a40b-43d6-8aed-dc610e8bcaf2"
      unitRef="U_USD">6342000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_be66b4ed-2bb3-4f93-9e26-40ae7c28d47f"
      unitRef="U_USD">7563000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_7664a3aa-442f-4983-8610-6e6f84e066b7"
      unitRef="U_USD">-644000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_ae839f3a-0045-4eca-a9b6-d2a2104149eb"
      unitRef="U_USD">10508000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_ee963342-6ee0-4679-803b-09d1d2862c1f"
      unitRef="U_USD">3408000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_f94ca225-c507-4e53-b997-0b514b9cf00e"
      unitRef="U_USD">1428000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_e586d958-0d2a-4f2b-b587-4ae20b3f679d"
      unitRef="U_USD">24599000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_5bdf6938-1f64-4feb-8012-93486728fc12"
      unitRef="U_USD">-4049000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_413772fd-aedf-4578-a470-86c1b82cc198"
      unitRef="U_USD">2169000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_742f56c0-5691-4899-a3e4-89e9e90a400f"
      unitRef="U_USD">11459000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_5c85573a-dea1-4d91-b4c4-15201cc5c0ea"
      unitRef="U_USD">26862000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_4863b5c2-1cad-4e20-98c4-0002f99de12f"
      unitRef="U_USD">9641000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_35226bd9-b60a-4a11-b19a-f1a950aad9cb"
      unitRef="U_USD">-275209000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_07bcbd7e-7d2e-4a2c-9900-4cfef503b40c"
      unitRef="U_USD">-185064000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_ae24822b-8a70-4266-abb0-fa4bcd9b8c76"
      unitRef="U_USD">-99739000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_79198637-3511-40a9-83ed-9fee997f8d8a"
      unitRef="U_USD">1057766000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_4e92007e-8d7c-40af-af49-e805d0f8d7f7"
      unitRef="U_USD">1024963000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_22cd4984-f969-476f-8faa-91d53433af6f"
      unitRef="U_USD">459486000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_773e63d3-ecb3-4024-96da-9103d389c013"
      unitRef="U_USD">933689000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_53c72cdd-4250-4053-b7a1-ce9a058b69b0"
      unitRef="U_USD">451449000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_6c977748-5aca-4b9e-84ff-75b02af53ebc"
      unitRef="U_USD">315959000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_f46e80bb-1155-46ef-89b6-f0f09e23a818"
      unitRef="U_USD">-124077000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_d4c4e458-c3a7-44f2-abdb-21b2425519ed"
      unitRef="U_USD">-573514000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_7592029d-aec4-408c-823b-8fb32d060be2"
      unitRef="U_USD">-143527000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_8ae94172-2e36-4324-964d-64837aed6328"
      unitRef="U_USD">515722000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_e753f624-b847-4fef-a328-cee35085191a"
      unitRef="U_USD">569987000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_6c50b845-7559-45c0-a231-889cc057e3bb"
      unitRef="U_USD">338480000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_e47fe4ca-6e94-4683-b9f6-2e2cd15dfd48"
      unitRef="U_USD">382000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_97fe3f34-81f2-4254-8879-7319ff945f2e"
      unitRef="U_USD">483000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_a0ecb895-2696-40fd-985f-108967e20a5c"
      unitRef="U_USD">856000</us-gaap:PaymentsOfStockIssuanceCosts>
    <nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_04376436-cb1a-4d85-a2f3-9f27dd94bc40"
      unitRef="U_USD">0</nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty>
    <nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_56b83a07-e11f-4ed0-bef5-a6f34e555c10"
      unitRef="U_USD">622000</nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty>
    <nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_c0c7e57b-eb6f-43b0-97fc-09e149e8d666"
      unitRef="U_USD">777000</nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_275e3a9c-520b-4806-b8cd-62f0da96d5c4"
      unitRef="U_USD">515340000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_b40dca52-949e-4202-bc3c-dfa915ac4a65"
      unitRef="U_USD">568882000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_66191f69-56d2-452b-8dfb-cb8ec8af89f5"
      unitRef="U_USD">336847000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_e1ba247f-f022-4876-8c6d-0b5077fd3b62"
      unitRef="U_USD">116054000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_50a08c74-722f-4d23-b12f-395175616314"
      unitRef="U_USD">-189696000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_a767f57a-f14f-49e8-9a51-c725527abad4"
      unitRef="U_USD">93581000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_87397fdb-11d9-41a0-9cf3-30c76eb4b9ce"
      unitRef="U_USD">145691000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a7c68923-25e9-4e81-bde0-d29cb0d28c74"
      decimals="-3"
      id="F_1e42d52f-9dae-4e9d-a44f-aab051c5aa2e"
      unitRef="U_USD">335387000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_eba66bbe-f103-4138-86da-3992c8897615"
      decimals="-3"
      id="F_62701e2f-7b40-4cde-a98f-867844b86602"
      unitRef="U_USD">241806000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_f5292e25-4b76-46ca-836a-7bdc5ad0adef"
      unitRef="U_USD">261745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_146adba5-0820-498f-9544-881ec789a664"
      unitRef="U_USD">145691000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a7c68923-25e9-4e81-bde0-d29cb0d28c74"
      decimals="-3"
      id="F_790173ae-b2ea-4b83-bddf-3f6196159210"
      unitRef="U_USD">335387000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_65f42082-9856-416d-a884-54bd1704791f"
      unitRef="U_USD">798000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_8e11eca2-da2f-45fb-a94d-4f2d2d95ae6e"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_6d10820d-e893-49c5-b18a-bb698285f420"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <nuvl:EquityIssuanceCostsIncurredButNotYetPaid
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_25028b75-75a1-430c-9630-a746951bb81b"
      unitRef="U_USD">336000</nuvl:EquityIssuanceCostsIncurredButNotYetPaid>
    <nuvl:EquityIssuanceCostsIncurredButNotYetPaid
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_cff21163-4dd9-49ca-9249-837212e14ca9"
      unitRef="U_USD">6000</nuvl:EquityIssuanceCostsIncurredButNotYetPaid>
    <nuvl:EquityIssuanceCostsIncurredButNotYetPaid
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_7e8645c2-f075-44dd-bea4-4e4ab997467c"
      unitRef="U_USD">0</nuvl:EquityIssuanceCostsIncurredButNotYetPaid>
    <nuvl:InsurancePremiumFinancedByThirdParty
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_27ce9ca0-becf-4c01-bf94-3780602a6eb1"
      unitRef="U_USD">0</nuvl:InsurancePremiumFinancedByThirdParty>
    <nuvl:InsurancePremiumFinancedByThirdParty
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_4b3e98a1-381e-48f1-adea-1b8daf3fb35a"
      unitRef="U_USD">0</nuvl:InsurancePremiumFinancedByThirdParty>
    <nuvl:InsurancePremiumFinancedByThirdParty
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_b1febc81-0fce-49e1-b807-3311f4331e68"
      unitRef="U_USD">1399000</nuvl:InsurancePremiumFinancedByThirdParty>
    <us-gaap:NatureOfOperations
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_a3eef388-5f59-4769-8455-792eeb930ce4">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Nature of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Nuvalent, Inc. (the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The Company was founded in January 2017 as a Delaware corporation. The Company is headquartered in Cambridge, Massachusetts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to risks similar to those of other pre-commercial stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of which are larger and better capitalized, the need for adequate financing to fund the development of its product candidates, the need to obtain and maintain adequate protection for the Company&#x2019;s intellectual property, and the impact of geopolitical events on the Company&#x2019;s business. There can be no assurance that the Company&#x2019;s research and development will be successful, that adequate protection for the Company&#x2019;s intellectual property will be obtained and maintained, that any product candidates will receive required regulatory approval, or that approved products, if any, will be commercially viable. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has incurred recurring losses since inception, including net losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;425.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;260.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2025, 2024 and 2023, respectively. As of December 31, 2025, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;972.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company expects to continue to generate net losses for the foreseeable future. The Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the date of issuance of these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NetIncomeLoss
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-5"
      id="F_5c2a2955-8f69-41ea-989f-4d97267be289"
      unitRef="U_USD">-425400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-5"
      id="F_38c1f440-d48e-4289-aaa9-b5b647f0e507"
      unitRef="U_USD">-260800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-5"
      id="F_bf455fc4-48cf-4e32-874a-9d2aa1597264"
      unitRef="U_USD">-126200000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-5"
      id="F_0a1b8e6d-b93d-42ff-af3c-cb4b2f2484bf"
      unitRef="U_USD">-972400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_4e2a9a8f-1d77-484c-9d77-353cd8cc43ba">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and under the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nuvalent Securities Corporation. All intercompany balances and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain prior period amounts have been reclassified to conform with current period presentation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair value of the related party revenue share liability, the accounting for research and development contracts, including clinical trial accruals, and valuation of equity instruments. The Company bases its estimates, assumptions, and judgments on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of credit risk and of significant suppliers&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company&#x2019;s cash, cash equivalents and marketable securities may be held in accounts at financial institutions that may exceed federally insured limits. However, the Company mitigates credit risk by maintaining a diversified portfolio, placing its cash with high credit quality financial institutions and limiting the amount of investment exposure as to maturity and investment type according to its investment policy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant credit risk beyond the standard credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is dependent on third-party vendors for the manufacturing of its product candidates. In particular, the Company relies, and expects to continue to rely, on a small number of vendors to manufacture materials and components required for the production of its product candidates. These programs could be adversely affected by a significant interruption in the manufacturing process.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents may include money market funds and marketable securities. The Company records interest income received on cash, cash equivalents, and marketable securities to other income (expense) in the consolidated statements of operations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;comprehensive loss. The Company invests its excess cash in money market funds, commercial paper, corporate bonds, government and agency securities and U.S. treasury bills.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair value measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company follows the provision of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;ASC 820&#x201d;), which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1 &#x2014; quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2 &#x2014; quoted prices for similar assets or liabilities in active markets or inputs that are observable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3 &#x2014; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s cash equivalents, marketable securities, and related party revenue share liability are carried at fair value, determined according to the fair value hierarchy described above (see Note 4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for marketable securities in accordance with FASB ASC Topic 320, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments - Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company&#x2019;s marketable securities are classified as available-for-sale debt securities and recorded at fair value based on inputs that are observable, either directly or indirectly, such as quoted prices for identical securities in active markets (Level 1) or quoted prices for similar securities in active markets or inputs that are observable (Level 2). At the time of purchase, the Company classifies marketable securities with maturities of three months or less as cash equivalents on the consolidated balance sheets. The Company&#x2019;s available-for-sale securities are classified as current assets as they are readily available to be converted to cash and for use in the Company&#x2019;s current operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unrealized gains and losses are included as a component of accumulated other comprehensive income (loss) in the consolidated statements of stockholders&#x2019; equity. Realized gains and losses are recorded to other income (expense) in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When the fair value is below the amortized cost of an available-for-sale security, the Company must determine if the decline in fair value below the amortized cost basis has resulted from a credit loss or other factors. If the Company determines that the decline in fair value below the amortized cost basis is due to credit-related factors, the Company measures the credit loss and recognizes an allowance for credit losses in the consolidated balance sheet and the credit-related impairment in the consolidated statements of operations and comprehensive loss. The allowance for credit losses is measured as the amount by which the amortized cost basis exceeds the present value of expected cash flows, limited to the difference between the amortized cost basis and the security&#x2019;s fair value. The Company subsequently assesses whether the measurement of credit losses has increased or decreased and adjusts the allowance for credit losses with corresponding gains or losses recognized in the consolidated statements of operations and comprehensive loss. Impairments not relating to credit losses are recorded to other comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the Company intends to sell the available for sale security or it is more likely than not that the Company will be required to sell the security prior to the recovery of its amortized cost basis, then the allowance for the credit losses is written off and the excess of the amortized cost basis of the asset over its fair value is recorded in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair value option for related party revenue share liability&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has a revenue sharing agreement with Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund IV, L.P. (collectively, &#x201c;Deerfield&#x201d;), each an investor in the Company, to pay a fixed low single-digit percentage rate of net sales of certain commercial products, which represents a freestanding financial instrument. In accordance with FASB ASC Topic 825, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company elected the fair value option. Accordingly, the related party revenue share liability was measured at fair value upon issuance and is remeasured at the end of each reporting period with changes in fair value recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The fair value of the related party revenue share liability is estimated using a discounted cash flow model to calculate the estimated payments that could become due following commercialization. Assumptions in the model include but are not limited to the following: probability and timing of product approval, future product revenues and discount rate. The fair value measurement is based on significant inputs that are not observable in the market and thus represents a Level 3 measurement.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and development and clinical trial accruals&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. These consist primarily of salaries and related costs, including stock-based compensation, for personnel engaged in research and development functions; costs incurred in connection with the advancement of the Company&#x2019;s discovery programs and product candidates in preclinical and clinical studies, including under agreements with contract&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;research organizations (&#x201c;CROs&#x201d;); and the cost of developing and scaling the Company&#x2019;s manufacturing process, including under agreements with contract manufacturing organizations, to manufacture drug substance and drug product for use in the Company&#x2019;s research and preclinical and clinical studies and manufacture commercial-scale validation batches in preparation for the commercial launch of the Company&#x2019;s product candidates that obtain regulatory approval.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and may be reflected in the consolidated balance sheets as prepaid or accrued expenses. Determining the prepaid and accrued expenses balances at the end of any reporting period incorporates certain judgments and estimates by management that are based on information available to the Company including information provided by employees and vendors regarding the progress to completion of specific tasks or costs incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Compensation &#x2014; Stock Compensation &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;ASC 718&#x201d;). The Company has granted stock options and restricted stock units (&#x201c;RSUs&#x201d;), both of which are subject to service-based vesting conditions, and RSUs with performance-based vesting conditions (&#x201c;PSUs&#x201d;). In accordance with ASC 718, the Company recognizes stock-based compensation expense in the consolidated statements of operations and comprehensive loss based on a stock award&#x2019;s grant-date fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. For RSUs and PSUs, the fair value is equal to the market price of a share of the Company&#x2019;s Class A common stock on the grant date. The Company recognizes forfeitures as they occur. Stock-based compensation expense for stock awards with service-based vesting conditions is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting period. Stock awards with service-based vesting conditions generally vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_2bc711c3-dec2-4073-ad3b-8876b685c8e8;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;- or&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; service periods and stock options expire after &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Stock-based compensation expense for stock awards with performance-based vesting conditions is recognized on a straight-line basis over the requisite &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;service period for&lt;/span&gt;&lt;span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;each separately vesting portion of the underlying stock award when the performance-based vesting condition is deemed probable to occur. The Company reassesses the probability of vesting at each reporting period and adjusts stock-based compensation expense, if applicable, based on its probability assessment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records stock-based compensation expense to research and development expense or general and administrative expense based on the underlying function of the individual that was granted the award. Shares issued upon stock option exercise and RSU and PSU vesting are newly-issued shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions used in the Company&#x2019;s Black-Scholes option-pricing model for stock options are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2014; As the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the Company utilizes the &#x201c;simplified&#x201d; method, as prescribed in the SEC&#x2019;s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetical average of the vesting term and the original contractual term of the stock option.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2014; The expected volatility is based on the historical volatility of the Company and that of similar entities within the Company&#x2019;s industry for periods corresponding with the expected term of the grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2014; The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant for a period that corresponds with the expected term of the grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Dividends&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2014; The expected dividend yield is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% as the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions used in the Company&#x2019;s Black-Scholes option-pricing model are inherently subjective and represent management&#x2019;s best estimates. These assumptions involve a number of variables, uncertainties and the application of management&#x2019;s judgment. If any assumptions change, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net income (loss) per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, including potentially dilutive common shares. For periods in which the Company reported a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company prospectively &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_9bb6efd4-414b-479c-bbd1-d6eec4dc4cc3;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-09&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;) on an annual basis, which requires public entities to provide disclosure of specific categories in their income tax rate reconciliations, as well as disclosure of income taxes paid disaggregated by jurisdiction.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;ASU 2024-03&#x201d;), which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the consolidated financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company does not expect the impact of the adoption of this standard to be material to its consolidated financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2025, the FASB issued ASU 2025-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangibles &#x2014; Goodwill and Other &#x2014; Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASU 2025-06&#x201d;), which modernizes the accounting for internal use software. The standard removes references to project stages and clarifies the criteria for capitalizing software costs. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company does not expect the impact of the adoption of this standard to be material to its consolidated financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_16c8f743-ff5f-43e6-994b-001ac8089376">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and under the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nuvalent Securities Corporation. All intercompany balances and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain prior period amounts have been reclassified to conform with current period presentation.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_2999d14f-1e6a-4dee-a09d-42217ce5d540">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and under the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nuvalent Securities Corporation. All intercompany balances and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain prior period amounts have been reclassified to conform with current period presentation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_f5436379-1f7d-42b2-a4ab-019ea40dd315">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair value of the related party revenue share liability, the accounting for research and development contracts, including clinical trial accruals, and valuation of equity instruments. The Company bases its estimates, assumptions, and judgments on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <nuvl:ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_3b523126-0f51-4670-9561-1aa51e47d176">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of credit risk and of significant suppliers&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company&#x2019;s cash, cash equivalents and marketable securities may be held in accounts at financial institutions that may exceed federally insured limits. However, the Company mitigates credit risk by maintaining a diversified portfolio, placing its cash with high credit quality financial institutions and limiting the amount of investment exposure as to maturity and investment type according to its investment policy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant credit risk beyond the standard credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is dependent on third-party vendors for the manufacturing of its product candidates. In particular, the Company relies, and expects to continue to rely, on a small number of vendors to manufacture materials and components required for the production of its product candidates. These programs could be adversely affected by a significant interruption in the manufacturing process.&lt;/span&gt;&lt;/p&gt;</nuvl:ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_d5baa16a-6761-46c5-858a-908a5f514fd2">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents may include money market funds and marketable securities. The Company records interest income received on cash, cash equivalents, and marketable securities to other income (expense) in the consolidated statements of operations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;comprehensive loss. The Company invests its excess cash in money market funds, commercial paper, corporate bonds, government and agency securities and U.S. treasury bills.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_5220b512-fd9f-48ce-b91c-a73f1700d9f8">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair value measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company follows the provision of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;ASC 820&#x201d;), which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1 &#x2014; quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2 &#x2014; quoted prices for similar assets or liabilities in active markets or inputs that are observable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3 &#x2014; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s cash equivalents, marketable securities, and related party revenue share liability are carried at fair value, determined according to the fair value hierarchy described above (see Note 4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_0921dd8b-f694-45e5-b819-5b821e9392ae">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for marketable securities in accordance with FASB ASC Topic 320, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments - Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company&#x2019;s marketable securities are classified as available-for-sale debt securities and recorded at fair value based on inputs that are observable, either directly or indirectly, such as quoted prices for identical securities in active markets (Level 1) or quoted prices for similar securities in active markets or inputs that are observable (Level 2). At the time of purchase, the Company classifies marketable securities with maturities of three months or less as cash equivalents on the consolidated balance sheets. The Company&#x2019;s available-for-sale securities are classified as current assets as they are readily available to be converted to cash and for use in the Company&#x2019;s current operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unrealized gains and losses are included as a component of accumulated other comprehensive income (loss) in the consolidated statements of stockholders&#x2019; equity. Realized gains and losses are recorded to other income (expense) in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When the fair value is below the amortized cost of an available-for-sale security, the Company must determine if the decline in fair value below the amortized cost basis has resulted from a credit loss or other factors. If the Company determines that the decline in fair value below the amortized cost basis is due to credit-related factors, the Company measures the credit loss and recognizes an allowance for credit losses in the consolidated balance sheet and the credit-related impairment in the consolidated statements of operations and comprehensive loss. The allowance for credit losses is measured as the amount by which the amortized cost basis exceeds the present value of expected cash flows, limited to the difference between the amortized cost basis and the security&#x2019;s fair value. The Company subsequently assesses whether the measurement of credit losses has increased or decreased and adjusts the allowance for credit losses with corresponding gains or losses recognized in the consolidated statements of operations and comprehensive loss. Impairments not relating to credit losses are recorded to other comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the Company intends to sell the available for sale security or it is more likely than not that the Company will be required to sell the security prior to the recovery of its amortized cost basis, then the allowance for the credit losses is written off and the excess of the amortized cost basis of the asset over its fair value is recorded in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_b886b0c8-fc20-4ca7-b162-9d3be46ff579">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair value option for related party revenue share liability&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has a revenue sharing agreement with Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund IV, L.P. (collectively, &#x201c;Deerfield&#x201d;), each an investor in the Company, to pay a fixed low single-digit percentage rate of net sales of certain commercial products, which represents a freestanding financial instrument. In accordance with FASB ASC Topic 825, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company elected the fair value option. Accordingly, the related party revenue share liability was measured at fair value upon issuance and is remeasured at the end of each reporting period with changes in fair value recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The fair value of the related party revenue share liability is estimated using a discounted cash flow model to calculate the estimated payments that could become due following commercialization. Assumptions in the model include but are not limited to the following: probability and timing of product approval, future product revenues and discount rate. The fair value measurement is based on significant inputs that are not observable in the market and thus represents a Level 3 measurement.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_619583cc-a6c3-4cf1-b25e-69cbec0a27cd">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and development and clinical trial accruals&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. These consist primarily of salaries and related costs, including stock-based compensation, for personnel engaged in research and development functions; costs incurred in connection with the advancement of the Company&#x2019;s discovery programs and product candidates in preclinical and clinical studies, including under agreements with contract&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;research organizations (&#x201c;CROs&#x201d;); and the cost of developing and scaling the Company&#x2019;s manufacturing process, including under agreements with contract manufacturing organizations, to manufacture drug substance and drug product for use in the Company&#x2019;s research and preclinical and clinical studies and manufacture commercial-scale validation batches in preparation for the commercial launch of the Company&#x2019;s product candidates that obtain regulatory approval.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and may be reflected in the consolidated balance sheets as prepaid or accrued expenses. Determining the prepaid and accrued expenses balances at the end of any reporting period incorporates certain judgments and estimates by management that are based on information available to the Company including information provided by employees and vendors regarding the progress to completion of specific tasks or costs incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_bc19dbbd-2108-4daa-bfe8-fdfe5391365b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_34967d6a-f479-42bb-9a30-c1fdf972ebe5">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Compensation &#x2014; Stock Compensation &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;ASC 718&#x201d;). The Company has granted stock options and restricted stock units (&#x201c;RSUs&#x201d;), both of which are subject to service-based vesting conditions, and RSUs with performance-based vesting conditions (&#x201c;PSUs&#x201d;). In accordance with ASC 718, the Company recognizes stock-based compensation expense in the consolidated statements of operations and comprehensive loss based on a stock award&#x2019;s grant-date fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. For RSUs and PSUs, the fair value is equal to the market price of a share of the Company&#x2019;s Class A common stock on the grant date. The Company recognizes forfeitures as they occur. Stock-based compensation expense for stock awards with service-based vesting conditions is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting period. Stock awards with service-based vesting conditions generally vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_2bc711c3-dec2-4073-ad3b-8876b685c8e8;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;- or&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; service periods and stock options expire after &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Stock-based compensation expense for stock awards with performance-based vesting conditions is recognized on a straight-line basis over the requisite &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;service period for&lt;/span&gt;&lt;span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;each separately vesting portion of the underlying stock award when the performance-based vesting condition is deemed probable to occur. The Company reassesses the probability of vesting at each reporting period and adjusts stock-based compensation expense, if applicable, based on its probability assessment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records stock-based compensation expense to research and development expense or general and administrative expense based on the underlying function of the individual that was granted the award. Shares issued upon stock option exercise and RSU and PSU vesting are newly-issued shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions used in the Company&#x2019;s Black-Scholes option-pricing model for stock options are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2014; As the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the Company utilizes the &#x201c;simplified&#x201d; method, as prescribed in the SEC&#x2019;s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetical average of the vesting term and the original contractual term of the stock option.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2014; The expected volatility is based on the historical volatility of the Company and that of similar entities within the Company&#x2019;s industry for periods corresponding with the expected term of the grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2014; The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant for a period that corresponds with the expected term of the grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Dividends&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2014; The expected dividend yield is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% as the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions used in the Company&#x2019;s Black-Scholes option-pricing model are inherently subjective and represent management&#x2019;s best estimates. These assumptions involve a number of variables, uncertainties and the application of management&#x2019;s judgment. If any assumptions change, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_4012f4dc-f825-4c85-81de-f4ed79e455ba"
      id="F_2e2e21f0-2542-4789-b802-a2f64eb433b9">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_59e85967-08c8-41ab-9f65-d108262ec6c3"
      id="F_d8de07f3-e36e-4de5-a2b2-b1aa425d184e">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_f3c080af-d4c2-49f3-8df9-cd2df9d5375f"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_e3bec4af-f152-4218-8600-5cc07e904bde">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net income (loss) per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, including potentially dilutive common shares. For periods in which the Company reported a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_4184cc40-064a-4b76-a60b-308eacd082d6">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_d7b67733-e920-41ef-99ba-57942c13febb">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company prospectively &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_9bb6efd4-414b-479c-bbd1-d6eec4dc4cc3;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-09&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;) on an annual basis, which requires public entities to provide disclosure of specific categories in their income tax rate reconciliations, as well as disclosure of income taxes paid disaggregated by jurisdiction.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;ASU 2024-03&#x201d;), which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the consolidated financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company does not expect the impact of the adoption of this standard to be material to its consolidated financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2025, the FASB issued ASU 2025-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangibles &#x2014; Goodwill and Other &#x2014; Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASU 2025-06&#x201d;), which modernizes the accounting for internal use software. The standard removes references to project stages and clarifies the criteria for capitalizing software costs. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company does not expect the impact of the adoption of this standard to be material to its consolidated financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      id="F_15279d41-3622-409e-adb0-40d89efade77">2025-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      id="F_5d845723-e597-43c6-ba4a-9c9eadc96af0">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_17935072-b37c-4b02-93f7-a9017319a0a5">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables provide the amortized cost and fair value of the Company&#x2019;s available-for-sale securities by security type (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.93%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;772,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;774,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,107,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,110,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.93%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;972,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;972,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the amortized cost and fair value of the Company&#x2019;s available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due within one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;523,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;524,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due after one year through three years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;584,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;585,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,107,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,110,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; credit losses recorded during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, 2024 and 2023. Interest income for the years ended December 31, 2025, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_ae8945a6-beab-425a-beed-79405ff04bcf">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables provide the amortized cost and fair value of the Company&#x2019;s available-for-sale securities by security type (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.93%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;772,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;774,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,107,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,110,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.93%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;972,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;972,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d4753189-18cd-4f14-9c1a-96a8faae97b4"
      decimals="-3"
      id="F_77a015f9-fa8a-4c5b-bc2c-a33f9259f0e4"
      unitRef="U_USD">107889000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d4753189-18cd-4f14-9c1a-96a8faae97b4"
      decimals="-3"
      id="F_4e6e51ff-4a05-415a-88a9-4e709e78435e"
      unitRef="U_USD">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d4753189-18cd-4f14-9c1a-96a8faae97b4"
      decimals="-3"
      id="F_24bd43a0-151d-4dd5-8f00-870a1ce21cb3"
      unitRef="U_USD">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d4753189-18cd-4f14-9c1a-96a8faae97b4"
      decimals="-3"
      id="F_9d6a8935-973c-4fb7-872a-a899defb9800"
      unitRef="U_USD">107884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e296d935-9d7a-4619-b857-c867a08d6bf1"
      decimals="-3"
      id="F_9ab5329a-ad66-43c1-8588-4a00418415cc"
      unitRef="U_USD">772457000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e296d935-9d7a-4619-b857-c867a08d6bf1"
      decimals="-3"
      id="F_55aaa139-8f85-4d7a-a910-2e28c224a143"
      unitRef="U_USD">2233000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e296d935-9d7a-4619-b857-c867a08d6bf1"
      decimals="-3"
      id="F_efca8337-405c-4d4c-a966-00b67014e9c7"
      unitRef="U_USD">184000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e296d935-9d7a-4619-b857-c867a08d6bf1"
      decimals="-3"
      id="F_2c3e9ee3-c6a8-43b5-b22b-6a1c8c2661cd"
      unitRef="U_USD">774506000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5b2c061b-d1fc-4fbb-80d8-2da875f202a6"
      decimals="-3"
      id="F_3dcdffe3-54fa-4a70-92dc-76f810b0d222"
      unitRef="U_USD">207684000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_5b2c061b-d1fc-4fbb-80d8-2da875f202a6"
      decimals="-3"
      id="F_4336a6e3-3d3b-4e9c-bf46-71ce619eabe4"
      unitRef="U_USD">340000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_5b2c061b-d1fc-4fbb-80d8-2da875f202a6"
      decimals="-3"
      id="F_d606832f-1cbf-4de4-9bb5-011251cca867"
      unitRef="U_USD">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5b2c061b-d1fc-4fbb-80d8-2da875f202a6"
      decimals="-3"
      id="F_4dbe60b5-f891-4662-bca1-aebd1502fd7e"
      unitRef="U_USD">207990000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ce0c1f70-1e86-4aae-bde4-2bb3ccddfaa6"
      decimals="-3"
      id="F_08631bf4-f19f-48f2-a9cd-a09d5fb26996"
      unitRef="U_USD">19824000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ce0c1f70-1e86-4aae-bde4-2bb3ccddfaa6"
      decimals="-3"
      id="F_74cab563-1b53-4613-96da-5a7684751fdf"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ce0c1f70-1e86-4aae-bde4-2bb3ccddfaa6"
      decimals="-3"
      id="F_31bd3403-c1b2-42c9-b626-e0c3f8f1f9b6"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ce0c1f70-1e86-4aae-bde4-2bb3ccddfaa6"
      decimals="-3"
      id="F_735a419e-20c7-41fe-8b7e-94a45bc354c0"
      unitRef="U_USD">19827000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_ce2de8d0-e9c9-40c5-973c-8889e24fe6b1"
      unitRef="U_USD">1107854000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_df664bd7-b8a0-4d3c-80d0-7c921d789400"
      unitRef="U_USD">2593000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_78861d2a-14df-45e7-aa65-0fd64def7d37"
      unitRef="U_USD">240000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_8a9e1ebe-2624-47cc-9d01-07e4562eba90"
      unitRef="U_USD">1110207000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a4c171d8-3da3-4eb9-89e1-62dacc43ee28"
      decimals="-3"
      id="F_a7bcf7e5-daa3-4286-a756-df93dec9a9da"
      unitRef="U_USD">251473000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a4c171d8-3da3-4eb9-89e1-62dacc43ee28"
      decimals="-3"
      id="F_d226947e-fe62-4c2f-8382-f70e0ffe657d"
      unitRef="U_USD">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a4c171d8-3da3-4eb9-89e1-62dacc43ee28"
      decimals="-3"
      id="F_e6496cb1-21fd-4d30-9444-bdb779af3922"
      unitRef="U_USD">176000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a4c171d8-3da3-4eb9-89e1-62dacc43ee28"
      decimals="-3"
      id="F_f1bb7b7b-c018-4e89-ae45-001a7d819475"
      unitRef="U_USD">251309000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5ecefa5a-caed-49e8-bd54-e1b9762e2e0e"
      decimals="-3"
      id="F_b561c923-f6a3-4315-9770-6081dcdeb393"
      unitRef="U_USD">468673000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_5ecefa5a-caed-49e8-bd54-e1b9762e2e0e"
      decimals="-3"
      id="F_f8eed0ae-0963-4c1c-a979-8df9d10c21ef"
      unitRef="U_USD">532000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_5ecefa5a-caed-49e8-bd54-e1b9762e2e0e"
      decimals="-3"
      id="F_f71613cc-2df9-4467-ad1e-d7277136b5df"
      unitRef="U_USD">588000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5ecefa5a-caed-49e8-bd54-e1b9762e2e0e"
      decimals="-3"
      id="F_c9f681d5-0487-4f12-a301-b1ebf339c68d"
      unitRef="U_USD">468617000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_84e19387-66ac-4596-b28a-643c9b3fb129"
      decimals="-3"
      id="F_f229a214-f33a-4ff9-85a9-9b6cb54c6d9b"
      unitRef="U_USD">162783000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_84e19387-66ac-4596-b28a-643c9b3fb129"
      decimals="-3"
      id="F_9608aa7f-58b0-4d38-be23-7999fe9355e8"
      unitRef="U_USD">132000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_84e19387-66ac-4596-b28a-643c9b3fb129"
      decimals="-3"
      id="F_d67eade2-08a3-4430-82d7-ed10cb19e28f"
      unitRef="U_USD">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_84e19387-66ac-4596-b28a-643c9b3fb129"
      decimals="-3"
      id="F_94e2f4b0-64ed-40c2-b8a8-8b72f09dd27e"
      unitRef="U_USD">162886000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5ced912f-8b63-48e6-a3cd-afdf5cd699b3"
      decimals="-3"
      id="F_114aaf3c-0fd9-4ce6-a76b-59c2996b8b64"
      unitRef="U_USD">89741000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_5ced912f-8b63-48e6-a3cd-afdf5cd699b3"
      decimals="-3"
      id="F_a5bee53b-f896-456a-a752-1d9e0cfa460c"
      unitRef="U_USD">60000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_5ced912f-8b63-48e6-a3cd-afdf5cd699b3"
      decimals="-3"
      id="F_ec975bb8-deb3-4190-b8d4-bd1c5ef4c370"
      unitRef="U_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5ced912f-8b63-48e6-a3cd-afdf5cd699b3"
      decimals="-3"
      id="F_f731c899-57b0-49d6-b9d5-48feece2c54f"
      unitRef="U_USD">89799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_780d920e-73ce-497d-aa4a-6880d4e07201"
      unitRef="U_USD">972670000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_8c7e6bb9-485b-4ab3-9f38-014cb4d60b9a"
      unitRef="U_USD">736000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_225cd399-2bd3-4c8f-a286-a2158052b289"
      unitRef="U_USD">795000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_0ad48e36-2d4b-4a6c-8e78-4cb93a938873"
      unitRef="U_USD">972611000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_e9ec5836-44bb-4ad8-b7a1-823c9ac65f24">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the amortized cost and fair value of the Company&#x2019;s available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due within one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;523,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;524,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due after one year through three years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;584,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;585,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,107,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,110,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_249fe9c5-035a-4be4-bda3-5a7f5c5d842f"
      decimals="-3"
      id="F_5f36293a-6d05-4717-bed4-36ab0c15f639"
      unitRef="U_USD">523630000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_249fe9c5-035a-4be4-bda3-5a7f5c5d842f"
      decimals="-3"
      id="F_d2d11018-d445-47cc-8c83-4553ca128310"
      unitRef="U_USD">524421000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1933430c-8e7f-4e70-bb06-113d64f132d9"
      decimals="-3"
      id="F_e75ed1d7-3171-40ba-82a4-d6966e2e2c47"
      unitRef="U_USD">584224000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1933430c-8e7f-4e70-bb06-113d64f132d9"
      decimals="-3"
      id="F_548d2039-ea89-4683-976a-dace7d739bd9"
      unitRef="U_USD">585786000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_1a8405aa-34cc-4ae0-903f-5ba03dc0ee4b"
      unitRef="U_USD">1107854000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_ad9a07a8-2369-4ca3-8008-13c56e6c9cdb"
      unitRef="U_USD">1110207000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="INF"
      id="F_97aa6a23-2aad-430a-af0d-2b8e388b3a72"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="INF"
      id="F_a146a6a2-9c28-48b3-8cb9-4fb2d0f462ac"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="INF"
      id="F_a1322991-256b-4682-a78c-24ce39d59ecc"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-5"
      id="F_9c4354ca-2acb-4de5-8913-1a44632cdb27"
      unitRef="U_USD">44800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-5"
      id="F_9fe1cc20-8178-429b-9e74-4624e6e50279"
      unitRef="U_USD">38400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-5"
      id="F_04db7a0e-b561-4341-b281-2fc542604350"
      unitRef="U_USD">23300000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_31490cec-25c5-41bd-a41e-910fdc318298">&lt;p id="fn_4_fair_value_measurements" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present the Company&#x2019;s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.99%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.958%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.978%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.978%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.097999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;774,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;774,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,110,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,361,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Related party revenue share liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;972,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,108,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Related party revenue share liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents were valued by the Company based on quoted market prices for identical securities, which represent a Level 1 measurement within the fair value hierarchy. Commercial paper, corporate bonds, government and agency securities, and U.S. treasury bills were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. During the periods presented, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; transfers in or out of Level 3. The carrying values of the Company&#x2019;s accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these liabilities.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the changes in estimated fair value of the Company&#x2019;s related party revenue share liability for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, which represents a Level 3 measurement within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:83.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated fair value as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated fair value as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of the related party revenue share liability was estimated using a discounted cash flow model to calculate the estimated payments that could become due following commercialization. Assumptions in the model include but are not limited to the following: probability and timing of product approval, future product revenues and discount rate. Changes in fair value each reporting period are recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. See Note 10 for additional information regarding the revenue sharing agreement with Deerfield&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_0b6145a5-b2a4-48ce-91b9-998c0c8bfda9">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present the Company&#x2019;s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.99%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.958%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.978%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.978%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.097999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;774,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;774,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,110,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,361,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Related party revenue share liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;972,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,108,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Related party revenue share liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_cdee423f-13dc-4cee-9db9-89de0a74a37e"
      decimals="-3"
      id="F_e7c5e23e-614f-4a49-ad08-dec28bb644b8"
      unitRef="U_USD">251567000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a35f2a79-4ef6-43ea-a2a6-e4132c6ac5cf"
      decimals="-3"
      id="F_e399400c-da07-4218-8592-957aa37b55b0"
      unitRef="U_USD">251567000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0000066a-157e-4f4a-ba87-0eadc35447f3"
      decimals="-3"
      id="F_0c1624fe-e7a1-4200-ad77-5d96704bfed6"
      unitRef="U_USD">107884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_311675e3-d4bb-45f1-8ba5-f59f04c6601e"
      decimals="-3"
      id="F_8f58ecf9-1293-4a11-8ffe-3f0412b8441b"
      unitRef="U_USD">107884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a59b2dc3-40a3-4254-a8ce-3b9d4e32e2ab"
      decimals="-3"
      id="F_b9de4f68-d6da-41aa-af6b-04e1aebc77e6"
      unitRef="U_USD">774506000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7d73a6a9-9a14-4d7d-ac5c-0d24cfad2b78"
      decimals="-3"
      id="F_131170b8-bd58-4f7d-b06e-b6f99524f3e4"
      unitRef="U_USD">774506000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_62eeefb2-1e14-4bca-8787-bc752cc63c08"
      decimals="-3"
      id="F_401e7453-b301-4551-907f-753a4b94e64d"
      unitRef="U_USD">207990000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7ab55318-ef2a-434f-8bd9-380fef2ea246"
      decimals="-3"
      id="F_801f1641-9cc5-4aa4-920f-c469bb912027"
      unitRef="U_USD">207990000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6edd2b6c-842b-450b-bfa3-6954cfc7acbe"
      decimals="-3"
      id="F_e0fd68d0-c4df-4ada-82be-8d987999e969"
      unitRef="U_USD">19827000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_04cf2475-3d52-4702-8abf-c08e477d27e7"
      decimals="-3"
      id="F_b50ed9ad-7f0f-4886-bce1-a438d5a780b5"
      unitRef="U_USD">19827000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_cdee423f-13dc-4cee-9db9-89de0a74a37e"
      decimals="-3"
      id="F_b2df387f-dd02-40d0-ae8b-f8fb614485d0"
      unitRef="U_USD">251567000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_dcbf0a58-6a1b-4202-9cdf-1ee677e03399"
      decimals="-3"
      id="F_c2c558a8-7ff7-4fc7-8dc0-762c7cfac36b"
      unitRef="U_USD">1110207000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a35f2a79-4ef6-43ea-a2a6-e4132c6ac5cf"
      decimals="-3"
      id="F_6b59fbc5-ef16-493a-bdf1-d65507b17ad8"
      unitRef="U_USD">1361774000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_804b901c-8280-4ee4-8d08-720119428cfc"
      decimals="-3"
      id="F_44619aa4-6518-4f33-874f-fba07dd6b995"
      unitRef="U_USD">73160000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_466cca9b-97be-4208-8bc1-360fd88d3e92"
      decimals="-3"
      id="F_32a27351-77a8-4a42-93fa-f132b4683f7c"
      unitRef="U_USD">73160000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_9197732a-6f19-4a46-a09e-bbf59e2e5565"
      decimals="-3"
      id="F_f1230e37-1bf1-4507-86d6-9f067cbacbd4"
      unitRef="U_USD">135902000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5375c9d0-2105-44e2-b95c-e77a2e65b0ee"
      decimals="-3"
      id="F_7b74733b-9aa2-4ca3-9cf8-eec78bb296a2"
      unitRef="U_USD">135902000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_40396d26-77ba-42d0-a54a-49ced53d5b71"
      decimals="-3"
      id="F_ca42f460-a140-40db-a3e5-f72f139b7c9f"
      unitRef="U_USD">251309000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e4d077ae-e343-4a79-ae30-25df3168dd9b"
      decimals="-3"
      id="F_40d50fa6-834a-40c0-8572-9821cb90c54a"
      unitRef="U_USD">251309000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b96b8a89-ec86-4975-9a70-f67d031a9eca"
      decimals="-3"
      id="F_f05065e6-e5cc-42e4-9c6e-0defa9c8ebf6"
      unitRef="U_USD">468617000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c2cf0b0d-1d62-4db0-b62f-ddbc77d261d4"
      decimals="-3"
      id="F_5b46a176-309f-4c3d-bd8e-173da6342042"
      unitRef="U_USD">468617000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e1e6998a-a42a-435c-9db6-9c17a1e2d9d3"
      decimals="-3"
      id="F_1ff3b17c-fc06-4d08-8250-9b7c0acf4d0d"
      unitRef="U_USD">162886000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_115fa72c-632f-4dc3-a356-8cde960ebdc7"
      decimals="-3"
      id="F_c6478776-f70c-4345-95ef-be4fb95647f1"
      unitRef="U_USD">162886000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_651bca55-01de-4bcf-b62d-18da05e75cbb"
      decimals="-3"
      id="F_dd680b98-68f8-4f72-94fb-e5b8bd0d3e46"
      unitRef="U_USD">89799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b4f67603-f7f4-4146-9b75-51864e400238"
      decimals="-3"
      id="F_b3375830-2a87-477a-9e25-c53b7e4c7b49"
      unitRef="U_USD">89799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9197732a-6f19-4a46-a09e-bbf59e2e5565"
      decimals="-3"
      id="F_b81b1748-df00-435e-be48-c0522c1ed11a"
      unitRef="U_USD">135902000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_caf3d18a-ea80-40be-9716-306c4b3b915d"
      decimals="-3"
      id="F_da9789d0-b410-4803-9a35-65e1ddc5db02"
      unitRef="U_USD">972611000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5375c9d0-2105-44e2-b95c-e77a2e65b0ee"
      decimals="-3"
      id="F_5a6a8e14-1b8c-4cdd-99d8-54a46f55c23e"
      unitRef="U_USD">1108513000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_87166674-75a3-43e1-b506-e4931d232803"
      decimals="-3"
      id="F_bbc8aba0-8833-45ba-b361-05619ff8ced8"
      unitRef="U_USD">17940000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_1199f4a9-3a4a-4346-9b3c-1e5dfe502dce"
      decimals="-3"
      id="F_d7fe232b-733b-4efe-922d-9bc4b0a18ca7"
      unitRef="U_USD">17940000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_c5ea0780-5bdc-46f9-bea8-cc1a17833fff"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_be4e064d-4563-4586-b85c-9e8c30b53840"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_76c93c25-168c-4a30-8791-ac24eaa41fb5">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the changes in estimated fair value of the Company&#x2019;s related party revenue share liability for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, which represents a Level 3 measurement within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:83.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated fair value as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated fair value as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_d099b530-0cf4-48be-a348-63560b2d2db7"
      decimals="-3"
      id="F_17ff202a-fb38-4dc0-b6dd-490c628f3788"
      unitRef="U_USD">17940000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_cbcb2363-568f-4092-88ad-525c58d12120"
      decimals="-3"
      id="F_887c8a9e-6046-44b6-9adb-149f6579e659"
      unitRef="U_USD">55220000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_11b35f3d-891f-4171-b4d4-acada2917088"
      decimals="-3"
      id="F_94885505-e810-48c0-86d2-5b85be0b31d7"
      unitRef="U_USD">73160000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_7fa3f80b-03ab-4474-9f46-616961136983">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:60.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.203%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.722%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical and other research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued manufacturing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <nuvl:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_c5c8ef4a-5967-4b86-a9a2-c94dd320dbc6">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:60.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.203%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.722%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical and other research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued manufacturing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</nuvl:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_4ff10a88-8ab3-47d3-9f48-0da0446c8d7e"
      unitRef="U_USD">30235000</nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses>
    <nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_ceebddb0-ed45-4d9c-99bd-3c13d7bfbd45"
      unitRef="U_USD">25555000</nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses>
    <nuvl:AccruedManufacturingExpenses
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_4e40c7c1-c23b-4ffb-8953-998e179aeda2"
      unitRef="U_USD">10976000</nuvl:AccruedManufacturingExpenses>
    <nuvl:AccruedManufacturingExpenses
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_b3d56848-4069-431e-87d8-df935ccdb382"
      unitRef="U_USD">11511000</nuvl:AccruedManufacturingExpenses>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_4717fbd0-dc6d-44bd-9103-a168781d53b4"
      unitRef="U_USD">16935000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_9e4e224f-e83a-431f-9052-3ce234f062a5"
      unitRef="U_USD">10452000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nuvl:AccruedOtherAndOtherLiabilitiesCurrent
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_8eaa256f-107a-447d-9c8e-7a09c8252f22"
      unitRef="U_USD">2867000</nuvl:AccruedOtherAndOtherLiabilitiesCurrent>
    <nuvl:AccruedOtherAndOtherLiabilitiesCurrent
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_12f9ac23-c118-440d-a6f0-be3baa7a0a46"
      unitRef="U_USD">1277000</nuvl:AccruedOtherAndOtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_4186d6b6-070c-4078-b9d9-a284d763f5f7"
      unitRef="U_USD">61013000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_6cb344b2-5f36-4e0e-8e9a-bd012cd8a471"
      unitRef="U_USD">48795000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_a790c75d-970b-4727-870d-5efeb26cd5ae">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2025, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;4,950,496&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its Class A common stock in an underwritten public offering at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;101.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share (the &#x201c;2025 Public Offering&#x201d;). Upon the closing of the 2025 Public Offering, the Company received net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;471.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting equity issuance costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in addition to underwriting discounts and commissions. In addition, the underwriters exercised their option in full to purchase an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;742,574&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s Class A common stock (the &#x201c;Additional Shares&#x201d;) from Deerfield. The Company did not receive any proceeds from the sale of the Additional Shares by Deerfield.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2024, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,750,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its Class A common stock in an underwritten public offering, including the exercise in full by the underwriters of their option to purchase an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;750,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s Class A common stock, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share (the &#x201c;2024 Public Offering&#x201d;). Upon the closing of the 2024 Public Offering, the Company received net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;540.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting equity issuance costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in addition to underwriting discounts and commissions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2023, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,160,714&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its Class A common stock in an underwritten public offering, including the exercise in full by the underwriters of their option to purchase an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;803,571&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s Class A common stock, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share (the &#x201c;2023 Public Offering&#x201d;). Upon the closing of the 2023 Public Offering, the Company received net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;323.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting equity issuance costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in addition to underwriting discounts and commissions.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d76a48ae-1458-49f4-880c-993e1969d630"
      decimals="INF"
      id="F_2bb2c6d1-41bd-4d86-ad8c-b3b76d005af1"
      unitRef="U_shares">4950496</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_8c05b7a3-8cdf-43a6-a7e8-093ffb97f438"
      decimals="2"
      id="F_ee3a4075-da4d-4dcf-b865-32fe18bbb7dc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">101</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_b3cff3c2-044c-46b7-89c3-2f4680873e9a"
      decimals="-5"
      id="F_ff15236d-3320-44af-8994-fc594fb48636"
      unitRef="U_USD">471800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <nuvl:EquityIssuanceCosts
      contextRef="C_b3cff3c2-044c-46b7-89c3-2f4680873e9a"
      decimals="-5"
      id="F_07eaae10-942e-4735-9810-7a8efa423d3e"
      unitRef="U_USD">700000</nuvl:EquityIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0f57ea6c-80f3-41df-a06f-6bbb78d913d8"
      decimals="INF"
      id="F_a956e966-7a5a-4431-a205-b8d0dcc4d75b"
      unitRef="U_shares">742574</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_794390d5-c9fe-4091-8a4b-34dc63c137c2"
      decimals="INF"
      id="F_e7b06a76-5a78-4503-b9fa-5b29507c438b"
      unitRef="U_shares">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9bf007c6-b63f-40c9-9e02-abfd50766d7d"
      decimals="INF"
      id="F_3547899f-c501-4fd6-b21c-3b9bb319407e"
      unitRef="U_shares">750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_a9763b57-1db2-4f46-9ff1-ae604892960c"
      decimals="2"
      id="F_120fb6af-3a32-4d2e-9057-18028515cd4a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">100</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_01cd509e-be11-4515-a517-f7b5049d7dd3"
      decimals="-5"
      id="F_274d51ff-a720-42b5-9851-244c62c50d4a"
      unitRef="U_USD">540000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <nuvl:EquityIssuanceCosts
      contextRef="C_01cd509e-be11-4515-a517-f7b5049d7dd3"
      decimals="-5"
      id="F_add0fe51-2d04-4855-94bb-019f7d76bee6"
      unitRef="U_USD">500000</nuvl:EquityIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_93c55488-e02d-4971-b17c-5355e98cdfa9"
      decimals="INF"
      id="F_3529fe26-a7c1-4e08-97ed-1df936dc37ea"
      unitRef="U_shares">6160714</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1d01bc0b-7ded-4bd0-9911-fdca86bb46a7"
      decimals="INF"
      id="F_ebea4d66-15dc-405e-be28-c72bc6fcee19"
      unitRef="U_shares">803571</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_7ba5c3d8-bf4d-45c7-b12b-5b3d1c87d47e"
      decimals="2"
      id="F_ebeb748f-d094-4d26-8870-666c41582290"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">56</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_9f83a502-9a23-4e89-997b-59b9c16ccdcc"
      decimals="-5"
      id="F_d28f04f3-b61a-44b7-84ce-c4f4690f4ac1"
      unitRef="U_USD">323500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <nuvl:EquityIssuanceCosts
      contextRef="C_9f83a502-9a23-4e89-997b-59b9c16ccdcc"
      decimals="-5"
      id="F_337f1a8e-6ddd-4246-948a-bc751847f645"
      unitRef="U_USD">800000</nuvl:EquityIssuanceCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_217a7142-87c2-472a-91bb-352a4ce12b2c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recorded stock-based compensation expense within its consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:60.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.040000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.040000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the 2021 Plan (as defined below), the Company has granted stock options, RSUs and PSUs. As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, total unrecognized compensation cost, excluding unrecognized compensation cost related to PSUs, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;170.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted-average period of&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. Stock-based compensation expense for PSUs is recognized on a straight-line basis over the requisite service period for each separately vesting portion of the PSUs when the performance-based vesting condition is deemed probable to occur. The performance-based vesting conditions under the PSUs have not been deemed probable to occur, and accordingly, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; stock-based compensation expense has been recognized. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, total unrecognized compensation cost related to PSUs was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which will be recognized when the performance-based vesting conditions are deemed probable to occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2021 equity incentive plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2021, the Company adopted the 2021 Stock Option and Incentive Plan (the &#x201c;2021 Plan&#x201d;). The 2021 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, RSUs (including PSUs), unrestricted stock awards, cash-based awards and dividend equivalent rights. The number of shares of Class A common stock reserved for issuance under the 2021 Plan is subject to increase on each January 1 thereafter by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of the number of shares of the Company&#x2019;s Class A and Class B common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#x2019;s board of directors or compensation committee of the board of directors. The shares of Class A common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expired or are otherwise&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;terminated &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(other than by exercise) under the 2021 Plan will be added back to the shares of Class A common stock available under the 2021 Plan. As of December 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,244,716&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock remained available for future issuance under the 2021 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2021 employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2021, the Company adopted the 2021 Employee Stock Purchase Plan (as amended and restated, the &#x201c;ESPP&#x201d;). The ESPP permits eligible employees to purchase shares of Class A common stock at a discount in accordance with the terms of the offering and consists of consecutive, overlapping 12-month offering periods, each consisting of two six-month purchase periods. As of December 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,322,110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remained available for issuance and sale under the ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the range of assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="5" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average expected option term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Range of expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Range of risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s stock option activity since &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:52.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.120000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,980,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.45&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;398,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,544,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,672,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,717,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;476,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,701,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.95&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;369,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value of stock options exercised during the years ended December 31, 2025, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock on the date of exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average grant-date fair value of stock options granted during the years ended December 31, 2025, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53.07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s RSU activity since &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:55.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:20%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Grant-Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;716,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;657,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;252,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,091,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The RSU activity above includes &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,935&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of outstanding PSUs. The total fair value of RSUs vested during the year ended December 31, 2025 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; RSUs vested during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_89200fa5-0f5a-4500-be17-1d1739c78beb">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recorded stock-based compensation expense within its consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:60.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.040000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.040000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f59252bc-b763-4e51-83d2-54d4bba5a6f8"
      decimals="-3"
      id="F_43eef0fe-e486-4e80-b15d-519d493dff4f"
      unitRef="U_USD">48097000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4b81bd74-b327-44d2-baca-063efd69c11c"
      decimals="-3"
      id="F_6d91fee4-e614-4003-b82e-e5f96435148d"
      unitRef="U_USD">31369000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c6bbbfaf-9812-4257-bac4-0186503112d4"
      decimals="-3"
      id="F_358207a2-c139-4364-8dd2-100582a3241e"
      unitRef="U_USD">11600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0ed9a5c8-bc77-4159-80cc-631b58767dd4"
      decimals="-3"
      id="F_7411a013-8737-425d-9324-6e93f6fc6ff9"
      unitRef="U_USD">38405000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1c1aeab6-5cb0-40f4-a1b3-94770256e0b4"
      decimals="-3"
      id="F_e21a4e94-00aa-4702-8340-7be990c42d67"
      unitRef="U_USD">29210000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1cd91e04-8d02-4ef7-b3c0-68167cbe59fc"
      decimals="-3"
      id="F_7d55dbe5-48e6-4cab-917e-3eba47841632"
      unitRef="U_USD">13963000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_f8d8f3cd-7805-4054-a07e-2e5422a65e79"
      unitRef="U_USD">86502000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_399a9e88-9d88-4405-aa1d-ca5f65546387"
      unitRef="U_USD">60579000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_b78dab88-5a95-496a-ba4e-0e8b6047ba5d"
      unitRef="U_USD">25563000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_7afb1013-38c2-4d5e-b701-12fe832c3317"
      decimals="-5"
      id="F_97426675-d38a-4ce3-8815-0229629e913e"
      unitRef="U_USD">170400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_7eb103db-61c7-4a1d-bd4c-ff51a5d2f879"
      id="F_d920e19a-aa39-4bcd-8d04-ff5cb8d866ef">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e2c0f06b-9e84-41cf-840f-bb816b9bcc96"
      decimals="INF"
      id="F_48cfbafe-1689-4263-b9b7-27b9b1225615"
      unitRef="U_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_a003efa2-9b6b-4b5b-8e24-3f682b981042"
      decimals="-5"
      id="F_4183fee3-653c-4dcb-9d80-6ffc21d6cd9b"
      unitRef="U_USD">11100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <nuvl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage
      contextRef="C_9cdf4307-9ead-4afc-bdf8-f81ea96995ae"
      decimals="INF"
      id="F_42a61614-3c1a-447e-80c2-3d7eb225ef83"
      unitRef="U_pure">0.05</nuvl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_57e49bd8-5824-43bf-b177-9a36dba04b3c"
      decimals="INF"
      id="F_d3acdaab-4200-4c99-b4f1-cffcee923159"
      unitRef="U_shares">8244716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_22a8e1ba-3f11-4756-a8b5-7e71665e826e"
      decimals="INF"
      id="F_5e2081e6-ba6c-400c-9d9f-719aab96452d"
      unitRef="U_shares">2322110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_ad66c881-0439-4e96-9e64-38dbd9d5f418">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the range of assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="5" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average expected option term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Range of expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Range of risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_8a299053-6b3e-444e-8f34-36cad9345bc9">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      id="F_10598e9a-00a9-4c26-aad0-35e58ceaa51d">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      id="F_945320ef-9522-4c58-b8c4-d2207ff8a6a8">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_e3737f21-6e55-4694-bde6-5af81f26e41a"
      unitRef="U_pure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_d5d31215-1d27-473e-b7d0-00f108f831c5"
      unitRef="U_pure">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="2"
      id="F_fde80fcf-8f11-4418-be28-327cc394ebb7"
      unitRef="U_pure">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="2"
      id="F_8c00e2c0-e09a-469e-af36-16dfd608620d"
      unitRef="U_pure">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="2"
      id="F_cf93c1ce-ddf0-47fe-a808-4d279388d04f"
      unitRef="U_pure">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="2"
      id="F_68ee586f-6b13-4da1-8768-569f40b1f25d"
      unitRef="U_pure">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_8dd11834-a41e-4801-b719-dc71527ea0af"
      unitRef="U_pure">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="2"
      id="F_706a1703-26f9-4554-92f1-37137d0a2f68"
      unitRef="U_pure">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="2"
      id="F_0ca6ca5b-fc8c-44a5-8264-c1b7f76b154b"
      unitRef="U_pure">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="3"
      id="F_d832dd20-e922-4e0d-8a2d-b778c3ca18b1"
      unitRef="U_pure">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="3"
      id="F_a497d092-9262-43aa-ab87-4359c4bf8f55"
      unitRef="U_pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="3"
      id="F_70d9eee8-444c-4f6a-b427-8f2b94131587"
      unitRef="U_pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="3"
      id="F_885507dd-aa95-4afe-8c1d-0483840706c9"
      unitRef="U_pure">0.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="3"
      id="F_010c694b-e81b-4025-a59c-c107109cfe6c"
      unitRef="U_pure">0.034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="3"
      id="F_e4e75072-0579-43e0-87d0-95b447c28586"
      unitRef="U_pure">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_e3941197-e573-42a4-939a-4ce95702cd1e"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="2"
      id="F_ecf1fbcc-fd58-4f32-9093-3fe9126c228e"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="2"
      id="F_3c636a88-d8cb-4341-a417-b1db5206cd76"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_cb1e486f-6df9-4382-9990-5ff4d2202ef9">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s stock option activity since &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:52.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.120000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,980,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.45&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;398,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,544,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,672,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,717,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;476,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,701,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.95&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;369,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="INF"
      id="F_59546cc3-6ab9-471a-85fc-66b23ca4e0d5"
      unitRef="U_shares">7980047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="2"
      id="F_66cccfb4-1fab-40a8-97b2-0ca5f491dc9a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">28.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      id="F_c8627a07-b43f-44ac-8783-931654268f7e">P7Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_1952d4de-c8cb-4cdf-9053-9280f82659ad"
      unitRef="U_USD">398407000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="INF"
      id="F_af16a85a-59d2-4e7e-9c04-02ab034f0172"
      unitRef="U_shares">1544070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_d6e90d04-4913-4e74-b061-eb31883dd04e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">78.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="INF"
      id="F_78cb0b2e-6b4f-4d48-95ff-7028cf5fa28d"
      unitRef="U_shares">1672786</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_b963bf3a-c40a-4531-8cbc-bfb9694a5f53"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">25.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="INF"
      id="F_1c2c2212-f9b1-4147-9163-425d448f35fd"
      unitRef="U_shares">133690</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_3dce7b28-407f-4ba7-9f2f-ca976225b010"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">73.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="INF"
      id="F_14fa97a1-f427-400c-9a9e-bf2ec5f1c564"
      unitRef="U_shares">7717641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="2"
      id="F_d2c112f9-3d61-4845-8db6-f17dc509b5b5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">38.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_c4fb1e45-df2b-4d0b-ae22-a8ccf3b47a7b">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_1c8a6b8d-604e-49ef-b33b-af8e1212b57d"
      unitRef="U_USD">476355000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="INF"
      id="F_7be742de-fa20-433c-b303-265913c5d37d"
      unitRef="U_shares">4701612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="2"
      id="F_51941c17-3036-473f-be51-e63a9900f1a4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_1b3a001e-f319-4c72-abd5-c189492a7125">P5Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_a64c65e5-9e34-4279-bb4f-b5936cfe781f"
      unitRef="U_USD">369254000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-5"
      id="F_61840871-1793-47e4-aa3b-4c858e7bde66"
      unitRef="U_USD">107600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-5"
      id="F_951a2dc3-444b-42b4-ab60-d8bc701c6c10"
      unitRef="U_USD">102300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-5"
      id="F_c07fda8a-ea72-4371-9181-5042b1816e33"
      unitRef="U_USD">52300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_5daceb74-b17f-45e5-84bb-8f89175e24cc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">51.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="2"
      id="F_853ac31d-a56b-43ba-9689-f4cb11f23237"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">53.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="2"
      id="F_26228a59-2e93-488e-9028-2c72ccbd7d20"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_a3ea395f-4c7f-4411-9331-a1606790f58a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s RSU activity since &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:55.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:20%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Grant-Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;716,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;657,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;252,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,091,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_b5d7c4e7-18e6-4f91-bcaf-b360fe129db5"
      decimals="INF"
      id="F_0a936c76-2bc4-4303-87fb-1191d815c943"
      unitRef="U_shares">716921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_b5d7c4e7-18e6-4f91-bcaf-b360fe129db5"
      decimals="2"
      id="F_a991edf0-17ae-45aa-88e1-436e4337926b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">75.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2"
      decimals="INF"
      id="F_ac543a1e-d50c-4089-8e8e-0d267e0642e5"
      unitRef="U_shares">657148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2"
      decimals="2"
      id="F_70648255-76f5-41dd-bcaa-c43653324753"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">78.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2"
      decimals="INF"
      id="F_8e0effac-61d1-4669-be7d-4c9c4dd921df"
      unitRef="U_shares">252814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2"
      decimals="2"
      id="F_f5668d5f-fdf0-4d3a-9c98-89096243b774"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">75.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2"
      decimals="INF"
      id="F_540c1878-6b62-46f0-829f-b963eeec3402"
      unitRef="U_shares">30139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2"
      decimals="2"
      id="F_d7a69d40-6553-4bb2-bcf7-0e50c9e179e2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">77.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_2eb94656-ce71-41b7-8316-033ff3cd4fea"
      decimals="INF"
      id="F_603700d8-05e6-4078-8648-57250ce5ce95"
      unitRef="U_shares">1091116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_2eb94656-ce71-41b7-8316-033ff3cd4fea"
      decimals="2"
      id="F_89b11864-4f16-41e3-b64d-144c540ca528"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">76.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_a003efa2-9b6b-4b5b-8e24-3f682b981042"
      decimals="INF"
      id="F_b957bf38-63e1-4dbc-a7aa-f082d92a97d2"
      unitRef="U_shares">141935</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_4b0d8869-05bc-4ec5-b323-60d01f4fcae2"
      decimals="-5"
      id="F_8a686909-aa1f-4232-b174-2b8576afebfa"
      unitRef="U_USD">19000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_64c133f5-2609-4c1b-9738-f16ce3dfd8c2"
      decimals="0"
      id="F_f387c378-b019-4206-880a-595d1de75dc2"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_aee1bc3b-ea55-48a0-b0ff-337c01baa3ba"
      decimals="0"
      id="F_e6b8f015-b498-495f-ba74-54b9970cbf39"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_55d695b5-7752-4bf5-bc41-45cfd323b410">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has two classes of common stock outstanding: Class A common stock and Class B common stock. The rights of the holders of Class A common stock and Class B common stock are substantially identical, except with respect to voting and conversion.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Each share of Class A common stock is entitled to one vote. Class B common stock is nonvoting&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;each share of Class B common stock is convertible into one share of Class A common stock at the option of the holder at any time, subject to the ownership limitations provided for in the Company&#x2019;s amended and restated certificate of incorporation.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company allocates undistributed earnings attributable to common stock between the common stock classes on a one-to-one basis when computing net loss per share. As a result, basic and diluted net loss per share of Class A common stock and per share of Class B common stock are equivalent.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.27%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.097%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.097%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,717,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,980,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,034,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,091,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;716,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,827,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,696,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,034,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:CommonStockVotingRights
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_c721f272-9179-460f-b731-8899a4cf3962">Each share of Class A common stock is entitled to one vote. Class B common stock is nonvoting</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockConversionFeatures
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_1570cb88-3496-4e8c-b598-d6507cb29f47">each share of Class B common stock is convertible into one share of Class A common stock at the option of the holder at any time, subject to the ownership limitations provided for in the Company&#x2019;s amended and restated certificate of incorporation.</us-gaap:CommonStockConversionFeatures>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_01accf24-f7a9-4773-8fb7-bc2221020604">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.27%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.097%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.097%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,717,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,980,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,034,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,091,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;716,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,827,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,696,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,034,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f2bb14c0-23f4-4a61-858f-bd386111223c"
      decimals="0"
      id="F_dc397491-d2a2-409b-87a8-6f190d2034a5"
      unitRef="U_shares">7717641</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c712640c-07a0-45da-b2b2-bcb02c4fd3e7"
      decimals="0"
      id="F_2017c4d3-7fb5-42f8-b25c-27e9bcc3152a"
      unitRef="U_shares">7980047</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e69823d8-ed01-4d08-984d-1b2999947be0"
      decimals="0"
      id="F_fcf7bdd6-a6b0-4cee-b1de-205054e0c8b5"
      unitRef="U_shares">8034755</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_79da2e27-729f-4d64-9d13-dfa7ed04d4ac"
      decimals="0"
      id="F_b3e8181f-0e13-46fe-a240-c89dcf2210ea"
      unitRef="U_shares">1091116</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ef0a437f-257a-4262-a85f-63baab8addb5"
      decimals="0"
      id="F_4a0ef687-2945-44b6-8404-46f2f96e11c2"
      unitRef="U_shares">716921</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a45f72dc-0315-4ee6-825d-858c0027d5b1"
      decimals="0"
      id="F_02bce5a4-7e12-46a9-853b-be5410f7f91f"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e20707b9-ffb3-4b91-af22-0d9378f431f6"
      decimals="0"
      id="F_3cfc24c9-779a-4725-94ae-8ff2875e3eff"
      unitRef="U_shares">18400</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6c8c683b-7a90-4cec-ad1b-80a3610a19bc"
      decimals="0"
      id="F_7fc37056-fa62-4327-8ee9-02a2b4807991"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_be9e56dd-5d09-42b5-a3e0-25987a1ec13c"
      decimals="0"
      id="F_01c84b7f-96a6-4d18-9618-3b31875580b0"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="0"
      id="F_790fdc6c-b536-42e3-9f50-dca805a33db3"
      unitRef="U_shares">8827157</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="0"
      id="F_7a8ad3e9-3b7f-4f18-8df1-a6143fc9d4e3"
      unitRef="U_shares">8696968</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="0"
      id="F_831aa4ed-1d7b-4abd-982a-db5a48b02664"
      unitRef="U_shares">8034755</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_492677ce-aaea-48da-8b91-043b8d8b0f3f">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All of the Company&#x2019;s net losses have been generated in the United States. The Company recognized income tax provisions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, as a result of investment income earned in Nuvalent Securities Corporation. The Company recognized &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; income tax provision during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Reconciliation of federal statutory income tax rate to effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has elected to prospectively adopt the guidance in ASU 2023-09. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present reconciliations of the U.S. federal statutory income tax rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to the Company&#x2019;s effective income tax rate for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (dollar values in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:60.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State and local income tax, net of federal (national) income tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign tax effects&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of changes in tax laws or rates enacted in the current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of cross-border tax laws&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Orphan drug credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in valuation allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits generated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in deferred tax asset valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2025, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each year, due to its uncertainty of realizing a benefit from those items.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of related party revenue share liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;362,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;362,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, the Company had U.S. federal and state net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;503.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;531.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, which may be available to offset future taxable income. The federal net operating losses include $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million which expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;502.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million which carryforward indefinitely, but may only be used to offset &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of annual taxable income. The state net operating losses expire at various dates beginning in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of December 31, 2025, the Company also had federal and state research and development tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, and federal orphan drug credits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which may be available to offset future tax liabilities. The federal and state research and development tax credit carryforwards and the federal orphan drug credits expire at various dates beginning in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2033&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Utilization of the U.S. federal and state net operating loss carryforwards, as well as the research and development tax credit carryforwards and federal orphan drug credits may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986 (&#x201c;IRC&#x201d;), and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards, research and development tax credit carryforwards or the federal orphan drug credits would be subject to an annual limitation under Section 382. Any limitation may result in expiration of a portion of the net operating loss carryforwards, research and development tax credit carryforwards or the federal orphan drug credits before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has evaluated the positive and negative evidence bearing upon its ability to realize the net deferred tax assets. Management has considered the Company&#x2019;s history of cumulative net losses incurred since inception and that the Company has yet to commercialize any of its product candidates to generate revenue from product sales and has concluded that it is more likely than not that the Company will not realize the benefits of the net deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2025 and 2024. Management reevaluates the positive and negative evidence at each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;142.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the years ended December 31, 2025, 2024 and 2023, respectively, primarily as a result of increases in net operating loss carryforwards, research and development tax credit carryforwards, the change in fair value of related party revenue share liability and research and development costs capitalized under Section 174 of the IRC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Unrecognized tax benefits and tax examinations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recorded any amounts for unrecognized tax benefits. The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_b03806a6-1c81-405a-b304-d4fc62c72a8c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to the present.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-5"
      id="F_14e119ce-5079-4da0-9a39-c346150768b4"
      unitRef="U_USD">600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-5"
      id="F_6073a905-4d44-42b8-b5b9-8c0097fd203a"
      unitRef="U_USD">800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-6"
      id="F_bc1ba153-58c0-452c-8942-c5ffc8334fad"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_338781c3-1b30-47cb-96e4-2cb3a1dfb8e5">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present reconciliations of the U.S. federal statutory income tax rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to the Company&#x2019;s effective income tax rate for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (dollar values in thousands):&lt;/span&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:60.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State and local income tax, net of federal (national) income tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign tax effects&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of changes in tax laws or rates enacted in the current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of cross-border tax laws&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Orphan drug credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in valuation allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits generated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in deferred tax asset valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_76b50ddf-be3c-4d4d-9a44-5bbb57366348"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="2"
      id="F_40da1c99-4de7-4437-bbf4-eb30a866c293"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="2"
      id="F_ec055a24-5029-401f-ae31-97692895e1d2"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_af963288-7ad5-48f7-812c-6de987e29401"
      unitRef="U_USD">-89206000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="3"
      id="F_01b98f07-c58f-45f2-bbc7-e793031fc697"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_73e46d97-0ef7-41d4-aedb-702b518182de"
      unitRef="U_USD">585000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="3"
      id="F_f4efa60d-8a52-4200-8cc2-4405690458af"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_d8252134-775c-454f-92e9-8ff3ef6cc317"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_cc5fe61f-ca91-46f5-b5e2-3a2bdf0220aa"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_511a4bf2-64b2-42ac-a77e-5a6b14429a3c"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_1d216386-3a6d-4791-a5e4-ea2140f35504"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_432b7cb5-9da4-454e-a6ee-f6f4b60e6c62"
      unitRef="U_USD">0</us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_661f7ab9-2ce2-4ed2-8d08-a57a973c0013"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent>
    <nuvl:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_b5ce758d-dc1e-44e8-b2c7-1f88f19ea141"
      unitRef="U_USD">27137000</nuvl:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedAmount>
    <nuvl:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="3"
      id="F_a723f68a-6556-4d43-9385-c7ba2a4bfb4a"
      unitRef="U_pure">-0.064</nuvl:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugRelatedPercent>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_bc877a4a-4a20-403c-8b3e-1ae13117d70f"
      unitRef="U_USD">-1061000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="3"
      id="F_5702fe55-6e81-4458-90f1-fc86f888cb3e"
      unitRef="U_pure">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_87c1337f-6b7c-41a7-8e65-2f17fe8b8ec0"
      unitRef="U_USD">114819000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="3"
      id="F_714fb330-5e68-4671-81e8-02d3435dbfa3"
      unitRef="U_pure">-0.27</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <nuvl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_c71b48ea-56fe-4387-ac6f-d58030ab622f"
      unitRef="U_USD">12316000</nuvl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationAmount>
    <nuvl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="3"
      id="F_c2cb7b5e-494b-4a9f-a739-c2e6cb457c76"
      unitRef="U_pure">-0.029</nuvl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162MLimitationPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_bb77ee73-1ab8-4bd9-a15a-b979f2e5bd0e"
      unitRef="U_USD">-12413000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="3"
      id="F_e85246f4-51e3-4b11-94e3-9659ce9136e5"
      unitRef="U_pure">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_dc456cff-8dd9-4fe3-9db4-940a2327c6ae"
      unitRef="U_USD">113000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_6e8dafe1-377f-4c59-b2c2-bd22573adc06"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_e80b7922-8a61-4790-8354-9752bab572d0"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="2"
      id="F_f7cb2469-d2b3-4a96-becf-9f9106646354"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_3b4e47f1-43a3-41c5-88e4-055f7df6779b"
      unitRef="U_USD">447000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="3"
      id="F_f635e850-6ec1-464c-80c3-74e7ff40ee9b"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_67dba121-3731-4972-9741-ec20f6b810d6"
      unitRef="U_USD">585000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="3"
      id="F_6c615cab-1961-40ff-8570-014430a07667"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="3"
      id="F_7ad10dc8-47e3-437f-8399-1f2f06be581b"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="3"
      id="F_47486161-7743-4c50-a6dd-914bc379d60e"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="3"
      id="F_5660442d-adbe-4048-b532-ba08ec6cf370"
      unitRef="U_pure">0.067</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="3"
      id="F_3d7b077b-d75e-4551-9821-fbb4af2fd66b"
      unitRef="U_pure">0.083</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="3"
      id="F_cbc85169-da9a-4eb8-8513-a9a66d43e6f4"
      unitRef="U_pure">-0.143</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="3"
      id="F_f698b4ac-e72c-4e4f-9385-97abc72cb4f5"
      unitRef="U_pure">-0.057</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="3"
      id="F_50807843-398c-44aa-8374-ef3dbe766146"
      unitRef="U_pure">-0.458</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="3"
      id="F_aa878fa0-c798-49e6-b206-23ded666c390"
      unitRef="U_pure">-0.387</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="3"
      id="F_12e9b4d6-2d59-417d-84c6-5787f88a7fe8"
      unitRef="U_pure">0.036</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="3"
      id="F_5cbae004-d18d-4e0e-a1b8-84b147c288fd"
      unitRef="U_pure">0.035</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="3"
      id="F_f9c9ca30-7c34-4726-a40e-b016d21a89e8"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="3"
      id="F_2e8dea2a-5f93-498b-a3e6-d8665ecd6f2b"
      unitRef="U_pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="3"
      id="F_42428d12-a286-49bd-9669-31839b1c1da2"
      unitRef="U_pure">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="2"
      id="F_d22cb1c0-911c-4377-a0a7-e273bbe44f12"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_1b7c2420-1c2c-4ebf-8428-9cac99f1ca29"
      decimals="INF"
      id="F_07d629a9-ec03-42be-86a8-35f2788057bb"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_12c1df21-95c0-4db5-83c4-037d4d91afe3"
      decimals="INF"
      id="F_321e1cfb-c827-4f37-abf3-cd59fe208e8f"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_07fcdeda-4594-41d5-be5c-795db943ad90"
      decimals="INF"
      id="F_12005634-a146-4342-b846-ffec85fca265"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20130f2c-c4db-45fd-abba-1f8188d4bd9a"
      decimals="INF"
      id="F_32f89643-1d0e-49d3-a77f-5564abe0a3e3"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_3b49c627-bb81-455e-91fc-cab076e3df66"
      decimals="INF"
      id="F_897c6ee0-de41-4e4a-82c3-15c01016899c"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ade98c0e-cd81-4850-a29e-7a084963f5ce"
      decimals="INF"
      id="F_7c7b24a1-832a-4414-9964-5b7f97f3dc47"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_8423f05c-9cf2-4a1e-8983-6d8836289446">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of related party revenue share liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;362,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;362,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_b46e4b5a-f570-4c09-9a58-2868aacba441"
      unitRef="U_USD">139120000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_12e13536-e0ca-4b1a-8f82-fffd3a49c97c"
      unitRef="U_USD">56677000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <nuvl:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_13e5fb44-616b-4cab-88c1-b408db8495bc"
      unitRef="U_USD">103127000</nuvl:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <nuvl:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_20034f11-53f4-4e0b-8cfd-ebeda93c1075"
      unitRef="U_USD">94002000</nuvl:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_64b28085-858b-4f7a-a6c3-b83a8246a373"
      unitRef="U_USD">82361000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_3767e649-1271-4b48-a60d-84d9538cf1b5"
      unitRef="U_USD">52117000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <nuvl:DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_2dd8bff7-c2ea-4bd2-a981-9f788bd52c0c"
      unitRef="U_USD">19284000</nuvl:DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability>
    <nuvl:DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_0f22b317-5b37-49ed-8fb8-3e452a75c10b"
      unitRef="U_USD">4785000</nuvl:DeferredTaxAssetsFairValueOfRelatedPartyRevenueShareLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_4995675f-786d-4b49-ba8c-43c01bd7ca5c"
      unitRef="U_USD">14225000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_0e7d46ad-6737-4ac8-9a9c-98353acbcd9d"
      unitRef="U_USD">9705000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_68307125-4b8e-4eed-a352-2215cd87b939"
      unitRef="U_USD">4648000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_0c304980-2560-4717-a09e-7354c0cbc9e0"
      unitRef="U_USD">2714000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_2d7c59ee-7403-48ff-bad2-762472bfb90b"
      unitRef="U_USD">362765000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_cf144aba-ff6a-4390-a2da-3c071d904a8b"
      unitRef="U_USD">220000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_d949d7ff-e74e-4991-9394-eaa495e97c8a"
      unitRef="U_USD">362495000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_5b731392-ba17-4f79-b2d3-c7b5d7ebb131"
      unitRef="U_USD">220000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_85276c30-ab11-455f-9dc1-ee865e4079b6"
      unitRef="U_USD">270000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_95ff5ec8-e09a-4f97-be7f-379ea0a27d0d"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_d6ce3562-e9bb-44a9-b994-41dc08da6c54"
      unitRef="U_USD">270000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_6b69e0ec-a3e0-429d-910b-22298dedc88b"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_e0b1bbf7-8cfa-4959-9851-0c26d0363821"
      unitRef="U_USD">270000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_6c0d6b84-f344-4062-a5b7-3b511b96bbd5"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="-3"
      id="F_de0de38c-1444-4b18-8f5f-14d8e788e810"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="-3"
      id="F_dbee00a5-3fc0-4e2c-8ff8-82a7c302406d"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_cdabc5c6-3cd2-4eb9-9dc6-41bbf0db7742"
      decimals="-5"
      id="F_a578ec95-a07a-4cc0-93c9-490d6e48e361"
      unitRef="U_USD">503200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_35482e0d-c33b-47c3-848d-21781d777547"
      decimals="-5"
      id="F_751b40f9-9939-47f3-a42a-32708345670a"
      unitRef="U_USD">531100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_3d1f51e0-4a93-4b50-a43a-e08057aecfba"
      decimals="-5"
      id="F_a317644b-f078-4cb1-a38b-90d55df20fc7"
      unitRef="U_USD">1200000</us-gaap:OperatingLossCarryforwards>
    <nuvl:OperatingLossCarryforwardExpirationYearStart
      contextRef="C_7ce3ca05-ba69-4be9-a104-7719ff79cd1a"
      id="F_16486249-4cfa-488c-b1ad-c417c753c504">2037</nuvl:OperatingLossCarryforwardExpirationYearStart>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_f95ded5a-49e8-49b9-b5a3-63dc2b4d4aa1"
      decimals="-5"
      id="F_2b509224-786c-4696-99e2-7f1a1c0606c7"
      unitRef="U_USD">502000000</us-gaap:OperatingLossCarryforwards>
    <nuvl:OperatingLossCarryforwardOffsetLimitPercentage
      contextRef="C_f899193c-c2e3-484b-bdb4-f0e98446f558"
      decimals="2"
      id="F_7df4e036-7c4c-4ec5-9a94-414354756a12"
      unitRef="U_pure">0.80</nuvl:OperatingLossCarryforwardOffsetLimitPercentage>
    <nuvl:OperatingLossCarryforwardExpirationYearStart
      contextRef="C_1e086995-98e4-44a7-b73f-1985518eb0f9"
      id="F_42aca9a7-bc5a-49da-9409-132b21b093d4">2037</nuvl:OperatingLossCarryforwardExpirationYearStart>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_cd8ca3b9-735d-497f-8b2f-206e366ae9a9"
      decimals="-5"
      id="F_4b3a0900-d451-4077-9381-e7afffd382de"
      unitRef="U_USD">14600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_5b210e3a-65e3-4ee7-b4af-e26ecefa2931"
      decimals="-5"
      id="F_72df05b8-578b-49b6-9850-7eae412e6b7a"
      unitRef="U_USD">14100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_e991fd94-9f04-42a7-9ea3-29c75a8aa6ed"
      decimals="-5"
      id="F_12237d21-d6e0-415e-b369-c2c60e38a94d"
      unitRef="U_USD">56500000</us-gaap:TaxCreditCarryforwardAmount>
    <nuvl:ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_929e775e-e257-4c04-80c4-92e58b09ce41">2033</nuvl:ResearchAndDevelopmentTaxCreditCarryforwardExpirationYearStart>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-5"
      id="F_f06324e4-efc9-4462-87b1-d652904513ed"
      unitRef="U_USD">142500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-5"
      id="F_7cbe5e44-5859-4c59-9561-674aa9f1df12"
      unitRef="U_USD">119100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-5"
      id="F_f20a8f1a-bc0a-4f4d-a275-6d04e34d3c60"
      unitRef="U_USD">48800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="0"
      id="F_9a869287-9987-42e3-83f5-7de120959efb"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="0"
      id="F_607c664e-d1dd-4d81-bf11-ad41a020bfc5"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationDescription
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_10b08993-461b-475f-a113-30d41eb50525"> In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from 2022 to the present.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_fc1cc93c-1942-42c2-a018-30df20c8bd48">&lt;p id="fn_10_commitments_and_contingencies" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue sharing agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has a revenue sharing agreement with Deerfield pursuant to which the Company is obligated to pay Deerfield a fixed low single-digit percentage rate of net sales of certain commercial products (the &#x201c;Deerfield Revenue Sharing Agreement&#x201d;). The Company is also party to a revenue sharing agreement with its scientific founder pursuant to which the Company was obligated to pay the scientific founder &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net sales of certain commercial products (the &#x201c;Scientific Founder Revenue Sharing Agreement&#x201d; and together with the Deerfield Revenue Sharing Agreement, the &#x201c;Revenue Sharing Agreements&#x201d;). In December 2025, the scientific founder assigned the Scientific Founder Revenue Sharing Agreement to Royalty Pharma plc (&#x201c;Royalty Pharma&#x201d;) and, as a result, any payments the Company is obligated to make under the Scientific Founder Revenue Sharing Agreement will be made to Royalty Pharma.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Revenue Sharing Agreements, the payment obligation in respect of such products expires on the later of 12 years from the first commercial sale in a country or the expiration of the last-to-expire patent in that country. The Company accounts for the liability with Deerfield at fair value with changes recognized in the consolidated statements of operations and comprehensive loss (see Note 4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;). The Company accounts for the obligation to Royalty Pharma as a contingent liability and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t accrued any liability as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 or 2024. The Company has not recorded any net sales and, as a result, has not paid any amounts under the Revenue Sharing Agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Indemnification agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, CROs, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <nuvl:PercentageOfNetSalesPayable
      contextRef="C_d47345ec-2ef1-4025-9501-8c6905454377"
      decimals="3"
      id="F_c3a31252-6a90-4dc5-bff4-b9f0f199bae6"
      unitRef="U_pure">0.015</nuvl:PercentageOfNetSalesPayable>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_995479a7-c042-4eed-b4f4-cb48506a82ad"
      decimals="INF"
      id="F_9a76e12e-3ec5-4aee-9229-a05a8ae83f58"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_315a253c-12d3-4e3f-8582-c49af65387fa"
      decimals="INF"
      id="F_aa77e5b2-ca8b-461b-b6da-2c9cf8796d1d"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_0684b5f8-9a18-4a90-8330-bfbd40325c3d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is a clinical-stage biopharmaceutical company and has not generated any revenue since commencing significant operations in 2018. The Company&#x2019;s operations are organized and reported as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment, which includes all activities related to the discovery, development, and commercialization of precisely targeted therapies for patients with cancer. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;This presentation is consistent with how the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d7650aa4-5b78-4427-b72b-9d9f6eb1e03c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, assesses the performance of the Company and makes operating decisions on a consolidated basis. The accounting policies of the consolidated segment are the same as those described in the summary of significant accounting policies (see &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;). The CODM assesses performance and decides how to allocate resources based on consolidated net loss as reported on the consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_c878b86a-9508-4bbd-ac26-41dc1d148b19;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM uses consolidated net loss to monitor budget versus actual results, assess cash runway, and benchmark against the Company&#x2019;s competitors.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The measure of segment assets is reported on the consolidated balance sheets as total assets. The Company&#x2019;s assets are held in the United States.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the Company&#x2019;s segment information (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.020000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.020000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Direct external expenses by program:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Zidesamtinib&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Neladalkib&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;NVL-330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Discovery programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative professional and consultant fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of related party revenue share liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Consolidated net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;425,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;260,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:6.7pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other segment items included in consolidated net loss include expenses for commercialization preparation activities, research and development consulting services, information technology, insurance, employee recruitment and other miscellaneous activities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="INF"
      id="F_4c4290d8-9055-493a-a458-ffa510ef149c"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_3e06cdd7-6632-4a1e-b4e6-1817f32bdb47">This presentation is consistent with how the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), its Chief Executive Officer, assesses the performance of the Company and makes operating decisions on a consolidated basis. The accounting policies of the consolidated segment are the same as those described in the summary of significant accounting policies (see Note 2). The CODM assesses performance and decides how to allocate resources based on consolidated net loss as reported on the consolidated statements of operations and comprehensive loss. The CODM uses consolidated net loss to monitor budget versus actual results, assess cash runway, and benchmark against the Company&#x2019;s competitors. The measure of segment assets is reported on the consolidated balance sheets as total assets. The Company&#x2019;s assets are held in the United States.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_c0323470-1add-4bcc-b9af-62538ff52465">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the Company&#x2019;s segment information (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.020000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.020000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Direct external expenses by program:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Zidesamtinib&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Neladalkib&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;NVL-330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Discovery programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative professional and consultant fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of related party revenue share liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Consolidated net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;425,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;260,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other segment items included in consolidated net loss include expenses for commercialization preparation activities, research and development consulting services, information technology, insurance, employee recruitment and other miscellaneous activities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <nuvl:DirectExpensesRelatedToProgram
      contextRef="C_9e99d067-33f9-44b7-ad37-2b11d6b976ab"
      decimals="-3"
      id="F_d60fc2ef-be1d-4fe7-80be-a6543d2c25ec"
      unitRef="U_USD">59519000</nuvl:DirectExpensesRelatedToProgram>
    <nuvl:DirectExpensesRelatedToProgram
      contextRef="C_3eba6714-0731-48ae-b4f4-7f4ce2c35d2b"
      decimals="-3"
      id="F_011ee3b7-ff1c-40a2-bf81-669701f9aa29"
      unitRef="U_USD">62110000</nuvl:DirectExpensesRelatedToProgram>
    <nuvl:DirectExpensesRelatedToProgram
      contextRef="C_b91245ac-3eac-4609-a0fd-52cfb27df07b"
      decimals="-3"
      id="F_6a919322-8022-44b6-84c2-8f25fbffde22"
      unitRef="U_USD">27878000</nuvl:DirectExpensesRelatedToProgram>
    <nuvl:DirectExpensesRelatedToProgram
      contextRef="C_116dea71-ba5e-4119-8d49-e7ee6561f1e6"
      decimals="-3"
      id="F_31042129-ad78-4792-bff8-f0af866261fb"
      unitRef="U_USD">105446000</nuvl:DirectExpensesRelatedToProgram>
    <nuvl:DirectExpensesRelatedToProgram
      contextRef="C_0750e3c9-8640-41ad-9503-347848c2d04a"
      decimals="-3"
      id="F_b6fec522-46a9-4e13-9fae-c79e3c5a90f4"
      unitRef="U_USD">67778000</nuvl:DirectExpensesRelatedToProgram>
    <nuvl:DirectExpensesRelatedToProgram
      contextRef="C_93b7517e-8570-4d83-b09d-74c6833d8f47"
      decimals="-3"
      id="F_331dd354-a19d-443a-832e-41e1cfb76ccf"
      unitRef="U_USD">31894000</nuvl:DirectExpensesRelatedToProgram>
    <nuvl:DirectExpensesRelatedToProgram
      contextRef="C_6094352e-f262-4238-af9a-9fad395992a8"
      decimals="-3"
      id="F_08146d94-0911-44b0-a2aa-3d498e85c077"
      unitRef="U_USD">21819000</nuvl:DirectExpensesRelatedToProgram>
    <nuvl:DirectExpensesRelatedToProgram
      contextRef="C_246b0188-59cf-48e1-84da-c53c20eff235"
      decimals="-3"
      id="F_d38a60e3-3316-432d-b2fc-0d56ed4c88a7"
      unitRef="U_USD">8293000</nuvl:DirectExpensesRelatedToProgram>
    <nuvl:DirectExpensesRelatedToProgram
      contextRef="C_21c5a8f9-d69c-4f2f-9b56-7302217a3a00"
      decimals="-3"
      id="F_094cd678-2d67-43a3-82d4-36979cb21cc5"
      unitRef="U_USD">10634000</nuvl:DirectExpensesRelatedToProgram>
    <nuvl:DirectExpensesRelatedToProgram
      contextRef="C_13717a87-7c59-4d14-9edc-e3677683fc0b"
      decimals="-3"
      id="F_d142bd4c-f97d-4d9e-90b4-1b18df754342"
      unitRef="U_USD">11875000</nuvl:DirectExpensesRelatedToProgram>
    <nuvl:DirectExpensesRelatedToProgram
      contextRef="C_ee20e1d0-82c0-4f31-a59e-df781ca5bef7"
      decimals="-3"
      id="F_eb01da37-1987-474a-b8a1-d2b6dd0bd79b"
      unitRef="U_USD">9178000</nuvl:DirectExpensesRelatedToProgram>
    <nuvl:DirectExpensesRelatedToProgram
      contextRef="C_a88ce5aa-19e3-4d4f-ad4b-227efe228c24"
      decimals="-3"
      id="F_d61cc4cd-0927-4ec6-8f01-a89a90f9f45c"
      unitRef="U_USD">8586000</nuvl:DirectExpensesRelatedToProgram>
    <us-gaap:LaborAndRelatedExpense
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_40124466-5ddd-4e36-8709-ba7117ec6d71"
      unitRef="U_USD">73163000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_b7513ec7-a618-44a9-b57e-21d4e9769df8"
      unitRef="U_USD">44121000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_69015115-2c4a-4a27-ad77-a528c2c769f7"
      unitRef="U_USD">29225000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_85bcbf95-55be-41dd-9149-0ba315f9ba6f"
      unitRef="U_USD">86502000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_7f798b4f-fd53-492c-83c1-9c81b5d64ade"
      unitRef="U_USD">60579000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_617e3096-6193-4fc2-9a29-87e7fe2f0079"
      unitRef="U_USD">25563000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProfessionalFees
      contextRef="C_0ed9a5c8-bc77-4159-80cc-631b58767dd4"
      decimals="-3"
      id="F_26fd97fc-19df-49d2-ac01-3f28b13118e6"
      unitRef="U_USD">15033000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_1c1aeab6-5cb0-40f4-a1b3-94770256e0b4"
      decimals="-3"
      id="F_2d328e1f-416c-47e0-9456-660a2be30585"
      unitRef="U_USD">10854000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_1cd91e04-8d02-4ef7-b3c0-68167cbe59fc"
      decimals="-3"
      id="F_a9f0d6f6-f047-4838-976b-ced0ddcaa32a"
      unitRef="U_USD">6423000</us-gaap:ProfessionalFees>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_d332cbe2-c3c6-4046-8db5-f23b69b757bd"
      unitRef="U_USD">-55220000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_f3e4287c-73e9-4f61-b84a-d18e75232197"
      unitRef="U_USD">-17940000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_a390e94b-a87e-4e9d-872a-3d28be6af82d"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_4058e24e-cab6-4039-bb53-349182c185d9"
      unitRef="U_USD">44794000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_ff27a853-01df-4f1b-bb08-3ee618c53e08"
      unitRef="U_USD">38372000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_88be9365-586c-443a-a3ee-88ac92d28cb4"
      unitRef="U_USD">23277000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_99d37f8b-f9bc-44f2-8755-46a77d453983"
      unitRef="U_USD">41009000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_7ea2888c-43cb-4789-b097-84b1ddb9f65a"
      unitRef="U_USD">17511000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_534a07f3-eb73-4e0f-a151-8b1ec63eab1e"
      unitRef="U_USD">9293000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_11c45c09-c88c-43e8-8cb5-3a981467782b"
      unitRef="U_USD">585000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_25c4dc10-2009-4598-a093-e5dd0c953acf"
      unitRef="U_USD">764000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_5328c4e2-a662-4a26-abef-bfc89096d456"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      decimals="-3"
      id="F_43700a42-cde9-4db2-bb3d-f72ca2c8727a"
      unitRef="U_USD">-425377000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93016deb-ee08-467a-a576-f8fa9b49422a"
      decimals="-3"
      id="F_9e671d86-b279-46fa-bac7-59d8de8695b7"
      unitRef="U_USD">-260756000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7026295c-45c4-4065-af2d-da1e39b72fb6"
      decimals="-3"
      id="F_3e88590d-33b6-4260-bba0-e6786f55a3e9"
      unitRef="U_USD">-126219000</us-gaap:NetIncomeLoss>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_1dad83de-cc46-4271-b61b-c56d9259a2a0"
      id="F_d89a0294-18db-4a12-8ab8-cd078a493431">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table describes for the quarterly period ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a Rule 10b5-1 trading arrangement) or (2) a &#x201c;non-Rule 10b5-1 trading arrangement&#x201d; (as defined in Item 408(c) of Regulation S-K):&lt;/span&gt;&lt;/p&gt;
     &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
      &lt;tr style="visibility:collapse;"&gt;
       &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:14.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:22%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:12%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:26%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:12.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:8pt;background-color:#f2f2f2;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Name (Title)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Action Taken &lt;br/&gt;(Date of Action)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Type of Trading Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Nature of Trading &lt;br/&gt;Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Duration of Trading &lt;br/&gt;Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Number &lt;br/&gt;of Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Alexandra Balcom&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Chief Financial Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adoption&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;December 23, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rule 10b5-1 trading arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sale&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;Until &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 11, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;, or such earlier date upon which all transactions are completed or expire without execution&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;Up to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;shares of Class A common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:9pt;background-color:#f2f2f2;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Henry Pelish&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Chief Scientific Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adoption&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;December 11, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rule 10b5-1 trading arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sale&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;Until &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;November 30, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;, or such earlier date upon which all transactions are completed or expire without execution&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;Up to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,306&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;shares of Class A common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;James Porter&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adoption&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;December 4, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rule 10b5-1 trading arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sale&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;Until &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;March 10, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;, or such earlier date upon which all transactions are completed or expire without execution&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;Up to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;390,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;shares of Class A common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:9pt;background-color:#f2f2f2;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Anna Protopapas&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Director&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adoption&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;December 7, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rule 10b5-1 trading arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sale&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;Until &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;March 31, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;, or such earlier date upon which all transactions are completed or expire without execution&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;Up to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;shares of Class A common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
     &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName
      contextRef="C_e04f47c1-ee6d-40d2-ad63-924abbcdd776"
      id="F_aca48628-ecce-49d4-90aa-924840ee78ff">Alexandra Balcom</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_e04f47c1-ee6d-40d2-ad63-924abbcdd776"
      id="F_580ae24b-6786-4deb-af8e-34085f2eaccc">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_e04f47c1-ee6d-40d2-ad63-924abbcdd776"
      id="F_49eb2a05-328a-4266-a4c7-46fcc126318f">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_e04f47c1-ee6d-40d2-ad63-924abbcdd776"
      id="F_11799ffd-2fd4-4759-9a27-a85c33b05036">December 23, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate
      contextRef="C_e04f47c1-ee6d-40d2-ad63-924abbcdd776"
      id="F_77ef289b-469d-419b-a5c7-d2dfdb386b3d">December 11, 2026</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_afdd3fb0-ef69-40ad-bdc6-6e7c62bedfaf"
      decimals="INF"
      id="F_430cff61-62c6-40cd-b0ae-6cb5b4d199ff"
      unitRef="U_shares">128000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName
      contextRef="C_c5190b6e-fe0c-4289-8dbf-a33c66c7be66"
      id="F_ffef0de4-6418-4dfe-b9d5-230d4266199c">Henry Pelish</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_c5190b6e-fe0c-4289-8dbf-a33c66c7be66"
      id="F_5a15f78b-3779-446b-9c60-c3404679bf78">Chief Scientific Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_c5190b6e-fe0c-4289-8dbf-a33c66c7be66"
      id="F_10d3f965-aae5-47a0-aabd-7de4cb129ca8">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_c5190b6e-fe0c-4289-8dbf-a33c66c7be66"
      id="F_2120a01a-e8c2-462d-988f-ab75922b251e">December 11, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate
      contextRef="C_c5190b6e-fe0c-4289-8dbf-a33c66c7be66"
      id="F_81bc2c0e-e59d-426d-9348-5cec4a1aa009">November 30, 2027</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_4fff95ac-8ff6-451a-8631-2a1193c942a6"
      decimals="INF"
      id="F_37c7c21a-8bb5-4bba-9e01-936c0cfbf7ff"
      unitRef="U_shares">116306</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName
      contextRef="C_47a42871-276f-471d-89af-7b2d8728791f"
      id="F_0f229b54-99c3-485b-9bbe-aac2fc5477b4">James Porter</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_47a42871-276f-471d-89af-7b2d8728791f"
      id="F_7809f62d-8ac2-421c-b100-935c82447600">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_47a42871-276f-471d-89af-7b2d8728791f"
      id="F_e1891381-c091-417c-88f0-f7aaa703ee43">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_47a42871-276f-471d-89af-7b2d8728791f"
      id="F_518ac040-bde4-4e8d-a650-5afa62411199">December 4, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate
      contextRef="C_47a42871-276f-471d-89af-7b2d8728791f"
      id="F_99d2ff3c-37ae-420c-b9ae-ffdd4c91eba6">March 10, 2027</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_72818106-430d-4e9d-ac04-dff4e3f376f2"
      decimals="INF"
      id="F_892627f0-3cd3-497b-bae4-d3dbd6af7f42"
      unitRef="U_shares">390000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName
      contextRef="C_4c059091-923a-455f-b4b2-a218c67cdf6b"
      id="F_3ea89e93-ee76-4b81-80fc-53416cd7e1b5">Anna Protopapas</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_4c059091-923a-455f-b4b2-a218c67cdf6b"
      id="F_97e69462-4621-4276-acc6-ddfbbdce4b42">Director</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_4c059091-923a-455f-b4b2-a218c67cdf6b"
      id="F_b67065c1-d6cb-4c7a-b69f-95fbf9af4201">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_4c059091-923a-455f-b4b2-a218c67cdf6b"
      id="F_fe38609c-e7ef-4e4d-8a47-694ca94e632f">December 7, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate
      contextRef="C_4c059091-923a-455f-b4b2-a218c67cdf6b"
      id="F_5393bce6-eef1-4c10-836c-e8713d4c82dd">March 31, 2027</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_7113a74e-6c90-4126-9b38-7b6f500f4532"
      decimals="INF"
      id="F_de9eb739-a266-445a-adda-75781adde251"
      unitRef="U_shares">20000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_0efe00a0-1bde-4f33-b74e-ef42c404d2ea"
      id="F_d7d34bef-706f-43a0-9abe-715e28760e4e">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_534a07f3-eb73-4e0f-a151-8b1ec63eab1e"
          xlink:label="F_534a07f3-eb73-4e0f-a151-8b1ec63eab1e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_99d37f8b-f9bc-44f2-8755-46a77d453983"
          xlink:label="F_99d37f8b-f9bc-44f2-8755-46a77d453983"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_7ea2888c-43cb-4789-b097-84b1ddb9f65a"
          xlink:label="F_7ea2888c-43cb-4789-b097-84b1ddb9f65a"
          xlink:type="locator"/>
        <link:footnote id="FNT_2c80a555-b7c4-4850-83cf-ca017df36dc6" xlink:label="FNT_2c80a555-b7c4-4850-83cf-ca017df36dc6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items included in consolidated net loss include expenses for commercialization preparation activities, research and development consulting services, information technology, insurance, employee recruitment and other miscellaneous activities.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_534a07f3-eb73-4e0f-a151-8b1ec63eab1e"
          xlink:to="FNT_2c80a555-b7c4-4850-83cf-ca017df36dc6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_99d37f8b-f9bc-44f2-8755-46a77d453983"
          xlink:to="FNT_2c80a555-b7c4-4850-83cf-ca017df36dc6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7ea2888c-43cb-4789-b097-84b1ddb9f65a"
          xlink:to="FNT_2c80a555-b7c4-4850-83cf-ca017df36dc6"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
